



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 153283

TO: Terra Gibbs
Location: REM-2D10/2C18
Art Unit: 1635
Thursday, May 12, 2005

Case Serial Number: 10/029115

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: 571-272-2527

paul.schulwitz@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

Pending Nucleic Acid and Pending Amino Acid database searches generate two sets of results each. The Pending databases have been split into two parts to reduce the amount of time required for their daily updates. This results in more machine time being available for processing searches.

Searches run against the Nucleic Acid Pending database produce two sets of results, with the extensions **.rnpn** and **.rnpn**

Searches run against the Amino Acid Pending database produce two sets of results, with the extensions **.rapn** and **.rapn**

Because they contain data that is confidential, the results of Pending database searches should not be left in the case .

THIS PAGE BLANK (USPTO)

Schreiber, David

153 283

From: STIC-Biotech/ChemLib
Sent: Monday, May 02, 2005 6:39 AM
To: Schreiber, David
Subject: FW: Sequence search request...

-----Original Message-----

From: STIC-ILL
Sent: Monday, May 02, 2005 6:37 AM
To: STIC-Biotech/ChemLib
Subject: FW: Sequence search request...

-----Original Message-----

From: Gibbs, Terra
Sent: Sunday, May 01, 2005 6:57 PM
To: STIC-ILL
Subject: Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of SEQ ID NO:1 in USSN 10/029,115, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 80 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. I also need the interference databases searched.

*Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
Mailbox 2C18
571-272-0758*

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 12, 2005, 11:23:08 ; Search time 14 Seconds
(without alignments)
3.393 Million cell updates/sec

Title: us-10-029-115-1

Perfect score: 3951

Sequence: 1 gccctatggcgaccagc.....tcataactggtgaaaggsc 3951

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 286 seqs, 6012 residues

Total number of hits satisfying chosen parameters: 572

Minimum DB seq length: 8

Maximum DB seq length: 80

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 297 summaries

Database : rgddb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	41.4	1.0	51	1	ACCSSION:184400
2	34	0.9	42	1	ACCSSION:184400
3	31.2	0.8	36	1	ACCSSION:184400
4	29.4	0.7	33	1	ACCSSION:184400
5	28.4	0.7	30	1	ACCSSION:184400
6	28.4	0.7	30	1	ACCSSION:184400
7	28.4	0.7	30	1	ACCSSION:184400
8	28.4	0.7	30	1	ACCSSION:184400
9	28.4	0.7	30	1	ACCSSION:184400
10	28.4	0.7	31	1	ACCSSION:184400
11	27.8	0.7	33	1	ACCSSION:184400
12	27.2	0.7	36	1	ACCSSION:184400
13	26.2	0.7	31	1	ACCSSION:184400
14	26.2	0.7	31	1	ACCSSION:184400
15	26.2	0.7	31	1	ACCSSION:184400
16	26.2	0.7	31	1	ACCSSION:184400
17	24.8	0.6	31	1	ACCSSION:184400
18	24.6	0.6	31	1	ACCSSION:184400
19	24.6	0.6	31	1	ACCSSION:184400
20	24.6	0.6	31	1	ACCSSION:184400
21	24.6	0.6	31	1	ACCSSION:184400
22	23	0.6	23	1	ACCSSION:184400
23	23	0.6	23	1	ACCSSION:184400
24	23	0.6	23	1	ACCSSION:184400
25	23	0.6	23	1	ACCSSION:184400
26	23	0.6	23	1	ACCSSION:184400
27	23	0.6	23	1	ACCSSION:184400
28	22.4	0.6	24	1	ACCSSION:184400
29	22.2	0.6	27	1	ACCSSION:184400
30	22.2	0.6	25	1	ACCSSION:184400
31	22.2	0.6	25	1	ACCSSION:184400
32	22.2	0.6	25	1	ACCSSION:184400
33	22.2	0.6	25	1	ACCSSION:184400

34	21	0.5	21	1	BD243875	ACCSSION:BD243875
35	21	0.5	21	1	AR435628	ACCSSION:AR435628
36	21	0.5	21	1	AR435628	ACCSSION:AR435628
37	21	0.5	25	1	AX754187	ACCSSION:AX754187
38	21	0.5	25	1	AX754192	ACCSSION:AX754192
39	20.6	0.5	51	1	I84400	ACCSSION:I84400
40	20	0.5	20	1	BD243876	ACCSSION:BD243876
41	20	0.5	20	1	AR435629	ACCSSION:AR435629
42	20	0.5	20	1	AR435629	ACCSSION:AR435629
43	20	0.5	25	1	AX754186	ACCSSION:AX754186
44	20	0.5	25	1	AX754193	ACCSSION:AX754193
C 45	19.6	0.5	26	1	BD174259	ACCSSION:BD174259
C 46	19.4	0.5	21	1	AR053160	ACCSSION:AR053160
47	19.4	0.5	21	1	AR084539	ACCSSION:AR084539
48	19.4	0.5	21	1	AR084551	ACCSSION:AR084551
C 49	19.4	0.5	21	1	AR084571	ACCSSION:AR084571
C 50	19.4	0.5	21	1	AR084577	ACCSSION:AR084577
C 51	19.4	0.5	21	1	AR084580	ACCSSION:AR084580
C 52	19.4	0.5	21	1	AR084598	ACCSSION:AR084598
C 53	19.4	0.5	21	1	AX104588	ACCSSION:AX104588
C 54	19.4	0.5	21	1	AX355212	ACCSSION:AX355212
C 55	19.4	0.5	21	1	AX547641	ACCSSION:AX547641
56	19.4	0.5	24	1	BD169605	ACCSSION:BD169605
57	19.4	0.5	24	1	BD182475	ACCSSION:BD182475
58	19.4	0.5	24	1	BD102725	ACCSSION:BD102725
C 59	19	0.5	19	1	BD243879	ACCSSION:BD243879
C 60	19	0.5	19	1	AR435632	ACCSSION:AR435632
C 61	19	0.5	19	1	AR435632	ACCSSION:AR435632
C 62	19	0.5	21	1	AX235403	ACCSSION:AX235403
63	19	0.5	25	1	AX754185	ACCSSION:AX754185
64	19	0.5	25	1	AX754194	ACCSSION:AX754194
C 65	18.8	0.5	22	1	AX360164	ACCSSION:AX360164
66	18.8	0.5	23	1	AX767321	ACCSSION:AX767321
67	18.8	0.5	24	1	AX468116	ACCSSION:AX468116
68	18.8	0.5	25	1	A27143	ACCSSION:A27143
C 69	18.4	0.5	20	1	AR036870	ACCSSION:AR036870
C 70	18.4	0.5	20	1	AR193130	ACCSSION:AR193130
C 71	18.4	0.5	20	1	AX317754	ACCSSION:AX317754
C 72	18.4	0.5	23	1	AX926737	ACCSSION:AX926737
C 73	18.2	0.5	23	1	AR447287	ACCSSION:AR447287
C 74	18.2	0.5	23	1	AR493161	ACCSSION:AR493161
C 75	18	0.5	18	1	BD274822	ACCSSION:BD274822
C 76	18	0.5	18	1	AR205288	ACCSSION:AR205288
C 77	18	0.5	20	1	AX488408	ACCSSION:AX488408
C 78	18	0.5	42	1	A62705	ACCSSION:A62705
C 79	17.8	0.5	21	1	BD235623	ACCSSION:BD235623
80	17.8	0.5	22	1	BD243908	ACCSSION:BD243908
81	17.8	0.5	22	1	AR435659	ACCSSION:AR435659
82	17.8	0.5	22	1	AR453262	ACCSSION:AR453262
C 83	17.8	0.5	22	1	AX207461	ACCSSION:AX207461
84	17.8	0.5	23	1	AX458712	ACCSSION:AX458712
85	17.8	0.5	23	1	AX481219	ACCSSION:AX481219
C 86	17.8	0.5	23	1	AB086529	ACCSSION:AB086529
87	17.4	0.4	19	1	AR038671	ACCSSION:AR038671
C 88	17.4	0.4	20	1	BD244919	ACCSSION:BD244919
C 89	17.4	0.4	20	1	CQ784093	ACCSSION:CQ784093
C 90	17.4	0.4	20	1	AR193157	ACCSSION:AR193157
C 91	17.4	0.4	20	1	AR366677	ACCSSION:AR366677
C 92	17.4	0.4	20	1	AX053082	ACCSSION:AX053082
C 93	17.4	0.4	20	1	AX053091	ACCSSION:AX053091
C 94	17.4	0.4	20	1	AX167902	ACCSSION:AX167902
C 95	17.4	0.4	20	1	AX487367	ACCSSION:AX487367
C 96	17.4	0.4	20	1	AX546302	ACCSSION:AX546302
C 97	17.4	0.4	20	1	AX546392	ACCSSION:AX546392
C 98	17.4	0.4	20	1	BD128017	ACCSSION:BD128017
C 99	17.4	0.4	21	1	BD266062	ACCSSION:BD266062
C 100	17.4	0.4	21	1	AX697037	ACCSSION:AX697037
C 101	17.2	0.4	20	1	AX149325	ACCSSION:AX149325
102	17.2	0.4	22	1	AX088799	ACCSSION:AX088799
103	17	0.4	17	1	AX216911	ACCSSION:AX216911
104	17	0.4	17	1	AX753820	ACCSSION:AX753820
105	17	0.4	17	1	AX753821	ACCSSION:AX753821
106	17	0.4	17	1	AX753822	ACCSSION:AX753822

107	17	0.4	17	1	AX753823	ACCESSION:AX753823	180	15.8	0.4	19	1	AR295468	ACCESSION:AR295468
108	17	0.4	17	1	AX753824	ACCESSION:AX753824	181	15.8	0.4	19	1	AR937835	ACCESSION:AR937835
109	17	0.4	17	1	AX753825	ACCESSION:AX753825	182	15.8	0.4	20	1	AR1336	ACCESSION:AR1336
110	17	0.4	18	1	AR084528	ACCESSION:AR084528	183	15.8	0.4	20	1	A95627	ACCESSION:A95627
111	17	0.4	18	1	AX598368	ACCESSION:AX598368	C 184	15.8	0.4	20	1	AR126724	ACCESSION:AR126724
112	17	0.4	21	1	AX146085	ACCESSION:AX146085	C 185	15.8	0.4	20	1	AR163954	ACCESSION:AR163954
113	16.8	0.4	20	1	BD243911	ACCESSION:BD243911	C 186	15.8	0.4	20	1	BD142670	ACCESSION:BD142670
114	16.8	0.4	20	1	BD243911	ACCESSION:BD243911	C 187	15.8	0.4	20	1	BD266348	ACCESSION:BD266348
115	16.8	0.4	20	1	AR193135	ACCESSION:AR193135	C 188	15.8	0.4	20	1	CQ801587	ACCESSION:CQ801587
116	16.8	0.4	20	1	AR193155	ACCESSION:AR193155	C 189	15.8	0.4	20	1	AR193134	ACCESSION:AR193134
117	16.8	0.4	20	1	AR366676	ACCESSION:AR366676	C 190	15.8	0.4	20	1	AR221426	ACCESSION:AR221426
118	16.8	0.4	20	1	AR428075	ACCESSION:AR428075	C 191	15.8	0.4	20	1	AR312313	ACCESSION:AR312313
119	16.8	0.4	20	1	AR435662	ACCESSION:AR435662	C 192	15.8	0.4	20	1	AR315939	ACCESSION:AR315939
120	16.8	0.4	20	1	AR453265	ACCESSION:AR453265	C 193	15.8	0.4	20	1	AR342452	ACCESSION:AR342452
121	16.8	0.4	20	1	AR559473	ACCESSION:AR559473	C 194	15.8	0.4	20	1	AR342476	ACCESSION:AR342476
122	16.8	0.4	20	1	AX241159	ACCESSION:AX241159	C 195	15.8	0.4	20	1	AR342848	ACCESSION:AR342848
123	16.8	0.4	20	1	AX486754	ACCESSION:AX486754	C 196	15.8	0.4	20	1	AR429226	ACCESSION:AR429226
124	16.8	0.4	20	1	AX487218	ACCESSION:AX487218	C 197	15.8	0.4	20	1	AX076817	ACCESSION:AX076817
125	16.8	0.4	20	1	BD089219	ACCESSION:BD089219	C 198	15.8	0.4	20	1	AX139720	ACCESSION:AX139720
126	16.8	0.4	20	1	AB068052	ACCESSION:AB068052	C 199	15.8	0.4	20	1	AX149057	ACCESSION:AX149057
127	16.8	0.4	21	1	CQ846768	ACCESSION:CQ846768	C 200	15.8	0.4	20	1	BD075817	ACCESSION:BD075817
128	16.8	0.4	21	1	CQ846786	ACCESSION:CQ846786	C 201	15.8	0.4	20	1	BD091431	ACCESSION:BD091431
129	16.6	0.4	31	1	AR078304	ACCESSION:AR078304	C 202	15.8	0.4	21	1	AR084552	ACCESSION:AR084552
130	16.6	0.4	33	1	AR084540	ACCESSION:AR084540	C 203	15.8	0.4	21	1	AR084564	ACCESSION:AR084564
131	16.6	0.4	36	1	AR084542	ACCESSION:AR084542	C 204	15.8	0.4	21	1	AR084570	ACCESSION:AR084570
132	16.4	0.4	18	1	AR134262	ACCESSION:AR134262	C 205	15.8	0.4	21	1	AR084575	ACCESSION:AR084575
133	16.4	0.4	18	1	AR137293	ACCESSION:AR137293	C 206	15.8	0.4	21	1	AR084581	ACCESSION:AR084581
134	16.4	0.4	18	1	AR137299	ACCESSION:AR137299	C 207	15.8	0.4	21	1	AR084594	ACCESSION:AR084594
135	16.4	0.4	18	1	BD231276	ACCESSION:BD231276	C 208	15.8	0.4	21	1	AR097224	ACCESSION:AR097224
136	16.4	0.4	18	1	BD231282	ACCESSION:BD231282	C 209	15.8	0.4	21	1	AR139576	ACCESSION:AR139576
137	16.4	0.4	18	1	AX037415	ACCESSION:AX037415	C 210	15.8	0.4	21	1	BD223665	ACCESSION:BD223665
138	16.4	0.4	18	1	AX037421	ACCESSION:AX037421	C 211	15.8	0.4	21	1	BD250882	ACCESSION:BD250882
139	16.4	0.4	18	1	BD075167	ACCESSION:BD075167	C 212	15.8	0.4	21	1	E30433	ACCESSION:E30433
140	16.4	0.4	18	1	BD075173	ACCESSION:BD075173	C 213	15.8	0.4	21	1	I95513	ACCESSION:I95513
141	16.4	0.4	20	1	AR108646	ACCESSION:AR108646	C 214	15.8	0.4	21	1	AR530576	ACCESSION:AR530576
142	16.4	0.4	20	1	AR126643	ACCESSION:AR126643	C 215	15.8	0.4	21	1	AX096601	ACCESSION:AX096601
143	16.4	0.4	20	1	AR223403	ACCESSION:AR223403	C 216	15.8	0.4	21	1	AX0706249	ACCESSION:AX0706249
144	16.4	0.4	20	1	AR424698	ACCESSION:AR424698	C 217	15.6	0.4	30	1	AR045389	ACCESSION:AR045389
145	16.4	0.4	20	1	AR492683	ACCESSION:AR492683	C 218	15.6	0.4	30	1	AR045395	ACCESSION:AR045395
146	16.4	0.4	20	1	AX486781	ACCESSION:AX486781	C 219	15.6	0.4	30	1	AR165925	ACCESSION:AR165925
147	16.4	0.4	20	1	AX764064	ACCESSION:AX764064	C 220	15.6	0.4	30	1	E34522	ACCESSION:E34522
148	16.4	0.4	20	1	AX764066	ACCESSION:AX764066	C 221	15.6	0.4	30	1	I84405	ACCESSION:I84405
149	16.4	0.4	21	1	A64605	ACCESSION:A64605	C 222	15.4	0.4	17	1	AR045387	ACCESSION:AR045387
150	16.4	0.4	21	1	CQ846769	ACCESSION:CQ846769	C 223	15.4	0.4	17	1	AR045389	ACCESSION:AR045389
151	16.4	0.4	21	1	CQ846771	ACCESSION:CQ846771	C 224	15.4	0.4	17	1	AR045395	ACCESSION:AR045395
152	16.4	0.4	21	1	CQ846787	ACCESSION:CQ846787	C 225	15.4	0.4	17	1	BD253914	ACCESSION:BD253914
153	16.4	0.4	21	1	AR241911	ACCESSION:AR241911	C 226	15.4	0.4	17	1	CQ623062	ACCESSION:CQ623062
154	16.2	0.4	21	1	AR072482	ACCESSION:AR072482	C 227	15.4	0.4	17	1	I44894	ACCESSION:I44894
155	16.2	0.4	21	1	BD243871	ACCESSION:BD243871	C 228	15.4	0.4	17	1	I52439	ACCESSION:I52439
156	16.2	0.4	21	1	CQ846801	ACCESSION:CQ846801	C 229	15.4	0.4	17	1	I52441	ACCESSION:I52441
157	16.2	0.4	21	1	AR435624	ACCESSION:AR435624	C 230	15.4	0.4	17	1	I52447	ACCESSION:I52447
158	16.2	0.4	21	1	AR453225	ACCESSION:AR453225	C 231	15.4	0.4	17	1	AR327104	ACCESSION:AR327104
159	16.2	0.4	31	1	AX249447	ACCESSION:AX249447	C 232	15.4	0.4	17	1	AR464125	ACCESSION:AR464125
160	16	0.4	16	1	A35651	ACCESSION:A35651	C 233	15.4	0.4	17	1	AX004427	ACCESSION:AX004427
161	16	0.4	16	1	A35684	ACCESSION:A35684	C 234	15.4	0.4	17	1	AX215324	ACCESSION:AX215324
162	16	0.4	17	1	AX216912	ACCESSION:AX216912	C 235	15.4	0.4	17	1	AX215325	ACCESSION:AX215325
163	16	0.4	17	1	AX272814	ACCESSION:AX272814	C 236	15.4	0.4	17	1	AX216107	ACCESSION:AX216107
164	16	0.4	17	1	AX272955	ACCESSION:AX272955	C 237	15.4	0.4	17	1	AX216112	ACCESSION:AX216112
165	16	0.4	17	1	AX753819	ACCESSION:AX753819	C 238	15.4	0.4	17	1	AX216350	ACCESSION:AX216350
166	16	0.4	17	1	AX753826	ACCESSION:AX753826	C 239	15.4	0.4	17	1	AX216928	ACCESSION:AX216928
167	16	0.4	18	1	AR121115	ACCESSION:AR121115	C 240	15.4	0.4	17	1	AX273039	ACCESSION:AX273039
168	16	0.4	18	1	AR134263	ACCESSION:AR134263	C 241	15.4	0.4	17	1	AX423572	ACCESSION:AX423572
169	16	0.4	20	1	AR107612	ACCESSION:AR107612	C 242	15.4	0.4	17	1	AX530712	ACCESSION:AX530712
170	16	0.4	20	1	AR107613	ACCESSION:AR107613	C 243	15.4	0.4	17	1	AX738227	ACCESSION:AX738227
171	16	0.4	20	1	AR107614	ACCESSION:AR107614	C 244	15.4	0.4	17	1	AX753836	ACCESSION:AX753836
172	16	0.4	20	1	AR107615	ACCESSION:AR107615	C 245	15.4	0.4	18	1	CQ816652	ACCESSION:CQ816652
173	16	0.4	20	1	AR107616	ACCESSION:AR107616	C 246	15.4	0.4	18	1	AR229576	ACCESSION:AR229576
174	16	0.4	20	1	AX053083	ACCESSION:AX053083	C 247	15.4	0.4	18	1	AR229577	ACCESSION:AR229577
175	16	0.4	20	1	AX053092	ACCESSION:AX053092	C 248	15.4	0.4	18	1	AR336922	ACCESSION:AR336922
176	16	0.4	20	1	AX546303	ACCESSION:AX546303	C 249	15.4	0.4	18	1	AX398208	ACCESSION:AX398208
177	16	0.4	20	1	AX546393	ACCESSION:AX546393	C 250	15.4	0.4	18	1	AX663784	ACCESSION:AX663784
178	16	0.4	21	1	AR530865	ACCESSION:AR530865	C 251	15.4	0.4	18	1	BD097068	ACCESSION:BD097068
179	16	0.4	21	1	AX096890	ACCESSION:AX096890	C 252	15.4	0.4	19	1	AR267638	ACCESSION:AR267638

```
C 253 15.4 0.4 19 1 AR293745
C 254 15.4 0.4 20 1 AR086207
C 255 15.4 0.4 20 1 AR108704
C 256 15.4 0.4 20 1 AR176773
C 257 15.4 0.4 20 1 BD143962
C 258 15.4 0.4 20 1 CO868870
C 259 15.4 0.4 20 1 AR224718
C 260 15.4 0.4 20 1 AR261783
C 261 15.4 0.4 20 1 AR489922
C 262 15.4 0.4 20 1 AX662846
C 263 15.2 0.4 20 1 DOG2144P01
C 264 15.2 0.4 20 1 AR103769
C 265 15.2 0.4 20 1 AR117718
C 266 15.2 0.4 20 1 AR121002
C 267 15.2 0.4 20 1 AR129483
C 268 15.2 0.4 20 1 AR130120
C 269 15.2 0.4 20 1 AR130133
C 270 15.2 0.4 20 1 AR159548
C 271 15.2 0.4 20 1 AR162425
C 272 15.2 0.4 20 1 AR163981
C 273 15.2 0.4 20 1 BD230672
C 274 15.2 0.4 20 1 BD250356
C 275 15.2 0.4 20 1 BD272623
C 276 15.2 0.4 20 1 CO784337
C 277 15.2 0.4 20 1 AR193126
C 278 15.2 0.4 20 1 AR193131
C 279 15.2 0.4 20 1 AR193159
C 280 15.2 0.4 20 1 AR225891
C 281 15.2 0.4 20 1 AR231469
C 282 15.2 0.4 20 1 AR314455
C 283 15.2 0.4 20 1 AR337050
C 284 15.2 0.4 20 1 AR373625
C 285 15.2 0.4 20 1 AR531371
C 286 15.2 0.4 20 1 AX038745
C 287 15.2 0.4 20 1 AX149138
C 288 15.2 0.4 20 1 AX164704
C 289 15.2 0.4 20 1 AX294455
C 290 15.2 0.4 20 1 AX295117
C 291 15.2 0.4 20 1 AX297351
C 292 15.2 0.4 20 1 AX418622
C 293 15.2 0.4 20 1 AX467415
C 294 15.2 0.4 20 1 AX611052
C 295 15.2 0.4 20 1 BD062072
C 296 15.2 0.4 20 1 BD128261
C 297 15.2 0.4 20 1 BD129999
```

ALIGNMENTS

```
RESULT 1
184400/C
LOCUS 184400 51 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 1 from patent US 5695933.
ACCESSION 184400
VERSION 184400.1 GI:3021920
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 51)
AUTHORS Schalling,M., Hudson,T.J. and Housman,D.E.
TITLE Direct detection of expanded nucleotide repeats in the human genome
JOURNAL Patent: US 5695933-A 1 09-DEC-1997;
FEATURES
source
1..51
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 41.4; DB 1; Length 51;
Best Local Similarity 88.2%; Pred. No. 0.94;
Matches 45; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
```

```
1441 CTGACGACGACCAACAGCAGCAGCTTCAGAAACAGCAGCAGCAG 1491
Db | ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
51 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 1
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
RESULT 2
A62705 42 bp DNA linear PAT 12-MAR-1998
LOCUS Sequence 6 from Patent WO9717445.
DEFINITION A62705
ACCESSION A62705
VERSION A62705.1 GI:3716589
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Torä,L., Lutz,Y., Trottier,Y., Mandel and Jean-Louis.
TITLE METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING A 1C2 ANTIBODY
OR A FRAGMENT OR DERIVATIVE THEREOF, AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS
JOURNAL Patent: WO 9717445-A 6 15-MAY-1997;
COMMENT CENTRE NAT RECH SCIENT (FR)
FEATURES
source
1..42
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/clone="AAD20"
Query Match 0.9%; Score 34; DB 1; Length 42;
Best Local Similarity 88.1%; Pred. No. 5.1;
Matches 37; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
1444 CAGCAGCAGCAGCAGCAGCAGCAGCTTCAGAAACAGCAGCAG 1485
Db | ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 42
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
RESULT 3
A62704 36 bp DNA linear PAT 12-MAR-1998
LOCUS Sequence 5 from Patent WO9717445.
DEFINITION A62704
ACCESSION A62704.1 GI:3716588
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Torä,L., Lutz,Y., Trottier,Y., Mandel and Jean-Louis.
TITLE METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING A 1C2 ANTIBODY
OR A FRAGMENT OR DERIVATIVE THEREOF, AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS
JOURNAL Patent: WO 9717445-A 5 15-MAY-1997;
COMMENT CENTRE NAT RECH SCIENT (FR)
FEATURES
source
1..36
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/clone="DAN26"
Query Match 0.8%; Score 31.2; DB 1; Length 36;
Best Local Similarity 91.7%; Pred. No. 8.4;
Matches 33; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
1456 CAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCAG 1491
Db | ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 36
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```

```
RESULT 4
AR084540/c
LOCUS AR084540 33 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 29 from patent US 5981185.
ACCESSION AR084540
VERSION AR084540.1 GI:10011311
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 33)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 29 09-NOV-1999;
FEATURES
    source
        Location/Qualifiers
            1..33
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 29.4; DB 1; Length 33;
Best Local Similarity 96.8%; Pred. No. 12;
Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
Db 33 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 3

RESULT 5
AR084541
LOCUS AR084541 30 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 30 from patent US 5981185.
ACCESSION AR084541
VERSION AR084541.1 GI:10011312
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 30 09-NOV-1999;
FEATURES
    source
        Location/Qualifiers
            1..30
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 6
AR165925
LOCUS AR165925 30 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 4 from patent US 6280938.
ACCESSION AR165925
VERSION AR165925.1 GI:16241014
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Ranum,L.P.W., Koob,M.D., Moseley-Allredge,M.L. and Benzow,K.A.
TITLE SCA7 gene and method of use
JOURNAL Patent: US 6280938-A 4 28-AUG-2001;
FEATURES
    source
        Location/Qualifiers
            1..30
                /organism="unknown"

RESULT 7
E34522
LOCUS E34522 30 bp DNA linear PAT 18-JUN-2001;
DEFINITION SCA7 gene and utilization thereof.
ACCESSION E34522
VERSION E34522.1 GI:13018890
KEYWORDS JP 1999206393-A/4.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 30)
AUTHORS Laura,B.W.R. and Michael,D.K.
TITLE SCA7 Gene and utilization thereof
JOURNAL Patent: JP 1999206393-A 4 03-AUG-1999;
COMMENT THE REGENTS OF THE UNIVERSITY OF MINNESOTA
OS Homo sapiens (human)
PN JP 1999206393-A/4
PD 03-AUG-1999
PF 19-AUG-1998 JP 1998294732
PR 19-AUG-1997 US 60/056170
PI LAURA B W RANUM,MICHAEL D KUBU
PC C12N15/09,C07K14/47,C07K16/18,C12Q1/68,G01N33/53, PC
G01N33/566//C12P21/02,
PC C12N15/00
CC
FH Key Location/Qualifiers
FT source
    Location/Qualifiers
        1..30
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

RESULT 8
I84405
LOCUS I84405 30 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 6 from patent US 5695933.
ACCESSION I84405
VERSION I84405.1 GI:3021925
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Schalling,M., Hudson,T.J. and Housman,D.E.
TITLE Direct detection of expanded nucleotide repeats in the human genome
JOURNAL Patent: US 5695933-A 6 09-DEC-1997;
FEATURES
    source
        Location/Qualifiers
            1..30
                /organism="unknown"
                /mol_type="unassigned DNA"

/mol_type="unassigned DNA"
```


Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 9
184410/c
LOCUS 184410 30 bp DNA PAT 04-APR-1998
DEFINITION Sequence 11 from patent US 5695933.
ACCESSION 184410
VERSION 184410.1 GI:3021930
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Schalling, M., Hudson, T.J. and Housman, D.E.
TITLE Direct detection of expanded nucleotide repeats in the human genome
JOURNAL Patent: US 5695933-A 11 09-DEC-1997;
FEATURES
Location/Qualifiers
source 1..30
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 30 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 1

RESULT 10
AR078304
LOCUS AR078304 31 bp DNA PAT 31-AUG-2000
DEFINITION Sequence 14 from patent US 5962332.
ACCESSION AR078304
VERSION AR078304.1 GI:10005050
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 31)
AUTHORS Singer, R.H. and Taneja, K.L.
TITLE Detection of trinucleotide repeats by in situ hybridization
JOURNAL Patent: US 5962332-A 14 05-OCT-1999;
FEATURES
Location/Qualifiers
source 1..31
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 28.4; DB 1; Length 31;
Best Local Similarity 96.7%; Pred. No. 14;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 11
AR241963
LOCUS AR241963 33 bp DNA PAT 20-DEC-2002
DEFINITION Sequence 251 from patent US 6472154.
ACCESSION AR241963
VERSION AR241963.1 GI:27287775
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 33)
AUTHORS Garner, H.R., Wren, J.D., Minna, J.D. and Fondon, J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 251 29-OCT-2002;
FEATURES
Location/Qualifiers
source 1..33
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 27.8; DB 1; Length 33;
Best Local Similarity 93.5%; Pred. No. 18;
Matches 29; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGTAGCAGC 31

RESULT 12
AR084542
LOCUS AR084542 36 bp DNA PAT 01-SEP-2000
DEFINITION Sequence 31 from patent US 5981185.
ACCESSION AR084542
VERSION AR084542.1 GI:10011313
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 36)
AUTHORS Matson, R.S., Coassin, P.J., Rampal, J.B. and Caskey, C. Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 31 09-NOV-1999;
FEATURES
Location/Qualifiers
source 1..36
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 27.2; DB 1; Length 36;
Best Local Similarity 90.6%; Pred. No. 25;
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1148
|||||
Db 2 CAGCAGCAGCAGCAGCAGCAGCAGCAGCGCGCG 33

RESULT 13
AR316834/c
LOCUS AR316834 31 bp DNA PAT 17-AUG-2003
DEFINITION Sequence 27 from patent US 6562580.
ACCESSION AR316834
VERSION AR316834.1 GI:33695825
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 31)
AUTHORS Fu, C.A.
TITLE Germinal center kinase cell cycle proteins, compositions and methods of use
JOURNAL Patent: US 6562580-A 27 13-MAY-2003;
FEATURES
Location/Qualifiers
source 1..31
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 26.2; DB 1; Length 31;
Best Local Similarity 90.3%; Pred. No. 25;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

Qy 152 AGCTGGTGCATCAAGTTCATGGATGTCAC 182
Db 31 AGCTTGAGCCATCAAGTTATGGATGTCAC 1

RESULT 14
AR316859/c
LOCUS AR316859 31 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 27 from patent US 6562591.
ACCESSION AR316859
VERSION AR316859.1 GI:33695925
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 31)
AUTHORS Luo, Y., Fu, C.A. and Shen, M.
TITLE Germinal center kinase cell cycle proteins, compositions and
methods of use
JOURNAL Patent: US 6562591-A 27 13-MAY-2003;
FEATURES Location/Qualifiers
source
1..31
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 26.2; DB 1; Length 31;
Best Local Similarity 90.3%; Pred. No. 25;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 152 AGCTGGTGCATCAAGTTCATGGATGTCAC 182
Db 31 AGCTTGAGCCATCAAGTTATGGATGTCAC 1

RESULT 15
AR338493/c
LOCUS AR338493 31 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 27 from patent US 6569658.
ACCESSION AR338493
VERSION AR338493.1 GI:33725301
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 31)
AUTHORS Luo, Y., Fu, C.A. and Shen, M.
TITLE Germinal center kinase cell cycle proteins
JOURNAL Patent: US 6569658-A 27 27-MAY-2003;
FEATURES Location/Qualifiers
source
1..31
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 26.2; DB 1; Length 31;
Best Local Similarity 90.3%; Pred. No. 25;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 152 AGCTGGTGCATCAAGTTCATGGATGTCAC 182
Db 31 AGCTTGAGCCATCAAGTTATGGATGTCAC 1

RESULT 16
AX127212/c
LOCUS AX127212 31 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 27 from Patent WO0129197.
ACCESSION AX127212
VERSION AX127212.1 GI:14041170
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
synthetic construct
other sequences; artificial sequences.

Qy 152 AGCTGGTGCATCAAGTTCATGGATGTCAC 182
Db 31 AGCTTGAGCCATCAAGTTATGGATGTCAC 1

RESULT 17
AX249447
LOCUS AX249447 31 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 1526 from Patent WO0166800.
ACCESSION AX249447
VERSION AX249447.1 GI:15864070
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Cargill, M., Ireland, J.S. and Lander, E.S.
TITLE Human single nucleotide polymorphisms
JOURNAL Patent: WO 0166800-A 1526 13-SEP-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES Location/Qualifiers
source
1..31
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 24.8; DB 1; Length 31;
Best Local Similarity 86.7%; Pred. No. 37;
Matches 26; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1119 GCAGCAGCAGCTGCAGCAGCAGCAGCAGCG 1148
Db 2 GCAGCGCAGCGCGCGCAGCGCAGCGCAGCG 31

RESULT 18
AR316833
LOCUS AR316833 31 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6562580.
ACCESSION AR316833
VERSION AR316833.1 GI:33695824
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 31)
AUTHORS Fu, C.A.
TITLE Germinal center kinase cell cycle proteins, compositions and
methods of use
JOURNAL Patent: US 6562580-A 26 13-MAY-2003;
FEATURES Location/Qualifiers
source
1..31
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 24.6; DB 1; Length 31;

```

```

AUTHORS Luo, Y., Fu, C.A. and Shen, M.
TITLE Novel germinal center kinase cell cycle proteins, compositions and
methods of use
JOURNAL Patent: WO 0129197-A 27 26-APR-2001;
Rigel Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source
1..31
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="synthetic"

```

```

Query Match 0.7%; Score 26.2; DB 1; Length 31;
Best Local Similarity 90.3%; Pred. No. 25;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 152 AGCTGGTGCATCAAGTTCATGGATGTCAC 182
Db 31 AGCTTGAGCCATCAAGTTATGGATGTCAC 1

```

```

RESULT 17
AX249447
LOCUS AX249447 31 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 1526 from Patent WO0166800.
ACCESSION AX249447
VERSION AX249447.1 GI:15864070
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Cargill, M., Ireland, J.S. and Lander, E.S.
TITLE Human single nucleotide polymorphisms
JOURNAL Patent: WO 0166800-A 1526 13-SEP-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES Location/Qualifiers
source
1..31
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

```

Query Match 0.6%; Score 24.8; DB 1; Length 31;
Best Local Similarity 86.7%; Pred. No. 37;
Matches 26; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1119 GCAGCAGCAGCTGCAGCAGCAGCAGCAGCG 1148
Db 2 GCAGCGCAGCGCGCGCAGCGCAGCGCAGCG 31

```

```

RESULT 18
AR316833
LOCUS AR316833 31 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6562580.
ACCESSION AR316833
VERSION AR316833.1 GI:33695824
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 31)
AUTHORS Fu, C.A.
TITLE Germinal center kinase cell cycle proteins, compositions and
methods of use
JOURNAL Patent: US 6562580-A 26 13-MAY-2003;
FEATURES Location/Qualifiers
source
1..31
/organism="unknown"
/mol_type="genomic DNA"

```

```

Query Match 0.6%; Score 24.6; DB 1; Length 31;

```

```
Best Local Similarity 87.1%; Pred. No. 39;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGTCCATCAAGGTCATGGATGTAC 182
||||| ||||||| ||||||| ||||||| |||||||
Db 1 AGCTGCAGCCATCAGGGTTATGGATGTAC 31

RESULT 19
AR316858
LOCUS AR316858 31 bp DNA PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6562591.
ACCESSION AR316858
VERSION AR316858.1 GI:33695924
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 31)
AUTHORS Luo, Y., Fu, C.A. and Shen, M.
TITLE Germinal center kinase cell cycle proteins, compositions and
methods of use
JOURNAL Patent: US 6562591-A 26 13-MAY-2003;
FEATURES Location/Qualifiers
source 1..31
/mol_type="genomic DNA"

Query Match 0.6%; Score 24.6; DB 1; Length 31;
Best Local Similarity 87.1%; Pred. No. 39;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGTCCATCAAGGTCATGGATGTAC 182
||||| ||||||| ||||||| ||||||| |||||||
Db 1 AGCTGCAGCCATCAGGGTTATGGATGTAC 31

RESULT 20
AR338492
LOCUS AR338492 31 bp DNA PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6569658.
ACCESSION AR338492
VERSION AR338492.1 GI:33725300
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 31)
AUTHORS Luo, Y., Fu, C.A. and Shen, M.
TITLE Germinal center kinase cell cycle proteins
JOURNAL Patent: US 6569658-A 26 27-MAY-2003;
FEATURES Location/Qualifiers
source 1..31
/mol_type="genomic DNA"

Query Match 0.6%; Score 24.6; DB 1; Length 31;
Best Local Similarity 87.1%; Pred. No. 39;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGTCCATCAAGGTCATGGATGTAC 182
||||| ||||||| ||||||| ||||||| |||||||
Db 1 AGCTGCAGCCATCAGGGTTATGGATGTAC 31

RESULT 21
AX127211
LOCUS AX127211 31 bp DNA PAT 11-MAY-2001
DEFINITION Sequence 26 from Patent WO0129197.
ACCESSION AX127211
VERSION AX127211.1 GI:14041169
KEYWORDS
SOURCE synthetic construct

Best Local Similarity 87.1%; Pred. No. 39;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGTCCATCAAGGTCATGGATGTAC 182
||||| ||||||| ||||||| ||||||| |||||||
Db 1 AGCTGCAGCCATCAGGGTTATGGATGTAC 31

RESULT 22
BD243877/c
LOCUS BD243877/c 23 bp DNA linear PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
ACCESSION BD243877
VERSION BD243877.1 GI:33053647
KEYWORDS JP 2002522009-A/39.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman, G., Martinez, R. and Whyte, D.
TITLE STE20-related protein kinases
JOURNAL Patent: JP 2002522009-A 39 23-JUL-2002;
COMMENT SUGEN INC
OS Artificial Sequence
PN JP 2002522009-A/39
PD 23-JUL-2002
PF 13-APR-1999 JP 2000543584
PR 14-APR-1998 US 60/081784
PI GREGORY PLOWMAN, RICARDO MARTINEZ, DAVID WHYTE
PC Cl2N15/09, A61K38/55, A61P9/00, A61P13/12, A61P25/00, PC
A61P35/00,
PC A61P37/00, C07K16/40, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/
PC 12, C12Q1/68,
PC Cl2N15/00, A61K37/64, C12N5/00
CC Synthesized nucleic acid molecule
FH Key Location/Qualifiers
FT source 1..23
/mol_type="Artificial Sequence".
FEATURES Location/Qualifiers
source 1..23
/mol_type="synthetic construct"
/db_xref="taxon:32630"

Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3454 ACAGTAGAGGGGGCAGCGGCT 3476
||||| ||||||| ||||||| ||||||| |||||||
Db 23 ACAGTAGAGGGGGCAGCGGCT 1

RESULT 23
BD243878
LOCUS BD243878 23 bp DNA linear PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
```

```
ACCESSION BD243878
VERSION BD243878.1 GI:33053648
KEYWORDS JP 2002522009-A/40,
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE STE20-related protein kinases
JOURNAL Patent: JP 2002522009-A 40 23-JUL-2002;
SUGEN INC
COMMENT OS Artificial Sequence
PN JP 2002522009-A/40
PD 23-JUL-2002
PF 13-APR-1999 JP 2000543584
PR 14-APR-1998 US 60/081784
PI GREGORY PLOWMAN,RICARDO MARTINEZ,DAVID WHYTE
PC C12N15/09,A61K38/55,A61P9/00,A61P13/12,A61P25/00, PC
A61P35/00,
PC A61P37/00,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/
12,C12O1/68,
PC C12N15/00,A61K37/64,C12N5/00
CC Synthesized nucleic acid molecule
FH Key Location/Qualifiers
FT source 1..23
FEATURES
source
Location/Qualifiers
1..23
/organism="Artificial Sequence".
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 242 ACCGCAACATCGCCACTACTAC 264
Db 1 ACCGCAACATCGCCACTACTAC 23
RESULT 24
AR435630/c
LOCUS AR435630 23 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 60 from patent US 6656716.
ACCESSION AR435630
VERSION AR435630.1 GI:40198611
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polypeptide fragments of human PAK5 protein kinase
JOURNAL Patent: US 6656716-A 60 02-DEC-2003;
FEATURES
source
Location/Qualifiers
1..23
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 242 ACCGCAACATCGCCACTACTAC 264
Db 1 ACCGCAACATCGCCACTACTAC 23
RESULT 24
AR435630/c
LOCUS AR435630 23 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 60 from patent US 6656716.
ACCESSION AR435630
VERSION AR435630.1 GI:40198611
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polypeptide fragments of human PAK5 protein kinase
JOURNAL Patent: US 6656716-A 60 02-DEC-2003;
FEATURES
source
Location/Qualifiers
1..23
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3454 ACAGTAGAGGAGGGGCGCGCT 3476
Db 23 ACAGTAGAGGAGGGGCGCGCT 1
RESULT 25
AR435631
LOCUS AR435631 23 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 61 from patent US 6656716.
ACCESSION AR435631
VERSION AR435631.1 GI:40198612
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polypeptide fragments of human PAK5 protein kinase
JOURNAL Patent: US 6656716-A 61 02-DEC-2003;
FEATURES
source
Location/Qualifiers
1..23
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 242 ACCGCAACATCGCCACTACTAC 264
Db 1 ACCGCAACATCGCCACTACTAC 23
RESULT 26
AR453231/c
LOCUS AR453231 23 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 60 from patent US 6680170.
ACCESSION AR453231
VERSION AR453231.1 GI:42685485
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polynucleotides encoding STE20-related protein kinases and methods of use
JOURNAL Patent: US 6680170-A 60 20-JAN-2004;
FEATURES
source
Location/Qualifiers
1..23
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3454 ACAGTAGAGGAGGGGCGCGCT 3476
Db 23 ACAGTAGAGGAGGGGCGCGCT 1
RESULT 27
AR453232
LOCUS AR453232 23 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 61 from patent US 6680170.
ACCESSION AR453232
VERSION AR453232.1 GI:42685486
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polynucleotides encoding STE20-related protein kinases and methods of use
JOURNAL Patent: US 6680170-A 61 20-JAN-2004;
FEATURES
source
Location/Qualifiers
1..23
/organism="unknown"
/mol_type="genomic DNA"
```

Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 242 ACCGCAACATGCCACCTACTAC 264
|||||
Db 1 ACCGCAACATGCCACCTACTAC 23
|||||

RESULT 28
AX754188
LOCUS AR084605 24 bp DNA PAT 01-SEP-2000
DEFINITION Sequence 94 from patent US 5981185.
ACCESSION AR084605
VERSION AR084605.1 GI:10011376
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 94 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 44;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1119 GCAGCAGCAGCTGCAGCAGCAGCA 1142
|||||
Db 1 GCAGCAGCAGCAGCAGCAGCA 24
|||||

RESULT 29
AX754188
LOCUS AR193121 27 bp DNA PAT 20-APR-2002
DEFINITION Sequence 6 from patent US 6346416.
ACCESSION AR193121
VERSION AR193121.1 GI:20239086
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dean,N.M. and Cowser,L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 6 12-FEB-2002;
FEATURES Location/Qualifiers
source
1..27
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 22.2; DB 1; Length 27;
Best Local Similarity 88.9%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 467 TCAAGGGCCAGAGTGTGCTGTGACAG 493
- 1 TCAAGGGCCAGAGTGTGCTGTGACTG 27
|||||

RESULT 30
AX754188
LOCUS AX754188 25 bp DNA PAT 23-JUN-2003
DEFINITION Sequence 535 from Patent WO03037931.
ACCESSION AX754188
VERSION AX754188.1 GI:32166885
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Shannon,M. and Phan,T.
AUTHORS Human angiotensin-like protein 1
TITLE Patent: WO 03037931-A 535 08-MAY-2003;
JOURNAL Amersham Biosciences SV Corp. (US)
FEATURES Location/Qualifiers
source
1..25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 GCAGCAGCAGCAACAGCAGCAG 1464
|||||
Db 4 GCAGCAGCAGCAACAGCAGCAG 25
|||||

RESULT 31
AX754189
LOCUS AX754189 25 bp DNA PAT 23-JUN-2003
DEFINITION Sequence 536 from Patent WO03037931.
ACCESSION AX754189
VERSION AX754189.1 GI:32166886
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Shannon,M. and Phan,T.
AUTHORS Human angiotensin-like protein 1
TITLE Patent: WO 03037931-A 536 08-MAY-2003;
JOURNAL Amersham Biosciences SV Corp. (US)
FEATURES Location/Qualifiers
source
1..25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 GCAGCAGCAGCAACAGCAGCAG 1464
|||||
Db 3 GCAGCAGCAGCAACAGCAGCAG 24
|||||

RESULT 32
AX754190
LOCUS AX754190 25 bp DNA PAT 23-JUN-2003
DEFINITION Sequence 537 from Patent WO03037931.
ACCESSION AX754190
VERSION AX754190.1 GI:32166887
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Shannon,M. and Phan,T.
AUTHORS Human angiotensin-like protein 1
TITLE Patent: WO 03037931-A 537 08-MAY-2003;
JOURNAL Amersham Biosciences SV Corp. (US)
FEATURES Location/Qualifiers
source
1..25
/organism="Homo sapiens"

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
  0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 GCAGCAGCAGCAACAGCAGCAG 1464
|||||
Db 2 GCAGCAGCAGCAACAGCAGCAG 23

RESULT 33
AX754191
LOCUS AX754191 25 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 538 from Patent WO03037931.
ACCESSION AX754191
VERSION AX754191.1 GI:32166988
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 538 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
  source
    location/Qualifiers
      1..25
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 GCAGCAGCAGCAACAGCAGCAG 1464
|||||
Db 1 GCAGCAGCAGCAACAGCAGCAG 22

RESULT 34
BD243875
LOCUS BD243875 21 bp DNA linear PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
ACCESSION BD243875
VERSION BD243875.1 GI:33053645
KEYWORDS JP 2002522009-A/37.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE STE20-related protein kinases
JOURNAL Patent: JP 2002522009-A 37 23-JUL-2002;
SUGEN INC
COMMENT OS Artificial Sequence
PN JP 2002522009-A/37
PD 23-JUL-2002
PF 13-APR-1998 US 60/081784
PR 14-APR-1998 JP 2000543584
PI GREGORY PLOWMAN,RICARDO MARTINEZ,DAVID WHYTE
PC .C12N15/09,A61K38/55,A61P9/10,A61P13/12,A61P25/00,PC
A61P35/00,
PC A61P37/00,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/
PC 12,C12Q1/68,
PC C12N15/00,A61K37/64,C12N5/00
CC Synthesized nucleic acid molecule
FH Key Location/Qualifiers
FT source 1..21
/organism='Artificial Sequence'.

/mol_type="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
  0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3379 CCCAAACCTTACCACAAATTC 3399
|||||
Db 1 CCCAAACCTTACCACAAATTC 21

RESULT 35
AR435628
LOCUS AR435628 21 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 58 from patent US 6656716.
ACCESSION AR435628
VERSION AR435628.1 GI:40198609
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polypeptide fragments of human PAK5 protein kinase
JOURNAL Patent: US 6656716-A 58 02-DEC-2003;
LOCATION/Qualifiers
  source
    location/Qualifiers
      1..21
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
  0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3379 CCCAAACCTTACCACAAATTC 3399
|||||
Db 1 CCCAAACCTTACCACAAATTC 21

RESULT 36
AR453229
LOCUS AR453229 21 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 58 from patent US 6680170.
ACCESSION AR453229
VERSION AR453229.1 GI:42685483
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polynucleotides encoding STE20-related protein kinases and methods of use
JOURNAL Patent: US 6680170-A 58 20-JAN-2004;
FEATURES
  source
    location/Qualifiers
      1..21
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
  0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3379 CCCAAACCTTACCACAAATTC 3399
|||||
Db 1 CCCAAACCTTACCACAAATTC 21

RESULT 37
AR453229
LOCUS AR453229 21 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 58 from patent US 6680170.
ACCESSION AR453229
VERSION AR453229.1 GI:42685483
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE Polynucleotides encoding STE20-related protein kinases and methods of use
JOURNAL Patent: US 6680170-A 58 20-JAN-2004;
FEATURES
  source
    location/Qualifiers
      1..21
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
  0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3379 CCCAAACCTTACCACAAATTC 3399
|||||
Db 1 CCCAAACCTTACCACAAATTC 21

RESULT 37
```

AX754187
LOCUS AX754187 25 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 534 from Patent WO03037931.
ACCESSION AX754187
VERSION AX754187.1 GI:32166884
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Shannon,M. and Phan,T.
HUMAN ANGIOMOTIN-LIKE PROTEIN 1
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 534 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1..25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.5%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1443 GCAGCAGCAGCAACAGCAGCA 1463
|||||
DB 5 GCAGCAGCAGCAACAGCAGCA 25
RESULT 38
AX754192
LOCUS AX754192 25 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 539 from Patent WO03037931.
ACCESSION AX754192
VERSION AX754192.1 GI:32166889
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Shannon,M. and Phan,T.
HUMAN ANGIOMOTIN-LIKE PROTEIN 1
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 539 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1..25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.5%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1444 CAGCAGCAGCAACAGCAGCAG 1464
|||||
DB 1 CAGCAGCAGCAACAGCAGCAG 21
RESULT 39
I84400
LOCUS I84400 51 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 1 from patent US 5695933.
ACCESSION I84400
VERSION I84400.1 GI:3021920
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 51)
AUTHORS Schalling,M., Hudson,T.J. and Housman,D.E.
TITLE Direct detection of expanded nucleotide repeats in the human genome
JOURNAL Patent: US 5695933-A 1 09-DEC-1997;
FEATURES
source
1..51
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.5%; Score 20.6; DB 1; Length 51;
Best Local Similarity 62.7%; Pred. No. 1.7e+02;
Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 1441 CTGCAGCAGCAGCAACAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAG 1491
|||||
DB 1 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 51
RESULT 40
BD243876
LOCUS BD243876 20 bp DNA linear PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
ACCESSION BD243876
VERSION BD243876.1 GI:33053646
KEYWORDS JP 2002522009-A/38
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE STE20-related protein kinases
JOURNAL Patent: JP 2002522009-A 38 23-JUL-2002;
SUGEN INC
COMMENT OS Artificial Sequence
PN JP 2002522009-A/38
PD 23-JUL-2002
PF 13-APR-1999 JP 2000543584
PR 14-APR-1998 US 60/081784
PI GREGORY FLOWMAN,RICARDO MARTINEZ,DAVID WHYTE
PC C12N15/09,A61K38/55,A61P9/00,A61P9/10,A61P13/12,A61P25/00, PC
A61P35/00,
PC A61P37/00,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/
PC 12,C12Q1/68,
PC C12N15/00,A61K37/64,C12N5/00
CC Synthesized nucleic acid molecule
FH Key Location/Qualifiers
FT source 1..20
/organism="Artificial Sequence".
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 286 CCCCCGGGAAACGATGACCA 305
|||||
DB 1 CCCCCGGGAAACGATGACCA 20
RESULT 41
AR435629
LOCUS AR435629 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 59 from patent US 6656716.
ACCESSION AR435629
VERSION AR435629.1 GI:40198610
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.

[illegible]


```
Query Match      0.5%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1115 AACAGCAGCAGCAGCTGCAGCAGCAG 1140
|||||
Db 26 AACAGCAGCGGCAGCAGCAGCAAGTAG 1

RESULT 46
AR053160/c
LOCUS AR053160 21 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 66 from patent US 5834183.
ACCESSION AR053160
VERSION AR053160.1 GI:5978022
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Orr,H.T., Rannum,L.P.W., Chung,M.-Y. and Zoghbi,H.Y.
TITLE Gene sequence for spinocerebellar ataxia type 1 and method for
diagnosis
JOURNAL Patent: US 5834183-A 66 10-NOV-1998;
FEATURES Location/Qualifiers
source
1..21
/mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGC 1138
|||||
Db 21 AGCAGCAGCAGCAGCAGCAGC 1

RESULT 47
AR084539
LOCUS AR084539 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 28 from patent US 5981185.
ACCESSION AR084539
VERSION AR084539.1 GI:10011310
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 28 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGC 1137
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAGC 21

RESULT 48
AR084551
LOCUS AR084551 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 40 from patent US 5981185.
ACCESSION AR084551
VERSION AR084551.1 GI:10011322
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 40 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/mol_type="unassigned DNA"
```

```
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 40 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

--QY 1118 AGCAGCAGCAGCTGCAGCAGC 1138
|||||
Db 1 AGCAGCAGCAGCAGCAGCAGC 21

RESULT 49
AR084571/c
LOCUS AR084571 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 60 from patent US 5981185.
ACCESSION AR084571
VERSION AR084571.1 GI:10011342
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 60 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGC 1137
|||||
Db 21 CAGCAGCAGCAGCAGCAGCAGC 1

RESULT 50
AR084577
LOCUS AR084577 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 66 from patent US 5981185.
ACCESSION AR084577
VERSION AR084577.1 GI:10011348
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 66 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGCA 1139
|||||
```

```
Db      1  GCAGCAGCAGCAGCAGCAGCA 21
|||||
RESULT 51
AR084580/c
LOCUS      AR084580      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 69 from patent US 5981185.
ACCESSION AR084580
VERSION    AR084580.1 GI:10011351
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE       Oligonucleotide repeat arrays
JOURNAL     Patent: US 5981185-A 69 09-NOV-1999;
FEATURES    Location/Qualifiers
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGC 1138
|||||
Db      21  AGCAGCAGCAGCAGCAGCAGC 1

RESULT 52
AR084598/c
LOCUS      AR084598      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 87 from patent US 5981185.
ACCESSION AR084598
VERSION    AR084598.1 GI:10011369
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE       Oligonucleotide repeat arrays
JOURNAL     Patent: US 5981185-A 87 09-NOV-1999;
FEATURES    Location/Qualifiers
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGCA 1139
|||||
Db      21  GCAGCAGCAGCAGCAGCAGCA 1

RESULT 53
AX104588/c
LOCUS      AX104588      21 bp      DNA      linear      PAT 30-APR-2001
DEFINITION Sequence 780 from Patent WO0122972.
ACCESSION AX104588
VERSION    AX104588.1 GI:13920785
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Krieg,A.M., Schetter,C. and Vollmer,J.C.
TITLE       Immunostimulatory nucleic acids

JOURNAL     Patent: WO 0122972-A 780 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES    Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match      0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
|||||
Db      21  CAGCAGCAGCAGCAGCAGCAG 1

RESULT 55
AX547641/c
LOCUS      AX547641      21 bp      DNA      linear      PAT 01-MAR-2003
DEFINITION Sequence 780 from Patent WO02053141.
ACCESSION AX547641
VERSION    AX547641.1 GI:25812785
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Bratzler,R.L.
TITLE       Inhibition of angiogenesis by nucleic acids
JOURNAL     Patent: WO 02053141-A 780 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES    Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Synthetic Sequence"
```

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 78;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
|||||
Db 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 56
BD169605
LOCUS 24 bp DNA linear PAT 17-JAN-2003
DEFINITION Novel G protein-coupled receptor and its DNA.
ACCESSION BD169605
VERSION BD169605.1 GI:27875417
KEYWORDS WO 0244368-A/37.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 24)
AUTHORS Terao, Y., Shintani, Y., Harada, M., Shimomura, Y. and Mori, M.
TITLE Novel G protein-coupled receptor and its DNA
JOURNAL Patent: WO 0244368-A 37 06-JUN-2002;
TAKEDA CHEMICAL INDUSTRIES LTD, YASUKO TERAO, YASUSHI SHINTANI, MIOKO HARADA, YUKIO SHIMOMURA, MASAOKI MORI
COMMENT OS Artificial Sequence
PN WO 0244368-A/37
PD 06-JUN-2002
PF 29-NOV-2001 WO 2001JP010418
PR 30-NOV-2000 JP 00P 364801, 26-MAR-2001 JP 01P 087482 PR
15-MAY-2001 JP 01P 145434, 06-SEP-2001 JP 01P 270838 PI YASUKO TERAO, YASUSHI SHINTANI, MIOKO HARADA, YUKIO SHIMOMURA, MASAOKI MORI
PC C12N15/12, C07K14/705, C07K16/28, C12P21/02, C12Q1/68, A61K45/00, A61P25/00,
A61P29/00, A61P35/00, A61P37/02, A61P1/00 CC
Primer
FH Key Location/Qualifiers
FT source 1. .24
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 97;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 1 CAGCGGCAGCAGCAGCAGCAG 21

RESULT 57
BD182475
LOCUS 24 bp DNA linear PAT 15-MAY-2003
DEFINITION Screening method.
ACCESSION BD182475
VERSION BD182475.1 GI:30793393
KEYWORDS WO 02093161-A/34.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 24)
AUTHORS Mori, M., Shimomura, Y. and Goto, M.
TITLE Screening method
JOURNAL Patent: WO 02093161-A 34 21-NOV-2002;
TAKEDA CHEMICAL INDUSTRIES LTD, MASAOKI MORI, YUKIO SHIMOMURA, MIKA GOTO
COMMENT OS Artificial Sequence
PN WO 02093161-A/34

PD 21-NOV-2002
PF 14-MAY-2002 WO 2002JP004635
PR 15-MAY-2001 JP 01P 145411
PI MASAOKI MORI, YUKIO SHIMOMURA, MIKA GOTO
PC G01N33/15, G01N33/50, C07K14/705, C07K14/435
CC Primer
FH Key Location/Qualifiers
FT source 1. .24
/organism="Artificial Sequence".

FEATURES
source
1. .24
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 97;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 1 CAGCGGCAGCAGCAGCAGCAG 21

RESULT 58
BD102725
LOCUS 24 bp DNA linear PAT 27-AUG-2002
DEFINITION Ligand for GPR8 and its DNA.
ACCESSION BD102725
VERSION BD102725.1 GI:22648299
KEYWORDS WO 0198494-A/34.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 24)
AUTHORS Mori, M., Shimomura, Y., Harada, M., Kurihara, M., Kitada, C., Asami, T., Matsumoto, Y., Adachi, Y., Watanabe, T., Sugo, T. and Abe, M.
TITLE Ligand for GPR8 and its DNA
JOURNAL Patent: WO 0198494-A 34 27-DEC-2001;
TAKEDA CHEMICAL INDUSTRIES LTD, MASAOKI MORI, YUKIO SHIMOMURA, MIOKO HARADA, MIKA KURIHARA, CHIEKO KITADA, TAJIJI ASAMI, YOSHIO MATSUMOTO, YUKA ADACHI, TAKUYA WATANABE, TSUKASA SUGO, MICHIO ABE
COMMENT OS Artificial Sequence
PN WO 0198494-A/34
PD 27-DEC-2001
PF 20-JUN-2001 WO 2001JP005257
PR 21-JUN-2000 JP 00P 191089, 06-SEP-2000 JP 00P 275013 PR
13-APR-2001 JP 01P 116000
PI MASAOKI MORI, YUKIO SHIMOMURA, MIOKO HARADA, MIKA KURIHARA, CHIEKO KITADA,
TAJJIJI ASAMI, YOSHIO MATSUMOTO, YUKA ADACHI, TAKUYA WATANABE, PI TSUKASA SUGO,
MI CHIEKO ABE
PC C12N15/12, C07K14/47, C12N1/21, C07K16/18, G01N33/53, G01N33/50, PC G01N33/15,
C12P21/02, C12P21/08, A61K31/711, A61K38/17, A01K67/027, A61P1/14,
A61P3/04
CC Primer
FH Key Location/Qualifiers
FT source 1. .24
/organism="Artificial Sequence".

FEATURES
source
1. .24
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 97;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146

QY 2544 GGTGGTCCACGACGTCGAG 2562

```
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 532 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.5%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGC 1461
|||||
Db 7 GCAGCAGCAGCAACAGCAGC 25

RESULT 64
AX754194
LOCUS AX754194 25 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 541 from Patent WO03037931.
ACCESSION AX754194
VERSION AX754194.1 GI:32166891
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 541 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.5%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1446 GCAGCAGCAGCAACAGCAGC 1464
|||||
Db 1 GCAGCAGCAGCAACAGCAGC 19

RESULT 65
AX360164/c
LOCUS AX360164 22 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 120 from Patent WO0200860.
ACCESSION AX360164
VERSION AX360164.1 GI:18675731
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Plowman,G., Whyte,D., Sudarsanam,S., Manning,G., Caenepeel,S. and
Charydczak,G.
TITLE Novel proteases
JOURNAL Patent: WO 0200860-A 120 03-JAN-2002;
Sugen, Inc. (US)
FEATURES
source
1. .22
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Magnani,M., Graziano,F. and Ruzzo,A.
TITLE Mutations of the germinal line in the gene promoter of e-cadherine
and diagnosis method to identify greater susceptibility to gastric
carcinoma
JOURNAL Patent: WO 03042409-A 2 22-MAY-2003;
Universita' Degli Studi Di Urbino (It)
FEATURES
source
1. .23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:3630"
/Note="PCR primer for identification of SNP on human
E-Cadherine"

Query Match 0.5%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1125 GCAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 2 GTACCTGCAGCAGCAGCAGCAG 23

RESULT 67
AX468116
LOCUS AX468116 24 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 6 from Patent WO0246410.
ACCESSION AX468116
VERSION AX468116.1 GI:21900989
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Lin,B.
TITLE Prostate-specific polypeptide pump and encoding nucleic acid
molecules
JOURNAL Patent: WO 0246410-A 6 13-JUN-2002;
The Institute for Systems Biology (US)
FEATURES
source
1. .24
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 63 GGACCTGCTGGATCTTTGAG 84
Db 3 GGACCTGCTGGATCTTTGAG 24

RESULT 68
A27143
LOCUS A27143 25 bp DNA linear PAT 22-AUG-1996
DEFINITION synthetic leader.
ACCESSION A27143
VERSION A27143.1 GI:1831891
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 25)
AUTHORS
JOURNAL
FEATURES
source
Patent: CA 1306208-A 1 11-AUG-1992;
Location/Qualifiers
1..25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.5%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1442 TGCAGCAGCAGCAACGACGCA 1463
Db 4 TGCAGCAGCAGCAGCAGCAGCA 25

RESULT 69
AR036870/c
LOCUS AR036870 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5800990.
ACCESSION AR036870
VERSION AR036870.1 GI:5954726
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Raynolds,M.V. and Perryman,M.Benjamin.
TITLE Angiotensin-converting enzyme genetic variant screens
JOURNAL Patent: US 5800990-A 1 01-SEP-1998;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 93;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1449 GCAGCAACGACGACGACG 1468
Db 20 GCAGCAACGACGACGCGCAGC 1

RESULT 70
AR193130/c
LOCUS AR193130 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 15 from patent US 6346416.
ACCESSION AR193130
VERSION AR193130.1 GI:20239095
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense inhibition of Hpx/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 15 12-FEB-2002;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 93;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 615 TGAGAACCTGATGCCACCT 634
Db 20 TGAGAACCCAGATGCCACCT 1

RESULT 71
AX317754/c
LOCUS AX317754 20 bp DNA linear PAT 14-DEC-2001
DEFINITION Sequence 15 from Patent WO0190313.
ACCESSION AX317754
VERSION AX317754.1 GI:17900639
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Feinberg,A.T., Strichman-Almaashanu,L.T. and Jiang,S.C.
TITLE Methods for assaying gene imprinting and methylated cpG islands
JOURNAL Patent: WO 0190313-A 15 29-NOV-2001;
The Johns Hopkins University (US)
FEATURES
source
Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 93;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACGACGCA 1463
Db 20 CAGTAGCAGCAACGACGCA 1

RESULT 72
AX926737/c
LOCUS AX926737 23 bp DNA linear PAT 19-DEC-2003
DEFINITION Sequence 20 from Patent WO03085133.
ACCESSION AX926737
VERSION AX926737.1 GI:40247059
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Nagaraju,J.G.
TITLE Novel fssr-pcr primers and method of identifying genotyping
diverse genomes of plant and animal systems including rice
varieties, a kit thereof
JOURNAL Patent: WO 03085133-A 20 16-OCT-2003;
Centre for DNA Fingerprinting and Diagnostics, Centre for; the
Department of Biotechnology, Ministry of Science & Technology (IN)
Department of Biotechnology, Ministry of Science & Technology (IN)
FEATURES
source
Location/Qualifiers
1..23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="A novel FISSR-PCR primer for genotyping eukaryotes"
```

Candida albicans
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; mitosporic Saccharomycetales; Candida.

REFERENCE 1
AUTHORS Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
TITLE Gene disruption methodologies for drug target discovery
JOURNAL Patent: WO 02053728-A 5708 11-JUL-2002;
Elitra Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source 1..20
/organism="Candida albicans"
/mol_type="unassigned DNA"
/db_xref="taxon:5476"
Query Match 0.5%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1475 AACAGCAGCAGCAGCAGC 1492
DB 18 AACAGCAGCAGCAGCAGC 1
RESULT 78
A62705/c
LOCUS Sequence 6 from Patent WO9717445. 42 bp DNA linear PAT 12-MAR-1998
DEFINITION A62705
ACCESSION A62705
VERSION A62705.1 GI:3716589
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1
AUTHORS Tora,L., Lutz,Y., Trottier,Y., Mandel and Jean-Louis.
TITLE METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING A 1C2 ANTIBODY
OR A FRAGMENT OR DERIVATIVE THEREOF, AND CORRESPONDING
PHARMACEUTICAL COMPOSITIONS
JOURNAL Patent: WO 9717445-A 6 15-MAY-1997;
CENTRE NAT RECH SCIENT (FR)
COMMENT Other publication FR 2741088 19970516.
FEATURES Location/Qualifiers
source 1..42
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/clone="AAD20"
Query Match 0.5%; Score 18; DB 1; Length 42;
Best Local Similarity 64.3%; Pred. No. 2.3e+02;
Matches 27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
QY 1456 CAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCTCTGT 1497
DB 42 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1
RESULT 79
BD235623
LOCUS Gene. 21 bp DNA linear PAT 17-JUL-2003
DEFINITION BD235623
ACCESSION BD235623
VERSION BD235623.1 GI:33045393
KEYWORDS JP 2002522073-A/24.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Robinson,I.C.A.F., Stoye,J.P., Flavell,D., Wells,S.E. and Tissier,P.L.
TITLE Patent: JP 2002522073-A 24 23-JUL-2002;
JOURNAL MEDICAL RESEARCH COUNCIL
COMMENT OS Artificial Sequence
PN JP 2002522073-A/24
PD 23-JUL-2002

PF 12-AUG-1999 JP 2000565123
PR 12-AUG-1998 GB 9817566.4, 06-MAY-1999 GB 9910522.3 PI
IAIN CLIVE ANDREW FRANKLIN ROBINSON, JONATHAN PAUL STOVE, DAVID PI
FLAVELL,
PI SARA ELIZABETH WELLS, PAUL LE TISSIER
PC C12N15/09, A01K67/027, C07K14/47, C12N1/15, C12N1/19, C12N1/21, PC
C12N5/10,
PC C12P21/02, C12Q1/68, G01N33/15, G01N33/50, C12N15/00, C12N5/00 CC
Gene
FH Key Location/Qualifiers
FT source 1..21
FT Location/Qualifiers
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1335 GCAGCGGAGCGTGCAGCAGGA 1355
DB 1 GCAGGAGGAGCGGAGCAGGA 21
RESULT 80
BD243908
LOCUS 22 bp DNA linear PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
ACCESSION BD243908
VERSION BD243908.1 GI:33053678
KEYWORDS JP 2002522009-A/70.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 22)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE STE20-related protein kinases
JOURNAL Patent: JP 2002522009-A 70 23-JUL-2002;
SUGEN INC
COMMENT OS Homo sapiens (human)
PN JP 2002522009-A/70
PD 23-JUL-2002
PF 13-APR-1999 JP 2000543584
PR 14-APR-1998 US 60/081784
PI GREGORY PLOWMAN, RICARDO MARTINEZ, DAVID WHYTE
PC C12N15/09, A61K38/55, A61P9/00, A61P13/12, A61P25/00, PC
A61P35/00,
PC A61P37/00, C07K16/40, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/1
PC 12, C12Q1/68,
PC C12N15/00, A61K37/64, C12N5/00
CC Mammalian ZC1
FH Key Location/Qualifiers
FT source 1..22
FT Location/Qualifiers
FEATURES
source 1..22
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.5%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3858 CAAGGTGTTTTCCTCAGT 3878
DB 1 CAAGGTGTTTTCCTCAGT 21


```
RESULT 81
AR435659
LOCUS AR435659 22 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 133 from patent US 6656716.
ACCESSION AR435659
VERSION AR435659.1 GI:40198640
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Plozman,G., Martinez,R. and Whyte,D.
TITLE Polypeptide fragments of human PAK5 protein kinase
JOURNAL Patent: US 6656716-A 133 02-DEC-2003;
FEATURES
source
1..22
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3858 CAAGGTGTTTTCCTCAGT 3878
Db 1 CAAGGTGTTTTCCTCAGT 21

RESULT 82
AR453262
LOCUS AR453262 22 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 133 from patent US 6680170.
ACCESSION AR453262
VERSION AR453262.1 GI:42685516
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Plozman,G., Martinez,R. and Whyte,D.
TITLE Polynucleotides encoding STE20-related protein kinases and methods
JOURNAL Patent: US 6680170-A 133 20-JAN-2004;
FEATURES
source
1..22
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3858 CAAGGTGTTTTCCTCAGT 3878
Db 1 CAAGGTGTTTTCCTCAGT 21

RESULT 83
AX207461/c
LOCUS AX207461/c 22 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 74 from Patent WO0155356.
ACCESSION AX207461
VERSION AX207461.1 GI:15395256
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Plozman,G., Whyte,D., Manning,G., Sudarsanam,S. and Martinez,R.
TITLE Human protein kinases and protein kinase-like enzymes
JOURNAL Patent: WO 0155356-A 74 02-AUG-2001;
Sugen, Inc. (US)

RESULT 84
AX458712
LOCUS AX458712 23 bp DNA linear PAT 08-JUL-2002
DEFINITION Sequence 14 from Patent WO0245524.
ACCESSION AX458712
VERSION AX458712.1 GI:21725371
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Dekker,P.J., van der Hoeven,R.A., Edens,L. and de Lange,L.
TITLE Protein hydrolysates enriched in peptides having a carboxy terminal
JOURNAL Patent: WO 0245524-A 14 13-JUN-2002;
DSM N.V. (NL)
FEATURES
source
1..23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

modified_base 3
/mod_base=i
modified_base 6
/mod_base=i
modified_base 9
/mod_base=i
modified_base 12
/mod_base=i
modified_base 15
/mod_base=i
modified_base 18
/mod_base=i

Query Match 0.5%; Score 17.8; DB 1; Length 23;
Best Local Similarity 82.6%; Pred. No. 1.3e+02;
Matches 19; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GCAGCAACAGCAGCAGCAGCTTC 1471
Db 1 GGAGTAACAGCAGCAGCAGCTTC 23

RESULT 85
AX481219
LOCUS AX481219 23 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 14 from Patent WO0245523.
ACCESSION AX481219
VERSION AX481219.1 GI:22217660
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Edens,L., Hoeven,V.D. and Delest,V.
TITLE Protein hydrolysates enriched in peptides having a carboxy terminal
JOURNAL Patent: WO 0245523-A 14 13-JUN-2002;

FEATURES
source
1..22
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.5%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3625 CTGCTGTGCTGAGGAGCAGG 3645
Db 22 CTGCTGTGCTGAGGAGCAGG 2

RESULT 86
AX481219
LOCUS AX481219 23 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 14 from Patent WO0245523.
ACCESSION AX481219
VERSION AX481219.1 GI:22217660
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Edens,L., Hoeven,V.D. and Delest,V.
TITLE Protein hydrolysates enriched in peptides having a carboxy terminal
JOURNAL Patent: WO 0245523-A 14 13-JUN-2002;
```

```
DSM N.V. (NL)
FEATURES
  source      1..23
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
  modified_base 3
               /mod_base=i
  modified_base 6
               /mod_base=i
  modified_base 9
               /mod_base=i
  modified_base 12
               /mod_base=i
  modified_base 15
               /mod_base=i
  modified_base 18
               /mod_base=i
  modified_base 18
               /mod_base=i

Query Match      0.5%; Score 17.8; DB 1; Length 23;
Best Local Similarity 82.6%; Pred. No. 1.3e+02;
Matches 19; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GCAGCAACGACGACGACGACGCTTC 1471
      |||||
Db 1 GGAGTAACGACGACGACGACGCTC 23

RESULT 86
AB086529/c
LOCUS      23 bp DNA linear SYN 21-MAY-2003
DEFINITION Synthetic construct DNA, forward primer for Japanese flounder
            microsatellite sequence Pol1136TUF.
ACCESSION  AB086529
VERSION     AB086529.1 GI:28804381
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Coimbra,M.R.M., Kobayashi,K., Koretsugu,S., Hasegawa,O., Ohara,E.,
            Ozaki,A., Sakamoto,T., Naruse,K. and Okamoto,N.
TITLE      A genetic linkage map of the Japanese Flounder, (Paralichthys
            olivaceus)
JOURNAL    Unpublished
AUTHORS    Coimbra,M.R.M., Kobayashi,K., Koretsugu,S., Hasegawa,O., Ohara,E.,
            Ozaki,A., Sakamoto,T., Naruse,K. and Okamoto,N.
TITLE      Direct Submission
JOURNAL    Submitted (14-JUN-2002) Nobuaki Okamoto, Tokyo University of
            Fisheries, Department of Aquatic Biosciences, 4-5-7 Konan,
            Minato-ku, Tokyo 108-8477, Japan
            (E-mail:nokamoto@tokyo-u-fish.ac.jp, Tel:81-3-5463-0547,
            Fax:81-3-5463-0552)
FEATURES
  source      1..23
               Location/Qualifiers
               ..23
               /organism="synthetic construct"
               /mol_type="genomic DNA"
               /db_xref="taxon:32630"
  misc_feature 1..23
               /notes="forward primer for Japanese flounder microsatellite
               sequence Pol1136TUF"

Query Match      0.5%; Score 17.8; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3721 GCCTACATCTGCTCCCAACGAC 3741
      |||||
Db 21 GCCTACATCTCCATCCCAACGAC 1

RESULT 87
```

```
AR038671
LOCUS      19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 5 from patent US 5807678.
ACCESSION  AR038671
VERSION     AR038671.1 GI:5958034
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 19)
AUTHORS    Miller,W.L., Lin,D. and Strauss,J.F. III.
TITLE      Identification of gene mutations associated with congenital lipoid
            adrenal hyperplasia
JOURNAL    Patent: US 5807678-A 5 15-SEP-1998;
FEATURES
  source      1..19
               Location/Qualifiers
               ..19
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAG 1137
      |||||
Db 1 GCAGCAGCAGCGCGCAGCAG 19

RESULT 88
BD244919/c
LOCUS      20 bp DNA linear PAT 17-JUL-2003
DEFINITION Modulation of gene expression by combination therapy.
ACCESSION  BD244919
VERSION     BD244919.1 GI:33054689
KEYWORDS   JP 2002528391-A/47.
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Besterman,J.M., Macleod,A.R. and Siders,W.M.
TITLE      Modulation of gene expression by combination therapy
JOURNAL    Patent: JP 2002528391-A 47 03-SEP-2002;
            METHYLGENE INC
COMMENT    OS Artificial Sequence
            PN JP 2002528391-A/47
            PD 03-SEP-2002
            PF 19-OCT-1999 JP 2000576885
            PR 19-OCT-1998 US 60/104804
            PI JEFFREY M BESTERMAN,ALAN ROBERT MACLEOD,WILLIAM M SIDERS PC
            A61K48/00,A61K31/165,A61K31/19,A61K31/513,A61K31/517,A61K31/
            706,
            PC
            A61K31/7068,A61K31/7088,A61K31/7125,A61K45/00,A61P35/00,C12N15/
            09//
            CC C12N5/10,C12N15/00,C12N5/00
            CC antisense
            FH Key Location/Qualifiers
            FT source 1..20
            FT /organism='Artificial Sequence'.
            FT Location/Qualifiers
            ..20
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCAGC 1147
      |||||
Db 20 CGGCAGCAGCAGCAGCAGC 2
```

RESULT 89
CQ784093/c
LOCUS 20 bp DNA linear PAT 17-MAR-2004
DEFINITION Sequence 4233 from Patent EP1396543.
ACCESSION CQ784093
VERSION CQ784093.1 GI:45538581
KEYWORDS
SOURCE synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Ota,T., Nihikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
TITLE Primers for synthesizing full length cDNA clones and their use
JOURNAL Patent: EP 1396543-A 4233 10-MAR-2004; (JP)
RESEARCH Association for Biotechnology (JP)
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: an artificially
synthesized primer se q uence"

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3614 GCATGGAGATGCTGCTGTG 3632
|||
DB 19 GCTTGGAGATGCTGCTGTG 1

RESULT 90
AR193157/c
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 42 from patent US 6346416.
ACCESSION AR193157
VERSION AR193157.1 GI:20239122
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 42 12-FEB-2002;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3695 AGTGGGGGAGATGCCTAC 3713
|||
DB 20 AGTGGGGGAGATGCCTAC 2

RESULT 91
AR366677/c
LOCUS 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 39 from patent US 6329203.
ACCESSION AR366677
VERSION AR366677.1 GI:34599269
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Wyatt,J.
TITLE Antisense modulation of glioma-associated oncogene-1 expression
JOURNAL Patent: US 6329203-A 39 11-DEC-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1121 AGCAGCAGCTGCAGCAGCA 1139
|||
DB 20 AGCAGCAGCTGCAGCAGCA 2

RESULT 92
AX053082/c
LOCUS 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 6 from Patent WO0071703.
ACCESSION AX053082
VERSION AX053082.1 GI:12227139
KEYWORDS
SOURCE synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Macleod,A.R., Li,Z. and Besterman,J.M.
TITLE Inhibition of histone deacetylase
JOURNAL Patent: WO 0071703-A 6 30-NOV-2000;
Methylgene, Inc. (CA)
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCAGC 1147
|||
DB 20 CGGCAGCAGCAGCAGCAGC 2

RESULT 93
AX053091/c
LOCUS 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 15 from Patent WO0071703.
ACCESSION AX053091
VERSION AX053091.1 GI:12227148
KEYWORDS
SOURCE synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Macleod,A.R., Li,Z. and Besterman,J.M.
TITLE Inhibition of histone deacetylase
JOURNAL Patent: WO 0071703-A 15 30-NOV-2000;
Methylgene, Inc. (CA)
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Combined DNA/RNA Molecule: Positions
1-4 and 17-20 are 2'-methoxyribose substituted
nucleotides; positions 5-16 are deoxyribonucleotides"

```
Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCAGC 1147
Db 20 CGGCAGCAGCAGCAGCAGC 2

RESULT 94
AX167902/c
LOCUS
DEFINITION
Sequence 86 from Patent WO0142307.
ACCESSION
AX167902
VERSION
AX167902.1 GI:14597222
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Saito, K., Ohe, N. and Satoh, H.
TITLE
Mutant  $\epsilon$ g(a), and test systems for transactivation
JOURNAL
Patent: WO 0142307-A 86 14-JUN-2001;
Sumitomo Chemical Company, Limited (JP)
FEATURES
Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Designed oligonucleotide primer for PCR"

Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1130 TGCAGCAGCAGCAGCAGCG 1148
Db 20 TGCAGCAGCAGCAGCAGCG 2

RESULT 95
AX487367/c
LOCUS
DEFINITION
Sequence 4667 from Patent WO02053728.
ACCESSION
AX487367
VERSION
AX487367.1 GI:22321515
KEYWORDS
Candida albicans
SOURCE
Candida albicans
ORGANISM
Candida albicans
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE
1
AUTHORS
Roemer, T., Jiang, B., Boone, C., Bussey, H. and Ohlsen, K.L.
TITLE
Gene disruption methodologies for drug target discovery
JOURNAL
Patent: WO 02053728-A 4667 11-JUL-2002;
Elitra Pharmaceuticals, Inc. (US)
FEATURES
Location/Qualifiers
source
1..20
/organism="Candida albicans"
/mol_type="unassigned DNA"
/db_xref="taxon:5476"

Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAGCAGC 1468
Db 20 CAACACAGCAGCAGCAGC 2

RESULT 96
AX546302/c
LOCUS
DEFINITION
Sequence 51 from Patent EPI243290.
ACCESSION
AX546302
VERSION
AX546302.1 GI:25811493
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Besterman, J.M., Macleod, A.R. and Siders, W.M.
TITLE
Modulation of gene expression by combination therapy
JOURNAL
Patent: EP 1243290-A 51 25-SEP-2002;
Methylgene, Inc. (CA)
FEATURES
Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="oligonucleotide"

Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCAGC 1147
Db 20 CGGCAGCAGCAGCAGCAGC 2

RESULT 97
AX546392/c
LOCUS
DEFINITION
Sequence 51 from Patent EPI243289.
ACCESSION
AX546392
VERSION
AX546392.1 GI:25811583
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Besterman, J.M., Macleod, A.R. and Siders, W.M.
TITLE
Modulation of gene expression by combination therapy
JOURNAL
Patent: EP 1243289-A 51 25-SEP-2002;
Methylgene, Inc. (CA)
FEATURES
Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="oligonucleotide"

Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCAGC 1147
Db 20 CGGCAGCAGCAGCAGCAGC 2

RESULT 98
BD128017/c
LOCUS
DEFINITION
Primer for synthesizing full-length cDNA and use thereof.
ACCESSION
BD128017
VERSION
BD128017.1 GI:23222962
KEYWORDS
JP 2002017375-A/3448.
SOURCE
unidentified
ORGANISM
unidentified
REFERENCE
1 (bases 1 to 20)
AUTHORS
Ota, T., Nishikawa, T., Isogai, T., Hayashi, K., Ishii, S., Kawai, Y.,
Wakamatsu, A., Sugiyama, T., Nagai, K., Kojima, S., Otsuki, T. and
```

```

Koga, H.
Primer for synthesizing full-length cDNA and use thereof
Patent: JP 2002017375-A 3448 22-JAN-2002;
HELIX RESEARCH INSTITUTE
OS Unidentified
PN JP 2002017375-A/3448
PD 22-JAN-2002
PF 07-JUL-2000 JP 200253172
PI TOSHIO OTA, TETSUO NISHIKAWA, TAKAO ISOGAI, KOJI HAYASHI, SHIZUKO
PI ISHII,
PI YURI KAWAI, AI WAKAMATSU, TOMOYASU SUGIYAMA, KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI, HISASHI KOGA
PC
C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
10, C12P21/02, C12Q1/68, C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC
Description of Artificial Sequence: an artificially CC
synthesized primer
CC sequence
FH Key Location/Qualifiers
FT source 1..20
/organism='Unidentified'
/organism='Unidentified'
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3614 GCATGAGATGCTGCTGTG 3632
Db 19 GCTTGAGATGCTGCTGTG 1

RESULT 99
BD266062-
LOCUS Universal arrays. 21 bp DNA linear PAT 17-JUL-2003
DEFINITION
ACCESSION BD266062
VERSION BD266062.1 GI:33075830
KEYWORDS JP 2002539849-A/62.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 21)
Pan, J.B., Hirschhorn, J.N., Huang, X., Kaplan, P., Lander, E.S.,
Lockhart, D.J., Ryder, T. and Sklar, P.
Universal arrays
Patent: JP 2002539849-A 62 26-NOV-2002;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
OS Homo sapiens (human)
PN JP 2002539849-A/62
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PI
JIAN BING FAN, JOEL N HIRSCHORN, XIAOHUA
HUANG, PAUL KAPLAN, ERIC
PI S LANDER,
PI DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR
PC C12Q1/68, C12M1/00, C12N15/09, C12N15/09, G01N33/53, PC
G01N33/566,
PC G01N37/00, C12N15/00, C12N15/00, C12N15/00
CC Universal arrays
FH Key Location/Qualifiers
FT source 1..21
/organism='Homo sapiens (human)'
/organism='Homo sapiens (human)'

TITLE Primer for synthesizing full-length cDNA and use thereof
JOURNAL HELIX RESEARCH INSTITUTE
COMMENT OS Unidentified
PN JP 2002017375-A/3448
PD 22-JAN-2002
PF 07-JUL-2000 JP 200253172
PI TOSHIO OTA, TETSUO NISHIKAWA, TAKAO ISOGAI, KOJI HAYASHI, SHIZUKO
PI ISHII,
PI YURI KAWAI, AI WAKAMATSU, TOMOYASU SUGIYAMA, KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI, HISASHI KOGA
PC
C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
10, C12P21/02, C12Q1/68, C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC
Description of Artificial Sequence: an artificially CC
synthesized primer
CC sequence
FH Key Location/Qualifiers
FT source 1..20
/organism='Unidentified'
/organism='Unidentified'
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.3e+02;
Matches 18; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1472 AGAACAGCAGCAGCAGCAGCAGC 1492
Db 1 AGGACAGCAGCAGCAGCAGCAGC 21

RESULT 100
AX697037/c
LOCUS AX697037 21 bp DNA linear PAT 02-APR-2003
DEFINITION Sequence 105 from Patent WO0078961.
ACCESSION AX697037
VERSION AX697037.1 GI:29498021
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Ferrara, N., Stewart, T.A., Williams, P.M., Baker, K.P., Desnoyers, L.,
Eaton, D.L., Gao, W.Q., Pan, J., Botstein, D., Fong, S., Goddard, A.,
Godowski, P.J., Gurney, A.L., Smith, V., Tamas, D., Wood, W.I.,
Grimaldi, C.J., Hillan, K.J., Paoni, N.F., Roy, M.A. and Watanabe, C.K.
Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: WO 0078961-A 105 28-DEC-2000;
Genentech Inc. (US)
FEATURES
source 1..21
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGCAGC 2

RESULT 101
AX149325/c
LOCUS AX149325 20 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 10 from Patent WO0136602.
ACCESSION AX149325
VERSION AX149325.1 GI:14347848
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Dahlberg, M., Moll, J. and Galvani, A.
TITLE Pak5 a member of the p21-activated kinase (pak) protein family,
nucleic acids and methods related to the same
JOURNAL Patent: WO 0136602-A 10 25-MAY-2001;
PHARMACIA & UPJOHN S.P.A. (IT)
FEATURES
source 1..20
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='primer'

Query Match 0.4%; Score 17.2; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.3e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```

[illegible]

```

TITLE      Human angiomotin-like protein 1
JOURNAL    Patent: WO 03037931-A 169 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445 AGCAGCAGCAACAGCAGC 1461
Db      1 AGCAGCAGCAACAGCAGC 17

RESULT 107
AX753823
LOCUS      AX753823      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 170 from Patent WO03037931.
ACCESSION  AX753823
VERSION     AX753823.1 GI:32166520
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M. and Phan,T.
TITLE       Human angiomotin-like protein 1
JOURNAL     Patent: WO 03037931-A 170 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES     Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1446 GCAGCAGCAACAGCAGC 1462
Db      1 GCAGCAGCAACAGCAGC 17

RESULT 108
AX753824
LOCUS      AX753824      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 171 from Patent WO03037931.
ACCESSION  AX753824
VERSION     AX753824.1 GI:32166521
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M. and Phan,T.
TITLE       Human angiomotin-like protein 1
JOURNAL     Patent: WO 03037931-A 171 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES     Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1446 GCAGCAGCAACAGCAGC 1462
Db      1 GCAGCAGCAACAGCAGC 17

RESULT 109
AX753825
LOCUS      AX753825      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 172 from Patent WO03037931.
ACCESSION  AX753825
VERSION     AX753825.1 GI:32166522
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M. and Phan,T.
TITLE       Human angiomotin-like protein 1
JOURNAL     Patent: WO 03037931-A 172 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES     Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1448 AGCAGCAACAGCAGCAGC 1464
Db      1 AGCAGCAACAGCAGCAGC 17

RESULT 110
AR084528/c
LOCUS      AR084528/c      18 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 17 from patent US 5981185.
ACCESSION  AR084528
VERSION     AR084528.1 GI:10011299
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE       Oligonucleotide repeat arrays
JOURNAL     Patent: US 5981185-A 17 09-NOV-1999;
            Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1131 GCAGCAGCAGCAGCAGC 1147
Db      18 GCAGCAGCAGCAGCAGC 2

RESULT 111
AX598368
LOCUS      AX598368      18 bp      DNA      linear      PAT 14-FEB-2003
DEFINITION Sequence 642 from Patent WO0244994.
ACCESSION  AX598368
VERSION     AX598368.1 GI:28398544
KEYWORDS
```

```

SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Brower,A., Brow,M.A., Cracauer,R.F., Fors,L., Granske,R., de arruda
            Indig,M., Kurensky,D., Luedtke,C., Lukowiak,A.A., Iyamichev,V.,
            Neri,B.P., Reimer,N.D., Roeven,R.T., Skrzypczynski,Z., Ziarno,W.A.,
            Comerford,J., Stump,S. and Viegut,D.D.
TITLE       Systems and method for detection assay production and sale
JOURNAL     Patent: WO 0244994-A 642 06-JUN-2002;
            THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match      0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAGC 1147
Db 1 GCAGCAGCAGCAGCAGC 17

RESULT 112
AX146085
LOCUS      AX146085                21 bp    DNA        linear    PAT 31-MAY-2001
DEFINITION Sequence 276 from Patent WO0134840.
ACCESSION AX146085
VERSION   AX146085.1 GI:14284603
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE  1
AUTHORS   Au,K.G., Chen,J.G., Patil,N. and Thomas,D.
TITLE     Genetic compositions and methods
JOURNAL   Patent: WO 0134840-A 276 17-MAY-2001;
            GLAXO GROUP LIMITED (GB) ; Affymetrix, Inc. (US)
FEATURES  Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
            variation
            1..21
            /notes="n' represents a polymorphic base"

Query Match      0.4%; Score 17; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1475 AACAGCAGCAGCAGCAGC 1492
Db 2 AACAGCAGCAGCAGCAGC 19

RESULT 113
AR067430
LOCUS      AR067430                20 bp    DNA        linear    PAT 29-SEP-1999
DEFINITION Sequence 30 from patent US 5851763.
ACCESSION AR067430
VERSION   AR067430.1 GI:5998652
KEYWORDS  Unknown.
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 20)
AUTHORS   Heym,B., Cole,S., Young,D., Zhang,Y., Honore,N., Telenti,A. and
            Bodmer,T.
TITLE     Rapid detection of antibiotic resistance in mycobacterium

SOURCE      tuberculosis
ORGANISM    Patent: US 5851763-A 30 22-DEC-1998;
REFERENCE   1
AUTHORS     Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2551 CACGACGTCGAGGAGATCAC 2570
Db 1 CAGGACGTCGAGGCGATCAC 20

RESULT 114
BD243911
LOCUS      BD243911                20 bp    DNA        linear    PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
ACCESSION BD243911
VERSION   BD243911.1 GI:33053681
KEYWORDS  JP 2002522009-A/73.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE  1 (bases 1 to 20)
AUTHORS   Plowman,G., Martinez,R. and Whyte,D.
TITLE     STE20-related protein kinases
JOURNAL   Patent: JP 2002522009-A 73 23-JUL-2002;
            SUGEN INC
COMMENT   OS Homo sapiens (human)
            PN JP 2002522009-A/73
            PD 23-JUL-2002
            PF 13-APR-1999 JP 2000543584
            PR 14-APR-1998 US 60/081784
            PI GREGORY PLOWMAN,RICARDO MARTINEZ,DAVID WHYTE
            PC C12N15/09,A61K38/55,A61P9/00,A61P13/12,A61P25/00, PC
            A61P35/00,
            PC A61P37/00,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/
            PC 12,C12Q1/68,
            PC C12N15/00,A61K37/64,C12N5/00
            CC Mammalian ZC3
            FH Key
            FT source
            Location/Qualifiers
            source
            1..20
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAAGTGGTGAAGG 3949
Db 1 CATCATGAAGTGGTGAAGG 20

RESULT 115
AR193135/c
LOCUS      AR193135/c              20 bp    DNA        linear    PAT 20-APR-2002
DEFINITION Sequence 20 from patent US 6346416.
ACCESSION AR193135
VERSION   AR193135.1 GI:20239100
KEYWORDS  Unknown.
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 20)
```



```
AUTHORS      Dean,N.M. and Cowseert,L.M.
TITLE        Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL      Patent: US 6346416-A 20 12-FEB-2002;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GTGCCTGGAGAGTCGACTCT 1058
Db 20 GTGCCTGGAGTCTACTCT 1

RESULT 116
AR193155/c
LOCUS        AR193155
DEFINITION   Sequence 40 from patent US 6346416.
ACCESSION    AR193155
VERSION      AR193155.1 GI:20239120
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Dean,N.M. and Cowseert,L.M.
TITLE        Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL      Patent: US 6346416-A 40 12-FEB-2002;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3493 TCCAGTGGCTGCTCCATGC 3512
Db 20 TCCTGTGGATCCATGC 1

RESULT 117
AR366676/c
LOCUS        AR366676
DEFINITION   Sequence 38 from patent US 6329203.
ACCESSION    AR366676
VERSION      AR366676.1 GI:34599268
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.F. and Wyatt,J.
TITLE        Antisense modulation of glioma-associated oncogene-1 expression
JOURNAL      Patent: US 6329203-A 38 11-DEC-2001;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1479 GCAGCAGCAGCTCCTCGC 1498
Db 20 GCCGACGACGAGCTCCAGC 1

AUTHORS      Dean,N.M. and Cowseert,L.M.
TITLE        Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL      Patent: US 6346416-A 20 12-FEB-2002;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GTGCCTGGAGAGTCGACTCT 1058
Db 20 GTGCCTGGAGTCTACTCT 1

RESULT 118
AR428075
LOCUS        AR428075
DEFINITION   Sequence 5 from patent US 6641818.
ACCESSION    AR428075
VERSION      AR428075.1 GI:40187443
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Spear,P.G., Warner,M.S., Geraghty,R.J., Martinez,W.M.,
             Montgomery,R.I., Cohen,G.H., Eisenberg,R.J., Whitbeck,C.J. and
             Krummenacher,C.
TITLE        Cellular proteins which mediate herpesvirus entry
JOURNAL      Patent: US 6641818-A 5 04-NOV-2003;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1472 AGAAACAGCAGCAGCAGCAG 1491
Db 1 AGAAGCAGCAGCAGCAGCAGCAG 20

RESULT 119
AR435662
LOCUS        AR435662
DEFINITION   Sequence 136 from patent US 6656716.
ACCESSION    AR435662
VERSION      AR435662.1 GI:40198643
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Plowman,G., Martinez,R. and Whyte,D.
TITLE        Polypeptide fragments of human PAK5 protein kinase
JOURNAL      Patent: US 6656716-A 136 02-DEC-2003;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAACCTGCTGAAGG 3949
Db 1 CATCATGAACCTGCTGACGG 20

RESULT 120
AR453265
LOCUS        AR453265
DEFINITION   Sequence 136 from patent US 6680170.
ACCESSION    AR453265
VERSION      AR453265.1 GI:42685519
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Plowman,G., Martinez,R. and Whyte,D.
TITLE        Polynucleotides encoding STE20-related protein kinases and methods
JOURNAL      Patent: US 6680170-A 136 20-JAN-2004;
```

```
FEATURES
source
  Location/Qualifiers
  1..20
  /organism="unknown"
  /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAAGTGGTGAAG 3949
Db 1 CATCATGAAGTGGTGAAG 20

RESULT 121
AR559473
LOCUS AX559473 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 42 from patent US 6750019.
ACCESSION AR559473
VERSION AR559473.1 GI:53968889
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 20)
  Freier,S.M.
  Antisense modulation of insulin-like growth factor binding protein
  5 expression
  Patent: US 6750019-A 42 15-JUN-2004;
  Location/Qualifiers
  1..20
  /organism="unknown"
  /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1267 CTGCAGGAGGAGGAGCGCA 1286
Db 1 CTGCAGGAGGAGGAGCGCA 20

RESULT 122
AX241159
LOCUS AX241159 20 bp DNA linear PAT 26-SEP-2001
DEFINITION Sequence 397 from Patent WO0160975.
ACCESSION AX241159
VERSION AX241159.1 GI:15798034
KEYWORDS
  synthetic construct
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
  Roemer,T., Jiang,B., Boone,C. and Bussey,H.
  Gene disruption methodologies for drug target discovery
  Patent: WO 0160975-A 397 23-AUG-2001;
  Elitra Pharmaceuticals, Inc. (US)
  Location/Qualifiers
  1..20
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="DNA primer"

Query Match
Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 CCGAGGACGAGGAGGAG 201
Db 1 CCGAGGAGGAGGAGGAG 20

FEATURES
source
  Location/Qualifiers
  1..20
  /organism="Candida albicans"
  /mol_type="unassigned DNA"
  /db_xref="taxon:5476"

Query Match
Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 CCGAGGACGAGGAGGAG 201
Db 1 CCGAGGAGGAGGAGGAG 20

RESULT 123
AX486754
LOCUS AX486754 20 bp DNA linear PAT 16-AUG-2002
DEFINITION Sequence 4054 from Patent WO02053728.
ACCESSION AX486754
VERSION AX486754.1 GI:22320902
KEYWORDS
  Candida albicans
  Candida albicans
  Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
  Saccharomycetales; mitosporic Saccharomycetales; Candida.
SOURCE
ORGANISM
REFERENCE
  1
  Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
  Gene disruption methodologies for drug target discovery
  Patent: WO 02053728-A 4054 11-JUL-2002;
  Elitra Pharmaceuticals, Inc. (US)
  Location/Qualifiers
  1..20
  /organism="Candida albicans"
  /mol_type="unassigned DNA"
  /db_xref="taxon:5476"

Query Match
Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 CCGAGGACGAGGAGGAG 201
Db 1 CCGAGGAGGAGGAGGAG 20

RESULT 124
AX487218/c
LOCUS AX487218 20 bp DNA linear PAT 16-AUG-2002
DEFINITION Sequence 4518 from Patent WO02053728.
ACCESSION AX487218
VERSION AX487218.1 GI:22321366
KEYWORDS
  Candida albicans
  Candida albicans
  Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
  Saccharomycetales; mitosporic Saccharomycetales; Candida.
SOURCE
ORGANISM
REFERENCE
  1
  Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
  Gene disruption methodologies for drug target discovery
  Patent: WO 02053728-A 4518 11-JUL-2002;
  Elitra Pharmaceuticals, Inc. (US)
  Location/Qualifiers
  1..20
  /organism="Candida albicans"
  /mol_type="unassigned DNA"
  /db_xref="taxon:5476"

Query Match
Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 CAGCAGCTTCAGCAGCAGCA 1142
Db 20 CATCAGCTTCAGCAGCAGCA 1

RESULT 125
BD089219/c
LOCUS BD089219 20 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD089219
VERSION BD089219.1 GI:22634829
KEYWORDS
  JP 2001321190-A/1463.
  synthetic construct
  other sequences; artificial sequences.
SOURCE
ORGANISM
```

```

REFERENCE
AUTHORS      Soeda,E.
TITLE        A method of arraying genome clone
JOURNAL      Patent: JP 2001321190-A 1463 20-NOV-2001;
              THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
              GENOTECHS
COMMENT      OS Artificial Sequence
              PN JP 2001321190-A/1463
              PD 20-NOV-2001
              PF 12-MAR-2001 JP 2001068285
              PI EIICHI SOEDA
              PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
              PC C12N15/00
              CC Description of Artificial Sequence:Synthetic DNA FH Key
              . Location/Qualifiers
              FT source 1..20
              FT Location/Qualifiers
              /organism='Artificial Sequence'.
              1..20
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 578 CTCCTACTGGATGGCTCCA 597
Db 20 CTCCTAATGGATGCTCCA 1

RESULT 126
AB068052/c
LOCUS      AB068052      20 bp      DNA      linear      SYN 21-MAY-2003
DEFINITION Synthetic construct DNA, forward primer for human STS sts-R159A20F
at lp36.
ACCESSION AB068052
VERSION   AB068052.1 GI:15128856
KEYWORDS  synthetic construct
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.
REFERENCE 1
AUTHORS   Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
          Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
          Morohashi,A., Chira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
          and Soeda,E.
TITLE     A BAC-based STS-content map spanning a 35-Mb region of human
          chromosome 1p35-p36
JOURNAL   Genomics 74 (1), 55-70 (2001)
MEDLINE   21269192
PUBMED    11374902
REFERENCE 2 (bases 1 to 20)
AUTHORS   Horii,A.
TITLE     Direct Submission
JOURNAL   Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
          Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
          Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
          Tel:81-22-717-8042, Fax:81-22-717-8047)
          Location/Qualifiers
          source      1..20
          /organism="synthetic construct"
          /mol_type="genomic DNA"
          /db_xref="taxon:32630"
          misc_feature 1..20
          /notes="forward primer for human STS sts-R159A20F at 1p36
          sts-R159A20F obtained from clones B159A20, B184F11,
          B58124, Human BAC library RPCI-11"

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;


```

```

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 578 CTCCTACTGGATGGCTCCA 597
Db 20 CTCCTAATGGATGCTCCA 1

RESULT 127
CQ846768
LOCUS      CQ846768      21 bp      DNA      linear      PAT 02-AUG-2004
DEFINITION Sequence 17 from Patent WO2004036221.
ACCESSION  CQ846768
VERSION    CQ846768.1 GI:50895918
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   O'Toole,M.M. and Liu,W.
TITLE     Compositions and methods for diagnosing and treating autoimmune
            disease
JOURNAL   Patent: WO 2004036221-A 17 29-APR-2004;
            Wyeth (US); O'Toole, Margot Mary (US); Liu, Wei (US)
FEATURES   Location/Qualifiers
            source      1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2711 ACAGCAAGGCCCAAGCCCA 2730
Db 1 AAAGCAAGGCCCAAGCCCA 20

RESULT 128
CQ846786
LOCUS      CQ846786      21 bp      DNA      linear      PAT 02-AUG-2004
DEFINITION Sequence 35 from Patent WO2004036221.
ACCESSION  CQ846786
VERSION    CQ846786.1 GI:50895936
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   O'Toole,M.M. and Liu,W.
TITLE     Compositions and methods for diagnosing and treating autoimmune
            disease
JOURNAL   Patent: WO 2004036221-A 35 29-APR-2004;
            Wyeth (US); O'Toole, Margot Mary (US); Liu, Wei (US)
FEATURES   Location/Qualifiers
            source      1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2711 ACAGCAAGGCCCAAGCCCA 2730
Db 2 AAAGCAAGGCCCAAGCCCA 21

RESULT 129
AR078304/c

```

<hr/>					
Query Match 0.4%; Score 16.6; DB 1; Length 36;					
Best Local Similarity 71.0%; Pred. No. 2.6e+02;					
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;					
<hr/>					
QY	1117	CACGACGAGCAGCTGCAGCAGCAGCAGCAGCAGC 1147			
DB	34	CCGCCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGC 4			
<hr/>					
RESULT 132					
ARL134262/c linear PAT 16-MAY-2001					
LOCUS ARL134262 18 bp DNA					
DEFINITION Sequence 2687 from patent US 6194150.					
ACCESSION ARL134262					
VERSION ARL134262.1 GI:14123167					
KEYWORDS .					
SOURCE Unknown.					
ORGANISM Unknown.					
Unclassified.					
REFERENCE					
AUTHORS 1 (bases 1 to 18)					
TITLE Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.					
JOURNAL Nucleic acid based inhibition of CD40					
FEATURES Patent: US 6194150-A 2687 27-FEB-2001;					
Location/Qualifiers.					
source					
1..18					
/organism="unknown"					
/mol_type="unassigned DNA"					
<hr/>					
Query Match 0.4%; Score 16.4; DB 1; Length 18;					
Best Local Similarity 94.4%; Pred. No. 1.3e+02;					
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	1440	CCTGCAGCAGCAGCAACA 1457			
DB	18	CCTGCAGCAGCAGCACCA 1			
<hr/>					
RESULT 133					
ARL137293/c linear PAT 16-JUN-2001					
LOCUS ARL137293 18 bp DNA					
DEFINITION Sequence 40 from patent US 6197505.					
ACCESSION ARL137293					
VERSION ARL137293.1 GI:14478802					
KEYWORDS .					
SOURCE Unknown.					
ORGANISM Unknown.					
Unclassified.					
REFERENCE					
AUTHORS 1 (bases 1 to 18)					
Norbey,L.Torbjorn., Andersson,M.Kristina. and					
Lindstrom,P.Harry.Rutger.					
TITLE Methods for assessing cardiovascular status and compositions for					
use thereof					
JOURNAL Patent: US 6197505-A 40 06-MAR-2001;					
FEATURES Location/Qualifiers					
source					
1..18					
/organism="unknown"					
/mol_type="unassigned DNA"					
<hr/>					
Query Match 0.4%; Score 16.4; DB 1; Length 18;					
Best Local Similarity 94.4%; Pred. No. 1.3e+02;					
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	3136	GATGTGCTGGAGGGGCTC 3153			
DB	18	GAGTGTGAGGGGCTC 1			
<hr/>					
RESULT 134					
ARL137299/c linear PAT 16-JUN-2001					
LOCUS ARL137299 18 bp DNA					
DEFINITION Sequence 46 from patent US 6197505.					
ACCESSION ARL137299					
VERSION ARL137299.1 GI:14478808					

```

KEYWORDS
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Norberg,L.T., Torbjorn., Andersson,M.Kristina. and
              Lindstrom,P.Harry.Rutger.
TITLE        Methods for assessing cardiovascular status and compositions for
              use thereof
JOURNAL      Patent: US 6197505-A 46 06-MAR-2001;
FEATURES     Location/Qualifiers
              source
              1..18
              /organism="unknown"
              /mol_type="unassigned DNA"
              0.4%; Score 16.4; DB 1; Length 18;
Query Match  Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
Db 18 GAGGTGCTGAGGGGCTC 1

RESULT 135
BD231276/c
LOCUS
DEFINITION   BD231276 18 bp DNA linear PAT 17-JUL-2003
              Genes for assessing cardiovascular status and compositions for use
              thereof.
ACCESSION    BD231276
VERSION      BD231276.1 GI:33041046
KEYWORDS     JP 2002527079-A/40.
SOURCE       synthetic construct
ORGANISM     other sequences; artificial sequences.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Norberg,L.T., Andersson,M.K., Lindstrom,P.H.R. and Jonsson,L.
              Genes for assessing cardiovascular status and compositions for use
              thereof
TITLE        Patent: JP 2002527079-A 40 27-AUG-2002;
JOURNAL      PAIROSEAKENSINGU AB
COMMENT      OS Artificial Sequence
              PN JP 2002527079-A/40
              PD 27-AUG-2002
              PF 13-OCT-1999 JP 2000576056
              PR 14-OCT-1998 US 60/104286,14-OCT-1998 US 60/104302 PI
              LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
              RUTGER LINDSTROM,
              PI LENA JONSSON
              PC C12Q1/68,C12N15/09//G01N33/53,G01N33/566,C12N15/00 CC Genes
              for assessing cardiovascular status
              and compositions for
              CC use thereof
              FH Key Location/Qualifiers
              FT source 1..18
              /organism='Artificial Sequence'.
              /mol_type="synthetic construct"
              /db_xref="taxon:32630"

FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
Db 18 GAGGTGCTGAGGGGCTC 1

RESULT 136
BD231282/c
LOCUS
DEFINITION   BD231282 18 bp DNA linear PAT 17-JUL-2003
              Genes for assessing cardiovascular status and compositions for use
              thereof.
ACCESSION    BD231282
VERSION      BD231282.1 GI:33041052
KEYWORDS     JP 2002527079-A/46.
SOURCE       synthetic construct
ORGANISM     other sequences; artificial sequences.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Norberg,L.T., Andersson,M.K., Lindstrom,P.H.R. and Jonsson,L.
              Genes for assessing cardiovascular status and compositions for use
              thereof
TITLE        Patent: JP 2002527079-A 46 27-AUG-2002;
JOURNAL      PAIROSEAKENSINGU AB
COMMENT      OS Artificial Sequence
              PN JP 2002527079-A/46
              PD 27-AUG-2002
              PF 13-OCT-1999 JP 2000576056
              PR 14-OCT-1998 US 60/104286,14-OCT-1998 US 60/104302 PI
              LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
              RUTGER LINDSTROM,
              PI LENA JONSSON
              PC C12Q1/68,C12N15/09//G01N33/53,G01N33/566,C12N15/00 CC Genes
              for assessing cardiovascular status
              and compositions for
              CC use thereof
              FH Key Location/Qualifiers
              FT source 1..18
              /organism='Artificial Sequence'.
              /mol_type="synthetic construct"
              /db_xref="taxon:32630"

FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide primer"

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
Db 18 GAGGTGCTGAGGGGCTC 1

RESULT 136
BD231282/c
LOCUS
DEFINITION   BD231282 18 bp DNA linear PAT 17-JUL-2003
              Genes for assessing cardiovascular status and compositions for use
              thereof.
ACCESSION    BD231282
VERSION      BD231282.1 GI:33041052
KEYWORDS     JP 2002527079-A/46.
SOURCE       synthetic construct
ORGANISM     other sequences; artificial sequences.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Norberg,L.T., Andersson,M.K., Lindstrom,P.H.R. and Jonsson,L.
              Genes for assessing cardiovascular status and compositions for use
              thereof
TITLE        Patent: JP 2002527079-A 46 27-AUG-2002;
JOURNAL      PAIROSEAKENSINGU AB
COMMENT      OS Artificial Sequence
              PN JP 2002527079-A/46
              PD 27-AUG-2002
              PF 13-OCT-1999 JP 2000576056
              PR 14-OCT-1998 US 60/104286,14-OCT-1998 US 60/104302 PI
              LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
              RUTGER LINDSTROM,
              PI LENA JONSSON
              PC C12Q1/68,C12N15/09//G01N33/53,G01N33/566,C12N15/00 CC Genes
              for assessing cardiovascular status
              and compositions for
              CC use thereof
              FH Key Location/Qualifiers
              FT source 1..18
              /organism='Artificial Sequence'.
              /mol_type="synthetic construct"
              /db_xref="taxon:32630"

FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide primer"

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
Db 18 GAGGTGCTGAGGGGCTC 1

RESULT 137
AX037415/c
LOCUS
DEFINITION   AX037415 18 bp DNA linear PAT 16-NOV-2000
              Sequence 40 from Patent WO0056922.
ACCESSION    AX037415
VERSION      AX037415.1 GI:11226840
KEYWORDS     synthetic construct
SOURCE       synthetic construct
ORGANISM     other sequences; artificial sequences.
REFERENCE    1
AUTHORS      Norberg,L.T., Olaiasson,E., Jonsson,L., Lindstrom,P.H. and
              Sanders,R.
TITLE        Genetic polymorphism and polymorphic pattern for assessing disease
              status, and compositions for use thereof
JOURNAL      Patent: WO 0056922-A 40 28-SEP-2000;
              NORBERG LEIF TORBJORN (SE) ; OLAISSON ERIK (SE) ; JONSSON LENA (SE)
              ; GMINI GENOMICS AB (SE) ; LINDSTROM PER HARRY RUTGER (SE) ;
              SANDERS RHANNON (SE)
              Location/Qualifiers
              source
              1..18
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Oligonucleotide primer"

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
Db 18 GAGGTGCTGAGGGGCTC 1

```

```

Query Match
Best Local Similarity 0.4%; Score 16.4; DB 1; Length 18;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTGCTGGAGGGGCTC 3153
DB 18 GAGGTGCTGGAGGGGCTC 1
|||
|

/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

RESULT 140
BD075173/c
LOCUS
DEFINITION
BD075173 18 bp DNA linear PAT 27-AUG-2002
Methods for assessing cardiovascular status and compositions for
use thereof.
BD075173
ACCESSION
VERSION BD075173.1 GI:22620776
KEYWORDS JP 2001519660-A/46.
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 18)
REFERENCE
AUTHORS Norberg,L.T., Andersson,M.K. and Lindstrom,P.H.R.
TITLE Methods for assessing cardiovascular status and compositions for
use thereof
JOURNAL Patent: JP 2001519660-A 46 23-OCT-2001;
EURONA MEDICAL AB
OS Artificial Sequence
PN JP 2001519660-A/46
PD 23-OCT-2001
PF 01-APR-1998 JP 1998542530
PR 04-APR-1997 US 60/042930
PI LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
RUTGER LINDSTROM
PC C12Q1/68,C07K14/72,C07K14/575,C12N9/48
CC Description of Artificial Sequence: PCR PRIMER FH Key
Location/Qualifiers
FT source
FT 1..18
Location/Qualifiers
/organism='Artificial Sequence'.
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.4%; Score 16.4; DB 1; Length 18;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTGCTGGAGGGGCTC 3153
DB 18 GAGGTGCTGGAGGGGCTC 1
|||
|

/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

RESULT 141
AR108646/c
LOCUS
DEFINITION
AR108646 20 bp DNA linear PAT 14-FEB-2001
Sequence 10 from patent US 6111075.
ACCESSION
VERSION AR108646.1 GI:12824133
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 20)
AUTHORS Xu,W.-f., Presnell,S.R., Yee,D.P. and Foster,D.C.
TITLE Protease-activated receptor PAR4 (ZCHEMR2)
JOURNAL Patent: US 611075-A 10 29-AUG-2000;
Location/Qualifiers
FEATURES
source
1..20
Location/Qualifiers

```

```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGTGCTACGAG 3639
Db 18 ATGCTGCTGTGCTACGGG 1

RESULT 142
AR126643/c
LOCUS AR126643 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 72 from patent US 6180353.
ACCESSION AR126643
VERSION AR126643.1 GI:14113236
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseart,L.M.
TITLE Antisense modulation of daxx expression
JOURNAL Patent: US 6180353-A 72 30-JAN-2001;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGGAAGA 200
Db 19 GGAGGACGAGGAGGAAGA 2

RESULT 143
AR223403/c
LOCUS AR223403 20 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 10 from patent US 6436400.
ACCESSION AR223403
VERSION AR223403.1 GI:23331588
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Xu,W.-f., Presnell,S.R., Yee,D.P. and Foster,D.C.
TITLE Protease-activated receptor PAR4 ZCHEMR2
JOURNAL Patent: US 6436400-A 10 20-AUG-2002;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGTGCTACGAG 3639
Db 18 ATGCTGCTGTGCTACGGG 1

RESULT 144
AR242698/c
LOCUS AR242698 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 10 from patent US 6473765.
ACCESSION AR242698
```

```
VERSION AR242698.1 GI:27289188
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Fink,R.
TITLE Matching/merging two data warehouse physical data models
JOURNAL Patent: US 6473765-A 10 29-OCT-2002;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGTGCTACGAG 3639
Db 18 ATGCTGCTGTGCTACGGG 1

RESULT 145
AR492683
LOCUS AR492683 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 53 from patent US 6716975.
ACCESSION AR492683
VERSION AR492683.1 GI:47262197
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt,J.
TITLE Antisense modulation of EDGI expression
JOURNAL Patent: US 6716975-A 53 06-APR-2004;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1485 GCAGCAGCTCCTGCCTGG 1502
Db 1 GCAGCAGCTCCTGCCTGG 18

RESULT 146
AX486781/c
LOCUS AX486781 20 bp DNA linear PAT 16-AUG-2002
DEFINITION Sequence 4081 from Patent WO02053728.
ACCESSION AX486781
VERSION AX486781.1 GI:22320929
KEYWORDS
SOURCE
ORGANISM Candida albicans
Candida albicans
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE 1
AUTHORS Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
TITLE Gene disruption methodologies for drug target discovery
JOURNAL Patent: WO 02053728-A 4081 11-JUL-2002;
FEATURES
source
Location/Qualifiers
1..20
/organism="Candida albicans"
/mol_type="unassigned DNA"
/db_xref="taxon:5476"
```

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGAGCAGCAGCAG 1143
Db 18 CAGCTGAGCAGCAGCAG 1

RESULT 147
AX764064/c

LOCUS AX764064 20 bp DNA linear PAT 25-JUN-2003

DEFINITION Sequence 9 from Patent WO03040304.

ACCESSION AX764064

VERSION AX764064.1 GI:32258388

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Holmberg, J. and Frisen, J.

TITLE Method of proliferation in neurogenic regions

JOURNAL Patent: WO 03040304-A 9 15-MAY-2003;

Neuronova AB (SE)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="PCR Primer"

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1475 AACAGCAGCAGCAGCAGC 1492
Db 19 AACAGCAGCAGCAGCAGC 2

RESULT 148
AX764066/c

LOCUS AX764066 20 bp DNA linear PAT 25-JUN-2003

DEFINITION Sequence 11 from Patent WO03040304.

ACCESSION AX764066

VERSION AX764066.1 GI:32258390

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Holmberg, J. and Frisen, J.

TITLE Method of proliferation in neurogenic regions

JOURNAL Patent: WO 03040304-A 11 15-MAY-2003;

Neuronova AB (SE)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="PCR Primer"

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1475 AACAGCAGCAGCAGCAGC 1492
Db 19 AACAGCAGCAGCAGCAGC 2

RESULT 149
A64605

LOCUS A64605 21 bp DNA linear PAT 25-MAR-1999

DEFINITION Sequence 24 from Patent WO9728186.

ACCESSION A64605

VERSION A64605.1 GI:4530703

KEYWORDS unidentified

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1

AUTHORS Caput, D., Ferrara, P. and Kaghad, A.M.

TITLE PURIFIED SR-p70 PROTEIN

JOURNAL Patent: WO 9728186-A 24 07-AUG-1997;

SANOFI SA (FR)

COMMENT Other publication AU 1727597 19970822

Other publication FR 2744455 19970808.

FEATURES Location/Qualifiers

source 1..21

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3034 GTCACCTGCTGCTGGGC 3051
Db 1 GTCACCTGCTGCTGGGC 18

RESULT 150
CQ846769

LOCUS CQ846769 21 bp RNA linear PAT 02-AUG-2004

DEFINITION Sequence 18 from Patent WO2004036221.

ACCESSION CQ846769

VERSION CQ846769.1 GI:50895919

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS O'Toole, M.M. and Liu, W.

TITLE Compositions and methods for diagnosing and treating autoimmune disease

JOURNAL Patent: WO 2004036221-A 18 29-APR-2004;

Wyeth (US); O'Toole, Margot Mary (US); Liu, Wei (US)

FEATURES Location/Qualifiers

source 1..21

/organism="Homo sapiens"

/mol_type="unassigned RNA"

/db_xref="taxon:9606"

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2713 AGCAAGGCCAAGCCCA 2730
Db 1 AGCAAGGCCAAGCCCA 18

RESULT 151
CQ846771

LOCUS CQ846771 21 bp DNA linear PAT 02-AUG-2004

DEFINITION Sequence 20 from Patent WO2004036221.

ACCESSION CQ846771

VERSION CQ846771.1 GI:50895921

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS O'Toole,M.M. and Liu,W.
TITLE Compositions and methods for diagnosing and treating autoimmune disease
JOURNAL Patent: WO 2004036221-A 20 29-APR-2004;
Wyeth (US); O'Toole, Margot Mary (US); Liu, Wei (US)
FEATURES
source
1. .21
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2713 AGCAAGGCCAAGCCCA 2730
Db |||||||||||||||
2 AGCAAGGCCAAGCCCA 19
RESULT 152
LOCUS CQ846787 21 bp RNA linear PAT 02-AUG-2004
DEFINITION Sequence 36 from Patent WO2004036221.
ACCESSION CQ846787
VERSION CQ846787.1 GI:50895937
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS O'Toole,M.M. and Liu,W.
TITLE Compositions and methods for diagnosing and treating autoimmune disease
JOURNAL Patent: WO 2004036221-A 36 29-APR-2004;
Wyeth (US); O'Toole, Margot Mary (US); Liu, Wei (US)
FEATURES
source
1. .21
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2713 AGCAAGGCCAAGCCCA 2730
Db |||||||||||||||
2 AGCAAGGCCAAGCCCA 19
RESULT 153
LOCUS AR241911 21 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 199 from patent US 6472154.
ACCESSION AR241911
VERSION AR241911.1 GI:27287723
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 199 29-OCT-2002;
FEATURES
source
1. .21
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 16.4; DB 1; Length 21;

Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1270 CAGGAGAGGAGCAGCAGCAG 1287
Db |||||||||||||||
1 CAGGAGAGGAGCAGCAGCAG 18
RESULT 154
LOCUS AR072482 21 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 285 from patent US 5948611.
ACCESSION AR072482
VERSION AR072482.1 GI:9999246
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Prockop,D.J., Ala-Kokko,L., Williams,C.J., Ritvaniemi,P., Baldwin,C., Hopkinson,I. and Ahmad,N.Nina.
TITLE Primers and methods for detecting mutations in the procollagen II gene (COL2A1) that indicate a genetic predisposition for a COL2A1-associated disease
JOURNAL Patent: US 5948611-A 285 07-SEP-1999;
FEATURES
source
1. .21
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1571 AGGTAGAGGAGAGCAAGGA 1591
Db |||||||||||||||
1 AGTTAGAGGAGAGCAAGGA 21
RESULT 155
LOCUS BD243871 21 bp DNA linear PAT 17-JUL-2003
DEFINITION STE20-related protein kinases.
ACCESSION BD243871
VERSION BD243871.1 GI:33053641
KEYWORDS JP 2002522009-A/33.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Plowman,G., Martinez,R. and Whyte,D.
TITLE STE20-related protein kinases
JOURNAL Patent: JP 2002522009-A 33 23-JUL-2002;
SUGEN INC
COMMENT OS Artificial Sequence
PN JP 2002522009-A/33
PD 23-JUL-2002
PF 13-APR-1999 JP 2000543584
PR 14-APR-1998 US 60/081784
PI GREGORY PLOWMAN, RICARDO MARTINEZ, DAVID WHYTE
PC C12N15/09,A61K38/55,A61P9/00,A61P13/12,A61P25/00, PC A61P35/00,
PC A61P37/00,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/12,C12Q1/68,
PC C12N15/00,A61K37/64,C12N5/00
CC Synthesized nucleic acid molecule
FH Key Location/Qualifiers
FT source 1. .21
FT /organism='Artificial Sequence'.
FEATURES
source
1. .21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"

```

/db_xref="taxon:32630"

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 166 AAGGTCATGATGTCACGGAG 186
||||| ||||| ||||| ||||| |||||
Db 1 AAGGTTATGGATGTCACAGG 21

RESULT 156
CQ846801
LOCUS          21 bp      DNA          linear          PAT 02-AUG-2004
DEFINITION     Sequence 50 from Patent WO2004036221.
ACCESSION      CQ846801
VERSION        CQ846801.1 GI:50895951
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
AUTHORS        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 O'Toole,M.M. and Liu,W.
AUTHORS        Compositions and methods for diagnosing and treating autoimmune
TITLE          disease
JOURNAL        Patent: WO 2004036221-A 50 29-APR-2004;
FEATURES       source
                location/Qualifiers
                1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2707 GAGACAGCAAGGCCAAGC 2727
||||| ||||| ||||| ||||| |||||
Db 1 GACCAAGCAAGGCCAAGC 21

RESULT 157
AR435624
LOCUS          21 bp      DNA          linear          PAT 18-DEC-2003
DEFINITION     Sequence 54 from patent US 6656716.
ACCESSION      AR435624
VERSION        AR435624.1 GI:40198605
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 21)
AUTHORS        Plozman,G., Martinez,R. and Whyte,D.
TITLE          Polypeptide fragments of human PAK5 protein kinase
JOURNAL        Patent: US 6656716-A 54 02-DEC-2003;
FEATURES       source
                location/Qualifiers
                1..21
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 166 AAGGTCATGATGTCACGGAG 186
||||| ||||| ||||| ||||| |||||
Db 1 AAGGTTATGGATGTCACAGG 21

RESULT 158
AR453225
LOCUS          21 bp      DNA          linear          PAT 20-FEB-2004
DEFINITION     Sequence 54 from patent US 6680170.
ACCESSION      AR453225
VERSION        AR453225.1 GI:42685479
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 21)
AUTHORS        Plozman,G., Martinez,R. and Whyte,D.
TITLE          Polynucleotides encoding STE20-related protein kinases and methods
JOURNAL        Patent: US 6680170-A 54 20-JAN-2004;
FEATURES       source
                location/Qualifiers
                1..21
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 166 AAGGTCATGATGTCACGGAG 186
||||| ||||| ||||| ||||| |||||
Db 1 AAGGTTATGGATGTCACAGG 21

RESULT 159
AX249447/c
LOCUS          31 bp      DNA          linear          PAT 28-SEP-2001
DEFINITION     Sequence 1526 from Patent WO0166800.
ACCESSION      AX249447
VERSION        AX249447.1 GI:15864070
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
AUTHORS        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 Cargill,M., Ireland,J.S. and Lander,E.S.
AUTHORS        Human single nucleotide polymorphisms
TITLE          Patent: WO 0166800-A 1526 13-SEP-2001;
JOURNAL        WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES       source
                location/Qualifiers
                1..31
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match          0.4%; Score 16.2; DB 1; Length 31;
Best Local Similarity 72.4%; Pred. No. 2.6e+02;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGCAGCAGC 1147
||||| ||||| ||||| ||||| |||||
Db 30 GCTGTCGCGCTGTCGCGCTGCGCTGC 2

RESULT 160
A35651
LOCUS          16 bp      DNA          linear          PAT 02-DEC-1996
DEFINITION     Synthetic human IFN-alpha 2 gene oligo.
ACCESSION      A35651
VERSION        A35651.1 GI:1927033
KEYWORDS
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Camble,R. and Edge,M.D.
TITLE          Analogous interferon polypeptides, process for their preparation
JOURNAL        Patent: EP 0194006-A 96 10-SEP-1986

```

```

FEATURES
  source
    IMPERIAL CHEMICAL INDUSTRIES PLC
    Location/Qualifiers
      1..16
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"

Query Match
  Best Local Similarity 0.4%; Score 16; DB 1; Length 16;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAG 1134
Db 1 GCAGCAGCAGCTGCAG 16

RESULT 161
A35684
LOCUS A35684 Synthetic human IFN-alpha 2 gene oligo. 16 bp DNA linear PAT 02-DEC-1996
DEFINITION A35684
ACCESSION A35684
VERSION A35684.1 GI:1927066
KEYWORDS
SOURCE synthetic construct
  ORGANISM
    other sequences; artificial sequences.
REFERENCE
  1 (bases 1 to 16)
  Camble,R. and Edge,M.D.
  Analogous interferon polypeptides, process for their preparation
  and pharmaceutical compositions containing them
  Patent: EP 0194006-A 129 10-SEP-1986;
  JOURNAL IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES
  source
    Location/Qualifiers
      1..16
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"

Query Match
  Best Local Similarity 100.0%; Pred. No. 1.2e+02;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAG 1134
Db 1 GCAGCAGCAGCTGCAG 16

RESULT 162
AX216912
LOCUS AX216912 Sequence 2354 from Patent WO0159103. 17 bp RNA linear PAT 07-SEP-2001
DEFINITION AX216912
ACCESSION AX216912
VERSION AX216912.1 GI:15526973
KEYWORDS
SOURCE synthetic construct
  ORGANISM
    other sequences; artificial sequences.
REFERENCE
  1
  Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  Method and reagent for the modulation and diagnosis of cd20 and
  nogo gene expression
  Patent: WO 0159103-A 2354 16-AUG-2001;
  JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
  McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32630"
      /note="Nucleic Acid"

Query Match
  Best Local Similarity 100.0%; Score 16; DB 1; Length 17;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGC 1138
Db 1 CAGCAGCTGCAGCAGC 16

RESULT 163
AX272814
LOCUS AX272814 Sequence 383 from Patent WO0162911. 17 bp RNA linear PAT 29-OCT-2001
DEFINITION AX272814
ACCESSION AX272814
VERSION AX272814.1 GI:16545551
KEYWORDS
SOURCE Homo sapiens (human)
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
  Ellis,J.H.
  Method and reagent for the inhibition of grid
  Patent: WO 0162911-A 383 30-AUG-2001;
  JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned RNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 100.0%; Score 16; DB 1; Length 17;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGC 1138
Db 2 CAGCAGCTGCAGCAGC 17

RESULT 164
AX272955
LOCUS AX272955 Sequence 524 from Patent WO0162911. 17 bp RNA linear PAT 29-OCT-2001
DEFINITION AX272955
ACCESSION AX272955
VERSION AX272955.1 GI:16545692
KEYWORDS
SOURCE Homo sapiens (human)
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
  Ellis,J.H.
  Method and reagent for the inhibition of grid
  Patent: WO 0162911-A 524 30-AUG-2001;
  JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned RNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 100.0%; Score 16; DB 1; Length 17;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGC 1138
Db 1 CAGCAGCTGCAGCAGC 16

RESULT 165
AX753819
```

LOCUS AX753819 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 166 from Patent WO03037931.
ACCESSION AX753819
VERSION AX753819.1 GI:32166516
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 166 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1443 GCAGCAGCAGCAGCAG 1458
Db 2 GCAGCAGCAGCAGCAG 17
RESULT 166
AX753826
LOCUS AX753826 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 173 from Patent WO03037931.
ACCESSION AX753826
VERSION AX753826.1 GI:32166523
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 173 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1449 GCAGCAACAGCAGCAG 1464
Db 1 GCAGCAACAGCAGCAG 16
RESULT 167
AR121115
LOCUS AR121115 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 11 from patent US 6159697.
ACCESSION AR121115
VERSION AR121115.1 GI:14104691
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia,B.P. and Cowseert,L.M.
TITLE Antisense modulation of Smad7 expression

JOURNAL Patent: US 6159697-A 11 12-DEC-2000;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1476 ACAGCAGCAGCAGCAG 1491
Db 3 ACAGCAGCAGCAGCAG 18
RESULT 168
AR134263/c
LOCUS AR134263 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2688 from patent US 6194150.
ACCESSION AR134263
VERSION AR134263.1 GI:14123168
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2688 27-FEB-2001;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1439 CCTGCAGCAGCAGCA 1454
Db 16 CCTGCAGCAGCAGCA 1
RESULT 169
AR107612/c
LOCUS AR107612 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 52 from patent US 6110664.
ACCESSION AR107612
VERSION AR107612.1 GI:12823099
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowseert,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 52 29-AUG-2000;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1112 TAAACAGCAGCAGCA 1127
Db 16 TAAACAGCAGCAGCA 1
RESULT 170
AR107613/c

LOCUS AR107613 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 53 from patent US 6110664.
ACCESSION AR107613
VERSION AR107613.1 GI:12823100
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 53 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 17 TAAACAGCAGCAGCA 2

RESULT 171
AR107614/c
LOCUS AR107614 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 54 from patent US 6110664.
ACCESSION AR107614
VERSION AR107614.1 GI:12823101
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 54 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 18 TAAACAGCAGCAGCA 3

RESULT 172
AR107615/c
LOCUS AR107615 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 55 from patent US 6110664.
ACCESSION AR107615
VERSION AR107615.1 GI:12823102
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 55 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 18 TAAACAGCAGCAGCA 3

RESULT 173
AR107616/c
LOCUS AR107616 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 56 from patent US 6110664.
ACCESSION AR107616
VERSION AR107616.1 GI:12823103
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 56 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 19 TAAACAGCAGCAGCA 4

RESULT 174
AX053083/c
LOCUS AX053083 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 7 from Patent WO0071703.
ACCESSION AX053083
VERSION AX053083.1 GI:12227140
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Macleod,A.R., Li,Z. and Beaterman,J.M.
TITLE Inhibition of histone deacetylase
JOURNAL Patent: WO 0071703-A 7 30-NOV-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
|||||
Db 20 GCAGCAGCAGCAGCAG 5

RESULT 175
AX053092/c
LOCUS AX053092 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 16 from Patent WO0071703.
ACCESSION AX053092

LOCUS AR107613 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 53 from patent US 6110664.
ACCESSION AR107613
VERSION AR107613.1 GI:12823100
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 53 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 17 TAAACAGCAGCAGCA 2

RESULT 171
AR107614/c
LOCUS AR107614 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 54 from patent US 6110664.
ACCESSION AR107614
VERSION AR107614.1 GI:12823101
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 54 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 18 TAAACAGCAGCAGCA 3

RESULT 172
AR107615/c
LOCUS AR107615 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 55 from patent US 6110664.
ACCESSION AR107615
VERSION AR107615.1 GI:12823102
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 55 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 18 TAAACAGCAGCAGCA 3

RESULT 173
AR107616/c
LOCUS AR107616 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 56 from patent US 6110664.
ACCESSION AR107616
VERSION AR107616.1 GI:12823103
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsett,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 56 29-AUG-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACAGCAGCAGCA 1127
|||||
Db 19 TAAACAGCAGCAGCA 4

RESULT 174
AX053083/c
LOCUS AX053083 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 7 from Patent WO0071703.
ACCESSION AX053083
VERSION AX053083.1 GI:12227140
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Macleod,A.R., Li,Z. and Beaterman,J.M.
TITLE Inhibition of histone deacetylase
JOURNAL Patent: WO 0071703-A 7 30-NOV-2000;
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
|||||
Db 20 GCAGCAGCAGCAGCAG 5

RESULT 175
AX053092/c
LOCUS AX053092 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 16 from Patent WO0071703.
ACCESSION AX053092

VERSION AX053092.1 GI:12227149
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Macleod,A.R., Li,Z. and Besterman,J.M.
TITLE Inhibition of histone deacetylase
JOURNAL Patent: WO 0071703-A 16 30-NOV-2000;
Methylgene, Inc. (CA)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Combined DNA/RNA Molecule: Positions 1-4 and 17-20 are 2'-methoxyribose substituted nucleotides; positions 5-16 are deoxyribonucleotides"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
Db 20 GCAGCAGCAGCAGCAG 5

RESULT 176
AX546303/c
LOCUS
DEFINITION Sequence 52 from Patent EP1243290. PAT 26-NOV-2002
ACCESSION AX546303
VERSION AX546303.1 GI:25811494
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Besterman,J.M., Macleod,A.R. and Siders,W.M.
TITLE Modulation of gene expression by combination therapy
JOURNAL Patent: EP 1243290-A 52 25-SEP-2002;
Methylgene, Inc. (CA)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="oligonucleotide"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
Db 20 GCAGCAGCAGCAGCAG 5

RESULT 177
AX546393/c
LOCUS
DEFINITION Sequence 52 from Patent EP1243289. PAT 26-NOV-2002
ACCESSION AX546393
VERSION AX546393.1 GI:25811584
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Besterman,J.M., Macleod,A.R. and Siders,W.M.
TITLE Modulation of gene expression by combination therapy
JOURNAL Patent: EP 1243289-A 52 25-SEP-2002;

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="oligonucleotide"

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
Db 20 GCAGCAGCAGCAGCAG 5

RESULT 178
AR530865/c
LOCUS
DEFINITION Sequence 2068 from patent US 6727063. PAT 08-OCT-2004
ACCESSION AR530865
VERSION AR530865.1 GI:53919302
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2068 27-APR-2004;
FEATURES
source Location/Qualifiers
1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 16; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2596 GGCACATGGTGGTCCAG 2613
Db 18 GGCACCCYGGTGGTCCAG 1

RESULT 179
AX096890/c
LOCUS
DEFINITION Sequence 2068 from Patent WO0118250. PAT 30-MAR-2001
ACCESSION AX096890
VERSION AX096890.1 GI:13513158
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2068 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 16; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
QY 2596 GGCACCATGGTGGTCCAG 2613
Db 18 GGCACCCCGGTGGTCCAG 1

RESULT 180
LOCUS AR295468
DEFINITION Sequence 7203 from patent US 6537751.
ACCESSION AR295468
VERSION AR295468.1 GI:31682752
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 7203 25-MAR-2003;
FEATURES
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3243 AGAAGTGGAGAGAGCAG 3261
Db 1 AGAAGTGGAGAGAGAGTAG 19

RESULT 181
LOCUS AX937835
DEFINITION Sequence 103 from Patent WO03091381.
ACCESSION AX937835
VERSION AX937835.1 GI:40713817
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Rappold,G.A. and Kirsch,S.
TITLE Height-related gene
JOURNAL Patent: WO 03091381-A 103 06-NOV-2003;
Rappold, Gudrun A. (DE)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Primer: C17C forward"

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1027 TCCATCATGAACGTGCCTG 1045
Db 1 TCCATCTGAAAGTGCTG 19

RESULT 182
LOCUS AB1336
DEFINITION Sequence 13 from Patent WO9911668.
ACCESSION AB1336
VERSION AB1336.1 GI:6731660
KEYWORDS

QY 2596 GGCACCATGGTGGTCCAG 2613
Db 18 GGCACCCCGGTGGTCCAG 1

RESULT 180
LOCUS AR295468
DEFINITION Sequence 7203 from patent US 6537751.
ACCESSION AR295468
VERSION AR295468.1 GI:31682752
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 7203 25-MAR-2003;
FEATURES
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3243 AGAAGTGGAGAGAGCAG 3261
Db 1 AGAAGTGGAGAGAGAGTAG 19

RESULT 181
LOCUS AX937835
DEFINITION Sequence 103 from Patent WO03091381.
ACCESSION AX937835
VERSION AX937835.1 GI:40713817
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Rappold,G.A. and Kirsch,S.
TITLE Height-related gene
JOURNAL Patent: WO 03091381-A 103 06-NOV-2003;
Rappold, Gudrun A. (DE)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Primer: C17C forward"

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1027 TCCATCATGAACGTGCCTG 1045
Db 1 TCCATCTGAAAGTGCTG 19

RESULT 182
LOCUS AB1336
DEFINITION Sequence 13 from Patent WO9911668.
ACCESSION AB1336
VERSION AB1336.1 GI:6731660
KEYWORDS

SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Ivanov,T.R. and Piletz,J.E.
TITLE DNA MOLECULES ENCODING IMIDAZOLINE RECEPTIVE POLYPEPTIDES AND
POLYPEPTIDES ENCODED THEREBY
JOURNAL Patent: WO 9911668-A 13 11-MAR-1999;
IVANOV TINA R (US); PILETZ JOHN E (US)
FEATURES
source 1..20
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1006 GGAGAGGAAGGAGGCCAA 1024
Db 2 GGAGAGGAAGGAGGCCAA 20

RESULT 183
LOCUS A95627
DEFINITION Sequence 29 from Patent WO9925815.
ACCESSION A95627
VERSION A95627.1 GI:6779564
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Herrmann,B. and Kispert,A.
TITLE NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATIONS
THEREOF
JOURNAL Patent: WO 9925815-A 29 27-MAY-1999;
HERRMANN BERNHARD (DE); MAX PLANCK GESELLSCHAFT (DE)
FEATURES
source 1..20
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1449 GCAGCAACAGCAGCAGCAG 1467
Db 2 GCAGCAACAGCAGCAGCAG 20

RESULT 184
LOCUS AR126724/c
DEFINITION Sequence 153 from patent US 6180353.
ACCESSION AR126724
VERSION AR126724.1 GI:14113317
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowsert,L.M.
TITLE Antisense modulation of daxx expression
JOURNAL Patent: US 6180353-A 153 30-JAN-2001;
FEATURES
source 1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
```

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2444 GTGAGGACGACGAGGAGGA 2462
||||| ||||| ||||| ||||| |||||
Db 20 GTGAGGAGGAGGAGGAGGA 2

RESULT 185
AR163954/c
LOCUS
DEFINITION
Sequence 152 from patent US 6271030. PAT 17-OCT-2001
ACCESSION
AR163954
VERSION
AR163954.1 GI:16234817
KEYWORDS
Unknown.
SOURCE
ORGANISM
Unknown.

REFERENCE
1 (bases 1 to 20)
AUTHORS
Monis,B.P., Butler,M.M. and Wyatt,J.
TITLE
Antisense inhibition of C/EBP beta expression
JOURNAL
Patent: US 6271030-A 152 07-AUG-2001;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1249 GAGCGGAGCAGCGGAGC 1267
||||| ||||| ||||| ||||| |||||
Db 19 GAGCGGAGCAGCGGAGC 1

RESULT 186
BD142670/c
LOCUS
DEFINITION
Polypeptide controlling phosphoric acid metabolism, calcium
metabolism, calcification and vitamin D metabolism and DNA encoding
the same.
ACCESSION
BD142670.1 GI:23237615
KEYWORDS
WO 0214504-A/28.
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.

REFERENCE
1 (bases 1 to 20)
AUTHORS
Yamashita,T., Shimada,T., Mizutani,S. and Fukumoto,S.
TITLE
Polypeptide controlling phosphoric acid metabolism, calcium
metabolism, calcification and vitamin D metabolism and DNA encoding
Patent: WO 0214504-A 28 21-FEB-2002;
JOURNAL
KIRIN BREWERY CO LTD,TAKEYOSHI YAMASHITA,TAKASHI SHIMADA, SATORU
MIZUTANI, SEIJI FUKUMOTO
OS Artificial Sequence
PN WO 0214504-A/28
PD 21-FEB-2002
PF 10-AUG-2001 WO 2001JP006944
PR 11-AUG-2000 JP 00P 245144, 21-SEP-2000 JP 00P 287684 PR
22-DEC-2000 JP 00P 391077, 19-APR-2001 JP 01P 121527 PI
TAKAYOSHI YAMASHITA, TANAKASHI SHIMADA, SATORU MIZUTANI, SEIJI PI
FUKUMOTO
PC C12N15/09, C07K7/08, C07K14/47, C07K16/18, C12P21/08, A61K38/17, PC
A61K39/395,
PC A61K48/00, A61P3/02, A61P3/14, A61P13/12, A61P19/00, A61P19/08, PC
A61P19/10
PC A61P35/00
CC synthetic DNA
PH Key
FT source
Location/Qualifiers
1..20

FT
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2208 TCACGGGACCTCCCCCAG 2226
||||| ||||| ||||| ||||| |||||
Db 19 TCACGGGACCTCCCCCAG 1

RESULT 187
BD266348/c
LOCUS
DEFINITION
Universal arrays. PAT 17-JUL-2003
ACCESSION
BD266348
VERSION
BD266348.1 GI:33076116
KEYWORDS
JP 2002539849-A/348.
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.

REFERENCE
1 (bases 1 to 20)
AUTHORS
Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE
Universal arrays
JOURNAL
Patent: JP 2002539849-A 348 26-NOV-2002;
COMMENT
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
OS Artificial Sequence
PN JP 2002539849-A/348
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PI
JIAN BING FAN, JOEL N HIRSCHHORN, XIAOHUA
HUANG, PAUL KAPLAN, ERIC
PI S LANDER,
PI DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR
PC C12Q1/68, C12M1/00, C12N15/09, C12N15/09, G01N33/53, PC
G01N33/566,
PC G01N37/00, C12N15/00, C12N15/00, C12N15/00
CC Primer
CH Key
FT source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 991 GAAGATGACGACCATGGAG 1009
||||| ||||| ||||| ||||| |||||
Db 19 GAAGATGACGACCATGGAG 1

RESULT 188
CQ801587
LOCUS
DEFINITION
Sequence 97 from Patent WO2004033723.
ACCESSION
CQ801587
VERSION
CQ801587.1 GI:47058177
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Mitchell, J. and de Belleruche, J.
TITLE Neurodegenerative disease-associated gene
JOURNAL Patent: WO 2004033723-A 97 22-APR-2004;
IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source 1. .20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 335 CTGGTTCAGTGACCTGACCT 353
Db 1 CTAGTTCAGTGCCCTGACCT 19

RESULT 189
AR193134/c
LOCUS AR193134 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 19 from patent US 6346416.
ACCESSION AR193134
VERSION AR193134.1 GI:20239099
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean, N.M. and Cowse, L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 19 12-FEB-2002;
FEATURES
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2446 GAGGACGACGAGGAGGAG 2464
Db 20 GAGGACGACGAGGAGGAG 2

RESULT 190
AR221426/c
LOCUS AR221426 20 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 65 from patent US 6426220.
ACCESSION AR221426
VERSION AR221426.1 GI:23328476
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett, C.F. and Cowse, L.M.
TITLE Antisense modulation of calreticulin expression
JOURNAL Patent: US 6426220-A 65 30-JUL-2002;
FEATURES
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2446 GAGGACGACGAGGAGGAG 2464

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Mitchell, J. and de Belleruche, J.
TITLE Neurodegenerative disease-associated gene
JOURNAL Patent: WO 2004033723-A 97 22-APR-2004;
IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source 1. .20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 335 CTGGTTCAGTGACCTGACCT 353
Db 1 CTAGTTCAGTGCCCTGACCT 19

RESULT 191
AR312313/c
LOCUS AR312313 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 2850 from patent US 6559294.
ACCESSION AR312313
VERSION AR312313.1 GI:31705739
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais, R., Hoiseth, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A.,
Sankaran, B. and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 2850 06-MAY-2003;
FEATURES
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1598 AGCAGCAGAACTCTCCCTT 1616
Db 2 AGCAGCAGAACTCTCTCAT 20

RESULT 192
AR315939/c
LOCUS AR315939 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 6476 from patent US 6559294.
ACCESSION AR315939
VERSION AR315939.1 GI:31709365
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais, R., Hoiseth, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A.,
Sankaran, B. and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 6476 06-MAY-2003;
FEATURES
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAGCAGC 1462
Db 19 CAGCAGCAGCAACAGCAGC 1

RESULT 193
AR342452/c
LOCUS AR342452 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 2 from patent US 6576423.
ACCESSION AR342452
VERSION AR342452.1 GI:33737462
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Batra,S.K., Brand,R.E., Ringel,J., Faulmann,G., Lohr,M. and Varshney,G.C.
TITLE Specific mucin expression as a marker for pancreatic cancer
JOURNAL Patent: US 6576423-A 2 10-JUN-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 156 GGCTGCCATCAAGGTCATG 174
||||| ||||| ||||| ||||| |||||
Db 20 GGCTGCCCTCAAGGTCGTG 2
RESULT 194
AR342476/c
LOCUS AR342476 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6576423.
ACCESSION AR342476
VERSION AR342476.1 GI:33737486
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Batra,S.K., Brand,R.E., Ringel,J., Faulmann,G., Lohr,M. and Varshney,G.C.
TITLE Specific mucin expression as a marker for pancreatic cancer
JOURNAL Patent: US 6576423-A 26 10-JUN-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 156 GGCTGCCATCAAGGTCATG 174
||||| ||||| ||||| ||||| |||||
Db 20 GGCTGCCCTCAAGGTCGTG 2
RESULT 195
AR342848
LOCUS AR342848 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 14 from patent US 6576742.
ACCESSION AR342848
VERSION AR342848.1 GI:33738121
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Filetz,J.E. and Ivanov,T.R.
TITLE DNA sequence encoding a human imidazoline receptor and method for cloning the same
JOURNAL Patent: US 6576742-A 14 10-JUN-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1006 GGAGAGGAAGGAGGCCAA 1024
||||| ||||| ||||| ||||| |||||

Db 2 GGAGAGAAAGGTCAGCCAA 20
RESULT 196
AR429226
LOCUS AR429226 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 29 from patent US 6642369.
ACCESSION AR429226
VERSION AR429226.1 GI:40189375
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Herrmann,B., Koschorz,B. and Kispert,A.
TITLE Nucleic acids involved in the responder phenotype and applications thereof
JOURNAL Patent: US 6642369-A 29 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1449 GCAGCAACGACGACGACG 1467
||||| ||||| ||||| ||||| |||||
Db 2 GCAGCAAAAGCAGGAGCAG 20
RESULT 197
AX076817
LOCUS AX076817 20 bp DNA linear PAT 06-FEB-2001
DEFINITION Sequence 18 from Patent WO0070024.
ACCESSION AX076817
VERSION AX076817.1 GI:12711257
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Rigal,D., Ghernati,I., Corbine,A. and Darlix,J.L.
TITLE Infectious retroviruses from a leukemic dog cell line with extensive homologies to murine leukemia viruses
JOURNAL Patent: WO 0070024-A 18 23-NOV-2000;
FEATURES Etablissement Francais du Sang (FR)
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3421 GACCTCCCCCACCAGCGCTC 3439
||||| ||||| ||||| ||||| |||||
Db 2 GACCACCCCCACCAGCGCTC 20
RESULT 198
AX139720
LOCUS AX139720 20 bp DNA linear PAT 30-MAY-2001
DEFINITION Sequence 18 from Patent EP1061129.
ACCESSION AX139720
VERSION AX139720.1 GI:14275303
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM

Qy 1449 GCAGCAACAGCAGCAG 1467

```
Db      2 GCAGCAAAAGCAGGAGCAG 20
||||||| ||||| ||||| |||||
RESULT 202
AR084552
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 41 from patent US 5981185.
ACCESSION AR084552
VERSION    AR084552.1 GI:10011323
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 41 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      2 GGAGGAGGAGGAGGAGGAG 20

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      2 GGAGGAGGAGGAGGAGGAG 20

RESULT 203
AR084564/c
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 53 from patent US 5981185.
ACCESSION AR084564
VERSION    AR084564.1 GI:10011335
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 53 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      2 GGAGGAGGAGGAGGAGGAG 20

RESULT 204
AR084570/c
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 59 from patent US 5981185.
ACCESSION AR084570
VERSION    AR084570.1 GI:10011341
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
```

```
JOURNAL    Patent: US 5981185-A 59 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      19 GGAGGAGGAGGAGGAGGAG 1

RESULT 205
AR084575
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 64 from patent US 5981185.
ACCESSION AR084575
VERSION    AR084575.1 GI:10011346
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 64 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      3 GGAGGAGGAGGAGGAGGAG 21

RESULT 206
AR084581
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 70 from patent US 5981185.
ACCESSION AR084581
VERSION    AR084581.1 GI:10011352
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 70 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      3 GGAGGAGGAGGAGGAGGAG 21

RESULT 207
AR084594/c
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 70 from patent US 5981185.
ACCESSION AR084594
VERSION    AR084594.1 GI:10011352
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 70 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      183 GGAGGACGAGGAGGAGAG 201
||||| ||||| ||||| |||||
Db      1 GGAGGAGGAGGAGGAGGAG 19

RESULT 207
AR084594/c
LOCUS      21 bp      DNA      linear      PAT 01-SEP-2000
DEFINITION Sequence 70 from patent US 5981185.
ACCESSION AR084594
VERSION    AR084594.1 GI:10011352
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
```

Query Match	0.4%;	Score 15.8;	DB 1;	Length 21;
Best Local Similarity	89.5%;	Pred. No. 1.9e+02;		
Matches 17;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
QY 3252	GAAGAGCAGGGCTGGACC	3270		
DB 1	GAGGAGCAGGGCTGGAGC	19		
RESULT 210				
BD223665				
LOCUS	BD223665			
DEFINITION	Mutations in and genomic structure of HERG - a long QT syndrome gene.			
ACCESSION	BD223665			
VERSION	BD223665.1	GI:33033435		
KEYWORDS	JP 2002521065-A/91.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
AUTHORS	Keating,M.T. and Splawski,I.			
TITLE	Mutations in and genomic structure of HERG - a long QT syndrome gene			
JOURNAL	Patent: JP 2002521065-A 91 16-JUL-2002;			
COMMENT	UNIVERSITY OF UTAH RESEARCH FOUNDATION			
	OS Homo sapiens (human)			
	PN JP 2002521065-A/91			
	PD 16-JUL-2002			
	PF 20-JUL-1999 JP 2000562554			
	PR 27-JUL-1998 US 09/128847,06-JAN-1999 US 09/226012 P1			
	MARK T KEATING,IGOR SPLAWSKI			
	PC C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N1/15,C12N1/19,PC C12N1/21,			
	PC C12N5/10,C12N5/10,C12Q1/02,C12Q1/68,G01N33/15,G01N33/50,G01N33/PC 53,			
	PC G01N33/53,G01N33/566,G01N33/577//C12P21/08,C12N15/00,C12N5/00,PC C12N5/00			
	CC Mutations in and genomic structure of HERG - a long QT CC syndrome gene			
	FH Key Location/Qualifiers			
	FT source 1..21			
	FT Location/Qualifiers			
	1..21			
	/organism="Homo sapiens"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:9606"			
FEATURES				
source				
Query Match	0.4%;	Score 15.8;	DB 1;	Length 21;
Best Local Similarity	89.5%;	Pred. No. 1.9e+02;		
Matches 17;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
QY 3252	GAAGAGCAGGGCTGGACC	3270		
DB 1	GAGGAGCAGGGCTGGAGC	19		
RESULT 211				
BD250882/c				
LOCUS	BD250882			
DEFINITION	A plant disease resistance signalling gene: materials and methods relating thereto.			
ACCESSION	BD250882			
VERSION	BD250882.1	GI:33060652		
KEYWORDS	JP 2002524044-A/15.			
SOURCE	synthetic construct			
ORGANISM	other sequences; artificial			
REFERENCE	1 (bases 1 to 21)			

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolik, S., Daley, G.Q. and McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 1779 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.9e+02;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2107 CCCCTGCTCAGCCCTGCG 2127.
||| |||||:|||||
Db 1 CCACCGCTCGCCCGCTGCG 21

RESULT 216
AX706249/c
LOCUS AX706249
DEFINITION Sequence 381 from Patent WO03014145.
ACCESSION AX706249
VERSION AX706249.1 GI:29562720
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Liu, C., Edgington, T.S. and Prescott, M.P.
TITLE Peptides that bind to atherosclerotic lesions
JOURNAL Patent: WO 03014145-A 381 20-FEB-2003;
Novartis AG (CH) ; Novartis Pharma GmbH (AT) ; The Scripps Research Institute (US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="A sequence from a combinatorial phage display library."

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1181 ACCAGCGGCGCGCGCAT 1199
||||| |||||:|||||
Db 20 ACCAGCGGCGCGCGCAT 2

RESULT 217
AR084541/c
LOCUS AR084541
DEFINITION Sequence 30 from patent US 5981185.
ACCESSION AR084541
VERSION AR084541.1 GI:10011312
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)
AUTHORS Matson, R.S., Coassin, P.J., Rampal, J.B. and Caskey, C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 30 09-NOV-1999;
FEATURES Location/Qualifiers
source 1..30
/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 2.8e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
||||| |||||:|||||
Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 218
AR165925/c
LOCUS AR165925
DEFINITION Sequence 4 from patent US 6280938.
ACCESSION AR165925
VERSION AR165925.1 GI:16241014
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Ranum, L.P.W., Koob, M.D., Moseley-Alldredge, M.L. and Benzow, K.A.
TITLE SCA7 gene and method of use
JOURNAL Patent: US 6280938-A 4 28-AUG-2001;
FEATURES Location/Qualifiers
source 1..30
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 2.8e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
||||| |||||:|||||
Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 219
E34522/c
LOCUS E34522
DEFINITION SCA7 gene and utilization thereof.
ACCESSION E34522
VERSION E34522.1 GI:13018890
KEYWORDS JP 1999206393-A/4.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 30)
AUTHORS Laura, B.W.R. and Michael, D.K.
TITLE SCA7 gene and utilization thereof
JOURNAL Patent: JP 1999206393-A 4 03-AUG-1999;
THE REGENTS OF THE UNIVERSITY OF MINNESOTA
COMMENT OS Homo sapiens (human)
PN JP 1999206393-A/4
PD 03-AUG-1999
PF 19-AUG-1998 JP 1998294732
PR 19-AUG-1997 US 60/056170
PI LAURA B W RANUM, MICHAEL D KUBU
PC C12N15/09, C07K14/47, C07K16/18, C12Q1/68, G01N33/53, PC
G01N33/566//C12P21/02,
PC C12N15/00
CC
FH Key Location/Qualifiers
FT Source 1..30
/organism="Homo sapiens (human)".
FEATURES Location/Qualifiers
source 1..30
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 2.8e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGAGCTGCAGCAGCAGCAGCAG 1146
| | | | | | | | | | | | | | | | | | | | | |
Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 220
184405/c
LOCUS 184405
DEFINITION Sequence 6 from patent US 5695933.
ACCESSION I84405
VERSION I84405.1 GI:3021925
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Schalling,M., Hudson,T.J. and Housman,D.E.
TITLE Direct detection of expanded nucleotide repeats in the human genome
JOURNAL Patent: US 5695933-A 6 09-DEC-1997;
FEATURES Location/Qualifiers
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 2.8e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGAGCTGCAGCAGCAGCAGCAG 1146
| | | | | | | | | | | | | | | | | | | | | |
Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 221
184410
LOCUS 184410
DEFINITION Sequence 11 from patent US 5695933.
ACCESSION I84410
VERSION I84410.1 GI:3021930
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Schalling,M., Hudson,T.J. and Housman,D.E.
TITLE Direct detection of expanded nucleotide repeats in the human genome
JOURNAL Patent: US 5695933-A 11 09-DEC-1997;
FEATURES Location/Qualifiers
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 2.8e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGAGCTGCAGCAGCAGCAGCAG 1146
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 30

RESULT 222
AR045387/c
LOCUS AR045387
DEFINITION Sequence 180 from patent US 5817796.
ACCESSION AR045387
VERSION AR045387.1 GI:5966852
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 180 06-OCT-1998;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGGAGGAGGAG 1218
| | | | | | | | | | | | | | | | | |
Db 17 AGGAGGAGAGGAGGAGGAG 1

RESULT 223
AR045389/c
LOCUS AR045389
DEFINITION Sequence 182 from patent US 5817796.
ACCESSION AR045389
VERSION AR045389.1 GI:5966854
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 182 06-OCT-1998;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1201 GAGGAGCAGAGGAGGAG 1217
| | | | | | | | | | | | | | | | | |
Db 17 GAGGAGGAGAGGAGGAGGAG 1

RESULT 224
AR045395/c
LOCUS AR045395
DEFINITION Sequence 188 from patent US 5817796.
ACCESSION AR045395
VERSION AR045395.1 GI:5966860
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 188 06-OCT-1998;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1201 GAGGAGCAGAGGAGGAG 1217
| | | | | | | | | | | | | | | | | |
Db 17 GAGGAGGAGAGGAGGAGGAG 1

RESULT 225
AR045387/c
LOCUS AR045387
DEFINITION Sequence 180 from patent US 5817796.
ACCESSION AR045387
VERSION AR045387.1 GI:5966852
KEYWORDS


```
Db      ||||||| |||||
17 TCACGGAGGAGGAG 1

RESULT 225
BD253914/c
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD253914
VERSION     BD253914.1 GI:33063684
KEYWORDS   JP 2002541795-A/1707.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt, L., Zwick, M., Pavco, P. and McSwiggen, J.
TITLE     Regulation of repressor genes using nucleic acid molecules
JOURNAL   Patent: JP 2002541795-A 1707 10-DEC-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT   OS Eukaryote
          PN JP 2002541795-A/1707
          PD 10-DEC-2002
          PF 11-APR-2000 JP 2000611654
          PR 12-APR-1999 US 60/129390
          PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
          C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02, C12P21/02/A61K31/711, (C12N5/10, C12R1/91), (C12P21/02, PC
          C12R1/91),
          PC (C12P21/02, C12R1/91), (C12P21/02, C12R1/91), C12N15/00, C12N5/00,
          PC A61K37/02,
          PC (C12N5/00, C12R1/91)
          CC Regulation of repressor genes using nucleic acid molecules FH
          Key source
          FT source
          FT Location/Qualifiers
             1..17
             /organism="Eukaryote".
             Location/Qualifiers
             1..17
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1669 TCCCCAGGGCCCCCAGG 1685
Db      ||||||| |||||
17 TCACCGAGGAGCCCGAG 1

RESULT 226
CQ623062
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7802 from Patent WO0192524.
ACCESSION  CQ623062
VERSION     CQ623062.1 GI:41673280
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
          Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7802 06-DEC-2001;
          Aecomica, Inc. (US)
FEATURES   source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"

Db      ||||||| |||||
17 TCACGGAGGAGGAG 1

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1669 TCCCCAGGGCCCCCAGG 1685
Db      ||||||| |||||
17 TCACCGAGGAGCCCGAG 1

RESULT 226
CQ623062
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7802 from Patent WO0192524.
ACCESSION  CQ623062
VERSION     CQ623062.1 GI:41673280
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
          Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7802 06-DEC-2001;
          Aecomica, Inc. (US)
FEATURES   source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
```

```
/db_xref="taxon:9606"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1120 CAGCAGCAGCTGCAGCA 1136
Db      ||||||| |||||
1 CAGCAGCAGCTGAAGCA 17

RESULT 227
144894/c
LOCUS      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 31 from patent US 5635617.
ACCESSION  144894
VERSION     144894.1 GI:2469607
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Doran, J.L., Kay, W.W., Collinson, S.Karen. and Clouthier, S.C.
TITLE     Methods and compositions comprising the agfa gene for detection of
          Salmonella
JOURNAL   Patent: US 5635617-A 31 03-JUN-1997;
          Location/Qualifiers
          source
             1..17
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db      ||||||| |||||
17 CCGGAACAGCTATGAC 1

RESULT 228
152439/c
LOCUS      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 180 from patent US 5646042.
ACCESSION  152439
VERSION     152439.1 GI:2473640
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 180 08-JUL-1997;
          Location/Qualifiers
          source
             1..17
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGGAGGAG 1218
Db      ||||||| |||||
17 AGGAGGAGGAGGAG 1

RESULT 229
152441/c
LOCUS      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 182 from patent US 5646042.
ACCESSION  152441
FEATURES   source
             1..17
             /organism="unassigned DNA"
```

```

VERSION      152441.1  GI:2473642
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myb targeted ribozymes
JOURNAL     Patent: US 5646042-A 182 08-JUL-1997;
FEATURES    Location/Qualifiers
            source
            1. .17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1201 GAGGAGCAGGAGGAGGA 1217
Db 17 GAGGAGGAGGAGGAGGA 1

RESULT 230
LOCUS      152447/c
DEFINITION Sequence 188 from patent US 5646042.
ACCESSION  152447
VERSION    152447.1  GI:2473648
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 188 08-JUL-1997;
FEATURES  Location/Qualifiers
            source
            1. .17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 179 TCACGGAGGACGAGGAG 195
Db 17 TCACGGAGGAGGAGGAG 1

RESULT 231
LOCUS      AR327104
DEFINITION Sequence 4506 from patent US 6566127.
ACCESSION  AR327104
VERSION    AR327104.1  GI:33712912
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE     Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL   Patent: US 6566127-A 4506 20-MAY-2003;
FEATURES  Location/Qualifiers
            source
            1. .17
            /organism="unknown"
            /mol_type="unassigned RNA"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;

QY 2641 CTGCATGCTGACAGCAA 2657
Db 1 CTGGATGCTGACAGCAA 17

RESULT 232
LOCUS      AR464125
DEFINITION Sequence 7802 from patent US 6686188.
ACCESSION  AR464125
VERSION    AR464125.1  GI:42699182
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 7802 03-FEB-2004;
FEATURES  Location/Qualifiers
            source
            1. .17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1120 CAGCAGCAGCTGCAGCA 1136
Db 1 CAGCAGCAGCTGAAGCA 17

RESULT 233
LOCUS      AX004427/c
DEFINITION Sequence 9 from Patent WO9916899.
ACCESSION  AX004427
VERSION    AX004427.1  GI:9927886
KEYWORDS
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
REFERENCE  1
AUTHORS   Anctil,J.L. and Cote,G.
TITLE     Molecular diagnostic of glaucomas associated with chromosomes 2 and 6
JOURNAL   Patent: WO 9916899-A 9 08-APR-1999;
            ANCTIL JEAN LOUIS (CA); COTE GILLES (CA)
FEATURES  Location/Qualifiers
            source
            1. .17
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="OLIGONUCLEOTIDE"

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AAGGATGGGAGTGGTGA 2753
Db 17 AAGGATGGGATGGTGA 1

RESULT 234
LOCUS      AX215324
DEFINITION Sequence 766 from Patent WO0159103.

```

```
ACCESSION AX215324
VERSION AX215324.1 GI:15525367
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1119 GCAGCAGCTGCAGC 1135
||| ||||| ||||| |||||
Db 1 GCGGCAGCAGCTGCAGC 17
RESULT 235
AX215325
LOCUS AX215325 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 767 from Patent WO0159103.
ACCESSION AX215325
VERSION AX215325.1 GI:15525368
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1122 GCAGCAGCTGCAGC 1138
||| ||||| ||||| |||||
Db 1 GCGGCAGCAGCTGCAGC 17
RESULT 236
AX216107
LOCUS AX216107 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1549 from Patent WO0159103.
ACCESSION AX216107
VERSION AX216107.1 GI:15526150
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1123 GCAGCAGCTGCAGCA 1139
||| ||||| ||||| |||||
Db 1 CAGCAGCTGCAGCATCA 17
RESULT 237
AX216112
LOCUS AX216112 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1554 from Patent WO0159103.
ACCESSION AX216112
VERSION AX216112.1 GI:15526155
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 182 CGGAGGACGAGGAGGAA 198
||| ||||| ||||| |||||
Db 1 CGGAGGACGAGGAGGAA 17
RESULT 238
AX216350
LOCUS AX216350 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1792 from Patent WO0159103.
ACCESSION AX216350
VERSION AX216350.1 GI:15526411
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 182 CGGAGGACGAGGAGGAA 198
||| ||||| ||||| |||||
Db 1 CGGAGGACGAGGAGGAA 17
RESULT 239
AX216350
LOCUS AX216350 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1792 from Patent WO0159103.
ACCESSION AX216350
VERSION AX216350.1 GI:15526411
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 182 CGGAGGACGAGGAGGAA 198
||| ||||| ||||| |||||
Db 1 CGGAGGACGAGGAGGAA 17
```

```

source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="Nucleic Acid"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1120 CAGCAGCAGCTGCAGCA 1136
Db 1 CGGCAGCAGCTGCAGCA 17

RESULT 239
AX216928
LOCUS AX216928 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2370 from Patent WO0159103.
ACCESSION AX216928
VERSION AX216928.1 GI:15526989
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2370 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="Nucleic Acid"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGCAGCAGGAGGAAGA 200
Db 1 GAGCAGCAGGAGCAGAGA 17

RESULT 240
AX273039
LOCUS AX273039 17 bp RNA linear PAT 29-OCT-2001
DEFINITION Sequence 608 from Patent WO0162911.
ACCESSION AX273039
VERSION AX273039.1 GI:16545776
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlwiltz, I., Mcswiggen, J.A., Hamblin, P.A. and
Ellis, J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 608 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1369 CAGCTGGAGGAGCAGCG 1385
Db 17 CACCTGGAGGAGCAGCG 1

RESULT 243
AX738227
LOCUS AX738227 17 bp DNA linear PAT 08-MAY-2003

```

```

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCA 1145
Db 1 CTGCAGCAGCAGCAGCA 17

RESULT 241
AX423572/c
LOCUS AX423572/c 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1908 from Patent WO0188124.
ACCESSION AX423572
VERSION AX423572.1 GI:21526954
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlwiltz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1908 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3788 CGGGCCACCTCGACGGG 3804
Db 17 CGGGCCACCTCGTCGGG 1

RESULT 242
AX530712/c
LOCUS AX530712/c 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 221 from Patent EP1239051.
ACCESSION AX530712
VERSION AX530712.1 GI:25253229
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 221 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1369 CAGCTGGAGGAGCAGCG 1385
Db 17 CACCTGGAGGAGCAGCG 1

RESULT 243
AX738227
LOCUS AX738227 17 bp DNA linear PAT 08-MAY-2003

```

```
DEFINITION Sequence 3817 from Patent WO03025177.
ACCESSION AX738227
VERSION AX738227.1 GI:30517515
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL
FEATURES
source
1 Telerman,A., Anson,R. and Tuijinder,M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 3817 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 213 GATCAACATGCTGAAAA 229
Db 1 GATCAACATGCTGAAAA 17
RESULT 244
AX753836/c
LOCUS AX753836
DEFINITION Sequence 183 from Patent WO03037931.
ACCESSION AX753836
VERSION AX753836.1 GI:32166533
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Shannon,M. and Phan,T.
JOURNAL Human angiotensin-like protein 1
Patent: WO 03037931-A 183 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3428 CCCACCGCCCTGCTGCTG 3444
Db 17 CCCACCGCCCTGCTGCTG 1
RESULT 245
CQ816652
LOCUS CQ816652
DEFINITION Sequence 3 from Patent WO2004016651.
ACCESSION CQ816652
VERSION CQ816652.1 GI:48144923
KEYWORDS Euprosthonops sp. WO2004016651
SOURCE Euprosthonops sp. WO2004016651
ORGANISM Eukaryota; Metazoa; Arthropoda; Chelicerata; Arachnida; Araneae;
REFERENCE Araneomorphae; Entelegynae; Lycosoidea; Pisauridae; Euprosthonops.
1
QY 1003 CATGGAGAGGAGGAGA 1019
Db 17 CCTGGAGAGGAGGAGA 1
AUTHORS mcqueen Mason,S. and Pouchkina,N.
TITLE Spider silk polypeptide
PATENT: WO 2004016651-A 3 26-FEB-2004;
The University of York (GB)
FEATURES
source
1..18
Location/Qualifiers
/organism="Euprosthonops sp. WO2004016651"
/mol_type="unassigned DNA"
/db_xref="taxon:280596"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1128 GCTGCAGCAGCAGCAGC 1144
Db 1 GCTGCAGCAGCAGCAGC 17
RESULT 246
AR229576
LOCUS AR229576
DEFINITION Sequence 21 from patent US 6449562.
ACCESSION AR229576
VERSION AR229576.1 GI:27269203
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Chandler,V.S., Fulton,J.R. and Chandler,M.B.
TITLE Multiplexed analysis of clinical specimens apparatus and method
JOURNAL Patent: US 6449562-A 21 10-SEP-2002;
Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1003 CATGGAGAGGAGGAGA 1019
Db 2 CCTGGAGAGGAGGAGA 18
RESULT 247
AR229577/c
LOCUS AR229577
DEFINITION Sequence 22 from patent US 6449562.
ACCESSION AR229577
VERSION AR229577.1 GI:27269204
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Chandler,V.S., Fulton,J.R. and Chandler,M.B.
TITLE Multiplexed analysis of clinical specimens apparatus and method
JOURNAL Patent: US 6449562-A 22 10-SEP-2002;
Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1003 CATGGAGAGGAGGAGA 1019
Db 17 CCTGGAGAGGAGGAGA 1
```

```
RESULT 248
AX336922 LOCUS AX336922 18-bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 30 from patent US 6566131.
ACCESSION AR336922
VERSION AR336922.1 GI:33722776
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Cowsett,L.M.
TITLE Antisense modulation of Smad6 expression
JOURNAL Patent: US 6566131-A 30 20-MAY-2003;
FEATURES
source
1. .18
Location/Qualifiers
/mol_type="genomic DNA"
/organism="unknown"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1128 GCTGCAGCAGCAGCAGC 1144
|||||
Db 1 GCTCAGCAGCAGCAGC 17

RESULT 249
AX398208 LOCUS AX398208 18 bp DNA linear PAT 27-MAY-2002
DEFINITION Sequence 13 from Patent WO220790.
ACCESSION AX398208
VERSION AX398208.1 GI:21261023
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Geraci,D., Colombo,P., Duro,G., Izzo,V. and Costa,M.A.
TITLE Parietaria judaica ns-ltp antigen variants, uses thereof and
compositions comprising them
JOURNAL Patent: WO 0220790-A 13 14-MAR-2002;
CONSIGLIO NAZIONALE DELLE RICERCHE (IT)
FEATURES
source
1. .18
Location/Qualifiers
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
misc_feature 4
/notes="Residue mutated with respect to the corresponding
position in Par j1.0102"
misc_feature 6
/notes="Residue mutated with respect to the corresponding
position in Par j1.0102"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1278 GGAGCAGCAGCGCGGC 1294
|||||
Db 2 GGAGCAGCAGCGCGGC 18

RESULT 250
AX663784 LOCUS AX663784 18 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 159 from Patent WO2097127.
ACCESSION AX663784
```

```
VERSION AX663784.1 GI:29163964
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and
Kroegel,C.
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis
and treatment of chronic lung disease
JOURNAL Patent: WO 02097127-A 159 05-DEC-2002;
Bayer Aktiengesellschaft (DE)
FEATURES
source
1. .18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="M36820 forward sequence"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1270 CAGGAGCAGCAGCAGCA 1286
|||||
Db 17 CAGGAGCAGCAGCAGCA 1

RESULT 251
BD097068 LOCUS BD097068 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Therapeutic agents.
ACCESSION BD097068
VERSION BD097068.1 GI:22642656
KEYWORDS WO 0151480-A/27.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Enoki,T., Yamashita,S., Nishimura,K., Sagawa,H. and Kato,I.
TITLE Therapeutic agents
JOURNAL Patent: WO 0151480-A 27 19-JUL-2001;
TAKARA SHUZO CO LTD,TATSUJI ENOKI,SHUSAKU YAMASHITA,KAORI
NISHIMURA, HIROAKI SAGAWA,IKUNOSHIN KATO
COMMENT OS Artificial Sequence
PN WO 0151480-A/27
PD 19-JUL-2001
PF 11-JAN-2001 WO 2001JP000082
PR 13-JAN-2000 JP 00P 4989,03-OCT-2000 JP 00P 303711 PI
TATSUJI ENOKI,SHUSAKU YAMASHITA,KAORI NISHIMURA,HIROAKI SAGAWA,
PI IKUNOSHIN KATO
PC C07D309/32,C07D493/08,A61K31/351,A61K31/357,A61P43/00,A61P43/
PC 111,A61P1/16,
PC A61P29/00
CC Designed primer based on nucleotide sequence of human CC
macrophage
CC inflammatory protein-2-alpha mRNA.
FH Key Location/Qualifiers
FT source
1. .18
Location/Qualifiers
/organism="Artificial Sequence".
FEATURES
source
1. .18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1270 CAGGAGCAGCAGCAGCA 1286
|||||
Db 17 CAGGAGCAGCAGCAGCA 1
```

```
RESULT 252
AR267638/c
LOCUS           AR267638           19 bp      DNA      linear      PAT 10-APR-2003
DEFINITION      Sequence 26 from patent US 6497880.
ACCESSION       AR267638
VERSION         AR267638.1 GI:29697745
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 19)
AUTHORS        Wisniewski,J.
TITLE          Heat shock genes and proteins from Neisseria meningitidis, Candida
              glabrata and Aspergillus fumigatus
JOURNAL        Patent: US 6497880-A 26 24-DEC-2002;
FEATURES       Location/Qualifiers
               source
               1..19
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2979 CCGAAGTACAGAAGC 2995
Db 18 CCGAAGTACAGAAGC 2

RESULT 253
AR293745/c
LOCUS           AR293745           19 bp      DNA      linear      PAT 12-JUN-2003
DEFINITION      Sequence 5480 from patent US 6537751.
ACCESSION       AR293745
VERSION         AR293745.1 GI:31681029
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 19)
AUTHORS        Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE          Biallelic markers for use in constructing a high density
              disequilibrium map of the human genome
JOURNAL        Patent: US 6537751-A 5480 25-MAR-2003;
FEATURES       Location/Qualifiers
               source
               1..19
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1568 GAGAGGTAGAGAGAGA 1584
Db 19 GAGAGGTAGAGAGAGA 3

RESULT 254
AR086207
LOCUS           AR086207           20 bp      DNA      linear      PAT 07-SEP-2000
DEFINITION      Sequence 28 from patent US 5985558.
ACCESSION       AR086207
VERSION         AR086207.1 GI:10012973
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 20)
AUTHORS        Dean,N.M., McKay,R., Miraglia,L. and Baker,B.
TITLE          Antisense oligonucleotide compositions and methods for the

inhibition of c-Jun and c-Fos
Patent: US 5985558-A 28 16-NOV-1999;
Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 CCGCCGAGGCTCAAGTC 770
Db 2 CCTCCGAGGCTCAAGTC 18

RESULT 255
AR108704
LOCUS           AR108704           20 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION      Sequence 3 from patent US 611085.
ACCESSION       AR108704
VERSION         AR108704.1 GI:12824191
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 20)
AUTHORS        Cook,P.Dan. and Manoharan,M.
TITLE          Carbamate-derivatized nucleosides and oligonucleosides
JOURNAL        Patent: US 611085-A 3 29-AUG-2000;
FEATURES       Location/Qualifiers
               source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCCAGGCTCCC 1672
Db 3 CATCCCCCAGGCCACCC 19

RESULT 256
AR176773
LOCUS           AR176773           20 bp      DNA      linear      PAT 17-DEC-2001
DEFINITION      Sequence 28 from patent US 6312900.
ACCESSION       AR176773
VERSION         AR176773.1 GI:17919128
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 20)
AUTHORS        Dean,N.M., McKay,R., Miraglia,L. and Baker,B.
TITLE          Antisense oligonucleotide compositions and methods for the
              modulation of activating protein 1
JOURNAL        Patent: US 6312900-A 28 06-NOV-2001;
FEATURES       Location/Qualifiers
               source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 CCGCCGAGGCTCAAGTC 770
Db 2 CCTCCGAGGCTCAAGTC 18
```

```
RESULT 257
BD143962/c
LOCUS      BD143962      20 bp      DNA      linear      PAT 17-JAN-2003
DEFINITION Human bladder cancer antigen.
ACCESSION  BD143962
VERSION    BD143962.1 GI:27849720
KEYWORDS   JP 2002112779-A/10.
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Kawakami,H., Fujita,T. and Ito,K.
TITLE      Human bladder cancer antigen
JOURNAL    Patent: JP 2002112779-A 10 16-APR-2002;
KEIO UNIVERSITY
COMMENT    OS Artificial Sequence
          PN JP 2002112779-A/10
          PD 16-APR-2002
          PF 03-OCT-2000 JP 2000304143
          PI HIROSHI KAWAKAMI,TOMONOBU FUJITA,KEIICHI ITO
          PC C12N15/09,A01K67/027,A61K38/00,A61K39/00,A61K45/00,A61P35/00,
          PC C07K14/82,
          PC C07K16/32,C07K19/00,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12P21/ PC
          02, C12P21/08,C12Q1/68,G01N33/15,G01N33/50,G01N33/53,G01N33/53, PC
          G01N33/566,
          PC G01N33/574,G01N33/577,C12N15/00,A61K37/02,C12N5/00 CC
          Description of Artificial Sequence:KU-BL-2 Antisense Primer FH
          Key Location/Qualifiers
          FT source 1..20
          FT /organism='Artificial Sequence'.
FEATURES
source     1..20
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      184 GAGGACGAGGAGGAAGA 200
Db      20 GAGGAGAGGAGGAGAGA 4
|||||
|||||

RESULT 258
CQ868870
LOCUS      CQ868870      20 bp      DNA      linear      PAT 13-SEP-2004
DEFINITION Sequence 24 from Patent WO2004074429.
ACCESSION  CQ868870
VERSION    CQ868870.1 GI:51998797
KEYWORDS   synthetic construct
SOURCE     other sequences; artificial sequences.
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS    freskg Rd,P.O., Gouliaev,A.H., Thisted,T. and Olsen,E.K.
TITLE      Method for producing second-generation library
JOURNAL    Patent: WO 2004074429-A 24 02-SEP-2004;
          Nuevolution A/S (DK)
FEATURES
source     1..20
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="synthetic construct"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1656 CATCCCCCAGGCTCCC 1672
Db      3 CATCCCCCAGGCCACCC 19
|||||
|||||

RESULT 261
AR489922/c
LOCUS      AR489922      20 bp      DNA      linear      PAT 15-MAY-2004
DEFINITION Sequence 45 from patent US 6710174.
ACCESSION  AR489922
VERSION    AR489922.1 GI:47257035
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Bennett,C.F. and Watt,A.T.
TITLE      Antisense modulation of glioma-associated oncogene-2 expression
JOURNAL    Patent: US 6440739-A 23 27-AUG-2002;
          Location/Qualifiers
          FT source 1..20
          FT /organism="unknown"
          FT /mol_type="genomic DNA"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1477 CAGCAGCAGCAGCAGCT 1493
Db      17 CAGCAGCAGCAGCAACT 1
|||||
|||||

RESULT 260
AR261783
LOCUS      AR261783      20 bp      DNA      linear      PAT 29-JAN-2003
DEFINITION Sequence 3 from patent US 6322987.
ACCESSION  AR261783
VERSION    AR261783.1 GI:28072917
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Cook,P.D. and Manoharan,M.
TITLE      Carbamate-derivatized nucleosides and oligonucleosides
JOURNAL    Patent: US 6322987-A 3 27-NOV-2001;
          Location/Qualifiers
          FT source 1..20
          FT /organism="unknown"
          FT /mol_type="genomic DNA"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1656 CATCCCCCAGGCTCCC 1672
Db      3 CATCCCCCAGGCCACCC 19
|||||
|||||

RESULT 261
AR489922/c
LOCUS      AR489922      20 bp      DNA      linear      PAT 15-MAY-2004
DEFINITION Sequence 45 from patent US 6710174.
ACCESSION  AR489922
VERSION    AR489922.1 GI:47257035
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Bennett,C.F. and Watt,A.T.
TITLE      Antisense modulation of glioma-associated oncogene-2 expression
JOURNAL    Patent: US 6440739-A 23 27-AUG-2002;
          Location/Qualifiers
          FT source 1..20
          FT /organism="unknown"
          FT /mol_type="genomic DNA"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1656 CATCCCCCAGGCTCCC 1672
Db      3 CATCCCCCAGGCCACCC 19
|||||
|||||

RESULT 261
AR489922/c
LOCUS      AR489922      20 bp      DNA      linear      PAT 15-MAY-2004
DEFINITION Sequence 45 from patent US 6710174.
ACCESSION  AR489922
VERSION    AR489922.1 GI:47257035
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Bennett,C.F. and Watt,A.T.
TITLE      Antisense modulation of glioma-associated oncogene-2 expression
JOURNAL    Patent: US 6440739-A 23 27-AUG-2002;
          Location/Qualifiers
          FT source 1..20
          FT /organism="unknown"
          FT /mol_type="genomic DNA"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1656 CATCCCCCAGGCTCCC 1672
Db      3 CATCCCCCAGGCCACCC 19
|||||
|||||

RESULT 261
AR489922/c
LOCUS      AR489922      20 bp      DNA      linear      PAT 15-MAY-2004
DEFINITION Sequence 45 from patent US 6710174.
ACCESSION  AR489922
VERSION    AR489922.1 GI:47257035
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Bennett,C.F. and Watt,A.T.
TITLE      Antisense modulation of glioma-associated oncogene-2 expression
JOURNAL    Patent: US 6440739-A 23 27-AUG-2002;
          Location/Qualifiers
          FT source 1..20
          FT /organism="unknown"
          FT /mol_type="genomic DNA"
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1656 CATCCCCCAGGCTCCC 1672
Db      3 CATCCCCCAGGCCACCC 19
|||||
|||||
```


TITLE Antisense inhibition of vascular endothelial growth factor
receptor-1 expression
JOURNAL Patent: US 6710174-A 45 23-MAR-2004;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2641 CTCATGCTGACAGCAA 2657
|||||
Db 20 CTGATGCTGACAGCAA 4

RESULT 262
LOCUS AX662846 20 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 57 from Patent WO20061134.
ACCESSION AX662846
VERSION AX662846.1 GI:29163427
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Roninson, I.B. and Chang, B.D.
TITLE Reagents and methods for identifying and modulating expression of tumor senescence genes
JOURNAL Patent: WO 02061134-A 57 08-AUG-2002;
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US)
FEATURES Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="PCR primer"

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 462 AGACATCAAGGGGCGAGA 478
|||||
Db 1 AGACATCAAGGGGCGAGA 17

RESULT 263
LOCUS DOG2144P01/c 20 bp DNA linear MAM 29-NOV-1996
DEFINITION Canis familiaris (clone 2144F) DNA, STS primer.
ACCESSION L78629
VERSION L78629.1 GI:1372918
KEYWORDS genetic marker; microsatellite; tetranucleotide repeat.
SOURCE Canis familiaris (dog)
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1 (bases 1 to 20)
AUTHORS Francisco, L.V., Langston, A.A., Mellersh, C.S., Neal, C.L. and Ostrander, E.A.
TITLE A class of highly polymorphic tetranucleotide repeats for canine genetic mapping
JOURNAL Mamm. Genome 7 (5), 359-362 (1996)
MEDLINE 96269603
PUBMED 8661717
FEATURES Location/Qualifiers
source
1..20
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"

primer_bind /clone="2144F"
complement(1..20)
/note="2144F"
/evidence=experimental

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 269 CCTTCATCAAGAGAGCCCC 288
|||||
Db 20 CCTTCATCAAGAGAGCCAC 1

RESULT 264
LOCUS AR103769/c 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 293 from patent US 6087485.
ACCESSION AR103769
VERSION AR103769.1 GI:12815357
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Brooks-Wilson, A.R., Buckler, A., Cardon, L., Carey, A.H., Galvin, M., Miller, A. and North, M.
TITLE Asthma related genes
JOURNAL Patent: US 6087485-A 293 11-JUL-2000;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2104 GGGCCCCCTGCTCAGCCCC 2123
|||||
Db 20 GGCACCCCTGCTCAGCCTCC 1

RESULT 265
LOCUS AR117718/c 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 26 from patent US 6140126.
ACCESSION AR117718
VERSION AR117718.1 GI:14098624
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett, C. Frank. and Cowse, L.M.
TITLE Antisense modulation of Y-box binding protein 1 expression
JOURNAL Patent: US 6140126-A 26 31-OCT-2000;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 15 CCCAGCCCCCGCCCGCAGCC 34
|||||
Db 20 CCAGCAGCCGCGCCCGCC 1

RESULT 266
LOCUS AR121002/c

LOCUS AR121002 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 23 from patent US 6159694.
ACCESSION AR121002
VERSION AR121002.1 GI:14104578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kartas, J.G.
TITLE Antisense modulation of stat3 expression
JOURNAL Patent: US 6159694-A 23 12-DEC-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;
Matches 17; Conservative 0;

QY 1118 AGCAGCAGCAGCTGCAGCAG 1137
Db 20 AGCAGCAGATGCTGGAGCAG 1

RESULT 267
AR129483
LOCUS AR129483 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 66 from patent US 6187533.
ACCESSION AR129483
VERSION AR129483.1 GI:14117380
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bell, G.I., Yamagata, K., Oda, N., Kaisaki, P.J., Furuta, H.,
Horikawa, Y. and Menzel, S.
TITLE Mutations in the diabetes susceptibility genes hepatocyte nuclear
factor (HNF) 1 alpha (.alpha.), HNF1.beta. and HNF4.alpha
JOURNAL Patent: US 6187533-A 66 13-FEB-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;
Matches 17; Conservative 0;

QY 481 GTGCTCTGACAGAGATGC 500
Db 1 GTGCGGGGACAGAGATGC 20

RESULT 268
AR130120
LOCUS AR130120 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 23 from patent US 6187587.
ACCESSION AR130120
VERSION AR130120.1 GI:14118017
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Popoff, I., Brown-Driver, V.L. and Cowse, L.M.
TITLE Antisense inhibition of e2f transcription factor 1 expression
JOURNAL Patent: US 6187587-A 23 13-FEB-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;
Matches 17; Conservative 0;

QY 2317 GACCACCGCTCAGCGCCAGG 2336
Db 1 GCCCACTGCTCTCGGCCAGG 20

RESULT 269
AR130133/c
LOCUS AR130133 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 36 from patent US 6187587.
ACCESSION AR130133
VERSION AR130133.1 GI:14118030
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Popoff, I., Brown-Driver, V.L. and Cowse, L.M.
TITLE Antisense inhibition of e2f transcription factor 1 expression
JOURNAL Patent: US 6187587-A 36 13-FEB-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;
Matches 17; Conservative 0;

QY 1271 AGGAGAAGCAGCAGCGG 1290
Db 20 AGGAGAGCGAGCAGCGCTG 1

RESULT 270
AR159548
LOCUS AR159548 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 8 from patent US 6251589.
ACCESSION AR159548
VERSION AR159548.1 GI:16222233
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Tsuji, S. and Sanpei, K.
TITLE Method for diagnosing spinocerebellar ataxia type 2 and primers
JOURNAL Patent: US 6251589-A 8 26-JUN-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;
Matches 17; Conservative 0;

QY 1444 CAGCAGCAGCAGCAGCA 1463
Db 1 CACCACCGAGCAGCAGCA 20

RESULT 271
AR162425/c
LOCUS AR162425 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 105 from patent US 6258600.
ACCESSION AR162425

```
VERSION AR162425.1 GI:16229604
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zhang,H. and Cowser,T.L.M.
TITLE Antisense modulation of caspase 8 expression
JOURNAL Patent: US 6258600-A 105 10-JUL-2001;
FEATURES Location/Qualifiers
source 1..20
/mol_type="unknown"
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 154 CTGGCTGCCATCAAGTTCAT 173
|||||
Db 20 CTGGCTGCCCTCAAGTTCT 1

RESULT 272
AR163981/c
LOCUS AR163981 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 179 from patent US 6271030.
ACCESSION AR163981
VERSION AR163981.1 GI:16234866
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Montia,B.P., Butler,M.M. and Wyatt,J.
TITLE Antisense inhibition of C/EBP beta expression
JOURNAL Patent: US 6271030-A 179 07-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/mol_type="unknown"
/organism="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1267 CTGCAGAGAGCAGCAGCA 1286
|||||
Db 20 CTGCAGAGAGGTGGAGCA 1

RESULT 273
BD230672/c
LOCUS BD230672 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Total genome radiation hybrid map of canine genome and its use for
identification of interesting genes.
ACCESSION BD230672
VERSION BD230672.1 GI:33040442
KEYWORDS JP 2002530091-A/541.
SOURCE Canis familiaris (dog)
ORGANISM Canis familiaris
REFERENCE 1 (bases 1 to 20)
AUTHORS Galibert,P. and Andre,C.
TITLE Total genome radiation hybrid map of canine genome and its use for
identification of interesting genes
JOURNAL Patent: JP 2002530091-A 541 17-SEP-2002;
COMMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
OS Canis familiaris (dog)
PN JP 2002530091-A/541
PD 17-SEP-2002
PF 15-NOV-1999 JP 2000582596

PR 13-NOV-1998 US 60/108193
PI FRANCIS GALIBERT,CATHERINE ANDRE
PC C12N15/09,C12Q1/68,C12N15/00
CC FH2144 Location/Qualifiers
FH Key 1..20
FT source /organism='Canis familiaris (dog)'
FT

FEATURES
source 1..20
/mol_type="genomic DNA"
/db_xref="taxon:9615"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 269 CCTTCATCAAGAGAGCCCC 288
|||||
Db 20 CCTTCATCAAGAGAGCCAC 1

RESULT 274
BD250356
LOCUS BD250356 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Enzyme.
ACCESSION BD250356
VERSION BD250356.1 GI:33060126
KEYWORDS JP 2002541794-A/1.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Talas,U.G., Dunlop,J. and Kelsell,D.P.
TITLE Enzyme
JOURNAL Patent: JP 2002541794-A 1 10-DEC-2002;
COMMENT QUEEN MARY AND WESTFIELD COLLEGE
OS Artificial Sequence
PN JP 2002541794-A/1
PD 10-DEC-2002
PP 12-APR-2000 JP 2000611653
PR 13-APR-1999 GB 9908458.4
PI ULVI GERST TALAS,JOHN DUNLOP,DAVID PETER KELSELL PC
PC C12N15/09,C07K16/40,C12N1/15,C12N1/19,C12N5/10,C12N9/PC
50,C12Q1/68,
PC C12Q1/68,G01N33/573,G01N33/574//C12P21/08,C12N15/00,C12N5/00
CC Primer
FH Key Location/Qualifiers
FT source 1..20
/mol_type="Artificial Sequence".

FEATURES
source 1..20
/mol_type="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2397 CAAGAAGCGCATGGACTACT 2416
|||||
Db 1 CAAGAAGCGCATGGCTACT 20

RESULT 275
BD272623/c
LOCUS BD272623 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense oligonucleotide modulation of STAT3 expression.
ACCESSION BD272623
VERSION BD272623.1 GI:33082391
KEYWORDS JP 2002541784-A/23.
SOURCE synthetic construct
```

ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Karras,J.G.
TITLE Antisense oligonucleotide modulation of STAT3 expression
JOURNAL Patent: JP 2002541784-A 23 10-DEC-2002;
ISIS PHARMACEUTICALS INC
COMMENT OS Artificial Sequence
PN JP 2002541784-A/23
PD 10-DEC-2002
PF 06-APR-2000 JP 2000611544
PI 08-APR-1999 US 09/288461
PR JAMES G KARRAS
PC C12N15/09,A61K31/711,A61K48/00,A61P29/00,A61P35/00,
A61P37/02
PC A61P43/00,C12N5/06,C12Q1/02,C12N15/00,C12N5/00 CC Antisense
oligonucleotide
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAG 1137
||||||| |||||
Db 20 AGCAGCAGATGCTGGAGCAG 1

RESULT 276
CQ784337
LOCUS 20 bp DNA linear PAT 17-MAR-2004
DEFINITION Sequence 4477 from Patent EP1396543.
ACCESSION CQ784337
VERSION CQ784337.1 GI:45538825
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Ota,T., Nishikawa,T., Isogai,T., Hayaishi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
TITLE Primers for synthesizing full length cDNA clones and their use
JOURNAL Patent: EP 1396543-A 4477 10-MAR-2004;
Research Association for Biotechnology (JP)
FEATURES
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: an artificially
synthesized primer sequence"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1471 CAGAAACAGCAGCAGCAGCA 1490
||||||| |||||
Db 1 CAGAAGCAGAAGCAGGAGCA 20

RESULT 277
AR193126/c
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 11 from patent US 6346416.

ACCESSION AR193126
VERSION AR193126.1 GI:20239091
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 11 12-FEB-2002;
FEATURES
source 1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 180 CACGGAGGACGAGGAGGAG 199
||||||| |||||
Db 20 CACTGAGGATGAAGGAGAG 1

RESULT 278
AR193131/c
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 16 from patent US 6346416.
ACCESSION AR193131
VERSION AR193131.1 GI:20239096
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 16 12-FEB-2002;
FEATURES
source 1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 709 GACATGCCACCCCATCGAGC 728
||||||| |||||
Db 20 GACATGCATCCAATGAGAGC 1

RESULT 279
AR193159/c
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 44 from patent US 6346416.
ACCESSION AR193159
VERSION AR193159.1 GI:20239124
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 44 12-FEB-2002;
FEATURES
source 1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 709 GACATGCCACCCCATCGAGC 728
||||||| |||||
Db 20 GACATGCATCCAATGAGAGC 1

RESULT 279
AR193159/c
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 44 from patent US 6346416.
ACCESSION AR193159
VERSION AR193159.1 GI:20239124
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense inhibition of HPK/GCK-like kinase expression
JOURNAL Patent: US 6346416-A 44 12-FEB-2002;
FEATURES
source 1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3886 GGGGCGAGCAGCCAGTTTA 3905
Db 20 GGTGGCAGCAGTCAGGTTTA 1

RESULT 280
AR225891/c
LOCUS 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 41 from patent US 6444464.
ACCESSION AR225891
VERSION AR225891.1 GI:27264045
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt, J.
TITLE Antisense modulation of E2F transcription factor 2 expression
JOURNAL Patent: US 6444464-A 41 03-SEP-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 784 AAGAAGTTCATTGACTTCAT 803
Db 20 AAGAAGTTCATTGACTTCCT 1

RESULT 281
AR231469/c
LOCUS 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 2 from patent US 6452065.
ACCESSION AR231469
VERSION AR231469.1 GI:27272605
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zheng, H., Jiang, P., Qian, S., Van Der Ploeg, L.H.T., Wong, P.C.Y. and Sisodia, S.S.
TITLE Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background
JOURNAL Patent: US 6452065-A 2 17-SEP-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1400 TCCAGAGCCAGCTGCAGCAG 1419
Db 20 TCCAGAGCCAGCTGCAGCAG 1

RESULT 282
AR314465/c
LOCUS 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5002 from patent US 6559294.
ACCESSION AR314465
VERSION AR314465.1 GI:31707891
KEYWORDS

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths, R., Hoiseith, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A., Sankaran, B., and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 5002 06-MAY-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCACAGCAGC 1462
Db 20 GCAGCAGCAGCATCGGCAGC 1

RESULT 283
AR337050
LOCUS 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 23 from patent US 6566133.
ACCESSION AR337050
VERSION AR337050.1 GI:33722904
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowse, L.M.
TITLE Antisense inhibition of dual specific phosphatase 9 expression
JOURNAL Patent: US 6566133-A 23 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1277 AGGAGCAGCAGCGCGGCTG 1296
Db 1 AGGAGCAGCAGCGCGGCGC 20

RESULT 284
AR373625
LOCUS 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 17 from patent US 6602857.
ACCESSION AR373625
VERSION AR373625.1 GI:40076036
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowse, L.M., Wyatt, J., Monia, B.P., Butler, M.M. and McKay, R.
TITLE Antisense modulation of PTP1B expression
JOURNAL Patent: US 6602857-A 17 05-AUG-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2114 CTCAGCCCTCGCCGCGCC 2133
Db 1 CTTAGCCCGAGGCGCGCC 20

RESULT 285
AX149138/c
LOCUS AX149138 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 23 from patent US 6727064.
ACCESSION AR531371
VERSION AR531371.1 GI:53919810
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Karris,J.G.
TITLE Antisense oligonucleotide modulation of STAT3 expression
JOURNAL Patent: US 6727064-A 23 27-APR-2004;
FEATURES
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCTGCAGCAG 1137
Db 20 AGCAGCAGATGCTGGAGCAG 1

RESULT 286
AX038745
LOCUS AX038745 20 bp DNA linear PAT 16-NOV-2000
DEFINITION Sequence 1 from Patent WO0061728.
ACCESSION AX038745
VERSION AX038745.1 GI:11228090
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Dunlop,J., Kelsell,D.P. and Gerst-Talas,U.
TITLE Enzyme
JOURNAL Patent: WO 0061728-A 1 19-OCT-2000;
DUNLOP JOHN (ES); KELSELL DAVID PETER (GB); GERST TALAS ULVI (GB)
; QUEEN MARY & WESTFIELD COLLEGE (GB)
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2397 CAAGAAGCGCATGCTACT 2416
Db 1 CAAGAAGCGCATGCTACT 20

RESULT 287
AX149138/c
LOCUS AX149138 20 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 340 from Patent WO0136625.
ACCESSION AX149138
VERSION AX149138.1 GI:14347662
KEYWORDS
SOURCE synthetic construct

ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Barany,F., Zirvi,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid
JOURNAL sequence differences using ligase detection reaction
Patent: WO 0179548-A 6217 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
Location/Qualifiers

ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Wright,J.A., Young,A.H. and Dugourd,D.
TITLE Antisense oligonucleotide sequences derived from groel and groes as
JOURNAL inhibitors of microorganisms
Patent: WO 0136625-A 340 25-MAY-2001;
GenSense Technologies Inc. (CA)
FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense oligonucleotide"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAGCAGCT 1469
Db 20 CAGCAACAGCAGCAGCTGTT 1

RESULT 288
AX164704
LOCUS AX164704 20 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 9 from Patent WO0136644.
ACCESSION AX164704
VERSION AX164704.1 GI:14545596
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Rastelli,L., Lewin,D., Taillon,B. and Andrew,D.P.
TITLE Wnt-regulated cytokine-like polypeptide and nucleic acids encoding
JOURNAL same
Patent: WO 0136644-A 9 25-MAY-2001;
Curagen Corporation (US)
FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2525 CAGCAGCGTCAGCACCATG 2544
Db 1 CAGCAGCAGTGAGCACCATG 20

RESULT 289
AX294455/c
LOCUS AX294455 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 6217 from Patent WO0179548.
ACCESSION AX294455
VERSION AX294455.1 GI:17056138
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Barany,F., Zirvi,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid
JOURNAL sequence differences using ligase detection reaction
Patent: WO 0179548-A 6217 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
Location/Qualifiers

```
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Hypothetical Probe Sequence"

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1394 AACGTCCTCCAGAGCGAGCTG 1413
Db 20 AACGGGTCCAGAGGAGCTG 1

RESULT 290
AX295117/c
LOCUS AX295117 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 6879 from Patent WO0179548.
ACCESSION AX295117
VERSION AX295117.1 GI:17056800
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Barany,F., Zirvi,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid
JOURNAL sequence differences using ligase detection reaction
Patent: WO 0179548-A 6879 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Hypothetical Probe Sequence"

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 459 TCGAGACATCAAGGGGAGCA 478
Db 20 TTGGGACATCAAGGGGAGCA 1

RESULT 291
AX297351
LOCUS AX297351 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 9113 from Patent WO0179548.
ACCESSION AX297351
VERSION AX297351.1 GI:17059042
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Barany,F., Zirvi,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid
JOURNAL sequence differences using ligase detection reaction
Patent: WO 0179548-A 9113 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Hypothetical Probe Sequence"

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2835 AGGCACTGGGACAGCATCC 2854
Db 1 AGCCAGTGGGTACAGCAGCC 20

RESULT 292
AX418622
LOCUS AX418622 20 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 17 from Patent WO0210378.
ACCESSION AX418622
VERSION AX418622.1 GI:21523485
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Cowert,L.M., Wyatt,J., Freier,S.M., Monia,B.P., Butler,M.M. and
McKay,R.
TITLE Antisense modulation of ptp1b expression
JOURNAL Patent: WO 0210378-A 17 07-FEB-2002;
ISIS PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Antisense Oligonucleotide"

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2114 CTCAGCCCTCGCCGCC 2133
Db 1 CTAGCCCGAGCGCCGCC 20

RESULT 293
AX467415
LOCUS AX467415 20 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 4 from Patent WO0246463.
ACCESSION AX467415
VERSION AX467415.1 GI:21900623
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Smith,C.A. and Coombs,N.
TITLE Nucleic acid extraction method and kit
JOURNAL Patent: WO 0246463-A 4 13-JUN-2002;
Genovar Diagnostics Ltd. (GB)
FEATURES
source
1. .20
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="PCR primer"
primer_bind

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 313 CTGGTCATGAGTCTGTGG 332
Db 1 CTGGGCATGAGTCTGTGG 20

RESULT 294
AX611052/c
```

LOCUS AX611052 20 bp DNA linear PAT 17-FEB-2003
DEFINITION Sequence 2077 from Patent WO02072882.
ACCESSION AX611052
VERSION AX611052.1- GI:28406481
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Cullen, P. and Seedorf, U.
TITLE Coronary chip
JOURNAL Patent: WO 02072882-A 2077 19-SEP-2002;
OCHAM GmbH (DE)
FEATURES
source 1..20
Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1602 GCAGAACTCTCCCTTGCCCA 1621
|||||
Db 20 GCAGGACTCCCTTGCTCCA 1
|||||
RESULT 295
BD062072/c
LOCUS BD062072 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Transgenic animal expressing non-native wild-type and familial
Alzheimer's disease mutant presenilin 1 protein on native
presenilin 1 null background.
ACCESSION BD062072
VERSION BD062072.1 GI:22607677
KEYWORDS JP 2001514528-A/2.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zheng, H., Qian, S., Der, L.H.T.V., Wong, P.C., Sisodia, S.S. and
Jiang, P.
TITLE Transgenic animal expressing non-native wild-type and familial
Alzheimer's disease mutant presenilin 1 protein on native
presenilin 1 null background
JOURNAL Patent: JP 2001514528-A 2 11-SEP-2001;
MERCK & CO INC. JOHNS HOPKINS UNIVERSITY
COMMENT PN JP 2001514528-A/2
PD 11-SEP-2001
PF 13-MAY-1998 JP 1998549461
PR 14-MAY-1997 US 60/046488, 18-MAR-1998 US 60/078465 PI
HUI ZHENG, SU QIAN, LEONARDUS H T VAN DER PLOEG, PHILIP C WONG, PI
SANGRAM S SISODIA, PING JIANG
PC C12N5/00, C12N15/00, A61K49/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers.
FEATURES
source 1..20
Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1400 TCACAGGCGAGCTGCAGCAG 1419
|||||
Db 20 TGCAGAGCCACTGCAGCAG 1
|||||

RESULT 296
BD128261

LOCUS BD128261 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD128261
VERSION BD128261.1 GI:23223206
KEYWORDS JP 2002017375-A/3692.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ota, T., Nishikawa, T., Isogai, T., Hayashi, K., Ishii, S., Kawai, Y.,
Wakamatsu, A., Sugiyama, T., Nagai, K., Kojima, S., Otsuki, T. and
Koga, H.
TITLE Primer for synthesizing full-length cDNA and use thereof
JOURNAL Patent: JP 2002017375-A 3692 22-JAN-2002;
HELIX RESEARCH INSTITUTE
COMMENT OS Unidentified
PN JP 2002017375-A/3692
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA, TETSUO NISHIKAWA, TAKAO ISOGAI, KOJI HAYASHI, SHIZUKO
PI ISHII,
PI YURI KAWAI, AI WAKAMATSU, TOMOYASU SUGIYAMA, KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUO OTSUKI, HISASHI KOGA
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
10,
PC C12P21/02, C12O1/68//C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC
Description of Artificial Sequence: an artificially CC
synthesized primer
CC Sequence
FH Key Location/Qualifiers
FT source 1..20
Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1471 CAGAAACGACGACGACGCA 1490
|||||
Db 1 CAGAGCAGACGACGACGCA 20
|||||

RESULT 297
BD129999/c

LOCUS BD129999 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Asthma-associated gene.
ACCESSION BD129999
VERSION BD129999.1 GI:23224944
KEYWORDS JP 2002500895-A/289.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wilson, A.R.B., Nuthall, A., Cardon, L., Carey, A.H., Galvin, M.,
Miller, A. and North, M.
TITLE Asthma-associated gene
JOURNAL Patent: JP 2002500895-A 289 15-JAN-2002;
AXYS PHARMACEUTICALS INC
COMMENT OS Unidentified
PN JP 2002500895-A/289
PD 15-JAN-2002
PF 21-JAN-1998 JP 2000528715

PI ANGELA R BROOKS WILSON,ALAN BUCKLER,LON
CARDON,ALISOUN H CAREY,
PI MARGARET GALVIN,ANDREW MILLER,MICHAEL NORTH
PC C12Q1/68.A01K67/027.C07K14/47.C12N15/09.C12N15/00 CC
Strandedness: Single;

CC Topology: Linear;
CC Asthma-associated gene
FH Key Location/Qualifiers
FT source 1..20
FT /organism='Unidentified'.

FEATURES
source
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2104 GGGCCCCCTGCTCAGCCCC 2123
|||
Db 20 GGCACCCCTGCTCAGCCTCC 1

Search completed: May 12, 2005, 11:23:23
Job time : 15 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 12, 2005, 11:24:49 ; Search time 19 Seconds
(without alignments)
3.684 Million cell updates/sec

Title: us-10-029-115-1

Perfect score: 3951

Sequence: 1 gccctatgggcaccagc.....tcataactggtgaagggc 3951

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 428 seqs, 8859 residues

Total number of hits satisfying chosen parameters: 856

Minimum DB seq length: 8

Maximum DB seq length: 80

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 439 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	40.4	1.0	51	1	ADCI7063
2	34	0.9	42	1	AAT78911
3	34	0.9	42	1	AAS13782
4	31.2	0.8	36	1	AAT78910
5	30.2	0.8	35	1	ABZ81770
6	30	0.8	39	1	ABZ81763
7	28.4	0.7	30	1	AZ44310
8	28.4	0.7	30	1	AAS13781
9	28.4	0.7	30	1	ADN97224
10	28.4	0.7	31	1	AAQ98457
11	28.4	0.7	31	1	AAZ24996
12	27.8	0.7	33	1	ABX79926
13	26.8	0.7	30	1	ABZ81777
14	24.6	0.6	31	1	ADE34157
15	23.6	0.6	31	1	AAI31038
16	23.4	0.6	25	1	ABZ81767
17	23.4	0.6	25	1	ABZ81768
18	23.4	0.6	30	1	ADE34158
19	23	0.6	23	1	AAZ40517
20	23	0.6	23	1	AAZ40518
21	23	0.6	23	1	ABJ39570
22	22.4	0.6	24	1	ADN97255
23	22.4	0.6	24	1	ADN97164
24	22.4	0.6	24	1	ADN97164
25	22.2	0.6	27	1	ABK11030
26	22.2	0.6	29	1	AAA03952
27	22	0.6	25	1	ADN97164
28	22	0.6	25	1	ADN97164
29	22	0.6	25	1	ADN97164
30	22	0.6	25	1	ADN97164
31	21.4	0.5	27	1	ADN97164
32	21	0.5	21	1	AAZ40515
33	21	0.5	25	1	ADN97164

Human AMLPia scann	25	0.5	21	34	ADC38185
Human Pur alpha an	22	0.5	20.4	35	ABX88725
Human STE20-relate	20	0.5	20	36	AAZ40516
Oligonucleotide pr	21	0.5	20	37	AAQ14196
Human AMLPia scann	25	0.5	20	38	ADC38191
Human AMLPia scann	25	0.5	20	39	ADC38194
PCR primer 1 relat	25	0.5	20	40	ADJ92110
Human GPCR ligand	26	0.5	19.8	41	ABS71093
Angiogenesis inhib	26	0.5	19.6	42	ADD69029
Immunostimulatory	21	0.5	19.4	43	AAZ40519
Angiogenesis inhib	21	0.5	19.4	44	ABX78296
Immunostimulatory	21	0.5	19.4	45	ABX78296
Double stranded DN	21	0.5	19.4	46	ABX78296
Immunostimulatory	21	0.5	19.4	47	ACH03118
Immunostimulatory	21	0.5	19.4	48	ADN97164
Porcine GPR8-relat	24	0.5	19.4	49	ABL61611
G-protein-coupled	24	0.5	19.4	50	ABX94601
Screening method r	24	0.5	19.4	51	ABX92931
GPR8 PCR primer, S	24	0.5	19.4	52	AAZ40519
Human STE20-relate	20	0.5	19	53	ABZ86076
Human oligonucleot	20	0.5	19	54	ABZ86076
Human stanniocalci	20	0.5	19	55	ABD22306
Human NOV-3 DNA am	21	0.5	19	56	ADN17771
DNA encoding secre	21	0.5	19	57	ABX03797
Human AMLPia scann	25	0.5	19	58	ADC38183
Human AMLPia scann	25	0.5	19	59	ADC38192
Human epithelial c	23	0.5	18.8	60	AAZ57112
Human prostate-spe	24	0.5	18.8	61	ABN83820
Digital karyotypin	25	0.5	18.8	62	ADN62597
Simple sequence re	42	0.5	18.6	63	AAS13782
Angiotensin-conver	20	0.5	18.4	64	AAV52748
PCR primer Snrpn-U	20	0.5	18.4	65	AAS20967
Human MEKK4 antise	20	0.5	18.4	66	AAZ37201
Human HPK/GCK-like	20	0.5	18.4	67	ABK44415
Human oligonucleot	20	0.5	18.4	68	ABZ86068
Human stanniocalci	20	0.5	18.4	69	ABD22398
Human CDC-like kin	20	0.5	18.4	70	ADH58803
Human CDC-like kin	20	0.5	18.4	71	ADH58730
5' anchored (ISSR)	23	0.5	18.4	72	ADD69462
Wheat microsatelli	23	0.5	18.2	73	AAT77693
Human SCA2 gene PC	23	0.5	18.2	74	AAT79645
Human HDR1 RT-PCR	24	0.5	18.2	75	ABK12118
PCR primer 2 relat	24	0.5	18.2	76	ADN92111
Primer of the inve	24	0.5	18.2	77	ADN97247
Antisense oligonuc	18	0.5	18	78	AAZ63144
Huntington's disea	18	0.5	18	79	ABZ81780
Huntington's disea	18	0.5	18	80	ABZ81779
Allele A oligo #2,	18	0.5	18	81	ABZ81637
Allele A oligo #1,	18	0.5	18	82	ADN16436
Candida albicans G	20	0.5	18	83	ABZ31489
ISSR-related PCR p	20	0.5	18	84	ADD69519
Poly-glutamine rep	42	0.5	18	85	AAT78911
Primer 6U for a hu	21	0.5	17.8	86	AAZ61533
Huntington's disea	21	0.5	17.8	87	ABZ81769
Human ZC1 primer #	22	0.5	17.8	88	AAZ40548
Human cysteine-ric	22	0.5	17.8	89	ABX94818
Spider silk protei	23	0.4	17.6	90	AAZ85350
Steroidogenesis ac	19	0.4	17.4	91	AAT39475
Human histone deac	20	0.4	17.4	92	AAZ55806
Human cDNA clone-s	20	0.4	17.4	93	AAH43988
Antisense oligo, c	20	0.4	17.4	94	AAH43116
Human oestrogen re	20	0.4	17.4	95	AAH57033
Human HDAC-2 antis	20	0.4	17.4	96	AAH89545
Human HDAC-2 PCR p	20	0.4	17.4	97	AAH89536
Human glioma-assoc	20	0.4	17.4	98	ABK30537
Candida albicans G	20	0.4	17.4	99	ABZ30516
Human HPK/GCK-like	20	0.4	17.4	100	ABK44442
Mouse mdm2 antisen	20	0.4	17.4	101	ADD21775
Clone specific PCR	20	0.4	17.4	102	ADL32200
Human CDC14A DNA a	20	0.4	17.4	103	ADW11408
Human CDC14A antis	20	0.4	17.4	104	ADN001250
Transcription fact	20	0.4	17.4	105	ADP20520
Human PRO1315 forv	21	0.4	17.4	106	AAA37188

107	17.4	0.4	21	1	AAC73260	SNP flanking seque	c 180	16.8	0.4	20	1	ABZ98885	Human PDE4A oligon
c 108	17.4	0.4	21	1	AAE54275	Primer #26 used in	c 181	16.8	0.4	20	1	ABZ98885	Toxicologically re
c 109	17.4	0.4	21	1	ACD68312	Novel human secret	c 182	16.8	0.4	20	1	ACC47666	Human IGFBP5 phosph
c 110	17.4	0.4	21	1	ACH04414	Human secreted/tra	c 183	16.8	0.4	20	1	ABS58313	Silkworm spider dr
c 111	17.4	0.4	21	1	ACD67958	Novel human secret	c 184	16.8	0.4	20	1	ADM57531	M. tuberculosis PC
c 112	17.4	0.4	21	1	ACD17974	Human PRO PCR prim	c 185	16.8	0.4	20	1	ADB22299	Human stannioalcalci
c 113	17.4	0.4	21	1	ADD70620	Human secreted/tra	c 186	16.8	0.4	20	1	ADB22300	Human stannioalcalci
c 114	17.4	0.4	21	1	ADD39697	Human secreted/tra	c 187	16.8	0.4	20	1	ABD31784	Human tryptase b-d
c 115	17.4	0.4	21	1	ADD70143	Human secreted/tra	c 188	16.8	0.4	20	1	ABD22307	Human stannioalcalci
c 116	17.4	0.4	21	1	ADD38284	Human secreted/tra	c 189	16.8	0.4	20	1	ABD31316	Human PDE4A-deri
c 117	17.4	0.4	21	1	ADD39220	Human secreted/tra	c 190	16.8	0.4	20	1	ADH44483	Extracellular-sign
c 118	17.4	0.4	21	1	ADD38743	Human secreted/tra	c 191	16.8	0.4	20	1	ADJ32626	Human ERK-6 specif
c 119	17.4	0.4	21	1	ADD40174	Human secreted/tra	c 192	16.8	0.4	20	1	ADJ60634	Oligonucleotide as
c 120	17.4	0.4	21	1	ADE50395	Human secreted/tra	c 193	16.8	0.4	20	1	ADJ60768	Oligonucleotide as
c 121	17.4	0.4	21	1	ADE20007	Human secreted/tra	c 194	16.8	0.4	20	1	ADO46257	Human oligonucleot
c 122	17.4	0.4	21	1	ADE49918	Human secreted/tra	c 195	16.8	0.4	20	1	ADO46123	Human oligonucleot
c 123	17.4	0.4	21	1	ADE21476	Human secreted/tra	c 196	16.8	0.4	20	1	ADO48050	Human HIP-1 antise
c 124	17.4	0.4	21	1	ADE27990	Human secreted/tra	c 197	16.8	0.4	20	1	ADO48119	Human HIP-1 target
c 125	17.4	0.4	21	1	ADF55794	Human secreted/tra	c 198	16.8	0.4	20	1	ADO55804	Human NIMA-related
c 126	17.4	0.4	21	1	ADH99238	Human secreted/tra	c 199	16.8	0.4	20	1	ADO55866	Human NIMA-related
c 127	17.4	0.4	21	1	ADE96478	Human secreted/tra	c 200	16.8	0.4	20	1	ADP20499	Transcription fact
c 128	17.4	0.4	21	1	ADF25789	Human secreted/tra	c 201	16.8	0.4	20	1	ADP27248	Human MMP11 DNA an
c 129	17.4	0.4	21	1	ADF24688	Human secreted/tra	c 202	16.8	0.4	20	1	ADP27093	Human matrix metal
c 130	17.4	0.4	21	1	ADF29424	Human secreted/tra	c 203	16.8	0.4	20	1	ADP27094	Human matrix metal
c 131	17.4	0.4	21	1	ADE96955	Human secreted/tra	c 204	16.8	0.4	20	1	ADP27249	Human MMP11 DNA an
c 132	17.4	0.4	21	1	ADH02993	Human secreted/tra	c 205	16.8	0.4	20	1	ADT00354	Novel mutant prote
c 133	17.4	0.4	21	1	ADH03947	Human secreted/tra	c 206	16.8	0.4	21	1	ABK70327	Synthetic antiense
c 134	17.4	0.4	21	1	ADH03470	Human secreted/tra	c 207	16.8	0.4	21	1	ABZ75847	Template (CTGA)6-A
c 135	17.4	0.4	21	1	ADH04424	Human secreted/tra	c 208	16.8	0.4	21	1	ADH87403	Human midline (MDK
c 136	17.4	0.4	21	1	ADH61425	Human secreted/tra	c 209	16.8	0.4	21	1	ADH87421	Human midline (MDK
c 137	17.4	0.4	21	1	ADL94624	Human secreted/tra	c 210	16.8	0.4	22	1	ADQ07028	Human Rad51 H1 RNA
c 138	17.4	0.4	23	1	ADMA4807	Probe #2 used to i	c 211	16.6	0.4	31	1	AAQ98457	Sense probe CAG-30
c 139	17.4	0.4	39	1	ABZ81763	Huntington's disea	c 212	16.6	0.4	31	1	AAZ24996	Oligonucleotide CA
c 140	17.2	0.4	20	1	AAD06425	Human p21-activate	c 213	16.4	0.4	18	1	AAK67192	Human CD40 hairpin
c 141	17.2	0.4	22	1	AAF76808	Codon-optimised HP	c 214	16.4	0.4	18	1	AAV08612	Primer ACP/3FT for
c 142	17.2	0.4	22	1	ABX72347	Human NOVX DNA PCR	c 215	16.4	0.4	18	1	AAV08618	Primer ACP/11FB fo
c 143	17.2	0.4	22	1	AAD50510	Human zcyto20 and	c 216	16.4	0.4	18	1	AAA38240	Human ACE regulato
c 144	17.2	0.4	30	1	ABZ81777	Huntington's disea	c 217	16.4	0.4	18	1	AAA38246	Human ACE regulato
c 145	17.4	0.4	17	1	ADK02353	Human NQO Amberzy	c 218	16.4	0.4	18	1	AAC61246	Human ACE, AGT and
c 146	17.4	0.4	17	1	ADK37823	Human AMLPia scann	c 219	16.4	0.4	18	1	AAC61240	Human ACE, AGT and
c 147	17.4	0.4	17	1	ADK37821	Human AMLPia scann	c 220	16.4	0.4	18	1	ADO26674	Synthetic leader s
c 148	17.4	0.4	17	1	ADK37818	Human AMLPia scann	c 221	16.4	0.4	18	1	ADO26644	Synthetic leader s
c 149	17.4	0.4	17	1	ADK37819	Human AMLPia scann	c 222	16.4	0.4	18	1	ADR06261	Short tandem (micr
c 150	17.4	0.4	17	1	ADK37820	Human AMLPia scann	c 223	16.4	0.4	18	1	ADS16441	Allele A oligo #4,
c 151	17.4	0.4	17	1	ADK37822	Human AMLPia scann	c 224	16.4	0.4	18	1	ADS16440	Allele A oligo #3,
c 152	17.4	0.4	18	1	AS13777	Simple sequence re	c 225	16.4	0.4	19	1	ADZ29427	Mitogen activated
c 153	17.4	0.4	18	1	ADN97239	Primer of the inve	c 226	16.4	0.4	19	1	ADZ29590	Mitogen activated
c 154	17.4	0.4	18	1	ADO26638	Synthetic leader s	c 227	16.4	0.4	19	1	ADF84082	Human breakpoint c
c 155	17.4	0.4	18	1	ADO26610	Synthetic leader s	c 228	16.4	0.4	19	1	ADF83819	Human breakpoint c
c 156	17.4	0.4	18	1	ADO26656	Synthetic leader s	c 229	16.4	0.4	19	1	ADL78959	Human HER2 (EGFR2)
c 157	17.4	0.4	18	1	ADO26614	Synthetic leader s	c 230	16.4	0.4	19	1	ADL79208	Human HER2 (EGFR2)
c 158	17.4	0.4	20	1	ABZ86071	Human oligonucleot	c 231	16.4	0.4	20	1	AAV68373	Adapter primer oli
c 159	17.4	0.4	20	1	ABZ86075	Human oligonucleot	c 232	16.4	0.4	20	1	AAZ32750	Human protease-act
c 160	17.4	0.4	20	1	ABD22301	Human stannioalcalci	c 233	16.4	0.4	20	1	AAF72971	Human dact inhibi
c 161	17.4	0.4	20	1	ABD22305	Human stannioalcalci	c 234	16.4	0.4	20	1	ABZ29930	Candida albicans G
c 162	16.8	0.4	20	1	AAO61483	PCR primer Brp22	c 235	16.4	0.4	20	1	AAZ56488	Human ephrin-A2 cd
c 163	16.8	0.4	20	1	AO68866	Mycobacterium lepr	c 236	16.4	0.4	20	1	ADZ56486	Human ephrin-A2 cd
c 164	16.8	0.4	20	1	AAV68372	Adapter primer oli	c 237	16.4	0.4	20	1	ADZ56486	Single nucleotide
c 165	16.8	0.4	20	1	AAZ40551	Human ZC3 primer #	c 238	16.4	0.4	20	1	ADH63098	FGF receptor 2 ant
c 166	16.8	0.4	20	1	ABA941159	Rifampin-tolerant	c 239	16.4	0.4	20	1	ABZ93335	Human oligonucleot
c 167	16.8	0.4	20	1	AAZ35086	Herpesvirus entry	c 240	16.4	0.4	20	1	ABZ93335	Human oligonucleot
c 168	16.8	0.4	20	1	AAZ37716	Primer A #30 used	c 241	16.4	0.4	20	1	ABD28489	Human oligonucleot
c 169	16.8	0.4	20	1	ABK30536	Human chroma-asso	c 242	16.4	0.4	20	1	ABD28489	R33851-derived oli
c 170	16.8	0.4	20	1	ABL44419	Human chromosome 1	c 243	16.4	0.4	20	1	ABD29565	AA664176-derived o
c 171	16.8	0.4	20	1	ABZ29903	Candida albicans G	c 244	16.4	0.4	20	1	ABD21825	Human stannioalcalci
c 172	16.8	0.4	20	1	ABZ30367	Candida albicans G	c 245	16.4	0.4	20	1	ADJ62127	Human EDG1 antise
c 173	16.8	0.4	20	1	ABK44440	Human HPK/GCK-like	c 246	16.4	0.4	20	1	ADP76620	Chimeric phosphoro
c 174	16.8	0.4	20	1	ABK44440	Human HPK/GCK-like	c 247	16.4	0.4	20	1	ADP76975	Chimeric phosphoro
c 175	16.8	0.4	20	1	ADK44440	Nucleic acid detec	c 248	16.4	0.4	20	1	ADP76520	Chimeric phosphoro
c 176	16.8	0.4	20	1	ADK44440	Nucleic acid detec	c 249	16.4	0.4	21	1	AAV01510	Sense primer to ge
c 177	16.8	0.4	20	1	ABZ86070	Human oligonucleot	c 250	16.4	0.4	21	1	AAV01510	Sense primer to ge
c 178	16.8	0.4	20	1	ABZ86077	Human oligonucleot	c 251	16.4	0.4	21	1	AAH89732	Human polymorphic
c 179	16.8	0.4	20	1	ABZ98753	Human tryptase b o	c 252	16.4	0.4	21	1	ABK65733	Human single nucle

253	16.4	0.4	21	1	ABX79874	EST polymorphic DN	326	15.8	0.4	20	1	ABD24432	AI652901-derived o
254	16.4	0.4	21	1	ACN79938	Thermus oshimai nu	327	15.8	0.4	20	1	ADF73043	Primer #1 of the i
255	16.4	0.4	21	1	ADN08366	3T3 cell transfeim	328	15.8	0.4	20	1	ADF73047	Primer #3 of the i
256	16.4	0.4	21	1	ADS87406	Human midkine (MDK	329	15.8	0.4	20	1	ADJ11745	Human amyloid beta
257	16.4	0.4	21	1	ADS87422	Human midkine (MDK	330	15.8	0.4	20	1	ADJ11781	Human amyloid beta
258	16.4	0.4	21	1	ADS87404	Human midkine (MDK	331	15.8	0.4	20	1	ADJ11781	Human LIM domain k
259	16.4	0.4	51	1	ADC17063	Human single nucle	332	15.8	0.4	20	1	ADJ138771	Human LIM domain k
260	16.2	0.4	20	1	ADOS6495	Human cyclin-depen	333	15.8	0.4	20	1	ADL70240	Murine p27kip1 PCR
261	16.2	0.4	21	1	AAQ65930	Type II procollage	334	15.8	0.4	20	1	ADL61407	Human protein tyro
262	16.2	0.4	21	1	AAQ26192	Human polymorphic	335	15.8	0.4	20	1	ADU57395	Kidney developmenp
263	16.2	0.4	21	1	AAZ40511	Human SFE20-relate	336	15.8	0.4	20	1	ADN02369	PCR primer 2 used
264	16.2	0.4	21	1	AAZ38134	Polynucleotide use	337	15.8	0.4	20	1	ADR033787	SPG probe for dete
265	16.2	0.4	21	1	ADU72441	Human GPI20 antibo	338	15.8	0.4	20	1	ADT11643	WT1/EGF human TCC
266	16.2	0.4	21	1	ADJ13904	Human DNA probe us	339	15.8	0.4	21	1	AAV10466	Human osteosarcoma
267	16.2	0.4	21	1	ADS87436	Human midkine (MDK	340	15.8	0.4	21	1	AAV07691	Reverse primer for
268	16.2	0.4	30	1	ADN97224	AGC1 locus. Unide	341	15.8	0.4	21	1	AAZ4677	E. coli strain 015
269	16.2	0.4	31	1	AA131038	Human single nucle	342	15.8	0.4	21	1	AAZ10649	PCR primer #3 used
270	16	0.4	17	1	ABK02334	Human NOGO Ambery	343	15.8	0.4	21	1	AAAS9901	Human OP-1 Wt-1/EG
271	16	0.4	17	1	ABL46891	Human GRID G-cleav	344	15.8	0.4	21	1	AAH62656	Synaptotagmin 5 po
272	16	0.4	17	1	ABL46750	Human GRID NCH rib	345	15.8	0.4	21	1	AAH62429	HERC1 polymorphism
273	16	0.4	17	1	ADC37824	Human AMLPia scann	346	15.8	0.4	21	1	AAH89947	Human polymorphic
274	16	0.4	17	1	ADC37817	Human AMLPia scann	347	15.8	0.4	21	1	ABK65628	Human single nucle
275	16	0.4	17	1	ADM54108	Human GRID mRNA su	348	15.8	0.4	21	1	ABK65740	Human single nucle
276	16	0.4	18	1	AAE671194	Human CD40 hairpin	349	15.8	0.4	21	1	ABK60283	Human polymorphism
277	16	0.4	18	1	AAE26668	Human Smad7 phosph	350	15.8	0.4	21	1	ABK99278	Hepatitis C virus
278	16	0.4	19	1	ADR75637	Human apolipoprote	351	15.8	0.4	21	1	ADD22525	Flatfish rhabdovir
279	16	0.4	19	1	ADR78255	Human apolipoprote	352	15.8	0.4	21	1	ADE78130	DNA oligo (Seqid 3
280	16	0.4	20	1	AAAS5807	Human histone deac	353	15.8	0.4	21	1	ADF75334	Human RT-PCR prime
281	16	0.4	20	1	AAAS4502	Antisense oligonuc	354	15.8	0.4	21	1	ADN02584	Primer #2 of the i
282	16	0.4	20	1	AAAS4504	Antisense oligonuc	355	15.8	0.4	21	1	ADK61698	Base containing SS
283	16	0.4	20	1	AAAS4503	Antisense oligonuc	356	15.8	0.4	21	1	ADOL1900	Single multiplex P
284	16	0.4	20	1	AAAS4505	Antisense oligonuc	357	15.6	0.4	30	1	AAZ44310	Human SCA7 primer
285	16	0.4	20	1	AAAS4506	Antisense oligonuc	358	15.6	0.4	30	1	AAAS13781	Simple sequence re
286	16	0.4	20	1	AAH43117	Antisense oligo. t	359	15.4	0.4	17	1	AAAT81046	Human c-myb hammer
287	16	0.4	20	1	AAAC95537	Human HDAC-2 PCR p	360	15.4	0.4	17	1	AAAT81049	Human c-myb hammer
288	16	0.4	20	1	AAAC89546	Human HDAC-2 antis	361	15.4	0.4	17	1	AAAT81045	Human c-myb hammer
289	16	0.4	20	1	ABZ85536	Human oligonucleot	362	15.4	0.4	17	1	AAAT74181	Salmonella enterit
290	16	0.4	20	1	ABZ88039	Human oligonucleot	363	15.4	0.4	17	1	AAAX36659	PCR primer for mar
291	16	0.4	20	1	ABD24269	Human calmodulin 2	364	15.4	0.4	17	1	AAAF01716	Hammerhead ribozym
292	16	0.4	20	1	ABD21826	Human erannioicaci	365	15.4	0.4	17	1	ABK00766	Human NOGO inozyme
293	15.8	0.4	19	1	AAZ72847	Human biallelic ma	366	15.4	0.4	17	1	ABK02370	Human NOGO Ambery
294	15.8	0.4	19	1	ADL79842	Human HER1 (EGFR)	367	15.4	0.4	17	1	ABK01554	Human NOGO G-cleav
295	15.8	0.4	19	1	ADL79535	Human HER1 (EGFR)	368	15.4	0.4	17	1	ABK00767	Human NOGO inozyme
296	15.8	0.4	19	1	ADG64260	Y copy of Adican	369	15.4	0.4	17	1	ABK01792	Human NOGO Zinzyme
297	15.8	0.4	19	1	ADH70599	Human Vbeta gene r	370	15.4	0.4	17	1	ABK01549	Human NOGO G-cleav
298	15.8	0.4	20	1	AAQ51743	Mycobacteria probe	371	15.4	0.4	17	1	ABL46975	Human GRID zinzyme
299	15.8	0.4	20	1	AAAT86505	S-adenosylmethioni	372	15.4	0.4	17	1	ABK07810	Human GDMPL-1 17-m
300	15.8	0.4	20	1	AAV35212	Hepatitis C virus	373	15.4	0.4	17	1	ABK19261	Human ERG Ambery
301	15.8	0.4	20	1	AAZ32971	Human HG38 DNA PCR	374	15.4	0.4	17	1	ABV89508	Human POSH1 scann
302	15.8	0.4	20	1	AAZ05303	PCR primer for clo	375	15.4	0.4	17	1	ADC37834	Human AMLPia scann
303	15.8	0.4	20	1	AAZ05303	PCR primer used to	376	15.4	0.4	17	1	ADT51314	Human tumour suppr
304	15.8	0.4	20	1	AAAS93524	PCR primer used to	377	15.4	0.4	17	1	ADM54298	Human GRID mRNA su
305	15.8	0.4	20	1	AAAS97150	PCR primer used to	378	15.4	0.4	17	1	ACN70900	Human GDMPL-1 prob
306	15.8	0.4	20	1	AAAC73254	Reverse primer #46	379	15.4	0.4	18	1	AAAT93486	DOAL allele determ
307	15.8	0.4	20	1	AAAF73052	Human dactx inhibit	380	15.4	0.4	18	1	AAAT93485	DOAL allele determ
308	15.8	0.4	20	1	AAAF24100	Lactococcus lactis	381	15.4	0.4	18	1	AAAX90265	DOAL gene PCR prim
309	15.8	0.4	20	1	AAH56611	Streptococcus pyog	382	15.4	0.4	18	1	AAAX90264	DOAL gene PCR prim
310	15.8	0.4	20	1	AAAC89128	Canine retroviral	383	15.4	0.4	18	1	AAH19623	Oligonucleotide co
311	15.8	0.4	20	1	ABK911138	ALS-2 control PCR	384	15.4	0.4	18	1	AAH19624	Complementary olig
312	15.8	0.4	20	1	ABQ78562	Primer Rb2 used to	385	15.4	0.4	18	1	AAH76247	Human macrophage i
313	15.8	0.4	20	1	ABQ78586	Primer Rb1 used to	386	15.4	0.4	18	1	ABQ78581	Human UDP-glucuron
314	15.8	0.4	20	1	ABV99473	Human NOV16a forwa	387	15.4	0.4	18	1	ABA93493	GAGA-B receptor 1a
315	15.8	0.4	20	1	ABV99470	Human NOV16a forwa	388	15.4	0.4	18	1	ABK11198	Oligonucleotide #1
316	15.8	0.4	20	1	ABLS0604	Mouse Napi-7 PCR p	389	15.4	0.4	18	1	ABK11199	Oligonucleotide #2
317	15.8	0.4	20	1	AAK39531	Human calreticulin	390	15.4	0.4	18	1	AAK36191	Human Smad6 antis
318	15.8	0.4	20	1	ABK44419	Human HPK/GCK-like	391	15.4	0.4	18	1	ABZ81759	Huntington's disea
319	15.8	0.4	20	1	ABL94386	Mouse C/EBP beta p	392	15.4	0.4	18	1	ACC46880	Human COPD relate
320	15.8	0.4	20	1	ADG34599	Phosphorothioate o	393	15.4	0.4	18	1	ADK7650	Huntington's disea
321	15.8	0.4	20	1	ADAA44765	Antisense oligonuc	394	15.4	0.4	18	1	ADK52169	Primer #4 of the i
322	15.8	0.4	20	1	ADH93846	Human gene PCR pri	395	15.4	0.4	18	1	ADN97298	Primer of the inve
323	15.8	0.4	20	1	ABZ88038	Human oligonucleot	396	15.4	0.4	19	1	AAZ10259	PCR primer used to
324	15.8	0.4	20	1	ABZ88202	Human oligonucleot	397	15.4	0.4	19	1	AAA49353	Primer for sequenc
325	15.8	0.4	20	1	ABD24268	Human calmodulin 2	398	15.4	0.4	19	1	AAA49370	Primer for selecti

```
C 399 15.4 0.4 19 1 AAA49347 Primer for amplify
C 400 15.4 0.4 19 1 AA271124 Human biallelic ma
C 401 15.4 0.4 19 1 AAH27306 Human TSG16 PCR pr
C 402 15.4 0.4 19 1 ADF93383 Human TERT transcr
C 403 15.4 0.4 19 1 ADF93637 Human TERT siNA lo
C 404 15.4 0.4 19 1 ADH01585 Protein tyrosine p
C 405 15.4 0.4 19 1 ADO23071 Human transforming
C 406 15.4 0.4 19 1 ADR46305 Cyclin D2 forward
C 407 15.4 0.4 20 1 AAV07418 Oligonucleotide co
C 408 15.4 0.4 20 1 AAV69992 Human c-fos protei
C 409 15.4 0.4 20 1 AA204615 PCR primer used to
C 410 15.4 0.4 20 1 AAX80212 Human CSF-1 antise
C 411 15.4 0.4 20 1 AAC92580 Human nucleolin ph
C 412 15.4 0.4 20 1 AAD31080 Wnt4 RT-PCR primer
C 413 15.4 0.4 20 1 AD371173 Human MEK4 antise
C 414 15.4 0.4 20 1 ABQ74714 RNF3 gene sense PC
C 415 15.4 0.4 20 1 ABS73433 Chimeric phosphoro
C 416 15.4 0.4 20 1 ABK52713 Human bladder canc
C 417 15.4 0.4 20 1 ABT34158 Human short hetero
C 418 15.4 0.4 20 1 ACC86750 Human VEGFR-1 chim
C 419 15.4 0.4 20 1 ABX17545 RTQ-PCR primer #2
C 420 15.4 0.4 20 1 ADF87724 Single nucleotide
C 421 15.4 0.4 20 1 AB286463 Human oligonucleot
C 422 15.4 0.4 20 1 ABZ98559 Human ICAM oligonu
C 423 15.4 0.4 20 1 ABD31590 Human ICAM-derived
C 424 15.4 0.4 20 1 ABD22693 Human myosin X-der
C 425 15.4 0.4 20 1 ADJ53556 Human PP3CB DNA a
C 426 15.4 0.4 20 1 ADJ53484 Human PP3CB DNA a
C 427 15.4 0.4 20 1 ADH80333 RNF3 PCR primer, S
C 428 15.4 0.4 20 1 ADH98171 Primer of the inve
C 429 15.4 0.4 20 1 ADJ60409 Oligonucleotide as
C 430 15.4 0.4 20 1 ADQ45898 Human oligonucleot
C 431 15.4 0.4 20 1 ADP76511 Chimeric phosphoro
C 432 15.4 0.4 20 1 ADP76836 Chimeric phosphoro
C 433 15.4 0.4 20 1 ADQ39969 Human FBP-interact
C 434 15.4 0.4 20 1 ADQ39938 Human FIR antisens
C 435 15.4 0.4 20 1 ADP44518 Human ABCCS DNA an
C 436 15.4 0.4 20 1 ADP44443 Human ABCCS DNA an
C 437 15.4 0.4 20 1 ADR30844 Identifier oligonu
C 438 15.4 0.4 20 1 ADR86867 Human ephrin B4 an
C 439 15.4 0.4 20 1 ADR82422 Human EphB4 antise
```

ALIGNMENTS

```
RESULT 1
ADCL17063/C
XX ADCL17063 standard; DNA; 51 BP.
XX ADC17063;
XX
XX DT 18-DEC-2003 (first entry)
XX
DE Human single nucleotide polymorphism (SNP) region Seq ID165.
DE
XX sequence polymorphism analysis; human identity; human relatedness;
XX single nucleotide polymorphism; SNP; genetic disease; cytostatic;
XX immunosuppressive; antiinflammatory; neuroprotective; antimicrobial;
XX fatty acid metabolism; glycolysis; amino acid metabolism;
XX paternity analysis; forensic; autoimmune disease; cancer; nervous system;
XX infection; pathogenic microorganism; human; ds.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX variation replace(26,C)
XX /*tag= a
XX /standard_name= "Single nucleotide polymorphism"
XX
XX WO200029622-A2.
XX
XX 25-MAY-2000.
XX
XX PD
```

```
XX
PF 17-NOV-1999; 99WO-US027283..
XX
XX 17-NOV-1998; 98US-0109024P.
XX 16-NOV-1999; 99US-00443199.
XX (CURA-) CURAGEN CORP.
XX
XX Shinkets RA, Leach MD;
XX
XX WPI; 2000-399731/34.
XX DR P-PSDB; ADC16846.
XX
XX Novel polynucleotide and polypeptide including one or more single
XX nucleotide polymorphisms, useful for diagnosing and treating conditions
XX associated with the presence of sequence polymorphism in humans and
XX animals.
XX
XX Claim 1; SEQ ID NO 165; 187pp; English.
XX
XX This invention relates to novel isolated nucleotide sequences which
XX comprise 217 defined polymorphic sequences. Sequence polymorphism-based
XX analysis of nucleic acid sequences can augment or replace previously
XX known methods for determining the identity and relatedness of
XX individuals. Single nucleotide polymorphisms (SNPs) tend to occur with
XX great frequency throughout the genome and may be located close to loci of
XX interest. Such variations can cause or be closely linked to pathological
XX conditions (genetic diseases). Hence the SNPs of the invention may be
XX useful in the development of compounds with cytostatic,
XX immunosuppressive, antiinflammatory, neuroprotective or antimicrobial
XX activities. Regulators of metabolic pathways such as fatty acid
XX metabolism, glycolysis, and amino acid metabolism may also be developed.
XX The compounds may be useful for treating a subject suffering from or at
XX risk for a pathology associated with the presence of a sequence
XX polymorphism. SNP detection is also useful in paternity analysis and
XX forensic application. Polymorphisms may contribute to the phenotype of an
XX organism and phenotypic traits include genetic diseases such as
XX autoimmune diseases, cancer, diseases of the nervous system and infection
XX by pathogenic microorganisms. The present sequence is the sequence
XX surrounding and including a human SNP of the invention.
XX
XX Sequence 51 BP; 3 A; 15 C; 15 G; 18 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 40.4; DB 1; Length 51;
XX Best Local Similarity 88.0%; Pred. No. 1.1;
XX Matches 44; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
XX
XX QY 1445 AGCAGCAGCAACAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCTC 1494
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 51 AGCAGCAGCAGCAGCAGCAGCAGCAACAGCAACAGTAGCAGCAGCAGTTC 2
XX
XX
XX RESULT 2
XX AAT78911
XX ID AAT78911 standard; cDNA; 42 BP.
XX
XX AC AAT78911;
XX
XX DT 09-FEB-1998 (first entry)
XX
XX DE Poly-glutamine repeat region coding sequence from clone AAD20.
XX
XX KW Monoclonal antibody; neurodegenerative disease; polyglutamine; TBP;
XX repeat region; affinity; TATA binding protein; Kennedy disease;
XX transcription initiation factor; lymphoblastic cell line; schizophrenia;
XX Huntington's disease; dominant autosomal spinocerebellar ataxia;
XX X-linked spin-bulbular muscular atrophy; familial spastic paraplegia;
XX dentarorubral-pallidolusial atrophy; bipolar affective disorder;
XX manic depressive psychosis; ss.
XX
XX OS Homo sapiens.
XX
XX XX WO9717445-A1.
XX
XX PN
```


PD 15-MAY-1997.
 XX
 PF 08-NOV-1996; 96WO-FR001773.
 XX
 PR 10-NOV-1995; 95FR-00013576.
 XX
 PA (CNRS) CNRS CENT NAT RECH SCI.
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 XX
 PI Tora L, Lutz Y, Trottier Y, Mandel J;
 XX
 XX WPI; 1997-281034/25.
 DR
 XX Antibody 1C2 used for treating or preventing neuro-degenerative diseases
 PT - associated with proteins containing long poly:glutamine repeats, e.g.
 PT Huntington's disease.
 PT
 XX
 PS Claim 21; Page 44; 69pp; French.
 XX
 CC The invention relates to a monoclonal antibody (MAB) 1C2 for the
 CC treatment of neurodegenerative diseases associated with the presence of
 CC polyglutamine repeat regions. This MAB is already known for its affinity
 CC to the TATA binding protein (TBP) transcription initiation factor,
 CC especially at the amino acid sequence LEEQRRQQQQQ found at the N-
 CC terminus of TBP. MAB 1C2 has been shown to have a high affinity for
 CC polyglutamine repeats with a proportional affinity to the number of
 CC glutamine repeats. This affinity has been used to identify genes encoding
 CC proteins containing long polyglutamine repeats which are implicated in
 CC neurodegenerative diseases. A screen of an expression library, generated
 CC from a lymphoblastic cell line from a patient suffering from
 CC spinocerebellar ataxia (SCA), with MAB 1C2 isolated 6 new sequences
 CC (AAAT78906-T78911) encoding polyglutamine repeats. This sequence is
 CC derived from clone DAN26 isolated from a patient suffering from dominant
 CC autosomal SCA type 7. MAB 1C2, active fragment of it or nucleic acids
 CC encoding it are specifically used to treat Huntington's disease, SCA
 CC types 1-5 or 7, X-linked spino-bulbar muscular atrophy (Kennedy
 CC disease), dentatorubral-pallidoluysal atrophy, dominant autosomal
 CC spinocerebellar ataxia, familial spastic paraplegia, bipolar affective
 CC disorder, manic depressive psychoses and schizophrenia
 XX
 SQ Sequence 36 BP; 13 A; 12 C; 11 G; 0 T; 0 U; 0 Other;
 Query Match 0.8%; Score 31.2; DB 1; Length 36;
 Best Local Similarity 91.7%; Pred. No. 8 6;
 Matches 33; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 1456 CAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAG 1491
 DB 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 36
 RESULT 5
 ABZ81770
 ID ABZ81770 standard; DNA; 35 BP.
 XX
 AC ABZ81770;
 XX
 DT 11-JUN-2003 (first entry)
 XX
 DE Huntington's disease gene target region for oligonucleotide HD37/25.
 DE
 DE Huntington's disease; neurotropic; anticonvulsant; huntingtin; human;
 KW gene therapy; ds.
 KW
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH misc_binding 5..15
 FT /tag= a
 FT /bound_moiety= "Oligonucleotide HD37/25"
 FT /note= "hybridises to bases 15-25 of sequence given in
 FT ABZ81771"
 FT
 FT misc_difference 16

FT /tag= b
 FT /note= "mismatch with oligonucleotide HD37/25"
 FT 17..29
 FT /tag= a
 FT /bound_moiety= "Oligonucleotide HD37/25"
 FT /note= "hybridises to bases 1-13 of sequence given in
 FT ABZ81771"
 XX
 PN WO2003013437-A2.
 XX
 PD 20-FEB-2003.
 XX
 XX 07-AUG-2002; 2002WO-US025352.
 PF
 XX 07-AUG-2001; 2001US-0310757P.
 PR
 XX 08-AUG-2001; 2001US-0310770P.
 PR
 XX 08-AUG-2001; 2001US-0310889P.
 PR
 XX 04-DEC-2001; 2001US-0337219P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Parekh-Olmedo H;
 PI
 XX WPI; 2003-256478/25.
 DR
 XX New single stranded oligonucleotides comprising a DNA domain having at
 PT least one mismatch with respect to the genetic sequence of the
 PT Huntington's disease gene to be altered, useful for treating or
 PT preventing Huntington's disease.
 XX
 XX Example 4; Fig 13a; 133pp; English.
 XX
 CC The present sequence is that of a portion of the glutamine triplet repeat
 CC region of exon 1 of the human Huntington's disease (HD) gene (see also
 CC ABZ81760). This region of exon 1 is targeted by a modified single-
 CC stranded oligonucleotide of the invention, HD37/25 (see ABZ81771), which
 CC has a single mismatch with respect to the present target sequence, and
 CC which converts a CAG (glutamine) codon in HD exon 1 to CTG (leucine).
 CC HD37/25 is an example of claimed oligonucleotides for targeted alteration
 CC of the HD gene that comprise a chemically modified single-stranded
 CC oligonucleotide having at least one mismatch with respect to the HD gene.
 CC Such oligonucleotides can be used for the treatment or prevention of HD,
 CC and also have the effect of inhibiting the formation of huntingtin
 CC aggregates, a characteristic of HD
 XX
 XX Sequence 35 BP; 10 A; 12 C; 9 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 30.2; DB 1; Length 35;
 Best Local Similarity 91.4%; Pred. No. 11;
 Matches 32; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 1433 TCAGTCCCTGCAGCAGCAGCAGCAGCAGCAGCAG 1467
 DB 1 TCAGTCCCTTCAGCAGCAGCAGCAGCAGCAGCAG 35
 RESULT 6
 ABZ81763
 ID ABZ81763 standard; DNA; 39 BP.
 XX
 AC ABZ81763;
 XX
 DT 11-JUN-2003 (first entry)
 XX
 DE Huntington's disease gene target region for oligonucleotide HD1.
 DE
 DE Huntington's disease; neurotropic; anticonvulsant; huntingtin; human;
 KW gene therapy; ds.
 KW
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH misc_binding 7..19


```
FT FT /*tag= a
FT FT /bound moiety= "Oligonucleotide HD1"
FT FT /note= "hybridises to bases 40-52 of sequence given in
FT FT ABZ81743"
FT FT misc_difference 20
FT FT /*tag= b
FT FT /notes= "mismatch with oligonucleotide HD1"
FT FT 21..26
FT FT /*tag= c
FT FT /bound moiety= "Oligonucleotide HD1"
FT FT /note= "hybridises to bases 26-39 of sequence given in
FT FT ABZ81743"
XX XX
PN PN WO2003013437-A2.
XX XX
XX XX 20-FEB-2003.
XX XX
PF PF 07-AUG-2002; 2002HQ-US025352.
XX XX
XX XX 07-AUG-2001; 2001US-0310757P.
PR PR 08-AUG-2001; 2001US-0310770P.
PR PR 08-AUG-2001; 2001US-0310889P.
PR PR 04-DEC-2001; 2001US-0337219P.
XX XX
XX XX (UYDE ) UNIV DELAWARE.
XX XX
XX XX Kniec EB, Parekh-Olmedo H;
XX XX
XX XX WPI; 2003-256478/25.
DR DR
XX XX
XX XX New single stranded oligonucleotides comprising a DNA domain having at
PT PT least one mismatch with respect to the genetic sequence of the
PT PT Huntington's disease gene to be altered, useful for treating or
PT PT preventing Huntington's disease.
XX XX
XX XX Example 1; Fig 3; 133pp; English.
XX XX
XX XX The present sequence is that of a portion of the glutamine triplet repeat
CC CC region of exon 1 of the human Huntington's disease (HD) gene (see also
CC CC ABZ81760). This region of exon 1 is targeted by a DNA-RNA hybrid
CC CC oligonucleotide of the invention, HD1 (see ABZ81743), which has a DNA
CC CC sequence having a single mismatch with respect to the present target
CC CC sequence. The oligonucleotide converts a CAG (Glutamine) codon to CTG
CC CC (leucine), as demonstrated in lymphoblastoid cell lines harbouring an HD
CC CC gene exon 1 with a CAG/An (n=84) or CAGn (n=24) expansion tract, and in a
CC CC neuronal PC12 cell line containing an HD gene exon 1 with a poly-
CC CC glutamine tract of 20. HD1 is an example of claimed oligonucleotides for
CC CC targeted alteration of the HD gene that comprise a chimeric RNA/DNA
CC CC sequence and have at least one mismatch with respect to the HD gene. Such
CC CC oligonucleotides can be used for the treatment or prevention of HD, and
CC CC have the effect of inhibiting the formation of huntingtin aggregates, a
CC CC characteristic of HD
XX XX
SQ Sequence 39 BP; 11 A; 14 C; 11 G; 3 T; 0 U; 0 Other;
```

```
XX XX
XX XX SCA7; human; spinocerebellar ataxia type 7; SCA1; SCA2; SCA3; SCA6;
KW KW repeat expansion detection; RED analysis; detection; primer; ss.
XX XX
XX XX Homo sapiens.
XX XX
XX XX CA2245310-A.
XX XX
XX XX 19-FEB-1999.
XX XX
XX XX 19-AUG-1998; 98CA-02245310.
XX XX
XX XX 19-AUG-1997; 97US-0056170P.
XX XX
XX XX (MINU ) UNIV MINNESOTA.
XX XX
XX XX Koob MD, Ranum LP;
XX XX
XX XX WPI; 2000-098181/09.
DR DR
XX XX
XX XX Identifying individuals at risk of developing spinocerebellar ataxia type
PT PT 7 by analyzing trinucleotide repeat regions of spinocerebellar ataxia
PT PT type 7 gene.
XX XX
XX XX Disclosure; Page 43; 66pp; English.
XX XX
XX XX This invention describes a novel method for identifying individuals at
CC CC risk for developing spinocerebellar ataxia type 7 (SCA7). The method
CC CC comprises analyzing the CAG repeat region of a SCA7 gene to detect CAG
CC CC repeats, where individuals at risk have at least 30 CAG repeats and those
CC CC not at risk have less than 19 CAG repeats. The method is useful for
CC CC identifying individuals at risk of developing SCA7 and also those at risk
CC CC of developing SCA1, 2, 3 or 6. The use of genomic DNA in the repeat
CC CC expansion detection (RED) analysis allows isolation of any potential
CC CC trinucleotide repeat expansion regardless of the expression pattern.
CC CC Utilization of different oligonucleotides in the RED assay allows of
CC CC the possible trinucleotide repeats to be detected, and the cycled nature
CC CC of the reaction makes it extremely sensitive. This sequence represents a
CC CC primer used to amplify the human SCA7 gene which is described in the
CC CC method of the invention
XX XX
XX XX Sequence 30 BP; 10 A; 10 C; 10 G; 0 T; 0 U; 0 Other;
```

Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 14;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
|||
DB 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 8
AAS13781

ID AAS13781 standard; DNA; 30 BP.

XX XX
AC AAS13781;

XX XX
DT 08-MAY-2002 (first entry)

XX XX
DE Simple sequence repeat, SSR, #52.

XX XX Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
KW cereal profiling; grass profiling; seed batch purity testing.

XX OS Synthetic.

XX XX NZ509193-A.

XX XX 25-MAY-2001.

XX XX 03-JAN-2001; 2001NZ-00509193.

XX XX

```

PR 24-DEC-1999; 99AU-00004906.
PR 04-MAY-2000; 2000AU-00007310.
XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
PA (UYSC-) UNIV SOUTHERN CROSS.
PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
PA (UYAD-) UNIV ADELAIDE.
PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX Forster JW, Jones ES;
XX WPI; 2001-512563/56.
XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
PT core elements isolated from ryegrass and fescue, useful for selecting of
PT genes in grass or cereal breeding or profiling grass or cereal species
PT varieties.
XX Claim 13; Page 53; 72pp; English.
XX The invention relates to a substantially purified or isolated nucleic
CC acid (I) from ryegrass or fescue species including a simple sequence
CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
CC 2-6 nucleotides in length. Also included are a nucleic acid primer
CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
CC library of ryegrass or fescue genomic DNA enriched for SSRs and
CC identifying clones in the library containing SSRs, a library of ryegrass
CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
CC a gene in grass or cereal breeding by identifying an SSR that is closely
CC associated with the gene such that the SSR and the gene are
CC preferentially co-inherited, and selecting for the SSR in the breeding, a
CC method for DNA profiling grass or cereal species varieties by assessing
CC variation between SSR varieties and testing the purity of grass or cereal
CC seed batches by assessing variation within seed batch of an SSR. The SSRs
CC may be used in the selection of genes in grass or cereal breeding, for
CC profiling grass or cereal species varieties, for testing the purity of
CC grass or cereal seed batches, and for DNA profiling to establish the
CC distinct identity, uniformity and/or stability of a cultivar. The present
CC sequence is a ryegrass or fescue SSR
XX
XX Sequence 30 BP; 10 A; 10 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 14;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGCAG 1146
DB 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30
RESULT 9
ADN97224
ID ADN97224 standard; DNA; 30 BP.
AC ADN97224;
XX ADN97224;
XX 01-JUL-2004 (first entry)
DT AGC1 locus.
DE DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
XX forensic identification; marijuana; ds.
XX Unidentified.
OS WO2004008841-A2.
PN 29-JAN-2004.
PD
XX 21-JUL-2003; 2003WO-US022887.
PF 19-JUL-2002; 2002US-0397179P.
PR
(UYAR-) UNIV ARIZONA.
PA (KEIM/) KEIM P.S.
PA (ZINN/) ZINNAMON K.
XX Keim PS, Zinnamon K;
XX WPI; 2004-143139/14.
XX New isolated nucleic acid for amplification of a short tandem repeat
PT located in DNA isolated from Cannabis sativa L species, useful for
PT forensic identification of marijuana or for linking a marijuana sample to
PT its plant source.
XX Example 7; SEQ ID NO 91; 79pp; English.
XX The present invention relates to DNA fingerprinting for Cannabis Sativa
CC using short tandem repeat markers. The nucleic acid is useful for
CC forensic identification of marijuana or for linking a marijuana sample to
CC its plant source. The present sequence represents a STR locus of the
CC invention.
XX Sequence 30 BP; 10 A; 10 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 14;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1118 AGCAGCAGCAGCTGCAGCAGCAGCAGCAGCAG 1147
DB 1 AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30
RESULT 10
AAQ98457
ID AAQ98457 standard; cDNA; 31 BP.
XX AAQ98457;
AC AAQ98457;
XX 23-APR-1996 (first entry)
DT Sense probe CAG-30.
DE Probe; trinucleotide repeat; myotonic dystrophy; DM; Mt-PK gene;
XX fluorescent label; fluorescein isothiocyanate; fragile X syndrome;
XX muscular dystrophy; Huntington's disease; ss.
XX Synthetic.
XX WO9525179-A1.
XX 21-SEP-1995.
XX 08-MAR-1995; 95WO-US002861.
XX 17-MAR-1994; 94US-00214823.
XX (UYMA-) UNIV MASSACHUSETTS MEDICAL CENT.
XX Singer RH, Taneja KL;
XX WPI; 1995-336982/43.
XX Detecting trinucleotide repeat expansion by in situ hybridisation - with
PT detection sensitive enough to distinguish between probe bound to expanded
PT and normal repeat regions, esp. for myotonic dystrophy diagnosis.
XX Disclosure; Page 38; 51pp; English.
XX The sequences represented by AAQ98457 and AAQ98458 are synthetic probes
CC for the trinucleotide repeat CTG. These probes can be used in a method of
CC in situ hybridisation for the detection of a trinucleotide repeat
CC expansion. These probes were used specifically to identify myotonic

```

CC dystrophy (DM). DM is associated with an expanded CTG repeat in the 3' untranslated region of the Mt-PK gene. These probes are labelled with a fluorescent label (e.g. fluorescein isothiocyanate) and then used to treat nucleated cells. The hybridisation of the probe to the expanded trinucleotide repeat can then be detected by fluorescence microscopy. Due to the large variation between expanded repeat size, and normal repeat size in DM (5-27 repeats in non-expanded, 50-2000 repeats in expanded), the expanded repeat will bind more probes. Only the expanded repeat will bind enough of the probes to give a detectable fluorescent signal. By detecting the number of transcripts in a cell of a diagnosed individual, progress of treatment, and severity of the disease can be monitored. This method can also be used to diagnose other diseases associated with trinucleotide repeat expansions, such as fragile X syndrome, muscular dystrophy and Huntington's disease. For some of these diseases a greater detection specificity would be required due to the smaller difference in repeat number between normal and infected individuals

SQ Sequence 31 BP; 10 A; 10 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 28.4; DB 1; Length 31;
Best Local Similarity 96.7%; Pred. No. 15;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 11
AAZ24996
ID AAZ24996 standard; DNA; 31 BP.
XX
AC AAZ24996;
XX
DT 24-DEC-1999 (first entry)
XX
DE Oligonucleotide CAG30 targeted to myotonic-protein kinase gene.
XX
KW Trinucleotide repeat; myotonic-protein kinase; myotonic dystrophy; probe; in situ hybridisation; detection; expansion; Fragile X syndrome; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5962332-A.
XX
PD 05-OCT-1999.
XX
PF 11-DEC-1995; 95US-00570155.
XX
PR 17-MAR-1994; 94US-00214823.
PR 07-MAR-1995; 95US-00399499.
XX
PA (UYMA-) UNIV MASSACHUSETTS.
XX
PI Taneja KL, Singer RH;
XX
DR WPI; 1999-579615/49.
XX
PT Detection of trinucleotide repeats.
XX
PS Disclosure; Col 25; 18pp; English.
XX
CC Oligonucleotides AAZ24983-Z24995 are targeted to the CTG trinucleotide repeats found in the myotonic-protein kinase (Mt-PK) gene. Excessive numbers of the trinucleotide repeats in the Mt-PK gene leads to the disease myotonic dystrophy. The oligonucleotides are used to probe the 5' -most 7 exons of 14 in the Mt-PK gene. This sequence is used as an antisense control oligonucleotide for the hybridisation reaction. The invention relates to a method for the detection of trinucleotide repeat expansion, e.g. in the Mt-PK gene or FMR1 gene (leading to Fragile X syndrome) by in situ hybridization

SQ Sequence 31 BP; 10 A; 10 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 28.4; DB 1; Length 31;
Best Local Similarity 96.7%; Pred. No. 15;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 12
ABX79926
ID ABX79926 standard; cDNA; 33 BP.
XX
AC ABX79926;
XX
DT 17-APR-2003 (first entry)
XX
DE EST polymorphic DNA repeat polynucleotide #251.
XX
KW EST: expressed sequence tag; ss; polymorphic repeat; tandem repeat; polymorphic marker prediction of ubiquitous simple sequences; POMPOUS; Rep-X; human; Genetic disease; drug-treatment; Machado-Joseph; Haw River syndrome; Huntington's disease; fragile-X syndrome; Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia; spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
OS Homo sapiens.
XX
PN US6472154-B1.
XX
PD 29-OCT-2002.
XX
PF 31-DEC-1999; 99US-00475947.
XX
PR 31-DEC-1999; 99US-00475947.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Garner HR, Wren JD, Minna JD, Fondon JW;
XX
DR WPI; 2003-208818/20.
XX
PT Identifying a candidate polymorphic repeat within a coding sequence, for understanding or treating genetic disease, comprises detecting tandem repeats in a target coding sequence and scoring the repeats for polymorphic probability.
XX
PS Example; Col 1089; 588pp; English.
XX
CC The invention discloses a method for identifying a candidate polymorphic repeat within a coding sequence (expressed sequence tag, EST), which comprises detecting tandem repeats in a target coding sequence, scoring the repeats for polymorphic probability and generating a dataset correlating the repeats with polymorphic probability to identify a candidate polymorphic repeat. The computational methods (polymorphic marker prediction of ubiquitous simple sequences, POMPOUS and Rep-X) are useful for identifying and detecting candidate polymorphic repeats in human genes, which can be used to understand, treat or eliminate genetic diseases, predispositions or adverse drug-treatment reactions. Examples of diseases linked to nucleotide repeats are Machado-Joseph, Haw River syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia, myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are the polymorphic repeats identified for a search of human ESTs

SQ Sequence 33 BP; 11 A; 10 C; 11 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 27.8; DB 1; Length 33;
Best Local Similarity 93.5%; Pred. No. 20;
Matches 29; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
 |||||
 Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 31

RESULT 13
 ABZ81777
 ID ABZ81777 standard; DNA; 30 BP.
 AC ABZ81777;
 XX
 DT 11-JUN-2003 (first entry)
 DE Huntington's disease gene mutated exon 1 region.
 XX
 KW Huntington's disease; neutropic; anticonvulsant; huntingtin; human;
 KW gene therapy; mutant; ds.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PH Key Location/Qualifiers
 FT mutation replace(5,A)
 FT /*tag= a
 XX
 PN WO2003013437-A2.
 XX
 PD 20-FEB-2003.
 XX
 PF 07-AUG-2002; 2002WO-US025352.
 XX
 PR 07-AUG-2001; 2001US-0310757P.
 PR 08-AUG-2001; 2001US-0310770P.
 PR 08-AUG-2001; 2001US-0310889P.
 PR 04-DEC-2001; 2001US-0337219P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Parekh-Olmedo H;
 XX
 XX WPI; 2003-256478/25.
 DR
 XX
 XX New single stranded oligonucleotides comprising a DNA domain having at
 PT least one mismatch with respect to the genetic sequence of the
 PT Huntington's disease gene to be altered, useful for treating or
 PT preventing Huntington's disease.
 XX
 PS Example 4; Fig 14; 133pp; English.
 XX
 XX The present sequence is that of a portion of a mutated glutamine (CAG)
 CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
 CC gene (see also ABZ81760). The triplet repeat region (see ABZ81770) is
 CC mutated following liposome transfection of neuronal PC12 cells bearing an
 CC HD gene exon 1-GFP fusion gene with phosphorothioate-modified single-
 CC stranded oligonucleotide HD3T/52 (see ABZ81774), which causes a CAG (Gln)
 CC to CAG (Ileu) gene alteration in the HD exon 1 repeats. HD3T/52 is an
 CC example of oligonucleotides of the invention for targeted alteration of
 CC the HD gene. Such oligonucleotides can be used for the treatment or
 CC prevention of HD
 XX
 SQ Sequence 30 BP; 9 A; 10 C; 10 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 26.8; DB 1; Length 30;
 Best Local Similarity 93.3%; Pred. No. 22;
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1146
 |||||
 Db 1 CAGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 14
 ADE34157

ID ADE34157 standard; DNA; 31 BP.
 AC ADE34157;
 XX
 DT 29-JAN-2004 (first entry)
 DE Mink3 Lys54Arg mutant, mutagenic oligonucleotide #1.
 XX
 KW ss; misshapen/NIKE-related kinase; Mink3; antiinflammatory;
 KW immunosuppressive; cytotstatic; germinal centre kinase;
 KW c-JUN N-terminal kinase; JNK; extracellular signal response kinase; ERK;
 KW growth factor induced-ERK activation; proliferation;
 KW cell proliferation disorder; cell survival;
 KW intracellular signal transduction; apoptosis; morphological change;
 KW cell migration; gene therapy; inflammatory disease; autoimmune disease;
 KW immunodeficiency; cancer.
 XX
 OS Unidentified.
 OS
 PN US2003077597-A1.
 XX
 PD 24-APR-2003.
 XX
 PF 19-OCT-2001; 2001US-00029115.
 XX
 PR 19-OCT-2001; 2001US-00029115.
 XX
 PA (LUOY/) LUO Y.
 PA (FUCA/) FU C A.
 PA (SHEN/) SHEN M.
 XX
 PI Luo Y, Fu CA, Shen M;
 XX
 DR WPI; 2003-635076/60.
 XX
 PT New misshapen/NIKE-related kinase nucleic acids and proteins useful in
 PT gene therapy and for treating disorders, e.g. acute and chronic
 PT inflammatory diseases.
 XX
 PS Example 13; Page 30; 53pp; English.
 CC
 CC The invention relates to a recombinant nucleic acid capable of
 CC hybridising to a Human DNA encoding misshapen/NIKEs-related kinase
 CC (Mink3a, 3b and 3c, germinal centre kinase proteins) appearing as
 CC ADE34151, ADE34153 and ADE34155, or at least 90% identity to them, or
 CC their complements. Also included are a recombinant polypeptide at least
 CC 95% sequence identity to Mink3a, 3b or 3c (appearing as ADE34150, capable
 CC of modulating c-JUN N-terminal kinase (JNK) or extracellular signal
 CC response kinase (ERK) phosphorylation or activity, screening for a
 CC candidate bioactive agent capable of modulating growth factor induced-ERK
 CC activation in a mammalian cell, screening for a candidate bioactive agent
 CC capable of modulating proliferation in a mammalian cell, diagnosing a
 CC mammalian cell proliferation disorder, a medicament for treating a
 CC mammalian cell proliferation disorder and screening for a candidate agent
 CC capable of modulating cell survival. The MINK3 (misshapen/NIKEs-related
 CC kinase) nucleic acids are useful in the modulation of intracellular
 CC signal transduction, cell proliferation, apoptosis, morphological change
 CC and migration of mammalian cells. MINK3 nucleic acids and proteins are
 CC specifically useful in gene therapy, and for treating, preventing or
 CC diagnosing acute and chronic inflammatory diseases, autoimmune diseases
 CC and diseases characterised by immunodeficiency. The compositions may also
 CC be used to treat MINK3 dysfunction related disorders, e.g. cancer. The
 CC nucleotide sequences may also be used as hybridisation probes, in
 CC chromosome and gene mapping, and in generating antisense RNA and DNA. The
 CC present sequence represents an oligonucleotide used to make a Mink3
 CC Lys54Arg mutant (in the kinase domain).
 XX
 SQ Sequence 31 BP; 7 A; 7 C; 9 G; 8 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 24.6; DB 1; Length 31;
 Best Local Similarity 87.1%; Pred. No. 46;
 Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
QY 152 AGCTGCGTCATCAAGGTCATGATGTCAC 182
   ||||| ||||| ||||| ||||| ||||| |||||
Db 1 AGCTTCAGCCATCAGGGTATGATGTCAC 31

RESULT 15
AAI31038
ID AAI31038 standard; DNA; 31 BP.
AC AAI31038;
XX
XX 04-NOV-2004 (revised)
DT 18-OCT-2001 (first entry)
DE Human single nucleotide polymorphism (SNP) MAZ 1.
XX
XX Human; resequence; genotype; disease; forensic; paternity testing;
KW single nucleotide polymorphism; SNP; ss.
XX
XX Homo sapiens.
OS
FH Key Location/Qualifiers
FT Variation 16
FT /tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200166800-A2.
PN
PD 13-SEP-2001.
XX
XX 07-MAR-2001; 2001WO-US007268.
PR
XX 07-MAR-2000; 2000US-0187510P.
PR 22-MAY-2000; 2000US-0206129P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA
PI Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2001-522952/57.
DR
XX
XX Nucleic acid molecules from the human genome which include polymorphic
PT sites, useful in methods for predicting the presence, absence or severity
PT of a particular phenotype or disorder (e.g. diabetes) associated with a
PT particular genotype.
XX
XX Claim 1; Page 124; 145pp; English.
PS
XX
XX The invention relates to the identification of nucleic acid molecules
CC (AAI29513-AAI31314) from the human genome which include polymorphic sites
CC which can predispose individuals to disease. Various genes from a number
CC of individuals were resequenced and single nucleotide polymorphisms
CC (SNPs) in these genes discovered. The method is useful for predicting the
CC presence, absence or severity of a particular phenotype or disorder (e.g.
CC diabetes) associated with a particular genotype. The nucleic acids
CC containing the polymorphic sites may be useful in forensics and paternity
CC testing
CC
CC Revised record issued on 04-NOV-2004 : Correction to Feature Table Key
XX
XX Sequence 31 BP; 5 A; 10 C; 16 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 23.6; DB 1; Length 31;
Best Local Similarity 86.7%; Pred. No. 61;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGCAGCAGCAGCG 1148
   ||||| ||||| ||||| ||||| ||||| |||||
Db 2 GCAGCGCAGCGCGCGCGCGCGCGCGCGCGCG 31

RESULT 16
```

```
ABZ81767
ID ABZ81767 standard; DNA; 25 BP.
AC ABZ81767;
XX
XX 11-JUN-2003 (first entry)
DT
DE Huntington's disease gene target region.
XX
XX Huntington's disease; nootropic; anticonvulsant; huntingtin; human;
KW gene therapy; ds.
XX
XX Homo sapiens.
OS
FH Key Location/Qualifiers
FT misc_binding 1..25
FT /tag= a
FT /bound moiety= "Oligonucleotide"
FT /note= "hybridises to bases 1-25 of sequence given in
FT ABZ81768"
XX
XX misc_difference 13
FT /tag= b
FT /note= "replaced by T following treatment"
XX
XX WO2003013437-A2.
PN
XX 20-FEB-2003.
XX
XX 07-AUG-2002; 2002WO-US025352.
XX
XX 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0337219P.
XX
XX (UYDE ) UNIV DELAWARE.
PA
XX
XX Kmiec EB, Parekh-Olmedo H;
PI
XX WPI; 2003-256478/25.
DR
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
XX Example 1; Fig 6a; 133pp; English.
PS
XX
XX The present sequence is that of a portion of the glutamine (CAG) triplet
CC repeat region of exon 1 of the human Huntington's disease (HD) gene (see
CC also ABZ81760). This region of exon 1 is targeted by a DNA-RNA hybrid
CC oligonucleotide of the invention (see ABZ81768), resulting in a CAG to
CC TAG (stop codon) nucleotide exchange due to sliding of the repeat region,
CC a phenomenon that can occur with the methods of this invention. The
CC oligonucleotide is an example of oligonucleotides of the invention for
CC targeted alteration of the HD gene. Such oligonucleotides can be used for
CC the treatment or prevention of HD
XX
XX Sequence 25 BP; 8 A; 9 C; 8 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 42;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGC 1141
   ||||| ||||| ||||| ||||| ||||| |||||
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGC 25

RESULT 17
ABZ81768/c
ID ABZ81768 standard; RNA; 25 BP.
XX
```

```
AC ABZ81768;
XX
XX 11-JUN-2003 (first entry)
XX
XX Huntington's disease gene targeting oligonucleotide.
XX
XX Huntington's disease; neotrophic; anticonvulsant; huntingtin; human;
XX gene therapy; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX misc_binding 1..25
XX /tag= a
XX /bound moiety= "HD gene exon 1 triplet repeat"
XX /note= "hybridises to bases 1-25 of sequence given in
XX ABZ81767"
XX
XX WO2003013437-A2.
XX
XX 20-FEB-2003.
XX
XX 07-AUG-2002; 2002WO-US025352.
XX
XX 07-AUG-2001; 2001US-0310757P.
XX
XX 08-AUG-2001; 2001US-0310770P.
XX
XX 08-AUG-2001; 2001US-0310889P.
XX
XX 04-DEC-2001; 2001US-0337219P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Parekh-Olmedo H;
XX
XX WPI; 2003-256478/25.
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
XX least one mismatch with respect to the genetic sequence of the
XX Huntington's disease gene to be altered, useful for treating or
XX preventing Huntington's disease.
XX
XX Example 1; Fig 6a; 133pp; English.
XX
XX The present sequence is that of a portion of a 52-mer RNA/DNA chimeric
XX oligonucleotide of the glutamine (CAG) that is targeted to triplet
XX repeat region (see ABZ81767) of exon 1 of the human Huntington's disease
XX (HD) gene. This targeting results in a CAG to TAG (stop codon) nucleotide
XX exchange due to sliding of the repeat region, a phenomenon that can occur
XX with the methods of this invention. The oligonucleotide is an example of
XX claimed oligonucleotides of the invention for targeted alteration of the
XX HD gene. Such oligonucleotides can be used for the treatment or
XX prevention of HD
XX
XX Sequence 25 BP; 0 A; 8 C; 9 G; 0 T; 8 U; 0 Other;
XX
XX Query Match 0.6%; Score 23.4; DB 1; Length 25;
XX Best Local Similarity 96.0%; Pred. No. 42;
XX Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1117 CAGCAGCAGCAGGTGTCAGCAGCAGC 1141
XX |||||
XX 25 CAGCAGCAGCAGCAGCAGCAGCAGCAGC 1
XX
XX RESULT 18
XX ADE34158/c
XX ID ADE34158 standard; DNA; 30 BP.
XX
XX ADE34158;
XX
XX 29-JAN-2004 (first entry)
XX
XX Mink3 Lys54Arg mutant, mutagenic oligonucleotide #2.
XX
XX
```

```
KW ss; misshapen/NIKs-related kinase; Mink3; antiinflammatory;
KW immunosuppressive; cytostatic; germinal centre kinase;
KW c-JUN N-terminal kinase; JNK; extracellular signal response kinase; ERK;
KW growth factor induced-ERK activation; proliferation;
KW cell proliferation disorder; cell survival;
KW intracellular signal transduction; apoptosis; morphological change;
KW cell migration; gene therapy; inflammatory disease; autoimmune disease;
KW immunodeficiency; cancer.
XX
XX Unidentified.
XX
XX US2003077597-A1.
XX
XX 24-APR-2003.
XX
XX 19-OCT-2001; 2001US-00029115.
XX
XX 19-OCT-2001; 2001US-00029115.
XX
XX (LUOY/) LUO Y.
XX (FUCA/) FU C A.
XX (SHEN/) SHEN M.
XX
XX Luo Y, Fu CA, Shen M;
XX
XX WPI; 2003-635076/60.
XX
XX New misshapen/NIKs-related kinase nucleic acids and proteins useful in
XX gene therapy and for treating disorders, e.g. acute and chronic
XX inflammatory diseases.
XX
XX Example 13; Page 30; 53pp; English.
XX
XX The invention relates to a recombinant nucleic acid capable of
XX hybridising to a Human DNA encoding misshapen/NIKs-related kinase
XX (Mink3a, 3b and 3c, germinal centre kinase proteins) appearing as
XX ADE34151, ADE34153 and ADE34155, or at least 90% identity to them, or
XX their complements. Also included are a recombinant polypeptide at least
XX 95 % sequence identity to Mink3a, 3b or 3c (appearing as ADE34150,
XX ADE34152 and ADE34154), screening for a candidate bioactive agent capable
XX of modulating c-JUN N-terminal kinase (JNK) or extracellular signal
XX response kinase (ERK) phosphorylation or activity, screening for a
XX candidate bioactive agent capable of modulating growth factor induced-ERK
XX activation in a mammalian cell, screening for a candidate bioactive agent
XX capable of modulating proliferation in a mammalian cell, diagnosing a
XX mammalian cell proliferation disorder, a medication for treating a
XX mammalian cell proliferation disorder and screening for a candidate agent
XX capable of modulating cell survival. The MINK3 (misshapen/NIKs-related
XX kinase) nucleic acids are useful in the modulation of intracellular
XX signal transduction, cell proliferation, apoptosis, morphological change
XX and migration of mammalian cells. MINK3 nucleic acids and proteins are
XX specifically useful in gene therapy, and for treating, preventing or
XX diagnosing acute and chronic inflammatory diseases, autoimmune diseases
XX and diseases characterised by immunodeficiency. The compositions may also
XX be used to treat MINK3 dysfunction related disorders, e.g. cancer. The
XX nucleotide sequences may also be used as hybridisation probes, in
XX chromosome and gene mapping, and in generating antisense RNA and DNA. The
XX present sequence represents an oligonucleotide used to make a Mink3
XX Lys54Arg mutant (in the kinase domain).
XX
XX Sequence 30 BP; 6 A; 8 C; 7 G; 8 T; 0 U; 1 Other;
XX
XX Query Match 0.6%; Score 23.4; DB 1; Length 30;
XX Best Local Similarity 88.9%; Pred. No. 61;
XX Matches 24; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX 156 GGCTGCCATCAAGGTGTCAGTGCAC 182
XX :|||
XX 27 KGCAGCCATCAAGTTATGATGTCAC 1
XX
XX RESULT 19
XX AA240517/c
```

AAZ40517 standard; DNA; 23 BP.
AAZ40517;
18-FEB-2000 (first entry)
Human STE20-related protein kinase gene primer #19.
Antirheumatic; antiarthritic; antiinflammatory; antiallergic; osteopathic;
antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
neuroprotective; cardiant; cerebroprotective; cytostatic; antidiabetic;
vulnery; STE20; protein kinase; STLK2; STLK3; STLK4; STLK5; STLK6; STLK7;
ZC1; ZC2; ZC3; ZC4; KHS2; SULU1; SULU3; GEK2; PAK4; PAK5; antagonist;
antibody; gene therapy; rheumatoid arthritis; atherosclerosis; asthma;
inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
myocardial infarction; cardiovascular disease; stroke; renal failure;
oxidative stress-related neurodegenerative disorder; Parkinson's disease;
amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;
mesangial disorder; growth regulation; wound healing; T cell activation;
immunosuppressant; primer; PCR; amplification; ss.
Synthetic.
OS Homo sapiens.
XX
XX
PN WO9953036-A2.
XX
XX
PD 21-OCT-1999.
XX
XX
PF 13-APR-1999; 99WO-US008150.
XX
XX
PR 14-APR-1998; 98US-0081784P.
XX
XX
PA (SUGE-) SUGEN INC.
XX
XX
PI Plowman G, Martinez R, Whyte D;
XX
XX
DR WPI; 1999-611301/52.
XX
XX
PT Novel kinase-related polypeptides used for the diagnosis and treatment of
PT Kinase-related diseases and disorders.
XX
XX
PS Disclosure; Page 323; 387pp; English.
XX
XX
CC This sequence represents a PCR primer used to amplify the coding sequence
CC for a novel STE20-related protein kinase. The invention relates to
CC nucleic acid molecule encoding a kinase polypeptide selected from STLK2,
CC STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
CC SULU3, GEK2, PAK4 and PAK5. The proteins are used to identify agonists
CC and antagonists, and to raise antibodies. The polynucleotides are useful
CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
CC antigens and agonists may be used to treat diseases such as immune-
CC related disorders and diseases (e.g. rheumatoid arthritis,
CC atherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
CC disease, multiple sclerosis, organ transplantation, myocardial
CC infarction, cardiovascular disease, stroke, renal failure, oxidative
CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral
CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
CC mellitus, fibrotic and mesangial disorders. The proteins may also be
CC useful for cell growth regulation (e.g. in wound healing), T cell
CC activation, mitosis control, and as immunosuppressants
XX
SQ Sequence 23 BP; 2 A; 11 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3454 ACAGTAGAGGGGCGCGCT 3476

DB 23 ACAGTAGAGGGGCGCGCT 1
RESULT 20
AAZ40518
ID AAZ40518 standard; DNA; 23 BP.
XX
XX
AC AAZ40518;
XX
XX
DT 18-FEB-2000 (first entry)
XX
DE Human STE20-related protein kinase gene primer #20.
XX
XX
KW Antirheumatic; antiarthritic; antiinflammatory; antiallergic; osteopathic;
KW antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
KW neuroprotective; cardiant; cerebroprotective; cytostatic; antidiabetic;
KW vulnery; STE20; protein kinase; STLK2; STLK3; STLK4; STLK5; STLK6; STLK7;
KW ZC1; ZC2; ZC3; ZC4; KHS2; SULU1; SULU3; GEK2; PAK4; PAK5; antagonist;
KW antibody; gene therapy; rheumatoid arthritis; atherosclerosis; asthma;
KW inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
KW rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
KW myocardial infarction; cardiovascular disease; stroke; renal failure;
KW oxidative stress-related neurodegenerative disorder; Parkinson's disease;
KW amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
KW ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;
KW mesangial disorder; growth regulation; wound healing; T cell activation;
KW immunosuppressant; primer; PCR; amplification; ss.
XX
XX
OS Synthetic.
OS Homo sapiens.
XX
XX
PN WO9953036-A2.
XX
XX
PD 21-OCT-1999.
XX
XX
PF 13-APR-1999; 99WO-US008150.
XX
XX
PR 14-APR-1998; 98US-0081784P.
XX
XX
PA (SUGE-) SUGEN INC.
XX
XX
PI Plowman G, Martinez R, Whyte D;
XX
XX
DR WPI; 1999-611301/52.
XX
XX
PT Novel kinase-related polypeptides used for the diagnosis and treatment of
PT Kinase-related diseases and disorders.
XX
XX
PS Disclosure; Page 323; 387pp; English.
XX
XX
CC This sequence represents a PCR primer used to amplify the coding sequence
CC for a novel STE20-related protein kinase. The invention relates to
CC nucleic acid molecule encoding a kinase polypeptide selected from STLK2,
CC STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
CC SULU3, GEK2, PAK4 and PAK5. The proteins are used to identify agonists
CC and antagonists, and to raise antibodies. The polynucleotides are useful
CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
CC antigens and agonists may be used to treat diseases such as immune-
CC related disorders and diseases (e.g. rheumatoid arthritis,
CC atherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
CC disease, multiple sclerosis, organ transplantation, myocardial
CC infarction, cardiovascular disease, stroke, renal failure, oxidative
CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral
CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
CC mellitus, fibrotic and mesangial disorders. The proteins may also be
CC useful for cell growth regulation (e.g. in wound healing), T cell
CC activation, mitosis control, and as immunosuppressants
XX
SQ Sequence 23 BP; 7 A; 11 C; 2 G; 3 T; 0 U; 0 Other;

```

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 242 ACCGCAACATCGCCACTACTAC 264
DB 1 ACCGCAACATCGCCACTACTAC 23

RESULT 21
ABL39570
ID ABL39570 standard; DNA; 23 BP.
AC ABL39570;
XX
DT 09-MAY-2002 (first entry)
DE Human cancer suppressing gene PP928 PCR primer #1.
KW Human; cancer suppression; cancer; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN CN1313318-A.
XX
PD 19-SEP-2001.
XX
PF 14-MAR-2000; 2000CN-00111997.
XX
PR 14-MAR-2000; 2000CN-00111997.
XX
PA (SHAN-) SHANGHAI INST ONCOLOGY.
XX
PI Gu J, Yang S;
XX
DR WPI; 2002-042196/06.
XX
PT New human protein able to suppress growth of cancer cells and its
  encoding polynucleotide.
XX
PS Example 2; Page 12 (Disclosure); 65pp; Chinese.
XX
CC The present invention describes human proteins with cancer suppressing
  activity. Also described are the polynucleotides encoding the proteins
  and a process for preparing the proteins by DNA recombination. The
  CC proteins and polynucleotides can be used in the treatment of diseases
  CC such as cancer. The present sequence represents a PCR primer for a human
  CC cancer suppressing gene, which is used in an example from the present
  CC invention
XX
SQ Sequence 23 BP; 10 A; 7 C; 6 G; 0 T; 0 U; 0 Other;

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2706 CGAGACAGCAAGGCCAAGCC 2728
DB 1 CGAGACAGCAAGGCCAAGCC 23

RESULT 22
ADN97255
ID ADN97255 standard; DNA; 24 BP.
XX
AC ADN97255;
XX
DT 01-JUL-2004 (first entry)
DE Primer of the invention #57.
XX
DE DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KW

Query Match      0.6%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 52;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGCAGC 1141
DB 1 AGCAGCAGCAGCAGCAGCAGCAGC 24

RESULT 23
ADN97164
ID ADN97164 standard; DNA; 24 BP.
XX
AC ADN97164;
XX
DT 01-JUL-2004 (first entry)
XX
DE Primer of the invention #3.
XX
KW DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KW forensic identification; marijuana; primer; ss.
XX
OS Synthetic.
XX
PN WO2004008841-A2.
XX
PD 29-JAN-2004.
XX
PF 21-JUL-2003; 2003WO-US022887.
XX
PR 19-JUL-2002; 2002US-0397179P.
XX
PA (UYAR-) UNIV ARIZONA.
PA (KEIM/) KEIM P S.
PA (ZINN/) ZINNAMON K.
XX
PI Keim PS, Zinnamon K;
XX

forensic identification; marijuana; primer; ss.
Unidentified.
WO2004008841-A2.
29-JAN-2004.
21-JUL-2003; 2003WO-US022887.
19-JUL-2002; 2002US-0397179P.
(UYAR-) UNIV ARIZONA.
(KEIM/) KEIM P S.
(ZINN/) ZINNAMON K.
Keim PS, Zinnamon K;
WPI; 2004-143139/14.
New isolated nucleic acid for amplification of a short tandem repeat
located in DNA isolated from Cannabis sativa L species, useful for
forensic identification of marijuana or for linking a marijuana sample to
its plant source.
Example 11; SEQ ID NO 122; 79pp; English.
The present invention relates to DNA fingerprinting for Cannabis Sativa
using short tandem repeat markers. The nucleic acid is useful for
forensic identification of marijuana or for linking a marijuana sample to
its plant source. The present sequence represents a primer of the
invention.
Sequence 24 BP; 8 A; 8 C; 8 G; 0 T; 0 U; 0 Other;

Query Match      0.6%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 52;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGCAGC 1141
DB 1 AGCAGCAGCAGCAGCAGCAGCAGC 24

RESULT 23
ADN97164
ID ADN97164 standard; DNA; 24 BP.
XX
AC ADN97164;
XX
DT 01-JUL-2004 (first entry)
XX
DE Primer of the invention #3.
XX
KW DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KW forensic identification; marijuana; primer; ss.
XX
OS Synthetic.
XX
PN WO2004008841-A2.
XX
PD 29-JAN-2004.
XX
PF 21-JUL-2003; 2003WO-US022887.
XX
PR 19-JUL-2002; 2002US-0397179P.
XX
PA (UYAR-) UNIV ARIZONA.
PA (KEIM/) KEIM P S.
PA (ZINN/) ZINNAMON K.
XX
PI Keim PS, Zinnamon K;
XX

forensic identification; marijuana; primer; ss.
Unidentified.
WO2004008841-A2.
29-JAN-2004.
21-JUL-2003; 2003WO-US022887.
19-JUL-2002; 2002US-0397179P.
(UYAR-) UNIV ARIZONA.
(KEIM/) KEIM P S.
(ZINN/) ZINNAMON K.
Keim PS, Zinnamon K;

```


DR WPI; 2004-143139/14.
 PT New isolated nucleic acid for amplification of a short tandem repeat
 PT located in DNA isolated from Cannabis sativa L species, useful for
 PT forensic identification of marijuana or for linking a marijuana sample to
 PT its plant source.
 XX
 PS Disclosure; SEQ ID NO 31; 79pp; English.
 XX
 CC The present invention relates to DNA fingerprinting for Cannabis sativa
 CC using short tandem repeat markers. The nucleic acid is useful for
 CC forensic identification of marijuana or for linking a marijuana sample to
 CC its plant source. The present sequence represents a primer of the
 CC invention.
 XX
 SQ Sequence 24 BP; 8 A; 8 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 52;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1118 AGCAGCAGCAGCTGTCAGCAGCAGC 1141
 |||||
 DB 1 AGCAGCAGCAGCAGCAGCAGCAGC 24
 |||||
 RESULT 24
 ADR68635/c
 ID ADR68635 standard; DNA; 24 BP.
 XX
 AC ADR68635;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 DE DNA G-quadruplex structure-fixing compound-related oligonucleotide #12.
 XX
 KW G-quadruplex structure; isomer; racemate; enantiomer; diastereoisomer;
 KW cytosolic; muscular-Gen; dermatological; vasotropic; endocrine-Gen;
 KW telomerase inhibitor; anticancer agent; genetic disorder;
 KW Bloom's syndrome; Werner's syndrome; Rothmund-Thomson syndrome;
 KW ataxia telangiectasia; ss.
 XX
 OS Unidentified.
 XX
 PN FR2850970-A1.
 XX
 PD 13-AUG-2004.
 XX
 PF 07-FEB-2003; 2003FR-00001478.
 XX
 PR 07-FEB-2003; 2003FR-00001478.
 XX
 PA (AVET) AVENTIS PHARMA SA.
 PA (CNRS) CNRS CENT NAT RECH SCI.
 PA (MUSE-) MUSEUM NAT HISTOIRE NATURELLE.
 PA (CURT-) INST CURIE.
 PA (COMS) COMMISSARIAT ENERGIE ATOMIQUE.
 PA (UYRE-) UNIV REIMS CHAMPAGNE-ARDENNE.
 XX
 PI Hittinger A, Caulfield T, Maillet P, Bouchard H, Mandine E;
 PI Belmokhtar C, Mergny JL, Guittat L, Riou JF, Gomez D;
 XX
 DR WPI; 2004-583573/57.
 XX
 PT New quaternary aromatic nitrogen heterocycle derivatives that fix the G-
 PT quadruplex structure of DNA or RNA are telomerase inhibitors, useful in
 PT the treatment of cancers and some genetic disorders.
 XX
 PS Disclosure; Page 25; 57pp; French.
 XX
 CC This invention relates to novel compounds that fix the G-quadruplex
 CC structure of DNA or RNA, their isomers, racemates, enantiomers,
 CC diastereoisomers, and their salts. The invention may be useful for the

CC production of compounds with a cytostatic, muscular-Gen, dermatological,
 CC vasotropic or endocrine-Gen activity acting as telomerase inhibitors. The
 CC compounds are useful as anticancer agents and for treatment of genetic
 CC disorders such as Bloom's syndrome, Werner's syndrome, Rothmund-Thomson
 CC syndrome and ataxia telangiectasia. The present sequence is that of an
 CC oligonucleotide which is related to the novel compounds of the invention.
 XX
 SQ Sequence 24 BP; 0 A; 8 C; 8 G; 8 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 52;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1117 CAGCAGCAGCAGCTGTCAGCAGCAGC 1140
 |||||
 DB 24 CAGCAGCAGCAGCAGCAGCAGCAGC 1
 |||||
 RESULT 25
 ABK11030
 ID ABK11030 standard; DNA; 27 BP.
 XX
 AC ABK11030;
 XX
 DT 05-JUN-2002 (first entry)
 XX
 DE Human HPK/GCK-like kinase, probe.
 XX
 KW Human; HPK/GCK-like kinase; antiinflammatory; cytostatic; antimicrobial;
 KW HGK; NIK; Nck-interacting kinase; infection; inflammation; tumour;
 KW antisense gene therapy; probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6346416-B1.
 XX
 PD 12-FEB-2002.
 XX
 PF 29-AUG-2000; 2000US-00651011.
 XX
 PR 29-AUG-2000; 2000US-00651011.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Dean NM, Cowsert LM;
 XX
 DR WPI; 2002-237091/29.
 XX
 PT New antisense compound, useful for preventing or delaying infection,
 PT inflammation or tumor formation, is targeted to nucleic acid molecule
 PT encoding HPK/GCK-like kinase (HGK) and hybridizes and inhibits HGK
 PT expression.
 XX
 PS Example 13; Col 42; 37pp; English.
 XX
 CC The invention relates to an antisense compound (I) of 8-50 nucleobases in
 CC length targeted to a start codon region, coding region or 3'-untranslated
 CC region of a nucleic acid molecule encoding HPK/GCK (undefined)-like
 CC kinase (HGK) (also known as NIK for Nck-interacting kinase), which
 CC specifically hybridizes with and inhibits expression of HGK. (I) is
 CC useful for inhibiting the expression of HPK/GCK-like kinase in cells or
 CC tissues in vitro. (I) is useful prophylactically e.g. to prevent or delay
 CC infection, inflammation and tumour formation. (I) is also useful as a
 CC diagnostic and research reagent. (I) is also useful for distinguishing
 CC functions of various members of a biological pathway and in antisense
 CC gene therapy. The present sequence represents a probe used to isolate the
 CC coding sequence of human HPK/GCK-like kinase
 XX
 SQ Sequence 27 BP; 6 A; 5 C; 9 G; 7 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22.2; DB 1; Length 27;
 Best Local Similarity 88.9%; Pred. No. 70;
 Matches 24; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 467 TCAAGGGCAGAGTGTCTGCTGACAG 493
Db 1 TCAAGGGCCAGAGTGTCTGCTGACTG 27

RESULT 26
AAA03952
ID AAA03952 standard; DNA; 29 BP.
XX
AC AAA03952;
XX
DT 22-MAY-2000 (first entry)
XX
DE Polymorphic fragment of hypertension associated gene APOA4.
XX
KW Polymorphism; hypertension; agammaglobulinemia; diabetes insipidus;
KW Lesch-Nyhan syndrome; muscular dystrophy; Wiskott-Aldrich syndrome;
KW Fabry's disease; familial hypercholesterolemia; hereditary spherocytosis;
KW polycystic kidney disease; von Willebrand's disease; forensic; human;
KW tuberous sclerosis; hereditary hemorrhagica telangiectasia;
KW familial colonic polyposis; osteogenesis imperfecta; porphyria;
KW Ehlers-Danlos syndrome; ss.
XX
OS Homo sapiens.
XX
PN EP955382-A2.
XX
PD 10-NOV-1999.
XX
PF 07-MAY-1999; 99EP-00250150.
XX
PR 07-MAY-1998; 98US-0084641P.
PR 03-MAY-1999; 99US-00304232.
XX
PA (AFFY-) AFFYMETRIX INC.
PA (UYCA-) UNIV CASE WESTERN RESERVE.
XX
PI Fan JB, Chakravarti A, Haluska MK;
XX WPI; 2000-107928/10.
DR
XX Novel nucleic acids containing polymorphisms used in the diagnosis of
PT hypertension.
XX
PS Claim 1; Page 21; 53pp; English.
XX
CC The invention provides polymorphic fragments of genes associated with
CC hypertension. The nucleic acids including the polymorphic sites can be
CC used as probes or primers for expressing variant proteins. Detection of
CC the polymorphisms is useful in designing prophylactic and therapeutic
CC regimes customized to underlying abnormalities. The polymorphisms can be
CC used for association studies for hypertension, and in hypertension
CC diagnostic assays. Where the polymorphisms have strong correlation with
CC hypertension, within a gene, they are likely to have a causative role in
CC hypertension. This information can be used to find the precise role of a
CC polymorphism in the disease, and this can be used to identify potential
CC drugs which combat the disease. The polymorphisms can be tested for
CC association with other diseases e.g. agammaglobulinemia, diabetes
CC insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich
CC syndrome, Fabry's disease, familial hypercholesterolemia, polycystic
CC kidney disease, hereditary spherocytosis, von Willebrand's disease,
CC tuberous sclerosis, hereditary hemorrhagica telangiectasia, familial
CC colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and
CC acute intermittent porphyria. The polymorphic forms can also be used in
CC forensics to identify individuals
XX
SQ Sequence 29 BP; 11 A; 8 C; 9 G; 0 T; 0 U; 1 Other;
Query Match 0.6%; Score 22.2; DB 1; Length 29;
Best Local Similarity 82.8%; Pred. No. 80;
Matches 24; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGTCGTCAGCAGCAGCA 1145
Db 1 CAGCAGGACACGACACGAGCAGCAGCA 29

RESULT 27
ADC38187
ID ADC38187 standard; DNA; 25 BP.
XX
AC ADC38187;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLPia scanning 25-mer oligonucleotide SEQ ID NO:536.
XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLPia; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX WPI; 2003-430501/40.
DR
XX New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 536; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLPia, which is used in an example from the
CC present invention.
XX
SQ Sequence 25 BP; 8 A; 7 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACACGACGACGAG 1464
Db 3 GCAGCAGCAGCAACACGACGACGAG 24

RESULT 28
ADC38189
ID ADC38189 standard; DNA; 25 BP.
XX
AC ADC38189;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLPia scanning 25-mer oligonucleotide SEQ ID NO:538.
XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLPia; ss.


```
Query Match      0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGCAG 1464
Db 2 GCAGCAGCAGCAACAGCAGCAG 23

RESULT 31
ID ADO43735/c
AC ADO43735;
XX
DT 29-JUL-2004 (first entry)
DE PCR primer used to amplify SEAP for cloning into pPerX8 and pPerX9.
KW transfection; eukaryotic cell; eukaryotic locus;
KW ferritin heavy chain locus; PCR; primer; ss;
KW secreted alkaline phosphatase; SEAP.
XX
OS Synthetic.
XX
XX WO2004037982-A2.
XX
XX 06-MAY-2004.
XX
XX 22-OCT-2003; 2003WO-US033433.
XX
XX 24-OCT-2002; 2002US-0421252P.
XX
XX (BIOJ ) BIOGEN INC.
XX
XX Prentice H;
XX
XX WPI; 2004-357431/33.
XX
XX New genetic vector comprising distal 5' flanking sequences and proximal
PT 5' regulatory sequences, an insertion site and proximal 3' regulatory
PT sequences, useful for transfecting and expressing a protein within
PT eukaryotic cells.
XX
XX Example 2; Page 23; Sipp; English.
XX
XX The specification describes a genetic vector for stable transfection and
CC expression of a desired protein within eukaryotic cells. The vector
CC comprises distal 5' flanking sequences of a eukaryotic locus, proximal 5'
CC regulatory sequences of a eukaryotic locus, at least a first insertion
CC site for a first heterologous coding sequence, and proximal 3' regulatory
CC sequences effective for transcription termination of a eukaryotic locus.
CC These sequences are operably joined in a 5' to 3' orientation, with
CC optional linker sequences between adjacent sequences. The distal flanking
CC sequences and proximal 5' regulatory sequences and the proximal 3'
CC regulatory sequences are derived from a ferritin heavy chain locus, and
CC have a total length of between 1000 and 10000 bases. The genetic vector
CC is useful for stably transfecting and expressing a desired protein within
CC eukaryotic cells. PCR primers ADO43734-ADO43735 were used to amplify
CC secreted alkaline phosphatase (SEAP) for insertion into pPerX8 and
CC pPerX9, vectors of the invention. SEAP was used as a reporter gene.
XX
XX Sequence 27 BP; 1 A; 9 C; 10 G; 7 T; 0 U; 0 Other;
SQ
Query Match      0.5%; Score 21.4; DB 1; Length 27;
Best Local Similarity 95.7%; Pred. No. 88;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAGCAGCAGCAGCT 1469
Db 24 CAGCAGCAGCAGCAGCAGCT 2
```

```
RESULT 32
AA240515
ID AA240515 standard; DNA; 21 BP.
XX
AC AA240515;
XX
DT 18-FEB-2000 (first entry)
XX
DE Human STE20-related protein kinase gene primer #17.
XX
XX Antirheumatic; antiarthritic; antiinflammatory; antiallergic; osteopathic;
KW antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
KW neuroprotective; cardiant; cerebroprotective; cyostatic; antidiabetic;
KW vulnery; STE20; protein kinase; STLK2; STLK3; STLK4; STLK5; STLK6; STLK7;
KW ZC1; ZC2; ZC3; ZC4; KHS2; SULU1; SULU3; GEK2; PAK4; PAK5; antagonist;
KW antibody; gene therapy; rheumatoid arthritis; artherosclerosis; asthma;
KW inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
KW rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
KW myocardial infarction; cardiovascular disease; stroke; renal failure;
KW oxidative stress-related neurodegenerative disorder; Parkinson's disease;
KW amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
KW ischemic disorder; inflammation; diabetes mellitus; fibrosis; micosis;
KW mesangial disorder; growth regulation; wound healing; T cell activation;
KW immunosuppressant; primer; PCR; amplification; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX WO9953036-A2.
XX
XX 21-OCT-1999.
XX
XX 13-APR-1999; 99WO-US008150.
XX
XX 14-APR-1998; 98US-0081784P.
XX
XX (SUGE-) SUGEN INC.
XX
XX Plowman G, Martinez R, Whyte D;
XX
XX WPI; 1999-611301/52.
XX
XX Novel kinase-related polypeptides used for the diagnosis and treatment of
PT kinase-related diseases and disorders.
XX
XX Disclosure; Page 322; 387pp; English.
XX
XX This sequence represents a PCR primer used to amplify the coding sequence
CC for a novel STE20-related protein kinase. The invention relates to
CC nucleic acid molecule encoding a kinase polypeptide selected from STLK2,
CC STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
CC SULU3, GEK2, PAK4 and PAK5. The proteins are used to identify agonists
CC and antagonists, and to raise antibodies. The polynucleotides are useful
CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
CC antagonists and agonists may be used to treat diseases such as immune-
CC related disorders and diseases (e.g. rheumatoid arthritis,
CC artherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
CC disease, multiple sclerosis, organ transplantation, myocardial
CC infarction, cardiovascular disease, stroke, renal failure, oxidative
CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral
CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
CC mellitus, fibrotic and mesangial disorders. The proteins may also be
CC useful for cell growth regulation (e.g. in wound healing), T cell
CC activation, mitosis control, and as immunosuppressants
XX
XX Sequence 21 BP; 8 A; 10 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 59;
```

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3379 CCCAACCCCTACCACAAATTC 3399
|||||
Db 1 CCCAACCCCTACCACAAATTC 21

RESULT 33
ADC38190
ID ADC38190 standard; DNA; 25 BP.

XX
AC ADC38190;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 25-mer oligonucleotide SEQ ID NO:539.
XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 539; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 25 BP; 8 A; 7 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAGCAGCAGCAG 1464
|||||
Db 1 CAGCAGCAGCAGCAGCAGCAG 21

RESULT 34
ADC38185
ID ADC38185 standard; DNA; 25 BP.

XX
AC ADC38185;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 25-mer oligonucleotide SEQ ID NO:534.
XX

KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 534; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 25 BP; 8 A; 7 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAGCAGCAGCA 1463
|||||
Db 5 GCAGCAGCAGCAGCAGCAGCA 25

RESULT 35
ABK88725/C
ID ABK88725 standard; DNA; 22 BP.

XX
AC ABK88725;
XX
DT 07-OCT-2002 (first entry)
XX
DE Human Pur alpha anti-sense strand, phosphorothioate oligonucleotide #4.
XX
KW Human; apoptotic cell death; proteinaceous transcription factor;
KW regulation of gene transcription; apoptosis; p53; CD95; TRA;
KW transcriptional regulator of apoptosis; Y-box family; YB-1; cancer;
KW tumour cell; embryonic cell; nervous system; intracellular pathogen;
KW DNA-damaging agent; retroviral infection; neurodegenerative disorder;
KW immune system dysfunction; anti-tumour; cytostatic; Pur alpha;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..22
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate internucleotide linkages"
XX
PN WO200244363-A1.


```
FT. /*tag= a
FT /note= "n = O2-P-O-CH2-CH2-O-CH2-CH2-S-S-CH2-CH2-O- CH2-
PT CH2-O-P-O3"
XX
XX WO9114696-A.
XX
XX 03-OCT-1991.
XX
XX 29-MAR-1990; 90US-00502361.
XX
XX 29-MAR-1990; 90US-00502361.
XX
XX (GILE-) GILEAD SCI INC.
XX
XX Latham JA, Lin KY, Matteucci M;
XX
XX WPI; 1991-310529/42.
XX
XX New oligo:nucleotide- transport agent di:sulphide conjugate(s) - for
PT inhibiting nucleotide expression in therapy and diagnosis of endogenous
PT nucleotide sequences in cells.
XX
XX Example; Page 37; 67pp; English.
XX
XX The oligonucleotide has a disulphide linker incorporated into the probe
CC which acts as a hybridisation-triggered crosslinking agent. This will
CC permit novel diagnostic assay modifications such as the use of
CC crosslinker to increase probe discrimination and incorporation of a
CC denaturing wash step to reduce background. Also carrying out
CC hybridisation and crosslinking at or near the melting temperature of the
CC hybrid DNA will reduce secondary structure in the target DNA and increase
CC probe specificity. See also AAQ14195
XX
XX Sequence 21 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 1 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 21;
XX Best Local Similarity 95.2%; Pred. No. 80;
XX Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1123 CAGCAGCTGCAGCAGCAGCAG 1143
XX |||||||
DB 1 CAGCAGCAGCAGCAGCAGCAG 21
XX
XX RESULT 38
XX ADC38191
XX ID ADC38191 standard; DNA; 25 BP.
XX
XX AC ADC38191;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human AMLP1a scanning 25-mer oligonucleotide SEQ ID NO:540.
XX
XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX AMLP1a; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO2003037931-A2.
XX
XX 08-MAY-2003.
XX
XX 01-NOV-2002; 2002WO-US035129.
XX
XX 01-NOV-2001; 2001US-0334773P.
XX
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Shannon M, Phan T;
XX
XX WPI; 2003-430501/40.
XX
XX
```

```
XX
XX New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
XX Example 2; SEQ ID NO 540; 172pp; English.
XX
XX The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
XX Sequence 25 BP; 8 A; 7 C; 10 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1445 AGCAGCAGCAGCAGCAGCAG 1464
XX |||||||
DB 1 AGCAGCAGCAGCAGCAGCAG 20
XX
XX RESULT 39
XX ADC38184
XX ID ADC38184 standard; DNA; 25 BP.
XX
XX AC ADC38184;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human AMLP1a scanning 25-mer oligonucleotide SEQ ID NO:533.
XX
XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX AMLP1a; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO2003037931-A2.
XX
XX 08-MAY-2003.
XX
XX 01-NOV-2002; 2002WO-US035129.
XX
XX 01-NOV-2001; 2001US-0334773P.
XX
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Shannon M, Phan T;
XX
XX WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
XX Example 2; SEQ ID NO 533; 172pp; English.
XX
XX The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
XX Sequence 25 BP; 8 A; 7 C; 10 G; 0 T; 0 U; 0 Other;
```

Query Match 0.5%; Score 20; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCACGACGACGACGACGACG 1462
 |||||
 DB 6 GCACGACGACGACGACGACG 25

RESULT 40
 ADJ92110/c
 ID ADJ92110 standard; DNA; 24 BP.
 AC ADJ92110;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE PCR primer 1 related to human plectin trans-splicing.
 XX
 KW pre-trans-splicing molecule; PTM; cytosolic; dermatological;
 KW antipsoriatic; genodermatosis; epidermal fragility; keratinisation;
 KW hair disorder; pigmentation; skin cancer; epidermolysis bullosa;
 KW psoriasis; human; ss; PCR; primer; plectin trans-splicing.
 XX
 OS Unidentified.
 XX
 PN WO2004006678-A1.
 XX
 PD 22-JAN-2004.
 XX
 PF 17-JUL-2003; 2003WO-US022469.
 XX
 PR 17-JUL-2002; 2002US-00198447.
 XX
 XX (INTR-) INTRONN INC.
 PA Mitchell LG, Puttaraju M, Dallinger G, Klaussegger A, Bauer J;
 PI
 XX WPI; 2004-122721/12.
 DR
 XX
 CC Novel pre-trans-splicing nucleic acid molecule useful for treating
 PT epidermal fragility disorders, keratinization disorders, hair disorders,
 PT pigmentation disorders, skin cancer, epidermolysis bullosa or psoriasis.
 XX
 PS Example; Page 42; 91pp; English.
 XX
 CC The invention relates to a novel pre-trans-splicing molecule (PTM)
 CC nucleic acid comprising one or more target binding domains that target
 CC binding of the nucleic acid to pre-mRNA expressed within a cell of the
 CC skin. The nucleic acid may have a 3' splice region comprising a branch
 CC point and a 3' splice acceptor site or 5' splice site, a spacer region
 CC that separates the 3' or 5' splice region from the target binding domain
 CC and a nucleotide sequence to be trans-spliced to the target pre-mRNA. The
 CC nucleic acid of the invention demonstrates cytostatic, dermatological and
 CC antipsoriatic activities and may be used within a skin application agent
 CC for treating specific disorders of the skin including genodermatosis,
 CC epidermal fragility disorders, keratinisation disorders, hair disorders,
 CC pigmentation disorders, skin cancer, epidermolysis bullosa or psoriasis.
 CC The current sequence is that of the RT-PCR primer 2 of the invention
 CC which is related to human plectin trans-splicing.
 XX
 SQ Sequence 24 BP; 1 A; 6 C; 10 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.8; DB 1; Length 24;
 Best Local Similarity 91.3%; Pred. No. 1.1e+02;
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1473 GAACAGCAGCAGCAGCAGCTCC 1495
 |||||
 DB 24 GAAGCAGCAGCAGCAGCTCC 2

RESULT 41
 ABS71093/c
 ID ABS71093 standard; DNA; 26 BP.
 XX
 AC ABS71093;
 XX
 DT 27-NOV-2002 (first entry)
 XX
 DE Human GPCR ligand Bv8 cDNA PCR primer hbv8-F1.
 XX
 KW G-protein coupled receptor; GPCR; ZAQ; human; ZAQ; ZAQ; rat; ZAQ1;
 KW rZAQ1; rZAQ2; mouse; ISE receptor; mISE; GPR73; Bv8 protein;
 KW digestive disorder; central nervous system disorder; CNS; diarrhoea;
 KW bowel inflammation; constipation; food absorption disorder; nootropic;
 KW Alzheimer's disease; Parkinson's disease; schizophrenia; laxative;
 KW antiinflammatory; antidiarrhoeic; neuroleptic; neuroprotective; PCR;
 KW primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200262944-A2.
 XX
 PD 15-AUG-2002.
 XX
 PF 01-FEB-2002; 2002WO-JP000852.
 XX
 PR 02-FEB-2001; 2001JP-00026820.
 XX
 PA (TAKE) TAKEDA CHEM IND LTD.
 XX
 PI Ohtaki T, Masuda Y, Takatsu Y, Watanabe T, Terao Y, Shintani Y;
 PI Hinuma S;
 XX
 XX WPI; 2002-627537/67.
 DR
 XX
 CC Screening of compounds modifying the binding of G-protein coupled
 PT receptor protein ZAQ and related proteins to their ligands for use in
 PT treatment and diagnosis of digestive disorders.
 XX
 PS Example 3; Page 117; 197pp; Japanese.
 XX
 CC The present invention relates to a screening method for compounds for
 CC their ability to modify the binding of G-protein coupled receptor (GPCR)
 CC protein ZAQ and related proteins (human ZAQ, human ZAQ, rat ZAQ1
 CC (rZAQ1), rZAQ2, human and mouse ISE (mISE) receptor, and mouse GPR73) to
 CC their ligands (the mature form of human, mouse or rat Bv8 protein). The
 CC receptor protein and ligand are contacted in the presence or absence of
 CC the test compound. The compounds are useful in a drug composition for the
 CC treatment, and prevention of digestive and central nervous system (CNS)
 CC disorders, including bowel inflammation, diarrhoea, constipation, food
 CC absorption disorders, Alzheimer's disease, Parkinson's disease and
 CC schizophrenia. The present sequence represents a PCR primer used in the
 CC examples of the present invention
 XX
 SQ Sequence 26 BP; 1 A; 9 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.6; DB 1; Length 26;
 Best Local Similarity 84.6%; Pred. No. 1.4e+02;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1115 AACAGCAGCAGCTGCAGCAGCAG 1140
 |||||
 DB 26 AACAGCAGCAGCAGCAGCAGTAG 1

RESULT 42
 ADD69029/c
 ID ADD69029 standard; DNA; 26 BP.
 XX
 AC ADD69029;
 XX
 DT 15-JAN-2004 (first entry)
 XX


```

DE Angiogenesis inhibitor-related PCR primer hbv8-F1.
KW angiogenesis inhibitor; cytostatic; antiinflammatory; cancer;
KW ovarian disease; diabetic retinopathy; inflammatory; ZAQ; Bv8; ISE; ss;
KW PCR; primer; hbv8-F1.
XX
XX Unidentified.
XX
XX WO2003066860-A1.
XX
XX 14-AUG-2003.
XX
XX 03-FEB-2003; 2003WO-JP001057.
XX
XX 04-FEB-2002; 2002JP-00027299.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Ohtaki T, Masuda Y, Takatsu Y;
XX WPI; 2003-646310/61.
XX
XX Angiogenesis inhibitors for treatment and prevention of cancer, ovarian
XX diseases and inflammatory disease.
XX
XX Example 3; SEQ ID NO 7; 308pp; Japanese.
XX
XX The invention relates to a novel angiogenesis inhibitor comprising a
XX compound that inhibits the activity of an amino acid sequence given in
XX the specification. Angiogenesis-related proteins Bv8, ZAQ and ISE were
XX utilised within the method of the invention. The molecules of the
XX invention demonstrate cytostatic and antiinflammatory activities whilst
XX the method may be useful for treatment and prevention of cancer, ovarian
XX diseases, diabetic retinopathy and inflammatory disease. The current
XX sequence is that of the angiogenesis inhibitor-related PCR primer of the
XX invention.
XX
XX Sequence 26 BP; 1 A; 9 C; 6 G; 10 T; 0 U; 0 Other;
SQ

```

Query Match 0.5%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

QY 1115 AACGACGACGACGCTGCAGCAGCAG 1140
    ||||| ||||| ||||| ||||| |||||
DB 26 AACGACGACGCGCAGCAGCAGAGTAG 1

```

RESULT 43
AAF99580/C
ID AAF99580 standard; DNA; 21 BP.
XX
XX AAF99580;
XX
XX 12-JUN-2001 (first entry)
DE Immunostimulatory nucleic acid #696.
XX
XX Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW immunostimulatory; tumour; viral infection; bacterial infection;
KW fungal infection; parasitic infection; cancer; asthma;
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
XX Synthetic.
XX
XX WO200122972-A2.
XX
XX 05-APR-2001.
XX
XX 25-SEP-2000; 2000WO-US026383.
XX
XX 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR

```

PR 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA ) UNIV IOWA RES FOUND.
XX (COLE-) COLEY PHARM GMBH.
XX
XX Krieg AM, Schetter C, Vollmer J;
XX WPI; 2001-273485/28.
XX
XX Vaccinating against tumors, infectious diseases, allergies and asthma
XX using immunostimulatory Py-rich and TG nucleic acids.
XX
XX Claim 101; Page 53; 338pp; English.
XX
XX The present invention relates to a method for stimulating an immune
XX response. The method comprises administering an immunostimulatory nucleic
XX acid to a non-rodent subject in sufficient quantity to stimulate an
XX immune response. The present sequence is one such immunostimulatory
XX nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
XX (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
XX against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
XX and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
XX haemophilus, campylobacter, clostridium, Escherichia coli and/or
XX staphylococcus), fungal antigens and/or parasitic antigens. The method is
XX also useful for preventing cancer, asthma, infectious disease, allergy or
XX immune deficiency. The present sequence can also be used to redirect a
XX Th2 to a Th1 immune response and to activate immune cells. Note: the
XX present sequence may have a phosphorothioate backbone
XX
XX Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;
SQ

```

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 95;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
    ||||| ||||| ||||| ||||| |||||
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

```

RESULT 44
ABS78296/C
ID ABS78296 standard; DNA; 21 BP.
XX
XX ABS78296;
XX
XX 13-DEC-2002 (first entry)
XX
XX Angiogenesis inhibitory oligonucleotide #780.
XX
XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubrosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophilic joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
XX Synthetic.
XX
XX WO200253141-A2.
XX
XX 11-JUL-2002.
XX
XX 14-DEC-2001; 2001WO-US048458.
XX
XX 14-DEC-2000; 2000US-0255534P.
XX
XX (COLE-) COLEY PHARM GROUP INC.
XX
XX Bratzler RL;
XX

DR WPI; 2002-566690/60.

XX Inhibiting angiogenesis in a subject, involves administering at least one

PT antiangiogenic nucleic acid molecule to the subject.

XX

PS Claim 2; Page 33; 276pp; English.

XX

CC The invention relates to inhibiting angiogenesis in a subject, comprising

CC administering at least one antiangiogenic nucleic acid molecule. Also

CC included is a kit comprising a first container housing the antiangiogenic

CC nucleic acids, and instructions for administering them to a subject

CC having a condition characterised by unwanted angiogenesis. The method is

CC useful for inhibiting angiogenesis associated with solid tumour growth,

CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,

CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,

CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,

CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque

CC neovascularisation, telangiectasia, haemophilic joints, scleroderma and

CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and

CC hypertrophic scars. The present sequence is an antiangiogenic nucleic

CC acid of the invention

XX

SQ Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 95;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCGTGCAGCAG 1137

Db 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 45

ABL38849/c

ID ABL38849 standard; DNA; 21 BP.

XX

AC ABL38849;

XX

XX 16-APR-2002 (first entry)

DE Immunostimulatory nucleic acid SEQ ID NO: 240.

XX

KW Antibody-induced cell lysis; cancer; immunostimulatory; CD20;

KW angiogenesis; metastasis; cytostatic; phosphorothioate backbone; ss.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT modified_base 1..21

FT /*tag= a

FT /*mod_base= OTHER

FT /*note= "phosphorothioate backbone"

XX

XX WO200197843-A2.

XX

XX 27-DEC-2001.

XX

XX 22-JUN-2001; 2001WO-US020154.

XX

XX 22-JUN-2000; 2000US-0213346P.

XX

XX (IOWA) UNIV IOWA RES FOUND.

XX

XX Weiner G, Hartmann G;

XX WPI; 2002-154611/20.

XX

XX Treating or preventing cancer, such as basal cell carcinoma, comprises

PT administering immunostimulatory nucleic acids that induce expression of

PT cell surface antigens and antibodies to a subject having or at risk of

PT developing cancer.

XX

PS Disclosure; Page 156; 312pp; English.

XX

CC The present invention relates to methods for treating or preventing

CC cancer, involving administering to a subject having or at risk of

CC developing cancer immunostimulatory nucleic acids that induce expression

CC of cell surface antigens and antibodies. The methods are useful for

CC treating or preventing cancer such as basal cell carcinoma, bladder

CC cancer, bone cancer, brain and central nervous system (CNS) cancer,

CC breast cancer, cervical cancer, colon and rectum cancer, connective

CC tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx

CC cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-

CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian

CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin

CC cancer, stomach cancer, testicular cancer, and uterine cancer. The

CC present sequence is an immunostimulatory oligonucleotide described in the

CC exemplification of the invention

XX

SQ Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 95;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCGTGCAGCAG 1137

Db 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 46

ABK10202/c

ID ABK10202 standard; DNA; 21 BP.

XX

AC ABK10202;

XX

XX 21-MAY-2002 (first entry)

DE Double stranded DNA isolation (CTG)7 repeat sequence.

XX

KW Single stranded DNA isolation; DNA purification; CTG repeat; ds.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT repeat_region 1..21

FT /*tag= a

FT /*rpt_type= TANDEM

FT repeat_unit 1..3

FT /*tag= b

FT /*note= "CTG type repeat"

XX

XX WO200210182-A2.

XX

XX 07-FEB-2002.

XX

XX 18-JUL-2001; 2001WO-US022782.

XX

XX 02-AUG-2000; 2000US-0222686P.

XX

XX (PEKE) PE CORP NY.

XX

XX Chiesa C, Schroth GP, Egholm M;

XX

XX WPI; 2002-188719/24.

XX

XX Isolating one strand of double-stranded nucleic acid, by contacting

PT double stranded nucleic acid having first and second strands with

PT competitor oligo to form first strand-oligo complex and isolating the

PT complex.

XX

XX Disclosure; Page 12; 61pp; English.

PS This invention relates to a novel method for isolating one strand of

XX double-stranded target nucleic acid. The method comprises contacting a

CC

CC double stranded target DNA molecule with a competitor oligonucleotide
 CC capable of hybridizing to the first strand of the double stranded
 CC molecule. The method is performed under conditions in which the first
 CC strand dissociates from the second and hybridizes with the competitor
 CC oligonucleotide to form a heteroduplex. The method of the invention is
 CC useful for separating a strand from a double-stranded target nucleic
 CC acid. The method is rapid, efficient and specific for isolating a single
 CC strand from a double-stranded nucleic acid. Because the method provides
 CC easy and efficient recovery of the single stranded DNA, the method is
 CC advantageously used to purify a first strand from a double- stranded
 CC nucleic acid that is a polymerase chain reaction (PCR) amplification
 CC product from a pool of related or unrelated sequences in high yield for
 CC subsequent use. The method also permits capture and/or recovery of the
 CC first strand of a double-stranded target nucleic acid from biological
 CC samples or other samples containing large molecule contaminants. The
 CC present sequence represents a double stranded (CTG)7 DNA molecule used to
 CC isolate double stranded DNA molecules in an example of a similar method
 CC to that of the invention
 SQ Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 95;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
 DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 47
 ACH03118/C
 ID ACH03118 standard; DNA; 21 BP.
 AC ACH03118;
 DT 25-SEP-2003 (first entry)
 XX Immunostimulatory nucleic acid #753.
 DE Immunostimulatory; dermatological; antipsoriatic;
 KW antitumor; gene therapy; vaccine; non-allergic inflammatory disease;
 KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
 KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
 OS Synthetic.
 XX US2003050268-A1.
 PN 13-MAR-2003.
 XX 29-MAR-2002; 2002US-00112653.
 XX 29-MAR-2001; 2001US-0279642P.
 PA (KRIE/) KRIEG A M.
 PA (BERG/) BERG D J.
 XX Krieg AM, Berg DJ;
 PI WPI; 2003-521815/49.
 XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
 XX allergic contact dermatitis, latex dermatitis or inflammatory bowel
 XX disease by administering an immunostimulatory nucleic acid.
 PS Disclosure; Page 29; 229pp; English.

CC The invention describes a method of treating non-allergic inflammatory
 CC disease comprising administering to a subject having or at risk of
 CC developing a non-allergic inflammatory disease an immunostimulatory
 CC nucleic acid for prevention or treatment of the disease. The method is
 CC useful for treating non-allergic inflammatory diseases, such as

CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
 CC This sequence represents an immunostimulatory nucleic acid
 XX Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 95;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
 DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 48
 ADB37082/C
 ID ADB37082 standard; DNA; 21 BP.

XX ADB37082;
 AC ADB37082;
 DT 04-DEC-2003 (first entry)
 XX Immunostimulatory nucleic acid #696.
 DE ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
 KW hypo-responsive subject; immunostimulatory.
 XX Synthetic.
 XX US2003087848-A1.
 PN 08-MAY-2003.
 XX 02-FEB-2001; 2001US-00776479.
 XX 03-FEB-2000; 2000US-0179991P.

XX (BRAT/) BRATZLER R L.
 PA (PETE/) PETERSEN D M.
 PA (FOUR/) FOURON Y.
 XX Bratzler RL, Petersen DM, Fouron Y;
 PI WPI; 2003-657977/62.
 XX Treating and/or preventing allergy or asthma using an immunostimulatory
 XX nucleic acid alone or in combination with an asthma/allergy medicament.
 PS Disclosure; Page 16; 221pp; English.

CC The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The methods and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.
 XX Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 95;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
 DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 49
 ABL61611
 ID ABL61611 standard; DNA; 24 BP.
 XX

```

AC ABL61611;
XX
DT 13-MAY-2002 (first entry)
XX
DE Porcine GPR8-related PCR primer #3.
XX
XX Anorectic; GPR8 ligand; central nervous system; obesity; pig;
KW appetite-stimulating agent; prolactin; porcine; PCR primer; ss.
XX
XX Sus scrofa.
XX
XX WO200198494-A1.
XX
PD 27-DEC-2001.
XX
XX 20-JUN-2001; 2001WO-JP005257.
XX
PR 21-JUN-2000; 2000JP-00191089.
PR 06-SEP-2000; 2000JP-00275013.
PR 13-APR-2001; 2001JP-00116000.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Mori M, Shimomura Y, Harada M, Kurihara M, Kitada C, Asami T;
PI Matsumoto Y, Adachi Y, Watanabe T, Sugo T, Abe M;
XX
XX WPI; 2002-139790/18.
XX
XX Ligand to GPR8 and encoded gene, useful in developing receptor-binding
PT assay system, diagnosis and screening candidate compounds for central
PT nervous system function-regulating drugs to treat e.g. obesity.
XX
XX Example 30; Page 184; 221pp; Japanese.
XX
XX The present invention relates to GPR8 ligands. The ligands as well as
CC their precursor proteins and DNAs are useful in developing receptor-
CC binding assay systems, diagnosis and screening candidate compounds for
CC central nervous system function-regulating drugs as preventives or
CC remedies for obesity, appetite-stimulating agents and prolactin
CC production promoters or inhibitors. The present PCR primer was used to
CC illustrate the invention
XX
XX Sequence 24 BP; 8 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146
Db 1 CAGCGCAGCAGCAGCAGCAG 21

RESULT 50
ABK94601
ID ABK94601 standard; DNA; 24 BP.
XX
XX AC ABK94601;
XX
XX DT 28-AUG-2002 (first entry)
XX
XX G-protein-coupled receptor DNA PCR primer #17.
XX
XX Human; rat; primer; ss; G protein-coupled receptor; anorectic; anabolic;
KW obesity; appetite enhancement; prolactin production; eating disorder;
KW PCR; pig; mouse.
XX
XX Sus scrofa.
XX
XX WO200244368-A1.
XX
XX 06-JUN-2002.
XX

```

```

PF 29-NOV-2001; 2001WO-JP010419.
XX
XX 30-NOV-2000; 2000JP-00364801.
PR 26-MAR-2001; 2001JP-00087482.
PR 15-MAY-2001; 2001JP-00145434.
PR 06-SEP-2001; 2001JP-00270838.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Terao Y, Shintani Y, Harada M, Shimomura Y, Mori M;
XX
XX WPI; 2002-471832/50.
XX
XX New rat and mouse brain-originated G protein-coupled receptor proteins
PT TGR26, useful in diagnosis and developing drugs for prevention or
PT treatment of obesity or an eating disorder.
XX
XX Example 11; Page 244; 312pp; Japanese.
XX
XX The invention relates to G protein-coupled receptor proteins and their
CC associated nucleic acids. The sequences are used in diagnosis of diseases
CC relating to function of the protein and can be used for treating obesity,
CC enhancing appetite or inhibiting prolactin production by administering
CC the compounds or their salts that can alter binding of the G protein-
CC coupled receptors. The proteins and encoded DNAs are useful in diagnosis
CC of and developing drugs for prevention or treatment of obesity and eating
CC disorders. This sequence represents a PCR primer used in production of
CC DNA encoding a G protein-coupled receptor protein
XX
XX Sequence 24 BP; 8 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146
Db 1 CAGCGCAGCAGCAGCAGCAG 21

RESULT 51
ABX92931
ID ABX92931 standard; DNA; 24 BP.
XX
XX AC ABX92931;
XX
XX DT 14-MAY-2003 (first entry)
XX
XX Screening method related primer #13.
XX
XX G protein-coupled receptor; GPR7; primer; ss; anorectic; cibophobia;
KW anorexia; appetite loss; excessive appetite; obesity-related disorder;
KW adipocyte malignancy; obesity; excessive insulin; blood volume change;
KW thyroid disorder; paediatric obesity; upper body obesity;
KW dietary obesity; cardiac obesity; whole body adipocyte disorder.
XX
XX OS Synthetic.
XX
XX WO200293161-A1.
XX
XX PD 21-NOV-2002.
XX
XX 14-MAY-2002; 2002WO-JP004635.
XX
XX 15-MAY-2001; 2001JP-00145411.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Mori M, Shimomura Y, Goto M;
PI WPI; 2003-129320/12.
XX
XX Screening compounds that modify the binding of G-protein coupled receptor
PT

```

PT GPR7 to its ligands for treatment of obesity and cibophobia.
PS Disclosure; Page 176; 223pp; Japanese.
XX
XX The invention relates to a method for screening compounds for their
CC ability to modify the binding of G protein-coupled receptor protein GPR7
CC to its polypeptide, ligands and their amides, esters and salts, by
CC measuring the binding in the presence and absence of the test compound.
CC The method is used for prevention and treatment of cibophobia, anorexia,
CC loss of appetite, excessive appetite and a broad range of obesity-related
CC disorders including adipocyte malignancy, obesity due to external
CC factors, excessive insulin, blood volume changes, thyroid disorders,
CC paediatric obesity, upper body obesity, dietary obesity, cardiac obesity
CC and whole body adipocyte disorder. This sequence represents a primer used
CC in the scope of the invention
XX
SQ Sequence 24 BP; 8 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146
DB 1 CAGCGGCAGCAGCAGCAGCAG 21

RESULT 53
AAZ40519/C
ID AAZ40519 standard; DNA; 19 BP.
XX AAZ40519;
AC AAZ40519;
XX
DT 18-FEB-2000 (first entry)
XX
DE Human STE20-related protein kinase gene primer #21.
XX
XX Antirheumatic; antiarthritic; antiinflammatory; antiallergic; osteopathic;
KW antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
KW neuroprotective; cardiant; cerebroprotective; cytostatic; antidiabetic;
KW vulnery; STE20; protein kinase; STLK2; STLK3; STLK4; STLK5; STLK6; STLK7;
KW ZC1; ZC2; ZC3; ZC4; KHS2; SULU1; SULU3; GEK2; PAK5; antagonist;
KW antibody; gene therapy; rheumatoid arthritis; artherosclerosis; asthma;
KW inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
KW rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
KW myocardial infarction; cardiovascular disease; stroke; renal failure;
KW oxidative stress-related neurodegenerative disorder; Parkinson's disease;
KW amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
KW ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;
KW mesangial disorder; growth regulation; wound healing; T cell activation;
KW immunosuppressant; primer; PCR; amplification; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9953036-A2.
PN
XX
PD 21-OCT-1999.
XX
PF 13-APR-1999; 99WO-US008150.
XX
PR 14-APR-1998; 98US-0081784P.
XX
PA (SUGEN-) SUGEN INC.
XX
PI Plowman G, Martinez R, Whyte D;
XX
DR WPI; 1999-611301/52.
XX
PT Novel kinase-related polypeptides used for the diagnosis and treatment of
PT kinase-related diseases and disorders.
XX
PS Disclosure; Page 323; 387pp; English.
XX
XX This sequence represents a PCR primer used to amplify the coding sequence
CC for a novel STE20-related protein kinase. The invention relates to
CC nucleic acid molecule encoding a kinase polypeptide selected from STLK2,
CC STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
CC SULU3, GEK2, PAK4 and PAK5. The proteins are used to identify agonists
CC and antagonists, and to raise antibodies. The polynucleotides are useful
CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
CC antagonists and agonists may be used to treat diseases such as immune-
CC related disorders and diseases (e.g. rheumatoid arthritis,
CC artherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
CC disease, multiple sclerosis, organ transplantation, myocardial

PT GPR7 to its ligands for treatment of obesity and cibophobia.
PS Disclosure; Page 176; 223pp; Japanese.
XX
XX The invention relates to a method for screening compounds for their
CC ability to modify the binding of G protein-coupled receptor protein GPR7
CC to its polypeptide, ligands and their amides, esters and salts, by
CC measuring the binding in the presence and absence of the test compound.
CC The method is used for prevention and treatment of cibophobia, anorexia,
CC loss of appetite, excessive appetite and a broad range of obesity-related
CC disorders including adipocyte malignancy, obesity due to external
CC factors, excessive insulin, blood volume changes, thyroid disorders,
CC paediatric obesity, upper body obesity, dietary obesity, cardiac obesity
CC and whole body adipocyte disorder. This sequence represents a primer used
CC in the scope of the invention
XX
SQ Sequence 24 BP; 8 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGCAG 1146
DB 1 CAGCGGCAGCAGCAGCAGCAG 21

RESULT 52
ADC51835
ID ADC51835 standard; DNA; 24 BP.
XX ADC51835;
AC ADC51835;
XX
DT 18-DEC-2003 (first entry)
XX
DE GPR8 PCR primer, SEQ ID 46.
XX
XX Body weight; GPR8L; brain; hyperphagia; obesity; anorectic; GPR8; PCR;
KW primer; ss.
XX
XX Unidentified.
OS
XX
XX WO2003057236-A1.
PN
XX
PD 17-JUL-2003.
XX
PF 27-DEC-2002; 2002WO-JP013781.
XX
PR 28-DEC-2001; 2001JP-00403260.
XX
PR 28-MAR-2002; 2002JP-00093096.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
XX Matsumoto H, Noguchi J, Harada M, Mori M;
PI
XX
DR WPI; 2003-569538/53.
XX
PT Composition comprising peptide of brain origin binding to orphan G-
PT protein coupled receptor GPR8 for treatment and prevention of obesity and
PT hyperphagia.
XX
XX Example 30; SEQ ID NO 46; 277pp; Japanese.
XX
XX The present invention relates to novel compositions for inhibiting body
CC weight gain, for lowering body weight, for inhibiting fat weight gain,
CC and for suppressing appetite, which contain as active component a peptide
CC ligand (GPR8L, ADC51805) of brain origin. The compositions can be used
CC for treatment and prevention of hyperphagia and obesity (including
CC malignant mastocytosis, exogenous obesity, hyperinsulinemic obesity,
CC hyperplasmic obesity, hypophyseal obesity, hypoplaemic obesity, infant
CC hyperthyroid obesity, hypothalamic obesity, symptomatic obesity, infant
CC obesity, upper body obesity, alimentary obesity, hypogonadal obesity,
CC systemic mastocytosis, simple obesity and central obesity). The present

CC infarction, cardiovascular disease, stroke, renal failure, oxidative
 CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral
 CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
 CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
 CC mellitus, fibrotic and mesangial disorders. The proteins may also be
 CC useful for cell growth regulation (e.g. in wound healing), T cell
 CC activation, mitosis control, and as immunosuppressants
 XX
 SQ Sequence 19 BP; 3 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 87;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2544 GGTGGTCCACGAGTCGAG 2562
 DB 19 GGTGGTCCACGAGTCGAG 1

RESULT 54
 ABZ86076/c
 ID ABZ86076 standard; DNA; 20 BP.
 XX
 AC ABZ86076;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Claim 15; SEQ ID NO 1318; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: the sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGC 1147
 DB 20 CTGCAGCAGCAGCAGC 2

RESULT 55
 ABD22306/c
 ID ABD22306 standard; DNA; 20 BP.
 XX
 AC ABD22306;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human stannocalcin-derived oligo SEQ ID 1318.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 1318; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has antiallergic, antiinflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

XX
SQ Sequence 20 BP; 1 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGCAGC 1147
Db 20 CTGCAGCAGCAGCAGCAGC 2
|||||

RESULT 56
AAD17771
ID AAD17771 standard; DNA; 21 BP.
XX
AC AAD17771;
XX
DT 10-DEC-2001 (first entry)
XX
DE Human NOV-3 DNA amplifying forward RT-PCR primer.
XX
KW Human; NOV-X protein; KIAA1233-like protein; STE20-like protein; tumour; trypsin inhibitor-like protein; gene therapy; haematopoietic; illness; immunological disorder; neurodegenerative disorder; Alzheimer's disease; Parkinson's disease; immunomodulatory; pharmacogenomic; haemostatic; human immunodeficiency virus; HIV; fertility disorder; neuroprotective; cytostatic; nootropic; anti-infertility; cancer; reverse transcription; RT; PCR primer; ss.

OS Homo sapiens.
XX
PN WO200162928-A2.
XX
PD 30-AUG-2001.
XX
PF 26-FEB-2001; 2001WO-US006151.
XX
PR 25-FEB-2000; 2000US-0184951P.
PR 28-FEB-2000; 2000US-0185548P.
PR 01-MAR-2000; 2000US-0185967P.
PR 18-APR-2000; 2000US-0197723P.
PR 27-APR-2000; 2000US-0199957P.
PR 23-FEB-2001; 2001US-00789390.
XX
PA (CURA-) CURAGEN CORP.
XX
XX Vernet CAM, Fernandes E, Shinkets RA, Macdougall J, Spaderna SK;
XX WPI; 2001-582051/65.
XX
XX New isolated KIAA1233-like, STE20-like, or trypsin inhibitor-like polypeptide for diagnosing and treating pathological disorders, such as Parkinson's disease and for use in pharmacogenomics.

XX Disclosure; Page 168; 189pp; English.
XX
CC The invention relates to novel human polypeptides referred as NOV-X and their corresponding nucleic acid sequences. NOV-X collectively include NOV-1, NOV-2a and NOV-2b which are novel KIAA1233-like polypeptides, NOV-3a, NOV-3b, NOV-3c and NOV-3d which are novel STE20-like polypeptides and NOV-4a, NOV-4b, NOV-4c, NOV-4d and NOV-4e which are novel trypsin inhibitor-like polypeptides. NOV-X is used to identify a potential therapeutic agent that can modulate its activity and can be used for treating a pathology related to aberrant expression or aberrant physiological interactions of NOV-X. NOV-X or its DNA is used to determine the presence or predisposition to a disease associated with altered levels of NOV-X. NOV-X, its DNA and its antibody are used to treat or prevent a pathology associated with NOV-X. The pathological states that can be treated or prevented are haematopoietic, cancer, immunological, tumour, neurodegenerative (e.g. Alzheimer's and Parkinson's disease), human immunodeficiency virus (HIV) illness and fertility disorders. NOV-X and its DNA are used in pharmacogenomics for predictive medicine. NOV-X DNA is used in gene therapy. The present sequence is a RT (reverse transcription)-PCR primer used to amplify DNA encoding human novel STE20-like proteins, NOV-3a, NOV-3b, NOV-3c and NOV-3d

XX
SQ Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 496 AATGCTGAGGTCAAGCTAG 514
Db 1 AATGCTGAGGTCAAGCTAG 19
|||||

RESULT 57
ABX03797/C
ID ABX03797 standard; cDNA; 24 BP.
XX
AC ABX03797;
XX
DT 09-JAN-2003 (first entry)
XX
DE DNA encoding secreted protein signal peptide sequence #6.
XX
KW Differential display method; leucine-rich motif; transmembrane protein; secreted protein; secreted protein signal peptide; ss.

XX Unidentified.
OS
XX WO200259259-A2.
XX
PN 01-AUG-2002.
XX
PD 23-JAN-2002; 2002WO-IL0000071.
XX
PF 23-JAN-2001; 2001US-0263158P.
XX
PR (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
XX
XX Wreschner DH;
XX WPI; 2002-599769/64.
XX P-PSDB; ABG98326.
XX
XX Differential display method for identifying secreted or transmembrane protein, comprises contacting a DNA with a first primer that hybridizes to a sequence coding for a leucine-rich motif and with a second oligonucleotide primer.

XX
PS Disclosure; Fig 2; 37pp; English.
XX
CC The invention relates to a differential display comprising contacting

CC cDNA with a first primer that hybridises to an oligonucleic sequence
CC coding for a leucine-rich motif, and with a second oligonucleotide primer
CC to form a cDNA-hybrid molecule. The method comprises obtaining mRNA from
CC at least 2 samples, synthesising cDNA from the RNA of each sample,
CC contacting the cDNA with a first primer that hybridises to an
CC oligonucleic sequence coding for a leucine-rich motif, and with a second
CC oligonucleotide primer to form cDNA-hybrid molecules, amplifying the cDNA
CC -hybrid molecules, detecting amplified products and comparing the
CC amplified products from each sample to identify distinctive amplified
CC products coding for at least one secreted or transmembrane protein. The
CC method is useful for discovering novel secreted and/or transmembrane
CC proteins which are important for cell processes and play an important
CC role in determining its phenotype, and which act as mediators for the
CC transfer of signals from external environment into the cell itself, thus
CC modulating gene expression. Sequences ABX03792-ABX03869 represent DNA
CC encoding secreted protein signal peptide sequences
XX
SQ Sequence 24 BP; 0 A; 9 C; 8 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAGCAGC 1468
Db 21 CAGCAACAGCAGCAGCAGC 3

RESULT 58
ADC38183
ID ADC38183 standard; DNA; 25 BP.
AC ADC38183;
XX
DT 18-DEC-2003 (first entry)
DE Human AMLP1a scanning 25-mer oligonucleotide SEQ ID NO:532.
XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 532; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX

SQ Sequence 25 BP; 8 A; 7 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGCAG 1461
Db 7 GCAGCAGCAGCAACAGCAGCAG 25

RESULT 59
ADC38192
ID ADC38192 standard; DNA; 25 BP.
XX
AC ADC38192;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 25-mer oligonucleotide SEQ ID NO:541.
XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 541; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 25 BP; 7 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1446 GCAGCAGCAGCAACAGCAGCAGCAG 1464
Db 1 GCAGCAGCAGCAACAGCAGCAGCAG 19

RESULT 60
AAL57112
ID AAL57112 standard; DNA; 23 BP.
XX
AC AAL57112;
XX


```
DT 17-SEP-2003 (first entry)
XX Human epithelial caderine PCR primer 2 (from primer pair A).
XX Human epithelial caderine; E caderine; gastric carcinoma; PCR; primer;
KW ss.
XX Homo sapiens.
XX WO2003042409-A2.
XX 22-MAY-2003.
XX 15-NOV-2002; 2002WO-IT000729.
XX 16-NOV-2001; 2001IT-TO001077.
XX (UYUR-) UNIV URBINO.
XX Magnani M, Graziano F, Ruzzo A;
XX WPI; 2003-449579/42.
XX Identifying greater susceptibility to gastric carcinoma by searching for
PT polymorphisms in the promoter of the E-caderine gene.
XX Claim 11; Page 12; 17pp; English.
XX This invention relates to a novel method for the diagnosis of greater
CC susceptibility to gastric carcinoma, comprising searching for a possible
CC polymorphism in the promoter of the epithelial caderine (E-caderine)
CC gene. The method is useful for identifying a genetic polymorphism that
CC leads to a greater predisposition to the onset of gastric carcinoma. The
CC method is relatively simple, quick, accurate and reliable. The present
CC sequence is that of E-caderine PCR primer 2 (from primer pair A) used
CC during a method to identify the genotype of an individual for a C to A
CC polymorphism at nucleotide -160 of the E-caderine gene and claimed in
XX claim 11 of the specification
XX Sequence 23 BP; 6 A; 7 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1125 GCAGCTGCAGCAGCAGCAG 1146
DB 2 GTACCTGCAGCAGCAGCAG 23
RESULT 61
ABN83820
ID ABN83820 standard; DNA; 24 BP.
XX
XX ABN83820;
XX
XX 10-SEP-2002 (first entry)
XX Human prostate-specific PAMP RACE primer 9E1-RC61.
XX PAMP; human; prostate; cancer; metastasis; gene therapy; vaccine;
KW diagnosis; RACE; primer; ss.
XX Homo sapiens.
XX
XX WO200246410-A2.
XX 13-JUN-2002.
XX
XX 04-DEC-2001; 2001WO-US046683.
XX
XX 04-DEC-2000; 2000US-00729653.
XX
```

```
PA (SYST-) INST SYSTEMS BIOLOGY.
XX
XX Lin B;
XX WPI; 2002-519666/55.
XX Novel substantially pure prostate specific polypeptide, termed PAMP,
PT useful for diagnosing or predicting susceptibility to prostate neoplastic
PT condition in individual, and for treating prostate neoplastic condition.
XX Example 1; Page 82; 121pp; English.
XX The present sequence is RACE primer 9E1-RC61, 1 of 4 RACE primers (see
CC ABN83817-20) used to isolate full-length PAMP cDNA (see ABN83816) from
CC human prostate cDNA. PAMP is highly expressed in normal and neoplastic
CC prostate epithelium relative to other human tissues. Expression is
CC androgen-regulated. The prostate-specific PAMP nucleic acid sequence and
CC its protein product are useful as diagnostic markers for neoplastic
CC conditions of the prostate and as targets for therapy. Methods are
CC claimed of diagnosing or predicting susceptibility to a prostate
CC neoplastic condition in a sample using a PAMP nucleic acid probe or
CC antibody, and of diagnosing metastatic prostate cancer by measuring the
CC expression level of PAMP RNA by hybridisation with a PAMP nucleic acid
CC probe. PAMP nucleic acid and polypeptides are also useful as vaccines
XX Sequence 24 BP; 5 A; 5 C; 9 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 63 GGACCCCTGCTGGGATCTTTGAG 84
DB 3 GGACCCCTGCTGGGATCTTTGAG 24
RESULT 62
ADN62597/c
ID ADN62597 standard; DNA; 25 BP.
XX
XX ADN62597;
XX
XX 12-AUG-2004 (first entry)
XX Digital karyotyping quantitative PCR primer #16.
XX digital karyotyping; cancer; hereditary disorder; infectious disease;
KW colorectal cancer; lymphoblastic cell; ss; primer; PCR.
XX Homo sapiens.
XX US2004096892-A1.
XX 20-MAY-2004.
XX
XX 13-NOV-2003; 2003US-00705874.
XX
XX 15-NOV-2002; 2002US-0426406P.
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
XX Wang T, Velculescu V, Kinzler K, Vogelstein B;
XX WPI; 2004-389156/36.
XX Digital karyotyping a genome of a test eukaryotic cell comprises
PT isolating and enumerating short sequence tags from specific genomic loci
PT and comparing the sequence tags to a genome of a reference cell.
XX Example 7; SEQ ID NO 18; 23pp; English.
XX The invention relates to a method of digital karyotyping a genome of a
CC test eukaryotic cell comprising isolating and enumerating short sequence
```


CC 25, using oligonucleotide primers in the 3' region of exon 25 and the 5' region of exon 26; (b) hybridising the genomic sequence with a detectable probe specific for the corresponding sequence with no mutations; and (c) detecting mismatches between the genomic sequence and the probe; (2) a method comprising: (a) isolating an ACE genomic DNA sequence as in (1); (b) amplifying the sequence; (c) hybridising the amplification products with a probe as in (1); and (d) detecting mismatches between the amplification products and the probe; (3) a method comprising: (a) isolating an ACE genomic DNA sequence as in (1); (b) denaturing the genomic sequence to obtain single-stranded DNA; (c) hybridising the single-stranded DNA with a probe as in (1); and (d) detecting mismatches between the single-stranded DNA and the probe; (4) a method comprising: (a) isolating an ACE genomic DNA sequence as in (1); (b) amplifying the sequence; (c) denaturing the amplification products to obtain single-stranded DNA; (d) hybridising the single-stranded DNA with a probe as in (1); and (e) detecting mismatches between the single-stranded DNA and the probe. The methods are used for assessing the patient's risk of developing cardiovascular disease. The present sequence represents a PCR primer for ACE

XX SQ Sequence 20 BP; 0 A; 7 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1449 GCAGCAACAGCAGCAGC 1468
|||||
DB 20 GCAGCAACAGCAGCAGC 1

RESULT 65
AAS20967/C
ID AAS20967 standard; DNA; 20 BP.
XX
AC AAS20967;
XX
DT 09-APR-2002 (first entry)
XX
DE PCR primer Snrpn-U relating to gene imprinting invention.
XX
KW Human; genomic imprinting; pluripotent mouse embryonic germ cell line; EG; methylated CpG island; DNA methylation; gene imprinting;
KW post-translational modification of histone; cancer; birth defect;
KW diabetes; aberrant imprinting; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200190313-A2.
XX
PD 29-NOV-2001.
XX
PF 22-MAY-2001; 2001WO-US016253.
XX
PR 22-MAY-2000; 2000US-0206158P.
PR 22-MAY-2000; 2000US-0206161P.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Feinberg A, Strichman-Almaashanu L, Jiang S;
XX
DR WPI; 2002-083100/11.
XX
PT Forming embryonic germ cells useful as model system to study imprinting involves mating genetically divergent male and female mammal of same mammal.
PT species, dissecting and dissociating embryo obtained from pregnant mammal.
PT
XX
PS Disclosure; Page 54; 125pp; English.
XX
CC The present invention relates to a model system for genomic imprinting using pluripotent mouse embryonic germ (EG) cell lines derived from an interspecific cross. Also disclosed is a library containing methylated

CC CpG islands and a method for assaying methylation in one or more imprintable genes. The gene imprinting assay is carried out by single-strand conformation polymorphism (SSCP), quantitative sequencing, single nucleotide primer extension or hot stop PCR. The assays are carried out to determine the post-translational modification of histones. The method further involves identifying a test substance as a candidate drug for treating cancer if the test substance enhances imprinting of a gene whose imprinting is lost in cancer, or if the test substance inhibits imprinting of a gene whose imprinting is gained in cancer. The methylated CpG islands are useful for providing an assessment of the risk of developing cancer, or for providing diagnostic information relative to cancer which involves determining the methylation status of the CpG island in a patient's DNA. The EG cells allow the accession of imprinted genes which are useful for detecting birth defects, diabetes and cancers associated with aberrant imprinting. The EG cell lines represent the first in vitro model system in which genomic imprinting can be followed dynamically and the two alleles can be distinguished. AAS20953-AAS20969 represent PCR primers described in the present invention

XX SQ Sequence 20 BP; 1 A; 5 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAGCAGCA 1463
|||||
DB 20 CAGTACGACGACAGCAGCA 1

RESULT 66
AAD37201
ID AAD37201 standard; DNA; 20 BP.
XX
AC AAD37201;
XX
DT 21-AUG-2002 (first entry)
XX
DE Human MEK4 antisense oligonucleotide, ISIS #123136.
XX
KW Human; MEK4 modulation; mitogen-activated protein kinase kinase 4; MTX1; MAPK4; MAP three kinase 1; MAP/ERK kinase kinase 4; MAPKK4; cytoskeletal; prophyllaxis; immunological; hyperproliferative disorder; cancer; therapy; antipneum; inflammatory; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT modified_base 2
FT /note= "2'-methoxyethyl nucleotides"
FT /tag= d
FT /mod_base= m5c
FT modified_base 5
FT /tag= e
FT /mod_base= m5c
FT modified_base 8
FT /tag= f
FT /mod_base= m5c
FT modified_base 11
FT /tag= g
FT /mod_base= m5c
FT modified_base 14
FT /tag= h
FT /mod_base= m5c
FT modified_base 16..20

FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 17
FT /*tag= i
FT /mod_base= m5c
FT modified_base 20
FT /*tag= j
FT /mod_base= m5c
XX
PN WO200227033-A1.
XX
XX
PD 04-APR-2002.
XX
XX 28-SEP-2001; 2001WO-US030549.
XX
XX 29-SEP-2000; 2000US-00676436.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Ward DT, Gaarde WA, Monia BP, Wyatt JR;
XX WPI; 2002-416486/44.
XX
XX New antisense compound targeted to nucleic acid encoding mitogen-
PT activated protein kinase 4, useful for treating immunologic disorder,
PT inflammatory disorder or cancer.
XX
XX Claim 3; Page 93; 132pp; English.

XX The present invention relates to antisense compounds, compositions and
CC methods for modulating the expression of MEK4 (also referred as mitogen-
CC activated protein kinase kinase 4; MAP3K4; MAP three kinase 1; MAP/ERK
CC kinase kinase 4; MAPKKK4; MPK1). The antisense oligos are useful for
CC inhibiting the expression of MEK4 in cells or tissues. They are also
CC useful for treating an animal having a disease or condition associated
CC with MEK4 such as immunological, inflammatory, hyperproliferative
CC disorder or cancer. Sequences of the invention are also useful for
CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targeted to human MEK4 DNA. This sequence is
CC used in the exemplification of the invention
XX
SQ Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGC 1138
Db 1 GCAGCAGCAGCAGCAGCAGC 20

RESULT 67
ABK44415/c
ID ABK44415 standard; DNA; 20 BP.
XX
XX ABK44415;

05-JUN-2002 (first entry)

Human HPK/GCK-like kinase antisense oligonucleotide, ISIS 105314.

Human; HPK/GCK-like kinase; antiinflammatory; cytostatic; antimicrobial;
KW HGK; NIK; Nck-interacting kinase; infection; inflammation; tumour;
KW antisense gene therapy; antisense oligonucleotide; ss.

OS Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers
FT modified_base 1. .20

FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
FT modified_base 1. .5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethyl (2'MOE) nucleotides"
FT modified_base 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethyl (2'MOE) nucleotides"
XX
XX US6346416-B1.
XX
PD 12-FEB-2002.
XX
XX 29-AUG-2000; 2000US-00651011.
PF
XX 29-AUG-2000; 2000US-00651011.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Dean NM, Cowseert LM;
PI WPI; 2002-237091/29.
XX
XX New antisense compound, useful for preventing or delaying infection,
PT inflammation or tumor formation, is targeted to nucleic acid molecule
PT encoding HPK/GCK-like kinase (HGK) and hybridizes and inhibits HGK
PT expression.
XX
XX Claim 14; Col 43-44; 37pp; English.

XX The invention relates to an antisense compound (I) of 8-50 nucleobases in
CC length targeted to a start codon region, coding region or 3'-untranslated
CC region of a nucleic acid molecule encoding HPK/GCK (undefined)-like
CC kinase (HGK) (also known as NIK for Nck-interacting kinase), which
CC specifically hybridizes with and inhibits expression of HGK. (I) is
CC useful for inhibiting the expression of HPK/GCK-like kinase in cells or
CC tissues in vitro. (I) is useful prophylactically e.g. to prevent or delay
CC infection, inflammation and tumour formation. (I) is also useful as a
CC diagnostic and research reagent. (I) is also useful for distinguishing
CC functions of various members of a biological pathway and in antisense
CC gene therapy. The present sequence represents an antisense
CC oligonucleotide targeted to human HPK/GCK-like kinase

SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 1.2e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 615 TCAGAACCCCTGATGCCACCT 634

Db 20 TCAGAACCCAGATGCCACCT 1

RESULT 68
ABZ86068/c

ID ABZ86068 standard; DNA; 20 BP.

XX
XX ABZ86068;

17-OCT-2003 (first entry)

Human oligonucleotide sequence.

Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.
OS Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
DR WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Claim 15; SEQ ID NO 1310; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, anti-allergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1129 CTGCAGCAGCAGCAGCAGCG 1148
Db 20 CGGCAGCAGCAGCAGCAGCG 1
RESULT 69
ABD22298/c
ID ABD22298 standard; DNA; 20 BP.
XX
AC ABD22298;
XX
XX 29-JUL-2004 (first entry)
XX Human stannocalcin-derived oligo SEQ ID 1310.
DE
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
DR WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 1310; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1129 CTGCAGCAGCAGCAGCAGCG 1148
Db 20 CGGCAGCAGCAGCAGCAGCG 1
RESULT 70
ADH58803
ID ADH58803 standard; DNA; 20 BP.

XX ADH58803;
 AC
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human CDC-like kinase 1 antisense oligonucleotide #85.
 XX
 KW antisense oligonucleotide; CDC-like kinase 1; cancer;
 KW autoimmune disorder; infection; inflammation; tumour formation; human;
 KW ss; 2'-O-methoxyethyl gapmer; phosphorothioate backbone.
 XX
 OS Homo sapiens.
 XX
 PN US2003219895-A1.
 XX
 PD 27-NOV-2003.
 XX
 PF 22-MAY-2002; 2002US-00154708.
 XX
 PR 22-MAY-2002; 2002US-00154708.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Watt AT;
 XX
 XX WPI; 2004-051714/05.
 XX
 DR New antisense oligonucleotides targeted to nucleic acid molecules
 PT encoding CDC-like kinase 1, useful for treating diseases or conditions
 PT associated with expression of CDC-like kinase 1, e.g. cancers or
 PT autoimmune disorders.
 XX
 PS Example 15; SEQ ID NO 98; 64pp; English.
 XX
 CC The invention comprises antisense oligonucleotides that are targeted to
 CC CDC-like kinase 1. The antisense oligonucleotides of the invention are
 CC useful for modulating the expression of CDC-like kinase 1, and for
 CC treating diseases or conditions associated with expression of CDC-like
 CC kinase 1 (e.g. cancers and autoimmune disorders). The antisense
 CC oligonucleotides may also be used to prevent or delay infection,
 CC inflammation and tumour formation. The present DNA sequence represents an
 CC antisense oligonucleotide of the invention that is targeted to human CDC-
 CC like kinase 1. NOTE: The present sequence is a 2'-O-methoxyethyl gapmer
 CC with a phosphorothioate backbone.
 XX
 XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 PS
 XX
 CC The invention comprises antisense oligonucleotides that are targeted to
 CC CDC-like kinase 1. The antisense oligonucleotides of the invention are
 CC useful for modulating the expression of CDC-like kinase 1, and for
 CC treating diseases or conditions associated with expression of CDC-like
 CC kinase 1 (e.g. cancers and autoimmune disorders). The antisense
 CC oligonucleotides may also be used to prevent or delay infection,
 CC inflammation and tumour formation. The present DNA sequence represents an
 CC antisense oligonucleotide of the invention that is targeted to human CDC-
 CC like kinase 1. NOTE: The present sequence is a 2'-O-methoxyethyl gapmer
 CC with a phosphorothioate backbone.
 XX
 XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 1.2e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1373 TGGAGGAGCAGCGGCGAGTCA 1392
 DB 1 TGGAGGAGCAGCGGCGAGTCA 20
 RESULT 71
 ADH58730/c
 ID ADH58730 standard; DNA; 20 BP.
 XX
 AC ADH58730;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human CDC-like kinase 1 antisense oligonucleotide #12.
 XX
 KW antisense oligonucleotide; CDC-like kinase 1; cancer;
 KW autoimmune disorder; infection; inflammation; tumour formation; human;
 KW ss; 2'-O-methoxyethyl gapmer; phosphorothioate backbone.
 XX
 OS Homo sapiens.
 XX
 PN US2003219895-A1.

XX 27-NOV-2003.
 XX
 PF 22-MAY-2002; 2002US-00154708.
 XX
 PR 22-MAY-2002; 2002US-00154708.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Watt AT;
 XX
 XX WPI; 2004-051714/05.
 XX
 DR New antisense oligonucleotides targeted to nucleic acid molecules
 PT encoding CDC-like kinase 1, useful for treating diseases or conditions
 PT associated with expression of CDC-like kinase 1, e.g. cancers or
 PT autoimmune disorders.
 XX
 PS Claim 1; SEQ ID NO 25; 64pp; English.
 XX
 CC The invention comprises antisense oligonucleotides that are targeted to
 CC CDC-like kinase 1. The antisense oligonucleotides of the invention are
 CC useful for modulating the expression of CDC-like kinase 1, and for
 CC treating diseases or conditions associated with expression of CDC-like
 CC kinase 1 (e.g. cancers and autoimmune disorders). The antisense
 CC oligonucleotides may also be used to prevent or delay infection,
 CC inflammation and tumour formation. The present DNA sequence represents an
 CC antisense oligonucleotide of the invention that is targeted to human CDC-
 CC like kinase 1. NOTE: The present sequence is a 2'-O-methoxyethyl gapmer
 CC with a phosphorothioate backbone.
 XX
 XX Sequence 20 BP; 2 A; 8 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 1.2e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1373 TGGAGGAGCAGCGGCGAGTCA 1392
 DB 20 TGGAGGAGCAGCGGCGAGTCA 1
 RESULT 72
 ADD69462/c
 ID ADD69462 standard; DNA; 23 BP.
 XX
 AC ADD69462;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE 5' anchored (ISSR)-PCR primer - SEQ ID 20.
 XX
 KW inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
 KW animal; Basmati rice; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003085133-A2.
 XX
 PD 16-OCT-2003.
 XX
 PF 09-JAN-2003; 2003WO-IB000041.
 XX
 PR 08-APR-2002; 2002IN-CH000260.
 XX
 PA (DNAP-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
 XX
 PI Nagaraju JG;
 XX
 XX WPI; 2003-804317/75.
 DR
 XX
 PT New set of inter-simple sequence repeats (ISSR)-PCR primers for
 PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and

PT animal systems.
 PS Claim 1; SEQ ID NO 20; 60pp; English.
 XX.
 CC The invention relates to a novel set of inter-simple sequence repeats
 CC (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
 CC invention may be useful for genotyping diverse genomes of plant and
 CC animal systems, in particular for distinguishing Basmati rice varieties
 CC from non-Basmati rice varieties and traditional Basmati rice varieties
 CC from evolved Basmati rice varieties. The current sequence is that of the
 CC 5' anchored (ISSR)-PCR primer of the invention.
 XX
 SQ Sequence 23 BP; 3 A; 6 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 23;
 Best Local Similarity 95.0%; Pred. No. 1.5e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1475 AACGACGACGACGACGCTC 1494
 Db 23 AGCAGCAGCAGCAGCAGCTC 4
 RESULT 73
 AAT77693/C
 ID AAT77693 standard; DNA; 23 BP.
 XX
 AC AAT77693;
 XX
 DT 15-SEP-1997 (first entry)
 XX
 DE Wheat microsatellite WMS255 left primer.
 XX
 KW Microsatellite marker; hypervariable genomic fragment; Triticum aestivum;
 KW wheat; Triticeae; sequence tagged site; STS; primer; PCR; amplify;
 KW polymorphism; genetic analysis; hexaploid; tetraploid; mapping; ss.
 XX
 OS Synthetic.
 XX
 PN DE19525284-A1.
 XX
 PD 02-JAN-1997.
 XX
 PF 28-JUN-1995; 95DE-01025284.
 XX
 PR 28-JUN-1995; 95DE-01025284.
 XX
 PA (PFLA-) INST PFLANZENGENTIK & KULTURPFLANZENFOR.
 XX
 PI Roeder M, Plaschke J, Ganai M;
 XX
 DR WPI; 1997-053731/06.
 XX
 PT Primers for STS microsatellite markers for wheat and related species -
 PT useful for genetic mapping, analysis and labelling etc. of wheat.
 XX
 PS Claim 5; Page 8; 8pp; German.
 XX
 CC Microsatellite markers based on hypervariable genomic fragments, from
 CC Triticum aestivum (wheat) or the tribe Triticeae, consist of a sequence
 CC tagged site (STS), defined by 2 specific primers (of mean size 17-23
 CC bases) that flank a microsatellite sequence at both ends, which can be
 CC amplified to polymorphisms (PCR products of different sizes). The
 CC microsatellites are n-fold tandem repeats (n = 10 or more) of di-, tri-,
 CC or tetra-nucleotide sequences, combination microsatellite sequences or an
 CC imperfect sequence in which individual bases are mutated. The
 CC microsatellite markers can be used for genetic analysis of hexaploid and
 CC tetraploid forms of wheat and for genetic mapping or labelling of
 CC monogenic and polygenic properties, and for their selection; for
 CC analysing relationships and identifying varieties; and for evaluating
 CC varietal purity, hybrid identification and plant growth. The markers can
 CC differentiate between almost all European wheat lines and show a higher
 CC degree of DNA polymorphism than known probes for the wheat genome. They

CC can be detected by PCR, so large numbers of samples can be analysed
 CC easily (e.g. several hundred per day). Microsatellite marker-related
 CC polymorphisms are stably inherited so can also serve as genetic markers.
 CC AAT77003-22 and AAT77535-716 are primer pairs that define the
 CC microsatellite markers. WMS255 has a GA type repeat
 XX
 SQ Sequence 23 BP; 5 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.2; DB 1; Length 23;
 Best Local Similarity 87.0%; Pred. No. 1.6e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 101 GCAATGGAACCTACGACGAGGTG 123
 Db 23 GCAATGGAACCTACGACGAGTTG 1
 RESULT 74
 AAT99645/C
 ID AAT99645 standard; DNA; 23 BP.
 XX
 AC AAT99645;
 XX
 DT 06-JUL-1998 (first entry)
 XX
 DE Human SCA2 gene PCR primer 65B6.
 XX
 KW SCA2 gene; spinocerebellar ataxia-2; ataxin-2; human; diagnosis;
 KW olivoponto-cerebellar atrophy; PCR; primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9742314-A1.
 XX
 PD 13-NOV-1997.
 XX
 PF 08-MAY-1997; 97WO-US007725.
 XX
 PR 08-MAY-1996; 96US-0017388P.
 PR 19-JUL-1996; 96US-0022207P.
 PR 08-OCT-1996; 96US-00727084.
 XX
 PA (CEDA-) CEDARS SINAI MEDICAL CENT.
 XX
 PI Pulst S;
 XX
 DR WPI; 1998-086523/08.
 XX
 PT Nucleic acids encoding human and mouse ataxin 2 - a product of the
 PT spinocerebellar ataxia 2 gene, SCA2; useful in the diagnosis of ataxia
 PT type 2.
 XX
 PS Example 4; Page 46; 98pp; English.
 XX
 CC Primers 65B6 and 65A6 (see AAT99644) were used to generate a probe
 CC sequence from plasmid P65122B (see AAV06551), which comprises human
 CC genomic DNA from the CAG repeat region of the novel spinocerebellar
 CC ataxin-2 (SCA2) gene. A second probe was generated from P65122B using
 CC primers 65A3 and 65B5 (see AAT99642-43). The probes were labelled with
 CC 32P and used to screen a trisomy 21 foetal brain cDNA library and an
 CC adult human frontal cortex cDNA library. PCR fragments were subsequently
 CC used to screen the frontal cortex library. Isolated clones, plus clones
 CC obtained from placental cDNA, were used to produce a composite sequence
 CC (see AAV06552) for human SCA2 cDNA. Methods are provided for diagnosing
 CC SCA2 based on the number of CAG repeats in a CAG repeat region of the
 CC SCA2 gene
 XX
 SQ Sequence 23 BP; 1 A; 6 C; 9 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.2; DB 1; Length 23;
 Best Local Similarity 87.0%; Pred. No. 1.6e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
QY 1432 CTCAAGTCCTCGACGACGAGCA 1454
Db 23 CTGAGCCCCGAGGACGACGAGCA 1

RESULT 75
ABK12118
ID ABK12118 standard; DNA; 24 BP.
XX
AC ABK12118;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human hRDRI RT-PCR primer #1.
XX
KW Human; ss; PCR; ribonucleotide diphosphate reductase inhibitor 10.23;
KW hRDRI; malignant tumour; haemopathy; HIV; immunological disease;
KW human immunodeficiency virus infection; inflammation; cytostatic;
KW haemostatic; virucide; immunomodulatory; antiinflammatory; primer.
XX
OS Homo sapiens.
XX
PN WO200212303-A1.
XX
PD 14-FEB-2002.
XX
PF 18-JUN-2001; 2001WO-CN000983.
XX
PR 19-JUN-2000; 2000CN-00116569.
XX
PA (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.
XX
PI Mao Y, Xie Y;
XX
PR 2002-172133/22.
XX
PT Human ribosomal diphosphate reductase inhibitor 10.23 polypeptide and
PT encoding polynucleotide, used in diagnosis and treatment of malignant
PT tumors, hemopathy, human immunodeficiency virus infection, immunological
PT diseases and inflammation.
XX
XX Example 2; Page 12; 37pp; Chinese.
XX
CC The invention relates to an isolated polypeptide of ribonucleotide
CC diphosphate reductase inhibitor 10.23 (hRDRI) the cDNA encoding it, and
CC its fragment, analogue or derivative. Also included are vectors
CC expressing the protein, a host cell comprising the vector, the isolation
CC of modulators of the protein and an anti-hRDRI antibody. The protein and
CC nucleic acid are used in diagnosis and treatment of a malignant tumour,
CC haemopathy, human immunodeficiency virus (HIV) infection, immunological
CC diseases and various inflammations. The present sequence is a reverse
CC transcriptase (RT)-PCR primer used to isolate the cDNA encoding the
CC ribonucleotide diphosphate reductase inhibitor 10.23
XX
SQ Sequence 24 BP; 7 A; 5 C; 12 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1269 GCAGGAGAGGAGCAGCAGCGGC 1291
Db 1 GGGAGGAGGAGCAGCAGCAGC 23

RESULT 76
ADJ92111/c
ID ADJ92111 standard; DNA; 24 BP.
XX
AC ADJ92111;
XX
DT 06-MAY-2004 (first entry)
XX
```

```
XX
DE PCR primer 2 related to human plectin trans-splicing.
XX
KW pre-trans-splicing molecule; PTM; cytostatic; dermatological;
KW antipsoriasis; genodermatosis; epidermal fragility; keratinisation;
KW hair disorder; pigmentation; skin cancer; epidermolysis bullosa;
KW psoriasis; human; ss; PCR; primer; plectin trans-splicing.
XX
OS Unidentified.
XX
PN WO2004006678-A1.
XX
PD 22-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-US022469.
XX
PR 17-JUL-2002; 2002US-00198447.
XX
PA (INTR-) INTRONN INC.
XX
PI Mitchell LG, Puttaraaju M, Dallinger G, Klausegger A, Bauer J;
XX
DR WPI; 2004-122721/12.
XX
PT Novel pre-trans-splicing nucleic acid molecule useful for treating
PT epidermal fragility disorders, keratinization disorders, hair disorders,
PT pigmentation disorders, skin cancer, epidermolysis bullosa or psoriasis.
XX
PS Example; Page 42; 91pp; English.
XX
CC The invention relates to a novel pre-trans-splicing molecule (PTM)
CC nucleic acid comprising one or more target binding domains that target
CC binding of the nucleic acid to pre-mRNA expressed within a cell of the
CC skin. The nucleic acid may have a 3' splice region comprising a branch
CC point and a 3' splice acceptor site or 5' splice site, a spacer region
CC that separates the 3' or 5' splice region from the target binding domain
CC and a nucleotide sequence to be trans-spliced to the target pre-mRNA. The
CC nucleic acid of the invention demonstrates cytostatic, dermatological and
CC antipsoriatic activities and may be used within a skin application agent
CC for treating specific disorders of the skin including genodermatosis,
CC epidermal fragility disorders, keratinisation disorders, hair disorders,
CC pigmentation disorders, skin cancer, epidermolysis bullosa or psoriasis.
CC The current sequence is that of the RT-PCR primer 2 of the invention
CC which is related to human plectin trans-splicing.
XX
SQ Sequence 24 BP; 1 A; 6 C; 11 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1473 GAAACAGCAGCAGCAGCAGCTCC 1495
Db 24 GCAGCAGCAGCAGCAGCAGCTCC 2

RESULT 77
ADN97247
ID ADN97247 standard; DNA; 24 BP.
XX
AC ADN97247;
XX
DT 01-JUL-2004 (first entry)
XX
DE Primer of the invention #52.
XX
KW DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KW forensic identification; marijuana; primer; ss.
XX
OS Unidentified.
XX
PN WO2004008941-A2.
XX
```


PD 29-JAN-2004.
XX
PF 21-JUL-2003; 2003WO-US022887.
XX
PR 19-JUL-2002; 2002US-0397179P.
XX
PA (UYAR-) UNIV ARIZONA.
PA (KEIM/) KEIM P S.
PA (ZINN/) ZINNAMON K.
XX
PI Keim PS, Zinnamon K;
XX
DR WPI; 2004-143139/14.
XX
XX New isolated nucleic acid for amplification of a short tandem repeat
PT located in DNA isolated from Cannabis sativa L species, useful for
PT forensic identification of marijuana or for linking a marijuana sample to
PT its plant source.
XX
PS Example 10; SEQ ID NO 114; 79pp; English.
XX
CC The present invention relates to DNA fingerprinting for Cannabis Sativa
CC using short tandem repeat markers. The nucleic acid is useful for
CC forensic identification of marijuana or for linking a marijuana sample to
CC its plant source. The present sequence represents a primer of the
CC invention.
XX
XX Sequence 24 BP; 8 A; 5 C; 11 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1118 AGCAGCAGCAGCTGCAGCAGCAG 1140
DB 1 AGCAGCAGCAGCAGCAGGAG 23
RESULT 78
AAA63144/c
ID AAA63144 standard; DNA; 18 BP.
XX
AC AAA63144;
XX
DT 07-DEC-2000 (first entry)
XX
DE Antisense oligonucleotide for use in RNase H mapping assay SEQ ID NO: 48.
XX
KW Immunoregulator; antisense oligonucleotide; cancer; tumour cell vaccine;
KW rheumatoid arthritis; autoimmune disease; diabetes mellitus; thyroiditis;
KW ss.
XX
OS Mus sp.
XX
PN WO200034467-A1.
XX
PD 15-JUN-2000.
XX
PF 24-NOV-1999; 99NO-US028096.
XX
PR 04-DEC-1998; 98US-00205995.
XX
PA (ANTI-) ANTIGEN EXPRESS INC.
XX
PI Xu M, Qiu G, Humphreys R;
XX
DR WPI; 2000-423417/36.
XX
PT Cancer cell vaccine for treating malignancies, autoimmune disorders and
PT isolating autodeterminant peptides comprises a regulator of invariant
PT chain protein expression or immunoregulatory function.
XX
PS Claim 21; Page 47; 94pp; English.

XX
CC The present sequence is an antisense oligonucleotide which was used in an
CC RNase mapping experiment. This enables the identification of sites within
CC the Ii RNA strand which hybridise to antisense DNA. These sites can then
CC be used as targets for antisense strands which may, using gene therapy,
CC be used as tumour cell vaccines (for example to treat carcinomas, lung,
CC melanoma, leukaemia, lymphomas, stomach, breast, colon or rectum, lung,
CC prostate, bladder, pancreas, brain and ovarian cancers), or they can be
CC used to treat autoimmune diseases including rheumatoid arthritis.
XX
XX diabetes mellitus and thyroiditis
SQ Sequence 18 BP; 0 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAG 1464
DB 18 CAGCAGCAACAGCAGCAG 1
RESULT 79
AB281780
ID AB281780 standard; DNA; 18 BP.
XX
AC AB281780;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
KW Huntington's disease; nontropic; anticonvulsant; huntingtin; human;
KW gene therapy; mutant; ds.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mutation replace(5,A)
FT /*tag= a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PF 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0337219P.
XX
XX (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Parekh-Olmedo H;
XX
DR WPI; 2003-256478/25.
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
XX Example 7; Fig 20; 133pp; English.
XX
CC The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also AB281760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD38/52 (see AB281756). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD38/25 is an

CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1126 CAGCTGCAGCAGCAGCAG 1143
DB 1 CAGCTGCAGCAGCAGCAG 18
RESULT 80
ABZ81779
ID ABZ81779 standard; DNA; 18 BP.
XX
AC ABZ81779;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
KW Huntington's disease; nootropic; anticonvulsant; huntingtin; human;
KW gene therapy; mutant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mutation replace(5,A)
FT /*tags a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PF 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0337219P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kniec EB, Parekh-Olmedo H;
XX
DR WPI; 2003-256478/25.
XX
PT New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7; Fig 20; 133pp; English.
XX
CC The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also ABZ81760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD38/25 (see ABZ81755). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD38/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1126 CAGCTGCAGCAGCAGCAG 1143
DB 1 CAGCTGCAGCAGCAGCAG 18
RESULT 81
ADS16437/C
ID ADS16437 standard; DNA; 18 BP.
XX
AC ADS16437;
XX
DT 02-DEC-2004 (first entry)
XX
DE Allele A oligo #2, used in polynucleotide sequence detection.
XX
KW Single nucleotide polymorphism; SNP; genotyping; ss.
XX
OS Synthetic.
XX
PN US2004175704-A1.
XX
PD 09-SEP-2004.
XX
PF 12-MAY-2003; 2003US-00436231.
XX
PR 06-MAR-2003; 2003US-0452481P.
XX
PA (STRA-) STRATAGENE.
XX
PI Sorge JA, Firmin A;
XX
DR WPI; 2004-642120/62.
XX
PT Determining polynucleotide sequence differences by amplifying
PT polynucleotide in presence of labeled nucleotide and detecting variation
PT based on incorporation frequency of labeled nucleotide compared to known
PT reference frequency.
XX
PS Disclosure; SEQ ID NO 2; 52pp; English.
XX
CC The invention relates to compositions, kits and methods for detecting
CC polynucleotide sequence differences. The method involves amplifying the
CC polynucleotide of interest in the presence of a labelled nucleotide and
CC detecting variation based on incorporation frequency of labelled
CC nucleotide compared to known reference frequency. The method is useful
CC for determining a sequence difference such as a single nucleotide
CC polymorphism (SNP) or a tandem repeat, between a region of interest in a
CC polynucleotide and a reference sequence. It is useful for determining the
CC presence of a mutation in a region of interest in a polynucleotide and is
CC also useful for genotyping. The present sequence is an allelic
CC oligonucleotide used in polynucleotide sequence detection.
XX
SQ Sequence 18 BP; 0 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1474 AAACAGCAGCAGCAGCAG 1491
DB 18 AAACAGCAGCAGCAGCAG 1
RESULT 82
ADS16436
ID ADS16436 standard; DNA; 18 BP.
XX
AC ADS16436;
XX
DT 02-DEC-2004 (first entry)

```
XX DE Allele A oligo #1, used in polynucleotide sequence detection.
XX KW Single nucleotide polymorphism ; SNP; genotyping; ss.
XX OS Unidentified.
XX PN US2004175704-A1.
XX PD 09-SEP-2004.
XX XX
XX PF 12-MAY-2003; 2003US-00436231.
XX PR 06-MAR-2003; 2003US-0452481P.
XX PA (STRA-) STRATAGENE.
XX PI Sorge JA, Firmin A;
XX XX
XX DR WPI; 2004-642120/62.
XX PT Determining polynucleotide sequence differences by amplifying
XX PT polynucleotide in presence of labeled nucleotide and detecting variation
XX PT based on incorporation frequency of labeled nucleotide compared to known
XX PT reference frequency.
XX PS Disclosure; SEQ ID NO 1; 52pp; English.
XX XX
XX CC The invention relates to compositions, kits and methods for detecting
XX CC polynucleotide sequence differences. The method involves amplifying the
XX CC polynucleotide of interest in the presence of a labelled nucleotide and
XX CC detecting variation based on incorporation frequency of labelled
XX CC nucleotide compared to known reference frequency. The method is useful
XX CC for determining a sequence difference such as a single nucleotide
XX CC polymorphism (SNP) or a tandem repeat, between a region of interest in a
XX CC polynucleotide and a reference sequence. It is useful for determining the
XX CC presence of a mutation in a region of interest in a polynucleotide and is
XX CC also useful for genotyping. The present sequence is an allelic
XX CC oligonucleotide used in polynucleotide sequence detection.
XX XX
XX SQ Sequence 18 BP; 8 A; 5 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1474 AACACGACGACGACGACG 1491
DB 1 AACACGACGACGACGACG 18
RESULT 83
ABZ31489/c
ID ABZ31489 standard; DNA; 20 BP.
XX
XX AC ABZ31489;
XX
XX DT 30-JAN-2003 (first entry)
XX DE Candida albicans GRACE strain PCR primer SEQ ID NO 5708.
XX
XX KW Fungus; Yeast; tetracycline; promoter; GRACE strain; biosynthesis;
XX KW signal transduction; DNA replication; cell division; growth;
XX KW proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
XX OS Candida albicans.
XX XX
XX PN WO200253728-A2.
XX XX
XX PD 11-JUL-2002.
XX XX
XX PF 26-DEC-2001; 2001WO-US049486.
XX XX

PR 29-DEC-2000; 2000US-0259128P.
PR 20-FEB-2001; 2001US-00792024.
PR 22-AUG-2001; 2001US-0314050P.
XX
XX PA (ELIT-) ELITRA PHARM INC.
XX
XX PI Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;
XX XX
XX DR WPI; 2002-566694/60.
XX
XX PT Constructing strains for identifying gene products as effective targets
XX PT for therapeutic intervention, by inactivating in the strain one allele of
XX PT a gene and placing other allele of the gene under conditional expression.
XX
XX PS Claim 36; SEQ ID NO 5708; 167pp + Sequence Listing; English.
XX
XX CC The invention relates to constructing (M1) a strain of diploid fungal
XX CC cells in which both alleles of a gene are modified, comprising modifying
XX CC one allele by insertion or replacement by a cassette having an
XX CC expressible selectable marker and modifying other allele by
XX CC recombination, of a promoter replacement fragment with a heterologous
XX CC promoter, so that expression of the second allele is regulated by the
XX CC promoter. (M1) is useful for constructing a strain of diploid fungal
XX CC cells in which both alleles of a gene are modified. The diploid fungal
XX CC cells having both alleles modified are useful for identifying a gene that
XX CC is essential to the survival or growth of a fungus, a gene that
XX CC contributes to the virulence and/or pathogenicity of a fungus, a gene
XX CC that contributes to the resistance of a diploid fungus to an antifungal
XX CC agent, an antifungal agent that inhibits the growth of a diploid fungus
XX CC and for identifying a therapeutic agent for treatment of a mammalian
XX CC disease. (M1) is useful for identifying a compound which modulates the
XX CC activity of a gene product, preferably enzymatic activity, carbon
XX CC compound catabolism, biosynthetic, transporter, transcriptional,
XX CC translational, signal transduction, DNA replication and cell division
XX CC activity. The method is useful for identifying a compound having the
XX CC ability to inhibit growth or proliferation of C. albicans cells and for
XX CC treating infection by C. albicans. The present sequence is that of a PCR
XX CC primer used in the method of the invention. Note: The sequence data for
XX CC this patent is not represented in the printed specification but is based
XX CC on sequence information supplied to Derwent by the European Patent Office
XX
XX SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1475 AACACGACGACGACGACG 1492
DB 18 AACACGACGACGACGACG 1
RESULT 84
ADD69519/c
ID ADD69519 standard; DNA; 20 BP.
XX
XX AC ADD69519;
XX
XX DT 15-JAN-2004 (first entry)
XX DE ISSR-related PCR primer 6.
XX
XX KW inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
XX KW animal; Baomai rice; ss.
XX
XX OS Unidentified.
XX XX
XX PN WO2003085133-A2.
XX XX
XX PD 16-OCT-2003.
XX XX
XX PF 09-JAN-2003; 2003WO-IB0000041.
XX XX
```

PR 08-APR-2002; 2002IN-CH000260.
XX (DNAP-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
PA Nagaraju JG;
XX WPI; 2003-804317/75.
DR New set of inter-simple sequence repeats (ISSR)-PCR primers for
PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and
PT animal systems.
XX Disclosure; Page 19; 60pp; English.
PS The invention relates to a novel set of inter-simple sequence repeats
XX (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
CC invention may be useful for genotyping diverse genomes of plant and
CC animal systems, in particular for distinguishing Basmati rice varieties
CC from non-Basmati rice varieties and traditional Basmati rice varieties
CC from evolved Basmati rice varieties. The current sequence is that of the
CC ISSR-related PCR primer of the invention.
XX
SQ Sequence 20 BP; 1 A; 6 C; 6 G; 6 T; 0 U; 1 Other;

Query Match 0.5%; Score 18; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1451 AGCAACAGCAGCAGCTT 1470
DB 20 AGCAGCAGCAGCAGCTY 1
|||||
1451 AGCAACAGCAGCAGCTT 1470
20 AGCAGCAGCAGCAGCTY 1

RESULT 85
AA78911/c
ID AAT78911 standard; cDNA; 42 BP.
XX
AC AAT78911;
XX
DT 09-FEB-1998 (first entry)
XX
DE Poly-glutamine repeat region coding sequence from clone AAD20.
XX
KW Monoclonal antibody; neurodegenerative disease; polyglutamine; TBP;
KW repeat region; affinity; TATA binding protein; Kennedy disease;
KW transcription initiation factor; lymphoblastic cell line; schizophrenia;
KW Huntington's disease; dominant autosomal spinocerebellar ataxia;
KW X-linked spino-bulbar muscular atrophy; familial spastic paraplegia;
KW dentarubral-pallidolusial atrophy; bipolar affective disorder;
KW manic depressive psychosis; ss.
XX
OS Homo sapiens.
XX
XX WO9717445-A1.
PN
XX 15-MAY-1997.
PD
XX 08-NOV-1996; 96WO-FR001773.
PF
XX 10-NOV-1995; 95FR-00013576.
PR
XX (CNRS) CNRS CENT NAT RECH SCI.
PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
PA
XX Tora L, Lutz Y, Trotter Y, Mandel J;
PI
XX WPI; 1997-281034/25.
DR
XX Antibody 1C2 used for treating or preventing neuro-degenerative diseases
PT - associated with proteins containing long poly-glutamine repeats, e.g.
PT Huntington's disease.
XX
XX Claim 21; Page 44; 69pp; French.

XX The invention relates to a monoclonal antibody (MAB) 1C2 for the
CC treatment of neurodegenerative diseases associated with the presence of
CC polyglutamine repeat regions. This MAB is already known for its affinity
CC to the TATA binding protein (TBP) transcription initiation factor,
CC especially at the amino acid sequence LEEQRRQQQQQ found at the N-
CC terminus of TBP. MAB 1C2 has been shown to have a high affinity for
CC polyglutamine repeats with a proportional affinity to the number of
CC glutamine repeats. This affinity has been used to identify genes encoding
CC proteins containing long polyglutamine repeats which are implicated in
CC neurodegenerative diseases. A screen of an expression library, generated
CC from a lymphoblastic cell line from a patient suffering from
CC spinocerebellar ataxia (SCA), with MAB 1C2 isolated 6 new sequences
CC (AA78906-778911) encoding polyglutamine repeats. This sequence is
CC derived from clone AAD20 isolated from a patient suffering from SCA2. MAB
CC 1C2, active fragment of it or nucleic acids encoding it are specifically
CC used to treat Huntington's disease, SCA types 1-5 or 7, X-linked spino-
CC bulbar muscular atrophy (Kennedy disease), dentarubral-pallidolusial
CC atrophy, dominant autosomal spinocerebellar ataxia, familial spastic
CC paraplegia, bipolar affective disorder, manic depressive psychoses and
CC schizophrenia
XX
SQ Sequence 42 BP; 14 A; 14 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 42;
Best Local Similarity 64.3%; Pred. No. 3.4e+02;
Matches 27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 1456 CAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCTCTG 1497
DB 42 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1
|||||
1456 CAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCTCTG 1497
42 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 86
AAZ61533
ID AAZ61533 standard; DNA; 21 BP.
XX
AC AAZ61533;
XX
DT 19-JUN-2000 (first entry)
XX
DE Primer 6U for a human 5'-OT EST (oxytocin expressed sequence tag).
XX
KW Oxytocin expressed sequence tag; 5'-OT EST; obesity; fertility; male;
KW transgenic animal; human late onset obesity; late onset visceral obesity;
KW male infertility; wasting; anorexia; cachexia; malabsorptive state;
KW catabolic state; inflammatory condition; Crohn's disease; AIDS wasting;
KW burn; cancer; bone disease; PCR primer; probe; ss.
XX
OS Homo sapiens.
XX
XX WO200009686-A1.
PN
XX 24-FEB-2000.
PD
XX 12-AUG-1999; 99WO-GB002658.
PF
XX 12-AUG-1998; 98GB-00017566.
PR 06-MAY-1999; 99GB-00010522.
PR
XX (MEDI-) MEDICAL RES COUNCIL.
PA
XX Robinson ICAF, Stoye JP, Flavell D, Wells SE, Le Tissier P;
PI
XX WPI; 2000-224331/19.
DR
XX New anti-obesity polypeptide useful for treating obesity or infertility
PT in mammals.
PT
XX Disclosure; Page 26; 162pp; English.
PS
XX PCR primers and probes AAZ61533-34 are used to amplify and identify human
CC 5'-OT-EST (oxytocin expressed sequence tag) cDNA sequences. The 5'-OT EST

CC Gene is involved in the control of obesity and fertility in males. 5'-OT
CC EST nucleic acids are useful for producing transgenic animals. The
CC transgenic animals created serve as a model for human late onset obesity
CC and other related disorders and are also used for identifying the genetic
CC cause of obesity. Compounds which modulate 5'-OT EST expression or
CC activity are useful in the treatment or modulation of late onset visceral
CC obesity or male infertility particularly in the disorders related to
CC these conditions such as wasting, or anorexia, or cachexia associated
CC with prolonged illness, or malabsorptive states or catabolic states
CC associated with other diseases such as inflammatory conditions, Crohn's
CC disease or AIDS wasting, or burns, or cancer, or bone disease
XX
SQ Sequence 21 BP; 6 A; 3 C; 12 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1335 GCAGCGGAGCGTGCAGCA 1355
Db 1 GCAGGAGGAGCGGAGCA 21
||||| ||||| ||||| ||||| |||||

RESULT 87
ABZ81769
ID ABZ81769 standard; DNA; 21 BP.
AC ABZ81769;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
KW Huntington's disease; neutropic; anticonvulsant; huntingtin; human;
KW gene therapy; mutant; ds.
XX
OS Homo sapiens.
OS Synthetic.
FH Key Location/Qualifiers
FT mutation replace(10,C)
FT /*tag= a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PF 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0337219P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Parekh-Olmedo H;
XX
XX WPI; 2003-256478/25.

DR New single stranded oligonucleotides comprising a DNA domain having at
XX least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
XX Example 1; Fig 6b; 133pp; English.
XX
XX The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also ABZ81760). The triplet repeat region (see ABZ81767) is
CC mutated following treatment with an RNA/DNA chimeric oligonucleotide (see
CC ABZ81769) that causes a CAG (Gln) to TAG (stop) gene alteration in the HD
CC exon 1 repeats due to sliding of the repeat region, a phenomenon that can

CC occur with the methods of this invention. The RNA/DNA chimeric
CC oligonucleotide is an example of oligonucleotides of the invention for
CC targeted alteration of the HD gene. Such oligonucleotides can be used for
CC the treatment or prevention of HD
XX
SQ Sequence 21 BP; 7 A; 6 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
Db 1 CAGCAGCAGTAGCAGCAGCAG 21
||||| ||||| ||||| ||||| |||||

RESULT 88
AAZ40548
ID AAZ40548 standard; DNA; 22 BP.
XX
AC AAZ40548;
XX
DT 18-FEB-2000 (first entry)
XX
DE Human ZC1 primer #2.
XX
KW Antirheumatic; antiathritic; antiinflammatory; antiallergic; osteopathic;
KW antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
KW neuroprotective; cardiant; cerebroprotective; cytostatic; antidiabetic;
KW vulnery; STE20; protein kinase; STIK2; STIK3; STIK4; STIK5; STIK6; STIK7;
KW ZC1; ZC2; ZC4; KHS2; SULU1; SULU3; GEK2; PAK4; PAK5; antagonist;
KW antibody; gene therapy; rheumatoid arthritis; arteriosclerosis; asthma;
KW inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
KW rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
KW myocardial infarction; cardiovascular disease; stroke; renal failure;
KW oxidative stress-related neurodegenerative disorder; Parkinson's disease;
KW amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
KW ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;
KW mesangial disorder; growth regulation; wound healing; T cell activation;
KW immunosuppressant; primer; PCR; amplification; ss.

XX Synthetic.
OS Homo sapiens.
XX
PN WO9953036-A2.
XX
PD 21-OCT-1999.
XX
PF 13-APR-1999; 99WO-US008150.
XX
PR 14-APR-1998; 98US-0081784P.
XX
PA (SUGS-) SUGEN INC.
XX
PI Plowman G, Martinez R, Whyte D;
XX
DR WPI; 1999-611301/52.
XX
PT Novel kinase-related polypeptides used for the diagnosis and treatment of
PT kinase-related diseases and disorders.
XX
PS Disclosure; Page 384; 387pp; English.

XX This sequence represents a PCR primer used to amplify the coding sequence
CC for a novel STE20-related protein kinase. The invention relates to
CC nucleic acid molecule encoding a kinase polypeptide selected from STIK2,
CC STIK3, STIK4, STIK5, STIK6, STIK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
CC SULU3, GEK2, PAK4 and PAK5. The proteins are used to identify agonists
CC and antagonists, and to raise antibodies. The polynucleotides are useful
CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
CC antagonists and agonists may be used to treat diseases such as immune-
CC related disorders and diseases (e.g. rheumatoid arthritis,
CC arteriosclerosis, chronic inflammatory bowel disease (e.g. Crohn's

CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
 CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
 CC disease, multiple sclerosis, organ transplantation, myocardial
 CC infarction, cardiovascular disease, stroke, renal failure, oxidative
 CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral
 CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
 CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
 CC mellitus, fibrotic and mesangial disorders. The proteins may also be
 CC useful for cell growth regulation (e.g. in wound healing), T cell
 CC activation, mitosis control, and as immunosuppressants
 XX
 XX Sequence 22 BP; 2 A; 5 C; 5 G; 10 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3858 CAAGGTGTTTTCCTCAGT 3878
 Db ||||||| ||||||| ||
 1 CAAGGTGTTTTCCTCCTGT 21
 RESULT 89
 ABX94818
 ID ABX94818 standard; DNA; 22 BP.
 XX
 AC ABX94818;
 XX
 DT 11-JUL-2003 (first entry)
 XX
 DE Human cysteine-rich FGF receptor (CFR) PCR primer CFR-For1.
 XX
 KW Human; antibody; murine antibody NM58-49/69; cysteine-rich FGF receptor;
 KW glycoprotein receptor; proliferating cell; stomach carcinoma; vaccine;
 KW CFR-1 protein; human antibody 103/51; immunoglobulin M; cytosolic; gut;
 KW antibacterial; antiinflammatory; receptor antagonism; cancer; stomach;
 KW oesophagus; rectum; liver; gall bladder; pancreas; lung; bronchus;
 KW breast; cervix; prostate; heart; ovary; uterus; metaplasia of oesophagus;
 KW Helicobacter pylori-associated gastritis; tubular adenoma; tumour marker;
 KW villous adenoma; Barrett dysplasia; cervical intraepithelial neoplasia;
 KW anticancer agent; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1 /*tag= a
 FT /mod_base= OTHER
 FT /note= "This nucleotide is depicted as o in the
 FT specification"
 XX
 PN WO2003011907-A2.
 XX
 PD 13-FEB-2003.
 XX
 PF 23-JUL-2002; 2002WO-DR002699.
 XX
 PR 24-JUL-2001; 2001DE-01036009.
 PR 09-MAR-2002; 2002DE-01010425.
 XX
 PA (MUEL/) MUELLER-HERMELINK H K.
 PA (VOLL/) VOLLMERS H.
 PA (HENS/) HENSEL F.
 XX
 PI Mueller-Hermelink HK, Vollmers H, Hensel F;
 XX
 DR WPI; 2003-256436/25.
 XX
 PT New glycoprotein receptor on surface of cancer cells, useful for
 PT specific and diagnosis of cancer and for drug screening, also new
 PT treatment antibody.
 XX
 PS Disclosure; Page 21; 49pp; German.

XX This invention describes a novel glycoprotein receptor, present on the
 CC surface membrane of strongly proliferating cells, especially stomach
 CC carcinoma, having at least one determinant that corresponds with a
 CC determinant of CFR-1 protein and binding specifically to human antibody
 CC 103/51 and/or the murine antibody 58/47-69 (immunoglobulin M). The
 CC products of the invention have cytostatic, antibacterial and
 CC antiinflammatory activity and can be used in a vaccine or for receptor
 CC antagonism. The novel receptor is used for therapeutic in vivo generation
 CC of antibodies, for treatment and prevention of cancer (of oesophagus,
 CC stomach, gut, rectum, liver, gall bladder, pancreas, lung, bronchi,
 CC breast, cervix, prostate, heart, ovary and/or uterus), for treating a
 CC wide range of precancerous states (e.g. Helicobacter pylori-associated
 CC gastritis, tubular or villous adenoma, Barrett dysplasia/metaplasia of
 CC oesophagus, cervical intraepithelial neoplasia etc.), for diagnosis (as a
 CC tumour marker) and for identifying potential anticancer agents from their
 CC ability to bind selectively to the glycoprotein receptor. This sequence
 CC represents a PCR primer used to amplify the human cysteine-rich FGF
 CC receptor (CFR) described in the disclosure of the invention
 XX
 XX Sequence 22 BP; 7 A; 7 C; 5 G; 2 T; 0 U; 1 Other;
 SQ
 Query Match 0.5%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1125 GCAGCTGCAGCAGCAGCA 1145
 Db ||||||| ||||||| |||||
 2 GCAGCTTCAGCAGCAGCA 22
 RESULT 90
 AAT85350
 ID AAT85350 standard; DNA; 23 BP.
 XX
 AC AAT85350;
 XX
 DT 09-DEC-1997 (first entry)
 XX
 DE Spider silk protein target DNA primer (xv).
 XX
 KW High strength film; fibre; woven article; parachutes; sails; absorber;
 KW body armour; heavy metal; biological weapon; chemical; flavour;
 KW fragrance; Nephila clavipes; ss.
 XX
 OS Synthetic.
 XX
 PN WO9708315-A1.
 XX
 PD 06-MAR-1997.
 XX
 PF 22-AUG-1996; 96WO-US013767.
 XX
 PR 22-AUG-1995; 95US-00517694.
 XX
 PA (BASE/) BASEL R M.
 PA (ELIO/) ELION G R.
 XX
 PI Basel RM, Elion GR;
 XX
 DR WPI; 1997-179272/16.
 XX
 PT New opt. multimerised DNA sequences encoding spider silk protein - contg.
 PT both repetitive and non-repetitive sequences, useful for making high
 PT strength films, fibres, woven articles etc.
 XX
 PS Claim 7; Page 54; 57pp; English.
 XX
 CC A process has been developed for the production of a DNA fragment
 CC encoding silk protein. The process involves: (a) selecting target DNA,
 CC from a silk-producing spider, that contains many repetitive and non-
 CC repetitive regions; (b) selecting a single-stranded DNA primer of at
 CC least 10 nucleotides with a sequence that is complementary to a region of

CC the target; (c) repetitively combining the primer with melted target DNA,
 CC incubating the mixture with nucleotides and a DNA polymerase with
 CC proofreading activity to produce a DNA fragment which is complementary to
 CC the target and is at least 2 kb long. The present sequence represents a
 CC specifically claimed primer for use in this process. The DNA fragment can
 CC be used to make fibres, films, woven articles, e.g. for use in
 CC parachutes, sails, body armour, and absorbers (e.g. of heavy metals,
 CC biological weapons, DNA, chemicals, flavours and fragrances). The high
 CC molecular weight (90-250 kD) of spider silk proteins can be produced on a
 CC commercial scale (at over 2 g/l cell mass). It has better tensile
 CC strength and elasticity than silkworm silk. Inclusion of both repetitive
 CC and non-repetitive regions ensures isolation of stable clones
 XX
 SQ Sequence 23 BP; 4 A; 6 C; 10 G; 2 T; 0 U; 1 Other;
 Query Match 0.4%; Score 17.6; DB 1; Length 23;
 Best Local Similarity 94.4%; Pred. No. 1.9e+02;
 Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1117 CAGCAGCAGCAGCTGCAG 1134
 DB 5 CAGCAGCAGCAGCTGCWG 22
 RESULT 91
 AAT39475
 ID AAT39475 standard; DNA; 19 BP.
 XX
 AC AAT39475;
 XX
 XX
 DT 21-MAY-1997 (first entry)
 XX
 DE Steroidogenesis acute regulatory protein sense PCR primer 1.
 XX
 KW Human; steroidogenesis; acute regulatory protein; hSTAR; analysis;
 KW mutation; detection; prenatal; genetic defect; congenital; protein;
 KW lipid adrenal hyperplasia; treatment; prevention; gene;
 KW replacement therapy; hypercholesterolaemia; primer; PCR;
 KW polymerase chain reaction; ss.
 XX
 OS Synthetic.
 XX
 XX WO9629338-A1.
 PN
 XX
 PD 26-SEP-1996.
 XX
 XX 22-MAR-1996; 96WO-US003896.
 PF
 XX 23-MAR-1995; 95US-00410540.
 PR
 XX (REGC) UNIV CALIFORNIA.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PA
 PI Miller WL, Lin D, Straus JF;
 XX
 DR WPI; 1996-443130/44.
 XX
 XX Isolated human steroidogenesis acute regulatory protein gene - used for
 PT detection of mutation(s) of this gene that cause congenital lipid
 PT adrenal hyperplasia.
 XX
 XX Disclosure; Page 4; 89pp; English.
 PS
 XX The present sequence is a PCR primer (nt 66-84) for the human
 CC steroidogenesis acute regulatory protein (hSTAR) cDNA. The hSTAR gene can
 CC be analysed for mutations to detect (e.g. prenatally) genetic defects
 CC associated with congenital lipid adrenal hyperplasia (CAH), or its
 CC transmission to children. CAH can be treated by protein or gene
 CC replacement therapy, which can also be used to prevent or treat
 CC hypercholesterolaemia. A human adrenal cortex cDNA library was screened
 CC with a mouse STAR probe to isolate a 1.6 kb insert, including an ORF for
 CC a 285 residue protein. When it was cloned into pSPORT and expressed in
 CC COS-1 cells cotransfected with pP450acc abd pADX, it increased the level

CC of pregnenolone synthesis from cholesterol or 20-alpha-hydroxycholesterol
 SQ Sequence 19 BP; 5 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 1.4e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1119 GCAGCAGCAGCTGCAGCAG 1137
 DB 1 GCAGCAGCAGCGCAGCAG 19
 RESULT 92
 AAA55806/c
 ID AAA55806 standard; DNA; 20 BP.
 XX
 AC AAA55806;
 XX
 DT 01-SEP-2000 (first entry)
 XX
 DE Human histone deacetylase HD2 antisense oligonucleotide SEQ ID NO:51.
 XX
 KW Human; DNA methyltransferase; DNA MeTase; antisense oligonucleotide;
 KW modulation; inhibition; gene expression; combination therapy; p16;
 KW histone deacetylase; HDAC; thymidylate synthase; tumour suppressor;
 KW methylation; gene therapy; tumour; cytostatic; antiasthmatic;
 KW antiinflammatory; inflammation; asthma; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200023112-A1.
 PN
 XX 27-APR-2000.
 PD
 XX 19-OCT-1999; 99WO-US024278.
 PF
 XX 19-OCT-1998; 98US-0104804P.
 PR
 XX (METH-) METHYLGENE INC.
 PA
 XX Besterman JM, Macleod AR, Siders WM;
 PI
 XX WPI; 2000-339532/29.
 DR
 XX
 XX Inhibiting gene expression e.g. DNA methyltransferase, by treating cells
 PT with a synergistic amount of antisense oligonucleotide and protein
 PT effectors e.g. 5-aza-cytidine of gene products, useful for gene therapy
 PT of e.g. tumors.
 XX
 XX Disclosure; Page 29; 99pp; English.
 PS
 XX The present invention describes a method for inhibiting the expression of
 CC a gene in a cell comprising contacting the cell with an effective
 CC synergistic amount of an antisense oligonucleotide which inhibits
 CC expression of the gene, and an effective synergistic amount of a protein
 CC effector of a product of the gene. Also described are: (1) a method for
 CC treating a disease responsive to inhibition of a gene in a mammal; (2) a
 CC method for inhibiting tumour growth in mammal; (3) an inhibitor of a gene
 CC comprising an antisense oligonucleotide which inhibits expression of the
 CC gene in operable association with a protein effector of a gene product;
 CC and (4) a pharmaceutical composition comprising the inhibitor of (3). The
 CC methods and compositions are useful as analytical tools for transgenic
 CC studies and as therapeutic tools, e.g. as gene therapy tools for human
 CC diseases including benign and malignant tumours, inflammation or asthma.
 CC The methods, inhibitors and compositions of the invention that inhibit
 CC expression or activity of a gene or gene product may be used to treat
 CC patients having, or predisposed to developing, a disease responsive to
 CC inhibition of the gene. These may also be used to activate silenced genes
 CC to provide missing gene functions and improve a given condition.
 CC Furthermore, the methods and compositions are useful as probes of the
 CC physiological function of a gene product in an experimental cell culture
 CC or animal system; and to evaluate the effect of inhibiting gene activity

CC or expression. AAA55758 to AAA5842 represent oligonucleotide sequences
 CC which are used in the exemplification of the present invention
 XX
 SQ Sequence 20 BP; 0 A; 7 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1129 CTGCAGCAGCAGCAGC 1147
 Db 20 CGGCAGCAGCAGCAGC 2

RESULT 93
 AAK94988/C
 ID AAK94988 standard; DNA; 20 BP.
 XX
 AC AAK94988;
 DT 06-NOV-2001 (first entry)
 XX
 DE Human cDNA clone-specific primer, SEQ ID NO: 4233.
 XX
 KW Human; full length cDNA; cDNA synthesis; oligo-capping; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 FN EP1130094-A2.
 PD 05-SEP-2001.
 XX
 PF 07-JUL-2000; 2000EP-00114089.
 XX
 PR 08-JUL-1999; 99JP-00194486.
 PR 11-JAN-2000; 2000JP-00118774.
 PR 02-MAY-2000; 2000JP-00183765.
 XX
 PA (HELI-) HELIX RES INST.
 XX
 PI Ota T, Nishikawa T, Isogai T, Hayaashi K, Ishii S, Kawai Y;
 PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
 XX
 DR WPI; 2001-524255/58.
 XX
 XX
 PT 830 Primers useful for synthesizing full length cDNA clones and their use
 PT in genetic manipulation.
 XX
 PS Example 18; Page 128; 1380pp + Sequence Listing; English.

CC The invention relates to primers for synthesizing full length cDNA
 CC clones. 830 cDNA molecules encoding a human protein have been isolated
 CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
 CC been determined. Primers for synthesizing the full length cDNA are useful
 CC for clarifying the function of the protein encoded by the cDNA. The full
 CC length clones were obtained by construction of full length enriched cDNA
 CC libraries that were synthesised by the oligo-capping method. The primers
 CC enable the production of the full length cDNA easily without any special
 CC methods. The present sequence is a primer used to amplify a human cDNA
 CC clone provided in the invention
 XX
 SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3614 GCATGGAGATGCTGCTGTG 3632
 Db 19 GCTTGGAGATGCTGCTGTG 1

RESULT 94

AAH43116/C
 ID AAH43116 standard; DNA; 20 BP.
 XX
 AC AAH43116;
 XX
 DT 19-SEP-2001 (first entry)
 XX
 DE Antisense oligo, target HDAC-2 121-141.
 XX
 KW Antisense; histone deacetylase; HDAC-1; HDAC-2; HDAC-4; inhibitor;
 KW cell proliferation; cancer; restenosis; psoriasis; protozoal infection;
 KW fungal infections; ss.
 XX
 OS Synthetic.
 XX
 PN WO200138322-A1.
 XX
 PD 31-MAY-2001.
 XX
 PF 22-NOV-2000; 2000WO-IB001881.
 XX
 PR 23-NOV-1999; 99US-0167035P.
 XX
 PA (METH-) METHYLGENE INC.
 XX
 PI Delorme D, Ruel R, Lavoie R, Thibault C, Abou-Khalil E;
 XX
 DR WPI; 2001-432601/46.
 XX
 PT New inhibitors of histone deacetylase e.g. N-hydroxy-5-(4-
 PT (benzenesulfonylamino)-phenyl)-4-yn-2-pentanamide for treating cancer,
 PT restenosis or fungal infections.
 XX
 PS Disclosure; Page 40; 147pp; English.

CC The sequences given in AAH43115-21 are oligonucleotides which are
 CC antisense to the histone deacetylase gene, HDAC-2. These oligonucleotides
 CC may be used in combination with an inhibitor of histone deacetylase
 CC enzyme function, to given an improved inhibitory effect, thereby reducing
 CC the amount of inhibitor required to obtain a given inhibitory effect.
 CC Compounds containing these oligonucleotides may be used to treat cell
 CC proliferation conditions such as cancer, restenosis or psoriasis. They
 CC can also be used to treat protozoal and fungal infections
 XX
 SQ Sequence 20 BP; 0 A; 7 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1129 CTGCAGCAGCAGCAGC 1147
 Db 20 CGGCAGCAGCAGCAGC 2

RESULT 95
 AAH57033/C
 ID AAH57033 standard; DNA; 20 BP.
 XX
 AC AAH57033;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human oestrogen receptor alpha search PCR primer 58.
 XX
 KW Ligand dependent transcriptional factor; oestrogen receptor; ER;
 KW glucocorticoid receptor protein; GR; mineralocorticoid receptor protein;
 KW MR; peroxisome proliferator-activated receptor protein; PPAR;
 KW progesterone receptor protein; PR; pregnane X receptor protein; PXR;
 KW thyroid hormone receptor protein; TR; vitamin D receptor protein; VDR;
 KW transactivation; Eralpha; breast cancer; PCR primer; probe; ss.
 XX
 OS Homo sapiens.

XX PN WO200142307-A1.
XX PD
XX PP 14-JUN-2001.
XX PF 01-DEC-2000; 2000WO-IP008553.
XX PR 07-DEC-1999; 99JP-00348022.
XX PR 27-DEC-1999; 99JP-00370667.
XX PR 27-JUL-2000; 2000JP-00207011.
XX PR 21-JUL-2000; 2000JP-00220508.
XX PR 02-AUG-2000; 2000JP-00234053.
XX PR 03-AUG-2000; 2000JP-00235460.
XX PR 03-AUG-2000; 2000JP-00235461.
XX PR 03-AUG-2000; 2000JP-00235463.
XX PA (SUMO) SUMITOMO CHEM CO LTD.
XX PI Saito K, Ohe N, Satoh H;
XX DR WPI; 2001-367866/38.
XX PT Ligand dependent transcriptional factors, nucleic acids encoding them and
XX PT cells comprising them and a specified reporter gene, useful for screening
XX PT agents for the treatment of breast cancer.
XX PS Example 9; Page 226; 276pp; English.
XX CC The present invention relates to ligand dependent transcriptional factors
XX CC including oestrogen receptor (ER) alpha and beta protein, glucocorticoid
XX CC receptor protein (GR), mineralocorticoid receptor protein (MR),
XX CC peroxisome proliferator-activated receptor protein (PPAR), progesterone
XX CC receptor protein (PR), pregnane X receptor protein (PXR), thyroid hormone
XX CC receptor protein (TR) and vitamin D receptor protein (VDR), the nucleic
XX CC acids encoding them and cells comprising them and a specified reporter
XX CC gene for the ligand dependent transcriptional factor. These proteins are
XX CC useful in the modulation of ligand dependent transcriptional factor
XX CC activity. The cells, mutant ERalpha and the polynucleotide encoding it
XX CC may be used in assays for qualitatively analysing an activity for
XX CC transactivation of a reporter gene by a test ERalpha, for screening
XX CC mutant ligand dependent transcriptional factors, for evaluating an
XX CC activity for transactivation of a reporter gene by a test ERalpha and/or
XX CC for screening a compound useful for treating a disorder of a mutant
XX CC ERalpha, especially breast cancer
XX SQ Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1130 TGCAGCAGCAGCAGCAGCG 1148
DB 20 TGCAGCAGCAGCAGCAGCG 2
RESULT 96
AAC89545/c
ID AAC89545 standard; DNA; 20 BP.
XX AC AAC89545;
XX DT 08-MAR-2001 (first entry)
XX DE Human HDAC-2 antisense sequence SEQ ID NO: 15.
XX KW Histone deacetylase; HDAC-1; HDAC-2; HDAC-3; HDAC-4; HDAC-5; HDAC-C;
XX KW HDAC-D; cell cycle; tumorigenesis; cancer; inhibitor; antisense;
XX KW gene therapy; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200071703-A2.
Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1130 TGCAGCAGCAGCAGCAGCG 1148
DB 20 TGCAGCAGCAGCAGCAGCG 2
RESULT 96
AAC89545/c
ID AAC89545 standard; DNA; 20 BP.
XX AC AAC89545;
XX DT 08-MAR-2001 (first entry)
XX DE Human HDAC-2 antisense sequence SEQ ID NO: 15.
XX KW Histone deacetylase; HDAC-1; HDAC-2; HDAC-3; HDAC-4; HDAC-5; HDAC-C;
XX KW HDAC-D; cell cycle; tumorigenesis; cancer; inhibitor; antisense;
XX KW gene therapy; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200071703-A2.

XX PD 30-NOV-2000.
XX PF 03-MAY-2000; 2000WO-IB001252.
XX PR 03-MAY-1999; 99US-0132287P.
XX PA (METH-) METHYLGENE INC.
XX PI Macleod AR, Li Z, Besterman JM;
XX DR WPI; 2001-016407/02.
XX PT Antisense oligonucleotide that inhibits expression of a histone
XX PT deacetylase, useful for treating and/or alleviating the symptoms of
XX PT neoplasia, or for inhibiting neoplastic cell growth in an animal.
XX PS Example 1; Page 24; 125pp; English.
XX CC The present invention provides inhibitors of histone deacetylase enzymes
XX CC such as HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C and HDAC-D. These
XX CC inhibitors may be antisense strands or they may be compounds identified
XX CC by contacting the enzyme with the compound and measuring the resulting
XX CC enzyme activity. These inhibitors are useful for treating cancers and for
XX CC identifying which histone deacetylase is involved in a neoplasia
XX SQ Sequence 20 BP; 0 A; 7 C; 7 G; 4 T; 2 U; 0 Other;
Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1129 CTGCAGCAGCAGCAGCAGC 1147
DB 20 CGGCAGCAGCAGCAGCAGC 2
RESULT 97
AAC89536/c
ID AAC89536 standard; DNA; 20 BP.
XX AC AAC89536;
XX DT 08-MAR-2001 (first entry)
XX DE Human HDAC-2 PCR primer SEQ ID NO: 6.
XX KW Histone deacetylase; HDAC-1; HDAC-2; HDAC-3; HDAC-4; HDAC-5; HDAC-C;
XX KW HDAC-D; cell cycle; tumorigenesis; cancer; inhibitor; antisense;
XX KW gene therapy; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200071703-A2.
XX PD 30-NOV-2000.
XX PF 03-MAY-2000; 2000WO-IB001252.
XX PR 03-MAY-1999; 99US-0132287P.
XX PA (METH-) METHYLGENE INC.
XX PI Macleod AR, Li Z, Besterman JM;
XX DR WPI; 2001-016407/02.
XX PT Antisense oligonucleotide that inhibits expression of a histone
XX PT deacetylase, useful for treating and/or alleviating the symptoms of
XX PT neoplasia, or for inhibiting neoplastic cell growth in an animal.
XX PS Disclosure; Page 12; 125pp; English.
XX

CC The present invention provides inhibitors of histone deacetylase enzymes
CC such as HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C and HDAC-D. These
CC inhibitors may be antisense strands or they may be compounds identified
CC by contacting the enzyme with the compound and measuring the resulting
CC enzyme activity. These inhibitors are useful for treating cancers and for
CC identifying which histone deacetylase is involved in a neoplasia
XX

SQ . Sequence 20 BP; 0 A; 7 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGC 1147
DB 20 CGCAGCAGCAGCAGCAGC 2

RESULT 98
ABK30537/c
ID ABK30537 standard; DNA; 20 BP.

XX AC ABK30537;

XX DT 23-APR-2002 (first entry)

XX DE Human glioma-associated oncogene-1 antisense oligonucleotide ISIS 124869.

XX KW Human; glioma-associated oncogene-1 associated disease; infection;
XX inflammation; tumour formation; cytostatic; antiinflammatory; antisense;
XX phosphorothioate; ss.

XX OS Homo sapiens.

XX US6329203-B1.

XX PD 11-DEC-2001.

XX PF 08-SEP-2000; 2000US-00657042.

XX PR 08-SEP-2000; 2000US-00657042.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Wyatt J;

XX DR WPI; 2002-138363/18.

XX PT Novel antisense compounds targeted to nucleic acids encoding glioma-
XX associated oncogene-1, for modulating the gene expression and treating
XX diseases associated with expression of the oncogene in humans.

PS Example 15; Col 45-46; 43pp; English.

XX The present invention relates to antisense compounds and methods for
XX modulating the expression of human glioma-associated oncogene-1. The
XX antisense compounds, particularly antisense oligonucleotides, target and
XX inhibit the expression of human glioma-associated oncogene-1. The
XX antisense compounds are useful for inhibiting the expression of human
XX glioma-associated oncogene-1 in human cells or tissues and for treating
XX an animal, particularly a human suspected of having or being prone to a
XX disease or condition associated with expression of glioma-associated
XX oncogene-1. The compounds are useful for diagnostics, therapeutics and as
XX research reagent, e.g. prophylactically to prevent or delay infection,
XX inflammation or tumour formation. The antisense compounds are safely and
XX effectively administered to humans. ABK30509-ABK30586 represent the
XX antisense oligonucleotides of the invention which comprise a
XX phosphorothioate backbone

SQ . Sequence 20 BP; 2 A; 5 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1121 AGCAGCAGCTGCAGCAGCA 1139
DB 20 AGCAGCAGCTCCAGCAGCA 2

RESULT 99

ABZ30516/c

ID ABZ30516 standard; DNA; 20 BP.

XX AC ABZ30516;

XX DT 30-JAN-2003 (first entry)

XX DE Candida albicans GRACE strain PCR primer SEQ ID NO 4667.

XX KW Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;
XX signal transduction; DNA replication; cell division; growth;
XX proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX OS Candida albicans.

XX PN WO200253728-A2.

XX PD 11-JUL-2002.

XX PF 26-DEC-2001; 2001WO-US049486.

XX PR 29-DEC-2000; 2000US-0259128P.

XX PR 20-FEB-2001; 2001US-00792024.

XX PR 22-AUG-2001; 2001US-0314050P.

XX PA (ELIT-) ELITRA PHARM INC.

XX PI Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;

XX DR WPI; 2002-566694/60.

XX PT Constructing strains for identifying gene products as effective targets
XX for therapeutic intervention, by inactivating in the strain one allele of
XX a gene and placing other allele of the gene under conditional expression.

XX PS Claim 36; SEQ ID NO 4667; 167pp + Sequence Listing; English.

XX The invention relates to constructing (M1) a strain of diploid fungal
XX cells in which both alleles of a gene are modified, comprising modifying
XX one allele by insertion or replacement by a cassette having an
XX expressible selectable marker and modifying other allele by
XX recombination, of a promoter replacement fragment with a heterologous
XX promoter, so that expression of the second allele is regulated by the
XX promoter. (M1) is useful for constructing a strain of diploid fungal
XX cells in which both alleles of a gene are modified. The diploid fungal
XX cells having both alleles modified are useful for identifying a gene that
XX is essential to the survival or growth of a fungus, a gene that
XX contributes to the virulence and/or pathogenicity of a fungus, a gene
XX that contributes to the resistance of a diploid fungus to an antifungal
XX agent, an antifungal agent that inhibits the growth of a diploid fungus
XX and for identifying a therapeutic agent for treatment of a mammalian
XX disease. (M1) is useful for identifying a compound which modulates the
XX activity of a gene product, preferably enzymatic activity, carbon
XX compound catabolism, biosynthetic, transporter, transcriptional,
XX translational, signal transduction, DNA replication and cell division
XX activity. The method is useful for identifying a compound having the
XX ability to inhibit growth or proliferation of C. albicans cells and for
XX treating infection by C. albicans. The present sequence is that of a PCR
XX primer used in the method of the invention. Note: The sequence data for
XX this patent is not represented in the printed specification but is based
XX on sequence information supplied to Derwent by the European Patent Office

SQ . Sequence 20 BP; 0 A; 4 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;


```
RESULT 102
ADL32200/c
XX ADL32200 standard; DNA; 20 BP.
AC ADL32200;
XX
XX 20-MAY-2004 (first entry)
XX
XX Clone specific PCR primer to amplify human full length cDNA SeqID 4233.
XX human, medicine, signal transduction; glycoprotein; transcription;
XX oligo-capping method; ss; PCR; primer.
XX
XX Homo sapiens.
XX
XX EP1396543-R2.
XX
XX 10-MAR-2004.
XX
XX 07-JUL-2000; 2003EP-00025638.
XX
XX 08-JUL-1999; 99JP-00194486.
XX
XX 11-JAN-2000; 2000JP-00118774.
XX
XX 02-MAY-2000; 2000JP-0018365.
XX
XX 07-JUL-2000; 2000EP-00114089.
XX
XX (REAS-) RES ASSOC BIO TECHNOLOGY.
XX
XX Ota T, Nishikawa T, Isogai T, Hayaishi K, Ishii S, Kawai Y;
XX Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX WPI; 2004-204755/20.
XX
XX New oligonucleotide primers (830 cDNAs) useful for synthesizing full
XX length human cDNAs.
XX
XX Example 18; SEQ ID NO 4233; 1340pp; English.
XX
XX This invention relates to a novel primers useful for synthesizing full
XX length cDNA molecules that encode human proteins. Specifically, it refers
XX to secretory or membrane proteins that are potential therapeutic agents/
XX target molecules in the field of medicine, and in particular genes
XX encoding proteins that are associated with signal transduction,
XX glycoproteins and transcription. The present invention describes a method
XX for efficiently cloning a full length human cDNA from both the 5' and 3'
XX ends using the oligo-capping method. This oligonucleotide sequence is a
XX human clone specific PCR primer used in an exemplification of the
XX invention.
XX
XX Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 17.4; DB 1; Length 20;
XX Best Local Similarity 94.7%; Pred. No. 1.5e+02;
XX Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 3614 GCATGGAGATGCTGCTGTG 3632
XX 19 GCTTGGAGATGCTGCTGTG 1
XX
XX RESULT 103
ADM11408/c
XX ADM11408 standard; DNA; 20 BP.
XX
XX ADM11408;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human CDC14A antisense oligonucleotide #2.
XX
XX Human; CDC14A; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; cytostatic.
XX
```

```
XX Homo sapiens.
XX
XX US2004077085-A1.
XX
XX 22-APR-2004.
XX
XX 17-OCT-2002; 2002US-00274387.
XX
XX 17-OCT-2002; 2002US-00274387.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM;
XX
XX WPI; 2004-340010/31.
XX
XX New antisense oligonucleotides for modulating CDC14A expression, useful
XX for diagnosing, preventing or treating diseases or conditions associated
XX with CDC14A, such as a hyperproliferative disorder, particularly cancer.
XX
XX Example 15; SEQ ID NO 13; 49pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding the human CDC14A polypeptide. The compound is an antisense
XX oligonucleotide that specifically hybridizes with the nucleic acid and
XX inhibits expression of the polypeptide. The antisense oligonucleotide
XX comprises at least one modified internucleoside linkage i.e. a
XX phosphorothioate linkage, at least one modified sugar moiety, preferably
XX a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
XX comprising a 5-methylcytosine. The antisense compounds are useful for
XX modulating the expression of the human CDC14A polypeptide and in
XX preparation of a composition for treating hyperproliferative disorders,
XX e.g. cancer. This sequence represents an antisense oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 17.4; DB 1; Length 20;
XX Best Local Similarity 94.7%; Pred. No. 1.5e+02;
XX Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1122 GCAGCAGCTGCAGCAGCAG 1140
XX 20 GCAGCAGCTGCAGCAGCCG 2
XX
XX RESULT 104
ADO01250/c
XX ADO01250 standard; DNA; 20 BP.
XX
XX ADO01250;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human CDC14A antisense oligonucleotide ISIS #131181.
XX
XX Antisense; human; CDC14A protein; cancer; antisense therapy;
XX phosphorothioate; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone where all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
```

```
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX US2004077571-A1.
XX 22-APR-2004.
XX 17-OCT-2002; 2002US-00274311.
XX 17-OCT-2002; 2002US-00274311.
XX (ISIS-) ISIS PHARM INC.
XX (ABBO ) ABBOTT LAB.
XX Freier SM, Sarthy A, Megonigal T;
XX WPI; 2004-340036/31.
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding human CDC14A protein, to inhibit its expression.
XX Antisense compounds of the invention are useful in preparing a
XX composition for treating a disease or condition associated with CDC14A
XX e.g. cancer. The invention is also useful in antisense gene therapy. The
XX present sequence is an antisense oligonucleotide targeted to human CDC14A
XX DNA. This sequence is used in the exemplification of the invention.
XX Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1122 GCAGCAGCTGCAGCAGCAG 1140
DB 20 GCAGCAGCTGCAGCAGCG 2
RESULT 105
ADP20520
ID ADP20520 standard; DNA; 20 BP.
XX AC ADP20520;
XX XX
XX 26-AUG-2004 (first entry)
XX DE Transcription factor AP-2 antisense oligonucleotide seqid 67.
XX KW cytosstatic; AP-2-Inhibitor-Alpha; AP-2 alpha; AP-2 alpha modulator;
XX AP-2 alpha associated disorder; hyperproliferative disorder; human;
XX KW transcription factor; antisense oligonucleotide; antisense technology;
XX ss.
XX OS Homo sapiens.
XX US2004109848-A1.
XX 10-JUN-2004.
XX 09-DEC-2002; 2002US-00315962.
XX 09-DEC-2002; 2002US-00315962.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Dean NM, Freier SM, Dobie KW;
```

```
XX WPI; 2004-440306/41.
XX New compounds targeted to nucleic acid molecules encoding AP-2 alpha and
XX inhibits the expression of AP-2 alpha, useful for treating AP-2 alpha-
XX associated disease or condition, particularly a hyperproliferative
XX disorder.
XX Example 15; SEQ ID NO 67; 58pp; English.
XX The invention describes a compound (I) 8-80 nucleobases in length
XX targeted to a nucleic acid molecule encoding AP-2 alpha. The compound
XX specifically hybridizes with a nucleic acid molecule encoding AP-2 alpha
XX (1986 bp, SEQ ID NO: 4), and inhibits the expression of AP-2 alpha. Also
XX described are: inhibiting the expression of AP-2 alpha in cells or tissues
XX comprising contacting the cells or tissues with (I); screening for a
XX modulator of AP-2 alpha by contacting a preferred target segment of a
XX nucleic acid molecule encoding AP-2 alpha with one or more candidate
XX modulators of AP-2 alpha, and identifying one or more modulators of AP-2
XX alpha expression, which modulate the expression of AP-2 alpha; a
XX diagnostic method for identifying a disease state; and a kit or assay
XX device comprising (I). The compound is useful for treating an animal
XX having a disease or condition associated with AP-2 alpha, particularly a
XX hyperproliferative disorder. The compounds may be used for diagnostics,
XX therapeutics prophylaxis and as research reagents; or as tools in
XX differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion or the entire complement of genes expressed within
XX cells and tissues. This sequence represents a human transcription factor.
XX AP-2 antisense oligonucleotide.
XX Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1128 GCTGCAGCAGCAGCAGCAG 1146
DB 1 GCGGCAGCAGCAGCAGCAG 19
RESULT 106
AAA37188/c
ID AAA37188 standard; DNA; 21 BP.
XX AC AAA37188;
XX XX
XX 08-AUG-2000 (first entry)
XX DE Human PRO1315 forward PCR primer SEQ ID NO:105.
XX KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
XX KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
XX KW PCR primer; hybridisation; probe; ss.
XX OS Homo sapiens.
XX WO200012708-A2.
XX 09-MAR-2000.
XX 01-SEP-1999; 99WO-US020111.
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098749P.
XX 02-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 02-SEP-1998; 98US-0098936P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
```

PR	09-SEP-1998;	98US-0099642P.	PR	26-OCT-1998;	98US-0105694P.
PR	10-SEP-1998;	98US-0099741P.	PR	27-OCT-1998;	98US-0105807P.
PR	10-SEP-1998;	98US-0099754P.	PR	27-OCT-1998;	98US-0105881P.
PR	10-SEP-1998;	98US-0099763P.	PR	27-OCT-1998;	98US-0105882P.
PR	10-SEP-1998;	98US-0099792P.	PR	27-OCT-1998;	98US-0106063P.
PR	10-SEP-1998;	98US-0099808P.	PR	28-OCT-1998;	98US-0106023P.
PR	10-SEP-1998;	98US-0099812P.	PR	28-OCT-1998;	98US-0106029P.
PR	10-SEP-1998;	98US-0099815P.	PR	28-OCT-1998;	98US-0106030P.
PR	10-SEP-1998;	98US-0099816P.	PR	28-OCT-1998;	98US-0106032P.
PR	15-SEP-1998;	98US-0100385P.	PR	28-OCT-1998;	98US-0106033P.
PR	15-SEP-1998;	98US-0100388P.	PR	28-OCT-1998;	98US-0106178P.
PR	15-SEP-1998;	98US-0100390P.	PR	29-OCT-1998;	98US-0106248P.
PR	16-SEP-1998;	98US-0100584P.	PR	29-OCT-1998;	98US-0106384P.
PR	16-SEP-1998;	98US-0100627P.	PR	29-OCT-1998;	98US-0108500P.
PR	16-SEP-1998;	98US-0100661P.	PR	30-OCT-1998;	98US-0106464P.
PR	16-SEP-1998;	98US-0100662P.	PR	03-NOV-1998;	98US-0106856P.
PR	16-SEP-1998;	98US-0100664P.	PR	03-NOV-1998;	98US-0108902P.
PR	17-SEP-1998;	98US-0100683P.	PR	03-NOV-1998;	98US-0108905P.
PR	17-SEP-1998;	98US-0100684P.	PR	03-NOV-1998;	98US-0106919P.
PR	17-SEP-1998;	98US-0100710P.	PR	03-NOV-1998;	98US-0106932P.
PR	17-SEP-1998;	98US-0100711P.	PR	03-NOV-1998;	98US-0106934P.
PR	17-SEP-1998;	98US-0100819P.	PR	10-NOV-1998;	98US-0107783P.
PR	17-SEP-1998;	98US-0100830P.	PR	17-NOV-1998;	98US-0108775P.
PR	18-SEP-1998;	98US-0100848P.	PR	17-NOV-1998;	98US-0108779P.
PR	18-SEP-1998;	98US-0100849P.	PR	17-NOV-1998;	98US-0108787P.
PR	18-SEP-1998;	98US-0101014P.	PR	17-NOV-1998;	98US-0108788P.
PR	18-SEP-1998;	98US-0101068P.	PR	17-NOV-1998;	98US-0108801P.
PR	18-SEP-1998;	98US-0101071P.	PR	17-NOV-1998;	98US-0108802P.
PR	22-SEP-1998;	98US-0101279P.	PR	17-NOV-1998;	98US-0108808P.
PR	23-SEP-1998;	98US-0101471P.	PR	17-NOV-1998;	98US-0108807P.
PR	23-SEP-1998;	98US-0101472P.	PR	17-NOV-1998;	98US-0108867P.
PR	23-SEP-1998;	98US-0101474P.	PR	17-NOV-1998;	98US-0108925P.
PR	23-SEP-1998;	98US-0101475P.	PR	18-NOV-1998;	98US-0108848P.
PR	23-SEP-1998;	98US-0101476P.	PR	18-NOV-1998;	98US-0108849P.
PR	23-SEP-1998;	98US-0101477P.	PR	18-NOV-1998;	98US-0108850P.
PR	23-SEP-1998;	98US-0101479P.	PR	18-NOV-1998;	98US-0108851P.
PR	24-SEP-1998;	98US-0101738P.	PR	18-NOV-1998;	98US-0108852P.
PR	24-SEP-1998;	98US-0101741P.	PR	18-NOV-1998;	98US-0108858P.
PR	24-SEP-1998;	98US-0101743P.	PR	18-NOV-1998;	98US-0108904P.
PR	24-SEP-1998;	98US-0101915P.	XX		
PR	24-SEP-1998;	98US-0101916P.	PA	(GETH) GENENTECH INC.	
PR	29-SEP-1998;	98US-0102207P.	XX		
PR	29-SEP-1998;	98US-0102240P.	PI	Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;	
PR	29-SEP-1998;	98US-0102307P.	XX	WPI; 2000-237871/20.	
PR	29-SEP-1998;	98US-0102330P.	DR		
PR	29-SEP-1998;	98US-0102331P.	XX		
PR	30-SEP-1998;	98US-0102484P.	XX		
PR	30-SEP-1998;	98US-0102487P.	PT	New mammalian DNA sequences encoding transmembrane, receptor or secreted	
PR	30-SEP-1998;	98US-0102570P.	PT	PRO polypeptides, useful for screening of potential peptide or small	
PR	30-SEP-1998;	98US-0102571P.	PT	molecule inhibitors of the relevant receptor/ligand interactions.	
PR	01-OCT-1998;	98US-0102684P.	XX		
PR	01-OCT-1998;	98US-0102687P.	PS	Example 34; Page 402; 773pp; English.	
PR	02-OCT-1998;	98US-0102685P.	XX		
PR	06-OCT-1998;	98US-0103258P.	CC	AAA37022 to AAA37144 encode the new isolated human transmembrane	
PR	06-OCT-1998;	98US-0103449P.	CC	receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The	
PR	07-OCT-1998;	98US-0103314P.	CC	transmembrane and receptor PRO proteins can be used for screening of	
PR	07-OCT-1998;	98US-0103315P.	CC	potential peptide or small molecule inhibitors of the relevant	
PR	07-OCT-1998;	98US-0103328P.	CC	receptor/ligand interactions. The polypeptides and nucleotide sequences	
PR	07-OCT-1998;	98US-0103395P.	CC	encoding then have various industrial applications, including uses as	
PR	07-OCT-1998;	98US-0103396P.	CC	pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent PCR	
PR	07-OCT-1998;	98US-0103401P.	CC	primers and hybridisation probes used in the isolation of the PRO	
PR	08-OCT-1998;	98US-0103678P.	CC	polypeptides from the present invention	
PR	08-OCT-1998;	98US-0103679P.	XX		
PR	08-OCT-1998;	98US-0103711P.	SQ	Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;	
PR	14-OCT-1998;	98US-0104257P.			
PR	20-OCT-1998;	98US-0104987P.			
PR	20-OCT-1998;	98US-0105000P.			
PR	20-OCT-1998;	98US-0105002P.			
PR	21-OCT-1998;	98US-0105104P.			
PR	22-OCT-1998;	98US-0105169P.			
PR	26-OCT-1998;	98US-0105693P.			
					Query Match 0.4%; Score 17.4; DB 1; Length 21;
					Best Local Similarity 94.7%; Pred. No. 1.7e+02;
					Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	1447	CAGCAGCAACAGCAGCAGC 1465			
DB	20	CAGGAGCAACAGCAGCAGC 2			

```
RESULT 107
AAC73260
ID AAC73260 standard; DNA; 21 BP.
XX
XX
AC AAC73260;
XX
DT 02-FEB-2001 (first entry)
XX
DE SNP flanking sequence #48 used in multiplexing PCR/SBE assay.
XX
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
XX polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
XX
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
XX WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
XX Example 7; Page 52; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one such polymorphic locus
CC used in the present invention. The amplified nucleic acid product is then
CC used as a template in a SBE reaction with an extension primer. The SBE
CC reaction products are used to form the oligonucleotide array. Note: This
CC sequence includes a SNP represented by the degenerate codon in the
CC sequence
XX
SQ Sequence 21 BP; 8 A; 5 C; 7 G; 0 T; 0 U; 1 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1472 AGAAGACGACGACGACGACGACG 1492
DB 1 AGGACAGGCAKACGAGGACGACG 21

RESULT 108
AAF54275/C
ID AAF54275 standard; DNA; 21 BP.
XX
XX
AC AAF54275;
XX
DT 02-APR-2001 (first entry)
XX
DE Primer #26 used in the identification of proteins.
XX
XX Secreted; transmembrane; gene therapy; ss.
XX

OS Unidentified.
XX
PN WO200078961-A1.
XX
XX
PD 28-DEC-2000.
XX
PF 18-FEB-2000; 2000WO-US004342.
XX
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 29-OCT-1999; 99US-0162508P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2001-071395/08.
XX
PT Secreted and transmembrane proteins and nucleic acids designated PRO.
PT useful as hybridization probes, in chromosome and gene mapping and gene
PT therapy.
XX
XX Example 34; Page 416; 787pp; English.
XX
CC The present invention relates to secreted and transmembrane proteins.
CC These proteins and the DNA encoding them may be used as hybridization
CC probes, in chromosome and gene mapping and in the generation of anti-
CC sense RNA and DNA. They may also be used to generate either for
CC transgenic animals or knockout animals which are in turn useful for
CC development and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy
XX
SQ Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACGACGACGACG 1465
DB 20 CAGGAGCAACGACGACGACG 2

RESULT 109
ACD68312/C
ID ACD68312 standard; DNA; 21 BP.
XX
XX
AC ACD68312;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein related primer #23.
XX
KW Human; secreted and transmembrane protein; PRO; angiogenesis;
KW endothelial cell proliferation; wound healing; immune response;
KW T-lymphocytes proliferation; neonatal heart hypertrophy; tumour;
KW cardiac insufficiency disorder; calcium flux; inflammation;
KW vascular endothelial growth factor-stimulated proliferation;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW nephropathy; Schanlein-Henoch purpura; celiac disease; Crohn's disease;
KW dermatitis herpetiformis; diabetes; haemoglobin switch; insulinemia;
KW pancreatic beta-cell precursor cell differentiation; thalassemias;
KW obesity; auditory hair cell regeneration; hearing loss; bone disorder;
KW
```

KW cartilage disorder; sports injury; arthritis; PCR; primer; ss.

XX OS Homo sapiens.

XX PN US2003073130-A1.

XX XX

XX PD 17-APR-2003.

XX PF 11-DEC-2001; 2001US-00015869.

XX PR 01-SEP-1998; 98US-0098716P.

PR 01-SEP-1998; 98US-0098723P.

PR 01-SEP-1998; 98US-0098749P.

PR 01-SEP-1998; 98US-0098750P.

PR 02-SEP-1998; 98US-0098803P.

PR 02-SEP-1998; 98US-0098821P.

PR 02-SEP-1998; 98US-0098843P.

PR 09-SEP-1998; 98US-0098936P.

PR 09-SEP-1998; 98US-0098959P.

PR 09-SEP-1998; 98US-0099602P.

PR 09-SEP-1998; 98US-0099642P.

PR 10-SEP-1998; 98US-0099741P.

PR 10-SEP-1998; 98US-0099754P.

PR 10-SEP-1998; 98US-0099792P.

PR 10-SEP-1998; 98US-0099808P.

PR 10-SEP-1998; 98US-0099812P.

PR 10-SEP-1998; 98US-0099815P.

PR 15-SEP-1998; 98US-0099816P.

PR 15-SEP-1998; 98US-0100385P.

PR 15-SEP-1998; 98US-0100388P.

PR 15-SEP-1998; 98US-0100390P.

PR 16-SEP-1998; 98US-0100384P.

PR 16-SEP-1998; 98US-0100627P.

PR 16-SEP-1998; 98US-0100661P.

PR 16-SEP-1998; 98US-0100662P.

PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.

PR 17-SEP-1998; 98US-0100684P.

PR 17-SEP-1998; 98US-0100710P.

PR 17-SEP-1998; 98US-0100711P.

PR 17-SEP-1998; 98US-0100910P.

PR 17-SEP-1998; 98US-0100930P.

PR 18-SEP-1998; 98US-0100848P.

PR 18-SEP-1998; 98US-0100849P.

98US-0103258P.

98US-0103449P.

98US-0103314P.

98US-0103315P.

98US-0103328P.

98US-0103395P.

98US-0103396P.

98US-0103401P.

98US-0103633P.

98US-0103678P.

98US-0103679P.

98US-0103711P.

98US-0104257P.

98US-0104987P.

98US-0105000P.

98US-0105002P.

98US-0105104P.

98US-0105169P.

98US-0105266P.

98US-0105693P.

98US-0105694P.

98US-0105807P.

98US-0105881P.

98US-0105882P.

98US-0106062P.

98US-0106023P.

98US-0106023P.

98US-0106030P.

98US-0106032P.

98US-0106033P.

98US-0106178P.

98US-0106248P.

98US-0106384P.

98US-0108500P.

98US-0106464P.

98US-0106856P.

98US-0106902P.

98US-0106905P.

98US-0106913P.

98US-0106932P.

98US-0106934P.

98US-0107783P.

98US-0108775P.

98US-0108779P.

98US-0108787P.

98US-0108788P.

98US-0108801P.

98US-0108802P.

98US-0108806P.

98US-0108807P.

98US-0108867P.

98US-0108925P.

98US-0108848P.

98US-0108849P.

98US-0108850P.

98US-0108851P.

98US-0108852P.

98US-0108858P.

98US-0108904P.

98US-0113296P.

98US-0114223P.

99WO-US000106.

98US-0129674P.

99US-0141037P.

99US-0144758P.

99WO-US020111.

99WO-US021194.

99US-0162506P.

99WO-US028313.

99WO-US028551.

99WO-US030095.

2000WO-US000219.

PR 06-OCT-1998;

PR 06-OCT-1998;

PR 07-OCT-1998;

PR 07-OCT-1998;

PR 07-OCT-1998;

PR 07-OCT-1998;

PR 07-OCT-1998;

PR 07-OCT-1998;

PR 08-OCT-1998;

PR 08-OCT-1998;

PR 08-OCT-1998;

PR 08-OCT-1998;

PR 14-OCT-1998;

PR 20-OCT-1998;

PR 20-OCT-1998;

PR 20-OCT-1998;

PR 21-OCT-1998;

PR 22-OCT-1998;

PR 22-OCT-1998;

PR 26-OCT-1998;

PR 26-OCT-1998;

PR 27-OCT-1998;

PR 27-OCT-1998;

PR 27-OCT-1998;

PR 28-OCT-1998;

PR 28-OCT-1998;

PR 28-OCT-1998;

PR 29-OCT-1998;

PR 29-OCT-1998;

PR 29-OCT-1998;

PR 30-OCT-1998;

PR 03-NOV-1998;

PR 03-NOV-1998;

PR 03-NOV-1998;

PR 03-NOV-1998;

PR 03-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 17-NOV-1998;

PR 18-NOV-1998;

PR 18-NOV-1998;

PR 18-NOV-1998;

PR 18-NOV-1998;

PR 18-NOV-1998;

PR 18-NOV-1998;

PR 18-NOV-1998;

PR 22-DEC-1998;

PR 22-DEC-1998;

PR 05-JAN-1999;

PR 16-APR-1999;

PR 23-JUN-1999;

PR 20-JUL-1999;

PR 26-JUL-1999;

PR 01-SEP-1999;

PR 15-SEP-1999;

PR 29-OCT-1999;

PR 30-NOV-1999;

PR 02-DEC-1999;

PR 16-DEC-1999;

PR 05-JAN-2000;


```
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004342.
PR 24-FEB-2000; 2000WO-US0005004.
PR 02-MAR-2000; 2000WO-US0005841.
PR 15-MAR-2000; 2000WO-US0006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US0006520.
PR 01-MAR-2001; 2001WO-US0006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-585293/55.
XX
PT Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 that modulate glucose or free fatty acid uptake by skeletal
PT muscle cells, and are useful for treating diabetes, hyper- or hypo-
PT insulinemia.
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2
|||||
RESULT 110
ACH04414/C
XX ACH04414 standard; DNA; 21 BP.
XX ACH04414;
AC ACH04414;
XX ACH04414;
DT 01-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; vulnery;
KW cardiant; antidiabetic; anorectic; antiarthritic; angiogenesis; cancer;
KW adrenal cortical capillary; endothelial cell growth; wound healing;
KW stimulated T-lymphocyte proliferation; immune response suppression;
KW neonatal heart hypertrophy; cardiac insufficiency disorder;
KW vascular endothelial growth factor; inflammation; mononuclear cell;
KW eosinophil; diabetes; obesity; or hyper-insulinaemia; hypo-insulinaemia;
KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW sports injury; arthritis; primer.
XX
OS Homo sapiens.
XX
PN US2003044841-A1.
XX
PD 06-MAR-2003.
XX
PF 06-DEC-2001; 2001US-00006856.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-010207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-010248P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
```

PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX (GETH) GENENTECH INC.
PA
XX
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-492259/46.
XX
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating various cardiac insufficiency
PT disorders, bone and/or cartilage disorders such as sports injuries and
PT arthritis.
XX
Query Match ~ 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2
|||||||
RESULT 111
ACD67958/c
ID ACD67958 standard; DNA; 21 BP.
XX
AC ACD67958;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein related primer #23.
KW Human; secreted and transmembrane protein; PRO; gene therapy; vaccine;
KW tissue typing; chromosome identification; vaccine; PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX US2003073129-A1.
PN
XX
PD 17-APR-2003.
XX
PF 04-SEP-2001; 2001US-00946374.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.

PR 10-SEP-1998; 98US-00999754P.
 PR 10-SEP-1998; 98US-00999763P.
 PR 10-SEP-1998; 98US-00999792P.
 PR 10-SEP-1998; 98US-00999808P.
 PR 10-SEP-1998; 98US-00999812P.
 PR 10-SEP-1998; 98US-00999815P.
 PR 10-SEP-1998; 98US-00999816P.
 PR 15-SEP-1998; 98US-00999835P.
 PR 15-SEP-1998; 98US-01003388P.
 PR 15-SEP-1998; 98US-01003909P.
 PR 16-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.
 PR 16-SEP-1998; 98US-0100661P.
 PR 16-SEP-1998; 98US-0100662P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100684P.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100711P.
 PR 17-SEP-1998; 98US-0100919P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 18-SEP-1998; 98US-0100848P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-01010168P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101279P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103396P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.

PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-00218517.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 98US-0114223P.
 PR 12-APR-1999; 98US-00284291.
 PR 16-APR-1999; 98US-0129674P.
 PR 23-JUN-1999; 98US-0141037P.
 PR 20-JUL-1999; 98US-0144758P.
 PR 26-JUL-1999; 98US-0145698P.
 PR 01-SEP-1999; 98US-0145698P.
 PR 15-SEP-1999; 98US-0020111.
 PR 15-SEP-1999; 98US-0020119.
 PR 18-OCT-1999; 98US-00403297.
 PR 30-NOV-1999; 98US-0028313.
 PR 02-DEC-1999; 98US-0028313.
 PR 16-DEC-1999; 98US-0030095.
 PR 05-JAN-2000; 98US-0030095.
 PR 06-JAN-2000; 98US-0030095.
 PR 11-FEB-2000; 98US-0030376.
 PR 18-FEB-2000; 98US-0030376.
 PR 24-FEB-2000; 98US-0030376.
 PR 02-MAR-2000; 98US-0030376.
 PR 15-MAR-2000; 98US-0030376.
 PR 17-MAY-2000; 98US-0030376.
 PR 22-MAY-2000; 98US-0030376.
 PR 30-MAY-2000; 98US-0030376.
 PR 02-JUN-2000; 98US-0030376.
 PR 23-AUG-2000; 98US-0030376.
 PR 24-AUG-2000; 98US-0030376.
 PR 08-NOV-2000; 98US-0030376.
 PR 10-NOV-2000; 98US-0030376.
 PR 01-DEC-2000; 98US-0030376.
 PR 28-FEB-2001; 98US-0030376.
 PR 01-MAR-2001; 98US-0030376.
 PR 01-JUN-2001; 98US-0030376.
 PR 01-JUN-2001; 98US-0030376.
 PR 14-JUN-2001; 98US-0030376.

```
PR 20-JUN-2001; 2001WO-US019692. 98US-0100385P.
PR 29-JUN-2001; 2001WO-US021066. 98US-0100388P.
PR 09-JUL-2001; 2001WO-US021735. 98US-0100390P.
XX PA (GETH ) GENENTECH INC. 98US-0100584P.
XX 98US-0100627P.
XX 98US-0100661P.
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S; 98US-0100662P.
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ; 98US-0100664P.
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK; 98US-0100683P.
PI Williams PM, Wood WI; 98US-0100684P.
XX 98US-0100710P.
DR WPI; 2003-585292/55. 98US-0100711P.
XX 98US-0100919P.
XX Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the 98US-0100930P.
PT preparation of a medicament for treating a condition responsive to PRO 98US-0100848P.
PT polypeptide, and as therapeutic agents e.g. vaccines. 98US-0100849P.
XX Example 34; Page 235; 561pp; English. 98US-0101014P.
XX The invention describes an isolated PRO (secreted and transmembrane) 98US-0101068P.
CC polypeptide (I), having at least 80% sequence identity to a sequence 98US-0101071P.
CC selected from any one of the 123 amino acid sequences given in 98US-0101279P.
Query Match 0.4%; Score 17.4; DB 1; Length 21; 98US-0101471P.
Best Local Similarity 94.7%; Pred. No. 1.7e+02; 98US-0101472P.
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0; 98US-0101474P.
98US-0101475P.
QY 1447 CAGCAGCACAGCAGCAGC 1465 98US-0101477P.
DB ||||| 98US-0101479P.
||| 98US-0101738P.
||| 98US-0101743P.
||| 98US-0101743P.
||| 98US-0101915P.
||| 98US-0101916P.
||| 98US-0102207P.
||| 98US-0102240P.
||| 98US-0102330P.
||| 98US-0102331P.
||| 98US-0102484P.
||| 98US-0102487P.
||| 98US-0102570P.
||| 98US-0102571P.
||| 98US-0102684P.
||| 98US-0102687P.
||| 98US-0102965P.
||| 98US-0103258P.
||| 98US-0103449P.
||| 98US-0103314P.
||| 98US-0103315P.
||| 98US-0103328P.
||| 98US-0103395P.
||| 98US-0103396P.
||| 98US-0103401P.
||| 98US-0103633P.
||| 98US-0103678P.
||| 98US-0103679P.
||| 98US-0103711P.
||| 98US-0104257P.
||| 98US-0104987P.
||| 98US-0105000P.
||| 98US-0105002P.
||| 98US-0105002P.
||| 98US-0105169P.
||| 98US-0105266P.
||| 98US-0105693P.
||| 98US-0105694P.
||| 98US-0105807P.
||| 98US-0105881P.
||| 98US-0105882P.
||| 98US-0106026P.
||| 98US-0106023P.
||| 98US-0106023P.
||| 98US-0106030P.
||| 98US-0106032P.
RESULT 112
ADCL1974/C
ID ADC1974 standard; DNA; 21 BP.
XX AC ADC1974;
XX AC
XX DT 18-DEC-2003 (first entry)
XX DE Human PRO PCR primer #26.
XX KW Human; PRO; PCR; ss; protein electrophoresis; chromosome mapping;
XX KW gene mapping; genetic disorder; primer.
XX OS Homo sapiens.
XX PN US2003064925-A1.
XX PD 03-APR-2003.
XX PF 10-DEC-2001; 2001US-00013907.
XX PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099753P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
```

```
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US0201194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US005520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX Williams PM, Wood WI;
```

```
XX WPI; 2003-555602/52.
XX Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
XX preparation of a medicament for treating a condition responsive to PRO
XX polypeptide, and as therapeutic agents e.g. vaccines.
XX Example 34; SEQ ID NO 105; 555pp; English.
XX The invention relates to human PRO polypeptides and the polynucleotides
XX encoding them. The sequences are useful in the preparation of a
XX medicament for treating a condition responsive to a PRO polypeptide. The
XX polypeptides are useful in a number of functional biological assays, as
XX molecular weight markers for protein electrophoresis and as therapeutic
XX agents. The polynucleotides are useful as hybridisation probes for a cDNA

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2

RESULT 113
ADD70620/c
ID ADD70620 standard; DNA; 21 BP.
XX AC ADD70620;
XX DT 15-JAN-2004 (first entry)
XX DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX OS Homo sapiens.
XX US2003099625-A1.
XX 29-MAY-2003.
XX 12-DEC-2001; 2001US-00015386.
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
```

PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.

PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 03-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99WO-US020111.
PR 29-OCT-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillian KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams FM, Wood WI;
XX WPI; 2003-874602/81.
XX

PT Novel isolated PRO polypeptides e.g., PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
XX cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
PS Example 34; SEQ ID NO 105; 553pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2

RESULT 114
ADD39697/c
ID ADD39697 standard; DNA; 21 BP.
XX
AC ADD39697;
XX
DT 15-JAN-2004 (first entry)
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
OS Homo sapiens.
XX
XX US2003083462-A1.
PN
XX
PD 01-MAY-2003.
XX
XX
PF 10-DEC-2001; 2001US-00013913.
XX
PR 05-JAN-1999; 99WO-US000106.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 28-JUN-2001; 2001WO-US019692.
PR 23-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX

(GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WJ;
XX WPI; 2003-755122/71.
XX
XX New secreted and transmembrane PRO polypeptides useful for treating
PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
PT hypo-insulinemia, sports injuries and arthritis.
XX
XX Example 34; SEQ ID NO 105; 557pp; English.
PS
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimaeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassaemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.
XX
XX Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2

RESULT 115
ADD70143/c
ID ADD70143 standard; DNA; 21 BP.
XX
XX ADD70143;
XX
DT 15-JAN-2004 (first entry)
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;

KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX Homo sapiens.
OS US2003054406-A1.
XX 20-MAR-2003.
XX 06-DEC-2001; 2001US-00006818.
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101379P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108464P.
PR 30-OCT-1998; 98US-0108466P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 98US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 16-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.


```
PR 05-JAN-2000; 2000WO-US0000219.
PR 06-JAN-2000; 2000WO-US0000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004342.
PR 24-FEB-2000; 2000WO-US0005004.
PR 02-MAR-2000; 2000WO-US0005841.
PR 15-MAR-2000; 2000WO-US0006884.
PR 17-MAY-2000; 2000WO-US0113705.
PR 22-MAY-2000; 2000WO-US0114042.
PR 30-MAY-2000; 2000WO-US0114941.
PR 02-JUN-2000; 2000WO-US0115264.
PR 23-AUG-2000; 2000WO-US0235222.
PR 24-AUG-2000; 2000WO-US0233328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-708344/67.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
PS Example 34; SEQ ID NO 105; 549pp; English.
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. NO. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCACAGCAGCAGC 1465
DB 20 CAGGAGCACAGCAGCAGC 2
RESULT 116
ID ADD38264/C
XX ID ADD38264 standard; DNA; 21 BP.
XX
AC ADD38264;
DT
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003096955-A1.
XX
PD 22-MAY-2003.
XX
07-DEC-2001; 2001US-00012755.
01-SEP-1998; 98US-0098716P.
01-SEP-1998; 98US-0098723P.
01-SEP-1998; 98US-0098749P.
01-SEP-1998; 98US-0098750P.
02-SEP-1998; 98US-0098803P.
02-SEP-1998; 98US-0098821P.
02-SEP-1998; 98US-0098843P.
09-SEP-1998; 98US-0099536P.
09-SEP-1998; 98US-0099598P.
09-SEP-1998; 98US-0099602P.
09-SEP-1998; 98US-0099642P.
10-SEP-1998; 98US-0099741P.
10-SEP-1998; 98US-0099754P.
10-SEP-1998; 98US-0099763P.
10-SEP-1998; 98US-0099792P.
10-SEP-1998; 98US-0099808P.
10-SEP-1998; 98US-0099812P.
10-SEP-1998; 98US-0099815P.
15-SEP-1998; 98US-0099816P.
15-SEP-1998; 98US-0100388P.
15-SEP-1998; 98US-0100390P.
16-SEP-1998; 98US-0100584P.
16-SEP-1998; 98US-0100627P.
16-SEP-1998; 98US-0100661P.
16-SEP-1998; 98US-0100662P.
17-SEP-1998; 98US-0100664P.
17-SEP-1998; 98US-0100683P.
17-SEP-1998; 98US-0100684P.
17-SEP-1998; 98US-0100710P.
17-SEP-1998; 98US-0100711P.
17-SEP-1998; 98US-0100913P.
17-SEP-1998; 98US-0100930P.
18-SEP-1998; 98US-0100848P.
18-SEP-1998; 98US-0100849P.
18-SEP-1998; 98US-0101014P.
18-SEP-1998; 98US-0101068P.
18-SEP-1998; 98US-0101071P.
22-SEP-1998; 98US-0101279P.
23-SEP-1998; 98US-0101471P.
23-SEP-1998; 98US-0101472P.
23-SEP-1998; 98US-0101474P.
23-SEP-1998; 98US-0101475P.
23-SEP-1998; 98US-0101476P.
23-SEP-1998; 98US-0101477P.
24-SEP-1998; 98US-0101479P.
24-SEP-1998; 98US-0101738P.
24-SEP-1998; 98US-0101741P.
24-SEP-1998; 98US-0101915P.
24-SEP-1998; 98US-0101916P.
29-SEP-1998; 98US-0102207P.
29-SEP-1998; 98US-0102240P.
29-SEP-1998; 98US-0102307P.
29-SEP-1998; 98US-0102330P.
29-SEP-1998; 98US-0102331P.
30-SEP-1998; 98US-0102484P.
30-SEP-1998; 98US-0102487P.
30-SEP-1998; 98US-0102570P.
30-SEP-1998; 98US-0102571P.
01-OCT-1998; 98US-0102684P.
01-OCT-1998; 98US-0102687P.
02-OCT-1998; 98US-0102963P.
06-OCT-1998; 98US-0103258P.
06-OCT-1998; 98US-0103449P.
07-OCT-1998; 98US-0103314P.
07-OCT-1998; 98US-0103315P.
07-OCT-1998; 98US-0103328P.
07-OCT-1998; 98US-0103395P.
07-OCT-1998; 98US-0103396P.
```

PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0108500P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 10-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108825P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 15-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 26-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 15-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021194.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PW, Wood WI;
 XX WPI; 2003-787000/74.
 DR Novel isolated PRO polypeptide, useful for treating cancerous tumors,
 PT cardiac insufficiency disorders, wound healing, diabetes mellitus,
 PT thalassemias.
 XX Example 34; SEQ ID NO 105; 556pp; English.
 XX The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as

Query Match 0.4%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 94.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
 DB 20 CAGGAGCAACAGCAGCAGC 2

RESULT 117
 ADD39220/C
 ID ADD39220 standard; DNA; 21 BP.
 XX
 AC ADD39220;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
 XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schönlein-Henoch purpura; coliac disease;
 KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
 XX Homo sapiens.
 XX US2003096954-A1.
 PD 22-MAY-2003.
 XX
 PF 07-DEC-2001; 2001US-00011671.
 XX
 PR 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.

PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098536P.
PR 09-SEP-1998; 98US-0098596P.
PR 09-SEP-1998; 98US-0098598P.
PR 09-SEP-1998; 98US-0098602P.
PR 09-SEP-1998; 98US-0098642P.
PR 10-SEP-1998; 98US-0098741P.
PR 10-SEP-1998; 98US-0098754P.
PR 10-SEP-1998; 98US-0098763P.
PR 10-SEP-1998; 98US-0098792P.
PR 10-SEP-1998; 98US-0098808P.
PR 10-SEP-1998; 98US-0098812P.
PR 10-SEP-1998; 98US-0098815P.
PR 10-SEP-1998; 98US-0098816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100394P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100819P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.

PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106026P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0108902P.
PR 03-NOV-1998; 98US-0108905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.

```
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-786999/74.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
XX Example 34; SEQ ID NO 105; 550pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2
RESULT 118
ADD38743/c
ID ADD38743 standard; DNA; 21 BP.
XX
AC ADD38743;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX
OS Homo sapiens.
XX
XX US2003092061-A1.
XX
XX 15-MAY-2003.
XX
XX 06-DEC-2001; 2001US-00007194.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-010207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 21-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
```

```
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US0005520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-765477/72.
XX
XX New isolated PRO polypeptide such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1244, PRO1246, useful for treating cancerous tumors, cardiac
PT insufficiency disorders, wound healing, Crohn's disease, celiac disease.
XX
XX Example 34; SEQ ID NO 105; 555pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2
||| ||||| ||||| |||||
||| ||||| ||||| |||||

RESULT 119
ADD40174/C
ID ADD40174 standard; DNA; 21 BP.
XX
AC ADD40174;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; celiac disease;
KW dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX US2003082627-A1.
XX
XX 01-MAY-2003.
XX
XX 06-DEC-2001; 2001US-00006117.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
```

PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 20-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.

PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX (GETH) GENENTECH INC.
PA Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2003-755104/71.
XX
XX
XX New isolated PRO polypeptides such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1444, PRO1246, are useful for treating cancerous tumors and cardiac
PT insufficiency disorders.
XX
XX Example 34; SEQ ID NO 105; 550pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
||| ||||| ||||| |||||
Db 20 CAGGAGCAACAGCAGCAGC 2

RESULT 120
ADE50395/c
ID ADE50395 standard; DNA; 21 BP.
XX
AC ADE50395;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX US2003069179-A1.
XX
XX 10-APR-2003.
XX
XX 11-DEC-2001; 2001US-00015393.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.

PR	30-OCT-1998;	98US-0106464P.	PT	polypeptide and as therapeutic agents e.g. vaccines.
PR	03-NOV-1998;	98US-0106856P.	PS	Example 34; SEQ ID NO 105; 555pp; English.
PR	03-NOV-1998;	98US-0106902P.	XX	The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity
PR	03-NOV-1998;	98US-0106905P.	CC	
PR	03-NOV-1998;	98US-0106919P.	Query Match	0.4%; Score 17.4; DB 1; Length 21;
PR	03-NOV-1998;	98US-0106932P.	Best Local Similarity	94.7%; Pred. No. 1.7e+02;
PR	03-NOV-1998;	98US-0106934P.	Matches 18; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
PR	10-NOV-1998;	98US-0107783P.	QY	1447 CAGCAGCAACAGCAGCAGC 1465
PR	17-NOV-1998;	98US-0108775P.	Db	20 CAGGAGCAACAGCAGCAGC 2
PR	17-NOV-1998;	98US-0108779P.	RESULT 121	
PR	17-NOV-1998;	98US-0108787P.	ADE20007/c	
PR	17-NOV-1998;	98US-0108788P.	ID	ADE20007 standard; DNA; 21 BP.
PR	17-NOV-1998;	98US-0108801P.	XX	AC ADE20007;
PR	17-NOV-1998;	98US-0108802P.	XX	29-JAN-2004 (first entry)
PR	17-NOV-1998;	98US-0108806P.	XX	Human secreted/transmembrane protein PRO1315 PCR primer #1.
PR	17-NOV-1998;	98US-0108807P.	XX	Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
PR	17-NOV-1998;	98US-0108867P.	XX	immune response; cardiac insufficiency disorder; calcium flux;
PR	17-NOV-1998;	98US-0108867P.	KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;
PR	18-NOV-1998;	98US-0108848P.	KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
PR	18-NOV-1998;	98US-0108849P.	KW	Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
PR	18-NOV-1998;	98US-0108850P.	KW	dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
PR	18-NOV-1998;	98US-0108851P.	XX	
PR	18-NOV-1998;	98US-0108852P.	OS	Homo sapiens.
PR	18-NOV-1998;	98US-0108858P.	XX	US2003092883-A1.
PR	18-NOV-1998;	98US-0108904P.	XX	15-MAY-2003.
PR	23-DEC-1998;	98US-0113296P.	PD	10-DEC-2001; 2001US-00013430.
PR	30-DEC-1998;	98US-0114232P.	XX	01-SEP-1998; 98US-0098716P.
PR	05-JAN-1999;	99WO-US000106.	PR	01-SEP-1998; 98US-0098723P.
PR	16-APR-1999;	99US-0129674P.	PR	01-SEP-1998; 98US-0098749P.
PR	23-JUN-1999;	99US-0141037P.	PR	01-SEP-1998; 98US-0098750P.
PR	20-JUL-1999;	99US-0144758P.	PR	02-SEP-1998; 98US-0098803P.
PR	26-JUL-1999;	99US-0145698P.	PR	02-SEP-1998; 98US-0098821P.
PR	01-SEP-1999;	99WO-US020111.	PR	02-SEP-1998; 98US-0098843P.
PR	15-SEP-1999;	99WO-US021194.	PR	02-SEP-1998; 98US-0099536P.
PR	30-OCT-1999;	99US-0162506P.	PR	09-SEP-1998; 98US-0099596P.
PR	30-NOV-1999;	99WO-US028313.	PR	09-SEP-1998; 98US-0099598P.
PR	02-DEC-1999;	99WO-US028551.	PR	09-SEP-1998; 98US-0099602P.
PR	16-DEC-1999;	99WO-US030095.	PR	09-SEP-1998; 98US-0099642P.
PR	05-JAN-2000;	2000WO-US000219.	PR	09-SEP-1998; 98US-0099741P.
PR	06-JAN-2000;	2000WO-US000376.	PR	10-SEP-1998; 98US-0099754P.
PR	11-FEB-2000;	2000WO-US003565.	PR	10-SEP-1998; 98US-0099763P.
PR	18-FEB-2000;	2000WO-US004342.	PR	10-SEP-1998; 98US-0099792P.
PR	24-FEB-2000;	2000WO-US005041.	PR	10-SEP-1998; 98US-0099808P.
PR	02-MAR-2000;	2000WO-US005841.	PR	10-SEP-1998; 98US-0099812P.
PR	15-MAR-2000;	2000WO-US006584.	PR	10-SEP-1998; 98US-0099815P.
PR	17-MAY-2000;	2000WO-US013705.	PR	10-SEP-1998; 98US-0099816P.
PR	22-MAY-2000;	2000WO-US014042.	PR	15-SEP-1998; 98US-0100385P.
PR	30-MAY-2000;	2000WO-US014941.	PR	15-SEP-1998; 98US-0100388P.
PR	02-JUN-2000;	2000WO-US015264.	PR	15-SEP-1998; 98US-0100390P.
PR	23-AUG-2000;	2000WO-US023522.	PR	16-SEP-1998; 98US-0100584P.
PR	24-AUG-2000;	2000WO-US023328.	PR	16-SEP-1998; 98US-0100627P.
PR	08-NOV-2000;	2000WO-US030952.	PR	16-SEP-1998; 98US-0100661P.
PR	10-NOV-2000;	2000WO-US030873.	PR	16-SEP-1998; 98US-0100662P.
PR	01-DEC-2000;	2000WO-US032678.	PR	16-SEP-1998; 98US-0100664P.
PR	28-FEB-2001;	2001WO-US006520.	PR	17-SEP-1998; 98US-0100683P.
PR	01-MAR-2001;	2001WO-US006666.	PR	17-SEP-1998; 98US-0100684P.
PR	01-JUN-2001;	2001WO-US017800.	PR	17-SEP-1998; 98US-0100710P.
PR	20-JUN-2001;	2001WO-US016692.	PR	17-SEP-1998; 98US-0100711P.
PR	29-JUN-2001;	2001WO-US021066.		
PR	09-JUL-2001;	2001WO-US021735.		
PR	04-SEP-2001;	2001US-00946374.		
XX	(GETH) GENENTECH INC.			
PA	Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;			
XX	Pi Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;			
PI	Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;			
PI	Williams PM, Wood WI;			
XX	WPI; 2003-708395/67.			
XX	Novel secreted and transmembrane PRO polypeptides useful in the			
PT	preparation of a medicament for treating a condition responsive to PRO			


```
Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGGAGCAACAGCAGCAGC 2

RESULT 122
ADE49918/C
ID      ADE49918 standard; DNA; 21 BP.
XX
AC      ADE49918;
XX
DT      29-JAN-2004 (first entry)
XX
DE      Human secreted/transmembrane protein PRO315 PCR primer #1.
XX
KW      Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW      immune response; cardiac insufficiency disorder; calcium flux;
KW      umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW      arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW      Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW      dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
XX
OS      Homo sapiens.
XX
XX      US2003082626-A1.
PN
PD      01-MAY-2003.
XX
XX      06-DEC-2001; 2001US-00006116.
XX
PR      01-SEP-1998; 98US-0098716P.
PR      01-SEP-1998; 98US-0098723P.
PR      01-SEP-1998; 98US-0098749P.
PR      01-SEP-1998; 98US-0098750P.
PR      02-SEP-1998; 98US-0098803P.
PR      02-SEP-1998; 98US-0098821P.
PR      02-SEP-1998; 98US-0098843P.
PR      09-SEP-1998; 98US-00989536P.
PR      09-SEP-1998; 98US-00989598P.
PR      09-SEP-1998; 98US-00989602P.
PR      09-SEP-1998; 98US-00989642P.
PR      10-SEP-1998; 98US-00989741P.
PR      10-SEP-1998; 98US-00989754P.
PR      10-SEP-1998; 98US-00989763P.
PR      10-SEP-1998; 98US-00989808P.
PR      10-SEP-1998; 98US-00989812P.
PR      10-SEP-1998; 98US-00989815P.
PR      10-SEP-1998; 98US-00989816P.
PR      15-SEP-1998; 98US-01003885P.
PR      15-SEP-1998; 98US-0100390P.
PR      16-SEP-1998; 98US-0100584P.
PR      16-SEP-1998; 98US-0100627P.
PR      16-SEP-1998; 98US-0100661P.
PR      16-SEP-1998; 98US-0100662P.
PR      16-SEP-1998; 98US-0100663P.
PR      17-SEP-1998; 98US-0100683P.
PR      17-SEP-1998; 98US-0100684P.
PR      17-SEP-1998; 98US-0100710P.
PR      17-SEP-1998; 98US-0100711P.
PR      17-SEP-1998; 98US-0100919P.
PR      18-SEP-1998; 98US-0100930P.
PR      18-SEP-1998; 98US-0100848P.
PR      18-SEP-1998; 98US-0100849P.
PR      18-SEP-1998; 98US-0101014P.
PR      18-SEP-1998; 98US-0101068P.
PR      18-SEP-1998; 98US-0101071P.
PR      22-SEP-1998; 98US-0101279P.
PR      23-SEP-1998; 98US-0101471P.
PR      23-SEP-1998; 98US-0101472P.
PR      23-SEP-1998; 98US-0101474P.
PR      23-SEP-1998; 98US-0101475P.
PR      23-SEP-1998; 98US-0101476P.
PR      23-SEP-1998; 98US-0101477P.
PR      23-SEP-1998; 98US-0101479P.
PR      24-SEP-1998; 98US-0101738P.
PR      24-SEP-1998; 98US-0101741P.
PR      24-SEP-1998; 98US-0101743P.
PR      24-SEP-1998; 98US-0101915P.
PR      24-SEP-1998; 98US-0101916P.
PR      29-SEP-1998; 98US-0102207P.
PR      29-SEP-1998; 98US-0102240P.
PR      29-SEP-1998; 98US-0102307P.
PR      29-SEP-1998; 98US-0102330P.
PR      29-SEP-1998; 98US-0102331P.
PR      30-SEP-1998; 98US-0102484P.
PR      30-SEP-1998; 98US-0102487P.
PR      30-SEP-1998; 98US-0102570P.
PR      30-SEP-1998; 98US-0102571P.
PR      01-OCT-1998; 98US-0102684P.
PR      01-OCT-1998; 98US-0102687P.
PR      02-OCT-1998; 98US-0102965P.
PR      06-OCT-1998; 98US-0103258P.
PR      06-OCT-1998; 98US-0103449P.
PR      07-OCT-1998; 98US-0103314P.
PR      07-OCT-1998; 98US-0103315P.
PR      07-OCT-1998; 98US-0103328P.
PR      07-OCT-1998; 98US-0103395P.
PR      07-OCT-1998; 98US-0103396P.
PR      07-OCT-1998; 98US-0103401P.
PR      08-OCT-1998; 98US-0103633P.
PR      08-OCT-1998; 98US-0103678P.
PR      08-OCT-1998; 98US-0103679P.
PR      08-OCT-1998; 98US-0103711P.
PR      14-OCT-1998; 98US-0104257P.
PR      20-OCT-1998; 98US-0104987P.
PR      20-OCT-1998; 98US-0105000P.
PR      20-OCT-1998; 98US-0105002P.
PR      21-OCT-1998; 98US-0105104P.
PR      22-OCT-1998; 98US-0105169P.
PR      22-OCT-1998; 98US-0105266P.
PR      26-OCT-1998; 98US-0105693P.
PR      26-OCT-1998; 98US-0105694P.
PR      27-OCT-1998; 98US-0105807P.
PR      27-OCT-1998; 98US-0105881P.
PR      27-OCT-1998; 98US-0105882P.
PR      27-OCT-1998; 98US-0106062P.
PR      28-OCT-1998; 98US-0106023P.
PR      28-OCT-1998; 98US-0106029P.
PR      28-OCT-1998; 98US-0106030P.
PR      28-OCT-1998; 98US-0106032P.
PR      28-OCT-1998; 98US-0106033P.
PR      28-OCT-1998; 98US-0106178P.
PR      29-OCT-1998; 98US-0106248P.
PR      29-OCT-1998; 98US-0106384P.
PR      29-OCT-1998; 98US-0108500P.
PR      30-OCT-1998; 98US-0108464P.
PR      03-NOV-1998; 98US-0108656P.
PR      03-NOV-1998; 98US-0106902P.
PR      03-NOV-1998; 98US-0106905P.
PR      03-NOV-1998; 98US-0106919P.
PR      03-NOV-1998; 98US-0106932P.
PR      03-NOV-1998; 98US-0106934P.
PR      10-NOV-1998; 98US-0107783P.
PR      17-NOV-1998; 98US-0108775P.
PR      17-NOV-1998; 98US-0108779P.
PR      17-NOV-1998; 98US-0108787P.
PR      17-NOV-1998; 98US-0108788P.
PR      17-NOV-1998; 98US-0108801P.
PR      17-NOV-1998; 98US-0108802P.
```

```
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX Williams PM, Wood WI;
XX
XX WPI; 2003-765413/72.
XX
XX Novel isolated PRO polypeptides useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2
```

RESULT 123

ADE21476/c

ID ADE21476 standard; DNA; 21 BP.

XX ADE21476;

AC ADE21476;

XX 29-JAN-2004 (first entry)

XX Human secreted/transmembrane protein PRO1315 PCR primer #1.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;

XX Immune response; cardiac insufficiency disorder; calcium flux;

KW Umbilical vein endothelial cell; bone disorder; cartilage disorder;

KW Arthritis; wound healing; diabetes; skeletal muscle cells; obesity;

KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;

KW Dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.

XX

OS Homo sapiens.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

```
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103349P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.

PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006686.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX (GETH ) GENENTECH INC.
PA Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski RJ, Grimaldi JC, Gurney AL, Hillen KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PW, Wood WI;
XX WPI; 2003-755105/71.
DR
XX
XX Novel secreted and transmembrane PRO polypeptides useful for treating
PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
PT hypo-insulinemia, sports injuries and arthritis.
XX
PS Example 34; SEQ ID NO 105; 548pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. NO. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2
||| ||||| ||||| |||||
RESULT 124
ADF29901/c
ID ADF29901 standard; DNA; 21 BP.
XX
AC ADF29901;
```

XX 12-FEB-2004 (first entry)
DT Human secreted/transmembrane protein PRO1315 PCR primer #1.
DE Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassaemia; ss.
XX
OS Homo sapiens.
XX
XX US2003204053-A1.
PN
XX 30-OCT-2003.
PD
XX
PF 10-DEC-2001; 2001US-00013915.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100819P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 29-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-NOV-1998; 98US-0106856P.
PR 30-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106903P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.


```
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Fan J, Faoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-567191/53.
XX
XX
XX Novel secreted and transmembrane polypeptide useful identifying agonists
PT or antagonists of polypeptide, as molecular weight markers, and in tissue
PT typing.
XX
XX Example 34; SEQ ID NO 105; 553bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCACAGCAGCAGC 1465
DB 20 CAGGAGCACAGCAGCAGC 2
RESULT 127
ADE96478/c
ID ADE96478 standard; DNA; 21 BP.
XX
```

```
AC ADE96478;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003195347-A1.
XX
XX 16-OCT-2003.
XX
XX 12-DEC-2001; 2001US-00015385.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 18-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101068P.
XX 18-SEP-1998; 98US-0101071P.
XX 22-SEP-1998; 98US-0101279P.
XX 23-SEP-1998; 98US-0101471P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101474P.
XX 23-SEP-1998; 98US-0101475P.
XX 23-SEP-1998; 98US-0101476P.
XX 23-SEP-1998; 98US-0101479P.
XX 24-SEP-1998; 98US-0101738P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101743P.
XX 24-SEP-1998; 98US-0101915P.
XX 24-SEP-1998; 98US-0101916P.
XX 29-SEP-1998; 98US-0102207P.
```



```
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 20-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105593P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108948P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108504P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.

PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX
XX
PA (GETH ) GENENTECH INC.
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PW, Wood WI;
XX
XX WPI; 2004-021098/02.
XX
PT New secreted and transmembrane PRO nucleic acid, for use in molecular
PT biology, chromosome and gene mapping, in generating antisense RNA and
PT DNA, in various diagnostic assays and in gene therapy.
XX
PS Example 34; SEQ ID NO 105; 552pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e-02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2

RESULT 128
ADP25789/c
ID ADF25789 standard; DNA; 21 BP.
XX
XX ADF25789;
AC
XX
XX 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
```

KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.

XX
OS Homo sapiens.
XX
XX
PN US2003199675-A1.
XX
PD 23-OCT-2003.
XX
XX 11-DEC-2001; 2001US-00015389.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098936P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100819P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108464P.
PR 03-NOV-1998; 98US-0108856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108789P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.


```
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103634P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104357P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106501P.
PR 30-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108948P.
PR 18-NOV-1998; 98US-0108949P.
PR 18-NOV-1998; 98US-0108950P.
PR 18-NOV-1998; 98US-0108951P.
PR 18-NOV-1998; 98US-0108952P.
PR 18-NOV-1998; 98US-0108958P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113266P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-041347/04.
XX
XX Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX Example 34; SEQ ID NO 105; 553pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Fred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2
|||||
|||||

RESULT 130
ADF29424/c
ID ADF29424 standard; DNA; 21 BP.
XX
XX ADF29424;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpetiformis; Crohn's disease; thalassaemia; ss.
XX
XX Homo sapiens.
XX
XX US2003203401-A1.
XX
XX 30-OCT-2003.
XX
XX 11-DEC-2001; 2001US-00015519.
XX
```

PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100583P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100931P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 22-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.

PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 14-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 20-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114221P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021134.
PR 29-OCT-1999; 99US-0162508P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003585.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

```
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WJ;
XX
XX WPI; 2004-041478/04.
XX
XX New isolated PRO polypeptide useful for tissue typing, modulating the
PT biological activity of a cell, as molecular weight markers in protein
PT electrophoresis, and for treating e.g. arthritis, or tumor.
XX
XX Example 34; SEQ ID NO 105; 551pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCACGACGACGAGC 1465
DB 20 CAGGACGACGACGACGAGC 2
RESULT 131
ID ADE96955/C
XX ADE96955 standard; DNA; 21 BP.
XX
XX ADE96955;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX
XX Homo sapiens.
XX
XX US2003195334-A1.
XX
XX 16-OCT-2003.
XX
XX 07-DEC-2001; 2001US-00012753.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
```

```
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 29-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 21-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99WO-US020111.
PR 30-DEC-1999; 99WO-US028313.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US00376.
PR 18-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US004342.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX (GETH ) GENENTECH INC.
PA Baker KP, Botstein D, Deenoyers L, Baton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2004-041280/04.
XX New isolated PRO polypeptides useful for treating diseases such as cancer
PT and diabetes.
XX Example 34; SEQ ID NO 105; 551pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2
|||||
RESULT 132
ADH02993/C
ID ADH02993 standard; DNA; 21 BP.
XX AC ADH02993;
XX DT 11-MAR-2004 (first entry)
XX DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX Humo; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
OS Homo sapiens.
XX US2003216562-A1.
PN 20-NOV-2003.
PD 12-DEC-2001; 2001US-00015390.
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
```

PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 23-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.

PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 03-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015284.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-DEC-2000; 2000WO-US030873.
PR 01-NOV-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

PR PA (GETH) GENENTECH INC.
XX XX

PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2004-021867/02.
XX Novel isolated PRO polypeptide useful for treating tumor, kidney
PT disorders, diabetes mellitus, thalassemias.
XX Example 34; SEQ ID NO 105; 552pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2
RESULT 133
ADH03947/c
ID ADH03947 standard; DNA; 21 BP.
AC ADH03947;
XX
DT 11-MAR-2004 (first entry)
XX Human secreted/transmembrane protein PRO1315 PCR primer #1.
DE Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
XX Homo sapiens.
XX OS
XX US2003220471-A1.
XX 27-NOV-2003.
XX 06-DEC-2001; 2001US-00006746.
XX 04-SEP-2001; 2001US-00946374.
XX (GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2004-010888/01.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Example 34; SEQ ID NO 105; 554pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either

or without their associated signal peptides. Also include are the
nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
host cell comprising the vector, producing PRO, a chimeric molecule
comprising PRO fused to a heterologous amino acid sequence, and an anti-
PRO antibody. PRO is useful as molecular weight markers for protein
electrophoresis and also for chromosome identification. PRO is also
useful for tissue typing. PRO and PRO NA are useful as hybridisation
probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
useful for generating transgenic animals or knock-out animals which are
useful in development and screening useful reagents. PRO NA is also
useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
polypeptides are useful for suppressing immune response. PRO1246
polypeptide is useful for treating cardiac insufficiency disorders.
PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
PRO1561 polypeptide are useful for stimulating calcium flux in human
umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
polypeptides are useful for treating bone and/or cartilage disorders
(e.g., arthritis) and wound healing. PRO130, PRO1275 and PRO1418
polypeptides are useful for treating diabetes in skeletal muscle cells
and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
treating Berger disease or other nephropathies associated with Schonlein-
Henoch purpura, coeliac disease, dermatitis, herpetiformis or Crohn's
disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1305, PRO1418,
PRO1410 and PRO1575 are useful in treating thalassemias. The present
sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
the invention.
XX Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;
QY Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGGAGCAACAGCAGCAGC 2
RESULT 134
ADH03470/c
ID ADH03470 standard; DNA; 21 BP.
AC ADH03470;
XX
XX 11-MAR-2004 (first entry)
XX Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
XX Homo sapiens.
XX OS
XX US2003224478-A1.
XX 04-DEC-2003.
XX 21-AUG-2002; 2002US-00226254.
XX 29-OCT-1999; 99US-0162506P.
PR 18-FEB-2000; 2000WO-US004342.
PR 04-SEP-2001; 2001US-00946374.
XX (GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;


```
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105593P.
PR 26-OCT-1998; 98US-0105594P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 98WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Fan J, Paoni NF, Roy WA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2004-081719/08.
XX
XX Novel isolated PRO polypeptide, useful for treating diabetes mellitus,
PT cancerous tumors, cardiac insufficiency disorders, thalassemia,
PT arthritis.
XX
XX Example 34; SEQ ID NO 105; 563pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGGAGCAACAGCAGCAGC 2

RESULT 136
ADH61425/c
ID ADH61425 standard; DNA; 21 BP.
XX
XX ADH61425;
XX
XX 22-APR-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1315 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
XX dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
XX Homo sapiens.
XX
XX US2004014130-A1.
XX
XX 22-JAN-2004.
XX
XX 07-DEC-2001; 2001US-00012231.
XX
XX 01-SEP-1998; 98US-0098716P.
```

PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100629P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 01-JUN-2001; 2001WO-US017800.
 20-JUN-2001; 2001WO-US019692.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 04-SEP-2001; 2001US-00946374.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI;
 XX WPI; 2004-108212/11.
 XX PT Novel isolated PRO polypeptide useful for tissue typing, modulating
 PT biological activity of cell, as molecular weight markers in protein
 PT electrophoresis, for treating arthritis, tumor.
 XX PS Example 34; SEQ ID NO 105; 562pp; English.
 XX CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides). Also include are the
 CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
 CC host cell comprising the vector, producing PRO, a chimeraic molecule
 CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
 CC PRO antibody. PRO is useful as molecular weight markers for protein
 CC electrophoresis and also for chromosome identification. PRO is also
 CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
 CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
 CC useful for generating transgenic animals or knock-out animals which are
 CC useful in development and screening useful reagents. PRO NA is also
 CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
 CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
 CC polypeptides are useful for suppressing immune response. PRO1246
 CC polypeptide is useful for treating cardiac insufficiency disorders.
 CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
 CC PRO1561 polypeptide are useful for stimulating calcium flux in human
 CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
 CC polypeptides are useful for treating bone and/or cartilage disorders
 CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
 CC polypeptides are useful for treating diabetes in skeletal muscle cells
 CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
 CC treating Berger disease or other nephropathies associated with Schonlein-
 CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
 CC disease. PRO1478, PRO1285, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
 CC PRO1410 and PRO1575 are useful in treating thalassaemias. The present
 CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
 CC the invention.
 XX SQ Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 94.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1447 CAGCAGCAACAGCAGCAGC 1465
 Db 20 CAGGAGCAACAGCAGCAGC 2
 RESULT 137
 ADL94624/c
 ID ADL94624 standard; DNA; 21 BP.
 XX AC ADL94624;
 XX DT 01-JUL-2004 (first entry)
 XX DE Human secreted/transmembrane protein PRO1315 PCR primer #1.
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
 KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
 XX OS Homo sapiens.
 XX US2004073015-A1.
 XX PD 15-APR-2004.
 XX PF 12-DEC-2001; 2001US-00015395.
 XX PR 23-SEP-1998; 98US-0101477P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 04-SEP-2001; 2001US-00946374.
 XX PA (GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI;
 XX WPI; 2004-315422/29.
 XX New PRO polynucleotides and polypeptides, useful in promoting wound
 PT healing and in diagnosing and treating cancer, neurodegenerative
 PT diseases, stroke, hypertension or diabetes mellitus.
 XX PS Example 34; SEQ ID NO 105; 550pp; English.
 XX CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides). Also include are the
 CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
 CC host cell comprising the vector, producing PRO, a chimeraic molecule
 CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
 CC PRO antibody. PRO is useful as molecular weight markers for protein
 CC electrophoresis and also for chromosome identification. PRO is also
 CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
 CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
 CC useful for generating transgenic animals or knock-out animals which are
 CC useful in development and screening useful reagents. PRO NA is also
 CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
 CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
 CC polypeptides are useful for suppressing immune response. PRO1246
 CC polypeptide is useful for treating cardiac insufficiency disorders.
 CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
 CC PRO1561 polypeptide are useful for stimulating calcium flux in human
 CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
 CC polypeptides are useful for treating bone and/or cartilage disorders
 CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
 CC polypeptides are useful for treating diabetes in skeletal muscle cells
 CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
 CC treating Berger disease or other nephropathies associated with Schonlein-
 CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
 CC disease. PRO1478, PRO1285, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
 CC PRO1410 and PRO1575 are useful in treating thalassaemias. The present
 CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
 CC the invention.
 XX SQ Sequence 21 BP; 0 A; 7 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 94.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1447 CAGCAGCAACAGCAGCAGC 1465
 Db 20 CAGGAGCAACAGCAGCAGC 2
 RESULT 138
 ADM48407/c
 ID ADM48407 standard; DNA; 23 BP.
 XX AC ADM48407;
 XX DT 03-JUN-2004 (first entry)
 XX DE Probe #2 used to illustrate the method of the invention.
 KW Detection; protein-protein interaction; protein-drug interaction; probe;
 KW ss.
 XX OS Unidentified.
 XX US2003215825-A1.


```

PF 14-NOV-2000; 2000WO-EP010736.
XX
PR 15-NOV-1999; 99US-00439756.
XX
PA (PHAA ) PHARMACIA & UPJOHN SPA.
XX
PI Dahlberg M, Moll J, Galvani A;
XX
DR WPI; 2001-355626/37.
XX
XX New nucleic acid encoding p21-activated kinase 5 protein for inducing an
PT immune response, treating cancers, angiogenesis-related disorders,
PT disorders of the central nervous system and immune-related disorders.
XX
PS Example 2; Page 37; 76pp; English.
XX
XX The present sequence is degenerate antisense PCR primer used for
CC amplifying human p21-activated kinase 5 (PAK5) cDNA which encodes PAK5 a
CC serine-threonine kinase. PAK5 is useful for inducing an immune response
CC in a mammal against PAK5 polypeptide. PAK5 proteins are useful in
CC regulating cell proliferation, cell migration, cell differentiation,
CC cytoskeletal organisation, gene expression, cell cycle progression, and
CC cell death. PAK5, is useful in the search for novel agents that can
CC modify and/or control the above processes. PAK5 DNA is useful for
CC screening restriction fragment length polymorphism (RFLP) associated with
CC certain disorders, as well as for genetic mapping. PAK5 DNA is also
CC useful as diagnostic tools for probing gene expression in various
CC tissues. PAK5 polypeptides are also useful as antigens for raising
CC antibodies, and for screening compounds that modulate the activity of
CC PAK5. PAK5 is also useful in pharmaceutical compositions, and in the
CC manufacture of medicaments for treating diseases such as cancers,
CC angiogenesis-related diseases, diseases of the central nervous system and
CC diseases due to inappropriate activation of immune responses. PAK5 DNA is
CC also useful in gene therapy
XX
SQ Sequence 20 BP; 4 A; 6 C; 3 G; 3 T; 0 U; 4 Other;
Query Match 0.4%; Score 17.2; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 583 TACTGGATGGCTCCAGAGGT 602
Db 20 TAYTGGATGGCTCCAGAGST 1
|||||
|||||

RESULT 141
AAF76808
ID AAF76808 standard; DNA; 22 BP.
XX
AC AAF76808;
XX
XX 14-MAY-2001 (first entry)
DT
DE Codon-optimised HPV6 E2 fragment 6PM.
XX
XX Human papillomavirus; HPV; HPV16; HPV6a; HPV18; L1; E2; E7; E1;
KW antiviral; immunostimulant; vaccine; immunogen; infection; ss.
XX
XX Human papillomavirus.
OS
OS Synthetic.
XX
PN WO200114416-A2.
XX
XX 01-MAR-2001.
PD
XX
XX 21-AUG-2000; 2000WO-US022932.
PF
XX
XX 25-AUG-1999; 99US-0150728P.
PR
XX 07-JUN-2000; 2000US-0210143P.
PR
XX (MERI ) MERCK & CO INC.
PA
XX

```

```

PI Keeper MP, McClements WL, Jansen KU, Schultz LD, Chen L, Wang X;
XX
XX WPI; 2001-218428/22.
XX
XX Novel synthetic polynucleotide encoding human papillomavirus (HPV)
PT protein or mutated HPV protein useful as anti-HPV vaccines, comprises
PT optimized-codons for expression of the viral proteins in human host
PT cells.
XX
XX Example 6; Fig 23; 119pp; English.
XX
XX The present sequence is an oligomer which was used in the assembly of one
CC of a number of synthetic polynucleotides that encode a human
CC papillomavirus (HPV) protein, or a mutated form of a HPV protein. The
CC mutated HPV proteins have reduced protein function as compared to wild
CC type proteins but maintain immunogenicity. The proteins comprise codons
CC for optimised expression in humans. The polynucleotides are useful as a
CC vaccine which provides effective immunoprophylaxis against papillomavirus
CC infection through stimulation of neutralising antibody and cell-mediated
CC immunity
XX
SQ Sequence 22 BP; 9 A; 9 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1441 CTGCGAGCAGCAGCACGAGC 1462
Db 1 CCGCACACACGACGACGAGC 22
|||||
|||||

RESULT 142
ABX72347/c
ID ABX72347 standard; DNA; 22 BP.
XX
AC ABX72347;
XX
XX 03-JUN-2003 (first entry)
DT
DE Human NOVX DNA PCR primer #48.
XX
XX Human; NOVX; PCR; ss; metabolic disorder; cardiomyopathy; diabetes; ASD;
KW hypertension; congenital heart defect; aortic stenosis; valve disease;
KW atrial septal defect; atrioventricular canal defect; ductus arteriosus;
KW pulmonary stenosis; subaortic stenosis; ventricular septal defect; VSD;
KW tuberosus sclerosis; scleroderma; atherosclerosis; infectious disease;
KW obesity; anorexia; neurodegenerative disorder; Alzheimer's disease;
KW Parkinson's disease; immune disorder; haematopoietic disorder; primer;
KW haemophilia; hypercoagulation; Crohn's disease; cancer.
XX
XX Homo sapiens.
XX
XX WO200281498-A2.
FN
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010780.
PF
XX
XX 03-APR-2001; 2001US-0281086P.
PR
XX 03-APR-2001; 2001US-0281136P.
PR
XX 05-APR-2001; 2001US-0281863P.
PR
XX 06-APR-2001; 2001US-0281906P.
PR
XX 10-APR-2001; 2001US-0282020P.
PR
XX 10-APR-2001; 2001US-0282930P.
PR
XX 10-APR-2001; 2001US-0282934P.
PR
XX 12-APR-2001; 2001US-0283512P.
PR
XX 13-APR-2001; 2001US-0283710P.
PR
XX 17-APR-2001; 2001US-0284234P.
PR
XX 19-APR-2001; 2001US-0285325P.
PR
XX 20-APR-2001; 2001US-0285381P.
PR
XX 20-APR-2001; 2001US-0285609P.
PR
XX 23-APR-2001; 2001US-0285748P.

```


KW human; angiotensin-like protein 1; AMLP1; cytostatic; gene therapy;
 KW AMLP1a; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX WO2003037931-A2.
 XX
 XX
 PD 08-MAY-2003.
 XX
 XX 01-NOV-2002; 2002WO-US035129.
 PF
 XX
 XX 01-NOV-2001; 2001US-0334773P.
 PR
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 PA
 XX Shannon M, Phan T;
 PI
 XX WPI; 2003-430501/40.
 DR
 XX New isolated nucleic acid molecule encoding a human angiotensin-like
 PT protein, useful for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of AMLP1.
 PT
 PS Example 2; SEQ ID NO 171; 172pp; English.
 XX
 XX The present invention describes the human angiotensin-like protein 1
 CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
 CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
 CC compositions of the present invention can be used for treating or
 CC preventing a disorder associated with decreased or increased expression
 CC or activity of AMLP1. The present sequence represents a scanning
 CC oligonucleotide for human AMLP1a, which is used in an example from the
 CC present invention.
 CC
 XX
 SQ Sequence 17 BP; 7 A; 6 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1447 CAGCAGCAACAGCAGCA 1463
 Db 1 CAGCAGCAACAGCAGCA 17
 RESULT 152
 AAS13717/C
 ID AAS13717 standard; DNA; 18 BP.
 XX
 AC AAS13717;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE Simple sequence repeat, SSR, #14.
 XX
 XX Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 KW
 XX Poae.
 OS
 XX NZ509193-A.
 PN
 XX
 PD 25-MAY-2001.
 XX
 XX 03-JAN-2001; 2001NZ-00509193.
 PF
 XX 24-DEC-1999; 99AU-00004906.
 PR
 XX 04-MAY-2000; 2000AU-00007310.
 PR
 XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 PA (UYSC-) UNIV SOUTHERN CROSS.
 PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 PA

PA (UYAD-) UNIV ADELAIDE.
 PA (ITWA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX
 PI Forster JW, Jones ES;
 XX
 DR WPI; 2001-512563/56.
 XX
 XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.
 PT
 XX Claim 6; Page 51; 72pp; English.
 PS
 XX The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ Sequence 18 BP; 0 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1131 GCAGCAGCAGCAGCAGC 1147
 Db 18 GCAGCAGCAGCAGCAGC 2
 RESULT 153
 ADN97239
 ID ADN97239 standard; DNA; 18 BP.
 XX
 AC ADN97239;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Primer of the invention #47.
 XX
 KW DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
 KW forensic identification; marijuana; primer; ss.
 XX
 XX Unidentified.
 OS
 XX WO2004008841-A2.
 PN
 XX
 PD 29-JAN-2004.
 XX
 XX 21-JUL-2003; 2003WO-US022887.
 PF
 XX 19-JUL-2002; 2002US-0397179P.
 PR
 XX (UYAR-) UNIV ARIZONA.
 PA (KEIM/) KEIM P S.
 PA (ZINN/) ZINNAMON K.
 XX
 XX Keim PS, Zinnamon K;
 PI


```

PS Example 1; SEQ ID NO 3; 86pp; English.
XX
CC The present invention describes a method for constructing a synthetic
CC polynucleotide from which a polypeptide is producible to confer a
CC selected phenotype to an organism of interest or part in a different
CC quality than that conferred by a parent polynucleotide that encodes the
CC same polypeptide. The method comprises: (a) selecting a first codon of
CC the parent polynucleotide for replacement with a synonymous codon, where
CC the synonymous codon is selected on the basis that it exhibits a
CC different phenotypic preference than the first codon in a comparison of
CC phenotypic preferences in test organisms or parts, where the test
CC organism are selected from organisms of the same species as the organism
CC of interest and organisms that are related to the organisms of interest;
CC and (b) replacing the first codon with the synonymous codon to construct
CC the synthetic polynucleotide. Also described: (1) a method for
CC determining the phenotypic preference of a first codon in an organism of
CC interest or its parts; (2) a synthetic polynucleotide constructed from
CC the method above; (3) an organism or interest or part containing a
CC synthetic polynucleotide constructed from the method above; (4) an
CC organism or interest or part containing a synthetic construct that
CC comprises a regulatory polynucleotide operably linked to a tandem repeat
CC of a first codon fused in frame with a reporter polynucleotide that
CC encodes a reporter protein, which produces, or is predicted to produce a
CC selected phenotype or a phenotype of the same class as the selected
CC phenotype in the organism or part; (5) a method of modulating the quality
CC of a selected phenotype that is displayed by an organism of interest or
CC part and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide; (6) a method of enhancing the quality of a
CC selected phenotype that is displayed by an organism of interest or part
CC and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide; and (7) a method of reducing the quality of a
CC selected phenotype that is displayed by an organism of interest or part
CC and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide. The method is useful for constructing a
CC synthetic polynucleotide from which a polypeptide is producible to confer
CC a selected phenotype to an organism of interest or part in a different
CC quality than that conferred by a parent polynucleotide that encodes the
CC same polypeptide. It is useful for modulating the quality of a selected
CC phenotype displayed by an organism or part. The present sequence encodes
CC a synthetic leader sequence, which is used in an example from the present
CC invention.
XX
SQ Sequence 18 BP; 6 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1131 GCAGCAGCAGCAGCAGC 1147
DB 1 GCAGCAGCAGCAGCAGC 17
RESULT 156
ADO26696
XX ADO26696 standard; DNA; 18 BP.
XX ADO26696;
XX
XX 12-AUG-2004 (first entry)
XX Synthetic leader sequence encoding DNA SEQ ID NO:89.
XX phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX Synthetic.
XX
XX WO2004042059-A1.
XX
XX 21-MAY-2004.
XX
XX 10-NOV-2003; 2003WO-AU001487.
XX

```

```

PR 08-NOV-2002; 2002US-0425163P.
XX (UYQU ) UNIV QUEENSLAND.
PA
XX Frazer IH;
PI
XX WPI; 2004-411519/38.
DR P-PSDB; ADO26697.
XX
XX Constructing synthetic polynucleotide for modulating the quality of a
XX selected phenotype displayed by an organism comprises replacing a first
XX codon with a synonymous codon to construct the synthetic polynucleotide.
XX
XX Example 1; SEQ ID NO 89; 86pp; English.
XX
XX The present invention describes a method for constructing a synthetic
XX polynucleotide from which a polypeptide is producible to confer a
XX selected phenotype to an organism of interest or part in a different
XX quality than that conferred by a parent polynucleotide that encodes the
XX same polypeptide. The method comprises: (a) selecting a first codon of
XX the parent polynucleotide for replacement with a synonymous codon, where
XX the synonymous codon is selected on the basis that it exhibits a
XX different phenotypic preference than the first codon in a comparison of
XX phenotypic preferences in test organisms or parts, where the test
XX organism are selected from organisms of the same species as the organism
XX of interest and organisms that are related to the organisms of interest;
XX and (b) replacing the first codon with the synonymous codon to construct
XX the synthetic polynucleotide. Also described: (1) a method for
XX determining the phenotypic preference of a first codon in an organism of
XX interest or its parts; (2) a synthetic polynucleotide constructed from
XX the method above; (3) an organism or interest or part containing a
XX synthetic polynucleotide constructed from the method above; (4) an
XX organism or interest or part containing a synthetic construct that
XX comprises a regulatory polynucleotide operably linked to a tandem repeat
XX of a first codon fused in frame with a reporter polynucleotide that
XX encodes a reporter protein, which produces, or is predicted to produce a
XX selected phenotype or a phenotype of the same class as the selected
XX phenotype in the organism or part; (5) a method of modulating the quality
XX of a selected phenotype that is displayed by an organism of interest or
XX part and that results from the expression of a parent polynucleotide that
XX encodes the polypeptide; (6) a method of enhancing the quality of a
XX selected phenotype that is displayed by an organism of interest or part
XX and that results from the expression of a parent polynucleotide that
XX encodes the polypeptide; and (7) a method of reducing the quality of a
XX selected phenotype that is displayed by an organism of interest or part
XX and that results from the expression of a parent polynucleotide that
XX encodes the polypeptide. The method is useful for constructing a
XX synthetic polynucleotide from which a polypeptide is producible to confer
XX a selected phenotype to an organism of interest or part in a different
XX quality than that conferred by a parent polynucleotide that encodes the
XX same polypeptide. It is useful for modulating the quality of a selected
XX phenotype displayed by an organism or part. The present sequence encodes
XX a synthetic leader sequence, which is used in an example from the present
XX invention.
XX
XX Sequence 18 BP; 6 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 17; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1131 GCAGCAGCAGCAGCAGC 1147
DB 2 GCAGCAGCAGCAGCAGC 18
RESULT 157
ADO26614/c
XX ADO26614 standard; DNA; 18 BP.
XX
XX ADO26614;
XX
XX 12-AUG-2004 (first entry)
XX

```

XX Synthetic leader sequence encoding DNA SEQ ID NO:7.
XX phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX Synthetic.
XX WO2004042059-A1.
XX 21-MAY-2004.
XX 10-NOV-2003; 2003WO-AU001487.
XX 08-NOV-2002; 2002US-0425163P.
XX (UYQU) UNIV QUEENSLAND.
XX Frazer IH;
XX WPI; 2004-411519/38.
XX P-PSDB; ADO26615.
XX Constructing synthetic polynucleotide for modulating the quality of a
PT selected phenotype displayed by an organism comprises replacing a first
PT codon with a synonymous codon to construct the synthetic polynucleotide.
XX
XX Example 1; SEQ ID NO 7; 86pp; English.
XX The present invention describes a method for constructing a synthetic
CC polynucleotide from which a polypeptide is producible to confer a
CC selected phenotype to an organism of interest or part in a different
CC quality than that conferred by a parent polynucleotide that encodes the
CC same polypeptide. The method comprises: (a) selecting a first codon of
CC the parent polynucleotide for replacement with a synonymous codon, where
CC the synonymous codon is selected on the basis that it exhibits a
CC different phenotypic preference than the first codon in a comparison of
CC phenotypic preferences in test organisms or parts, where the test
CC organism are selected from organisms of the same species as the organism
CC of interest and organisms that are related to the organisms of interest;
CC and (b) replacing the first codon with the synonymous codon to construct
CC the synthetic polynucleotide. Also described: (1) a method for
CC determining the phenotypic preference of a first codon in an organism of
CC interest or its parts; (2) a synthetic polynucleotide constructed from
CC the method above; (3) an organism of interest or part containing a
CC synthetic polynucleotide constructed from the method above; (4) an
CC organism of interest or part containing a synthetic construct that
CC comprises a regulatory polynucleotide operably linked to a tandem repeat
CC of a first codon fused in frame with a reporter polynucleotide that
CC encodes a reporter protein, which produces, or is predicted to produce a
CC selected phenotype or a phenotype of the same class as the selected
CC phenotype in the organism or part; (5) a method of modulating the quality
CC of a selected phenotype that is displayed by an organism of interest or
CC part and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide; (6) a method of enhancing the quality of a
CC selected phenotype that is displayed by an organism of interest or part
CC and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide; and (7) a method of reducing the quality of a
CC selected phenotype that is displayed by an organism of interest or part
CC and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide. The method is useful for constructing a
CC synthetic polynucleotide from which a polypeptide is producible to confer
CC a selected phenotype to an organism of interest or part in a different
CC quality than that conferred by a parent polynucleotide that encodes the
CC same polypeptide. It is useful for modulating the quality of a selected
CC phenotype displayed by an organism or part. The present sequence encodes
CC a synthetic leader sequence, which is used in an example from the present
XX invention.
XX Sequence 18 BP; 0 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

QY 1131 GCAGCAGCAGCAGCAGC 1147
Db 17 GCAGCAGCAGCAGCAGC 1
RESULT 158
ABZ86071/c
ID ABZ86071 standard; DNA; 20 BP.
XX
AC ABZ86071;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 1313; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 0.4%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1132	CAGCAGCAGCAGCAGC 1148	QY	1132	CAGCAGCAGCAGCAGC 1148
DB	20	CAGCAGCAGCAGCAGC 4	DB	20	CAGCAGCAGCAGCAGC 4
RESULT 159					
ABZ86075/c			ABD22301/c		
ID	ABZ86075	standard; DNA; 20 BP.	ID	ABD22301	standard; DNA; 20 BP.
XX	ABZ86075;		XX	ABD22301;	
DT	17-OCT-2003	(first entry)	DT	29-JUL-2004	(first entry)
XX	Human oligonucleotide sequence.		XX	Human stannocalcin-derived oligo SEQ ID 1313.	
XX	Human; antisense; lung dysfunction; nasal airway dysfunction;		XX	Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;	
KW	antiinflammatory steroid; ubiquinone; antiinflammatory; antiasthmatic;		KW	respiratory tract inflammation; adenosine sensitivity; lung; cancer;	
KW	antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;		KW	surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;	
KW	antisense gene therapy; respiratory; lung; adenosine sensitivity;		KW	analgesic; hypotensive; immunosuppressive; cytosolic; cystic fibrosis;	
KW	adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;		KW	beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;	
KW	lung inflammation; respiratory disease; db.		KW	respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;	
OS	Homo sapiens.		KW	emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;	
XX			XX	pulmonary transplantation rejection; ss; primer.	
PN	WO200285308-A2.		OS	Homo sapiens.	
PD	31-OCT-2002.		XX	WO200285309-A2.	
XX			PN		
PF	23-APR-2002; 2002WO-US013135.		XX	31-OCT-2002.	
XX			PD		
PR	24-APR-2001; 2001US-0286137P.		PF		
XX			XX	23-APR-2002; 2002WO-US013143.	
PA	(EPIC-) EPIGENESIS PHARM INC.		PR		
XX			XX	24-APR-2001; 2001US-0286036P.	
PI	Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;		XX	(EPIC-) EPIGENESIS PHARM INC.	
PI	Miller S, Tang L, Shahabuddin S;		XX		
DR	WPI; 2003-229219/22.		PI	Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;	
XX			PI	Miller S, Tang L, Shahabuddin S;	
XX	Pharmaceutical composition for treating ailments associated with impaired		XX		
PT	respiration, has oligo(s) antisense to specific gene(s) or its		DR	WPI; 2003-093058/08.	
PT	corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or		XX		
PT	ubiquinone.		XX	Pharmaceutical composition for treating asthma, has antisense	
XX			PT	oligonucleotide containing less percentage of adenosine, targeted to	
PS	Claim 15; SEQ ID NO 1317; 872pp; English.		PT	nucleic acids associated with lung airway or lung dysfunction, and	
XX			PT	bronchodilating agent.	
CC	The invention relates to a novel pharmaceutical composition, which has a		XX	Claim 15; SEQ ID NO 1313; 763pp; English.	
CC	first active agent comprising an oligonucleotide antisense to the		CC	This invention describes a novel composition (a) a first active agent,	
CC	initiation codon, coding region, 5' or 3' end genomic flanking regions,		CC	comprising oligonucleotides, effective for alleviating	
CC	5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of		CC	bronchoconstriction, respiratory tract inflammation, allergies and	
CC	junctions of genes encoding a polypeptide associated with lung and/or		CC	reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,	
CC	nasal airway dysfunction and a second active agent comprising an		CC	surfactant depletion or hyposecretion, when administered to a mammal. The	
CC	antiinflammatory steroid and ubiquinone. A composition of the invention		CC	oligonucleotides are derived from a gene encoding or regulating	
CC	has antiinflammatory, antiasthmatic, antiasthmatic, hypotensive,		CC	expression of a target polypeptide associated with lung airway or lung	
CC	immunosuppressive, and cytosolic activity. The composition may have a		CC	dysfunction or cancer and can be anti-sense to the corresponding mRNA.	
CC	use in antisense gene therapy. The composition is useful for treating or		CC	The invention also describes a kit, that comprises: (a) a delivery	
CC	preventing a respiratory, lung or malignant disease or condition, also		CC	device, in separate containers, (b) the oligonucleotides, (c)	
CC	for enhancing the prophylactic or therapeutic respiratory effect of an		CC	instructions for adding a carrier and for use of the kit. The composition	
CC	antiinflammatory steroid in a subject, for reducing or depleting levels		CC	of the invention has antiasthmatic, antiinflammatory, antiasthmatic,	
CC	of, or reducing sensitivity to adenosine, reducing levels of adenosine		CC	analgesic, hypotensive, immunosuppressive and cytosolic activity, is a	
CC	receptor, producing bronchodilation, increasing levels of ubiquinone or		CC	beta-adrenergic agonist. The composition is useful for preventing or	
CC	lung surfactant in a subject's tissue, or treating bronchoconstriction,		CC	treating a respiratory, lung or malignant disease. The administered	
CC	lung inflammation, lung allergies, or a respiratory disease or condition.		CC	composition comprises oligo and is administered to reduce the production	
CC	Note: The sequence data for this patent is not represented in the printed		CC	or availability, or to increase the degradation of the target mRNA or to	
CC	specification, but was obtained in electronic format directly from WIPO		CC	reduce the amount of target polypeptide present in the lungs. The	
CC	at ftp.wipo.int/pub/published_sequences		CC	pulmonary obstruction, and/or bronchoconstriction and/or lung	
XX			CC	inflammation, allergies and/or surfactant hypoproduction are associated	
SQ	Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;		CC	with a disease or condition such as pulmonary vasoconstriction,	
Query Match		0.4%; Score 17; DB 1; Length 20;	CC	inflammation, allergies, asthma, impeded respiration, respiratory	
Best Local Similarity		100.0%; Pred. No. 1.7e+02;	CC	distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary	
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			CC	hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary	

CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1132 CAGCAGCAGCAGCAGCG 1148
 DB 20 CAGCAGCAGCAGCAGCG 4
 RESULT 161
 ABD22305/C
 ID ABD22305 standard; DNA; 20 BP.
 AC ABD22305;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human stanniocalcin-derived oligo SEQ ID 1317.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegna A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 1317; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal.
 CC The oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1132 CAGCAGCAGCAGCAGCG 1148
 DB 20 CAGCAGCAGCAGCAGCG 4
 RESULT 162
 AAQ61483
 ID AAQ61483 standard; DNA; 20 BP.
 XX
 AC AAQ61483;
 XX
 DT 25-MAR-2003 (revised)
 DT 17-MAY-1994 (first entry)
 XX
 DE PCR primer Btpo22 to amplify M.leprae rpoB gene.
 XX
 KW rifampicin; antibiotic; susceptibility; sensitive; resistant; rpoB;
 KW mutant; Mycobacterium leprae; ss.
 XX
 OS Synthetic.
 XX
 PN WO9322454-A1.
 XX
 PD 11-NOV-1993.
 XX
 PF 30-APR-1993; 93WO-EP001063.
 XX
 PR 30-APR-1992; 92US-00875940.
 PR 14-AUG-1992; 92US-00929206.
 PR 17-SEP-1992; 92FR-00011098.
 PR 16-APR-1993; 93FR-00004545.
 XX
 PA (INSP) INST PASTEUR.
 PA (MEDI-) MEDICAL RES COUNCIL.
 PA (ASSI-) ASSISTANCE PUBLIQUE.
 PA (UYFA-) UNIV CURIE PARIS VI P & M.
 PA (UYBE-) UNIV BERNE.
 XX
 PI Heym B, Cole S, Young D, Zhang Y, Honore N, Telenti A, Bodmer T;
 XX WPI; 1993-368812/46.
 DR
 XX Rapid detection of antibiotic resistance in Mycobacteria - esp.
 PT isoniazid, rifampicin or streptomycin resistance in tuberculosis by
 PT detecting mutation in katG, rpoB or rpsL genes.
 XX
 PS Example 2; Page 49; 97pp; English.
 XX

CC PCR amplification (see AAQ61483-Q61492 for primer sequences) was used to
 CC obtain rpoB genes from rifampicin-resistant Mycobacterium leprae strains.
 CC A comparison with the sequence of the rpoB gene from sensitive strains
 CC (AAQ51532) revealed mutations in the region encoding amino acids 400-450.
 CC The corresp. region was isolated from M.tuberculosis (AAQ61457). A common
 CC mutation seen in resistant strains occurs at codon 425 where Ser is
 CC substituted, most frequently by Leu. (Updated on 25-MAR-2003 to correct
 CC PN field.)
 CC
 SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2551 CAGGACGTCGAGGATCAG 2570
 DB 1 CAGGACGTCGAGGATCAG 20
 RESULT 163
 AAQ68866
 ID AAQ68866 standard; DNA; 20 BP.
 AC AAQ68866;
 XX
 XX 25-MAR-2003 (revised)
 DT 01-JUN-1995 (first entry)
 XX
 DE Mycobacterium leprae rpoB gene biotinylated primer 1.
 XX
 KW Deoxyribonucleotide 5'-triphosphate ester; 3'-RT-dNTP;
 KW chain extension inhibitor; chain termination sequencing method;
 KW fluorophore; anthranilate; RNA polymerase beta-subunit; rpoB gene; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /tag= a
 FT /note= "biotinylated"
 XX
 XX FR2703052-A1.
 XX
 XX 30-SEP-1994.
 XX
 XX 26-MAR-1993; 93FR-00003538.
 XX
 XX 26-MAR-1993; 93FR-00003538.
 XX
 XX (INSP) INST PASTEUR.
 XX
 XX Canard B, Sarfati S;
 XX
 XX WPI; 1994-312169/39.
 XX
 XX New labelled ester(s) of nucleotide 5'-tri-phosphate deriva - block chain
 XX extension reaction but can be hydrolysed to release the label after which
 XX mutation(s).
 XX
 XX Example; Page 18; 38pp; French.
 XX
 CC Part of the gene coding for the beta-subunit of RNA polymerase in
 CC Mycobacterium leprae (the rpoB gene) was amplified by PCR using the
 CC primers AAQ68866 and AAQ68867. Primer 1 is 5'-biotinylated and primer 2
 CC has a sequence corresponding to the M.leprae wild-type rpoB gene
 CC downstream of codon 425. An amino acid change at position 425 confers
 CC rifampicin resistance of M.leprae. The novel esters of
 CC deoxyribonucleotides (3'-RT-dNTPs) were used to analyse the amplified
 CC region by sequence determination. The 3'-RT-dNTPs are pref. derived by
 CC esterification of the 3'-OH by fluorophore or anthranilate groups. The
 CC nucleotide analogues do not contain free 3'-OH groups so their

CC incorporation into a DNA strand results in chain termination. The
 CC esterifying groups can be hydrolysed without altering the chain all ready
 CC formed, to allow chain extension to continue. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 CC
 SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2551 CAGGACGTCGAGGATCAG 2570
 DB 1 CAGGACGTCGAGGATCAG 20
 RESULT 164
 AAV68372/c
 ID AAV68372 standard; DNA; 20 BP.
 XX
 XX AAV68372;
 XX
 XX 10-MAR-1999 (first entry)
 DT
 DE Adapter primer oligonucleotide #11 for CAG repeat analysis.
 XX
 XX CAG repeat; human; genome analysis; adapter primer; medical diagnostic;
 KW nucleic acid analysis; variation assessment; neurological disease;
 KW Huntington's chorea; PCR suppression; ss.
 XX
 OS Synthetic.
 XX
 XX WO9849345-A1.
 XX
 XX 05-NOV-1998.
 PD
 XX
 XX 29-APR-1998; 98WO-US008616.
 XX
 XX 29-APR-1997; 97US-0045078P.
 XX
 XX (UYBO-) UNIV BOSTON.
 PA
 PI Smith CL;
 XX
 XX WPI; 1998-594983/50.
 DR
 XX
 XX Analysing nucleic acid samples - using amplification primers which
 PT contain CAG or CTG tri-nucleotide repeats for differential display of
 PT samples from different sources.
 XX
 XX Example; Page 31; 44pp; English.
 XX
 CC This sequence represents an adapter primer oligonucleotide. It was used
 CC to isolate CAG repeat containing sequences from the human genome to test
 CC the method of the invention. The method is for analysing nucleic acids in
 CC a sample, and comprises: (a) providing a sample containing nucleic acid,
 CC a first oligonucleotide primer comprising a CAG repeat, a second
 CC oligonucleotide primer comprising a CAG repeat and a polymerase and PCR
 CC reagents; (b) preparing said nucleic acid so that it is amplifiable; (c)
 CC amplifying the nucleic acid with the first and second primers; and (d)
 CC detecting the amplified product. The method is used to distinguish
 CC between the expression of genes in two or more biological samples, e.g.
 CC body fluids, cells, solid tissue or solid and liquid foods. It can be
 CC used in medical diagnostics, e.g. to differentiate between normal and
 CC diseased tissue or to assess the variation within monozygotic twin pairs.
 CC The method allows the isolation and analysis of genome subsets containing
 CC CAG repeats which are known to be important in a number of neurological
 CC diseases including Huntington's chorea. The method uses PCR suppression,
 CC in which only fragments which contain a target repeat are efficiently
 CC amplified. This allows accurate identification of differentially
 CC expressed genes in various cell types. Genome complexity is reduced by
 CC the new method which targets genomic subsets containing CAG repeats
 XX

SQ Sequence 20 BP; 1 A; 6 C; 6 G; 6 T; 0 U; 1 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAGCT 1469
 |||||
 DB 20 CAGCAGCAGCAGCAGCAGT 1

RESULT 165
 AAZ40551
 ID AAZ40551 standard; DNA; 20 BP.
 XX AAZ40551;
 AC AAZ40551;
 XX 18-FEB-2000 (first entry)
 DT 18-FEB-2000 (first entry)
 XX Human ZC3 primer #1.
 DE Human ZC3 primer #1.
 XX Antirheumatic; antiarthritic; antiinflammatory; antiallergic; osteopathic;
 KW antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
 KW neuroprotective; cardiac; cerebroprotective; cytoprotective; antidiabetic;
 KW vulnary; STK20; protein kinase; STK3; STK4; STK5; STK6; STK7;
 KW ZC1; ZC2; ZC4; KHS2; SUTU1; SUTU3; GSK2; PAK4; PAK5; antagonist;
 KW antibody; gene therapy; rheumatoid arthritis; artherosclerosis; asthma;
 KW inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
 KW thinitis; autoimmunity; organ transplantation; multiple sclerosis;
 KW myocardial infarction; cardiovascular disease; stroke; renal failure;
 KW oxidative stress-related neurodegenerative disorder; Parkinson's disease;
 KW amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
 KW ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;
 KW mesangial disorder; growth regulation; wound healing; T cell activation;
 KW immunosuppressant; primer; PCR; amplification; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX MO9953036-A2.
 PN 21-OCT-1999.
 PD 21-OCT-1999.
 XX 13-APR-1999; 99MO-US008150.
 PF 13-APR-1999; 99MO-US008150.
 XX 14-APR-1998; 98US-0081784P.
 PR 14-APR-1998; 98US-0081784P.
 XX (SUGB-) SUGEN INC.
 PA Plowman G, Martinez R, Whyte D;
 XX WPI; 1999-611301/52.
 DR WPI; 1999-611301/52.
 XX Novel kinase-related polypeptides used for the diagnosis and treatment of
 PT kinase-related diseases and disorders.
 CC Disclosure; Page 385; 387pp; English.
 XX This sequence represents a PCR primer used to amplify the coding sequence
 CC for a novel STK20-related protein kinase. The invention relates to
 CC nucleic acid molecule encoding a kinase polypeptide selected from STK2,
 CC STK3, STK4, STK5, STK6, STK7, ZC1, ZC2, ZC3, ZC4, KHS2, SUTU1,
 CC SUTU3, GSK2, PAK4 and PAK5. The proteins are used to identify agonists
 CC and antagonists, and to raise antibodies. The polynucleotides are useful
 CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
 CC antagonists and agonists may be used to treat diseases such as immune-
 CC related disorders and diseases (e.g. rheumatoid arthritis,
 CC artherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
 CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
 CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
 CC disease, multiple sclerosis, organ transplantation, myocardial
 CC infarction, cardiovascular disease, stroke, renal failure, oxidative
 CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral

CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
 CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
 CC mellitus, fibrotic and mesangial disorders. The proteins may also be
 CC useful for cell growth regulation (e.g. in wound healing), T cell
 CC activation, mitosis control, and as immunosuppressants
 CC

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAACCTGCTGAAGG 3949
 |||||
 DB 1 CATCATGAACCTGCTGAAGG 20

RESULT 166
 ABA94159
 ID ABA94159 standard; DNA; 20 BP.
 XX ABA94159;
 AC ABA94159;
 XX 08-MAY-2002 (first entry)
 DT 08-MAY-2002 (first entry)
 XX Rifampin-tolerant Mycobacterium leprae related PCR primer rpo22.
 DE Rifampin-tolerant Mycobacterium leprae related PCR primer rpo22.
 XX Rifampin-tolerant; Mycobacterium leprae; mutant; PCR primer; ss.
 XX Mycobacterium leprae.
 OS Mycobacterium leprae.
 XX KR98068824-A.
 PN KR98068824-A.
 XX 26-OCT-1998.
 PD 26-OCT-1998.
 XX 24-FEB-1997; 97KR-00005613.
 PF 24-FEB-1997; 97KR-00005613.
 XX 24-FEB-1997; 97KR-00005613.
 PR 24-FEB-1997; 97KR-00005613.
 XX (SUHJ/) SUH J W.
 PA (CHAE/) CHAE G T.
 XX Suh JW, Chae GT, Kim SO;
 PI Suh JW, Chae GT, Kim SO;
 XX WPI; 1999-607936/52.
 DR WPI; 1999-607936/52.
 XX New mutant strains of rifampin-tolerant Mycobacterium leprae and its
 PT nucleotide sequence - No Abstract.
 CC Disclosure; Page 3; 10pp; Korean.
 XX The present invention describes new mutant strains of rifampin-tolerant
 CC Mycobacterium leprae and its nucleotide sequence. The present sequence
 CC represents a PCR primer which is used in the exemplification of the
 CC present invention
 CC

SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2551 CAGCAGCTGAGAGATCAG 2570
 |||||
 DB 1 CAGCAGCTGAGAGATCAG 20

RESULT 167
 AAZ35086
 ID AAZ35086 standard; DNA; 20 BP.
 XX AAZ35086;
 AC AAZ35086;
 XX

DT	13-MAR-2000	(first entry)	
XX			
DE	Herpesvirus entry protein B (HvEb) PCR primer PPR2A8.		
XX			
KM	Herpesvirus entry protein B; HvEb; tumour necrosis factor receptor;		
KM	alphaherpesvirus; infection; therapy; human; PCR; primer; ss.		
OS	Synthetic.		
OS	'Homo sapiens.		
XX			
PN	MO9963063-A1.		
XX			
PD	09-DEC-1999.		
XX			
PP	02-JUN-1999; 99WO-US012235.		
PR	03-JUN-1998; 98US-0087862P.		
XX			
PA	(NOUN) UNIV NORTHWESTERN.		
XX	(TYPE-) UNIV PENNSYLVANIA.		
P1	Spear PG, Warner MS, Geraghty RG, Martinez WM, Montgomery RI;		
P1	Cohen GH, Eisenberg RJ, Whitbeck CJ, Krummenacher C;		
XX			
DR	WPI; 2000-097325/08.		
XX			
PT	Novel proteins used to prevent viral infection and to identify other		
PT	inhibitors.		
XX			
PS	Example 1; Page 57; 144pp; English.		
XX			
CC	Primer PPR2A8 was used in the PCR amplification of herpesvirus entry		
CC	protein B (HvEb) cDNA (see also AA235084). HvEb is a novel member of the		
CC	human tumour necrosis factor receptor family that mediates entry of an		
CC	alphaherpesvirus (aHV) into cells. Cellular herpesvirus entry proteins		
CC	(I) such as HvEb, their mutants, homologues, derivatives, variants and		
CC	active fragments are claimed, as are recombinant cells (especially CHO,		
CC	murine melanoma, swine testes), vectors, and anti-cellular herpesvirus		
CC	protein compounds (II). Suitable (II) include antisense oligonucleotides,		
CC	antibodies specific for (I), peptides and peptidomimetics. Methods of		
CC	identifying (II), of inhibiting entry of an aHV into a cell using (II),		
CC	and of treating an aHV infection in an animal, especially a human, using		
CC	(II) are also claimed		
XX			
SQ	Sequence 20 BP; 8 A; 6 C; 6 G; 0 T; 0 U; 0 Other;		
XX			
Query Match	0.4%; Score 16.8; DB 1; Length 20;		
Best Local Similarity	90.0%; Pred. No. 1.8e+02;		
Matches 18; Conservative	0; Mismatches 2; Indels 0; Gaps 0;		
QY	1472 AGAAGCAGCAGCAGCAGCAG 1491		
Db	1 AGAAGCAGCAGCAGCAGCAG 20		
XX			
RESULT 168			
AA523716			
ID	AA523716 standard; DNA; 20 BP.		
XX			
AC	AA523716;		
XX			
DT	04-DEC-2001 (first entry)		
XX			
DE	Primer A #30 used as probe for identifying C. albicans GRACE strain.		
XX			
KM	Gene identification; essential gene; GRACE; pathogenic fungus;		
KM	gene replacement and conditional expression; fungal infection; probe; ss.		
XX			
OS	Candida albicans.		
OS	Synthetic.		
XX			
XX	WO200160975-A2.		
XX			

BD	23-AUG-2001.
XX	20-FEB-2001; 2001WO-US005551.
Pf	18-FEB-2000; 2000US-0183534P.
XX	(ELIT-) ELITRA PHARM INC.
PA	Roemer T, Jiang B, Boone C, Bussey H;
XX	WPI; 2001-489080/53.
DR	Identifying genes essential to fungal metabolisms and identifying
PT	potential therapeutic agents that target these genes.
XX	Disclosure; Page 306; 324pp; English.
XX	The present invention relates to novel methods for constructing fungal
CC	strains useful for identification and validation of gene products as
CC	targets for therapeutic agents, for creating a collection of identified
CC	essential genes, and screening assays for the discovery of new drugs. The
CC	invention provides the GRACE (gene replacement and conditional
CC	expression) method for the construction of mutant organisms referred to
CC	as GRACE strings of the organism. The invention can be applied to any
CC	organism, particularly a pathogenic fungus e.g. Candida albicans,
CC	Aspergillus fumigatus and Cryptococcus neoformans. The methods are useful
CC	to identify agents that may be used in the treatment of fungal
CC	infections. AAS33687-AAS23747 represent primers A #1-61 used as probes
CC	for identifying C. albicans GRACE strains
XX	Sequence 20 BP; 6 A; 1 C; 13 G; 0 T; 0 U; 0 Other;
SQ	
Query Match	0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity	90.0%; Pred.No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Oy	182 CGGAGCAGCGAGGAGAAG 201
Db	1 CGGAGGAGGAGGAGGAGG 20
RESULT 169	
ABK30536/c	
ID	ABK30536 standard; DNA; 20 BP.
XX	ABK30536;
AC	
XX	23-APR-2002 (first entry)
DT	
DE	Human glioma-associated oncogene-1 antisense oligonucleotide ISIS 124868.
XX	
KW	Human; glioma-associated oncogene-1 associated disease; infection;
KW	inflammation; tumour formation; cytostatic; antiinflammatory; antisense;
KW	phosphorothioate; ss.
XX	Homo sapiens.
OS	
XX	US6329203-B1.
PN	
PD	11-DEC-2001.
XX	
Pf	08-SEP-2000; 2000US-00657042.
XX	
PR	08-SEP-2000; 2000US-00657042.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	Bennett CF, Wyatt J;
Pi	
DR	WPI; 2002-138363/18.
XX	
PT	Novel antisense compounds targeted to nucleic acids encoding glioma-
XX	associated oncogene-1, for modulating the gene expression and treating

PT diseases associated with expression of the oncogene in humans.
XX
PS Claim 1; Col 45-46; 43pp; English.
XX
CC The present invention relates to antisense compounds and methods for
CC modulating the expression of human glioma-associated oncogene-1. The
CC antisense compound, particularly antisense oligonucleotides, target and
CC inhibit the expression of human glioma-associated oncogene-1. The
CC antisense compounds are useful for inhibiting the expression of human
CC glioma-associated oncogene-1 in human cells or tissues and for treating
CC an animal, particularly a human suspected of having or being prone to a
CC disease or condition associated with expression of glioma-associated
CC oncogene-1. The compounds are useful for diagnostics, therapeutics and as
CC research reagent, e.g. prophylactically to prevent or delay infection,
CC inflammation or tumour formation. The antisense compounds are safely and
CC effectively administered to humans. ABK30509-ABK30586 represent the
CC antisense oligonucleotides of the invention which comprise a
CC phosphorothioate backbone
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1479 GCAGCAGCAGCTCTCTGC 1498
DB 20 GCCGACGACGAGCTCCAGC 1
RESULT 170
ABL44419/C
ID ABL44419 standard; DNA; 20 BP.
XX
AC ABL44419;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 1p36-35 PCR primer SEQ ID NO:11463.
XX
KM Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
XX PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
XX (GENO-) GENOTEX YG.
XX
DR WPI; 2002-144136/19.
XX
PT Arraying genome clones.
XX
PS Claim 4; Page 33; 528pp; Japanese.
XX
CC The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified

CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 578 CTCCTACTGATGAGTCCCA 597
DB 20 CTCCTATGATGATTCCTCA 1
RESULT 171
ABZ29903
ID ABZ29903 standard; DNA; 20 BP.
XX
AC ABZ29903;
XX
DT 30-JAN-2003 (first entry)
XX
DE Candida albicans GRACE strain PCR primer SEQ ID NO 4054.
XX
KM Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;
XX signal transduction; DNA replication; cell division; growth;
XX proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
OS Candida albicans.
XX
PN WO200253728-A2.
XX
PD 11-JUL-2002.
XX
PF 26-DEC-2001; 2001WO-US049486.
XX
PR 29-DEC-2000; 2000US-0259128P.
XX 20-FEB-2001; 2001US-00792024.
XX 22-AUG-2001; 2001US-0314050P.
XX
PA (ELIT-) ELITRA PHARM INC.
XX
PI Roemer T, Jiang B, Boone C, Busey H, Ohlsen KL;
XX
DR WPI; 2002-566694/60.
XX
PT Constructing strains for identifying gene products as effective targets
PT for therapeutic intervention, by inactivating in the strain one allele of
PT a gene and placing other allele of the gene under conditional expression.
XX
PS Claim 36; SEQ ID NO 4054; 167pp + Sequence Listing; English.
XX
CC The invention relates to constructing (M1) a strain of diploid fungal
CC cells in which both alleles of a gene are modified, comprising modifying
CC one allele by insertion or replacement by a cassette having an
CC expressible selectable marker and modifying other allele by
CC recombination, of a promoter replacement fragment with a heterologous
CC promoter, so that expression of the second allele is regulated by the
CC promoter. (M1) is useful for constructing a strain of diploid fungal
CC cells in which both alleles of a gene are modified. The diploid fungal
CC cells having both alleles modified are useful for identifying a gene that
CC is essential to the survival or growth of a fungus, a gene that
CC contributes to the virulence and/or pathogenicity of a fungus, a gene
CC that contributes to the resistance of a diploid fungus to an antifungal
CC agent, an antifungal agent that inhibits the growth of a diploid fungus

CC and for identifying a therapeutic agent for treatment of a mammalian
CC disease. (M1) is useful for identifying a compound which modulates the
CC activity of a gene product, preferably enzymatic activity, carbon
CC compound catabolism, biosynthetic, transporter, transcriptional,
CC translational, signal transduction, DNA replication and cell division
CC activity. The method is useful for identifying a compound having the
CC ability to inhibit growth or proliferation of C. albicans cells and for
CC treating infection by C. albicans. The present sequence is that of a PCR
CC primer used in the method of the invention. Note: The sequence data for
CC this patent is not represented in the printed specification but is based
CC on sequence information supplied to Derwent by the European Patent Office
XX
SQ Sequence 20 BP, 6 A, 1 C, 13 G, 0 T, 0 U, 0 Other;
XX
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18, Conservative 0, Mismatches 2, Indels 0, Gaps 0;
QY 182 CGGAGAGAGAGAGAGAG 201
Db 1 CGGAGAGAGAGAGAGAG 20
RESULT 172
ABZ30367/c
ID ABZ30367 standard; DNA; 20 BP.
XX
AC ABZ30367;
XX
DT 30-JUN-2003 (first entry)
XX
DE Candida albicans GRACE strain PCR primer SEQ ID NO 4518.
XX
KM Fungus; Yeast; tetracycline; promoter; GRACE strain; biosynthesis;
XX signal transduction; DNA replication; cell division; growth; ss.
XX proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
OS Candida albicans.
XX
PN MO200253728-A2.
PD 11-JUL-2002.
XX
XX 26-DEC-2001; 2001WO-05049486.
XX
XX 29-DEC-2000; 2000US-0259128P.
XX 20-FEB-2001; 2001US-00792024.
XX 22-AUG-2001; 2001US-0314050P.
XX
XX (ELITRA) ELITRA PHARM INC.
XX
XX Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;
XX WPI, 2002-566694/60.
XX
XX Constructing strains for identifying gene products as effective targets
XX for therapeutic intervention, by inactivating in the strain one allele of
XX a gene and placing other allele of the gene under conditional expression.
XX
XX Claim 36; SEQ ID NO 4518; 167bp + Sequence Listing; English.
XX
XX The invention relates to constructing (M1) a strain of diploid fungal
XX cells in which both alleles of a gene are modified, comprising modifying
XX one allele by insertion or replacement by a cassette having an
XX expressible selectable marker and modifying other allele by
XX recombination, of a promoter replacement fragment with a heterologous
XX promoter, so that expression of the second allele is regulated by the
XX promoter. (M1) is useful for constructing a strain of diploid fungal
XX cells in which both alleles of a gene are modified. The diploid fungal
XX cells having both alleles modified are useful for identifying a gene that
XX is essential to the survival or growth of a fungus, a gene that
XX contributes to the virulence and/or pathogenicity of a fungus, a gene
XX that contributes to the resistance of a diploid fungus to an antifungal

CC agent, an antifungal agent that inhibits the growth of a diploid fungus
CC and for identifying a therapeutic agent for treatment of a mammalian
CC disease. (M1) is useful for identifying a compound which modulates the
CC activity of a gene product, preferably enzymatic activity, carbon
CC compound catabolism, biosynthetic, transporter, transcriptional,
CC translational, signal transduction, DNA replication and cell division
CC activity. The method is useful for identifying a compound having the
CC ability to inhibit growth or proliferation of C. albicans cells and for
CC treating infection by C. albicans. The present sequence is that of a PCR
CC primer used in the method of the invention. Note: The sequence data for
CC this patent is not represented in the printed specification but is based
CC on sequence information supplied to Derwent by the European Patent Office
XX
SQ Sequence 20 BP, 3 A, 4 C, 7 G, 6 T, 0 U, 0 Other;
XX
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18, Conservative 0, Mismatches 2, Indels 0, Gaps 0;
QY 1123 CAGCAGCTGCAGCAGCAGCA 1142
Db 20 CATCAGCTTCAGCAGCAGCA 1
RESULT 173
ABK44440/c
ID ABK44440 standard; DNA; 20 BP.
XX
XX ABK44440;
XX
XX 05-JUN-2002 (first entry)
XX
XX Human HPK/GCK-like kinase antisense oligonucleotide, ISIS 105339.
XX
XX Human: HPK/GCK-like kinase; antiinflammatory; cytosaratic; antimicrobial;
XX HSK; NIK; Nck-interacting kinase; infection; inflammation; tumour;
XX antisense gene therapy; antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; all cytidines are 5-
XX methylcytidines"
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX /note= "Optionally 2'-methoxyethyl (2'WOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "Optionally 2'-methoxyethyl (2'WOE) nucleotides"
XX
XX US6346416-B1.
XX
XX 29-AUG-2000; 2000US-00651011.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Dean NM, Cowsett LM,
XX WPI, 2002-237091/29.
XX
XX New antisense compound, useful for preventing or delaying infection,
XX inflammation or tumor formation, is targeted to nucleic acid molecule
XX encoding HPK/GCK-like kinase (HPK) and hybridizes and inhibits HPK

PT expression.
XX
PS Claim 14; Col 43-44; 37pp; English.
XX
CC The invention relates to an antisense compound (I) of 8-50 nucleobases in
CC length targeted to a start codon region, coding region or 3'-untranslated
CC region of a nucleic acid molecule encoding HPK/GCK (undefined)-like
CC kinase (HGK) (also known as NIK for Nck-interacting kinase), which
CC specifically hybridizes with and inhibits expression of HGK. (I) is
CC useful for inhibiting the expression of HPK/GCK-like kinase in cells or
CC tissues in vitro. (I) is useful prophylactically e.g. to prevent or delay
CC infection, inflammation and tumour formation. (I) is also useful as a
CC diagnostic and research reagent. (I) is also useful for distinguishing
CC functions of various members of a biological pathway and in antisense
CC gene therapy. The present sequence represents an antisense
CC oligonucleotide targeted to human HPK/GCK-like kinase
XX
SQ Sequence 20 BP; 7 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3493 TCCAGTCTGCTTCATGC 3512
Db 20 TCCGTGCTGATTCATGC 1
RESULT 174
ABK44420/c
ID ABK44420 standard; DNA; 20 BP.
XX
XX ABK44420;
XX
XX 05-JUN-2002 (first entry)
XX
XX Human HPK/GCK-like kinase antisense oligonucleotide, ISIS 105319.
DE
XX
XX Human; HPK/GCK-like kinase; antiinflammatory; cyostatic; antimicrobial;
KM HGK; NIK; Nck-interacting kinase; infection; inflammation; tumour;
XX antisense gene therapy; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethyl (2'MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethyl (2'MOE) nucleotides"
XX
XX US6346416-B1.
XX
XX 12-FEB-2002.
XX
XX 29-AUG-2000; 2000US-00651011.
XX
XX 29-AUG-2000; 2000US-00651011.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Dean NM, Cowbert LM;
XX
XX WPI; 2002-237091/29.

XX
XX New antisense compound, useful for preventing or delaying infection,
PT inflammation or tumor formation, is targeted to nucleic acid molecule
PT encoding HPK/GCK-like kinase (HGK) and hybridizes and inhibits HGK
PT expression.
XX
PS Claim 14; Col 43-44; 37pp; English.
XX
CC The invention relates to an antisense compound (I) of 8-50 nucleobases in
CC length targeted to a start codon region, coding region or 3'-untranslated
CC region of a nucleic acid molecule encoding HPK/GCK (undefined)-like
CC kinase (HGK) (also known as NIK for Nck-interacting kinase), which
CC specifically hybridizes with and inhibits expression of HGK. (I) is
CC useful for inhibiting the expression of HPK/GCK-like kinase in cells or
CC tissues in vitro. (I) is useful prophylactically e.g. to prevent or delay
CC infection, inflammation and tumour formation. (I) is also useful as a
CC diagnostic and research reagent. (I) is also useful for distinguishing
CC functions of various members of a biological pathway and in antisense
CC gene therapy. The present sequence represents an antisense
CC oligonucleotide targeted to human HPK/GCK-like kinase
XX
SQ Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1039 GTGCTGAGAGTGCACCT 1058
Db 20 GTGCTGAGAGTCTACTCT 1
RESULT 175
ADD71322
ID ADD71322 standard; DNA; 20 BP.
XX
XX ADD71322;
XX
XX 15-JAN-2004 (first entry)
DE
XX
XX Nucleic acid detection method-related universal DNA sequence #2.
DE
XX
XX Nucleic acid detection; nucleic acid quantitation; universal sequence;
KM ss.
XX
XX Synthetic.
OS
XX
XX WO2003078587-A2.
XX
XX 25-SEP-2003.
XX
XX 13-MAR-2003; 2003WO-US007818.
XX
XX 13-MAR-2002; 2002US-0364230P.
XX
XX (SYGN) SYNGENTA PARTICIPATIONS AG.
XX
XX (SHIL/) SHI L.
XX
XX Shi L;
XX
XX WPI; 2003-803888/75.
XX
XX
XX Detecting the presence of a target nucleic acid molecule in templates by
PT combining a detection probe, a first oligonucleotide, second
PT oligonucleotide, a primer and templates suspected of containing the
PT target nucleic acid molecule.
XX
XX
XX Example 2; SEQ ID NO 9; 42pp; English.
XX
XX The invention comprises a method for detecting a target nucleic acid
CC molecule in a plurality of templates, the method involves combining a
CC detection probe, a first oligonucleotide, second oligonucleotide, a
CC primer and a plurality of templates suspected of containing the target

CC nucleic acid molecule. The method of the invention is useful for
CC detecting the presence of a target nucleic acid molecule in a plurality
CC of templates. The method is also useful for quantitating a particular
CC nucleic acid molecule in a sample. The invention provides a rapid,
CC reliable and cost-effective method for detecting a particular nucleic
CC acid molecule in a sample. The present DNA sequence represents a
CC universal sequence that was used in an example of the invention.

XX
SQ Sequence 20 BP; 7 A; 0 C; 13 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 183 GGAGAGCAGAGAGAGAGA 202

Db 1 GGAGAGCAGAGAGAGAGA 20

RESULT 176
ABZ86069/c
ID ABZ86069 standard; DNA; 20 BP.

AC ABZ86069;

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.

XX Homo sapiens.

PN WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Claim 15; SEQ ID NO 1311; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1123 CAGCAGCTGCAGCAGCAGCA 1142

Db 20 CAGCAGCTGCAGCAGCAGCA 1

RESULT 177
ABZ86070/c
ID ABZ86070 standard; DNA; 20 BP.

AC ABZ86070;

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.

XX Homo sapiens.

PN WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Claim 15; SEQ ID NO 1312; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCAGCA 1116
DB 20 CAGCAGCAGCAGCAGCA 1

RESULT 178

AB286077/c
ID AB286077 standard; DNA; 20 BP.

AC AB286077;

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence:

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytoskeletal; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX NO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002MO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX WPI, 2003-229219/22.

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Claim 15; SEQ ID NO 1319; 872bp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytoskeletal activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 1 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 CAGCAGCAGCAGCAGCA 1142
DB 20 CAGCAGCAGCAGCAGCA 1

RESULT 179

AB298753
ID AB298753 standard; DNA; 20 BP.

AC AB298753;

DT 17-OCT-2003 (first entry)

DE Human cryptase b oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytoskeletal; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX NO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002MO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX WPI, 2003-229219/22.

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Disclosure; SEQ ID NO 13995; 872bp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytoskeletal activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCA 1136

Db 1 CAGCAGCAGCAGATTTCAGCA 20

RESULT 180
ABZ98885/c
ID ABZ98885 standard; DNA; 20 BP.

AC ABZ98885;

DT 17-OCT-2003 (first entry)

DE Human PDB4A oligonucleotide sequence.

KM Human; antiense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM adenosine gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX MO200285308-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013135.

PR 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

PI Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.

PS Disclosure; SEQ ID NO 14127; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 0 A; 10 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGAGAGAGAGAGAGAGA 202

Db 20 GGAGAGAGAGAGAGAGAAA 1

RESULT 181
ABZ84008/c
ID ABZ84008 standard; DNA; 20 BP.

AC ABZ84008;

DT 14-MAY-2003 (first entry)

DE Toxicologically relevant rat PCR primer #1167.

KM Toxicologically relevant gene; toxicological response; PCR primer; ss.
KM Rattus sp.
OS Synthetic.
XX MO2003016500-A2.

XX 27-FEB-2003.

PF 16-AUG-2002; 2002WO-US026514.

PR 16-AUG-2001; 2001US-0313080P.

XX (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.

PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schweisler K;

PI Alen P;

DR WPI; 2003-268322/26.

XX Determining a toxicological response to an agent, useful for screening of
PT drugs, comprises comparing the expression profile of one or more human
PT toxic response genes to a reference gene expression profile indicative of
XX toxicity.

PS Claim 1; Page 327; 455pp; English.

XX The present invention describes a method (M1) for determining a
CC toxicological response to an agent, which comprises comparing the
CC expression profile of one or more human toxic response genes to a
CC reference gene expression profile indicative of toxicity, and so
CC determining the presence of a toxic response to the agent. Also
CC described: (1) an array comprising one or more polynucleotides selected
CC from the genes corresponding to the partial sequences given in ABZ82842
CC ; and (2) determining if a gene putatively identified to be a toxic
CC response gene plays a role on toxic response pathways by determining the
CC expression profile of the gene after exposure of cells or a human subject
CC to a known toxic pharmaceutical or industrial agent, comprising: (a)
CC exposing cells to an agent or isolating cells from a human subject who
CC was exposed to an agent; (b) obtaining the test gene expression profile
CC for a putatively identified toxic response gene after exposure to a known
CC toxic pharmaceutical or industrial agent; and (c) comparing the test
CC profile to the expression profile of a gene with a similar function or

CC comparing the test profile to the expression profile of that gene after
 CC exposure to other known toxic compounds. The methods are useful for
 CC predicting and determining toxicological responses on a cellular, organ
 CC or system level. The arrays comprising the human genes are useful for
 CC toxicological screening of drugs, pharmaceutical compounds and chemicals
 CC

SO Sequence 20 BP; 0 A; 6 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.44; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1447 CAGCAGCAGCAGCAGCA 1466
 Db 20 CAGCAGCAGCAGCAGCA 1

RESULT 182

ACC47666
 ID. ACC47666 standard; DNA; 20 BP.

AC ACC47666;

DT 16-SEP-2003 (first entry)

XX Human IGFBP5 phosphorothioate antisense oligonucleotide, SEQ ID NO:42.

XX Human; insulin-like growth factor binding protein 5; IGFBP5; IBP5;
 XX chromosome 2q33-34; IGF signal transduction; IGF regulation; apoptosis;
 XX bone growth stimulator; hyperproliferative disorder; cancer; tumour;
 XX breast; prostate; pancreas; neuroendocrine; inflammatory disorder;
 XX colitis; developmental disorder; growth disorder;
 XX Duchenne muscular dystrophy; metabolic disorder; diabetes; osteoporosis;
 XX osteopetrosis; cytostatic; antiinflammatory; expression inhibition;
 XX phosphorothioate; antisense oligonucleotide; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 5 nucleotides in length. Also all
 FT cytosine residues are 5-methylcytosines"

XX MO2003030826-A2.

XX 17-APR-2003.

XX 07-OCT-2002; 2002MO-US032060.

XX 09-OCT-2001; 2001US-00975123.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM;

XX WPI; 2003-381673/36.

XX New antisense oligonucleotides for modulating insulin-like growth factor
 PT binding protein 5 gene expression, useful for preventing or treating
 PT cancers, inflammatory disorders, developmental disorders or metabolic
 PT disorders.

XX Claim 3; Page 76; 105pp; English.

XX Sequences ACC47637-ACC47667 represent phosphorothioate antisense
 CC oligonucleotides targeted to the human insulin-like growth factor binding
 CC protein 5 (IGFBP5) gene, which inhibit its expression. The antisense
 CC oligonucleotides were designed to target different regions of human
 CC IGFBP5 RNA, and were analysed for their effect on IGFBP5 expression by

CC quantitative real-time PCR. IGFBP5 (also known as IBP5) is a member of
 CC the insulin-like growth factor superfamily, which are involved in the
 CC regulation of IGF action and bioavailability, and which also mediate IGF-
 CC independent actions, including inhibition or enhancement of apoptosis.
 CC IGFBP5 is a key component of the IGF system in bone, having a high
 CC specific binding affinity for hydroxyapatite and extracellular matrix
 CC proteins, and appears to act as a growth factor, stimulating bone
 CC formation via an IGF-independent mechanism. IGFBP5 is also expressed in
 CC other tissues, such as kidney, liver, gut endothelium, lung tubules and
 CC mesenchyme, meninges, notochord, muscle and tongue. Its levels are also
 CC increased in inflamed colon smooth muscle cells in an experimental model
 CC of colitis. It is also thought to play a role in prostate cancer
 CC progression, is expressed with high frequency in neuroendocrine tumours,
 CC and has been shown to be induced in breast cancer cells upon treatment
 CC with antiestrogens used to abolish tamoxifen resistant proliferation.
 CC The oligonucleotides of the invention are useful for diagnosis,
 CC prevention and treatment of IGFBP5-related disorders, such as
 CC hyperproliferative disorders (particularly cancers of the breast,
 CC prostate, pancreas or neuroendocrine system), inflammatory disorders
 CC (e.g., colitis), developmental or growth disorders (e.g., Duchenne
 CC muscular dystrophy), or metabolic disorders (e.g., diabetes,
 CC osteopetrosis, or osteoporosis)

SO Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.44; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1267 CTCGAGAGAGAGAGCAGCA 1286
 Db 1 CTCGAGAGAGAGAGCGCGA 20

RESULT 183

ABSS58313
 ID ABSS58313 standard; DNA; 20 BP.

AC ABSS58313;

DT 21-FEB-2003 (first entry)

XX Silkworm spider dragline silk gene (MasP1) specific PCR primer #1.

XX Silkworm; primer; ss; spider drag-line; silk; fibroin; PCR; light chain;

XX L chain; MasP1.

XX Bombyx mori.

XX US2002137211-A1.

XX 26-SEP-2002.

XX 04-OCT-2001; 2001US-00969852.

XX 02-JAN-2001; 2001CN-00106406.

XX (UYSI-) UNIV SICHUAN TIANYOU BIOLOGIC ENG CO LTD.

XX Liu T, Liu H, Li W, Zhao L;

XX WPI; 2003-110604/10.

XX Establishing expression systems of spider drag-line silk genes in
 PT silkworms, by fusing silkworm fibroin L-chain cDNA and its promoter
 PT upstream of spider drag-line silk gene cDNA to direct drag-line protein
 PT expression and secretion.

XX Example 1; Page 2; 19pp; English.

XX This invention relates to a novel method for establishing an expression
 CC system of spider drag-line silk genes in silkworm by fusing the silkworm
 CC fibroin L-chain cDNA and its promoter upstream of the spider drag-line

CC silk gene cDNA, ligating the fused gene with a reporter gene and
CC inserting into a transposon to obtain a recombinant transposon which can
CC be used to transform a silkworm egg. The method of the invention is
CC useful for establishing an expression system of spider drag-line silk
CC gene in B. mori. The spider dragline silk gene product accounts for 30%
CC of total silk proteins. This method provides a rate of transformation of
CC about 0.5-1%. The present sequence represents a PCR primer used to
CC amplify the silkworm spider dragline silk gene (waspi) sequence used in
CC the method of the invention

XX
SQ Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Dy 1281 GCAGCAGCGCGCTGGAGG 1300
Db 1 GCAGCAGCAGCAGCTGGAGG 20

RESULT 184

ID ADM57531 standard; DNA; 20 BP.

XX ADM57531;

DT 03-JUN-2004 (first entry)

DE M. tuberculosis PCR primer katG-2154, 872-SEQ-R.

KW antibacterial; vaccine; mmp6; Mycobacterium; BCG; Tbd1; ss; PCR; primer.

OS Mycobacterium tuberculosis.

XX EP1338657-A1.

XX 27-AUG-2003.

PF 25-FEB-2002; 2002EP-00290458.

PR 25-FEB-2002; 2002EP-00290458.

XX (INSP) INST PASTEUR.

PI Cole S, Brosch R, Gordon S, Eiglmeier K, Garnier T;

DR WPI; 2003-699254/67.

PT New Tbd1 nucleic acids having the mutation CTG to CCG at codon 463 of
PT gene katG, useful for distinguishing Mycobacterium tuberculosis infection
PT from M. africanum, M. canettii, M. microti, M. bovis BCG
PT infection.

XX disclosure; Page 21; 73pp; English.

CC The invention relates to a novel isolated or purified nucleic acid. A
CC polypeptide encoded by a nucleic acid of the invention has antibacterial
CC activity, and may have a use in a vaccine. The nucleic acid is a Tbd1
CC nucleic acid having a fully defined sequence of 3953 bp given in the
CC specification. The Tbd1 deletion or mmp6 551 polymorphism is useful as a
CC genetic marker for the differentiation of Mycobacterium strain of M.
CC tuberculosis complex. The genetic marker in association with at least one
CC genetic markers selected from RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8,
CC RD9, RD10, RD11, RD13, RD14, RVD1, RVD2, RVD3, RVD4, RVD5, katG463,
CC gyrA5, oxyR285, and pncA57, may be used for the differentiation of
CC Mycobacterium strain of M. tuberculosis complex. The nucleic acids may
CC also be used to distinguish an infection resulting from M. tuberculosis
CC from an infection resulting from M. africanum, M. canettii, M. microti, M.
CC bovis, M. bovis BCG. The present sequence is used in the exemplification
CC of the invention.

SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Dy 446 ACAAGTGATCCATCGAGAC 465
Db 1 ACAAGTGATCCATCGAGAC 20

RESULT 185

ID ABD22299 standard; DNA; 20 BP.

XX ABD22299;

DT 29-JUL-2004 (first entry)

DE Human stemlocalcin-derived oligo SEQ ID 1311.

XX Human; antitense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX WO200285509-A2.

XX 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013143.

PR 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nwee JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

DR Miller S, Tang L, Shahbuddin S;

DR WPI; 2003-093058/08.

PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 1311; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC surfactant adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction.
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
CC
XX Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1123 CAGCAGCTGCAGCAGCA 1142
Db 20 CAGCGCGCGCAGCAGCA 1
RESULT 186
ABD22300/c
ID ABD22300 standard; DNA: 20 BP.
XX
AC ABD22300;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human stemlocalcin-derived oligo SEQ ID 1312.
XX
KW Human; anti-sense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
XX MO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
XX (EPiG-) EPIGENESIS PHARM INC.
XX
PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
XX
PT Pharmaceutical composition for treating asthma, has anti-sense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 1312; 763bp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or surfactant hypoproduction are associated
CC inflammation, allergies and/or bronchoconstriction and/or lung
CC with a disease or condition such as pulmonary vasoconstriction.
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
CC
XX Sequence 20 BP; 0 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1117 CAGCAGCAGCTGCAGCA 1136
Db 20 CAGCAGCAGCGCGCAGCA 1
RESULT 187
ABD31784
ID ABD31784 standard; DNA: 20 BP.
XX
AC ABD31784;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human Trypsinase b-derived oligonucleotide SEQ ID 13995.
XX
XX
KW Human; anti-sense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
XX MO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
XX (EPiG-) EPIGENESIS PHARM INC.
XX
PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
XX
PT Pharmaceutical composition for treating asthma, has anti-sense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and

PT 'bronchodilating agent.
 XX
 PS 'Claim 15; SEQ ID NO 13995; 763bp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1117 CAGCAGCAGCAGCTGCAGCA 1136
 Db 1 CAGCAGCAGCAGATTCAGCA 20
 RESULT 188
 ABB22307/C
 ID ABB22307 standard; DNA; 20 BP.
 XX
 AC ABB22307;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human stemlocalcin-derived oligo SEQ ID 1319.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KM surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KM analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KM respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KM pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX

PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIC-) EPIGENESIS PHARM INC.
 XX
 PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS 'Claim 15; SEQ ID NO 1319; 763bp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1123 CAGCAGCTGCAGCAGCA 1142
 Db 20 CAGCAGCTGCAGCAGCA 1
 RESULT 189
 ABB31916/C
 ID ABB31916 standard; DNA; 20 BP.
 XX
 AC ABB31916;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human PDB4A-derived oligonucleotide SEQ ID 14127.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KM surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KM analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KM

ID	Sequence	Score	DB	Length
RESULT 191				
ADJ32626/c	ADJ32626 standard; DNA, 20 BP.			
XX	ADJ32626;			
DT	22-APR-2004 (first entry)			
XX				
DE	Human ERK-6 specific antisense oligo, ISIS 157019.			
XX				
KW	Extracellular-signal-regulated kinase-6; ERK-6;			
KW	hyperproliferative disorder; cancer; inflammatory disorder;			
KW	neurodegenerative disorder; Alzheimer's disease; angiogenesis;			
KW	tubular formation; matrix degradation; human; antisense;			
KW	phosphorothioate backbone; therapy; ss.			
XX				
OS	Homo sapiens.			
XX	Synthetic.			
FT	Key	Location/Qualifiers		
FT	modified_base	1..20		
FT		/*tag= b		
FT		/mod_base= OTHER		
FT		/note= "Phosphorothioate backbone in which all cytidines		
FT		are 5-methylcytidines"		
FT	modified_base	1..5		
FT		/*tag= a		
FT		/mod_base= OTHER		
FT		/note= "2'-methoxyethyl residues"		
FT	modified_base	16..20		
FT		/*tag= c		
FT		/mod_base= OTHER		
FT		/note= "2'-methoxyethyl residues"		
XX				
XX	US2003232778-A1.			
PD	18-DEC-2003.			
XX				
XX	17-JAN-2003; 2003US-00348431.			
XX				
PR	17-JUN-2002; 2002US-00174465.			
XX				
PA	(MARC/) MARCUSON E G.			
PA	(BENN/) BENNETT C F.			
PA	(DOBI/) DOBIE K W.			
XX				
PI	Marcusson EG, Bennett CF, Dobie KW;			
DR	WPI; 2004-061312/06.			
XX				
PT	New compound targeted to a nucleic acid molecule encoding extracellular-			
PT	signal-regulated kinase-6, useful for treating angiogenic,			
PT	hyperproliferative (cancer), inflammatory or neurodegenerative disorders			
PT	(Alzheimer's disease).			
XX				
PS	Example 15; SEQ ID NO 19; 47bp; English.			
CC	The invention relates to antisense compounds, compositions and methods			
CC	for modulating the expression of extracellular-signal-regulated kinase-6			
CC	(ERK-6). The compound is useful in treating an animal having a disease o			
CC	condition associated with ERK-6, e.g. a hyperproliferative disorder			
CC	(especially cancer), an inflammatory disorder or a neurodegenerative			
CC	disorder (especially Alzheimer's disease). It is also useful for			
CC	inhibiting angiogenesis, for preventing tubular formation of blood			
CC	vessels, and for preventing degradation of extracellular matrix for new			
CC	blood vessel formation. The present sequence is an antisense			
CC	oligonucleotide targeted towards human ERK-6 DNA. This sequence is used			
CC	to illustrate the method of the invention.			
XX				
XX	Sequence 20 BP; 1 A; 8 C; 4 G; 7 T; 0 U; 0 Other;			
XX				
Query Match	0.43; Score 16.8; DB 1; Length 20;			
Best Local Similarity	90.03; Pred No. 1.8e+02;			

	Matches	18;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	1001	GC	CGATG	GAGGAGGAGGAG	1020					
DB	20	GC	CGATG	GAGGAGGAGGAG	1					
RESULT 192										
ID	ADJ60634	standard; DNA; 20 BP.								
XX	ADJ60634;									
AC	ADJ60634;									
XX	06-MAY-2004	(first entry)								
DE	Oligonucleotide	associated to Tryptase-b #3.								
XX	interleukin; IL-4 receptor; IL-5 receptor; lung disease;									
DE	airway inflammation; allergy; asthma; impeded respiration;									
XX	cystic fibrosis; acute respiratory distress syndrome;									
KW	pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;									
KW	8S.									
XX	Homo sapiens.									
OS	WO2004011613-A2.									
XX	05-FEB-2004.									
PD	25-JUL-2003;	2003WO-US023509.								
XX	25-JUL-2002;	2002US-0399076P.								
PF	29-JUL-2002;	2002US-0399076P.								
XX	(EPIG-) EPIGENESIS PHARM INC.									
PA	Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;									
PI	Shahabuddin S, Lu H, Cong H;									
PI	WPI; 2004-203534/19.									
DR	Novel single or multiple target oligonucleotide anti-sense to e.g.									
XX	initiation codons and introns of respiratory disease-relevant genes e.g.,									
PT	CCG1, RANES, MCP4, useful for prophylaxis or treating respiratory									
PT	disease e.g., asthma.									
XX	Claim 2; SEQ ID NO 1490; 85bp; English.									
PS	The present invention relates to an oligonucleotide anti-sense to e.g.,									
XX	initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-									
CC	end of nucleic acid target comprising gene(s) chosen from e.g.									
CC	interleukin (IL)-4 receptor, IL-5 receptor or salts of the									
CC	oligonucleotide and optionally surfactant operatively linked to the									
CC	oligonucleotide. The method is useful for preventing or treating a									
CC	respiratory or lung disease, which involves administering to the airways									
CC	of a subject an effective amount of an inhibitor. The oligonucleotide is									
CC	useful for production of a medicament for the prevention and/or treatment									
CC	of a respiratory or lung disease. The respiratory or lung disease is									
CC	chosen from airway inflammation, allergy(ies), asthma, impeded									
CC	respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases									
CC	(COPD), allergic rhinitis (AR), acute respiratory distress syndrome									
CC	(ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway									
CC	obstruction. The present sequence represents an oligonucleotide of the									
XX	invention.									
XX	Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;									
SQ	Query Match	0.4%; Score 16.8; DB 1; Length 20;								
	Best Local Similarity	90.0%; Pred. No. 1.8e+02;								
	Matches 18; Conservative	0; Mismatches 2; Indels 0; Gaps 0;								
QY	1117	CAG	CAGAGGAGGAGGAGGAGGAG	1136						
DB	1	CAG	CAGAGGAGGAGGAGGAGGAG	20						

XX SQ Sequence 20 BP; 0 A; 10 C; 0 G; 10 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 183 GGAGGACGAGGAGGAGGAGA 202
Db 20 GGAGGAGGAGGAGGAGGAGAA 1
RESULT 195
ADO46123
ID ADO46123 standard; DNA: 20 BP.
XX ADO46123;
AC
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1489.
XX
XX Human, s8; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KM CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KM tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KM lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KM asthma; lung allergy; inflammation; inflammatory disease;
KM airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KM chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KM acute respiratory distress syndrome; pulmonary hypertension;
KM lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
XX Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX PR 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX PA (SAND/) SANDRASAGRA A.
XX PA (TANG/) TANG L.
XX PA (AGUI/) AGUIAR D.
XX PA (MILL/) MILLER S.
XX PA (SHAH/) SHAHABUDDIN S.
XX PA (LUHH/) LU H.
XX PA (CONG/) CONG H.
XX
XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S,
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1490; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
CC 5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX SQ Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCAGCTGAGCA 1136
Db 1 CAGCAGCAGCAGATTGAGCA 20
RESULT 196
ADO48050
ID ADO48050 standard; DNA: 20 BP.
XX ADO48050;
AC
XX
XX 12-AUG-2004 (first entry)
XX
XX Human H1P-1 antisense oligonucleotide ISIS 251705.
XX
XX s8; Huntingtin interacting protein 1; H1P-1; H1P-1 protein interactor;
KM apoptosis dysregulation; antisense.
XX
XX Homo sapiens.
XX OS Synthetic.
XX PN US2004096834-A1.
XX
XX 20-MAY-2004.
XX
XX 19-NOV-2002; 2002US-00300263.
XX PF 19-NOV-2002; 2002US-00300263.
XX
XX 19-NOV-2002; 2002US-00300263.
XX PR 19-NOV-2002; 2002US-00300263.
XX
XX (ISIS-) ISIS PHARM INC.
XX PA
XX
XX Dobie KM;
XX
XX WPI; 2004-389149/36.
XX
XX New compounds targeted to a nucleic acid molecule encoding H1P-1 protein
PT interactor, useful for treating an animal having a disease or condition
PT associated with H1P-1 protein interactor, such as dysregulation of
PT apoptosis.
XX
XX Example 15; SEQ ID NO 60; 76pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding Huntingtin interacting protein 1 (H1P-1) protein interactor. The
CC compound is useful for treating an animal having a disease or condition
CC associated with H1P-1 protein interactor, such as dysregulation of
CC apoptosis. The compound may also be used for diagnostics, therapeutics,
CC prophylaxis and as research agents and kits; or to elucidate the function
CC of particular genes or to distinguish between functions of various
CC members of a biological pathway. The present sequence represents a human
CC H1P-1 antisense oligonucleotide.

XX Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

SO Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 AGCAGCAGCAGCTTCAGAAA 1476
 DB 1 AGCAGCAGCAGCTTCAGAAA 20

RESULT 197
 ADO48119/c
 ID ADO48119 standard; DNA; 20 BP.
 XX ADO48119;
 AC ADO48119;
 XX
 XX 12-AUG-2004 (first entry)
 DT
 XX
 XX Human HIP-1 target sequence ISIS 168221.
 DE
 XX
 XX ss; Huntingtin interacting protein 1; HIP-1; HIP-1 protein interactor;
 KW apoptosis dysregulation.
 KM
 XX Homo sapiens.
 OS
 XX US2004096834-A1.
 PN
 XX 20-MAY-2004.
 PD
 XX 19-NOV-2002; 2002US-00300263.
 XX
 XX 19-NOV-2002; 2002US-00300263.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Dobie KW;
 PI
 XX WPI; 2004-389149/36.
 DR
 XX
 XX
 XX New compounds targeted to a nucleic acid molecule encoding HIP-1 protein
 PT interactor, useful for treating an animal having a disease or condition
 PT associated with HIP-1 protein interactor, such as dysregulation of
 PT apoptosis.
 PT
 XX Example 15; SEQ ID NO 129; 76pp; English.
 PS
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding Huntingtin interacting protein 1 (HIP-1) protein interactor. The
 CC compound is useful for treating an animal having a disease or condition
 CC associated with HIP-1 protein interactor, such as dysregulation of
 CC apoptosis. The compound may also be used for diagnostics, therapeutics,
 CC prophylaxis and as research agents and kits; or to elucidate the function
 CC of particular genes or to distinguish between functions of various
 CC members of a biological pathway. The present sequence represents a human
 CC HIP-1 antisense oligonucleotide target sequence.
 CC
 SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 1457 AGCAGCAGCAGCTTCAGAAA 1476
 20 AGCAGCAGCAGCTTCAGAAA 1

RESULT 198
 ADO55804/c
 ID ADO55804 standard; DNA; 20 BP.
 XX

AC ADO55804;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 XX Human NIMA-related kinase 6 DNA, antisense oligonucleotide #27.
 DE
 XX Antisense therapy; human; NIMA-related kinase 6;
 XX never in mitosis gene a-related kinase 6; hyperproliferative disorder;
 KM cancer; cytoskeletal phosphorothioate; ss.
 KW
 XX Homo sapiens.
 XX
 OS
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 5 nucleotides in length at each
 FT end. All cytidine residues are 5-methylcytidines"
 XX
 XX US2004097441-A1.
 PN
 XX 20-MAY-2004.
 PD
 XX 16-NOV-2002; 2002US-00295471.
 PF
 XX 16-NOV-2002; 2002US-00295471.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Dobie KW;
 PI
 XX WPI; 2004-389184/36.
 DR
 XX
 XX
 XX New antisense oligonucleotides for modulating never in mitosis, gene a
 PT (NIMA)-related kinase 6 expression, useful for diagnosing, preventing or
 PT treating diseases associated with the kinase, e.g. hyperproliferative
 PT disorders.
 PT
 XX Example 15; SEQ ID NO 41; 51pp; English.
 PS
 XX The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding human never in mitosis gene a-related kinase 6
 CC (NIMA-related kinase 6). The antisense compound comprises an antisense
 CC oligonucleotide that specifically hybridizes with the nucleic acid and
 CC inhibits the expression of NIMA-related kinase 6. The antisense
 CC oligonucleotide is a chimeric oligonucleotide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
 CC moiety. The antisense oligonucleotide further comprises at least one
 CC modified nucleobase, preferably a 5-methylcytosine. The antisense
 CC oligonucleotides are useful for the treatment of diseases such as
 CC hyperproliferative disorders, e.g. cancer. The present sequence
 CC represents an antisense oligonucleotide used in the examples of the
 CC present invention.
 CC
 SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 451 GTGATCCATGAGACATCAA 470
 20 GTGATCCATGAGACATCAA 1

RESULT 199
 ADO55866
 ID ADO55866 standard; DNA; 20 BP.
 XX

AC	AD055866;
XX	
DT	12-AUG-2004 (first entry)
XX	
DE	Human NIMA-related kinase 6 DNA target sequence #20.
XX	
KW	Antisense therapy; human; NIMA-related kinase 6; never in mitosis gene a-related kinase 6; hyperproliferative disorder; cancer; cytostatic; ds.
XX	
OS	Homo sapiens.
PN	'US2004097441-A1.
PD	20-MAY-2004.
XX	
PX	16-NOV-2002; 2002US-00295471.
PR	16-NOV-2002; 2002US-00295471.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Doble KM;
XX	
WP	WPI; 2004-389184/36.
XX	
PT	New antisense oligonucleotides for modulating never in mitosis, gene a (NIMA)-related kinase 6 expression, useful for diagnosing, preventing or treating diseases associated with the kinase, e.g. hyperproliferative disorders.
PS	Example 15; SEQ ID NO 112; 51pp; English.
XX	
CC	The present invention relates to antisense compounds targeted to a nucleic acid encoding human never in mitosis gene a-related kinase 6 (NIMA-related kinase 6). The antisense compound comprises an antisense oligonucleotide that specifically hybridises with the nucleic acid and inhibits the expression of NIMA-related kinase 6. The antisense oligonucleotide is a chimeric oligonucleotide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotides are useful for the treatment of diseases such as hyperproliferative disorders, e.g. cancer. The present sequence represents a human NIMA-related kinase 6 DNA target sequence for an antisense oligonucleotide.
XX	
SQ	Sequence 20 BP, 7 A, 5 C, 5 G, 3 T, 0 U, 0 Other;
XX	
Query Match	0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity	90.0%; Pred. No. 1.8e+02;
Matches	18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
YY	451 GTGATCCATCGAGACATCAA 470
Db	1 GTGATGCACCGAGACATCAA 20
RESULT 200	
ADP20499	
ID	ADP20499 standard; DNA; 20 BP.
XX	
AC	ADP20499;
XX	
DT	26-AUG-2004 (first entry)
XX	
DE	Transcription factor AP-2 antisense oligonucleotide seqid 46.
XX	
KM	cyclostatic; AP-2-Inhibitor-Alpha; AP-2 alpha; AP-2 alpha modulator; AP-2 alpha associated disorder; hyperproliferative disorder; human; transcription factor; antisense oligonucleotide; antisense technology;

XX	SS.
XX	Homo sapiens.
XX	US2004109848-A1.
PN	
XX	10-JUN-2004.
PD	
XX	09-DEC-2002; 2002US-00315962.
PF	
XX	09-DEC-2002; 2002US-00315962.
XX	09-DEC-2002; 2002US-00315962.
PR	
XX	(ISIS-) ISIS PHARM INC.
PA	
XX	Bennett CF, Dean NM, Freter SM, Doble KW;
PI	
XX	WPI; 2004-440306/41.
DR	
XX	New compounds targeted to nucleic acid molecules encoding AP-2 alpha and
PT	inhibits the expression of AP-2 alpha, useful for treating AP-2 alpha-
PT	disease or condition, particularly a hyperproliferative
PT	disorder.
XX	
PS	Example 15; SEQ ID NO 46; 58pp; English.
XX	
CC	The invention describes a compound (I) 8-80 nucleobases in length
CC	targeted to a nucleic acid molecule encoding AP-2 alpha. The compound
CC	specifically hybridizes with a nucleic acid molecule encoding AP-2 alpha
CC	(1868 bp, SEQ ID NO: 4), and inhibits the expression of AP-2 alpha. Also
CC	described are: inhibiting the expression of AP-2 alpha in cells or tissues
CC	comprising contacting the cells or tissues with (I); screening for a
CC	modulator of AP-2 alpha by contacting a preferred target segment of a
CC	nucleic acid molecule encoding AP-2 alpha with one or more candidate
CC	modulators of AP-2 alpha, and identifying one or more modulators of AP-2
CC	alpha expression, which modulate the expression of AP-2 alpha; a
CC	diagnostic method for identifying a disease state; and a kit or assay
CC	device comprising (I). The compound is useful for treating an animal
CC	having a disease or condition associated with AP-2 alpha, particularly a
CC	hyperproliferative disorder. The compounds may be used for diagnostic,
CC	therapeutics prophylaxis and as research reagents; or as tools in
CC	differential and/or combinatorial analyses to elucidate expression
CC	patterns of a portion or the entire complement of genes expressed within
CC	cells and tissues. This sequence represents a human transcription factor
CC	AP-2 antisense oligonucleotide.
SQ	
XX	Sequence 20 BP; 6 A; 6 C; 7 G; 1 T; 0 U; 0 Other;
XX	
Query Match	0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity	90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0.	
OY	1119 GCAGCAGCAGCTGCAGCAGC 1138 1 GCACGACGACGACGACGTAGC 20
DB	
RESULT 201	
ADP27248/c	
ID	ADP27248 standard; DNA; 20 BP.
XX	
AC	ADP27248;
XX	
DT	26-AUG-2004 (first entry)
XX	
DE	Human MMP1 DNA antisense oligonucleotide target region #2.
XX	
KM	Human; matrix metalloproteinase 11; MMP11; ss, antisense oligonucleotide;
KM	phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
XX	5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX	
OS	Homo sapiens.
PN	US2004110152-A1.

XX 10-JUN-2004.
PD 10-DEC-2002; 2002US-00316755.
XX 10-DEC-2002; 2002US-00316755.
XX 10-DEC-2002; 2002US-00316755.
XX (ISIS-) ISIS PHARM INC.
PA Baker BF, Cowseert LM;
XX WPI; 2004-440341/41.
XX MPI; 2004-440341/41.
PT New oligonucleotide compound that inhibits expression of matrix
PT metalloproteinase 11, useful for preparing a composition for treating
XX hyperproliferative disorder, e.g., cancer.
XX Example 16; SEQ ID NO 174; 76bp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
CC is an antisense oligonucleotide that specifically hybridizes with the
CC nucleic acid and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of the MMP11 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents a human MMP11 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1131 GCAGCAGCAGCAGCAGCAG 1150
DB 20 GCAGCAGCAGCAGCAGCAGCAG 1
RESULT 202
ADP27093
ID ADP27093 standard; DNA; 20 BP.
XX
AC ADP27093;
XX
XX 26-AUG-2004 (first entry)
DT Human matrix metalloproteinase 11 DNA antisense oligonucleotide #2.
DE Human matrix metalloproteinase 11 DNA antisense oligonucleotide #2.
XX Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KM 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX
XX Homo sapiens.
OS
XX
XX US2004110152-A1.
PN 10-JUN-2004.
PD 10-DEC-2002; 2002US-00316755.
PF 10-DEC-2002; 2002US-00316755.
XX 10-DEC-2002; 2002US-00316755.
XX (ISIS-) ISIS PHARM INC.
PA Baker BF, Cowseert LM;
XX WPI; 2004-440341/41.
XX

PT New oligonucleotide compound that inhibits expression of matrix
PT metalloproteinase 11, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX Example 15; SEQ ID NO 19; 76bp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
CC is an antisense oligonucleotide that specifically hybridizes with the
CC nucleic acid and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of the MMP11 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents an antisense oligonucleotide
CC targeted to DNA encoding the human MMP11 polypeptide of the invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1131 GCAGCAGCAGCAGCAGCAG 1150
DB 1 GCAGCAGCAGCAGCAGCAGCAG 20
RESULT 203
ADP27094
ID ADP27094 standard; DNA; 20 BP.
XX
AC ADP27094;
XX
XX 26-AUG-2004 (first entry)
DT Human matrix metalloproteinase 11 DNA antisense oligonucleotide #3.
DE Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KM 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX
XX Homo sapiens.
OS
XX
XX US2004110152-A1.
PN 10-JUN-2004.
PD 10-DEC-2002; 2002US-00316755.
PF 10-DEC-2002; 2002US-00316755.
XX 10-DEC-2002; 2002US-00316755.
XX (ISIS-) ISIS PHARM INC.
PA Baker BF, Cowseert LM;
XX WPI; 2004-440341/41.
XX
XX MPI; 2004-440341/41.
PT New oligonucleotide compound that inhibits expression of matrix
PT metalloproteinase 11, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX Example 15; SEQ ID NO 20; 76bp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
CC is an antisense oligonucleotide that specifically hybridizes with the
CC nucleic acid and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of the MMP11 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents an antisense oligonucleotide
CC targeted to DNA encoding the human MMP11 polypeptide of the invention.

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of the MMP11 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents an antisense oligonucleotide
CC targeted to DNA encoding the human MMP11 polypeptide of the invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 9 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1125 GCAGCTGCAGCAGCAGCAGC 1144
DB 1 GCAGCTGCAGCAGCAGCAGC 20
RESULT 204
ADP27249/c
XX ADP27249 standard; DNA; 20 BP.
XX
AC ADP27249,
XX
DT 26-AUG-2004 (first entry)
XX
DE Human MMP11 DNA antisense oligonucleotide target region #3.
XX
XX Human: matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
KM phosphothioate linkage; 2'-O-methoxyethyl sugar moiety;
KM 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX
OS Homo sapiens.
XX
PN US2004110152-A1.
XX
PD 10-TUN-2004.
XX
XX 10-DEC-2002; 2002US-00316755.
XX
XX 10-DEC-2002; 2002US-00316755.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Baker BF, Cowseart LM;
XX
DR WPI; 2004-440341/41.
XX
XX 'New oligonucleotide compound that inhibits expression of matrix
PT metalloproteinase 11, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX
XX Example 16; SEQ ID NO 175; 76pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
CC is an antisense oligonucleotide that specifically hybridizes with the
CC nucleic acid and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of the MMP11 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents a human MMP11 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 1 A; 9 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1125 GCAGCTGCAGCAGCAGCAGC 1144

DB 20 GCAGCTGCAGCAGCAGCAGC 1
RESULT 205
ADT00354
ID ADT00354 standard; DNA; 20 BP.
XX
XX ADT00354;
AC
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID342.
XX
XX tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KM tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KM GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
KM guanylate cyclase stimulator; ss.
XX
XX Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
XX 18-FEB-2004; 2004WO-US004452.
XX
XX 21-FEB-2003; 2003US-0448537P.
PR 29-MAY-2003; 2003US-0473895P.
XX
XX (UYUO) UNIV JOHNS HOPKINS.
XX
XX Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
PI WPI; 2004-718702/70.
XX
XX
XX Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.
XX
PS Disclosure; SEQ ID NO 342; 363pp; English.
XX
XX This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytostatic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2976 GATCCGAGATACAGAGAC 2995
DB 1 GATCCGAGATACAGAGATGC 20
RESULT 206
ABK70327
ID ABK70327 standard; DNA; 21 BP.
XX
XX ABK70327;
XX

or failure, or for preparing pharmaceutical for preventing or treating disease or failure. (1) has antidiabetic, nootropic, hypotensive, antihypertensive, antierectile, anorectic, cytotactic, antiallergic, antibacterial, carian, CNS, antifertility, ophthalmological and virulence activities, and can be used as a suppressor of pathogen gene expression. (1) is useful in cancer treatment, preferably for hematopoietic tumor. The factor causing RNAi with respect to a pathogen gene of (1) is useful for preventing or treating the disease or failure resulting from a pathogen gene, which involves administering the factor of (1) to the subject for preventing or treating the diseases or failure. (1) is useful for treating cancer such as breast cancer, hepatic carcinoma, stomach cancer, cervical cancer, prostatic cancer, rectinoblastoma, malignant lymphoma, oesophageal cancer, brain tumour and is also useful for treating infectious disease by virus or bacteria, allergy, hypertension, hyperlipidaemia, diabetes, cerebral infarction, dementia, obesity, arteriosclerosis, sterility, central-nervous disease, cataract, progeria. (1) enhances the effect of another anticancer agent or radiotherapy in treating cancer. The present sequence represents a human Rad51 related RNA oligonucleotide, which is used in the exemplification of the present invention.

Sequence 22 BP, 6 A, 4 C, 6 G, 0 T, 6 U, 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 22;
Best Local Similarity 60.0%; Pred. No. 2.1e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 3499 GCTGCTTCATGCTGTGGA 3518
DB 3 GCTGGAUUCACUACUGUGA 22

RESULT 211
AA098457/C

ID AA098457 standard; cDNA; 31 BP.

AC AA098457;

XX 23-APR-1996 (first entry)

DE Sense probe CAG-30.

XX Probe; trinucleotide repeat; myotonic dystrophy; DM; Mt-PK gene;
KM fluorescent label; fluorescein isothiocyanate; fragile X syndrome;
KM muscular dystrophy; Huntington's disease; ss.

XX Synthetic.

OS W09525179-A1.

PN 21-SEP-1995.

XX 08-MAR-1995; 95MO-US002861.

XX 17-MAR-1994; 94US-00214823.

XX (UYMA-) UNITV MASSACHUSETTS MEDICAL CENT.

PI Slinger RH, Taneja KL;

DR WPI; 1995-336982/43.

XX Detecting tri-nucleotide repeat expansion by in situ hybridisation - with
PT detection sensitive enough to distinguish between probe bound to expanded
PT and normal repeat regions, esp. for myotonic dystrophy diagnosis.

XX Disclosure; Page 38; 51pp; English.

XX The sequences represented by AA098457 and AA098458 are synthetic probes
CC for the trinucleotide repeat CTG. These probes can be used in a method of
CC in situ hybridisation for the detection of a trinucleotide repeat
CC expansion. These probes were used specifically to identify myotonic
CC dystrophy (DM). DM is associated with an expanded CTG repeat in the 3'

CC untranslated region of the Mt-PK gene. These probes are labelled with a
CC fluorescent label (e.g. fluorescein isothiocyanate) and then used to
CC treat nucleated cells. The hybridisation of the probe to the expanded
CC trinucleotide repeat can then be detected by fluorescence microscopy. Due
CC to the large variation between expanded repeat size, and normal repeat
CC size in DM (5-27 repeats in non-expanded, 50-2000 repeats in expanded),
CC the expanded repeat will bind more probes. Only the expanded repeat will
CC bind enough of the probes to give a detectable fluorescent signal. By
CC detecting the number of transcripts in a cell of a diagnosed individual,
CC progress of treatment, and severity of the disease can be monitored. This
CC method can also be used to diagnose other diseases associated with
CC trinucleotide repeat expansions, such as fragile X syndrome, muscular
CC dystrophy and Huntington's disease. For some of these diseases a greater
CC detection specificity would be required due to the smaller difference in
CC repeat number between normal and infected individuals

Sequence 31 BP, 10 A, 10 C, 10 G, 1 T, 0 U, 0 Other;

Query Match 0.4%; Score 16.6; DB 1; Length 31;
Best Local Similarity 71.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1116 ACAGCAGCAGCAGCTGACGACGACGAG 1146
DB 31 ACTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 212
AAZ24996/C

ID AAZ24996 standard; DNA; 31 BP.

AC AAZ24996;

XX 24-DEC-1999 (first entry)

DE Oligonucleotide CAG30 targeted to myotonic-protein kinase gene.

XX Trinucleotide repeat; myotonic-protein kinase; myotonic dystrophy; probe;
KM in situ hybridisation; detection; expansion; fragile X syndrome; ss.

XX Synthetic.

OS Homo sapiens.

XX US5962332-A.

XX 05-OCT-1999.

XX 11-DEC-1995; 95US-00570155.

XX 17-MAR-1994; 94US-00214823.

XX 07-MAR-1995; 95US-00399499.

XX (UYMA-) UNITV MASSACHUSETTS.

PI Taneja KL, Slinger RH;

DR WPI; 1999-579615/49.

XX Detection of trinucleotide repeats.

XX Disclosure; Col 25; 18pp; English.

XX Oligonucleotides AAZ24983-224995 are targeted to the CTG trinucleotide
CC repeats found in the myotonic-protein kinase (Mt-PK) gene. Excessive
CC numbers of the trinucleotide repeats in the Mt-PK gene leads to the
CC disease myotonic dystrophy. The oligonucleotides are used to probe the 5'
CC -most 7 exons of 14 in the Mt-PK gene. This sequence is used as an
CC antisense control oligonucleotide for the hybridisation reaction. The
CC inversion relates to a method for the detection of trinucleotide repeat
CC expansion, e.g. in the Mt-PK gene or FMR1 gene (leading to fragile X
CC syndrome) by in situ hybridization

Sequence 31 BP, 10 A, 10 C, 10 G, 1 T, 0 U, 0 Other;

Query Match 0.4%; Score 16.6; DB 1; Length 31;
 Best Local Similarity 71.0%; Pred. No. 3.6e+02;
 Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1116 ACAGCAGCAGCAGCTGCAGCAGCAGCAG 1146
 DB 31 ACTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 213
 ID AAX67192/C
 AC AAX67192 standard; RNA; 18 BP.
 XX AAX67192;
 XX

DT 20-JUL-1999 (first entry)
 XX
 XX Human CD40 hairpin ribozyme target SEQ ID NO:3824.

XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 KM hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KM streptolysin; synovial membrane; joint; arthritis; osteoarthritis;
 KM rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KM diagnosis; ss.

XX Homo sapiens.

XX MO9618736-A2.

XX 20-JUN-1996.

XX 22-NOV-1995; 95MO-US015516.

XX 13-DEC-1994; 94US-00354920.

XX 23-DEC-1994; 94US-00363253.

XX 17-FEB-1995; 95US-00390850.

XX 20-APR-1995; 95US-00426124.

XX 02-MAY-1995; 95US-00432874.

XX 04-MAY-1995; 95US-00434509.

XX 07-JUL-1995; 95US-0000951P.

XX 07-JUL-1995; 95US-0000974P.

XX 07-AUG-1995; 95US-00512861.

XX 05-OCT-1995; 95US-00541365.

XX (RIBO-) RIBOZYME PHARM INC.

XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P,
 PI Moswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpelsky A, Thompson JD, Modak A, Burgin A;
 XX WPI; 1996-300653/30.

XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.

XX Claim 10; Page 218; 307pp; English.

XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC (iii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and streptolysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an allograft of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC streptolysin without introducing the non-specific effects upon gene

CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

XX Sequence 18 BP; 1 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

QY 1440 CCTGCAGCAGCAGCAACA 1457
 DB 18 CCTGCAGCAGCAGCAACA 1

RESULT 214
 ID AAV08612/C
 AC AAV08612 standard; DNA; 18 BP.
 XX AAV08612;
 XX

DT 15-FEB-1999 (first entry)
 XX
 XX Primer ACP/3FT for human ACE gene.

XX PCR primer; human; ACE; angiotensin converting enzyme; angiotensinogen;
 KM cardiovascular status; AGT; AT1; type 1 angiotensin II receptor; stroke;
 KM polymorphic pattern; blood pressure; electrocardiographic profile;
 KM cardiac condition diagnosis; myocardial infarction; atherosclerosis;
 KM hypertension; cardiovascular disease; ss.

XX Synthetic.

XX Homo sapiens.

XX MO9845477-A2.

XX 15-OCT-1998.

XX 01-APR-1998; 98MO-IB000475.

XX 04-APR-1997; 97US-0042930P.

XX (EURO-) EURONA MEDICAL AB.

XX Norberg LT, Andersson MK, Lindstrom PHR;
 XX WPI; 1998-568361/48.

XX Assessing cardiovascular status in humans by polymorphic analysis - of
 PT genes for angiotensin converting enzyme, angiotensinogen and angiotensin
 PT II receptor, used to diagnose predisposition to disease and to predict
 PT effect of therapy.

XX Example 1; Page 29; 71pp; English.

XX This sequence represents a PCR primer for the human ACE (angiotensin
 CC converting enzyme) gene, and can be used in the method of the invention.
 CC The method is for assessing cardiovascular status in humans by
 CC determining the sequence of at least one polymorphic site in the ACE
 CC (angiotensin converting enzyme), AGT (angiotensinogen) and/or AT1 (type 1
 CC angiotensin II receptor) genes, and comparing the polymorphic pattern
 CC with that in patients with predetermined markers of status. The method is
 CC used to assess blood pressure or electrocardiographic profile, to
 CC diagnose a cardiac condition such as (silent) myocardial infarction (MI),
 CC hypertension, atherosclerosis or stroke. They can also be used to predict
 CC response to treatments with ACE inhibitors, angiotensin II receptor
 CC antagonists, diuretics, alpha- or beta-adrenergic receptor antagonists,
 CC etc. It is also used to identify susceptibility to cardiovascular
 CC disease. Libraries of nucleic acids containing polymorphic positions in
 CC the 3 genes, and libraries of targets corresponding to the peptides from
 CC the genes are used to screen for cardiovascular agents. The nucleic acids

CC contained in the library can be is used as source of probes
 XX Sequence 18 BP, 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGCTCTGAGGGGCTC 3153
 DB 18 GAGGTCTGAGGGGCTC 1

RESULT 215
 AA08618/c
 ID AA08618 standard; DNA; 18 BP.

XX AA08618;
 DT 15-FEB-1999 (first entry)
 DE Primer ACP/11PB for human ACE gene.

XX PCR primer; human; ACE; angiotensin converting enzyme; angiotensinogen;
 KM cardiovascular status; AGT; AT1; type 1 angiotensin II receptor; stroke;
 KM polymorphic pattern; blood pressure; electrocardiographic profile;
 KM cardiac condition diagnosis; myocardial infarction; atherosclerosis;
 KM hypertension; cardiovascular disease; ss.

XX Synthetic.
 OS Homo sapiens.

XX MO9845477-A2.

XX 15-OCT-1998.

XX 01-APR-1998; 98WO-IB000475.

XX 04-APR-1997; 97US-0042930P.

XX (EURO-) EURONA MEDICAL AB.

PI Norberg LT, Andersson MK, Lindstroem PHR;

XX WPI; 1998-568361/48.

XX Assessing cardiovascular status in humans by polymorphic analysis - of
 PT genes for angiotensin converting enzyme, angiotensinogen and angiotensin
 PT II receptor, used to diagnose predisposition to disease and to predict
 PT effect of therapy.

XX Example 1; Page 29; 71pp; English.

XX This sequence represents a PCR primer for the human ACE (angiotensin
 CC converting enzyme) gene, and can be used in the method of the invention.
 CC The method is for assessing cardiovascular status in humans by
 CC determining the sequence of at least one polymorphic site in the ACE
 CC (angiotensin converting enzyme), AGT (angiotensinogen) and/or AT1 (type 1
 CC angiotensin II receptor) genes, and comparing the polymorphic pattern
 CC with that in patients with predetermined markers of status. The method is
 CC used to assess blood pressure or electrocardiographic profile, to
 CC diagnose a cardiac condition such as (silent) myocardial infarction (MI),
 CC hypertension, atherosclerosis or stroke. They can also be used to predict
 CC response to treatments with ACE inhibitors, angiotensin II receptor
 CC antagonists, diuretics, alpha- or beta-adrenergic receptor antagonists,
 CC etc. It is also used to identify susceptibility to cardiovascular
 CC disease, libraries of nucleic acids containing polymorphic positions in
 CC the 3 genes, and libraries of targets corresponding to the peptides from
 CC the 3 genes are used to screen for cardiovascular agents. The nucleic acids
 CC contained in the library can be is used as source of probes
 XX Sequence 18 BP; 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGCTCTGAGGGGCTC 3153
 DB 18 GAGGTCTGAGGGGCTC 1

RESULT 216
 AAA38240/c
 ID AAA38240 standard; DNA; 18 BP.

XX AAA38240;
 DT 21-AUG-2000 (first entry)
 DE Human ACE regulatory region PCR primer, SEQ ID NO:40.

XX Angiotensin-converting enzyme gene; ACE; regulatory region; polymorphism;
 KM polymorphic marker; cardiovascular disease; myocardial infarction;
 KM unstable angina; hypertension; atherosclerosis; stroke; prognosis;
 KM drug screening; treatment outcome; human; PCR primer; ss.

XX Homo sapiens.

XX MO200022166-A2.

XX 20-APR-2000.

XX 13-OCT-1999; 99WO-IB001678.

XX 14-OCT-1998; 98US-0104286P.

XX 14-OCT-1998; 98US-0104302P.

XX (EURO-) EURONA MEDICAL AB.

PI Norberg LT, Andersson MK, Lindstrom PHR, Jonsson L;

XX WPI; 2000-318010/27.

XX Assessing cardiovascular status in humans involves comparing test
 PT polymorphic pattern comprising polymorphic positions within genes
 PT encoding specific proteins, with reference polymorphic pattern.
 XX Example 1; Page 50; 126pp; English.

XX The invention relates to a novel method of assessing the cardiovascular
 CC status in an individual and to newly identified polymorphisms in the
 CC genes encoding angiotensin-converting enzyme (ACE), angiotensin II
 CC receptor type 1 (AT1) and type 2 (AT2), angiotensinogen (AGT), renin,
 CC aldosterone synthase, endothelin receptor type A and beta-adrenergic
 CC receptors 1 and 2. The method comprises determining the sequence at one
 CC or more polymorphic positions within these genes, and comparing the
 CC pattern of polymorphisms from the individual with a reference polymorphic
 CC pattern obtained from a population of individuals exhibiting a
 CC predetermined cardiovascular disease status. The polymorphic markers are
 CC useful for determining the predisposition of an individual to
 CC cardiovascular disorders such as myocardial infarction, unstable angina,
 CC hypertension, atherosclerosis and stroke. They are also useful for
 CC predicting the likely cardiovascular status of a patient given a
 CC treatment regimen comprising administration of cardiovascular drugs
 CC (e.g., ACE inhibitors, beta-adrenergic receptor antagonists (beta-
 CC blockers) or calcium channel blockers). One or more polymorphic markers
 CC provides a basis for predicting the outcome of a treatment regimen.
 CC Fragments of the genes comprising a polymorphic site may be used as
 CC primers and probes for detecting genetic polymorphisms or in molecular
 CC library arrays for high throughput screening. The genes, and the proteins
 CC they encode are useful in the screening of potential cardiovascular
 CC drugs. Determination of an individual's polymorphic pattern reduces or
 CC eliminates trial and error in selecting a treatment for a particular
 CC individual cardiovascular patient. It also provides the ability to
 CC eliminate patients from clinical trials who are predicted to be non-

CC responsive, or at a risk for an adverse response, to a particular
 CC treatment regimen. Adverse results in an early trial can be evaluated to
 CC identify polymorphic patterns so that the adverse results can be
 CC correlated with a sub-population of the test population, permitting
 CC exclusion of such sub-populations from the treatment group. Beneficial
 CC drugs can be approved for use in the appropriate population, thereby
 CC decreasing the number of patients required for a clinical trial, which in
 CC turn decreases the duration and cost of such trials. Sequences AAA38240-
 CC A38251 represent PCR primers used in an exemplification of the invention
 CC to amplify short fragments of the human ACE gene regulatory region
 CC (AAA38329) for sequence determination

XX
 SQ Sequence 18 BP; 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
 DB 18 GAGGTCTGTGAGGGGCTC 1

RESULT 217
 AAA38246/C
 ID AAA38246 standard; DNA; 18 BP.
 AC AAA38246;
 XX
 DT 21-AUG-2000 (first entry)
 XX
 DE Human ACE regulatory region PCR primer, SEQ ID NO:46.
 XX
 XX Angiotensin-converting enzyme gene; ACE; regulatory region; polymorphism;
 KM polymorphic marker; cardiovascular disease; myocardial infarction;
 KM unstable angina; hypertension; atherosclerosis; stroke; prognosis;
 KM drug screening; treatment outcome; human; PCR primer; 58.
 XX
 XX Homo sapiens.
 OS
 XX WO200022166-A2.
 PN
 XX 20-APR-2000.
 PD
 XX 13-OCT-1999; 99WO-1B001678.
 PF
 XX 14-OCT-1998; 98US-0104286P.
 PR 14-OCT-1998; 98US-0104302P.
 XX
 XX (EURO-) EURONA MEDICAL AB.
 PA
 XX Norberg LT, Andersson MK, Lindstrom PHR, Jonsson L;
 PI
 XX WPI; 2000-318010/27.
 DR
 XX
 XX Assessing cardiovascular status in humans involves comparing test
 PT polymorphic pattern comprising polymorphic positions within genes
 PT encoding specific proteins, with reference polymorphic pattern.
 XX
 XX Example 1; Page 50; 126pp; English.
 PS
 XX The invention relates to a novel method of assessing the cardiovascular
 CC status in an individual and to newly identified polymorphisms in the
 CC genes encoding angiotensin-converting enzyme (ACE), angiotensin II
 CC receptor type 1 (AT1) and type 2 (AT2), angiotensinogen (AGT), renin,
 CC aldosterone synthase, endothelin receptor type A and beta-adrenergic
 CC receptors 1 and 2. The method comprises determining the sequence at one
 CC or more polymorphic positions within these genes, and comparing the
 CC pattern of polymorphisms from the individual with a reference polymorphic
 CC pattern obtained from a population of individuals exhibiting a
 CC predetermined cardiovascular disease status. The polymorphic markers are
 CC useful for determining the predisposition of an individual to
 CC cardiovascular disorders such as myocardial infarction, unstable angina,

CC hypertension, atherosclerosis and stroke. They are also useful for
 CC predicting the likely cardiovascular status of a patient given a
 CC treatment regimen comprising administration of cardiovascular drugs
 CC (e.g., ACE inhibitors, beta-adrenergic receptor antagonists (beta-
 CC blockers) or calcium channel blockers). One or more polymorphic markers
 CC provides a basis for predicting the outcome of a treatment regimen.
 CC Fragments of the genes comprising a polymorphic site may be used as
 CC primers and probes for detecting genetic polymorphisms or in molecular
 CC library arrays for high throughput screening. The genes, and the proteins
 CC they encode are useful in the screening of potential cardiovascular
 CC drugs. Determination of an individual's polymorphic pattern reduces or
 CC eliminates trial and error in selecting a treatment for a particular
 CC individual cardiovascular patient. It also provides the ability to
 CC eliminate patients from clinical trials who are predicted to be non-
 CC responsive, or at a risk for an adverse response, to a particular
 CC treatment regimen. Adverse results in an early trial can be evaluated to
 CC identify polymorphic patterns so that the adverse results can be
 CC correlated with a sub-population of the test population, permitting
 CC exclusion of such sub-populations from the treatment group. Beneficial
 CC drugs can be approved for use in the appropriate population, thereby
 CC decreasing the number of patients required for a clinical trial, which in
 CC turn decreases the duration and cost of such trials. Sequences AAA38240-
 CC A38251 represent PCR primers used in an exemplification of the invention
 CC to amplify short fragments of the human ACE gene regulatory region
 CC (AAA38329) for sequence determination

XX
 SQ Sequence 18 BP; 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTCGTGAGGGGCTC 3153
 DB 18 GAGGTCTGTGAGGGGCTC 1

RESULT 218
 AAC61246/C
 ID AAC61246 standard; DNA; 18 BP.
 AC AAC61246;
 XX
 DT 30-JAN-2001 (first entry)
 XX
 DE Human ACE, AGT and AT1 genes polymorphisms PCR primer SEQ ID NO: 46.
 XX
 XX Human; genetic polymorphism; disease diagnosis; treatment; cancer;
 KM cardiovascular system; nervous system; glaucoma; PCR primer; 58.
 XX
 XX Homo sapiens.
 OS
 XX WO200056922-A2.
 PN
 XX 28-SEP-2000.
 PD
 XX 23-MAR-2000; 2000WO-GB001102.
 PF
 XX 23-MAR-1999; 99US-0126046P.
 PR 23-MAR-1999; 99WO-1B000497.
 PR 24-MAR-1999; 99US-0126243P.
 PR 23-DEC-1999; 99US-00471890.
 XX
 XX (GEMI-) GEMINI GENOMICS AB.
 PA
 XX Lindstrom PHR, Norberg LT, Jonsson L, Olaiasson E, Sanders R;
 PI
 XX WPI; 2000-638268/61.
 DR
 XX
 XX Assessing disease status in individual by determining sequence(s) at one
 PT or more polymorphic positions within the human genes encoding the
 PT protein(s) involved in physiological pathway associated with treatment
 PT regime.

```

XX PS Example 1, Page 57; 141pp; English.
XX CC The present invention is related to methods for determining the
XX CC polymorphic pattern of an individual and using the results to determine
XX CC their risk of a number of diseases, including cancer, cardiovascular
XX CC diseases, glaucoma and nervous system disorders such as depression and
XX CC neurodegenerative diseases. In addition, the methods can be used to
XX CC determine the effects of different types of treatment for individuals,
XX CC and thus enable appropriate therapies to be prescribed. The PCR primers
XX CC shown in sequences AAC61201-C61371 were all used to demonstrate the
XX CC methods of the invention
SQ Sequence 18 BP; 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;
QY Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DB 3136 GATGTGCTGAGGGGCTC 3153
18 GAGTGCTGAGGGGCTC 1
RESULT 219
AAC61240/C
ID AAC61240 standard; DNA; 18 BP.
AC AAC61240;
XX 30-JAN-2001 (first entry)
XX DE Human ACE, AGT and ATI genes polymorphisms PCR primer SEQ ID NO: 40.
XX KW Human; genetic polymorphism; disease diagnosis; treatment; cancer;
XX KW cardiovascular system; nervous system; glaucoma; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200056922-A2.
XX PD 28-SEP-2000.
XX PR 23-MAR-2000; 2000MO-GB001102.
XX PR 23-MAR-1999; 99US-0126046P.
XX PR 23-MAR-1999; 99WO-1B000497.
XX PR 24-MAR-1999; 99US-0126243P.
XX PR 23-DEC-1999; 99US-00471890.
XX PA (GEM1-) GEMINI GENOMICS AB.
XX PI Lindstrom PHR, Norberg LT, Jonsson L, Olafsson E, Sanders R;
XX DR WPI; 2000-638268/61.
XX PT Assessing disease status in individual by determining sequence(s) at one
XX PT or more polymorphic positions within the human genes encoding the
XX PT protein(s) involved in physiological pathway associated with treatment
XX PT regime.
XX PS Example 1, Page 57; 141pp; English.
XX CC The present invention is related to methods for determining the
XX CC polymorphic pattern of an individual and using the results to determine
XX CC their risk of a number of diseases, including cancer, cardiovascular
XX CC diseases, glaucoma and nervous system disorders such as depression and
XX CC neurodegenerative diseases. In addition, the methods can be used to
XX CC determine the effects of different types of treatment for individuals,
XX CC and thus enable appropriate therapies to be prescribed. The PCR primers
XX CC shown in sequences AAC61201-C61371 were all used to demonstrate the
XX CC methods of the invention

```

```

SQ Sequence 18 BP; 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;
QY Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DB 3136 GATGTGCTGAGGGGCTC 3153
18 GAGTGCTGAGGGGCTC 1
RESULT 220
ADO26674/C
ID ADO26674 standard; DNA; 18 BP.
AC ADO26674;
XX 12-AUG-2004 (first entry)
XX DE Synthetic leader sequence encoding DNA SEQ ID NO:67.
XX KW phenotypic; phenotypic preference; phenotype modulation; leader; ds.
XX OS Synthetic.
XX PN WO2004042059-A1.
XX PD 21-MAY-2004.
XX PF 10-NOV-2003; 2003WO-AU001487.
XX PR 08-NOV-2002; 2002US-0425163P.
XX PA (UYOU ) UNITV QUEENSLAND.
XX PI Frazer IH;
XX DR WPI; 2004-411519/38.
XX PR P-PsDB; ADO26675.
XX PT Constructing synthetic polynucleotide for modulating the quality of a
XX PT selected phenotype displayed by an organism comprises replacing a first
XX PT codon with a synonymous codon to construct the synthetic polynucleotide.
XX PS Example 1; SEQ ID NO 67; 86pp; English.
XX CC The present invention describes a method for constructing a synthetic
XX CC polynucleotide from which a polypeptide is producible to confer a
XX CC selected phenotype to an organism of interest or part in a different
XX CC quality than that conferred by a parent polynucleotide that encodes the
XX CC same polypeptide. The method comprises: (a) selecting a first codon of
XX CC the parent polynucleotide for replacement with a synonymous codon, where
XX CC the synonymous codon is selected on the basis that it exhibits a
XX CC different phenotypic preference than the first codon in a comparison of
XX CC phenotypic preferences in test organisms or parts, where the test
XX CC organism are selected from organisms of the same species as the organism
XX CC of interest and organisms that are related to the organisms of interest;
XX CC and (b) replacing the first codon with the synonymous codon to construct
XX CC the synthetic polynucleotide. Also described: (1) a method for
XX CC determining the phenotypic preference of a first codon in an organism of
XX CC interest or its parts; (2) a synthetic polynucleotide constructed from
XX CC the method above; (3) an organism of interest or part containing a
XX CC synthetic polynucleotide constructed from the method above; (4) an
XX CC organism of interest or part containing a synthetic construct that
XX CC comprises a regulatory polynucleotide operably linked to a tandem repeat
XX CC of a first codon fused in frame with a reporter polynucleotide that
XX CC encodes a reporter protein, which produces, or is predicted to produce a
XX CC selected phenotype or a phenotype of the same class as the selected
XX CC phenotype in the organism or part; (5) a method of modulating the quality
XX CC of a selected phenotype that is displayed by an organism of interest or
XX CC part and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide; (6) a method of enhancing the quality of a
XX CC selected phenotype that is displayed by an organism of interest or part

```

CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide; and (7) a method of reducing the quality of a
 CC selected phenotypic trait that is displayed by an organism of interest or part
 CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide. The method is useful for constructing a
 CC synthetic polynucleotide from which a polypeptide is producible to confer
 CC a selected phenotypic trait to an organism of interest or part in a different
 CC quality than that conferred by a parent polynucleotide that encodes the
 CC same polypeptide. It is useful for modulating the quality of a selected
 CC phenotypic trait displayed by an organism or part. The present sequence encodes
 CC a synthetic leader sequence, which is used in an example from the present
 CC invention.

XX Sequence 18 BP; 0 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAG 1134
 Db 18 CAGCAGCAGCAGCAGCAG 1

RESULT 221
 ADO26644 ID ADO26644 standard; DNA; 18 BP.
 XX ADO26644;
 AC ADO26644;
 XX 12-AUG-2004 (first entry)
 DT
 XX Synthetic leader sequence encoding DNA SEQ ID NO:37.
 DE
 XX phenotypic preference; phenotypic modulation; leader; ds.
 KM
 XX Synthetic.
 OS
 XX MO2004042059-A1.
 PN
 XX 21-MAY-2004.
 PD
 XX 10-NOV-2003; 2003MO-AU001487.
 PF
 XX 08-NOV-2002; 2002US-0425163P.
 PR
 XX (UYOU) UNIT QUBENS LAND.
 PA
 XX Frazer IH;
 PI
 XX MPI; 2004-411519/38.
 DR
 XX P-PSDB; ADO26645.
 XX

PT Constructing synthetic polynucleotide for modulating the quality of a
 PT selected phenotypic trait displayed by an organism comprising replacing a first
 PT codon with a synonymous codon to construct the synthetic polynucleotide.
 PT

XX Example 1; SEQ ID NO 37; 86bp; English.
 PS
 XX The present invention describes a method for constructing a synthetic
 XX polynucleotide from which a polypeptide is producible to confer a
 XX selected phenotypic trait to an organism of interest or part in a different
 XX quality than that conferred by a parent polynucleotide that encodes the
 XX same polypeptide. The method comprises: (a) selecting a first codon of
 XX the parent polynucleotide for replacement with a synonymous codon, where
 XX the synonymous codon is selected on the basis that it exhibits a
 XX different phenotypic preference than the first codon in a comparison of
 XX phenotypic preferences in test organisms or parts, where the test
 XX organism are selected from organisms of the same species as the organism
 XX of interest and organisms that are related to the organisms of interest;
 XX and (b) replacing the first codon with the synonymous codon to construct
 XX the synthetic polynucleotide. Also described: (1) a method for
 CC determining the phenotypic preference of a first codon in an organism of

CC interest or its parts; (2) a synthetic polynucleotide constructed from
 CC the method above; (3) an organism of interest or part containing a
 CC synthetic polynucleotide constructed from the method above; (4) an
 CC organism of interest or part containing a synthetic construct that
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat
 CC of a first codon fused in frame with a reporter polynucleotide that
 CC encodes a reporter protein, which produces, or is predicted to produce a
 CC selected phenotypic trait or a phenotype of the same class as the selected
 CC phenotypic trait in the organism or part; (5) a method of modulating the quality
 CC of a selected phenotypic trait that is displayed by an organism of interest or
 CC part and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide; (6) a method of enhancing the quality of a
 CC selected phenotypic trait that is displayed by an organism of interest or part
 CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide; and (7) a method of reducing the quality of a
 CC selected phenotypic trait that is displayed by an organism of interest or part
 CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide. The method is useful for constructing a
 CC synthetic polynucleotide from which a polypeptide is producible to confer
 CC a selected phenotypic trait to an organism of interest or part in a different
 CC quality than that conferred by a parent polynucleotide that encodes the
 CC same polypeptide. It is useful for modulating the quality of a selected
 CC phenotypic trait displayed by an organism or part. The present sequence encodes
 CC a synthetic leader sequence, which is used in an example from the present
 CC invention.

XX Sequence 18 BP; 6 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAG 1134
 Db 1 CAGCAGCAGCAGCAGCAG 18

RESULT 222
 ADR06261 ID ADR06261 standard; DNA; 18 BP.
 XX ADR06261;
 AC ADR06261;
 XX 04-NOV-2004 (first entry)
 DT
 XX Short tandem (microsatellite) repeat #1.
 DE
 XX amplification data; DNA marker; biological sample identification;
 KM microorganism detection; virus detection; bacteria detection;
 KM lung detection; protozoa detection; HIV-1;
 KM human T-cell lymphotropic virus type 1; HTLV-1; Hepatitis B virus; HBV;
 KM Hepatitis C virus; HCV; Herpes Simplex virus; paternity screening;
 KM genetic screening; prenatal diagnosis; presymptomatic diagnosis;
 KM disease carrier detection; forensic chemical analysis;
 KM short tandem repeat; microsatellite repeat; ds.
 KM

XX Unidentified.
 OS
 XX US2004157220-A1.
 PN
 XX 12-AUG-2004.
 PD
 XX 10-FEB-2003; 2003US-00360854.
 PF
 XX 10-FEB-2003; 2003US-00360854.
 PR
 XX (KURU/) KURUOL P.
 PA (WUBB/) WU B.
 PA (BANK/) BANKS P.
 XX Kurnool P, Wu B, Banks P;
 PI MPI; 2004-614752/59.
 DR

XX Identifying biological sample of mammal, involves obtaining amplification
PT data indicative of amplification of DNA markers of genomic DNA of mammal,
PT generating indicia indicative of amplification data, associating indicia
PT with sample.
PS Example; Page 19; 39pp; English.
XX
XX The invention describes a method of identifying (M1) a biological sample
CC comprising a biological material of a mammal. The method involves
CC obtaining amplification data indicative of amplification of at least two
CC DNA markers of genomic DNA of the mammal, generating indicia indicative
CC of the amplification data, and associating the indicia with the
CC biological sample, where the indicia is used to identify the biological
CC sample. (M1) is useful: in identifying biological sample of a subject
CC undergoing diagnosis to determine whether the subject is afflicted with a
CC particular disease or disorder; for identifying a biological sample of a
CC subject, undergoing screening for genetic lesions or mutations; for
CC identifying a biological sample of a subject, being diagnosed for the
CC presence of target microorganism chosen from virus, bacteria, fungi or
CC protozoa, where the virus includes HIV-1, human T-cell lymphotropic
CC virus type 1 (HTLV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV)
CC and Herpes Simplex, the bacteria includes Mycobacterium tuberculosis,
CC Rickettsia rickettsii, Ehrlichia chaffeensis, Borrelia burgdorferi and
CC Yersinia pestis, the fungi includes Cryptococcus neoformans, Pneumocystis
CC carinii and Histoplasma capsulatum, and the protozoa is chosen from
CC Trypanosoma cruzi, Leishmania sp., Plasmodium, Entamoeba histolytica,
CC Babesia microti, Giardia lamblia, Cyclospora sp. and Eimeria sp.; in
CC identifying a biological sample of a subject undergoing paternity
CC screening, genetic screening, prenatal diagnosis, presymptomatic
CC diagnosis, disease carrier detection or forensic chemical analysis; in
CC identifying a biological sample during the screening of the plant to
CC detect the presence of the target microorganism, or during carrier
CC detection analysis or forensic chemical analysis of a plant; and in
CC diagnostic medicines, for identification of genetically inherited
CC diseases in humans, family relationship analysis and microbial typing.
CC (M1) enables simultaneous analysis and tracking of biological samples.
CC The molecular barcode of the genomic DNA of the sample can be determined
CC at any time during the collection or processing of a biological sample.
CC This sequence represents an example of a short tandem or microsatellite
CC repeat that can be used in DNA fingerprinting to identify a biological
CC material.
CC
SQ Sequence 18 BP; 6 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1117 CAGCAGACGACGCTGCAG 1134
DB 1 CAGCAGACGACGACGACGAG 18
RESULT 223
ADSI6441/C
ID ADSI6441 standard; DNA; 18 BP.
XX
AC ADSI6441;
XX
DT 02-DEC-2004 (first entry)
XX
DE Allele A oligo #4, used in polynucleotide sequence detection.
XX
KM Single nucleotide polymorphism; SNP; genotyping; ss.
XX
OS Synthetic.
XX
PN US2004175704-A1.
XX
PD 09-SEP-2004.
XX
PF 12-MAY-2003; 2003US-00436231.

XX
XX 06-MAR-2003; 2003US-0452481P.
XX
XX (STRA-) STRATAGENE.
XX
PI Sorge JA, Firmin A;
XX
XX WPI; 2004-642120/62.
XX
XX
PT Determining polynucleotide sequence differences by amplifying
PT polynucleotide in presence of labeled nucleotide and detecting variation
PT based on incorporation frequency of labeled nucleotide compared to known
PT reference frequency.
XX
PS Disclosure; SEQ ID NO 6; 52pp; English.
XX
XX The invention relates to compositions, kits and methods for detecting
CC polynucleotide sequence differences. The method involves amplifying the
CC polynucleotide of interest in the presence of a labelled nucleotide and
CC detecting variation based on incorporation frequency of labelled
CC nucleotide compared to known reference frequency. The method is useful
CC for determining a sequence difference such as a single nucleotide
CC polymorphism (SNP) or a tandem repeat, between a region of interest in a
CC polynucleotide and a reference sequence. It is useful for determining the
CC presence of a mutation in a region of interest in a polynucleotide and is
CC also useful for genotyping. The present sequence is an allelic
CC oligonucleotide used in polynucleotide sequence detection.
XX
SQ Sequence 18 BP; 0 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1477 CAGCAGACGACGACGCTC 1494
DB 18 CAGCAGACGACGACGACCC 1
RESULT 224
ADSI6440
ID ADSI6440 standard; DNA; 18 BP.
XX
AC ADSI6440;
XX
DT 02-DEC-2004 (first entry)
XX
DE Allele A oligo #3, used in polynucleotide sequence detection.
XX
KM Single nucleotide polymorphism; SNP; genotyping; ss.
XX
OS Synthetic.
XX
PN US2004175704-A1.
XX
PD 09-SEP-2004.
XX
PF 12-MAY-2003; 2003US-00436231.
XX
PR 06-MAR-2003; 2003US-0452481P.
XX
PA (STRA-) STRATAGENE.
XX
PI Sorge JA, Firmin A;
XX
XX WPI; 2004-642120/62.
XX
XX
PT Determining polynucleotide sequence differences by amplifying
PT polynucleotide in presence of labeled nucleotide and detecting variation
PT based on incorporation frequency of labeled nucleotide compared to known
PT reference frequency.
XX
PS Disclosure; SEQ ID NO 5; 52pp; English.

XX The invention relates to compositions, kits and methods for detecting
CC polynucleotide sequence differences. The method involves amplifying the
CC polynucleotide of interest in the presence of a labelled nucleotide and
CC detecting variation based on incorporation frequency of labelled
CC nucleotide compared to known reference frequency. The method is useful
CC for determining a sequence difference such as a single nucleotide
CC polymorphism (SNP) or a tandem repeat, between a region of interest in a
CC polynucleotide and a reference sequence. It is useful for determining the
CC presence of a mutation in a region of interest in a polynucleotide and is
CC also useful for genotyping. The present sequence is an allelic
CC oligonucleotide used in polynucleotide sequence detection.

SQ Sequence 18 BP; 5 A; 8 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1477 CAGCAGCAGCAGCAGCTC 1494
Db 1 CAGCAGCAGCAGCAGCCC 18
|||||
|||

RESULT 225
ADE29427
ID ADE29427 standard; RNA; 19 BP.
XX
AC ADE29427;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:49.
XX
KM short interfering nucleic acid; siNA; downregulation; inhibition;
KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KM cytosolic; anorectic; antidiabetic; antiinflammatory; antiaesthetic;
KM immunosuppressive; antibacterial; antirheumatic; antiaesthetic;
KM antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KM psoriasis; inflammatory bowel disease; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
PF 28-JAN-2003; 2003WO-US002510.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswigen J, Beigelman L, Usman N, Haeblerl P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
PS Example 3; SEQ ID NO 49; 164bp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase

CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNA
CC have cytosolic, anorectic, antidiabetic, antibacterial, antiinflammatory,
CC antiaesthetic, immunosuppressive, antibacterial, antirheumatic,
CC antiaesthetic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNA can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.

SQ Sequence 19 BP; 3 A; 2 C; 6 G; 0 T; 8 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 9; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 648 TGATATTGCTCTTAGG 665
Db 1 UGAUUVUGUCUGVAGG 18
|||||
:|:|:|:|:|:|:|:|

RESULT 226
ADE29590/c
ID ADE29590 standard; RNA; 19 BP.
XX
AC ADE29590;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:212.
XX
KM short interfering nucleic acid; siNA; downregulation; inhibition;
KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KM cytosolic; anorectic; antidiabetic; antiinflammatory; antiaesthetic;
KM immunosuppressive; antibacterial; antirheumatic; antiaesthetic;
KM antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KM psoriasis; inflammatory bowel disease; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
PF 28-JAN-2003; 2003WO-US002510.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswigen J, Beigelman L, Usman N, Haeblerl P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.


```
XX
PS Example 3; SEQ ID NO 212; 164pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells; tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antibacterial, antirheumatic,
CC antisthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antitumor, antiproliferative and gastrointestinal activities. The MAPK
CC siNA can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity, diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 8 A; 6 C; 2 G; 0 T; 3 U; 0 Other;

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      648 TGATATTGCTCTCTAGG 665
      |||||
      19 TGATATTGCTCTCTAGG 2

RESULT 227
ADF84082/c
ID ADF84082 standard; RNA; 19 BP.
XX
XX ADF84082;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human breakpoint cluster region-targeted siRNA - SEQ ID 376.
DE
XX
XX short interfering nucleic acid; siNA; breakpoint cluster region;
KM v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KM cytostatic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
XX Homo sapiens.
OS
XX
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409233P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcswiggen J, Beigelman L, Chowrira B;
PI
XX
XX WPI; 2003-679889/64.
DR
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
```

```
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 376; 197pp; English.
PS
XX
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human BCR-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 3 A; 4 C; 7 G; 0 T; 5 U; 0 Other;

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      821 AGACTTACTCTGAGCCGCC 838
      |||||
      18 AGACTTACTCTGAGCCACC 1

Db
ADFB3819
ID ADFB3819 standard; RNA; 19 BP.
XX
XX ADFB3819;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human breakpoint cluster region-targeted siRNA - SEQ ID 113.
DE
XX
XX short interfering nucleic acid; siNA; breakpoint cluster region;
KM v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KM cytostatic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
XX Homo sapiens.
OS
XX
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409233P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcswiggen J, Beigelman L, Chowrira B;
PI
XX
XX WPI; 2003-679889/64.
DR
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 113; 197pp; English.
PS
XX
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
```

CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human BCR-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 5 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 821 AGACTTACCTGAGCCGCC 838
|||:|||||:
Db 2 AGACUUAACUGAGCCACC 19
RESULT 229
ADL78959
AC ADL78959 standard; RNA; 19 BP.
XX
XX ADL78959;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human HER2 (EGFR2) transcript target sequence/siNA upper strand, SEQ:124.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping; cancer;
KM cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KM HER2; EGFR2; neu; erbB2; c-erbB-2; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005045.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
PI Mewsigen J, Pavco P, Beigelman L, Fossnaugh K, Jamison S;
XX
XX MPI; 2003-697612/66.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 124; 171pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may

CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesized,
CC expressed from a vector or enzymatically synthesized. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA, conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER2 (EGFR2)-targeted double-stranded siNA, which is identical to
CC the HER2 transcript target sequence.
XX
SQ Sequence 19 BP; 8 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.8e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 2975 AGATCCGAGTACAGAGA 2992
|||:|||||:
Db 2 AGAUCGGAAGUACAGCA 19
RESULT 230
ADL79208/c
ID ADL79208 standard; RNA; 19 BP.
XX
XX ADL79208;
XX
XX 20-MAY-2004 (first entry)
XX
XX
DE Human HER2 (EGFR2) siNA lower strand, SEQ ID NO:373.
XX
XX
XX RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping; cancer;
KM cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KM HER2; EGFR2; neu; erbB2; c-erbB-2; ss.
XX
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005045.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
PI Mewsigen J, Pavco P, Beigelman L, Fossnaugh K, Jamison S;

XX WPI, 2003-697612/66.
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of cancer, downregulates expression of the epidermal growth
XX factor receptor gene.
XX Example 3; SEQ ID NO 373; 171bp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
XX downregulate expression of one or more human epidermal growth factor
XX receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
XX interference. The siNA may or may not comprise ribonucleotides and may
XX be double or single stranded. They further comprise sense and antisense
XX regions, or alternatively are assembled from a sense oligonucleotide and
XX an antisense oligonucleotide. Specifically, the siNA include short
XX interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
XX hairpin RNA (shRNA). The siNA can be unmodified or chemically modified,
XX can contain deoxyribonucleotides, and can be chemically synthesised,
XX expressed from a vector or enzymatically synthesised. The invention also
XX relates to kits for the in vitro or in vivo delivery of siNA; conjugates
XX and/or complexes of siNA; and vectors that express siNA. The siNA are
XX used to modulate expression of EGFR genes in cells, tissue explants or
XX organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
XX for the treatment of a variety of conditions. They may be used for
XX treating a wide range of cancers such as breast and ovarian cancer. The
XX siNA are also useful for drug screening, diagnosis, therapeutic target
XX identification and validation, genetic engineering, pharmacogenomics,
XX studying gene function, and gene mapping (e.g., of single nucleotide
XX polymorphisms). The present sequence represents the lower strand of a
XX HER2 (EGFR2)-targeted double-stranded siNA.
XX
XX Sequence 19 BP; 2 A; 5 C; 4 G; 0 T; 8 U; 0 Other;
SQ
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2975 AGATCCGGAAGTACAGA 2992
DB 18 AGATCCGGAAGTACAGA 1
RESULT 231
AAV68373/C
ID AAV68373 standard; DNA; 20 BP.
XX
XX AAV68373;
AC
XX
XX 10-MAR-1999 (first entry)
DT
XX
XX Adapter primer oligonucleotide #12 for CAG repeat analysis.
DE
XX
XX CAG repeat; human; genome analysis; adapter primer; medical diagnostic;
KM nucleic acid analysis; variation assessment; neurological disease;
KM Huntington's chorea; PCR suppression; ss.
XX
XX Synthetic.
OS
XX
XX MO9849345-A1.
PN
XX
XX 05-NOV-1998.
PD
XX
XX 29-APR-1998; 98MO-US008616.
PF
XX
XX 29-APR-1997; 97US-0045078P.
PR
XX
XX (UYBO-) UNIV BOSTON.
PA
XX
XX Smith CL,
PI
XX
XX WPI, 1998-594983/50.
DR
XX

PT Analysing nucleic acid samples - using amplification primers which
PT contain CAG or CTG tri-nucleotide repeats for differential display of
PT samples from different sources.
XX
XX Example; Page 31; 44pp; English.
XX
XX This sequence represents an adapter primer oligonucleotide. It was used
XX to isolate CAG repeat containing sequences from the human genome to test
XX the method of the invention. The method is for analysing nucleic acids in
XX a sample, and comprises: (a) providing a sample containing nucleic acid,
XX a first oligonucleotide primer comprising a CTG repeat, a second
XX oligonucleotide primer comprising a CAG repeat and a polymerase and PCR
XX reagents; (b) preparing said nucleic acid so that it is amplifiable; (c)
XX amplifying the nucleic acid with the first and second primers; and (d)
XX detecting the amplified product. The method is used to distinguish
XX between the expression of genes in two or more biological samples, e.g.
XX body fluids, cells, solid tissue or solid and liquid foods. It can be
XX used in medical diagnostics, e.g. to differentiate between normal and
XX diseased tissue or to assess the variation within monozygotic twin pairs.
XX The method allows the isolation and analysis of genome subsets containing
XX CAG repeats which are known to be important in a number of neurological
XX diseases including Huntington's chorea. The method uses PCR suppression,
XX in which only fragments which contain a target repeat are efficiently
XX amplified. This allows accurate identification of differentially
XX expressed genes in various cell types. Genome complexity is reduced by
XX the new method which targets genomic subsets containing CAG repeats
XX
XX Sequence 20 BP; 1 A; 7 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCAGCTGCAG 1134
DB 18 CAGCAGCAGCAGCAGCAG 1
RESULT 232
AAZ32750/C
ID AAZ32750 standard; DNA; 20 BP.
XX
XX AAZ32750;
AC
XX
XX 31-JUN-2000 (first entry)
DT
XX
XX Human protease-activated receptor PAR4 PCR primer #10.
DE
XX
XX Protease-activated receptor; PAR4; G protein coupled;
KM cellular signalling; protease; tethered ligand; N-terminal; proteolysis;
KM thrombin; trypsin; cleavage; hexapeptide; agonist; antagonist;
KM cellular response; physiological response; clotting pathway; platelet;
KM proliferation; differentiation; mediation; inflammatory process;
KM vascular injury; chemotaxis; mitogenesis; growth factor; production;
KM tissue distribution; lung; thyroid; testis; small intestine; PCR; primer;
KM ss.
XX
XX Synthetic.
OS
XX
XX Homo sapiens.
XX
XX MO9950415-A2.
PN
XX
XX 07-OCT-1999.
PD
XX
XX 31-MAR-1999; 99MO-US007100.
PF
XX
XX 01-APR-1998; 98US-00053866.
PR
XX
XX (ZYMO) ZYMOGENETICS INC.
PA
XX
XX (UNIW) UNIV WASHINGTON.
PI
XX
XX Xu W, Presnell SR, Yee DP, Foster DC;
XX

DR WPI, 1999-633640/54.

XX Novel protease activated receptor 4, useful for screening for
PT (ant)agonists for promoting the proliferation and/or differentiation of
PT platelets and in mediating inflammatory events.

XX Example 6, Page 66; 85pp; English.

PS This sequence represents human protease-activated receptor PAR4 PCR
CC primer #10, used with primer #9 (AAZ32749) to amplify a portion of human
CC PAR4 (protease-activated receptor) cDNA for use as a probe in tissue
CC distribution studies. PAR4 was found to be expressed in most of the
CC tissues tested, with especially high levels in lung, thyroid, testis and
CC small intestine. Protease-activated receptors (PARs) are a subfamily of G
CC protein coupled receptors which are capable of mediating cellular
CC signalling in response to proteases (e.g., thrombin). They are
CC characterized by a tethered peptide ligand at the extracellular N-
CC terminus that is generated by proteolysis. PAR4 is activated by thrombin
CC or trypsin cleavage at Arg47/Gly48, which generates a new N-terminus
CC corresponding to the tethered ligand (a hexapeptide). Agonists of PAR4
CC are useful for upregulating cellular or physiological responses whereas
CC antagonists are used to downregulate these activities. The PAR4 protein
CC is further useful for dissecting the effects of thrombin or other
CC activating proteases in the clotting pathway from the effects of these
CC proteases at the cellular level. Agonists are specifically useful in
CC promoting the proliferation and/or differentiation of platelets, in
CC mediating inflammatory events, responses to vascular injury, chemotaxis
CC or mitogenesis, and in producing growth factors. Antagonists are useful
CC as research reagents for characterising sites of ligand-receptor
CC interaction

XX Sequence 20 BP; 5 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3622 ATGCTGCTGTGCTAGGAG 3639

DB 18 ATGCTGCTGTGCTAGGAG 1

RESULT 233

ID AAF72971/c

XX AAF72971 standard; DNA; 20 BP.

AC AAF72971;

DT 24-APR-2001 (first entry)

XX Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ.72.

XX Antisense oligonucleotide; daxx; inhibition; phosphorothioate;

XX Fas binding protein; CENP-C binding protein; daps; EAP; cycostatic;

XX antiinflammatory; death associated protein 6; Ets-1 associated protein;

XX infection; inflammation; tumour formation; ss.

XX Homo sapiens.

XX US6180353-B1.

XX 30-JAN-2001.

XX 24-JAN-2000; 2000US-00490692.

XX 24-JAN-2000; 2000US-00490692.

XX (ISIS-) ISIS PHARM INC.

XX Dean NM, Cowser LM;

XX WPI, 2001-217744/22.

PT Novel antisense compounds capable of modulating expression of daxx useful
PT for diagnosis, prophylaxis and treatment of diseases associated with
PT expression of daxx.

PS Claim 1; Col 43; 59pp; English.

XX The present invention describes an antisense compound (I) up to 30
CC nucleobases in length, where (I) inhibits expression of daxx (also known
CC as Fas binding protein, CENP-C binding protein, daps for death associated
CC protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
CC antiinflammatory activity, and can be used in antisense therapy and as a
CC modulator of daxx. (I) is useful for inhibiting the expression of daxx in
CC cells or tissues in vitro. (I) can be utilised for diagnostics,
CC therapeutics for the treatment of diseases associated with the expression
CC of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC tumour formation and as research reagent. The present sequence represents
CC an inhibitory human daxx antisense phosphorothioate oligonucleotide which
CC is used in the exemplification of the present invention

XX Sequence 20 BP; 0 A; 9 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 183 GGAAGACGAGAGGAGA 200

DB 19 GGAAGACGAGAGGAGA 2

RESULT 234

ID ABZ29930/c

XX ABZ29930 standard; DNA; 20 BP.

AC ABZ29930;

DT 30-JUN-2003 (first entry)

XX Candida albicans GRACE strain PCR primer SEQ ID NO 4081.

XX Fungus; Yeast; tetracyclin; promoter; GRACE strain; biosynthesis;

XX signal transduction; DNA replication; cell division; growth;

XX proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.

XX Candida albicans.

XX WO200253728-A2.

XX 11-UTL-2002.

XX 26-DEC-2001; 2001WO-US049486.

XX 29-DEC-2000; 2000US-0259128P.

XX 20-FEB-2001; 2001US-00793024.

XX 22-AUG-2001; 2001US-0314050P.

XX (ELIT-) ELITRA PHARM INC.

XX Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL,

XX WPI, 2002-566694/60.

XX Constructing strains for identifying gene products as effective targets

XX for therapeutic intervention, by inactivating in the strain one allele of

XX a gene and placing other allele of the gene under conditional expression.

XX Claim 36; SEQ ID NO 4081; 167pp + Sequence Listing; English.

XX The invention relates to constructing (M1) a strain of diploid fungal

XX cells in which both alleles of a gene are modified, comprising modifying

XX one allele by insertion or replacement by a cassette having an

XX expressible selectable marker and modifying other allele by

XX recombination, of a promoter replacement fragment with a heterologous

CC promoter, so that expression of the second allele is regulated by the
CC promoter. (M1) is useful for constructing a strain of diploid fungal
CC cells in which both alleles of a gene are modified. The diploid fungal
CC cells having both alleles modified are useful for identifying a gene that
CC is essential to the survival or growth of a fungus, a gene that
CC contributes to the virulence and/or pathogenicity of a fungus, a gene
CC that contributes to the resistance of a diploid fungus to an antifungal
CC agent, an antifungal agent that inhibits the growth of a diploid fungus
CC and for identifying a therapeutic agent for treatment of a mammalian
CC disease. (M1) is useful for identifying a compound which modulates the
CC activity of a gene product, preferably enzymatic activity, carbon
CC compound catabolism, biosynthetic, transporter, transcriptional,
CC transnational, signal transduction, DNA replication and cell division
CC activity. The method is useful for identifying a compound having the
CC ability to inhibit growth or proliferation of C. albicans cells and for
CC treating infection by C. albicans. The present sequence is that of a PCR
CC primer used in the method of the invention. Note: The sequence data for
CC this patent is not represented in the printed specification but is based
CC on sequence information supplied to Derwent by the European Patent Office
XX

SO Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1126 CAGCTGACGACGACGACG 1143
DB 18 CAGCTGACGACGACGACG 1

RESULT 235
AAD56488/c
ID AAD56488 standard; DNA; 20 BP.

AC AAD56488;

XX 27-AUG-2003 (first entry)

DE Human ephrin-A2 cDNA amplifying RT-PCR primer. SEQ ID 11.

XX BbA7; ephrin-A5; ephrin-A2; borderline personality disorder; ischaemia;
XX epilepsy; trauma; infection; multiple sclerosis; autism; cerebral palsy;
XX Huntington's disease; Alzheimer's disease; schizophrenia; gene therapy;
XX memory disorder; Parkinson's disease; phobia; dementia; sleep disorder;
XX amyotrophic lateral sclerosis; attention deficit disorder; depression;
XX injury; human; RT; reverse transcription; PCR; primer; ss.

OS Homo sapiens.

XX WO2003040304-A2.

XX 15-MAY-2003.

PF 11-NOV-2002; 2002WO-IB004930.

XX 09-NOV-2001; 2001US-0345206P.

XX 02-JUL-2002; 2002US-0393272P.

XX (NEUR-) NEURONOVA AB.

XX Holmberg J, Friksen J;

XX WPI; 2003-441543/41.

PT Alleviating a symptom of a disease or disorder of the nervous system by
PT administering a modulator of neural stem or neural progenitor cell
PT activity in vivo to a patient.

XX Example 6; Page 54; 93pp; English.

XX The invention relates to a method for alleviating a symptom of a disease
XX or disorder of nervous system which involves administering a modulator to

CC modulate an activity of a neural stem cell or a neural progenitor cell in
CC vivo to a patient suffering from the disease or disorder of the nervous
CC system (the modulator disrupts an interaction between BbA7 and ephrin-A5
CC or an interaction between BbA7 and ephrin-A2). The method is useful for
CC alleviating a symptom of a disease or disorder of the nervous system,
CC e.g., drug and alcohol abuse, neurological traumas, or neurodegenerative,
CC neural stem cell, neural progenitor, ischemic, affective,
CC neuropsychiatric or learning and memory disorders, such as Parkinson's
CC disease, Huntington's disease, Alzheimer's disease, spinal ischaemia,
CC amyotrophic lateral sclerosis, ischaemic stroke, spinal cord injury or
CC cancer-related brain/spinal cord injury, schizophrenia, psychoses,
CC depression, bipolar depression/disorder, anxiety syndromes/disorders,
CC phobias, stress and related syndromes, cognitive function disorders,
CC aggression, obsessive compulsive behaviour syndromes, multi-infarct
CC dementia, seasonal mood disorder, Lewy body dementia, borderline
CC personality disorder, cerebral palsy, age related/geriatric dementia,
CC epilepsy and injury related to epilepsy, spinal cord injury, brain
CC injury, trauma related brain/spinal cord injury, anticancer treatment
CC related brain/spinal cord tissue injury, infection and inflammation
CC related brain/spinal cord injury, environmental toxin related brain/
CC spinal cord injury, multiple sclerosis, autism, attention deficit
CC disorders, narcolepsy, retinal degenerative disorders, injury or trauma
CC to the retina or sleep disorders. The invention is also used in gene
CC therapy. The present sequence is a RT (reverse transcription)-PCR primer
CC used for amplifying human ephrin-A2 cDNA. This sequence is used to
CC illustrate the method of the invention

SO Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1475 AACAGCAGCAGCAGCAGC 1492
DB 19 AACAGCAGCAGCAGCAGC 2

RESULT 236
AAD56486/c
ID AAD56486 standard; DNA; 20 BP.

AC AAD56486;

XX 27-AUG-2003 (first entry)

DE Human ephrin-A2 cDNA amplifying RT-PCR primer. SEQ ID 9.

XX BbA7; ephrin-A5; ephrin-A2; borderline personality disorder; ischaemia;
XX epilepsy; trauma; infection; multiple sclerosis; autism; cerebral palsy;
XX Huntington's disease; Alzheimer's disease; schizophrenia; gene therapy;
XX memory disorder; Parkinson's disease; phobia; dementia; sleep disorder;
XX amyotrophic lateral sclerosis; attention deficit disorder; depression;
XX injury; human; RT; reverse transcription; PCR; primer; ss.

OS Homo sapiens.

XX WO2003040304-A2.

XX 15-MAY-2003.

PF 11-NOV-2002; 2002WO-IB004930.

XX 09-NOV-2001; 2001US-0345206P.

XX 02-JUL-2002; 2002US-0393272P.

XX (NEUR-) NEURONOVA AB.

XX Holmberg J, Friksen J;

XX WPI; 2003-441543/41.

PT Alleviating a symptom of a disease or disorder of the nervous system by

PT administering a modulator of neural stem or neural progenitor cell
PT activity in vivo to a patient.
XX
PS Example 6; Page 54; 93bp; English.
XX
CC The invention relates to a method for alleviating a symptom of a disease
CC or disorder of nervous system which involves administering a modulator to
CC modulate an activity of a neural stem cell or a neural progenitor cell in
CC vivo to a patient suffering from the disease or disorder of the nervous
CC system (the modulator disrupts an interaction between EphA7 and ephrin-A5
CC or an interaction between EphA7 and ephrin-A2). The method is useful for
CC alleviating a symptom of a disease or disorder of the nervous system,
CC e.g., drug and alcohol abuse, neurological traumas, or neurodegenerative,
CC neural stem cell, neural progenitor, ischemic, affective,
CC neuropsychiatric or learning and memory disorders, such as Parkinson's
CC disease, Huntington's disease, Alzheimer's disease, spinal ischemia,
CC amyotrophic lateral sclerosis, ischemic stroke, spinal cord injury or
CC cancer-related brain/spinal cord injury, schizophrenia, psychosis,
CC depression, bipolar depression/disorder, anxiety syndromes/disorders,
CC phobias, stress and related syndromes, cognitive function disorders,
CC aggression, obsessive compulsive behaviour syndromes, multi-infarct
CC dementia, seasonal mood disorder, Lewy body dementia, borderline
CC personality disorder, cerebral palsy, age related/geriatric dementia,
CC epilepsy and injury related to epilepsy, spinal cord injury, brain
CC injury, trauma related brain/spinal cord injury, anticancer treatment
CC related brain/spinal cord tissue injury, infection and inflammation/
CC related brain/spinal cord injury, environmental toxin related brain/
CC spinal cord injury, multiple sclerosis, autism, attention deficit
CC disorders, narcolepsy, retinal degenerative disorders, injury or trauma
CC to the retina or sleep disorders. The invention is also used in gene
CC therapy. The present sequence is a RT (reverse transcription)-PCR primer
CC used for amplifying human ephrin-A2 cDNA. This sequence is used to
CC illustrate the method of the invention
SQ Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1;
QY 1475 AACAGCAGCAGCAGC 1492
DB 19 AACAGCAGCAGCAGC 2
RESULT 237
ADP87614
ID ADF87614 standard; DNA; 20 BP.
XX
AC ADF87614;
XX
DT 26-FEB-2004 (first entry)
XX
DE Single nucleotide polymorphism detection primer, SEQ ID NO 1197.
XX
KW human; single nucleotide polymorphism; microarray; side effect; ss;
KM primer; PCR.
XX
XX
OS Synthetic.
OS Homo sapiens.
XX
PN JP2003235571-A.
XX
PD 26-AUG-2003.
XX
PF 12-FEB-2002; 2002JP-00034717.
XX
PR 12-FEB-2002; 2002JP-00034717.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI, 2003-820454/77.
XX

PT Novel polynucleotide useful for detecting single nucleotide polymorphisms
PT in human gene.
XX
XX Claim 2; SEQ ID NO 1197; 704bp; Japanese.
XX
CC The invention relates to a novel polynucleotide isolated and purified
CC from a human gene having any one of 935 fully defined sequences as given
CC in specification, or a sequence having a base substitution. The invention
CC further relates to: an oligonucleotide containing single nucleotide
CC polymorphisms; a PCR primer set chosen from the combination of two DNA
CC fragments from any one of 1220 fully defined sequences as given in
CC specification; a labelling probe containing the SNP containing oligo, and
CC a microarray equipped with the SNP containing oligo. The isolated human
CC gene of the invention is useful for detecting the single nucleotide
CC polymorphisms in human gene. The isolated human gene is also useful for
CC diagnosis of disease and determination of side effect to a medical agent.
CC The isolated human gene is also effective in detecting single nucleotide
CC polymorphisms in a human gene. This polynucleotide sequence represents
CC one of the PCR primers used in the single nucleotide polymorphism
CC detection method of the invention.
SQ Sequence 20 BP; 7 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1;
QY 1620 CAAGACGAGCCAGCAG 1637
DB 1 CAAGACGAGCCAGCAG 18
RESULT 238
ADH63098
ID ADH63098 standard; DNA; 20 BP.
XX
AC ADH63098;
XX
DT 25-MAR-2004 (first entry)
XX
DE FGF receptor 2 antisense oligonucleotide, ISIS143358, SEQ ID 52.
XX
KW Cytostatic; vulnerrary; Gene Therapy; Antisense;
KW fibroblast growth factor receptor 2; FGF receptor 2;
KM hyperproliferative disorder; cancer; developmental disorder;
KM wound healing; ss; phosphorothioate.
XX
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note="This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidine"
XX
PN WO2003024987-A1.
XX
PD 27-MAR-2003.
XX
PF 12-SEP-2002; 2002WO-US029149.
XX
PR 14-SEP-2001; 2001US-00954556.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freiler SM, Cooper SR;
XX
DR WPI, 2003-354582/33.
XX
PT New antisense oligonucleotides for modulating expression of genes

PT encoding fibroblast growth factor receptor 2, useful for treating
PT hyperproliferative (e.g. cancer of the colon, lung, breast or skin) or
PT developmental disorders.
XX
XX
XX Example 15; SEQ ID NO 52; 200bp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADH63077-
CC ADH63154) targeted to fibroblast growth factor (FGF) receptor 2 coding
CC sequences (ADH63049 and ADH63056), which specifically hybridize with and
CC inhibit FGF receptor 2 expression. The antisense oligonucleotides are
CC useful for treating or preventing diseases or conditions associated with
CC FGF receptor 2 in an animal, e.g. hyperproliferative disorders
CC (particularly cancer of the colon, lung, breast or skin), or
CC developmental disorders. The antisense compound may also be used in wound
CC healing. The antisense compounds are useful for diagnosis,
CC therapeutics, prophylaxis, or as research reagents or kits.
CC
SQ Sequence 20 BP; 1 A; 5 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3490 GGCTCCAGTCTGCTTC 3507
DB 1 GGCTCCAGTCTGCTTC 18

RESULT 239
AB293335/c
ID AB293335 standard; DNA; 20 BP.
XX
AC AB293335;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX MO200285308-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002MO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
XX Disclosure; SEQ ID NO 8577; 872bp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, increasing levels of ubiquinone or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pat_sequences
CC
SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3614 GCATGAGATGCTGCTGT 3631
DB 19 GCATGAGATGCTGCTGT 2

RESULT 240
AB292259
ID AB292259 standard; DNA; 20 BP.
XX
AC AB292259;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX MO200285308-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002MO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
XX Disclosure; SEQ ID NO 7501; 872bp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 ACTGAAGTTCCCTCAT 872
|||||
DB 3 ACTGAAGTTCCCATCAT 20

RESULT 241
AB285595/c
ID AB285595 standard; DNA; 20 BP.

XX AB285595;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antisthmatic; hypotensive; immunosuppressive; cytotostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

OS Homo sapiens.
XX
XX MO200285308-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002MO-US013135.

PF 24-APR-2001; 2001US-0286137P.

PR (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Claim 15; SEQ ID NO 837; 872bp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1477 CAGCAGCAGCAGCAGCTC 1494
|||||
DB 20 CAGCAGCAGCAGCAGCAC 3

RESULT 242
ABD28489
ID ABD28489 standard; DNA; 20 BP.

XX ABD28489;
XX
DT 29-JUL-2004 (first entry)
XX
DE R33851-derived oligonucleotide SEQ ID 7501.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytotostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.
XX

PN MO200285309-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002MO-US013143.

PR 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 7501; 763bp; English.

XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
CC
CC
SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 855 ACTGAAGTTCCTTCAT 872
|||
Db 3 ACTGAAGTTCCTTCAT 20

RESULT 243
ABD29565/c
ID ABD29565 standard; DNA; 20 BP.

AC ABD29565;

XX 29-JUL-2004 (first entry)

DE AA664176-derived oligonucleotide SEQ ID 8577.

XX Human; anti-sense; bronchoconstriction, allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX MO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002MO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (BPIG-) EPIGENESIS PHARM INC.

XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;

XX WPI; 2003-093058/08.
DR
XX Pharmaceutical composition for treating asthma, has anti-sense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX
PS Claim 15; SEQ ID NO 8577; 763bp; English.

XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
CC
CC
SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3614 GCATGAGATGCTGCTGT 3631
|||
Db 19 GCATGAGATGCTGCTGT 2

RESULT 244
ABD21825/c
ID ABD21825 standard; DNA; 20 BP.

AC ABD21825;

XX 29-JUL-2004 (first entry)

DE Human stemlocalcin-derived oligo SEQ ID 837.

XX Human; anti-sense; bronchoconstriction, allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX

PN W0200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002MO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIC-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 837; 763bp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
 XX
 QY Query Match 0.4%; Score 16.4; DB 1; Length 20;
 DB Best Local Similarity 94.4%; Pred. No. 2e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1477 CAGCAGCAGCAGCAGCTC 1494
 DB 20 CAGCAGCAGCAGCAGCAGC 3
 XX
 RESULT 245
 ADJ62127
 ID ADJ62127 standard; DNA; 20 BP.
 XX
 AC ADJ62127;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 XX Human EDG1 antisense oligonucleotide ISIS126586.

XX Human; ss; antisense gene therapy; endothelial differentiation gene 1;
 KM EDG1; G protein-coupled receptor; development; wound healing;
 KM tissue regeneration; cellular proliferation; apoptosis; cancer;
 KM angiogenesis; inflammation; hyperproliferative disorder;
 XX developmental disorder.
 XX Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "All linkages are phosphorothioate linkages and
 FT all cytidines are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl residue"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl residue"
 FT
 FT US2004029273-A1.
 XX
 PN 12-FEB-2004.
 XX
 PD 09-AUG-2002; 2002US-00215448.
 XX
 PF 09-AUG-2002; 2002US-00215448.
 XX
 PR 09-AUG-2002; 2002US-00215448.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Wyatt J;
 XX WPI; 2004-179673/17.
 DR
 XX
 XX New antisense oligonucleotide targeted to nucleic acid encoding
 PT endothelial differentiation sphingolipid G-protein-coupled receptor 1,
 PT for treating cancer, developmental disorder or a condition arising from
 PT aberrant apoptosis.
 PT
 XX Example 15; SEQ ID NO 53; 50bp; English.
 PS
 XX The invention relates to a compound 8-80 nucleobases in length targeted
 CC to, and which specifically hybridises with a nucleic acid molecule
 CC encoding endothelial differentiation gene 1 (EDG1, a G protein coupled
 CC receptor, involved in development, wound healing, tissue regeneration,
 CC cellular proliferation, apoptosis, cancer, angiogenesis and
 CC inflammation), and inhibits the expression of EDG1, i.e. is an antisense
 CC (AS) oligonucleotide. Also included are a composition comprising the
 CC compound and a carrier or diluent and a method for screening an antisense
 CC compound (by contacting a preferred target region of a nucleic acid
 CC molecule encoding EDG1 with one or more candidate antisense compounds
 CC comprising at least an 8-nucleobase portion that is complementary to the
 CC preferred target region and selecting for one or more candidate antisense
 CC compounds that inhibit the expression of a nucleic acid encoding EDG1).
 CC The compound, composition and methods are useful for treating a disease
 CC or condition associated with EDG1, such as a hyperproliferative disorder,
 CC developmental disorder or a disease or condition arising from aberrant
 CC apoptosis. They are also useful in research and diagnostics for
 CC modulating the expression of EDG1. Experimental protocols are described
 CC but no results are given. The present sequence is an AS oligonucleotide
 CC targeting human EDG1.
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.4%; Score 16.4; DB 1; Length 20;
 DB Best Local Similarity 94.4%; Pred. No. 2e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1485 GCAGCAGCTCTGCTGTG 1502

```
Db      1 GCAGCAGCTCTCCCTCG 18
|||||
RESULT 246
ADP76620
ID      ADP76620 standard; DNA; 20 BP.
XX
XX      ADP76620;
AC
XX      12-AUG-2004 (first entry)
XX
XX      Chimeric phosphorothioate oligonucleotide #419.
DE
XX      GFAT; Antidiabetic; Cardiant;
XX      Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
XX      reperfusion; ss.
XX
XX      Synthetic.
OS
XX
XX      Key      Location/Qualifiers
FH      modified_base 1..4
FT      /*tag= a
FT      /mod_base= other
FT      /note= "2-methoxyethyl wing"
FT      modified_base 17..20
FT      /*tag= b
FT      /mod_base= other
FT      /note= "2-methoxyethyl wing"
XX
XX      WO2004035763-A2.
XX
XX      29-APR-2004.
XX
XX      02-OCT-2003; 2003WO-US033332.
XX
XX      17-OCT-2002; 2002US-0419268P.
XX
XX      (PHAA ) PHARMACIA CORP.
XX
XX      Brosechat KO, Crosby SD;
XX
XX      MPI; 2004-348453/32.
XX
XX      New compounds, particularly antisense oligonucleotides targeted to a
XX      nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
XX      (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
XX      ischemia/reperfusion injury.
XX
XX      Claim 4; SEQ ID NO 419; 175bp; English.
XX
XX      The present invention relates to a compound which specifically hybridizes
XX      with a nucleic acid molecule encoding GFAT, and inhibits the expression
XX      of GFAT. Specifically claimed are antisense oligonucleotides capable of
XX      modulating the expression of GFAT, and which comprise any of the 3063
XX      sequences of 20 base pairs, given in the specification. The compound,
XX      composition and methods are useful for treating a disease or condition
XX      associated with GFAT, such as a disease or condition, e.g. diabetes, a
XX      cardiovascular or neurological disorder, ischemia/reperfusion injury.
XX      They are also useful in research and diagnostics for modulating the
XX      expression of GFAT. The present sequence represents a chimeric
XX      phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
XX      oligonucleotides inhibit human GFAT expression.
XX
XX      Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1;
XX      855 ACTGAAGTTCCCTTCAT 872
XX      |||||
XX      1 ACTGAAGTTGCCCTTCAT 18
```

```
Db      1 GCAGCAGCTCTCCCTCG 18
|||||
RESULT 247
ADP76975
ID      ADP76975 standard; DNA; 20 BP.
XX
XX      ADP76975;
AC
XX      12-AUG-2004 (first entry)
XX
XX      Chimeric phosphorothioate oligonucleotide #774.
DE
XX      GFAT; Antidiabetic; Cardiant;
XX      Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
XX      reperfusion; ss.
XX
XX      Synthetic.
OS
XX
XX      Key      Location/Qualifiers
FH      modified_base 1..4
FT      /*tag= a
FT      /mod_base= other
FT      /note= "2-methoxyethyl wing"
FT      modified_base 17..20
FT      /*tag= b
FT      /mod_base= other
FT      /note= "2-methoxyethyl wing"
XX
XX      WO2004035763-A2.
XX
XX      29-APR-2004.
XX
XX      02-OCT-2003; 2003WO-US033332.
XX
XX      17-OCT-2002; 2002US-0419268P.
XX
XX      (PHAA ) PHARMACIA CORP.
XX
XX      Brosechat KO, Crosby SD;
XX
XX      MPI; 2004-348453/32.
XX
XX      New compounds, particularly antisense oligonucleotides targeted to a
XX      nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
XX      (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
XX      ischemia/reperfusion injury.
XX
XX      Claim 4; SEQ ID NO 774; 175bp; English.
XX
XX      The present invention relates to a compound which specifically hybridizes
XX      with a nucleic acid molecule encoding GFAT, and inhibits the expression
XX      of GFAT. Specifically claimed are antisense oligonucleotides capable of
XX      modulating the expression of GFAT, and which comprise any of the 3063
XX      sequences of 20 base pairs, given in the specification. The compound,
XX      composition and methods are useful for treating a disease or condition
XX      associated with GFAT, such as a disease or condition, e.g. diabetes, a
XX      cardiovascular or neurological disorder, ischemia/reperfusion injury.
XX      They are also useful in research and diagnostics for modulating the
XX      expression of GFAT. The present sequence represents a chimeric
XX      phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
XX      oligonucleotides inhibit human GFAT expression.
XX
XX      Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 1;
XX      855 ACTGAAGTTCCCTTCAT 872
XX      |||||
XX      2 ACTGAAGTTGCCCTTCAT 19
```

```

RESULT 248
ADP76520 ID ADP76520 standard; DNA; 20 BP.
XX
XX AC ADP76520;
XX
DT 12-AUG-2004 (first entry)
DE 'Chimeric phosphorothioate oligonucleotide #319.
XX
XX 'GFAT; Antidiabetic; Cardiant;
KM Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KM reperfusion; ss.
XX
XX Synthetic.
OS
FH Key location/Qualifiers
FT modified_base 1..4
FT /tag= a
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
FT modified_base 17..20
FT /tag= b
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
XX
XX WO2004035763-A2.
XX
XX 29-APR-2004.
XX
XX '02-OCT-2003; 2003WO-US033332.
XX
XX 17-OCT-2002; 2002US-0419268P.
XX
XX (PMAA ) PHARMACIA CORP.
XX
XX Brosnath KO, Croesby SD;
XX
XX WPI; 2004-348453/32.
XX
XX 'New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
XX (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
XX ischemia/reperfusion injury.
XX
XX Claim 4; SEQ ID NO 319; 175bp; English.
XX
XX The present invention relates to a compound which specifically hybridizes
XX with a nucleic acid molecule encoding GFAT, and inhibits the expression
XX of GFAT. Specifically claimed are antisense oligonucleotides capable of
XX modulating the expression of GFAT, and which comprise any of the 3063
XX sequences of 20 base pairs, given in the specification. The compound,
XX composition and methods are useful for treating a disease or condition
XX associated with GFAT, such as a disease or condition, e.g. diabetes, a
XX cardiovascular or neurological disorder, ischemia/reperfusion injury.
XX They are also useful in research and diagnostics for modulating the
XX expression of GFAT. The present sequence represents a chimeric
XX phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
XX oligonucleotides inhibit human GFAT expression.
XX
XX Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 2e+02;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0.
XX
XX 855 ACTGAAGTTCCCTTCAT 872
XX |||||
XX 3 ACTGAAGTTCCCTTCAT 20

```

ID	AAV01510 standard; DNA; 21 BP.
XX	
AC	AAV01510;
XX	
DT	27-APR-1998 (first entry)
XX	
DE	Sense primer to generate chimeric SR-p70 fusion protein.
XX	
KM	SR-p70; transcription factor; tumour suppressor gene; fusion protein;
KW	homology; differential splicing; diagnosis; cancer; neuroblastoma; p53;
XX	gene therapy; apoptosis; primer; PCR; amplification; chimeric; ss.
XX	
OS	Synthetic.
OS	Cercopithecus aethiops.
XX	
PN	MO9728186-A1.
XX	
PD	07-AUG-1997.
XX	
PF	03-FEB-1997; 97WO-FR000214.
XX	
PR	02-FEB-1996; 96FR-00001309.
XX	
PA	(SNFI) SANOFI SA.
XX	
P1	Caput D, Ferrara P, Kaghad A;
XX	
DR	WPI; 1997-402550/37.
XX	
PT	New polypeptide(s) encoded by the SR-p70 tumour suppressor gene - and
PT	related nucleic acid, useful for diagnosis and treatment of tumours.
XX	
PS	Claim 16; Page 81; 136DP; French.
XX	
CC	Primers AAV01510-V01511 were used to PCR amplify the C-terminal portion
CC	of the gene encoding the monkey SR-p70a protein (AAV01496), in order to
CC	generate a fusion protein with glutathione-S-transferase. SR-p70 are
CC	transcription factors which may control the activity of p53-regulated
CC	genes, and are expressed by tumour suppressor genes related to the p53
CC	gene family. SR-p70 sequences (see AAV01496-V01505) can be used in the
CC	diagnosis and monitoring of cancer, especially neuroblastoma. The nucleic
CC	acid sequences and corresponding antisense sequences, are also useful in
CC	gene therapy, e.g. to regulate apoptosis
XX	
SO	Sequence 21 BP; 4 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
XX	
Query Match	0.4%; Score 16.4; DB 1; Length 21;
Match Local Similarity	94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	3034 GTCACCTGCTGCTGGGC 3051
Db	1 GTCAACGACGCTGCTGGGC 18
RESULT 250	
AAFA97303/C	
ID	AAFA97303 standard; DNA; 21 BP.
AC	AAFA97303;
XX	
DT	18-NOV-2004 (revised)
DT	06-JUN-2001 (first entry)
XX	
DE	Human gene single nucleotide polymorphism #2064.
XX	
KM	Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW	polymorphism; vascular disease; coronary artery disease; forensics;
KW	myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW	pulmonary embolism; paternity test; ds.
XX	
OS	Homo sapiens.
OS	Unidentified.

```

XX Key Location/Qualifiers
FH variation 11
FT /+tag= a
FT /standard_name= "Single nucleotide polymorphism"
XX
XX MO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000MO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
XX
XX 26-JUL-2000; 2000US-0220947P.
XX
XX 16-AUG-2000; 2000US-0225724P.
XX
XX (WHEB ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX applications such as forensics, paternity testing, medicine, genetic
XX analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis.
XX
XX Example; Page 188; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
XX polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX genes. The sequences at a number of polymorphic sites are also provided
XX in the specification. In particular, the method can be used in the
XX diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX useful in forensics, paternity testing, genetic analysis and phenotype
XX correlations to diseases. The present sequence is an example of one of
XX the human gene SNPs shown in the specification
XX
XX Revised record issued on 18-NOV-2004 : The variation feature was
XX incorrectly given a capital V
XX
XX Sequence 21 BP; 4 A; 8 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 16.4; DB 1; Length 21;
XX Best Local Similarity 94.4%; Pred. No. 2.2e+02;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2596 GGCACCATGGTGTCCAG 2613
XX | | | | | | | | | | | | | | | | | | | |
XX 18 GGCACCCCTGGTGTCCAG 1
XX
XX RESULT 251
XX AAH89072
XX ID AAH89072 standard; DNA; 21 BP.
XX
XX AAH89072;
XX
XX 09-SEP-2004 (revised)
XX
XX 27-FEB-2002 (first entry)
XX
XX Human polymorphic oligonucleotide L21952 fragment.
XX
XX Human; single nucleotide polymorphic; SNP; forensic science;
XX paternity testing; phenotypic trait; genetic mapping; animal breeding;
XX plant breeding; de.
XX
XX Homo sapiens.
XX
XX Unidentified.

```

```

XX Key Location/Qualifiers
FH variation 11
FT /+tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
XX MO200134840-A2.
XX
XX 17-MAY-2001.
XX
XX 10-NOV-2000; 2000MO-US030766.
XX
XX 10-NOV-1999; 99US-0164596P.
XX
XX (GLAX ) GLAXO GROUP LTD.
XX
XX (AFPI-) AFFIMETRIX INC.
XX
XX Au K, Chen J, Patil N, Thomas D;
XX
XX WPI; 2001-335945/35.
XX
XX New polymorphic sites derived from the human genome are useful to
XX determine sites correlating with phenotypic traits, particularly disease,
XX and also in forensics and paternity testing.
XX
XX Claim 82; Page 13; 43pp; English.
XX
XX The present invention relates to human oligonucleotides comprising a
XX single nucleotide polymorphic site (SNP: AAH88797-AAH89219). The present
XX sequence is one such oligonucleotide. The oligonucleotides can be used in
XX forensics, paternity testing, correlation of polymorphisms with
XX phenotypic traits, genetic mapping of phenotypic traits and marker
XX assisted breeding of animals and crop plants
XX
XX Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
XX Sequence 21 BP; 7 A; 7 C; 6 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 16.4; DB 1; Length 21;
XX Best Local Similarity 94.4%; Pred. No. 2.2e+02;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1121 AGCAGCAGCTGCAGCAGC 1138
XX | | | | | | | | | | | | | | | | | | | |
XX 2 AACAGCAGCTGCAGCAGC 19
XX
XX RESULT 252
XX ABK65733
XX ID ABK65733 standard; DNA; 21 BP.
XX
XX ABK65733;
XX
XX 02-JUL-2002 (first entry)
XX
XX Human single nucleotide polymorphism #353.
XX
XX Human; single nucleotide polymorphism; SNP; sickle cell anaemia;
XX agammaglobulinaemia; diabetes insipidus; Lesch-Nyhan syndrome;
XX muscular dystrophy; Wiskott-Aldrich syndrome; Fabry's disease;
XX familial hypercholesterolaemia; polycystic kidney disease; cancer;
XX hereditary spherocytosis; Von Willebrand's disease; tubercous sclerosis;
XX hereditary haemorrhagic telangiectasia; familial colonic polyposis;
XX Ehlers-Danlos syndrome; osteogenesis imperfecta; autoimmune disease;
XX acute intermittent porphyria; inflammation; nervous system disorder;
XX infection; rheumatoid arthritis; multiple sclerosis; diabetes;
XX systemic lupus erythematosus; Graves disease; longevity; obesity;
XX baldness; fertility; forensic; paternity testing; de.
XX
XX Homo sapiens.
XX
XX US2002037508-A1.
XX

```

PD 28-MAR-2002.
XX
XX 18-JAN-2001; 2001US-00765081.
XX
XX 19-JAN-2000; 2000US-0176861P.
PR
XX (CARG/) CARGILL M.
PA (IREL/) IRELAND J S.
PA (LAND/) LANDER E S.
XX
PI Cargill M, Ireland US, Lander ES;
XX
XX WPI; 2002-315108/35.
DR
XX
XX Nucleic acid comprising single nucleotide polymorphisms, useful in
PT forensics, paternity testing and diagnosis of disease.
PT
XX
XX Claim 1; Page 80; 96pp; English.
PS
XX
XX The invention relates to a nucleic acid comprising single nucleotide
CC polymorphisms (SNPs) associated with diseases. The nucleic acids
CC comprising the SNPs and probes and primers for detecting them may be used
CC in assays for the diagnosis of diseases associated with SNPs (such as
CC sickle cell anaemia, agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan
CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
CC familial hypercholesterolaemia, polycystic kidney disease, hereditary
CC spherocytosis, Von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, and acute intermittent porphyria,
CC symptoms of, or susceptibility to, multifactorial diseases of which a
CC component is or may be genetic, such as autoimmune diseases,
CC inflammation, cancer, diseases of the nervous system, and infection by
CC pathogenic microorganisms, autoimmune diseases including rheumatoid
CC arthritis, multiple sclerosis, diabetes (insulin-dependent and non-
CC independent), systemic lupus erythematosus and Graves disease, cancers
CC including cancers of the bladder, brain, breast, colon, oesophagus,
CC kidney, leukaemia, liver, lung, oral cavity, ovary, pancreas, prostate,
CC skin, stomach and uterus, longevity, appearance (e.g., baldness,
CC obesity), strength, speed, endurance, fertility, and susceptibility or
CC receptivity to particular drugs or therapeutic treatments), in forensics
CC and in paternity testing. ABK65381-ABK65841 represent human single
CC nucleotide polymorphisms of the invention
XX
SQ Sequence 21 BP; 4 A; 10 C; 5 G; 1 T; 0 U; 1 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1746 GTCCCTGACAGACCAACCA 1765
Db 2 GTCCGAGCCGACCAACCA 21
RESULT 253
ABX79874
ID ABX79874 standard; cDNA; 21 BP.
XX
XX ABX79874;
XX
XX 17-APR-2003 (first entry)
XX
XX EST polymorphic DNA repeat polynucleotide #199.
XX
XX EST, expressed sequence tag; ss; polymorphic repeat; tandem repeat;
KM polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
KM Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
KM Haw River syndrome; Huntington's disease; fragile-X syndrome;
KM Friedrich's ataxis; myotonic dystrophy; hyperandrogenaemia;
KM spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
XX Homo sapiens.
OS
XX

PN US6472154-B1.
XX
XX 29-OCT-2002.
XX
XX 31-DEC-1999; 99US-00475947.
XX
XX 31-DEC-1999; 99US-00475947.
PR 31-DEC-1999; 99US-00475947.
XX
XX (TEXA) UNIV TEXAS SYSTEM.
XX
PI Garner HR, Wren JD, Minna JD, Fondon JW;
XX
XX WPI; 2003-208818/20.
DR
XX
XX Identifying a candidate polymorphic repeat within a coding sequence, for
PT understanding or treating genetic disease, comprises detecting tandem
PT repeats in a target coding sequence and scoring the repeats for
PT polymorphic probability.
XX
XX Example; Col 877; 588pp; English.
XX
XX The invention discloses a method for identifying a candidate polymorphic
CC repeat within a coding sequence (expressed sequence tag, EST), which
CC comprises detecting tandem repeats in a target coding sequence, scoring
CC the repeats for polymorphic probability and generating a dataset
CC correlating the repeats with polymorphic probability to identify a
CC candidate polymorphic repeat. The computational methods (polymorphic
CC marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
CC useful for identifying and detecting candidate polymorphic repeats in
CC human genes, which can be used to understand, treat or eliminate genetic
CC diseases, predispositions or adverse drug-treatment reactions. Examples
CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
CC myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and
CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
CC the polymorphic repeats identified for a search of human ESTs
XX
SQ Sequence 21 BP; 9 A; 3 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1270 CAGGAGAGAGAGCGCAG 1287
Db 1 CAGGAGAGAGAGCGCAG 18
RESULT 254
ACCT9938/c
ID ACCT9938 standard; DNA; 21 BP.
XX
XX ACCT9938;
XX
XX 09-SEP-2003 (first entry)
XX
XX Thermus oshimai nucleic acid polymerase PCR primer SEQ ID NO:31.
XX
XX Thermus oshimai; nucleic acid polymerase; enzyme; DNA sequencing;
KM amplification; reverse transcription; RNA amplification;
KM primer extension; PCR primer; ss.
XX
XX Thermus oshimai.
OS Synthetic.
XX
XX WO2003048310-A2.
PN
XX 12-JUN-2003.
PD
XX 22-NOV-2002; 2002WO-US037764.
PF
XX
XX 30-NOV-2001; 2001US-0334798P.
PR
XX

PA (APPL-) APPLERA CORP.
XX
PI Bolchakova E, Rozzelle J;
XX
DR WPI; 2003-505286/47.
XX
PT New nucleic acid, useful for DNA sequencing or amplification, reverse
transcription, RNA amplification or primer extension reactions.
XX
PS Example 1; Page 51; 64pp; English.
XX
CC The present invention describes a nucleic acid (1) encoding a nucleic
acid polymerase or a derivative nucleic acid polymerase with a mutation
that decreases 5-3' exonuclease activity or that reduces discrimination
against dideoxynucleotide triphosphates. Also described: (1) a vector
comprising the nucleic acid (1); (2) a host cell comprising the nucleic
acid (1); (3) a nucleic acid polymerase or its derivative; (4) a kit
comprising a nucleic acid polymerase of (3); (6) synthesizing a DNA; (7)
making the nucleic acid polymerase of (3); (6) synthesizing a DNA; (7)
thermocyclic amplification of nucleic acid; and (8) primer extending a
DNA. The nucleic acid (1) is useful for DNA sequencing or amplification,
reverse transcription, RNA amplification or primer extension reactions.
CC The present sequence represents a PCR primer for Thermus oshimai nucleic
acid polymerase, which is used in an example from the present invention
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 372 CAAGCCCTGAGAGGA 389
DB 20 CAAGCCCTGAGAGGA 3
RESULT 255
ADN08366
ID ADN08366 standard; DNA; 21 BP.
XX
AC ADN08366;
XX
DT 15-JUL-2004 (first entry)
XX
DE 3T3 cell transformation promoting human DNA primer, SEQ ID NO 66.
XX
KW transformation; 3T3 cell; genetic engineering; cytostatic;
KW recombinant protein; gene therapy; cancer; human; ss; primer.
XX
OS Homo sapiens.
XX
PN WO2004033493-A1.
XX
PD 22-APR-2004.
XX
PF 07-AUG-2003; 2003WO-CN000636.
XX
PR 07-AUG-2002; 2002CN-00136401.
PR 16-SEP-2002; 2002CN-00136998.
PR 16-SEP-2002; 2002CN-00136999.
XX
PA (NEMO-) NEMOGEN LTD.
XX
PI Yang S, Gu J;
XX
DR WPI; 2004-330446/30.
XX
PT Human protein for promoting transformation of 3T3 cells and its encoded
polynucleotide, applicable in producing recombinant proteins and in gene
therapy of e.g. cancer.
XX
PS Example 2; SEQ ID NO 66; 68pp; Chinese.
XX

CC The invention relates to a novel isolated human protein for promoting the
transformation of 3T3 cells and contains any of the 31 amino acid
sequences defined in the specification. The invention further provides:
CC an isolated polynucleotide that encodes any of the proteins described
above; a vector containing any of the said polynucleotides; a host cell
CC for genetic engineering, which is transformed or transduced by the
polynucleotide or vector described above; a process for producing the
human protein by culturing such transformed cells for expression and
collecting the product; and an antibody binding specifically with the
human protein. The 3T3 transformation promoting human protein has
cytostatic activity. The protein and its encoded polynucleotide are
useful for promoting the transformation of 3T3 cells, together with
expression vectors and transfectants for the application in producing
recombinant proteins and in gene therapy for the treatment of disorders,
such as cancer. This polynucleotide sequence represents a primer for the
DNA encoding one of the 3T3 transformation promoting human proteins of
the invention.
XX
SQ Sequence 21 BP; 8 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3237 TGACCCAGAGTGAGAA 3254
DB 1 TGACCCAGAGTGAGAA 18
RESULT 256
ADS87406
ID ADS87406 standard; DNA; 21 BP.
XX
AC ADS87406;
XX
DT 18-NOV-2004 (first entry)
XX
DE Human midkine (MDK) siRNA target DNA fragment SeqID20.
XX
KW systemic lupus erythematosus; lupus nephritis; midkine gene;
KW antiinflammatory; dermatological; immunosuppressive; MDK; siRNA;
KW short inhibitory RNA; ds; human.
XX
OS Homo sapiens.
XX
PN WO2004036221-A2.
XX
PD 29-APR-2004.
XX
PF 17-OCT-2003; 2003WO-US033054.
XX
PR 18-OCT-2002; 2002US-0419088P.
XX
PA (AMHP) WYETH.
PA (OTOOL/) O'TOOLE M M.
PA (LIUW/) LIU W.
XX
PI O'toole MM, Liu W;
XX
DR WPI; 2004-389600/36.
XX
PT Diagnosing systemic lupus erythematosus or lupus nephritis, by detecting
expression level of midkine gene in biological sample of mammal and
PT comparing expression level to reference expression level of midkine gene
in control sample.
XX
PS Claim 16; SEQ ID NO 20; 99pp; English.
XX
CC This invention relates to a novel method of diagnosing systemic lupus
erythematosus or lupus nephritis, which comprises detecting an expression
level of the midkine (MDK) gene in a biological sample isolated from a
mammal of interest, and comparing the expression level to a reference
expression level of the midkine gene in one or more control sample. The

CC invention may be useful for the production of compounds with an
CC antiinflammatory, dermatological or immunosuppressive activity acting
CC through modulation of midkine gene expression activity, inhibitors of
CC midkine gene expression by RNAi, stimulators of an immune response or
CC midkine polypeptide antagonists. The invention is useful for diagnosing
CC or treating systemic lupus erythematosus or lupus nephritis in a mammal
CC such as human. The present sequence is that of a human midkine gene short
CC inhibitory RNA (siRNA) target DNA sequence which is related to the method
CC of the invention.

XX
SQ Sequence 21 BP; 11 A; 5 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2713 AGCAAGGCCCAAGCCCA 2730
DB 2 AGCAAGGCCCAAGCCCA 19

RESULT 257

ADS87422
ID ADS87422 standard; RNA; 21 BP.

XX ADS87422;

DT 18-NOV-2004 (first entry)

DE Human midkine (MDK) short inhibitory RNA (siRNA) SeqID36.

XX systemic lupus erythematosus; lupus nephritis; midkine gene;

KM antiinflammatory; dermatological; immunosuppressive; MDK; siRNA;

XX short inhibitory RNA; human; ss.

OS Homo sapiens.

PN WO2004036221-A2.

PD 29-APR-2004.

PF 17-OCT-2003; 2003WO-US033054.

PR 18-OCT-2002; 2002US-0419088P.

XX (AMHP) WYETH.

PA (OTOO/) O'TOOLE M M.

XX (LIUW/) LIU W.

PI O'toole MM, Liu W;

DR WPI; 2004-389600/36.

XX
PT Diagnosing systemic lupus erythematosus or lupus nephritis, by detecting

PT expression level of midkine gene in biological sample of mammal and

PT comparing expression level to reference expression level of midkine gene

PT in control sample.

XX
PS Claim 16; SEQ ID NO 36; 99pp; English.

XX This invention relates to a novel method of diagnosing systemic lupus

XX erythematosus or lupus nephritis, which comprises detecting an expression

XX level of the midkine (MDK) gene in a biological sample isolated from a

XX mammal of interest, and comparing the expression level to a reference

XX expression level of the midkine gene in one or more control sample. The

XX invention may be useful for the production of compounds with an

XX antiinflammatory, dermatological or immunosuppressive activity acting

XX through modulation of midkine gene expression activity, inhibitors of

XX midkine gene expression by RNAi, stimulators of an immune response or

XX midkine polypeptide antagonists. The invention is useful for diagnosing

XX or treating systemic lupus erythematosus or lupus nephritis in a mammal

XX such as human. The present sequence is that of a short inhibitory RNA

XX (siRNA) molecule, targeting the human midkine gene, which may be used in

CC the method of the invention.

XX
SQ Sequence 21 BP; 10 A; 5 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2713 AGCAAGGCCCAAGCCCA 2730
DB 2 AGCAAGGCCCAAGCCCA 19

RESULT 258

ADS87404
ID ADS87404 standard; RNA; 21 BP.

XX ADS87404;

DT 18-NOV-2004 (first entry)

DE Human midkine (MDK) short inhibitory RNA (siRNA) SeqID18.

XX systemic lupus erythematosus; lupus nephritis; midkine gene;

KM antiinflammatory; dermatological; immunosuppressive; MDK; siRNA;

XX short inhibitory RNA; human; ss.

OS Homo sapiens.

PN WO2004036221-A2.

PD 29-APR-2004.

PF 17-OCT-2003; 2003WO-US033054.

PR 18-OCT-2002; 2002US-0419088P.

XX (AMHP) WYETH.

PA (OTOO/) O'TOOLE M M.

XX (LIUW/) LIU W.

PI O'toole MM, Liu W;

DR WPI; 2004-389600/36.

XX
PT Diagnosing systemic lupus erythematosus or lupus nephritis, by detecting

PT expression level of midkine gene in biological sample of mammal and

PT comparing expression level to reference expression level of midkine gene

PT in control sample.

XX
PS Claim 16; SEQ ID NO 18; 99pp; English.

XX This invention relates to a novel method of diagnosing systemic lupus

XX erythematosus or lupus nephritis, which comprises detecting an expression

XX level of the midkine (MDK) gene in a biological sample isolated from a

XX mammal of interest, and comparing the expression level to a reference

XX expression level of the midkine gene in one or more control sample. The

XX invention may be useful for the production of compounds with an

XX antiinflammatory, dermatological or immunosuppressive activity acting

XX through modulation of midkine gene expression activity, inhibitors of

XX midkine gene expression by RNAi, stimulators of an immune response or

XX midkine polypeptide antagonists. The invention is useful for diagnosing

XX or treating systemic lupus erythematosus or lupus nephritis in a mammal

XX such as human. The present sequence is that of a short inhibitory RNA

XX (siRNA) molecule, targeting the human midkine gene, which may be used in

OY 2713 AGCAAGGCCAAGCCCA 2730
 |||||
 DB 1 AGCAAGGCCAAGCCCA 18

RESULT 259
 ID ADCL7063
 XX ADCL7063 standard; DNA; 51 BP.
 XX ADCL7063;
 DT 18-DEC-2003 (first entry)
 XX
 DE Human single nucleotide polymorphism (SNP) region seq ID165.
 XX
 KW sequence polymorphism analysis; human identity; human relatedness;
 KW single nucleotide polymorphism; SNP; genetic disease; cytostatic;
 KW immunosuppressive; antiinflammatory; neuroprotective; antitubercular;
 KW fatty acid metabolism; glycolysis; amino acid metabolism;
 KW paternity analysis; forensic; autoimmune disease; cancer; nervous system;
 KW infection; pathogenic microorganism; human; db.
 XX
 OS Homo sapiens.
 XX
 FH Key location/Qualifiers
 FT variation replace(26,C)
 FT /tag= a
 FT /standard_name= "Single nucleotide polymorphism"

MO20029622-A2:
 XX
 PD 25-MAY-2000.
 XX
 PF 17-NOV-1999; 99MO-US027283.
 XX
 PR 17-NOV-1998; 98US-0109024P.
 XX
 PR 16-NOV-1999; 99US-00443199.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Shimkete RA, Leach MD;
 XX
 DR WPI: 2000-399731/34.
 XX
 DR P-PSDB; ADCL6846.
 XX
 PT Novel polynucleotide and polypeptide including one or more single
 PT nucleotide polymorphisms, useful for diagnosing and treating conditions
 PT associated with the presence of sequence polymorphism in humans and
 PT animals.
 PS
 PS Claim 1; SEQ ID NO 165; 187bp; English.

This invention relates to novel isolated nucleotide sequences which
 comprise 217 defined polymorphic sequences. Sequence polymorphism-based
 analysis of nucleic acid sequences can augment or replace previously
 known methods for determining the identity and relatedness of
 individuals. Single nucleotide polymorphisms (SNPs) tend to occur with
 great frequency throughout the genome and may be located close to loci of
 interest. Such variations can cause or be closely linked to pathological
 conditions (genetic diseases). Hence the SNPs of the invention may be
 useful in the development of compounds with cytostatic,
 immunosuppressive, antiinflammatory, neuroprotective or antimicrobial
 activities. Regulators of metabolic pathways such as fatty acid
 metabolism, glycolysis, and amino acid metabolism may also be developed.
 The compounds may be useful for treating a subject suffering from or at
 risk for a pathology associated with the presence of a sequence
 polymorphism. SNP detection is also useful in paternity analysis and
 forensic application. Polymorphisms may contribute to the phenotype of an
 organism and phenotypic traits include genetic diseases such as
 autoimmune diseases, cancer, diseases of the nervous system and infection
 by pathogenic microorganisms. The present sequence is the sequence
 surrounding and including a human SNP of the invention.

SQ Sequence 51 BP; 3 A; 15 C; 15 G; 18 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 51;
 Best Local Similarity 61.9%; Pred. No. 3.5e+02;
 Matches 26; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1457 AGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCTCTGC 1498
 |||||
 DB 3 AACTGCTGCTGCTACCTGTTGCTGCTGCTGCTGCTGCTGC 44

RESULT 260
 ID ADO56495
 XX ADO56495 standard; DNA; 20 BP.
 AC ADO56495;
 DT 12-AUG-2004 (first entry)
 XX
 DE Human cyclin-dependent kinase 10, CDK10 proximal SNP probe #20.
 XX
 KW gene therapy; human; ss; melanoma;
 KW melanoma associated polymorphic variation; SNP;
 KW single nucleotide polymorphism; cyclin-dependent kinase 10; CDK10; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2004044164-A2.
 XX
 PD 27-MAY-2004.
 XX
 PF 06-NOV-2003; 2003MO-US035879.
 XX
 PR 06-NOV-2002; 2002US-0424475P.
 XX
 PR 23-JUL-2003; 2003US-0489703P.
 XX
 PA (SEQU-) SEQUENOM INC.
 XX
 PI Roth RB, Nelson MR, Braun A, Kammerer SM;
 XX
 DR WPI: 2004-411721/38.
 XX
 PT Identifying a subject at risk of melanoma, useful for treating melanoma,
 PT comprises detecting the presence or absence of one or more polymorphic
 PT variations associated with melanoma in a nucleic acid sample from a
 PT subject.
 XX
 PS Example 5; Page 84; 295bp; English.

The invention relates to a method of identifying a subject at risk of
 melanoma comprising detecting the presence or absence of one or more
 polymorphic variations associated with melanoma in a nucleic acid sample
 from a subject. Preventing melanoma in a subject comprises detecting the
 presence or absence of one or more polymorphic variations associated with
 melanoma in a nucleic acid sample from a subject, and administering a
 melanoma preventative to a subject in need thereof based upon the
 presence or absence of the one or more polymorphic variations in the
 nucleic acid sample. The preventative reduces ultraviolet (UV) light
 exposure to the subject. The methods, nucleic acids, proteins, and
 compositions are useful for treating melanoma. The present sequence
 represents a human cyclin-dependent kinase 10, CDK10, proximal SNP probe.

SQ Sequence 20 BP; 1 A; 11 C; 0 G; 7 T; 0 U; 1 Other;
 Query Match 0.4%; Score 16.2; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.1e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 728 CCTCTTCCCTCATTCCT 744
 |||||
 DB 4 CCTCTTCCCTCATTCCH 20

RESULT 261
AAQ65930
ID AAQ65930 standard; DNA; 21 BP.
XX
AC AAQ65930;
XX
DT 25-MAR-2003 (revised)
DT 06-JAN-1995 (first entry)
XX
DE Type II procollagen PCR antisense sequencing primer (exon 3).
XX
KW Type II procollagen; COL2A1; amplification; primer;
KW polymerase chain reaction; PCR; osteoarthritis; cartilage; ss.
XX
OS Synthetic.
XX
PN MO9411532-A1.
XX
PD 26-MAY-1994.
XX
PF 12-NOV-1993; 93MO-US010964.
XX
PR 13-NOV-1992; 92US-00977284.
XX
PA (UYE-) UNIV JEFFERSON THOMAS.
XX
PI Prockop DJ, Ala-Kokko L, Williams CJ, Rytvanemi P, Baldwin C;
XX Hopkinson I, Ahmad NN;
XX WPI; 1994-183530/22.
DR
XX
XX Detecting genetic pre-disposition to osteoarthritis - and other diseases
PT involving mutation in cartilage protein genes, by amplification and
PT analysis of DNA and comparison with standards.
XX
PS Claim 18; Page 39; 112bp; English.
XX
CC Claim 18 claims primers for use in detecting mutations in a mammalian
CC gene for a structural protein of cartilage comprising a sequence
CC identified in Table I (Page 18-31). Table I includes 179 primer sequences
CC (see AAQ65728-Q65906). The sequences of Table IA are given in AAQ65907-
CC Q65938. (Updated on 25-MAR-2003 to correct PN field.)
CC
XX
SQ Sequence 21 BP; 9 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1571 AGGTAGAGAGAGACAAGCA 1591
DB 1 AGTTAGAGAGAGACAAGCA 21

RESULT 262
AAZ26192/c
ID AAZ26192 standard; DNA; 21 BP.
XX
AC AAZ26192;
XX
DT 30-NOV-1999 (first entry)
XX
DE Human polymorphic region 381.
XX
KW Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
KW cell viability; loss of heterozygosity; precancerous condition; ASI;
KW allele specific inhibitor; somatic cell; diagnosis; prevention;
KW atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
KW graft versus host disease; malignant cell removal; bone marrow; ss.
XX
XX Homo sapiens.

PN MO9841648-A2.
XX
PD 24-SEP-1998.
XX
PF 19-MAR-1998; 98MO-US005419.
XX
PR 20-MAR-1997; 97US-0041057P.
XX
PA (VARI-) VARIAGENICS INC.
XX
PI Housman D, Ledley FD, Stanton VP;
XX WPI; 1998-521232/44.
DR
XX
XX Identifying target genes for allele-specific drugs - used for diagnosis,
PT prevention and treatment of, e.g. cancers, atherosclerotic plaque,
PT dysplastic lesions, endometriosis or graft versus host disease.
XX
XX
XX Disclosure; Fig 7; 605bp; English.
XX
PS
XX
CC This invention describes a novel method for identifying an inhibitor
CC potentially useful for treatment of cancer, where the inhibitor is active
CC on a gene vital for cell growth or viability, and where the gene is
CC subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
CC used for preventing the development of cancer in a patient having a
CC precancerous condition, by administering to the patient a first allele
CC specific inhibitor (ASI) targeted to an allele of a first essential gene
CC present in cells of the precancerous condition, where the normal somatic
CC cells of the patient are heterozygous for the first gene, the inhibitor
CC is active on at least one but less than all allelic forms of the gene
CC present in a population and targets only one allelic form present in the
CC normal somatic cells, and the first gene. The products and methods can be
CC used in the diagnosis, prevention and treatment of LOH disorders, e.g.
CC cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic
CC lesions, benign tumours, endometriosis, polycystic kidney disease, and
CC graft versus host disease. The method can also be used to remove
CC malignant cells from bone marrow transplants. AAZ25812-Z26825 represent
CC human polymorphic sites described in the method of the invention
XX
SQ Sequence 21 BP; 2 A; 7 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGAGCA 1139
DB 21 GCAGCAGCAGCTCTGCAGCA 1

RESULT 263
AAZ40511
ID AAZ40511 standard; DNA; 21 BP.
XX
AC AAZ40511;
XX
DT 18-FEB-2000 (first entry)
XX
DE Human STR20-related protein kinase gene primer #13.
XX
KW Antirheumatic; antiarthritic; antiinflammatory; anti allergic; osteopathic;
KW antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosuppressive;
KW neuroprotective; cardiant; cerebroprotective; cytostatic; antidiabetic;
KW vulnery; STR20; protein kinase; STRK2; STRK3; STRK4; STRK5; STRK7;
KW ZC1; ZC2; ZC3; ZC4; KHS2; SNU1; SNU3; GEX2; PKA4; PKA5; antagonist;
KW antibody; gene therapy; rheumatoid arthritis; atherosclerosis; asthma;
KW inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
KW rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
KW myocardial infarction; cardiovascular disease; stroke; renal failure;
KW oxidative stress-related neurodegenerative disorder; Parkinson's disease;
KW amyotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
KW ischemic disorder; inflammation; diabetes mellitus; fibrosis; microtia;
KW mesangial disorder; growth regulation; wound healing; T cell activation;

KM Immunosuppressant; primer; PCR; amplification; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX W09953036-A2.
 XX 21-OCT-1999.
 PD 13-APR-1999; 99MO-US008150.
 XX 14-APR-1998; 98US-0081784P.
 PR (SUGB-) SUGEN INC.
 PA Plowman G, Martinez R, Whyte D;
 PI WPI; 1999-611301/52.
 DR Novel kinase-related polypeptides used for the diagnosis and treatment of
 XX kinase-related diseases and disorders.
 PT Disclosure; Page 321; 387pp; English.
 XX This sequence represents a PCR primer used to amplify the coding sequence
 CC for a novel STR20-related protein kinase. The invention relates to
 CC nucleic acid molecule encoding a kinase polypeptide selected from STK2,
 CC STK3, STK4, STK5, STK6, STK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
 CC SULU2, GSK2, PAK4 and PAK5. The proteins are used to identify agonists
 CC and antagonists, and to raise antibodies. The polynucleotides are useful
 CC in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
 CC antagonists and agonists may be used to treat diseases such as immune-
 CC related disorders and diseases (e.g. rheumatoid arthritis, Crohn's
 CC artherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
 CC disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
 CC autoimmunity, and organ transplantation, chronic inflammatory pelvic
 CC disease, multiple sclerosis, organ transplantation, myocardial
 CC infarction, cardiovascular disease, stroke, renal failure, oxidative
 CC stress-related neurodegenerative disorders (e.g. amyotrophic lateral
 CC sclerosis, Parkinson's disease and Leigh syndrome), cancer,
 CC cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
 CC mellitus, fibrotic and mesangial disorders. The proteins may also be
 CC useful for cell growth regulation (e.g. in wound healing), T cell
 CC activation, mitosis control, and as immunosuppressants
 XX SQ Sequence 21 BP; 6 A; 2 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 2.3e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 166 AAGTCATGATGTCACGGG 186
 DB 1 AAGTTATGATGTCACAGG 21
 RESULT 264
 AAA38134/c
 ID AAA38134 standard; DNA; 21 BP.
 XX AAA38134;
 AC 30-AUG-2000 (first entry)
 DT Polynucleotide used for ddl gene detection.
 XX Polynucleotide used for ddl gene detection.
 DE D alanine; D alanine ligase; ddl; detect; Streptococcus; Enterococcus; ss.
 XX Streptococcus oralis.
 OS US6054269-A.
 XX 25-APR-2000.

XX 25-JUN-1997; 97US-00882501.
 PF 25-JUN-1997; 97US-00882501.
 PR (INSP) INST PASTEUR.
 XX Gartner F, Gerbaud G, Dutka-Malen S, Charles M, Evers S;
 PI Casadewall B, Gailmond M, Courvalin P;
 DR WPI; 2000-338486/29.
 XX New polynucleotides derived from unknown sequences internal to the ddl
 PT genes coding for D-Alanine:D-Alanine ligase of various bacterial strains
 PT belonging to Enterococci or Streptococci genus, useful as probes.
 PS Claim 2; Col 57; 42pp; English.
 XX Sequences AAA38133-A38148 represent polynucleotides that hybridize with a
 CC nucleic acid sequence encoding a D-alanine:D-alanine ligase of a given
 CC species belonging to the Streptococci or Enterococci species. The
 CC polynucleotides are used to detect bacteria belonging to the Streptococci
 CC and Enterococci genus in a sample. The polynucleotides are also used as
 CC probes or primers that are specific for particular species or groups of
 CC species belonging to Streptococci or Enterococci genus. The
 CC oligonucleotide probes are also useful as capture probes immobilized on a
 CC substrate to capture a target nucleic acid and can be used in a detection
 CC device comprising a matrix library of probes immobilized on a substrate
 XX SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 2.3e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1850 CTCTCATCCGCCAGATTGAG 1870
 DB 21 CTGTCAATGCGTCAGATTGAG 1
 RESULT 265
 ADJ72441/c
 ID ADJ72441 standard; DNA; 21 BP.
 XX ADJ72441;
 AC 06-MAY-2004 (first entry)
 DT Human GP120 antibody VL CDR2 degenerate oligo to introduce Ala.
 XX GP120; antibody; scFv; ss; library; immunoglobulin; IgG; prototype;
 KW walk-through mutagenesis; anti-HIV; CDR;
 KM complementarity determining region.
 XX Synthetic.
 OS WO2003088911-A2.
 XX WO2003088911-A2.
 XX 30-OCT-2003.
 PD 16-APR-2003; 2003WO-US011936.
 PF 17-APR-2002; 2002US-0373558P.
 PR (CREA/) CREA R.
 XX Crea R;
 PI WPI; 2003-854029/79.
 DR New libraries for a prototype IgG (IgG) comprising mutated IgG or nucleic
 XX acids encoding a mutated IgG, useful for generating specific information
 PT on particular mutations that alter interaction of an IgG with its

PT antigen.
 XX Example B; Fig 8a; 57bp; English.
 PS
 XX This invention relates to a novel library of immunoglobulin (IgG)
 CC molecules. Specifically, it refers to prototype IgG molecules that each
 CC may comprise a mutation where a single predetermined amino acid has been
 CC substituted in one or more positions within one or more of the six
 CC complementary-determining regions (CDRs) of the anti-HIV human GP-120
 CC monoclonal antibody (scFv). The present invention describes a method for
 CC generating a library of prototype mutant IgGs (for example IgM, IgA, IgD
 CC or a Fab fragment of IgG), which can be used to study protein structure
 CC and function via a walk-through mutagenesis procedure. Accordingly, the
 CC libraries may be used for the systematic analysis of the binding regions
 CC of prototype IgG molecules. Furthermore, it provides specific information
 CC regarding particular mutations that alter the interaction of an IgG with
 CC its antigen, including multiple interactions by amino acids of the
 CC varying CDRs. This oligonucleotide sequence is a degenerate human GP120
 CC antibody VL CDR2 DNA oligo designed to introduce a targeted amino acid at
 CC one or more positions, a method of the invention.
 XX
 SQ Sequence 21 BP; 0 A; 4 C; 3 G; 6 T; 0 U; 8 Other;
 XX
 QY Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 57.1%; Pred. No. 2.3e+02;
 Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
 DB 1121 AGCAGAGCTGCAGCAGC 1141
 21 AGACGACSGCKYAGMARCAC 1
 OY
 DB
 RESULT 266
 ADJ13904/c
 ID ADJ13904 standard; DNA; 21 BP.
 XX
 AC ADJ13904;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human DNA probe used to immobilise Cpg methylated DNA SeqID 1031.
 XX
 KW probe; ss; chemical modification; methylation; array; Cpg island;
 XX tumour suppressor; p16; human; H69; H1618.
 XX
 OS Homo sapiens.
 XX
 PN US2003152950-A1.
 XX
 PD 14-AUG-2003.
 XX
 PF 27-JUN-2002; 2002US-00184085.
 XX
 PR 27-JUN-2001; 2001US-0301370P.
 XX
 PA (GARN/) GARNER H R.
 XX (MINN/) MINNA J D.
 PA (LUEB/) LUEBKE K J.
 PA (BALO/) BALOG R P.
 XX
 PI Garner HR, Minna JD, Luebke KJ, Balog RP;
 PT WPI; 2003-874843/81.
 XX
 PT Analysis of chemical modification of DNA involves obtaining sample of DNA
 PT to be analysed, treating DNA with chemical reagents that result in
 PT different base sequences, and determining sequence of resulting DNA.
 XX
 PS Example 1; SEQ ID NO 1031; 210bp; English.
 XX
 CC This invention relates to a novel method for analysing chemically
 CC modified macromolecules. Specifically, it refers to a high throughput
 CC method for the parallel analysis of many potential sites of chemical

CC modification (e.g. methylation) in DNA. The present invention describes
 CC treating the DNA with one or more chemical reagents that result in
 CC different base sequences depending upon the presence or absence of the
 CC modification of interest. Accordingly, a device comprising an array of
 CC probes is provided to hybridise with and select the altered DNA sequences
 CC that comprise the modifications of interest such as a Cpg island. In
 CC particular, this invention refers to analysing the methylation pattern of
 CC a region of the promoter for the tumour suppressor gene p16 from two
 CC human lung tumour cell lines H69 and H1618. This oligonucleotide sequence
 CC is a human DNA probe used to immobilise Cpg methylated DNA of the
 CC invention.
 XX
 SQ Sequence 21 BP; 2 A; 12 C; 3 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 2.3e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 DB 3460 GAGGAGGGGCGAGCGGCTCAG 3480
 21 GATGAGGGGCGAGCGGCTGAGG 1
 OY
 DB
 RESULT 267
 ADS87436
 ID ADS87436 standard; DNA; 21 BP.
 XX
 AC ADS87436;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Human midkine (MDK) siRNA target DNA fragment SeqID50.
 XX
 KW systemic lupus erythematosus; lupus nephritis; midkine gene;
 XX antiinflammatory; dermatological; immunosuppressive; MDK; siRNA;
 XX short inhibitory RNA; der; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2004036221-A2.
 XX
 PD 29-APR-2004.
 XX
 PF 17-OCT-2003; 2003WO-US033054.
 XX
 PR 18-OCT-2002; 2002US-0419088P.
 XX
 PA (AMHP) WYETH.
 PA (OTOO/) O'TOOLE M M.
 PA (LITW/) LITW W.
 XX
 PI O'toole MM, Liu W;
 PT WPI; 2004-389600/36.
 XX
 DR
 PT Diagnosing systemic lupus erythematosus or lupus nephritis, by detecting
 PT expression level of midkine gene in biological sample of mammal and
 PT comparing expression level to reference expression level of midkine gene
 PT in control sample.
 XX
 PS Claim 16; SEQ ID NO 50; 99bp; English.
 XX
 CC This invention relates to a novel method of diagnosing systemic lupus
 CC erythematosus or lupus nephritis, which comprises detecting an expression
 CC level of the midkine (MDK) gene in a biological sample isolated from a
 CC mammal of interest, and comparing the expression level to a reference
 CC expression level of the midkine gene in one or more control sample. The
 CC invention may be useful for the production of compounds with an
 CC antiinflammatory, dermatological or immunosuppressive activity acting
 CC through modulation of midkine gene expression activity, inhibitors of
 CC midkine gene expression by RNAi, stimulators of an immune response or
 CC midkine polypeptide antagonists. The invention is useful for diagnosing
 CC or treating systemic lupus erythematosus or lupus nephritis in a mammal

Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic; cerebroprotective; nootropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NCOG; hammerhead ribozyme; DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; Parkinson's disease; ataxia; Huntington's disease; Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

Human sapiens.
Synthetic.
WO200159103-A2.
16-AUG-2001.
09-FEB-2001; 2001WO-US004273.
11-FEB-2000; 2000US-0181797P.
28-FEB-2000; 2000US-0185516P.
06-MAR-2000; 2000US-0187128P.
(RIBO-) RIBOZYME PHARM INC.
(BLAT/) BLATT L.
(MCSM/) MCSWIGGEN J.
(CHOW/) CHOWRIRA B M.
Blatt L, Mcswigen J, Chowrira BM,
WPI; 2001-607195/69.
Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.
Claim 88; Page 130; 200pp; English.
The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NCOG). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberyne (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapeutics. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NCOG-targeting nucleic acid is used to cleave RNA of the NCOG gene in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid may be contacted with a cell to reduce NCOG activity of the cell and treat a patient having a condition associated with the level of NCOG. The treatment may further comprise the use of one or more therapeutics. In particular, the NCOG-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NCOG expression. The present sequence is an amberyne molecule of the invention

Sequence 17 BP; 8 A; 1 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 185 AGGACGAGGAGGAGAGA 200
Db 1 AGGACGAGGAGGAGAGA 16
|||||
RESULT 271
ABL46891
ID ABL46891 standard; RNA; 17 BP.
XX
AC ABL46891;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID G-cleaver ribozyme substrate oligonucleotide #32.
XX
KW Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
PI Jarvis T, Von Carlowitz I, Mcswigen JA, Hamblin PA, Ellis JH;
XX
DR WPI; 2001-550088/61.
XX
PT New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
PS Claim 4; Page 69; 108pp; English.
XX
CC The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1123 CAGCAGCTGCAGCAGC 1138
Db 1 CAGCAGCTGCAGCAGC 16
|||||
RESULT 272
ABL46750
ID ABL46750 standard; RNA; 17 BP.
XX

AC ABL46750;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID NCH ribozyme substrate oligonucleotide #204.
XX
KM Human; Grb2-related with Insert Domain; GRID; T-cell;
KM co-stimulatory adaptor protein; tissue rejection; graft rejection;
KM Leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001MO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
PI Jarvis T, Von Carlowitz I, Mcawiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550086/61.
DR
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
PS Claim 4; Page 66; 108pp; English.
XX
CC The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGC 1138
Db 2 CAGCAGCTGCAGCAGC 17

RESULT 273
AD37824
ID ADC37824 standard; DNA; 17 BP.
XX
AC ADC37824;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:173.
XX
KM human; angiotenin-like protein 1; AMLP1; cytostatic; gene therapy;
KM AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX

PF 01-NOV-2002; 2002MO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiotenin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 173; 172pp; English.
XX
CC The present invention describes the human angiotenin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1449 GCAGCAACGACGACG 1464
Db 1 GCAGCAACGACGACG 16

RESULT 274
AD37817
ID ADC37817 standard; DNA; 17 BP.
XX
AC ADC37817;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:166.
XX
KM human; angiotenin-like protein 1; AMLP1; cytostatic; gene therapy;
KM AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002MO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiotenin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 166; 172pp; English.
XX
CC The present invention describes the human angiotenin-like protein 1

CC (AMLP1). human AMLP1 has cytosstatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1443 GCAGCAGCAGCAACAG 1458
Db 2 GCAGCAGCAGCAACAG 17
XX
RESULT 275
ID ADMS4108 standard; mRNA; 17 BP.
XX
AC ADMS4108;
XX
XX 03-JUN-2004 (first entry)
XX
DE Human GRID mRNA substrate sequence #383.
XX
KM Human; ss; GRID; Grb2-related with insert domain, hammerhead ribozyme;
KM NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; amberyze; Inozyme;
KM hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX
XX Homo sapiens.
OS
XX US2003134806-A1.
XX
XX 17-JUL-2003.
PD
PF 23-FEB-2001; 2001US-00792818.
XX
XX 10-FEB-2000; 2000US-0181584P.
PR
XX (JARY/) JARVIS T.
PA (CARL/) CARLOWITZ I V.
PA (MCSW/) MCSWIGEN J.
PA (HAMB/) HAMBLIN P A.
PA (BLIT/) BLITS J H.
XX
PI Jarvis T, Carlowitz IV, Mcswigen J, Hamblin PA, Ellis JH;
XX
XX WPI; 2003-829646/77.
DR
XX
XX New nucleic acid molecule that down-regulates expression of Grb2-related
PT with insert domain (GRID) gene, useful for treating a condition
PT associated with the level of GRID, e.g. tissue/graft rejection and
PT leukemia.
XX
XX Claim 4; SEQ ID NO 383; 74pp; English.
PS
XX
XX The invention relates to a nucleic acid molecule that down-regulates
CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme,
CC amberyze, Inozyme or hairpin ribozyme. Also include are a mammalian cell
CC including the novel nucleic acid molecule, reducing GRID activity in a
CC cell by contacting the cell with the novel nucleic acid molecule,
CC treating a patient having a condition associated with the level of GRID
CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
CC contacting the cell with the novel nucleic acid molecule, an expression
CC vector comprising a nucleic acid sequences (encoding at least the novel
CC nucleic acid molecule in a manner that allows its expression), a
CC mammalian cell including the expression vector and an enzymatic nucleic

CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
CC molecule is useful for treating a condition associated with the level of
CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
CC a target region for the enzymatic nucleic acids of the invention.
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;
XX
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1123 CAGCAGCTCAGCAGC 1138
Db 2 CAGCAGCTCAGCAGC 17
XX
RESULT 276
ID AAX67194/C
XX
XX AAX67194 standard; RNA; 18 BP.
XX
AC AAX67194;
XX
XX 20-JUL-1999 (first entry)
XX
DE Human CD40 hairpin ribozyme target SEQ ID NO:3826.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KM hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KM streptolysin; synovial membrane; joint; arthritis; osteoarthritis;
KM rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KM diagnosis; ss.
XX
XX Homo sapiens.
OS
XX WO9618736-A2.
XX
XX 20-JUN-1996.
PD
XX
XX 22-NOV-1995; 95WO-US015516.
PF
XX
XX 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0009851P.
PR 07-JUL-1995; 95US-0009774P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Payco P;
PI Mcswigen J, Gustofson J, Usman N, Wincoff F, Matulic-Adamic J;
PI Karpelsky A, Thompson JD, Modak A, Burgin A;
XX
XX WPI; 1996-300653/30.
DR
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
XX Claim 10; Page 218; 307pp; English.
PS
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC (iii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also

CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The RNA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC streptomycin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention

XX
SQ Sequence 18 BP; 1 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1439 CCCTGCAGCAGCAGCA 1454
16 CCCTGCAGCAGCAGCA 1

Db

RESULT 277
AAF26668
ID AAF26668 standard; DNA; 18 BP.
XX
AC AAF26668;
XX
DT 09-SEP-2004 (revised)
DT 02-APR-2001 (first entry)
XX
DE Human Smad7 phosphorothioate antisense oligonucleotide SEQ ID NO:11.
XX
KW Human; Smad7; antisense oligonucleotide; phosphorothioate; inhibition;
KW inflammatory; cytostatic; infection; inflammation; tumour formation;
KW ss.
XX
OS Homo sapiens.
OS unidentified.

XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /mod_base
FT /note="phosphorothioate linkages"

XX
PN US6159697-A.
XX
PD 12-DEC-2000.
XX
PF 09-JAN-2000; 2000US-00487444.
XX
PR 09-JAN-2000; 2000US-00487444.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monica BP, Cowseert LM;
XX
DR WPI; 2001-070108/08.
XX
PT Antisense compound capable of inhibiting the expression of human Smad7,
PT useful for preventing or delaying infection, inflammation or tumor
PT formation.

XX
PS Claim 1; Col 40; 33pp; English.
XX
XX The present invention describes an antisense compound (I) of up to 30
CC nucleobases in length capable of inhibiting the expression of human
CC Smad7. (I) has antiinflammatory and cytostatic, and is a modulator of
CC Smad7 expression. (I) can be useful for inhibiting the expression of
CC human Smad7 in human cells or tissues, in vitro. (I) is commonly used as
CC a research reagent and in diagnostics for example, to elucidate the

CC function of particular genes. (I) is also useful for distinguishing
CC between functions of various members of a biological pathway and for
CC research use. (I) is also utilized for diagnostics, therapeutics, and
CC prophylaxis and in kits. (I) is also useful prophylactically, e.g. to
CC prevent or delay infection, inflammation or tumour formation. AAF26667 to
CC AAF26706 represent human Smad7 antisense oligonucleotides from the
CC present invention

XX
CC Revised record issued on 09-SEP-2004 : Correction to feature table key

XX
SQ Sequence 18 BP; 6 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1476 ACAGCAGCAGCAGCAG 1491
3 ACAGCAGCAGCAGCAG 18

Db

RESULT 278
ADR75637/c
ID ADR75637 standard; DNA; 19 BP.
XX
AC ADR75637;
XX
DT 16-DEC-2004 (first entry)
DT
XX
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 122.
XX
KW antilipemic; cardiac; vasotropic; antiarteriosclerotic; antidiabetic;
KW cyrostatic; anticonvulsant; nootropic; muscular; anti-HIV;
KW RNA interference; lRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
XX Homo sapiens.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 14-MAR-2003; 2003US-0455050P.
PR 17-APR-2003; 2003US-0462894P.
PR 25-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465655P.
PR 09-MAY-2003; 2003US-0465802P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALANY-) ALANYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense

PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 122; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilizing (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterized by elevated or
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance, the
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 0 A; 7 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1133 AGCAGCAGCAGCAGCG 1148
 DB 19 AGCAGCAGCAGCAGCG 4
 RESULT 279
 ADR78255/C
 ID ADR78255 standard; DNA; 19 BP.
 XX
 AC ADR78255;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 2740.
 XX
 XX antilipemic; cardiact; vasotropic; antiarteriosclerotic; antidiabetic;
 KM cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KM RNA interference; iRNA; antisense technology; lipid metabolism;
 KM cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KM coronary artery disease; CAD; coronary heart disease; CHD;
 KM atherosclerosis; hepatic glucose production;
 KM glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KM colon cancer; lung cancer; neurological disease; Huntington disease;
 KM spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004MO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR

PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-MAR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465655P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 XX Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 DR
 XX
 PT Interference RNA agent useful for treating dyslipidaemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX Example 5; SEQ ID NO 2740; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilizing (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterized by elevated or
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance, the
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 0 A; 7 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1133 AGCAGCAGCAGCAGCG 1148
 DB 19 AGCAGCAGCAGCAGCG 4
 RESULT 280
 AAA55807/C
 ID AAA55807 standard; DNA; 20 BP.
 XX
 AC AAA55807;
 XX

DT 01-SEP-2000 (first entry)
XX
DE Human histone deacetylase HD2 antisense oligonucleotide SEQ ID NO:52.
XX
KW Human; DNA methyltransferase; DNA Metase; antisense oligonucleotide;
XX modulation; inhibition; gene expression; combination therapy; p16;
KM histone deacetylase; HDAC; thymidylate synthase; tumour suppressor;
KW methylation; gene therapy; tumour; cytostatic; antiasthmatic;
XX antiinflammatory; inflammation; asthma; ss.
XX
OS Homo sapiens.
XX
PN NC0200023112-A1.
XX
PD 27-APR-2000.
XX
PF 19-OCT-1999; 99WO-US024278.
XX
PR 19-OCT-1998; 98US-0104804P.
XX
PA (METH-) METHYLGENE INC.
XX
PI Besterman JM, Macleod AR, Siders WM;
XX
DR WPI; 2000-339532/29.
XX
PT Inhibiting gene expression e.g. DNA methyltransferase, by treating cells
PT with a synergistic amount of antisense oligonucleotide and protein
PT effectors e.g. 5-aza-cytidine of gene products, useful for gene therapy
XX of e.g. tumors.
XX
PS Disclosure; Page 29; 99pp; English.
XX
XX The present invention describes a method for inhibiting the expression of
CC a gene in a cell comprising contacting the cell with an effective
CC synergistic amount of an antisense oligonucleotide which inhibits
CC expression of the gene, and an effective synergistic amount of a protein
CC effector of a product of the gene. Also described are: (1) a method for
CC treating a disease responsive to inhibition of a gene in a mammal; (2) a
CC method for inhibiting tumour growth in mammal; (3) an inhibitor of a gene
CC comprising an antisense oligonucleotide which inhibits expression of the
CC gene in operable association with a protein effector of a gene product;
CC and (4) a pharmaceutical composition comprising the inhibitor of (3). The
CC methods and compositions are useful as analytical tools for transgenic
CC studies and as therapeutic tools, e.g. as gene therapy tools for human
CC diseases including benign and malignant tumours, inflammation or asthma.
CC The methods, inhibitors and compositions of the invention that inhibit
CC expression or activity of a gene or gene product may be used to treat
CC patients having, or predisposed to developing, a disease responsive to
CC inhibition of the gene. These may also be used to activate silenced genes
CC to provide missing gene functions and improve a given condition.
CC Furthermore, the methods and compositions are useful as probes of the
CC physiological function of a gene product in an experimental cell culture
CC or animal system; and to evaluate the effect of inhibiting gene activity
CC or expression. AAAS5758 to AAAS5842 represent oligonucleotide sequences
CC which are used in the exemplification of the present invention
XX
SQ Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1131 GCAGCAGCAGCAGCAG 1146
DB 20 GCAGCAGCAGCAGCAG 5
XX
RESULT 281
AAA94502/c
ID AAA94502 standard; DNA; 20 BP.
XX
AC AAA94502;

XX
DT 09-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide #20941 targeted to human G-alpha-S1.
XX
KW G-alpha-S1; infection; inflammation; tumour; antisense; human;
XX phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW G-alpha short form; ss.
XX
XX Homo sapiens.
XX
OS
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "optionally the internucleotide linkages are
FT phosphorothioate"
FT 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
XX
PN US6110664-A.
XX
PD 29-AUG-2000.
XX
PF 25-JUN-1999; 99US-00344914.
XX
PR 25-JUN-1999; 99US-00344914.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowsett LM;
XX
DR WPI; 2000-586346/55.
XX
PT New antisense compounds for modulating the expression of G-alpha-S1,
PT especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
PT prevent or delay infection, inflammation or tumor formation.
XX
PS Claim 3; Col 39; 37pp; English.
XX
XX The present invention relates to antisense compounds 8-30 bases long
CC targeted to a coding region, a stop codon, or a 3' untranslated region of
CC human G-alpha-S1 (see AA94511). The antisense compounds specifically
CC hybridize with and inhibit the expression of human G-alpha-S1. The
CC antisense compounds are useful for diagnostics, therapeutics and
CC prophylaxis, e.g. to prevent or delay infection, inflammation or tumour
CC formation. Particularly, the antisense oligonucleotides are useful for
CC treating humans prone to a disease or condition associated with
CC expression of G-alpha-S1. The present sequence an antisense
CC oligonucleotide targeted to the 3' untranslated region of human G-alpha-
CC S1
XX
SQ Sequence 20 BP; 2 A; 3 C; 4 G; 11 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1112 TAAACAGCAGCAGCA 1127
DB 16 TAAACAGCAGCAGCA 1
XX
RESULT 282
AAA94504/c

```
ID AAA94504 standard; DNA; 20 BP.
XX
XX AAA94504;
XX
XX
DT 09-JAN-2001 (first entry)
XX
XX Antisense oligonucleotide #20943 targeted to human G-alpha-S1.
XX
XX G-alpha-S1; infection; inflammation; tumour; antisense; human;
XX phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
XX Gs-alpha short form; ss.
XX
XX Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
FT phosphorothioate"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT
FT
XX
XX US6110664-A.
XX
XX 29-AUG-2000.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowseart LM;
XX
XX WPI; 2000-586346/55.
XX
XX
XX New antisense compounds for modulating the expression of G-alpha-S1,
XX especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
XX prevent or delay infection, inflammation or tumor formation.
XX
XX Claim 3; Col 39; 37pp; English.
XX
XX The present invention relates to antisense compounds 8-30 bases long
XX targeted to a coding region, a stop codon, or a 3' untranslated region of
XX human G-alpha-S1 (see AA94451). The antisense compounds specifically
XX hybridize with and inhibit the expression of human G-alpha-S1. The
XX antisense compounds are useful for diagnostics, therapeutics and
XX prophylaxis, e.g. to prevent or delay infection, inflammation or tumor
XX formation. Particularly, the antisense oligonucleotides are useful for
XX treating humans prone to a disease or condition associated with
XX expression of G-alpha-S1. The present sequence an antisense
XX oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1
SQ Sequence 20 BP; 1 A; 3 C; 4 G; 12 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1112 TAAACAGCAGCAGCA 1127
DB 18 TAAACAGCAGCAGCA 3
```

```
RESULT 283
ID AAA94503/c
XX AAA94503 standard; DNA; 20 BP.
XX
XX
XX AAA94503;
XX
XX 09-JAN-2001 (first entry)
XX
XX Antisense oligonucleotide #20942 targeted to human G-alpha-S1.
XX
XX G-alpha-S1; infection; inflammation; tumour; antisense; human;
XX phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
XX Gs-alpha short form; ss.
XX
XX Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
FT phosphorothioate"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT
FT
XX
XX US6110664-A.
XX
XX 29-AUG-2000.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowseart LM;
XX
XX WPI; 2000-586346/55.
XX
XX
XX New antisense compounds for modulating the expression of G-alpha-S1,
XX especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
XX prevent or delay infection, inflammation or tumor formation.
XX
XX Claim 3; Col 39; 37pp; English.
XX
XX The present invention relates to antisense compounds 8-30 bases long
XX targeted to a coding region, a stop codon, or a 3' untranslated region of
XX human G-alpha-S1 (see AA94451). The antisense compounds specifically
XX hybridize with and inhibit the expression of human G-alpha-S1. The
XX antisense compounds are useful for diagnostics, therapeutics and
XX prophylaxis, e.g. to prevent or delay infection, inflammation or tumor
XX formation. Particularly, the antisense oligonucleotides are useful for
XX treating humans prone to a disease or condition associated with
XX expression of G-alpha-S1. The present sequence an antisense
XX oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1
SQ Sequence 20 BP; 1 A; 3 C; 4 G; 12 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1112 TAAACAGCAGCAGCA 1127
```

Db 17 TAAACGACGACGCA 2

RESULT 284
AAA94505/c
AAA94505 standard; DNA; 20 BP.

AC AAA94505;

DT 09-JAN-2001 (first entry)

DE Antisense oligonucleotide #20944 targeted to human G-alpha-S1.

KM G-alpha-S1; infection; inflammation; tumour; antisense; human;
KM phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW G-alpha short form; ss.

OS Homo sapiens.

FT Key Location/Qualifiers
FT modified_base 1..20

FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
phosphorothioate"

FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
and cytidine residues are 5-methylcytidines"

FT modified_base 16..20

FT /tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
and cytidine residues are 5-methylcytidines"

PN US6110664-A.

PD 29-AUG-2000.

PF 25-JUN-1999; 99US-00344914.

PR 25-JUN-1999; 99US-00344914.

PA (ISIS-) ISIS PHARM INC.

PI Cowbert LM;

PT WPI; 2000-586346/55.

DR New antisense compounds for modulating the expression of G-alpha-S1,
especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
prevent or delay infection, inflammation or tumor formation.

PS Claim 3; Col 39; 37pp; English.

XX The present invention relates to antisense compounds 8-30 bases long
XX targeted to a coding region, a stop codon, or a 3' untranslated region of
XX human G-alpha-S1 (see AAA94451). The antisense compounds specifically
XX hybridize with and inhibit the expression of human G-alpha-S1. The
XX antisense compounds are useful for diagnostics, therapeutics and
XX prophylaxis, e.g. to prevent or delay infection, inflammation or tumor
XX formation. Particularly, the antisense oligonucleotides are useful for
XX treating humans prone to a disease or condition associated with
XX expression of G-alpha-S1. The present sequence an antisense
XX oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1

CC Sequence 20 BP; 1 A; 3 C; 5 G; 11 T; 0 U; 0 Other;

Query Match 0.44; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1112 TAAACGACGACGCA 1127
19 TAAACGACGACGCA 4

RESULT 285
AAA94506/c
AAA94506 standard; DNA; 20 BP.

AC AAA94506;

DT 09-JAN-2001 (first entry)

DE Antisense oligonucleotide #20945 targeted to human G-alpha-S1.

KM G-alpha-S1; infection; inflammation; tumour; antisense; human;
KM phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW G-alpha short form; ss.

OS Homo sapiens.

FT Key Location/Qualifiers
FT modified_base 1..20

FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
phosphorothioate"

FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
and cytidine residues are 5-methylcytidines"

FT modified_base 16..20

FT /tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
and cytidine residues are 5-methylcytidines"

PN US6110664-A.

PD 29-AUG-2000.

PF 25-JUN-1999; 99US-00344914.

PR 25-JUN-1999; 99US-00344914.

PA (ISIS-) ISIS PHARM INC.

PI Cowbert LM;

PT WPI; 2000-586346/55.

DR New antisense compounds for modulating the expression of G-alpha-S1,
especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
prevent or delay infection, inflammation or tumor formation.

PS Claim 3; Col 39; 37pp; English.

XX The present invention relates to antisense compounds 8-30 bases long
XX targeted to a coding region, a stop codon, or a 3' untranslated region of
XX human G-alpha-S1 (see AAA94451). The antisense compounds specifically
XX hybridize with and inhibit the expression of human G-alpha-S1. The
XX antisense compounds are useful for diagnostics, therapeutics and
XX prophylaxis, e.g. to prevent or delay infection, inflammation or tumor
XX formation. Particularly, the antisense oligonucleotides are useful for
XX treating humans prone to a disease or condition associated with
XX expression of G-alpha-S1. The present sequence an antisense
XX oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1

CC Sequence 20 BP; 1 A; 3 C; 5 G; 11 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACGACGACGACGA 1127
 |||||
 DB 20 TAAACGACGACGACGA 5

RESULT 286
 AAH43117/C
 ID AAH43117 standard; DNA; 20 BP.
 XX
 AC AAH43117;
 XX
 DT 19-SEP-2001 (first entry)
 XX
 DE Antisense oligo, target HDAC-2 132-152.
 XX
 KM Antisense; histone deacetylase; HDAC-1; HDAC-2; HDAC-4; inhibitor;
 XX cell proliferation; cancer; restenosis; psoriasis; protozoal infection;
 KM fungal infections; ss.
 XX
 OS Synthetic.
 XX
 PN WO200138322-A1.
 XX
 PD 31-MAY-2001.
 XX
 PF 22-NOV-2000; 2000WO-IB001881.
 XX
 PR 23-NOV-1999; 99US-0167035P.
 XX
 PA (METH-) METHYLGENE INC.
 XX
 PI Delorme D, Ruel R, Lavote R, Thibault C, Abou-Khalil E;
 XX
 DR WPI; 2001-432601/46.
 XX
 PT New inhibitors of histone deacetylase e.g. N-hydroxy-5-(4-
 PT (benzenesulfonylamino)-phenyl)-4-yn-2-pentanamide for treating cancer,
 PT restenosis or fungal infections.
 XX
 PS Disclosure; Page 40; 147pp; English.
 XX
 CC The sequences given in AAH43115-21 are oligonucleotides which are
 CC antisense to the histone deacetylase gene, HDAC-2. These oligonucleotides
 CC may be used in combination with an inhibitor of histone deacetylase
 CC enzyme function, to given an improved inhibitory effect, thereby reducing
 CC the amount of inhibitor required to obtain a given inhibitory effect.
 CC Compounds containing these oligonucleotides may be used to treat cell
 CC proliferation conditions such as cancer, restenosis or psoriasis. They
 CC can also be used to treat protozoal and fungal infections
 CC
 SQ Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
 |||||
 DB 20 GCAGCAGCAGCAGCAG 5

RESULT 287
 AAC89537/C
 ID AAC89537 standard; DNA; 20 BP.
 XX
 AC AAC89537;
 XX
 DT 08-MAR-2001 (first entry)

XX
 DE Human HDAC-2 PCR primer SEQ ID NO: 7.
 XX
 KM Histone deacetylase; HDAC-1; HDAC-2; HDAC-3; HDAC-4; HDAC-5; HDAC-C;
 KM HDAC-D; cell cycle; tumorigenesis; cancer; inhibitor; antisense;
 KM gene therapy; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200071703-A2.
 XX
 PD 30-NOV-2000.
 XX
 PF 03-MAY-2000; 2000WO-IB001252.
 XX
 PR 03-MAY-1999; 99US-0132287P.
 XX
 PA (METH-) METHYLGENE INC.
 XX
 PI Macleod AR, Li Z, Besterman JM;
 XX
 DR WPI; 2001-016407/02.
 XX
 PT Antisense oligonucleotide that inhibits expression of a histone
 PT deacetylase, useful for treating and/or alleviating the symptoms of
 PT neoplasia, or for inhibiting neoplastic cell growth in an animal.
 XX
 PS Disclosure; Page 12; 125pp; English.
 XX
 CC The present invention provides inhibitors of histone deacetylase enzymes
 CC such as HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C and HDAC-D. These
 CC inhibitors may be antisense strands or they may be compounds identified
 CC by contacting the enzyme with the compound and measuring the resulting
 CC enzyme activity. These inhibitors are useful for treating cancers and for
 CC identifying which histone deacetylase is involved in a neoplasia
 CC
 SQ Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
 |||||
 DB 20 GCAGCAGCAGCAGCAG 5

RESULT 288
 AAC89546/C
 ID AAC89546 standard; DNA; 20 BP.
 XX
 AC AAC89546;
 XX
 DT 08-MAR-2001 (first entry)
 XX
 DE Human HDAC-2 antisense sequence SEQ ID NO: 16.
 XX
 KM Histone deacetylase; HDAC-1; HDAC-2; HDAC-3; HDAC-4; HDAC-5; HDAC-C;
 KM HDAC-D; cell cycle; tumorigenesis; cancer; inhibitor; antisense;
 KM gene therapy; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200071703-A2.
 XX
 PD 30-NOV-2000.
 XX
 PF 03-MAY-2000; 2000WO-IB001252.
 XX
 PR 03-MAY-1999; 99US-0132287P.
 XX
 PA (METH-) METHYLGENE INC.
 XX

PI Macleod AR, Li Z, Beestman JM;
XX
XX WPI, 2001-016407/02.
XX
XX Antisense oligonucleotide that inhibits expression of a histone
PT deacetylase, useful for treating and/or alleviating the symptoms of
PT neoplasia, or for inhibiting neoplastic cell growth in an animal.
XX
XX
PS Example 1; Page 24; 125pp; English.
XX
XX The present invention provides inhibitors of histone deacetylase enzymes
CC such as HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C and HDAC-D. These
CC inhibitors may be antisense strands or they may be compounds identified
CC by contacting the enzyme with the compound and measuring the resulting
CC enzyme activity. These inhibitors are useful for treating cancers and for
CC identifying which histone deacetylase is involved in a neoplasia
XX
SQ Sequence 20 BP; 0 A; 9 C; 5 G; 4 T; 2 U; 0 Other;
XX
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1131 GCAGCAGCAGCAGCAG 1146
DB 20 GCAGCAGCAGCAGCAG 5
RESULT 289
ABZ85596/c
ID ABZ85596 standard; DNA; 20 BP.
XX
XX ABZ85596;
XX
DT 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;
XX
XX WPI, 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 838; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to, adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 5 C; 8 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1132 CAGCAGCAGCAGCAGC 1147
DB 17 CAGCAGCAGCAGCAGC 2
RESULT 290
ABZ88039
ID ABZ88039 standard; DNA; 20 BP.
XX
XX ABZ88039;
XX
DT 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;
XX
XX WPI, 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 3281; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX WPI; 2003-093058/08.
DR
XX
XX
PT pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15, SEQ ID NO 838; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or surfactant hypoproduction are associated
CC inflammation, allergies and/or bronchoconstriction and/or lung
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
CC
XX
SQ Sequence 20 BP; 0 A; 5 C; 8 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1132 CAGCAGCAGCAGCAGC 1147
Db 17 CAGCAGCAGCAGCAGC 2
RESULT 293
AAZ72847
ID AAZ72847 strand; DNA; 19 BP.
XX
AC AAZ72847;
XX
DT 10-SEP-2001 (first entry)
XX
XX Human biallelic marker upstream amplification primer SEQ ID NO:7203.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
KM genomic map; haplotype; polymorphic base; genotyping;
KM haplotyping; hybridisation; identification; characterisation;
KM amplification; single nucleotide polymorphism; SNP; PCR primer;
KM diagnosis; ss.
XX
XX Homo sapiens.
OS
XX
XX MO954500-A2.
PN
XX
XX 28-OCT-1999.
PD

XX
PF 21-APR-1999; 99MO-IB000822.
XX
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
XX (GEST) GENSET.
XX
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
XX WPI; 2000-013267/01.
DR
XX
XX Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
XX
PS Claim 9, Page 1766; 2745pp; English.
XX
XX AA265654 to AA269578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AA269579 to AA277440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
XX
SQ Sequence 19 BP; 10 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3243 AGAAGTGAGAGAGAGCAG 3261
Db 1 AGAAGTGAGAGAGAGTAG 19
RESULT 294
ADL79842
ID ADL79842 strand; RNA; 19 BP.
XX
AC ADL79842;
XX
XX
DT 20-MAY-2004 (first entry)
XX
XX Human HBR1 (EGFR) siRNA lower strand, SEQ ID NO:1007.
XX
XX RNA interference; short interfering nucleic acid; siRNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping; cancer;
KM cytotoxic; human; oncogene; epidermal growth factor receptor; EGFR;
KM HBR1; c-erb-B-1; ss.
XX
XX
OS Homo sapiens.
XX
XX MO2003070912-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003MO-US005045.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 29-MAY-2002; 2002MO-US016840.
PD

PR 06-JUN-2002; 2002US-00163552.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393924P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 19-SEP-2002; 2002US-00251117.
 PR 21-OCT-2002; 2002US-00277494.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Mswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
 DR WPI; 2003-697612/66.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of the epidermal growth
 PT factor receptor gene.
 XX
 PS Example 3; SEQ ID NO 1007; 171pp; English.
 XX
 CC The invention relates to short interfering nucleic acids (siNA) which
 CC downregulate expression of one or more human epidermal growth factor
 CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
 CC interference. The siNAs may or may not comprise ribonucleotides and may
 CC be double or single stranded. They further comprise sense and antisense
 CC regions, or alternatively are assembled from a sense oligonucleotide and
 CC an antisense oligonucleotide. Specifically, the siNAs include short
 CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
 CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
 CC can contain deoxyribonucleotides, and can be chemically synthesised,
 CC expressed from a vector or enzymatically synthesised. The invention also
 CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
 CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
 CC used to modulate expression of EGFR genes in cells, tissue explants or
 CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
 CC for the treatment of a variety of conditions. They may be used for
 CC treating a wide range of cancers such as breast and ovarian cancer. The
 CC siNAs are also useful for drug screening, diagnosis, therapeutic target
 CC identification and validation, genetic engineering, pharmacogenomics,
 CC studying gene function, and gene mapping (e.g., of single nucleotide
 CC polymorphisms). The present sequence represents the lower strand of a
 CC human HER1 (EGFR)-targeted double-stranded siNA.
 CC
 XX
 SQ Sequence 19 BP; 5 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 68.4%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 OY 477 GAATGCTGCTGACAG 495
 Db 1 GAAUGUGUGUGUACACAG 19
 ADL79535/C
 ID ADL79535 standard; RNA; 19 BP.
 AC
 XX ADL79535;
 DT 20-MAY-2004 (first entry)
 XX
 DE Human HER1 (EGFR) transcript target sequence/siNA upper strand, SEQ:700.
 XX
 KW RNA interference; short interfering nucleic acid; siNA;
 KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
 KW short hairpin RNA; shRNA; expression modulation; gene therapy;
 KW drug screening; diagnosis; therapeutic target identification;
 KW pharmacogenomics; gene function analysis; gene mapping; cancer;
 KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
 KW HER1; c-erb-B-1; target sequence; ss.

XX
 OS Homo sapiens.
 XX
 PN WC02003070912-A2.
 XX
 PD 28-AUG-2003.
 XX
 PF 20-FEB-2003; 2003WO-US005045.
 XX
 XX 20-FEB-2002; 2002US-038580P.
 PR 11-MAR-2002; 2002US-0361324P.
 PR 29-MAY-2002; 2002WO-US015840.
 PR 06-JUN-2002; 2002US-00163552.
 PR 03-JUL-2002; 2002US-0393924P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 19-SEP-2002; 2002US-00251117.
 PR 21-OCT-2002; 2002US-00277494.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Mswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
 DR WPI; 2003-697612/66.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of the epidermal growth
 PT factor receptor gene.
 XX
 PS Example 3; SEQ ID NO 700; 171pp; English.
 XX
 CC The invention relates to short interfering nucleic acids (siNA) which
 CC downregulate expression of one or more human epidermal growth factor
 CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
 CC interference. The siNAs may or may not comprise ribonucleotides and may
 CC be double or single stranded. They further comprise sense and antisense
 CC regions, or alternatively are assembled from a sense oligonucleotide and
 CC an antisense oligonucleotide. Specifically, the siNAs include short
 CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
 CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
 CC can contain deoxyribonucleotides, and can be chemically synthesised,
 CC expressed from a vector or enzymatically synthesised. The invention also
 CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
 CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
 CC used to modulate expression of EGFR genes in cells, tissue explants or
 CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
 CC for the treatment of a variety of conditions. They may be used for
 CC treating a wide range of cancers such as breast and ovarian cancer. The
 CC siNAs are also useful for drug screening, diagnosis, therapeutic target
 CC identification and validation, genetic engineering, pharmacogenomics,
 CC studying gene function, and gene mapping (e.g., of single nucleotide
 CC polymorphisms). The present sequence represents the upper strand of a
 CC human HER1 (EGFR)-targeted double-stranded siNA, which is identical to
 CC the HER1 transcript target sequence.
 CC
 XX
 SQ Sequence 19 BP; 5 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 477 GAATGCTGCTGACAG 495
 Db 19 GAATGCTGCTGACAG 1
 ADG64260
 ID ADG64260 standard; DNA; 19 BP.
 XX

AA051743/c
 ID AA051743 standard; cDNA; 20 BP.
 XX
 AC AA051743;
 XX
 DT 25-MAR-2003 (revised)
 DT 31-MAY-1994 (first entry)
 XX
 DE Mycobacteria probe 14-10.
 XX
 KM Mycobacterium kansasii, probe; mycobacteria; diagnosis; ss.
 XX
 OS Synthetic.
 XX
 PN EP571911-A2.
 XX
 PD 01-DEC-1993.
 XX
 PF 24-MAY-1993; 93EP-00108325.
 XX
 PR 26-MAY-1992; 92US-00889651.
 XX
 PA (BECT) BECTON DICKINSON CO.
 XX
 PI Spears PA, Shank DD;
 XX
 DR WPI; 1993-378844/48.
 XX
 PT New oligo:nucleotide probes specific for Mycobacteria - used for
 PT detection and amplification of Mycobacteria nucleic acid in samples.
 XX
 PS Disclosure; Page 13; 23pp; English.
 XX
 CC Oligonucleotide probe 14-10 was used in a polymerase chain reaction as a
 CC primer, with plasmid MK14 as the template, to divide clone MK14
 CC (AA051735) into 1 of 5 smaller fragments. See also AA051735-42 and
 CC AA051744-59. (Updated on 25-MAR-2003 to correct PN field.)
 CC
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 1205 AGCAGAAGAGAGCGCG 1223
 DB 19 AGCACAAAGGTGAGCGCG 1
 XX
 RESULT 299
 ID AAT86505/c
 AC AAT86505 standard; DNA; 20 BP.
 XX
 AC AAT86505;
 XX
 DT 12-MAR-1998 (first entry)
 XX
 DE S-adenosylmethionine decarboxylase antisense oligonucleotide #6.
 XX
 KM S-adenosylmethionine decarboxylase; SAMDC; antisense oligonucleotide;
 KM antitumour; diagnosis; phosphorothioate; psoriasis; spermine; spermidine;
 KM ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "nucleotides are bonded via phosphorothioate
 FT linkages"
 XX
 PN WO9605298-A1.

XX
 PD 22-FEB-1996.
 XX
 PF 27-JUL-1995; 95MO-EP002985.
 XX
 PR 09-AUG-1994; 94US-00287753.
 XX
 PA (CIBA) CIBA GEIGY AG.
 XX
 PI Mett H, Haner R, Dean NM;
 XX
 DR WPI; 1996-139694/14.
 XX
 PT New oligo:nucleotide derivs. specific for S-adenosylmethionine
 PT decarboxylase related nucleic acid - useful as antisense inhibitors of
 PT this enzyme, esp. for treatment of tumours but also as hybridisation
 PT probes for diagnosis.
 XX
 PS Example 6; Page 45; 81pp; English.
 XX
 CC This sequence represents a phosphorothioate analogue of an antisense
 CC oligonucleotide which targets the translated region of S-
 CC adenosylmethionine decarboxylase (SAMDC) around nucleotides at positions
 CC 979 to 998. Antisense oligonucleotide analogues (AAT86500-14) which
 CC target the SAMDC gene are used to diagnose conditions associated with
 CC expression of SAMDC by specifically hybridising to RNA or DNA derived
 CC from the SAMDC gene. These antisense molecules are useful for therapeutic
 CC modulation (especially inhibition) of SAMDC synthesis, particularly to
 CC treat tumours (e.g. leukemia, prostatic carcinoma, colon or brain
 CC tumours, but especially bladder cancer), but also other hyper-
 CC proliferative diseases such as psoriasis. They cause tumour regression
 CC and prevent establishment/growth of (micro)metastases. Inhibition of
 CC SAMDC reduces the level of polyamines (spermine and spermidine in cells),
 CC resulting in cytostasis and possibly apoptosis
 CC
 XX
 SQ Sequence 20 BP; 0 A; 4 C; 5 G; 11 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 1445 AGCAGCAGCAGCAGCA 1463
 DB 19 AGAAGCAGCAACAACAGCA 1
 XX
 RESULT 300
 ID AAV35212/c
 AC AAV35212 standard; DNA; 20 BP.
 XX
 AC AAV35212;
 XX
 DT 10-SEP-1998 (first entry)
 XX
 DE Hepatitis C virus type 1b PCR primer #15.
 XX
 KM Nonstructural viral protein; hepatocyte; detection; replication;
 KM inhibition; RNA polymerase; PCR primer; ss.
 XX
 OS Synthetic.
 OS Hepatitis C virus.
 XX
 PN JP10165186-A.
 XX
 PD 23-JUN-1998.
 XX
 PF 13-DEC-1996; 96JP-00352920.
 XX
 PR 13-DEC-1996; 96JP-00352920.
 XX
 PA (KAGA) ZH KAGAKU & KESSHI RYOHO KENKYUSHO.
 XX
 DR WPI; 1998-406110/35.

XX Hepatitis C virus-sensitive recombinant hepatocyte - useful for, e.g.
 PT replicating HCV and producing its non-structural protein.
 XX
 XX Example 4; Page 9, 11pp; Japanese.
 XX
 CC AAV35197-V35200, AAV35202 and AAV35215 are primers used in a method for
 CC producing a nonstructural protein of hepatitis C virus (HCV) type 1b from
 CC a recombinant hepatocyte. Also described is a method for the replication
 CC of HCV which involves contacting HCV with the sensitive recombinant
 CC hepatocyte, and culturing the hepatocyte. The method may also be used for
 CC detecting a substance capable of inhibiting replication of HCV. The
 CC method can prepare HCV-sensitive recombinant hepatocyte capable of
 CC producing HCV RNA polymerase constitutively, and replicating HCV
 CC efficiently for a long period
 XX
 XX Sequence 20 BP; 5 A; 2 C; 9 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3584 ATGCATCATCTCTCTCC 3602
 DB 19 ATGCATCATCTCTCTCAC 1
 RESULT 301
 AAX23971
 ID AAX23971 standard; DNA; 20 BP.
 XX
 AC AAX23971;
 XX
 DT 25-JUN-1999 (first entry)
 XX
 DE Human HG38 DNA PCR primer 2.
 XX
 KM HG38: human; G-protein coupled glycoprotein hormone receptor; brain;
 KM receptor system; skeletal muscle; spinal cord; placenta; development;
 KM receptor activity modulator; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN MO9915660-A1.
 XX
 PD 01-APR-1999.
 XX
 PF 24-SEP-1998; 98MO-US019979.
 XX
 PR 24-SEP-1997; 97US-0059863P.
 XX
 PA (MER1) MERCK & CO INC.
 XX
 PI Liu Q, Bailey WJ, McDonald TP;
 DR WPI; 1999-254711/21.
 XX
 PT Human G-protein coupled glycoprotein hormone receptor HG38.
 XX
 PS Example 1; Page 37; 74pp; English.
 XX
 CC This invention describes a novel human G-protein coupled glycoprotein
 CC hormone receptor, HG38. Glycoprotein hormone receptors are important in
 CC the endocrine system and HG38 may be involved in development and function
 CC of the skeletal muscle, placenta and to a lesser extent, the
 CC brain. The transgenic animal may be useful for studying tissue and
 CC temporal specific expression or activity of the HG38 receptor, as well as
 CC for studying the ability of a variety of compounds to act as modulators
 CC of HG38 receptor activity
 CC
 CC Sequence 20 BP; 7 A; 3 C; 10 G; 0 T; 0 U; 0 Other;
 XX
 XX

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2067 GCAAGGCGGCGAGCGG 2085
 DB 2 GCAAGGCGGCGAGAGAG 20
 RESULT 302
 AAX76854
 ID AAX76854 standard; DNA; 20 BP.
 XX
 AC AAX76854;
 XX
 DT 05-AUG-1999 (first entry)
 XX
 DE PCR primer for cloning of T66Bk gene.
 XX
 KM Transcription unit; MARK2 kinase; rsk3 kinase; regulatory region; T66Bk;
 KM contraceptive; Responder/Distorter signalling cascade; t-Responder;
 KM PCR primer; ss.
 XX
 OS Synthetic.
 OS Mus sp.
 XX
 PN MO9925815-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 18-NOV-1998; 98MO-EP07395.
 XX
 PR 18-NOV-1997; 97EP-00120190.
 PR 02-MAR-1998; 98EP-00103596.
 XX
 PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
 XX
 PI Herrmann B, Koschorz B, Klapert A;
 DR WPI; 1999-347466/29.
 XX
 PT Nucleic acids involved in the Responder phenotype in mice.
 XX
 PS Example 7; Page 59; 117pp; English.
 XX
 CC This sequence is a PCR primer used in the cloning of the T66Bk gene. The
 CC invention related to a nucleic acid molecule (I) comprising a
 CC transcription unit encoding in its 5' portion a kinase having a homology
 CC to MARK2 kinase and the 3' portion of the nucleotide sequence has a high
 CC homology to rsk3 kinase. Sperm produced by transgenic creatures
 CC containing (I) are useful for production of offspring. T66Bk, its
 CC regulatory region, recombinant DNA, vectors, host cells, antibodies,
 CC etc., are useful for the isolation of receptors on the surface of sperm
 CC recognising attractants of the egg cell for the development and/or
 CC production of contraceptives. They can also be used to identify chemicals
 CC or biological compounds able to trigger the (premature) activation or
 CC inhibition of the Responder/Distorter signalling cascade, or to identify
 CC and isolate receptors and other members of the cascade that bind the
 CC expression products. The methods for detecting the sperm of the
 CC transgenic animal, and selecting against (I) also provide a means for
 CC distorting the transmission ratio of genetic traits by altering genes of
 CC the Responder/Distorter signal cascade other than the t-Responder. They
 CC also allow distortion, to a non-Mendelian ratio, of the transmission of a
 CC genetic trait, i.e. determination of sex, from male mammals to their
 CC offspring by expressing during spermatogenesis/spermiogenesis a gene
 CC involved in sperm motility and/or fertilisation. The genes and proteins
 CC involved in the responder phenotype and Responder/Distorter signalling
 CC cascade, as well as the inventive methods are advantageous in breeding
 CC strategies by allowing for specific selection of genetic traits and in
 CC particular, of sex
 CC
 CC Sequence 20 BP; 8 A; 5 C; 7 G; 0 T; 0 U; 0 Other;
 XX
 XX

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1449 GCAGCAACGACGACGAG 1467
 DB 2 GCAGCAACGACGACGAG 20

RESULT 303
 AAZ05303/c
 ID AAZ05303 standard; DNA; 20 BP.

XX
 AC AAZ05303;

DT 07-OCT-1999 (first entry)

XX PCR primer used to amplify an ORF of Chlamydia trachomatis.

XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
 KW paratrachoma; inclusion conjunctivitis; genital disease; peritropia;
 KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KW Bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.

OS Synthetic.
 OS Chlamydia trachomatis.

PN MO928475-A2.

PD 10-JUN-1999.

PF 27-NOV-1998; 98WO-IB001939.

XX 28-NOV-1997; 97FR-00015041.

PR 17-DEC-1997; 97FR-00016034.

XX 04-NOV-1998; 98US-0107077P.

PA (GEST) GENSET.

PI Griffiths R;

XX WPI; 1999-371125/31.

PT Genome sequence of Chlamydia trachomatis.

PS Disclosure; Page 1759; 1755pp; English.

XX PCR primers AAZ01426-206209 were used to amplify open reading frames
 CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
 CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
 CC be used to control growth of the microorganism. Chlamydia trachomatis is
 CC responsible for a large number of diseases, e.g. eye diseases such as
 CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
 CC conjunctivitis; genital diseases such as nongonococcal urethritis;
 CC epididymitis, cervicitis, salpingitis, peritropia, Bartholinitis;
 CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
 CC The polypeptides of the invention may be of use in treating these
 CC diseases

XX Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1592 TGAACAAGCGACGACATC 1610
 DB 20 TGAACAAGCGACGACATC 2

RESULT 304
 AAX93524

ID AAX93524 standard; DNA; 20 BP.

XX AAX93524;

AC 13-SEP-1999 (first entry)

XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.

OS Synthetic.
 OS Chlamydia pneumoniae.

PN MO927105-A2.

PD 03-JUN-1999.

PF 20-NOV-1998; 98WO-IB001890.

XX 21-NOV-1997; 97FR-00014673.

PR 04-NOV-1998; 98US-0107078P.

PA (GEST) GENSET.

PI Griffiths R;

XX WPI; 1999-357842/30.

PT Genome sequence of Chlamydia pneumoniae.

PS Page 1598; Disclosure; 1912pp; English.

XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis, and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY34584-AAY35879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotide sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae

XX Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1598 AGCAGCAAGACTCTCCCT 1616
 DB 2 AGCAGCAAGACTCTCTCAT 20

RESULT 305
 AAX97150/c
 ID AAX97150 standard; DNA; 20 BP.

XX AAX97150;

AC 13-SEP-1999 (first entry)

XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.

OS Synthetic.
 OS Chlamydia pneumoniae.

```

XX  MO9927105-A2.
XX  03-JUN-1999.
XX  20-NOV-1998; 98MO-IB001890.
XX  21-NOV-1997; 97FR-00014673.
XX  04-NOV-1998; 98US-0107078P.
XX  (GEST ) GENSET.
XX  Griffais R;
XX  WPI; 1999-357842/30.
XX  Genome sequence of Chlamydia pneumoniae.
XX  Page 1881; Disclosure; 1912pp; English.
XX  AAX91991-X97517 represent PCR primers used to amplify open reading frames
XX  and other nucleic acid sequences from the genome of Chlamydia pneumoniae
XX  (see AAX91990). C. pneumoniae causes respiratory disease such as
XX  pneumonia and bronchitis and is thought to be a contributing factor in
XX  heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
XX  nodosum or pharyngitis. The polypeptides encoded by the open reading
XX  frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
XX  in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
XX  nucleotide sequences can also be used as immunogenic compositions,
XX  especially where the vector directs the expression of a neutralising
XX  epitope of C. pneumoniae
XX  SQ Sequence 20 BP; 1 A; 3 C; 7 G; 9 T; 0 U; 0 Other;
XX  Query Match 0.4%; Score 15.8; DB 1; Length 20;
XX  Best Local Similarity 89.5%; Pred. No. 2.4e+02;
XX  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1444 CAGCAGCAGCAACGACG 1462
DB 19 CAGCAACAGCAACGACGAC 1
RESULT 306
AAC73254/C
ID AAC73254 standard; DNA; 20 BP.
XX AAC73254;
XX 02-FEB-2001 (first entry)
XX Reverse primer #46 used in multiplexing PCR/SBE assay.
XX Oligonucleotide array; genotyping; single base extension reaction; SBE;
XX PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX Unidentified.
XX WO200058516-A2.
XX 05-OCT-2000.
XX 27-MAR-2000; 2000MO-US008069.
XX 26-MAR-1999; 99US-0126473P.
XX 23-JUN-1999; 99US-0140359P.
XX (WHEB ) WHITEHEAD INST BIOMEDICAL RES.
XX (AFY-) AFYMETRIX INC.
XX Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
XX Ryder T, Sklar P;

```

```

DR WPI; 2000-656171/63.
XX Universal array of oligonucleotides tags attached to a solid substrate
XX along with locus-specific tagged oligonucleotides useful in genotyping
XX using single base extension reactions.
XX Example 7; Page 52; 70pp; English.
XX The present invention relates to an oligonucleotide array comprising
XX oligonucleotide tags fixed to a solid substrate. The oligonucleotide
XX array is useful for genotyping a nucleic acid sample at one or more loci
XX via single base extension (SBE) reactions. A pair of primers is used to
XX amplify a polymorphic locus in a sample e.g. a single nucleotide
XX polymorphism (SNP). The present sequence is one of the primers used in
XX the method of the present invention to amplify a polymorphic sample. The
XX amplified nucleic acid product is then used as a template in a SBE
XX reaction with an extension primer. The SBE reaction products are used to
XX form the oligonucleotide array
XX SQ Sequence 20 BP; 2 A; 7 C; 3 G; 8 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 991 GAAGATGACAGCCATGAG 1009
DB 19 GAAGATGACAGCCAGGGAG 1
RESULT 307
AAF73052/C
ID AAF73052 standard; DNA; 20 BP.
XX AAF73052;
XX 24-APR-2001 (first entry)
XX Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ.153.
XX Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
XX Fas binding protein; CENP-C binding protein; dap6; BAP; cytostatic;
XX antiinflammatory; death associated protein 6; Ets-1 associated protein;
XX infection; inflammation; tumour formation; ss.
XX Homo sapiens.
XX OS
XX US6180353-B1.
XX 30-JAN-2001.
XX 24-JAN-2000; 2000US-00490692.
XX 24-JAN-2000; 2000US-00490692.
XX (ISIS-) ISIS PHARM INC.
XX Dean NM, Cowseart LM;
XX WPI; 2001-217744/22.
XX Novel antisense compounds capable of modulating expression of daxx useful
XX for diagnosis, prophylaxis and treatment of diseases associated with
XX expression of daxx.
XX Claim 1; Col 49; 59pp; English.
XX The present invention describes an antisense compound (I) up to 30
XX nucleobases in length, where (I) inhibits expression of daxx (also known
XX as Fas binding protein, CENP-C binding protein), dap6, BAP, cytostatic and
XX protein 6 and BAP for Ets-1 associated protein). (I) has cytostatic and
XX antiinflammatory activity, and can be used in antisense therapy and as a
XX modulator of daxx. (I) is useful for inhibiting the expression of daxx in

```


CC cells or tissues in vitro. (1) can be utilized for diagnostics,
CC therapeutics for the treatment of diseases associated with the expression
CC of ddx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC tumour formation and as research reagent. The present sequence represents
CC an inhibitory human ddx antisense phosphorothioate oligonucleotide which
CC is used in the exemplification of the present invention

XX Sequence 20 BP; 1 A; 13 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2444 GTGAGGACGACGAGAGCA 2462
DB 20 GTGAGGACGAGAGAGCA 2

RESULT 308

AAF24100
ID AAF24100 standard; DNA; 20 BP.

XX AAF24100;

AC 14-MAY-2003 (revised)
DT 22-MAR-2001 (first entry)

DE Lactococcus lactis 16S rRNA probe.

XX Multi spectral identification; taxonomy; probe; 16S rRNA; ss.

OS Lactococcus lactis.

PN MO200075636-A1.

PD 14-DEC-2000.

PF 02-JUN-2000; 2000MO-US015384.

PR 04-JUN-1999; 99US-0137458P.

PA (KAIR-) KAIROS SCI INC.

PI Coleman W, Tanner M, Silva C, Bylina E, Robles M, Dilworth M;
PI Youvan D, Yang M;

DR MPI; 2001-061764/07.

PT Empirical calibration of optical system for multi spectral taxonomic
PT identification in biotechnology involves correcting vector data
PT representing uncorrected intensity of image pixel, by matrix
PT multiplication.

PS Disclosure; Fig 18; 93pp; English.

XX The present invention relates to empirically calibrating an optical
CC system for multi spectral taxonomic identification, involving collecting
CC calibration data as spectral groups and multiplied by a correction
CC matrix. The invention is used for multi spectral taxonomic identification
CC of biological cells, particularly those of bacteria and archaea, in
CC complex populations of microorganisms. (Updated on 14-MAY-2003 to correct
CC PS field.)

XX Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1973 CCACGCGCCCTTACACGAG 1991
DB 1 CCACGCGCTTTTACACGAG 19

RESULT 309
AAH56611/c
ID AAH56611 standard; DNA; 20 BP.

XX AAH56611;

XX 06-SEP-2001 (first entry)

DE Streptococcus pyogenes groEL antisense oligonucleotide SEQ ID NO:259.

XX Antisense oligonucleotide; groEL; groEL; inhibitor; growth;

XX microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;

XX Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;

XX antibacterial; antiviral; antiproliferative; antisense therapy;

XX microbial infection; ss.

XX Streptococcus pyogenes.

XX WO200136625-A2.

XX 25-MAY-2001.

XX 20-NOV-2000; 2000MO-CA001347.

XX 18-NOV-1999; 99US-0166249P.

XX (GENE-) GENSENSE TECHNOLOGIES INC.

XX Wright JA, Young AH, Dugourd D;

XX MPI; 2001-355633/37.

XX Claim 3; Page 48; 110pp; English.

PT Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT Gene of microorganism, which hybridize with and inhibit expression of the
PT genes, useful to inhibit growth of microorganism having the genes.
PS Claim 3; Page 48; 110pp; English.
XX The present invention specifically claims AAH56368 to AAH56832 which are
CC antisense oligonucleotides to nucleotide sequences encoding groE. More
CC generally, antisense compounds (1) comprising antisense oligonucleotides
CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC shock protein (HSP) 60) (GL) and groES (HSP10) (GS) gene from a
CC microorganism, where the antisense compound is complementary to GL or GS
CC of a microorganism and specifically hybridizes with and inhibits the
CC expression of GL or GS, is claimed. (1) have antibacterial, antiviral and
CC antiproliferative activities, and can be used in antisense therapy and
CC for inhibition of expression of groES or groEL. (1) are useful for
CC inhibiting expression of GL or GS in cells or tissues in vitro. (1) are
CC also useful for inhibiting the growth of a microorganism, or inhibiting
CC the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC virus) having a GL or GS gene which involves administering to the
CC microorganism or to a cell infected with the microorganism, (1). (1) are
CC also useful for treating a mammalian pathological condition mediated by
CC the microorganisms which involves identifying a eukaryotic organism
CC having a pathological condition mediated by microorganisms having a GL or
CC GS gene and administering (1) such that the growth of microorganism is
CC inhibited. The antisense compounds are utilized for diagnostics,
CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC prevent or delay microbial infections in humans. They are also useful as
CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC represent PCR primers for groE sequences which are used in the
CC exemplification of the present invention. AAH56855 to AAH56870 represent
CC groE nucleotide sequence given in the present invention

XX Sequence 20 BP; 1 A; 4 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1473 GAAACGACGACGACGAG 1491


```

XX DR WPI; 2002-643346/69.
XX
XX PT diagnosing pancreatic adenocarcinoma, particularly for the early
XX PT detection of the pancreatic cancer, comprises employing primers or
XX PT antibodies that are specific for the MUC4-encoding nucleic acid or MUC4
XX PT protein, respectively.
XX
XX PS Example 1; Page 28; 63pp; English.
XX
CC PCR primers ABQ78561-62 were used to amplify the ribosomal housekeeping
CC gene RPL13A from reverse transcribed cell samples. This gene was
CC amplified to confirm the presence and integrity of cDNA encoding mucin 4
CC (MUC4). Peripheral blood monocytes (PBMCs) isolated from pancreatic
CC cancer patients are positive for MUC4, while MUC4 expression is not
CC observed in PBMCs isolated from normal patients or from patients
CC suffering from chronic pancreatitis or other types of cancers. Expression
CC of MUC4 can therefore be used as an indication of pancreatic cancer. The
CC specification describes a method for detecting a MUC4-encoding nucleic
CC acid or a MUC4 protein in a biological sample as a tumour marker for
CC pancreatic cancer. The method comprises contacting a nucleic acid
CC extracted from the sample with oligonucleotide primers that specifically
CC hybridise to the MUC4 nucleic acid, or contacting a biological sample
CC with an antibody (or its fragment) that has specific binding affinity for
CC MUC4. The method is useful for diagnosing pancreatic cancer or pancreatic
CC adenocarcinoma, particularly for early detection of pancreatic cancer
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other:
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 156 GGCTGCCATCAAGTCTATG 174
Db 20 GGCTGCCCTCAAGTCTGTG 2

```

RESULT 313
ABQ7856/c
ABQ7856 standard; DNA; 20 BP.

AC ABQ78586;
XX
XX 25-NOV-2002 (first entry)
XX
XX Primer Rb1 used to amplify RPL13A gene.
DE
XX RPL13A; mucin 4; MUC4; peripheral blood monocyte; PMBC; tumour marker;
XX pancreatic cancer; pancreatic adenocarcinoma; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX WO200259368-A1.
XX
XX 01-AUG-2002.
XX
XX 07-DEC-2001; 2001MO-USO46887.
XX
XX 08-DEC-2000; 2000US-00733444.
XX
XX (UYNE-) UNIV NEBRASKA.
XX
XX Batra SK, Brand RE, Ringel J, Faulmann G, Lohr M, Varehny GC;
XX WPI; 2002-643346/69.
XX
XX Diagnosing pancreatic adenocarcinoma, particularly for the early
XX PT detection of the pancreatic cancer, comprises employing primers or
XX PT antibodies that are specific for the MUC4-encoding nucleic acid or MUC4
XX PT protein, respectively.
XX
XX Example 1; Page 30; 63pp; English.

```

XX CC PCR primers ABQ78585-86 were used to amplify the ribosomal housekeeping
XX CC gene RPL13A. Peripheral blood monocytes (PBMCs) isolated from pancreatic
XX CC cancer patients are positive for mucin 4 (MUC4), while MUC4 expression is
XX CC not observed in PBMCs isolated from normal patients or from patients
XX CC suffering from chronic pancreatitis or other types of cancers. Expression
XX CC of MUC4 can therefore be used as an indication of pancreatic cancer. The
XX CC specification describes a method for detecting a MUC4-encoding nucleic
XX CC acid or a MUC4 protein in a biological sample as a tumour marker for
XX CC pancreatic cancer. The method comprises contacting a nucleic acid
XX CC extracted from the sample with oligonucleotide primers that specifically
XX CC hybridise to the MUC4 nucleic acid, or contacting a biological sample
XX CC with an antibody (or its fragment) that has specific binding affinity for
XX CC MUC4. The method is useful for diagnosing pancreatic cancer or pancreatic
XX CC adenocarcinoma, particularly for early detection of pancreatic cancer
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other:
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 156 GGCTGCCATCAAGTCTATG 174
Db 20 GGCTGCCCTCAAGTCTGTG 2

```

RESULT 314
ABV99473
ABV99473 standard; DNA; 20 BP.

AC ABV99473;
XX
XX 27-JAN-2003 (first entry)
XX
XX Human NOV16a forward PCR primer Ag3517.
DE
XX Human; anti-HIV; cytostatic; antidiabetic; antisthmatic; cachexia; AIDS;
XX antinflammatory; cardiac; haemostatic; neuroprotective; anorectic;
XX nootropic; immunosuppressive; osteopathic; antiparkinsonian; cancer;
XX antifertility; cerebroprotective; gene therapy; NOVX; NOV; fertility;
XX metabolic disorder; diabetes; obesity; infectious disease; anorexia;
XX neurodegenerative disease; Alzheimer's disease; Parkinson's disease;
XX immune disorder; haematopoietic disorder; cardiovascular disorder;
XX bronchial asthma; dyslipidemia; metabolic disturbance; neurogenesis;
XX metabolic syndrome X; wasting disorder; cell differentiation; primer;
XX cell proliferation; haematopoiesis; wound healing; angiogenesis; ss.
XX
XX Homo sapiens.
OS
XX WO200272771-A2.
XX
XX 19-SEP-2002.
XX
XX 08-MAR-2002; 2002MO-US007288.
XX
XX 08-MAR-2001; 2001US-0274101P.
XX
XX 08-MAR-2001; 2001US-0274194P.
XX
XX 08-MAR-2001; 2001US-0274281P.
XX
XX 08-MAR-2001; 2001US-0274322P.
XX
XX 09-MAR-2001; 2001US-0274849P.
XX
XX 12-MAR-2001; 2001US-0275235P.
XX
XX 13-MAR-2001; 2001US-0275578P.
XX
XX 13-MAR-2001; 2001US-0275579P.
XX
XX 14-MAR-2001; 2001US-0275601P.
XX
XX 16-MAR-2001; 2001US-0276776P.
XX
XX 19-MAR-2001; 2001US-0276994P.
XX
XX 20-MAR-2001; 2001US-0277239P.
XX
XX 20-MAR-2001; 2001US-0277321P.
XX
XX 20-MAR-2001; 2001US-0277327P.
XX
XX 20-MAR-2001; 2001US-0277338P.
XX
XX 21-MAR-2001; 2001US-0277791P.
XX

PR 22-MAR-2001; 2001US-0277833P.
 PR 23-MAR-2001; 2001US-0278152P.
 PR 26-MAR-2001; 2001US-0278889P.
 PR 27-MAR-2001; 2001US-0278939P.
 PR 27-MAR-2001; 2001US-0279036P.
 PR 28-MAR-2001; 2001US-0279344P.
 PR 30-MAR-2001; 2001US-0279955P.
 PR 30-MAR-2001; 2001US-0280233P.
 PR 02-APR-2001; 2001US-0280822P.
 PR 02-APR-2001; 2001US-0280822P.
 PR 02-APR-2001; 2001US-0280900P.
 PR 04-APR-2001; 2001US-0281194P.
 PR 13-APR-2001; 2001US-0283675P.
 PR 30-APR-2001; 2001US-0287424P.
 PR 02-MAY-2001; 2001US-0288066P.
 PR 03-MAY-2001; 2001US-0288342P.
 PR 03-MAY-2001; 2001US-0288528P.
 PR 15-MAY-2001; 2001US-0291190P.
 PR 16-MAY-2001; 2001US-0291099P.
 PR 16-MAY-2001; 2001US-0291240P.
 PR 30-MAY-2001; 2001US-0294485P.
 PR 31-MAY-2001; 2001US-0294889P.
 PR 31-MAY-2001; 2001US-0294899P.
 PR 18-JUN-2001; 2001US-0299027P.
 PR 19-JUN-2001; 2001US-0299303P.
 PR 19-JUN-2001; 2001US-0299310P.
 PR 10-JUL-2001; 2001US-0304354P.
 PR 10-JUL-2001; 2001US-0309188P.
 PR 16-AUG-2001; 2001US-0312903P.
 PR 10-SEP-2001; 2001US-0318462P.
 PR 12-SEP-2001; 2001US-0318770P.
 PR 27-SEP-2001; 2001US-0325430P.
 PR 27-SEP-2001; 2001US-0325681P.
 PR 18-OCT-2001; 2001US-0330380P.
 PR 31-OCT-2001; 2001US-0335301P.
 PR 14-NOV-2001; 2001US-0332172P.
 PR 14-NOV-2001; 2001US-0332271P.
 PR 14-NOV-2001; 2001US-0332727P.
 PR 14-NOV-2001; 2001US-0333164P.
 PR 14-NOV-2001; 2001US-0333272P.
 PR 21-NOV-2001; 2001US-0332094P.
 PR 03-DEC-2001; 2001US-0337426P.
 PR 03-DEC-2001; 2001US-0338092P.
 PR 04-DEC-2001; 2001US-0337185P.
 PR 03-JAN-2002; 2002US-0345705P.
 PR 08-MAR-2002; 2002US-00093463.
 (CURA-) CURAGEN CORP.

PA Rastelli L, Meares PD, Smithson G, Guo X, Gerlach V, Casman ST;
 XX Boldog FU, Li L, Zethusen BD, Tchervnev VT, Gangolli EA, Vernet CAM;
 PI Pena CE, Burgess CE, Liu X, Spytek KA, Gorman L, Spaderna SK;
 PI Voss EZ, Malyankar UM, Anderson DW, Paturajan M, Miller CE;
 PI Taupler RJ, Padigar M, Shenoy SG, Kekuda R, Gusev VY, Pochart PF,
 PI Zhong M;
 XX WPI, 2002-732824/79.

PT New NOVX polypeptides and polynucleotides, useful for preventing,
 PT diagnosing or treating NOVX-associated disorders e.g. diabetes, cancer,
 PT Alzheimer's disease, dyslipidemias, obesity, immune or hematopoietic
 PT disorders, and asthma.

XX Example C; Page 367; 619pp; English.

CC The present invention relates to new isolated proteins (NOVX) and their
 CC coding sequences (ABV99327-ABV9955 and ABP70049-ABP70149), where X is
 CC any number from 1 to 48. The NOVX proteins and coding sequences are
 CC useful in the manufacture of a medicament for treating a syndrome
 CC associated with a human disease, preferably a NOVX-associated disorder.
 CC The NOVX coding sequences and proteins are useful for treating,
 CC preventing or diagnosing diseases such as metabolic disorders, diabetes,
 CC obesity, infectious disease, anorexia, cancer-associated cachexia,

CC cancer, neurodegenerative diseases, Alzheimer's disease, Parkinson's
 CC disease, immune disorders, hematopoietic disorders, cardiovascular
 CC disorders, fertility, bronchial asthma, AIDS, dyslipidemia, metabolic
 CC disturbances associated with obesity, metabolic syndrome X or wasting
 CC disorders associated with chronic diseases or various cancers. The NOVX
 CC coding sequences and proteins may also be used as targets for the
 CC identification of small molecules that modulate or inhibit e.g.
 CC neurogenesis, cell differentiation, cell proliferation, hematopoiesis,
 CC wound healing and angiogenesis, in gene therapy, in generation of
 CC antibodies that bind immunospecifically to NOVX substances for use in
 CC therapeutic or diagnostic methods. The present sequence is a PCR primer,
 CC which was used in an example from the invention

SO Sequence 20 BP; 8 A; 3 C; 8 G; 1 T; 0 U; 0 Other;

Qy Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;

Db Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 1 CGAGAGAGAGCAGAGATAC 19

Qy 2480 CAGAGGGAGCAGAGATAC 2498
 ABV99470

AC ABV99470 standard; DNA; 20 BP.
 XX ABV99470;
 XX 27-JAN-2003 (first entry)

DE Human NOV16a forward PCR primer Ag3516.

XX Human; anti-HIV; cytostatic; antidiabetic; antisthmatic; cachexia; AIDS;
 XX antiinflammatory; cardiac; haemostatic; neuroprotective; anorectic;
 XX neurotropic; immunosuppressive; osteopathic; antiparkinsonian; cancer;
 XX antifertility; cerebroprotective; gene therapy; NOVX; NOV; fertility;
 XX metabolic disorder; diabetes; obesity; infectious disease; anorexia;
 XX neurodegenerative disease; Alzheimer's disease; Parkinson's disease;
 XX immune disorder; hematopoietic disorder; cardiovascular disorder;
 XX bronchial asthma; dyslipidemia; metabolic disturbance; neurogenesis; PCR;
 XX metabolic syndrome X; wasting disorder; cell differentiation; primer;
 XX cell proliferation; haematopoiesis; wound healing; angiogenesis; ss.

OS Homo sapiens.

PN WO200272771-A2.

PD 19-SEP-2002.

XX 08-MAR-2002; 2002WO-US007288.

XX 08-MAR-2001; 2001US-0274101P.

XX 08-MAR-2001; 2001US-0274194P.

XX 08-MAR-2001; 2001US-0274281P.

XX 08-MAR-2001; 2001US-0274322P.

XX 09-MAR-2001; 2001US-0274849P.

XX 12-MAR-2001; 2001US-0275235P.

XX 13-MAR-2001; 2001US-0275578P.

XX 13-MAR-2001; 2001US-0275579P.

XX 13-MAR-2001; 2001US-0275601P.

XX 14-MAR-2001; 2001US-0276000P.

XX 16-MAR-2001; 2001US-0276776P.

XX 19-MAR-2001; 2001US-0276994P.

XX 20-MAR-2001; 2001US-0277321P.

XX 20-MAR-2001; 2001US-0277327P.

XX 20-MAR-2001; 2001US-0277338P.

XX 21-MAR-2001; 2001US-0277791P.

XX 22-MAR-2001; 2001US-0277833P.

XX 23-MAR-2001; 2001US-0278152P.

XX 26-MAR-2001; 2001US-0278894P.

PR 27-MAR-2001; 2001US-0278999P.
 PR 27-MAR-2001; 2001US-0279036P.
 PR 28-MAR-2001; 2001US-0279344P.
 PR 30-MAR-2001; 2001US-0279959P.
 PR 30-MAR-2001; 2001US-0280233P.
 PR 02-APR-2001; 2001US-0280802P.
 PR 02-APR-2001; 2001US-0280822P.
 PR 02-APR-2001; 2001US-0280900P.
 PR 03-APR-2001; 2001US-0281194P.
 PR 13-APR-2001; 2001US-0283675P.
 PR 30-APR-2001; 2001US-0287424P.
 PR 02-MAY-2001; 2001US-0288066P.
 PR 03-MAY-2001; 2001US-0288342P.
 PR 03-MAY-2001; 2001US-0288528P.
 PR 15-MAY-2001; 2001US-0291190P.
 PR 16-MAY-2001; 2001US-0291099P.
 PR 16-MAY-2001; 2001US-0291240P.
 PR 30-MAY-2001; 2001US-0294485P.
 PR 31-MAY-2001; 2001US-0294889P.
 PR 31-MAY-2001; 2001US-0294899P.
 PR 18-JUN-2001; 2001US-0299027P.
 PR 19-JUN-2001; 2001US-0299303P.
 PR 19-JUN-2001; 2001US-0299310P.
 PR 10-JUL-2001; 2001US-0304354P.
 PR 31-JUL-2001; 2001US-0309188P.
 PR 16-AUG-2001; 2001US-0312903P.
 PR 10-SEP-2001; 2001US-0318462P.
 PR 12-SEP-2001; 2001US-0318770P.
 PR 27-SEP-2001; 2001US-0325430P.
 PR 27-SEP-2001; 2001US-0325681P.
 PR 18-OCT-2001; 2001US-0330380P.
 PR 31-OCT-2001; 2001US-0335301P.
 PR 14-NOV-2001; 2001US-0332172P.
 PR 14-NOV-2001; 2001US-0332271P.
 PR 14-NOV-2001; 2001US-0332272P.
 PR 14-NOV-2001; 2001US-0333184P.
 PR 14-NOV-2001; 2001US-0333272P.
 PR 21-NOV-2001; 2001US-0332094P.
 PR 03-DEC-2001; 2001US-0337426P.
 PR 03-DEC-2001; 2001US-0338092P.
 PR 04-DEC-2001; 2001US-0337185P.
 PR 03-JAN-2002; 2002US-0345705P.
 PR 08-MAR-2002; 2002US-00093463.
 XX
 XX
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 XX
 PI Rastelli L, Mees PD, Smithson G, Guo X, Gerlach V, Casman SJ, CAM,
 PI Boldo FL, Li L, Zetunuen BD, Tcherner VT, Gargolli EA, Vernet CE,
 PI Pena CEa, Burgess CE, Liu X, Spytek KA, Gorman L, Spaderna SK;
 PI Voss EZ, Malyankar UM, Anderson DW, Paturajan M, Miller CE;
 PI Tappier RJ, Padigaru M, Shenoy SG, Kekuda R, Guev VY, Pochart PF,
 PI Zhang M;
 XX
 DR WPI; 2002-732824/79.
 XX
 XX
 PT New NOXV polypeptides and polynucleotides, useful for preventing,
 PT diagnosing or treating NOXV-associated disorders e.g. diabetes, cancer,
 PT Alzheimer's disease, dyslipidemias, obesity, immune or hematopoietic
 PT disorders, and asthma.
 XX
 PS Example C; Page 367; 619p; English.
 XX
 CC The present invention relates to new isolated proteins (NOXV) and their
 CC coding sequences (ABV99327-ABV99595 and ABP70049-ABP70149), where X is
 CC any number from 1 to 48. The NOXV proteins and coding sequences are
 CC useful in the manufacture of a medicament for treating a syndrome
 CC associated with a human disease, preferably a NOXV-associated disorder.
 CC The NOXV coding sequences and proteins are useful for treating,
 CC preventing or diagnosing diseases such as metabolic disorders, diabetes,
 CC obesity, infectious disease, anorexia, cancer-associated cachexia,
 CC cancer, neurodegenerative diseases, Alzheimer's disease, Parkinson's
 CC disease, immune disorders, hematopoietic disorders, cardiovascular
 CC disorders, fertility, bronchial asthma, AIDS, dyslipidemia, metabolic

[illegible]


```

OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; all cytidines are 5-
FT methylycytidines"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethyl (2'MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethyl (2'MOE) nucleotides"
XX US6346416-B1.
XX 12-FEB-2002.
XX 29-AUG-2000; 2000US-00651011.
XX 29-AUG-2000; 2000US-00651011.
XX (ISIS-) ISIS PHARM INC.
XX Dean NM, Cowert LM;
XX WPI; 2002-237091/29.
XX New antisense compound, useful for preventing or delaying infection,
XX inflammation or tumor formation, is targeted to nucleic acid molecule
XX encoding HPK/GCK-like kinase (HGK) and hybridizes and inhibits HGK
XX expression.
XX Claim 14; Col 43-44; 37pp; English.
XX The invention relates to an antisense compound (I) of 8-50 nucleobases in
XX length targeted to a start codon region, coding region or 3'-untranslated
XX region of a nucleic acid molecule encoding HPK/GCK (undefined)-like
XX kinase (HGK) (also known as NIK for Nck-interacting kinase), which
XX specifically hybridizes with and inhibits expression of HGK. (I) is
XX useful for inhibiting the expression of HPK/GCK-like kinase in cells or
XX tissues in vitro. (I) is useful prophylactically e.g. to prevent or delay
XX infection, inflammation and tumor formation. (I) is also useful as a
XX diagnostic and research reagent. (I) is also useful for distinguishing
XX functions of various members of a biological pathway and in antisense
XX gene therapy. The present sequence represents an antisense
XX oligonucleotide targeted to human HPK/GCK-like kinase
XX
SQ Sequence 20 BP; 1 A; 10 C; 0 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2446 GAGCAGCAGCAGCAGCAG 2464
DB 20 GAGCAGCAGCAGCAGCAG 2
RESULT 319
ABL94386/c
ID ABL94386 standard; DNA; 20 BP.
AC ABL94386;
XX
XX 29-JUL-2002 (first entry)
XX
XX Mouse C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:152.
DE
XX
XX Mouse; murine; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EBP2;
KW

```

```

KW LAP; TCF5; CRP2; NFIL6; IL6DBP; NF-M; AGP/EBP; Apc/EBP;
KW transcription factor; tissue development; cellular function;
KW proliferation; differentiation; hormone responsiveness;
KW oxidative stress response; IL-6 signalling mediator; Interleukin-6;
KW carbohydrate metabolism; immunity; Th1 response; female fertility;
KW gluconeogenesis; ovarian cancer; tumour formation; type II; diabetes;
KW infection; inflammation; expression inhibition; phosphorothioate; ss.
XX
XX Mus musculus.
FH Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT cytosines are 5-methylcytosine"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT cytosines are 5-methylcytosine"
XX US6271030-B1.
XX 07-AUG-2001.
XX 14-JUN-2000; 2000US-00593711.
XX 14-JUN-2000; 2000US-00593711.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Butler MM, Wyatt J;
XX WPI; 2002-214451/27.
XX Novel antisense compound targeted to nucleic acids encoding human or
XX mouse CCAAT/enhancer binding protein (C/EBP) beta, useful in vitro for
XX inhibiting expression of human or mouse C/EBP beta in cells/tissues.
XX
XX Example 17; Col 49-50; 69pp; English.
XX Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted
XX to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha)
XX gene, which inhibit its expression. The antisense oligonucleotides were
XX designed to target different regions of the human and/or mouse C/EBP
XX alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels
XX by quantitative real-time PCR. The C/EBP family of proteins are a family
XX of transcription factors which regulate the expression of a wide range of
XX genes that control normal tissue development, cellular function, cellular
XX proliferation and functional differentiation. C/EBP beta (also known as
XX C/EBP2, LAP, TCF5, CRP2, NFIL6, IL6DBP, NF-M, AGP/EBP and Apc/EBP)
XX and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is
XX thought to be involved in carbohydrate metabolism, immunity, the Th1
XX response, female fertility and gluconeogenic pathways. C/EBP beta is
XX expressed in the liver, lung, spleen, kidney, brain, and testis, with the
XX highest expression found in the lung. It is also expressed at a higher
XX level in malignant ovarian tissue compared with normal ovarian tissue,
XX and its expression in pancreas is upregulated in response to chronically
XX elevated levels of glucose, indicating that it is involved in the
XX impairment of insulin secretion in type II diabetes. The oligonucleotides
XX of the invention are useful for diagnosis, prevention and treatment of
XX conditions associated with C/EBP beta expression, such as cancer
XX (particularly ovarian cancer), tumour formation, diabetes (particularly
XX type II diabetes), infection, or inflammation
XX
SQ Sequence 20 BP; 0 A; 9 C; 7 G; 4 T; 0 U; 0 Other;

```


Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1124 AGCAGCTGCAGCAGCA 1142
|||
DB 19 AGCAGCTGCAGCAGCTGCA 1

RESULT 322
ADH93846/c
ADH93846 standard; DNA; 20 BP.

AC ADH93846;
XX
XX 22-APR-2004 (first entry)
XX
XX Human gene PCR primer #691.
XX
XX human; gene sequence; single nucleotide polymorphism; SNP;
XX disease diagnosis; 89; PCR; primer.
XX Homo sapiens.
XX JP2003174883-A.
XX
XX 24-JUN-2003.
XX
XX 11-DEC-2001; 2001JP-00377637.
XX
XX 11-DEC-2001; 2001JP-00377637.
XX
XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
XX WPI; 2003-819215/77.
XX
XX Polynucleotide for detecting single nucleotide polymorphisms existing in
XX human gene, contains isolated human gene having specified sequence.
XX
XX Claim 2; SEQ ID NO 1683; 529bp; Japanese.

XX The invention comprises isolated human gene sequences and PCR primer
XX sequences which can be used to detect single nucleotide polymorphisms
XX (SNPs). The DNA sequences of the invention are useful for detecting SNPs
XX existing in human genes and for the diagnosis of human disease. The
XX present DNA sequence represents a human gene PCR primer of the invention.
XX
XX Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1172 ACCTGCTGCAGCAGCGCA 1190
|||
DB 19 ACCTACTGCAGCAGCAGCA 1

RESULT 323

ABZ88038
ID ABZ88038 standard; DNA; 20 BP.

AC ABZ88038;
XX
XX 17-OCT-2003 (first entry)
XX
XX

DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

XX Homo sapiens.
OS
XX
XX WO200285308-A2.
XX
XX
XX
XX 31-OCT-2002.
PD

XX 23-APR-2002; 2002WO-US011335.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIC-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahbuddin S;
XX
XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
XX Disclosure; SEQ ID NO 3280; 872bp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytostatic activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pot_sequences

XX Sequence 20 BP; 3 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1117 CAGCAGCAGCAGCTGCAGC 1135
|||
DB 2 CGCAGCAGCAGCAGCTGCAGC 20

RESULT 324

ABZ88202
ID ABZ88202 standard; DNA; 20 BP.

AC ABZ88202;
XX
XX 17-OCT-2003 (first entry)
XX
XX

DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ublquinone.
XX PS Disclosure; SEQ ID NO 3444; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antiinflammatory steroid and ublquinone. A composition of the invention
XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antiinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ublquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pat_sequences
XX SQ Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1255 GAGCAGCGGAGCTGCAGG 1273
XX |||||||
XX 1 GACCCAGCGGAGCTGCAGG 19
XX
XX RESULT 325
XX ABD24268
XX ID ABD24268 standard; DNA; 20 BP.
XX AC ABD24268;
XX XX
XX DT 29-JUL-2004 (first entry)
XX XX
XX DE Human calmodulin 2-derived oligonucleotide SEQ ID 3280.
XX XX
XX KM Human; antiense; bronchoconstriction; allergy; hyposecretion; pain;
XX KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX KM surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX KM analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX KM respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KM pulmonary transplantation rejection; ss; primer.
XX OS Homo sapiens.
XX PN WO200285309-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013143.
XX PR 24-APR-2001; 2001US-0286036P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-093058/08.
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 3280; 763pp; English.
XX XX
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC instructions for adding a carrier and for use of the kit. The composition
XX CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 20 BP; 3 A; 7 C; 9 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1117 CAGCAGCAGCAGCTGCAGC 1135
XX |||||||
XX 2 CGCGCGCAGCAGCTGCAGC 20
XX
XX RESULT 326
XX ABD24432
XX ID ABD24432 standard; DNA; 20 BP.
XX XX

DT 26-FEB-2004 (first entry)
 XX Primer #3 of the invention.
 XX cardiovascular syndrome; *fbgr*-adducin gene; Hypotensive; Antianemic; ss;
 KW primer.
 XX Synthetic.
 OS WO2003102229-A1.
 XX 11-DEC-2003.
 PD 02-JUN-2003; 2003WO-BE000095.
 XX
 XX 31-MAY-2002; 2002GB-00012645.
 PR 07-JUN-2002; 2002GB-00013028.
 XX
 XX (LEUV-) LEUVEN RES & DEV.
 PA
 XX Staessen J, Bianchi G;
 PI
 XX WPI; 2004-043132/04.
 DR
 XX
 XX Determining the predisposition of an individual to develop a hematologic
 PT syndrome and/or a renal or cardiovascular syndrome, comprises analyzing
 PT the DNA sequence of the beta-adducin gene in a tissue sample isolated
 PT from the individual.
 XX
 XX Example 2; SEQ ID NO 5; 37pp; English.
 PS
 XX The present invention relates to determining the predisposition of an
 CC individual to develop a hematologic syndrome and/or a renal or
 CC cardiovascular syndrome, comprises analyzing the DNA sequence of the *fbgr*
 CC -adducin gene in a tissue sample isolated from the individual and
 CC determining the polymorphism pattern for the C1797T polymorphic position
 CC in the *fbgr*-adducin gene. The method is useful for determining an
 CC appropriate treatment regimen for the tested individual, where the
 CC treatment regimen comprises preventing lifestyle measures, and
 CC administration of drug for the treatment or prevention of a hematologic
 CC disorder. The present sequence represents a primer of the invention.
 CC
 XX
 XX Sequence 20 BP; 6 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.44; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1010 AGGAGGAGGCGAGCTC 1028
 DB 1 AGGAGCGAGCGCAGCTC 19
 AC
 XX
 AC ADJ31745;
 XX
 DT 22-APR-2004 (first entry)
 XX
 XX Human amyloid beta precursor antisense oligonucleotide ISIS #156327.
 DE
 XX Amyloid beta protein precursor; neurodegenerative disorder;
 KW Alzheimer's disease; apoptosis; diagnosis; therapy; human; antisense; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT

FT
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note="2'- methoxyethyl (2'-MOE) nucleotides"
 FT 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note="2'- methoxyethyl (2'-MOE) nucleotides"
 FT
 XX US2003232435-A1.
 XX
 XX 18-DEC-2003.
 PD
 XX
 XX 14-JUN-2002; 2002US-00173208.
 PF
 XX
 XX 14-JUN-2002; 2002US-00173208.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Dobie KM;
 PI
 XX WPI; 2004-061283/06.
 DR
 XX
 XX New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding an amyloid beta protein precursor, useful for
 PT treating Alzheimer's disease or a disease involving aberrant apoptosis.
 PT
 XX
 XX Claim 1; SEQ ID NO 18; 48pp; English.
 PS
 XX The present invention is directed to antisense oligonucleotides targeted
 CC to a nucleic acid encoding amyloid beta protein precursor and which
 CC modulates the expression of amyloid beta protein precursor. The invention
 CC is useful for treating a disease or condition associated with amyloid
 CC beta protein precursor such as a neurodegenerative disorder e.g.
 CC Alzheimer's disease or a disease or condition involving aberrant
 CC apoptosis. They are also useful in research and diagnostics for
 CC modulating the expression of amyloid beta protein precursor. The present
 CC sequence is human amyloid beta protein precursor antisense
 CC oligonucleotide.
 CC
 XX
 XX Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.44; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1463 AGCAGCTCGAAGACGA 1481
 DB 20 AGCTGCTTCGAAAGACGA 2
 AC
 XX
 AC ADJ31781;
 XX
 DT 22-APR-2004 (first entry)
 XX
 XX Human amyloid beta precursor target oligonucleotide #7.
 DE
 XX Amyloid beta protein precursor; neurodegenerative disorder;
 KW Alzheimer's disease; apoptosis; diagnosis; therapy; human; ss.
 XX
 XX Homo sapiens.
 OS US2003232435-A1.
 XX
 XX 18-DEC-2003.
 PD
 XX
 XX 14-JUN-2002; 2002US-00173208.
 PF

```
XX 14-JUN-2002; 2002US-00173208.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Double KW;
XX
XX WPI; 2004-061283/06.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding an amyloid beta protein precursor, useful for
XX treating Alzheimer's disease or a disease involving aberrant apoptosis.
XX
XX Example 15; SEQ ID NO 54; 48bp; English.
XX
XX The present invention is directed to antisense oligonucleotides targeted
XX to a nucleic acid encoding amyloid beta protein precursor and which
XX modulates the expression of amyloid beta protein precursor. The invention
XX is useful for treating a disease or condition associated with amyloid
XX beta protein precursor such as a neurodegenerative disorder e.g.
XX Alzheimer's disease or a disease or condition involving aberrant
XX apoptosis. They are also useful in research and diagnostics for
XX modulating the expression of amyloid beta protein precursor. The present
XX sequence is human amyloid beta protein precursor target oligonucleotide.
XX
XX Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1463 AGCAGCTTCGAGAAACAGCA 1481
XX |||||
XX 1 AGCTGCTTCGAGAAAGAGCA 19
XX
XX
XX RESULT 331
XX ADI38836
XX ID ADI38836 standard; DNA; 20 BP.
XX
XX AC ADI38836;
XX
XX DT 22-APR-2004 (first entry)
XX
XX Human LIM domain kinase 1 antisense oligonucleotide #120.
XX
XX KM neuroprotective; LIM domain kinase 1; developmental disorder;
XX KM neurological disorder; diagnostic; prophylaxis; human; 88.
XX
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX FH modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "OTHER= Phosphorothioate backbone. All cytidines
XX FT are 5-methylcytidines"
XX FT 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX FT 15..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004014047-A1.
XX
XX 22-JAN-2004.
XX
XX 18-JUL-2002; 2002US-00199199.
XX
XX 18-JUL-2002; 2002US-00199199.
```

```
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowsert LM, Double KW;
XX
XX WPI; 2004-121553/12.
XX
XX New antisense oligonucleotides for modulating LIM domain kinase 1
XX expression, useful for diagnosing, preventing or treating conditions
XX associated with the kinase, e.g. neurological or developmental disorders.
XX
XX Example 15; SEQ ID NO 135; 81bp; English.
XX
XX The invention describes a compound 8-80 nucleobases in length targeted to
XX a nucleic acid molecule encoding LIM domain kinase 1. The compound
XX specifically hybridizes with the nucleic acid molecule encoding LIM
XX domain kinase 1 and inhibits the expression of LIM domain kinase 1. It
XX specifically hybridizes with at least an 8-nucleobase portion of a
XX preferred target region on the nucleic acid molecule encoding LIM domain
XX kinase 1. The antisense oligonucleotide is useful for modulating the
XX expression of LIM domain kinase 1 in cells or tissues to treat diseases
XX associated with their expression, such as a developmental disorder or a
XX neurological disorder. In addition, the compound is used for diagnostics,
XX prophylaxis, or as research reagents or kits. This sequence represents a
XX human LIM domain kinase 1 antisense oligonucleotide.
XX
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1126 CAGCTGCAGCAGAGCAGC 1144
XX |||||
XX 2 CGGCTGCAGCAGAGCAGCTGC 20
XX
XX
XX RESULT 332
XX ADI38771/C
XX ID ADI38771 standard; DNA; 20 BP.
XX
XX AC ADI38771;
XX
XX DT 22-APR-2004 (first entry)
XX
XX Human LIM domain kinase 1 antisense oligonucleotide #55.
XX
XX KM neuroprotective; LIM domain kinase 1; developmental disorder;
XX KM neurological disorder; diagnostic; prophylaxis; human; 88.
XX
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX FH modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "OTHER= Phosphorothioate backbone. All cytidines
XX FT are 5-methylcytidines"
XX FT 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX FT 15..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004014047-A1.
XX
XX 22-JAN-2004.
XX
XX 18-JUL-2002; 2002US-00199199.
XX
XX 18-JUL-2002; 2002US-00199199.
```

PS 18-JUL-2002; 2002US-00199199.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowart LM, Dobie KW;
XX
XX WPI; 2004-121553/12.
XX
XX New antisense oligonucleotides for modulating LIM domain kinase 1
PT expression, useful for diagnosing, preventing or treating conditions
PT associated with the kinase, e.g. neurological or developmental disorders.
XX
XX Example 15; SEQ ID NO 70; 81pp; English.
XX
XX The invention describes a compound 8-80 nucleobases in length targeted to
CC a nucleic acid molecule encoding LIM domain kinase 1. The compound
CC specifically hybridizes with the nucleic acid molecule encoding LIM
CC domain kinase 1 and inhibits the expression of LIM domain kinase 1. It
CC specifically hybridizes with at least an 8-nucleobase portion of a
CC preferred target region on the nucleic acid molecule encoding LIM domain
CC kinase 1. The antisense oligonucleotide is useful for modulating the
CC expression of LIM domain kinase 1 in cells or tissues to treat diseases
CC associated with their expression, such as a developmental disorder or a
CC neurological disorder. In addition, the compound is used for diagnostics,
CC prophylaxis, or as research reagents or kits. This sequence represents a
CC human LIM domain kinase 1 antisense oligonucleotide.
XX
XX Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2,4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1126 CAGCTGCAGCAGCAGCAGC 1144
DB 19 CGGCTCAGCAGCAGCAGCTGC 1
XX
XX RESULT 333
ADL70240
XX ADL70240 standard; DNA; 20 BP.
XX
XX ADL70240;
AC
XX 20-MAY-2004 (first entry)
XX
XX Murine p27Kip1 PCR primer.
XX
XX p27Kip1; neuron; dopamine; antiparkinsonian; dopaminergic; stem cell;
XX mouse; cyclin dependent kinase; enzyme; PCR; primer; ss.
XX
XX Mus sp.
XX unidentified.
XX
XX WO2004018643-A2.
XX
XX 04-MAR-2004.
XX
XX 26-AUG-2003; 2003WO-US026687.
XX
XX 26-AUG-2002; 2002US-0408132P.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX
XX Perlmann T, Joseph B;
XX
XX WPI; 2004-226832/21.
XX
XX New Nurrl derivatives, useful for generating dopamine producing cells,
PT inducing differentiation or maturation of dopamine producing neurons, or
PT treating central nervous system-related disorders, e.g. Parkinson's
PT disease.
XX

PS Example 2; SEQ ID NO 6; 27pp; English.
XX
XX The present sequence is that of a PCR primer for cyclin dependent kinase
CC p27Kip1. This primer, and a second primer ADL70241, were used in an
CC example from the invention in a RT-PCR amplification of RNA isolated from
CC doxocycline-treated MN9D-Nurrlret-On cells. These dopamine-synthesizing
CC neuronal cells express Nurrl ADL70235 under the control of tetracycline.
CC Experiments were performed to identify genes which influenced the
CC differentiation of the neuronal cells. The results indicated that Nurrl
CC regulates p21cip1 and p57kip2, but not p27kip1. The invention provides
CC methods for inducing dopamine-producing neuron differentiation or
CC maturation via administration of Nurrl or its derivative, and for
CC inducing development of neuronal cells by contacting stem cells with
CC Nurrl and p57kip2. The dopamine-producing neurons can be used to treat
CC Parkinson's disease.
XX
XX Sequence 20 BP; 8 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2,4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 189 CGAGAGGAAAGATCAAA 207
DB 2 CGAGAGGAAAGATCAAA 20
XX
XX RESULT 334
ADL61407/c
XX ADL61407 standard; DNA; 20 BP.
XX
XX ADL61407;
AC
XX 03-JUN-2004 (first entry)
XX
XX Human protein tyrosine kinase biomarker-related RT-PCR primer SEQ ID 331.
XX
XX
XX predictor set; protein tyrosine kinase biomarker; cytostatic;
XX antiangiogenic; vasotrophic; vulnery; pharmacogenomic; drug sensitivity;
XX breast cancer; hypervascular disease; angiogenesis; wound healing scar;
XX human; ss; RT-PCR; PCR; primer.
XX
XX Homo sapiens.
XX
XX WO2004020583-A2.
XX
XX 11-MAR-2004.
XX
XX 26-AUG-2003; 2003WO-US026491.
XX
XX 27-AUG-2002; 2002US-0406385P.
XX
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX
XX Huang F, Han X, Reeves KA, Amler L, Fairchild CR, Lee FY;
XX Shaw P;
XX
XX WPI; 2004-239171/22.
XX
XX New predictor sets with a plurality of polynucleotides and/or
PT polypeptides whose expression pattern predicts cell response to a
PT compound that modulates protein tyrosine kinase activity, useful in
PT treating breast cancer.
XX
XX Disclosure; SEQ ID NO 331; 649pp; English.
XX
XX The invention relates to a novel predictor set comprising a plurality of
CC polynucleotides and/or polypeptides whose expression pattern is
CC predictive of the response of cells to treatment with a compound that
CC modulates protein tyrosine kinase activity or members of the protein
CC tyrosine kinase pathway. The molecules of the invention demonstrate
CC cytostatic, antiangiogenic, vasotrophic and vulnery activities and may
CC be useful in the field of pharmacogenomics, in particular for determining

CC drug sensitivity and in treating breast cancer, hypervascular diseases,
CC angiogenesis and scars in wound healing. The current sequence is that of
CC a human protein tyrosine kinase biomarker-related RT-PCR primer of the
CC invention.

SO Sequence 20 BP; 3 A; 2 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 GTGATCCCAACCAACCC 2953
DB 20 GTGACTCCCACTACACCC 2

RESULT 335

ID AD057395 standard; DNA; 20 BP.

AC AD057395;

DT 15-JUL-2004 (first entry)

DE Kidney development/protein expression associated probe #1.

XX nephrotropic; cardiac; antifertility; cerebroprotective;
XX neuroprotective; muscular; cytoskeletal; gene therapy;
XX kidney development; kidney disorder; developmental disorder;
XX 'circulatory disorder; hearing disorder; heart defect; infertility;
XX stroke; mental retardation; muscle defect; proliferative disorder;
XX bone defect; bone disorder; probe; ss; packaging cell line.

OS Synthetic.

XX US2004068763-A1.

PD 08-APR-2004.

PF 28-MAR-2003; 2003US-00403571.

PR 29-MAR-2002; 2002US-0368760P.

XX (HOPK/) HOPKINS N.
XX (GOLL/) GOLING G.
XX (AMST/) AMSTERDAM A.
XX (SUNZ/) SUN Z.

PI Hopkins N, Golling G, Amsterdam A, Sun Z;

DR WPI; 2004-304692/28.

PT New 459 nucleic acids and encoded polypeptides, useful for diagnosing,
PT treating or preventing a kidney disorder in an organism, or in screening
PT for compounds that modulate the development of an organism.

PS Disclosure; Page 82; 347pp; English.

XX The invention describes an isolated nucleic acid molecule (I) comprising
CC a sequence having at least 75% sequence identity to the 459 nucleic acid
CC sequence of 2808 base pairs (SEQ ID NO: 59) given in the specification,
CC over at least 600 contiguous base pairs, where the nucleic acid functions
CC in kidney development. (I) is useful for treating or preventing a kidney
CC disorder in an organism, where the nucleic acid elicits an alteration in
CC expression of a 459 nucleic acid sequence in the organism and
CC subsequently treats or prevents a kidney disorder. The nucleic acid may
CC also be used in diagnosing, preventing and treating a variety of
CC mammalian diseases and developmental disorders (e.g. circulatory
CC disorders, hearing disorders, heart defect, infertility, stroke, mental
CC retardation, muscle defects, proliferative disorders, or bone defects or
CC disorders) as well as in screening for compounds that modulate the
CC development of an organism as a whole or of specific tissues or organs
CC within that organism. This sequence represents a probe used to identify

CC zebrafish embryos comprising altered kidney development proteins by
CC detection of viral sequences of the packaging cell line used to introduce
CC the mutated DNA.

SO Sequence 20 BP; 3 A; 12 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3417 TGCGACCTCCCGCACGCGC 3435
DB 2 TGCTGACACCCCGCACGCGC 20

RESULT 336

ID ADN02369 standard; DNA; 20 BP.

AC ADN02369;

DT 15-JUL-2004 (first entry)

DE PCR primer 2 used to amplify human D-amino acid oxidase exon 10 gDNA.

XX late-onset neurodegenerative disease; D-amino acid oxidase; DAO;
XX flavin dinucleotide; FAD-dependent oxidase;
XX D-amino acid oxidative deamination; EC.1.4.3.3; neuroprotective;
XX antiparkinsonian; amyotrophic lateral sclerosis; ALS; Parkinson's;
XX Alzheimer's; gene therapy; human; ss; PCR; primer; chromosome 12;
XX exon 10.

OS Homo sapiens.

XX WO2004033723-A2.

PD 22-APR-2004.

PF 06-OCT-2003; 2003WO-GB004337.

PR 09-OCT-2002; 2002GB-00023424.

XX (IMCO-) IMPERIAL COLLEGE INNOVATIONS LTD.

PI Mitchell J, De Belleiroche J;

DR WPI; 2004-348204/32.

PT Determining an increased risk of a late-onset neurodegenerative disease
PT to a patient comprises analyzing a sample from the patient to determine
PT whether the patient has a D-amino acid oxidase (DAO) abnormality.

PS Example 1; SEQ ID NO 97; 209pp; English.

XX The invention relates to a novel method for determining an increased risk
CC of a late-onset neurodegenerative disease to a patient which comprises
CC analysing a sample from the patient to determine whether the patient has
CC a D-amino acid oxidase (DAO) abnormality, where the presence of a DAO
CC abnormality is an indication that the patient has an increased risk of
CC the late-onset neurodegenerative disease. DAO is a flavin dinucleotide
CC (FAD)-dependent oxidase which catalyses the oxidative deamination of D-
CC amino acids (EC.1.4.3.3). The method of the invention has neuroprotective
CC and antiparkinsonian applications and may be useful in determining an
CC increased risk of a late-onset neurodegenerative disease to a patient, as
CC well as in preparing a medicament for treating a late-onset
CC neurodegenerative disease, such as amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease (PD) or Alzheimer's disease (AD), possibly via gene
CC therapy. The current sequence is that of a PCR primer 2 of the invention
CC which was used to amplify human D-amino acid oxidase exon 10 gDNA.

SO Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 335 CTGGTTCAGTGACTGACCT 353
1 CTAGTTCAGTGACCTGACCT 19

RESULT 337
ADR03787

ID ADR03787 standard; DNA; 20 BP.

AC ADR03787;

DT 07-OCT-2004 (first entry)

DE SFG probe for detection of retroviral sequence in mutated zebrafish.

XX Seryl tRNA synthetase; zebrafish development;
KM insertional mutagenesis screen; blood circulation; angiogenic activity;
KM angiogenic disease; vascular disease; heart disease; circulatory disease;
KM cancer; rheumatoid arthritis; psoriasis; vascular disease; stroke;
KM heart disease; circulatory disease; zebrafish; ss; probe; SFG;
KM transfer RNA.

OS Moloney murine leukemia virus.

Key Location/Qualifiers

modified_base 1

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= FAM. FAM is 6-carboxyfluorescein"

FT modified_base 20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= TAMRA. TAMRA is N,N,N,N-tetramethyl-6-carboxyrhodamine"

XX US2004142440-A1.

XX 22-JUL-2004.

XX 06-AUG-2003; 2003US-00635145.

XX 06-AUG-2002; 2002US-0401556P.

XX (MASI) MASSACHUSETTS INST TECHNOLOGY.

XX Hopkings NH, Amsterdam AH, Swindell EC;

XX WPI; 2004-591956/57.

XX New seryl transfer RNA synthetase polypeptide, useful in diagnosis and
PT treatment of angiogenic (e.g. cancer, rheumatoid arthritis, or
PT psoriasis), vascular (e.g. stroke), heart, or circulatory diseases.

XX Example; SEQ ID NO 5; 40pp; English.

XX The present invention relates to an isolated gene encoding seryl transfer
CC RNA (tRNA) synthetase, identified through a large-scale mutagenesis
CC screen, to identify genes involved in zebrafish development. The screen
CC involved an insertional mutagenesis screen comprising infecting zebrafish
CC with a retrovirus, and breeding the fish such that the mutation is
CC brought to homozygosity. A mutation in this gene in zebrafish results in
CC a phenotype where blood circulation and angiogenic activity is affected.
CC The mutation results in decreased seryl tRNA synthase biological activity
CC and/or levels. Described is a mutation in an intron of the gene, for
CC example, between the first and second introns. Also described is a
CC mutation caused by a proviral insertion in an intron of the gene. Once a
CC mutant phenotype was observed, the inserted retroviral DNA was used as a
CC tag to clone the mutated gene involved. The invention describes methods
CC of identifying compounds which modulate the expression of a seryl tRNA
CC synthetase gene, or activity of the enzyme. The activity of the enzyme is

CC angiogenic activity. A method is described for diagnosing an angiogenic
CC disease, a vascular disease, a heart disease or a circulatory disease in
CC a subject. The enzyme, gene, and compound identified in the tests, are
CC useful for diagnosing and treating angiogenic diseases such as cancer,
CC rheumatoid arthritis, psoriasis, vascular diseases (e.g. stroke), heart,
CC or circulatory diseases. The current sequence is SFG probe for detection
CC of retroviral sequence in zebrafish.

XX Sequence 20 BP; 3 A; 12 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3417 TGCCGACCTCCCCACCGC 3435

DB 2 TGCTGACACCCCCACCGC 20

RESULT 338

AAT11643/c

ID AAT11643 standard; DNA; 21 BP.

XX AAT11643;

DT 16-APR-1996 (first entry)

DE WT1/EGF human TCC binding site.

XX Osteogenic protein; OP-1; reporter gene; screening; identification;

KM intron; non-coding sequence; ss.

XX Homo sapiens.

XX WO9533831-A1.

XX 14-DEC-1995.

XX 07-JUN-1995; 95MO-US007349.

XX 07-JUN-1994; 94US-00255250.

XX (CREA-) CREATIVE BIOMOLECULES INC.

XX Ozkaynak E, Oppermann H;

XX WPI; 1996-040236/04.

XX Isolation of compounds to modulate OP-1 expression - by monitoring
PT expression changes in a cell transformed to express osteogenic protein-1
PT and having additional steroid binding site.

XX Disclosure; Page 58; 77pp; English.

XX The human and murine osteogenic protein-1 (OP-1) non-coding sequences can
CC be used in the construction of expression vectors comprising a reporter
CC gene which has the non-coding sequence lying contiguous to the reporter
CC gene, the non-coding sequence being able to act on and affect expression
CC of the reporter gene when bound to by candidate compounds. The method is
CC used to identify compounds capable of modulating OP-1 expression. The
CC vector may optionally comprise a second non-coding sequence and the non-
CC coding sequence(s) used define at least one, preferably 1-6, WT1/EGF
CC binding elements, at least one FTZ (Fushi-Tarazu) binding element or a
CC steroid binding element

XX Sequence 21 BP; 0 A; 14 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGGAGAG 201

||||| ||||||| |||

DB 21 GGAGGAGGAGGAGGAG 3

RESULT 339
AAV10466/c
ID AAV10466 standard; DNA; 21 BP.
XX
XX AAV10466;
AC
XX
XX 17-JUN-1998 (first entry)
DT
XX
XX Human osteosarcoma PCR primer #2.
DE
XX
XX Osteosarcoma; haematopoietic cell; osteoblast; human; immature; antibody;
KM immunoreactive; cell antigen; CD34; blood; bone marrow; treatment;
KM disorder; PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US5733541-A.
PN
XX
XX 31-MAR-1998.
PD
XX
XX 21-APR-1995; 95US-00426792.
PF
XX
XX 21-APR-1995; 95US-00426792.
PR
XX
XX 21-APR-1995; 95US-00426792.
XX
XX (UNMI) UNIV MICHIGAN.
PA
XX
XX Emerson SG, Taichman RS;
PI
XX
XX WPI; 1998-229763/20.
DR
XX
XX Maintenance of haematopoietic cells in culture - by co-culturing with
PT osteoblast(s).
PT
XX
XX Example 4; Col 19; 38pp; English.
PS
XX
XX Primers AAV10465-V10492 are used to amplify regions of the human
CC osteosarcoma cell lines MG-63 and SMOs-2 which contain ligands and growth
CC factors and have been designed to cross intron/exon boundaries. The
CC products are used in a process for propagating and maintaining the
CC immature morphology of mammalian haematopoietic cells. The process
CC involves obtaining an enriched population of mammalian haematopoietic
CC cells having the immature morphology of CD34+, HLA-DR+, Thy-1+ and lin-
CC and co-culturing this population in the presence of osteoblast cells for
CC between 2 weeks and 8 weeks. The immature cells can be detected by
CC exposing them to an anti-CD34 antibody immunoreactive with the
CC haematopoietic cell antigen CD34, and removing cells that do not immuno-
CC react with the antibody. Such haematopoietic cells can be infused into
CC the blood stream or bone-marrow cavity to treat blood disorders
XX
XX
XX Sequence 21 BP; 0 A; 11 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2447 AGGACGACGAGGAGGAGG 2465
DB 21 AGGAGGAGGAGGAGGAGG 3

RESULT 340
AA07691
ID AAA07691 standard; DNA; 21 BP.
XX
XX AAA07691;
AC
XX
XX 19-JUN-2000 (first entry)
DT
XX
XX Reverse primer for amplifying HERG gene exon 14.
DE

XX
XX HERG; mutation; long QT syndrome; LQT syndrome; gene therapy; human;
KM PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200006772-A1.
PN
XX
XX 10-FEB-2000.
PD
XX
XX 20-JUL-1999; 99WO-US016337.
PF
XX
XX 27-JUL-1998; 98US-00122847.
PR
XX
XX 06-JAN-1999; 99US-00226012.
XX
XX (UTAH) UNIV UTAH RES FOUND.
PA
XX
XX Keating MT, Splawski I;
PI
XX
XX WPI; 2000-195319/17.
DR
XX
XX New isolated mutant HERG nucleic acids, useful for developing products
PT for the diagnosis, prevention and treatment of long QT syndrome.
PT
XX
XX Claim 7; Page 72; 163pp; English.
PS
XX
XX The invention relates to a HERG protein having a mutation compared to
CC wild-type HERG, and is useful for developing products for the diagnosis,
CC prevention and treatment of long QT (LQT) syndrome. The products and
CC methods can be used for the diagnosis of subjects with LQT syndrome. They
CC can also be used to screen for drugs for treating or preventing LQT
CC syndrome. The HERG nucleic acids can also be used for gene therapy and
CC HERG peptides can be used for peptide therapy. Sequences AAA07654-693
CC represent primers for amplifying HERG exons
XX
XX
XX Sequence 21 BP; 5 A; 3 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3252 GAAGAGCAGCGCTGAGC 3270
DB 1 GAAGAGCAGCGCTGAGC 19

RESULT 341
AAZ44677/c
ID AAZ44677 standard; DNA; 21 BP.
XX
XX AAZ44677;
AC
XX
XX 14-APR-2000 (first entry)
DT
XX
XX E. coli strain 0157:H7 verotoxin VT2 primer 3.
DE
XX
XX Verotoxin; VT2; detection; bacteria; fluorescence polarization;
KM amplification; fluorescein; primer; ss.
KM
XX
XX Escherichia coli.
OS
XX
XX JP11346798-A.
PN
XX
XX 21-DEC-1999.
PD
XX
XX 04-JUN-1998; 98JP-00156208.
PF
XX
XX 04-JUN-1998; 98JP-00156208.
PR
XX
XX (TSUR/) TSURUOKA M.
PA (KARO/) KAROBE M.
PA (NGCM) NISHIKAWA GOMU KOGYO KK.
XX

DR WPI; 2000-109699/10.
XX Determination of nucleic acid and a process for detection of vero toxin
PT producing bacteria - useful for diagnosing and treatment of diseases
PT related to these microorganisms.
XX Example 1; Page 6; 8pp; Japanese.
PS
XX This invention describes a novel method for the rapid, reproducible and
CC accurate determination of verotoxin producing bacteria with fluorescence
CC polarization. Determination of nucleic acid comprises: (1) amplification
CC of a nucleic acid in a sample with a gene amplification method,
CC particularly in 25 cycles or over, at initial concentration of 1-200 nm
CC of at least one primer labelled with fluorescence, particularly
CC fluorescein isothiocyanate (FITC) or fluorescein, and (2) comparative
CC determination of the nucleic acid in the amplified sample with
CC fluorescence polarization prior and post gene amplification, used for
CC detection of verotoxin producing bacteria. This sequence represents a
CC primer used in the detection of verotoxin VT2 from *Escherichia coli*
CC strain 0157:H7
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 489 GACAGCAATGCTGAGCTC 507
DB 21 GACAGTGAATGCTGAGCTC 3
RESULT 342
ID AAA10649/c
XX AAA10649 standard; cDNA; 21 BP.
AC AAA10649;
XX
XX 29-JUN-2000 (first entry)
DT
XX
XX PCR primer #3 used in barley YAC screening.
DE
XX
XX Rarl1, resistance response; pathogen defense; antifungal; barley;
KM transgenic plant; powdery mildew; increase resistance; gene modification;
KM PCR primer; yeast artificial chromosome; YAC; ss.
XX
XX Synthetic.
OS
XX
XX WO200008160-A2.
PN
XX
XX 17-FEB-2000.
PD
XX
XX 06-AUG-1999; 99WO-GB002590.
PF
XX
XX 06-AUG-1998; 98GB-00017169.
PR
XX
XX (PLAN-) PLANT BIOSCIENCE LTD.
PA
XX
XX Schulze-Lefert PMU, Shirasu K, Lahaye T;
PI
XX
XX WPI; 2000-317041/27.
DR
XX
XX Novel polynucleotide encoding a Rarl polypeptide from barley, useful for
PT producing transgenic plants with increased pathogen resistance e.g. to
PT powdery mildew, and for identifying homologous sequences in other
PT species.
XX
XX Example 1; Page 98; 131pp; English.
PS
XX This sequence represents a PCR primer used in barley YAC (yeast
CC artificial chromosome) screening. The invention relates to barley Rarl
CC sequences and to putative homologues of Rarl, OsRarl-h1 (from rice) and
CC AtRarl-h1 (from *Arabidopsis thaliana*). Rarl is a protein involved in the

CC Barley resistance signalling pathways, and plant pathogen defence
CC response signalling pathway. Rarl is required for the action of the R
CC (resistance) gene Mla-12. Rarl has antifungal and antifungal
CC properties, and functions via gene modification. The Rarl polynucleotides
CC are useful in the production of transgenic plants in which a defence
CC response is modulated, especially barley with improved resistance to
CC pathogens e.g. powdery mildew. They can be used to produce probes and
CC primers useful to identify or isolate the polynucleotides (e.g. in a
CC plant or plant cell) by standard methods and to isolate Rarl homologues
CC from other species, which in turn are useful to manipulate resistance to
CC agronomically important diseases. The polypeptides and antibodies raised
CC against them are useful to identify and isolate the polypeptides or
CC homologous polypeptides e.g. in other species
XX
SQ Sequence 21 BP; 3 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3660 CACGTACGGCGCATCAT 3678
DB 20 CACGCACGGCGCATCAT 2
RESULT 343
ID AAA59901/c
XX AAA59901 standard; DNA; 21 BP.
AC AAA59901;
XX
XX 16-OCT-2000 (first entry)
DT
XX
XX Human OP-1 Wt-1/Bgr-1 binding site.
DE
XX
XX Osteogenic protein-1; OP-1; morphogenic protein; human; osteoporosis;
KM morphogen concentration; bone metabolism disease; ss.
XX
XX Homo sapiens.
OS
XX
XX US6071695-A.
PN
XX
XX 06-JUN-2000.
PD
XX
XX 07-JUN-1995; 95US-00486343.
PF
XX
XX 21-FEB-1992; 92US-00841646.
PR
XX
XX 01-NOV-1993; 93US-00147023.
PR
XX
XX 07-JUN-1994; 94US-00255250.
PR
XX
XX 23-MAY-1995; 95US-00449700.
PR
XX
XX 24-MAY-1995; 95US-00449699.
PR
XX
XX (CREA-) CREATIVE BIOMOLECULES INC.
PA
XX
XX Oepertmann H, Ozkaynak E;
PI
XX
XX WPI; 2000-422077/36.
DR
XX
XX Screening for compounds able to modulate osteogenic protein-1 (OP-1)
PT expression by incubating a candidate compound with a nucleic acid with a
PT reporter gene operatively associated with an OP-1 non-coding nucleic acid
PT fragment.
XX
XX disclosure; Col 47; 33pp; English.
PS
XX
XX A method for screening a candidate compound for its ability to modulate
CC the expression of osteogenic protein-1 (OP-1) uses a cell transfected
CC with a nucleic acid sequence comprising a reporter gene and an upstream
CC non-coding sequence from OP-1. OP-1 is a tissue morphogenic protein. The
CC method is useful for screening compounds capable of stimulating or
CC inhibiting transcription and/or translation of the OP-1 gene, as well as
CC compounds which may be used as therapeutics for in vivo and ex vivo
CC mammalian applications, e.g. morphogen expression inducing compounds for

CC correcting and alleviating a diseased condition or to regenerate lost or
CC damaged tissue. The compounds may also be used to maintain viability of
CC the differentiated phenotype of cells in culture. Morphogen expression
CC inhibiting compounds identified by the new method can be used to modulate
CC the degree and/or timing of morphogen concentration. Compounds which up-
CC regulate levels of circulating OP-1 in vivo can be used to correct bone
CC metabolism diseases such as osteoporosis. This sequence represents the
CC TCC binding sequence or Wt-1/Egr-1 binding site sequence contained in the
CC upstream region of the osteogenic protein-1 (OP-1) gene. The DNA binding
CC proteins Wt-1 and Egr-1 bind to and control transcription of DNA
CC sequences at these sites

SQ Sequence 21 BP; 0 A; 14 C; 0 G; 7 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 183 GGAGGACGAGGAGGAGGAG 201.
21 GGAGGAGGAGGAGGAGGAG 3

RESULT 344
AAH62656/c
ID AAH62656 standard; DNA; 21 BP.

XX AAH62656;

DT 09-SEP-2004 (revised)
DT 12-SEP-2001 (first entry)

XX Synaptotagmin 5 polymorphism containing DNA fragment #557.

KM Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KM heart disease; paternity testing; forensic science; ds.

XX Homo sapiens.
OS Unidentified.

FT Key Location/Qualifiers
FT variation 11 /tag= a
/standard_name= "single nucleotide polymorphism"

PN MO200138576-A2.

XX 31-MAY-2001.

XX 17-NOV-2000; 2000WO-US031639.

XX 24-NOV-1999; 99US-0167334P.

XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX Cargill M, Ireland JS, Lander ES;

XX MPI; 2001-367705/38.

PT New nucleic acid segments of the human genome, particularly from genes
PT including polymorphic sites, for phenotype correlation, forensics,
PT paternity testing, medicine and genetic analysis.

XX Claim 1; Page 74; 80pp; English.

CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
CC contain single nucleotide polymorphisms (SNPs). A method is included in
CC the invention for analysing a nucleic acid sample, which consists of
CC determining the base occupying any one of the polymorphic sites given in
CC the SNP containing sequences. The nucleotide sequences can be used in the
CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
CC diseases, diseases of the cardiovascular system, and infection by
CC microorganisms. The oligonucleotides are also useful in the manufacture

CC of a medicament for the treatment or prophylaxis of the diseases, and as
CC a pharmaceutical. SNP containing oligonucleotides are useful in
CC applications such as phenotype correlation, forensics, paternity testing,
CC medicine and genetic analysis

CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key

SQ Sequence 21 BP; 2 A; 3 C; 12 G; 4 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 1794 CCATGACCCCGACCTGCC 1812
20 CCATGACCCACACCTGCC 2

RESULT 345
AAH62429/c
ID AAH62429 standard; DNA; 21 BP.

XX AAH62429;

DT 09-SEP-2004 (revised)
DT 12-SEP-2001 (first entry)

XX HERC1 polymorphism containing DNA fragment #330.

KM Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KM heart disease; paternity testing; forensic science; ds.

XX Homo sapiens.
OS Unidentified.

FT Key Location/Qualifiers
FT variation 11 /tag= a
/standard_name= "single nucleotide polymorphism"

PN MO200138576-A2.

XX 31-MAY-2001.

XX 17-NOV-2000; 2000WO-US031639.

XX 24-NOV-1999; 99US-0167334P.

XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX Cargill M, Ireland JS, Lander ES;

XX MPI; 2001-367705/38.

PT New nucleic acid segments of the human genome, particularly from genes
PT including polymorphic sites, for phenotype correlation, forensics,
PT paternity testing, medicine and genetic analysis.

XX Claim 1; Page 56; 80pp; English.

CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
CC contain single nucleotide polymorphisms (SNPs). A method is included in
CC the invention for analysing a nucleic acid sample, which consists of
CC determining the base occupying any one of the polymorphic sites given in
CC the SNP containing sequences. The nucleotide sequences can be used in the
CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
CC diseases, diseases of the cardiovascular system, and infection by
CC microorganisms. The oligonucleotides are also useful in the manufacture
CC of a medicament for the treatment or prophylaxis of the diseases, and as
CC applications such as phenotype correlation, forensics, paternity testing,
CC medicine and genetic analysis

CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX Sequence 21 BP; 3 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2582 CCCCATACGGGGCGGCAC 2600
DB 21 CCCCATACCTGGGGCGGCAC 3
RESULT 346
AAH88947/C
ID AAH88947 standard; DNA; 21 BP.
XX
XX AAH88947;
AC
XX 09-SEP-2004 (revised)
DT 27-FEB-2002 (first entry)
XX
XX Human polymorphic oligonucleotide AF049497 fragment #1.
XX Human; single nucleotide polymorphic; SNP; forensic science;
XX paternity testing; phenotypic trait; genetic mapping; animal breeding;
XX plant breeding; ds.
XX
XX Homo sapiens.
OS Unidentified.
XX
XX
FH Key location/Qualifiers
FT 11 /tag= a
FT variation /standard_name= "single nucleotide polymorphism"
XX
XX WO200134840-A2.
XX
XX 17-MAY-2001.
XX
XX 10-NOV-2000; 2000WO-US030766.
XX
XX 10-NOV-1999; 99US-0164596P.
XX
XX (GLAX) GLAXO GROUP LTD.
XX (AFY-) AFFYMETRIX INC.
XX
XX Au K, Chen J, Patil N, Thomas D;
XX
XX WPI; 2001-335945/35.
XX
XX New polymorphic sites derived from the human genome are useful to
XX determine sites correlating with phenotypic traits, particularly disease,
XX and also in forensics and paternity testing.
XX
XX Claim 42; Page 10; 43pp; English.
XX
XX The present invention relates to human oligonucleotides comprising a
XX single nucleotide polymorphic site (SNP: AAH88797-AAH89219). The present
XX sequence is one such oligonucleotide. The oligonucleotides can be used in
XX forensics, paternity testing, correlation of polymorphisms with
XX phenotypic traits, genetic mapping of phenotypic traits and marker
XX assisted breeding of animals and crop plants
XX
XX Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
XX Sequence 21 BP; 2 A; 7 C; 4 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 2.6e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1005 TGGAGAGAGAGAGAGCA 1023

DB 21 TGGAGAGAGAGAGAGCA 3
RESULT 347
ABK65628
ID ABK65628 standard; DNA; 21 BP.
XX
XX ABK65628;
AC
XX 02-JUL-2002 (first entry)
DE
XX
XX Human single nucleotide polymorphism #248.
XX
XX Human; single nucleotide polymorphism; SNP; sickle cell anaemia;
XX agammaglobulinemia; diabetes insipidus; Lesch-Nyhan syndrome;
XX muscular dystrophy; Wiskott-Aldrich syndrome; Fabry's disease;
XX familial hypercholesterolaemia; polycystic kidney disease; cancer;
XX hereditary spherocytosis; Von Willebrand's disease; tubercous sclerosis;
XX hereditary haemorrhagic telangiectasia; familial colonic polyposis;
XX Ehlers-Danlos syndrome; osteogenesis imperfecta; autoimmune disease;
XX acute intermittent porphyria; inflammation; nervous system disorder;
XX infection; rheumatoid arthritis; multiple sclerosis; diabetes;
XX systemic lupus erythematosus; Graves disease; longevity; obesity;
XX baldness; fertility; forensic; paternity testing; ss.
XX
XX Homo sapiens.
OS
XX
XX US2002037508-A1.
XX
XX 28-MAR-2002.
XX
XX 18-JAN-2001; 2001US-00765081.
XX
XX 19-JAN-2000; 2000US-0176861P.
XX
XX (CARG/) CARGILL M.
XX (IREL/) IRELAND J S.
XX (LAND/) LANDER E S.
XX
XX Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2002-315108/35.
XX
XX Nucleic acid comprising single nucleotide polymorphisms, useful in
XX forensics, paternity testing and diagnosis of disease.
XX
XX Claim 1; Page 66; 96pp; English.
XX
XX The invention relates to a nucleic acid comprising single nucleotide
XX polymorphisms (SNPs) associated with disease. The nucleic acids
XX comprising the SNPs and probes and primers for detecting them may be used
XX in assays for the diagnosis of diseases associated with SNPs (such as
XX sickle cell anaemia, agammaglobulinemia, diabetes insipidus, Lesch-Nyhan
XX syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
XX familial hypercholesterolaemia, polycystic kidney disease, hereditary
XX spherocytosis, Von Willebrand's disease, tubercous sclerosis, hereditary
XX haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
XX syndrome, osteogenesis imperfecta, and acute intermittent porphyria,
XX symptoms of, or susceptibility to, multifactorial diseases of which a
XX component is or may be genetic, such as autoimmune diseases,
XX inflammation, cancer, diseases of the nervous system, and infection by
XX pathogenic microorganisms, autoimmune diseases including rheumatoid
XX arthritis, multiple sclerosis, diabetes (insulin-dependent and non-
XX independent), systemic lupus erythematosus and Graves disease, cancers
XX including cancers of the bladder, brain, breast, colon, oesophagus,
XX kidney, leukaemia, liver, lung, oral cavity, ovary, pancreas, prostate,
XX skin, stomach and uterus, longevity, appearance (e.g., baldness,
XX obesity), strength, speed, endurance, fertility, and susceptibility or
XX receptivity to particular drugs or therapeutic treatments), in forensics
XX and in paternity testing. ABK65381-ABK65841 represent human single
XX nucleotide polymorphisms of the invention

SQ Sequence 21 BP; 2 A; 13 C; 5 G; 0 T; 0 U; 1 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 2091 CCCAAGCCTCCAGGCCCC 2111
DB 1 CCCAGAGCCCMGAGGCCCC 21
RESULT 348
ABK65740
ID ABK65740 standard; DNA; 21 BP.
AC ABK65740;
XX
XX 02-JUL-2002 (first entry)
DE Human single nucleotide polymorphism #360.
XX
XX Human; single nucleotide polymorphism; SNP; sickle cell anemia;
KM agammaglobulinemia; diabetes insipidus; Lesch-Nyhan syndrome;
KM muscular dystrophy; Wiskott-Aldrich syndrome; Fabry's disease;
KM familial hypercholesterolemia; polycystic kidney disease; cancer;
KM hereditary spherocytosis; Von Willebrand's disease; tuberous sclerosis;
KM hereditary haemorrhagic telangiectasia; familial colonic polyposis;
KM Ehlers-Danlos syndrome; osteogenesis imperfecta; autoimmune disease;
KM acute intermittent porphyria; inflammation; nervous system disorder;
KM infection; rheumatoid arthritis; multiple sclerosis; diabetes;
KM systemic lupus erythematosus; Graves disease; longevity; obesity;
KM baldness; fertility; forensic; paternity testing; ss.
XX
XX Homo sapiens.
XX
XX US2002037508-A1.
XX
XX 28-MAR-2002.
XX
XX 18-JAN-2001; 2001US-00765081.
XX
XX 19-JAN-2000; 2000US-0176861P.
XX
XX (CARG/) CARGILL M.
PA (IREL/) IRELAND J S.
PA (LAND/) LANDER E S.
XX
PI Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2002-315108/35.
XX
XX Nucleic acid comprising single nucleotide polymorphisms, useful in
PT forensics, paternity testing and diagnosis of disease.
XX
XX Claim 1; Page 81; 96pp; English.
XX
XX The invention relates to a nucleic acid comprising single nucleotide
CC polymorphisms (SNPs) associated with diseases. The nucleic acids
CC comprising the SNPs and probes and primers for detecting them may be used
CC in assays for the diagnosis of diseases associated with SNPs (such as
CC sickle cell anemia, agammaglobulinemia, diabetes insipidus, Lesch-Nyhan
CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
CC familial hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, Von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, and acute intermittent porphyria,
CC symptoms of, or susceptibility to, multifactorial diseases of which a
CC component is or may be genetic, such as autoimmune diseases,
CC inflammation, cancer, diseases of the nervous system, and infection by
CC pathogenic microorganisms, autoimmune diseases including rheumatoid
CC arthritis, multiple sclerosis, diabetes (insulin-dependent and non-
CC independent), systemic lupus erythematosus and Graves disease, cancers
CC including cancers of the bladder, brain, breast, colon, oesophagus,

CC kidney, leukaemia, liver, lung, oral cavity, ovary, pancreas, prostate,
CC skin, stomach and uterus, longevity, appearance (e.g., baldness;
CC obesity), strength, speed, endurance, fertility, and susceptibility or
CC receptivity to particular drugs or therapeutic treatments), in forensics
CC and in paternity testing. ABK65381-ABK65841 represent human single
CC nucleotide polymorphisms of the invention
XX
XX
SQ Sequence 21 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 1 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 586 TGGAGGCTCCAGAGGTCATC 606
DB 1 TGGACAGCTCTYAGAGGCATC 21
RESULT 349
ABS60283/C
ID ABS60283 standard; DNA; 21 BP.
XX
XX ABS60283;
AC
XX
XX 05-NOV-2002 (first entry)
DE Human polymorphism associated DNA sequence #177.
XX
XX Aminopectidase P; XPNP2; bradykinin receptor B1; ds; BDKRB1;
KM tachykinin receptor B1; TACR1, C1 esterase inhibitor; C1NH; kallikrein 1,
KM KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
KM angiotensin converting enzyme 2; ACE2; protease inhibitor 4; PI4;
KM polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
KM cardiovascular disease; angina pectoris; hypertension; heart failure;
KM myocardial infarction; ventricular hypertrophy; vascular disease;
KM aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
KM arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
KM autoimmune disease; inflammatory arthritis; cancer; wound;
KM viral infection; bacterial infection; fungal infection; COPD;
KM Chronic obstructive pulmonary disease; enterocolitis.
XX
XX
XX Homo sapiens.
XX
XX WO200261131-A2.
XX
XX 08-AUG-2002.
XX
XX 03-DEC-2001; 2001WO-US047235.
XX
XX 04-DEC-2000; 2000US-0251015P.
PR 23-JAN-2001; 2001US-0263678P.
PR 02-MAR-2001; 2001US-0273037P.
XX
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
PA (TSCC/) TSUCHIHASHI Z.
PA (HUIL/) HUI L.
XX
XX Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonde M, Perrone MH;
PI Swanson BN, Powell JR;
XX
XX WPI; 2002-619265/66.
XX
XX New isolated nucleic acid with at least one polymorphic position, useful
PT for detecting, diagnosing and treating disorders such as angioedema,
PT cancer, viral, bacterial or fungal infection, cardiovascular and
PT autoimmune diseases.
XX
XX
XX Disclosure; Page 727; 977pp; English.
XX
XX The invention relates to an isolated nucleic acid from a human gene
CC encoding aminopeptidase P (XPNP2), bradykinin receptor B1 (BDKRB1),
CC tachykinin receptor B1 (TACR1), C1 esterase inhibitor (C1NH), kallikrein
CC 1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme

CC 2 (ACE2) or protease inhibitor 4 (PI4), comprising at least one
 CC polymorphic position. Also included are (1) a probe that hybridises to a
 CC nucleotide polymorphism comprising additional 5' and 3' flanking genomic
 CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising
 CC obtaining the sample from one or more individuals and determining the
 CC nucleic acid sequence at one or more polymorphic positions in a gene
 CC encoding a protein selected from the group above; (3) constructing (M2)
 CC haplotypes using the genes comprising grouping at least two nucleic acids
 CC; (4) identifying (M3) an individual at risk of developing a disorder
 CC upon administration of an ACE inhibitor and/or vasopeptidase inhibitor
 CC using the polymorphic data; (5) a library of nucleic acids, each of which
 CC comprises one or more polymorphic positions within a gene encoding a
 CC human protein selected from the group above; and (6) genotyping (M4) an
 CC individual comprising obtaining a nucleic acid sample, determining the
 CC nucleotide present in at least one polymorphic position, and comparing at
 CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
 CC and compositions are useful for detecting, diagnosing, treating,
 CC preventing various disorders such as angiodaema and diseases which
 CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
 CC disease, trachomas, and cardiovascular diseases like angina pectoris,
 CC hypertension, heart failure, myocardial infarction, ventricular
 CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
 CC artery disease, arteriosclerosis and/or atherosclerosis, and
 CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
 CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
 CC obstructive pulmonary disease (COPD) and enterocolitis (many other
 CC diseases and disorders are listed in the specification). The
 CC polynucleotides are also useful for chromosome identification. Antibodies
 CC against the proteins may be utilised for immunophenotyping of cell lines
 CC and biological samples. The present sequence is included in the sequence
 CC listing but is not referred to anywhere else in the specification

XX Sequence 21 BP; 7 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 863 TTCCTTCATCGGAGCA 881
 |||||
 DB 20 TTCCTTCATCTGGAACA 2

RESULT 350
 ABK99278/c
 ID ABK99278 standard; RNA; 21 BP.
 AC
 XX ABK99278;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 XX Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #8.
 DE
 XX
 XX Hepatitis C virus; HCV; NS5B replicase; ss, RNA polymerase.
 KM
 XX
 OS Synthetic.
 PN
 XX US2002064771-A1.
 PN
 XX 30-MAY-2002.
 PD
 XX
 XX 06-APR-2001; 2001US-00828034.
 PF
 XX
 XX 07-APR-2000; 2000US-0195852P.
 PR
 XX
 XX (ZHON/) ZHONG W.
 PA (HONG/) HONG Z.
 PA (FERR/) FERRARI E.
 PA
 XX
 XX Zhong W, Hong Z, Ferrari E;
 PI
 XX
 XX WPI; 2002-582330/62.

XX
 PT Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3
 PT nucleotide-long template to which a 2 nucleotide-long primer is annealed,
 PT and template and primer which do not form a stable duplex in the absence
 PT of HCV NS5B.
 PT
 XX

PS Example; Page 6; 17pp; English.

CC The invention relates to a replicase complex comprising a hepatitis C
 CC virus (HCV) NS5B replicase protein, a linear nucleic acid template and a
 CC complementary nucleic acid primer which is annealed to the 3' terminus of
 CC the template, where the template is at least three nucleotides and the
 CC primer is two or three nucleotides, and the template and primer do not
 CC form a stable duplex in solution in the absence of the HCV NS5B protein.
 CC The complex is useful for detecting HCV replicase activity and permits
 CC establishment of sensitive RNA-dependent RNA polymerase assays to screen
 CC and evaluate antiviral inhibitors and to improve the specificity and
 CC efficacy of the inhibitors. The complex is also useful in the development
 CC of a reliable system for determining kinetic and thermodynamic constants
 CC of HCV NS5B-catalysed nucleotide incorporation and investigation of
 CC mechanistic inhibitors for mis-incorporation or chain termination.
 CC Specifically, the short RNA template and primer pairs are useful in
 CC screening assays which are used for determining kinetic, thermodynamic
 CC and mechanistic properties of NS5B replication and ultimately in the
 CC development of inhibitors of NS5B. Newly identified inhibitors of
 CC replicase activity may be used for developing anti-HCV pharmaceuticals.
 CC Sequences ABK99271-ABK99296 represent HCV NS5B replicase RNA synthesis
 CC templates
 XX

Sequence 21 BP; 0 A; 14 C; 0 G; 0 T; 7 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGAGGAGGAGGAG 201
 |||||
 DB 21 GGAGGAGGAGGAGGAG 3

RESULT 351
 ADD22525/c
 ID ADD22525 standard; DNA; 21 BP.
 AC
 XX ADD22525;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 XX Flatfish rhabdovirus oligo #16.
 DE
 XX
 XX DNA vaccine; flatfish rhabdovirus; HIRRV; fish; immunity;
 KM transcripional-control; cytomegalovirus immediate-type promoter;
 KM immunogenic; virucide; gene gun; ss; primer.
 XX
 OS H1xame rhabdovirus.
 PN
 XX JP2003155254-A.
 PN
 XX 27-MAY-2003.
 PD
 XX
 XX 26-SEP-2001; 2001JP-00294473.
 PF
 XX
 XX 06-SEP-2001; 2001JP-00271068.
 PR 10-SEP-2001; 2001JP-00274202.
 XX
 XX (MEIJ) MEIJI SEIKA KAISHA LTD.
 PA (AOKI/) AOKI H.
 PA
 XX
 XX WPI; 2003-818526/77.
 DR
 XX
 XX DNA vaccine for flatfish rhabdovirus infected fishes has DNA construct
 PT comprising a transcripional control sequence coupled to a nucleotide
 PT sequence encoding an immunogenic protein of flatfish rhabdovirus.

XX Example 6; Fig 5; 13pp; Japanese.
PS The invention relates to a novel DNA vaccine for flatfish rhabdovirus
XX (HIRRV) infected fishes, which provides immunity against HIRRV. The
CC 'vaccination method uses a DNA construct comprising a transcriptional-
CC control sequence containing cytomegalovirus immediate-type promoter,
CC operably coupled to a nucleotide sequence encoding an immunogenic
CC polypeptide of HIRRV. The DNA vaccine has virucide activity. The HIRRV
CC DNA vaccine is useful for administering to a fish belonging to the
CC flatfish family by gene gun. The HIRRV DNA vaccine is useful for
CC immune response in fish infected by HIRRV and is also useful for
CC preventing HIRRV infection in flatfish. The HIRRV DNA vaccine is
CC effective in enhancing immunity of fish infected by HIRRV. This
CC polynucleotide sequence represents an oligo used in the analysis of the
CC mRNA expression level from the muscles of flatfish, following an
CC inoculation with the flatfish rhabdovirus vaccine of the invention.
XX Sequence 21 BP; 4 A; 3 C; 8 G; 6 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1544 CCGCTGACAAACCGCCTG 1562
DB 21 CAGCTCACAAACCGCCTG 3

RESULT 352
ADE78130/C
ID ADE78130 standard; DNA; 21 BP.
XX
AC ADE78130;
XX
DT 29-JUN-2004 (first entry)
XX
DE DNA oligo (SeqID 381) encodes peptide that binds atherosclerotic lesions.
XX
KW ss: gene: atherosclerotic lesion; antiatherosclerotic; cerebroprotective;
KW antiangiogenic; thrombolytic; cardiatic; ophthalmologic; neuroprotective;
KW nephrotropic; vasotropic; atherosclerosis; stroke; angina; thrombosis;
KW myocardial infarction; ischaemic heart disease;
KW transplantation-induced sclerosis; intermittent claudication; diabetes;
KW peripheral artery disease; congestive heart failure; retinopathy;
KW neuropathy; nephropathy; thrombosis.
XX
OS Synthetic.
XX
PN WO2003014145-A2.
XX
PD 20-FEB-2003.
XX
PF 09-AUG-2002; 2002WO-EP008942.
XX
PR 10-AUG-2001; 2001US-0311507P.
XX
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.
PA (SCRT) SCRIPPS RES INST.
XX
PI Liu C, Edgington TS, Prescott MF;
XX
DR MPI; 2003-278468/27.
XX
P-PSDB; ADE78131.
XX
PT Novel peptide which selectively bind to mammalian atherosclerotic
XX lesions, useful for treating atherosclerosis in a mammal, and for
XX identifying location of atherosclerotic lesion in mammal.
PS Claim 16; SEQ ID NO 381; 286pp; English.
XX
CC This invention relates to novel isolated peptides that selectively bind

CC to mammalian atherosclerotic lesions and as such can be used to detect
CC and/or treat vascular problems. Specifically, it refers to methods for
CC the in vivo identification of such peptides by using phase display
CC libraries, and also methods for identifying the targets of biomolecules
CC bound by the peptides. Diagnosis of pathological conditions of the
CC endothelial tissue occurs by administration of a peptide conjugated to a
CC reporter molecule or therapeutic agent. As such, these peptides can be
CC described variously as antiatherosclerotic, cerebroprotective,
CC antiangiogenic, thrombolytic, cardiatic, ophthalmologic, neuroprotective,
CC nephrotropic and vasotropic. The present invention describes these
CC peptides as useful for treating atherosclerosis, as well as identifying
CC the location and severity of an atherosclerotic lesion in a mammal.
CC Atherosclerosis causes stroke, angina, thrombosis, myocardial infarction,
CC ischaemic heart disease, transplantation-induced sclerosis and
CC intermittent claudication. Furthermore, it is associated with diabetes,
CC which in turn can lead to peripheral artery disease, congestive heart
CC failure, retinopathy, neuropathy, nephropathy or thrombosis. This
CC oligonucleotide sequence, isolated from a combinatorial phage display
CC library, encodes a peptide that binds to atherosclerotic lesions, the aim
CC of the invention.
XX
SQ Sequence 21 BP; 1 A; 6 C; 9 G; 5 T; 0 U; 0 Other;
XX

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1181 ACCAGCGGACGCGCGCAT 1199
DB 20 ACCAGCGGACGCGCGCAT 2

RESULT 353
ADF75334
ID ADF75334 standard; DNA; 21 BP.
XX
AC ADF75334;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID14).
XX
KW human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;
KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;
KW oesophageal squamous cell carcinoma; BSCC; gene therapy;
KW methyltransferase inhibitor; 5aza-dC; histone deacetylase inhibitor.
XX
OS Homo sapiens.
XX
PN WO2003076594-A2.
XX
PD 18-SEP-2003.
XX
PF 07-MAR-2003; 2003WO-US007245.
XX
PR 07-MAR-2002; 2002US-0362577P.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Sidransky D;
XX
DR MPI; 2003-756817/71.
XX
PT Identifying at least one epigenetically silenced gene associated with
XX cancer useful for treating cancer comprises contacting an array of genome
XX with nucleic acid molecule that reactivates expression of epigenetically
XX silenced gene.
PS Example 1; SEQ ID NO 14; 97pp; English.
XX
CC This invention relates to novel methods of screening to identify
CC epigenetically silenced genes. Specifically, it refers to the detection
CC of epigenetically silenced tumour suppressor genes in cancer cells, which

CC are transcriptionally inactive due to aberrant methylation at normally
 CC methylated CpG islands. Accordingly, these genes provide diagnostic
 CC markers for immortalized and transformed cells and hence can be used to
 CC diagnose various proliferative disorders, particularly oesophageal cancer
 CC and head and neck cancer. The present invention describes a genomic
 CC screening method to identify silenced genes in a cell suspected of a
 CC predisposition to, or exhibiting, unregulated growth. Accordingly,
 CC oligonucleotides of the genes identified herein are useful for detecting
 CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell
 CC carcinoma. Furthermore, treatment can occur via gene therapy, using a
 CC demethylation agent such as a methyltransferase inhibitor (5aza-dc) or a
 CC histone deacetylase inhibitor to restore expression of at least one
 CC methylation silenced gene in cancer cells. This oligonucleotide sequence
 CC is an RT-PCR primer used to amplify those genes that were up-regulated as
 CC a result of treatment with a demethylation agent i.e. epigenetically
 CC silenced genes of the invention.

XX
 SQ Sequence 21 BP; 8 A; 3 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1200 AGAGGACGAGGAGGAG 1218
 |||||
 DB 1 AGAGGACGAGGAGGAG 19

RESULT 354
 ADN02584
 ID ADN02584 standard; DNA; 21 BP.
 AC ADN02584;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Primer #2 of the invention.
 XX
 KW human ring finger proteinase; hPFI; ss; primer.
 XX
 OS Synthetic.
 XX
 PN CN1394959-A.
 PD 05-FEB-2003.
 PF 01-MAR-2002; 2002CN-00110935.
 PR 01-MAR-2002; 2002CN-00110935.
 PA (UYFU-) UNIV FUDAN.
 PI Yu L, Tang L, Guo J;
 WPI; 2003-442215/42.
 PT Human ring finger proteinase code sequence, its preparation method and
 application.
 PS Example 1; SEQ ID NO 6; 14pp; Chinese.
 CC The present invention relates to a new human gene nucleotide sequence,
 CC specifically, it relates to cDNA sequence of human ring finger proteinase
 CC (hPFI) and said sequence coded polypeptide. Said invention also relates
 CC to production method of the described polynucleotide sequence and
 CC described polypeptide and their application. The present sequence
 CC represents a primer of the invention.

XX
 SQ Sequence 21 BP; 8 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GCCATCAGGTGATGATG 178
 |||||
 DB 1 GCCATCAGGTGATGATG 19

RESULT 355
 ADK61698
 ID ADK61698 standard; DNA; 21 BP.
 AC ADK61698;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Base containing SSR sequence #2.
 XX
 KW rice variety; amplification genetic marker; ds.
 XX
 OS Oryza sp.
 PN JP2003319782-A.
 PD 11-NOV-2003.
 PF 02-MAY-2002; 2002JP-00130645.
 PR 02-MAY-2002; 2002JP-00130645.
 PA (HOKU-) HOKUREN NOGYO KYODO KUMIJI.
 PA (HOKK-) HOKKAIDO GREEN BIO KENKYUSHO KK.
 WPI; 2004-003560/01.
 PT Identifying rice variety using base sequence containing SSR sequence and
 PT amplifying genetic marker.
 PS Claim 6; SEQ ID NO 2; 30pp; Japanese.
 CC The present invention relates to identifying a rice variety as
 CC amplification genetic marker and identifying whether test rice variety is
 CC any one of the 32 rice varieties e.g., Kasalath, breath which came or
 CC Hayamasari, Itailica Livorno, Dungan Shail, Arroza Terra, Fany, USSR22,
 CC Nihonbare. The method is useful for identifying rice variety and
 CC identifies excellent rice variety. The present sequence represents a base
 CC - containing SSR sequence of the invention.

XX
 SQ Sequence 21 BP; 7 A; 0 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGGAG 201
 |||||
 DB 1 GGAGGACGAGGAGGAG 19

RESULT 356
 AD011900/c
 ID AD011900 standard; DNA; 21 BP.
 AC AD011900;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Single multiplex PCR primer #1272.
 XX
 KW ss; primer; simultaneous amplification;
 KW single multiplex polymerase chain reaction; multifactorial disease;
 KW gene expression profiling; pharmacogenetic reaction; genotyping; polymorphism;
 XX
 OS Synthetic.

XX WO2004033649-A2.
 XX 22-APR-2004.
 PD
 XX
 PF 07-OCT-2003; 2003MO-US031874.
 XX
 PR 07-OCT-2002; 2002US-0417009P.
 XX
 PA (UYNE-) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 XX
 PI Li H, Li J;
 XX
 DR WPI; 2004-340914/31.
 XX
 PT Designing primers for simultaneous amplification of target DNA fragments
 PT in a single multiplex polymerase chain reaction, for high throughput
 PT multiplex DNA sequence amplification, comprises aligning two primers.
 PS
 XX Disclosure; Page 39; 120pp; English.
 XX
 CC The invention relates to a method of designing primers for simultaneous
 CC amplification of target DNA fragments in a single multiplex polymerase
 CC chain reaction by aligning a first primer and a second primer. The method
 CC comprises: (a) aligning a first primer and a second primer; and (b)
 CC selecting the first primer where the first primer at its 3' end does not
 CC contain four or more bases that are perfectly matching to the 3' end
 CC of sequence of the first primer or a second primer, the first primer at its
 CC 3' end does not contain seven or more bases that are perfectly matching
 CC except one mismatch to the 3' end sequence of the first primer or the
 CC second primer, the first primer at its 3' end does not contain six or
 CC more bases that are perfectly matching to a sequence anywhere of the
 CC first primer or the second primer, and the first primer at its 3' end
 CC does not contain eleven or more bases that are perfectly matching except
 CC one mismatch to a sequence anywhere of the first primer or the second
 CC primer. The method is useful for designing primers for simultaneous
 CC amplification of target DNA fragments in a single multiplex polymerase
 CC chain reaction. It is also useful in the identification of multiple genes
 CC related to multifactorial diseases, the genome-scale detection of genetic
 CC alterations, the studies in pharmacogenetic reactions, the genotyping
 CC genetic polymorphisms in a large population, the gene expression
 CC profiling in various samples and high throughput genotyping technologies.
 CC This sequence corresponds to an example of a primer of the invention.
 CC
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 303 CCAGCTCTGCTGCTGATG 321
 Db 19 CCAGCTCTGGAAGTATG 1
 XX
 RESULT 357
 AA244310/c
 ID AA244310 standard; DNA; 30 BP.
 XX
 AC AA244310;
 XX
 DT 04-APR-2000 (first entry)
 XX
 DE Human SCA7 primer 1.
 XX
 KW SCA7, human; spinocerebellar ataxia type 7; SCA1; SCA2; SCA3; SCA6;
 KW repeat expansion detection; RED analysis; detection; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN CA2245310-A.
 XX
 PD 19-FEB-1999.

XX
 PF 19-AUG-1998; 98CA-02245310.
 XX
 PR 19-AUG-1997; 97US-0056170P.
 XX
 PA (MINU) UNIV MINNESOTA.
 XX
 PI Koob MD, Rannum LP;
 XX
 DR WPI; 2000-098181/09.
 XX
 PT Identifying individuals at risk of developing spinocerebellar ataxia type
 PT 7 by analyzing trinucleotide repeat regions of spinocerebellar ataxia
 PT type 7 gene.
 PS
 XX Disclosure; Page 43; 66pp; English.
 XX
 CC This invention describes a novel method for identifying individuals at
 CC risk for developing spinocerebellar ataxia type 7 (SCA7). The method
 CC comprises analyzing the CAG repeat region of a SCA7 gene to detect CAG
 CC repeats, where individuals at risk have at least 30 CAG repeats and those
 CC not at risk have less than 19 CAG repeats. The method is useful for
 CC identifying individuals at risk of developing SCA7 and also those at risk
 CC of developing SCA1, 2, 3 or 6. The use of genomic DNA in the repeat
 CC expansion detection (RED) analysis allows isolation of any potential
 CC trinucleotide repeat expansion regardless of the expression pattern.
 CC Utilization of different oligonucleotides in the RED assay allows any of
 CC of the possible trinucleotide repeats to be detected, and the cyclic nature
 CC of the reaction makes it extremely sensitive. This sequence represents a
 CC primer used to amplify the human SCA7 gene which is described in the
 CC method of the invention
 CC
 XX
 SQ Sequence 30 BP; 10 A; 10 C; 10 G; 0 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 15.6; DB 1; Length 30;
 Best Local Similarity 70.0%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
 QY 1117 CAGCAGCAGCAGCAGCAGCAGCAGCAG 1146
 Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1
 XX
 RESULT 358
 AAS13781/c
 ID AAS13781 standard; DNA; 30 BP.
 XX
 AC AAS13781;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE Simple sequence repeat, SSR, #52.
 XX
 KW Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 XX
 OS Synthetic.
 XX
 PN NZ509193-A.
 XX
 PD 25-MAY-2001.
 XX
 PF 03-JAN-2001; 2001NZ-00509193.
 XX
 PR 24-DEC-1999; 99AU-00004906.
 PR 04-MAY-2000; 2000AU-00007310.
 XX
 PA (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 PA (UYSC-) UNIV SOUTHERN CROSS.
 PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 PA (UYAD-) UNIV ADELAIDE.
 PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX

PI Forster JW, Jones ES;
 XX
 DR MPI; 2001-512563/56.
 XX
 PT New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.
 XX
 PS Claim 13; Page 53; 72pp; English.
 XX
 CC The invention relates to a substantially purified or isolated nucleic
 CC acid (1) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SO Sequence 30 BP; 10 A; 10 C; 10 G; 0 T; 0 U; 0 Other;
 OY
 Query Match 0.4%; Score 15.6; DB 1; Length 30;
 Best Local Similarity 70.0%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
 DB 1117 GAGCAGCAGCGTGCAGCAGCAGCAGCAG 1146
 30 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1
 RESULT 359
 AAT81046/c
 ID AAT81046 standard; RNA; 17 BP.
 XX
 AC AAT81046;
 XX
 DT 26-SEP-1997 (first entry)
 XX
 DE Human c-myb hammerhead ribozyme target sequence (nt. position 29).
 XX
 KM Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
 KM smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
 KM coronary angioplasty; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09531541-A2.
 XX
 PD 23-NOV-1995.
 XX
 PF 18-MAY-1995; 95MO-US006368.
 XX
 PR 18-MAY-1994; 94US-00245466.
 PR 13-JAN-1995; 95US-00373124.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Draper K, Mcswigen J, Jarvis T;
 XX
 DR MPI; 1996-010927/01.

PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.
 XX
 PS Claim 1; Page 64; 128pp; English.
 XX
 CC The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers
 XX
 SO Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;
 OY
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 DB 1201 GAGCAGCAGAGAGAGA 1217
 17 GAGCAGCAGAGAGAGA 1
 RESULT 360
 AAT81049/c
 ID AAT81049 standard; RNA; 17 BP.
 XX
 AC AAT81049;
 XX
 DT 26-SEP-1997 (first entry)
 XX
 DE Human c-myb hammerhead ribozyme target sequence (nt. position 37).
 XX
 KM Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
 KM smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
 KM coronary angioplasty; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09531541-A2.
 XX
 PD 23-NOV-1995.
 XX
 PF 18-MAY-1995; 95MO-US006368.
 XX
 PR 18-MAY-1994; 94US-00245466.
 PR 13-JAN-1995; 95US-00373124.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Draper K, Mcswigen J, Jarvis T;
 XX
 DR MPI; 1996-010927/01.
 XX
 PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.
 XX
 PS Claim 1; Page 64; 128pp; English.
 XX
 CC The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC activities optimised by either varying the length of the binding arms or

CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty.
 CC and in cancers

SQ Sequence 17 BP, 1 A, 9 C, 2 G, 0 T, 5 U, 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 179 TCACGAGACGACGAG 195
 17 TCACGAGAGGAGAG 1

RESULT 361
 AAT81045/c
 ID AAT81045 standard; RNA; 17 BP.

AC AAT81045;

XX 26-SEP-1997 (first entry)

XX Human c-myb hammerhead ribozyme target sequence (nt. position 28).

XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;

KM smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;

KM coronary angioplasty; ss.

OS Homo sapiens.

PN W09531541-A2.

XX 23-NOV-1995.

PF 18-MAY-1995; 95WO-US006368.

XX 18-MAY-1994; 94US-00245466.

PR 13-JAN-1995; 95US-00373124.

XX (RIBO-) RIBOZYME PHARM INC.

PI Scinchcomb DT, Draper K, Mcswiggen J, Jarvis T;

XX WPI; 1996-010927/01.

PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 for treating restenosis or cancer.

XX Claim 1; Page 64; 128pp; English.

CC The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers

SQ Sequence 17 BP, 0 A, 10 C, 0 G, 0 T, 7 U, 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGGAG 1218
 ||||| ||||| ||||| |||||

Db 17 AGGAGCAGAGGAG 1

RESULT 362
 AAT74181/c
 ID AAT74181 standard; DNA; 17 BP.

XX AAT74181;

XX 25-MAR-2003 (revised)

DT 29-SEP-1997 (first entry)

XX Salmonella enteritidis sef gene cluster reverse palmer.

XX Enteropathogenic bacteria; enterobacteria; S. enteritidis; antibody;

XX polymerase chain reaction; ss.

XX Synthetic.

XX US5635617-A.

XX 03-JUN-1997.

XX 26-APR-1994; 94US-00233788.

XX 26-APR-1993; 93US-00054452.

XX (UYVI-) UNIV VICTORIA INNOVATION & DEV CORP.

XX Collinson SK, Kay WW, Doran JL;

XX WPI; 1997-309886/28.

XX Isolated Salmonella gene agfa - used for diagnosis of Salmonella or

XX enteropathogenic bacteria of the Enterobacteria family.

XX Example 9; Col 45; 85pp; English.

CC The present sequence represents a reverse palmer used for the sequencing
 CC of the coding sequence of the sef gene cluster of Salmonella enteritidis.
 CC Twelve internal oligonucleotide primers were used to sequence the
 CC opposite strand. The nucleic acid produced can be used to provide
 CC diagnostic assays for Salmonella and/or enteropathogenic bacteria of the
 CC family Enterobacteria. It can also be used to provide proteins and
 CC antibodies which can be used for assays. The nucleic acid sequence can be
 CC used to provide probes or primers which can specifically hybridise to
 CC nucleic acid molecules from greater than 99% of Salmonella strains that
 CC are pathogenic to warm-blooded animals relative to nucleic acid molecules
 CC from virtually all other microbial organisms. (updated on 25-MAR-2003 to
 CC correct PF field.)

SQ Sequence 17 BP, 2 A, 5 C, 4 G, 6 T, 0 U, 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543
 17 CGGGAACAGCTATGAC 1

RESULT 363
 AAX36659/c
 ID AAX36659 standard; DNA; 17 BP.

XX AAX36659;

XX 13-JUL-1999 (first entry)

XX PCR primer for marker D282209.

XX PCR primer; detection; glaucoma allele; haplotype analysis; human; GLC1B;

KW chromosome 2; chromosome 6; GLC6p25; haplotype profile;
 KW presymptomatic glaucoma; symptomatic glaucoma; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX MO9916899-A2.
 PN 08-APR-1999.
 XX 29-SEP-1998; 98MO-CA000924.
 PF 30-SEP-1997; 97CA-02217097.
 PR (UYLA-) UNIV LAVAL.
 XX Raymond V, Morissette J, Falardeau P, Cote G, Anctil J;
 XX WPI; 1999-263704/22.
 DR Haplotype analyses for indirect detection of glaucoma.
 XX Claim 7; Page 27; 41pp; English.
 XX This sequence represents a PCR primer used in the method of the
 CC invention. The method is for detecting the presence of alleles for
 CC glaucoma comprising haplotype analysis of human chromosome 2 and 6
 CC respectively, where the haplotypes are associated with loci GLC1B and
 CC GLC6p25 respectively. The primers are used to amplify gene sequences to
 CC generate information necessary to compile haplotype profiles. The
 CC haplotype profiles can be used to detect presymptomatic and symptomatic
 CC glaucoma. They can also be used to localise, isolate and identify the
 CC GLC1B and GLC6p25 loci so that detection of individuals with glaucoma is
 CC enhanced. The haplotype analyses also provide means for identification
 CC and following of mutant alleles in pedigrees or populations.
 CC Identification of presymptomatic individuals using the methods allows
 CC intervention in the disease process and obviates the impact of inheriting
 CC a mutant allele causing disease, by medically disrupting the initiation
 CC or progression of the disease
 XX Sequence 17 BP; 4 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 0; Gaps 0;
 QY 2737 AAGCATGGAGTGGTGA 2753
 DB 17 AAGCATGGAGTGGTGA 1
 RESULT 364
 AAF01716/c
 ID AAF01716 standard; DNA; 17 BP.
 XX AAF01716;
 AC 16-FEB-2001 (first entry)
 DT Hammerhead ribozyme substrate #11.
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 OS MO200061729-A2.
 PN 19-OCT-2000.
 PD 11-APR-2000; 2000MO-US009721.
 PF 12-APR-1999; 99US-0129390P.

XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 DR Enzymatic and antisense nucleic acid inhibition of repressor genes,
 XX useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX Claim 37; Page 56; 164pp; English.
 PS The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the IR2 Orphan receptor, EARS/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX Sequence 17 BP; 1 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 0; Gaps 0;
 QY 1669 TCCCCAGGGGCCCCAGG 1685
 DB 17 TCCCCAGGGGCCCCAGG 1
 RESULT 365
 ABEK00766
 ID ABEK00766 standard; RNA; 17 BP.
 XX ABEK00766;
 AC 12-MAR-2002 (first entry)
 DT Human NOGO Inozyme #36.
 XX Human: ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotrophic; neuroprotective; antiparinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNAzyme; inozyme; G-cleaver; ambezyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX Homo sapiens.
 OS Synthetic.
 XX MO200159103-A2.
 PN 16-AUG-2001.
 PD 09-FEB-2001; 2001MO-US004273.
 PF 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-018516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLATT) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.

PI	Blatt L, Mcwigen J, Chowira BM;
XI	
DR	WPI; 2001-607195/69.
XX	
PT	Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.
PT	
XX	
PS	Claim 88; Page 78; 200pp; English.
XX	
CC	The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOCO). The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberzyme (cleaving RNA with an NGN triplet), a zincyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), human myeloid leukaemia (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOCO-targeting nucleic acid is used to cleave RNA of the NOCO gene in the presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, the nucleic acid may be contacted with a cell to reduce NOCO activity of the cell and treat a patient having a condition associated with the level of NOCO. The treatment may further comprise the use of one or more therapies. In particular, the NOCO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapeutic-induced neuropathic pain, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOCO expression. The present sequence is an inozyme of the invention
CC	
CC	
XX	
SQ	Sequence 17 BP; 3 A; 6 C; 7 G; 1 U; 0 Other;
	Query Match 0.4%; Score 15.4; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2e+02; 1; Indels 0;
	Matches 15; Conservative 1; Mismatches 1; Gaps 0;
Qy	1119 GCAGCAGCGCTGCAGC 1135
Db	1 GCAGCAGCGCTGCAGC 17
ID	ABK02370 standard; RNA; 17 BP.
AC	ABK02370;
XX	
DT	12-MAR-2002 (first entry)
XX	
DE	Human NOCO Amberzyme #42.
KM	Human, sex, antiseize therapy; cytostatic; antiinflammatory; haemostatic; cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KM	muscular; CD20; neurite growth inhibitor gene; NOCO; hammerhead ribozyme; DNAzyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;
KM	B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KM	human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KM	MCL; immunocytoplasma; IMC; immune thrombocytopenia; stroke; dementia;
KM	inflammatory arthropathy; central nervous system injury;

XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 XX Parkinson's disease; ataxia; Huntington's disease;
 XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 OS Homo sapiens.
 OS Synthetic.
 XX WO200159103-A2.
 XX 16-AUG-2001.
 XX PD
 XX 09-FEB-2001; 2001WO-US004273.
 XX PF
 XX 11-FEB-2000; 2000US-0181797P.
 XX PR 28-FEB-2000; 2000US-0185516P.
 XX PR 06-MAR-2000; 2000US-0187128P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (BLAT/) BLATT L.
 XX PA (MCSW/) MCSWIGGEN J.
 XX PA (CHOW/) CHOWMIRA B M.
 XX PI Blat L, Mcswigen J, Chowira BM;
 XX WPI: 2001-607195/69.
 XX DR
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX Claim 88; Page 131; 2000P; English.
 XX PS
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acid may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOCO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOCO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOCO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOCO expression. The present
 CC sequence is an amberzyme molecule of the invention
 XX
 XX Sequence 17 BP; 7 A; 2 C; 8 G; 0 T; 0 U; 0 Other;
 XX SQ
 XX Query Match 0.4%; Score 15.4; DB 1; Length 17;
 XX Best Local Similarity 94.1%; Pred. No. 2e+02;
 XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

DB      1 GAGGACGACGACGAGA 17
|||||
RESULT 367
ABK01554
XX      ABK01554 standard; RNA; 17 BP.
XX
AC      ABK01554;
XX
DT      12-MAR-2002 (first entry)
XX
DE      Human NOGO G-Cleaver #10.
XX
KM      Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KM      cerebroprotective; neuroprotective; antiparkinsonian;
KM      muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KM      DNase; inozyme; G-cleaver; amberyse; zinzyme; lymphoma; leukaemia;
KM      B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KM      human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KM      MCL; immunocyto; IMC; immune thrombocytopaenia; stroke; dementia;
KM      inflammatory arthropathy; central nervous system injury;
KM      cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KM      chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KM      Parkinson's disease; ataxia; Huntington's disease;
KM      Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS      Homo sapiens.
OS      Synthetic.
XX
PN      MO200159103-A2.
XX
PD      16-AUG-2001.
XX
PF      09-FEB-2001; 2001MO-US004273.
XX
PR      11-FEB-2000; 2000US-0181797P.
PR      28-FEB-2000; 2000US-0185516P.
PR      06-MAR-2000; 2000US-0187128P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
PA      (BLAT/) BLATT L.
PA      (MCSW/) MCSWIGGEN J.
PA      (CHOW/) CHOWRIRA B M.
XX
PI      Blatt L, Mcswiggen J, Chowrira BM;
XX
DR      MPI; 2001-607195/69.
XX
PT      Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT      constructs, which down regulate expression of a CD20 gene or neurite
PT      growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT      central nervous system injury.
XX
PS      Claim 88; Page 92; 2000p; English.
XX
CC      The invention relates to a nucleic acid molecule which down regulates
CC      expression of a CD20 gene and a nucleic acid molecule which down
CC      regulates expression of a neurite growth inhibitor gene (NOGO). The
CC      nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC      DNase) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC      possessing an NCH motif), a G-cleaver (cleaving RNA with a NNN motif) or
CC      an amberyse (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC      with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC      of CD20 in the presence of a divalent cation that is preferably Mg2+.
CC      Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC      the cell and treat a patient having a condition associated with the level
CC      of CD20. The treatment may further comprise the use of one or more
CC      therapies. In particular, the CD20 targeting nucleic acid may be used to
CC      treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC      Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC      leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC      lymphoma (MCL), immunocytoema (IMC), small B-cell lymphocytic lymphoma,

```

```

CC      immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC      targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC      presence of a divalent cation that is preferably Mg2+. Furthermore, the
CC      nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC      cell and treat a patient having a condition associated with the level of
CC      NOGO. The treatment may further comprise the use of one or more
CC      therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC      treat central nervous system (CNS) injury and cerebrovascular accident
CC      (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC      chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC      Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC      disease, muscular dystrophy, and/or other neurodegenerative disease
CC      states which respond to the modulation of NOGO expression. The present
CC      sequence is a G-cleaver molecule of the invention
XX
SQ      Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
XX
Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY      182 CCGAGGACGACGACGAGA 198
DB      1 CCGAGGACGACGACGAGA 17
|||||
RESULT 368
ABK00767
ID      ABK00767 standard; RNA; 17 BP.
XX
AC      ABK00767;
XX
DT      12-MAR-2002 (first entry)
XX
DE      Human NOGO Inozyme #37.
XX
KM      Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KM      cerebroprotective; neuroprotective; antiparkinsonian;
KM      muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KM      DNase; inozyme; G-cleaver; amberyse; zinzyme; lymphoma; leukaemia;
KM      B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KM      human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KM      MCL; immunocyto; IMC; immune thrombocytopaenia; stroke; dementia;
KM      inflammatory arthropathy; central nervous system injury;
KM      cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KM      chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KM      Parkinson's disease; ataxia; Huntington's disease;
KM      Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS      Homo sapiens.
OS      Synthetic.
XX
PN      MO200159103-A2.
XX
PD      16-AUG-2001.
XX
PF      09-FEB-2001; 2001MO-US004273.
XX
PR      11-FEB-2000; 2000US-0181797P.
PR      28-FEB-2000; 2000US-0185516P.
PR      06-MAR-2000; 2000US-0187128P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
PA      (BLAT/) BLATT L.
PA      (MCSW/) MCSWIGGEN J.
PA      (CHOW/) CHOWRIRA B M.
XX
PI      Blatt L, Mcswiggen J, Chowrira BM;
XX
DR      MPI; 2001-607195/69.
XX
PT      Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT      constructs, which down regulate expression of a CD20 gene or neurite

```

PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 78; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NNN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an inozyme of the invention
 CC
 XX
 XX Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1122 GCAGCAGCTGCGACGAC 1138
 Db 1 GCAGCAGCTGCGACGAC 17
 RESULT 369
 ABK01792
 ID ABK01792 standard; RNA; 17 BP.
 XX
 AC ABK01792;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Zinzyme #114.
 XX
 XX Human: ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 XX Homo sapiens.
 OS Synthetic.

XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001MO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-018516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B. M.
 PI Blatt L, Meswiggen J, Chowrira BW;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 97; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NNN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a zinzyme molecule of the invention
 CC
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1120 CAGCAGCAGCTGCGACGA 1136
 Db 1 CAGCAGCAGCTGCGACGA 17
 RESULT 370
 ABK01549
 ID ABK01549 standard; RNA; 17 BP.

XX ABK01549;
 AC- 12-MAR-2002 (first entry)
 XX DE Human NOGO G-Cleaver #5.
 XX Human; ss; antisense therapy; cytosstatic; antiinflammatory; haemostatic;
 KM cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KM DNazyme; inozyme; G-cleaver; amberyzyme; zinzyme; lymphoma; leukaemia;
 KM B-cell lymphoma; non-hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX Homo sapiens.
 OS Synthetic.
 XX MO200159103-A2.
 XX 16-AUG-2001.
 PF 09-FEB-2001; 2001MO-US004273.
 XX 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLAT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 PS Claim 88; Page 92; 2000P; English.
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to

CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a G-cleaver molecule of the invention
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;
 QY Query Match 0.4%; Score 15.4; DB 1; Length 17;
 DB Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1123 CAGCAGCTGACGACGCA 1139
 DB 1 CAGCAGCTGACGACGCA 17
 RESULT 371
 ID ABL46975 standard; RNA; 17 BP.
 XX ABL46975;
 AC 27-JUN-2003 (first entry)
 DT Human GRD zinzyme substrate oligonucleotide #59.
 XX Human; Grb2-related with Insert Domain; GRD; T-cell;
 KM co-stimulatory adaptor protein; tissue rejection; graft rejection;
 KM leukemia; cytostatic; ss.
 XX Homo sapiens.
 OS MO200162911-A2.
 XX 30-AUG-2001.
 PD 23-FEB-2001; 2001MO-US005957.
 PF 24-FEB-2000; 2000US-0184594P.
 PR (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 PI Jarvis T, Von Carlwiltz I, Mcswiggen JA, Hamblin PA, Ellis JH;
 XX WPI; 2001-550088/61.
 XX New nucleic acid(e) for regulating the Grb2-related with Insert Domain
 PT (GRD) gene comprises using antisense and enzymatic nucleic acid
 PT molecules such as hammerhead ribozymes.
 PS Claim 4; Page 72; 108pp; English.
 XX The present invention relates to oligonucleotides that downregulate the
 CC expression of human Grb2-related with Insert Domain (GRD) gene. GRD is
 CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
 CC for modulating the expression of GRD, to treat conditions such as
 CC tissue/graft rejection and leukemia. The oligonucleotides can also be
 CC administered in conjunction with other therapies such as radiation,
 CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
 CC used to illustrate the invention
 XX
 SQ Sequence 17 BP; 5 A; 7 C; 4 G; 0 T; 1 U; 0 Other;
 QY Query Match 0.4%; Score 15.4; DB 1; Length 17;
 DB Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1129 CTCGACGACGACGACGCA 1145
 DB 1 CTCGACGACGACGACGCA 17

D6	I	CUGCAGACGACCACGA	17
RESULT	372		
ABN07810			
ID	ABN07810	standard; DNA,	17 BP.
XX	ABN07810;		
AC			
XX			
DT	29-MAY-2002	(first entry)	
DE	Human GDMLP-1	17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7802.	
KW	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;		
KM	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;		
XX	skeletal muscle disorder; amplicon; screening; ss.		
OS	Homo sapiens.		
XX			
PN	WO200192524-A2.		
PD	06-DEC-2001.		
XX			
PF	25-MAY-2001; 2001WO-US016981.		
XX			
PR	26-MAY-2000; 2000US-0207456P.		
PR	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
PR	04-OCT-2000; 2000GB-00024263.		
PR	30-JAN-2001; 2001WO-US000661.		
PR	30-JAN-2001; 2001WO-US000662.		
PR	30-JAN-2001; 2001WO-US000663.		
PR	30-JAN-2001; 2001WO-US000664.		
PR	30-JAN-2001; 2001WO-US000665.		
PR	30-JAN-2001; 2001WO-US000666.		
PR	30-JAN-2001; 2001WO-US000667.		
PR	30-JAN-2001; 2001WO-US000668.		
PR	30-JAN-2001; 2001WO-US000669.		
PR	30-JAN-2001; 2001WO-US000670.		
PR	05-FEB-2001; 2001US-0268680P.		
XX			
PA	(ABOM-) AEOMICA INC.		
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;		
PT	WPI; 2002-179446/23.		
XX			
DR			
XX			
PS	Disclosure; SEQ ID NO 7802; 214pp; English.		
CC	The present invention describes a human genome-derived myosin-like		
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-		
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1		
CC	nucleic acids can be used as probes to detect, characterise and quantify		
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to		
CC	provide initial substrates for the recombinant engineering of hGDMLP-1		
CC	protein variants having desired phenotypic improvements, and for		
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be		
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP-		
CC	-1 proteins, as standards in assays used to determine the concentration		
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule		
CC	capture probes for surface-enhanced laser desorption/ionisation, as		
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1		
CC	production, and in vaccines or for replacement therapy. The		
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a		
CC	disorder associated with the expression of hGDMLP-1, in particular heart		
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22,		
CC	the present sequence represents an oligomer used in the screening of the		
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.		
CC	The sequence data for this patent did not form part of the printed		

CC	specification, but was obtained in electronic format directly from MIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	
XX	
SQ	Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
OY	Query March 0.4%; Score 15.4; DB 1; Length 17; Beet Local Similarity 94.1%; Pred. No. 2e+02; Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0
Dy	1120 CAGCAGCAGCTGCAGCA 1136 1 CAGCAGCAGCGCTGAAGCA 17
ID	ABK19261 standard; RNA; 17 BP.
RESULT 373	
ABK19261/C	
AC	ABK19261; (first entry)
DT	09-APR-2002
DE	Human ERG Amberzyme target sequence Seq ID No 1908.
XX	
KM	Human; hammerhead ribozyme; cytosolic; ariltumour; antidiabetic;
KM	ophthalmological; antiarthritic; antipsoriatic; viricide; osteopathic;
KM	vulnerable; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KM	tumour angiogenesis; diabetic retinopathy; macular degeneration;
KM	neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KM	angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KM	Sturge Weber syndrome; Kipkel-Trennaway-Weber syndrome; leukaemia; ss;
KM	Osler-Weber-trendu syndrome; Leukaemia; osteoporosis; DNAzyme; Inozyme;
OS	Homo sapiens.
FN	WO200189124-A2.
PD	22-NOV-2001.
PE	16-MAY-2001; 2001WO-US015866.
PR	16-MAY-2000; 2000US-00572021.
PA	(RIBO-) RIBOZYME PHARM INC. (GLAX) GLAXO GROUP LTD.
Pt	Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM; WPI; 2002-082995/11.
PT	Novel polynucleotide which down regulates expression of Ets-related gene, useful for treating cancer, diabetic retinopathy, macular degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber Syndrome.
PS	Claim 4; Page 124; 149pp; English.
CC	The invention relates to a nucleic acid molecule (I) which down regulates expression of an Ets-related gene (ERG). (I) is useful for treating conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma, tumour angiogenesis, diabetic retinopathy, macular degeneration, neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge Weber syndrome, Kipkel-Trennaway-Weber syndrome, Osler-Weber-trendu syndrome, Leukemia, osteoporosis and wound healing. (I) is useful for treating a patient having a condition associated with the level of ERG, by contacting cells of the patient with (I) under conditions suitable for the treatment. The method comprises the use of one or more therapies under conditions suitable for the treatment. Leukemia or tumour angiogenesis is treated by administering (I) to the patient in conjunction with one or more of other therapies such as radiation or chemotherapy treatment. (I) is useful for reducing ERG activity in a cell, by contacting the cell with (I). (I) is useful for cleaving RNA of

CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (II) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention

XX Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3788 CGGGCCACCTCGACGGG 3804
 Db 17 CGGGCCACCTCGTCGGG 1

RESULT 374

ABV89508/c

ID ABV89508 standard; DNA; 17 BP.

XX ABV89508;

DT 23-DEC-2002 (first entry)

XX Human POSHL1 scanning oligonucleotide SEQ ID NO 221.

XX Human: POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;

XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;

XX gene therapy; transgenic; ss.

XX Homo sapiens.

XX EP1239051-A2.

XX 11-SEP-2002.

XX 28-JAN-2002; 2002EP-00001165.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 30-JAN-2001; 2001WO-US000670.

XX 23-MAY-2001; 2001US-00864761.

XX 10-OCT-2001; 2001US-0328205P.

XX (ABOM-) ABOVICA INC.

XX Shannon M;

XX WPI; 2002-684061/74.

XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL

XX -1, useful for treating disorders associated with decreased expression or

XX activity of human POSHL1.

XX Example 2; SEQ ID NO 221; 60bp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling

XX protein 1 (POSHL 1) polypeptide (II), comprising a sequence of 730 amino

XX acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),

XX (SI) having 95% deviations, especially conservative substitutions or a

XX fragment of the sequences comprising at least 8 contiguous amino acids.

XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an

XX adaptor protein that interacts with Rho family small GTPases as well as

CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (II) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office

XX Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1369 CAGCTGAGGAGCAGCG 1385
 Db 17 CACCTGAGGAGCAGCG 1

RESULT 375

ADC37834/c

ID ADC37834 standard; DNA; 17 BP.

XX ADC37834;

DT 18-DEC-2003 (first entry)

XX Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO.183.

XX human; angiomotin-like protein 1; AMLP1; cytoskeletal; gene therapy;

XX AMLP1a; ss.

XX Synthetic.

XX Homo sapiens.

XX WO2003037931-A2.

XX 08-MAY-2003.

XX 01-NOV-2002; 2002WO-US035129.

XX 01-NOV-2001; 2001US-0334773P.

XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX Shannon M, Phan T;

XX WPI; 2003-430501/40.

XX New isolated nucleic acid molecule encoding a human angiomotin-like

XX protein, useful for treating or preventing a disorder associated with

XX decreased or increased expression or activity of AMLP1.

XX Example 2; SEQ ID NO 183; 172pp; English.

XX The present invention describes the human angiomotin-like protein 1

XX (AMLP1). human AMLP1 has cytoskeletal activity, and can be used in gene

XX therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and

XX compositions of the present invention can be used for treating or

XX preventing a disorder associated with decreased or increased expression

XX or activity of AMLP1. The present sequence represents a scanning

XX oligonucleotide for human AMLP1a, which is used in an example from the

XX present invention.

XX Sequence 17 BP; 2 A; 3 C; 11 G; 1 T; 0 U; 0 Other;

XX Query Match 0.4%; Score 15.4; DB 1; Length 17;

XX Best Local Similarity 94.1%; Pred. No. 2e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3428 CCCACCGCCCTCTGCTG 3444
 DB 17 CCCACCGCCCTCTGCTG 1

RESULT 376

AD151314
 ID AD151314 standard; DNA; 17 BP.

XX
 AC AD151314;

XX
 DT 15-APR-2004 (first entry)

XX
 DE Human tumour suppression/reversion-related DNA sequence SegID3817.

XX
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytosolic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX
 OS Homo sapiens.

XX
 PN WO2003025177-A2.

XX
 PD 27-MAR-2003.

XX
 PF 17-SEP-2002; 2002WO-IB004523.

XX
 PR 17-SEP-2001; 2001FR-00011980.

XX
 PA (MOLE-) MOLECULAR ENGINES LAB.

PI Teleman A, Amson R, Tuijnder M;

XX
 DR MPI; 2003-313354/30.

XX
 PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumours and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX
 PS Disclosure; SEQ ID NO 3817; 30bp; French.

XX
 CC This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration, The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct_sequences

XX
 SQ Sequence 17 BP; 8 A; 2 C; 4 G; 3 T; 0 U; 0 Other;

XX
 QY Query Match 0.4%; Score 15.4; DB 1; Length 17;

XX
 Best Local Similarity 94.1%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

XX
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX
 DB 213 GATCAACATGCTGAAAA 229

XX
 1 GATCAACATGCTGAAAA 17

XX
 RESULT 377

ADMS4298
 ID ADMS4298 standard; mRNA; 17 BP.

XX
 AC ADMS4298;

XX
 DT 03-JUN-2004 (first entry)

XX
 DE Human GRID mRNA substrate sequence #608.

XX
 KW Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;

KW NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNzyme; amberyzyme; Inozyme;

XX
 KW hairpin ribozyme; tissue rejection; graft rejection; leukemia.

XX
 OS Homo sapiens.

XX
 PN US2003134806-A1.

XX
 PD 17-JUL-2003.

XX
 PF 23-FEB-2001; 2001US-00792818.

XX
 PR 10-FEB-2000; 2000US-0181594P.

XX
 PA (JARY/) JARYS T.

XX
 PA (CARL/) CARLOWITZ I V.

XX
 PA (MCSW/) MCSWIGGEN J.

XX
 PA (HAMB/) HAMBELIN P A.

XX
 PA (ELLIS/) ELLIS J H.

XX
 PI Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;

XX
 DR MPI; 2003-829646/77.

XX
 PT New nucleic acid molecule that down-regulates expression of Grb2-related

PT with insert domain (GRID) gene, useful for treating a condition

PT associated with the level of GRID, e.g. tissue/graft rejection and

PT leukemia.

XX
 PS Claim 4; SEQ ID NO 608; 74bp; English.

XX
 CC The invention relates to a nucleic acid molecule that down-regulates

CC expression of Grb2-related with insert domain (GRID) gene, e.g. a

CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNzyme,

CC amberyzyme, Inozyme or hairpin ribozyme. Also include are a mammalian cell

CC including the novel nucleic acid molecule, reducing GRID activity in a

CC cell by contacting the cell with the novel nucleic acid molecule,

CC treating a patient having a condition associated with the level of GRID

CC (e.g. tissue/graft rejection or leukemia) by contacting the cell with

CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by

CC contacting the cell with the novel nucleic acid molecule, an expression

CC vector comprising a nucleic acid sequences (encoding at least the novel

CC nucleic acid molecule in a manner that allows its expression), a

CC mammalian cell including the expression vector and an enzymatic nucleic

CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid

CC molecule is useful for treating a condition associated with the level of

CC GRID, e.g. tissue/graft rejection and leukemia. The present sequence is

CC a target region for the enzymatic nucleic acids of the invention.

XX
 SQ Sequence 17 BP; 5 A; 7 C; 4 G; 0 T; 1 U; 0 Other;

XX
 QY Query Match 0.4%; Score 15.4; DB 1; Length 17;

XX
 Best Local Similarity 88.2%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

XX
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

XX
 DB 1129 CTGCAGCAGCAGCAGCA 1145

XX
 1 CTGCAGCAGCAGCAGCA 17

XX
 RESULT 378

XX
 ACN70900

XX
 ID ACN70900 standard; DNA; 17 BP.

AC ACN70900;
 XX
 XX 02-DEC-2004 (first entry)
 DE Human GDMMP-1 probe SEQ ID NO:7802.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMMP-1;
 KM hGDMMP-1 agonist hGDMMP-1 antagonist; hGDMMP inhibitor; heart disorder;
 KM skeletal muscle function.
 XX
 XX Homo sapiens.
 XX US2004137589-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GVYX/) GU Y.
 PA (JYX/) JI Y.
 PA (PENNY) PENN S G.
 PA (HANK/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX
 XX Disclosure; SEQ ID NO 7802; 0pp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (SI) of myosin-like protein-1 (hGDMMP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (SI), 95% deviation from (SI) which are conservative substitutions, and
 CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMMP-1, or as an inhibitor of hGDMMP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMMP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1120 CAGCAGAGCTGACGA 1136

Db 1 CAGCAGAGCTGACGA 17

RESULT 379

AAT93486/c
 ID AAT93486 standard; DNA; 18 BP.

XX
 AC AAT93486;

XX 11-FEB-1998 (first entry)

XX DQA1 allele determining DNA DQA101N strand B.

XX DQA1; DQA101N; histocompatibility locus; allele; resequencing analysis;
 KM flow cytometry; Differentially fluorescent microsphere; DRB; human;
 KM multiplex assay; bead-set; fluorophore; epitope mapping; screening;
 KM therapeutic drug; multiple analyte; gene mutation; PCR primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9714028-A2.

XX 17-APR-1997.

PF 10-OCT-1996; 96WO-US016198.

XX 11-OCT-1995; 95US-00540814.

PR 11-OCT-1995; 95US-00542401.

XX (LUMI-) LUMINEX CORP.

XX Chandler VS, Pulcon RJ, Chandler MB;

XX WPI; 1997-236023/21.

PT Bead-sets for simultaneous assay of multiple analyses by cytometric
 PT analysis - comprise many subsets carrying specific reagent and
 PT identifiable from all other subsets by fluorescence parameters,
 PT especially for clinical assays, and detecting gene mutation.

XX Disclosure; Page 102; 293pp; English.

XX This DNA sequence DQA101N determines DQA1 allele. The alleles specific
 CC for this DNA are 0101, 0102, 0201, 0301. The 8 major alleles of the DQA1
 CC gene are determined by fourteen unique DNA sequences contained within a
 CC 227 bp PCR product. This is used in flow cytometry to perform
 CC resequencing analysis of the PCR products where the presence or absence
 CC of all fourteen DNA sequences can be determined simultaneously in a
 CC single reaction tube containing the mixed bead-set. The system is based
 CC on competitive hybridisation between the PCR product and complementary
 CC oligonucleotide pairs representing the unique DNA sequences. This strand
 CC is coupled to a unique subset of microspheres and the complementary
 CC strand of this oligonucleotide pair is labelled with a green emitting
 CC fluorophore. The fluorescent oligonucleotide and the PCR product are
 CC added to the bead-set containing the microsphere subset and the mixture
 CC is hybridised and analysed by flow cytometry. The other DNA pairs of
 CC sequences are labelled and coupled similarly. The ability of the PCR
 CC product to inhibit the hybridisation of the fluorescent oligonucleotides
 CC to their respective microsphere subset is used to determine the DNA
 CC sequence and the corresponding alleles present in the PCR product. The
 CC flow cytometry method using the novel bead-sets can also be used in
 CC quantitative and qualitative assay of illicit or therapeutic drugs,
 CC nucleic acids, auto antibodies, analytes commonly elevated during pregnancy or
 CC nucleic acids, epitope screening of a monoclonal antibody and for

XX Sequence 18 BP; 1 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1003 CATGAGAGAGAGAGA 1019
 Db 17 CCTGAGAGAGAGAGA 1

RESULT 380
 AAT93485
 AAT93485 standard; DNA; 18 BP.
 AC AAT93485;
 XX
 DT 11-FEB-1998 (first entry)
 XX
 DE DQA1 allele determining DNA DQA4101N strand A.
 XX
 KM DQA1, DQA2501N; histocompatibility locus; allele; resequencing analysis;
 KM flow cytometry; differentially fluorescent microsphere; DPM; human;
 KM multiplex assay; bead-set; fluorophore; epitope mapping; screening;
 KM therapeutic drug; multiple analyte; gene mutation; PCR primer; ss.
 XX
 OS Synthetic.
 XX Homo sapiens.
 XX
 PN MO9714028-A2.
 XX
 PD 17-APR-1997.
 XX
 PF 10-OCT-1996; 96MO-US016198.
 XX
 PR 11-OCT-1995; 95US-00540814.
 PR 11-OCT-1995; 95US-00542401.
 XX
 PA (LUMI-) LUMINEX CORP.
 XX
 PI Chandler VS, Fulcon RJ, Chandler MB;
 XX
 DR WPI; 1997-236023/21.
 XX
 PT Bead-sets for simultaneous assay of multiple analytes by cytometric
 PT analysis - comprise many subsets carrying specific reagent and
 PT identifiable from all other subsets by fluorescence parameters,
 PT especially for clinical assays, and detecting gene mutation.
 XX
 PS Disclosure; Page 102; 293pp; English.
 XX
 CC This DNA sequence DQA2501N determines DQA1 allele. The alleles specific
 CC for this DNA are 0101, 0102, 0201, 0301. The 8 major alleles of the DQA1
 CC gene are determined by fourteen unique DNA sequences contained within a
 CC 227 bp PCR product. This is used in flow cytometry to perform
 CC resequencing analysis of the PCR products where the presence or absence
 CC of all fourteen DNA sequences can be determined simultaneously in a
 CC single reaction tube containing the mixed bead-set. The system is based
 CC on competitive hybridisation between the PCR product and complementary
 CC oligonucleotide pairs representing the unique DNA sequences. This strand
 CC is labelled with a green emitting fluorophore and the complementary
 CC strand of this oligonucleotide pair is coupled to a unique subset of
 CC microspheres. This fluorescent oligonucleotide and the PCR product are
 CC added to the bead-set containing the microsphere subset and the mixture
 CC is hybridised and analysed by flow cytometry. The other DNA pairs of
 CC sequences are labelled and coupled similarly. The ability of the PCR
 CC product to inhibit the hybridisation of the fluorescent oligonucleotides
 CC to their respective microsphere subset is used to determine the DNA
 CC sequence and the corresponding alleles present in the PCR product. The
 CC flow cytometry method using the novel bead-sets can also be used in
 CC quantitative and qualitative assay of illicit or therapeutic drugs,
 CC antigens, auto antibodies, analytes commonly elevated during pregnancy or
 CC nucleic acids, epitope screening of a monoclonal antibody and for
 CC detecting specific gene mutations
 XX
 SQ Sequence 18 BP; 7 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1003 CATGAGAGAGAGAGA 1019
 Db 2 CCTGAGAGAGAGAGA 18

RESULT 381
 AAX90265/c
 ID AAX90265 standard; DNA; 18 BP.
 XX
 AC AAX90265;
 XX
 DT 27-SEP-1999 (first entry)
 XX
 DE DQA1 gene PCR primer DQA4101N B strand.
 XX
 KM Monoclonal antibody; epitope; multiplexed analysis; diagnosis;
 KM genetic analysis; flow cytometry; human myelin basic protein; MBP;
 KM microbial antigen; viral antigen; pathological condition; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 PN MO936564-A1.
 XX
 PD 22-JUL-1999.
 XX
 PF 15-JAN-1999; 99MO-US000918.
 XX
 PR 16-JAN-1998; 98US-00008387.
 XX
 PA (LUMI-) LUMINEX CORP.
 XX
 PI Chandler VS, Fulcon JR, Chandler MB;
 XX
 DR WPI; 1999-444409/37.
 XX
 PT Beadset for simultaneous detection of many analytes by flow cytometry,
 PT e.g. for detecting antigens, antibodies, or nucleic acid mutations.
 XX
 PS Example; Page 102; 301pp; English.
 XX
 CC The present invention describes a beadset (A), able to detect many
 CC analytes (1) in a single sample by flow cytometry (FC). (A) is produced
 CC by: (i) providing many subsets of beads which, within each subset, are
 CC homogeneous as regards at least 3 selected class parameters (C) but
 CC sufficiently different in at least one C from beads in FC; (ii) coupling
 CC to provide a profile of C values unique for each subset in FC; (iii) coupling
 CC the beads in each subset with a reactant (R), specific for a given (1)
 CC and (iii) mixing the subsets to form an (A) in which subsets (and thus
 CC bound R) are identifiable in FC from the unique profile of C. A method of
 CC flow cytometry analysis using (A) is used to detect a very wide range of
 CC (1), e.g. microbial or viral antigens (particularly from pathogens that
 CC cause venereal, pulmonary or gastrointestinal disease); therapeutic or
 CC illicit drugs; antigens or antibodies associated with particular
 CC pathological conditions (malignancy, allergy, autoimmune disease, blood-
 CC borne viruses or cardiovascular disease); hormones, including those
 CC indicative of pregnancy; enzymes; immunoglobulins (Ig), particularly of
 CC different (sub)classes; Ig that form part of a particular epitope
 CC (specifically an epitope of human immune deficiency virus) or nucleic
 CC acids (particularly for detecting a wide variety of mutations, e.g. those
 CC present in the ret proto-oncogene, the low density lipoprotein receptor,
 CC the Duchenne muscular dystrophy, angiotensin p53, and Rb genes. The
 CC process is particularly used for diagnosis of disease and for genetic
 CC analysis. The present sequence represents a DQA gene PCR primer used in
 CC the exemplification of the present invention
 XX
 SQ Sequence 18 BP; 1 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1003 CATGAGAGGAGGAGA 1019
 | |||||
 DB 17 CCTGAGAGGAGGAGCA 1

RESULT 382

ID AAX90264 standard; DNA; 18 BP.
 AAX90264;

AC AAX90264;
 DT 27-SEP-1999 (first entry)

DE DQA1 gene PCR primer DQA101N A strand.

KW Monoclonal antibody; epitope; multiplexed analysis; diagnosis;
 KW genetic analysis; flow cytometry; human myelin basic protein; MBP;
 KW microbial antigen; viral antigen; pathological condition; PCR primer; ss.

OS Synthetic.

PN W0936564-A1.

PD 22-JUL-1999.

PF 15-JAN-1999; 99MO-US000918.

PR 16-JAN-1998; 98US-00008387.

PA (LUMI-) LUMINEX CORP.

PI Chandler VS, Fulcon JR, Chandler MB,

DR WPI, 1999-444409/37.

PT Beadset for simultaneous detection of many analytes by flow cytometry,
 e.g. for detecting antigens, antibodies, or nucleic acid mutations.

PS Example; Page 102; 301pp; English.

XX The present invention describes a beadset (A), able to detect many
 CC analytes (I) in a single sample by flow cytometry (FC). (A) is produced
 CC by: (i) providing many subsets of beads which, within each subset, are
 CC homogeneous as regards at least 3 selected class parameters (C) but
 CC sufficiently different in at least one C from beads in other subsets to
 CC provide a profile of C values unique for each subset in FC; (ii) coupling
 CC the beads in each subset with a reactant (R), specific for a given (I)
 CC and (iii) mixing the subsets to form an (A) in which subsets (and thus
 CC bound R) are identifiable in FC from the unique profile of C. A method of
 CC flow cytometry analysis using (A) is used to detect a very wide range of
 CC (I), e.g. microbial or viral antigens (particularly from pathogens that
 CC cause venereal, pulmonary or gastrointestinal disease); therapeutic or
 CC illicit drugs; antigens or antibodies associated with particular
 CC pathological conditions (malignancy, allergy, autoimmune disease, blood-
 CC borne viruses or cardiovascular disease); hormones, including those
 CC indicative of pregnancy; enzymes; immunoglobulins (Ig), particularly of
 CC different (sub)classes; Ig that form part of a particular epitope
 CC (specifically an epitope of human immune deficiency virus) or nucleic
 CC acids (particularly for detecting a wide variety of mutations, e.g. those
 CC present in the ret proto-oncogene, the low density lipoprotein receptor,
 CC the Duchenne muscular dystrophy, angiotensin p53, and Rb genes. The
 CC process is particularly used for diagnosis of disease and for genetic
 CC analysis. The present sequence represents a DQA gene PCR primer used in
 CC the exemplification of the present invention

XX Sequence 18 BP; 7 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1003 CATGAGAGGAGGAGA 1019
 | |||||

DB 2 CCTGAGAGGAGGAGCA 18

RESULT 383

ID AAH19623 standard; DNA; 18 BP.

AC AAH19623;

DT 31-JUL-2001 (first entry)

DE Oligonucleotide containing a mixture of CAG/CNA codons.

KW Polyglutamine region; polypeptide aggregation; aggregation disruption;
 KW Huntington's disease; Alzheimer's disease; Parkinson's disease;
 KW spinocerebellar ataxia; multiple myeloma; amyloidosis; anticonvulsant;
 KW spongiform encephalopathy; neuroprotective; nootropic; antiparkinsonian;
 KW ss.

OS Synthetic.

PN W0200123412-A2.

PD 05-APR-2001.

PF 27-SEP-2000; 2000MO-US041008.

PR 27-SEP-1999; 99US-00405048.

PA (MASI) MASSACHUSETTS INST TECHNOLOGY.

PI Housman DE, Preisinger EA, Kazantsev AG;

DR WPI, 2001-300097/31.

PT Screening for agents which disrupt aggregation of polypeptides for
 treating aggregation-associated disorders e.g. Alzheimer's disease, by
 PT using aggregation-disposed polypeptides or cell expressing the
 PT polypeptides.

PS Example 1; Page 25; 42pp; English.

XX The present sequence was used to generate a polypeptide with extended
 CC polyglutamine regions. This was performed in an example illustrating a
 CC method for identifying a compound which disrupts polypeptide aggregation.
 CC The method is carried out using a cell which has been genetically
 CC modified to express aggregation-disposed polypeptides, or using purified
 CC aggregation-disposed polypeptides. The compounds identified by this
 CC method are useful for treating disorders associated with such polypeptide
 CC aggregation, including Huntington's disease, Alzheimer's disease,
 CC Parkinson's disease, spinocerebellar ataxia, multiple myeloma,
 CC amyloidosis, and spongiform encephalopathies like Creutzfeldt-Jakob
 CC disease and kuru in humans. The present sequence was annealed to its
 CC complement to generate double stranded duplex DNA with trinucleotide
 CC extensions

XX Sequence 18 BP; 9 A; 6 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAGCA 1460
 | |||||
 DB 1 CAACAGCAGCAGCA 17

RESULT 384

AAH19624/C
 ID AAH19624 standard; DNA; 18 BP.

AC AAH19624;

DT 31-JUL-2001 (first entry)
 XX Complementary oligo of sequence containing a mixture of CAG/CAA codons.
 DE
 XX
 XX Polyglutamine region; polypeptide aggregation; aggregation disruption;
 KW Huntington's disease; Alzheimer's disease; Parkinson's disease;
 KW spinocerebellar ataxia; multiple myeloma; amyloidosis; anticonvulsant;
 KW spongiform encephalopathy; neuroprotective; nootropic; antiparkinsonian;
 KW ss.
 XX
 XX Synthetic.
 OS
 XX
 XX WO200123412-A2.
 PN
 PD 05-APR-2001.
 XX
 XX 27-SEP-2000; 2000WO-US041008.
 PF
 XX 27-SEP-1999; 99US-00405048.
 PR
 XX (MASI) MASSACHUSETTS INST TECHNOLOGY.
 PA
 XX Houseman DE, Preisinger EA, Kazantsev AG;
 PI WPI, 2001-300097/31.
 DR
 XX
 XX Screening for agents which disrupt aggregation of polypeptides for
 PT treating aggregation-associated disorders e.g. Alzheimer's disease, by
 PT using aggregation-disposed polypeptides or cell expressing the
 PT polypeptides.
 PS
 XX Example 1; Page 25; 42pp; English.
 XX
 XX The present sequence was used to generate a polypeptide with extended
 CC polyglutamine regions. This was performed in an example illustrating a
 CC method for identifying a compound which disrupts polypeptide aggregation.
 CC The method is carried out using a cell which has been genetically
 CC modified to express aggregation-disposed polypeptides, or using purified
 CC aggregation-disposed polypeptides. The compounds identified by this
 CC method are useful for treating disorders associated with such polypeptide
 CC aggregation, including Huntington's disease, Alzheimer's disease,
 CC Parkinson's disease, spinocerebellar ataxia, multiple myeloma,
 CC amyloidosis, and spongiform encephalopathies like Creutzfeldt-Jakob
 CC disease and kuru in humans. The present sequence was annealed to its
 CC complement to generate double stranded duplex DNA with trinucleotide
 CC extensions
 CC
 SQ Sequence 18 BP; 0 A; 3 C; 6 G; 9 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1447 CAGCAGCAGCAGCAGCA 1463
 DB 18 CAGCAGCAGCAGCAGCA 2
 RESULT 395
 AAH76247/c
 ID AAH76247 standard; DNA; 18 BP.
 AC
 XX AAH76247;
 XX
 DT 29-OCT-2001 (first entry)
 DE Human macrophage inflammatory protein-2-alpha primer MIP2alpha-F.
 XX
 XX Pyrene; gene therapy; antiinflammatory; gene expression; interleukin;
 KW hemoxygenase-1; prostaglandin G/H synthase-2; RANTES; TNF alpha; p78;
 KW macrophage inflammatory protein; chemokine; growth regulated protein-1;
 KW matrix metalloproteinase-9; migration inhibitory factor-related protein;
 KW lysozyme; GABA(A) receptor-associated protein; interferon; SCO homolog-2;

KW transketolase; adenosine A2a receptor; CD37 antigen prepeptid P factor;
 KW G-protein; Netf-associated factor-1; signal peptidase; PCR primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200151480-A1.
 PN
 PD 19-JUL-2001.
 XX
 XX 11-JAN-2001; 2001WO-JP000082.
 PF
 XX
 XX 13-JAN-2000; 2000JP-00004989.
 PR
 XX 03-OCT-2000; 2000JP-00303711.
 XX
 XX (TAKI) TAKARA SHUZO CO LTD.
 PA
 XX
 XX Enoki T, Yamashita S, Nishimura K, Sagawa H, Kato I;
 PI WPI, 2001-514436/56.
 DR
 XX
 XX Agent for correcting gene expression regulation error comprises pyrene
 PT compound or dihydroxy compound.
 PT
 XX
 XX Example 6; Page 72; 93pp; Japanese.
 PS
 XX
 XX The invention provides an agent comprising a pyrene compound or dihydroxy
 CC compound of specified formulae given in the specification. The agent is
 CC used for correcting gene expression regulation errors. Errors in the
 CC following genes may be corrected: IL-6, IL-10, hemoxygenase-1,
 CC prostaglandin G/H synthase-2, macrophage inflammatory protein-1-alpha,
 CC RANTES, IL-1alpha, IL-1beta, TNF alpha, IL-7 receptor, macrophage
 CC inflammatory protein -1beta, liver and activation-regulated chemokine,
 CC macrophage-derived chemokine, macrophage inflammatory protein-2-beta,
 CC matrix metalloproteinase-9, migration inhibitory factor-related protein -
 CC 8, lysozyme, GABA(A) receptor-associated protein, interferon-induced 17 -
 CC kDa/15-kDa protein, interferon-inducible protein p78, SCO homolog-2,
 CC transketolase, adenosine A2a receptor, CD37 antigen prepeptid P factor,
 CC regulator of G-protein signaling-2, Netf-associated factor-1, myeloid
 CC leukemia cell differentiation protein-1, signal peptidase complex, and
 CC also side-effects caused by them such as inflammation. Sequences AAH76220
 CC -76280 represent PCR primers used in the course of the invention
 CC
 XX
 SQ Sequence 18 BP; 0 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1270 CAGCAGCAGCAGCAGCA 1286
 DB 17 CAGCAGCAGCAGCAGCA 1
 RESULT 386
 ABS97881
 ID ABS97881 standard; DNA; 18 BP.
 AC
 XX ABS97881;
 XX
 DT 23-DEC-2002 (first entry)
 DE Human UDP-glucuronosyl transferase 2A6 gene sequencing primer #10.
 XX
 XX Human; ss; primer; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR117;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; BPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermostable; STM;

KM UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KM UGT2B7; UDP-glucuronosyl transferase; UGT2B15; uridine kinase receptor; uRA;
 KM multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KM multidrug resistance associated protein 3; cancer; prostate;
 KM acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KM altered drug metabolism; cardiovascular function; colorectal tumour;
 KM central nervous system; pulmonary; immunological; sequencing.

XX Homo sapiens.
 OS
 PN WO200257410-A2.

XX 25-JUL-2002.

XX 28-NOV-2001; 2001WO-US044838.

XX 28-NOV-2000; 2000US-00724389.

XX (DNAS-) DNA SCI LAB INC.

XX Guida M, Hall J;

XX WPI; 2002-698522/75.

PT Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome p450 and catepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.

PS Example 18; Page 133; 714pp; English.

CC This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
 CC cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADBR1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), catepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glucathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HNMT), (Kallikrein 2) KLK2, nicotinamide-N-methyl
 CC sulfoltransferase thiolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), uridine kinase receptor (uRA), multidrug resistance 1
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterizing the genes that
 CC are responsible for specific traits within the genome and eventually
 CC identifying the genes responsible for a variety of disorder-related
 CC traits as a result of their e.g., overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorder. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502B1, AHR,
 CC ARNT, EPHX2, GST12, HNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HNMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a
 CC sequencing primer used to sequence the polymorphic genes of the invention
 XX
 SQ Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3827 AGAGGCTCAAGTCCG 3843
 DB 2 AGAGGCTCAAGTCCG 18

RESULT 387

ABA93493
 ID ABA93493 standard; DNA; 18 BP.

XX ABA93493;

AC 25-APR-2002 (first entry)

XX GAGA-B receptor 1a (gb1a) antisense oligonucleotide.

XX Identification; gamma-amino-butyric acid; GABA; GABA-B receptor;
 KM gamma-amino-butyric acid B receptor; epilepsy; pain syndrome;
 KM antisense oligonucleotide; ss.

XX Homo sapiens.

OS Synthetic.

PN WO200198779-A2.

XX 27-DEC-2001.

XX 19-JUN-2001; 2001WO-CA000909.

XX 19-JUN-2000; 2000US-0212426P.

PR 24-APR-2001; 2001US-0285969P.

XX (MERI) MERCK FROST CANADA & CO.

XX Ng G;

XX WPI; 2002-062650/08.

PT Identifying agonists of GABA(B) receptors, useful for treating epilepsy
 PT and certain pain syndromes, comprises determining that the substance is
 PT not an agonist of GABA(B) receptors with gb-1b or gb-1c subunits.

PS Example 7; Page 79; 142pp; English.

XX The present invention describes a method for identifying gb-1a subtype-
 CC specific agonists of the gamma-amino-butyric acid B (GABA-B) receptor,
 CC comprising determining the substance is an agonist of GABA-B receptors
 CC with a gb-1a subunit, and is not an agonist of GABA-B receptors
 CC comprising gb-1b or gb-1c subunits. The method can be used for
 CC identifying agonists of GABA-B receptors which are heteromers of gb-1a
 CC and gb2 subunits. The substances are useful for treating conditions such
 CC as epilepsy, and pain syndromes. The method identifies substances that
 CC are not agonists of GABA-A receptors, which exhibit more selectivity for
 CC effector pathways and distinct mechanisms of action compared to other
 CC compounds such as baclofen. The present sequence represents a GAGA-B
 CC receptor 1a (gb1a) antisense oligonucleotide, which is used in an example
 CC from the present invention
 XX

SQ Sequence 18 BP; 6 A; 7 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1475 AACAGCAGCAGCAGCAG 1491
 DB 2 ACCAGCAGCAGCAGCAG 18

RESULT 388
 ABK1198
 ID ABK1198 standard; DNA; 18 BP.

XX ABK1198;
AC
XX
XX 05-JUN-2002 (first entry)
DT
XX
XX Oligonucleotide #1 used to generate DNA with trinucleotide extensions.
DE
XX
XX Inhibition of protein-protein interaction; Alzheimer's disease;
KW
KW polyglutamine-containing transcription factor; hexamerisation of p53;
KW homodimerisation of jun; expanded trinucleotide repeat; CAG repeat;
KW Huntington's disease; HD; primate and bulbar muscular atrophy; SBMA;
KW dentatorubral-pallidoluysian atrophy; spinocerebellar ataxia type 1;
KW spinocerebellar ataxia type 2; spinocerebellar ataxia type 6;
KW spinocerebellar ataxia type 7; Machado-Joseph disease; MJD/SCA3;
KW neurotrophic; anticonvulsant; cerebroprotective; neuroprotective; ss.
XX
XX Synthetic.
OS
XX
XX WO200216644-A1.
PN
XX
XX 28-FEB-2002.
PD
XX
XX 20-AUG-2001; 2001WO-US026097.
PF
XX
XX 18-AUG-2000; 2000US-0226502P.
PR
XX
XX (MASI) MASSACHUSETTS INST TECHNOLOGY.
PA
XX
XX Kazantsev A, Thompson L, Housman DE;
PI
XX
XX WPI, 2002-280948/32.
DR
XX
XX Novel agent for inhibiting protein-protein interaction useful to treat
PT Alzheimer's disease, has two domains which bind first, second proteins
PT with seven consecutive glutamine residues and a domain separating two
PT domains.
XX
XX
XX Disclosure; Page 8; 40pp; English.
PS
XX
XX The present invention relates to therapeutic agents comprising a first
CC domain (D1) that binds a protein having at least seven consecutive
CC glutamine (Glu) residues, a second domain (D2) that binds another protein
CC having at least 7 consecutive Glu residues, and a third domain (D3) that
CC separates D1 from D2. The therapeutic agents of the invention are useful
CC for inhibiting protein-protein interactions (e.g. aggregation,
CC dimerisation or other physiologically significant association), and can
CC be used for treating Alzheimer's disease, and disorders in which
CC polyglutamine-containing transcription factors or coactivators are
CC desirably active (e.g. disorders associated with homodimerisation of jun
CC or hexamerisation of p53. The therapeutic agents can also be used to
CC treat various disorders, including those associated with expanded
CC trinucleotide (CAG) repeats. For example such disorders can include
CC Huntington's disease (HD), primate and bulbar muscular atrophy (SBMA),
CC dentatorubral-pallidoluysian atrophy, spinocerebellar ataxia type 1, type
CC 2, type 6 or type 7, or Machado-Joseph disease (MJD/SCA3). The present
CC sequence represents an oligonucleotide used to generate double stranded
CC DNA with trinucleotide extensions
XX
XX
SQ Sequence 18 BP; 9 A; 6 C; 3 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAGCAGCA 1460
DB 1 CAGCAGCAGCAGCAGCA 17

RESULT 389
ABK1199/C
ID ABK1199 standard; DNA; 18 BP.
XX

AC ABK1199;
XX
XX
XX 05-JUN-2002 (first entry)
DT
XX
XX Oligonucleotide #2 used to generate DNA with trinucleotide extensions.
DE
XX
XX Inhibition of protein-protein interaction; Alzheimer's disease;
KW
KW polyglutamine-containing transcription factor; hexamerisation of p53;
KW homodimerisation of jun; expanded trinucleotide repeat; CAG repeat;
KW Huntington's disease; HD; primate and bulbar muscular atrophy; SBMA;
KW dentatorubral-pallidoluysian atrophy; spinocerebellar ataxia type 1;
KW spinocerebellar ataxia type 2; spinocerebellar ataxia type 6;
KW spinocerebellar ataxia type 7; Machado-Joseph disease; MJD/SCA3;
KW neurotrophic; anticonvulsant; cerebroprotective; neuroprotective; ss.
XX
XX Synthetic.
OS
XX
XX WO200216644-A1.
PN
XX
XX 28-FEB-2002.
PD
XX
XX 20-AUG-2001; 2001WO-US026097.
PF
XX
XX 18-AUG-2000; 2000US-0226502P.
PR
XX
XX (MASI) MASSACHUSETTS INST TECHNOLOGY.
PA
XX
XX Kazantsev A, Thompson L, Housman DE;
PI
XX
XX WPI, 2002-280948/32.
DR
XX
XX Novel agent for inhibiting protein-protein interaction useful to treat
PT Alzheimer's disease, has two domains which bind first, second proteins
PT with seven consecutive glutamine residues and a domain separating two
PT domains.
XX
XX
XX Disclosure; Page 8; 40pp; English.
PS
XX
XX The present invention relates to therapeutic agents comprising a first
CC domain (D1) that binds a protein having at least seven consecutive
CC glutamine (Glu) residues, a second domain (D2) that binds another protein
CC having at least 7 consecutive Glu residues, and a third domain (D3) that
CC separates D1 from D2. The therapeutic agents of the invention are useful
CC for inhibiting protein-protein interactions (e.g. aggregation,
CC dimerisation or other physiologically significant association), and can
CC be used for treating Alzheimer's disease, and disorders in which
CC polyglutamine-containing transcription factors or coactivators are
CC desirably active (e.g. disorders associated with homodimerisation of jun
CC or hexamerisation of p53. The therapeutic agents can also be used to
CC treat various disorders, including those associated with expanded
CC trinucleotide (CAG) repeats. For example such disorders can include
CC Huntington's disease (HD), primate and bulbar muscular atrophy (SBMA),
CC dentatorubral-pallidoluysian atrophy, spinocerebellar ataxia type 1, type
CC 2, type 6 or type 7, or Machado-Joseph disease (MJD/SCA3). The present
CC sequence represents an oligonucleotide used to generate double stranded
CC DNA with trinucleotide extensions
XX
XX
SQ Sequence 18 BP; 0 A; 3 C; 6 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAGCAGCAGCA 1463
DB 18 CAGCAGCAGCAGCAGCA 2

RESULT 390
AAD36191
ID AAD36191 standard; DNA; 18 BP.
AC AAD36191;
XX

XX 09-AUG-2002 (first entry)
 DT Human Smad6 antisense oligonucleotide, ISIS #28559.
 XX
 DE Human Smad6 protein; antisense; cardiovascular disease; infection;
 KM inflammation; cancer; therapy; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT 1. .18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = Phosphorothioate backbone"
 FT 1. .4
 FT /*tag= b
 FT /note= "2'methoxyethyl nucleotides"
 FT 2
 FT /*tag= d
 FT /mod_base= m5c
 FT 4. .5
 FT /*tag= e
 FT /mod_base= m5c
 FT 8
 FT /*tag= f
 FT /mod_base= m5c
 FT 11
 FT /*tag= g
 FT /mod_base= m5c
 FT 14
 FT /*tag= h
 FT /mod_base= m5c
 FT 15. .18
 FT /*tag= c
 FT /note= "2'methoxyethyl nucleotides"
 FT 17.18
 FT /*tag= i
 FT /mod_base= m5c
 FT
 FT
 PN WO200228878-A1.
 XX
 XX 11-APR-2002.
 PD
 XX
 PF 01-OCT-2001; 2001WO-US030645.
 XX
 PF 04-OCT-2000; 2000US-00679298.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Cowseert LM;
 XX
 DR WPI; 2002-394345/42.
 XX
 XX Oligonucleotides, useful for the modulation of Smad6 expression in the
 PT treatment or prophylaxis of e.g. cardiovascular disease, are targeted to
 PT nucleic acid molecule encoding Smad6.
 CC
 XX
 PS Example 16; Page 90; 110pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeted to a
 CC nucleic acid molecule encoding human Smad6 protein, which specifically
 CC hybridizes with the nucleic acid and inhibits its expression. Antisense
 CC compounds of the invention are used for inhibiting the expression of
 CC Smad6 in cells and tissues in the treatment of a disease or condition
 CC associated with Smad6 such as cardiovascular disease, cancer, infection
 CC and inflammation. They are also useful in the diagnostics, as research
 CC reagents, in kits and in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targeted to human Smad6
 XX
 SO Sequence 18 BP; 4 A; 8 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1128 GCTGCAGCAGCAGCAGC 1144
 DB 1 GCTGCAGCAGCAGCAGC 17
 RESULT 391
 AB281759
 ID AB281759 standard; DNA; 18 BP.
 XX
 AC AB281759;
 XX
 DT 11-JUN-2003 (first entry)
 XX
 DE Huntington's disease exon 1 triplet repeat sequence.
 XX
 KM Huntington's disease; noctropic; anticonvulsant; huntingtin; human;
 KM gene therapy; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003013437-A2.
 XX
 PD 20-FEB-2003.
 XX
 PF 07-AUG-2002; 2002WO-US025352.
 XX
 PR 07-AUG-2001; 2001US-0310757P.
 PR 08-AUG-2001; 2001US-0310770P.
 PR 08-AUG-2001; 2001US-0310889P.
 PR 04-DEC-2001; 2001US-0337219P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kniec EB, Parekh-Olmedo H;
 XX
 DR WPI; 2003-256478/25.
 XX
 XX New single stranded oligonucleotides comprising a DNA domain having at
 PT least one mismatch with respect to the genetic sequence of the
 PT Huntington's disease gene to be altered, useful for treating or
 PT preventing Huntington's disease.
 XX
 PS Example 5; Page 72; 133pp; English.
 XX
 CC The present sequence is an example of a poly-glutamine triplet repeat
 CC region found in exon 1 of the Huntington's disease (HD) gene. In an
 CC example from the invention, neuronal PC12 cells were engineered to
 CC include an HD gene exon 1 containing this sequence. These cells were used
 CC to demonstrate the ability of single-stranded chemically-modified
 CC oligonucleotides (see AB281747-51) to decrease the formation of
 CC Huntington's protein (huntingtin) aggregates in cell culture. The
 CC invention provides chemically modified oligonucleotides that target
 CC sequence alterations to the triplet repeat region of the HD gene exon 1
 CC and/or which reduce the formation of huntingtin protein-containing
 CC aggregates. These are useful for the treatment or prevention of HD
 CC
 SO Sequence 18 BP; 9 A; 6 C; 3 G; 0 T; 0 U; 0 Other;
 QY Query Match 0.4%; Score 15.4; DB 1; Length 18;
 DB Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1444 CAGCAGCAGCAGCAGCA 1460
 DB 1 CAGCAGCAGCAGCAGCA 17
 RESULT 392
 ACC46880/c

```

ID ACC46880 standard; DNA; 18 BP.
XX
XX ACC46880;
XX
AC AC46880;
XX
XX 05-JUN-2003 (first entry)
XX
XX Human COPD related gene forward PCR primer SEQ ID NO:159.
XX
XX Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;
XX PCR primer; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200297127-A2.
XX
XX 05-DEC-2002.
XX
XX 28-MAY-2002; 2002WO-EP05835.
XX
XX 31-MAY-2001; 2001GB-00013266.
XX
XX (PARB ) BAYER AG.
XX
XX Oellers N, Gehrmann M, Kallabis H, Hall R, Schulze T, Kroegel C;
XX WPI; 2003-140492/13.
XX
XX Predicting, diagnosing or prognosing chronic lung disease, by detecting a
XX chronic obstructive pulmonary disease (COPD) gene in a biological sample.
XX
XX Example 1; Page 213; 214pp; English.
XX
XX The present invention describes a method for predicting, diagnosing or
XX prognosing chronic lung disease by detecting a chronic obstructive
XX pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to
XX ACC46777, which encode the COPD related proteins in ABP96779 to
XX ABP96806). The method is useful for predicting, diagnosing or prognosing
XX chronic lung disease in a biological sample. The COPD genes and proteins
XX encoded by them from the present invention (I) can be used for treating
XX or preventing chronic lung disease in a mammal. (I) can be used in an
XX animal model for determining the efficacy, toxicity, or side effects of
XX treatment with (I), and determining the mechanism of action of (I).
XX ACC46778 to ACC46903 represent COPD related PCR primers and probes used
XX in an example from the present invention
XX
XX Sequence 18 BP; 0 A; 7 C; 5 G; 6 T; 0 U; 0 Other:
XX
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1270 CAGGAGAGGAGGAGCA 1286
DB 17 CAGGAGAGGAGGAGCA 1

```

RESULT 393

```

ADK67650
ID ADK67650 standard; DNA; 18 BP.
XX
XX ADK67650;
XX
XX 06-MAY-2004 (first entry)
XX
XX Huntingcon's disease gene exon 1 DNA fragment.
XX
XX Huntingcon's disease; huntingtin; protein aggregation; gene therapy;
XX human; ds.
XX
XX Homo sapiens.
XX
XX WO2004014306-A2.
XX

```

```

XX
XX 19-FEB-2004.
XX
XX 07-AUG-2003; 2003WO-US024868.
XX
XX 07-AUG-2002; 2002US-0402196P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Parekh-Olmedo H;
XX WPI; 2004-180536/17.
XX
XX Identifying the oligonucleotide species that disrupts aggregation of a
XX protein aggregate in a cell by introducing the oligonucleotide species or
XX composition separately into cells that have or are likely to develop
XX aggregation.
XX
XX Example 1; Page 26; 59pp; English.
XX
XX The present sequence is that of a fragment of exon 1 of the Huntingcon's
XX disease (HD) gene comprising alternating repeating codons for Gln. A
XX fusion gene comprising HD gene exon 1 and an enhanced green fluorescent
XX protein gene was used in examples from the invention investigating the
XX ability of different oligonucleotides to reduce protein aggregation in
XX PC12 cells containing integrated copies of the fusion gene. The invention
XX is based on the discovery that oligonucleotides unrelated in sequence to
XX that of a nucleic acid which encodes a protein aggregate can be effective
XX in disrupting or preventing aggregation in disorders of protein assembly.
XX A claimed method for identifying, from a plurality of oligonucleotide
XX species differing in sequence and/or composition, those oligonucleotide species
XX that disrupt aggregation of a protein aggregate in a cell, comprises
XX introducing the oligonucleotides separately into cells that have or are
XX likely to develop protein aggregates, and identifying those that are
XX effective at preventing, reducing or disrupting aggregation. The
XX oligonucleotides are useful for treating a disorder of protein assembly
XX such as HD, Alzheimer's disease, cystic fibrosis, amyotrophic lateral
XX sclerosis, Parkinson's disease, spinobulbar muscular atrophy,
XX spinocerebellar ataxia types 1, 2, 3, 6 and 7, dentatorubral-
XX pallidolysian atrophy, prion diseases, scrapie, bovine spongiform
XX encephalopathy, Creutzfeldt-Jacob disease, new variant CJD, Pick's
XX disease, diabetes type II, multiple myeloma-plasma cell dyscrasia,
XX medullary carcinoma of the thyroid, chronic renal failure, congestive
XX heart failure, chronic inflammation, atherosclerosis (apoB1) or familial
XX amyloidosis.
XX
XX Sequence 18 BP; 9 A; 6 C; 3 G; 0 T; 0 U; 0 Other:
XX
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1444 CAGCAGCAGCAACAGCA 1460
DB 1 CAGCAGCAGCAACAGCA 17

```

RESULT 394

```

ADK52169
ID ADK52169 standard; DNA; 18 BP.
XX
XX ADK52169;
XX
XX 20-MAY-2004 (first entry)
XX
XX Primer #4 of the invention.
XX
XX spider silk; artificial tendons; wound-closure system;
XX hemostatic dressing; bulletproof vest; lightweight body armour; ss;
XX primer.
XX
XX Synthetic.
XX

```

PN WO2004016651-A2.
XX
PD 26-FEB-2004.
XX
PF 15-AUG-2003; 2003WO-GB003578.
XX
PR 15-AUG-2002; 2002GB-00018977.
XX
PA (UYYO-) UNIV YORK.
XX
PI McQueen Mason S, Pouchkina N;
XX WPI; 2004-257184/24.
XX
XX New nucleic acid molecules for producing spider (i.e. Euprocthenops
PT spider) silk polypeptides useful in the manufacture of medical or
PT industrial materials, e.g. artificial tendons/ligaments, sutures,
PT bulletproof vests or ropes.
XX
PS Disclosure; SEQ ID NO 4; 24pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a spider silk polypeptide. The composition and methods are
CC useful for producing spider silk polypeptides. The silk polypeptide is
CC used in manufacturing materials for medical and industrial applications,
CC such as artificial tendons/ligaments, wound-closure systems such as
CC vascular wound repair devices, hemostatic dressings, patches, glues and
CC sutures, bulletproof vests, lightweight body armour, cables, ropes and
CC parachute cords, and even fishing lines. The present sequence represents
CC a primer of the invention.
XX
SQ Sequence 18 BP; 3 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1128 GCTGCAGCAGCAGC 1144
Db 1 GCTGCCGACGACGACG 17
XX
RESULT 395
ADN97298
ID ADN97298 standard; DNA; 18 BP.
XX
AC ADN97298;
XX
DT 01-JUL-2004 (first entry)
XX
DE Primer of the invention #88.
XX
XX DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KM forensic identification; marijuana; primer; ss.
XX
OS Synthetic.
XX
PN WO2004008841-A2.
XX
PD 29-JAN-2004.
XX
PF 21-JUL-2003; 2003WO-US022887.
XX
PR 19-JUL-2002; 2002US-0397179P.
XX
PA (UYAR-) UNIV ARIZONA.
XX (KEIM/) KEIM P S.
PA (ZINN/) ZINNAMON K.
XX
PI Keim PS, Zinnamon K;
XX WPI; 2004-143139/14.
XX

PT New isolated nucleic acid for amplification of a short tandem repeat
PT located in DNA isolated from Cannabis sativa L species, useful for
PT forensic identification of marijuana or for linking a marijuana sample to
PT its plant source.
XX
PS Disclosure; SEQ ID NO 165; 79pp; English.
XX
XX The present invention relates to DNA fingerprinting for Cannabis Sativa
CC using short tandem repeat markers. The nucleic acid is useful for
CC forensic identification of marijuana or for linking a marijuana sample to
CC its plant source. The present sequence represents a primer of the
CC invention.
XX
SQ Sequence 18 BP; 6 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1131 GCAGCAGCAGCAGC 1147
Db 2 GCAGCAGCAGCAGCAGC 18
XX
RESULT 396
AAZ10259
ID AAZ10259 standard; DNA; 19 BP.
XX
AC AAZ10259;
XX
DT 01-NOV-1999 (first entry)
XX
DE PCR primer used to amplify green fluorescent protein DNA fragment.
XX
XX Green fluorescent protein; GFP; DNA integration; sperm;
KM transgenic animal; PCR primer; ss.
XX
OS Synthetic.
OS Aequorea victoria.
XX
PN WO9942569-A1.
XX
PD 26-AUG-1999.
XX
PF 22-FEB-1999; 99WO-IL000110.
XX
PR 22-FEB-1998; 98IL-00123411.
XX
PA (KIMR-) KIMRON VETERINARY INST.
XX
PI Shemesh M, Gurevich M, Stram Y, Benvenisti L, Shore LS;
XX WPI; 1999-527468/44.
XX
XX Novel methods for integrating exogenous DNA into genomic DNA of sperm
PT with high efficiency.
XX
PS Example 1; Page 24; 54pp; English.
XX
XX PCR primers AAZ10258-60 were used to amplify green fluorescent protein
CC (GFP) DNA. The GFP DNA was integrated into the chicken cells using the
CC method of the invention. The specification describes methods and
CC compositions for stably integrating exogenous DNA into the genomic DNA of
CC sperm. These sperm can then be used to fertilize oocytes and produce
CC transgenic embryos. The methods are used to produce transgenic sperm
CC which are used to fertilize oocytes by artificial insemination, in vitro
CC fertilization, or other fertilization methods, thereby producing
CC transgenic animals with exogenous DNA stably integrated into their
CC genomes. This exogenous DNA could contain a gene(s) coding for production
CC of proteins or ribozymes, of commercial, industrial, agricultural and/or
CC medical importance. These products can be isolated from the tissues,
XX cells, milk, eggs, or cell lines of the transgenic animals
XX

SQ Sequence 19 BP; 1 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.4e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3793 CACCTCGACGGGTCCTT 3809
 |||||
 3 CACCTCGACGGGTCCTT 19

Db

RESULT 397
 AAA49353/C
 ID AAA49353 standard; DNA; 19 BP.
 XX
 AC AAA49353;
 XX
 DT 25-SEP-2000 (first entry)
 XX
 DE Primer for sequencing Neisseria meningitidis Hsp70 sequence.
 XX
 KM Hsp70; Hsp60; heat shock protein; immunogen; immunity; vaccine;
 KM detection; Neisseria meningitidis; Aspergillus fumigatus;
 KM Candida glabrata; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO200034465-A2.
 XX
 PD 15-JUN-2000.
 XX
 PF 01-DEC-1999; 99WO-CA001152.
 XX
 PR 08-DEC-1998; 98US-00207388.
 XX
 PA (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.
 XX
 PI Wisniewski J;
 XX
 DR WPI; 2000-423415/36.
 XX
 PT Isolated nucleic acid molecule for eliciting immune response in mammal
 PT encodes Neisseria meningitidis heat shock protein 70, Aspergillus
 PT fumigatus Hsp60 and Candida glabrata Hsp60 polypeptide.
 XX
 PS Example 1; Page 47; 118pp; English.
 XX
 CC The Hsp70 heat shock protein or fragments derived from Neisseria
 CC meningitidis and the Hsp60 heat shock protein or fragments derived from
 CC Aspergillus fumigatus or Candida glabrata can be used as immunogens to
 CC give protective immunity from these microorganisms. Nucleotide sequences
 CC encoding these proteins are useful for producing recombinant proteins for
 CC immunizing an animal or as probes and/or primers to detect the
 CC microorganisms in a biological sample. Two primers (AAA49350, AAA49351)
 CC were used to sequence an Hsp70 internal sequence cloned from Neisseria
 CC meningitidis and inserted into the vector PCR2.1. Two more primers
 CC (AAA49352, AAA49353) were then designed for additional sequencing
 CC reactions
 CC
 SQ Sequence 19 BP; 1 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.4e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2979 CCGAAGTACAGAGAC 2995
 |||||
 18 CCGAAGTACAGAGAC 2

Db

RESULT 398
 AAA49370/C
 ID AAA49370 standard; DNA; 19 BP.

XX
 AC AAA49370;
 XX
 DT 25-SEP-2000 (first entry)
 XX
 DE Primer for selective amplification of N. meningitidis Hsp70 sequence.
 XX
 KM Hsp70; Hsp60; heat shock protein; immunogen; immunity; vaccine;
 KM detection; Neisseria meningitidis; Aspergillus fumigatus;
 KM Candida glabrata; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO200034465-A2.
 XX
 PD 15-JUN-2000.
 XX
 PF 01-DEC-1999; 99WO-CA001152.
 XX
 PR 08-DEC-1998; 98US-00207388.
 XX
 PA (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.
 XX
 PI Wisniewski J;
 XX
 DR WPI; 2000-423415/36.
 XX
 PT Isolated nucleic acid molecule for eliciting immune response in mammal
 PT encodes Neisseria meningitidis heat shock protein 70, Aspergillus
 PT fumigatus Hsp60 and Candida glabrata Hsp60 polypeptide.
 XX
 PS Example 5; Page 55; 118pp; English.
 XX
 CC The Hsp70 heat shock protein or fragments derived from Neisseria
 CC meningitidis and the Hsp60 heat shock protein or fragments derived from
 CC Aspergillus fumigatus or Candida glabrata can be used as immunogens to
 CC give protective immunity from these microorganisms. Nucleotide sequences
 CC encoding these proteins are useful for producing recombinant proteins for
 CC immunizing an animal or as probes and/or primers to detect the
 CC microorganisms in a biological sample. Two primers (AAA49369, AAA49370)
 CC were used to amplify DNA from a mixture of bacterial genomic DNA
 CC sequences. Only N. meningitidis Hsp70 sequence was amplified
 CC
 SQ Sequence 19 BP; 1 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.4e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2979 CCGAAGTACAGAGAC 2995
 |||||
 18 CCGAAGTACAGAGAC 2

Db

RESULT 399
 AAA49347/C
 ID AAA49347 standard; DNA; 19 BP.
 XX
 AC AAA49347;
 XX
 DT 25-SEP-2000 (first entry)
 XX
 DE Primer for amplifying Neisseria meningitidis Hsp70 sequence.
 XX
 KM Hsp70; Hsp60; heat shock protein; immunogen; immunity; vaccine;
 KM detection; Neisseria meningitidis; Aspergillus fumigatus;
 KM Candida glabrata; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO200034465-A2.
 XX
 PD 15-JUN-2000.

```

XX
PF 01-DEC-1999; 99WO-CA001152.
XX
XX 08-DEC-1998; 98US-00207388.
XX
PA (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.
XX
PI Wistniewski J;
XX
XX MPI; 2000-423415/36.
XX
XX Isolated nucleic acid molecule for eliciting immune response in mammal
PT encodes Neisseria meningitidis heat shock protein 70, Aspergillus
PT fungigatus Hsp60 and Candida glabrata Hsp60 polypeptide.
XX
XX Disclosure; Page 18; 118pp; English.
XX
XX The Hsp70 heat shock protein or fragments derived from Neisseria
CC meningitidis and the Hsp60 heat shock protein or fragments derived from
CC Aspergillus fumigatus or Candida glabrata can be used as immunogens to
CC give protective immunity from these microorganisms. Nucleotide sequences
CC encoding these proteins are useful for producing recombinant proteins for
CC immunizing an animal or as probes and/or primers to detect the
CC microorganisms in a biological sample. Two primers (AA449346, AA449347)
CC can be used to amplify an Hsp70 sequence specifically from Neisseria
CC meningitidis.
XX
SQ Sequence 19 BP; 1 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
XX
XX
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2979 CCGAAGTACCAAGAGC 2995
DB 18 CCGAAGTACCAAGAGC 2
XX
RESULT 400
AAZ71124/C
ID AAZ71124 standard; DNA; 19 BP.
XX
XX AAZ71124;
AC
XX 10-SEP-2001 (first entry)
DT
XX
XX Human biallelic marker upstream amplification primer SEQ ID NO:5480.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
XX Homo sapiens.
OS
XX WO954500-A2.
XX
XX 28-OCT-1999.
PD
XX
XX 21-APR-1999; 99WO-IB000822.
PF
XX 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
XX (GEST ) GENSET.
PA
XX Cohen D, Blumenfeld M, Chumakov I;
PI
XX MPI; 2000-013267/01.
DR
XX Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.

```

```

XX
PS Claim 8; Page 1399; 2745pp; English.
XX
XX AA265654 to AA269578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AA269579 to AA277440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 2 A; 7 C; 0 G; 10 T; 0 U; 0 Other;
XX
XX
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1568 GAGAGCTAGAGAGAGA 1584
DB 19 GAGAGCTAGAGAGAGA 3
XX
RESULT 401
AAH27306/C
ID AAH27306 standard; DNA; 19 BP.
XX
XX AAH27306;
AC
XX 08-AUG-2001 (first entry)
DT
XX
XX Human TSG16 PCR primer #6.
XX
XX Tumour suppressor gene 16; TSG16; human; immune response modulator;
KW inflammatory response modulator; signal transduction activator;
KW cytokine inhibitor; gene therapy; anticancer; anti-inflammatory;
KW autoimmune disorder; infection; chromosome 16q24.3;
KW cellular proliferation suppressor; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200132861-A1.
XX
XX 10-MAY-2001.
PD
XX
XX 30-OCT-2000; 2000WO-AU001329.
PF
XX 29-OCT-1999; 99AU-00003771.
PR
XX (WOMEN-) WOMEN'S & CHILDREN'S HOSPITAL.
XX
XX Callen DF, Whitmore SA, Kremmidiotis G, Kochetkova M, Crawford J;
PI MPI; 2001-316439/33.
XX
XX New nucleic acid representing the human tumor suppressor gene TSG16,
PT useful e.g. for diagnosis and treatment of tumors, inflammatory and
PT immunological disorders.
XX
XX Claim 84; Page 183; 215pp; English.
XX
XX The present invention relates to human tumour suppressor gene 16 (TSG16;
CC see AAH23688). TSG16 was isolated from chromosome 16q24.3. TSG16
CC suppresses cellular proliferation. TSG16 is useful for treating disorders
CC associated with decreased expression or activity of TSG16, e.g. cancers,
CC (auto)immune disorders, inflammation, complications of wound healing and

```

CC infections (by viruses, bacteria, fungi, parasites, protozoa or
CC helminths). The present sequence is a PCR primer, which was used in the
CC present invention
XX
SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DY 1455 ACAGCAGCAGCAGCTTC 1471
DB 17 ACCGACGACGACGCTTC 1
RESULT 402
ADP93383/C
ID ADP93383 standard; RNA; 19 BP.
XX
AC ADP93383;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TERT transcript target sequence/siNA upper strand, SEQ ID 100.
XX
CYCOSTATIC; VASOTROPIC; PROTOZOACIDE; IMMUNOSUPPRESSIVE; DERMATOLOGICAL;
KM neuroprotective; anti-HIV; ophthalmological; anti-ulcer; antirheumatic;
KM antiarthritic; antiinflammatory; gene therapy; telomerase; human; terc;
KM RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping; TERC; TERT; ss.
XX
OS Homo sapiens.
XX
PN WO2003070742-A1.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US004088.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 17-JUL-2002; 2002US-0396600P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-689777/55.
XX
PT New short interfering nucleic acid downregulates expression of the
telomerase gene useful e.g. for treatment and diagnosis of cancer.
XX
PS Example 3; SEQ ID NO 100; 145pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the one or more telomerase genes by RNA
CC interference. The siNA may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNA include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNA can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesized,
CC expressed from a vector or enzymatically synthesized. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates

CC and/or complexes of siNA; and vectors that express siNA. The siNA are
CC used to modulate expression of the telomerase genes in cells, tissue
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC transplants for the treatment of a variety of conditions. They may be
CC used for treating cancer, restenosis, infectious diseases (specifically
CC protozoal), transplant rejection, or autoimmune or age-related diseases,
CC e.g. multiple sclerosis, lupus erythematosus, AIDS, macular degeneration,
CC skin ulcers and rheumatoid arthritis. The siNA are also useful for drug
CC screening, diagnosis, therapeutic target identification and validation,
CC genetic engineering, pharmacogenomics, studying gene function, and gene
CC mapping (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the upper strand of a human TERT-targeted double-stranded
CC siNA, which is identical to the c-fos transcript target sequence.
XX
SQ Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DY 1463 AGCAGCTCGAAGACAG 1479
DB 19 AGCAGCTCGAAGACAG 3
RESULT 403
ADP93637
ID ADP93637 standard; RNA; 19 BP.
XX
AC ADP93637;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TERT siNA lower strand, SEQ ID 364.
XX
CYCOSTATIC; VASOTROPIC; PROTOZOACIDE; IMMUNOSUPPRESSIVE; DERMATOLOGICAL;
KM neuroprotective; anti-HIV; ophthalmological; anti-ulcer; antirheumatic;
KM antiarthritic; antiinflammatory; gene therapy; telomerase; human; terc;
KM RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping; TERC; TERT; ss.
XX
OS Homo sapiens.
XX
PN WO2003070742-A1.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US004088.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 17-JUL-2002; 2002US-0396600P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-689777/55.
XX
PT New short interfering nucleic acid downregulates expression of the
telomerase gene useful e.g. for treatment and diagnosis of cancer.
XX
PS Example 3; SEQ ID NO 364; 145pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which

XX Example 1; Page 19; 58bp; English.
 PS
 XX
 CC The invention relates to screening, identifying or predicting, and
 CC assembling 19-25 nt double-stranded oligonucleotides (termed short double
 CC stranded oligonucleotides, SDOs) as active pharmaceutical compositions
 CC for the treatment of viral infections, malignant tumours, and genetic and
 CC metabolic diseases, comprising screening and identifying a specific DNA
 CC sequence in an abnormal gene encoding a protein with gene chip and
 CC protein chip microarrays. The above method comprises screening the
 CC disease-causing genes, over-expressing in cells and/or tissues, with the
 CC gene chip and protein chip microarrays, identifying a specific DNA
 CC sequence within the abnormal gene encoding a protein or playing other
 CC biological roles with the assistance of computer and specific software,
 CC predicting efficacious 19-25 nt double-stranded oligonucleotides with a
 CC 5'-AT(7)CCG-3' or 5'-U(7)CCG-3' special pattern complementary to at
 CC least a portion of an RNA molecule and making sure that selected sequence
 CC is not localised within the stem-loop of target mRNA with any related
 CC software. Also included are pharmaceutical compositions of gene drugs
 CC (such as Dermogene, Lungene, Hepatogene, Leukogene, Lymphogene,
 CC Prostagene, Breastogene, Brainumogene and Skin-whitogene including but
 CC being not limited to part or all of the following components: single or a
 CC group of specific 19-25 nt dsRNA, 19-25 nt sRNA-cDNA, 19-25 nt dsRNA
 CC and/or single-stranded RNA and/or DNA with the special pattern, 5'-
 CC CCGAT(U)-3' or its derivatives, one or more nucleic acid condensation
 CC agents (or none), one or more pharmaceutical carriers, one or more
 CC specific cell-targeting proteins and other active agents and additional
 CC materials) and a simplified method for predicting and selecting a
 CC specific and efficacious small double-stranded oligonucleotides (SDSO),
 CC antisense oligonucleotide molecules or short interfering RNA (siRNA)
 CC comprising identifying a special pattern that can be localised in any
 CC position of an oligonucleotide sequence evaluating the specificity of a
 CC selected sequence). The short interfering RNA (siRNA) are targeted
 CC against genes involved in viral infection, malignant tumours, genetic and
 CC metabolic diseases. The methods are useful for designing and selecting
 CC short double-stranded oligonucleotides as a gene drug that can
 CC specifically inactivate a group of corresponding genes. The composition
 CC may be used for treating diseases or disorders associated with abnormal
 CC expression of genes in cells or tissues of humans or animals, such as
 CC viral infections, cancer, or genetic or metabolic diseases. The present
 CC sequence is a target region for an SDO from an human cDNA.
 CC
 XX Sequence 19 BP; 3 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.4e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GGCACCTCCCCGAGCT 2229
 DB 18 GGCACCTCCCCCTGGCT 2
 RESULT 406
 ADR46305
 ID ADR46305 standard; DNA; 19 BP.
 AC ADR46305;
 XX
 XX 18-NOV-2004 (first entry)
 DT
 XX
 XX Cyclin D2 forward PCR primer.
 DE
 XX
 XX Cyclin D2; Bex4; ovarian cancer; cytostatic; human; gene therapy;
 KM tumour suppressor protein; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004072269-A2.
 PN
 XX
 XX 26-AUG-2004.
 PD
 XX
 PF 12-FEB-2004; 2004MO-US004413.

XX
 PR 12-FEB-2003; 2003US-0446877P.
 XX
 XX
 PA (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
 XX
 PI Shridhar V, Chien J;
 XX
 XX WPI; 2004-625868/60.
 DR
 XX
 XX New vector comprising an isolated nucleic acid encoding a Bex4
 PT polypeptide, useful for treating cancer, e.g. ovarian, cervical, brain,
 PT breast, prostate or liver cancer.
 PT
 PS Example 1; SEQ ID NO 18; 47bp; English.
 XX
 XX The present sequence is that of a forward PCR primer for cyclin D2. The
 CC primer was used in a semiquantitative RT-PCR in an examination of the
 CC differential expression of genes in ovarian tumour cell lines, and in
 CC early-stage and late-stage primary tumours. The invention is based on the
 CC discovery that Bex4 (or prosoprotic protein on chromosome X (PAPX))
 CC ADR46296 is down-regulated in cancer cells. Claimed methods for killing a
 CC tumour cell comprise administering to the tumour a nucleic acid that
 CC encodes a Bex4 polypeptide, a vector comprising the nucleic acid, or a
 CC Bex4 polypeptide. The tumour cell is selected from an ovarian, cervical,
 CC brain, breast, prostate and hepatic tumour cell. Detection of a lower
 CC than normal level of Bex4 polypeptide in cells in a sample indicates a
 CC predisposition of an individual to develop cancer. A claimed method for
 CC detecting cancer recurrence in an individual diagnosed with and treated
 CC for cancer comprises measuring the level of bex4 gene methylation. The
 CC presence of hypermethylation indicates recurrence. The cancer is ovarian,
 CC breast, prostate, cervical, brain or liver cancer.
 CC
 XX Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.4e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3624 GCTGCTGTCTACGAGC 3640
 DB 2 GCTGCTGTCTACGAGC 18
 RESULT 407
 AAV07418
 ID AAV07418 standard; DNA; 20 BP.
 XX
 AC AAV07418;
 XX
 XX 10-SEP-1998 (first entry)
 DT
 XX
 XX Oligonucleotide containing carbamate-derivatised nucleoside.
 DE
 XX Carbamate-derivatised nucleoside; therapy; protein production;
 KM DNA degradation; ss.
 XX
 XX Synthetic.
 OS
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /tag= a
 FT /note= "2'-Carbamate-derivatised uridine"
 FT modified_base 20
 FT /tag= b
 FT /note= "3'-Carbamate-derivatised uridine"
 XX
 XX WO9811123-A1.
 EN
 XX
 XX 19-MAR-1998.
 PD
 XX
 XX 10-SEP-1997; 97WO-US015970.
 PF
 XX
 PR 13-SEP-1996; 96US-00713742.

XX (ISIS-) ISIS PHARM INC.
 XX Cook PD, Manoharan M;
 PI WPI; 1998-271659/24.
 XX Nucleoside compounds - which contain carbamate moiety at 2'-O or 3'-O
 PT position of sugar or at 5-position of pyrimidine base.
 XX
 XX Example 6; Page 17; 49pp; English.
 XX The invention relates to nucleoside compounds which contain carbamate
 CC moiety at 2'-O or 3'-O position of sugar or at 5-position of pyrimidine
 CC base. The may be incorporated into oligonucleosides or oligonucleotides
 CC for use in diagnostics, research and therapy. The nucleoside or
 CC oligonucleoside or oligonucleotide can be used, e.g. for modulating
 CC production of certain proteins by an organism (and treatment of diseases
 CC related to production of these proteins), for inducing degradation of
 CC particular regions of double stranded DNA, for killing cells or viruses,
 CC or for detecting the presence or absence of RNA in biological samples.
 CC The present sequence represents an example of an oligonucleotide
 CC containing carbamate-derivatised uridines
 XX
 SQ Sequence 20 BP; 3 A; 11 C; 3 G; 1 T; 0 U; 2 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1656 CATCCCCGAGGCTCC 1672
 DB 3 CATCCCCGAGGCCAACC 19
 RESULT 408
 AAV69992
 ID AAV69992 standard; DNA; 20 BP.
 XX
 AC AAV69992;
 XX
 DT 04-FEB-1999 (first entry)
 XX
 DE Human c-fos protein antisense oligonucleotide #28.
 XX
 KM Human; c-fos; c-jun; activating protein 1; AP-1; diagnosis; metastasis;
 KM antisense oligonucleotide; phosphorothioate; regulation;
 KM malignant tumour; cell cycle expression; hyperproliferative disease; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate linkages"
 FT
 XX
 XX W09846272-A1.
 PN
 XX
 PD 22-OCT-1998.
 XX
 PF 14-APR-1998; 98WO-US007386.
 XX
 PR 14-APR-1997; 97US-00837201.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Dean NM, McKay R, Miraglia L, Baker B;
 XX WPI; 1998-60906/51.
 DR
 XX Antisense oligonucleotides regulating Activating Protein 1 subunits -
 PT hybridise with c-fos and c-jun mRNA, used for regulating metastasis, cell

PT cycle expression and hyperproliferative disease.
 XX
 PS Example 1; Page 39; 120pp; English.
 XX
 CC The present sequence represents an antisense oligonucleotides which is
 CC specifically hybridisable with a region of a nucleic acid encoding human
 CC c-Fos protein. The antisense compound regulates the expression of the c-
 CC Fos protein. The present invention also describes antisense
 CC oligonucleotides which regulate the c-Jun protein. The antisense
 CC oligonucleotides are used for the diagnosis and treatment of disease or
 CC disorders associated with Activating Protein 1 expression, of which c-Fos
 CC and c-Jun are subunits. The antisense oligonucleotides are used in
 CC compositions as c-Fos and/or c-Jun together with a carrier and a
 CC chemotherapeutic agent. They are used to regulate the expression of c-Fos
 CC or c-Jun in cells or tissues, preferably by inhibiting metastasis. They
 CC also regulate cell cycle expression and can be used to treat an animal
 CC with, or being prone to, a hyperproliferative disease
 XX
 SQ Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 754 CCGCCGAGGCTCAAGTC 770
 DB 2 CCGCCGAGGCTCAAGTC 18
 RESULT 409
 AA204615/c
 ID AA204615 standard; DNA; 20 BP.
 XX
 AC AA204615;
 XX
 DT 07-OCT-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
 XX
 KM Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
 KM paratrachoma; inclusion conjunctivitis; genital disease; peritrititis;
 KM nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KM Bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
 XX
 OS Synthetic.
 OS Chlamydia trachomatis.
 OS
 PN W09928475-A2.
 XX
 PD 10-JUN-1999.
 XX
 PF 27-NOV-1998; 98WO-IB001939.
 XX
 PR 28-NOV-1997; 97FR-00015041.
 PR 17-DEC-1997; 97FR-00016034.
 PR 04-NOV-1998; 98US-0107077P.
 XX
 XX (GEST) GENSET.
 PA
 XX Griffais R;
 PI
 XX
 DR WPI; 1999-371125/31.
 XX
 PT Genome sequence of Chlamydia trachomatis.
 PS
 XX Disclosure; Page 1703; 1755pp; English.
 XX
 CC PCR primers AA201426-Z06209 were used to amplify open reading frames
 CC (ORFs) of the genome of Chlamydia trachomatis (see AA201425). These ORFs
 CC encode polypeptides (see AA136754-Y37949) which can be used as vaccines
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
 CC be used to control growth of the microorganism. Chlamydia trachomatis is
 CC responsible for a large number of diseases, e.g. eye diseases such as

CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis;
CC epididymitis, cervicitis, salpingitis, perihepatitis, bartolinitis;
CC pneumonia in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
XX
SQ Sequence 20 BP; 1 A; 7 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1124 AGCAGCTGCAGCAGCAG 1140
DB 20 AGAAGCTGCAGCAGCAG 4
RESULT 410
AA80212
ID AA80212 standard; DNA; 20 BP.
XX
AC AA80212;
XX
DT 20-AUG-1999 (first entry)
XX
DE Human CSF-1 antisense oligonucleotide.
XX
KM Human; M-CSF-1; colony stimulating factor; angiogenesis; tumour;
KM proliferative disorder; wound healing; cellular proliferative disease;
KM diabetic retinopathy; cancer; solid tumour; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO929345-A1.
XX
PD 17-JUN-1999.
XX
PF 04-DEC-1998; 98MO-US025791.
XX
PR 05-DEC-1997; 97US-0067591P.
XX
PA (LJOL-) LA JOLLA INST EXPERIMENTAL MEDICINE.
XX
PI Bourdon MA, Deryugina E, Rao PS, Borgstrom P;
XX
XX WPI; 1999-385494/32.
XX
PT Inhibition of angiogenesis by macrophage intervention, useful for
XX
XX inhibiting tumor growth.
XX
PS Disclosure; Page 11; 30pp; English.
XX
XX The present invention describes a method for the inhibition a
XX
XX angiogenesis in a cell population in a mammal comprising inhibiting a
XX
XX host cells angiogenic effect in the said mammal. The method can be used
XX
XX to inhibit angiogenesis in tumours, wounds surrounding cells or cells
XX
XX characteristic of a proliferative disorder. Therefore the method is
XX
XX useful in the treatment of wound healing and cellular proliferative
XX
XX diseases, e.g. diabetic retinopathy, and cancers, especially associated
XX
XX with the presence of solid tumours. The method can be used in combination
XX
XX with additional treatment, including surgery, radiation therapy and
XX
XX chemotherapy. The present sequence represents a human colony stimulating
XX
XX factor (CSF-1) antisense oligonucleotide as given in the present
XX
XX invention
SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 143 AGACGGGCGAGCTGGCT 159
DB 4 ATACGGGCGAGCTGGCT 20
RESULT 411
AAC92580/C
ID AAC92580 standard; DNA; 20 BP.
XX
AC AAC92580;
XX
DT 27-MAR-2001 (first entry)
XX
DE Human nucleolin phosphorothioate antisense oligonucleotide, SEQ ID NO:30.
XX
KM Human nucleolin; P92; C23; phosphoprotein; ribosome biogenesis;
KM ribosome transport; cytokinesis; nucleogenesis; cell proliferation;
KM cell growth; transcriptional repression; replication;
KM signal transduction; chromatin decondensation; Ag-NOR family;
KM nucleolin antibody; systemic connective tissue disease; SLE;
KM systemic lupus erythematosus;
KM scleroderma-like chronic graft versus host disease;
KM expression inhibition; tumour formation; cancer; inflammation;
KM immune disorder; phosphorothioate; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN US615786-A.
XX
PD 26-DEC-2000.
XX
PF 03-NOV-1999; 99US-00433699.
XX
PR 03-NOV-1999; 99US-00433699.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowsett LM;
XX
XX WPI; 2001-079848/09.
XX
DR
XX
PT Novel antisense compound targeted to human nucleolin which specifically
XX
XX hybridizes with and inhibits the expression of human nucleolin, useful
XX
XX for modulating the expression of nucleolin in cells.
XX
PS Example 15; Col 41-42; 41pp; English.
XX
XX Sequences AAC92560-C92639 represent antisense oligonucleotides targeted
XX
XX to the human nucleolin gene, which inhibit its expression. The antisense
XX
XX oligonucleotides were designed to target different regions of the human
XX
XX nucleolin mRNA, and were analysed for their effect on nucleolin mRNA
XX
XX levels by quantitative real-time PCR. Nucleolin (also known as p92 or
XX
XX C23) is the most abundant nucleolar phosphoprotein in actively growing
XX
XX cells. Nucleolin primarily participates in ribosome biogenesis and
XX
XX transport of ribosomal components, being able to transiently bind to pre-
XX
XX ribosomes in the nucleolus via a ribonucleoprotein consensus sequence.
XX
XX However, it has also been shown to be involved in cytokinesis,
XX
XX nucleogenesis, cell proliferation and growth, transcriptional repression,
XX
XX replication, signal transduction, and chromatin decondensation. Nucleolin
XX
XX is a member of the Ag-NOR (active ribosomal gene located in the nucleolar
XX
XX organizer region) family of proteins which are markers of active
XX
XX ribosomal genes, and whose expression is associated with the prediction
XX
XX of tumour growth rate. The presence of antibodies against nucleolin are
XX
XX associated with systemic connective tissue diseases such as systemic
XX
XX lupus erythematosus (SLE) and scleroderma-like chronic graft versus host
XX
XX disease. The oligonucleotides of the invention are useful for diagnosis,
XX
XX prevention and treatment of conditions associated with nucleolin
XX
XX expression, such as tumour formation, immune disorders and inflammation
SQ Sequence 20 BP; 3 A; 9 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 985 GAGGAGGAGATGACAG 1001
Db 19 GAGGAGGATGATGACAG 3
RESULT 412
AAD21080
ID AAD21080 standard; DNA; 20 BP.
AC AAD21080;
XX
DT 15-JAN-2002 (first entry)
XX
DE Wnt4 RT-PCR primer #1 used in the method for modulating hair growth.
XX
KW Signal transduction; Wnt protein; dermal papilla; DP; beta-catenin;
KM GSK3beta kinase; genetic pattern baldness; hormonal disorder;
KM chemotherapy; anagen phase; hair growth promoter; RT-PCR primer; ss.
XX
OS Unidentified.
XX
PN MO200174164-A1.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001MO-US010164.
XX
PR 31-MAR-2000; 2000US-0193771P.
PR 12-JAN-2001; 2001US-0261690P.
XX
PA (GEHO) GEN HOSPITAL CORP.
PI Kishimoto J, Burgesson R, Morgan BA;
XX
XX WPI; 2001-648492/74.
XX
PT Promoting or inhibiting hair growth in a subject by inducing or
PT mimicking, or inhibiting effect of Wnt-promoted signal transduction,
PT respectively.
XX
PS Disclosure; Page 22; 63pp; English.
XX
CC The present invention relates to promoting hair growth in a subject which
CC involves inducing or mimicking the effect of Wnt-promoted signal
CC transduction in a subject and inhibiting hair growth in a subject
CC involves inhibiting level of Wnt protein or inhibiting an effect of Wnt-
CC promoted signal transduction in a subject. The invention is used for
CC providing and maintaining dermal papilla (DP) cell graft which involves
CC culturing a DP cell from a subject under conditions that induce or mimic
CC the effect of Wnt-promoted signal transduction, thereby providing and
CC maintaining a DP cell graft. Preferably, the DP cell is cultured in the
CC presence of Wnt, its fragment or analogue; lithium chloride, beta-catenin
CC and/or LEF1, an agent which inhibits beta-catenin phosphorylation or
CC GSK3beta kinase, or an agent which promotes beta-catenin accumulation.
CC Hair growth is promoted in subject's scalp, or face e.g., beard and/or
CC mustache, or in conditions where subject suffers from genetic pattern
CC baldness, suffers from a hormonal disorder which decreases hair growth,
CC has received a treatment, e.g., radiation or chemotherapy, or a drug
CC which inhibits hair growth, or has had a surgical procedure, e.g., skin
CC graft, which is in need of hair growth. Hair growth is inhibited on the
CC subject's scalp, subject's face, e.g., beard and/or mustache, facial hair
CC growth, or eyebrow growth, back, legs, chest, armpits. Promoting hair
CC growth is useful for maintaining or promoting hair inductive activity.
CC Inhibiting hair growth is useful for maintaining hair inductive activity.
CC phase gene expression in the subject's scalp, face e.g., upper lip and/or
CC chin. The present sequence is Wnt4 RT-PCR primer used in the method for
CC modulating hair growth
XX
SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1400 TCCAGAGGACGCTGCAG 1416
Db 4 TCCAGAGGACGCTGCAG 20
RESULT 413
AAD37173
ID AAD37173 standard; DNA; 20 BP.
XX
AC AAD37173;
XX
DT 21-AUG-2002 (first entry)
XX
DE Human MEKK4 antisense oligonucleotide, ISIS #123108.
XX
XX Human; MEKK4 modulation; mitogen-activated protein kinase kinase 4; MTX1;
KM MAP3K4; MAP three kinase 1; MAP/ERK kinase kinase 4; MAPKKK4; cytosolic;
KM prophylaxis; immunological; hyperproliferative disorder; cancer; therapy;
KM antisense; inflammatory; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 2
FT /tag= d
FT /mod_base= m5c
FT modified_base 3
FT /tag= e
FT /mod_base= m5c
FT modified_base 6
FT /tag= f
FT /mod_base= m5c
FT modified_base 9
FT /tag= g
FT /mod_base= m5c
FT modified_base 15
FT /tag= h
FT /mod_base= m5c
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
XX
PN MO200227033-A1.
XX
XX 04-APR-2002.
PD
XX 28-SEP-2001; 2001MO-US030549.
XX
XX 29-SEP-2000; 2000US-00676436.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Ward DT, Gaarde WA, Monia BP, Wyatt JR;
PI
XX WPI; 2002-416486/44.
XX
XX New antisense compound targeted to nucleic acid encoding mitogen-
PT activated protein kinase 4, useful for treating immunologic disorder,
PT inflammatory disorder or cancer.

PS Claim 3, Page 92, 132pp; English.

XX The present invention relates to antisense compounds, compositions and

CC methods for modulating the expression of MEK4 (also referred as mitogen-

CC activated protein kinase kinase 4; MAPKK4; MAP3K4; MAP3 kinase 1; MAP/ERK

CC kinase kinase 4; MAPKK4; MKK1). The antisense oligos are useful for

CC inhibiting the expression of MEK4 in cells or tissues. They are also

CC useful for treating an animal having a disease or condition associated

CC with MEK4 such as immunological, inflammatory, hyperproliferative

CC disorder or cancer. Sequences of the invention are also useful for

CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.

CC They are also useful in antisense therapy. The present sequence is an

CC antisense oligonucleotide targeted to human MEK4 DNA. This sequence is

CC used in the exemplification of the invention

XX

SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3927 CTGCATCATGACGCTG 3943

DB 3 CTCGACGATGACTGCT 19

RESULT 414

ABQ74714

ID ABQ74714 standard; DNA; 20 BP.

AC ABQ74714;

XX

XX 24-OCT-2002 (first entry)

DT

XX

DE RNF3 gene sense PCR primer SEQ ID NO:57.

KW

KM Human; PCR primer; identification; tumour senescence; cytotoxic; ss;

XX abnormal cell proliferation; neoplastic cell growth; growth-inhibitory.

OS Homo sapiens.

OS Synthetic.

XX

PN WO200261134-A2.

PD

XX

PD 08-AUG-2002.

XX

PF 21-DEC-2001; 2001WO-US050574.

XX

PR 21-DEC-2000; 2000US-0257907P.

XX

PR 17-DEC-2001; 2001US-00257907.

XX

PA (UNIT) UNIV ILLINOIS FOUND.

XX

PI Roninson IB, Chang B;

XX

DR WPI; 2002-619266/66.

XX

PT Identifying a compound that induces senescence in a mammalian p53

PT deficient or tumor cell comprises assaying expression of cellular genes

PT in the presence of the compound with expression of the genes in the

PT absence of the compound.

XX

XX Example 4; Page 52; 73pp; English.

XX

XX The present invention describes a method for identifying a compound that

CC induces senescence in a mammalian cell comprising culturing the cell in

CC the presence and absence of the compound, assaying expression of at least

CC one cellular gene (G1a) from 56 or a gene (G2) from 64 genes, with

CC corresponding accession numbers given in the specification, and

CC identifying compounds that induce senescence when expression of (G1a) or

CC expression of (G2) is lower, in the presence of the compound. Also

CC described: (1) a compound that induces senescence in a mammalian cell;

CC (2) assessing efficacy of a treatment of a disease or condition relating

CC to abnormal cell proliferation or neoplastic cell growth; (3) treating a

CC disease or condition relating to abnormal cell proliferation or

CC neoplastic cell growth; or (4) identifying a compound that inhibits

CC senescence-associated induction of cellular gene expression. The compound

CC is useful for treating or for assessing efficacy of treatment of a

CC disease or condition relating to abnormal cell proliferation or

CC neoplastic cell growth. The compound of the invention has a growth-

CC inhibitory effect without producing systemic side effects found with

CC other growth-inhibitory compounds. ABQ74611 to ABQ74734 represent PCR

CC primers which are used in an example from the present invention

XX

SQ Sequence 20 BP; 7 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 462 AGACATCAAGGGGAG 478

DB 1 AGACATCAAGGGGAG 17

RESULT 415

ABST73433/C

ID ABST73433 standard; DNA; 20 BP.

XX

AC ABST73433;

XX

XX 03-DEC-2002 (first entry)

DT

XX

DE Chimeric phosphorothioate oligonucleotide #14.

XX

KW Human; glioma-associated oncogene-2; antisense compound; infection;

KM inflammation; tumour formation; antiinflammatory; antitumour;

KM inhibitor of human glioma-associated oncogene-2 expression;

XX antisense gene therapy; phosphorothioate; ss.

XX

OS Homo sapiens.

OS Synthetic.

OS Chimeric.

XX

PN US6440739-B1.

PD

XX

PD 27-AUG-2002.

XX

PF 17-JUL-2001; 2001US-00907843.

XX

PR 17-JUL-2001; 2001US-00907843.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Bennett CF, Freier SM;

XX

DR WPI; 2002-697096/75.

XX

XX

PT Novel antisense compound that hybridizes and inhibits nucleic acid

PT encoding human glioma-associated oncogene-2, useful for treatment of

PT diseases associated with human glioma-associated oncogene-2.

XX

XX Example 15; Col 45; 43pp; English.

XX

XX The present invention relates to a new antisense compound targeted to

CC human glioma-associated oncogene-2. The invention is useful for

CC inhibiting the expression of human glioma-associated oncogene-2 in cells

CC or tissues. The invention is also useful for treatment of diseases

CC associated with human glioma-associated oncogene-2. The invention is

CC further useful for diagnostics, therapeutics, prophylaxis, as research

CC reagents and kits, for distinguishing functions of various members of a

CC biological pathway, and in antisense gene therapy. The invention is also

CC useful prophylactically, e.g., to prevent or delay infection,

CC inflammation or tumour formation. The present nucleic acid sequence

CC represents an oligonucleotide that was used in the methods of the

CC invention to inhibit human glioma-associated oncogene-2

XX Sequence 20 BP; 2 A; 5 C; 7 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1477 CAGCAGCAGCAGCAGCT 1493
DB 17 CAGCAGCAGCAGCAACT 1
RESULT 416
ABK52713/C
ID ABK52713 standard; DNA; 20 BP.
AC ABK52713;
XX
XX 27-AUG-2002 (first entry)
DT
XX Human bladder cancer antigen KU-BL-1, PCR primer #9.
DE
XX Human; bladder cancer antigen KU-BL-1; immunotherapy; cytostatic; cancer;
KM PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX JP2002112779-A.
PN
XX 16-APR-2002.
PD
XX 03-OCT-2000; 2000JP-00304143.
PF
XX 03-OCT-2000; 2000JP-00304143.
XX
XX 03-OCT-2000; 2000JP-00304143.
PR
XX (KEIO-) GH KEIO GIYUKU.
PA
XX WPI; 2002-448753/48.
XX
XX
XX Cancer antigens, particularly human bladder cancer antigen KU-BL-1 and
PT genes encoding for the antigens for their diagnosis and immune therapy.
XX
XX
XX Disclosure; Page 16; 30pp; Japanese.
PS
XX The invention relates to a novel human bladder cancer antigen KU-BL-1 and
CC the DNA encoding it. The antigen is used for immunotherapy of cancers,
CC particularly human bladder cancer. The present sequence represents a
CC human bladder cancer antigen KU-BL-1-associated PCR primer
CC
SQ Sequence 20 BP; 0 A; 10 C; 0 G; 10 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 184 GAGCAGCAGCAGCAGCA 200
DB 20 GAGCAGCAGCAGCAGCA 4
RESULT 417
ABT34158/C
ID ABT34158 standard; DNA; 20 BP.
AC ABT34158;
XX
XX 12-JUN-2003 (first entry)
DT
XX Human short heterodimer partner-1 expression oligo SEQ ID NO 33.
DE
XX Anticardiosclerotic; cardiant; vasotropic; antiinfective; cytostatic;
KM antiinflammatory; inhibitor; antisense gene therapy; atherosclerosis;
KM short heterodimer partner-1; abnormal; lipid; cholesterol metabolism;
KM

KM cardiovascular disease; infection; inflammation; tumour formation; human;
XX antisense; ds.
XX
XX Unidentified.
OS
XX WO2003012033-A2.
PN
XX
XX 13-FEB-2003.
PD
XX 17-JUL-2002; 2002WO-US023245.
PF
XX 31-JUL-2001; 2001US-00919197.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Crooke RM, Graham MJ;
XX WPI; 2003-248161/24.
DR
XX
XX New antisense oligonucleotide targeted to a nucleic acid encoding short
PT heterodimer partner-1, useful for treating diseases involving abnormal
PT lipid or cholesterol metabolism, e.g atherosclerosis or cardiovascular
PT diseases.
XX
XX Claim 3; Page 94; 121pp; English.
PS
XX The invention relates to a novel compound of 8 - 50 nucleobases in length
CC targeted to a nucleic acid molecule encoding a short heterodimer partner-
CC 1. The novel compound specifically hybridizes with a nucleic acid
CC molecule encoding the short heterodimer partner-1, and inhibits the
CC expression of the nucleic acid molecule. The compound, and a composition
CC comprising it are useful for treating a disease or condition associated
CC with the short heterodimer partner-1, particularly a condition involving
CC abnormal lipid or cholesterol metabolism such as atherosclerosis or a
CC cardiovascular disease. They are also useful in research and diagnostics
CC for modulating the expression of short heterodimer partner-1. They can
CC also be useful prophylactically in preventing or delaying infection,
CC inflammation or tumour formation. This polynucleotide sequence represents
CC a human antisense oligo relating to the heterodimer partner-1 of the
CC invention
CC
SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1406 GGCAGCTGCAGCAGAG 1422
DB 18 GGCAGCTGCAGCAGAG 2
RESULT 418
ACC86750/C
ID ACC86750 standard; DNA; 20 BP.
AC ACC86750;
XX
XX 04-AUG-2003 (first entry)
DT
XX
XX Human VEGFR-1 chimeric phosphorothioate oligonucleotide SEQ ID NO:45.
DE
XX Vascular endothelial growth factor receptor 1; VEGF receptor; VEGFR;
KM inhibitor; cytostatic; antitumour; antiarthritic; antiangiogenic;
KM antiinflammatory; antisense gene therapy; hyperproliferative disorder;
KM cancer; rheumatoid arthritis; angiogenesis; infection; inflammation;
KM tumour formation; phosphorothioate; 2'-O-methoxyethyl; 2'-MOE; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT

```
FT      /+tag= a
FT      /note= OTHER
FT      /note= "This oligonucleotide has a phosphorothioate
FT      backbone and 2'-O-methoxyethyl (2'-MOE) wings at the 5'
FT      and 3' ends, which are 5 nucleotides in length. Also all
FT      cytidine residues are 5-methylcytidines."
XX
XX      WO2003022227-A2.
XX
XX      20-MAR-2003.
XX
XX      12-SEP-2002; 2002WO-US029148.
XX
XX      13-SEP-2001; 2001US-00953318.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Bennett CF, Walt AT;
XX
XX      WPI; 2003-301004/29.
XX
XX      New antisense oligonucleotide targeted to a nucleic acid encoding
XX      vascular endothelial growth factor receptor-1, useful for diagnosing or
XX      treating cancer, rheumatoid arthritis, or diseases or conditions
XX      involving angiogenesis.
XX
XX      Claim 3; Page 83; 150pp; English.
XX
XX      The present invention describes a compound (C) 8-50 nucleobases in length
XX      targeted to a nucleic acid molecule encoding vascular endothelial growth
XX      factor receptor-1 (VEGFR-1), where the compound inhibits the expression
XX      of VEGFR-1 and specifically hybridises with the nucleic acid encoding
XX      VEGFR-1 or with an 8-nucleobase portion of an active site on the nucleic
XX      acid molecule encoding VEGFR-1. Also described: (1) a composition
XX      comprising (C) and a carrier or diluent; (2) inhibiting the expression of
XX      VEGFR-1 in cells or tissues by contacting the cells or tissues with (C)
XX      so that the expression of VEGFR-1 is inhibited; and (3) treating an
XX      animal having a disease or condition associated with VEGFR-1 by
XX      administering (C) to the animal so that the expression of VEGFR-1 is
XX      inhibited. (C) has antiangiogenic, antirheumatic, antiarthritic,
XX      cytostatic and antiinflammatory activities, and can be used in antisense
XX      gene therapy. The antisense compounds are useful for modulating the
XX      expression of VEGFR-1 and for treating diseases or conditions associated
XX      with the expression of VEGFR-1, such as hyperproliferative disorders
XX      (e.g. cancer), rheumatoid arthritis, or diseases or conditions involving
XX      angiogenesis. The antisense compounds are also useful for diagnostics,
XX      therapeutics, prophylaxis, e.g. to prevent or delay infection,
XX      inflammation or tumour formation, as research reagents and kits, and in
XX      distinguishing between functions of various members of a biological
XX      pathway. The present sequence represents a human VEGFR-2 chimeric
XX      phosphorothioate antisense oligonucleotide, which is used in an example
XX      from the present invention
XX
XX      Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX      Query Match      0.4%; Score 15.4; DB 1; Length 20;
XX      Best Local Similarity 94.1%; Pred. No. 2.6e+02;
XX      Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX      QY      2641 CTGCATGCTGACGCA 2657
XX      ||| ||||| ||||| |||||
XX      DB      20 CTGCATGCTGACGCA 4
XX
XX      RESULT 419
XX      ABX17545
XX      ID      ABX17545 standard; DNA; 20 BP.
XX
XX      AC      ABX17545;
XX
XX      DT      05-FEB-2003 (first entry)
XX
XX      DE      RTQ-PCR primer #2 for human protein NOV1.
```

```
XX      XX
XX      Human; ss; NOVX; adrenoleukodystrophy; haemophilia; stroke; VHL; PCR;
XX      congenital adrenal hyperplasia; haemophilia; hypercoagulation;
XX      idiopathic thrombocytopenic purpura; autoimmune disease; allergy;
XX      immunodeficiencies; transplantation; Von Hippel-Lindau syndrome;
XX      Alzheimer's disease; tubular sclerosis; Parkinson's disease; epilepsy;
XX      Huntington's disease; cerebral palsy; Lesch-Nyhan syndrome; pain;
XX      multiple sclerosis; ataxia-cerebellar ataxia; leukodystrophy; anxiety;
XX      behavioural disorder; addiction; neuroprotection; diabetes; AIDS;
XX      renal artery stenosis; interstitial nephritis; glomerulonephritis;
XX      polycystic kidney disease; systemic lupus erythematosus; IGA; primer;
XX      renal tubular acidosis; immunoglobulin A nephropathy; hypercalcaemia;
XX      cirrhosis; transplantation; asthma; emphysema; scleroderma; GVHD;
XX      adult respiratory distress syndrome; graft versus host disease;
XX      lymphedema; fertility; pancreatitis; obesity; haemophilia; ulcer;
XX      anaemia; cancer; trauma; regeneration; infection; RTQ-PCR;
XX      real-time quantitative PCR.
XX
XX      Homo sapiens.
XX
XX      WO200281629-A2.
XX
XX      17-OCT-2002.
XX
XX      PD
XX      03-APR-2002; 2002WO-US010522.
XX
XX      PF
XX      03-APR-2001; 2001US-0281086P.
XX      03-APR-2001; 2001US-0281136P.
XX      05-APR-2001; 2001US-0281863P.
XX      05-APR-2001; 2001US-0281906P.
XX      06-APR-2001; 2001US-0282020P.
XX      10-APR-2001; 2001US-0282934P.
XX      12-APR-2001; 2001US-0283512P.
XX      19-APR-2001; 2001US-0283525P.
XX      23-APR-2001; 2001US-0285890P.
XX      24-APR-2001; 2001US-0286068P.
XX      25-APR-2001; 2001US-0286292P.
XX      27-APR-2001; 2001US-0287213P.
XX      02-MAY-2001; 2001US-0288257P.
XX      12-MAY-2001; 2001US-0291134P.
XX      17-MAY-2001; 2001US-0291725P.
XX      31-MAY-2001; 2001US-0294771P.
XX      08-JUN-2001; 2001US-0296965P.
XX      18-JUN-2001; 2001US-0299128P.
XX      12-JUL-2001; 2001US-0305063P.
XX      14-NOV-2001; 2001US-032780P.
XX      04-JAN-2002; 2002US-0345221P.
XX      02-APR-2002; 2002US-00345221.
XX
XX      (CURA-) CURAGEN CORP.
XX
XX      SPYtek RA, Li L, Edinger SR, Ellerman K, Stone DJ, Malyankar UM;
XX      Shinkets RA, Guo X, Anderson DW, Patturajan M, Berghs C, Gerlach V;
XX      Taupier RJ, Pena CE, Padigaru M, Liu Y, Burgess CE, Miller CE;
XX      Gusev VV, Kekuda R, Gorman L, Zernusen BD, Baumgartner JC,
XX      Tchernev VT, Vernet CAM, Smithson G, Heyes MP, Shenoy SG, Liu X;
XX      Gangolli EA;
XX
XX      WPI; 2003-046863/04.
XX
XX      DR
XX      New polypeptides, designated NOVX polypeptides, useful for treating
XX      hemophilia, idiopathic thrombocytopenic purpura, autoimmune disease,
XX      allergies, transplantation, Alzheimer's disease and stroke.
XX
XX      PS      Example C; Page 189; 320pp; English.
XX
XX      The invention relates to an isolated NOVX polypeptide selected from NOV1-
XX      NOV27 polypeptides, a mature form of NOVX, a variant of NOVX or a
XX      fragment of NOVX. Also included are determining the presence or amount of
XX      NOVX in a sample (by using an antibody that immunospecifically bind to
XX      the polypeptide), determining the presence of or predisposition to
XX      disease associated with altered levels of NOVX in a first mammalian
XX      subject, identifying a potential therapeutic agent for use in the
```

CC treatment of pathology related to aberrant expression of physiological
CC interactions of NOX¹ screening for a modulator of activity or of latency
CC or predilection to a pathology associated with NOX¹, the nucleic acid
CC encoding NOX¹, vectors and host cells. NOX¹ is useful for identifying an
CC agent (a cellular receptor or downstream effector) that binds to NOX¹.
CC NOX¹ and NOX² nucleic acids are useful for treating or preventing NOX-
CC associated disorders in humans, and in the manufacture of a medicament
CC for treating a NOX¹ related disease human disease e.g.
CC adrenoleukodystrophy, congenital adrenal hyperplasia, hemophilia,
CC hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune
CC disease, allergies, immunodeficiencies, transplantation, Von Hippel-
CC Lindau (VHL) syndrome, Alzheimer's disease, stroke, tubular sclerosis,
CC Parkinson's disease, Huntington's disease, cerebellar palsy, epilepsy,
CC Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia,
CC leukodystrophies, behavioural disorders, addiction, anxiety, pain,
CC neuroprotection, diabetes, renal artery stenosis, interstitial nephritis,
CC glomerulonephritis, polycystic kidney disease, systemic lupus
CC erythematosus, renal tubular acidosis, immunoglobulin (Ig) A nephropathy,
CC hypercalcaemia, cirrhosis, transplantation, asthma, emphysema,
CC scleroderma, adult respiratory distress syndrome (ARDS), graft versus
CC host disease (GVHD), lymphedema, fertility, pancreatitis, obesity,
CC haemophilia, ulcers, anaemia, cancer, trauma, regeneration, and viral,
CC bacterial or parasitic infections. The present sequence is a real-time
CC quantitative (RTO)-PCR primer used to determine the tissue specific
CC expression of a NOX¹ mRNA
XX

SEQ Sequence 20 BP; 10 A; 4 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1084 CAGGAAATGAGGCAA 1100.
DB 4 CAGGAAATGAGGCAA 20
|||||
ADP87724/C
ID ADF87724 standard; DNA; 20 BP.
XX
AC ADF87724;
XX
DT 26-FEB-2004 (first entry)
XX
DE Single nucleotide polymorphism detection primer, SEQ ID NO 1307.
XX
KW human; single nucleotide polymorphism; microarray; side effect; ss;
KM primer; PCR.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN JP2003235571-A.
XX
PD 26-AUG-2003.
XX
PF 12-FEB-2002; 2002JP-00034717.
XX
PR 12-FEB-2002; 2002JP-00034717.
XX
PA (KAGA-) KAGAKU GIUTTSU SHINKO JIGYODAN.
XX
DR WPI; 2003-820454/77.
XX
PT Novel polynucleotide useful for detecting single nucleotide polymorphisms
PT in human gene.
XX
PS Claim 2; SEQ ID NO 1307; 704pp; Japanese.
XX
CC The invention relates to a novel polynucleotide isolated and purified
CC from a human gene having any one of 935 fully defined sequences as given
CC in specification, or a sequence having a base substitution. The invention

CC further relates to: an oligonucleotide containing single nucleotide
CC polymorphisms; a PCR primer set chosen from the combination of two DNA
CC fragments from any one of 1220 fully defined sequences as given in
CC specification; a labelling probe containing the SNP containing oligo; and
CC a microarray equipped with the SNP containing oligo. The isolated human
CC gene of the invention is useful for detecting the single nucleotide
CC polymorphisms in human gene. The isolated human gene is also useful for
CC diagnosis of disease and determination of side effect to a medical agent.
CC The isolated human gene is also effective in detecting single nucleotide
CC polymorphisms in a human gene. This polynucleotide sequence represents
CC one of the PCR primers used in the single nucleotide polymorphism
CC detection method of the invention.
XX

SEQ Sequence 20 BP; 3 A; 1 C; 11 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 236 CTCACGACGCGCAATC 252
DB 20 CTCACGACGCGCAATC 4
|||||
ABZ86463/C
ID ABZ86463 standard; DNA; 20 BP.
XX
AC ABZ86463;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; de.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 1705; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Db Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3489 TGGCTCCAGTGTGCT 3505
 Db 17 TGGCTCCAGTGTGCT 1

RESULT 422
 ABZ98559/c
 ID ABZ98559 standard; DNA; 20 BP.

XX ABZ98559;

XX 17-OCT-2003 (first entry)

XX Human ICAM oligonucleotide sequence.

KW Human: antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAse, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.

XX Disclosure; SEQ ID NO 13801; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Db Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1491 GCTCTGCTGCTGGGACA 1507
 Db 17 GCTCTGCTGCTGGGACA 1

RESULT 423
 ABD31590/c
 ID ABD31590 standard; DNA; 20 BP.

XX ABD31590;

XX 29-UTL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13801.

KW Human: antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antisthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13801; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity levels of adenosine (a) or (b) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-gene to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiallergic,
CC analgesic, hypotensive, immunosuppressive and cytoskeletal activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX

SO. Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1491 GCTCTGCTGCTGGGACA 1507
DB 17 GCTCTGCTGCTGGGACA 1

RESULT 424
ABD22693/C
ID ABD22693 standard; DNA; 20 BP.
XX
AC ABD22693;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human myosin X-derived oligonucleotide SEQ ID 1705.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KM surfactant depletion; antiallergic; antiinflammatory; antiallergic;
KM analgesic; hypotensive; immunosuppressive; cytoskeletal; cystic fibrosis;
KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KM respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KM pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandraesgra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 1705; 763pp; English.
XX
PS This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiallergic,
CC analgesic, hypotensive, immunosuppressive and cytoskeletal activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX

SO. Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3489 TGCTCTGCTGCTGCTGCT 3505
DB 17 TGCTCTGCTGCTGCTGCT 1

RESULT 425
ADJ53556
ID ADJ53556 standard; DNA; 20 BP.
XX
AC ADJ53556;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human PPP3CB DNA antisense oligonucleotide target region #7.
XX
XX Human; PPP3CB; ss; antisense oligonucleotide; phosphorothioate linkage;
KM 2'-O-methoxyethyl sugar moiety; 5-methylcytosine; autoimmune disorder;
KM Alzheimer's disease; immunosuppressive; nootropic; neuroprotective.
XX
XX Homo sapiens.
OS
XX
PN US2004023382-A1.
XX
PD 05-FEB-2004.
XX
PF 31-JUL-2002; 2002US-00210723.
XX
PR 31-JUL-2002; 2002US-00210723.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX (ISIS-) ISIS PHARM INC.

```

XX  Dean NM, Bennett CF, Dobie KM;
XX  WPI; 2004-142663/14.
XX
XX  New compounds, particularly antisense oligonucleotides targeted to a
XX  nucleic acid encoding PPP3CB, useful for treating an autoimmune disorder,
XX  or Alzheimer's disease.
XX
XX  Example 15; SEQ ID NO 92; 91pp; English.
XX
XX  The invention relates to an antisense oligonucleotide targeted to a
XX  nucleic acid encoding the human PPP3CB polypeptide and inhibits
XX  expression of the PPP3CB polypeptide. The antisense oligonucleotide
XX  comprises at least one modified internucleoside linkage, i.e. a
XX  phosphorothioate linkage, at least one modified sugar moiety, preferably
XX  a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
XX  comprising a 5-methylcytosine. The antisense oligonucleotides are useful
XX  for inhibiting expression of the PPP3CB polypeptide and in preparation of
XX  a composition for treating autoimmune disorders or Alzheimer's disease.
XX  This sequence represents an antisense oligonucleotide target region of
XX  the invention.
XX
XX  Sequence 20 BP; 6 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
XX
XX  Query Match          0.4%; Score 15.4; DB 1; Length 20;
XX  Best Local Similarity 94.1%; Pred. No. 2.6e+02;
XX  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX  2432 AGGTGGAAAGCAGTGAG 2448
XX  |||||
XX  4 AGGTGGAGAGCAGTGAG 20
XX
XX  RESULT 426
XX  ADJ53484/C
XX  ID ADJ53484 standard; DNA; 20 BP.
XX
XX  ADJ53484;
XX
XX  06-MAY-2004 (first entry)
XX
XX  Human PPP3CB DNA antisense oligonucleotide #7.
XX
XX  Human; PPP3CB; ss; antisense oligonucleotide; phosphorothioate linkage;
XX  2'-O-methoxyethyl sugar moiety; 5-methylcytosine; autoimmune disorder;
XX  Alzheimer's disease; immunosuppressive; nootropic; neuroprotective.
XX
XX  Homo sapiens.
XX
XX  US2004023382-A1.
XX
XX  05-FEB-2004.
XX
XX  31-JUL-2002; 2002US-00210723.
XX
XX  31-JUL-2002; 2002US-00210723.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Dean NM, Bennett CF, Dobie KM;
XX  WPI; 2004-142663/14.
XX
XX  New compounds, particularly antisense oligonucleotides targeted to a
XX  nucleic acid encoding PPP3CB, useful for treating an autoimmune disorder,
XX  or Alzheimer's disease.
XX
XX  Example 15; SEQ ID NO 20; 91pp; English.
XX
XX  The invention relates to an antisense oligonucleotide targeted to a
XX  nucleic acid encoding the human PPP3CB polypeptide and inhibits
XX  expression of the PPP3CB polypeptide. The antisense oligonucleotide

```

```

CC  comprises at least one modified internucleoside linkage, i.e. a
CC  phosphorothioate linkage, at least one modified sugar moiety, preferably
CC  a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC  comprising a 5-methylcytosine. The antisense oligonucleotides are useful
CC  for inhibiting expression of the PPP3CB polypeptide and in preparation of
CC  a composition for treating autoimmune disorders or Alzheimer's disease.
CC  This sequence represents an antisense oligonucleotide of the invention.
XX
XX  Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX  Query Match          0.4%; Score 15.4; DB 1; Length 20;
XX  Best Local Similarity 94.1%; Pred. No. 2.6e+02;
XX  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX  2432 AGGTGGAAAGCAGTGAG 2448
XX  |||||
XX  17 AGGTGGAGAGCAGTGAG 1
XX
XX  RESULT 427
XX  ADH80333
XX  ID ADH80333 standard; DNA; 20 BP.
XX
XX  ADH80333;
XX
XX  06-MAY-2004 (first entry)
XX
XX  RNF3 PCR primer, SEQ ID 57.
XX
XX  Cytostatic; human; senescence; tumour; PCR; primer; ss; RNF3.
XX
XX  Homo sapiens.
XX
XX  WO2004005462-A2.
XX
XX  15-JAN-2004.
XX
XX  27-JUN-2003; 2003WO-US020425.
XX
XX  03-JUL-2002; 2002US-0394121P.
XX
XX  (UNIT ) UNIT ILLINOIS FOUND.
XX
XX  Roninson IB, Chang B;
XX
XX  WPI; 2004-091347/09.
XX
XX  Identifying compounds that induce senescence in mammalian cells, useful
XX  for treating e.g. cancer, comprises assaying the expression of cellular
XX  genes in the cell in the presence and absence of the compound.
XX
XX  Example 4; SEQ ID NO 57; 102pp; English.
XX
XX  The present invention relates to a method for identifying a compound that
XX  induces senescence in a mammalian cell. The method comprises assaying the
XX  expression of cellular genes in the cell in the presence and absence of
XX  the compound. The method is useful for identifying and modulating
XX  expression of tumour senescence genes. These may be used in treating
XX  diseases or conditions related to abnormal cell proliferation or
XX  neoplastic cell growth, in assessing the efficacy of the treatment of the
XX  disease or condition, or in identifying compounds that induce senescence
XX  in mammalian cells or that inhibit senescence-associated induction of
XX  cellular gene expression. PCR primers ADH80277-ADH80400 were used to
XX  amplify genes that are up- or downregulated in doxorubicin-induced
XX  accelerated senescence to identify senescence-inducing compounds.
XX
XX  Sequence 20 BP; 7 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX  Query Match          0.4%; Score 15.4; DB 1; Length 20;
XX  Best Local Similarity 94.1%; Pred. No. 2.6e+02;
XX  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX  462 AGACATCAAGGCGCAGA 478

```

Db 1 AGACATCAAGGGGAGAGA 17
|||||
|||
RESULT 428
ADK98171
ID ADK98171 standard; DNA; 20 BP.
XX
AC ADK98171;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #1891.
XX
KM human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.
XX
PF 08-MAR-2002; 2002JP-00064373.
XX
PR 08-MAR-2002; 2002JP-00064373.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2004-093977/10.
XX
PT Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 7200; 2627bp; Japanese.
XX
SQ The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 209 AGGAGATCAACATGCTG 225
Db 1 AGGAGATCAACATCTG 17
|||||
|||
RESULT 429
ADJ60409/c
ID ADJ60409 standard; DNA; 20 BP.
XX
AC ADJ60409;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICM #183.
XX
KM interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KM allergy; inflammation; allergy; asthma; impeded respiration;
KM cystic fibrosis; acute respiratory distress syndrome;
KM pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KM ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX

PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
PF
XX
XX 29-JUL-2002; 2002US-0399076P.
PR
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nye JW, Tang L, Sandraaagra A, Aguilar D, Miller S,
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1265; 85pp; English.
XX
SQ The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene (s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from asthma, inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, allergy
CC obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1491 GCTCTGCTGGGAGACA 1507
Db 17 GCTCTGCTGGGAGACA 1
|||||
|||
RESULT 430
ADO45898/c
ID ADO45898 standard; DNA; 20 BP.
XX
AC ADO45898;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1264.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICM; VCM; tryptase a;
XX tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX lung disease; hyper-responsiveness; adenosis; adenosis A receptor;
XX asthma; lung allergy; inflammation; inflammatory disease; cystic fibrosis; CF;
XX allergy; inflammation; allergy; impeded respiration; cystic fibrosis; CF;
XX chronic obstructive pulmonary disease; COPD; allergic rhinitis;
XX acute respiratory distress syndrome; pulmonary hypertension;
XX lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX

XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 PT
 PS Claim 2; SEQ ID NO 1265; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC 5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, triptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, triptase a,
 CC triptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1491 GCTCCTGCTGGGAGCA 1507
 Db 17 GCTCCTGCTGGGAGCA 1
 XX
 RESULT 431
 ID ADP76511
 XX ADP76511 standard; DNA; 20 BP.
 AC ADP76511;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Chimeric phosphorothioate oligonucleotide #310.
 XX

KW GFAT; Antidiabetic; Cardiant;
 KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
 KW reperfusion; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..4
 FT /*tag= a
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"
 FT modified_base 17..20
 FT /*tag= b
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"
 PN W02004035763-A2.
 XX
 PD 29-APR-2004.
 XX
 XX 02-OCT-2003; 2003WO-US033332.
 XX
 PR 17-OCT-2002; 2002US-0419268P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Broschat KO, Crosby SD;
 XX
 DR WPI; 2004-348453/32.
 XX
 PT New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
 PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
 PT ischemia/reperfusion injury.
 XX
 PS Claim 4; SEQ ID NO 310; 175pp; English.
 XX
 CC The present invention relates to a compound which specifically hybridizes
 CC with a nucleic acid molecule encoding GFAT, and inhibits the expression
 CC of GFAT. Specifically claimed are antisense oligonucleotides capable of
 CC modulating the expression of GFAT, and which comprise any of the 3063
 CC sequences of 20 base pairs, given in the specification. The compound,
 CC composition and methods are useful for treating a disease or condition
 CC associated with GFAT, such as a disease or condition, e.g., diabetes, a
 CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
 CC They are also useful in research and diagnostics for modulating the
 CC expression of GFAT. The present sequence represents a chimeric
 CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
 CC oligonucleotides inhibit human GFAT expression.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
 XX
 QY Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 855 ACTGAAGTTCCCTTCA 871
 Db 4 ACTGAAGTTCCCTTCA 20
 XX
 RESULT 432
 ID ADP76836
 XX ADP76836 standard; DNA; 20 BP.
 AC ADP76836;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Chimeric phosphorothioate oligonucleotide #635.
 XX
 KW GFAT; Antidiabetic; Cardiant;
 KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;

PT modified_base residues are 5-methylcyridines"
 FT 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) bases"
 FT modified_base 16..20
 FT /*tag= C
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) bases"
 XX
 XX US2004096833-A1.
 XX
 XX 20-MAY-2004.
 XX
 XX 16-NOV-2002; 2002US-00298954.
 XX
 XX 16-NOV-2002; 2002US-00298954.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Chiang M, Dobie KW;
 XX
 XX WPI; 2004-389148/36.
 XX
 XX New compounds targeted to a nucleic acid molecule encoding FBP-
 PT interacting repressor, for treating an animal having a disease or
 PT condition associated with FBP-interacting repressor, such as a
 PT hyperproliferative disorder.
 XX
 XX Example 15; SEQ ID NO 32; 36pp; English.
 XX
 XX The invention relates to compounds, compositions and methods for
 CC modulating the expression of far upstream element (FUSE)-binding protein
 CC (FBP)-interacting repressor (FIR). FIR is also called as pyrimidine tract
 CC binding splicing factor. Ro ribonucleoprotein-binding protein 1, SIAH
 CC binding protein 1 and poly-U-binding splicing factor PUF60. The compound
 CC is useful for treating an animal having a disease or condition associated
 CC with FIR, such as a hyperproliferative disorder. The compound may also be
 CC used for diagnostics, therapeutics, prophylaxis and as research agents
 CC and kits; or to elucidate the function of particular genes or to
 CC distinguish between functions of various members of a biological pathway.
 CC The present sequence is an antisense oligonucleotide targeted to human
 CC FIR DNA. This sequence is used to illustrate the method of the invention
 CC
 XX
 XX Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1478 AGCAGCAGCAGCAGCTC 1494
 Db 20 ACCAGCAGCAGCAGCTC 4
 RESULT 435
 ADP44518/c
 ID ADP44518 standard; DNA; 20 BP.
 XX
 XX ADP44518;
 AC
 XX 09-SEP-2004 (first entry)
 XX
 XX Human ABCC5 DNA antisense oligonucleotide target region #56.
 DE
 XX Human; ABCC5; ss; antisense oligonucleotide; phosphorothioate linkage;
 KM 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KM hyperproliferative disorder; cancer; cytostatic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WPI; 2004-115649-A1.
 XX
 XX

PD 17-JUN-2004.
 XX
 XX 12-DEC-2002; 2002US-00319893.
 PF
 XX 12-DEC-2002; 2002US-00319893.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Dobie KW;
 XX
 XX WPI; 2004-449386/42.
 XX
 XX New oligonucleotide compound that inhibits expression of ABCC5, useful
 PT for preparing a composition for treating hyperproliferative disorder,
 PT e.g., cancer.
 XX
 XX Example 15; SEQ ID NO 144; 57pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding the human ABCC5 polypeptide. The compound is an antisense
 CC oligonucleotide that specifically hybridizes with the nucleic acid and
 CC inhibits expression of the polypeptide. The antisense oligonucleotide
 CC comprises at least one modified internucleoside linkage i.e. a
 CC phosphorothioate linkage, at least one modified sugar moiety, preferably
 CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
 CC comprising a 5-methylcytosine. The antisense compounds are useful for
 CC modulating the expression of the human ABCC5 polypeptide and in
 CC preparation of a composition for treating hyperproliferative disorders,
 CC e.g. cancer. This sequence represents a human ABCC5 DNA antisense
 CC oligonucleotide target region of the invention.
 CC
 XX
 XX Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 995 ATGACGCCATGAGAG 1011
 Db 17 ATGATCGCCATGAGAG 1
 RESULT 436
 ADP44443
 ID ADP44443 standard; DNA; 20 BP.
 XX
 XX ADP44443;
 AC
 XX 09-SEP-2004 (first entry)
 XX
 XX Human ABCC5 DNA antisense oligonucleotide #59.
 DE
 XX Human; ABCC5; ss; antisense oligonucleotide; phosphorothioate linkage;
 KM 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KM hyperproliferative disorder; cancer; cytostatic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2004115649-A1.
 XX
 XX 17-JUN-2004.
 XX
 XX 12-DEC-2002; 2002US-00319893.
 PF
 XX 12-DEC-2002; 2002US-00319893.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Dobie KW;
 XX
 XX WPI; 2004-449386/42.
 XX
 XX New oligonucleotide compound that inhibits expression of ABCC5, useful
 PT

PT for preparing a composition for treating hyperproliferative disorder,
PT e.g., cancer.
XX
PS Example 15; SEQ ID NO 69; 57bp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding the human ABCG5 polypeptide. The compound is an antisense
CC oligonucleotide that specifically hybridizes with the nucleic acid and
CC inhibits expression of the polypeptide. The antisense oligonucleotide
CC comprises at least one modified internucleoside linkage i.e., a
CC phosphorothioate linkage, at least one modified sugar moiety, preferably
CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC comprising a 5-methylcytosine. The antisense compounds are useful for
CC modulating the expression of the human ABCG5 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g., cancer. This sequence represents an antisense oligonucleotide
CC targeted to DNA encoding the human ABCG5 polypeptide of the invention.
XX
SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

995 ATGACAGCCATGAGAG 1011
DB 4 ATGACTGCCATGAGAG 20

RESULT 437
ID ADR30844
ID ADR30844 standard; DNA; 20 BP.
XX
AC ADR30844;
XX
DT 18-NOV-2004 (first entry)
XX
DE Identifier oligonucleotide used for Q-PCR quantification.
XX
KW second-generation library; second-generation compound library;
KW improved desired property profile; lower diversity;
KW Identifier oligonucleotide; Q-PCR; quantification; ss.
XX
OS Synthetic.
XX
PN WO2004074429-A2.
XX
PD 02-SEP-2004.
XX
PF 23-FEB-2004; 2004WO-DK000117.
XX
PR 21-FEB-2003; 2003DK-00000268.
XX
PR 21-FEB-2003; 2003DK-00000269.
XX
PR 21-FEB-2003; 2003US-0448460P.
XX
PR 21-FEB-2003; 2003US-0448480P.
XX
PR 18-SEP-2003; 2003DK-00001356.
XX
PR 22-SEP-2003; 2003US-0504748P.
XX
PA (NUREV-) NUCLEOTIDE SEQUENCE AS.
XX
PI Freshgard P, Gouliav AH, Thisted T, Olsen EK;
XX
DR WPI, 2004-635552/61.
XX
PT Producing a second-generation library of molecules with improved desired
PT property using an initial library with a plurality of encoded molecules
PT associated with an identifier nucleic acid sequence.
XX
PS Example 4; Page 68; 128bp; English.
XX
CC The present invention describes a method for producing a composition of
CC molecules with an improved desired property. The method comprises: (1)
CC providing an initial library comprising a plurality of different encoded

CC molecules associated with a corresponding identifier nucleic acid
CC sequence, where each encoded molecule comprises a reaction product of
CC multiple chemical entities and the identifier nucleic acid sequence
CC comprises codons identifying the chemical entities; (1i) subjecting the
CC initial library to a condition partitioning members having encoded
CC molecules displaying a predetermined property from the remainder of the
CC initial library; (1ii) identifying codons of the identifier nucleic acid
CC sequences of the partitioned members of the initial library; and (1iv)
CC preparing a second-generation library of encoded molecules using the
CC chemical entities coded for by the codons of the partitioned members of
CC the initial library or its part. Also described: (1) a composition of
CC molecules with an improved desired property, obtainable by the method
CC described above; and (2) a molecule identifiable by subjecting a
CC composition of molecules obtainable by the method described above to a
CC condition partitioning members having encoded molecules displaying a
CC predetermined property from the remainder of the composition, and
CC identifying the partitioned encoded molecule(s). The methods and
CC compositions of the present invention are useful for producing a second-
CC generation compound library with an improved desired property profile and
CC lower diversity. The present sequence represents an identifier
CC oligonucleotide used for Q-PCR quantification, which is used in an example
CC from the present invention.
XX
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

QY Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

3648 TGTCTACGTCAACACGT 3664
DB 1 TGTCTACGTCAACACGT 17

RESULT 438
ID ADR86867/C
ID ADR86867 standard; DNA; 20 BP.
XX
AC ADR86867;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 172.
XX
KW cytosstatic; antiinflammatory; antirheumatic; antiproliferative;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASCULAR THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Kerecz N, Reddy R, Gill P;
XX
DR WPI, 2004-668883/55.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

XX Example 8; Page 93; 198pp; English.
PS
XX
CC 'The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
SQ Sequence 20 BP; 4 A; 8 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 CCTGTCGCCCTCGCGG 64
DB 17 CCTGTGCGCCCTCGCGG 1
RESULT 439
ADR82422/c
ID ADR82422 standard; DNA; 20 BP.
XX
AC ADR82422;
XX
DT 16-DEC-2004 (first entry)
XX
DB Human EphB4 antisense probe #93.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antineumatic; antiproliferative;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX
PS Example 8; Page 100; 206pp; English.
XX
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
SQ Sequence 20 BP; 4 A; 8 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 CCTGTCGCCCTCGCGG 64
DB 17 CCTGTGCGCCCTCGCGG 1

Search completed: May 12, 2005, 11:25:12
Job time : 22 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 12, 2005, 11:27:16 ; Search time 25 Seconds
(without alignments)
3.557 Million cell updates/sec

Title: us-10-029-115-1

Perfect score: 3951
Sequence: 1 gccctatgsggcagccaccgc.....tcattgacgcygaaagggc 3951

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 609 seqs, 11255 residues

Total number of hits satisfying chosen parameters: 1218

Minimum DB seq length: 8

Maximum DB seq length: 80

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 623 summaries

Database : rntdb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	41.4	1.0	51	1	US-08-068-747-1	Sequence 1, App1
C 2	29.4	0.7	33	1	US-08-863-639A-29	Sequence 29, App1
C 3	28.4	0.7	30	1	US-08-068-747-6	Sequence 6, App1
C 4	28.4	0.7	30	1	US-08-068-747-11	Sequence 11, App1
C 5	28.4	0.7	30	1	US-08-863-639A-30	Sequence 30, App1
C 6	28.4	0.7	30	1	US-09-135-994-4	Sequence 4, App1
C 7	28.4	0.7	30	1	US-09-684-843A-4	Sequence 4, App1
C 8	28.4	0.7	31	1	US-08-570-155-14	Sequence 14, App1
C 9	28.4	0.7	31	1	PCT-US95-02861-14	Sequence 14, App1
C 10	27.8	0.7	33	1	US-09-475-947A-251	Sequence 251, App1
C 11	27.2	0.7	36	1	US-08-863-639A-31	Sequence 31, App1
C 12	26.2	0.7	31	1	US-09-645-456A-27	Sequence 27, App1
C 13	26.2	0.7	31	1	US-09-425-324A-27	Sequence 27, App1
C 14	26.2	0.7	31	1	US-09-645-791-27	Sequence 27, App1
C 15	24.6	0.6	31	1	US-09-645-456A-26	Sequence 26, App1
C 16	24.6	0.6	31	1	US-09-425-324A-26	Sequence 26, App1
C 17	24.6	0.6	31	1	US-09-645-791-26	Sequence 26, App1
C 18	23	0.6	23	1	US-09-688-188B-60	Sequence 60, App1
C 19	23	0.6	23	1	US-09-688-188B-61	Sequence 60, App1
C 20	23	0.6	23	1	US-09-291-417D-60	Sequence 60, App1
C 21	23	0.6	23	1	US-09-291-417D-61	Sequence 60, App1
C 22	22.2	0.6	24	1	US-08-863-639A-94	Sequence 94, App1
C 23	22.2	0.6	27	1	US-09-651-011A-6	Sequence 6, App1
C 24	22.2	0.6	29	1	US-09-304-232-152	Sequence 152, App1
C 25	21	0.5	21	1	US-09-688-188B-58	Sequence 58, App1
C 26	21	0.5	21	1	US-09-291-417D-58	Sequence 58, App1
C 27	20.6	0.5	51	1	US-08-068-747-1	Sequence 1, App1
C 28	20	0.5	20	1	US-09-688-188B-59	Sequence 59, App1
C 29	20	0.5	20	1	US-09-291-417D-59	Sequence 59, App1
C 30	19.4	0.5	21	1	US-08-267-803B-66	Sequence 66, App1
C 31	19.4	0.5	21	1	US-08-863-639A-28	Sequence 28, App1
C 32	19.4	0.5	21	1	US-08-863-639A-40	Sequence 40, App1
C 33	19.4	0.5	21	1	US-08-863-639A-60	Sequence 60, App1

C 34	19.4	0.5	21	1	US-08-863-639A-66	Sequence 66, App1
C 35	19.4	0.5	21	1	US-08-863-639A-69	Sequence 69, App1
C 36	19.4	0.5	21	1	US-08-863-639A-87	Sequence 87, App1
C 37	19.2	0.5	25	1	US-09-396-1966-43760	Sequence 43760, A
C 38	19	0.5	19	1	US-09-688-188B-62	Sequence 62, App1
C 39	19	0.5	19	1	US-09-291-417D-62	Sequence 62, App1
C 40	18.8	0.5	25	1	US-09-396-1966-18665	Sequence 18665, A
C 41	18.4	0.5	20	1	US-08-568-271-1	Sequence 1, App1
C 42	18.4	0.5	20	1	US-09-651-011A-15	Sequence 15, App1
C 43	18.2	0.5	23	1	US-09-083-268-11	Sequence 11, App1
C 44	18.2	0.5	23	1	US-08-983-605-193	Sequence 193, App1
C 45	18	0.5	18	1	US-09-205-995-48	Sequence 48, App1
C 46	17.8	0.5	22	1	US-09-688-188B-133	Sequence 133, App1
C 47	17.8	0.5	22	1	US-09-291-417D-133	Sequence 133, App1
C 48	17.4	0.4	19	1	US-08-410-540-5	Sequence 5, App1
C 49	17.4	0.4	20	1	US-09-657-042A-39	Sequence 39, App1
C 50	17.4	0.4	20	1	US-09-651-011A-42	Sequence 42, App1
C 51	17	0.4	18	1	US-08-863-639A-17	Sequence 17, App1
C 52	16.8	0.4	20	1	US-08-113-185-30	Sequence 30, App1
C 53	16.8	0.4	20	1	US-09-082-614A-30	Sequence 30, App1
C 54	16.8	0.4	20	1	US-09-657-042A-38	Sequence 38, App1
C 55	16.8	0.4	20	1	US-09-651-011A-20	Sequence 20, App1
C 56	16.8	0.4	20	1	US-09-651-011A-40	Sequence 40, App1
C 57	16.8	0.4	20	1	US-09-661-753-35	Sequence 35, App1
C 58	16.8	0.4	20	1	US-09-723-368-5	Sequence 5, App1
C 59	16.8	0.4	20	1	US-09-688-188B-136	Sequence 136, App1
C 60	16.8	0.4	20	1	US-09-291-417D-136	Sequence 136, App1
C 61	16.8	0.4	20	1	US-09-575-123-42	Sequence 42, App1
C 62	16.8	0.4	20	1	US-09-792-024-397	Sequence 397, App1
C 63	16.6	0.4	31	1	US-08-570-155-14	Sequence 14, App1
C 64	16.6	0.4	31	1	PCT-US95-02861-14	Sequence 14, App1
C 65	16.6	0.4	36	1	US-08-863-639A-29	Sequence 29, App1
C 66	16.6	0.4	36	1	US-08-863-639A-31	Sequence 31, App1
C 67	16.4	0.4	18	1	US-08-585-684B-2687	Sequence 2687, App1
C 68	16.4	0.4	18	1	US-09-038-073-2687	Sequence 2687, App1
C 69	16.4	0.4	18	1	US-09-050-159-46	Sequence 46, App1
C 70	16.4	0.4	18	1	US-09-050-159-46	Sequence 46, App1
C 71	16.4	0.4	20	1	US-09-053-866-10	Sequence 10, App1
C 72	16.4	0.4	20	1	US-09-490-692-72	Sequence 72, App1
C 73	16.4	0.4	20	1	US-09-479-130-10	Sequence 10, App1
C 74	16.4	0.4	20	1	US-09-472-130A-10	Sequence 10, App1
C 75	16.4	0.4	20	1	US-10-215-140A-53	Sequence 53, App1
C 76	16.4	0.4	21	1	US-09-475-947A-199	Sequence 199, App1
C 77	16.2	0.4	21	1	US-08-256-426B-285	Sequence 285, App1
C 78	16.2	0.4	21	1	US-08-882-501-2	Sequence 2, App1
C 79	16.2	0.4	21	1	US-09-688-188B-54	Sequence 54, App1
C 80	16.2	0.4	21	1	US-09-291-417D-54	Sequence 54, App1
C 81	16	0.4	18	1	US-08-585-684B-2688	Sequence 2688, App1
C 82	16	0.4	18	1	US-09-487-444-11	Sequence 11, App1
C 83	16	0.4	18	1	US-09-038-073-2688	Sequence 2688, App1
C 84	16	0.4	20	1	US-09-344-914-52	Sequence 52, App1
C 85	16	0.4	20	1	US-09-344-914-53	Sequence 53, App1
C 86	16	0.4	20	1	US-09-344-914-54	Sequence 54, App1
C 87	16	0.4	20	1	US-09-344-914-55	Sequence 55, App1
C 88	16	0.4	20	1	US-09-344-914-56	Sequence 56, App1
C 89	16	0.4	21	1	US-09-657-472-2068	Sequence 2068, App1
C 90	15.8	0.4	19	1	US-09-422-978-7203	Sequence 7203, App1
C 91	15.8	0.4	20	1	US-07-889-651-9	Sequence 9, App1
C 92	15.8	0.4	20	1	US-08-650-766-14	Sequence 14, App1
C 93	15.8	0.4	20	1	US-08-914-961-6	Sequence 6, App1
C 94	15.8	0.4	20	1	US-08-922-635-13	Sequence 13, App1
C 95	15.8	0.4	20	1	US-09-490-699-153	Sequence 153, App1
C 96	15.8	0.4	20	1	US-09-593-711A-152	Sequence 152, App1
C 97	15.8	0.4	20	1	US-09-651-011A-19	Sequence 19, App1
C 98	15.8	0.4	20	1	US-09-702-327-65	Sequence 65, App1
C 99	15.8	0.4	20	1	US-09-198-452A-2850	Sequence 2850, App1
C 100	15.8	0.4	20	1	US-09-198-452A-6476	Sequence 6476, App1
C 101	15.8	0.4	20	1	US-09-733-444-2	Sequence 2, App1
C 102	15.8	0.4	20	1	US-09-733-444-26	Sequence 26, App1
C 103	15.8	0.4	20	1	US-09-389-487-14	Sequence 14, App1
C 104	15.8	0.4	20	1	US-09-554-726A-29	Sequence 29, App1
C 105	15.8	0.4	21	1	US-08-426-792-2	Sequence 2, App1
C 106	15.8	0.4	21	1	US-08-863-639A-41	Sequence 41, App1

C 107	15.8	0.4	21	1	US-08-863-639A-53	Sequence 53, Appl	C 180	15	0.4	33	1	US-09-475-947A-251	Sequence 251, App
C 108	15.8	0.4	21	1	US-08-863-639A-59	Sequence 59, Appl	C 181	14.8	0.4	18	1	US-08-758-306-499	Sequence 499, App
C 109	15.8	0.4	21	1	US-08-863-639A-64	Sequence 64, Appl	C 182	14.8	0.4	18	1	US-08-974-565C-13	Sequence 13, Appl
C 110	15.8	0.4	21	1	US-08-863-639A-70	Sequence 70, Appl	C 183	14.8	0.4	18	1	US-09-106-038A-24	Sequence 24, Appl
C 111	15.8	0.4	21	1	US-08-863-639A-83	Sequence 83, Appl	C 184	14.8	0.4	18	1	US-09-255-911-31	Sequence 31, Appl
C 112	15.8	0.4	21	1	US-08-486-343A-5	Sequence 5, Appl1	C 185	14.8	0.4	18	1	US-09-289-466-18	Sequence 18, Appl
C 113	15.8	0.4	21	1	US-09-226-012-93	Sequence 93, Appl	C 186	14.8	0.4	18	1	US-09-205-995-55	Sequence 55, Appl
C 114	15.8	0.4	21	1	US-09-472-472-1779	Sequence 1779, Ap	C 187	14.8	0.4	18	1	US-09-091-952A-115	Sequence 115, Appl
C 115	15.8	0.4	21	1	PCT-US95-07349-5	Sequence 5, Appl1	C 188	14.8	0.4	18	1	US-09-475-947B-340	Sequence 340, App
C 116	15.6	0.4	30	1	US-08-068-747-6	Sequence 6, Appl1	C 189	14.8	0.4	18	1	US-09-280-030-28	Sequence 28, Appl
C 117	15.6	0.4	30	1	US-08-863-639A-30	Sequence 11, Appl	C 190	14.8	0.4	19	1	US-09-517-467B-5	Sequence 5, Appl1
C 118	15.6	0.4	30	1	US-08-863-639A-30	Sequence 30, Appl	C 191	14.8	0.4	19	1	US-09-475-947A-178	Sequence 178, App
C 119	15.6	0.4	30	1	US-09-135-994-4	Sequence 4, Appl1	C 192	14.8	0.4	19	1	US-09-422-978-910	Sequence 910, Ap
C 120	15.6	0.4	30	1	US-09-684-843A-4	Sequence 4, Appl1	C 193	14.8	0.4	19	1	US-09-422-978-9749	Sequence 9749, Ap
C 121	15.4	0.4	17	1	US-08-233-788A-31	Sequence 31, Appl	C 194	14.8	0.4	19	1	US-09-361-111-5	Sequence 11, Appl
C 122	15.4	0.4	17	1	US-08-373-124A-180	Sequence 180, App	C 195	14.8	0.4	19	1	US-09-119-737-12	Sequence 12, Appl
C 123	15.4	0.4	17	1	US-08-373-124A-182	Sequence 182, App	C 196	14.4	0.4	17	1	US-08-167-069-17	Sequence 17, Appl
C 124	15.4	0.4	17	1	US-08-373-124A-188	Sequence 188, App	C 197	14.4	0.4	17	1	US-08-885-126-3	Sequence 3, Appl1
C 125	15.4	0.4	17	1	US-08-435-628-180	Sequence 180, App	C 198	14.4	0.4	17	1	US-08-960-111-5	Sequence 5, Appl1
C 126	15.4	0.4	17	1	US-08-435-628-182	Sequence 182, App	C 199	14.4	0.4	17	1	US-09-490-774-5	Sequence 5, Appl1
C 127	15.4	0.4	17	1	US-08-435-628-188	Sequence 188, App	C 200	14.4	0.4	17	1	US-08-679-645-666	Sequence 666, App
C 128	15.4	0.4	17	1	US-09-371-772B-4506	Sequence 4506, Ap	C 201	14.4	0.4	17	1	US-09-474-432B-734	Sequence 734, App
C 129	15.4	0.4	17	1	US-09-866-108A-7802	Sequence 7802, Ap	C 202	14.4	0.4	17	1	US-09-476-387-732	Sequence 732, App
C 130	15.4	0.4	18	1	US-09-000-286A-21	Sequence 21, Appl	C 203	14.4	0.4	17	1	US-09-827-998-117	Sequence 117, App
C 131	15.4	0.4	18	1	US-09-000-286A-22	Sequence 22, Appl	C 204	14.4	0.4	17	1	US-09-827-998-118	Sequence 118, Appl
C 132	15.4	0.4	18	1	US-09-679-298A-30	Sequence 30, Appl	C 205	14.4	0.4	17	1	US-09-866-108A-6414	Sequence 6414, Ap
C 133	15.4	0.4	19	1	US-09-207-388-26	Sequence 26, Appl	C 206	14.4	0.4	17	1	US-09-866-108A-6415	Sequence 6415, Ap
C 134	15.4	0.4	19	1	US-09-432-978-5480	Sequence 5480, Ap	C 207	14.4	0.4	17	1	US-09-866-108A-7795	Sequence 7795, Ap
C 135	15.4	0.4	20	1	US-08-837-201C-28	Sequence 28, Appl	C 208	14.4	0.4	17	1	US-09-866-108A-7796	Sequence 7796, Ap
C 136	15.4	0.4	20	1	US-08-713-742-3	Sequence 3, Appl1	C 209	14.4	0.4	17	1	US-09-866-108A-7801	Sequence 7801, Ap
C 137	15.4	0.4	20	1	US-09-433-699-30	Sequence 30, Appl	C 210	14.4	0.4	17	1	US-09-866-108A-7803	Sequence 7803, Ap
C 138	15.4	0.4	20	1	US-09-372-856-3	Sequence 3, Appl1	C 211	14.4	0.4	17	1	US-09-866-108A-8002	Sequence 8002, Ap
C 139	15.4	0.4	20	1	US-09-364-416-28	Sequence 28, Appl	C 212	14.4	0.4	17	1	US-09-866-108A-8003	Sequence 8003, Ap
C 140	15.4	0.4	20	1	US-09-688-394-6	Sequence 3, Appl1	C 213	14.4	0.4	17	1	US-09-866-108A-8649	Sequence 8649, Ap
C 141	15.4	0.4	20	1	US-09-907-843-23	Sequence 23, Appl	C 214	14.4	0.4	17	1	US-09-866-108A-8650	Sequence 8650, Ap
C 142	15.4	0.4	20	1	US-09-953-318-45	Sequence 45, Appl	C 215	14.4	0.4	18	1	US-08-568-271-4	Sequence 344, App
C 143	15.4	0.4	20	1	US-09-934-138B-3	Sequence 3, Appl1	C 216	14.4	0.4	18	1	US-08-568-271-8	Sequence 4, Appl1
C 144	15.2	0.4	20	1	US-09-009-913-293	Sequence 293, App	C 217	14.4	0.4	18	1	US-08-257-963B-27	Sequence 27, Appl
C 145	15.2	0.4	20	1	US-09-429-323-26	Sequence 26, Appl	C 218	14.4	0.4	18	1	US-08-529-878B-10	Sequence 10, Appl
C 146	15.2	0.4	20	1	US-09-288-461-23	Sequence 23, Appl	C 219	14.4	0.4	18	1	US-08-529-878B-48	Sequence 48, Appl
C 147	15.2	0.4	20	1	US-08-927-219-66	Sequence 66, Appl	C 220	14.4	0.4	18	1	US-09-205-922-19	Sequence 19, Appl
C 148	15.2	0.4	20	1	US-09-517-584A-23	Sequence 23, Appl	C 221	14.4	0.4	18	1	US-09-487-444-14	Sequence 14, Appl
C 149	15.2	0.4	20	1	US-09-517-584A-36	Sequence 36, Appl	C 222	14.4	0.4	18	1	US-09-115-027-2	Sequence 2, Appl1
C 150	15.2	0.4	20	1	US-09-043-303-8	Sequence 8, Appl1	C 223	14.4	0.4	18	1	US-09-115-027-2	Sequence 2, Appl1
C 151	15.2	0.4	20	1	US-09-487-445-105	Sequence 105, App	C 224	14.4	0.4	18	1	US-08-367-841A-27	Sequence 27, Appl
C 152	15.2	0.4	20	1	US-09-487-368A-17	Sequence 17, Appl	C 225	14.4	0.4	18	1	US-09-496-694B-165	Sequence 165, App
C 153	15.2	0.4	20	1	US-09-593-711A-179	Sequence 179, App	C 226	14.4	0.4	18	1	US-09-205-995-42	Sequence 42, Appl
C 154	15.2	0.4	20	1	US-09-651-011A-11	Sequence 11, Appl	C 227	14.4	0.4	18	1	US-09-805-630-2	Sequence 2, Appl1
C 155	15.2	0.4	20	1	US-09-651-011A-16	Sequence 16, Appl	C 228	14.4	0.4	18	1	US-09-818-186A-165	Sequence 165, App
C 156	15.2	0.4	20	1	US-09-651-011A-44	Sequence 44, Appl	C 229	14.4	0.4	18	1	PCT-US95-07201-27	Sequence 27, Appl
C 157	15.2	0.4	20	1	US-09-658-679A-41	Sequence 41, Appl	C 230	14.4	0.4	19	1	US-09-275-505-1	Sequence 1, Appl1
C 158	15.2	0.4	20	1	US-09-078-871A-2	Sequence 2, Appl1	C 231	14.4	0.4	19	1	US-09-422-978-513	Sequence 513, Ap
C 159	15.2	0.4	20	1	US-09-629-644A-17	Sequence 17, Appl	C 232	14.4	0.4	19	1	US-09-982-212-40	Sequence 40, Appl
C 160	15.2	0.4	20	1	US-09-629-644A-17	Sequence 17, Appl	C 233	14.4	0.4	19	1	US-09-696-791-545	Sequence 545, App
C 161	15.2	0.4	20	1	US-09-198-452A-5002	Sequence 5002, Ap	C 234	14.4	0.4	19	1	US-09-696-791-545	Sequence 3081, Ap
C 162	15.2	0.4	20	1	US-09-922-146-23	Sequence 23, Appl	C 235	14.4	0.4	18	1	US-08-149-105-11	Sequence 11, Appl
C 163	15.2	0.4	20	1	US-09-758-881-23	Sequence 23, Appl	C 236	14.2	0.4	18	1	US-08-317-847-11	Sequence 11, Appl
C 164	15	0.4	15	1	US-09-491-356C-19	Sequence 19, Appl	C 237	14	0.4	14	1	US-09-230-652-26	Sequence 26, Appl
C 165	15	0.4	17	1	US-08-146-504-20	Sequence 20, Appl	C 238	14	0.4	15	1	US-09-180-437-104	Sequence 104, App
C 166	15	0.4	17	1	US-08-725-976-20	Sequence 20, Appl	C 239	14	0.4	15	1	US-09-163-485-13	Sequence 13, Appl
C 167	15	0.4	17	1	US-08-271-882B-20	Sequence 20, Appl	C 240	14	0.4	15	1	US-09-475-947B-304	Sequence 304, App
C 168	15	0.4	17	1	US-08-726-278-20	Sequence 20, Appl	C 241	14	0.4	17	1	US-09-866-108A-7671	Sequence 7671, Ap
C 169	15	0.4	17	1	US-09-671-954A-2	Sequence 2, Appl1	C 242	14	0.4	17	1	US-09-866-108A-7672	Sequence 7672, Ap
C 170	15	0.4	18	1	US-08-146-504-6	Sequence 6, Appl1	C 243	14	0.4	17	1	US-09-866-108A-7673	Sequence 7673, Ap
C 171	15	0.4	18	1	US-08-725-976-6	Sequence 6, Appl1	C 244	14	0.4	17	1	US-09-866-108A-7674	Sequence 7674, Ap
C 172	15	0.4	18	1	US-08-271-882B-6	Sequence 6, Appl1	C 245	14	0.4	18	1	US-09-630-706-64	Sequence 64, Appl
C 173	15	0.4	18	1	US-08-726-278-6	Sequence 6, Appl1	C 246	13.8	0.3	17	1	US-09-866-108A-8649	Sequence 8649, Ap
C 174	15	0.4	18	1	US-09-555-313B-16	Sequence 16, Appl	C 247	13.8	0.3	17	1	US-08-032-842-6	Sequence 6, Appl1
C 175	15	0.4	18	1	US-09-478-189-28	Sequence 28, Appl	C 248	13.8	0.3	17	1	US-08-052-681-14	Sequence 14, Appl
C 176	15	0.4	20	1	US-09-344-914-51	Sequence 51, Appl	C 249	13.8	0.3	17	1	US-07-912-7400-16	Sequence 6, Appl1
C 177	15	0.4	20	1	US-09-344-914-57	Sequence 57, Appl	C 250	13.8	0.3	17	1	US-08-035-634-4	Sequence 4, Appl1
C 178	15	0.4	20	1	US-09-198-452A-2277	Sequence 2277, Ap	C 251	13.8	0.3	17	1	US-08-211-202-122	Sequence 122, App
C 179	15	0.4	20	1	US-09-863-049B-21	Sequence 21, Appl	C 252	13.8	0.3	17	1	US-08-112-817C-6	Sequence 6, Appl1

253	13.8	0.3	17	1	US-08-324-301-26	Sequence 26, App1	326	13.8	0.35	17	1	US-09-065-474-49	Sequence 49, App1
254	13.8	0.3	17	1	US-08-390-850-452	Sequence 452, App	327	13.8	0.3	17	1	US-09-127-829-8	Sequence 8, App1
C 255	13.8	0.3	17	1	US-08-390-850-557	Sequence 557, App	328	13.8	0.357	17	1	US-08-654-618-17	Sequence 17, App1
C 256	13.8	0.3	17	1	US-08-330-850-624	Sequence 624, App	329	13.8	0.3	17	1	US-08-654-575-3	Sequence 3, App1
257	13.8	0.3	17	1	US-08-196-218-2	Sequence 2, App1	330	13.8	0.3	17	1	US-08-953-171-42	Sequence 42, App1
C 258	13.8	0.3	17	1	US-08-373-124A-178	Sequence 178, App1	331	13.8	0.3	17	1	US-09-071-845-1679	Sequence 1679, App
C 259	13.8	0.3	17	1	US-08-373-124A-190	Sequence 190, App	332	13.8	0.3	17	1	US-09-071-845-1756	Sequence 1756, App
260	13.8	0.3	17	1	US-08-373-124A-566	Sequence 566, App	333	13.8	0.3	17	1	US-09-071-845-1764	Sequence 1764, App
261	13.8	0.3	17	1	US-08-416-831B-8	Sequence 8, App1	334	13.8	0.3	17	1	US-09-071-845-1864	Sequence 1864, App
262	13.8	0.3	17	1	US-08-681-953-2	Sequence 2, App1	335	13.8	0.3	17	1	US-09-071-845-1885	Sequence 875, App
C 263	13.8	0.3	17	1	US-08-434-823-12	Sequence 12, App1	336	13.8	0.3	17	1	US-09-050-783-67	Sequence 67, App1
264	13.8	0.3	17	1	US-08-434-823-13	Sequence 13, App1	337	13.8	0.3	17	1	US-09-230-380-2	Sequence 2, App1
265	13.8	0.3	17	1	US-08-241-465B-10	Sequence 10, App1	338	13.8	0.3	17	1	US-09-179-558-28	Sequence 28, App1
C 266	13.8	0.3	17	1	US-08-457-366-12	Sequence 12, App1	339	13.8	0.3	17	1	US-09-142-355B-6	Sequence 6, App1
C 267	13.8	0.3	17	1	US-08-457-366-13	Sequence 13, App1	340	13.8	0.3	17	1	US-09-077-312A-2	Sequence 2, App1
C 268	13.8	0.3	17	1	US-08-435-634-452	Sequence 452, App	341	13.8	0.3	17	1	US-08-617-010C-9	Sequence 9, App1
C 269	13.8	0.3	17	1	US-08-435-634-557	Sequence 557, App	342	13.8	0.357	17	1	US-09-287-141-30	Sequence 30, App1
C 270	13.8	0.3	17	1	US-08-435-634-624	Sequence 624, App	343	13.8	0.3	17	1	US-09-050-159-45	Sequence 45, App1
271	13.8	0.3	17	1	US-08-307-619-67	Sequence 67, App1	344	13.8	0.3	17	1	US-09-050-159-51	Sequence 51, App1
272	13.8	0.3	17	1	US-08-078-090-8	Sequence 8, App1	345	13.8	0.3	17	1	US-09-228-942-2	Sequence 2, App1
273	13.8	0.3	17	1	US-08-460-806-26	Sequence 26, App1	346	13.8	0.3	17	1	US-08-969-815-25	Sequence 25, App1
274	13.8	0.3	17	1	US-08-760-335A-11	Sequence 11, App1	347	13.8	0.3	17	1	US-08-969-815-38	Sequence 38, App1
275	13.8	0.3	17	1	US-08-325-630-26	Sequence 26, App1	348	13.8	0.36	17	1	US-09-120-025-25	Sequence 25, App1
276	13.8	0.3	17	1	US-08-920-812-25	Sequence 25, App1	349	13.8	0.3	17	1	US-09-120-025-38	Sequence 38, App1
277	13.8	0.3	17	1	US-08-920-827-25	Sequence 25, App1	350	13.8	0.35	17	1	US-09-431-613-30	Sequence 30, App1
278	13.8	0.3	17	1	US-08-462-195-8	Sequence 8, App1	351	13.8	0.3	17	1	US-09-504-245-30	Sequence 30, App1
279	13.8	0.3	17	1	US-08-921-177-25	Sequence 25, App1	352	13.8	0.35	17	1	US-08-256-799-6	Sequence 6, App1
280	13.8	0.3	17	1	US-08-362-577C-25	Sequence 25, App1	353	13.8	0.3	17	1	US-08-591-189-5	Sequence 5, App1
281	13.8	0.3	17	1	US-08-800-751-10	Sequence 10, App1	354	13.8	0.3	17	1	US-09-402-002-7	Sequence 7, App1
C 282	13.8	0.3	17	1	US-08-435-628-178	Sequence 178, App	355	13.8	0.3	17	1	US-09-260-527-5	Sequence 5, App1
C 283	13.8	0.3	17	1	US-08-435-628-190	Sequence 190, App	356	13.8	0.3	17	1	US-08-462-437-6	Sequence 6, App1
284	13.8	0.3	17	1	US-08-435-628-566	Sequence 566, App	357	13.8	0.3	17	1	US-09-387-682-30	Sequence 30, App1
285	13.8	0.3	17	1	US-09-031-485-49	Sequence 49, App1	358	13.8	0.3	17	1	US-09-566-591-9	Sequence 9, App1
286	13.8	0.3	17	1	US-08-528-523-5	Sequence 5, App1	359	13.8	0.3	17	1	US-09-381-862-8	Sequence 8, App1
287	13.8	0.3	17	1	US-08-528-523-9	Sequence 9, App1	360	13.8	0.3	17	1	US-09-287-679-30	Sequence 30, App1
288	13.8	0.3	17	1	US-08-847-429A-49	Sequence 49, App1	361	13.8	0.39	17	1	US-09-376-781-17	Sequence 17, App1
289	13.8	0.3	17	1	US-08-190-199A-32	Sequence 32, App1	362	13.8	0.3	17	1	US-09-381-849-8	Sequence 8, App1
290	13.8	0.3	17	1	US-08-636-883-8	Sequence 8, App1	363	13.8	0.3	17	1	US-09-397-766-30	Sequence 30, App1
291	13.8	0.3	17	1	US-08-472-659-24	Sequence 24, App1	364	13.8	0.34	17	1	US-09-287-681-30	Sequence 30, App1
292	13.8	0.3	17	1	US-08-448-418-85	Sequence 85, App1	365	13.8	0.35	17	1	US-09-302-682-8	Sequence 8, App1
293	13.8	0.3	17	1	US-08-292-620A-1679	Sequence 1679, App	366	13.8	0.3	17	1	US-09-495-444-30	Sequence 30, App1
294	13.8	0.3	17	1	US-08-292-620A-1756	Sequence 1756, App	367	13.8	0.3	17	1	US-09-635-747-36	Sequence 36, App1
295	13.8	0.3	17	1	US-08-292-620A-1764	Sequence 1764, App	368	13.8	0.3	17	1	US-09-479-128-21	Sequence 21, App1
296	13.8	0.3	17	1	US-08-292-620A-1864	Sequence 1864, App	369	13.8	0.3	17	1	US-08-584-040-7308	Sequence 7308, App
297	13.8	0.3	17	1	US-08-292-620A-1885	Sequence 1885, App	370	13.8	0.3	17	1	US-08-584-040-7309	Sequence 7309, App
298	13.8	0.3	17	1	US-08-283-917-30	Sequence 30, App1	371	13.8	0.3	17	1	US-08-584-040-7491	Sequence 7491, App
299	13.8	0.3	17	1	US-08-920-828-25	Sequence 25, App1	372	13.8	0.3	17	1	US-08-679-645-749	Sequence 749, App
300	13.8	0.3	17	1	US-08-273-146-31	Sequence 31, App1	373	13.8	0.3	17	1	US-09-557-034-49	Sequence 49, App1
301	13.8	0.3	17	1	US-08-525-742-39	Sequence 39, App1	374	13.8	0.39	17	1	US-09-540-014-19	Sequence 19, App1
302	13.8	0.3	17	1	US-08-652-816A-31	Sequence 31, App1	375	13.8	0.3	17	1	US-09-710-481-25	Sequence 25, App1
303	13.8	0.3	17	1	US-08-652-816A-31	Sequence 31, App1	376	13.8	0.3	17	1	US-09-710-481-38	Sequence 38, App1
304	13.8	0.3	17	1	US-08-474-661-34	Sequence 34, App1	377	13.8	0.3	17	1	US-09-368-588-4	Sequence 4, App1
305	13.8	0.3	17	1	US-08-961-716-30	Sequence 30, App1	378	13.8	0.3	17	1	US-09-426-290-24	Sequence 24, App1
306	13.8	0.3	17	1	US-08-990-818-10	Sequence 10, App1	379	13.8	0.3	17	1	US-09-255-703-17	Sequence 17, App1
307	13.8	0.3	17	1	US-08-500-857A-14	Sequence 14, App1	380	13.8	0.3	17	1	US-08-744-481A-19	Sequence 19, App1
308	13.8	0.3	17	1	US-08-613-965-8	Sequence 8, App1	381	13.8	0.3	17	1	US-09-367-293-16	Sequence 16, App1
309	13.8	0.3	17	1	US-08-350-260A-113	Sequence 113, App	382	13.8	0.3	17	1	US-09-612-204B-26	Sequence 26, App1
310	13.8	0.3	17	1	US-08-350-260A-302	Sequence 302, App	383	13.8	0.3	17	1	US-09-463-238-17	Sequence 17, App1
311	13.8	0.3	17	1	US-08-611-977-24	Sequence 24, App1	384	13.8	0.34	17	1	US-09-464-122A-10	Sequence 10, App1
312	13.8	0.3	17	1	US-08-810-599-72	Sequence 72, App1	385	13.8	0.3	17	1	US-09-464-122A-16	Sequence 16, App1
313	13.8	0.3	17	1	US-08-665-302-110	Sequence 110, App	386	13.8	0.3	17	1	US-09-146-979-85	Sequence 85, App1
314	13.8	0.3	17	1	US-08-918-966-8	Sequence 8, App1	387	13.8	0.3	17	1	US-09-104-337A-113	Sequence 113, App
315	13.8	0.3	17	1	US-08-256-627-6	Sequence 6, App1	388	13.8	0.3	17	1	US-09-104-337A-302	Sequence 302, App
316	13.8	0.3	17	1	US-08-809-740A-7	Sequence 7, App1	389	13.8	0.3	17	1	US-09-699-931A-6	Sequence 6, App1
317	13.8	0.3	17	1	US-08-700-670A-24	Sequence 24, App1	390	13.8	0.3	17	1	US-09-207-388-34	Sequence 34, App1
318	13.8	0.3	17	1	US-08-487-799-31	Sequence 31, App1	391	13.8	0.34	17	1	US-09-796-416-30	Sequence 30, App1
319	13.8	0.3	17	1	US-08-921-655-8	Sequence 8, App1	392	13.8	0.3	17	1	US-09-315-574-110	Sequence 110, App
320	13.8	0.3	17	1	US-08-589-939-68	Sequence 68, App1	393	13.8	0.3	17	1	US-09-553-875-38	Sequence 38, App1
C 321	13.8	0.3	17	1	US-08-757-024-866	Sequence 866, App	394	13.8	0.36	17	1	US-09-553-875-38	Sequence 38, App1
322	13.8	0.3	17	1	US-09-184-658-54	Sequence 54, App1	395	13.8	0.34	17	1	US-09-474-432B-508	Sequence 508, App
323	13.8	0.3	17	1	US-08-617-256-30	Sequence 30, App1	396	13.8	0.3	17	1	US-09-474-432B-512	Sequence 512, App
324	13.8	0.3	17	1	US-08-985-162-3	Sequence 3, App1	397	13.8	0.3	17	1	US-09-722-825-28	Sequence 28, App1
C 325	13.8	0.3	17	1	US-08-985-162-331	Sequence 331, App	398	13.8	0.3	17	1	US-09-722-487-28	Sequence 28, App1

399	13.8	0.3	17	1	US-09-893-055-8	Sequence 8, Appl1	C 472	13.8	0.3	18	1	US-08-050-073-200	Sequence 200, App
400	13.8	0.3	17	1	US-09-501-612A-9	Sequence 9, Appl1	C 473	13.8	0.3	18	1	US-08-050-073-300	Sequence 1005, App
401	13.8	0.3	17	1	US-09-303-040-43	Sequence 43, Appl1	C 474	13.8	0.3	18	1	US-08-390-850-1075	Sequence 1075, Ap
402	13.8	0.3	17	1	US-09-371-772B-3117	Sequence 3117, Ap	C 475	13.8	0.3	18	1	US-08-390-850-1116	Sequence 1116, Ap
403	13.8	0.3	17	1	US-09-371-772B-3118	Sequence 3118, Ap	C 476	13.8	0.3	18	1	US-08-390-850-1133	Sequence 1133, Ap
404	13.8	0.3	17	1	US-09-371-772B-3287	Sequence 3297, Ap	C 477	13.8	0.3	18	1	US-08-317-433A-11	Sequence 11, Appl
405	13.8	0.3	17	1	US-09-371-772B-4385	Sequence 4385, Ap	C 478	13.8	0.3	18	1	US-08-363-585-106	Sequence 106, App
406	13.8	0.3	17	1	US-09-371-772B-5374	Sequence 5374, Ap	C 479	13.8	0.3	18	1	US-08-471-601-3	Sequence 3, Appl1
407	13.8	0.3	17	1	US-09-768-670-25	Sequence 25, Appl1	C 480	13.8	0.3	18	1	US-08-474-556-3	Sequence 3, Appl1
408	13.8	0.3	17	1	US-09-768-670-38	Sequence 38, Appl1	C 481	13.8	0.3	18	1	US-08-363-240A-1122	Sequence 1122, Ap
409	13.8	0.3	17	1	US-09-722-708-28	Sequence 28, Appl1	C 482	13.8	0.3	18	1	US-08-435-634-1075	Sequence 1075, Ap
410	13.8	0.3	17	1	US-09-879-341-30	Sequence 30, Appl1	C 483	13.8	0.3	18	1	US-08-435-634-1116	Sequence 1116, Ap
411	13.8	0.3	17	1	US-08-621-038-12	Sequence 12, Appl1	C 484	13.8	0.3	18	1	US-08-435-634-1133	Sequence 1133, Ap
412	13.8	0.3	17	1	US-09-724-877-30	Sequence 30, Appl1	C 485	13.8	0.3	18	1	US-08-351-899-3	Sequence 3, Appl1
413	13.8	0.3	17	1	US-09-476-387-507	Sequence 507, App	C 486	13.8	0.3	18	1	US-08-479-382-3	Sequence 3, Appl1
414	13.8	0.3	17	1	US-09-476-387-541	Sequence 541, App	C 487	13.8	0.3	18	1	US-08-470-354-3	Sequence 3, Appl1
415	13.8	0.3	17	1	US-09-401-063-3	Sequence 3, Appl1	C 488	13.8	0.3	18	1	US-08-479-383-3	Sequence 3, Appl1
416	13.8	0.3	17	1	US-09-401-063-331	Sequence 331, Appl	C 489	13.8	0.3	18	1	US-08-512-681-27	Sequence 27, Appl
417	13.8	0.3	17	1	US-09-084-303B-171	Sequence 171, Appl	C 490	13.8	0.3	18	1	US-08-758-306-501	Sequence 501, App
418	13.8	0.3	17	1	US-09-504-262D-54	Sequence 54, Appl1	C 491	13.8	0.3	18	1	US-08-758-306-955	Sequence 955, App
419	13.8	0.3	17	1	US-09-536-977-98	Sequence 98, Appl1	C 492	13.8	0.3	18	1	US-08-758-306-1339	Sequence 1339, Ap
420	13.8	0.3	17	1	US-09-827-998-116	Sequence 116, App	C 493	13.8	0.3	18	1	US-08-480-917-8	Sequence 8, Appl1
421	13.8	0.3	17	1	US-09-827-998-119	Sequence 119, App	C 494	13.8	0.3	18	1	US-08-639-363-16	Sequence 16, Appl
422	13.8	0.3	17	1	US-09-827-998-119	Sequence 119, App	C 495	13.8	0.3	18	1	US-08-411-098-34	Sequence 34, Appl1
423	13.8	0.3	17	1	US-09-827-998-615	Sequence 615, App	C 496	13.8	0.3	18	1	US-08-479-041-3	Sequence 3, Appl1
424	13.8	0.3	17	1	US-08-809-254A-9	Sequence 9, Appl1	C 497	13.8	0.3	18	1	US-08-795-006A-9	Sequence 9, Appl1
425	13.8	0.3	17	1	US-09-377-986-2	Sequence 2, Appl1	C 498	13.8	0.3	18	1	US-08-710-330A-8	Sequence 8, Appl1
426	13.8	0.3	17	1	US-09-912-935-46	Sequence 46, Appl1	C 499	13.8	0.3	18	1	US-08-505-617-12	Sequence 12, Appl
427	13.8	0.3	17	1	US-09-647-468-5	Sequence 5, Appl1	C 500	13.8	0.3	18	1	US-08-432-871C-33	Sequence 33, Appl
428	13.8	0.3	17	1	US-09-866-108A-1655	Sequence 1655, Ap	C 501	13.8	0.3	18	1	US-08-751-189-10	Sequence 10, Appl
429	13.8	0.3	17	1	US-09-866-108A-1877	Sequence 1877, Ap	C 502	13.8	0.3	18	1	US-09-205-922-17	Sequence 17, Appl
430	13.8	0.3	17	1	US-09-866-108A-1996	Sequence 1996, Ap	C 503	13.8	0.3	18	1	US-09-197-378-20	Sequence 20, Appl
431	13.8	0.3	17	1	US-09-866-108A-2222	Sequence 2222, Ap	C 504	13.8	0.3	18	1	US-09-018-170-12	Sequence 12, Appl
432	13.8	0.3	17	1	US-09-866-108A-2327	Sequence 2327, Ap	C 505	13.8	0.3	18	1	US-08-948-364-2	Sequence 2, Appl1
433	13.8	0.3	17	1	US-09-866-108A-6413	Sequence 6413, Ap	C 506	13.8	0.3	18	1	US-09-060-836-10	Sequence 10, Appl
434	13.8	0.3	17	1	US-09-866-108A-6544	Sequence 6544, Ap	C 507	13.8	0.3	18	1	US-08-815-448-10	Sequence 10, Appl
435	13.8	0.3	17	1	US-09-866-108A-7302	Sequence 7302, Ap	C 508	13.8	0.3	18	1	US-08-890-980-86	Sequence 86, Appl
436	13.8	0.3	17	1	US-09-866-108A-7670	Sequence 7670, Ap	C 509	13.8	0.3	18	1	US-09-256-496-9	Sequence 9, Appl1
437	13.8	0.3	17	1	US-09-866-108A-7670	Sequence 7670, Ap	C 510	13.8	0.3	18	1	US-09-256-496-15	Sequence 15, Appl
438	13.8	0.3	17	1	US-09-866-108A-7797	Sequence 7797, Ap	C 511	13.8	0.3	18	1	US-09-106-038A-23	Sequence 23, Appl
439	13.8	0.3	17	1	US-09-866-108A-8004	Sequence 8004, Ap	C 512	13.8	0.3	18	1	US-09-106-038A-25	Sequence 25, Appl
440	13.8	0.3	17	1	US-09-866-108A-8005	Sequence 8005, Ap	C 513	13.8	0.3	18	1	US-09-205-921-12	Sequence 12, Appl
441	13.8	0.3	17	1	US-09-866-108A-8076	Sequence 8076, Ap	C 514	13.8	0.3	18	1	US-08-574-022-11	Sequence 11, Appl
442	13.8	0.3	17	1	US-09-866-108A-8077	Sequence 8077, Ap	C 515	13.8	0.3	18	1	US-08-757-024-856	Sequence 856, App
443	13.8	0.3	17	1	US-09-866-108A-8078	Sequence 8078, Ap	C 516	13.8	0.3	18	1	US-08-757-024-943	Sequence 943, App
444	13.8	0.3	17	1	US-09-866-108A-8079	Sequence 8079, Ap	C 517	13.8	0.3	18	1	US-08-757-024-943	Sequence 943, App
445	13.8	0.3	17	1	US-09-866-108A-8646	Sequence 8646, Ap	C 518	13.8	0.3	18	1	US-08-890-979-75	Sequence 75, Appl
446	13.8	0.3	17	1	US-09-866-108A-8648	Sequence 8648, Ap	C 519	13.8	0.3	18	1	US-09-156-807-28	Sequence 28, Appl
447	13.8	0.3	17	1	US-09-866-108A-8651	Sequence 8651, Ap	C 520	13.8	0.3	18	1	US-09-339-993-11	Sequence 11, Appl
448	13.8	0.3	17	1	US-09-866-108A-8942	Sequence 8942, Ap	C 521	13.8	0.3	18	1	US-08-885-942A-65	Sequence 65, Appl
449	13.8	0.3	17	1	US-09-866-108A-9536	Sequence 9536, Ap	C 522	13.8	0.3	18	1	US-09-344-579-9	Sequence 9, Appl1
450	13.8	0.3	17	1	US-09-866-108A-9539	Sequence 9539, Ap	C 523	13.8	0.3	18	1	US-08-765-626-29	Sequence 29, Appl
451	13.8	0.3	17	1	US-09-710-279-4472	Sequence 4472, Ap	C 524	13.8	0.3	18	1	US-09-147-550-115	Sequence 115, App
452	13.8	0.3	17	1	US-09-581-822-21	Sequence 21, Appl	C 525	13.8	0.3	18	1	US-08-488-214A-65	Sequence 65, Appl
453	13.8	0.3	17	1	US-09-771-439-1	Sequence 11, Appl1	C 526	13.8	0.3	18	1	US-08-488-208A-65	Sequence 86, Appl
454	13.8	0.3	17	1	US-10-101-957B-11	Sequence 11, Appl1	C 527	13.8	0.3	18	1	US-09-032-894-86	Sequence 3, Appl1
455	13.8	0.3	17	1	US-09-600-932-6	Sequence 6, Appl1	C 528	13.8	0.3	18	1	US-08-987-574-3	Sequence 31, Appl
456	13.8	0.3	17	1	US-10-088-045-8	Sequence 8, Appl1	C 529	13.8	0.3	18	1	US-08-987-574-31	Sequence 31, Appl
457	13.8	0.3	17	1	US-09-685-915-21	Sequence 21, Appl	C 530	13.8	0.3	18	1	US-08-987-574-32	Sequence 32, Appl
458	13.8	0.3	17	1	US-09-685-664B-3117	Sequence 3117, Ap	C 531	13.8	0.3	18	1	US-09-184-445-10	Sequence 10, Appl
459	13.8	0.3	17	1	US-09-685-664B-3118	Sequence 3118, Ap	C 532	13.8	0.3	18	1	US-09-184-073-9	Sequence 9, Appl1
460	13.8	0.3	17	1	US-09-685-664B-3297	Sequence 3297, Ap	C 533	13.8	0.3	18	1	US-08-535-168-31	Sequence 3, Appl1
461	13.8	0.3	17	1	US-09-093-972C-866	Sequence 866, App	C 534	13.8	0.3	18	1	US-08-535-168-32	Sequence 32, Appl
462	13.8	0.3	17	1	US-09-339-103-5	Sequence 5, Appl1	C 535	13.8	0.3	18	1	US-09-050-159-120	Sequence 120, App
463	13.8	0.3	17	1	US-10-091-841A-19	Sequence 19, Appl1	C 536	13.8	0.3	18	1	US-09-031-626-86	Sequence 86, Appl
464	13.8	0.3	17	1	PCT-US93-01281-6	Sequence 6, Appl1	C 537	13.8	0.3	18	1	US-09-307-392-10	Sequence 10, Appl
465	13.8	0.3	17	1	5179198-12	Patent No. 5179198	C 538	13.8	0.3	18	1	US-09-018-584A-55	Sequence 55, Appl
466	13.8	0.3	18	1	US-08-244-113-21	Sequence 21, Appl1	C 539	13.8	0.3	18	1	US-09-138-736-8	Sequence 8, Appl1
467	13.8	0.3	18	1	US-08-156-020-11	Sequence 11, Appl1	C 540	13.8	0.3	18	1	US-09-461-697-466	Sequence 466, App
468	13.8	0.3	18	1	US-08-388-381-29	Sequence 29, Appl1	C 541	13.8	0.3	18	1	US-09-380-786A-10	Sequence 10, Appl
469	13.8	0.3	18	1	US-08-145-704-3	Sequence 3, Appl1	C 542	13.8	0.3	18	1	US-09-380-786A-10	Sequence 28, Appl
470	13.8	0.3	18	1	US-08-145-704-31	Sequence 31, Appl1	C 543	13.8	0.3	18	1	US-09-380-786A-10	Sequence 28, Appl
471	13.8	0.3	18	1	US-08-145-704-32	Sequence 32, Appl1	C 544	13.8	0.3	18	1	US-08-819-646-3	Sequence 3, Appl1


```

; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Muehch
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 33 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-08-863-639A-29

Query Match      0.7%; Score 29.4; DB 1; Length 33;
Best Local Similarity 96.8%; Pred. No. 19;
Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
DB      33 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 3

RESULT 3
US-08-068-747-6
; Sequence 6, Application US/08068747
; Patent No. 5695933
; GENERAL INFORMATION:
; APPLICANT: Schalling, Martin
; APPLICANT: Hudson, Thomas J.
; APPLICANT: Housman, David E.
; TITLE OF INVENTION: Direct Determination of Expanded
; TITLE OF INVENTION: Nucleotide Repeats in the Human Genome
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/068,747
; FILING DATE: 28-MAY-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
```

```

; REFERENCE/DOCKET NUMBER: MIT-6141
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-861-6240
; TELEFAX: 617-861-9540
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Synthetic"
; US-08-068-747-6

Query Match      0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 19;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB      1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 4
US-08-068-747-11/C
; Sequence 11, Application US/08068747
; Patent No. 5695933
; GENERAL INFORMATION:
; APPLICANT: Schalling, Martin
; APPLICANT: Hudson, Thomas J.
; APPLICANT: Housman, David E.
; TITLE OF INVENTION: Direct Determination of Expanded
; TITLE OF INVENTION: Nucleotide Repeats in the Human Genome
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/068,747
; FILING DATE: 28-MAY-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: MIT-6141
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-861-6240
; TELEFAX: 617-861-9540
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Synthetic"
; US-08-068-747-11

Query Match      0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 19;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB      1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
```

Db 30 CAGCAGCAGCAGCAGCAGCAGCAGCAG 1

RESULT 5

US-08-863-639A-30

Sequence 30, Application US/08863639A

Patent No. 5981185

GENERAL INFORMATION:

APPLICANT: Matson, Robert S.

APPLICANT: Coasadin, Peter J.

APPLICANT: Rampal, Jang B.

APPLICANT: Caskey, C. T.

TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS

NUMBER OF SEQUENCES: 95

CORRESPONDENCE ADDRESS:

ADDRESSEE: Sheldon & Mak

STREET: 225 South Lake Avenue, 9th Floor

CITY: Pasadena

STATE: CA

COUNTRY: USA

ZIP: 91101

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: Windows 95

SOFTWARE: Corel WordPerfect 8 version

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/863,639A

FILING DATE: May 28, 1997

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Joseph E. Muech

REGISTRATION NUMBER: 20,532

REFERENCE/DOCKET NUMBER: 11859-1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (626) 796-4000

TELEFAX: (626) 795-6321

INFORMATION FOR SEQ ID NO: 30:

SEQUENCE CHARACTERISTICS:

LENGTH: 30 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid

US-08-863-639A-30

Query Match 0.7%; Score 28.4; DB 1; Length 30;

Best Local Similarity 96.7%; Pred. No. 19;

Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146

Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 6

US-09-135-994-4

Sequence 4, Application US/09135994A

Patent No. 6280938

GENERAL INFORMATION:

APPLICANT: Rannum et al.

TITLE OF INVENTION: SCA7 GENE AND METHODS OF USE

FILE REFERENCE: University of Minnesota

CURRENT APPLICATION NUMBER: US/09/135,994A

CURRENT FILING DATE: 1998-08-18

EARLIER APPLICATION NUMBER: 60/056,170

EARLIER FILING DATE: 1997-08-19

NUMBER OF SEQ ID NOS: 14

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 4

LENGTH: 30

TYPE: DNA

ORGANISM: Homo sapiens

US-09-135-994-4

Query Match 0.7%; Score 28.4; DB 1; Length 30;

Best Local Similarity 96.7%; Pred. No. 19;

Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146

Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 7

US-09-684-843A-4

Sequence 4, Application US/09684843A

Patent No. 6514755

GENERAL INFORMATION:

APPLICANT: Rannum et al.

TITLE OF INVENTION: SCA7 GENE AND METHODS OF USE

FILE REFERENCE: Regents of the University of Minnesota

CURRENT APPLICATION NUMBER: US/09/684,843A

CURRENT FILING DATE: 2000-10-06

PRIOR APPLICATION NUMBER: 60/056,170

PRIOR FILING DATE: 1997-08-19

PRIOR APPLICATION NUMBER: 09/135,994

PRIOR FILING DATE: 1998-08-18

NUMBER OF SEQ ID NOS: 14

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 4

LENGTH: 30

TYPE: DNA

ORGANISM: Homo sapiens

US-09-684-843A-4

Query Match 0.7%; Score 28.4; DB 1; Length 30;

Best Local Similarity 96.7%; Pred. No. 19;

Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146

Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 8

US-08-570-155-14

Sequence 14, Application US/08570155

Patent No. 5962332

GENERAL INFORMATION:

APPLICANT: Singer, Robert H.

APPLICANT: Taneja, Krishan L.

TITLE OF INVENTION: DETECTION OF TRINUCLEOTIDE REPEATS

TITLE OF INVENTION: BY IN SITU HYBRIDIZATION

NUMBER OF SEQUENCES: 17

CORRESPONDENCE ADDRESS:

ADDRESSEE: FISH & RICHARDSON P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: Massachusetts

COUNTRY: U.S.A.

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version

SOFTWARE: #1.30B

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/570,155

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/399,499

FILING DATE: 07 March 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/214,823
FILING DATE: 17 March 1994
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 06353/011001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-570-153-14

Query Match 0.7%; Score 28.4; DB 1; Length 31;
Best Local Similarity 96.7%; Pred. No. 21;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 9
PCT-US95-02861-14
Sequence 14, Application PC/TUS9502861

GENERAL INFORMATION:
APPLICANT: Singer, Robert H.
APPLICANT: Taneja, Krishan L.
TITLE OF INVENTION: DETECTION OF TRINUCLEOTIDE
TITLE OF INVENTION: REPEATS
TITLE OF INVENTION: BY IN SITU HYBRIDIZATION
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: FISH & RICHARDSON P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0,
SOFTWARE: Version

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/02861
FILING DATE: 08 March 1995

CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/214,823
FILING DATE: 17 March 1994

ATTORNEY/AGENT INFORMATION:

NAME: Creason, Gary L.
REGISTRATION NUMBER: 34,310
REFERENCE/DOCKET NUMBER: 06353/010M01

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: cDNA
PCT-US95-02861-14

Query Match 0.7%; Score 28.4; DB 1; Length 31;
Best Local Similarity 96.7%; Pred. No. 21;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 10
US-09-475-947A-251
Sequence 251, Application US/09475947A

GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTSD0667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 251
LENGTH: 33
TYPE: DNA
ORGANISM: human
US-09-475-947A-251

Query Match 0.7%; Score 27.8; DB 1; Length 33;
Best Local Similarity 93.5%; Pred. No. 32;
Matches 29; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
DB 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 31

RESULT 11
US-08-863-639A-31
Sequence 31, Application US/08863639A

GENERAL INFORMATION:

APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.

TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:

ADDRESSEE: Sheldon & Mak

STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA

COUNTRY: USA
ZIP: 91101

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.50 inch, 1.44 MB storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Joseph E. Mueh
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:


```

; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 36 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-08-863-639A-31

Query Match
Best Local Similarity 90.6%; Score 27.2; DB 1; Length 36;
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGTCAGCAGCAGCAGCG 1148
DB 2 CAGCAGCAGCAGCAGCAGCAGCAGCGCGCG 33

RESULT 12
US-09-645-456A-27/c
; Sequence 27, Application US/09645456A
; Patent No. 6562580
; GENERAL INFORMATION:
; APPLICANT: Fu, C. Alan
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND
; FILE REFERENCE: A-68344/RMS/DHR
; CURRENT APPLICATION NUMBER: US/09/645,456A
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: US/09/425,324
; PRIOR FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-09-645-456A-27

Query Match
Best Local Similarity 90.7%; Score 26.2; DB 1; Length 31;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 152 AGCTGGCTGCCATCAAGTCATGATGTCAC 182
DB 31 AGCTTGACGCATCAAGTTATGATGTCAC 1

RESULT 13
US-09-425-324A-27/c
; Sequence 27, Application US/09425324A
; Patent No. 6562591
; GENERAL INFORMATION:
; APPLICANT: Fu, C. Alan
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND
; FILE REFERENCE: A-68344/RMS/DHR
; CURRENT APPLICATION NUMBER: US/09/425,324A
; PRIOR FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-09-425-324A-27
```

```

Query Match
Best Local Similarity 90.3%; Score 26.2; DB 1; Length 31;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 152 AGCTGGCTGCCATCAAGTCATGATGTCAC 182
DB 31 AGCTTGACGCATCAAGTTATGATGTCAC 1

RESULT 14
US-09-645-791-27/c
; Sequence 27, Application US/09645791
; Patent No. 6569658
; GENERAL INFORMATION:
; APPLICANT: Luo, Ying
; APPLICANT: Fu, Alan C
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND
; FILE REFERENCE: A-68344-1/RMS/DHR
; CURRENT APPLICATION NUMBER: US/09/645,791
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: US 09/425,324
; PRIOR FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-09-645-791-27

Query Match
Best Local Similarity 90.7%; Score 26.2; DB 1; Length 31;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 152 AGCTGGCTGCCATCAAGTCATGATGTCAC 182
DB 31 AGCTTGACGCATCAAGTTATGATGTCAC 1

RESULT 15
US-09-645-456A-26
; Sequence 26, Application US/09645456A
; Patent No. 6562580
; GENERAL INFORMATION:
; APPLICANT: Fu, C. Alan
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND
; FILE REFERENCE: A-68344/RMS/DHR
; CURRENT APPLICATION NUMBER: US/09/645,456A
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: US/09/425,324
; PRIOR FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-09-645-456A-26

Query Match
Best Local Similarity 87.1%; Score 24.6; DB 1; Length 31;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGCTGCCATCAAGTCATGATGTCAC 182
DB 1 AGCTTGACGCATCAAGTTATGATGTCAC 31
```

RESULT 16
US-09-425-324A-26
; Sequence 26, Application US/09425324A
; Patent No. 6562591
; GENERAL INFORMATION:
; APPLICANT: FU, C. Alan
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE
; FILE REFERENCE: A-68344/RMS/DHR
; CURRENT APPLICATION NUMBER: US/09/425,324A
; CURRENT FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 26
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-09-425-324A-26

Query Match 0.6%; Score 24.6; DB 1; Length 31;
Best Local Similarity 87.1%; Pred. No. 68;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGCTGCATCAAGTCATGATGTCAC 182
DB 1 AGCTTGACGCATCAGGCTTATGATGTCAC 31

RESULT 17
US-09-645-791-26
; Sequence 26, Application US/09645791
; Patent No. 6563658
; GENERAL INFORMATION:
; APPLICANT: Luo, Yang
; APPLICANT: Fu, Alan C
; APPLICANT: Shen, Mary
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE
; FILE REFERENCE: A-68344-1/RMS/DHR
; CURRENT APPLICATION NUMBER: US/09/645,791
; CURRENT FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: US 09/425,324
; PRIOR FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 26
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-09-645-791-26

Query Match 0.6%; Score 24.6; DB 1; Length 31;
Best Local Similarity 87.1%; Pred. No. 68;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGGCTGCATCAAGTCATGATGTCAC 182
DB 1 AGCTTGACGCATCAGGCTTATGATGTCAC 31

RESULT 18
US-09-688-188B-60/C
; Sequence 60, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
; APPLICANT: PLOOMMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: MARTINEZ, RICARDO

; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/09/688,188B
; CURRENT FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-688-188B-60

Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3454 ACAGTAGAGAGAGGCGCGCGCT 3476
DB 23 ACAGTAGAGAGAGGCGCGCGCT 1

RESULT 19
US-09-688-188B-61
; Sequence 61, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
; APPLICANT: PLOOMMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/09/688,188B
; CURRENT FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 61
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-688-188B-61

Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 242 ACCGCAACATGCCACCTACTAC 264
DB 1 ACCGCAACATGCCACCTACTAC 23

RESULT 20
US-09-291-417D-60/C
; Sequence 60, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:
; APPLICANT: PLOOMMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0329

```

; CURRENT APPLICATION NUMBER: US/09/291.417D
; CURRENT FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-291-417D-60

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3454 ACAGTAGAGGAGGAGCGGCT 3476
DB      23  ACAGTAGAGGAGGAGCGGCT 1

RESULT 21
US-09-291-417D-61
; Sequence 61, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:
; APPLICANT: PLOMAY, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0329
; CURRENT APPLICATION NUMBER: US/09/291.417D
; CURRENT FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 61
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-291-417D-61

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      242  ACCGCAACATCGCCACTACTAC 264
DB      1  ACCGCAACATCGCCACTACTAC 23

RESULT 22
US-08-863-639A-94
; Sequence 94, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coaslin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
```

```

; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel Wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Muech
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-94

Query Match      0.6%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 56;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1119 GCAGCAGAGCTGACGACGACA 1142
DB      1  GCAGCAGAGCTGACGACGACA 24

RESULT 23
US-09-651-011A-6
; Sequence 6, Application US/09651011A
; Patent No. 6346416
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
; FILE REFERENCE: RTS-0168
; CURRENT APPLICATION NUMBER: US/09/651,011A
; CURRENT FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 6
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-651-011A-6

Query Match      0.6%; Score 22.2; DB 1; Length 27;
Best Local Similarity 88.9%; Pred. No. 88;
Matches 24; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      467  TCAAGGGGAGATGTGTGTGACAG 493
DB      1  TCAAGGGGAGATGTGTGTGACAG 27

RESULT 24
US-09-304-232-152
; Sequence 152, Application US/09304232
; Patent No. 6525185
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian Bing
; APPLICANT: Chakravarti, Aravinda
; APPLICANT: Halushka, Marc Kenneth
; APPLICANT: Case Western Reserve University School of Medicine
```


RESULT 28
US-09-688-188B-59
; Sequence 59, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/09/688,188B
; CURRENT FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-688-188B-59

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 CCCCCGGGAACGATGACCA 305
Db 1 CCCCCGGGAACGATGACCA 20

RESULT 29
US-09-291-417D-59
; Sequence 59, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0329
; CURRENT APPLICATION NUMBER: US/09/291,417D
; CURRENT FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-291-417D-59

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 CCCCCGGGAACGATGACCA 305
Db 1 CCCCCGGGAACGATGACCA 20

RESULT 30
US-08-267-803B-66/C
; Sequence 66, Application US/08267803B

Patent No. 5834183
; GENERAL INFORMATION:
; APPLICANT: Orr, Harry T.
; APPLICANT: Ramm, Laura P.W.
; APPLICANT: Chung, Ming-Yi
; APPLICANT: Zoghbi, Huda Y.
; TITLE OF INVENTION: Gene Sequence for Spinocerebellar Ataxia
; Patent No. 5834183
; TITLE OF INVENTION: Type 1 and Method for Diagnosis
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Meeting, Raasch, Gebhardt & Schwappach, P.A.
; STREET: P.O. Box 581415
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55458-1415
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; APPLICATION NUMBER: US/08/267,803B
; FILING DATE: 28-JUN-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McCormack, Myra H.
; REGISTRATION NUMBER: 36,602
; REFERENCE/DOCKET NUMBER: 110,00030120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-305-1217
; TELEFAX: 612-305-1228
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-267-803B-66

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGC 1138
Db 21 AGCAGCAGCAGCAGCAGCAGC 1

RESULT 31
US-08-863-639A-28
; Sequence 28, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Watson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 MB storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95

SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-28

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 1 CAGCAGCAGCAGCAGCAGCAG 21

RESULT 32
US-08-863-639A-40
Sequence 40, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-40

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1118 AGCAGCAGCAGCTGCAGCAGC 1138
DB 1 AGCAGCAGCAGCAGCAGCAGC 21

RESULT 33
US-08-863-639A-60/c
Sequence 60, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 60:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-60

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 34
US-08-863-639A-66
Sequence 66, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:

ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueh
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 66:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-66

Query Match
Best Local Similarity 95.2%; Score 19.4; DB 1; Length 21;
Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1119 GCAGCAGCAGCTGCAGCAGCA 1139
DB 1 GCAGCAGCAGCAGCAGCAGCA 21

RESULT 35
US-08-863-639A-69/C
Sequence 69, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueh
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000

TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-69

Query Match
Best Local Similarity 95.2%; Score 19.4; DB 1; Length 21;
Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1118 AGCAGCAGCAGCTGCAGCAGC 1138
DB 21 AGCAGCAGCAGCAGCAGCAGC 1

RESULT 36
US-08-863-639A-87/C
Sequence 87, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueh
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-87

Query Match
Best Local Similarity 95.2%; Score 19.4; DB 1; Length 21;
Pred. No. 88;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1119 GCAGCAGCAGCTGCAGCAGCA 1139
DB 21 GCAGCAGCAGCAGCAGCAGCA 1

RESULT 37
US-09-396-196G-43760

```
; Sequence 43760, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 43760
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-43760
```

```
Query Match 0.5%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1444 CACGACGACGACGACGACGACG 1467
Db 2 CACGACGTGACGACGACGACGACG 25
```

```
RESULT 38
US-09-688-188B-62/C
; Sequence 62, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/09/688,188B
; CURRENT FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 62
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-688-188B-62
```

```
Query Match 0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2544 GGTGTCACGACGACGTCGAG 2562
Db 19 GGTGTCACGACGACGTCGAG 1
```

```
RESULT 39
US-09-291-417D-62/C
; Sequence 62, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
```

```
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0329
; CURRENT APPLICATION NUMBER: US/09/291,417D
; CURRENT FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 62
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-291-417D-62
```

```
Query Match 0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2544 GGTGTCACGACGACGTCGAG 2562
Db 19 GGTGTCACGACGACGTCGAG 1
```

```
RESULT 40
US-09-396-196G-18665
; Sequence 18665, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18665
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-18665
```

```
Query Match 0.5%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1130 TGCAGCAGCAGCAGCGCAGA 1151
Db 4 TGCAGCAGCAGCGCGCAGCACA 25
```

```
RESULT 41
US-08-568-271-1/C
; Sequence 1, Application US/08568271
; Patent No. 5800990
; GENERAL INFORMATION:
; APPLICANT: RAYNOLDS, MARY V.
; APPLICANT: PERRYMAN, M. BENJA
; TITLE OF INVENTION: ANGIOTENSIN-CONVERTING ENZYME GENETIC
; TITLE OF INVENTION: VARIANT SCREENS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DILWORTH & BARRESE
; STREET: 4350 LA JOLLA VILLAGE DRIVE, SUITE 300
; CITY: SAN DIEGO
; STATE: CALIFORNIA
; COUNTRY: U.S.A.
```



```

      ZIP: 92122
      COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: Patentin Release #1.0, Version #1.25
      CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/568,271
      FILING DATE: 06-DEC-1995
      CLASSIFICATION: 435
      ATTORNEY/AGENT INFORMATION:
      NAME: PEPPER PH.D., FREDERICK W.
      REGISTRATION NUMBER: 31,286
      REFERENCE/DOCKET NUMBER: 491-7
      TELECOMMUNICATION INFORMATION:
      TELEPHONE: 619-546-4410
      TELEFAX: 619-453-2839
      INFORMATION FOR SEQ ID NO: 1:
      SEQUENCE CHARACTERISTICS:
      LENGTH: 20 base pairs
      TYPE: nucleic acid
      STRANDEDNESS: single
      TOPOLOGY: linear
      MOLECULE TYPE: cDNA
      US-08-568-271-1

Query Match          0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred.No.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1449 GCAGCAACAGACGACGACG 1468
      |||||
DB      20 GCAGCAACAGACGCGGACGAC 1

      RESULT 42
      US-09-651-011A-15/c
      Sequence 15, Application US/09651011A
      Patent No. 6346416
      GENERAL INFORMATION:
      APPLICANT: Nicholas M. Dean
      TITLE OF INVENTION: ANTISENSE MODULATION OF HKK/GCK-LIKE KINASE EXPRESSION
      FILE REFERENCE: R1S-0168
      CURRENT APPLICATION NUMBER: US/09/651,011A
      CURRENT FILING DATE: 2000-08-29
      NUMBER OF SEQ ID NOS: 49
      SEQ ID NO 15
      LENGTH: 20
      TYPE: DNA
      ORGANISM: Artificial Sequence
      FEATURE:
      OTHER INFORMATION: Antisense Oligonucleotide
      US-09-651-011A-15

Query Match          0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred.No.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      615 TGAGAACCTGATGCCACCT 634
      |||||
DB      20 TGAGAACCCAGATGCCACCT 1

      RESULT 43
      US-09-083-268-11/c
      Sequence 11, Application US/09083268
      Patent No. 6673535
      GENERAL INFORMATION:
      APPLICANT: Pulsf., Stefan M
      TITLE OF INVENTION: NUCLEIC ACID ENCODING SPINOCEREBELLAR
      TITLE OF INVENTION: ATRX1A-2 AND PRODUCTS RELATED THERETO
      NUMBER OF SEQUENCES: 18

```

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Mueeting, Raasch & Gebhardt, P.A.
STREET: 119 No. 6673535th Fourth Street
CITY: Minneapolis
STATE: Minnesota
COUNTRY: USA
ZIP: 55401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,268
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/727,084
FILING DATE: 08-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: McCormack, Myra H
REGISTRATION NUMBER: 36,602
REFERENCE/DOCKET NUMBER: 232.00010101
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612/305-1220
TELEFAX: 612/305-1228
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-083-268-11

Query Match      0.5%  Score 18.2;  DB 1;  Length 23;
Best Local Similarity 87.0%;  Pred. No. 1.7e+02;
Matches 20;  Conservative 0;  Mismatches 3;  Indels 0;  Gaps 0

1432 CTCAAGTCCTCGACGACGACGA 1454
||| ||| ||| ||| ||| ||| |||
23 CTGAAGCCCCGACGACGACGACGA 1

RESULT 44
US-08-983-605-193/c
Sequence 193, Application US/08983605A
Patent No. 6720137
GENERAL INFORMATION:
APPLICANT: Rodet, Marion
TITLE OF INVENTION: Microsatellite Markers for plants of the Species
TITLE OF INVENTION: Trilicium aestivum and Tribe Trilicace and the Use of
TITLE OF INVENTION: Said Markers
FILE REFERENCE: 2936.10400
CURRENT APPLICATION NUMBER: US/08/983,605A
CURRENT FILING DATE: 1998-05-01
EARLIER APPLICATION NUMBR: DE 195 25 284.5
EARLIER FILING DATE: 1995-06-28
NUMBER OF SEQ ID NOS: 466
SOFTWARE: Patentn Ver. 2.0
SEQ ID NO 193
LENGTH: 23
TYPE: DNA
ORGANISM: Trilicium aestivum
US-08-983-605-193

Query Match      0.5%  Score 18.2;  DB 1;  Length 23;
Best Local Similarity 87.0%;  Pred. No. 1.7e+02;
Matches 20;  Conservative 0;  Mismatches 3;  Indels 0;  Gaps 0;

101 GCATGGAACCTACGACAGGTG 123
||||| ||| ||| ||| ||| |||
23 GCATGGAACCTACGACAGGTG 1

```

RESULT 45

US-09-205-995-48/C
; Sequence 48, Application US/09205995
; Patent No. 6368855
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995, (CIP)
; CURRENT APPLICATION NUMBER: US/09/205,995
; CURRENT FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
; PRIOR APPLICATION NUMBER: 08/661,627
; PRIOR FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 48
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide corresponding to a specific region
; OTHER INFORMATION: of the mouse i1 gene.
US-09-205-995-48

Query Match

Best Local Similarity 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAG 1464
DB 18 CAGCAGCAACAGCAGCAG 1

RESULT 46

US-09-688-188B-133
; Sequence 133, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: MAYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/09/688,188B
; CURRENT FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 133
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-688-188B-133

Query Match

Best Local Similarity 0.5%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3858 CAAGTGTTTGGCTCAGT 3878
DB 1 CAAGTGTTTGGCTCAGT 21

RESULT 47

US-09-291-417D-133
; Sequence 133, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: MAYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0329
; CURRENT APPLICATION NUMBER: US/09/291,417D
; CURRENT FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 133
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-291-417D-133

Query Match

Best Local Similarity 0.5%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3858 CAAGTGTTTGGCTCAGT 3878
DB 1 CAAGTGTTTGGCTCAGT 21

RESULT 48

US-08-410-540-5
; Sequence 5, Application US/08410540
; Patent No. 5807678
; GENERAL INFORMATION:
; APPLICANT: Miller, Walter L.
; APPLICANT: Lin, Dong
; APPLICANT: Straus III, Jerome F.
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neesley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/000US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO

ANTI-SENSE: NO
US-08-410-540-5

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGACGACG 1137
DB 1 GCAGCAGCAGCTGACGACG 19

RESULT 49
US-09-657-042A-39/c
Sequence 39, Application US/09657042A
Patent No. 6329203
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
TITLE OF INVENTION: Antisense Modulation of Glioma-Associated Oncogene-1 Expression
FILE REFERENCE: RTS-0148
CURRENT APPLICATION NUMBER: US/09/657,042A
CURRENT FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 39
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-657-042A-39

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1121 AGCAGCAGCTGACGACGCA 1139
DB 20 AGCAGCAGCTGACGACGCA 2

RESULT 50
US-09-651-011A-42/c
Sequence 42, Application US/09651011A
Patent No. 6346416
GENERAL INFORMATION:
APPLICANT: Nicholas M. Dean
TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
FILE REFERENCE: RTS-0168
CURRENT APPLICATION NUMBER: US/09/651,011A
CURRENT FILING DATE: 2000-08-29
NUMBER OF SEQ ID NOS: 49
SEQ ID NO 42
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-651-011A-42

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3695 AGTGGGGAGATGCTAC 3713
DB 20 AGTGGGGAGATGCTAC 2

RESULT 51
US-08-863-639A-17/c
Sequence 17, Application US/08863639A

Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coasasin, Peter J.
APPLICANT: Rampall, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSER: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph B. Muehle
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-17

Query Match 0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAGC 1147
DB 18 GCAGCAGCAGCAGCAGC 2

RESULT 52
US-08-313-185-30
Sequence 30, Application US/08313185
Patent No. 5851763
GENERAL INFORMATION:
APPLICANT: Heym, Beate
APPLICANT: Cole, Stewart
APPLICANT: Young, Douglas
APPLICANT: Zhang, Ying
APPLICANT: Honore, Nadine
APPLICANT: Telenti, Amalio
APPLICANT: Bodmer, Thomas
TITLE OF INVENTION: Rapid Detection of Antiprotic Resistance
TITLE OF INVENTION: in Mycobacterium Tuberculosis
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSER: Finnegan, Henderson, Farabow, Garrett &
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/313,185
FILING DATE: 12-OCT-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 02356.0068-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 408-4000
TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-313-185-30

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2551 CACGAGCTCGAGGATC 2570
DB 1 CAGGACGTCGAGGATC 20

RESULT 53
US-09-082-614A-30
Sequence 30, Application US/09082614A
Patent No. 6124098
GENERAL INFORMATION:
APPLICANT: Heym, Beate
APPLICANT: Cole, Stewart
APPLICANT: Young, Douglas
APPLICANT: Zhang, Ying
APPLICANT: Honore, Nadine
APPLICANT: Telenci, Amalio
APPLICANT: Bodmer, Thomas
TITLE OF INVENTION: Rapid Detection of Antibiotic Resistance
TITLE OF INVENTION: in Mycobacterium Tuberculosis
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESSEE: Dunner
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/082,614A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/313,185
FILING DATE: 12-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 02356.0068-00000
TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 408-4000
TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-082-614A-30

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2551 CACGAGCTCGAGGATC 2570
DB 1 CAGGACGTCGAGGATC 20

RESULT 54
US-09-657-042A-38/c
Sequence 38, Application US/09657042A
Patent No. 6328203
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-1 EXPRESSION
FILE REFERENCE: RTS-0148
CURRENT APPLICATION NUMBER: US/09/657,042A
CURRENT FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 38
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-657-042A-38

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1479 GCAGCAGCAGCTCTGC 1498
DB 20 GCCGACGACGAGCTCCAG 1

RESULT 55
US-09-651-011A-20/c
Sequence 20, Application US/09651011A
Patent No. 6346416
GENERAL INFORMATION:
APPLICANT: Nicholas M. Dean
APPLICANT: Lex M. Cowsett
TITLE OF INVENTION: ANTISENSE MODULATION OF HPR/GSK-LIKE KINASE EXPRESSION
FILE REFERENCE: RTS-0168
CURRENT APPLICATION NUMBER: US/09/651,011A
CURRENT FILING DATE: 2000-08-29
NUMBER OF SEQ ID NOS: 49
SEQ ID NO 20
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-651-011A-20

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GTGCTGTGAGTGTGACTCT 1058
DB 20 GTGCTGTGAGTGTGACTCT 1

RESULT 56
US-09-651-011A-40/c
; Sequence 40A, Application US/09651011A
; Patent No. 6346416
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
; FILE REFERENCE: RTS-0168
; CURRENT APPLICATION NUMBER: US/09/651.011A
; CURRENT FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-651-011A-40

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3493 TCCAGTGTGCTGCTTCATGC 3512
DB 20 TCCGTGTGCTGATTCATGC 1

RESULT 57
US-09-661-753-35
; Sequence 35, Application US/09661753
; Patent No. 6436909
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan F. Murray
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA
; FILE REFERENCE: ISPH-0498
; CURRENT APPLICATION NUMBER: US/09/661.753
; CURRENT FILING DATE: 2000-09-14
; EARLIER APPLICATION NUMBER: 60/154,546
; EARLIER FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 68
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-661-753-35

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGC 1138
DB 1 GTAGCAGCAGCGGAGCAGC 20

RESULT 58
US-09-723-368-5
; Sequence 5, Application US/09723368
; Patent No. 6641818
; GENERAL INFORMATION:
; APPLICANT: NORTHWESTERN UNIVERSITY
; APPLICANT: SPEAR, Patricia G.
; APPLICANT: WARNER, Morgyn S.

; APPLICANT: GERAGHTY, Robert G.
; APPLICANT: MARTINEZ, Wanda M.
; APPLICANT: MONTGOMERY, Rebecca I.
; APPLICANT: COHEN, Gary H.
; APPLICANT: EISENBERG, Roselyn J.
; APPLICANT: WHITEBCK, Charles J.
; APPLICANT: KRUMENACHER, Claude
; APPLICANT: UNIVERSITY OF PENNSYLVANIA
; TITLE OF INVENTION: CELLULAR PROTEINS WHICH MEDIATE HERPESVIRUS ENTRY
; FILE REFERENCE: 200290.0050/201
; CURRENT APPLICATION NUMBER: US/09/723.368
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: U.S. 60/087,862
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: PCT/US99/12235
; PRIOR FILING DATE: 1999-06-02
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer PRR2A8
US-09-723-368-5

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1472 AGAAGCAGCAGCAGCAGCAG 1491
DB 1 AGAAGCAGCAGCAGCAGCAG 20

RESULT 59
US-09-688-188B-136
; Sequence 136, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/09/688.188B
; CURRENT FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-688-188B-136

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAAGTGTGAAGG 3949
DB 1 CATCATGAAGTGTGAAGG 20

RESULT 60
US-09-291-417D-136
; Sequence 136, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:

APPLICANT: PLOWMAN, GREGORY
APPLICANT: MARTINEZ, RICARDO
APPLICANT: WHITE, DAVID
TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
FILE REFERENCE: 038602/0329
CURRENT APPLICATION NUMBER: US/09/291,417D
CURRENT FILING DATE: 1999-04-13
PRIOR APPLICATION NUMBER: 60/081,784
PRIOR FILING DATE: 1998-04-14
NUMBER OF SEQ ID NOS: 155
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO: 136
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-09-291-417D-136

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAAGTGTGAAGG 3949
DB 1 CATCATGAAGTGTGAAGG 20

RESULT 61
US-09-975-123-42
Sequence 42, Application US/09975123
Patent No. 6750019
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN
FILE REFERENCE: RTS-0253
CURRENT APPLICATION NUMBER: US/09/975,123
CURRENT FILING DATE: 2001-10-09
NUMBER OF SEQ ID NOS: 43
SEQ ID NO: 42
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-975-123-42

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1267 CTGCAGAGAGAGAGAGCA 1286
DB 1 CTGCAGAGAGAGAGAGCGGA 20

RESULT 62
US-09-792-024-397
Sequence 397, Application US/09792024
Patent No. 6783985
GENERAL INFORMATION:
APPLICANT: Roemer, Terry
APPLICANT: Jiang, Bo
APPLICANT: Boone, Charles
APPLICANT: Bussey, Howard
TITLE OF INVENTION: Gene Disruption Methodologies for Drug
FILE REFERENCE: 10182-004-999
CURRENT APPLICATION NUMBER: US/09/792,024
CURRENT FILING DATE: 2001-02-20
NUMBER OF SEQ ID NOS: 490
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO: 397
LENGTH: 20

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: DNA primer
US-09-792-024-397

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 CGAGAGAGAGAGAGAGAG 201
DB 1 CGAGAGAGAGAGAGAGAG 20

RESULT 63
US-08-570-155-14/C
Sequence 14, Application US/08570155
Patent No. 5962332
GENERAL INFORMATION:
APPLICANT: Singer, Robert H.
APPLICANT: Taneja, Krishan L.
TITLE OF INVENTION: DETECTION OF TRINUCLEOTIDE REPEATS
TITLE OF INVENTION: BY IN SITU HYBRIDIZATION
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: FISH & RICHARDSON P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version
SOFTWARE: #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/570,155
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/399,499
FILING DATE: 07 March 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/214,823
FILING DATE: 17 March 1994
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 06353/011001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-570-155-14

Query Match 0.4%; Score 16.6; DB 1; Length 31;
Best Local Similarity 71.0%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1116 ACAGCAGCAGAGCTGCAGCAGCAGCAG 1146
DB 31 ACTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 64
PCT-US95-02861-14/C
Sequence 14, Application PC/TUS9502861
GENERAL INFORMATION:
APPLICANT: Singer, Robert H.
APPLICANT: Taneja, Krishan L.
TITLE OF INVENTION: DETECTION OF TRINUCLEOTIDE
TITLE OF INVENTION: REPEATS
TITLE OF INVENTION: BY IN SITU HYBRIDIZATION
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: FISH & RICHARDSON P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0,
SOFTWARE: Version
SOFTWARE: #1.308
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02861
FILING DATE: 08 March 1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/214,823
FILING DATE: 17 March 1994
ATTORNEY/AGENT INFORMATION:
NAME: Creason, Gary L.
REGISTRATION NUMBER: 34,310
REFERENCE/DOCKET NUMBER: 06353/010M01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
PCT-US95-02861-14

Query Match 0.4%; Score 16.6; DB 1; Length 31;
Best Local Similarity 71.0%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1116 ACAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB 31 ACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 65
US-08-863-639A-29
Sequence 29, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueeth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 795-6321
TELEFAX: (626) 796-4000
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:

STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueeth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 795-6321
TELEFAX: (626) 796-4000
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:

US-08-863-639A-29
Query Match 0.4%; Score 16.6; DB 1; Length 33;
Best Local Similarity 71.0%; Pred. No. 5.5e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
DB 1 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 31

RESULT 66
US-08-863-639A-31/C
Sequence 31, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueeth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 795-6321
TELEFAX: (626) 796-4000
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:

US-08-863-639A-31/C
Query Match 0.4%; Score 16.6; DB 1; Length 33;
Best Local Similarity 71.0%; Pred. No. 5.5e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
DB 1 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 31

RESULT 66
US-08-863-639A-31/C
Sequence 31, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueeth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 795-6321
TELEFAX: (626) 796-4000
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:

LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-31

Query Match 0.4%; Score 16.6; DB 1; Length 36;
Best Local Similarity 71.0%; Pred. No. 5.7e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCTGCAGCAGCAGCAGC 1147
DB 34 CCGCCGCCGCTGCTGCTGCTGCTGC 4

RESULT 67
US-08-585-684B-2687/C
Sequence 2687, Application US/08585684B

PATENT No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2687:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2687

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1440 CCTGCAGCAGCAGCAGCA 1457
DB 18 CCTGCAGCAGCAGCAGCA 1

RESULT 68
US-09-038-073-2687/C
Sequence 2687, Application US/09038073
PATENT No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2687:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2687

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1440 CCTGCAGCAGCAGCAGCA 1457
DB 18 CCTGCAGCAGCAGCAGCA 1

RESULT 69
US-09-050-159-40/C
Sequence 40, Application US/09050159A
PATENT No. 6197505
GENERAL INFORMATION:
APPLICANT: No. 6197505berg, Leif T
APPLICANT: Anderson, Maria K
TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
FILE REFERENCE: 1248/1D042
CURRENT APPLICATION NUMBER: US/09/050,159A
FILING DATE: 1998-03-27
EARLIER APPLICATION NUMBER: 60/042,930
PRIOR FILING DATE: 1997-04-03
NUMBER OF SEQ ID NOS: 133

SOFTWARE: Patentin Ver. 2.1
SEQ ID NO: 40
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-40

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTGCTGAGGGGCTC 3153
DB 18 GAGGTGCTGAGGGGCTC 1

RESULT 70
US-09-050-159-46/c
Sequence 46; Application US/09050159A
Patent No. 6197505
GENERAL INFORMATION:
APPLICANT: Anderson, Maria K
APPLICANT: Linstrom, Per H
TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
TITLE OF INVENTION: COMPOSITIONS FOR USE THEREOF
FILE REFERENCE: 1248/1D042
CURRENT APPLICATION NUMBER: US/09/050,159A
CURRENT FILING DATE: 1998-03-27
EARLIER APPLICATION NUMBER: 60/042,930
EARLIER FILING DATE: 1987-04-03
NUMBER OF SEQ ID NOS: 133
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO: 46
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-46

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3136 GATGTGCTGAGGGGCTC 3153
DB 18 GAGGTGCTGAGGGGCTC 1

RESULT 71
US-09-053-866-10/c
Sequence 10; Application US/09053866
Patent No. 611075
GENERAL INFORMATION:
APPLICANT: Xu, Wenfeng
APPLICANT: Presnell, Scott R.
APPLICANT: Yee, David P.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR
TITLE OF INVENTION: PAR4 (ZCHEMR2)
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Zymogenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/053,866
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Leitch, Debra K
REGISTRATION NUMBER: 32,619
REFERENCE/DOCKET NUMBER: 98-10
TELEPHONE: 206-442-6674
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-053-866-10

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGCTAGCGAG 3639
DB 18 ATGCTGCTGCTAGCGAG 1

RESULT 72
US-09-490-692-72/c
Sequence 72; Application US/09490692
Patent No. 6180353
GENERAL INFORMATION:
APPLICANT: Nicholas M. Dean
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
FILE REFERENCE: RTS-0120
CURRENT APPLICATION NUMBER: US/09/490,692
CURRENT FILING DATE: 2000-01-24
NUMBER OF SEQ ID NOS: 176
SEQ ID NO: 72
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-72

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 183 GGAGGACGAGAGAGAGA 200
DB 19 GGAGGACGAGAGAGAGA 2

RESULT 73
US-09-479-130-10/c
Sequence 10; Application US/09479130
Patent No. 6436400
GENERAL INFORMATION:
APPLICANT: Xu, Wenfeng
APPLICANT: Presnell, Scott R.
APPLICANT: Yee, David P.
APPLICANT: Foster, Donald C.

TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR
TITLE OF INVENTION: PAR4 (ZCHEMR2)
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Zymogenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/479,130
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Leitch, Debra K
REGISTRATION NUMBER: 32,619
REFERENCE/DOCKET NUMBER: 98-10
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6674
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-479-130-10

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGTGCTACGAG 3639
DB 18 ATGCTGCTGTGCTACGAG 1

RESULT 74
US-09-472-130A-10/C
Sequence 10, Application US/09472130A
Patent No. 6473765
GENERAL INFORMATION:
APPLICANT: Xu, Wenfeng
APPLICANT: Presnell, Scott R.
APPLICANT: Yee, David P.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR PAR4
FILE REFERENCE: 98-10D2
CURRENT APPLICATION NUMBER: US/09/472,130A
CURRENT FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 09/053,866
PRIOR FILING DATE: 1998-04-01
NUMBER OF SEQ ID NOS: 21
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 10
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer.
US-09-472-130A-10

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGTGCTACGAG 3639
DB 18 ATGCTGCTGTGCTACGAG 1

RESULT 75
US-10-215-448-53
Sequence 53, Application US/10215448
Patent No. 6716975
GENERAL INFORMATION:
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF EDG1 EXPRESSION
FILE REFERENCE: RTS-0179
CURRENT APPLICATION NUMBER: US/10/215,448
CURRENT FILING DATE: 2002-08-09
NUMBER OF SEQ ID NOS: 105
SEQ ID NO 53
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-215-448-53

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1485 GCAGCAGCTCTGCTCTGG 1502
DB 1 GCAGCAGCTCTCTCTCTGG 18

RESULT 76
US-09-475-947A-199
Sequence 199, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS00667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 199
LENGTH: 21
TYPE: DNA
ORGANISM: human
US-09-475-947A-199

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1270 CAGGAGAGGAGGAGGAG 1287
DB 1 CAGGAGAGGAGGAGGAG 18

RESULT 77
US-08-256-426B-285
Sequence 285, Application US/08256426B
Patent No. 5948611
GENERAL INFORMATION:
APPLICANT: Prockop, Darwin J.
APPLICANT: Ala-Kokko, Leena

```
APPLICANT: Williams, Charlene J.
APPLICANT: Rivkantiem, Periti
APPLICANT: Baldwin, Clinton
APPLICANT: Hopkinson, Ian
APPLICANT: Ahmad, Nilofar Mina
TITLE OF INVENTION: Methods of Detecting A Genetic
NUMBER OF SEQUENCES: 293
CORRESPONDENCE ADDRESSES:
ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 59486111ris
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 3.1
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/256,426B
FILING DATE: 03-FEB-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10964
FILING DATE: 12-NOV-1993
PRIOR APPLICATION NUMBER: US 07/977,284
APPLICATION NUMBER: 13-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Mark Deluca
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TDU-1082
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 285:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: NUCLEIC ACID
STRANDEDNESS: SINGLE
TOPOLOGY: LINEAR
US-08-256-426B-285

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1571 AGGTAGAGAGACAGACAGGA 1591
DB 1 AGTTAGAGAGACAGACAGGA 21

RESULT 78
US-08-882-501-2/c
Sequence 2, Application US/08882501
Patent No. 6054269
GENERAL INFORMATION:
APPLICANT: GARNIER, Fabien
APPLICANT: GERBAUD, Guy
APPLICANT: GALIMAND, Marc
APPLICANT: COURVALIN, Patrice
APPLICANT: DUKTA-MALEN, Sylvie
APPLICANT: CHARLES, Murielle
APPLICANT: EVERS, Stefan
APPLICANT: CASADEWALL, Barbara
TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR
TITLE OF INVENTION: DETECTING ENTEROCOCCI AND STREPTOCOCCI BACTERIAL STRAINS
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESS: Finnegan, Henderson, Farabow, Garrett &
ADDRESS: Dunner, L.L.P.
STREET: 1300 I Street, N.W.
```

```
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/882,501
FILING DATE: 25-JUN-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McDonnell, Leslie A.
REGISTRATION NUMBER: 34,872
REFERENCE/DOCKET NUMBER: 03495.0155-00000
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-882-501-2

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1850 CTGTATCGCGCCAGATTGAG 1870
DB 21 CTGTATCGGTGATGATGAG 1

RESULT 79
US-09-688-188B-54
Sequence 54, Application US/09688188B
Patent No. 6656716
GENERAL INFORMATION:
APPLICANT: PLOMMAN, GREGORY
APPLICANT: MARTINEZ, RICARDO
APPLICANT: WHITE, DAVID
TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
FILE REFERENCE: 038602/0328
CURRENT APPLICATION NUMBER: US/09/688,188B
CURRENT FILING DATE: 2000-10-16
PRIOR APPLICATION NUMBER: 09/291,417
PRIOR FILING DATE: 1999-04-14
PRIOR APPLICATION NUMBER: 60/081,784
PRIOR FILING DATE: 1998-04-14
NUMBER OF SEQ ID NOS: 155
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 54
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-688-188B-54

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 166 AAGTCATGATGATCGAGG 186
DB 1 AAGTTATGATGATCGAGG 21
```

RESULT 80
US-09-291-417D-54
Sequence 54, Application US/09291417D
Patent No. 6680170
GENERAL INFORMATION:
APPLICANT: PLOWMAN, GREGORY
APPLICANT: MARTINEZ, RICARDO
APPLICANT: WHITE, DAVID
TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
FILE REFERENCE: 038602/0329
CURRENT APPLICATION NUMBER: US/09/291.417D
CURRENT FILING DATE: 1999-04-13
PRIOR APPLICATION NUMBER: 60/081,784
PRIOR FILING DATE: 1998-04-14
NUMBER OF SEQ ID NOS: 155
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 54
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
US-09-291-417D-54
OTHER INFORMATION: Description of Artificial Sequence: Primer
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 166 AACGTCATGATGTCACGGAG 186
DB 1 AAGGTATGATGTCACAGGG 21
RESULT 81
US-08-585-684B-2688/C
Sequence 2688, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 2688:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2688
Query Match 0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1439 CCCTGCAGCAGCAGCA 1454
DB 16 CCCTGCAGCAGCAGCA 1
RESULT 82
US-09-487-444-11
Sequence 11, Application US/09487444
Patent No. 6159697
GENERAL INFORMATION:
APPLICANT: Brett P. Morita
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
FILE REFERENCE: RTS-0133
CURRENT APPLICATION NUMBER: US/09/487,444
CURRENT FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 49
SEQ ID NO 11
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
US-09-487-444-11
OTHER INFORMATION: Antisense Oligonucleotide
Query Match 0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1476 ACAGCAGCAGCAGCAG 1491
DB 3 ACAGCAGCAGCAGCAG 18
RESULT 83
US-09-038-073-2688/C
Sequence 2688, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:

```

; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2688:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-038-073-2688

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 18;
Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1439 CCCTGCAGCAGCAGCA 1454
DB 16 CCCTGCAGCAGCAGCA 1

RESULT 84
US-09-344-914-52/C
; Sequence 52; Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-344-914-52

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 20;
Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACGACGACGCA 1127
DB 16 TAAACGACGACGCA 1

RESULT 85
US-09-344-914-53/C
; Sequence 53; Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-344-914-53

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 20;
Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACGACGACGCA 1127
DB 17 TAAACGACGACGCA 2

RESULT 86
US-09-344-914-54/C
; Sequence 54; Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-344-914-54

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 20;
Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACGACGACGCA 1127
DB 18 TAAACGACGACGCA 3

RESULT 87
US-09-344-914-55/C
; Sequence 55; Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-344-914-55

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 20;
Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1112 TAAACGACGACGCA 1127
DB 19 TAAACGACGACGCA 4

RESULT 88
US-09-344-914-56/C
; Sequence 56; Application US/09344914
; Patent No. 6110664
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Lex M. Cowser
/ TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
/ FILE REFERENCE: RTS-0068
/ CURRENT APPLICATION NUMBER: US/09/344,914
/ NUMBER OF SEQ ID NOS: 87
/ SEQ ID NO 56
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
/ US-09-344-914-56

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 20;
Pred. No. 2.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 0;

Qy 1112 TAAACAGCAGCAGCA 1127
Db 20 TAAACAGCAGCAGCA 5

RESULT 89
US-09-657-472-2068/c
/ Sequence 2068, Application US/09657472
/ Patent No. 6727063
/ GENERAL INFORMATION:
/ APPLICANT: Lander, Eric S.
/ APPLICANT: Cargill, Michele
/ APPLICANT: Ireland, James S.
/ APPLICANT: Bolk, Stacey
/ APPLICANT: Daley, George O.
/ APPLICANT: McCarthy, Jeanette J.
/ TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
/ FILE REFERENCE: 2825.1027-001
/ CURRENT APPLICATION NUMBER: US/09/657,472
/ PRIOR FILING DATE: 2000-09-07
/ PRIOR APPLICATION NUMBER: US 60/153,357
/ PRIOR FILING DATE: 1999-09-10
/ PRIOR APPLICATION NUMBER: US 60/220,947
/ PRIOR FILING DATE: 2000-07-26
/ PRIOR APPLICATION NUMBER: US 60/225,724
/ PRIOR FILING DATE: 2000-08-16
/ NUMBER OF SEQ ID NOS: 2551
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 2068
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-657-472-2068

Query Match
Best Local Similarity 88.9%; Score 16; DB 1; Length 21;
Pred. No. 2.4e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 16; Conservative 1;

Qy 2596 GGCACCATGATGTCAG 2613
Db 18 GGCACCATGATGTCAG 1

RESULT 90
US-09-422-978-7203
/ Sequence 7203, Application US/09422978
/ Patent No. 6537751
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marla
/ APPLICANT: Chumakov, Ilya
/ TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
/ FILE REFERENCE: GENSET.020CPI
/ CURRENT APPLICATION NUMBER: US/09/422,978
```

```
/ CURRENT FILING DATE: 1999-10-20
/ EARLIER APPLICATION NUMBER: US 09/298,850
/ EARLIER FILING DATE: 1999-04-21
/ EARLIER APPLICATION NUMBER: US 60/109,732
/ EARLIER FILING DATE: 1998-11-23
/ EARLIER APPLICATION NUMBER: US 60/082,614
/ EARLIER FILING DATE: 1998-04-21
/ NUMBER OF SEQ ID NOS: 11796
/ SEQ ID NO 7203
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer bind
/ LOCATION: 1..19
/ OTHER INFORMATION: upstream amplification primer 99-2903 for SEQ 3269,
/ US-09-422-978-7203

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Pred. No. 1.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 17; Conservative 0;

Qy 3243 AGAAGTGAGAGAGAGCAG 3261
Db 1 AGAAGTGAGAGAGAGTAG 19

RESULT 91
US-07-889-651-9/c
/ Sequence 9, Application US/07889651
/ Patent No. 5352580
/ GENERAL INFORMATION:
/ APPLICANT: Speare, Patricia A.
/ APPLICANT: Shank, Daryl D.
/ TITLE OF INVENTION: Mycobacteria Probes
/ NUMBER OF SEQUENCES: 25
/ CORRESPONDENCE ADDRESSES:
/ ADDRESSEE: Richard J. Rodrick
/ STREET: 1 Becton Drive
/ CITY: Franklin Lakes
/ STATE: New Jersey
/ COUNTRY: USA
/ ZIP: 07417-1890
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/889,651
/ FILING DATE: 19920526
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stierwalt, Brian K.
/ REGISTRATION NUMBER: 33,213
/ REFERENCE/DOCKET NUMBER: P-2512
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 201-847-5317
/ TELEFAX: 201-848-9228
/ INFORMATION FOR SEQ ID NO: 9:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
/ US-07-889-651-9

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 20;
Pred. No. 2.2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 17; Conservative 0;

Qy 1205 AGCAGAGAGAGAGCGCGC 1223
```

Db 19 AGCAGCAAGTGTGAGCGCG 1

RESULT 92

US-08-650-766-14
Sequence 14, Application US/08650766D
Patent No. 6015690
GENERAL INFORMATION:
APPLICANT: PILETZ, John E.
APPLICANT: IVANOV, Tina R.
TITLE OF INVENTION: DNA SEQUENCE ENCODING A HUMAN IMIDAZOLINE RECEPTOR AND
FILE REFERENCE: CORRECTED SEQUENCE LISTING
Patent No. 6015690
CURRENT APPLICATION NUMBER: US/08/650,766D
CURRENT FILING DATE: 1996-05-20
EARLIER APPLICATION NUMBER: US 60/012,600
EARLIER FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 21
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 14
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-08-650-766-14

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1006 GGAGAGAGAGAGAGCCAA 1024

Db 2 GGAGAGAGAGTGTAGCCAA 20

RESULT 93

US-08-914-961-6/C
Sequence 6, Application US/08914961
Patent No. 6018042
GENERAL INFORMATION:
APPLICANT: Mett, Helmut
APPLICANT: Dean, Robert
TITLE OF INVENTION: Antitumor Antisense Oligonucleotides
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII Editor
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/914,961
FILING DATE: 20-AUG-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/287,753
FILING DATE: 09-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Spruill, W. Murray
REGISTRATION NUMBER: 32,943
REFERENCE/DOCKET NUMBER: 4-20047/P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919) 541-8615
TELEFAX: (919) 541-8689
INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
POSITION IN GENOME:
MAP POSITION: 979
UNITS: bp
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..20
OTHER INFORMATION: /note="All nucleotides are of the
OTHER INFORMATION: phosphorothioate type"
US-08-914-961-6

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1445 AGCAGCAGCAACGACGACA 1463

Db 19 AGAAGCAGCAACACACAGCA 1

RESULT 94

US-08-922-635-13
Sequence 13, Application US/08922635A
Patent No. 6031871
GENERAL INFORMATION:
APPLICANT: PILETZ, John E.
APPLICANT: IVANOV, Tina R.
TITLE OF INVENTION: DNA MOLECULES ENCODING IMIDAZOLINE RECEPTIVE POLYPEPTIDES
FILE REFERENCE: CORRECTED SEQUENCE LISTING
Patent No. 6031871
CURRENT APPLICATION NUMBER: US/08/922,635A
CURRENT FILING DATE: 1997-09-03
EARLIER APPLICATION NUMBER: 08/650,766
EARLIER FILING DATE: 1996-05-20
EARLIER APPLICATION NUMBER: 60/012,600
EARLIER FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 22
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 13
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-08-922-635-13

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1006 GGAGAGAGAGAGAGCCAA 1024

Db 2 GGAGAGAGAGTGTAGCCAA 20

RESULT 95

US-09-490-692-153/C
Sequence 153, Application US/09490692
Patent No. 6180353
GENERAL INFORMATION:
APPLICANT: Nicholas M. Dean
APPLICANT: Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
FILE REFERENCE: RTS-0120
CURRENT APPLICATION NUMBER: US/09/490,692
CURRENT FILING DATE: 2000-01-24
NUMBER OF SEQ ID NOS: 176
SEQ ID NO 153

```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-153

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2444 GTGAGACGACGACGAGCA 2462
DB      20   GTGAGGAGGAGGAGGAGCA 2

RESULT 96
US-09-593-711A-152/c
; Sequence 152, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTS-0118
; CURRENT APPLICATION NUMBER: US/09/593,711A
; CURRENT FILING DATE: 2000-06-14
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 152
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-152

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1249 GAGCGGAGCAGCGGAGC 1267
DB      19   GAGCGGAGCAGCGGAGC 1

RESULT 97
US-09-651-011A-19/c
; Sequence 19, Application US/09651011A
; Patent No. 6346416
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
; FILE REFERENCE: RTS-0168
; CURRENT APPLICATION NUMBER: US/09/651,011A
; CURRENT FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-651-011A-19

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2446 GAGGACGACGACGAGAG 2464
DB      20   GAGGAGAGAGGAGGAGAG 2
```

```

RESULT 98
US-09-702-327-65/c
; Sequence 65, Application US/09702327
; Patent No. 6426220
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF CALRETICULIN EXPRESSION
; FILE REFERENCE: RTS-0097
; CURRENT APPLICATION NUMBER: US/09/702,327
; CURRENT FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-702-327-65

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2446 GAGGACGACGACGAGAG 2464
DB      19   GAGGAGAGATGAGGAGAG 1

RESULT 99
US-09-198-452A-2850
; Sequence 2850, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2850
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2850

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1598 AGCAGCAACTCTCCCTT 1616
DB      2   AGCAGCAACTCTCTCAT 20

RESULT 100
US-09-198-452A-6476/c
; Sequence 6476, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6476
```


LENGTH: 20
TYPE: DNA
ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6476

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAGCAGC 1462
DB 19 CAGCAGCAGCAGCAGC 1

RESULT 101
US-09-733-444-2/c
Sequence 2, Application US/09733444
Patent No. 6576423
GENERAL INFORMATION:
APPLICANT: Batra, Surlinder K.
APPLICANT: Brandt, Randall E.
APPLICANT: Ringel, Jerry
APPLICANT: Paulmann, Grit
APPLICANT: L'hr, Matchias
APPLICANT: Varshney, Gish C.
APPLICANT: University of Nebraska Board of Regents
TITLE OF INVENTION: Specific Mucin Expression as a Marker
FILE REFERENCE: UMC 63155
CURRENT APPLICATION NUMBER: US/09/733,444
CURRENT FILING DATE: 2000-12-08
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatSeq for Windows Version 3.0
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-733-444-2

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 GGCTGCCATCAGTCTATG 174
DB 20 GGCTGCCCTCAGTCTGTG 2

RESULT 102
US-09-733-444-26/c
Sequence 26, Application US/09733444
Patent No. 6576423
GENERAL INFORMATION:
APPLICANT: Batra, Surlinder K.
APPLICANT: Brandt, Randall E.
APPLICANT: Ringel, Jerry
APPLICANT: Paulmann, Grit
APPLICANT: L'hr, Matchias
APPLICANT: Varshney, Gish C.
APPLICANT: University of Nebraska Board of Regents
TITLE OF INVENTION: Specific Mucin Expression as a Marker
FILE REFERENCE: UMC 63155
CURRENT APPLICATION NUMBER: US/09/733,444
CURRENT FILING DATE: 2000-12-08
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatSeq for Windows Version 3.0
SEQ ID NO 26
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Primer
US-09-733-444-26

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 GGCTGCCATCAGTCTATG 174
DB 20 GGCTGCCCTCAGTCTGTG 2

RESULT 103
US-09-389-487-14
Sequence 14, Application US/09389487
Patent No. 6576742
GENERAL INFORMATION:
APPLICANT: PILETZ, John E.
APPLICANT: IVANOV, Tina R.
TITLE OF INVENTION: DNA SEQUENCE ENCODING A HUMAN IMIDAZOLINE RECEPTOR AND
FILE REFERENCE: Corrected Sequence Listing
Patent No. 6576742
CURRENT APPLICATION NUMBER: US/09/389,487
CURRENT FILING DATE: 1999-09-03
EARLIER APPLICATION NUMBER: US 08/650,766
EARLIER FILING DATE: 1996-05-20
NUMBER OF SEQ ID NOS: 21
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 14
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-09-389-487-14

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1006 GGAGAGGAGGAGGAGCCAA 1024
DB 2 GGAGAGAAAGGTAGCCAA 20

RESULT 104
US-09-554-726A-29
Sequence 29, Application US/09554726A
Patent No. 6642369
GENERAL INFORMATION:
APPLICANT: HERRMANN, Bernhard
APPLICANT: KOSCHORZ, Birgit
APPLICANT: KISPERS, Andreas
TITLE OF INVENTION: NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATION:
FILE REFERENCE: 258 0009 0101
CURRENT APPLICATION NUMBER: US/09/554,726A
CURRENT FILING DATE: 2000-05-18
PRIOR APPLICATION NUMBER: PCT/EP 98/07395
PRIOR FILING DATE: 1998-11-18
PRIOR APPLICATION NUMBER: EP 98 10 3596.7
PRIOR FILING DATE: 1998-03-02
PRIOR APPLICATION NUMBER: EP 97 12 0190.0
PRIOR FILING DATE: 1997-11-18
NUMBER OF SEQ ID NOS: 53
SOFTWARE: PatentIn version 3.1
SEQ ID NO 29
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-554-726A-29

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1449 GCAGCAGCAGCAGCAGCAG 1467
DB 2 GCAGCAGCAGCAGCAGCAG 20

RESULT 105

US-08-426-792-2/c
; Sequence 2, Application US/08426792
; Patent No. 5733541
; GENERAL INFORMATION:
; APPLICANT: Taichman, Russell S.
; TITLE OF INVENTION: Hematopoietic Cells: Compositions and
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/426,792
; FILING DATE: 21-Apr-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UMIC010---
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-426-792-2

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2447 AGGACGACGAGGAGGAGG 2465
DB 21 AGGACGAGAGGAGGAGGAGG 3

RESULT 106

US-08-863-639A-41
; Sequence 41, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sheldon & Mak

STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueeth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 41:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-41

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GCAGCAGCAGGAGGAGG 201
DB 2 GCAGGAGGAGGAGGAGGAGG 20

RESULT 107

US-08-863-639A-53/c
; Sequence 53, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueeth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321

INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-53

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGAGAG 201
DB 20 GGAGGACGAGGAGAGAG 2

RESULT 108
US-08-863-639A-59/C
Sequence 59, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-59

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGAGAG 201
DB 19 GGAGGACGAGGAGAGAG 1

RESULT 109
US-08-863-639A-64
Sequence 64, Application US/08863639A

Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-64

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGAGAG 201
DB 3 GGAGGACGAGGAGAGAGAG 21

RESULT 110
US-08-863-639A-70
Sequence 70, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 70:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-70

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGGAG 201
DB 1 GGAGGAGGAGGAGGAG 19

RESULT 111
US-08-863-639A-83/C
Sequence 83, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coasash, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-83

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 183 GGAGGACGAGGAGGAG 201
DB 21 GGAGGAGGAGGAGGAG 3

RESULT 112
US-08-486-343A-5/C
Sequence 5, Application US/08486343A
Patent No. 6071695
GENERAL INFORMATION:
APPLICANT: OZAKYAK, ENGIN
APPLICANT: OPPERMAN, HERMANN
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING
TITLE OF INVENTION: MORPHOGENIC PROTEIN EXPRESSION
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
ADDRESSEE: INC.
STREET: 45 SOUTH STREET
CITY: HOPKINTON
STATE: MA
COUNTRY: USA
ZIP: 07148
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,343A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: RITCHER, Edmund R.
REGISTRATION NUMBER: 27,829
REFERENCE/DOCKET NUMBER: CRP-091CP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)-248-7000
TELEFAX: (617)-248-7100
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..21
OTHER INFORMATION: /note= "WT1/EGF HUMAN TCC BINDING
OTHER INFORMATION: SITE"
US-08-486-343A-5

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGGAG 201
DB 21 GGAGGAGGAGGAGGAG 3

RESULT 113
US-09-226-012-93
Sequence 93, Application US/09226012
Patent No. 6207383
GENERAL INFORMATION:
APPLICANT: Keating, Mark T.
APPLICANT: Splawski, Igor
TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
TITLE OF INVENTION: SYNDROME GENE

FILE REFERENCE: 2323-136
CURRENT APPLICATION NUMBER: US/09/226,012
CURRENT FILING DATE: 1999-01-06
EARLIER APPLICATION NUMBER: 09/122,847
EARLIER FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 116
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 93
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens
US-09-226-012-93

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3252 GAGAGACGAGGCTGACG 3270
DB 1 GAGAGACGAGGCTGAGAC 19

RESULT 114
US-09-657-472-1779
Sequence 1779, Application US/09657472
Patent No. 6727063
GENERAL INFORMATION:
APPLICANT: Lander, Eric S.
APPLICANT: Cargill, Michele
APPLICANT: Ireland, James S.
APPLICANT: Bolk, Stacey
APPLICANT: Daley, George O.
APPLICANT: McCarthy, Jeanette J.
TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
FILE REFERENCE: 2825.1027-001
CURRENT APPLICATION NUMBER: US/09/657,472
CURRENT FILING DATE: 2000-09-07
PRIOR APPLICATION NUMBER: US 60/153,357
PRIOR FILING DATE: 1999-09-10
PRIOR APPLICATION NUMBER: US 60/220,947
PRIOR FILING DATE: 2000-07-26
PRIOR APPLICATION NUMBER: US 60/225,724
PRIOR FILING DATE: 2000-08-16
NUMBER OF SEQ ID NOS: 2551
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1779
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens
US-09-657-472-1779

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2107 CCCCCTGCTAGCCCTGCG 2127
DB 1 CCACCCGCTGCGCCCTGCG 21

RESULT 115
PCT-US95-07349-5/C
Sequence 5, Application PC/TUS9507349
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING
MORPHOGEN EXPRESSION
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
ADDRESS: INC.
STREET: 45 SOUTH STREET
CITY: HOPKINTON

STATE: MA
COUNTRY: USA
ZIP: 07148
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/07349
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/938,021
FILING DATE: 28-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: KELLEY, ROBIN D
REGISTRATION NUMBER: 34,637
REFERENCE/DOCKET NUMBER: CRP-091PC
TELEPHONE: (508)-435-9901
TELEFAX: (508)-435-0992
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..21
OTHER INFORMATION: /note= "WT1 HUMAN TCC BINDING SITE"
PCT-US95-07349-5

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GAGAGACGAGGAGGAG 201
DB 21 GAGAGACGAGGAGGAG 3

RESULT 116
US-08-068-747-6/C
Sequence 6, Application US/08068747
Patent No. 5695933
GENERAL INFORMATION:
APPLICANT: Schalling, Martin
APPLICANT: Hudson, Thomas J.
APPLICANT: Housman, David B.
TITLE OF INVENTION: Direct Determination of Expanded
Nucleotide Repeats in the Human Genome
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Millitia Drive
CITY: Lexington
STATE: Massachusetts
COUNTRY: USA
ZIP: 02173
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/068,747
FILING DATE: 28-MAY-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia

REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: MIT-6141
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic"
US-08-068-747-6

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 5.7e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAG 1146
Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 117
US-08-068-747-11
Sequence 11, Application US/08068747
Patent No. 5695933
GENERAL INFORMATION:
APPLICANT: Schelling, Martin
APPLICANT: Hudson, Thomas J.
APPLICANT: Housman, David E.
TITLE OF INVENTION: Direct Determination of Expanded
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Militia Drive
CITY: Lexington
STATE: Massachusetts
COUNTRY: USA
ZIP: 02173
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/068,747
FILING DATE: 28-MAY-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: MIT-6141
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic"
US-08-068-747-11

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 5.7e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAG 1146

Db 1 CTGCTGCTGCTGCTGCTGCTGCTGCTG 30

RESULT 118
US-08-863-639A-30/C
Sequence 30, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Muech
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-30

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 5.7e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAG 1146
Db 30 CTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 119
US-09-135-994-4/C
Sequence 4, Application US/09135994A
Patent No. 6289938
GENERAL INFORMATION:
APPLICANT: Ranum et al.
TITLE OF INVENTION: SCAY GENE AND METHODS OF USE
FILE REFERENCE: University of Minnesota
CURRENT APPLICATION NUMBER: US/09/135,994A
CURRENT FILING DATE: 1998-08-18
EARLIER APPLICATION NUMBER: 60/056,170
NUMBER OF SEQ ID NOS: 14
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 4
LENGTH: 30
TYPE: DNA

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-180

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGGAGAG 1218
DB 17 AGAGAGAGAGAGAGAG 1

RESULT 123
US-08-373-124A-182/C
Sequence 182, Application US/08373124A
Patent No. 5646042

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995

Prior Application DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 182:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-373-124A-182

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1201 GAGGAGCAGAGAGAGA 1217
DB 17 GAGGAGGAGAGAGAGA 1

RESULT 124
US-08-373-124A-188/C
Sequence 188, Application US/08373124A
Patent No. 5646042

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
Prior Application DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 188:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-373-124A-188

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 179 TCACGAGCAGAGAGAG 195
DB 17 TCACGAGCAGAGAGAG 1

RESULT 125
US-08-435-628-180/C
Sequence 180, Application US/08435628


```
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-180

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 182:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-182

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1201 GAGAGCAGAGAGAGA 1217
Db      17 GAGAGCAGAGAGAGA 1

RESULT 127
US-08-435-628-188/c
; Sequence 188, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
```

```
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,442
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 188:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-188

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      179 TCACGAGCAGCAGCAG 195
DB      17 TCACGAGCAGCAGCAG 1

RESULT 128
US-09-371-772B-4506
Sequence 4506, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Becobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
LEVELS OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH90, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371, 772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
```

```
SEQ ID NO 4506
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-4506

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      2641 CAGCAGCTGACAGCA 2657
DB      1 CAGCAGCTGACAGCA 17

RESULT 129
US-09-866-108A-7802
Sequence 7802, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 7802
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-7802

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1120 CAGCAGCAGCTGACGA 1136
DB      1 CAGCAGCAGCTGACGA 17

RESULT 130
US-09-000-286A-21
Sequence 21, Application US/09000286A
```

```

; Patent No. 6449562
; GENERAL INFORMATION:
; APPLICANT: Lumitex Corporation
; APPLICANT: Chandler, Van S.
; APPLICANT: Fulton, Jerrold R.
; APPLICANT: Chandler, Mark B.
; TITLE OF INVENTION: Multiplexed Analysis of Clinical Specimens Apparatus and Method
; FILE REFERENCE: 112802.500
; CURRENT APPLICATION NUMBER: US/09/000.286A
; PRIOR FILING DATE: 1998-08-18
; PRIOR APPLICATION NUMBER: PCT/US96/16198
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-000-286A-21

Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1003 CATGAGAGGAGAGAGA 1019
DB      2 CCTGAGAGGAGAGAGA 18

RESULT 131
US-09-000-286A-22/c
; Sequence 22, Application US/09000286A
; Patent No. 6443562
; GENERAL INFORMATION:
; APPLICANT: Lumitex Corporation
; APPLICANT: Chandler, Van S.
; APPLICANT: Fulton, Jerrold R.
; APPLICANT: Chandler, Mark B.
; TITLE OF INVENTION: Multiplexed Analysis of Clinical Specimens Apparatus and Method
; FILE REFERENCE: 112802.500
; CURRENT APPLICATION NUMBER: US/09/000.286A
; PRIOR FILING DATE: 1998-08-18
; PRIOR APPLICATION NUMBER: PCT/US96/16198
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 22
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-000-286A-22

Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1003 CATGAGAGGAGAGAGA 1019
DB      17 CCTGAGAGGAGAGAGA 1

RESULT 132
US-09-679-298A-30
; Sequence 30, Application US/09679298A
; Patent No. 6566131
; GENERAL INFORMATION:
; APPLICANT: Bretz P. Monla
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD6 EXPRESSION
; FILE REFERENCE: RTS-0045
; CURRENT APPLICATION NUMBER: US/09/679.298A
; PRIOR FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 47
```

```

; SEQ ID NO 30
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-679-298A-30

Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1128 GCTGACGACGACGACG 1144
DB      1 GCTTCAGACGACGACG 17

RESULT 133
US-09-207-388-26/c
; Sequence 26, Application US/09207388
; Patent No. 6497880
; GENERAL INFORMATION:
; APPLICANT: Wisniewski, Jan
; TITLE OF INVENTION: HEAT SHOCK GENES AND PROTEINS FROM
; TITLE OF INVENTION: NEISSERIA MENINGITIDIS, CANDIDA GLABRATA AND ASPERGILLUS
; TITLE OF INVENTION: FUNGATUS
; FILE REFERENCE: 870109.411
; CURRENT APPLICATION NUMBER: US/09/207.388
; PRIOR FILING DATE: 1998-12-08
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer Used to clone Neisseria meningitidis Hsp70
; OTHER INFORMATION: Gene and to construct Neisseria meningitidis Hsp70
; US-09-207-388-26

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2979 CCGAAGTACAGAGAC 2995
DB      18 CCGAAGTACAGAGAC 2

RESULT 134
US-09-422-978-5480/c
; Sequence 5480, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marla
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422.978
; PRIOR FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298.850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109.732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082.614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5480
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
```

FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: upstream amplification primer 99-4541 for SEQ 1546,
US-09-422-978-5480

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1568 GAGAGGTAGAGAGAGA 1584
DB 19 GAGAGGTAGAGAGAGA 3

RESULT 135
US-08-837-201C-28
Sequence 28; Application US/08837201C
Patent No. 5985558
GENERAL INFORMATION:
APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
APPLICANT: Miraglia; Brenda F. Baker
TITLE OF INVENTION: Antisense Oligonucleotide
TITLE OF INVENTION: Compositions and Methods for the Modulation of
NUMBER OF SEQUENCES: 139
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: WINDOWS 95
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/837,201C
FILING DATE: April 14, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0209
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 810-1515
TELEFAX: (609) 810-1454
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-837-201C-28

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 CCGCCGAGGCTCAGTC 770
DB 2 CCGCCGAGGCTCAGTC 18

RESULT 136
US-08-713-742-3
Sequence 3; Application US/08713742

Patent No. 611085
GENERAL INFORMATION:
APPLICANT: Cook and Manoharan
TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
TITLE OF INVENTION: Oligonucleosides
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 611085-ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/713,742
FILING DATE: 17-SEP-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucchi
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2350
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-713-742-3

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCGAGGCTCCC 1672
DB 3 CATCCCCGAGGCTCCC 19

RESULT 137
US-09-433-699-30/C
Sequence 30; Application US/09433699B
Patent No. 6165786
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Lex M. Cowseart
TITLE OF INVENTION: ANTISENSE MODULATION OF NUCLEOLIN EXPRESSION
FILE REFERENCE: RTS-0109
CURRENT APPLICATION NUMBER: US/09/433,699B
CURRENT FILING DATE: 1999-11-03
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 30
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-433-699-30

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 985 GAGGAGAGATGACAG 1001
DB 19 GAGGAGAGATGACAG 3

RESULT 138
US-09-372-856-3
Sequence 3, Application US/09372856
Patent No. 6166188
GENERAL INFORMATION:
APPLICANT: Cook and Manoharan
TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
TITLE OF INVENTION: Oligonucleosides
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6166188aris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows NT 4.0
SOFTWARE: WordPerfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/372,856
FILING DATE: 12-AUG-1999
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/713,742
FILING DATE: 13-SEP-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucet
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-4070
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-372-856-3

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCCAGGCTCCC 1672
DB 3 CATCCCCCAGGCTCCC 19

RESULT 139
US-09-364-416-28
Sequence 28, Application US/09364416
Patent No. 6312900
GENERAL INFORMATION:
APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
APPLICANT: Miraglia, Brenda F. Baker
TITLE OF INVENTION: Antisense Oligonucleotide
TITLE OF INVENTION: Compositions and Methods for the Modulation of
NUMBER OF SEQUENCES: 139
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: WINDOWS 95
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/364,416
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/837,201
FILING DATE: April 14, 1997
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0209
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 810-1515
TELEFAX: (609) 810-1454
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-364-416-28

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 CCGCCAGGCTCAGTC 770
DB 2 CCGCCAGGCTCAGTC 18

RESULT 140
US-09-688-394-3
Sequence 3, Application US/09688394
Patent No. 6322987
GENERAL INFORMATION:
APPLICANT: Cook and Manoharan
TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
TITLE OF INVENTION: Oligonucleosides
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6322987ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows NT 4.0
SOFTWARE: WordPerfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/688,394
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/372,856
FILING DATE: 12-AUG-1999
APPLICATION NUMBER: 08/713,742
FILING DATE: 13-SEP-1996
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucet
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-4070
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-688-394-3

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCAGGCTCCC 1672
Db 3 CATCCCCAGGCTCCC 19

RESULT 141
US-09-907-843-23/c
; Sequence 23, Application US/09907843
; Patent No. 6440739
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-2 EXPRESSION
; FILE REFERENCE: RTS-0279
; CURRENT APPLICATION NUMBER: US/09/907,843
; CURRENT FILING DATE: 2001-07-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-907-843-23

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1477 CAGCAGCAGCAGCAGCT 1493
Db 17 CAGCAGCAGCAGCAGCT 1

RESULT 142
US-09-953-318-45/c
; Sequence 45, Application US/09953318
; Patent No. 6710174
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPT
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-45

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2641 CTGCATGCTGACAGCAA 2657

Db 20 CTGCATGCTGACAGCAA 4

RESULT 143
US-09-934-138B-3
; Sequence 3, Application US/09934138B
; Patent No. 6803198
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And Oligonucleosides
; FILE REFERENCE: ISIS-4802
; CURRENT APPLICATION NUMBER: US/09/934,138B
; CURRENT FILING DATE: 2002-06-25
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-09-934-138B-3

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCAGGCTCCC 1672
Db 3 CATCCCCAGGCTCCC 19

RESULT 144
US-09-009-913-293/c
; Sequence 293, Application US/09009913
; Patent No. 6087485
; GENERAL INFORMATION:
; APPLICANT: Axyx Pharmaceuticals, Inc.
; TITLE OF INVENTION: Asthma Related Genes
; NUMBER OF SEQUENCES: 339
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bozicevic & Reed, LLP
; STREET: 285 Hamilton Ave, Suite 200
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,913
; FILING DATE: 21-JAN-1998
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Sherwood, Pamela J
; REGISTRATION NUMBER: 36,677
; REFERENCE/DOCKET NUMBER: SEQ-4P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-327-3231
; TELEFAX: 650-327-3231
; TELEX:
; INFORMATION FOR SEQ ID NO: 293:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
US-09-009-913-293

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2104 GGGCCCCCTGCTAGCCCCC 2123
DB 20 GGACCCCTGCTCAGCCTCC 1

RESULT 145
US-09-429-323-26/c
Sequence 26; Application US/09429323A
Patent No. 6140126
Patent No. 6140126 6140123
GENERAL INFORMATION:
APPLICANT: Lex M. Cowsett
APPLICANT: C. Frank Bennett
TITLE OF INVENTION: ANTISENSE MODULATION OF Y-BOX BINDING PROTEIN 1 EXPRESSION
FILE REFERENCE: R1S-0092
CURRENT APPLICATION NUMBER: US/09/429,323A
CURRENT FILING DATE: 1999-10-26
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 26
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-429-323-26

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 15 CCCAGCCCCCGCCGCGCC 34
DB 20 CCCAGAGCCGCGCCGCGCC 1

RESULT 146
US-09-288-461-23/c
Sequence 23; Application US/09288461
Patent No. 6159694
GENERAL INFORMATION:
APPLICANT: Karraa, James G.
TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
FILE REFERENCE: ISPH-0338
CURRENT APPLICATION NUMBER: US/09/288,461
CURRENT FILING DATE: 1999-04-08
NUMBER OF SEQ ID NOS: 107
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 23
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Sequence
US-09-288-461-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAG 1137
DB 20 AGCAGCAGATGCTGCAGCAG 1

RESULT 147
US-08-927-219-66

Sequence 66; Application US/08927219

Patent No. 618753

GENERAL INFORMATION:

APPLICANT: Bell, Graeme I.

APPLICANT: Yamagata, Kazuya

APPLICANT: Oda, Naobisha

APPLICANT: Katsuki, Pamela J.

APPLICANT: Furuta, Hiroko

APPLICANT: Horikawa, Yukio

TITLE OF INVENTION: MUTATIONS IN THE DIABETES SUSCEPTIBILITY

GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA, HNF-1BETA

TITLE OF INVENTION: AND HNF-4ALPHA

NUMBER OF SEQUENCES: 147

CORRESPONDENCE ADDRESS:

ADDRESSEE: Arnold, White & Durkee

STREET: P.O. Box 4433

CITY: Houston

STATE: Texas

COUNTRY: USA

ZIP: 77210

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/927,219

FILING DATE: Concurrently Herewith

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/029,679

FILING DATE: 30-OCT-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/028,056

FILING DATE: 02-OCT-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/025,719

FILING DATE: 10-SEP-1996

ATTORNEY/AGENT INFORMATION:

NAME: Wilson, Mark B.

REGISTRATION NUMBER: 37,259

REFERENCE/DOCKET NUMBER: ARCD:272

TELECOMMUNICATION INFORMATION:

TELEPHONE: 512/418-3000

TELEFAX: 512/474-7577

INFORMATION FOR SEQ ID NO: 66:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-927-219-66

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 481 GTGCTGTCAGAGATGC 500
DB 1 GTGCGAGGAGCAGAGATGC 20

RESULT 148
US-09-517-584A-23
Sequence 23; Application US/09517584A
Patent No. 6187587
GENERAL INFORMATION:
APPLICANT: Ian Popoff
APPLICANT: Vickie L. Brown-Driver
APPLICANT: Lex M. Cowsett

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 1 EXPRESSION
; FILE REFERENCE: RTS-0121
; CURRENT APPLICATION NUMBER: US/09/517,584A
; CURRENT FILING DATE: 2000-03-22
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-584A-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2317 GACCACCGCTCAGCGCCAGG 2336
DB 1 GCCCACTGCTCTCGGCGCAGG 20

RESULT 149
US-09-517-584A-36/c
; Sequence 36, Application US/09517584A
; Patent No. 6187587
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Vickie L. Brown-Driver
; TITLE OF INVENTION: ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 1 EXPRESSION
; FILE REFERENCE: RTS-0121
; CURRENT APPLICATION NUMBER: US/09/517,584A
; CURRENT FILING DATE: 2000-03-22
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-584A-36

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1271 AGGAGAGGAGCGAGCGCG 1290
DB 20 AGGAGAGCGAGCGAGCGCTG 1

RESULT 150
US-09-043-303-8
; Sequence 8, Application US/09043303
; Patent No. 6251589
; GENERAL INFORMATION:
; APPLICANT: TSUJI, Shoji
; APPLICANT: SANPEI, Kazuhiro
; TITLE OF INVENTION: Method for Diagnosing Spinocerebellar Ataxia Type 2 and
; FILE REFERENCE: 0760-0241P
; CURRENT APPLICATION NUMBER: US/09/043,303
; CURRENT FILING DATE: 1998-05-18
; EARLIER APPLICATION NUMBER: PCT/JP96/01999
; EARLIER FILING DATE: 1996-07-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-09-043-303-8

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAGCAGCA 1463
DB 1 CACCACAGCAACAGCAGCA 20

RESULT 151
US-09-487-445-105/c
; Sequence 105, Application US/09487445
; Patent No. 6258600
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 8 EXPRESSION
; FILE REFERENCE: RTS-0107
; CURRENT APPLICATION NUMBER: US/09/487,445
; CURRENT FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-445-105

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 154 CTGGCTGCCATCAAGTTCAT 173
DB 20 CTGGCTGCCCTCAAGTTCT 1

RESULT 152
US-09-487-368A-17
; Sequence 17, Application US/09487368A
; Patent No. 6261840
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseart
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: RTS-0093
; CURRENT APPLICATION NUMBER: US/09/487,368A
; CURRENT FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 240
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-368A-17

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2114 CTCAGCCCCCTGCGCCGCC 2133
DB 1 CTTAGCCCCGAGGCCGCC 20

RESULT 153
US-09-593-711A-179/c
; Sequence 179, Application US/09593711A
```



```
; Patent No. 6271030
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTS-0118
; CURRENT APPLICATION NUMBER: US/09/593,711A
; CURRENT FILING DATE: 2000-06-14
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 179
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-593-711A-179

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1267 CTGCAGAGAGAGAGAGCA 1286
DB 20 CTGCAGAGAGAGAGAGCA 1

RESULT 154
US-09-651-011A-11/c
; Sequence 11, Application US/09651011A
; Patent No. 6346416
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
; FILE REFERENCE: RTS-0168
; CURRENT APPLICATION NUMBER: US/09/651,011A
; CURRENT FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-651-011A-11

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 180 CACGAGAGAGAGAGAGAG 199
DB 20 CACGAGAGAGAGAGAGAG 1

RESULT 155
US-09-651-011A-16/c
; Sequence 16, Application US/09651011A
; Patent No. 6346416
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
; FILE REFERENCE: RTS-0168
; CURRENT APPLICATION NUMBER: US/09/651,011A
; CURRENT FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; US-09-651-011A-16

; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-651-011A-16

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 709 GACATGACCCGATGAGC 728
DB 20 GACATGATCAATGAGAGC 1

RESULT 156
US-09-651-011A-44/c
; Sequence 44, Application US/09651011A
; Patent No. 6346416
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HPK/GCK-LIKE KINASE EXPRESSION
; FILE REFERENCE: RTS-0168
; CURRENT APPLICATION NUMBER: US/09/651,011A
; CURRENT FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-651-011A-44

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3886 GGGGCGACGAGCAAGTTA 3905
DB 20 GGTGGCGACGATGAGTTTA 1

RESULT 157
US-09-658-679A-41/c
; Sequence 41, Application US/09658679A
; Patent No. 6444464
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0186
; CURRENT APPLICATION NUMBER: US/09/658,679A
; CURRENT FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-658-679A-41

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 784 AAGAGTTCAATGACTTCAT 803
DB 20 AAGAGTTCAATGACTTCCT 1

RESULT 158
US-09-078-871A-2/c
; Sequence 2, Application US/09078871A
```

```
; Patent No. 6452065
; GENERAL INFORMATION:
; APPLICANT: Zheng, et al.
; TITLE OF INVENTION: Transgenic Animal Expressing
;                               No. 6452065-Native Wild-Type and Familial
;                               Alzheimer's Disease Mutant
;                               Presenilin 1 Protein on Native
;
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O. Box 2000, 126 E. Lincoln Ave.
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065-0900
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/078, 871A
; FILING DATE: 14-May-1998
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US98/09709
; FILING DATE: 13-MAY-1998
; APPLICATION NUMBER: 60/046,488
; FILING DATE: 14-MAY-1997
; APPLICATION NUMBER: 60/078,465
; FILING DATE: 18-MAR-1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Yablonsky, Michael D
; REGISTRATION NUMBER: 40,407
; REFERENCE/DOCKET NUMBER: 19954Y
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 732-594-4678
; TELEFAX: 732-594-4720
;
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-078-871A-2

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1400 TCCAGAGCGCAGCTGCAGCAG 1419
DB      20  TGCAGAGCCACCTGCAGCAG 1

RESULT 159
US-09-629-644A-17
; Sequence 17, Application US/09629644A
; Patent No. 6602857
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseert
; APPLICANT: Jacqueline Wyalt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION
; FILE REFERENCE: ISPH-0478
; CURRENT APPLICATION NUMBER: US/09/629,644A
; CURRENT FILING DATE: 2000-07-31
```

```
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 242
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-644A-17

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2114 CTCAGCCCCCTGCGCCGCC 2133
DB      1  CTTAGCCCGAGGCGCCGCC 20

RESULT 160
US-09-629-644A-17
; Sequence 17, Application US/09629644A
; Patent No. 6492345
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseert
; APPLICANT: Jacqueline Wyalt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION
; FILE REFERENCE: ISPH-0478
; CURRENT APPLICATION NUMBER: US/09/629,644A
; CURRENT FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 242
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-644A-17

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2114 CTCAGCCCCCTGCGCCGCC 2133
DB      1  CTTAGCCCGAGGCGCCGCC 20

RESULT 161
US-09-198-452A-5002/C
; Sequence 5002, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5002
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-5002
```

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGC 1462
DB 20 GCAGCAGCAGCAGCAGCAGC 1

RESULT 162
US-09-922-146-23
; Sequence 23, Application US/09922146
; Patent No. 6566133
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowert
; APPLICANT: Brett P. Mohla
; TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
; FILE REFERENCE: RTS-0252
; CURRENT APPLICATION NUMBER: US/09/922,146
; PRIOR FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1277 AGGAGCAGCAGCGCGCGCTG 1296
DB 1 AGGAGCAGCAGCGCGCGCGC 20

RESULT 163
US-09-758-881-23/c
; Sequence 23, Application US/09758881
; Patent No. 6727064
; GENERAL INFORMATION:
; APPLICANT: Karitas, James G
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
; FILE REFERENCE: ISPH-0532
; CURRENT APPLICATION NUMBER: US/09/758,881
; CURRENT FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: PCT/US00/09054
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 09/288,461
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 152
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-758-881-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAG 1137
DB 20 AGCAGCAGCAGCTGCAGCAG 1

RESULT 164
US-09-491-356C-19
; Sequence 19, Application US/09491356C
; Patent No. 656061
; GENERAL INFORMATION:
; APPLICANT: Philibert, Robert A.
; APPLICANT: Gims, Edward I.
; APPLICANT: Delisi, Lynn
; TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF XQ13
; FILE REFERENCE: 9465.6US11
; CURRENT APPLICATION NUMBER: US/09/491,356C
; CURRENT FILING DATE: 2000-01-26
; PRIOR APPLICATION NUMBER: PCT/US99/09365
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 60/083,465
; PRIOR FILING DATE: 1998-04-29
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-491-356C-19

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAG 1458
DB 1 CAGCAGCAGCAACAG 15

RESULT 165
US-08-146-504-20
; Sequence 20, Application US/08146504
; Patent No. 5605662
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J.; and Tu, Eugene
; TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
; TITLE OF INVENTION: MICROELECTRONIC SYSTEMS AND DEVICES FOR
; TITLE OF INVENTION: MOLECULAR BIOLOGICAL ANALYSIS AND
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/146,504
; FILING DATE: No. 560562ember 1, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; APPLICATION DATA: described below:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 203/218
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-146-504-20

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAAGAGA 1019
Db 2 TGGAGAGGAAGAGA 16

RESULT 166
US-08-725-976-20
; Sequence 20, Application US/08725976
; Patent No. 5929208
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J., and Tu, Eugene
; TITLE OF INVENTION: METHODS FOR ELECTRONIC SYNTHESIS OF POLYMERS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM compatible
; SOFTWARE: Wordperfect (Version 6.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/725,976
; FILING DATE: October 4, 1996
; CLASSIFICATION: 422
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/146,504
; FILING DATE: No. 5929208ember 1, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy, David B.
; REGISTRATION NUMBER: 31,125
; REFERENCE/DOCKET NUMBER: 222/211
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEFAX: 67-3510
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-725-976-20

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAAGAGA 1019
Db 2 TGGAGAGGAAGAGA 16

RESULT 167
US-08-271-882B-20

; Sequence 20, Application US/08271882B
; Patent No. 6017696
; GENERAL INFORMATION:
; APPLICANT: Michael J. Heller
; APPLICANT: Eugene Tu
; APPLICANT: Glen A. Evans
; APPLICANT: Ronald G. Sosnowski
; TITLE OF INVENTION: SELF-ADDRESSABLE
; TITLE OF INVENTION: SELF-ASSEMBLING
; TITLE OF INVENTION: MICROELECTRONIC SYSTEMS AND
; TITLE OF INVENTION: DEVICES FOR
; TITLE OF INVENTION: MOLECULAR BIOLOGICAL ANALYSIS
; AND DIAGNOSTICS
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: Wordperfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/271,882B
; FILING DATE: July 7, 1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/146,504
; FILING DATE: No. 6017696ember 1, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy, David B.
; REGISTRATION NUMBER: 31,125
; REFERENCE/DOCKET NUMBER: 207/263
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEFAX: 67-3510
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic
; TYPE: acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-271-882B-20

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAAGAGA 1019
Db 2 TGGAGAGGAAGAGA 16

RESULT 168
US-08-726-278-20
; Sequence 20, Application US/08726278
; Patent No. 6238624
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J.
; APPLICANT: Tu, Eugene
; APPLICANT: Evans, Glen A.
; APPLICANT: Sosnowski, Ronald G.
; TITLE OF INVENTION: METHODS FOR ELECTRONIC TRANSPORT IN MOLECULAR
; TITLE OF INVENTION: BIOLOGICAL ANALYSIS AND DIAGNOSTICS
; FILE REFERENCE: DAVID B. MURPHY/NANOGEN: 222-210
; CURRENT APPLICATION NUMBER: US/08/726,278

CURRENT FILING DATE: 1996-10-04
PRIOR APPLICATION NUMBER: 08/271,882
PRIOR FILING DATE: 1994-07-07
NUMBER OF SEQ ID NOS: 44
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 20
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Sequences for
US-08-726-278-20

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAGGAGA 1019
Db 2 TGGAGAGGAGGAGA 16

RESULT 169
US-09-671-954A-2/c
Sequence 2, Application US/09671954A
Patent No. 6780584
GENERAL INFORMATION:
APPLICANT: Nanogen, Inc.
APPLICANT: Edman, Carl F.
APPLICANT: Tu, Eugene
APPLICANT: Gurtner, Christian
APPLICANT: Westin, Lorelei
APPLICANT: Heller, Michael J.
TITLE OF INVENTION: Electronic Systems, Component Devices, Mechanisms, Methods, and
TITLE OF INVENTION: Procedures for Macroscopic and Microscopic Molecular Biological
FILE REFERENCE: 256/261 Nanogen -- Patrick S. Esigleman
CURRENT APPLICATION NUMBER: US/09/671,954A
CURRENT FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 17
SOFTWARE: Patentin version 3.1
SEQ ID NO 2
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Capture oligonucleotide
NAME/KEY: modified_base
LOCATION: (1)-(1)
OTHER INFORMATION: Base 1 modified with Biotin
US-09-671-954A-2

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAGGAGA 1019
Db 16 TGGAGAGGAGGAGA 2

RESULT 170
US-08-146-504-6/c
Sequence 6, Application US/08146504
Patent No. 5605662
GENERAL INFORMATION:
APPLICANT: Heller, Michael J.; and Tu, Eugene
TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
TITLE OF INVENTION: MICROELECTRONIC SYSTEMS AND DEVICES FOR
TITLE OF INVENTION: MOLECULAR BIOLOGICAL ANALYSIS AND
TITLE OF INVENTION: DIAGNOSTICS

NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: Wordperfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/146,504
FILING DATE: No. 560562eember 1, 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
APPLICATION NUMBER: described below:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 203/218
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-146-504-6

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAGGAGA 1019
Db 16 TGGAGAGGAGGAGA 2

RESULT 171
US-08-725-976-6/c
Sequence 6, Application US/08725976
Patent No. 5928208
GENERAL INFORMATION:
APPLICANT: Heller, Michael J.; and Tu, Eugene
TITLE OF INVENTION: METHODS FOR ELECTRONIC SYNTHESIS OF POLYMERS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM compatible
OPERATING SYSTEM: WINDOWS (VERSION 3.0)
SOFTWARE: Wordperfect (Version 6.0)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/725,976
FILING DATE: October 4, 1996
CLASSIFICATION: 422
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/146,504
FILING DATE: No. 5929208ember 1, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Murphy, David B.
REGISTRATION NUMBER: 31,125
REFERENCE/DOCKET NUMBER: 222/211
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEFAX: 67-3510
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-725-976-6

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAGGAGA 1019
DB 16 TGGAGAGGAGGAGA 2

RESULT 172
US-08-271-882B-6/C
Sequence 6, Application US/08271882B
Patent No. 6017696
GENERAL INFORMATION:
APPLICANT: Michael J. Heller
APPLICANT: Eugene Tu
APPLICANT: Glen A. Evans
APPLICANT: Ronald G. Sosnowski
TITLE OF INVENTION: SELF-ASSESSABLE
TITLE OF INVENTION: SELF-ASSEMBLING
TITLE OF INVENTION: MICROELECTRONIC SYSTEMS AND
TITLE OF INVENTION: DEVICES FOR
TITLE OF INVENTION: MOLECULAR BIOLOGICAL ANALYSIS
TITLE OF INVENTION: AND DIAGNOSTICS
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/271,882B
FILING DATE: July 7, 1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/146,504
FILING DATE: No. 6017696ember 1, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Murphy, David B.
REGISTRATION NUMBER: 31,125
REFERENCE/DOCKET NUMBER: 207/263
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEFAX: 67-3510
INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic
TYPE: acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-271-882B-6

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAGGAGA 1019
DB 16 TGGAGAGGAGGAGA 2

RESULT 173
US-08-726-278-6/C
Sequence 6, Application US/08726278
Patent No. 6238624
GENERAL INFORMATION:
APPLICANT: Heller, Michael J.
APPLICANT: Tu, Eugene
APPLICANT: Evans, Glen A.
APPLICANT: Sosnowski, Ronald G.
TITLE OF INVENTION: METHODS FOR ELECTRONIC TRANSPORT IN MOLECULAR
TITLE OF INVENTION: BIOLOGICAL ANALYSIS AND DIAGNOSTICS
FILE REFERENCE: DAVID B. MURPHY/NANGEN: 222-210
CURRENT APPLICATION NUMBER: US/08/726,278
CURRENT FILING DATE: 1996-10-04
PRIOR APPLICATION NUMBER: 08/271,882
PRIOR FILING DATE: 1994-07-07
NUMBER OF SEQ ID NOS: 44
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 6
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Sequences for
US-08-726-278-6

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TGGAGAGGAGGAGA 1019
DB 16 TGGAGAGGAGGAGA 2

RESULT 174
US-09-555-313B-16/C
Sequence 16, Application US/09555313B
Patent No. 6506580
GENERAL INFORMATION:
APPLICANT: FISCHHEISTER, Rudolph et al.
TITLE OF INVENTION: Splicing variants of the human serotonergic receptor
FILE REFERENCE: P06762US00/BAS
CURRENT APPLICATION NUMBER: US/09/555,313B
CURRENT FILING DATE: 2002-08-13
PRIOR APPLICATION NUMBER: FR 97/15037
PRIOR FILING DATE: 1997-11-28
NUMBER OF SEQ ID NOS: 24
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 16
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

```
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-555-313B-16
Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3233 ACAATGACCCAGAG 3247
DB      17 ACAATGACCCAGAG 3

RESULT 175
US-09-478-189-28/c
; Sequence 28, Application US/09478189
; Patent No. 6534293
; GENERAL INFORMATION:
; APPLICANT: Barany, Francis
; APPLICANT: Liu, Jianzhao
; APPLICANT: Kirk, Brian W.
; APPLICANT: Ziliv, Monib
; APPLICANT: Gerty, No. 6534293man P.
; APPLICANT: Pety, Philip B.
; TITLE OF INVENTION: ACCELERATING IDENTIFICATION OF SINGLE NUCLEOTIDE
; TITLE OF INVENTION: POLYMORPHISMS AND ALIGNMENT OF CLONES IN GENOMIC
; TITLE OF INVENTION: SEQUENCING
; FILE REFERENCE: 19603/2621
; CURRENT APPLICATION NUMBER: US/09/478,189
; PRIOR FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: 60/114,881
; PRIOR FILING DATE: 1999-01-06
; NUMBER OF SEQ ID NOS: 181
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: probe/primer
US-09-478-189-28
Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1280 AGCAGCAGCGCGGC 1294
DB      15 AGCAGCAGCGCGGC 1

RESULT 176
US-09-344-914-51/c
; Sequence 51, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-51
Query Match      0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1112 TAAACAGCAGCAGC 1126
DB      15 TAAACAGCAGCAGC 1

RESULT 177
US-09-344-914-57/c
; Sequence 57, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-57
Query Match      0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1113 AAAACAGCAGCAGCA 1127
DB      20 AAAACAGCAGCAGCA 6

RESULT 178
US-09-198-452A-2277
; Sequence 2277, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prever
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2277
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2277
Query Match      0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      812 GTCCTCATCAAGACTT 826
DB      3 GTCCTCATCAAGACTT 17

RESULT 179
US-09-863-049B-21/c
; Sequence 21, Application US/09863049B
; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenwright, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhy, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahl, Aemae
```

APPLICANT: Israel, Alain
APPLICANT: Pouscka, Annemarie
APPLICANT: Lewis, Richard A
APPLICANT: Levy, Moise
APPLICANT: Heise, Nina
TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
FILE REFERENCE: HO-P01961US1
CURRENT APPLICATION NUMBER: US/09/863,049B
CURRENT FILING DATE: 2001-05-22
PRIOR FILING DATE: 2000-05-22
NUMBER OF SEQ ID NOS: 79
SOFTWARE: PatentIn version 3.1
SEQ ID NO 21
LENGTH: 20
TYPE: DNA
ORGANISM: Human
US-09-863-049B-21

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2047 TCCGCTGGCAATC 2061
DB 15 TCCGCTGGCAATC 1

RESULT 180
US-09-475-947A-251/c
Sequence 251, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS00667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 251
LENGTH: 33
TYPE: DNA
ORGANISM: human
US-09-475-947A-251

Query Match 0.4%; Score 15; DB 1; Length 33;
Best Local Similarity 67.7%; Pred. No. 6.3e+02;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1468 CTTCAAGAACGACGACGACGCTCTGC 1498
DB 33 CTGCTGCTACTGCTGCTGCTGCTGCTGC 3

RESULT 181
US-08-758-306-499/c
Sequence 499, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fastseq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 499:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-499

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1257 GCAGCGGAGCTGCAGGA 1274
DB 18 GCAGCGGAGCTGCAGGA 1

RESULT 182
US-08-974-565C-13/c
Sequence 13, Application US/08974565C
Patent No. 5932423
GENERAL INFORMATION:
APPLICANT: Au-Young, Janice
APPLICANT: Cocks, Benjamin G.
APPLICANT: Coleman, Roger
APPLICANT: Selhamer, Jeffrey J.
APPLICANT: Fisher, Douglas A.
TITLE OF INVENTION: CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Dr.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/974,565C
FILING DATE: Herewith
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/624,663


```

; FILING DATE: March 25, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Murty, Lynn E.
; REGISTRATION NUMBER: 42,918
; REFERENCE/DOCKET NUMBER: PF-0057-1 CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-974-565C-13

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3378 CCCCACCTACACCA 3395
DB 18 CTCCTACCTACACCA 1

RESULT 183
US-09-106-038A-24
; Sequence 24, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-106-038A-24

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 CAGCAGTGCAGCAGCAG 1140
DB 1 CACCAGCGCAGCAGCAG 18
```

```

; FILING DATE: March 25, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Murty, Lynn E.
; REGISTRATION NUMBER: 42,918
; REFERENCE/DOCKET NUMBER: PF-0057-1 CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-974-565C-13

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3378 CCCCACCTACACCA 3395
DB 18 CTCCTACCTACACCA 1

RESULT 183
US-09-106-038A-24
; Sequence 24, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-106-038A-24

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 CAGCAGTGCAGCAGCAG 1140
DB 1 CACCAGCGCAGCAGCAG 18

RESULT 184
US-09-255-911-31/C
; Sequence 31, Application US/09255911
; Patent No. 6013522
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD1 EXPRESSION
; FILE REFERENCE: RTS-0040
; CURRENT APPLICATION NUMBER: US/09/255,911
; CURRENT FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 46
; SEQ ID NO 31
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-255-911-31

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1478 AGCAGCAGCAGCAGCTCC 1495
DB 18 AGCAGCAGCAGCAGCTAC 1

RESULT 185
US-09-289-466-18/C
; Sequence 19, Application US/09289466A
; Patent No. 6124272
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF PDK-1 EXPRESSION
; FILE REFERENCE: RTS-0060
; CURRENT APPLICATION NUMBER: US/09/289,466A
; CURRENT FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-289-466-18

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CGGAGAGCGCGGTGAG 951
DB 18 CGGAGAGCGCGCTGAG 1

RESULT 186
US-09-205-995-55
; Sequence 55, Application US/09205995
; Patent No. 6368655
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995
; CURRENT APPLICATION NUMBER: US/09/205,995
; CURRENT FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
```

PRIOR APPLICATION NUMBER: 08/661,627
PRIOR FILING DATE: 1996-06-11
NUMBER OF SEQ ID NOS: 79
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 55
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: antisense
OTHER INFORMATION: oligonucleotide corresponding to a specific region
OTHER INFORMATION: of the mouse It gene.
US-09-205-995-55

Query Match
Best Local Similarity 88.9%; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3480 GGTCTATGCTCCAG 3497
Db 1 GGTCTATGCTCCAG 18

RESULT 187
US-09-091-952A-115
Sequence 115, Application US/09091952A
Patent No. 6458532
GENERAL INFORMATION:
APPLICANT: Deterra-Wadleigh, Sevilla D.
Gershon, Elliot S.
Badner, Judith A.
Goldin, Lynn R.
Berrettini, Wade H.
Yoshikawa, Takeo
Sanders, Alan R.
Esterling, Lisa E.
TITLE OF INVENTION: Chromosomal Markers and Diagnostic
Tests for Manic-Depressive Illness
NUMBER OF SEQUENCES: 197
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/091,952A
FILING DATE: 19-Apr-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/029,278
FILING DATE: 28-OCT-1996
APPLICATION NUMBER: PCT/US97/19381
FILING DATE: 28-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Smith, Timothy L.
REGISTRATION NUMBER: 35,367
REFERENCE/DOCKET NUMBER: 015280-297100US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 115:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..18
OTHER INFORMATION: Clone 3 reverse primer
US-09-091-952A-115

Query Match
Best Local Similarity 88.9%; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3176 GGAAGAGCAACTGC 3193
Db 1 GGAAGAGCAACTGC 18

RESULT 188
US-09-475-947A-340
Sequence 340, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS0667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO: 340
LENGTH: 18
TYPE: DNA
ORGANISM: human
US-09-475-947A-340

Query Match
Best Local Similarity 88.9%; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1119 GCAGCAGCTGCAGCA 1136
Db 1 GCAGCAGCAGCTGCAGCA 18

RESULT 189
US-09-280-030-28/c
Sequence 28, Application US/09280030A
Patent No. 6506595
GENERAL INFORMATION:
APPLICANT: Sato, Seiji
APPLICANT: Higashikuni, Naohiko
APPLICANT: Kudo, Toshiyuki
APPLICANT: Kondo, Masaaki
TITLE OF INVENTION: DNAs ENCODING NEW FUSION PROTEINS AND PROCESSES FOR THE
TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
FILE REFERENCE: 382.1026
CURRENT APPLICATION NUMBER: US/09/280,030A
CURRENT FILING DATE: 1999-03-26
EARLIER APPLICATION NUMBER: JP10-87339/1998
EARLIER FILING DATE: 1998-03-31
NUMBER OF SEQ ID NOS: 66
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 28
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Designated is
OTHER INFORMATION: a reverse primer for PCR amplification of

OTHER INFORMATION: MMAP-MMP5 DNA
US-09-280-030-28

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1269 GCAGAGAGAGAGAGCA 1286
DB 18 GCAGAGAGAGAGAGCA 1

RESULT 190
US-09-517-467B-5/c
Sequence 5, Application US/09517467B
Patent No. 6451602
GENERAL INFORMATION:
APPLICANT: Ian Popoff
TITLE OF INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
FILE REFERENCE: RTS-0150
CURRENT APPLICATION NUMBER: US/09/517,467B
PRIOR FILING DATE: 2001-03-02
PRIOR FILING DATE: 2000-03-02
NUMBER OF SEQ ID NOS: 345
SEQ ID NO 5
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PCR Primer
US-09-517-467B-5

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3082 AGTGGCAGGCGCAAGTGTG 3099
DB 18 AGTGTGAGGCGCAAGTGTG 1

RESULT 191
US-09-475-947A-178/c
Sequence 178, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS0667
CURRENT APPLICATION NUMBER: US/09/475,947A
PRIOR FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 178
LENGTH: 19
TYPE: DNA
ORGANISM: human
US-09-475-947A-178

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3273 CGTGGGAGATGAGGCG 3290
DB 18 CATGGGGAGACGAGGG 1

RESULT 192

US-09-422-978-9120/c
Sequence 9120, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marla
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
PRIOR FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 9120
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: downstream amplification primer 99-22356 for SEQ 1255, in compleme

US-09-422-978-9120

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3591 CATCTTCCTCCCAACAC 3608
DB 19 CTTCATCTTCCTCCCAACAC 2

RESULT 193
US-09-422-978-9749
Sequence 9749, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marla
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
PRIOR FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 9749
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: downstream amplification primer 99-7107 for SEQ 1884, in compleme

US-09-422-978-9749

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2424 CAGCAGAGAGTGAAG 2441
DB 2 CAGTGAAGTGTGAAG 19

RESULT 194
US-09-782-361-14/c
Sequence 16, Application US/09782361
Patent No. 6811974
GENERAL INFORMATION:
APPLICANT: Hu, Yu-Wen
TITLE OF INVENTION: PRIMER-SPECIFIC AND MISPAIR EXTENSION ASSAY FOR IDENTIFYING GEN
TITLE OF INVENTION: VARIATION
FILE REFERENCE: 2883-4757US
CURRENT APPLICATION NUMBER: US/09/782,361
CURRENT FILING DATE: 2001-02-13
NUMBER OF SEQ ID NOS: 49
SOFTWARE: PatentIn version 3.0
SEQ ID NO 14
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: primer for PSMEA
US-09-782-361-14

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2094 AAGCCTCCAGGCCCC 2111
DB 18 ACAGCCTCCAGGCCCC 1

RESULT 195
US-09-719-737-12
Sequence 12, Application US/09719737
Patent No. 6823087
GENERAL INFORMATION:
APPLICANT: RENZI, Paolo
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR TREATING
TITLE OF INVENTION: OR PREVENTING ATOPIC DISEASES AND NEOPLASTIC CELL
TITLE OF INVENTION: PROLIFERATION
FILE REFERENCE: 13424-1PCT
CURRENT APPLICATION NUMBER: US/09/719,737
CURRENT FILING DATE: 2001-01-29
PRIOR APPLICATION NUMBER: CA2235420
PRIOR FILING DATE: 1998-06-17
NUMBER OF SEQ ID NOS: 23
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 12
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense oligonucleotide inhibiting the common
US-09-719-737-12

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1305 GCAGGCTGTGCGCGGA 1322
DB 1 GCAGGCTGTGCGCGGA 18

RESULT 196
US-08-367-069-17
Sequence 17, Application US/08367069
Patent No. 5811538
GENERAL INFORMATION:
APPLICANT: Timothy A. Riley
APPLICANT: Mark A. Reynolds

APPLICANT: Lloyd R. Snyder
APPLICANT: Robert E. Klem
TITLE OF INVENTION: IMPROVED PROCESS FOR THE
TITLE OF INVENTION: PURIFICATION OF OLIGOMERS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
City: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq version 1.5
CURRENT APPLICATION DATA:
FILING DATE: December 30, 1994
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below: 1
FILING DATE: 30 December 1993
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: BIGGS, SUZANNE L.
REGISTRATION NUMBER: 30,158
REFERENCE/DOCKET NUMBER: 210/209
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-367-069-17

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGAGCAGAGGAG 199
DB 1 GAGAGCAGAGGAG 16

RESULT 197
US-08-885-126-3
Sequence 3, Application US/08885126A
Patent No. 5955597
GENERAL INFORMATION:
APPLICANT: Arnold, Lyle J.
APPLICANT: Riley, Timothy A.
APPLICANT: Reynolds, Mark A.
APPLICANT: Schwartz, David A.
TITLE OF INVENTION: CHIRALLY ENRICHED SYNTHETIC PHOSPHATE
TITLE OF INVENTION: OLIGOMERS
FILE REFERENCE: GENA.020FW2
CURRENT APPLICATION NUMBER: US/08/885,126A
CURRENT FILING DATE: 1997-06-30
EARLIER APPLICATION NUMBER: 08/343,018
EARLIER FILING DATE: 1994-11-21
EARLIER APPLICATION NUMBER: 08/154,013
EARLIER FILING DATE: 1993-11-16
NUMBER OF SEQ ID NOS: 22

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Chemically synthesized oligomer
US-08-885-126-3

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      184 GAGGACGAGGAGGAG 199
Db      1 GAGGACGAGGAGGAG 16

RESULT 198
US-08-960-111-5
; Sequence 5, Application US/08960111
; Patent No. 6060456
; GENERAL INFORMATION:
; APPLICANT: Arnold Jr., Lyle J
; APPLICANT: Reynolds, Mark A
; APPLICANT: Giachetti, Christina
; TITLE OF INVENTION: Chimeric Oligonucleoside Compounds
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth St.
; CITY: Los Angeles
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/960,111
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US/08/238,177
; FILING DATE: 04-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Meier, Paul H.
; REGISTRATION NUMBER: 32,274
; REFERENCE/DOCKET NUMBER: 207/174
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 213/489-1600
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: GAG oligomer
; IDENTIFICATION METHOD: synthesis experiment
US-08-960-111-5

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      184 GAGGACGAGGAGGAG 199
Db      1 GAGGACGAGGAGGAG 16

RESULT 199
US-09-490-774-5
; Sequence 5, Application US/09490774
; Patent No. 6262036
; GENERAL INFORMATION:
; APPLICANT: Arnold Jr., Lyle J
; APPLICANT: Reynolds, Mark A
; APPLICANT: Giachetti, Christina
; TITLE OF INVENTION: Chimeric Oligonucleoside Compounds
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth St.
; CITY: Los Angeles
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,774
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/960,111
; FILING DATE:
; APPLICATION NUMBER: US/08/238,177
; FILING DATE: 04-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Meier, Paul H.
; REGISTRATION NUMBER: 32,274
; REFERENCE/DOCKET NUMBER: 207/174
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 213/489-1600
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: GAG oligomer
; IDENTIFICATION METHOD: synthesis experiment
US-09-490-774-5

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      184 GAGGACGAGGAGGAG 199
Db      1 GAGGACGAGGAGGAG 16

RESULT 200
US-08-679-645-666
; Sequence 666, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
```

```

; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folckerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 666:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-679-645-666
;
Query Match
Best Local Similarity 81.2%; Score 14.4; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
;
Qy 1305 GCAGGCTCTGCGCGG 1320
Db 2 GCAGGGGCTGCGCGG 17
;
RESULT 201
US-09-474-432B-734
; Sequence 734, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
;

```

```

; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleoti
; FILE REFERENCE: MEBB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 734
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-474-432B-734
;
Query Match
Best Local Similarity 81.2%; Score 14.4; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
;
Qy 2977 ATCCGAGTACACAGA 2992
Db 1 AUCCGAGACACACGA 16
;
RESULT 202
US-09-476-387-733
; Sequence 733, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleoti
; FILE REFERENCE: MEBB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 733
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-476-387-733
;
Query Match
Best Local Similarity 81.2%; Score 14.4; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
;
Qy 2977 ATCCGAGTACACAGA 2992
Db 1 AUCCGAGACACACGA 16
;
RESULT 203

```

```
US-09-827-998-117/c
; Sequence 117, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMRP-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 117
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-117

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      895 CAGGTCCGATCCAGC 910
Db      17 CAGGTCCGATCCAGC 2

RESULT 204
US-09-827-998-118/c
; Sequence 118, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMRP-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 118
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-118

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      895 CAGGTCCGATCCAGC 910
Db      16 CAGGTCCGATCCAGC 1

RESULT 205
US-09-866-108A-6414
; Sequence 6414, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: SHANNON, Mark
```

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6414
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6414

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      3129 GCAGTGTGATGCTG 3144
Db      2 GCAGTGTGATGCTG 17

RESULT 206
US-09-866-108A-6415
; Sequence 6415, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6415

Query Match
Best local Similarity 93.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3129 GCAGATGATGTCCTG 3144
DB 1 GCAGATGATGCGCTG 16

RESULT 207
US-09-866-108A-7795
; Sequence 7795, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7795
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```

US-09-866-108A-7795

Query Match
Best local Similarity 93.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGC 1141
DB 2 CAGCTTCAGCAGCAGC 17

RESULT 208
US-09-866-108A-7796
; Sequence 7796, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7796
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7796

Query Match
Best local Similarity 93.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGC 1141
DB 1 CAGCTTCAGCAGCAGC 16

RESULT 209
US-09-866-108A-7801
; Sequence 7801, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
```



```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7801
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7801

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy' 1120 CAGCAGCAGCTGAGC 1135
Db 2 CAGCAGCAGCTGAGC 17

RESULT 210
US-09-866-108A-7803
; Sequence 7803, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8002
; LENGTH: 17
; TYPE: DNA
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7803
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7803

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1121 AGCAGCAGCTGAGCA 1136
Db 1 AGCAGCAGCTGAGCA 16

RESULT 211
US-09-866-108A-8002
; Sequence 8002, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8002
; LENGTH: 17
; TYPE: DNA
```

ORGANISM: Homo sapiens
US-09-866-108A-8003

Query Match
Best Local Similarity 93.8%; Pred. No. 2e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1366 AAGCAGCTGGAGCAGC 1381
DB 2 AAGCAGCTGGAGCAGC 17

RESULT 212

US-09-866-108A-8003

Sequence 8003, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

PRIOR FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aecmica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 8003

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-8003

Query Match
Best Local Similarity 93.8%; Pred. No. 2e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1366 AAGCAGCTGGAGCAGC 1381
DB 1 AAGCAGCTGGAGCAGC 16

RESULT 213

US-09-866-108A-8649

Sequence 8649, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

PRIOR FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aecmica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 8649

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-8649

Query Match
Best Local Similarity 93.8%; Pred. No. 2e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1407 GCAGCTGCAGCAGCAG 1422
DB 2 GCAGCTGCAGCAGCAG 17

RESULT 214

US-09-866-108A-8650

Sequence 8650, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

PRIOR FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeonica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 8650
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-8650

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1407 GCAGCTGCAGCAGAG 1422
DB 1 GCAGCTGCAGCTGAG 16

RESULT 215
US-09-404-912-344/C
Sequence 344, Application US/09404912
Patent No. 6703228
GENERAL INFORMATION:
APPLICANT: John Landers
APPLICANT: David Houseman
APPLICANT: Barbara Jordan
APPLICANT: Alain Charest
TITLE OF INVENTION: Methods and Products Related to
FILE REFERENCE: M0656/7045(HCL/MAT)
CURRENT APPLICATION NUMBER: US/09/404,912
CURRENT FILING DATE: 1999-09-24
PRIOR APPLICATION NUMBER: US 60/101,757
PRIOR FILING DATE: 1998-09-25
PRIOR APPLICATION NUMBER: PCT/US99/22283
PRIOR FILING DATE: 1999-09-24
NUMBER OF SEQ ID NOS: 691
SOFTWARE: PasteSeq for Windows Version 3.0
SEQ ID NO 344
LENGTH: 17
TYPE: DNA
ORGANISM: Homo Sapiens
US-09-404-912-344

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1471 CAGAAACAGCAGCAGC 1486
DB 17 CAGAAACAGCAGCAGC 2

RESULT 216
US-08-568-271-4/C
Sequence 4, Application US/08568271
Patent No. 5800990
GENERAL INFORMATION:
APPLICANT: RAYNOLDS, MARY V.
APPLICANT: PERRYMAN, M. BENJA

TITLE OF INVENTION: ANGIOTENSIN-CONVERTING ENZYME GENETIC
TITLE OF INVENTION: VARIANT SCREENS
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: DILWORTH & BARRESE
STREET: 4350 LA JOLLA VILLAGE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CALIFORNIA
COUNTRY: U.S.A.
ZIP: 92122

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/568,271
FILING DATE: 06-DEC-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: PEPPER PH.D., FREDERICK W.
REGISTRATION NUMBER: 31,286
REFERENCE/DOCKET NUMBER: 491-7
TELEPHONE: 619-546-4410
TELEFAX: 619-453-2839

INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-568-271-4

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3331 TTCCTGTCATCGCCC 3346
DB 16 TTCCTGTCATCGCCC 1

RESULT 217
US-08-568-271-8/C
Sequence 8, Application US/08568271
Patent No. 5800990
GENERAL INFORMATION:
APPLICANT: RAYNOLDS, MARY V.
APPLICANT: PERRYMAN, M. BENJA

TITLE OF INVENTION: ANGIOTENSIN-CONVERTING ENZYME GENETIC
TITLE OF INVENTION: VARIANT SCREENS
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: DILWORTH & BARRESE
STREET: 4350 LA JOLLA VILLAGE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CALIFORNIA
COUNTRY: U.S.A.
ZIP: 92122

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/568,271
FILING DATE: 06-DEC-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: PEPPER PH.D., FREDERICK W.
REGISTRATION NUMBER: 31,286

REFERENCE/DOCKET NUMBER: 491-7
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-546-4410
TELEFAX: 619-453-2839
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-568-271-8

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3331 TTCCTGTCATCGCCC 3346
DB 16 TTCCTGGCATCGCCC 1

RESULT 218
US-08-257-963B-27/C
Sequence 27, Application US/08257963B
Patent No. 5840686
GENERAL INFORMATION:
APPLICANT: Chader, Gerald J.; Becerra, S.
APPLICANT: Patricia; Schwartz, Joan P.;
APPLICANT: Taniwaki, Takayuki;
TITLE OF INVENTION: PIGMENT EPITHELIAL
TITLE OF INVENTION: DERIVED FACTOR: CHARACTERIZATION OF ITS NOVEL
TITLE OF INVENTION: BIOLOGICAL ACTIVITY AND SEQUENCES ENCODING
TITLE OF INVENTION: AND EXPRESSING THE PROTEIN
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morgan & Finnegan
STREET: 345 Park Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/257,963B
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/952,796
FILING DATE: 24-SEPT-1992
ATTORNEY/AGENT INFORMATION:
NAME: DOROTHY R. AUTH
REGISTRATION NUMBER: 36434
REFERENCE/DOCKET NUMBER: 20264126US1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 Base Pairs
TYPE: Nucleic Acid
STRANDEDNESS: Double
TOPOLOGY: Unknown
MOLECULE TYPE: Genomic DNA
FEATURE:
NAME/KEY: 5' splice site of EXON 3
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION: 5' Splice Donor site

OTHER INFORMATION: is located between nucleotides 9 and 10
US-08-257-963B-27

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2695 CACTCACCACCGAGA 2710
DB 16 CACTCACCACCGAGA 1

RESULT 219
US-08-529-878B-10
Sequence 10, Application US/08529878B
Patent No. 5932556
GENERAL INFORMATION:
APPLICANT: Tam, Robert C.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: REGULATION OF CD28 EXPRESSION
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Crockett & Fish
STREET: 3000 S. Augusta Court
CITY: La Habra
STATE: California
COUNTRY: United States of America
ZIP: 90631
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/529,878B
FILING DATE: 13-SEP-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Fish, Robert D.
REGISTRATION NUMBER: 33,880
REFERENCE/DOCKET NUMBER: 213/003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-525-3433
TELEFAX: 714-525-3303
TELEX:
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-529-878B-10

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3422 ACCTCCCGACCGCCC 3437
DB 2 ACCTCCCGACCGACC 17

RESULT 220
US-08-529-878B-48
Sequence 48, Application US/08529878B
Patent No. 5932556
GENERAL INFORMATION:
APPLICANT: Tam, Robert C.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: REGULATION OF CD28 EXPRESSION
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:

ADDRESSER: Crockett & Fish
STREET: 3000 S. Augusta Court
CITY: La Habra
STATE: California
COUNTRY: United States of America
ZIP: 90631
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/529,878B
FILING DATE: 13-SEP-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Fish, Robert D.
REGISTRATION NUMBER: 33,880
REFERENCE/DOCKET NUMBER: 213/003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-525-3433
TELEFAX: 714-525-3303
TELEX:
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-529-878B-48

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3422 ACCTCCCGCAGCGCC 3437
DB 2 ACCTCCCGCAGCGCC 17

RESULT 221
US-09-205-922-19
Sequence 19, Application US/09205922
Patent No. 5951455
GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-11 EXPRESSION
FILE REFERENCE: RTS-0030
CURRENT APPLICATION NUMBER: US/09/205,922
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 19
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-922-19

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1458 GCAGCAGAGCTTCAG 1473
DB 1 GCAGCAGAGCTTCAG 16

RESULT 222
US-09-487-444-14/c
Sequence 14, Application US/09487444
Patent No. 6159697

GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
FILE REFERENCE: RTS-0133
CURRENT APPLICATION NUMBER: US/09/487,444
CURRENT FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 49
SEQ ID NO 14
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-444-14

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 184 GAGAGCAGAGGAG 199
DB 17 GAGAGCAGAGGAG 2

RESULT 223
US-09-115-027-2
Sequence 2, Application US/09115027
Patent No. 6242589
GENERAL INFORMATION:
APPLICANT: Cook, Phillip D
TITLE OF INVENTION: Phosphorothioate Oligonucleotides Having Modified
FILE OF INVENTION: Intermolecular Linkages
FILE REFERENCE: ISIS2953
CURRENT APPLICATION NUMBER: US/09/115,027
CURRENT FILING DATE: 1998-07-14
NUMBER OF SEQ ID NOS: 6
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 2
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6242589e1
US-09-115-027-2

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCGCAGGCTCC 1671
DB 3 CATCCCGCAGGCTCC 18

RESULT 224
US-08-367-841A-27/c
Sequence 27, Application US/08367841A
Patent No. 6319687
GENERAL INFORMATION:
APPLICANT: Chader, Gerald J.; Rodriguez,
APPLICANT: Ignacio R.; Mazuruk, Krzysztof;
TITLE OF INVENTION: TOMBIAN-TINK JOYCE
TITLE OF INVENTION: PIGMENT EPITHELIUM
TITLE OF INVENTION: DERIVED FACTOR: CHARACTERIZATION GENOMIC
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSER: Morgan & Flinnegan
STREET: 345 Park Avenue
CITY: New York

STATE: New York
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/367,841A
FILING DATE: 30-DEC-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,963
FILING DATE: 07-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/952,796
FILING DATE: 24-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: DOROTHY R. AUTH
REGISTRATION NUMBER: 36434
REFERENCE/DOCKET NUMBER: 20264126US2
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 Base Pairs
TYPE: Nucleic Acid
STRANDEDNESS: Double
TOPOLOGY: Unknown
MOLECULE TYPE: Genomic DNA
FEATURE:
NAME/KEY: 5' splice site of EXON 3
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION: 5' Splice Donor site
OTHER INFORMATION: 1s located between nucleotides 9 and 10
US-08-367-841A-27

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2695 CACTCACCCACGCGAGA 2710
DB 16 CACTCACCCACGCGAGA 1

RESULT 225
US-09-496-694B-165/C
Sequence 165, Application US/09496694B
Patent No. 6335194
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Elizabeth J. Ackermann
APPLICANT: Eric E. Swayze
APPLICANT: Lex M. Cowseart
TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: ISPH-0439
CURRENT APPLICATION NUMBER: US/09/496,694B
CURRENT FILING DATE: 2000-02-02
PRIOR APPLICATION NUMBER: 09/286,407
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 09/163,162
PRIOR FILING DATE: 1998-09-29
NUMBER OF SEQ ID NOS: 249
SEQ ID NO 165
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide

US-09-496-694B-165
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 953 AAGAGGACACAGATA 968
DB 18 ATGAGGAGACAGATA 3

RESULT 226
US-09-205-995-42/C
Sequence 42, Application US/09205995
Patent No. 6368855
GENERAL INFORMATION:
APPLICANT: Xu, Minzhen
APPLICANT: Qiu, Gang
TITLE OF INVENTION: CANCER CELL VACCINE
FILE REFERENCE: U.S. Application 09/205,995, (CIP)
CURRENT APPLICATION NUMBER: US/09/205,995
CURRENT FILING DATE: 1998-12-04
PRIOR APPLICATION NUMBER: 09/036,746
PRIOR FILING DATE: 1998-03-09
PRIOR APPLICATION NUMBER: 08/661,627
PRIOR FILING DATE: 1996-06-11
NUMBER OF SEQ ID NOS: 79
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 42
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: antisense
OTHER INFORMATION: oligonucleotide corresponding to a specific region
OTHER INFORMATION: of the mouse It gene.
US-09-205-995-42

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1482 GCAGCAGACGCTCTTG 1497
DB 18 GCAGCAGACGCGCTG 3

RESULT 227
US-09-805-630-2
Sequence 2, Application US/09805630
Patent No. 6811975
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Manoharan, Muthiah
TITLE OF INVENTION: Phosphorothioate Oligonucleotides Having Modified Internucleoside
FILE REFERENCE: ISIS-4718
CURRENT APPLICATION NUMBER: US/09/805,630
CURRENT FILING DATE: 2001-03-14
PRIOR APPLICATION NUMBER: 09/115,027
PRIOR FILING DATE: 1998-07-14
NUMBER OF SEQ ID NOS: 17
SOFTWARE: Patent In version 3.2
SEQ ID NO 2
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer
NAME/KEY: misc_feature
LOCATION: (1)..(2)

OTHER INFORMATION: MMI linkage
US-09-805-630-2

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCAGGCTCC 1671
DB 3 CATCCCCAGGCTCC 18

RESULT 228
US-09-918-186A-165/C
Sequence 165, Application US/09918186A
Patent No. 6838283
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Elizabeth J. Ackermann
APPLICANT: Eric E. Swayze
APPLICANT: Lex M. Cowart
TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: ISPH-0585
CURRENT APPLICATION NUMBER: US/09/918,186A
CURRENT FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 09/496,694
PRIOR FILING DATE: 2000-02-02
PRIOR APPLICATION NUMBER: 09/286,407
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 09/163,162
PRIOR FILING DATE: 1998-09-29
NUMBER OF SEQ ID NOS: 250
SEQ ID NO 165
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-186A-165

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 953 AAGAGAGACAGATA 968
DB 18 ATGAGAGACAGATA 3

RESULT 229
PCT-US95-07201-27/C
Sequence 27, Application PC/TUS9507201
GENERAL INFORMATION:
APPLICANT: Chader, Gerald J.; Becerra, Sofia
APPLICANT: Patricia; Schwartz, Joan P.;
APPLICANT: Taniwaki, Takayuki
TITLE OF INVENTION: PIGMENT EPITHELIAL
TITLE OF INVENTION: DERIVED FACTOR: CHARACTERIZATION GENOMIC
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESSES:
ADDRESSER: Morgan & Finnegan, L.L.P.
STREET: 345 Park Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/07201
FILING DATE: 06-JUN-1995

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/367,841
FILING DATE: 30-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,963
FILING DATE: 07-JUN-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/952,796
FILING DATE: 24-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: DOROTHY R. AUTH

REGISTRATION NUMBER: 36434
REFERENCE/DOCKET NUMBER: 20264126PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849

INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 Base Pairs
TYPE: Nucleic Acid
STRANDEDNESS: Double
TOPOLOGY: Unknown

MOLECULE TYPE: Genomic DNA
FEATURE:
NAME/KEY: 5' splice site of EXON 3
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION: 5' Splice Donor site

OTHER INFORMATION: is located between nucleotides 9 and 10
PCT-US95-07201-27

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2695 CACTCACCCAGCGAGA 2710
DB 16 CACTCACCCAGCGAGA 1

RESULT 230
US-09-275-505-1
Sequence 1, Application US/09275505
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Guzaev, Andrei P.
APPLICANT: Cook, Phillip Dan
APPLICANT: Bhat, Balkrishna
TITLE OF INVENTION: Nucleosidic And No. 6335434-Nucleosidic Folate Conjugates
FILE REFERENCE: ISIS-3453
CURRENT APPLICATION NUMBER: US/09/275,505
CURRENT FILING DATE: 1999-03-24
PRIOR APPLICATION NUMBER: 09/098,166
PRIOR FILING DATE: 1998-06-16
NUMBER OF SEQ ID NOS: 3
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: No. 6335434e1 Sequence
US-09-275-505-1

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCAGGCTCC 1671

Db 2 CATCCCCAGGCCACC 17

RESULT 231

US-09-422-978-5133

; Sequence 5133, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marla
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

; FILE REFERENCE: GENSET.020CP1

; CURRENT FILING DATE: 1999-10-20

; EARLIER APPLICATION NUMBER: US 09/298,850

; EARLIER FILING DATE: 1999-04-21

; EARLIER APPLICATION NUMBER: US 60/109,732

; EARLIER FILING DATE: 1998-11-23

; EARLIER APPLICATION NUMBER: US 60/082,614

; EARLIER FILING DATE: 1998-04-21

; NUMBER OF SEQ ID NOS: 11796

; SEQ ID NO 5133

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo Sapiens

; FEATURE:

; NAME/KEY: primer_bind

; LOCATION: 1..19

; OTHER INFORMATION: upstream amplification primer 99-21221 for SEQ 1199,

US-09-422-978-5133

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1268 TGCAGAGAGAGACA 1283

Db 3 TCCAGAGAGAGAGACA 18

RESULT 232

US-09-982-212-40

; Sequence 40, Application US/09982212

; Patent No. 6617137

; GENERAL INFORMATION:

; APPLICANT: Dean, Frank B.

; APPLICANT: Lasken, Roger S.

; TITLE OF INVENTION: NUCLEIC ACID AMPLIFICATION

; FILE REFERENCE: 13172.0012U2

; CURRENT APPLICATION NUMBER: US/09/982,212

; CURRENT FILING DATE: 2001-10-18

; PRIOR APPLICATION NUMBER: Unassigned

; PRIOR FILING DATE: 2001-10-15

; NUMBER OF SEQ ID NOS: 40

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 40

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence; No. 6617137e =

; OTHER INFORMATION: synthetic construct

US-09-982-212-40

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 374 AGGCCCTGAAGAGGA 389

Db 1 AGGCCCTGAAGAGGA 16

RESULT 233

US-09-696-791-545/c

; Sequence 545, Application US/09696791

; Patent No. 6770633

; GENERAL INFORMATION:

; APPLICANT: Robbins, Joan M.

; APPLICANT: Trletz, Richard

; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE

; TITLE OF INVENTION: SKIN AND EYE DISEASES

; FILE REFERENCE: 480124.407

; CURRENT APPLICATION NUMBER: US/09/696,791

; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 545

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: Cdke ribozyme binding site

US-09-696-791-545

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1159 GCACACATCAACACC 1174

Db 19 GCACACATCAACACC 4

RESULT 234

US-09-696-791-3081/c

; Sequence 3081, Application US/09696791

; Patent No. 6770633

; GENERAL INFORMATION:

; APPLICANT: Robbins, Joan M.

; APPLICANT: Trletz, Richard

; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE

; TITLE OF INVENTION: SKIN AND EYE DISEASES

; FILE REFERENCE: 480124.407

; CURRENT APPLICATION NUMBER: US/09/696,791

; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3081

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: Cyclin A1 ribozyme binding site

US-09-696-791-3081

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 989 AGGAGATGACGCCA 1004

Db 18 AGGAGATGACGCCA 3

RESULT 235

US-08-149-105-11/c

; Sequence 11, Application US/08149105

; Patent No. 5538892

; GENERAL INFORMATION:

; APPLICANT: Donahoe, Patricia K.

; APPLICANT: Gustafson, Michael

; APPLICANT: He, Wei W.

; APPLICANT: Wang, Xiao-Fan


```

; TITLE OF INVENTION: TGF- TYPE I RECEPTOR
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/149,105
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/029,673
; FILING DATE: March 11, 1993
; APPLICATION NUMBER: 07/853,396
; FILING DATE: March 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/211001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-149-105-11
;
Query Match 0.4%; Score 14.2; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
;
QY 589 ATGGCTCCAGAGTC 603
DB 15 ATGGCTCCAGAGTC 1
;
RESULT 236
US-08-317-847-11/C
; Sequence 11, Application US/08317847
; Patent No. 5547854
; GENERAL INFORMATION:
; APPLICANT: Donahoe, Patricia K.
; APPLICANT: Gustafson, Michael
; APPLICANT: He, Wei W.
; TITLE OF INVENTION: FOUR NOVEL RECEPTORS OF THE TGF-B
; TITLE OF INVENTION: FAMILY
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/317,847
;

```

```

; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/029,673
; FILING DATE: March 11, 1993
; APPLICATION NUMBER: 07/853,396
; FILING DATE: March 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/127002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-317-847-11
;
Query Match 0.4%; Score 14.2; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
;
QY 589 ATGGCTCCAGAGTC 603
DB 15 ATGGCTCCAGAGTC 1
;
RESULT 237
US-09-230-652-26
; Sequence 26, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
; APPLICANT: Joutel, Anne
; APPLICANT: Bousset, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; TITLE OF INVENTION: THERAPEUTIC APPLICATION
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/09/230,652A
; CURRENT FILING DATE: 1999-05-17
; EARLIER APPLICATION NUMBER: FR 96 09733
; EARLIER FILING DATE: 1996-08-01
; EARLIER APPLICATION NUMBER: FR 97 04680
; EARLIER FILING DATE: 1997-04-16
; EARLIER APPLICATION NUMBER: PCT/FR97/01433
; EARLIER FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
;
US-09-230-652-26
;
Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 1668 CTCGCCAGGGCCCC 1681
DB 1 CTCGCCAGGGCCCC 14
;
RESULT 238
US-09-180-437-104
;

```

; Sequence 104, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshitomi
; APPLICANT: KOSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 104
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: other nucleic
; OTHER INFORMATION: acid
US-09-180-437-104

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAGC 1456
DB 2 GCAGCAGCAGCAGC 15

RESULT 239
US-09-163-485-13/c
; Sequence 13, Application US/09163485
; Patent No. 6277571
; GENERAL INFORMATION:
; APPLICANT: FILMORE, HELEN
; APPLICANT: BROADBUSH, WILLIAM
; APPLICANT: GILLIES, GEORGE
; TITLE OF INVENTION: SEQUENTIAL CONSENSUS REGION-DIRECTED AMPLIFICATION OF
; FILE REFERENCE: VCU1P4B
; CURRENT APPLICATION NUMBER: US/09/163,485
; CURRENT FILING DATE: 1998-08-30
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide, consensus sequence from human
; OTHER INFORMATION: matrix metalloproteinases
US-09-163-485-13

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1133 AGCAGCAGCAGCAG 1146
DB 14 AGCAGCAGCAGCAG 1

RESULT 240
US-09-475-947A-304
; Sequence 304, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:

; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTS00667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 304
; LENGTH: 15
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-304

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1132 CAGCAGCAGCAGCA 1145
DB 1 CAGCAGCAGCAGCA 14

RESULT 241
US-09-866-108A-7671
; Sequence 7671, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Mengsheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7671
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7671

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3248 TGGAGAGAGCAG 3261
Db 4 TGGAGAGAGCAG 17

RESULT 242
US-09-866-108A-7672
Sequence 7672, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 7672
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-7672

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3248 TGGAGAGAGCAG 3261
Db 3 TGGAGAGAGCAG 16

RESULT 243
US-09-866-108A-7673
Sequence 7673, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

FILE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 7673
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-7673

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3248 TGGAGAGAGCAG 3261
Db 2 TGGAGAGAGCAG 15

RESULT 244
US-09-866-108A-7674
Sequence 7674, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7674
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7674

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3248 TCGAGAGAAGACAG 3261
DB 1 TCGAGAGAAGACAG 14

RESULT 245
US-09-630-706-64/C
; Sequence 64, Application US/09630706
; Patent No. 6277640
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HER-3 EXPRESSION
; FILE REFERENCE: RTS-0053
; CURRENT APPLICATION NUMBER: US/09/630,706
; CURRENT FILING DATE: 2000-08-01
; NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 64
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-630-706-64

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1769 GAAACCTGGCTGCC 1782
DB 16 GAAACCTGGCTGCC 3

RESULT 246
US-09-866-108A-8649/C
; Sequence 8649, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JT, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
```

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8649
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8649

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CTCGAGGACAGTGCA 1415
DB 17 CTCGAGGACAGTGCA 1

RESULT 247
US-08-032-842-6
; Sequence 6, Application US/08032842
; Patent No. 5306626
; GENERAL INFORMATION:
; APPLICANT: Filton, John Edward
; TITLE OF INVENTION: Processes
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cushman, Darby and Cushman
; STREET: 1100 New York Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/032,842
; FILING DATE: 19930316
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9205695.1
; FILING DATE: 16-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9225541.3
; FILING DATE: 07-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9300439.8
; FILING DATE: 12-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: KOKULIS, PAUL N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: 797279/PHM.36813/US
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (292) 861-3000
TELEFAX: (202) 822-0944
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
US-08-032-842-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 248
US-08-052-681-14
Sequence 14, Application US/08052681
Patent No. 5314819
GENERAL INFORMATION:
APPLICANT: KAZUNORI YAMADA et al.
TITLE OF INVENTION: NOVEL PROTEIN HAVING NITRILE HYDRATASE
TITLE OF INVENTION: ACTIVITY AND THE GENE ENCODING THE SAME, AND A METHOD FOR PRODUCING THE SAME
TITLE OF INVENTION: FROM NITRILES VIA A TRANSFORMANT CONTAINING THE GENE
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: WENDEROTH, LIND & PONACK
STREET: 805 FIFTEENTH STREET, N.W., #700
CITY: WASHINGTON
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 500 kb
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/052,681
FILING DATE: 19930427
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: WARREN M. CHEEK, JR.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-8850
TELEFAX:
TELEX:
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic DNA
HYPOTHETICAL:
ANTI-SENSE:
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM:
STRAIN:
INDIVIDUAL ISOLATE:
DEVELOPMENTAL STAGE:
HAPLOTYPE:

TISSUE TYPE:
CELL TYPE:
CELL LINE:
ORGANELLE:
IMMEDIATE SOURCE:
LIBRARY:
CLONE:
POSITION IN GENOME:
CHROMOSOME/SEGMENT:
MAP POSITION:
UNITS:
FEATURE:
NAME/KEY:
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
PUBLICATION INFORMATION:
AUTHORS:
TITLE:
JOURNAL:
VOLUME:
ISSUE:
PAGES:
DATE:
DOCUMENT NUMBER:
FILING DATE:
PUBLICATION DATE:
RELEVANT RESIDUES IN SEQ ID NO:
US-08-052-681-14

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 249
US-07-912-740D-6
Sequence 6, Application US/07912740D
Patent No. 5439815
GENERAL INFORMATION:
APPLICANT: FITTON, John E.
TITLE OF INVENTION: TIMMS, David
TITLE OF INVENTION: PROTEINS
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHVE P.C.
STREET: 1100 NORTH GLEBE ROAD
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/912,740D
FILING DATE: 13-JUL-1992
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 1586-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4100
TELEFAX: (703) 816-4100
TELEX: 200797 NIXN UR
INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-07-912-7400-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 250
US-08-035-634-4
Sequence 4, Application US/08035634
Patent No. 5459064
GENERAL INFORMATION:
APPLICANT: SHIONOGI & CO., LTD.
TITLE OF INVENTION: A No. 5459064e1 Protease
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Morrison & Foerster
STREET: 545 Middlefield Road, Suite 200
CITY: Menlo Park
STATE: California
COUNTRY: USA
ZIP: 94025
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: EPSON PC-286 Book type Laptop
OPERATING SYSTEM: MS-DOS 2.11
SOFTWARE: Wordstar 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/035,634
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/782,372
FILING DATE: 24-OCT-1991
APPLICATION NUMBER: Japanese Patent
APPLICATION NUMBER: Application No. 5459064 2-288110
FILING DATE: October 24, 1990
ATTORNEY/AGENT INFORMATION:
NAME: BOZICEVIC, KARL
REGISTRATION NUMBER: 28,807
REFERENCE/DOCKET NUMBER: 29900-20298.00
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 677-7000
TELEFAX: (415) 677-7522
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
MOLECULE TYPE: Synthetic DNA
US-08-035-634-4

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 251

US-08-211-202-122
Sequence 122, Application US/08211202
Patent No. 5565332

GENERAL INFORMATION:
APPLICANT: HOOGENBOOM, Hendricus Renerus Jacobus Mattheus
APPLICANT: BAYER, Michael
APPLICANT: JESPER, Laurent Stephane Anne Therese
TITLE OF INVENTION: Production of chimeric antibodies - a
TITLE OF INVENTION: combinatorial approach
NUMBER OF SEQUENCES: 144
CORRESPONDENCE ADDRESSES:
ADDRESSEE: David W. Clough, Marshall O'Toole Gerstein Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/211,202
FILING DATE: 23-SEP-1992
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9120252.3
FILING DATE: 23-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9120377.8
FILING DATE: 25-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/31960
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
TELEFAX: 312-474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 122:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-211-202-122

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 252
US-08-112-817C-6
Sequence 6, Application US/08112817C
Patent No. 5573928

GENERAL INFORMATION:
APPLICANT: Hsiung, Hansen M.
APPLICANT: Smith, Dennis P.
APPLICANT: Zhang, Xing-Yue
TITLE OF INVENTION: PORCINE VASOACTIVE INTESTINAL PEPTIDE
TITLE OF INVENTION: RECEPTOR
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Eli Lilly and Company
STREET: Lilly Corporate Center
CITY: Indianapolis
STATE: Indiana
COUNTRY: USA
ZIP: 46285
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Macintosh Ixci compatible
OPERATING SYSTEM: System 7
SOFTWARE: Microsoft Word for Macintosh v.5.1a
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/112,817C
FILING DATE:
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Murphy, Richard B.
REGISTRATION/DOCKET NUMBER: 35,296
REFERENCE/DOCKET NUMBER: X-9293
TELECOMMUNICATION INFORMATION:
TELEPHONE: 317-276-3589
TELEFAX: 317-276-1294
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-112-817C-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 253
US-08-324-301-26
Sequence 26, Application US/08324301
Patent No. 5597569
GENERAL INFORMATION:
APPLICANT: Siegall, Clay B.
APPLICANT: Gawlak, Susan L.
APPLICANT: Marguardt, Hans
TITLE OF INVENTION: A NEW RIBOSOME INACTIVATING PROTEIN
TITLE OF INVENTION: ISOLATED FROM THE PLANT BRYONICA DIOICA
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bristol-Myers Squibb Company
STREET: 3005 First Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98121
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/324,301

FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/141,891
FILING DATE: 25-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Poor, Brian W.
REGISTRATION/DOCKET NUMBER: 32,928
REFERENCE/DOCKET NUMBER: ON0109A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-728-4800
TELEFAX: 206-727-3601
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-324-301-26

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 254
US-08-390-850-452/C
Sequence 452, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McGisgen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215-December 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION/DOCKET NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 452:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-452

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1446 GCAGCAGCAACAGCAGC 1462
DB 17 GCAGCATCAACAGCATC 1

RESULT 255

US-08-390-850-557/c
Sequence 557, Application US/08390850
Patent No. 5612215

GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: December 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 557:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-557

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Sequence 2, Application US/08196218

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1491 AGAGAGAGAGATCAAA 207
DB 17 AGATGACAGCATCAA 1

RESULT 256

US-08-390-850-624/c
Sequence 624, Application US/08390850
Patent No. 5612215

GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: December 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 624:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-624

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 GCTTCAGAAACAGCAGC 1483
DB 17 GCTTCAAAAACAGCATC 1

RESULT 257

US-08-196-218-2
Sequence 2, Application US/08196218

Patent No. 5614619
GENERAL INFORMATION:
APPLICANT: Pieperberg, Wolfgang
APPLICANT: Stockmann, Michael
APPLICANT: Taleghani, Kamaliz Mansouri
APPLICANT: Dietler, Jurgen
APPLICANT: Grabley, Susanne
APPLICANT: Sichel, Petra
APPLICANT: Brau, Barbara
TITLE OF INVENTION: Secondary-Metabolite Biosynthesis Genes
TITLE OF INVENTION: From Actinomycetes, Method of Isolating Them, and Their
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pinnegan, Henderson, Farbow, Garrett &
ADDRESSEE: Dunner
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: United States
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/196,218
FILING DATE: 25-AUG-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Ogden, Stasia L.
REGISTRATION NUMBER: 36,228
REFERENCE/DOCKET NUMBER: 02481.1372-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-196-218-2

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543.
DB 1 CAGGAAACAGCTATGAC 17

RESULT 258
US-08-373-124A-178/C
Sequence 178, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 178:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-178

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGAGAGAG 1218
DB 17 AGGAGCAGAGAGAGAG 1

RESULT 259
US-08-373-124A-190/C
Sequence 190, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

US-08-373-124A-190

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

176 ATGTCACGAGAGAGAG 192
17 AGCTCAGGAGAGAGAG 1

US-08-373-124A-566

Sequence 566, Application US/08373124A
Patent No. 5646042

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 190:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-373-124A-566

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

176 ATGTCACGAGAGAGAG 192
17 AGCTCAGGAGAGAGAG 1

US-08-373-124A-566

Sequence 566, Application US/08373124A
Patent No. 5646042

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 190:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-373-124A-566

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

196 GAAGAGATCAACAGCA 212
1 GAUGGATUCAAACAGCA 17

US-08-416-831B-8

Sequence 8, Application US/08416831B
Patent No. 5708159

GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneo
APPLICANT: Hirotsu, Takuo
APPLICANT: Keshi, Hiroyuki
APPLICANT: Matsuhisa, Aiko
TITLE OF INVENTION: Probe for Diagnosing Infectious Diseases
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/416,831B
FILING DATE: 19-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP93/01555
FILING DATE: 25-OCT-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JPA 4-285802
FILING DATE: 23-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gass, David A.
REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 19036/32578
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

US-08-416-831B-8

Sequence 8, Application US/08416831B
Patent No. 5708159

GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneo
APPLICANT: Hirotsu, Takuo
APPLICANT: Keshi, Hiroyuki
APPLICANT: Matsuhisa, Aiko
TITLE OF INVENTION: Probe for Diagnosing Infectious Diseases
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/416,831B
FILING DATE: 19-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP93/01555
FILING DATE: 25-OCT-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JPA 4-285802
FILING DATE: 23-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gass, David A.
REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 19036/32578
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic DNA"
ANTI-SENSE: NO
US-08-416-831B-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 262
US-08-681-953-2
Sequence 2, Application US/08681953
Patent No. 5710032
GENERAL INFORMATION:
APPLICANT: Piepersberg, Wolfgang
APPLICANT: Stockmann, Michael
APPLICANT: Taleghani, Kamaliz Mansouri
APPLICANT: Dieler, Jurgen
APPLICANT: Grabley, Susanne
APPLICANT: Sichel, Petra
APPLICANT: Bräu, Barbara
TITLE OF INVENTION: Secondary-Metabolite Biosynthesis Genes
TITLE OF INVENTION: From Actinomycetes, Method of Isolating Them, and Their
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farbow, Garrett &
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: United States
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Releasee #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/681,953
FILING DATE: 30-JUL-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/196,218
FILING DATE: 25-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ogden, Scasia L.
REGISTRATION NUMBER: 36,228
REFERENCE/DOCKET NUMBER: 02481.1372-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-681-953-2

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

DB 1 CAGGAAACAGCTATGAC 17

RESULT 263
US-08-434-823-12/c
Sequence 12, Application US/08434823
Patent No. 5712248
GENERAL INFORMATION:
APPLICANT: Kalman, Sue S.
APPLICANT: Kiehne, Kristine L.
TITLE OF INVENTION: NOVEL INSECTICIDE PROTEIN AND GENE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sandoz Agro, Inc.
STREET: 975 California Avenue
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Releasee #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/434,823
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,998
FILING DATE: 16-FEB-1994
APPLICATION NUMBER: US 08/102,316
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/004,474
FILING DATE: 14-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/844,302
FILING DATE: 27-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Marcus-Wyner, Lynn
REGISTRATION NUMBER: 34,869
REFERENCE/DOCKET NUMBER: 2-702/CONT3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/354-3588
TELEFAX: 415/857-1125
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-434-823-12

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 17 CAGGAAACAGCTATGAC 1

RESULT 264
US-08-434-823-13
Sequence 13, Application US/08434823
Patent No. 5712248
GENERAL INFORMATION:
APPLICANT: Kalman, Sue S.
APPLICANT: Kiehne, Kristine L.
TITLE OF INVENTION: NOVEL INSECTICIDE PROTEIN AND GENE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:

ADDRESSER: Sandoz Agro, Inc.
STREET: 975 California Avenue
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/434,823
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,998
FILING DATE: 16-FEB-1994
APPLICATION NUMBER: US 08/102,316
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/004,474
FILING DATE: 14-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/844,302
FILING DATE: 27-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Marcus-Wyner, Lynn
REGISTRATION NUMBER: 34,869
REFERENCE/DOCKET NUMBER: Z-702/CONT3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/354-3588
TELEFAX: 415/857-1125
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-434-823-13

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17

RESULT 265
US-08-241-465B-10
Sequence 10. Application US/08241465B
Patent No. 5739125
GENERAL INFORMATION:
APPLICANT: FUJIO SUZUKI
APPLICANT: YUJI HIRAKI
APPLICANT: KAZUHIRO TAKAHASHI
APPLICANT: JUNKO SUZUKI
APPLICANT: ATSUKO KOKARA
APPLICANT: AKIKO MORI
APPLICANT: EI YAMADA
TITLE OF INVENTION: HUMAN CHONDROMODULIN-1 PROTEIN
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wenderoth, Lind & Ponack
STREET: 805 Fifteenth Street, N.W., #700
CITY: Washington
COUNTRY: D.C.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/241,465B
FILING DATE: May 11, 1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Warren M. Cheek, Jr.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 371-8850
TELEFAX:
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid, Synthetic DNA
US-08-241-465B-10

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17

RESULT 266
US-08-457-366-12/C
Sequence 12. Application US/08457366
Patent No. 5731194
GENERAL INFORMATION:
APPLICANT: KALMAN, Sue S.
APPLICANT: KIEHNE, Kristine L.
TITLE OF INVENTION: NOVEL INSECTICIDE PROTEIN AND GENE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sandoz Agro, Inc.
STREET: 975 California Avenue
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/457,366
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,998
FILING DATE: 16-FEB-1994
APPLICATION NUMBER: US 08/102,316
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/004,474
FILING DATE: 14-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/844,302
FILING DATE: 27-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Marcus-Wyner, Lynn
REGISTRATION NUMBER: 34,869
REFERENCE/DOCKET NUMBER: Z-702/CONT3

TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/354-3598
TELEFAX: 415/857-1125
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-457-366-12

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CGGGAAACAGCTATGAC 3543
Db 17 CAGGAAACAGCTATGAC 1

RESULT 267
US-08-457-366-13
Sequence 13, Application US/08457366
Patent No. 5731194
GENERAL INFORMATION:
APPLICANT: Kalman, Sue S.
TITLE OF INVENTION: NOVEL INSECTICIDE PROTEIN AND GENE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sandoz Agro, Inc.
STREET: 975 California Avenue
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/457,366
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,998
FILING DATE: 16-FEB-1994
APPLICATION NUMBER: US 08/102,316
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/004,474
FILING DATE: 14-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/844,302
FILING DATE: 27-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Marcus Wyner, Lynn
REGISTRATION NUMBER: 34,869
REFERENCE/DOCKET NUMBER: 2-702/CONT3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/354-3598
TELEFAX: 415/857-1125
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-457-366-13
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 3527 CGGGAAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 268
US-08-435-634-452/C
Sequence 452, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Payco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustafson, John T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295, September 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 452:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-452
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1446 GCAGCAGCAACAGCAGC 1462
Db 17 GCAGCAGCAACAGCAGC 1
RESULT 269

US-08-435-634-557/c
; Sequence 557, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295, September 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ. ID NO: 557:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-557
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 191 AGAGAGAGAGATCAAA 207
DB 17 AGAATGAGAGATCAAA 1
RESULT 270
US-08-435-634-624/c
; Sequence 624, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John

APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295, September 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ. ID NO: 624:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-624
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1467 GCTTCAGAAACAGCAGC 1483
DB 17 GCTTCAGAAACAGCAGC 1
RESULT 271
US-08-307-619-67
; Sequence 67, Application US/08307619
; Patent No. 5733743
; GENERAL INFORMATION:
; APPLICANT: Johnson, Kevin S
; APPLICANT: Winter, Gregory P
; APPLICANT: Griffiths, Andrew D
; APPLICANT: Smith, Andrew JH
; APPLICANT: Waterhouse, P
; TITLE OF INVENTION: Methods for producing members of specific
; TITLE OF INVENTION: binding pairs
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago

STATE: Illinois
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/307,619
FILING DATE: 16-SEP-1994
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 2811/32238
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 67:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-307-619-67

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 272
US-08-078-090-8
Sequence 8, Application US/08078090
Patent No. 5739407
GENERAL INFORMATION:
APPLICANT: BERGSTROM, SVEN
APPLICANT: HERVELL, OLE
APPLICANT: LOENNERDAL, BO
APPLICANT: HJALMARSSON, KARIN
APPLICANT: HANSSON, LENNART
APPLICANT: TOERNELL, JAN
APPLICANT: STROMQUIST, MATS
TITLE OF INVENTION: HUMAN BETA-CASIN PROCESS FOR PRODUCING
TITLE OF INVENTION: IT AND USE THEREOF
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 SEVENTH STREET, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/078,090

FILING DATE: 19930618
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: WO PCT/DK92/00236
FILING DATE: 19-AUG-1992
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: WO PCT/DK91/00233
FILING DATE: 19-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: COOPER, IVER P.
REGISTRATION NUMBER: 28,005
REFERENCE/DOCKET NUMBER: BERGSTROM2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 628-5197
TELEFAX: (202) 737-3528
TELEX: 248633
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-078-090-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 273
US-08-460-806-26
Sequence 26, Application US/08460806
Patent No. 5747241
GENERAL INFORMATION:
APPLICANT: MIYAMURA, TATSUO
APPLICANT: SAITO, IZUMU
APPLICANT: HARADA, SHIZUKO
APPLICANT: HONDA, YOSHIKAZU
TITLE OF INVENTION: DIAGNOSTIC REAGENT FOR HEPATITIS C
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,806
FILING DATE: 02-JUN-1995
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/08/325,630
FILING DATE: 19-OCT-1994
APPLICATION NUMBER: US 07/956,993
FILING DATE: 06-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Oblon, No. 5747241man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 4667-001-0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220

TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 26;
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-460-806-26

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 274
US-08-760-335A-11
Sequence 11, Application US/08760335A
Patent No. 5747310
GENERAL INFORMATION:
APPLICANT: SASAKI, Takashi
APPLICANT: SASAKI, Yasuko
APPLICANT: ITO, Yoshiyuki
APPLICANT: OTSU, Kumi
TITLE OF INVENTION: Gene integration into Chromosomes of
TITLE OF INVENTION: Lactobacillus delbrueckii Species and Integrants Thereof
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Bacon & Thomas
STREET: 625 Slater Lane - 4th Floor
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/760,335A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/193,055
FILING DATE: 04-MAR-1994
APPLICATION NUMBER: WO PCT/JP93/055
FILING DATE: 08-JUL-1993
ATTORNEY/AGENT INFORMATION:
NAME: DeBenedictis, Joseph
REGISTRATION NUMBER: 28,502
REFERENCE/DOCKET NUMBER: JDB/Sasaki/055
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-683-0500
TELEFAX: 703-683-1080
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-760-335A-11

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAACAGCTATGAC 17

DB 1 CAGGAACAGCTATGAC 17

RESULT 275
US-08-325-630-26
Sequence 26, Application US/08325630
Patent No. 5750331
GENERAL INFORMATION:
APPLICANT: MIYAMURA, TATSUO
APPLICANT: SAITO, IZUMU
APPLICANT: HARADA, SHIZUKO
APPLICANT: HONDA, YOSHIKAZU
TITLE OF INVENTION: DIAGNOSTIC REAGENT FOR HEPATITIS C
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESSES:
ADDRESSEE: OHLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/325,630
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/956,993
FILING DATE: 06-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Ohlson, No. 5750331man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 4667-001-0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220

TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-325-630-26

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 276
US-08-920-812-25
Sequence 25, Application US/08920812
Patent No. 5763188
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Matsuhisa, Akio
APPLICANT: Uehara, Hirotsugu
APPLICANT: Ede, Soji
TITLE OF INVENTION: Probe for Diagnosing Infectious Disease
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/920,812
FILING DATE: 29-AUG-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/362,577
FILING DATE: 27-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Rin-Lauree, Li-Hsien
REGISTRATION NUMBER: 33,547
REFERENCE/DOCKET NUMBER: 19036/32420
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ. ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-920-812-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17

RESULT 277
US-08-920-827-25
Sequence 25, Application US/08920827
Patent No. 5770375
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Matsuhisa, Akio
APPLICANT: Uehara, Hirotsugu
APPLICANT: Eda, Soji
TITLE OF INVENTION: Probe for Diagnosing Infectious Disease
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/920,827
FILING DATE: 29-AUG-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/362,577

FILING DATE: 27-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Rin-Lauree, Li-Hsien
REGISTRATION NUMBER: 33,547
REFERENCE/DOCKET NUMBER: 19036/32420
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ. ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-920-827-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17

RESULT 278
US-08-462-195-8
Sequence 8, Application US/08462195
Patent No. 5789544
GENERAL INFORMATION:
APPLICANT: MIYAMURA, TATSUO
APPLICANT: SAITO, IZUMU
APPLICANT: MATSURA, YOSHIMARU
APPLICANT: HONDA, YOSHIKAZU
APPLICANT: SEKI, MAKOTO
TITLE OF INVENTION: METHOD FOR PRODUCING ECTOPROTEIN OF
HEPATITIS C VIRUS
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,195
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/446,303
FILING DATE: 22-MAY-1995
APPLICATION NUMBER: US 06/074,584
FILING DATE: 11-JUN-1993
APPLICATION NUMBER: JP 152487/1992
FILING DATE: 11-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Oblon, No. 5789544man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 4169-003-0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-462-195-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 279
US-08-921-177-25
Sequence 25, Application US/08921177
Patent No. 5798211
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Matsuhisa, Akio
APPLICANT: Uehara, Hirotsugu
APPLICANT: Eda, Soji
TITLE OF INVENTION: Probe for Diagnosing Infectious Disease
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/921,177
FILING DATE: 29-AUG-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/362,577
FILING DATE: 27-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Rin-Laures, Li-Hsien
REGISTRATION NUMBER: 33,547
REFERENCE/DOCKET NUMBER: 19036/32420
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-921-177-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 280
US-08-362-577C-25
Sequence 25, Application US/08362577C
Patent No. 5807673
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Matsuhisa, Akio
APPLICANT: Uehara, Hirotsugu
APPLICANT: Eda, Soji
TITLE OF INVENTION: Probe for Diagnosing Infectious Disease
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/362,577C
FILING DATE: 27-MAR-1995
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Rin-Laures, Li-Hsien
REGISTRATION NUMBER: 33,547
REFERENCE/DOCKET NUMBER: 19036/32420
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-362-577C-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 281
US-08-800-751-10
Sequence 10, Application US/08800751
Patent No. 5807730
GENERAL INFORMATION:
APPLICANT: ITO, Kiyoshi
APPLICANT: YAMAKI, Toshifumi
APPLICANT: ARII, Tetsuo
APPLICANT: TSURUOKA, Miyuki
APPLICANT: NAKAMURA, Takeshi
TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia

COUNTRY: United States
ZIP: 2213-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/800,751
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 8-027004
FILING DATE: 14-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: Teekin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 028022-007
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-800-751-10

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAACAGCTATGAC 17

RESULT 282
US-08-435-628-178/c
Sequence 178, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
APPLICATION DATA:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124

FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 178:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-178

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGGAGGAG 1218
17 AGGAGAGGAGGAGGAG 1

RESULT 283
US-08-435-628-190/c
Sequence 190, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1992
APPLICATION NUMBER: 07/987,132

FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 190:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-190

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 176 ATGTCAAGAGAGAGAG 192
DB 17 AGGTCAAGAGAGAGAG 1

RESULT 284
US-08-435-628-566
Sequence 566, Application US/08435628
Patent No. 581796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,112
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 566:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-566

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 196 GAAGAGATCAACAGCA 212
DB 1 GAUGGATCAACAGCA 17

RESULT 285
US-09-031-485-49
Sequence 49, Application US/09031485
Patent No. 5824306
GENERAL INFORMATION:
APPLICANT: Tang, Liang
APPLICANT: Blehm, E. Scot
TITLE OF INVENTION: DIPOPIARIA AND BRUGIA ANKYRIN
TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND
TITLE OF INVENTION: USES THEREOF
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carol Talkington Verser, Ph.D.
STREET: 1825 Sharp Point Drive
CITY: Fort Collins
STATE: Colorado
COUNTRY: USA
ZIP: 80525
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Wordperfect for Windows, Version 7.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/031,485
FILING DATE:
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/847,429
FILING DATE: 24-APR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Verser, Carol Talkington
REGISTRATION NUMBER: 37,459
REFERENCE/DOCKET NUMBER: HW-5
TELECOMMUNICATION INFORMATION:
TELEPHONE: 970/493-7272
TELEFAX: 970/484-9505
INFORMATION FOR SEQ. ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULAR TYPE: primer
US-09-031-485-49
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 286

US-08-528-523-5
Sequence 5, Application US/08528523
Patent No. 5824782
GENERAL INFORMATION:
APPLICANT: Hoeizer, Wolfgang
APPLICANT: von Hoegen, Ilka
APPLICANT: Strittmatter, Wolfgang
APPLICANT: Matzku, Siegfried
TITLE OF INVENTION: Immunoconjugates II
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Millen, White, Zelano & Branigan, P.C.
STREET: 2200 Clarendon Boulevard, Suite 1400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/528,523
FILING DATE: 06-NOV-1992
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 94114572.4
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Hamlet-King, Diana
REGISTRATION NUMBER: 33,302
REFERENCE/DOCKET NUMBER: Merck 1717
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-243-6333
TELEFAX: 703-243-6410
TELEX: 64191
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "c-gamma1 5' primer"
HYPOTHETICAL: NO
US-08-528-523-5

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 287
US-08-528-523-9
Sequence 9, Application US/08528523
Patent No. 5824782
GENERAL INFORMATION:
APPLICANT: Hoeizer, Wolfgang
APPLICANT: von Hoegen, Ilka
APPLICANT: Strittmatter, Wolfgang
APPLICANT: Matzku, Siegfried
TITLE OF INVENTION: Immunoconjugates II

NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Millen, White, Zelano & Branigan, P.C.
STREET: 2200 Clarendon Boulevard, Suite 1400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/528,523
FILING DATE: 06-NOV-1992
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 94114572.4
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Hamlet-King, Diana
REGISTRATION NUMBER: 33,302
REFERENCE/DOCKET NUMBER: Merck 1717
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-243-6333
TELEFAX: 703-243-6410
TELEX: 64191
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "c-gamma1 5' primer"
HYPOTHETICAL: NO
US-08-528-523-9

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 288
US-08-847-429A-49
Sequence 49, Application US/08847429A
Patent No. 5827692
GENERAL INFORMATION:
APPLICANT: Tang, Liang
APPLICANT: Blehm, E. Scot
TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN
TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND
TITLE OF INVENTION: USES THEREOF
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carol Talkington Verese, Ph.D.
ADDRESS: Heeka Corporation
STREET: 1825 Sharp Point Drive
CITY: Fort Collins
STATE: Colorado
COUNTRY: USA
ZIP: 80525
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Wordperfect for Windows, Version 7.0
CURRENT APPLICATION DATA:

RESULT 291
US-08-472-659-24
Sequence 24, Application US/08472659
Patent No. 5831030
GENERAL INFORMATION:
APPLICANT: TSUJIMOTO, Masaaki
APPLICANT: IWASA, Fuyuki
APPLICANT: TSUBOYOKA, No. 5831030uo
APPLICANT: NAKAZATO, Hiroshi
APPLICANT: MIURA, Kenju
APPLICANT: KURIHARA, No. 5831030uhiro
APPLICANT: KURIHARA, Tatsuya
APPLICANT: YAMAGUCHI, No. 5831030omi
TITLE OF INVENTION: MEGAKARYOCYTE DIFFERENTIATION FACTOR
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Burns, Doane, Swecker & Mathis
STREET: P.O. Box 1404
City: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,659
FILING DATE: 07-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 4-212305
FILING DATE: 17-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 5-067339
FILING DATE: 04-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/091,028
FILING DATE: 14-JUL-1993
ATTORNEY/AGENT INFORMATION:
NAME: McGowan, Malcolm K.
REGISTRATION NUMBER: 39,300
REFERENCE/DOCKET NUMBER: 001560-248
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-472-659-24
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 292
US-08-448-418-85
Sequence 85, Application US/08448418
Patent No. 5831242
GENERAL INFORMATION:
APPLICANT: Holliger, Kaspar-Philipp

APPLICANT: Griffiths, Andrew D
APPLICANT: Hoogenboom, Hendricus RJM
APPLICANT: Malmqvist, Magnus
APPLICANT: Marks, James D
APPLICANT: McGuinness, Brian T
APPLICANT: Pope, Anthony R
APPLICANT: Prospero, Terence D
APPLICANT: Winter, Gregory P
TITLE OF INVENTION: Multivalent and Multispecific Binding
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall O'Toole Gerstein Murray and Borun
STREET: 6300 Sears Tower 233 South Wacker Drive
City: Chicago
STATE: Illinois
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/448,418
FILING DATE: 14-MAY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: C12N 15/62, 15/70, C07K 1/00
FILING DATE: 03-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9225453.1
FILING DATE: 04-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9300816.7
FILING DATE: 16-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: BP 93303614.7
FILING DATE: 10-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9319969.3
FILING DATE: 22-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32651
INFORMATION FOR SEQ ID NO: 85:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA primer
US-08-448-418-85
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 293
US-08-292-620A-1679
Sequence 1679, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 1679:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1679

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCACCTCCCGCAGC 2228
DB 1 GGGUACUCCCGCAGC 17

RESULT 294
US-08-292-620A-1756
Sequence 1756, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Scinichomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 1756:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1756

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCACCTCCCGCAGC 2228
DB 1 GGGUACUCCCGCAGC 17

RESULT 295
US-08-292-620A-1764
Sequence 1764, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Scinichomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.


```

; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1764:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1764

```

```

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2212 GGGCACCTCCCGCAGGC 2228
DB 1 GGGUACUCCCGCAGGC 17

```

```

RESULT 296
US-08-292-620A-1864
; Sequence 1864, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1864:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1864

```

```

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2212 GGGCACCTCCCGCAGGC 2228
DB 1 GGGUACUCCCGCAGGC 17

```

```

RESULT 297
US-08-292-620A-1885
; Sequence 1885, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:

```

CWO

APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1885:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1885

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGGACCTCCCGCAGGC 2228
DB 1 GGGUACUCCCGCCAGGC 17

RESULT 298
US-08-283-917-30
Sequence 30, Application US/08283917
Patent No. 5849557

GENERAL INFORMATION:
APPLICANT: ADACHI, HIDEKI
APPLICANT: TSUJIMOTO, MASAFUMI
APPLICANT: INOUE, KEIZO
APPLICANT: ARAI, HIROYUKI
TITLE OF INVENTION: OXIDIZED PHOPHOLIPID DEGRADING ENZYME
TITLE OF INVENTION: AND GENE THEREOF
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: OHION, SPIVAK, MCCLELLAND, MAIER &
ADDRESSEE: NEUSTADT, P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/283,917
FILING DATE: 03-AUG-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 209943/1993
FILING DATE: 03-AUG-1993

ATTORNEY/AGENT INFORMATION:
NAME: Ohion, No. 5849557man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 2292-030-0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid

STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: Other nucleic acid
US-08-283-917-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 299
US-08-920-828-25
Sequence 25, Application US/08920828
Patent No. 585398

GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Matsuhisa, Akio
APPLICANT: Uehara, Hirotsugu
APPLICANT: Eda, Soji
TITLE OF INVENTION: Probe for Diagnosing Infectious Disease
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/920,828
FILING DATE: 29-AUG-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/362,577
FILING DATE: 27-MAR-1995

ATTORNEY/AGENT INFORMATION:
NAME: Rin-Laures, Li-Hsien
REGISTRATION NUMBER: 33,547
REFERENCE/DOCKET NUMBER: 19036/32420
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-920-828-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 300
US-08-273-146-31

```
; Sequence 31, Application US/08273146
; Patent No. 5855885
; GENERAL INFORMATION:
; APPLICANT: Smith, Rodger
; APPLICANT: McCafferty, John
; APPLICANT: Chiswell, David
; APPLICANT: Daraley, Michael J.
; APPLICANT: Fitzgerald, Kevin
; APPLICANT: Kenten, John H.
; APPLICANT: Martin, Mark T.
; APPLICANT: Titmas, Richard C.
; APPLICANT: Williams, Richard O.
; TITLE OF INVENTION: The Isolation and Production of
; TITLE OF INVENTION: Catalytic Antibodies using Phage Technology
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: IGEN, Inc.
; STREET: 1530 East Jefferson St.
; CITY: Rockville
; STATE: MD
; COUNTRY: USA
; ZIP: 20852
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/273,146
; FILING DATE: 14-JUL-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Ryan, John W.
; REGISTRATION NUMBER: 33,771
; REFERENCE/DOCKET NUMBER: 09000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-984-8000
; TELEFAX: 301-230-0158
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-273-146-31

Query Match          0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CGGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 301
US-08-525-742-39
; Sequence 39, Application US/08555742
; Patent No. 5871742
; GENERAL INFORMATION:
; APPLICANT: Saito, Shuji
; APPLICANT: Ohkawa, Setsuko
; APPLICANT: Saeki, Sakiko
; APPLICANT: Ohsawa, Ikuroh
; APPLICANT: Funato, Hiroo
; APPLICANT: Iritani, Yoshikazu
; APPLICANT: Aoyama, Shigemi
; APPLICANT: Takahashi, Kiyochito
; TITLE OF INVENTION: NEW POLYPEPTIDE, DNA ENCODING THE
; TITLE OF INVENTION: POLYPEPTIDE, RECOMBINANT VECTOR BEARING THE DNA AND
; TITLE OF INVENTION: RECOMBINANT VIRUS UTILIZING THE RECOMBINANT VECTOR AS WELL
; TITLE OF INVENTION: AS USE THEREOF
; NUMBER OF SEQUENCES: 51
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARMSTRONG, WESTERMAN, HATTORI, MCLELAND &
; ADDRESSEE: NAUGHTON
; STREET: 1725 K Street, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/525,742
; FILING DATE: 25-SEP-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 05-074139
; FILING DATE: 31-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 05-245625
; FILING DATE: 30-SEP-1993
; APPLICATION NUMBER: PCT/JP94/00541
; FILING DATE: 31-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcleland, Le-Nhung
; REGISTRATION NUMBER: 31,541
; REFERENCE/DOCKET NUMBER: 950811
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-659-2930
; TELEFAX: 202-8870357
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-525-742-39

Query Match          0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CGGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 302
US-08-525-742-40
; Sequence 40, Application US/08525742
; Patent No. 5871742
; GENERAL INFORMATION:
; APPLICANT: Saito, Shuji
; APPLICANT: Ohkawa, Setsuko
; APPLICANT: Saeki, Sakiko
; APPLICANT: Ohsawa, Ikuroh
; APPLICANT: Funato, Hiroo
; APPLICANT: Iritani, Yoshikazu
; APPLICANT: Aoyama, Shigemi
; APPLICANT: Takahashi, Kiyochito
; TITLE OF INVENTION: NEW POLYPEPTIDE, DNA ENCODING THE
; TITLE OF INVENTION: POLYPEPTIDE, RECOMBINANT VECTOR BEARING THE DNA AND
; TITLE OF INVENTION: RECOMBINANT VIRUS UTILIZING THE RECOMBINANT VECTOR AS WELL
; TITLE OF INVENTION: AS USE THEREOF
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARMSTRONG, WESTERMAN, HATTORI, MCLELAND &
; ADDRESSEE: NAUGHTON
```

STREET: 1725 K Street, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/525,742
FILING DATE: 25-SEP-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 05-074139
FILING DATE: 31-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 05-245625
FILING DATE: 30-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP94/00541
FILING DATE: 31-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Mclelland, Le-Nhung
REGISTRATION NUMBER: 31,541
REFERENCE/DOCKET NUMBER: 950811
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-659-2930
TELEFAX: 202-8870357
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-525-742-40

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 303
US-08-652-816A-31
Sequence 31, Application US/08652816A
Patent No. 5872215
GENERAL INFORMATION:
APPLICANT: Osbourn, JK
APPLICANT: Allen, DJ
APPLICANT: McCafferty, JG
TITLE OF INVENTION: Specific binding members, materials and
TITLE OF INVENTION: methods.
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652,816A

FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.8
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 23-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9525004.9
FILING DATE: 07-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9610824.6
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/02240
FILING DATE: 02-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/33308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-652-816A-31

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 304
US-08-474-661-24
Sequence 24, Application US/08474661
Patent No. 5874253
GENERAL INFORMATION:
APPLICANT: TSUTSUMOTO, Masafumi
APPLICANT: IWASA, Fuyuki
APPLICANT: TSURUOKA, No. 5874253uo
APPLICANT: NAKAZATO, Hiroshi
APPLICANT: MIURA, Kenju
APPLICANT: ISHIDA, No. 5874253uhiro
APPLICANT: KURIHARA, Tatsuya
APPLICANT: YAMACHIT, Kozo
APPLICANT: YAMAGUCHI, No. 5874253omi
TITLE OF INVENTION: MEKAKARYOCYTE DIFFERENTIATION FACTOR
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Burns, Doane, Swecker & Mathis
STREET: George Mason Bldg., Washington & Prince Sts.
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22133-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,661
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/091,028
FILING DATE: 14-JUL-1993
APPLICATION NUMBER: JP 4-212305
FILING DATE: 17-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 5-067339
FILING DATE: 04-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: REA, TERESA STANER
REGISTRATION NUMBER: 30,427
REFERENCE/DOCKET NUMBER: 001560-204
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-6620
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-474-661-24

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAAACAGCTATGAC 17

RESULT 305
US-08-961-716-30
Sequence 30, Application US/08961716
Patent No. 5880272
GENERAL INFORMATION:
APPLICANT: ADACHI, HIDEKI
APPLICANT: TSUJIMOTO, MASAFUMI
APPLICANT: INOUE, KEIZO
APPLICANT: ARAI, HIROYUKI
TITLE OF INVENTION: OXIDIZED PHOPHOLIPID DEGRADING ENZYME
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER &
ADDRESSEE: NEUSTADT, P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/961,716
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/283,917
FILING DATE: 03-AUG-1994
APPLICATION NUMBER: JP 209943/1993

FILING DATE: 03-AUG-1993
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NO. 5880272man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 2292-030-0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: Other nucleic acid
US-08-961-716-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAAACAGCTATGAC 17

RESULT 306
US-08-990-818-10
Sequence 10, Application US/08990818
Patent No. 5910432
GENERAL INFORMATION:
APPLICANT: ITO, Kiyoshi
APPLICANT: YAMAKI, Toshifumi
APPLICANT: ARII, Teruo
APPLICANT: TSURUOKA, Miyuki
APPLICANT: NAKAMURA, Takeshi
TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/990,818
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/800,751
FILING DATE:
APPLICATION NUMBER: JP 8-027004
FILING DATE: 14-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: Teekin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 028022-007
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-990-818-10

Query Match
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 307
US-08-500-857A-14
Sequence 14, Application US/08500857A
Patent No. 5912156
GENERAL INFORMATION:
APPLICANT: OHATA, SHOZO
APPLICANT: USAMI, STORU
TITLE OF INVENTION: POLYPEPTIDE HAVING COLD-STABLE PYRUVATE,
TITLE OF INVENTION: ORTHOPHOSPHATE DIKINASE ACTIVITY, DNA ENCODING THE SAME
TITLE OF INVENTION: AND RECOMBINANT VECTOR AND TRANSFORMED PLANTS CONTAINING
TITLE OF INVENTION: THE DNA
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESSES:
ADDRESSEE: BIRCH, STEWART, KOLASCH AND BIRCH, LLP
STREET: 810 GATE HOUSE ROAD SUITE 500 EAST
CITY: FALLS CHURCH
STATE: VA
COUNTRY: USA
ZIP: 22042
COMPUTER READABLE FORM:
MEDIUM TYPE: IBM floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/500,857A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: MURPHY JR, GERALD M
REGISTRATION NUMBER: 28,977
REFERENCE/DOCKET NUMBER: 760-208P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 103-205-8050
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-500-857A-14

Query Match
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 308
US-08-613-965-8
Sequence 8, Application US/08613965
Patent No. 5916745
GENERAL INFORMATION:
APPLICANT: Robert M. Cook and Ahmed Raafat

TITLE OF INVENTION: Method For Determination
TITLE OF INVENTION: of Bovine Milk Production Potential
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ian C. McLeod
STREET: 2190 Commons Parkway
CITY: Okemos
STATE: Michigan
COUNTRY: USA
ZIP: 48864
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/613,965
FILING DATE:
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Ian C. McLeod
REGISTRATION NUMBER: 20,931
REFERENCE/DOCKET NUMBER: MSU 4.1-290
TELECOMMUNICATION INFORMATION:
TELEPHONE: (517) 347-4100
TELEFAX: (517) 347-4103
TELEX: No. 5916745e
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: nucleotides
STRANDEDNESS: Single
TOPOLOGY: Linear
MOLECULE TYPE:
DESCRIPTION: synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM:
STRAIN:
INDIVIDUAL ISOLATE:
CELL TYPE:
FEATURE:
NAME/KEY: primer
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
US-08-613-965-8

Query Match
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 309
US-08-350-260A-113
Sequence 113, Application US/08350260A
Patent No. 5962255
GENERAL INFORMATION:
APPLICANT: Winter, Gregory Paul
APPLICANT: Griffiths, Andrew David
APPLICANT: Williams, Samuel Cameron
APPLICANT: Waterhouse, Peter
APPLICANT: Nissim, Ahuva
APPLICANT: Johnson, Kevin Stuart

APPLICANT: Smith, Andrew John Hammond
TITLE OF INVENTION: Methods for producing members of specific
NUMBER OF SEQUENCES: 602
CORRESPONDENCE ADDRESS:
ADDRESSEE: David W. Clough
STREET: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/350,260A
FILING DATE: 05-DEC-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9110549.4
FILING DATE: 15-MAY-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB91/01134
FILING DATE: 10-JUL-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/150,002
FILING DATE: 31-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32372
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-350-260A-113

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 310
US-08-350-260A-302
Sequence 302, Application US/08350260A
Patent No. 5962235
GENERAL INFORMATION:
APPLICANT: Winter, Gregory Paul
APPLICANT: Griffiths, Andrew David
APPLICANT: Williams, Samuel Cameron

APPLICANT: Waterhouse, Peter
APPLICANT: Niasim, Abuva
APPLICANT: Johnson, Kevin Stuart
APPLICANT: Smith, Andrew John Hammond
TITLE OF INVENTION: Methods for producing members of specific
NUMBER OF SEQUENCES: 602
CORRESPONDENCE ADDRESS:
ADDRESSEE: David W. Clough
STREET: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/350,260A
FILING DATE: 05-DEC-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9110549.4
FILING DATE: 15-MAY-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB91/01134
FILING DATE: 10-JUL-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/150,002
FILING DATE: 31-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32372
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 302:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-350-260A-302

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 311
US-08-611-977-24
Sequence 24, Application US/08611977
Patent No. 5972886
GENERAL INFORMATION:

APPLICANT: TSUJIMOTO, Masafumi
APPLICANT: IWASA, Fuyuki
APPLICANT: TSUROJOKA, No. 5972886u
APPLICANT: NAKAZATO, Hiroshi
APPLICANT: MIURA, Kenju
APPLICANT: ISHIDA, No. 5972886hito
APPLICANT: KURIHARA, Tatsuya
APPLICANT: YAMAICHI, Kozo
APPLICANT: YAMAGUCHI, No. 5972886omi
TITLE OF INVENTION: MEGAKARYOCYTE DIFFERENTIATION FACTOR
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Burns, Doane, Swecker & Mathis
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/611,977
FILING DATE: 06-MAR-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/091,028
FILING DATE: 14-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 4-212305
FILING DATE: 17-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-067339
FILING DATE: 04-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: McGowan, Malcolm K.
REGISTRATION NUMBER: 39,300
REFERENCE/DOCKET NUMBER: 001560-204
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-611-977-24

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 312
US-08-610-599-72
Sequence 72, Application US/08810599
Patent No. 5976798
GENERAL INFORMATION:
APPLICANT: PARKER, W. Davis
APPLICANT: HERRNSTADT, Corinna
APPLICANT: GHOSH, Soumitra S.
APPLICANT: FAHY, Eoin
TITLE OF INVENTION: Methods for Detecting Mitochondrial Mutations
TITLE OF INVENTION: Diagnostic for Alzheimer's Disease and Methods for Determining
TITLE OF INVENTION: of Mitochondrial Nucleic Acid

NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: 1025 Connecticut Avenue, N.W., Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: US
ZIP: 20036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.25" Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1 for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/810,599
FILING DATE: Concurrent Herewith
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/757,438
FILING DATE: 27 No. 5976798 1996
APPLICATION NUMBER: US 08/614,072
FILING DATE: 12 Mar 1996
APPLICATION NUMBER: US 08/536,036
FILING DATE: 29 Sep 1995
APPLICATION NUMBER: US 08/414,969
FILING DATE: 31 Mar 1995
APPLICATION NUMBER: US 08/413,740
FILING DATE: 30 Mar 1995
APPLICATION NUMBER: US 08/410,658
FILING DATE: 24 MARCH 1995
APPLICATION NUMBER: US 08/397,808
FILING DATE: 3 Mar 1995
APPLICATION NUMBER: US 08/219,842
FILING DATE: 30 MARCH 1994
ATTORNEY/AGENT INFORMATION:
NAME: Toifenetti, Judith L.
REGISTRATION NUMBER: 39,048
REFERENCE/DOCKET NUMBER: 2105/17
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-429-1176
TELEFAX: 202-429-0796
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: No
ANTI-SENSE: No
US-08-610-599-72

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 313
US-08-665-202-110
Sequence 110, Application US/08665202
Patent No. 5977322
GENERAL INFORMATION:
APPLICANT: Maixes, James D.
APPLICANT: Schier, Robert
TITLE OF INVENTION: No. 5977322el High Affinity Human Antibodies to
TITLE OF INVENTION: Tumor Antigens
NUMBER OF SEQUENCES: 141
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP

STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/665,202
FILING DATE: 13-JUN-1996
CLASSIFICATION: 424
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 60/000,238
FILING DATE: 14-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/000,250
FILING DATE: 15-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Hunter, Tom
REGISTRATION NUMBER: 38,498
REFERENCE/DOCKET NUMBER: 02307E-061410
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 110:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-665-202-110

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 314
US-08-918-966-8
Sequence 8, Application US/08918966
Patent No. 5981187
GENERAL INFORMATION:
APPLICANT: Robert M. Cook and Ahmed Raafat
TITLE OF INVENTION: Method For Determination
TITLE OF INVENTION: of Bovine Milk Production Potential
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ian C. McLeod
STREET: 2190 Commons Parkway
CITY: Okemos
STATE: Michigan
COUNTRY: USA
ZIP: 48864
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/918,966
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Ian C. McLeod
REGISTRATION NUMBER: 20,931
REFERENCE/DOCKET NUMBER: MSU 4.1-290
TELECOMMUNICATION INFORMATION:
TELEPHONE: (517) 347-4100
TELEFAX: (517) 347-4103
TEXT: No. 5981187e
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: nucleotides
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: synthetic DNA
HYPOTHETICAL: No
ANTI-SENSE: No
ORIGINAL SOURCE:
ORGANISM:
STRAIN:
INDIVIDUAL ISOLATE:
CELL TYPE:
FEATURE:
NAME/KEY: primer
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
US-08-918-966-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 315
US-08-256-627-6
Sequence 6, Application US/08256627
Patent No. 5985548
GENERAL INFORMATION:
APPLICANT: EBERSOLE, RICHARD C.
APPLICANT: COLLIER, DAVID N.
APPLICANT: HATFIELD, TINA M.
APPLICANT: HENDRICKSON, EDWIN R.
APPLICANT: MORAN, JOHN
TITLE OF INVENTION: AMPLIFICATION OF ASSAY
TITLE OF INVENTION: REPORTERS BY NUCLEIC
TITLE OF INVENTION: ACID REPLICATION
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. DU PONT DE NEMOURS
STREET: AND COMPANY
CITY: WILMINGTON
STATE: DELAWARE
COUNTRY: U.S.A.
ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch,
MEDIUM TYPE: 1.0 MB
COMPUTER: MACINTOSH
OPERATING SYSTEM: MACINTOSH 6.0
SOFTWARE: MICROSOFT WORD, 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/256,627
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US93/01281
FILING DATE: 04-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: GEIGER, KATHLEEN M.
REGISTRATION NUMBER: 35,880
REFERENCE/DOCKET NUMBER: CR-8959-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 302-892-8112
TELEFAX: 302-892-7949
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-256-627-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
Db 1 CAGGAACGCTATGAC 17

RESULT 316
US-08-809-740A-7
Sequence 7, Application US/08809740A
Patent No. 5986077
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Process for producing anthracyclines
TITLE OF INVENTION: and intermediates thereof
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Evenson, McKee, Edwards and Lenahan
STREET: 1200 G Street, Suite 700
CITY: Washington
STATE: DC
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
FILING DATE: 27-MAR-1997
APPLICATION NUMBER: US/08/809,740A
Prior Application Data:
APPLICATION NUMBER: PCT/FI95/00537
FILING DATE: 30-SEP-1995
APPLICATION NUMBER: FI 944556
FILING DATE: 30-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: H. Thomas Anderson, Jr.
REGISTRATION NUMBER: 40,895
REFERENCE/DOCKET NUMBER: 1574/43419
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-809-740A-7

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
Db 1 CAGGAACGCTATGAC 17

RESULT 317
US-08-700-670A-24
Sequence 24, Application US/08700670A
Patent No. 5993821
GENERAL INFORMATION:
APPLICANT: FRAZER, Ian
APPLICANT: ZHOU, Jian
TITLE OF INVENTION: MODIFIED PAPILLOMA VIRUS L2 PROTEIN AND
TITLE OF INVENTION: VLPS FORMED THEREFROM
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
FILING DATE: 30-JUL-1996
CLASSIFICATION: 424
Prior Application Data:
APPLICATION NUMBER: WO PCT/AU95/00043
FILING DATE: 31-JAN-1995
Prior Application Data:
APPLICATION NUMBER: AU PM3588
FILING DATE: 31-JAN-1994
ATTORNEY/AGENT INFORMATION:
NAME: Saxe, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 65064/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-700-670A-24

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
Db 1 CAGGAACGCTATGAC 17

RESULT 318
US-08-487-799-31
Sequence 31, Application US/08487799C
Patent No. 6010908
GENERAL INFORMATION:
APPLICANT: Gruenert, Dieter C.
APPLICANT: Kunzelmann, Karl
TITLE OF INVENTION: GENE THERAPY BY SMALL FRAGMENTS HOMOLOGOUS REPLACEMENT
FILE REFERENCE: 480.18-1(HV)
CURRENT APPLICATION NUMBER: US/08/487,799C
FILING DATE: 1995-06-07

EARLIER APPLICATION NUMBER: 07/933,471
EARLIER FILING DATE: 1992-08-21
EARLIER APPLICATION NUMBER: 08/409,544
EARLIER FILING DATE: 1995-03-24
NUMBER OF SEQ ID NOS: 87
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 31
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic
OTHER INFORMATION: oligonucleotide
US-08-487-799-31

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 319
US-08-921-655-8
Sequence 8, Application US/08921655
Patent No. 6013496
GENERAL INFORMATION:
APPLICANT: Robert M. Cook and Ahmed Raafat
TITLE OF INVENTION: Method For Determination
TITLE OF INVENTION: of Bovine Milk Production Potential
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ian C. McLeod
STREET: 2190 Commons Parkway
CITY: Okemos
STATE: Michigan
COUNTRY: USA
ZIP: 48864
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 KB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/921,655
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Ian C. McLeod
REGISTRATION NUMBER: 20,931
REFERENCE/DOCKET NUMBER: MSU 4.1-290
TELECOMMUNICATION INFORMATION:
TELEPHONE: (517) 347-4100
TELEFAX: (517) 347-4103
TELEX: No. 60134966
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: nucleotides
STRANDEDNESS: Single
TOPOLOGY: Linear
MOLECULE TYPE: synthetic DNA
DESCRIPTION: NO
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM:

STRAIN:
INDIVIDUAL ISOLATE:
CELL TYPE:
FEATURE:
NAME/KEY: primer
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
US-08-921-655-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 320
US-08-589-939-68
Sequence 68, Application US/08589939
Patent No. 6015662
GENERAL INFORMATION:
APPLICANT: Hackett, Jr., John R.
APPLICANT: Hoff, Jane A.
APPLICANT: Ostrow, David H.
APPLICANT: Golden, Alan M.
TITLE OF INVENTION: REAGENTS FOR USE AS CALIBRATORS AND
TITLE OF INVENTION: CONTROLS
NUMBER OF SEQUENCES: 70
CORRESPONDENCE ADDRESS:
ADDRESSEE: Abbott Laboratories
STREET: 100 Abbott Park Road
CITY: Abbott Park
STATE: IL
COUNTRY: US
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/589,939
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Becker, Cheryl L.
REGISTRATION NUMBER: 35,441
REFERENCE/DOCKET NUMBER: 5865.US.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 847-935-1729
TELEFAX: 847-938-2623
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-589-939-68

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 321

US-08-757-024-866/C
; Sequence 866, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339ch Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELETYPE: 575102
; INFORMATION FOR SEQ ID NO: 866:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-866

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1908 CCCAGCCTGGTCCGCC 1924
DB 17 CCCAGCCTGGTCCGCC 1

RESULT 322
US-09-184-658-54
; Sequence 54, Application US/09184658
; Patent No. 6030792
; GENERAL INFORMATION:
; APPLICANT: Otterness, Ivan G.
; APPLICANT: Mezes, Peter S.
; APPLICANT: Downs, James T.
; APPLICANT: Johnson, Kimberly S.
; TITLE OF INVENTION: Assays for Measurement of Protein Fragments in
; FILE REFERENCE: PC9946-A
; CURRENT APPLICATION NUMBER: US/09/184,658
; CURRENT FILING DATE: 1998-11-02
; EARLIER APPLICATION NUMBER: 60/065,423
; EARLIER FILING DATE: 1997-11-13
; NUMBER OF SEQ ID NOS: 69
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 54
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing

; OTHER INFORMATION: oligonucleotide.
US-09-184-658-54
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 323
US-08-617-256-30
; Sequence 30, Application US/08617256
; Patent No. 6043031
; GENERAL INFORMATION:
; APPLICANT: Kyster, Hubert
; TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,256
; FILING DATE: March 18, 1996
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/406,199
; FILING DATE: March 17, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth A.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: SQI-013CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-617-256-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 324
US-08-985-162-3
; Sequence 3, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT

TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-3

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.3e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3790 GGGCACCCTGACGCGGT 3806
DB 1 GGGCACCCTGACGCGGT 17

RESULT 325
US-08-985-162-331/c
Sequence 331, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghit
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 331:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-331

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGGCTCCAGAGTCATC 606
DB 17 TGGATCCAAGTCATC 1

RESULT 326
US-09-065-474-49
Sequence 49, Application US/09065474
Patent No. 6063599
GENERAL INFORMATION:
APPLICANT: Tang, Liang
APPLICANT: Blehm, E. Scot
TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN
TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND
NUMBER OF SEQUENCES: 171
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carol Talkington Verese, Ph.D.
ADDRESSEE: Heeka Corporation
STREET: 1825 Sharp Point Drive
CITY: Fort Collins
STATE: Colorado
COUNTRY: USA
ZIP: 80525
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Wordperfect for Windows, Version 7.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/065,474
FILING DATE: 24-Apr-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Verese, Carol Talkington
REGISTRATION NUMBER: 37,459
REFERENCE/DOCKET NUMBER: HM-5-C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 970/484-9505
TELEFAX: 970/484-9505
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:

LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: primer
US-09-065-474-49

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 327
US-09-127-829-8
Sequence 8, Application US/09127829

PATENT No. 6063904
GENERAL INFORMATION:
APPLICANT: MIYAMURA, TATSUO
APPLICANT: SAITO, IZUMU
APPLICANT: MATSURA, YOSHIHARU
APPLICANT: HONDA, YOSHIKAZU
APPLICANT: SEKI, MAKOTO
TITLE OF INVENTION: METHOD FOR PRODUCING ECTOPROTEIN OF
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/127,829

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/446,303

FILING DATE:
APPLICATION NUMBER: US 08/074,584
FILING DATE: 11-JUN-1993
APPLICATION NUMBER: JP 152487/1992
FILING DATE: 11-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Oblon, No. 6063904man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 4169-003-0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220

TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
US-09-127-829-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 328
US-08-654-618-17
Sequence 17, Application US/08654618
Patent No. 6113899
GENERAL INFORMATION:
APPLICANT: MORTON, Halle
APPLICANT: CAVANAGH, Alice Christina
TITLE OF INVENTION: ANTAGONISTS TO CHAPERONIN 10
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/654,618
FILING DATE: 29-MAY-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Saxe, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 65064/110
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399

TELEX: 904136
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-654-618-17

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 329
US-08-654-575-3
Sequence 3, Application US/08654575
Patent No. 6117421
GENERAL INFORMATION:
APPLICANT: MORTON, Halle
APPLICANT: CAVANAGH, Alice Christina
TITLE OF INVENTION: CHAPERONIN 10
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/654,575
FILING DATE: 29-MAY-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Saxe, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 65064/110
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399

TELEX: 904136
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-654-575-3

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/654,575
FILING DATE: 29-MAY-1996
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/AU94/00740
FILING DATE: 30-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: AU PM 8234
FILING DATE: 16-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: AU PM 2705
FILING DATE: 30-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Saxe, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 65064/113
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-654-575-3

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 330
US-08-953-171-42
Sequence 42, Application US/08953171
Patent No. 6124094
GENERAL INFORMATION:
APPLICANT: LAJOIE, CURTIS
APPLICANT: LAYTON, ALICE
APPLICANT: KELLY, CHRISTINE
APPLICANT: SAYLER, GARY
APPLICANT: STAPLETON, RAYMOND
TITLE OF INVENTION: ZOOLOGICAL AND HYPOMICROBIUM
TITLE OF INVENTION: SPP. NUCLEIC ACIDS
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: 127 Peachtree Street, N.E., Suite 1200
CITY: Atlanta
STATE: GA
COUNTRY: USA
ZIP: 30303-1811
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/953,171
FILING DATE: 17-OCT-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Spratt, Gwendolyn DD
REGISTRATION NUMBER: 36,016
REFERENCE/DOCKET NUMBER: 05015.018
TELECOMMUNICATION INFORMATION:
TELEPHONE: 404 688 0770
TELEFAX: 404 688 9880
TELEX:
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-953-171-42

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 331
US-09-071-845-1679
Sequence 1679, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McGisgen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1679:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1679

Query Match
Best Local Similarity 82.4%; Score 13.8; DB 1; Length 17;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCAGCTCCCCAGGC 2228
Db 1 GGGUACUCCCCCAGGC 17

RESULT 332
US-09-071-845-1756
Sequence 1756, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
Prior Application Number: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1756:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
US-09-071-845-1756

Query Match
Best Local Similarity 82.4%; Score 13.8; DB 1; Length 17;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCAGCTCCCCAGGC 2228
Db 1 GGGUACUCCCCCAGGC 17

RESULT 333
US-09-071-845-1764
Sequence 1764, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
Prior Application Number: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1764:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1764

Query Match
Best Local Similarity 82.4%; Score 13.8; DB 1; Length 17;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCACTCCCCCAGGC 2228
DB 1 GGGUACUCCCCCAGGC 17

RESULT 334

US-09-071-845-1864
Sequence 1864, Application US/09071845

Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/071,845

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620

FILING DATE: August 17, 1994

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1864:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-071-845-1864

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCACTCCCCCAGGC 2228
DB 1 GGGUACUCCCCCAGGC 17

RESULT 335
US-09-071-845-1885

Sequence 1885, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/071,845

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620

FILING DATE: August 17, 1994

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1885:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-071-845-1885

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2212 GGGCACTCCCCCAGGC 2228
DB 1 GGGUACUCCCCCAGGC 17

RESULT 336
US-09-050-783-67
Sequence 67, Application US/09050783
Patent No. 6140471

GENERAL INFORMATION:
APPLICANT: Johnson, Kevin S
APPLICANT: Winter, Gregory P
APPLICANT: Griffiths, Andrew D
APPLICANT: Smith, Andrew JH

```
APPLICANT: Waterhouse, P
TITLE OF INVENTION: Methods for producing members of specific
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/050,783
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32238
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 67:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-050-783-67

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACGCTATGAC 3543
Db      1 CAGGAACGCTATGAC 17

RESULT 337
US-09-230-380-2
Sequence 2, Application US/09230380A
Patent No. 6172215
GENERAL INFORMATION:
APPLICANT: Keshi, Hiroyuki
APPLICANT: Eda, Soji
APPLICANT: Uehara, Hirotatsu
APPLICANT: Nishida, Keigo
APPLICANT: Matsubae, Akio
TITLE OF INVENTION: Probes For Detecting and Identifying Helicobacter
FILE REFERENCE: 19036/35268
CURRENT APPLICATION NUMBER: US/09/230,380A
CURRENT FILING DATE: 1999-07-12
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 2
LENGTH: 17
```

```
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthesized
US-09-230-380-2

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACGCTATGAC 3543
Db      1 CAGGAACGCTATGAC 17

RESULT 338
US-09-179-558-28
Sequence 28, Application US/09179558
Patent No. 6180612
GENERAL INFORMATION:
APPLICANT: Hockensmith, Joel W.
APPLICANT: Mathuswant, Robini
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TARGETING DNA METABOLIC PROCESSES USING
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESS: PENNIE & EDMONDS LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/179,558
FILING DATE: 27-OCT-1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: U.S. 09/060,470
FILING DATE: 15-APR-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: U.S. 60/063,898
FILING DATE: 31-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 9426-005-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 7909090
TELEFAX: (212) 8699741
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other
US-09-179-558-28

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACGCTATGAC 3543
Db      1 CAGGAACGCTATGAC 17
```

```
RESULT 339
US-09-142-355B-6
; Sequence 6, Application US/09142355B
; Patent No. 6184012
; GENERAL INFORMATION:
; APPLICANT: Neri, Dario
; APPLICANT: Demartini, Salvatore
; APPLICANT: Huber, Adrain
; APPLICANT: Viti, Francesca
; APPLICANT: Tawfik, Dan. S.
; APPLICANT: Winter, Gregory Paul
; TITLE OF INVENTION: Isolation of Enzymes
; FILE REFERENCE: 2224/08665
; CURRENT APPLICATION NUMBER: US/09/142.355B
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: GB 9608540.2
; PRIOR FILING DATE: 1996-04-25
; PRIOR APPLICATION NUMBER: PCT/GB97/01153
; PRIOR FILING DATE: 1997-04-25
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-142-355B-6

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 340
US-09-077-312A-2
; Sequence 2, Application US/09077312A
; Patent No. 6187575
; GENERAL INFORMATION:
; APPLICANT: SOBER, Harald
; APPLICANT: SCHMIDT, Manfred
; APPLICANT: FREY, Bruno
; APPLICANT: KALUZA, Klaus
; TITLE OF INVENTION: THERMOSTABLE URACIL-DNA-GLYCOSYLASE, PROCESS FOR ITS
; FILE REFERENCE: P1614-8039
; PREPARATION AND USE FOR REMOVING URACIL FROM DNA
; CURRENT APPLICATION NUMBER: US/09/077.312A
; PRIOR FILING DATE: 1998-08-06
; PRIOR APPLICATION NUMBER: PCT/EP96/05398
; PRIOR FILING DATE: 1996-12-04
; PRIOR APPLICATION NUMBER: DE 195 45 320.4
; PRIOR FILING DATE: 1995-12-05
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-077-312A-2

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 341
US-08-617-010C-9
; Sequence 9, Application US/08617010C
; Patent No. 6194144
; GENERAL INFORMATION:
; APPLICANT: Hubert K ster
; TITLE OF INVENTION: DNA SEQUENCING BY MASS SPECTROMETRY
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Heller Ehrman White & McLaughlin
; STREET: 4250 Executive Square, 7th Floor
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037-9103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617.010C
; FILING DATE: 18-MAR-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/178,216
; FILING DATE: 06-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/001,323
; FILING DATE: 07-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Seidman, Stephanie L.
; REGISTRATION NUMBER: 33,779
; REFERENCE/DOCKET NUMBER: 24736-2012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 858-450-8400
; TELEFAX: 619-587-5360
; TELEX:
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-617-010C-9

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 342
US-09-287-141-30
; Sequence 30, Application US/09287141
; Patent No. 6197498
; GENERAL INFORMATION:
; APPLICANT: K ster, Hubert
; TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Heller Ehrman White & McLaughlin
; STREET: 4250 Executive Square, 7th Floor
; CITY: La Jolla
```

```
STATE: CA
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/287,141
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2002D
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-450-8400
TELEFAX: 619-587-5360
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)227-5941
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-287-141-30

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 343
US-09-050-159-45
Sequence 45, Application US/09050159A
Patent No. 6197505
GENERAL INFORMATION:
APPLICANT: No. 6197505berg, Leif T
APPLICANT: Andersson, Maria K
APPLICANT: Linstrom, Per H
TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
TITLE OF INVENTION: COMPOSITIONS FOR USE THEREOF
FILE REFERENCE: 1248/1D042
CURRENT APPLICATION NUMBER: US/09/050,159A
CURRENT FILING DATE: 1998-03-27
EARLIER APPLICATION NUMBER: 60/042,930
EARLIER FILING DATE: 1987-04-03
NUMBER OF SEQ ID NOS: 133
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 45
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-45

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1441 CTGCAGCAGCAGCAACA 1457
DB 1 CGCGCGCAGCAGCAACA 17

RESULT 344
US-09-050-159-51
Sequence 51, Application US/09050159A
Patent No. 6197505
GENERAL INFORMATION:
APPLICANT: No. 6197505berg, Leif T
APPLICANT: Andersson, Maria K
APPLICANT: Linstrom, Per H
TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
TITLE OF INVENTION: COMPOSITIONS FOR USE THEREOF
FILE REFERENCE: 1248/1D042
CURRENT APPLICATION NUMBER: US/09/050,159A
CURRENT FILING DATE: 1998-03-27
EARLIER APPLICATION NUMBER: 60/042,930
EARLIER FILING DATE: 1987-04-03
NUMBER OF SEQ ID NOS: 133
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 51
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-51

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1441 CTGCAGCAGCAGCAACA 1457
DB 1 CGCGCGCAGCAGCAACA 17

RESULT 345
US-09-228-942-2
Sequence 2, Application US/09228942
Patent No. 6203988
GENERAL INFORMATION:
APPLICANT: Kambara, Hideki
APPLICANT: Uematsu, Chihito
TITLE OF INVENTION: DNA FRAGMENT ANALYSIS METHOD AND REAGENT KIT
FILE REFERENCE: ASA-757
CURRENT APPLICATION NUMBER: US/09/228,942
CURRENT FILING DATE: 1999-01-12
NUMBER OF SEQ ID NOS: 8
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 2
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
oligonucleotide ligated to 3' end of DNA fragment
US-09-228-942-2

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 346
```

US-08-969-815-25
; Sequence 25, Application US/08969815
; Patent No. 6207412
; GENERAL INFORMATION:
; APPLICANT: Witte, Owen N.
; APPLICANT: Meng, Zhigang
; TITLE OF INVENTION: IDENTIFICATION OF A G PROTEIN-COUPLED
; TITLE OF INVENTION: RECEPTOR TRANSCRIPTIONALLY REGULATED BY PROTEIN
; TITLE OF INVENTION: TYROSINE KINASE SIGNALING IN HEMATOPOIETIC CELLS
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/969,815
; FILING DATE:
; CLASSIFICATION: 435
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfeld, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: UCL015.001A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-969-815-25
; Query Match 0.3%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 2.3e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17
RESULT 347
US-08-969-815-38
; Sequence 38, Application US/08969815
; Patent No. 6207412
; GENERAL INFORMATION:
; APPLICANT: Witte, Owen N.
; APPLICANT: Meng, Zhigang
; TITLE OF INVENTION: IDENTIFICATION OF A G PROTEIN-COUPLED
; TITLE OF INVENTION: RECEPTOR TRANSCRIPTIONALLY REGULATED BY PROTEIN
; TITLE OF INVENTION: TYROSINE KINASE SIGNALING IN HEMATOPOIETIC CELLS
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/969,815
; FILING DATE:
; CLASSIFICATION: 435
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfeld, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: UCL015.001A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-969-815-38
; Query Match 0.3%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 2.3e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17
RESULT 348
US-09-120-025-25
; Sequence 25, Application US/09120025
; Patent No. 6214562
; GENERAL INFORMATION:
; APPLICANT: Meng, Zhigang.
; APPLICANT: Witte, Owen N.
; TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED
; TITLE OF INVENTION: RECEPTOR
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/120,025
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/969,815
; FILING DATE: 13-NOV-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfeld, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: UCL015.001CP1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:

INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-120-025-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543

DB 1 CAGGAACAGCTATGAC 17

RESULT 349

US-09-120-025-38

Sequence 38, Application US/09120025
Patent No. 6214562

GENERAL INFORMATION:

APPLICANT: Meng, Zhigang.

APPLICANT: Witte, Owen N.

TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESS:

ADDRESSEE: Knobbe, Martens, Olson & Bear

STREET: 620 Newport Center Drive, 16th Floor

CITY: Newport Beach

STATE: CA

COUNTRY: U.S.A.

ZIP: 92660

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/120,025

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/969,815

FILING DATE: 13-NOV-1997

ATTORNEY/AGENT INFORMATION:

NAME: Bartfield, Neil S

REGISTRATION NUMBER: 39,901

REFERENCE/DOCKET NUMBER: UCLA015.001CP1

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-235-8550

TELEFAX: 619-235-0176

TELEX:

INFORMATION FOR SEQ ID NO: 38:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-120-025-38

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543

DB 1 CAGGAACAGCTATGAC 17

RESULT 350

US-09-431-613-30

Sequence 30, Application US/09431613

Patent No. 6221601

GENERAL INFORMATION:

APPLICANT: K ster, Hubert

TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry

NUMBER OF SEQUENCES: 33

CORRESPONDENCE ADDRESS:

ADDRESSEE: Heller Ehrman White & McCauliffe

STREET: 4250 Executive Square, 7th Floor

CITY: La Jolla

STATE: CA

COUNTRY: USA

ZIP: 92037-9103

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/431,613

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/617,256

FILING DATE: 18-MAR-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/406,199

FILING DATE: 03-MAR-1995

ATTORNEY/AGENT INFORMATION:

NAME: Seidman, Stephanie L

REGISTRATION NUMBER: 33,779

REFERENCE/DOCKET NUMBER: 24736-2002G

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-450-8400

TELEFAX: 619-587-5360

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617)227-7400

TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 30:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

US-09-431-613-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543

DB 1 CAGGAACAGCTATGAC 17

RESULT 351

US-09-504-245-30

Sequence 30, Application US/09504245

Patent No. 6221605

GENERAL INFORMATION:

APPLICANT: K ster, Hubert

TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry

NUMBER OF SEQUENCES: 33

CORRESPONDENCE ADDRESS:

ADDRESSEE: Heller Ehrman White & McCauliffe LLP

STREET: 4250 Executive Square, 7th Floor

CITY: La Jolla

STATE: CA

COUNTRY: USA

ZIP: 92037-9103

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/504,245
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2002J
TELECOMMUNICATION INFORMATION:
TELEPHONE: 858-450-8400
TELEFAX: 858-587-5360
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-504-245-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 352
US-08-256-799-6
Sequence 6, Application US/08256799
Patent No. 6222094
GENERAL INFORMATION:
APPLICANT: HANSSON, Lennart
APPLICANT: STROEMQVIST, Mats
APPLICANT: BERGSTROM, Sven
APPLICANT: TOERNELL, Jan
TITLE OF INVENTION: DNA ENCODING KAPPA-CASEIN, PROCESS FOR
TITLE OF INVENTION: OBTAINING THE PROTEIN AND USE THEREOF
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEWMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/256,799
FILING DATE: 06-DEC-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DK 88/92
FILING DATE: 23-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: COOPER, Iver P.
REGISTRATION NUMBER: 28,005

REFERENCE/DOCKET NUMBER: HANSSON=1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5397
TELEFAX: 202-737-3528
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-256-799-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 353
US-08-991-184-5
Sequence 5, Application US/08991184
Patent No. 6225092
GENERAL INFORMATION:
APPLICANT: P. BO, Svante
APPLICANT: KILGER, Christian
TITLE OF INVENTION: Method for uncoupled, direct, exponential
TITLE OF INVENTION: amplification and sequencing of DNA molecules with the additior
TITLE OF INVENTION: thermostable DNA polymerase and its application
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nikaido, Marmelstein, Murray & Oram LLP
STREET: 655 Fifteenth Street, N.W., Suite 310
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005-5701

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
FILING DATE: 16-DEC-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DB 196 53 494.1
FILING DATE: 20-DEC-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Wong, King L.
REGISTRATION NUMBER: 37,500
REFERENCE/DOCKET NUMBER: 1614-7090
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 638-5000
TELEFAX: (202) 638-4810
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligonucleotide"
US-08-991-184-5

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 354

US-09-402-002-7
Sequence 7, Application US/09402002
Patent No. 6225453
GENERAL INFORMATION:
APPLICANT: Ueyama, Hiroshi
APPLICANT: Abe, Kanako
APPLICANT: Keshi, Hiroyuki
APPLICANT: Matsuhisa, Aki
TITLE OF INVENTION: PROBES FOR THE DIAGNOSIS OF INFECTIONS
TITLE OF INVENTION: CAUSED BY KLEBSIELLA PNEUMONIAE
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 233 South Wacker Drive/6300 Sears Tower
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/402,002
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 1997-71082
FILING DATE: 25-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP98/01286
FILING DATE: 23-MAR-1998
ATTORNEY/AGENT INFORMATION:
NAME: Cawley, Jr., Thomas A.
REGISTRATION NUMBER: 40,944
REFERENCE/DOCKET NUMBER: 19036/36276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic DNA"
US-09-402-002-7

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 355

US-09-260-527-5
Sequence 5, Application US/09260527A
Patent No. 6228599
GENERAL INFORMATION:
APPLICANT: Knox, J.P.
APPLICANT: Mikkelson, J.D.

APPLICANT: Willats, W. G.
TITLE OF INVENTION: ANTIBODY
FILE REFERENCE: DYOUI9.001AUS
CURRENT APPLICATION NUMBER: US/09/260,527A
CURRENT FILING DATE: 1999-02-26
NUMBER OF SEQ ID NOS: 7
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 5
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
OTHER INFORMATION: sequencing primer sequence LMB3
US-09-260-527-5

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 356
US-08-462-437-6
Sequence 6, Application US/08462437
Patent No. 6232094
GENERAL INFORMATION:
APPLICANT: HANSSON, Lennart
APPLICANT: STROMQVIST, Mats
APPLICANT: BERGSTROM, Sven
APPLICANT: HERNELL, Oile
APPLICANT: TOERNELL, Jan
TITLE OF INVENTION: DNA ENCODING KAPPA-CASEIN, PROCESS
TITLE OF INVENTION: FOR OBTAINING THE PROTEIN AND USE THEREOF
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,437
FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DK 88/92
FILING DATE: 23-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: COOPER, Iver P.
REGISTRATION NUMBER: 28,005
REFERENCE/DOCKET NUMBER: HANSSON=1A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
TELEX: 248633
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-462-437-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

DB 1 CAGGAAACGCTATGAC 17

RESULT 357
US-09-287-682-30
; Sequence 30, Application US/09287682
; Patent No. 6235478
; GENERAL INFORMATION:
; APPLICANT: K ater, Hubert
; APPLICANT: Little, Daniel P.
; APPLICANT: Brian, Andreas
; TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Heller Ehrman White & Mcauliffe
; STREET: 4250 Executive Square, 7th Floor
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037-9103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/287,682
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/617,256
; FILING DATE: 18-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/406,199
; FILING DATE: 03-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Seidman, Stephanie L.
; REGISTRATION NUMBER: 33,779
; REFERENCE/DOCKET NUMBER: 24736-2002E
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-450-8400
; TELEFAX: 619-587-5360
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-09-287-682-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

DB 1 CAGGAAACGCTATGAC 17

RESULT 358
US-09-566-591-9
; Sequence 9, Application US/09566591
; Patent No. 6238871
; GENERAL INFORMATION:

APPLICANT: Hubert K'ater
TITLE OF INVENTION: DNA SEQUENCING BY MASS SPECTROMETRY
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Heller Ehrman White & Mcauliffe
STREET: 4250 Executive Square, 7th Floor
CITY: La Jolla
STATE: CA

COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/566,591
FILING DATE: 08-May-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,010
FILING DATE: 18-MAR-1996
APPLICATION NUMBER: 08/178,216
FILING DATE: 06-JAN-1994
APPLICATION NUMBER: 08/001,323
FILING DATE: 07-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2012B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 858-450-8400
TELEFAX: 858-587-5360
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-566-591-9

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

DB 1 CAGGAAACGCTATGAC 17

RESULT 359
US-09-381-862-8
; Sequence 8, Application US/09381862
; Patent No. 6245906
; GENERAL INFORMATION:
; APPLICANT: Ueyama, Hiroshi
; APPLICANT: Abe, Kanako
; APPLICANT: Keshi, Hiroyuki
; APPLICANT: Matsubisa, Akio
; TITLE OF INVENTION: PROBES FOR THE DIAGNOSIS OF INFECTIONS
; TITLE OF INVENTION: CAUSED BY STREPTOCOCCUS PYOGENES
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606
; COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/381,862
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 1997-71077
FILING DATE: 25-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP98/01288
FILING DATE: 23-MAR-1998
ATTORNEY/AGENT INFORMATION:
NAME: Cawley, Jr., Thomas A.
REGISTRATION NUMBER: 40,944
REFERENCE/DOCKET NUMBER: 19036/36274
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic DNA"
US-09-381-862-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 360
US-09-287-679-30
Sequence 30, Application US/09287679
Patent No. 6258538
GENERAL INFORMATION:
APPLICANT: K ster, Hubert
APPLICANT: Lettelle, Daniel P.
APPLICANT: Braun, Andrei
TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Heller Ehrman White & Mcauliffe
STREET: 4250 Executive Square, 7th Floor
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/287,679
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:

NAME: Seidman, Stephanie L
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2002C
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-450-8400
TELEFAX: 619-587-5360
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)227-5941
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-287-679-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 361
US-09-376-781-17
Sequence 17, Application US/09376781
Patent No. 6261806
GENERAL INFORMATION:
APPLICANT: Banerjee, Papia T.
APPLICANT: Patience, Clive
APPLICANT: Andersson, Goran K.
TITLE OF INVENTION: Molecular Sequence of Swine Retrovirus and Methods of
Patent No. 6261806
FILE REFERENCE: 61750-267
CURRENT APPLICATION NUMBER: US/09/376,781
CURRENT FILING DATE: 1999-08-18
EARLIER APPLICATION NUMBER: 60/097,015
EARLIER FILING DATE: 1998-08-18
NUMBER OF SEQ ID NOS: 33
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 17
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:PCR reverse
OTHER INFORMATION: primer M13R.
US-09-376-781-17

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 362
US-09-381-849-8
Sequence 8, Application US/09381849
Patent No. 6265368
GENERAL INFORMATION:
APPLICANT: Ueyama, Hiroshi
APPLICANT: Abe, Kanako
APPLICANT: Keshi, Hiroyuki
APPLICANT: Matsuhisa, Akio
TITLE OF INVENTION: PROBES FOR THE DIAGNOSIS OF INFECTIONS

CAUSED BY BACTERIOIDES FRAGILIS

NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 233 South Wacker Drive/6300 Sears Tower
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/381,849
FILING DATE: 11-Jan-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 1997-71079
FILING DATE: 25-MAR-1997
APPLICATION NUMBER: PCT/JP98/01287
FILING DATE: 23-MAR-1998

ATTORNEY/AGENT INFORMATION:
NAME: Cawley, Jr., Thomas A.
REGISTRATION NUMBER: 40,944
REFERENCE/DOCKET NUMBER: 19036/35275
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic DNA"

US-09-381,849-8
SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 363
US-09-397-766-30
Sequence 30, Application US/09397766
Patent No. 6268144
GENERAL INFORMATION:
APPLICANT: K ster, Hubert
TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Heller Ehrman White & McCauliffe
STREET: 4250 Executive Square, 7th Floor
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/397,766
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-20021
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-587-5360
TELEFAX: 619-450-8400
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA

US-09-397-766-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 364
US-09-287-681-30
Sequence 30, Application US/09287681
Patent No. 6277573
GENERAL INFORMATION:
APPLICANT: K ster, Hubert
TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Heller Ehrman White & McCauliffe
STREET: 4250 Executive Square, 7th Floor
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/287,681
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2002F
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-587-5360
TELEFAX: 619-450-8400
TELECOMMUNICATION INFORMATION:

```

; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-09-287-681-30

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17

RESULT 365
US-09-302-682-8
; Sequence 8, Application US/09302682
; Patent No. 6291172
; GENERAL INFORMATION:
; APPLICANT: Davis, Robert E.
; APPLICANT: Herinstad, Corinna
; TITLE OF INVENTION: DIAGNOSTIC ASSAY FOR DIABETES MELLITUS
; TITLE OF INVENTION: BASED ON MUTATIONAL BURDEN
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/302,682
; FILING DATE: 30-APR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Rosenman, Stephen J.
; REGISTRATION NUMBER: 43,058
; REFERENCE/DOCKET NUMBER: 660088.406C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-09-302-682-8

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17

RESULT 366
US-09-495-444-30
; Sequence 30, Application US/09495444
```

```

; Patent No. 6300076
; GENERAL INFORMATION:
; APPLICANT: X ster, Hubert
; TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Heller Ehtman White & McAlliffe
; STREET: 4250 Executive Square, 7th Floor
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037-9103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/495,444
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/617,256
; FILING DATE: 18-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/406,199
; FILING DATE: 03-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Seidman, Stephanie L.
; REGISTRATION NUMBER: 33,779
; REFERENCE/DOCKET NUMBER: 24736-2002H
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 858-450-8400
; TELEFAX: 858-587-5360
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-09-495-444-30

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAAACGCTATGAC 17

RESULT 367
US-09-635-747-36
; Sequence 36, Application US/09635747
; Patent No. 6319673
; GENERAL INFORMATION:
; APPLICANT: Beck, James J.
; APPLICANT: Barnett, Jason
; TITLE OF INVENTION: PCR-BASED DETECTION AND QUANTIFICATION OF TAPEZIA
; FILE REFERENCE: PB/5-31084A
; CURRENT APPLICATION NUMBER: US/09/635,747
; CURRENT FILING DATE: 2000-08-10
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:reverse
; OTHER INFORMATION: Sequencing primer
```

US-09-635-747-36

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

DB 1 CAGGAACGCTATGAC 17

RESULT 368

US-09-479-128-21
Sequence 21, Application US/09479128
Patent No. 6319710
GENERAL INFORMATION:
APPLICANT: Berglund Ran Olofsdotter
APPLICANT: Jeffrey Gulcher
TITLE OF INVENTION: HUMAN NARCOLEPSY GENE
FILE REFERENCE: 2345.1005-001
CURRENT APPLICATION NUMBER: US/09/479,128
CURRENT FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 09/379,083
PRIOR FILING DATE: 1999-08-23
NUMBER OF SEQ ID NOS: 22
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO: 21
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: nucleic acid primers
US-09-479-128-21

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

DB 1 CAGGAACGCTATGAC 17

RESULT 369

US-08-584-040-7308
Sequence 7308, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Marburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7308:

SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7308

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1104 AGAGGCTTAAACAGC 1120

DB 1 AGAGGCTTAAACAGC 17

RESULT 370

US-08-584-040-7309
Sequence 7309, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Marburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7309:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7309

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1105 GAGGCTTAAACAGCA 1121
DB 1 GAGGCTUUAANAGCA 17

RESULT 371
US-08-584-040-7491
Sequence 7491, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7491:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7491

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.3e+02;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 3904 TACTCATGACTCTGAA 3920
DB 1 UACUCCAUCAUCUCUGAA 17

RESULT 372
US-08-679-645-749
Sequence 749, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
TITLE OF INVENTION: IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 749:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-749

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 603 CATGCGCTGTGATGAGA 619
DB 1 CAUCCGCTUCAGAUAGAA 17

RESULT 373
US-09-557-034-49
Sequence 49, Application US/09557034
Patent No. 6365569
GENERAL INFORMATION:
APPLICANT: Tang, Liang
Blehm, E. Scot
TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN
PROTEINS, NUCLEIC ACID MOLECULES, AND
USES THEREOF
NUMBER OF SEQUENCES: 171
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carol Talkington Verser, Ph.D.
STREET: 1825 Sharp Point Drive
CITY: Fort Collins
STATE: Colorado
COUNTRY: USA
ZIP: 80525
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: WordPerfect for Windows, Version 7.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/557, 034
FILING DATE: 21-Apr-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/065,474
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Verser, Carol Talkington
REGISTRATION NUMBER: 37,459
REFERENCE/DOCKET NUMBER: HW-5-C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 970/493-7272
TELEFAX: 970/484-9505
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: primer
SEQUENCE DESCRIPTION: SEQ ID NO: 49:
US-09-557-034-49
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17
RESULT 374
US-09-540-014-19
Sequence 19, Application US/09540014
Patent No. 6380372
GENERAL INFORMATION:
APPLICANT: Cho, Myeong-Je
APPLICANT: Del Val, Greg
APPLICANT: Caillau, Maxime
APPLICANT: Lemauz, Peggy G.
APPLICANT: Buchanan, Bob B.
TITLE OF INVENTION: Barley Gene for Thioredoxin and
TITLE OF INVENTION: NADP-Thioredoxin Reductase
FILE REFERENCE: 2001-0701.30
CURRENT APPLICATION NUMBER: US/09/540,014
CURRENT FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: US 60/127,198

PRIOR FILING DATE: 1999-03-31
PRIOR APPLICATION NUMBER: US 60/169,162
PRIOR FILING DATE: 1999-12-06
PRIOR APPLICATION NUMBER: US 60/177,740
PRIOR FILING DATE: 2000-01-21
PRIOR APPLICATION NUMBER: US 60/177,739
PRIOR FILING DATE: 2000-01-21
NUMBER OF SEQ ID NOS: 51
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 19
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: primer
US-09-540-014-19
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17
RESULT 375
US-09-710-481-25
Sequence 25, Application US/09710481
Patent No. 6383760
GENERAL INFORMATION:
APPLICANT: Weng, Zhigang.
Witte, Owen N.
TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED
RECEPTOR
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson & Bear
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: CA
COUNTRY: U.S.A.
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/710,481
FILING DATE: 09-NO. 6383760-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/120,025
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Bartfield, Neil S
REGISTRATION NUMBER: 39,901
REFERENCE/DOCKET NUMBER: UCLA015.001CP1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-710-481-25
Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

DB 1 CAGGAAACAGCTATGAC 17

RESULT 376

US-09-710-481-38
Sequence 38, Application US/09710481

Patent No. 6383760

GENERAL INFORMATION:

APPLICANT: Weng, Zhigang,
Mitte, Owen N.

TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED
RECEPTOR

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESS:

ADDRESSEE: Knobbe, Martens, Olson & Bear

STREET: 620 Newport Center Drive, 16th Floor

CITY: Newport Beach

STATE: CA

COUNTRY: U.S.A.

ZIP: 92660

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/710,481

FILING DATE: 09-NO. 6383760-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/120,025

FILING DATE: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Bartfeld, Neil S

REGISTRATION NUMBER: 39,901

REFERENCE/DOCKET NUMBER: UCLAD15.001CPI

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-235-8550

TELEFAX: 619-235-0176

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 38:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 38:

US-09-710-481-38

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

DB 1 CAGGAAACAGCTATGAC 17

RESULT 377

US-09-368-588-4

Sequence 4, Application US/09368588

Patent No. 6387683

GENERAL INFORMATION:

APPLICANT: ISHII, NOBUYOSHI

APPLICANT: SUZUKI, YASUO

APPLICANT: UCHIDA, KOJI

APPLICANT: MATSUO, YUSHI

APPLICANT: TANAKA, HIDEO

TITLE OF INVENTION: RECOMBENANT YEAST PDI AND PROCESS FOR PRODUCTION THEREOF

FILE REFERENCE: 159-52

CURRENT APPLICATION NUMBER: US/09/368,588

CURRENT FILING DATE: 1999-08-05

PRIOR APPLICATION NUMBER: PCT/JP98/00498

PRIOR FILING DATE: 1998-02-06

PRIOR APPLICATION NUMBER: JP 38588/1997

PRIOR FILING DATE: 1997-02-07

NUMBER OF SEQ ID NOS: 12

SOFTWARE: Patent In Ver. 2.0

SEQ ID NO 4

LENGTH: 17

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer

US-09-368-588-4

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

DB 1 CAGGAAACAGCTATGAC 17

RESULT 378

US-09-426-290-24

Sequence 24, Application US/09426290

Patent No. 6410712

GENERAL INFORMATION:

APPLICANT: Berglund Ran Olafsdottir

APPLICANT: Jeffrey Gulcher

TITLE OF INVENTION: HUMAN NARCOLEPSY GENE

FILE REFERENCE: 2345.2001-000

CURRENT APPLICATION NUMBER: US/09/426,290

CURRENT FILING DATE: 1999-10-25

NUMBER OF SEQ ID NOS: 24

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 24

LENGTH: 17

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: nucleic acid primers

US-09-426-290-24

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

DB 1 CAGGAAACAGCTATGAC 17

RESULT 379

US-09-255-703-17

Sequence 17, Application US/09255703

Patent No. 6417334

GENERAL INFORMATION:

APPLICANT: MORTON, Halle

APPLICANT: CAVANAGH, Alice Christina

TITLE OF INVENTION: ANTAGONISTS TO CHAPERONIN 10

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109


```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/255,703
FILING DATE: 23-Feb-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/654,618
FILING DATE: 29-MAY-1996
ATTORNEY/AGENT INFORMATION:
NAME: SAXE, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 65064/110
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-255-703-17

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      1 CAGGAAACAGCTATGAC 17

RESULT 380
US-08-744-481A-19
Sequence 19, Application US/08744481A
Patent No. 6428955
GENERAL INFORMATION:
APPLICANT: K ster, Hubert
TITLE OF INVENTION: DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY
NUMBER OF SEQUENCES: 55
CORRESPONDENCE ADDRESS:
ADDRESSEE: HELLER EHRMAN WHITE & MCAULIFFE
STREET: 4250 Executive Square, Suite 700
CITY: La Jolla
STATE: California
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/744,481A
FILING DATE: No. 6428955 September 6, 1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/617,256
FILING DATE: March 18, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 450-8400
TELEFAX: (617) 587-5360
INFORMATION FOR SEQ ID NO: 19:
```

```
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-744-481A-19

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      1 CAGGAAACAGCTATGAC 17

RESULT 381
US-09-367-293-16
Sequence 16, Application US/09367293
Patent No. 6444878
GENERAL INFORMATION:
APPLICANT: Donaldson, Iain A.
APPLICANT: Bojlsen, Kirsten
APPLICANT: Jorgensen, Kirsten
APPLICANT: Jorboe, Morten
TITLE OF INVENTION: SELECTION METHOD FOR TRANSGENIC PLANTS
FILE REFERENCE: DYOU21.001APC
CURRENT APPLICATION NUMBER: US/09/367,293
CURRENT FILING DATE: 1999-12-23
PRIOR APPLICATION NUMBER: PCT/GB98/00367
PRIOR FILING DATE: 1998-02-05
PRIOR APPLICATION NUMBER: GB 9702592.8
PRIOR FILING DATE: 1997-02-07
NUMBER OF SEQ ID NOS: 23
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 16
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Sequencing Primer, 5'fluorescein labelled.
US-09-367-293-16

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      1 CAGGAAACAGCTATGAC 17

RESULT 382
US-09-612-204B-26
Sequence 26, Application US/09612204B
Patent No. 6461811
GENERAL INFORMATION:
APPLICANT: Patience, Clive
TITLE OF INVENTION: Swine Gamma Herpesvirus DNA and Methods of Use
FILE REFERENCE: 61750-299
CURRENT APPLICATION NUMBER: US/09/612,204B
CURRENT FILING DATE: 2001-08-13
PRIOR APPLICATION NUMBER: U.S. 60/142,736
PRIOR FILING DATE: 1999-07-08
PRIOR APPLICATION NUMBER: U.S. 60/168,532
PRIOR FILING DATE: 1999-12-02
NUMBER OF SEQ ID NOS: 36
SOFTWARE: Patent in Ver. 2.1
SEQ ID NO 26
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
```

FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: M13 reverse
OTHER INFORMATION: sequencing primer for TOPO-pCRII: bases 205-222
US-09-612-204B-26

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 383
US-09-463-238-17
Sequence 17, Application US/09463238
Patent No. 6469230
GENERAL INFORMATION:
APPLICANT: Edwards, Elizabeth A
APPLICANT: Smith, Alison M
APPLICANT: Bustos Guillen, Regla
APPLICANT: Martin, Catherine R
TITLE OF INVENTION: Starch Debranching Enzymes
FILE REFERENCE: 97.118
CURRENT APPLICATION NUMBER: US/09/463,238
CURRENT FILING DATE: 2000-01-21
PRIOR APPLICATION NUMBER: PCT/GB98/02280
PRIOR FILING DATE: 1998-07-30
PRIOR APPLICATION NUMBER: GB 9716185.5
PRIOR FILING DATE: 1997-07-31
NUMBER OF SEQ ID NOS: 30
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 17
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Reverse primer
US-09-463-238-17

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 384
US-09-464-122A-10
Sequence 10, Application US/09464122A
Patent No. 6469103
GENERAL INFORMATION:
APPLICANT: MEDICAL RESEARCH COUNCIL
TITLE OF INVENTION: IN VITRO SORTING METHOD
FILE REFERENCE: 18396/1080
CURRENT APPLICATION NUMBER: US/09/464,122A
CURRENT FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/GB98/01889
PRIOR FILING DATE: 1998-06-29
PRIOR APPLICATION NUMBER: GB 97/14300.2
PRIOR FILING DATE: 1997-07-07
PRIOR APPLICATION NUMBER: GB 98/06393.6
PRIOR FILING DATE: 1998-03-25
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PatentIn version 3.1
SEQ ID NO 10
LENGTH: 17.
TYPE: DNA
ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide
US-09-464-122A-10

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 385
US-09-464-122A-16
Sequence 16, Application US/09464122A
Patent No. 6469103
GENERAL INFORMATION:
APPLICANT: MEDICAL RESEARCH COUNCIL
TITLE OF INVENTION: IN VITRO SORTING METHOD
FILE REFERENCE: 18396/1080
CURRENT APPLICATION NUMBER: US/09/464,122A
CURRENT FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/GB98/01889
PRIOR FILING DATE: 1998-06-29
PRIOR APPLICATION NUMBER: GB 97/14300.2
PRIOR FILING DATE: 1997-07-07
PRIOR APPLICATION NUMBER: GB 98/06393.6
PRIOR FILING DATE: 1998-03-25
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PatentIn version 3.1
SEQ ID NO 16
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide
US-09-464-122A-16

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 386
US-09-146-979-85
Sequence 85, Application US/09146979
Patent No. 6492123
GENERAL INFORMATION:
APPLICANT: Holliger, Kaspar-Philipp
APPLICANT: Griffiths, Andrew D
APPLICANT: Hoogenboom, Hendricus RUM
APPLICANT: Malmqvist, Magnus
APPLICANT: Marks, James D
APPLICANT: McGuinness, Brian T
APPLICANT: Pope, Anthony R
APPLICANT: Prospero, Terence D
APPLICANT: Winter, Gregory P
TITLE OF INVENTION: Multivalent and Multispecific Binding
TITLE OF INVENTION: Proteins, Their Manufacture and Use
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall O'Toole Gerstein Murray and Borun
STREET: 6300 Sears Tower 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/146,979
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/448,418
FILING DATE: 14-MAY-1996
APPLICATION NUMBER: PCT/GB93/02492
FILING DATE: 03-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9225453.1
FILING DATE: 04-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9300816.7
FILING DATE: 16-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93303614.7
FILING DATE: 10-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9319969.3
FILING DATE: 22-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32651
INFORMATION FOR SEQ ID NO: 85:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA primer
US-09-146-979-85

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
Db 1 CAGGAACGCTATGAC 17

RESULT 387
US-09-104-337A-113
Sequence 113, Application US/09104337A
Patent No. 6492160
GENERAL INFORMATION:
APPLICANT: Winter, Gregory Paul
Griffiths, Andrew David
Williams, Samuel Cameron
Waterhouse, Peter
Nissim, Ahuva
Johnson, Kevin Stuart
Smith, Andrew John Hammond
TITLE OF INVENTION: Methods for producing members of specific binding pairs
NUMBER OF SEQUENCES: 600
CORRESPONDENCE ADDRESS:
ADDRESSEE: Audrey L. Bartnicki
STREET: Marshall, Gerstein & Borun
6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/104,337A
FILING DATE: 25-Jun-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/350,260
FILING DATE: 05-DEC-1994
APPLICATION NUMBER: GB 9110549.4
FILING DATE: 15-MAY-1991
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
APPLICATION NUMBER: US 08/150,002
FILING DATE: 31-MAR-1994
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Bartnicki, Audrey L.
REGISTRATION NUMBER: 40,499
REFERENCE/DOCKET NUMBER: 28111/32372A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 113:
US-09-104-337A-113

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
Db 1 CAGGAACGCTATGAC 17

RESULT 388
US-09-104-337A-302
Sequence 302, Application US/09104337A
Patent No. 6492160
GENERAL INFORMATION:
APPLICANT: Winter, Gregory Paul
Griffiths, Andrew David
Williams, Samuel Cameron
Waterhouse, Peter
Nissim, Ahuva
Johnson, Kevin Stuart
Smith, Andrew John Hammond
TITLE OF INVENTION: Methods for producing members of specific binding pairs
NUMBER OF SEQUENCES: 600
CORRESPONDENCE ADDRESS:
ADDRESSEE: Audrey L. Bartnicki
STREET: Marshall, Gerstein & Borun
6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/104,337A
FILING DATE: 25-Jun-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/350,260
FILING DATE: 05-DEC-1994
APPLICATION NUMBER: GB 9110549.4
FILING DATE: 15-MAY-1991
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
APPLICATION NUMBER: US 08/150,002
FILING DATE: 31-MAR-1994
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Bartnicki, Audrey L.
REGISTRATION NUMBER: 40,499
REFERENCE/DOCKET NUMBER: 28111/32372A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 302:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 302:
US-09-104-337A-302

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 389
US-09-699-931-6
Sequence 6, Application US/09699931
Patent No. 6495673
GENERAL INFORMATION:
APPLICANT: Neri, Dario
APPLICANT: Demattis, Salvatore
APPLICANT: Huber, Adrian
APPLICANT: Viti, Francesca
APPLICANT: Tawfik, Dan. S.
APPLICANT: Winter, Gregory Paul
TITLE OF INVENTION: Isolation of Enzymes
FILE REFERENCE: 2224/08665
CURRENT APPLICATION NUMBER: US/09/699,931
CURRENT FILING DATE: 2000-10-30
PRIOR APPLICATION NUMBER: US/09/142,355
PRIOR FILING DATE: 1998-09-04
PRIOR APPLICATION NUMBER: GB 9608540.2
PRIOR FILING DATE: 1996-04-25
PRIOR APPLICATION NUMBER: PCT/GB97/01153
PRIOR FILING DATE: 1997-04-25
NUMBER OF SEQ ID NOS: 24
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 6
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer
US-09-699-931-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 390
US-09-207-388-34
Sequence 34, Application US/09207388
Patent No. 6497880
GENERAL INFORMATION:
APPLICANT: Wisniewski, Jan
TITLE OF INVENTION: HEAT SHOCK GENES AND PROTEINS FROM
TITLE OF INVENTION: NEISSERIA MENINGITIDIS, CANDIDA GLABRATA AND ASPERGILLUS
FILE REFERENCE: 870109.411
CURRENT APPLICATION NUMBER: US/09/207,388
CURRENT FILING DATE: 1998-12-08
NUMBER OF SEQ ID NOS: 102
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 34
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer used to clone Neisseria meningitidis Hsp70
OTHER INFORMATION: gene and to construct Neisseria meningitidis Hsp70
OTHER INFORMATION: expression vectors
US-09-207-388-34

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 391
US-09-796-416-30
Sequence 30, Application US/09796416
Patent No. 6500621
GENERAL INFORMATION:
APPLICANT: K"ster, Hubert
TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSER: Heller Ehrman White & McNuliffe LLP
STREET: 4250 Executive Square, 7th Floor
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Releasee #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/796,416
FILING DATE: 28-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/504,245
FILING DATE: 15-FEB-2000
APPLICATION NUMBER: 09/495,444
FILING DATE: 31-JAN-2000
APPLICATION NUMBER: 09/287,679
FILING DATE: 06-APR-1999
APPLICATION NUMBER: 08/617,256

;; FILING DATE: 18-MAR-1996
;; APPLICATION NUMBER: 08/406,199
;; FILING DATE: 03-MAR-1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Seidman, Stephanie L
;; REGISTRATION NUMBER: 33,779
;; REFERENCE/DOCKET NUMBER: 24736-2002L
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 858-450-8400
;; TELEFAX: 858-587-5360
;; INFORMATION FOR SEQ ID NO: 30:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
;; SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-09-796-416-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 392
US-09-315-574-110
;; Sequence 110, Application US/09315574
;; Patent No. 6512097
;; GENERAL INFORMATION:
;; APPLICANT: Marks, James D.
;; APPLICANT: Schier, Robert
;; TITLE OF INVENTION: No. 6512097el High Affinity Human Antibodies to
;; TITLE OF INVENTION: Tumor Antigens
;; NUMBER OF SEQUENCES: 141
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Majestic, Parsons, Siebert & Haue P.C.
;; STREET: Four Embarcadero Center, Suite 1100
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: USA
;; ZIP: 94111-4106
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Releasee #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/315,574
;; FILING DATE: 20-MAY-99
;; CLASSIFICATION: 530
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 60/000,238
;; FILING DATE: 14-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 60/000,250
;; FILING DATE: 15-JUN-1995
;; APPLICATION NUMBER: US 08/665,202
;; FILING DATE: 13-JUN-1996
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Hunter, Tom
;; REGISTRATION NUMBER: 38,498
;; REFERENCE/DOCKET NUMBER: 02307E-061411
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 576-0200
;; TELEFAX: (415) 576-0300
;; INFORMATION FOR SEQ ID NO: 110:
;; SEQUENCE CHARACTERISTICS:

;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-09-315-574-110

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 393
US-09-553-875-25
;; Sequence 25, Application US/09553875
;; Patent No. 6514696
;; GENERAL INFORMATION:
;; APPLICANT: Weng, Zhigang.
;; APPLICANT: Witte, Owen N.
;; TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED
;; RECEPTOR
;; NUMBER OF SEQUENCES: 40
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Knobbe, Martens, Olson & Bear
;; STREET: 620 Newport Center Drive, 16th Floor
;; CITY: Newport Beach
;; STATE: CA
;; COUNTRY: U.S.A.
;; ZIP: 92660
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: DOS
;; SOFTWARE: FastSeq for Windows Version 2.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/553,875
;; FILING DATE: 20-Apr-2000
;; APPLICATION DATA:
;; APPLICATION NUMBER: US/09/120,025
;; FILING DATE: 17-JUL-1998
;; APPLICATION NUMBER: 08/969,815
;; FILING DATE: 13-NOV-1997
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Bartfeld, Neil S
;; REGISTRATION NUMBER: 39,901
;; REFERENCE/DOCKET NUMBER: UCL015,001CPL
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619-235-8550
;; TELEFAX: 619-235-0176
;; TELEX: <Unknown>
;; INFORMATION FOR SEQ ID NO: 25:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-553-875-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 394

US-09-553-875-38
; Sequence 38, Application US/09553875
; Patent No. 6514696
; GENERAL INFORMATION:
; APPLICANT: Meng, Zhigang.
; Witte, Owen N.
; TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED
; RECEPTOR
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/553,875
; FILING DATE: 20-Apr-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/120,025
; FILING DATE: 17-JUL-1998
; APPLICATION NUMBER: 08/969,815
; FILING DATE: 13-NOV-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfeld, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: UCL015.001CPI
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 38:
US-09-553-875-38
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17
RESULT 395
US-09-474-432B-508
; Sequence 508, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Belgelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866

; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 508
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-508
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1830 CACGCCAGTGCCTGAG 1846
DB 1 CAGCCCTGCGCCGAG 17
RESULT 396
US-09-474-432B-542/C
; Sequence 542, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Belgelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 542
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-542
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1864 AATTCAGCCCACTC 1880
DB 17 AATTCAGACCACTC 1
RESULT 397
US-09-722-825-28
; Sequence 28, Application US/09722825
; Patent No. 6531306
; GENERAL INFORMATION:
; APPLICANT: Hockensmith, Joel W.
; Muthuwami, Rohini

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TARGETING DNA METABOLIC PROCESSES USING
AMINOGLYCOSIDE DERIVATIVES

NUMBER OF SEQUENCES: 66

CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036-2711

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 2.0

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/722,825
FILING DATE: 28-NO. 6531306-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/179,558
FILING DATE: 31-OCT-1997

ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 9426-005-999

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)7909090
TELEFAX: (212)8699741
TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other
SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-722-825-28

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 398
US-09-722-487-28
Sequence 28, Application US/09722487
Patent No. 6537791

GENERAL INFORMATION:
APPLICANT: Hockensmith, Joel W.
Muchuswami, Rohini
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TARGETING DNA METABOLIC PROCESSES USING
AMINOGLYCOSIDE DERIVATIVES

NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036-2711

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 2.0

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/722,487
FILING DATE: 28-NO. 6537791-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/179,558
FILING DATE: 31-OCT-1997

ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 9426-005-999

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)7909090
TELEFAX: (212)8699741
TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other
SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-722-487-28

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 399
US-09-893-055-8
Sequence 8, Application US/09893055
Patent No. 6544745

GENERAL INFORMATION:
APPLICANT: Davis, Robert E.
Herrnstadt, Corinna
TITLE OF INVENTION: DIAGNOSTIC ASSAY FOR DIABETES MELLITUS
BASED ON MUTATIONAL BURDEN

NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/893,055
FILING DATE: 27-Jun-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/302,682
FILING DATE: <Unknown>

ATTORNEY/AGENT INFORMATION:
NAME: Roseman, Stephen J
REGISTRATION NUMBER: 43,058
REFERENCE/DOCKET NUMBER: 660088, 406C2

TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-893-055-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 400

US-09-501-612A-9
Sequence 9, Application US/09501612A
Patent No. 6544765

GENERAL INFORMATION:

APPLICANT: Hjort, Carsten M.

APPLICANT: Pedersen, Henrik

TITLE OF INVENTION: Oxaloacetate Hydrolase Deficient Fungal Host Cells

FILE REFERENCE: 5789.200-US

CURRENT APPLICATION NUMBER: US/09/501, 612A

CURRENT FILING DATE: 2000-02-10

NUMBER OF SEQ ID NOS: 33

SOFTWARE: PatentIn version 3.1

SEQ ID NO 9

LENGTH: 17

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Primer

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 401

US-09-303-040-43
Sequence 43, Application US/09303040
Patent No. 6555671

GENERAL INFORMATION:

APPLICANT: Winslow, Barbara J.

APPLICANT: Cochran, Mark D.

TITLE OF INVENTION: Recombinant Virus Expressing Foreign DNA Encoding

FILE REFERENCE: Feline CD80, Feline CD86, Feline CD28, Feline CTLA-4 or

CURRENT APPLICATION NUMBER: US/09/303, 040

CURRENT FILING DATE: 1999-04-30

EARLIER APPLICATION NUMBER: 60/063, 870

NUMBER OF SEQ ID NOS: 82

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 43

LENGTH: 17

TYPE: DNA

ORGANISM: feline CD80 primer

US-09-303-040-43

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 402

US-09-371-772B-3117
Sequence 3117, Application US/09371772B
Patent No. 6566127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

FILE REFERENCE: MEHB00, 876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371, 772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005, 974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584, 040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3117

LENGTH: 17

TYPE: RNA

ORGANISM: Mus sp.

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1104 AGAGGCTTAACAGC 1120
DB 1 AGAGGCTTAACAGC 17

RESULT 403

US-09-371-772B-3118
Sequence 3118, Application US/09371772B
Patent No. 6566127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

FILE REFERENCE: MEHB00, 876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371, 772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005, 974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584, 040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3118

LENGTH: 17

TYPE: RNA

ORGANISM: Mus sp.

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;

Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1105 GAGGCTTAAAGCA 1121
|||:::|
Db 1 GAGGCUUUAUAGCA 17

RESULT 404
US-09-371-772B-3297
; Sequence 3297, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH80, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3297
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3297

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3904 TACTTCATGCTCTGAA 3920
:::|:::|
Db 1 UACUCCAUCCACUCUGAA 17

RESULT 405
US-09-371-772B-4385
; Sequence 4385, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH80, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4385

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 3581 CCCATGCATCATCTTC 3597
|||:::|
Db 1 CCCAUGCACACAUUUC 17

RESULT 406
US-09-371-772B-5374/C
; Sequence 5374, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH80, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5374
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5374

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 477 GAATGCTGCTGACAG 493
|||:::|
Db 17 GAATGCTGATGACG 1

RESULT 407
US-09-768-670-25
; Sequence 25, Application US/09768670
; Patent No. 6568995
; GENERAL INFORMATION:
; APPLICANT: Witte, Owen N.
; APPLICANT: Meng, Zhigang
; TITLE OF INVENTION: IDENTIFICATION OF A G PROTEIN-COUPLED RECEPTOR TRANSCRIPTIONALLY REGULATED BY PROTEIN TYROSINE KINASE SIGNALING IN HEMATOPOIETIC CELLS
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for windows version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/768,670
; FILING DATE: 23-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/969,815
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:

NAME: Bartfeld, Neil S
REGISTRATION NUMBER: 39,901
REFERENCE/DOCKET NUMBER: UCLA015.001A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-768-670-25

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAAACAGCTATGAC 17

Db 1 CAGGAAACAGCTATGAC 17

RESULT 408
US-09-768-670-38
Sequence 38, Application US/09768670
Patent No. 656995
GENERAL INFORMATION:
APPLICANT: Witte, Owen N.
Weng, Zhigang
TITLE OF INVENTION: IDENTIFICATION OF A G PROTEIN-COUPLED
RECEPTOR TRANSCRIPTIONALLY REGULATED BY PROTEIN
TYROSINE KINASE SIGNALING IN HEMATOPOIETIC CELLS
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson & Bear
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: CA
COUNTRY: U.S.A.
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/768,670
FILING DATE: 23-Jan-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/969,815
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Bartfeld, Neil S
REGISTRATION NUMBER: 39,901
REFERENCE/DOCKET NUMBER: UCLA015.001A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 38:
US-09-768-670-38

Query Match 0.3%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAAACAGCTATGAC 17

Db 1 CAGGAAACAGCTATGAC 17

RESULT 409
US-09-722-708-28
Sequence 28, Application US/09722708
Patent No. 6573060
GENERAL INFORMATION:
APPLICANT: Hockensmith, Joel W.
Muthuswami, Rohini
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TARGETING DNA METABOLIC PROCESSES USING
AMINOGLYCOSIDE DERIVATIVES
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/722,708
FILING DATE: 28-No. 6573060-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/179,558
FILING DATE: <Unknown>
APPLICATION NUMBER: U.S. 60/063,898
FILING DATE: 31-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Cotruzzi, Laura A
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 9426-005-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)7909090
TELEFAX: (212)869741
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other
SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-722-708-28

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAAACAGCTATGAC 17

Db 1 CAGGAAACAGCTATGAC 17

RESULT 410
US-09-879-341-30
Sequence 30, Application US/09879341
Patent No. 6589485
GENERAL INFORMATION:
APPLICANT: Keler, Hubert

TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Heller Ehrman White & McAnuliffe LLP
STREET: 4350 La Jolla Village Drive
CITY: San Diego
STATE: CA
COUNTRY: USA
ZIP: 92122-1246
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA: US/09/879,341
APPLICATION NUMBER: US/09/879,341
FILING DATE: 11-Jun-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/786,416
FILING DATE: 28-FEB-2001
APPLICATION NUMBER: 09/287,679
FILING DATE: 06-APR-1999
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2002M
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)227-5941
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-09-879-341-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 411
US-08-621-038-12
Sequence 12, Application US/08621038
Patent No. 6589527
GENERAL INFORMATION:
APPLICANT: Winter, Gregory P
APPLICANT: Holliger, Kaspar P
TITLE OF INVENTION: Retargeting Antibodies
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (SPO)
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/621,038
FILING DATE: 22-MAR-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB94/02019
FILING DATE: 16-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9319969.3
FILING DATE: 22-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9412166.2
FILING DATE: 17-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/02492
FILING DATE: 03-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-621-038-12

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 412
US-09-724-877-30
Sequence 30, Application US/09724877
Patent No. 6602662
GENERAL INFORMATION:
APPLICANT: Koester, Hubert
APPLICANT: Little, Daniel P.
Braun, Andreas
TITLE OF INVENTION: DNA Diagnostics Based on Mass Spectrometry
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Heller Ehrman White & McAnuliffe LLP
STREET: 4250 Executive Square, 7th Floor
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037-9103
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/724,877
FILING DATE: 28-NOV-6602662-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/287,679
FILING DATE: 06-APR-1999
APPLICATION NUMBER: 08/617,256
FILING DATE: 18-MAR-1996
APPLICATION NUMBER: 08/406,199
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 24736-2002K

```

;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 30:
;
; US-09-724-877-30
;
Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGACACGCTATGAC 3543
DB      1 CAGGAACAGCTATGAC 17

RESULT 413
US-09-476-387-507
; Sequence 507, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beauty, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,432
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 507
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-476-387-507
;
Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1830 CACGCCAGTCCCGCAG 1846
DB      1 CAGCCCGUUGCCCGAG 17

RESULT 414
US-09-476-387-541/c
; Sequence 541, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beauty, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,432
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-476-387-541
;
Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1864 AATTGACACCACTTC 1880
DB      17 AATTGACACCACTTC 17

RESULT 415
US-09-401-063-3
; Sequence 3, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
```

```

; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-476-387-541
;
Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1864 AATTGACACCACTTC 1880
DB      17 AATTGACACCACTTC 17

RESULT 415
US-09-401-063-3
; Sequence 3, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
```

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-401-063-3

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.3e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3790 GGGCACCCTGACGGGT 3806
DB 1 GGGCACCCTGACGGGT 17

RESULT 416
US-09-401-063-331/C
Sequence 331, Application US/09401063
Patent No. 6623962
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/401,063
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/985,162
FILING DATE: 04 December 1997
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 331:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-401-063-331

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGGCTCCAGAGGTATC 606
DB 17 TGGATCCAAAGTATC 1

RESULT 417
US-09-084-303B-171
Sequence 171, Application US/09084303B
Patent No. 6627746
GENERAL INFORMATION:
APPLICANT: Doberstein, Stephen
APPLICANT: Reddy, Bindu
APPLICANT: Platt, Darren
APPLICANT: Ferguson, Kimberly
TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS OF C. ELEGANS INSULIN-LIKE GENES AND US
TITLE OF INVENTION: THEREOF
FILE REFERENCE: 7326-069-999
CURRENT APPLICATION NUMBER: US/09/084,303B
CURRENT FILING DATE: 1998-05-26
NUMBER OF SEQ ID NOS: 302
SOFTWARE: PatentIn version 3.1
SEQ ID NO 171
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-09-084-303B-171

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGAAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 418
US-09-504-262D-54
Sequence 54, Application US/09504262D
Patent No. 6642007
GENERAL INFORMATION:
APPLICANT: Pfizer Inc.
APPLICANT: Saltarelli, Mary J.
APPLICANT: Johnson, Kimberly S.
TITLE OF INVENTION: Assays for Measurement of Type II Collagen Fragments in Urine
FILE REFERENCE: PC10189GPR - CIP of PC9946A
CURRENT APPLICATION NUMBER: US/09/504,262D
CURRENT FILING DATE: 2000-02-15
NUMBER OF SEQ ID NOS: 70
SOFTWARE: PatentIn version 3.1
SEQ ID NO 54
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: sequencing primer
NAME/KEY: misc feature
OTHER INFORMATION: Description of Artificial Sequence: Sequencing oligonucleotide.
US-09-504-262D-54

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 419

US-09-939-379B-6
; Sequence 6, Application US/09939379B
; Patent No. 6645720
; GENERAL INFORMATION:
; APPLICANT: Syngenta Biotechnology Inc.
; APPLICANT: Barnett, Charles Jason
; APPLICANT: Beck, Jim
; TITLE OF INVENTION: Detection of Almond Pathogens Using the Polymerase Chain Reaction
; FILE REFERENCE: 60063P1
; CURRENT APPLICATION NUMBER: US/09/939,379B
; CURRENT FILING DATE: 2002-04-08
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1) .. (17)
; OTHER INFORMATION: Primer REVERSE
US-09-939-379B-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 420

US-09-536-977-98
; Sequence 98, Application US/09536977
; Patent No. 6649409
; GENERAL INFORMATION:
; APPLICANT: FOMSGAARD, ANDERS
; TITLE OF INVENTION: METHOD FOR PRODUCING A NUCLEOTIDE SEQUENCE CONSTRUCT
; TITLE OF INVENTION: WITH OPTIMIZED CODONS FOR AN HIV GENETIC VACCINE BASED
; TITLE OF INVENTION: ON A PRIMARY, EARLY HIV ISOLATE AND SYNTHETIC ENVELOPE
; TITLE OF INVENTION: BX08 CONSTRUCTS
; FILE REFERENCE: 030307/0169
; CURRENT APPLICATION NUMBER: US/09/536,977
; CURRENT FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: 60/128,558
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: DK PA1999 00427
; PRIOR FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 98
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-536-977-98

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
Db 1 CAGGAACAGCTATGAC 17

RESULT 421
US-09-827-998-116/c
; Sequence 116, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDW0RF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 116
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-116

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 896 AGTCCGCATCCAGCTT 912
Db 17 AGTCCGCATCCAGCTT 1

RESULT 422

US-09-827-998-119/c
; Sequence 119, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDW0RF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 119
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-119

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 893 GGCAGTCCGATCCAG 909
Db 17 GGCAGTCCGATCCAG 1

RESULT 423

US-09-827-998-615/c
; Sequence 615, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:

```

; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMR-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecmica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 615
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-615

Query Match          0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1662 CCAGCCTCCCGCCAGGC 1678
DB      17 CTAAGCTCCCGCCAGGC 1

RESULT 424
US-08-809-254A-9
; Sequence 9, Application US/08809254A
; Patent No. 6660852
; GENERAL INFORMATION:
; APPLICANT: KISHI ET AL
; TITLE OF INVENTION: PROBE FOR DIAGNOSING INFECTIOUS DISEASES
; FILE REFERENCE: 19036/33767
; CURRENT APPLICATION NUMBER: US/08/809,254A
; CURRENT FILING DATE: 1997-05-16
; PRIOR APPLICATION NUMBER: PCT/JP95/02036
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: JP 236348
; PRIOR FILING DATE: 1994-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
; US-08-809-254A-9

Query Match          0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACGCTATGAC 3543
DB      1 CAGGAACAGCTATGAC 17

RESULT 425
US-09-377-986-2
; Sequence 2, Application US/09377986
; Patent No. 6673631
; GENERAL INFORMATION:
; APPLICANT: Terabe, Allan M.
; APPLICANT: Bitner, Rex M.
; APPLICANT: Koller, Susan C.
; APPLICANT: Smith, Craig E.
; APPLICANT: Kephart, Daniel D.
; APPLICANT: Ekenberg, Steven J.
; TITLE OF INVENTION: SIMULTANEOUS ISOLATION AND QUANTITATION OF DNA
```

```

; FILE REFERENCE: 16026-9043
; CURRENT APPLICATION NUMBER: US/09/377,986
; CURRENT FILING DATE: 1999-08-20
; PRIOR APPLICATION NUMBER: 08/785,097
; PRIOR FILING DATE: 1997-01-21
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Reverse
; US-09-377-986-2

Query Match          0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACGCTATGAC 3543
DB      1 CAGGAACAGCTATGAC 17

RESULT 426
US-09-912-935-46
; Sequence 46, Application US/09912935
; Patent No. 6673904
; GENERAL INFORMATION:
; APPLICANT: Nishikawa, Mitsuo et al.
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO STEM CELL GROWTH FACTOR-LIKE
; FILE REFERENCE: 32066/37483
; CURRENT APPLICATION NUMBER: US/09/912,935
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: PCT/US00/35260
; PRIOR FILING DATE: 2000-12-23
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 46
; LENGTH: 17
; TYPE: DNA
; ORGANISM: primer M13 Reverse
; US-09-912-935-46

Query Match          0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACGCTATGAC 3543
DB      1 CAGGAACAGCTATGAC 17

RESULT 427
US-09-647-468-5
; Sequence 5, Application US/09647468
; Patent No. 6677436
; GENERAL INFORMATION:
; APPLICANT: SATO, KOH
; APPLICANT: ADACHI, HIDEKI
; APPLICANT: YABUTA, NAOHITO
; TITLE OF INVENTION: HUMANIZED ANTIBODY AGAINST HUMAN TISSUE FACTOR (TF) AND
; FILE REFERENCE: 053466/0289
; CURRENT APPLICATION NUMBER: US/09/647,468
; CURRENT FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: PCT/JP99/01768
; PRIOR FILING DATE: 1999-04-02
; PRIOR APPLICATION NUMBER: JP 10-91850
; PRIOR FILING DATE: 1998-04-03
; NUMBER OF SEQ ID NOS: 183
```

SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 5
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: M13 Primer RV
US-09-647-468-5

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGACTATGAC 3543
DB 1 CAGGAACGACTATGAC 17

RESULT 428
US-09-866-108A-1655
Sequence 1655, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 1655
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-1655

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2067 GCAAGCGGCGCAGAC 2083
DB 1 GCAAGGAGGCGCAGAC 17

RESULT 429
US-09-866-108A-1877/c
Sequence 1877, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 1877
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-1877

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2677 GACGTGTCAGCCGAG 2693
DB 17 GACGTGTCAGCTGAG 1

RESULT 430
US-09-866-108A-1996/c
Sequence 1996, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26


```

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1996
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-1996

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1292 GGCTGAGACATCGCAG 1308
DB      17 GGCTGAGACATCGCAG 1

RESULT 431
; US-09-866-108A-2222/c
; Sequence 2222, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2222
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2222

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1804 GACCTGACATCCCGC 1820
DB      17 GACCTGACATCCCGC 1

RESULT 432
; US-09-866-108A-2327/c
; Sequence 2327, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2327
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2327

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2529 CAGCTGACATCCG 2545
DB      17 CAGCTGACATCCG 1
```

```
RESULT 433
US-09-866-108A-6413
; Sequence 6413, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6413
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6413

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      3127 CAGCAGATGATGTGCT 3143
DB      1 CTGCAGATGATGCGCT 17

RESULT 434
US-09-866-108A-6544/C
; Sequence 6544, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6544
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6544

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2215 CACCTCCCGCCAGCTGG 2231
DB      17 CACTGCCCGCCAGCTTG 1

RESULT 435
US-09-866-108A-7302
; Sequence 7302, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```

; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7302
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7302
```

```

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1582 AGACAAGATGAAACA 1598
Db      1 AGACAAGATGAAACA 17
```

```

RESULT 436
US-09-866-108A-7303
; Sequence 7303, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7303
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7303
```

```

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1583 GAACAAGATGAAACAAG 1599
Db      1 GAGCAAGCATGAACAAG 17
```

```

RESULT 437
US-09-866-108A-7670
; Sequence 7670, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7670
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7670
```

```

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      3244 GAAGTGAGAGAAGCA 3260
Db      1 GAGCTGAGAGAAGCA 17
```

```

RESULT 438
US-09-866-108A-7797
; Sequence 7797, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yongsang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
```

```

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmics Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7797
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7797

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1127 AGCTGCAGCAGCAGCAG 1143
Db      1 AGCTTCAGCAGCAGCTG 17

RESULT 439
US-09-866-108A-8004
; Sequence 8004, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmics Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8004
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8004

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1478 AGCAGCAGCAGCAGCTC 1494
Db      1 AGCAGCTGCAGCAGCTC 17

RESULT 440
US-09-866-108A-8005
; Sequence 8005, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmics Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8005
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8005

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1479 GCAGCAGCAGCAGCTCC 1495
Db      1 GCAGCTGCAGCAGCTCC 17
```

```
Db      1 GCAGTGCAGCAGCTCC 17

RESULT 441
US-09-866-108A-8076
; Sequence 8076; Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David K.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8076
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8076

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2444 GTGAGCAGCAGCAGCAG 2460
DB      1 GTGAGCAGCAGCAGCAG 17

RESULT 442
US-09-866-108A-8077
; Sequence 8077; Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8077
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8077

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2445 TGAGCAGCAGCAGCAG 2461
DB      1 TGAGCAGCAGCAGCAG 17

RESULT 443
US-09-866-108A-8078
; Sequence 8078; Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8078
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8078

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1201 GAGGACGAGGAGGAGA 1217
Db      1 GAGGACGAGGAGGAGA 17

RESULT 444
US-09-866-108A-8079
; Sequence 8079, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8079
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8079

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2447 AGGACGACGAGGAGGAGA 2463
```

```

Db      1 AGGACGACGAGGAGGAGA 17

RESULT 445
US-09-866-108A-8646
; Sequence 8646, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8646
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8646

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1115 AACGACGACGAGCTG 1131
Db      1 AACGACGACGAGCTG 17

RESULT 446
US-09-866-108A-8648/C
; Sequence 8648, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8648
```

```
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1400 TCCAGAGCAGCTGCAG 1416
Db 17 TCCAGCTGCAGCTGCAG 1

RESULT 447
US-09-866-108A-8651
; Sequence 8651, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8651
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8651
```

```
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Oy 1285 CAGCGCGGCTGAGGA 1301
Db 1 CAGCTGCAGCTGAGGA 17
```

```
RESULT 448
US-09-866-108A-8942
; Sequence 8942, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8942
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8942
```

```
Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1285 CAGCGCGCTGAGAGA 1301
DB 1 CAGCGCGCTGAGAGA 17

RESULT 449
US-09-866-108A-9536/c
Sequence 9536, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 9536
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-9536

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3246 AGTGAGAGAGAGCAGC 3262
DB 17 AGCGGAGAGAGAGCAGC 1

RESULT 450
US-09-866-108A-9539/c
Sequence 9539, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 9539
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-9539

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1497 GCCTGGGAGAGAGC 1513
DB 17 GCCAGGGAGAGAGC 1

RESULT 451
US-09-710-279-4472
Sequence 4472, Application US/09710279
Patent No. 6703492
GENERAL INFORMATION:
APPLICANT: KIMMERLY, WILLIAM JOHN
TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS
FILE REFERENCE: PUS480US
CURRENT APPLICATION NUMBER: US/09/710,279
CURRENT FILING DATE: 2000-11-09
PRIOR APPLICATION NUMBER: 60/164,258
PRIOR FILING DATE: 1999-11-09
NUMBER OF SEQ ID NOS: 4472
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4472
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-710-279-4472

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGAGACGATGAC 3543
DB 1 CAGGAAACGCTATGAC 17


```
RESULT 452
US-09-581-822-21
; Sequence 21, Application US/09581822
; Patent No. 6731253
; GENERAL INFORMATION:
; APPLICANT: Tillet, Daniel
; TITLE OF INVENTION: Method of Amplification of Nucleic Acid
; FILE REFERENCE: 400716/BSM
; CURRENT APPLICATION NUMBER: US/09/581,822
; PRIOR FILING DATE: 2000-05-01
; PRIOR APPLICATION NUMBER: AU PQ 0087
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 21
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer Sequence
US-09-581-822-21

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 453
US-09-771-439-1
; Sequence 1, Application US/09771439
; Patent No. 6777181
; GENERAL INFORMATION:
; APPLICANT: Kazuko MATSUMOTO
; TITLE OF INVENTION: Method for separating and collecting nucleic acids
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/771,439
; PRIOR FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: JP 2000-21842
; PRIOR FILING DATE: 2000-01-26
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 1
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer for PCR
US-09-771-439-1

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 454
US-10-101-957B-11
; Sequence 11, Application US/10101957B
; Patent No. 6777216
; GENERAL INFORMATION:
; APPLICANT: Bakovic, Marica; Poljuntienko, Arkadi
; TITLE OF INVENTION: Ethanolamphosphatase Cytidylyltransferase Gene and Promoter
; FILE REFERENCE: PAT 651-2
; CURRENT APPLICATION NUMBER: US/10/101,957B
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 24
```

```
; SOFTWARE: Patentin Version 3.0
; SEQ ID NO 11
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA sequence
US-10-101-957B-11

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 455
US-09-600-932-6
; Sequence 6, Application US/09600932
; Patent No. 6787639
; GENERAL INFORMATION:
; APPLICANT: Makamiya, No. 6787639utaka
; TITLE OF INVENTION: NOVEL COLLECTIN
; FILE REFERENCE: 19036/36615
; CURRENT APPLICATION NUMBER: US/09/600,932
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: PCT/JP98/03328
; PRIOR FILING DATE: 1998-07-24
; PRIOR APPLICATION NUMBER: JP 10-11281
; PRIOR FILING DATE: 1998-01-23
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: M13 Reverse
; OTHER INFORMATION: Primer Sequence for Sequencing
US-09-600-932-6

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 456
US-10-088-045-8
; Sequence 8, Application US/10088045
; Patent No. 6805868
; GENERAL INFORMATION:
; APPLICANT: Joelle Thonnard
; TITLE OF INVENTION: No. 6805868e1 Compounds
; FILE REFERENCE: BM45412
; CURRENT APPLICATION NUMBER: US/10/088,045
; PRIOR FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: 9921691.3
; PRIOR FILING DATE: 1999-09-14
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FaastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
```

US-10-088-045-8

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAAACAGCTATGAC 17

RESULT 457

US-09-896-915-21
; Sequence 21, Application US/09896915
; Patent No. 6808882
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: Griffiths, Andrew
; TITLE OF INVENTION: Optical Sorting Method
; FILE REFERENCE: 18396/2022
; CURRENT APPLICATION NUMBER: US/09/896,915
; PRIOR FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: GB9900298.2
; PRIOR FILING DATE: 1999-01-07
; PRIOR APPLICATION NUMBER: PCT/GB00/00030
; PRIOR FILING DATE: 2000-01-06
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide LMB3
US-09-896-915-21

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAAACAGCTATGAC 17

RESULT 458

US-09-685-664B-3117
; Sequence 3117, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3117
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3117

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1104 AGAGCTTTAAACAGC 1120

Db 1 AGAGCTTTAAACAGC 17

RESULT 459

US-09-685-664B-3118
; Sequence 3118, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3118
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3118

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1105 GAGGCTTTAAACAGCA 1121

Db 1 GAGGCTTTAAACAGCA 17

RESULT 460

US-09-685-664B-3297
; Sequence 3297, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3297
; LENGTH: 17

TYPE: RNA
ORGANISM: Mus musculus
US-09-685-664B-3297

Query Match
Best Local Similarity 58.8%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3904 TACTCATGACTCTGAA 3920
1 UACUCCACUCCACUCGAA 17

RESULT 461
US-09-093-972C-866/C
Sequence 866, Application US/09093972C
Patent No. 6825174
GENERAL INFORMATION:
APPLICANT: NYCE, Jonathan W.
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICITION, ALLERGY(IES) & INFLAMMATION
NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 866:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 866:
US-09-093-972C-866

Query Match
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1908 CCCAGCCTGGTCCGCC 1924
17 CCCAGCCTGGTCCGCC 1

RESULT 462
US-09-339-103-5
Sequence 5, Application US/09339103
Patent No. 6828094
GENERAL INFORMATION:
APPLICANT: P. BO, Svante
TITLE OF INVENTION: Method for uncoupled, direct, exponential
amplification and sequencing of DNA molecules with the additior
TITLE OF INVENTION: Second thermostable DNA polymerase and its application
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nikaido, Marmelestein, Murray & Oram LLP
STREET: 655 Fifteenth Street, N.W.; Suite 330
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005-5701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/339,103
FILING DATE: 24-JUN-1999
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 196 53 494.1
FILING DATE: 20-DEC-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/991,184
FILING DATE: 16-DEC-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Wong, King L.
REGISTRATION NUMBER: 37,500
REFERENCE/DOCKET NUMBER: 1614-8090
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 638-5000
TELEFAX: (202) 638-4810
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligonucleotide"
US-09-339-103-5

Query Match
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
1 CAGGAACAGCTATGAC 17

RESULT 463
US-10-091-841A-19
Sequence 19, Application US/10091841A
Patent No. 6833493
GENERAL INFORMATION:
APPLICANT: Cho, Myeong-Je
APPLICANT: del Val, Gregorio
APPLICANT: Caillaud, Maxime
APPLICANT: Lemaux, Peggy G.
APPLICANT: Buchanan, Bob B.

TITLE OF INVENTION: BARLEY GENE FOR THIOREDOXIN AND
FILE REFERENCE: NADP-THIOREDOXIN REDUCTASE
CURRENT APPLICATION NUMBER: US/10/091,841A
CURRENT FILING DATE: 2002-03-05
PRIOR APPLICATION NUMBER: US 09/540,014
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: US 60/127,198
PRIOR FILING DATE: 1999-03-31
PRIOR APPLICATION NUMBER: US 60/169,162
PRIOR FILING DATE: 1999-12-06
PRIOR APPLICATION NUMBER: US 60/177,740
PRIOR FILING DATE: 2000-01-21
PRIOR APPLICATION NUMBER: US 60/177,739
PRIOR FILING DATE: 2000-01-21
NUMBER OF SEQ ID NOS: 51
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO: 19
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-091-841A-19

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 464
PCT-US93-01281-6
Sequence 6, Application PC/TUS9301281
GENERAL INFORMATION:
APPLICANT: EBERSOLE, RICHARD C.
APPLICANT: COLLIER, DAVID N.
APPLICANT: HENDRICKSON, EDWIN R.
APPLICANT: HATFIELD, TINA M.
APPLICANT: MORAN, JOHN
TITLE OF INVENTION: AMPLIFICATION OF ASSAY
TITLE OF INVENTION: REPORTERS BY NUCLEIC
TITLE OF INVENTION: ACID REPLICATION
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. DU PONT DE NEMOURS
ADDRESSEE: AND COMPANY
STREET: 1007 MARKET STREET
CITY: WILMINGTON
STATE: DELAWARE
COUNTRY: U.S.A.
ZIP: 19898

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch,
MEDIUM TYPE: 1.0 MB
COMPUTER: MACINTOSH
OPERATING SYSTEM: MACINTOSH 6.0
SOFTWARE: MICROSOFT WORD, 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/01281
FILING DATE: 19930204
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/833,837
FILING DATE: 04-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: GEIGER, KATHLEEN W.
REGISTRATION NUMBER: 35,880
REFERENCE/DOCKET NUMBER: CR-8959-A
TELECOMMUNICATION INFORMATION:

TELEPHONE: 302-892-8112
TELEFAX: 302-892-7949
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US93-01281-6

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 465
5179198-12
Patent No. 5179198
APPLICANT: OKADA, HIDECHIKA;OKADA, NORIKO;NAGAMI, YOICHI;
TAKASHI, KAZUHIRO;TAKIZAWA, HISAO;KONDO, JUN
TITLE OF INVENTION: GLYCOPROTEIN AND GENE CODING THEREFOR
NUMBER OF SEQUENCES: 17
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/376,828
FILING DATE: 07-JUL-1989
SEQ ID NO:12
LENGTH: 17
5179198-12

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 466
US-08-244-113-21
Sequence 21, Application US/08244113
Patent No. 5455181
GENERAL INFORMATION:
APPLICANT: Strube, Karl-Hermann
APPLICANT: Bialojan, Siegfried
APPLICANT: Kroegeer, Burkhard
APPLICANT: Friedrich, Thomas
TITLE OF INVENTION: No. 5455181el thrombin-inhibitory proteins from terrestrial
TITLE OF INVENTION: Leeches.
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Keil & Weinkauff
STREET: 1101 Connecticut Avenue
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20036

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb storage
COMPUTER: IBM AT-compatible, 80486 processor
OPERATING SYSTEM: MS-DOS version 6.0
SOFTWARE: Wordperfect version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/244,113
FILING DATE:
CLASSIFICATION: 530
CLASSIFICATION: C07K 73/10
CLASSIFICATION: A61K 37/64

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP92/02661
FILING DATE: 19-NOV-1992
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-244-113-21

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 467
US-08-156-020-11
Sequence 11, Application US/08156020
Patent No. 5474920
GENERAL INFORMATION:
APPLICANT: Moses M.D., Robb E.
TITLE OF INVENTION: Modified Thermo-Resistant DNA
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Allegretti & Witcoff
STREET: 10 South Wacker Drive
CITY: Chicago
STATE: IL
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/156,020
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Greenfield Ph.D., Michael S.
REGISTRATION NUMBER: 37,142
REFERENCE/DOCKET NUMBER: 93,413
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312)715-1000
TELEFAX: (312)715-1234
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHEICAL: NO
FEATURE:
NAME/KEY: -
LOCATION: 1..18
OTHER INFORMATION: /note= "PCR reverse primer used for
OTHER INFORMATION: PUC18"
US-08-156-020-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

DB 1 CAGGAACAGCTATGAC 17

RESULT 468
US-08-388-381-29/c
Sequence 29, Application US/08388381
Patent No. 5552283
GENERAL INFORMATION:
APPLICANT: Diamandis, Efstherios
APPLICANT: Dunn, James M.
TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
TITLE OF INVENTION: and Targeted Screening for p53 Mutations
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Opedani & Larson
STREET: 1992 Commerce Street, Suite 309
CITY: Yorktown Heights
STATE: NY
COUNTRY: USA
ZIP: 10598-4412
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS 5.0
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,381
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/271,946
FILING DATE: 08-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Marina T. Larson
REGISTRATION NUMBER: 32,038
REFERENCE/DOCKET NUMBER: VGEN.P-003-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (914) 245-3252
TELEFAX: (914) 962-4330
TELEX:
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
HYPOTHEICAL: no
ANTI-SENSE: no
FRAGMENT TYPE: Internal
ORIGINAL SOURCE: human
ORGANISM: human
FEATURE:
NAME/KEY: sequencing primer for exon 5 of human p53 gene
US-08-388-381-29

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1669 TCCCGAGGCCCCCAGG 1685
DB 17 TCCCGAGGCCCCCAGG 1

RESULT 469
US-08-145-704-3/c
Sequence 3, Application US/08145704
Patent No. 5567604
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan

APPLICANT: Zendegui, Joseph G.
APPLICANT: Joshua O. Ojwang
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
ZIP: 77010-3095
COUNTRY: U.S.A.
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/145,704
FILING DATE: 28-OCT-1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-145-704-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTACCCACC 2706
DB 18 CCAGCCACTACCCACC 2

RESULT 470
US-08-145-704-31/c
Sequence 31, Application US/08145704
Patent No. 5567604
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendegui, Joseph G.
APPLICANT: Joshua O. Ojwang
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/145,704
FILING DATE: 28-OCT-1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety attached to 3'
OTHER INFORMATION: end"
US-08-145-704-31

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTACCCACC 2706
DB 18 CCAGCCACTACCCACC 2

RESULT 471
US-08-145-704-32/c
Sequence 32, Application US/08145704
Patent No. 5567604
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendegui, Joseph G.
APPLICANT: Joshua O. Ojwang
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/145,704
FILING DATE: 28-OCT-1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714

REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety attached to 3'
OTHER INFORMATION: end and phosphothioate backbone"
US-08-145-704-32

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.3%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
Db 18 CCACCACCCACCACC 2

RESULT 472
US-08-050-073-200/c
Sequence 200, Application US/08050073
Patent No. 5567809
GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Begovich, Ann B.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
APPLICANT: Griffith, Robert L.
APPLICANT: Scharf, Stephen J.
TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 315
CORRESPONDENCE ADDRESS:
ADDRESSER: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/050,073
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8769
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 200:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
US-08-050-073-200

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1214 AGAGCGGCGCCCGTGG 1231
Db 18 AGAGCGGCGCCCGTGG 1

RESULT 473
US-08-050-073-300/c
Sequence 300, Application US/08050073
Patent No. 5567809
GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Begovich, Ann B.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
APPLICANT: Griffith, Robert L.
APPLICANT: Scharf, Stephen J.
TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 315
CORRESPONDENCE ADDRESS:
ADDRESSER: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/050,073
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8769
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 300:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
US-08-050-073-300

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1214 AGAGCGGCGCCCGTGG 1231
Db 18 AGAGCGGCGCCCGTGG 1

RESULT 474
US-08-390-850-1075/c
Sequence 1075, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James

APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1075:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-1075

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1468 CTTGAGAAACAGCAGCA 1484
DB 17 CTTCAAAACAGCATCA 1

RESULT 475
US-08-390-850-1116/c
Sequence 1116, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1116:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-1116

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1446 GCAGCAGCAACAGCAGC 1462
DB 18 GCAGCATCAACAGCATC 2

RESULT 476
US-08-390-850-1133/c
Sequence 1133, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1133:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-1133

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1467 GCTTCAGAACAGCAGC 1483
Db 18 GCTTCAGAACAGCAGC 2

RESULT 477
US-08-317-431A-11
Sequence 11, Application US/08317431A
Patent No. 5650277
GENERAL INFORMATION:
APPLICANT: Nir Navot and Nurit Eyal
TITLE OF INVENTION: A method of determining the presence and
TITLE OF INVENTION: quantifying the number of di- and
TITLE OF INVENTION: trinucleotide repeats and instrument and
TITLE OF INVENTION: kits therefore
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mark M. Friedman c/o Robert Sheindelin
STREET: 2940 Birchtree space lane
CITY: Silver Spring
STATE: Maryland
COUNTRY: United States of America
ZIP: 20906
COMPUTER READABLE FORM:
MEDIUM TYPE: 1.44 megabyte, 3.5" microdisk
COMPUTER: Chicom NB5500/386SX
OPERATING SYSTEM: MS DOS version 6.2,
OPERATING SYSTEM: Windows version 3.1
SOFTWARE: Word for Windows version 2.0
SOFTWARE: conv. to ASCII,
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/317,431A
CLASSIFICATION: 435
FILING DATE: 4-Oct-94
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/084,505
FILING DATE: 1-Jul-93
ATTORNEY/AGENT INFORMATION:
NAME: Friedmann, Mark M.
REGISTRATION NUMBER: 33,883
REFERENCE/DOCKET NUMBER: 128/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: 972-3-6938541
TELEFAX: 972-3-6938542
TELEX:
INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-317-431A-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1444 CAGCAGCAGCAAGCA 1460
Db 1 CAGCAGCAGCAAGCA 17

RESULT 478
US-08-363-585-106/c
Sequence 106, Application US/08363585
Patent No. 5683872
GENERAL INFORMATION:
APPLICANT: Rudert, William A.
TITLE OF INVENTION: Trucco, Massimo
TITLE OF INVENTION: Polymers of Oligonucleotide Probes
TITLE OF INVENTION: As The Bound Ligands For Use In Reverse
TITLE OF INVENTION: Dot Blots
NUMBER OF SEQUENCES: 112
CORRESPONDENCE ADDRESS:
ADDRESSEE: University of Pittsburgh
STREET: Office of Intellectual Property
STREET: 911 William Pitt Union
CITY: Pittsburgh
STATE: Pennsylvania
COUNTRY: USA
ZIP: 15260
COMPUTER READABLE FORM:
MEDIUM TYPE: 5-1/4" low density diskette
COMPUTER: IBM PC or compatibles
OPERATING SYSTEM: MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,585
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/786,228
FILING DATE: 31-Oct-1991
ATTORNEY/AGENT INFORMATION:
NAME: Frederick H. Cohen; Mary-Elizabeth Buckles
REGISTRATION NUMBER: 28,061; 31,907
REFERENCE/DOCKET NUMBER: 92-232
TELECOMMUNICATION INFORMATION:
TELEPHONE: 412/288-4164
TELEFAX: 412/288-3063
TELEX: 277871
INFORMATION FOR SEQ ID NO: 106:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
PUBLICATION INFORMATION:
AUTHORS: Kimura, A.
TITLE: Eleventh International Histocompatibility
TITLE: Workshop Reference Protocol for the HLA-DNA-Typing
TITLE: Technique
JOURNAL: HLA 1991
VOLUME: 1
PAGES: 397-419
DATE: 1992
RELEVANT RESIDUES IN SEQ ID NO: 106: 1 to 18

US-08-363-585-106

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2038 CCGAGAACTCCGCTTG 2054

DB 17 CCGAGAACTCCCTCTG 1

RESULT 479

US-08-471-601-3

Sequence 3, Application US/08471601

Patent No. 5689049

GENERAL INFORMATION:

APPLICANT: CIGAN, Andrew M.

TITLE OF INVENTION: Reversible Nuclear Genetic System For

TITLE OF INVENTION: Male Sterility In Transgenic Plants

NUMBER OF SEQUENCES: 23

CORRESPONDENCE ADDRESS:

ADDRESSER: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/471.601

FILING DATE: 07-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/351,899

FILING DATE: 08-DEC-1994

ATTORNEY/AGENT INFORMATION:

NAME: BENT, Stephen A.

REGISTRATION NUMBER: 29,768

REFERENCE/DOCKET NUMBER: 33229/341/PIHI

TELEPHONE: (202) 672-5300

TELEFAX: (202) 672-5399

TELEX: 904136

INFORMATION FOR SEQ. ID NO: 3:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-471-601-3

QY 3527 CCGGGAACGCTATGAC 3543

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 1 CAGGAAACGCTATGAC 17

RESULT 480

US-08-474-556-3

Sequence 3, Application US/08474556

Patent No. 5689051

GENERAL INFORMATION:

APPLICANT: CIGAN, Andrew M.

TITLE OF INVENTION: Reversible Nuclear Genetic System For

TITLE OF INVENTION: Male Sterility In Transgenic Plants

US-08-474-556-3

Sequence 3, Application US/08474556

Patent No. 5689051

GENERAL INFORMATION:

APPLICANT: CIGAN, Andrew M.

TITLE OF INVENTION: Reversible Nuclear Genetic System For

NUMBER OF SEQUENCES: 23

CORRESPONDENCE ADDRESS:

ADDRESSER: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/474,556

FILING DATE: 07-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/351,899

FILING DATE: 08-DEC-1994

ATTORNEY/AGENT INFORMATION:

NAME: BENT, Stephen A.

REGISTRATION NUMBER: 29,768

REFERENCE/DOCKET NUMBER: 33229/329/PIHI

TELEPHONE: (202) 672-5300

TELEFAX: (202) 672-5399

TELEX: 904136

INFORMATION FOR SEQ. ID NO: 3:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-474-556-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

DB 1 CAGGAAACGCTATGAC 17

RESULT 481

US-08-363-240A-1122/C

Sequence 1122, Application US/08363240A

Patent No. 5705388

GENERAL INFORMATION:

APPLICANT: Couture, Larry

APPLICANT: MCSwigen, James

APPLICANT: Bisgaler, Charles

APPLICANT: Pape, Michael

TITLE OF INVENTION: METHOD AND REAGENT FOR

TITLE OF INVENTION: PREVENTION, INHIBITION OF

TITLE OF INVENTION: PROGRESSION AND REGRESSION

NUMBER OF SEQUENCES: 1243

CORRESPONDENCE ADDRESS:

ADDRESSER: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1122:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-1122

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCA 1142
DB 17 CATCTGCAGCAGCAGCA 1

RESULT 482
US-08-435-634-1075/C
Sequence 1075, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295, September 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1075:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-1075

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1468 CTTCAAGAAACAGCAGCA 1484
DB 17 CTTCAAAACAGCATCA 1

RESULT 483
US-08-435-634-1116/C
Sequence 1116, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295, September 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1116:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-1116

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1446 GCAGCAGCAACAGCAGC 1462
DB 18 GCAGCATCAACAGCATC 2

RESULT 484
US-08-435-634-1133/C
Sequence 1133, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295 September 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1133:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-1133
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 GCTTCAGAAACAGCAGC 1483
DB 18 GCTTCAAAAACAGCATC 2

RESULT 485
US-08-351-899-3
Sequence 3, Application US/08351899
Patent No. 5750868
GENERAL INFORMATION:
APPLICANT: CIGAN, Andrew M.
APPLICANT: ALBERTSEN, Marc C.
TITLE OF INVENTION: Reversible Nuclear Genetic System For
TITLE OF INVENTION: Male Sterility in Transgenic Plants
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/351,899
FILING DATE: 08-DEC-1994
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 33229/208/PIHI
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-351-899-3
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAGAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 486
US-08-479-382-3
Sequence 3, Application US/08479382
Patent No. 5763243
GENERAL INFORMATION:
APPLICANT: CIGAN, Andrew M.
APPLICANT: ALBERTSEN, Marc C.
TITLE OF INVENTION: Reversible Nuclear Genetic System For
TITLE OF INVENTION: Male Sterility in Transgenic Plants
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA

ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,382
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/351,899
FILING DATE: 08-DEC-1994
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 33229/339/PIHI
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TOPOLOGY: 11linear
US-08-479-382-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 487
US-08-470-354-3
Sequence 3, Application US/08470354
Patent No. 5792853
GENERAL INFORMATION:
APPLICANT: CIGAN, Andrew M.
TITLE OF INVENTION: Reversible Nuclear Genetic System For
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSER: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,354
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/351,899
FILING DATE: 08-DEC-1994
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 33229/337/PIHI
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TOPOLOGY: 11linear

INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: 11linear
US-08-470-354-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 488
US-08-479-383-3
Sequence 3, Application US/08479383
Patent No. 5795753
GENERAL INFORMATION:
APPLICANT: CIGAN, Andrew M.
TITLE OF INVENTION: Reversible Nuclear Genetic System For
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSER: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,383
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/351,899
FILING DATE: 08-DEC-1994
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 33229/340/PIHI
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TOPOLOGY: 11linear

US-08-479-383-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 489
US-08-512-681-27
Sequence 27, Application US/08512681

Patent No. 5795976
GENERAL INFORMATION:
APPLICANT: Oefner, Peter J.
APPLICANT: Underhill, Peter A.
TITLE OF INVENTION: Detection of DNA Heteroduplex Molecules
TITLE OF INVENTION: by Denaturing High Performance Liquid Chromatography and
TITLE OF INVENTION: Methods for Comparative Sequencing
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Ave., Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/512,681
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Evans, Susan T.
REGISTRATION NUMBER: 38,443
REFERENCE/DOCKET NUMBER: 8600-0155
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: 439-MER REVERSE PRIMER
US-08-512-681-27

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGACTGTGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 490
US-08-758-306-501/c
Sequence 501, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Marburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 501:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-501

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCA 1133
DB 17 CAGCAGGCGCAGCTGCA 1

RESULT 491
US-08-758-306-955/c
Sequence 955, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 955:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-955

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGACTGCA 1133
DB 17 CAGCAGCAGCAGCTGAA 1

RESULT 492
US-08-758-306-1339/c
Sequence 1339, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:

APPLICANT: Stinchcomb, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESSES:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-1339

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1339:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-1339

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1402 CAGAGCAGCTGCAGCA 1418
DB 17 CAGAGCAGCTGCAGCA 1

RESULT 493
US-08-480-917-8
Sequence 8, Application US/08480917
Patent No. 5820864
GENERAL INFORMATION:

APPLICANT: PARANHOS-BACCALA, Glauca
APPLICANT: LESNECHAL, Mylene
APPLICANT: JOLIVET, Michel
TITLE OF INVENTION: NEW TRYPARANOSOMA CRUZI ANTIGEN, AND GENE
TITLE OF INVENTION: ENCODING THE LATTER; THEIR APPLICATION TO THE DETECTION OF
TITLE OF INVENTION: CHAGAS DISEASE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESSES:

ADDRESSEE: Oliff & Berridge
STREET: 700 South Washington Street, Suite 300
CITY: Alexandria
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22314

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,917
FILING DATE: 07-JUN-1995

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: MPB 36400
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-480-917-8

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1130 TGCAGCAGCGCAGCAG 1146
DB 1 TGCAGCAGCGCAGCAG 17

RESULT 494
US-08-639-363-16
Sequence 16, Application US/08639363
Patent No. 5830655
GENERAL INFORMATION:

APPLICANT: Monforte, Joseph A.
APPLICANT: Becker, Christopher H.
APPLICANT: Shaler, Thomas A.
APPLICANT: Pollart, Daniel J.
TITLE OF INVENTION: Oligonucleotide Sizing Using Cleavable
TITLE OF INVENTION: Primers
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Dehlinger & Associates

STREET: P.O. Box 60850
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.A.
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/639,363
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/445,751
FILING DATE: 22-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Evans, Susan T.
REGISTRATION NUMBER: 38,443
REFERENCE/DOCKET NUMBER: 8255-0015.30
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-324-0880
TELEFAX: 415-324-0960
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: 5' biotinylated M13 reverse primer,
INDIVIDUAL ISOLATE: 5' (S)T at posn 14
FEATURE:
NAME/KEY: misc feature
LOCATION: 13..14
OTHER INFORMATION: /note= "primer is biotinylated at
OTHER INFORMATION: 5' end and contains a 5'(S)-T at positio..."
US-08-639-363-16
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17
RESULT 495
US-08-411-098-34
Sequence 34, Application US/08411098
Patent No. 5830755
GENERAL INFORMATION:
APPLICANT: HMU, PATRICK; NISHIMURA,
APPLICANT: MICHAEL, ROSENBERG, STEVEN A.
TITLE OF INVENTION: T-CELL RECEPTORS AND
TITLE OF INVENTION: THEIR USE IN THERAPEUTIC AND DIAGNOSTIC
NUMBER OF SEQUENCES: 39
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/411,098
FILING DATE: 27-MAR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: CAROL M. GRUPPI
REGISTRATION NUMBER: 37,341
REFERENCE/DOCKET NUMBER: 2026-4188
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
TELEX: 421792
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: NUCLEOTIDE
STRANDEDNESS: SINGLE
TOPOLOGY: UNKNOWN
US-08-411-098-34
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 533 CTCAGCTGACCGCACC 549
DB 2 CTCAGCTGACCGCACC 18
RESULT 496
US-08-479-041-3
Sequence 3, Application US/08479041
Patent No. 5837851
GENERAL INFORMATION:
APPLICANT: CIGAN, Andrew M.
APPLICANT: ALBERTSEN, Marc C.
TITLE OF INVENTION: Reversible Nuclear Genetic System For
TITLE OF INVENTION: Male Sterility In Transgenic Plants
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,041
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/351,899
FILING DATE: 08-DEC-1994
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 33229/338/PIH1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-479-041-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543

DB 1 CAGGAACGCTATGAC 17

RESULT 497

US-08-795-006A-9

Sequence 9, Application US/08795006A
Patent No. 5840579

GENERAL INFORMATION:

APPLICANT: Boeke, Jef

APPLICANT: Brachmann, Rainer

TITLE OF INVENTION: NUCLEIC ACIDS ENCODING P53

TITLE OF INVENTION: MUTATIONS WHICH SUPPRESS P53 CANCER MUTATIONS

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESSEE: Banner & Witcoff

STREET: 1001 G Street, NW

CITY: Washington

STATE: DC

COUNTRY: USA

ZIP: 20001

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM compatible

OPERATING SYSTEM: DOS

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

FILING DATE: 05-FEB-1997

CLASSIFICATION: 435

PRIORITY APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Kagan, Sarah A

REGISTRATION NUMBER: 32141

REFERENCE/DOCKET NUMBER: 01107.03170

TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-508-9100

TELEFAX: 202-508-9299

TELEX:

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-795-006A-9

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1378 GAGCAGCGGAGTCAG 1394

DB 1 GAGCAGCGGAGTCAG 17

RESULT 498

US-08-710-330A-8

Sequence 8, Application US/08710330A
Patent No. 5834041

GENERAL INFORMATION:

APPLICANT: Brayer, Gary D.

APPLICANT: Lee, Hung

APPLICANT: Mauk, Grant A.

APPLICANT: Smith, Michael

APPLICANT: Tong, Harry

TITLE OF INVENTION: MYOGLOBIN WITH PEROXIDASE ACTIVITY

NUMBER OF SEQUENCES: 11

CORRESPONDENCE ADDRESS:

ADDRESSEE: Campbell & Flores LLP

STREET: 4370 La Jolla Village Drive, Suite 700

CITY: San Diego

STATE: California

COUNTRY: USA

ZIP: 92122

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/710,330A

FILING DATE: 16-SEP-1996

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: GAY, David A.

REGISTRATION NUMBER: 39,200

REFERENCE/DOCKET NUMBER: P-SM 2262

TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 535-9001

TELEFAX: (619) 535-8949

INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-710-330A-8

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543

DB 1 CAGGAACGCTATGAC 17

RESULT 499

US-08-505-617-12

Sequence 12, Application US/08505617
Patent No. 5861378

GENERAL INFORMATION:

APPLICANT: IWANAGA, Sadaaki

APPLICANT: KAWABATA, Shun-ichiro

APPLICANT: SAITO, Tetsu

TITLE OF INVENTION: POLYPEPTIDES, AND PREPARATION AND DNA

TITLE OF INVENTION: ENCODING THEREOF

NUMBER OF SEQUENCES: 13

CORRESPONDENCE ADDRESS:

ADDRESSEE: Testa, Hurwitz & Thibault, LLP

STREET: 125 High Street

CITY: Boston

STATE: MA

COUNTRY: USA

ZIP: 02110

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/505,617

FILING DATE:

CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:

NAME: CAMPBELL, Paula A
REGISTRATION NUMBER: 32,503
REFERENCE/DOCKET NUMBER: FJN-041
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 248-7000
TELEFAX: (617) 248-7100
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-505-617-12

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 500
US-08-432-871C-33
Sequence 33, Application US/08432871C
Patent No. 5877010
GENERAL INFORMATION:
APPLICANT: Loeb, Lawrence A.
APPLICANT: Black, Margaret E.
TITLE OF INVENTION: THYMIDINE KINASE MUTANTS
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/432,871C
FILING DATE: 02-May-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McMaster, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 240052.409C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-432-871C-33

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 501
US-08-751-189-10
Sequence 10, Application US/08751189
Patent No. 5919656
GENERAL INFORMATION:
APPLICANT: Harrington, Lea A.
APPLICANT: Robinson, Murray O.
TITLE OF INVENTION: No. 5919656el Genes Encoding Telomerase Protein
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen, Inc.
STREET: 1840 De Havilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/751,189
FILING DATE: 15-NOV-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Oleski, Nancy A.
REGISTRATION NUMBER: 34,688
REFERENCE/DOCKET NUMBER: A-433
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligo nucleotide"
US-08-751-189-10

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 502
US-09-205-922-17/c
Sequence 17, Application US/09205922
Patent No. 5951455
GENERAL INFORMATION:
APPLICANT: Lex M. Cowsett
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-11 EXPRESSION
FILE REFERENCE: RTS-0030
CURRENT APPLICATION NUMBER: US/09/205,922
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 17
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-922-17

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1277 AGGAGCAGCGCGCG 1293

Db 18 AGAGCAGCTCGCGCG 2

RESULT 503

US-09-197-378-20/c
; Sequence 20, Application US/09197378
; Patent No. 5959097
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF MER2 EXPRESSION
; FILE REFERENCE: RTS-0017
; CURRENT APPLICATION NUMBER: US/09/197,378
; CURRENT FILING DATE: 1998-11-20
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 20
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-197-378-20

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3561 CATCCAGACCCAGATCA 3577

Db 18 CATCCGAGACGATCA 2

RESULT 504

US-09-018-170-12
; Sequence 12, Application US/09018170
; Patent No. 5965725
; GENERAL INFORMATION:
; APPLICANT: Iwanaga, Sadaki
; APPLICANT: KAWABATA, Shun-ichiro
; APPLICANT: SAITO, Tetsu
; TITLE OF INVENTION: POLYPEPTIDES, AND PREPARATION AND DNA
; TITLE OF INVENTION: ENCODING THEROP
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Tesca, Hurwitz & Thibault, LLP
; STREET: 125 High Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Releasee #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/018,170
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/505,617
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: CAMPBELL, Paula A
; REGISTRATION NUMBER: 32,503
; REFERENCE/DOCKET NUMBER: FJN-041
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 248-7000
; TELEFAX: (617) 248-7100
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-018-170-12

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

Db 1 CAGGAACGCTATGAC 17

RESULT 505
US-08-948-364-2
; Sequence 2, Application US/08948364
; Patent No. 5968743
; GENERAL INFORMATION:
; APPLICANT: Matsunaga, Hiroko
; APPLICANT: Okano, Kazumori
; APPLICANT: Kambara, Hideki
; TITLE OF INVENTION: DNA SEQUENCING METHOD AND REAGENTS KIT
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: FAY, SHARPE, BEALL, FAGAN, MINNICH & MCKEE
; STREET: 104 East Hume Avenue
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22301

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Releasee #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/948,364
; FILING DATE: 09-OCT-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 08-270564
; FILING DATE: 14-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Mattingly, John
; REGISTRATION NUMBER: 30,293
; REFERENCE/DOCKET NUMBER: ASA-678
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-884-1167
; TELEFAX: 703-884-1167
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
US-08-948-364-2

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543

Db 2 CAGGAACGCTATGAC 18

RESULT 506
US-09-060-836-10
; Sequence 10, Application US/09060836
; Patent No. 5981707
; GENERAL INFORMATION:

APPLICANT: Harrington, Lea A.
APPLICANT: Robinson, Murray O.
TITLE OF INVENTION: No. 5981707e1 Genes Encoding Telomerase Protein
TITLE OF INVENTION: 1
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen, Inc.
STREET: 1840 De Havilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/060,836
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/751,189
FILING DATE: 15-NOV-1996
ATTORNEY/AGENT INFORMATION:
NAME: Oleski, Nancy A.
REGISTRATION NUMBER: 34,688
REFERENCE/DOCKET NUMBER: A-433
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligo nucleotide"
US-09-060-836-10

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 507
US-08-815-448-10
Sequence 10, Application US/08815448
Patent No. 5994068
GENERAL INFORMATION:
APPLICANT: Guilfoyle, Richard A
APPLICANT: Guo, Zhen
TITLE OF INVENTION: Nucleic Acid Indexing
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Charles & Brady
STREET: 1 South Pinckney St.
CITY: Madison
STATE: WI
COUNTRY: US
ZIP: 53703
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/815,448
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:

NAME: Berson, Bennett J
REGISTRATION NUMBER: 37094
REFERENCE/DOCKET NUMBER: 960296.94053
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-251-5000
TELEFAX: 608-251-9166
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "M13revp reverse primer"
US-08-815-448-10

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 508
US-08-890-980-86
Sequence 86, Application US/08890980
Patent No. 5998141
GENERAL INFORMATION:
APPLICANT: Acton, Susan L.
TITLE OF INVENTION: SR-B1 NUCLEIC ACIDS AND USES THEREFOR
NUMBER OF SEQUENCES: 86
CORRESPONDENCE ADDRESS:
ADDRESSEE: FOLEY, HONG & ELIOT LLP
STREET: One Post Office Square
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109-2170
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/890,980
FILING DATE: 10-JUL-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Arnold, Beth E.
REGISTRATION NUMBER: 35,430
REFERENCE/DOCKET NUMBER: MIA-005.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-832-1000
TELEFAX: 617-832-7000
INFORMATION FOR SEQ ID NO: 86:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-890-980-86

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 509
US-09-256-496-9
Sequence 9, Application US/09256496
Patent No. 5998206
GENERAL INFORMATION:
APPLICANT: Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-12 EXPRESSION
FILE REFERENCE: RTS-0056
CURRENT APPLICATION NUMBER: US/09/256,496
CURRENT FILING DATE: 1999-02-23
NUMBER OF SEQ ID NOS: 86
SEQ ID NO 9
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-256-496-9

Query Match
Best Local Similarity 88.2%; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3467 GGCAGCGGCTCAGAGCTC 3483
Db 1 GGCAGCGGCTGAGGCTC 17

RESULT 510
US-09-256-496-15
Sequence 15, Application US/09256496
Patent No. 5998206
GENERAL INFORMATION:
APPLICANT: Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-12 EXPRESSION
FILE REFERENCE: RTS-0056
CURRENT APPLICATION NUMBER: US/09/256,496
CURRENT FILING DATE: 1999-02-23
NUMBER OF SEQ ID NOS: 86
SEQ ID NO 15
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-256-496-15

Query Match
Best Local Similarity 88.2%; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1456 CAGCAGCAGCAGCTCA 1472
Db 1 CAGCAGCAGCAGCTTCA 17

RESULT 511
US-09-106-038A-23
Sequence 23, Application US/09106038A
Patent No. 6007995
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker and Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
TITLE OF INVENTION: EXPRESSION
NUMBER OF SEQUENCES: 91
CORRESPONDENCE ADDRESS:
ADDRESSEE: Isis Pharmaceuticals, Inc.
STREET: 2292 Faraday Avenue
CITY: Carlsbad
STATE: CA
COUNTRY: U.S.A.

ZIP: 92008
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows NT
SOFTWARE: Microsoft Word 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/106,038A
FILING DATE: June 26, 1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Laurel Spear Bernstein
REGISTRATION NUMBER: 37,280
REFERENCE/DOCKET NUMBER: RTS-0004
TELEPHONE: (760) 931-9200
TELEFAX: (760) 603-3820
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-106-038A-23

Query Match
Best Local Similarity 88.2%; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1478 AGCAGCAGCAGCAGCTC 1494
Db 1 AGCGCAGCAGCAGCTC 17

RESULT 512
US-09-106-038A-25
Sequence 25, Application US/09106038A
Patent No. 6007995
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker and Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
TITLE OF INVENTION: EXPRESSION
NUMBER OF SEQUENCES: 91
CORRESPONDENCE ADDRESS:
ADDRESSEE: Isis Pharmaceuticals, Inc.
STREET: 2292 Faraday Avenue
CITY: Carlsbad
STATE: CA
COUNTRY: U.S.A.
ZIP: 92008
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows NT
SOFTWARE: Microsoft Word 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/106,038A
FILING DATE: June 26, 1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Laurel Spear Bernstein
REGISTRATION NUMBER: 37,280
REFERENCE/DOCKET NUMBER: RTS-0004
TELEPHONE: (760) 931-9200
TELEFAX: (760) 603-3820
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-106-038A-25

Query Match 0.3%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1232 AGGAGCAACAGCGCGG 1248
 DB 2 AGGAGCAACAGCGCGG 18

RESULT 513
 US-09-205-921-12
 Sequence 12, Application US/09205921A
 Patent No. 6008048
 GENERAL INFORMATION:
 APPLICANT: Brett P. Monia
 APPLICANT: ex M. Cowser
 TITLE OF INVENTION: ANTISENSE MODULATION OF EGR-1 EXPRESSION
 FILE REFERENCE: RTS-0028
 CURRENT APPLICATION NUMBER: US/09/205,921A
 CURRENT FILING DATE: 1998-12-04
 NUMBER OF SEQ ID NOS: 47
 SEQ ID NO 12
 LENGTH: 18
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Antisense Oligonucleotide
 US-09-205-921-12

Query Match 0.3%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1480 CAGCAGCAGCAGCTCCT 1496
 DB 1 CAGCAGCAGCAGCTCCT 17

RESULT 514
 US-08-974-022-11
 Sequence 11, Application US/08974022
 Patent No. 6015938
 GENERAL INFORMATION:
 APPLICANT: Boyle, William J.
 APPLICANT: Lacey, David L.
 APPLICANT: Calzone, Frank J.
 APPLICANT: Chang, Ming-Shi
 TITLE OF INVENTION: OSTEOPROTEGERIN
 NUMBER OF SEQUENCES: 53
 CORRESPONDENCE ADDRESSES:
 ADDRESSEE: Amgen Inc.
 STREET: 1840 Dehavilland Drive
 CITY: Thousand Oaks
 STATE: California
 COUNTRY: USA
 ZIP: 91320-1789
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/974,022
 FILING DATE: 12-DEC-1995
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/577,788
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Winter, Robert B.
 REFERENCE/DOCKET NUMBER: A-378
 INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: cDNA
 US-08-974-022-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
 DB 1 CAGGAACAGCTATGAC 17

RESULT 515
 US-08-757-024-856/c
 Sequence 856, Application US/08757024
 Patent No. 6025339
 GENERAL INFORMATION:
 APPLICANT: Nyce, Jonathan W.
 TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
 NUMBER OF SEQUENCES: 952
 CORRESPONDENCE ADDRESSES:
 ADDRESSEE: BELL, SELTZER, PARK & GIBSON
 STREET: P.O. Drawer 34009
 CITY: Charlotte
 STATE: No. 6025339ch Carolina
 COUNTRY: USA
 ZIP: 28234
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/757,024
 FILING DATE: 26-NOV-1996
 CLASSIFICATION: 514
 ATTORNEY/AGENT INFORMATION:
 NAME: Sibley, Kenneth D.
 REGISTRATION NUMBER: 31,665
 REFERENCE/DOCKET NUMBER: 5218-41
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 919-881-3140
 TELEFAX: 919-881-3175
 TELEX: 575102
 INFORMATION FOR SEQ ID NO: 856:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-08-757-024-856

Query Match 0.3%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1908 CCCAGCTGGATCCGCC 1924
 DB 18 CCCAGCTGTGCCGCC 2

RESULT 516
 US-08-757-024-865/c
 Sequence 865, Application US/08757024
 Patent No. 6025339
 GENERAL INFORMATION:
 APPLICANT: Nyce, Jonathan W.

TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
NUMBER OF SEQUENCES: 952
CORRESPONDENCE ADDRESS:
ADDRESSER: BELL, SELTZER, PARK & GIBSON
STREET: P.O. Drawer 34009
CITY: Charlotte
STATE: No. 6025339ch Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/757,024
FILING DATE: 26-NOV-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5218-41
TELEPHONE: 919-881-3140
TELEFAX: 919-881-3175
TELEX: 575102
INFORMATION FOR SEQ ID NO: 865:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-757-024-865

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1908 CCCAGCCTGGTCCGCC 1924

Db 17 CCCAGCCTGGTCCGCC 1

RESULT 517
US-08-757-024-943/c
Sequence 943, Application US/08757024
Patent No. 6025339
GENERAL INFORMATION:
APPLICANT: Nyce, Jonathan W.
TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
NUMBER OF SEQUENCES: 952
CORRESPONDENCE ADDRESS:
ADDRESSER: BELL, SELTZER, PARK & GIBSON
STREET: P.O. Drawer 34009
CITY: Charlotte
STATE: No. 6025339ch Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/757,024
FILING DATE: 26-NOV-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5218-41
TELECOMMUNICATION INFORMATION:

TELEPHONE: 919-881-3140
TELEFAX: 919-881-3175
TELEX: 575102
INFORMATION FOR SEQ ID NO: 943:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-757-024-943

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1908 CCCAGCCTGGTCCGCC 1924

Db 17 CCCAGCCTGGTCCGCC 1

RESULT 518
US-08-890-979-75
Sequence 75, Application US/08890979
Patent No. 6030778
GENERAL INFORMATION:
APPLICANT: Acton, Susan L.
TITLE OF INVENTION: DIAGNOSTIC ASSAYS AND KITS FOR BODY MASS
TITLE OF INVENTION: DISORDERS
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSER: FOLEY, HOAG & ELIOT LLP
STREET: One Post Office Square
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109-2170
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/890,979
FILING DATE: 10-JUL-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Arnold, Beth E.
REGISTRATION NUMBER: 35,430
REFERENCE/DOCKET NUMBER: MIA-005.02
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-832-1000
TELEFAX: 617-832-7000
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-890-979-75

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3527 CCGGAAACGCTATGAC 3543

Db 1 CAGGAACGCTATGAC 17

RESULT 519
US-09-156-807-28
Sequence 28, Application US/09156807
Patent No. 6030786
GENERAL INFORMATION:
APPLICANT: Cowser, Lex M.
TITLE OF INVENTION: ANTISENSE MODULATION OF Rhoc EXPRESSION
FILE REFERENCE: RTS-0014
CURRENT APPLICATION NUMBER: US/09/156,807
CURRENT FILING DATE: 1998-09-18
NUMBER OF SEQ ID NOS: 47
SEQ ID NO 28
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-156-807-28

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1166 TCACACCTCGTCGAC 1182
DB 2 TCACACCTCGTCGAC 18

RESULT 520
US-09-339-993-11
Sequence 11, Application US/09339993A
Patent No. 6040179
GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-12 EXPRESSION
FILE REFERENCE: RTS-0064
CURRENT APPLICATION NUMBER: US/09/339,993A
CURRENT FILING DATE: 1999-06-25
NUMBER OF SEQ ID NOS: 47
SEQ ID NO 11
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-339-993-11

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1456 CAGCAGCAGCAGCTCA 1472
DB 1 CAGCAGCAGCAGCTCA 17

RESULT 521
US-08-485-942A-65/C
Sequence 65, Application US/08485942A
Patent No. 6048837
GENERAL INFORMATION:
APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA,
APPLICANT: MARGHERITA WAFEL, JEFFREY HALAAS, KETAN GAJWALA, AND STEPHEN K. BURLE
TITLE OF INVENTION: OB POLYPEPTIDE AS MODULATORS OF BODY WEIGHT (AS
TITLE OF INVENTION: AMENDED)
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,942A
FILING DATE: JUNE 7, 1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/438,431
FILING DATE: May 10, 1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/347,563
FILING DATE: No. 6048837ember 30, 1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/292,345
FILING DATE: August 17, 1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2F
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
DESCRIPTION: sequence tagged-site specific PCR primer BWS1392
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Human
US-08-485-942A-65

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 817 ATCAAGACTTACTGAG 833
DB 17 ATCAAGACTTACTGAG 1

RESULT 522
US-09-344-579-9
Sequence 9, Application US/09344579
Patent No. 6054316
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF ETS-2 EXPRESSION
FILE REFERENCE: RTS-0063
CURRENT APPLICATION NUMBER: US/09/344,579
CURRENT FILING DATE: 1999-06-25
NUMBER OF SEQ ID NOS: 47
SEQ ID NO 9
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-579-9

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1202 AGGAGCAGAGAGAGAG 1218
DB 1 AGGAGCGGAGAGAGAG 17

RESULT 523
US-08-765-626-29/c
Sequence 29, Application US/08765626
Patent No. 6071726
GENERAL INFORMATION:
APPLICANT: Visible Genetics Inc.
APPLICANT: Diamandis, Eleftherios
APPLICANT: Dunn, James W.
APPLICANT: Stevens, John K.
TITLE OF INVENTION: Method, Reagents and Kit for diagnosis
TITLE OF INVENTION: and Targeted Screening for p53 Mutations
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Opedahl & Larson
STREET: 1992 Commerce Street, Suite 309
CITY: Yorktown Heights
STATE: NY
COUNTRY: USA
ZIP: 10598-4412
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS 5.0
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/765, 626
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/08605
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/08605
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/388,381
FILING DATE: 14-FEB-1995
ATTORNEY/AGENT INFORMATION:
NAME: Marina T. Larson
REGISTRATION NUMBER: 32,038
REFERENCE/DOCKET NUMBER: VGEN.P-003-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (914) 245-3252
TELEFAX: (914) 962-4330
TELEX:
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULAR TYPE: genomic DNA
HYPOTHETICAL: no
ANTI-SENSE: no
FRAGMENT TYPE: Internal
ORIGINAL SOURCE: human
ORGANISM: human
FEATURE:
NAME/KEY: sequencing primer for exon 5 of human p53 gene
US-08-765-626-29

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1669 TCCCGAGGCGGCGGAG 1685
DB 17 TGCCGAGGCTCCCGAG 1

RESULT 524
US-09-147-550-115
Sequence 115, Application US/09147550
Patent No. 6090540
GENERAL INFORMATION:
APPLICANT: Aida, Yoko
TITLE OF INVENTION: METHODS FOR JUDGING THE POSSIBILITY OF THE ONSET OF
TITLE OF INVENTION: BOVINE LEUKEMIA AND THE RESISTANCE THERETO
FILE REFERENCE: SEQUENCE LISTING FOR 09/147,550
CURRENT APPLICATION NUMBER: US/09/147,550
EARLIER FILING DATE: 1999-04-23
EARLIER APPLICATION NUMBER: PCT/JP97/02485
EARLIER FILING DATE: 1997-07-17
EARLIER APPLICATION NUMBER: JP 8-190933
EARLIER FILING DATE: 1996-07-19
EARLIER APPLICATION NUMBER: JP 9-77979
EARLIER FILING DATE: 1997-03-28
NUMBER OF SEQ ID NOS: 115
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 115
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PRIMER
US-09-147-550-115

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 525
US-08-488-214A-65/c
Sequence 65, Application US/08488214A
Patent No. 6124439
GENERAL INFORMATION:
APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA,
APPLICANT: MARGHERITA MARELLI, JEFFREY HALAS, KETAN GAJIWALA, AND STEPHEN K. BURLEY
TITLE OF INVENTION: OB POLYPEPTIDE ANTIBODIES AND METHOD OF MAKING
TITLE OF INVENTION: (AS AMENDED)
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,214A
FILING DATE: JUNE 7, 1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/438,431
FILING DATE: May 10, 1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/347,563
FILING DATE: No. 6124439 September 30, 1994
CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/292,345
FILING DATE: August 17, 1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2D
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
DESCRIPTION: sequence tagged-site specific PCR primer sWSS1392
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Human
US-08-488-214A-65

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 817 ATCAAGACTTACTGTGAG 833
DB 17 ATTAAGACATCACTGTGAG 1

RESULT 526
US-08-488-208A-65/C
Sequence 65, Application US/08488208A
Patent No. 6124448
GENERAL INFORMATION:
APPLICANT: THE ROCKEFELLER UNIVERSITY
TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING
TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC
NUMBER OF SEQUENCES: 98
NUMBER OF SEQUENCES: 98
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,208A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/485,943
FILING DATE: June 7, 1995
APPLICATION NUMBER: 08/438,431
FILING DATE: May 10, 1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/347,563
FILING DATE: No. 6124448ember 30, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/292,345
FILING DATE: August 17, 1994

CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-087 CIP2I
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
DESCRIPTION: sequence tagged-site specific PCR primer sWSS1392
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Human
US-08-488-208A-65

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 817 ATCAAGACTTACTGTGAG 833
DB 17 ATTAAGACATCACTGTGAG 1

RESULT 527
US-09-032-894-86
Sequence 86, Application US/09032894
Patent No. 6130041
GENERAL INFORMATION:
APPLICANT: Acton, Susan L.
TITLE OF INVENTION: SR-BI NUCLEIC ACIDS AND USES THEREFOR
FILE REFERENCE: MIA-005.03
CURRENT APPLICATION NUMBER: US/09/032,894
CURRENT FILING DATE: 1998-02-27
EARLIER APPLICATION NUMBER: 08/890,980
NUMBER OF SEQ ID NOS: 121
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 86
LENGTH: 18
TYPE: DNA
ORGANISM: Human
US-09-032-894-86

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 528
US-08-987-574-3/C
Sequence 3, Application US/08987574
Patent No. 6150339
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendegeul, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides

NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/987,574
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04529
FILING DATE: 28-OCT-1993
APPLICATION NUMBER: US 08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-987-574-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTACCCACC 2706
DB 18 CCAGCCACCACCCACC 2

RESULT 529
US-08-987-574-31/c
Sequence 31, Application US/08987574
Patent No. 6150339
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennewald, Susan
APPLICANT: Zendegui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael B.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/987,574
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04529
FILING DATE: 28-OCT-1993
APPLICATION NUMBER: US 08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety
OTHER INFORMATION: attached to 3' end"
US-08-987-574-31

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTACCCACC 2706
DB 18 CCAGCCACCACCCACC 2

RESULT 530
US-08-987-574-32/c
Sequence 32, Application US/08987574
Patent No. 6150339
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennewald, Susan
APPLICANT: Zendegui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael B.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/987,574
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04529
FILING DATE: 28-OCT-1993
APPLICATION NUMBER: US 08/053,027

FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine molty
OTHER INFORMATION: attached to 3' end and phosphothioate
OTHER INFORMATION: backbone"
US-08-987-574-32

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCAGCCACTCACCACC 2

RESULT 531
US-09-184-445-10
Sequence 10, Application US/09184445
Patent No. 6174703
GENERAL INFORMATION:
APPLICANT: Harrington, Lea A.
APPLICANT: Robinson, Murray O.
TITLE OF INVENTION: No. 6174703el Genes Encoding Telomerase Protein
TITLE OF INVENTION: 1
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen, Inc.
STREET: 1840 De Havilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/184,445
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/751,189
FILING DATE: 15-NOV-1996
ATTORNEY/AGENT INFORMATION:
NAME: Oleski, Nancy A.
REGISTRATION NUMBER: 34,688
REFERENCE/DOCKET NUMBER: A-433
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid

DESCRIPTION: /desc = "oligo nucleotide"
US-09-184-445-10
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGACGCTATGAC 3543
DB 1 CAGGAACGCTATGAC 17

RESULT 532
US-09-184-073-9
Sequence 9, Application US/09184073
Patent No. 6183964
GENERAL INFORMATION:
APPLICANT: Boeke, Jef
APPLICANT: Brachmann, Rainer
TITLE OF INVENTION: NUCLEIC ACIDS ENCODING P53
TITLE OF INVENTION: MUTATIONS WHICH SUPPRESS P53 CANCER MUTATIONS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff
STREET: 1001 G Street, NW
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/184,073
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/795,006
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A
REGISTRATION NUMBER: 32141
REFERENCE/DOCKET NUMBER: 01107.03170
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
TELEX:
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-184-073-9

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1378 GAGCAGCGGACTGACA 1394
DB 1 GAGGAGCGGACTGACA 17

RESULT 533
US-08-535-168-3/c
Sequence 3, Application US/08535168
Patent No. 6184369
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan

```
/ APPLICANT: Zendegui, Joseph G.
/ APPLICANT: Ojwang, Joshua O.
/ TITLE OF INVENTION: Anti-Viral Guanosine-Rich
/ NUMBER OF SEQUENCES: 52
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Fulbright & Jaworski
/ STREET: 1301 McKinney, Suite 5100
/ CITY: Houston
/ STATE: Texas
/ COUNTRY: U.S.A.
/ ZIP: 77010-3095
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/535,168
/ FILING DATE:
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US94/04529
/ FILING DATE: 28-OCT-1993
/ APPLICATION NUMBER: US 08/053,027
/ FILING DATE: 23-APR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Paul, Thomas D.
/ REGISTRATION NUMBER: 32,714
/ REFERENCE/DOCKET NUMBER: D-5574-CIP
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 713/651-5151
/ TELEFAX: 713/651-5246
/ TELEX: 762829
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/
/ US-08-535-168-3
/
/ Query Match 0.3%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 2.8e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 2690 CCAGCCACTCACCACC 2706
/ Db 18 CCACCACCACCACCACC 2
/
/ RESULT 534
/ US-08-535-168-31/c
/ Sequence 31, Application US/08535168
/ Patent No. 6184369
/ GENERAL INFORMATION:
/ APPLICANT: Rando, Robert F.
/ APPLICANT: Pennewald, Susan
/ APPLICANT: Zendegui, Joseph G.
/ APPLICANT: Ojwang, Joshua O.
/ APPLICANT: Hogan, Michael E.
/ TITLE OF INVENTION: Anti-Viral Guanosine-Rich
/ NUMBER OF SEQUENCES: 52
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Fulbright & Jaworski
/ STREET: 1301 McKinney, Suite 5100
/ CITY: Houston
/ STATE: Texas
/ COUNTRY: U.S.A.
/ ZIP: 77010-3095
```

```
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/535,168
/ FILING DATE:
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US94/04529
/ FILING DATE: 28-OCT-1993
/ APPLICATION NUMBER: US 08/053,027
/ FILING DATE: 23-APR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Paul, Thomas D.
/ REGISTRATION NUMBER: 32,714
/ REFERENCE/DOCKET NUMBER: D-5574-CIP
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 713/651-5151
/ TELEFAX: 713/651-5246
/ TELEX: 762829
/ INFORMATION FOR SEQ ID NO: 31:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: 18
/ OTHER INFORMATION: /note="Amine moiety
/ OTHER INFORMATION: attached to 3' end"
/
/ US-08-535-168-31
/
/ Query Match 0.3%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 2.8e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 2690 CCAGCCACTCACCACC 2706
/ Db 18 CCACCACCACCACCACC 2
/
/ RESULT 535
/ US-08-535-168-32/c
/ Sequence 32, Application US/08535168
/ Patent No. 6184369
/ GENERAL INFORMATION:
/ APPLICANT: Rando, Robert F.
/ APPLICANT: Pennewald, Susan
/ APPLICANT: Zendegui, Joseph G.
/ APPLICANT: Ojwang, Joshua O.
/ APPLICANT: Hogan, Michael E.
/ TITLE OF INVENTION: Anti-Viral Guanosine-Rich
/ NUMBER OF SEQUENCES: 52
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Fulbright & Jaworski
/ STREET: 1301 McKinney, Suite 5100
/ CITY: Houston
/ STATE: Texas
/ COUNTRY: U.S.A.
/ ZIP: 77010-3095
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/535,168
/ FILING DATE:
```

CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04529
FILING DATE: 28-OCT-1993
APPLICATION NUMBER: US 08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety
OTHER INFORMATION: attached to 3' end and phosphothioate
US-08-535-168-32

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCACCACCACCACC 2

RESULT 536
US-09-050-159-120
Sequence 120, Application US/09050159A
Patent No. 6197505
GENERAL INFORMATION:
APPLICANT: No. 6197505berg, Leif T
APPLICANT: Andersson, Maria K
APPLICANT: Linstrom, Per H
TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
FILE REFERENCE: 1248/10042
CURRENT APPLICATION NUMBER: US/09/050,159A
CURRENT FILING DATE: 1998-03-27
EARLIER APPLICATION NUMBER: 60/042,930
EARLIER FILING DATE: 1987-04-03
NUMBER OF SEQ ID NOS: 133
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 120
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-120

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 537

US-09-031-626-86
Sequence 86, Application US/09031626
Patent No. 6228581
GENERAL INFORMATION:
APPLICANT: Acton, Susan L.
APPLICANT: Ordovas, Jose M.
TITLE OF INVENTION: DIAGNOSTIC ASSAYS AND KITS FOR BODY MASS AND
FILE REFERENCE: MIA-005.04
CURRENT APPLICATION NUMBER: US/09/031,626
CURRENT FILING DATE: 1998-02-27
EARLIER APPLICATION NUMBER: 08/890,979
EARLIER FILING DATE: 1997-07-10
NUMBER OF SEQ ID NOS: 121
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 86
LENGTH: 18
TYPE: DNA
ORGANISM: Human
US-09-031-626-86

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 538
US-09-307-392-10
Sequence 10, Application US/09307392
Patent No. 6228999
GENERAL INFORMATION:
APPLICANT: Guilfoyle, Richard A
APPLICANT: Guo, Zhen
TITLE OF INVENTION: Nucleic Acid Indexing
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Quarles & Brady
STREET: 1 South Pinckney St.
CITY: Madison
STATE: WI
COUNTRY: US
ZIP: 53703
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/307,392
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/815,448
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Berson, Bennett J
REGISTRATION NUMBER: 37094
REFERENCE/DOCKET NUMBER: 960296.94053
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-251-5000
TELEFAX: 608-251-9166
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "M13revP reverse primer"

US-09-307-392-10

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

DB 1 CAGGAAACAGCTATGAC 17

RESULT 539

US-09-018-584A-55/c
Sequence 55, Application US/09018584A

Patent No. 6238863

GENERAL INFORMATION:

APPLICANT: Schumm, James W.

APPLICANT: Bachner, Jeffery W.

TITLE OF INVENTION: MATERIALS AND METHODS FOR IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM

TITLE OF INVENTION: REPEAT DNA MARKERS

NUMBER OF SEQUENCES: 147

CORRESPONDENCE ADDRESS:

ADDRESS: Promega Corporation

STREET: 2800 Woods Hollow Road

CITY: Madison

STATE: Wisconsin

COUNTRY: U.S.A.

ZIP: 53711-5399

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb

COMPUTER: IBM compatible PC

OPERATING SYSTEM: Windows 95

SOFTWARE: Word 97 (DOS text format)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/018,584A

FILING DATE: 04-Feb-1998

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Grady J. Frenchick

REGISTRATION NUMBER: 29,018

REFERENCE/DOCKET NUMBER: 16026.9180

TELECOMMUNICATION INFORMATION:

TELEPHONE: (608) 257-3501

TELEFAX: (608) 257-2275

INFORMATION FOR SEQ ID NO: 55:

SEQUENCE CHARACTERISTICS:

LENGTH: 18

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

US-09-018-584A-55

Query Match

Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3081 AAGTGGCAGGCGAAG 3097

DB 17 AAGTGGTGGTGGCAGG 1

RESULT 540

US-09-138-736-8

Sequence 8, Application US/09138736

Patent No. 6270767

GENERAL INFORMATION:

APPLICANT: PARANHOS-BACCALA, Glaucia

APPLICANT: LESNECHAL, Mylene

APPLICANT: JOLIVET, Michel

TITLE OF INVENTION: NEW TRYPAANOSOMA CRUZI ANTIGEN, AND GENE

TITLE OF INVENTION: ENCODING THE LATTER; THEIR APPLICATION TO THE DETECTION OF

TITLE OF INVENTION: CHAGAS DISEASE

NUMBER OF SEQUENCES: 13

CORRESPONDENCE ADDRESS:

ADDRESS: Oliff & Berridge

STREET: 700 South Washington Street, Suite 300

CITY: Alexandria

STATE: Virginia

COUNTRY: U.S.A.

ZIP: 22314

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/138,736

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/480,917

FILING DATE: 07-JUN-1995

ATTORNEY/AGENT INFORMATION:

NAME: Berridge, William P.

REGISTRATION NUMBER: 30,024

REFERENCE/DOCKET NUMBER: WPA 36400

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-836-6400

TELEFAX: 703-836-2787

INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-09-138-736-8

Query Match

Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1130 TGCAGCAGCGCAGCAG 1146

DB 1 TGCAGCAGCGCAGCAG 17

RESULT 541

US-09-461-697-466

Sequence 466, Application US/09461697

Patent No. 6277974

GENERAL INFORMATION:

APPLICANT: COSENT NEUROSCIENCE, Inc.

APPLICANT: Lo, Donald C.

APPLICANT: Barney, Shawn

APPLICANT: Thomas, Mary Beth

APPLICANT: Portman, Stuart D.

APPLICANT: Putnam, Kaeturi

APPLICANT: Katz, Lawrence C.

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING

TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING

FILE REFERENCE: 10001-005-999

CURRENT APPLICATION NUMBER: US/09/461,697

NUMBER OF SEQ ID NOS: 466

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 466

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Oligonucleotide

US-09-461-697-466

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
| | | | | | | | | | | | | | | | | |
DB 1 CAGGAAACGCTATGAC 17

RESULT 542
US-09-380-786A-10
; Sequence 10, Application US/09380786A
; Patent No. 6280948
; GENERAL INFORMATION:
; APPLICANT: Guilfoyle, Richard A
; APPLICANT: Guo, Zhen
; TITLE OF INVENTION: Nucleic Acid Indexing
; FILE REFERENCE: 960296, 96706
; CURRENT APPLICATION NUMBER: US/09/380, 786A
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/US98/04819
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: US 08/815,448
; PRIOR FILING DATE: 1997-03-11
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: M13RevP
US-09-380-786A-10

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
| | | | | | | | | | | | | | | | | |
DB 1 CAGGAAACGCTATGAC 17

RESULT 543
US-09-380-786A-28/c
; Sequence 28, Application US/09380786A
; Patent No. 6280948
; GENERAL INFORMATION:
; APPLICANT: Guilfoyle, Richard A
; APPLICANT: Guo, Zhen
; TITLE OF INVENTION: Nucleic Acid Indexing
; FILE REFERENCE: 960296, 96706
; CURRENT APPLICATION NUMBER: US/09/380, 786A
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/US98/04819
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: US 08/815,448
; PRIOR FILING DATE: 1997-03-11
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: adaptor
US-09-380-786A-28

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
| | | | | | | | | | | | | | | | | |
DB 18 CAGGAAACGCTATGAC 2

RESULT 544
US-08-819-646-3
; Sequence 3, Application US/08819646
; Patent No. 6281348
; GENERAL INFORMATION:
; APPLICANT: CITIGAN, Andrew M.
; APPLICANT: ALBERTSEN, Marc C.
; TITLE OF INVENTION: Reversible Nuclear Genetic System For
; TITLE OF INVENTION: Male Sterility In Transgenic Plants
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/819,646
; FILING DATE: 17-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/474,556
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/351,899
; FILING DATE: 08-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 33229/329/PIHI
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-819-646-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACGCTATGAC 3543
| | | | | | | | | | | | | | | | | |
DB 1 CAGGAAACGCTATGAC 17

RESULT 545
US-09-557-917-115
; Sequence 115, Application US/09557917
; Patent No. 6284457
; GENERAL INFORMATION:
; APPLICANT: Aida, Yoko
; TITLE OF INVENTION: METHODS FOR JUDGING THE POSSIBILITY OF THE ONSET OF
; TITLE OF INVENTION: BOVINE LEUKEMIA AND THE RESISTANCE THERETO
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/557,917
; CURRENT FILING DATE: 2000-04-21

PRIOR APPLICATION NUMBER: 09/147,550
PRIOR FILING DATE: 1999-04-23
PRIOR APPLICATION NUMBER: PCT/JP97/02485
PRIOR FILING DATE: 1997-07-17
PRIOR APPLICATION NUMBER: JP 8-190933
PRIOR FILING DATE: 1996-07-19
PRIOR APPLICATION NUMBER: JP 9-77979
PRIOR FILING DATE: 1997-03-28
NUMBER OF SEQ ID NOS: 115
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 115
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PRIMER
US-09-557-917-115

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 546
US-08-795-445A-11
Sequence 11, Application US/08795445A
Patent No. 6284485
GENERAL INFORMATION:
APPLICANT: Boyle, William J.
APPLICANT: Lacey, David L.
APPLICANT: Calzone, Frank J.
APPLICANT: Chang, Ming-Shi
TITLE OF INVENTION: OSTEOPROTEGERIN
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Amgen Inc.
STREET: 1840 Dehavilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/795,445A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/577,788
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Winter, Robert B.
REFERENCE/DOCKET NUMBER: A-378
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-795-445A-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 547
US-08-795-447A-11
Sequence 11, Application US/08795447A
Patent No. 6284728
GENERAL INFORMATION:
APPLICANT: Boyle, William J.
APPLICANT: Lacey, David L.
APPLICANT: Calzone, Frank J.
APPLICANT: Chang, Ming-Shi
TITLE OF INVENTION: Osteoprotegerin
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Amgen Inc.
STREET: One Amgen Center Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91362-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/795,447A
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Winter, Robert B.
REFERENCE/DOCKET NUMBER: A-378D2
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-795-447A-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 548
US-08-974-186-11
Sequence 11, Application US/08974186
Patent No. 6284740
GENERAL INFORMATION:
APPLICANT: Boyle, William J.
APPLICANT: Lacey, David L.
APPLICANT: Calzone, Frank J.
APPLICANT: Chang, Ming-Shi
TITLE OF INVENTION: OSTEOPROTEGERIN
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Amgen Inc.
STREET: 1840 Dehavilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/974,186
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/577,788
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Winter, Robert B.
REFERENCE/DOCKET NUMBER: A-378
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-974-186-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAAACAGCTATGAC 17

RESULT 549
US-08-795-446B-11
Sequence 11, Application US/08795446B
Patent No. 6288032
GENERAL INFORMATION:
APPLICANT: Boyle, William J.
APPLICANT: Lacey, David L.
APPLICANT: Calzone, Frank J.
APPLICANT: Chang, Ming-Shi
TITLE OF INVENTION: OSTEOPROTEGERIN
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen Inc.
STREET: 1840 Dehavenland Drive
STATE: Thousand Oaks
COUNTRY: California
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/795,446B
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/577,788
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Winter, Robert B.
REFERENCE/DOCKET NUMBER: A-378
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-795-446B-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAAACAGCTATGAC 17

RESULT 550
US-09-017-974-3/C
Sequence 3, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossam, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-017-974-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCGGCACTCACCACCC 2706

Db 18 CCACCACCACCCACCC 2

RESULT 551
US-09-017-974-31/C
Sequence 31, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:

```

; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18
; OTHER INFORMATION: /note= "Amine moiety
; OTHER INFORMATION: attached to 3' end"
;
; US-09-017-974-31
;
; Query Match 0.3%; Score 13.8; DB 1; Length 18;
; Best Local Similarity 88.2%; Pred. No. 2.8e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 2690 CCAGCCACTCACCACC 2706
; Db 18 CCAGCCACCACCACC 2
;
; RESULT 552
; US-09-017-974-32/C
; Sequence 32, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:

```

```

; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18
; OTHER INFORMATION: /note= "Amine moiety
; OTHER INFORMATION: attached to 3' end and phosphothioate
; OTHER INFORMATION: backbone"
;
; US-09-017-974-32
;
; Query Match 0.3%; Score 13.8; DB 1; Length 18;
; Best Local Similarity 88.2%; Pred. No. 2.8e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 2690 CCAGCCACTCACCACC 2706
; Db 18 CCAGCCACCACCACC 2
;
; RESULT 553
; US-08-483-211A-65/C
; Sequence 65, Application US/08483211A
; Patent No. 6309853
; GENERAL INFORMATION:
; APPLICANT: THE ROCKEFELLER UNIVERSITY
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING
; TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC
; TITLE OF INVENTION: USES THEREOF
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,211A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/485,943
; FILING DATE: June 7, 1995
; APPLICATION NUMBER: 08/438,431
; FILING DATE: May 10, 1995
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/347,563
; FILING DATE: No. 6309853ember 30, 1994
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/292,345
; FILING DATE: August 17, 1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Bsq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-087 CIP21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer sWS51392
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
;
US-08-483-211A-65

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 817 ATCAAGACTTACCTGAG 833
DB 17 ATTAAGACATACCTGAG 1

RESULT 554
US-09-301-456-4
; Sequence 4, Application US/09301456
; Patent No. 6312955
; GENERAL INFORMATION:
; APPLICANT: HRUBY, Dennis E.
; TITLE OF INVENTION: STREPTOCOCCUS GORDONII STRAINS RESISTANT TO
; TITLE OF INVENTION: STREPTOCOCCUS GORDONII STRAINS RESISTANT TO
; FILE REFERENCE: 016921-151
; CURRENT APPLICATION NUMBER: US/09/301,456
; CURRENT FILING DATE: 1999-04-29
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Streptococcus gordonii
;
US-09-301-456-4

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 3527 CGGGGAACGCTTATGAC 3543
DB 1 CAGGAACGCTTATGAC 17

RESULT 555
US-09-430-201-3/C
; Sequence 3, Application US/09430201
; Patent No. 6313373
; GENERAL INFORMATION:
; APPLICANT: Crisp, James F.
; TITLE OF INVENTION: Tissue Specific Promoters and Transgenic Animals for
; TITLE OF INVENTION: the Screening of Pharmaceuticals
; FILE REFERENCE: CASE-04022
; CURRENT APPLICATION NUMBER: US/09/430,201
; CURRENT FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: 60/106,495
; PRIOR FILING DATE: 1998-10-30
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
;
US-09-430-201-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 AGCAGCAGCTGACGACG 1137
DB 17 AGCAGCAGCTTAAACG 1

RESULT 556
US-09-355-947-6
; Sequence 6, Application US/09355947
; Patent No. 6316184
; GENERAL INFORMATION:
; APPLICANT: Aida, Yoko
; TITLE OF INVENTION: METHOD FOR JUDGING A POSSIBILITY OF THE ONSET OF OVINE
; TITLE OF INVENTION: LEUKEMIA
; FILE REFERENCE: Sequence Disclosure for P18364
; CURRENT APPLICATION NUMBER: US/09/355,947
; CURRENT FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: JP 9/031787
; PRIOR FILING DATE: 1997-02-17
; PRIOR APPLICATION NUMBER: PCT/JP98/00620
; PRIOR FILING DATE: 1998-02-16
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: ovine
;
US-09-355-947-6

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTTATGAC 3543
DB 1 CAGGAACGCTTATGAC 17

RESULT 557
US-08-682-255A-3/C
; Sequence 3, Application US/08682255A
; Patent No. 6323185
```

GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendeugui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Eyles
APPLICANT: Mazumber, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-682-255A-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCAGCCACC 2706
DB 18 CCAGCCACTCAGCCACC 2

RESULT 558
US-08-682-255A-31/c
Sequence 31, Application US/08682255A
Patent No. 6323185
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendeugui, Joseph G.

APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Eyles
APPLICANT: Mazumber, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /notes="Amine moiety
OTHER INFORMATION: attached to 3' end"
US-08-682-255A-31

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCAGCCACC 2706
DB 18 CCAGCCACTCAGCCACC 2

RESULT 559
US-08-682-255A-32/c
Sequence 32, Application US/08682255A
Patent No. 6323185
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan

APPLICANT: Zendequi, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Eyles
APPLICANT: Mazunder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety
OTHER INFORMATION: attached to 3' end and phosphothioate
OTHER INFORMATION: backbone"
US-08-682-255A-32
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2690 CCAGCCACTCACCACC 2706
Db 18 CCAGCCAGCCAGCCACC 2
RESULT 560
US-09-496-694B-170
Sequence 170, Application US/09496694B
Patent No. 6335194
GENERAL INFORMATION:

APPLICANT: C. Frank Bennett
APPLICANT: Elizabeth J. Ackermann
APPLICANT: Eric E. Swayze
APPLICANT: Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: ISPH-0439
CURRENT APPLICATION NUMBER: US/09/496,694B
CURRENT FILING DATE: 2000-02-02
PRIOR APPLICATION NUMBER: 09/286,407
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 09/163,162
PRIOR FILING DATE: 1998-09-29
NUMBER OF SEQ ID NOS: 249
SEQ ID NO 170
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-496-694B-170
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2686 CAGCCAGCCACTCACC 2702
Db 2 CAGCCAGCCAGCCACC 18
RESULT 561
US-08-488-223A-65/c
Sequence 65, Application US/08488223A
Patent No. 6350730
GENERAL INFORMATION:
APPLICANT: THE ROCKEFELLER UNIVERSITY
TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC
ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
NUMBER OF SEQUENCES: 98
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,223A
FILING DATE: 07-Jun-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/485,943
FILING DATE: <Unknown>
APPLICATION NUMBER: 08/347,563
FILING DATE: NO. 6350730eember 30, 1994
APPLICATION NUMBER: 08/292,345
FILING DATE: August 17, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-087 CIP21
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 343-1684
TELEFAX: 201 343-1684
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
DESCRIPTION: sequence tagged-site specific PCR primer sWSS1392
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Human
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-08-488-223A-65

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 817 ATCAGACTTACCTGAG 833
DB 17 ATTAAGACATACCTGAG 1

RESULT 562
US-08-679-645-555/C
Sequence 555, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwigen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Linding
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkeerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
TITLE OF INVENTION: IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: Storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 555:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
DESCRIPTION: sequence tagged-site specific PCR primer sWSS1392
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Human
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-08-488-223A-65

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2328 ACGCCAGCGCCGCGCG 2344
DB 17 ACGCCAGCGCGCGCGCG 1

RESULT 563
US-09-429-130-3/C
Sequence 3, Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendegeul, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Eyles
APPLICANT: Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSER: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,668
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
TELEX: 713-238-8008
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-429-130-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCAGCCACTCACCACC 2

RESULT 564
US-09-429-130-31/C
Sequence 31, Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
Fennewald, Susan
Zendeguit, Joseph G.
Ojwang, Joshua O.
Hogan, Michael E.
Pommler, Byres
Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety
attached to 3' end"
SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-429-130-31

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCAGCCACTCACCACC 2

RESULT 565
US-09-429-130-32/C
Sequence 32, Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
Fennewald, Susan
Zendeguit, Joseph G.
Ojwang, Joshua O.
Hogan, Michael E.
Pommler, Byres
Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214


```

;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 18 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 18
; OTHER INFORMATION: /note="Amine moiety
;   attached to 3' end and phosphothioate
;   backbone"
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 32:
; US-09-429-130-32

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2690 CCAGCCACTCACCACC 2706
DB      18 CCAGCCACCACCACC 2

RESULT 566
US-09-205-995-41
; Sequence 41, Application US/09205995
; Patent No. 6368855
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995, (CIP)
; CURRENT APPLICATION NUMBER: US/09/205,995
; CURRENT FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
; PRIOR APPLICATION NUMBER: 08/661,627
; PRIOR FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 41
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide corresponding to a specific region
; OTHER INFORMATION: of the mouse Il gene.
; US-09-205-995-41

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3481 GTCATCATGGCTCTAG 3497
DB      1 GTCATCATGGCTCTAG 17

RESULT 567
US-09-205-995-54
; Sequence 54, Application US/09205995
; Patent No. 6368855
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
```

```

;
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995, (CIP)
; CURRENT APPLICATION NUMBER: US/09/205,995
; CURRENT FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
; PRIOR APPLICATION NUMBER: 08/661,627
; PRIOR FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 54
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide corresponding to a specific region
; OTHER INFORMATION: of the mouse Il gene.
; US-09-205-995-54

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3480 GGTCACTATGGCTCCA 3496
DB      2 GGTCACTATGGCTCTA 18

RESULT 568
US-08-706-945D-5
; Sequence 5, Application US/08706945D
; Patent No. 6369027
; GENERAL INFORMATION:
; APPLICANT: Boyle, William
; APPLICANT: Lacey, David
; APPLICANT: Calzone, Frank
; APPLICANT: Chang, Ming-Shi
; TITLE OF INVENTION: Osteoprotegerin
; FILE REFERENCE: A-378CIP
; CURRENT APPLICATION NUMBER: US/08/706,945D
; CURRENT FILING DATE: 1996-09-03
; PRIOR APPLICATION NUMBER: 08/577,788
; PRIOR FILING DATE: 1995-12-22
; NUMBER OF SEQ ID NOS: 145
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; OTHER INFORMATION: Synthesis of Oligonucleotide
; US-08-706-945D-5

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      1 CAGGAACAGCTATGAC 17

RESULT 569
US-09-638-509C-1
; Sequence 1, Application US/09638509C
; Patent No. 6372435
; GENERAL INFORMATION:
; APPLICANT: Tang, Jianming
; APPLICANT: Kaslow, Richard A.
; TITLE OF INVENTION: Method of Surveying For CC (Beta) Chemokine
; TITLE OF INVENTION: Receptor Variants and Their Association With HIV-1
; TITLE OF INVENTION: Transmission and/or Disease Progression
```

```
/ FILE REFERENCE: D6217
/ CURRENT APPLICATION NUMBER: US/09/638,509C
/ CURRENT FILING DATE: 2000-08-11
/ PRIOR APPLICATION NUMBER: 60/148,530
/ PRIOR FILING DATE: 1999-08-12
/ NUMBER OF SEQ ID NOS: 35
/ SEQ ID NO 1
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ NAME/KEY: primer bind
/ OTHER INFORMATION: universal M13 primer
US-09-638-509C-1

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 18

RESULT 570
US-09-345-882-140
/ Sequence 140, Application US/09345882
/ Patent No. 6399373
/ GENERAL INFORMATION:
/ APPLICANT: Bougueret, Lydie
/ TITLE OF INVENTION: A NUCLEIC ACID ENCODING A RETINOBLASTOMA BINDING PROTEIN (RBB-7)
/ FILE REFERENCE: GENSET.031A
/ CURRENT APPLICATION NUMBER: US/09/345,882
/ CURRENT FILING DATE: 1999-06-30
/ PRIOR APPLICATION NUMBER: US 60/091,315
/ PRIOR FILING DATE: 1998-06-30
/ PRIOR APPLICATION NUMBER: US 60/111,909
/ PRIOR FILING DATE: 1998-12-10
/ NUMBER OF SEQ ID NOS: 140
/ SOFTWARE: Patent.pm
/ SEQ ID NO 140
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ NAME/KEY: misc binding
/ LOCATION: 1..18
/ OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-345-882-140

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 571
US-09-195-716-3
/ Sequence 3, Application US/09195716
/ Patent No. 6399856
/ GENERAL INFORMATION:
/ APPLICANT: CIGAN, Andrew M.
/ APPLICANT: ALBERTSEN, Marc C.
/ TITLE OF INVENTION: Reversible Nuclear Genetic System For
/ TITLE OF INVENTION: Male Sterility In Transgenic Plants
/ NUMBER OF SEQUENCES: 23
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Foley & Lardner
/ STREET: 3000 K Street, N.W., Suite 500
```

```
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20007-5109
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.10
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/195,716
/ FILING DATE: 19-NOV-1998
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/819,646
/ FILING DATE: 17-MAR-1997
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/474,556
/ FILING DATE: 07-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/351,899
/ FILING DATE: 08-DEC-1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: BENT, Stephen A.
/ REGISTRATION NUMBER: 29,768
/ REFERENCE/DOCKET NUMBER: 033229/0660
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202) 672-5300
/ TELEFAX: (202) 672-5399
/ TELEEX: 904136
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-09-195-716-3

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3527 CCGGGAACAGCTATGAC 3543
Db      1 CAGGAACAGCTATGAC 17

RESULT 572
US-08-988-242-4
/ Sequence 4, Application US/08988242
/ Patent No. 6403103
/ GENERAL INFORMATION:
/ APPLICANT: PARANHOS-BACCALA, GLAUCIA
/ APPLICANT: LESENECHAL, MYLENE
/ APPLICANT: JOUVET, MICHEL
/ APPLICANT: MAURAND, BERNARD
/ TITLE OF INVENTION: NEW TRYPAZOSOMA CRUZI ANTIGEN, GENE
/ TITLE OF INVENTION: ENCODING THEREFOR, AND METHODS OF DETECTING AND TREATING
/ NUMBER OF SEQUENCES: 19
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: OLIF & BERRIDGE, PLC
/ STREET: P.O. BOX 19928
/ CITY: Alexandria
/ STATE: Virginia
/ COUNTRY: U.S.A.
/ ZIP: 22320
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.10
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/988,242
```

```

; FILING DATE: 10-DEC-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB 36400A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6400
; TELEFAX: 703-836-2787
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-988-242-4

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1130 TGCAGCAGCGCAGCAG 1146
DB      1 TGCAGCAGCGCGCAGAG 17

RESULT 573
US-09-387-341-130
; Sequence 130, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; EARLIER FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 130
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; US-09-387-341-130

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1166 TCACACCTGCTGCAC 1182
DB      2 TCACACCTGCTGCAC 18

RESULT 574
US-08-438-431A-65/C
; Sequence 65, Application US/08438431A
; Patent No. 6429290
; GENERAL INFORMATION:
; APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA, MARGHERITA MAFFEI,
; APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA, MARGHERITA MAFFEI,
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PR
```

```

; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/438,431A
; FILING DATE: May 10, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/347,563
; FILING DATE: No. 6429290eomber 30, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/292,345
; FILING DATE: August 17, 1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-087 CIP1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer sWSS1392
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; US-08-438-431A-65

Query Match      0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      817 ATCAGACTTACTGTAG 833
DB      17 ATCAGACTTACTGTAG 1

RESULT 575
US-09-000-286A-23
; Sequence 23, Application US/09000286A
; Patent No. 6449562
; GENERAL INFORMATION:
; APPLICANT: Lumindex Corporation
; APPLICANT: Chandler, Van S.
; APPLICANT: Fulton, Jerrold R.
; TITLE OF INVENTION: Multiplexed Analysis of Clinical Specimens Apparatus and Method
; FILE REFERENCE: 112802.500
; CURRENT APPLICATION NUMBER: US/09/000,286A
; CURRENT FILING DATE: 1998-08-18
; PRIOR APPLICATION NUMBER: PCT/US96/16198
; PRIOR FILING DATE: 1996-10-10
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patentin version 3.1
```

SEQ ID NO 23
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-000-286A-23

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1003 CATGGAGAGGAGAGA 1019
DB 2 CCTGGAGAGGAGAGA 18

RESULT 576
US-09-000-286A-24/C
Sequence 24, Application US/09000286A
Patent No. 6449562
GENERAL INFORMATION:
APPLICANT: Lumindex Corporation
APPLICANT: Chandler, Van S.
APPLICANT: Fulton, Jerrold R.
APPLICANT: Chandler, Mark B.
TITLE OF INVENTION: Multiplexed Analysis of Clinical Specimens Apparatus and Method
FILE REFERENCE: 112802.500
CURRENT FILING DATE: 1998-08-18
PRIOR APPLICATION NUMBER: PCT/US96/16198
PRIOR FILING DATE: 1996-10-10
NUMBER OF SEQ ID NOS: 34
SOFTWARE: Patentin version 3.1
SEQ ID NO 24
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-000-286A-24

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1003 CATGGAGAGGAGAGA 1019
DB 17 CCTGGAGAGGAGAGA 1

RESULT 577
US-09-000-286A-25
Sequence 25, Application US/09000286A
Patent No. 6449562
GENERAL INFORMATION:
APPLICANT: Lumindex Corporation
APPLICANT: Chandler, Van S.
APPLICANT: Fulton, Jerrold R.
APPLICANT: Chandler, Mark B.
TITLE OF INVENTION: Multiplexed Analysis of Clinical Specimens Apparatus and Method
FILE REFERENCE: 112802.500
CURRENT APPLICATION NUMBER: US/09/000,286A
CURRENT FILING DATE: 1998-08-18
PRIOR APPLICATION NUMBER: PCT/US96/16198
PRIOR FILING DATE: 1996-10-10
NUMBER OF SEQ ID NOS: 34
SOFTWARE: Patentin version 3.1
SEQ ID NO 25
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-000-286A-25

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1003 CATGGAGAGGAGAGA 1019
DB 2 CCTGGAGAGGAGAGA 18

RESULT 578
US-09-000-286A-26/C
Sequence 26, Application US/09000286A
Patent No. 6449562
GENERAL INFORMATION:
APPLICANT: Lumindex Corporation
APPLICANT: Chandler, Van S.
APPLICANT: Fulton, Jerrold R.
APPLICANT: Chandler, Mark B.
TITLE OF INVENTION: Multiplexed Analysis of Clinical Specimens Apparatus and Method
FILE REFERENCE: 112802.500
CURRENT APPLICATION NUMBER: US/09/000,286A
CURRENT FILING DATE: 1998-08-18
PRIOR APPLICATION NUMBER: PCT/US96/16198
PRIOR FILING DATE: 1996-10-10
NUMBER OF SEQ ID NOS: 34
SOFTWARE: Patentin version 3.1
SEQ ID NO 26
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-000-286A-26

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1003 CATGGAGAGGAGAGA 1019
DB 17 CCTGGAGAGGAGAGA 1

RESULT 579
US-09-270-956-33
Sequence 33, Application US/09270956
Patent No. 6451571
GENERAL INFORMATION:
APPLICANT: Loeb, Lawrence A.
APPLICANT: Black, Margaret E.
TITLE OF INVENTION: THYMIDINE KINASE MUTANTS
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/270,956
FILING DATE: 17-Mar-1999
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McMaesters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 240052.409C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-270-956-33

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 580
US-09-502-558-40
Sequence 40, Application US/09502558
Patent No. 6453244

GENERAL INFORMATION:
APPLICANT: Peter J. Oefner
TITLE OF INVENTION: DETECTION OF POLYMORPHISMS BY DENATURING
FILE REFERENCE: Sun-174P
CURRENT APPLICATION NUMBER: US/09/502,558
CURRENT FILING DATE: 2000-02-10
NUMBER OF SEQ ID NOS: 40
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 40
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: synthetic oligonucleotide
US-09-502-558-40

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 581
US-09-750-580-6

Sequence 6, Application US/09750580
Patent No. 6455280
GENERAL INFORMATION:
APPLICANT: Yen, Frances
APPLICANT: Denison, Blake
APPLICANT: Bour, Barbara
APPLICANT: Bihain, Bernard
APPLICANT: Dumas Milne Edwards, Jean-Baptiste
APPLICANT: Duclert, Aymeric
APPLICANT: Bougueleret, Lydie
APPLICANT: Ebbers-Reed, Dana
APPLICANT: Salter-Cid, Luisa
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH
FILE REFERENCE: 89 US2, CIP
CURRENT APPLICATION NUMBER: US/09/750,580
CURRENT FILING DATE: 2000-12-28
PRIOR APPLICATION NUMBER: US 09/599,362
PRIOR FILING DATE: 2000-06-21
PRIOR APPLICATION NUMBER: PCT/IB00/0101
PRIOR FILING DATE: 2000-06-21
PRIOR APPLICATION NUMBER: PCT/IB99/02058
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: US 49/469/099
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: US 60/113,686
PRIOR FILING DATE: 1998-12-22

PRIOR APPLICATION NUMBER: US 60/141,032
PRIOR FILING DATE: 1999-06-25
NUMBER OF SEQ ID NOS: 6
SOFTWARE: Patent.pm
SEQ ID NO 6
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-750-580-6

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 582
US-08-488-225A-65/c
Sequence 65, Application US/08488225A
Patent No. 6471956

GENERAL INFORMATION:
APPLICANT: THE ROCKEFELLER UNIVERSITY
TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING
TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES
CORRESPONDENCE ADDRESSES:
ADDRESSER: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,225A
FILING DATE: June 7, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/483,211
FILING DATE: June 7, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/438,431
FILING DATE: May 10, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/347,563
FILING DATE: No. 6471956ember 30, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/292,345
FILING DATE: August 17, 1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-087 CIP2J
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer
; DESCRIPTION: 8MS31392
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; US-08-488-225A-65

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 817 ATCAAGCTTACTGTAG 833
DB 17 ATTAAGACATCACTGAG 1

RESULT 583
US-09-807-166-5
; Sequence 5, Application US/09807166
; Patent No. 6472517
; GENERAL INFORMATION:
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Nucleic acids encoding human CIDE-B protein and polymorphic markers
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/807,166
; PRIOR FILING DATE: 2001-04-09
; PRIOR APPLICATION NUMBER: US 60/103,729
; PRIOR FILING DATE: 1998-10-09
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patent.pm
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: sequencing oligonucleotide PrimerRP
; US-09-807-166-5

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 584
US-09-539-333D-231
; Sequence 231, Application US/09539333D
; Patent No. 6476208
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Bihaïn, Bernard
; APPLICANT: Bessieux, Laurent
; TITLE OF INVENTION: SCHIZOPHRENIA ASSOCIATED GENES, PROTEINS AND BIALLELIC MARKERS
; FILE REFERENCE: GENSET.047AUS
; CURRENT APPLICATION NUMBER: US/09/539,333D
; PRIOR FILING DATE: 2000-03-30
; PRIOR APPLICATION NUMBER: US 60/126,903
; PRIOR FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: US 60/131,971
; PRIOR FILING DATE: 1999-04-30
; PRIOR APPLICATION NUMBER: US 60/132,065
```

```

; PRIOR FILING DATE: 1999-04-30
; PRIOR APPLICATION NUMBER: US 60/143,928
; PRIOR FILING DATE: 1999-07-14
; PRIOR APPLICATION NUMBER: US 60/145,915
; PRIOR FILING DATE: 1999-07-27
; PRIOR APPLICATION NUMBER: US 60/146,453
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: US 60/146,452
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: US 60/162,288
; PRIOR FILING DATE: 1999-10-28
; PRIOR APPLICATION NUMBER: US 09/416,384
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 231
; SOFTWARE: Patent.pm
; SEQ ID NO 231
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: sequencing oligonucleotide PrimerRP
; US-09-539-333D-231

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 585
US-09-499-522-20
; Sequence 20, Application US/09499522
; Patent No. 6479238
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Bihaïn, Bernard
; TITLE OF INVENTION: POLYMORPHIC MARKERS OF THE LSR GENE
; FILE REFERENCE: GENSET.053AUS
; CURRENT APPLICATION NUMBER: US/09/499,522
; PRIOR FILING DATE: 2000-02-10
; PRIOR APPLICATION NUMBER: US 60/119,592
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: US 60/144,784
; PRIOR FILING DATE: 1999-07-20
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patent.pm
; SEQ ID NO 20
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: sequencing oligonucleotide PrimerRP
; US-09-499-522-20

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 586
US-09-506-286B-28
; Sequence 28, Application US/09506286B
; Patent No. 6482414
; GENERAL INFORMATION:
; APPLICANT: Dowling, Patricia W.
```

```

; APPLICANT: Youngner, Julius S.
; APPLICANT: The University of Pittsburgh, of the Commonwealth
; TITLE OF INVENTION: COLD-ADAPTED EQUINE INFLUENZA VIRUSES
; FILE REFERENCE: EQ-1-C2
; CURRENT APPLICATION NUMBER: US/09/506,286B
; CURRENT FILING DATE: 2000-02-16
; PRIOR APPLICATION NUMBER: 09/133,921
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: PCT/US99/18583
; PRIOR FILING DATE: 1999-08-12
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-506-286B-28

Query Match          0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      1 CAGGAAACAGCTATGAC 17

RESULT 587
US-09-153-242-11/C
; Sequence 11, Application US/09153242
; Patent No. 6482592
; GENERAL INFORMATION:
; APPLICANT: Lundberg, Joakim
; APPLICANT: Uhlen, Mathias
; TITLE OF INVENTION: MODULAR PROBES II
; FILE REFERENCE: 1181-242
; CURRENT APPLICATION NUMBER: US/09/153,242
; CURRENT FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: PCT/GB97/02629
; PRIOR FILING DATE: 1997-09-26
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: pUC18,
; OTHER INFORMATION: reverse, modulating module, generic
US-09-153-242-11

Query Match          0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      17 CAGGAAACAGCTATGAC 1

RESULT 588
US-09-920-760-64
; Sequence 64, Application US/09920760
; Patent No. 6492173
; GENERAL INFORMATION:
; APPLICANT: Lek M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN D2 EXPRESSION
; FILE REFERENCE: RTS-0275
; CURRENT APPLICATION NUMBER: US/09/920,760
; CURRENT FILING DATE: 2001-08-01
```

```

; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO: 64
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-760-64

Query Match          0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      724 CGAGCCCTCTCTCAT 740
DB      1 CGAGCTACTTCTCAT 17

RESULT 589
US-09-216-393B-346
; Sequence 346, Application US/09216393B
; Patent No. 6514694
; GENERAL INFORMATION:
; APPLICANT: Milhausen, Michael James
; TITLE OF INVENTION: TOXOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND USES THERE
; FILE REFERENCE: TX-1-C2
; CURRENT APPLICATION NUMBER: US/09/216,393B
; CURRENT FILING DATE: 1998-12-18
; PRIOR APPLICATION NUMBER: 08/994,825
; PRIOR FILING DATE: 1997-12-19
; NUMBER OF SEQ ID NOS: 366
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 346
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-09-216-393B-346

Query Match          0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3527 CCGGGAACAGCTATGAC 3543
DB      1 CAGGAAACAGCTATGAC 17

RESULT 590
US-09-671-317-493
; Sequence 493, Application US/09671317
; Patent No. 6528260
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Cohen, Amick
; TITLE OF INVENTION: BIALLELIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
; FILE REFERENCE: 62. US3.CIP
; CURRENT APPLICATION NUMBER: US/09/671,317
; CURRENT FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 09/536,178
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT/IB00/00403
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 60/126,269
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 60/131,961
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 977
; SOFTWARE: Patent.pm
; SEQ ID NO: 493
```

/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-671-317-493

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 591
US-09-292-542A-15
/ Sequence 15, Application US/09292542A
/ Patent No. 6531279
/ GENERAL INFORMATION:
/ APPLICANT: Blumenfeld, Marta
/ APPLICANT: Chumakov, Ilya
/ APPLICANT: Bougueleret, Lydie
/ TITLE OF INVENTION: Genomic Sequence Of The 5-Lipoxygenase-Activating Protein (FLAP)
/ Patent No. 6531279
/ TITLE OF INVENTION: Polymorphic Markers Thereof And Methods For Detection Of Asthma.
/ FILE REFERENCE: GENSET.026A
/ CURRENT FILING DATE: 1999-04-15
/ CURRENT APPLICATION NUMBER: US/09/292,542A
/ PRIOR APPLICATION NUMBER: US 60/081893
/ PRIOR FILING DATE: 1998-04-15
/ PRIOR APPLICATION NUMBER: US 60/091314
/ PRIOR FILING DATE: 1998-06-30
/ PRIOR APPLICATION NUMBER: US 60/123406
/ PRIOR FILING DATE: 1999-03-08
/ NUMBER OF SEQ ID NOS: 15
/ SOFTWARE: Patent.pm
/ SEQ ID NO 15
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-292-542A-15

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 592
US-09-536-059-24
/ Sequence 24, Application US/09536059
/ Patent No. 6544737
/ GENERAL INFORMATION:
/ APPLICANT: Blumenfeld, Marta
/ APPLICANT: Chumakov, Ilya
/ APPLICANT: Bougueleret, Lydie
/ APPLICANT: Cohen-Akenzie, Annick
/ TITLE OF INVENTION: GENOMIC SEQUENCE OF THE purH GENE AND purH-RELATED BIALLELIC
/ TITLE OF INVENTION: MARKERS.
/ FILE REFERENCE: GENSET.058AUS
/ CURRENT APPLICATION NUMBER: US/09/536,059
/ PRIOR FILING DATE: 2000-03-31
/ PRIOR APPLICATION NUMBER: US 60/125,961
/ PRIOR FILING DATE: 1999-03-24
/ NUMBER OF SEQ ID NOS: 24
/ SOFTWARE: Patent.pm

/ SEQ ID NO 24
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-536-059-24

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 593
US-09-655-804B-49
/ Sequence 49, Application US/09655804B
/ Patent No. 6548251
/ GENERAL INFORMATION:
/ APPLICANT: MALYKH, Andrei
/ APPLICANT: KOZYAVKIN, Sergei
/ APPLICANT: POLOUCHINE, Nikolai
/ APPLICANT: SLESAREV, Alexei
/ TITLE OF INVENTION: INHIBITION OF MOLECULAR AND BIOLOGICAL PROCESSES USING MODIFIED
/ TITLE OF INVENTION: OLIGONUCLEOTIDES
/ FILE REFERENCE: 107070
/ CURRENT APPLICATION NUMBER: US/09/655,804B
/ CURRENT FILING DATE: 2000-09-05
/ NUMBER OF SEQ ID NOS: 91
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 49
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Oligonucleotide
US-09-655-804B-49

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAACAGCTATGAC 17

RESULT 594
US-09-679-409-134
/ Sequence 134, Application US/09679409
/ Patent No. 6555316
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marta
/ APPLICANT: Chumakov, Ilya
/ APPLICANT: Bougueleret, Lydie
/ APPLICANT: Besson, Laurent
/ TITLE OF INVENTION: SCHIZOPHRENIA ASSOCIATED GENE, PROTEINS AND BIALLELIC MARKERS
/ FILE REFERENCE: 53.US15.CIP
/ CURRENT APPLICATION NUMBER: US/09/679,409
/ PRIOR FILING DATE: 2000-10-03
/ PRIOR APPLICATION NUMBER: 09/539,333
/ PRIOR FILING DATE: 2000-03-03
/ PRIOR APPLICATION NUMBER: 09/416,384
/ PRIOR FILING DATE: 1999-10-12
/ PRIOR APPLICATION NUMBER: 60/168,088
/ PRIOR FILING DATE: 1999-11-30
/ NUMBER OF SEQ ID NOS: 134
/ SOFTWARE: Patent.pm
/ SEQ ID NO 134

LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-679-409-134

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 595
US-09-762-861B-28
Sequence 28, Application US/09762861B
Patent No. 6579528

GENERAL INFORMATION:
APPLICANT: The University of Pittsburgh - of the Commonwealth System of Higher
APPLICANT: Education
APPLICANT: Downing, Patricia W.
APPLICANT: Youngner, Julius S.
TITLE OF INVENTION: COLD-ADAPTED EQUINE INFLUENZA VIRUSES
FILE REFERENCE: EQ-1-C1-PUS (formerly HKZ-033CPUS)
CURRENT APPLICATION NUMBER: US/09/762,861B
CURRENT FILING DATE: 2001-02-13
PRIOR APPLICATION NUMBER: PCT/US99/18583
PRIOR FILING DATE: 1999-08-12
PRIOR APPLICATION NUMBER: 09/133,921
PRIOR FILING DATE: 1998-08-13
NUMBER OF SEQ ID NOS: 43
SOFTWARE: PatentIn version 3.1
SEQ ID NO 28
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic primer
US-09-762-861B-28

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 596
US-09-569-852B-8
Sequence 8, Application US/09569852B
Patent No. 6582909
GENERAL INFORMATION:
APPLICANT: Bougueleret, Lydie
APPLICANT: Bihain, Bernard
APPLICANT: Denison, Blake
APPLICANT: Yen-Polin, Frances
TITLE OF INVENTION: APM1 Biallelic Markers and Uses Thereof
FILE REFERENCE: GEN-T113XC2
CURRENT APPLICATION NUMBER: US/09/569,852B
CURRENT FILING DATE: 2002-03-12
PRIOR APPLICATION NUMBER: PCT/IB99/01858
PRIOR FILING DATE: 1999-11-04
PRIOR APPLICATION NUMBER: US 09/434,848
PRIOR FILING DATE: 1999-11-04
PRIOR APPLICATION NUMBER: US 60/119,593
PRIOR FILING DATE: 1999-02-10
PRIOR APPLICATION NUMBER: US 60/107,113
PRIOR FILING DATE: 1998-11-04

NUMBER OF SEQ ID NOS: 8
SOFTWARE: PatentIn version 3.1
SEQ ID NO 8
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-569-852B-8

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 597
US-08-577-788C-11
Sequence 11, Application US/08577788C
Patent No. 6613544
GENERAL INFORMATION:
APPLICANT: Boyle, William
APPLICANT: Lacey, David
APPLICANT: Calzone, Frank
APPLICANT: Chang, Ming-Shi
TITLE OF INVENTION: Osteoprotegerin
FILE REFERENCE: A-378 Rev
CURRENT APPLICATION NUMBER: US/08/577,788C
CURRENT FILING DATE: 1995-12-22
NUMBER OF SEQ ID NOS: 58
SOFTWARE: PatentIn version 3.1
SEQ ID NO 11
LENGTH: 18
TYPE: DNA
ORGANISM: Rattus rattus
US-08-577-788C-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 598
US-09-204-865-6
Sequence 6, Application US/09204865
Patent No. 6638760
GENERAL INFORMATION:
APPLICANT: Chen, Jer-Kang
APPLICANT: Chies, Claudia
APPLICANT: FRY, George
APPLICANT: Furniss, Vergine
APPLICANT: Lambert, Stephen
APPLICANT: O'Neill, Roger
APPLICANT: Mehropouyan, Majid
TITLE OF INVENTION: METHODS AND APPARATUS FOR FLOW-THROUGH
FILE REFERENCE: 9584-0006-999
CURRENT APPLICATION NUMBER: US/09/204,865
CURRENT FILING DATE: 1998-12-03
NUMBER OF SEQ ID NOS: 8
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 6
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Sequencing primer
US-09-204-865-6

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 599
US-09-828-303-25
Sequence 25, Application US/09828303
Patent No. 6677504
GENERAL INFORMATION:
APPLICANT: COSTA E SILVA, OSWALDO DA
APPLICANT: BOHNER, HANS J.
APPLICANT: VAN THIELEN, NOCHA
APPLICANT: CHEN, ROUYING
TITLE OF INVENTION: TRANSCRIPTION FACTOR STRESS-RELATED PROTEINS AND
TITLE OF INVENTION: METHODS OF USE IN PLANTS
FILE REFERENCE: 16313-0030
CURRENT APPLICATION NUMBER: US/09/828,303
CURRENT FILING DATE: 2001-08-20
PRIOR APPLICATION NUMBER: 60/196,001
PRIOR FILING DATE: 2000-04-07
NUMBER OF SEQ ID NOS: 79
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 25
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-828-303-25

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 600
US-10-065-133A-28
Sequence 28, Application US/10065133A
Patent No. 6685946
GENERAL INFORMATION:
APPLICANT: Dowling, Patricia W.
APPLICANT: Younger, Julius S.
TITLE OF INVENTION: COLD-ADAPTED EQUINE INFLUENZA VIRUSES
FILE REFERENCE: EQ-1-C2-1
CURRENT APPLICATION NUMBER: US/10/065,133A
CURRENT FILING DATE: 2002-12-10
PRIOR APPLICATION NUMBER: PCT/US99/10583
PRIOR FILING DATE: 1999-08-12
PRIOR APPLICATION NUMBER: 09/133,921
PRIOR FILING DATE: 1998-08-13
NUMBER OF SEQ ID NOS: 108
SOFTWARE: PatentIn version 3.1
SEQ ID NO 28
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-10-065-133A-28
Query Match
0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 601
US-09-828-310-16
Sequence 16, Application US/09828310
Patent No. 6689939
GENERAL INFORMATION:
APPLICANT: COSTA E SILVA, OSWALDO DA
APPLICANT: BOHNER, HANS J.
APPLICANT: VAN THIELEN, NOCHA
APPLICANT: CHEN, ROUYING
TITLE OF INVENTION: GTP BINDING STRESS-RELATED PROTEINS AND METHODS OF USE
TITLE OF INVENTION: IN PLANTS
FILE REFERENCE: 16313-0039
CURRENT APPLICATION NUMBER: US/09/828,310
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: 60/196,001
PRIOR FILING DATE: 2000-04-07
NUMBER OF SEQ ID NOS: 50
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 16
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-828-310-16

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
DB 1 CAGGAAACAGCTATGAC 17

RESULT 602
US-09-657-013-90
Sequence 90, Application US/09657013
Patent No. 6709817
GENERAL INFORMATION:
APPLICANT: Zoghbi, Huda Y.
APPLICANT: Van den Veyver, Ignatia B
APPLICANT: Amir, Ruthie
APPLICANT: Francke, Uta
TITLE OF INVENTION: Methods of identifying mutations in a Methyl-CpG-Binding Domain
TITLE OF INVENTION: Containing Gene or Protein in Neurodevelopmental Disease and Tree
FILE REFERENCE: HO-P01893US1/0905371
CURRENT APPLICATION NUMBER: US/09/657,013
CURRENT FILING DATE: 2000-09-07
PRIOR APPLICATION NUMBER: US 60/152,778
PRIOR FILING DATE: 1999-09-07
NUMBER OF SEQ ID NOS: 114
SOFTWARE: PatentIn version 3.1
SEQ ID NO 90
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-657-013-90

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
| | | | | | | | | |
Db 1 CAGGAACAGCTATGAC 17

RESULT 603
US-09-828-062-10
Sequence 10, Application US/09828062
Patent No. 6710229
GENERAL INFORMATION:
APPLICANT: COSTA E SILVA, OSMALDO DA
APPLICANT: BOHNERT, HANS J.
APPLICANT: VAN THIELEN, NOCHA
APPLICANT: CHEN, RUYING
APPLICANT: SARRIA-MILLAN, RODRIGO
TITLE OF INVENTION: CELL CYCLE STRESS-RELATED PROTEINS AND METHODS OF USE
FILE REFERENCE: 16313-0031
CURRENT APPLICATION NUMBER: US/09/828,062
CURRENT FILING DATE: 2001-08-20
PRIOR APPLICATION NUMBER: 60/156,001
PRIOR FILING DATE: 2000-04-07
NUMBER OF SEQ ID NOS: 34
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 10
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-828-062-10

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
| | | | | | | | | |
Db 1 CAGGAACAGCTATGAC 17

RESULT 604
US-09-828-447-16
Sequence 16, Application US/09828447
Patent No. 6720477
GENERAL INFORMATION:
APPLICANT: COSTA E SILVA, OSMALDO DA
APPLICANT: BOHNERT, HANS J.
APPLICANT: VAN THIELEN, NOCHA
APPLICANT: CHEN, RUYING
APPLICANT: ISHITANI, MANABU
TITLE OF INVENTION: SIGNAL TRANSDUCTION STRESS-RELATED PROTEINS AND METHODS
FILE REFERENCE: 16313-0037
CURRENT APPLICATION NUMBER: US/09/828,447
CURRENT FILING DATE: 2001-08-20
PRIOR APPLICATION NUMBER: 60/156,001
PRIOR FILING DATE: 2000-04-07
NUMBER OF SEQ ID NOS: 41
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 16
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-828-447-16

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3527 CGGGGAACGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17
| | | | | | | | | |

RESULT 605
US-09-914-397-7
Sequence 7, Application US/09914397
Patent No. 6743584
GENERAL INFORMATION:
APPLICANT: BUB, Sabine
APPLICANT: TROESTER, Helmut
APPLICANT: RICHTER, Karsten
APPLICANT: HAKING, Ansgar
APPLICANT: RADDAZ, Stefan
APPLICANT: WIESLER, Manfred
APPLICANT: SPIESS, Eberhard
APPLICANT: TRENDLENBURG, Michael
TITLE OF INVENTION: MOLECULAR-BIOLOGICAL MARKER FOR ANALYTICAL ELECTRON MICROSCOPY
FILE REFERENCE: 38485-0006
CURRENT APPLICATION NUMBER: US/09/914,397
CURRENT FILING DATE: 2001-08-28
PRIOR APPLICATION NUMBER: PCT/DE00/00116
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: DE 199 00 511.7
PRIOR FILING DATE: 1999-01-08
NUMBER OF SEQ ID NOS: 13
SOFTWARE: Patentin version 3.1
SEQ ID NO 7
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: M13 primer
US-09-914-397-7

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CGGGGAACGCTATGAC 3543
| | | | | | | | | |
Db 1 CAGGAACAGCTATGAC 17

RESULT 606
US-09-326-402C-11
Sequence 11, Application US/09326402C
Patent No. 6759192
GENERAL INFORMATION:
APPLICANT: Bougueleret, Marta
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1 (PCTA-1)
FILE REFERENCE: GEN-T112XCI
CURRENT APPLICATION NUMBER: US/09/326,402C
CURRENT FILING DATE: 1999-06-04
PRIOR APPLICATION NUMBER: 60/088,187
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/102,324
PRIOR FILING DATE: 1998-09-28
NUMBER OF SEQ ID NOS: 22
SOFTWARE: Patentin version 3.1
SEQ ID NO 11
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: sequencing oligonucleotide PrimerRP
US-09-326-402C-11

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 607
US-09-471-703-3
; Sequence 3, Application US/09471703
; Patent No. 6762018
; GENERAL INFORMATION:
; APPLICANT: Merenkova, I. N.
; TITLE OF INVENTION: Analysis Of Nucleotide Polymorphisms
; FILE REFERENCE: TETRA9N.002A
; CURRENT APPLICATION NUMBER: US/09/471,703
; CURRENT FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-471-703-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 608
US-09-784-423-55/c
; Sequence 55, Application US/09784423
; Patent No. 6767703
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR
; IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
; REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 MB
; COMPUTER: IBM compatible PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/784,423
; FILING DATE: 15-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/018,584
; FILING DATE: 04-Feb-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Grady J. Frenchick
; REGISTRATION NUMBER: 29,018
; REFERENCE/DOCKET NUMBER: 16026.9180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 257-3501
; TELEFAX: (608) 257-2275

; INFORMATION FOR SEQ ID NO: 55
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 55
US-09-784-423-55

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3081 AAGTGGCAGGCGCAGG 3097
Db 17 AAGTGGGTAGGCGCAGG 1

RESULT 609
US-10-081-644-29
; Sequence 29, Application US/10081644
; Patent No. 6780976
; GENERAL INFORMATION:
; APPLICANT: Yamamoto, Hiroaki
; TITLE OF INVENTION: NOVEL ENONE REDUCTASES, METHODS FOR
; TITLE OF INVENTION: PRODUCING SAME, AND METHODS FOR SELECTIVELY REDUCING A
; TITLE OF INVENTION: CARBON-CARBON DOUBLE BOND OF AN ALPHA,BETA-UNSATURATED KETONE
; FILE REFERENCE: 06501-100001
; CURRENT APPLICATION NUMBER: US/10/081,644
; CURRENT FILING DATE: 2002-02-21
; PRIOR APPLICATION NUMBER: JP 2001-49363
; PRIOR FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificially synthesized primer sequence
US-10-081-644-29

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543
Db 1 CAGGAAACAGCTATGAC 17

RESULT 610
US-09-794-366-14
; Sequence 14, Application US/09794366
; Patent No. 6815158
; GENERAL INFORMATION:
; APPLICANT: AIDA, Yoko
; TITLE OF INVENTION: Methods for Judging Resistance to the Onset of Bovine Leukemia
; FILE REFERENCE: P20690
; CURRENT APPLICATION NUMBER: US/09/794,366
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 56093/2000
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA

US-09-794-366-14

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17

RESULT 611

US-09-828-302-16

Sequence 16, Application US/09828302

Patent No. 6818805

GENERAL INFORMATION:

APPLICANT: COSTA E SILVA, OSWALDO DA

APPLICANT: VAN THIELEN, NOCHA

APPLICANT: CHEN, ROUYING

APPLICANT: ISHITANI, MANABU

TITLE OF INVENTION: PHOSPHATASE STRESS-RELATED PROTEINS AND METHODS OF USE

FILE REFERENCE: 16313-0029

CURRENT APPLICATION NUMBER: US/09/828,302

CURRENT FILING DATE: 2001-08-20

PRIOR FILING DATE: 2000-04-07

NUMBER OF SEQ ID NOS: 46

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 16

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Primer

US-09-828-302-16

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17

RESULT 612

US-10-434-811A-28

Sequence 28, Application US/10434811A

Patent No. 6824784

GENERAL INFORMATION:

APPLICANT: The University of Pittsburgh of the Commonwealth System of Higher

APPLICANT: Education

APPLICANT: Dowling, Patricia W.

APPLICANT: Youngner, Julius S.

TITLE OF INVENTION: COLD-ADAPTED EQUINE INFLUENZA VIRUSES

FILE REFERENCE: EQ-1-C1-PUS-1

CURRENT APPLICATION NUMBER: US/10/434,811A

CURRENT FILING DATE: 2003-05-08

PRIOR APPLICATION NUMBER: PCT/US99/18583

PRIOR FILING DATE: 1999-08-12

PRIOR APPLICATION NUMBER: 09/133,921

PRIOR FILING DATE: 1998-08-13

NUMBER OF SEQ ID NOS: 43

SOFTWARE: PatentIn version 3.1

SEQ ID NO 28

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial sequence

FEATURE:

OTHER INFORMATION: Synthetic primer

US-10-434-811A-28

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17

RESULT 613

US-09-762-311-7

Sequence 7, Application US/09762311

Patent No. 6825004

GENERAL INFORMATION:

APPLICANT: BLUMENFELD, Marta

APPLICANT: BOUGUELET, Lydie

APPLICANT: CHUMAKOV, Ilya

TITLE OF INVENTION: Nucleic Acids Encoding Human TBC-1 Protein And Polymorphic Markers

FILE REFERENCE: 46 US2, PCT

CURRENT APPLICATION NUMBER: US/09/762,311

CURRENT FILING DATE: 2001-06-21

PRIOR APPLICATION NUMBER: US 60/095,653

PRIOR FILING DATE: 1998-08-07

NUMBER OF SEQ ID NOS: 7

SOFTWARE: Patent.pm

SEQ ID NO 7

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

NAME/KEY: misc binding

LOCATION: 1..18

OTHER INFORMATION: sequencing oligonucleotide PrimerRP

US-09-762-311-7

Query Match 0.3%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3527 CCGGGAACAGCTATGAC 3543

Db 1 CAGGAACAGCTATGAC 17

RESULT 614

US-09-093-972C-856/c

Sequence 856, Application US/09093972C

Patent No. 6825174

GENERAL INFORMATION:

APPLICANT: Nyce, Jonathan W.

TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION

OF & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH

BRONCHOCONSTRICITION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996

CORRESPONDENCE ADDRESS:

ADDRESSES: EPIGENESIS PHARMACEUTICALS, INC.

STREET: 7 Clarke Drive

CITY: Cranbury

STATE: New Jersey

COUNTRY: USA

ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

APPLICATION NUMBER: US/09/093,972C

FILING DATE: 09-Jun-1998

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/472,527

FILED DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 856:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 856:
US-09-093-972C-856

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1908 CCACGCTGTGCTCCGCC 1924
DB 18 CCACGCTGTGCTCCGCC 2

RESULT 615
US-09-093-972C-865/C
Sequence 865, Application US/09093972C
Patent No. 6825174
GENERAL INFORMATION:
APPLICANT: NYCE, Jonathan W.
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICITION, ALLERGY (IES) & INFLAMMATION
NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672

TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 865:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 865:
US-09-093-972C-865

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1908 CCACGCTGTGCTCCGCC 1924
DB 17 CCACGCTGTGCTCCGCC 1

RESULT 616
US-09-093-972C-943/C
Sequence 943, Application US/09093972C
Patent No. 6825174
GENERAL INFORMATION:
APPLICANT: NYCE, Jonathan W.
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICITION, ALLERGY (IES) & INFLAMMATION
NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 943:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 943:
US-09-093-972C-943

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1908 CCCAGCCTGGTCCGCC 1924
DB 17 CCCAGCCTGGTCCGCC 1

RESULT 617
US-09-918-186A-170
Sequence 170, Application US/09918186A

PATENT NO. 6838283
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Elizabeth J. Ackermann
APPLICANT: Eric E. Swayze
APPLICANT: Lex M. Cowsett
TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: ISPH-0585
CURRENT APPLICATION NUMBER: US/09/918,186A
CURRENT FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 09/496,694
PRIOR FILING DATE: 2000-02-02
PRIOR APPLICATION NUMBER: 09/286,407
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 09/163,162
PRIOR FILING DATE: 1998-09-29
NUMBER OF SEQ ID NOS: 250
SEQ ID NO 170
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-186A-170

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2686 CAGCCAGCCACTCACC 2702
DB 2 CAGCCAGCCACTCACC 18

RESULT 618
PCT-US95-08605-29/C
Sequence 29, Application PC/TUS9508605
GENERAL INFORMATION:
APPLICANT: Visible Genetics Inc.
APPLICANT: Diamandis, Eleftherios
APPLICANT: Dunn, James M.
APPLICANT: Stevens, John K.
TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
TITLE OF INVENTION: and Targeted Screening for p53 Mutations
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Oppedahl & Larson
STREET: 1992 Commerce Street, Suite 309
CITY: Yorktown Heights
STATE: NY
COUNTRY: USA
ZIP: 10598-4412
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS 5.0
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/08605

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/271,946

FILING DATE: 08-JUL-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/388,381

FILING DATE: 14-FEB-1995

ATTORNEY/AGENT INFORMATION:

NAME: Marina T. Larson

REGISTRATION NUMBER: 32,038

REFERENCE/DOCKET NUMBER: VGEN.P-003-US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (914) 245-3252

TELEFAX: (914) 962-4330

TELEX:

INFORMATION FOR SEQ ID NO: 29:

SEQUENCE CHARACTERISTICS:

LENGTH: 18

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: genomic DNA

HYPOTHETICAL: no

ANTI-SENSE: no

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: human

FEATURE:

NAME/KEY: sequencing primer for exon 5 of human p53 gene

PCT-US95-08605-29
Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1669 TCCCGAGGCGCCCGAG 1685
DB 17 TCCCGAGGCGCCCGAG 1

RESULT 619
PCT-US96-11786-3/C
Sequence 3, Application PC/TUS9611786
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zengewald, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Eyles
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/11786
FILING DATE: 17-JULY-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;
APPLICATION NUMBER: 60/015,714; 60/016,271
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-
FILING DATE: APRIL-96; 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US96-11786-3

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCAGCCACCACCACC 2

RESULT 620
PCT-US96-11786-31/c
Sequence 31, Application PC/TUS9611786
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Zennegwald, Susan
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Byes
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/11786
FILING DATE: 17-JULY-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;
APPLICATION NUMBER: 60/015,714; 60/016,271
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-
FILING DATE: APRIL-96; 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18
OTHER INFORMATION: /note="Amine moiety
OTHER INFORMATION: attached to 3' end"
PCT-US96-11786-31

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCAGCCACCACCACC 2

RESULT 621
PCT-US96-11786-32/c
Sequence 32, Application PC/TUS9611786
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Zennegwald, Susan
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Byes
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/11786
FILING DATE: 17-JULY-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;
APPLICATION NUMBER: 60/015,714; 60/016,271
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-
FILING DATE: APRIL-96; 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18

OTHER INFORMATION: /note="Amine moiety
OTHER INFORMATION: attached to 3' end and phosphocholate
PCT-US96-11786-32
OTHER INFORMATION: backbone"

Query Match 0.3%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2690 CCAGCCACTCACCACC 2706
DB 18 CCAGCCAGCCACCACC 2

RESULT 622
US-09-866-108A-8646/c
Sequence 8646, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecmca Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 8646
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-8646

Query Match 0.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1120 CAGCAGCTGCGAG 1134
DB 17 CAGCTGAGCTGCGAG 3

RESULT 623
US-09-866-108A-8648
Sequence 8648, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecmca Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 8648
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-8648

Query Match 0.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1407 GCAGCTGCGAGCA 1421
DB 3 GCAGCTGCGAGCTGA 17

Search completed: May 12, 2005, 11:27:45
Job time : 28 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 12, 2005, 11:29:25 ; Search time 21 Seconds
(without alignments)
3.506 Million cell updates/sec

Title: us-10-029-115-1

Perfect score: 3951

Sequence: 1 gccctatcgsgcgaccacgc.....tcattgactcgtgtaagggc 3951

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 451 segs, 9318 residues

Total number of hits satisfying chosen parameters: 902

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 457 summaries

Database : rmpbdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	40.4	1.0	51	1	US-10-393-815-165
C 2	28.8	0.7	36	1	US-10-418-182-90
C 3	28.4	0.7	30	1	US-10-011-993-35
C 4	28.4	0.7	30	1	US-10-357-322-4
C 5	28.2	0.7	36	1	US-10-418-182-55
C 6	26.8	0.7	30	1	US-10-215-432-43
C 7	26.2	0.7	31	1	US-10-029-115-9
C 8	26.2	0.7	31	1	US-09-163-164-9
C 9	24.8	0.6	31	1	US-09-801-274-1526
C 10	24.6	0.6	31	1	US-10-029-115-8
C 11	24.6	0.6	31	1	US-10-493-164-8
C 12	23.8	0.6	27	1	US-10-418-182-174
C 13	23	0.6	23	1	US-09-291-417-60
C 14	23	0.6	23	1	US-09-291-417-61
C 15	23	0.6	23	1	US-10-725-329-60
C 16	23	0.6	23	1	US-10-725-329-61
C 17	22.2	0.6	29	1	US-10-336-638-152
C 18	22	0.6	25	1	US-10-494-343-535
C 19	22	0.6	25	1	US-10-494-343-536
C 20	22	0.6	25	1	US-10-494-343-537
C 21	22	0.6	25	1	US-10-494-343-538
C 22	21.4	0.5	23	1	US-09-848-754A-9122
C 23	21.4	0.5	23	1	US-09-848-754A-9375
C 24	21	0.5	21	1	US-09-291-417-58
C 25	21	0.5	21	1	US-10-725-329-58
C 26	21	0.5	25	1	US-10-494-343-534
C 27	21	0.5	25	1	US-10-494-343-539
C 28	20.4	0.5	22	1	US-10-028-415-27
C 29	20.4	0.5	22	1	US-10-738-642-25
C 30	20.4	0.5	22	1	US-10-738-642-26
C 31	20.2	0.5	25	1	US-10-719-900-43548
C 32	20.2	0.5	25	1	US-10-719-900-181730
C 33	20	0.5	20	1	US-09-291-417-59

C 34	20	0.5	20	1	US-10-725-329-59	Sequence 59, App1
C 35	20	0.5	25	1	US-10-494-343-533	Sequence 533, App
C 36	20	0.5	25	1	US-10-494-343-540	Sequence 540, App
C 37	19.8	0.5	24	1	US-10-198-447A-21	Sequence 21, App1
C 38	19.8	0.5	24	1	US-10-621-867-21	Sequence 21, App1
C 39	19.8	0.5	25	1	US-10-719-900-505777	Sequence 505777, App1
C 40	19.6	0.5	26	1	US-10-467-019-7	Sequence 7, App1
C 41	19.4	0.5	21	1	US-09-888-326-240	Sequence 240, App
C 42	19.4	0.5	21	1	US-09-776-479-780	Sequence 780, App
C 43	19.4	0.5	21	1	US-09-776-479-780	Sequence 780, App
C 44	19.4	0.5	21	1	US-10-112-653-753	Sequence 753, App
C 45	19.4	0.5	21	1	US-10-017-995-780	Sequence 780, App
C 46	19.4	0.5	21	1	US-10-314-578-780	Sequence 780, App
C 47	19.4	0.5	21	1	US-10-418-182-96	Sequence 96, App1
C 48	19.4	0.5	21	1	US-10-831-778-780	Sequence 780, App
C 49	19.4	0.5	21	1	US-10-751-736-39220	Sequence 39220, A
C 50	19.4	0.5	24	1	US-10-433-561-46	Sequence 46, App1
C 51	19.4	0.5	24	1	US-10-477-726-46	Sequence 46, App1
C 52	19.2	0.5	25	1	US-10-719-900-151739	Sequence 151739, A
C 53	19.2	0.5	25	1	US-10-719-900-199979	Sequence 199979, A
C 54	19.2	0.5	25	1	US-10-809-189-43760	Sequence 43760, A
C 55	19	0.5	15	1	US-09-291-417-62	Sequence 62, App1
C 56	19	0.5	19	1	US-10-725-329-62	Sequence 62, App1
C 57	19	0.5	21	1	US-09-789-390-50	Sequence 50, App1
C 58	19	0.5	25	1	US-10-494-343-532	Sequence 532, App
C 59	19	0.5	25	1	US-10-494-343-531	Sequence 541, App
C 60	18.8	0.5	22	1	US-09-888-615-120	Sequence 120, App
C 61	18.8	0.5	24	1	US-09-729-653-6	Sequence 6, App1
C 62	18.8	0.5	25	1	US-10-705-874-18	Sequence 18, App1
C 63	18.8	0.5	25	1	US-10-719-900-817718	Sequence 817718, A
C 64	18.8	0.5	25	1	US-10-809-189-18665	Sequence 18665, A
C 65	18.4	0.5	20	1	US-09-861-893-15	Sequence 15, App1
C 66	18.4	0.5	20	1	US-10-371-477-63	Sequence 63, App1
C 67	18.4	0.5	20	1	US-10-154-708-25	Sequence 25, App1
C 68	18.4	0.5	20	1	US-10-154-708-98	Sequence 98, App1
C 69	18.4	0.5	21	1	US-10-418-182-132	Sequence 132, App
C 70	18.4	0.5	23	1	US-10-357-488-20	Sequence 20, App1
C 71	18.2	0.5	23	1	US-08-983-605-193	Sequence 193, App
C 72	18.2	0.5	23	1	US-10-750-323-11	Sequence 11, App1
C 73	18.2	0.5	24	1	US-10-198-447A-22	Sequence 22, App1
C 74	18.2	0.5	24	1	US-10-621-867-22	Sequence 22, App1
C 75	18	0.5	18	1	US-10-054-387-48	Sequence 48, App1
C 76	18	0.5	18	1	US-10-436-231-1	Sequence 1, App1
C 77	18	0.5	18	1	US-10-436-231-2	Sequence 2, App1
C 78	18	0.5	20	1	US-10-032-585-5708	Sequence 5708, App
C 79	17.8	0.5	21	1	US-10-215-432-37	Sequence 37, App1
C 80	17.8	0.5	21	1	US-10-215-432-44	Sequence 44, App1
C 81	17.8	0.5	21	1	US-10-751-736-40387	Sequence 40387, A
C 82	17.8	0.5	21	1	US-10-764-730-11	Sequence 11, App1
C 83	17.8	0.5	22	1	US-09-291-417-133	Sequence 133, App
C 84	17.8	0.5	22	1	US-10-182-243-74	Sequence 74, App1
C 85	17.8	0.5	22	1	US-10-725-329-133	Sequence 133, App
C 86	17.4	0.4	20	1	US-09-563-728A-6	Sequence 6, App1
C 87	17.4	0.4	20	1	US-09-563-728A-15	Sequence 15, App1
C 88	17.4	0.4	20	1	US-10-145-493B-51	Sequence 51, App1
C 89	17.4	0.4	20	1	US-10-315-965-67	Sequence 4667, App
C 90	17.4	0.4	20	1	US-10-005-344-340	Sequence 340, App
C 91	17.4	0.4	20	1	US-10-148-835-86	Sequence 86, App1
C 92	17.4	0.4	20	1	US-10-380-126-39	Sequence 39, App1
C 93	17.4	0.4	20	1	US-10-274-311-13	Sequence 13, App1
C 94	17.4	0.4	20	1	US-10-274-311-13	Sequence 13, App1
C 95	17.4	0.4	20	1	US-10-315-965-67	Sequence 67, App1
C 96	17.4	0.4	21	1	US-09-846-374-105	Sequence 105, App
C 97	17.4	0.4	21	1	US-10-006-858A-105	Sequence 105, App
C 98	17.4	0.4	21	1	US-10-006-858A-105	Sequence 105, App
C 99	17.4	0.4	21	1	US-10-006-485A-105	Sequence 105, App
C 100	17.4	0.4	21	1	US-10-013-907A-105	Sequence 105, App
C 101	17.4	0.4	21	1	US-10-015-499A-105	Sequence 105, App
C 102	17.4	0.4	21	1	US-10-015-393A-105	Sequence 105, App
C 103	17.4	0.4	21	1	US-10-015-862A-105	Sequence 105, App
C 104	17.4	0.4	21	1	US-10-012-121A-105	Sequence 105, App
C 105	17.4	0.4	21	1	US-10-006-116A-105	Sequence 105, App
C 106	17.4	0.4	21	1	US-10-006-117A-105	Sequence 105, App

C 107	17.4	0.4	21	1	US-10-017-527A-105	Sequence 105, App	180	16.8	0.4	20	1	US-09-969-852-11	Sequence 11, Appl
C 108	17.4	0.4	21	1	US-10-013-913A-105	Sequence 105, App	181	16.8	0.4	20	1	US-09-291-410-136	Sequence 136, Appl
C 109	17.4	0.4	21	1	US-10-007-194A-105	Sequence 105, App	182	16.8	0.4	20	1	US-09-948-020-35	Sequence 35, Appl
C 110	17.4	0.4	21	1	US-10-013-430A-105	Sequence 105, App	183	16.8	0.4	20	1	US-09-975-123-42	Sequence 42, Appl
C 111	17.4	0.4	21	1	US-10-011-671A-105	Sequence 105, App	184	16.8	0.4	20	1	US-10-032-588-4054	Sequence 4054, Appl
C 112	17.4	0.4	21	1	US-10-012-755A-105	Sequence 105, App	185	16.8	0.4	20	1	US-10-032-588-4518	Sequence 4518, Ap
C 113	17.4	0.4	21	1	US-10-015-386A-105	Sequence 105, App	186	16.8	0.4	20	1	US-10-174-465-19	Sequence 19, Appl
C 114	17.4	0.4	21	1	US-10-011-692A-105	Sequence 105, App	187	16.8	0.4	20	1	US-10-348-431-19	Sequence 19, Appl
C 115	17.4	0.4	21	1	US-10-006-768A-105	Sequence 105, App	188	16.8	0.4	20	1	US-10-388-329-9	Sequence 9, Appl
C 116	17.4	0.4	21	1	US-10-017-610A-105	Sequence 105, App	189	16.8	0.4	20	1	US-10-380-128-38	Sequence 38, Appl
C 117	17.4	0.4	21	1	US-10-006-063A-105	Sequence 105, App	190	16.8	0.4	20	1	US-10-633-163-35	Sequence 35, Appl
C 118	17.4	0.4	21	1	US-10-020-063A-105	Sequence 105, App	191	16.8	0.4	20	1	US-10-300-263-60	Sequence 60, Appl
C 119	17.4	0.4	21	1	US-10-015-391A-105	Sequence 105, App	192	16.8	0.4	20	1	US-10-300-263-129	Sequence 129, App
C 120	17.4	0.4	21	1	US-10-017-407A-105	Sequence 105, App	193	16.8	0.4	20	1	US-10-295-471-41	Sequence 41, Appl
C 121	17.4	0.4	21	1	US-10-011-833A-105	Sequence 105, App	194	16.8	0.4	20	1	US-10-295-471-112	Sequence 112, Appl
C 122	17.4	0.4	21	1	US-10-006-041A-105	Sequence 105, App	195	16.8	0.4	20	1	US-10-315-962-46	Sequence 46, Appl
C 123	17.4	0.4	21	1	US-10-015-822A-105	Sequence 105, App	196	16.8	0.4	20	1	US-10-316-755-19	Sequence 19, Appl
C 124	17.4	0.4	21	1	US-10-015-387A-105	Sequence 105, App	197	16.8	0.4	20	1	US-10-316-755-20	Sequence 20, Appl
C 125	17.4	0.4	21	1	US-10-006-130A-105	Sequence 105, App	198	16.8	0.4	20	1	US-10-316-755-174	Sequence 174, App
C 126	17.4	0.4	21	1	US-10-006-172A-105	Sequence 105, App	199	16.8	0.4	20	1	US-10-316-755-175	Sequence 175, App
C 127	17.4	0.4	21	1	US-10-017-253A-105	Sequence 105, App	200	16.8	0.4	20	1	US-10-725-329-136	Sequence 136, App
C 128	17.4	0.4	21	1	US-10-015-392A-105	Sequence 105, App	201	16.8	0.4	20	1	US-10-858-500-496	Sequence 496, App
C 129	17.4	0.4	21	1	US-10-017-306A-105	Sequence 105, App	202	16.8	0.4	20	1	US-10-491-712-42	Sequence 42, Appl
C 130	17.4	0.4	21	1	US-10-017-867A-105	Sequence 105, App	203	16.8	0.4	20	1	US-10-982-104-397	Sequence 397, App
C 131	17.4	0.4	21	1	US-10-012-064A-105	Sequence 105, App	204	16.8	0.4	21	1	US-10-380-193A-15	Sequence 15, Appl
C 132	17.4	0.4	21	1	US-10-013-909A-105	Sequence 105, App	205	16.8	0.4	21	1	US-10-479-510-11	Sequence 11, Appl
C 133	17.4	0.4	21	1	US-10-015-671A-105	Sequence 105, App	206	16.8	0.4	21	1	US-10-786-720-11947	Sequence 11947, A
C 134	17.4	0.4	21	1	US-10-015-610A-105	Sequence 105, App	207	16.8	0.4	21	1	US-10-786-720-11949	Sequence 11949, A
C 135	17.4	0.4	21	1	US-10-012-137A-105	Sequence 105, App	208	16.8	0.4	21	1	US-10-852-997-42	Sequence 42, Appl
C 136	17.4	0.4	21	1	US-10-012-752A-105	Sequence 105, App	209	16.8	0.4	21	1	US-10-827-759A-335	Sequence 335, App
C 137	17.4	0.4	21	1	US-10-012-754A-105	Sequence 105, App	210	16.8	0.4	21	1	US-10-751-736-617	Sequence 617, App
C 138	17.4	0.4	21	1	US-10-013-910A-105	Sequence 105, App	211	16.8	0.4	21	1	US-10-751-736-11681	Sequence 11681, A
C 139	17.4	0.4	21	1	US-10-013-911A-105	Sequence 105, App	212	16.8	0.4	21	1	US-10-751-736-19135	Sequence 134839, A
C 140	17.4	0.4	21	1	US-10-013-912A-105	Sequence 105, App	213	16.8	0.4	21	1	US-10-751-736-34849	Sequence 34849, A
C 141	17.4	0.4	21	1	US-10-015-653A-105	Sequence 105, App	214	16.8	0.4	21	1	US-10-751-736-37756	Sequence 37756, A
C 142	17.4	0.4	21	1	US-10-012-101B-105	Sequence 105, App	215	16.8	0.4	21	1	US-10-751-736-42789	Sequence 42789, A
C 143	17.4	0.4	21	1	US-10-015-480A-105	Sequence 105, App	216	16.6	0.4	36	1	US-10-418-182-55	Sequence 55, Appl
C 144	17.4	0.4	21	1	US-10-015-715A-105	Sequence 105, App	217	16.4	0.4	18	1	US-10-440-850-11112	Sequence 1112, Ap
C 145	17.4	0.4	21	1	US-10-012-237A-105	Sequence 105, App	218	16.4	0.4	18	1	US-10-360-854-11	Sequence 11, Appl
C 146	17.4	0.4	21	1	US-10-013-906A-105	Sequence 105, App	219	16.4	0.4	18	1	US-10-436-231-6	Sequence 6, Appl
C 147	17.4	0.4	21	1	US-10-015-388A-105	Sequence 105, App	220	16.4	0.4	19	1	US-10-251-117-1134	Sequence 124, App
C 148	17.4	0.4	21	1	US-10-012-753A-105	Sequence 105, App	221	16.4	0.4	19	1	US-10-251-117-1373	Sequence 373, App
C 149	17.4	0.4	21	1	US-10-015-385A-105	Sequence 105, App	222	16.4	0.4	19	1	US-10-696-633-3083	Sequence 3083, Ap
C 150	17.4	0.4	21	1	US-10-007-236A-105	Sequence 105, App	223	16.4	0.4	19	1	US-10-830-569-94	Sequence 94, Appl
C 151	17.4	0.4	21	1	US-10-015-389A-105	Sequence 105, App	224	16.4	0.4	19	1	US-10-830-569-401	Sequence 401, App
C 152	17.4	0.4	21	1	US-10-015-519A-105	Sequence 105, App	225	16.4	0.4	20	1	US-09-954-556-52	Sequence 52, Appl
C 153	17.4	0.4	21	1	US-10-013-915A-105	Sequence 105, App	226	16.4	0.4	20	1	US-10-181-846-72	Sequence 72, Appl
C 154	17.4	0.4	21	1	US-10-015-394A-105	Sequence 105, App	227	16.4	0.4	20	1	US-10-187-046-10	Sequence 10, Appl
C 155	17.4	0.4	21	1	US-10-015-390A-105	Sequence 105, App	228	16.4	0.4	20	1	US-10-032-585-4081	Sequence 4081, Ap
C 156	17.4	0.4	21	1	US-10-006-746A-105	Sequence 105, App	229	16.4	0.4	20	1	US-10-215-448-53	Sequence 53, Appl
C 157	17.4	0.4	21	1	US-10-226-254A-105	Sequence 105, App	230	16.4	0.4	20	1	US-10-688-706-419	Sequence 419, App
C 158	17.4	0.4	21	1	US-10-011-795A-105	Sequence 105, App	231	16.4	0.4	20	1	US-10-688-706-439	Sequence 439, App
C 159	17.4	0.4	21	1	US-10-012-231A-105	Sequence 105, App	232	16.4	0.4	20	1	US-10-688-706-774	Sequence 774, App
C 160	17.4	0.4	21	1	US-10-015-395A-105	Sequence 105, App	233	16.4	0.4	20	1	US-10-688-706-422	Sequence 222, App
C 161	17.4	0.4	21	1	US-10-751-736-39221	Sequence 39221, A	234	16.4	0.4	20	1	US-10-719-370A-922	Sequence 340, App
C 162	17.4	0.4	21	1	US-10-012-149A-105	Sequence 105, App	235	16.4	0.4	20	1	US-10-719-370A-940	Sequence 340, App
C 163	17.4	0.4	21	1	US-10-730-771-62	Sequence 62, App	236	16.4	0.4	21	1	US-09-765-081-353	Sequence 353, App
C 164	17.4	0.4	23	1	US-10-291-986-1	Sequence 1, Appl	237	16.4	0.4	21	1	US-10-303-109A-31	Sequence 31, Appl
C 165	17.4	0.4	23	1	US-10-967-592-2	Sequence 2, Appl	238	16.4	0.4	21	1	US-10-751-736-10540	Sequence 10541, A
C 166	17.2	0.4	22	1	US-10-114-270-284	Sequence 284, App	239	16.4	0.4	21	1	US-10-751-736-35223	Sequence 39223, A
C 167	17.2	0.4	22	1	US-10-114-270-284	Sequence 284, App	240	16.4	0.4	21	1	US-10-751-736-40388	Sequence 40388, A
C 168	17.2	0.4	22	1	US-10-215-432-43	Sequence 43, Appl	241	16.4	0.4	21	1	US-10-751-736-40594	Sequence 40594, A
C 169	17.2	0.4	30	1	US-09-780-533A-167	Sequence 2353, Ap	242	16.4	0.4	51	1	US-09-291-411-54	Sequence 165, Appl
C 170	17	0.4	17	1	US-10-494-343-167	Sequence 167, App	243	16.2	0.4	21	1	US-10-184-096A-1031	Sequence 54, Appl
C 171	17	0.4	17	1	US-10-494-343-168	Sequence 168, App	244	16.2	0.4	21	1	US-10-418-182-97	Sequence 1031, Ap
C 172	17	0.4	17	1	US-10-494-343-169	Sequence 169, App	245	16.2	0.4	21	1	US-10-418-182-305	Sequence 97, Appl
C 173	17	0.4	17	1	US-10-494-343-170	Sequence 170, App	246	16.2	0.4	21	1	US-10-786-720-12565	Sequence 12565, A
C 174	17	0.4	17	1	US-10-494-343-171	Sequence 171, App	247	16.2	0.4	21	1	US-10-786-720-15008	Sequence 15008, A
C 175	17	0.4	17	1	US-10-494-343-172	Sequence 172, App	248	16.2	0.4	21	1	US-10-786-720-20812	Sequence 20812, A
C 176	17	0.4	18	1	US-10-321-039-541	Sequence 541, App	249	16.2	0.4	21	1	US-10-725-329-54	Sequence 54, Appl
C 177	17	0.4	21	1	US-10-751-736-8809	Sequence 8809, Ap	250	16.2	0.4	21	1	US-10-751-736-11485	Sequence 11485, A
C 178	17	0.4	21	1	US-10-751-736-8810	Sequence 8810, Ap	251	16.2	0.4	21	1		
C 179	17	0.4	21	1	US-10-751-736-8810	Sequence 8810, Ap	252	16.2	0.4	21	1		

C 253	16.2	0.4	21	1	US-10-751-736-11486	Sequence 11486, A	326	15.8	0.4	21	1	US-10-751-736-37864	Sequence 37864, A
C 254	16.2	0.4	21	1	US-10-751-736-11680	Sequence 11680, A	327	15.8	0.4	21	1	US-10-751-736-37865	Sequence 37865, A
C 255	16.2	0.4	21	1	US-10-751-736-19138	Sequence 19138, A	328	15.8	0.4	21	1	US-10-751-736-38419	Sequence 38419, A
C 256	16.2	0.4	21	1	US-10-751-736-24853	Sequence 24853, A	329	15.8	0.4	21	1	US-10-751-736-42538	Sequence 42538, A
C 257	16.2	0.4	21	1	US-10-751-736-25318	Sequence 25318, A	330	15.8	0.4	21	1	US-10-751-736-42539	Sequence 42539, A
C 258	16.2	0.4	21	1	US-10-751-736-38416	Sequence 38416, A	C 331	15.6	0.4	30	1	US-10-011-993-35	Sequence 35, App1
C 259	16.2	0.4	21	1	US-10-751-736-42683	Sequence 42683, A	C 332	15.6	0.4	30	1	US-10-357-322-4	Sequence 4, App1
C 260	16.2	0.4	21	1	US-10-751-736-49825	Sequence 49825, A	C 333	15.4	0.4	17	1	US-09-866-108-7802	Sequence 7802, Ap
C 261	16.2	0.4	31	1	US-09-801-274-1525	Sequence 1526, Ap	C 334	15.4	0.4	17	1	US-09-780-5338-766	Sequence 766, App
C 262	16	0.4	17	1	US-09-780-5338-2254	Sequence 2354, Ap	C 335	15.4	0.4	17	1	US-09-780-5338-767	Sequence 767, App
C 263	16	0.4	17	1	US-09-792-818-383	Sequence 383, App	C 336	15.4	0.4	17	1	US-09-780-5338-1549	Sequence 1549, Ap
C 264	16	0.4	17	1	US-09-792-818-524	Sequence 524, App	C 337	15.4	0.4	17	1	US-09-780-5338-1554	Sequence 1554, Ap
C 265	16	0.4	17	1	US-10-494-343-166	Sequence 166, App	C 338	15.4	0.4	17	1	US-09-780-5338-1792	Sequence 1792, Ap
C 266	16	0.4	17	1	US-10-494-343-173	Sequence 173, App	C 339	15.4	0.4	17	1	US-09-780-5338-2370	Sequence 2370, Ap
C 267	16	0.4	18	1	US-10-181-603-11	Sequence 11, App1	C 340	15.4	0.4	17	1	US-09-792-818-608	Sequence 608, App
C 268	16	0.4	18	1	US-10-440-850-1113	Sequence 1113, Ap	C 341	15.4	0.4	17	1	US-10-061-201-221	Sequence 221, App
C 269	16	0.4	20	1	US-09-563-7288-7	Sequence 7, App1	C 342	15.4	0.4	17	1	US-10-138-674-4506	Sequence 4506, Ap
C 270	16	0.4	20	1	US-09-563-7288-16	Sequence 16, App1	C 343	15.4	0.4	17	1	US-10-287-9494-4506	Sequence 4506, Ap
C 271	16	0.4	20	1	US-10-145-4938-52	Sequence 52, App1	C 344	15.4	0.4	17	1	US-10-723-361-7802	Sequence 7802, Ap
C 272	15.8	0.4	19	1	US-09-263-959-793	Sequence 793, App	C 345	15.4	0.4	17	1	US-10-494-343-183	Sequence 183, App
C 273	15.8	0.4	19	1	US-10-251-117-754	Sequence 754, App	C 346	15.4	0.4	18	1	US-09-933-6388-9	Sequence 9, App1
C 274	15.8	0.4	19	1	US-10-251-117-1061	Sequence 1061, Ap	C 347	15.4	0.4	18	1	US-10-194-584-1	Sequence 1, App1
C 275	15.8	0.4	19	1	US-10-349-143-7203	Sequence 7203, Ap	C 348	15.4	0.4	18	1	US-10-194-584-2	Sequence 2, App1
C 276	15.8	0.4	19	1	US-10-830-569-188	Sequence 188, App	C 349	15.4	0.4	18	1	US-10-327-805-30	Sequence 30, App1
C 277	15.8	0.4	19	1	US-10-830-569-495	Sequence 495, App	C 350	15.4	0.4	18	1	US-10-169-983-27	Sequence 27, App1
C 278	15.8	0.4	20	1	US-09-791-406-65	Sequence 65, App1	C 351	15.4	0.4	18	1	US-10-380-002-13	Sequence 13, App1
C 279	15.8	0.4	20	1	US-09-733-444-2	Sequence 2, App1	C 352	15.4	0.4	19	1	US-10-269-557-26	Sequence 26, App1
C 280	15.8	0.4	20	1	US-09-733-444-26	Sequence 26, App1	C 353	15.4	0.4	19	1	US-10-449-143-5480	Sequence 5480, Ap
C 281	15.8	0.4	20	1	US-09-972-607-63	Sequence 63, App1	C 354	15.4	0.4	19	1	US-10-449-925-197	Sequence 197, App
C 282	15.8	0.4	20	1	US-10-181-846-153	Sequence 153, App	C 355	15.4	0.4	20	1	US-09-923-517-28	Sequence 28, App1
C 283	15.8	0.4	20	1	US-10-279-454-2	Sequence 2, App1	C 356	15.4	0.4	20	1	US-09-822-722-3	Sequence 3, App1
C 284	15.8	0.4	20	1	US-10-379-454-26	Sequence 26, App1	C 357	15.4	0.4	20	1	US-09-934-1388-3	Sequence 3, App1
C 285	15.8	0.4	20	1	US-10-420-845-13	Sequence 13, App1	C 358	15.4	0.4	20	1	US-09-919-197-33	Sequence 33, App1
C 286	15.8	0.4	20	1	US-10-093-463-245	Sequence 245, App	C 359	15.4	0.4	20	1	US-09-953-318-45	Sequence 45, App1
C 287	15.8	0.4	20	1	US-10-093-463-248	Sequence 248, App	C 360	15.4	0.4	20	1	US-10-771-476-35	Sequence 35, App1
C 288	15.8	0.4	20	1	US-10-421-763-14	Sequence 14, App1	C 361	15.4	0.4	20	1	US-10-430-196-28	Sequence 28, App1
C 289	15.8	0.4	20	1	US-10-173-208-18	Sequence 18, App1	C 362	15.4	0.4	20	1	US-10-446-373-45	Sequence 45, App1
C 290	15.8	0.4	20	1	US-10-173-208-54	Sequence 54, App1	C 363	15.4	0.4	20	1	US-10-115-482-72	Sequence 72, App1
C 291	15.8	0.4	20	1	US-10-289-762-2850	Sequence 2850, Ap	C 364	15.4	0.4	20	1	US-10-210-723-20	Sequence 20, App1
C 292	15.8	0.4	20	1	US-10-289-762-6476	Sequence 6476, Ap	C 365	15.4	0.4	20	1	US-10-210-723-92	Sequence 92, App1
C 293	15.8	0.4	20	1	US-10-454-224-29	Sequence 29, App1	C 366	15.4	0.4	20	1	US-10-298-954-32	Sequence 32, App1
C 294	15.8	0.4	20	1	US-10-199-199-70	Sequence 70, App1	C 367	15.4	0.4	20	1	US-10-298-954-63	Sequence 63, App1
C 295	15.8	0.4	20	1	US-10-199-199-135	Sequence 135, App	C 368	15.4	0.4	20	1	US-10-688-706-310	Sequence 310, App
C 296	15.8	0.4	20	1	US-10-628-841-63	Sequence 63, App1	C 369	15.4	0.4	20	1	US-10-688-706-635	Sequence 635, App
C 297	15.8	0.4	20	1	US-10-344-338-35	Sequence 35, App1	C 370	15.4	0.4	20	1	US-10-319-893-69	Sequence 69, App1
C 298	15.8	0.4	20	1	US-10-648-593-331	Sequence 331, App	C 371	15.4	0.4	20	1	US-10-319-893-69	Sequence 69, App1
C 299	15.8	0.4	20	1	US-10-635-145-5	Sequence 5, App1	C 372	15.4	0.4	20	1	US-10-319-893-144	Sequence 144, App
C 300	15.8	0.4	20	1	US-10-418-780-27	Sequence 27, App1	C 373	15.4	0.4	20	1	US-10-791-368-3	Sequence 3, App1
C 301	15.8	0.4	20	1	US-10-418-780-124	Sequence 124, App	C 374	15.4	0.4	20	1	US-10-835-208-33	Sequence 33, App1
C 302	15.8	0.4	20	1	US-10-487-176-6	Sequence 6, App1	C 375	15.4	0.4	20	1	US-10-672-866-202	Sequence 202, App
C 303	15.8	0.4	20	1	US-10-672-866-201	Sequence 201, App	C 376	15.4	0.4	20	1	US-10-672-866-319	Sequence 319, App
C 304	15.8	0.4	20	1	US-10-730-771-348	Sequence 348, App	C 377	15.4	0.4	20	1	US-10-628-043-3	Sequence 3, App1
C 305	15.8	0.4	20	1	US-10-889-447-49	Sequence 49, App1	C 378	15.4	0.4	20	1	US-10-800-350-165	Sequence 165, App
C 306	15.8	0.4	20	1	US-10-889-447-155	Sequence 155, App	C 379	15.2	0.4	20	1	US-09-758-881-23	Sequence 23, App1
C 307	15.8	0.4	20	1	US-10-947-444-13	Sequence 13, App1	C 380	15.2	0.4	20	1	US-09-078-8714-12	Sequence 12, App1
C 308	15.8	0.4	21	1	US-09-735-995-93	Sequence 93, App1	C 381	15.2	0.4	20	1	US-09-854-883-17	Sequence 17, App1
C 309	15.8	0.4	21	1	US-09-765-081-248	Sequence 248, App	C 382	15.2	0.4	20	1	US-09-935-338-65	Sequence 65, App1
C 310	15.8	0.4	21	1	US-09-765-081-360	Sequence 360, App	C 383	15.2	0.4	20	1	US-09-935-338-77	Sequence 77, App1
C 311	15.8	0.4	21	1	US-09-828-034-9	Sequence 9, App1	C 384	15.2	0.4	20	1	US-09-972-469-171	Sequence 171, App
C 312	15.8	0.4	21	1	US-10-005-956-473	Sequence 473, App	C 385	15.2	0.4	20	1	US-09-922-146-23	Sequence 23, App1
C 313	15.8	0.4	21	1	US-10-696-708-93	Sequence 93, App1	C 386	15.2	0.4	20	1	US-09-972-607-31	Sequence 31, App1
C 314	15.8	0.4	21	1	US-10-383-864-14	Sequence 14, App1	C 387	15.2	0.4	20	1	US-09-754-106-66	Sequence 66, App1
C 315	15.8	0.4	21	1	US-10-786-720-11948	Sequence 11948, A	C 388	15.2	0.4	20	1	US-10-181-177-105	Sequence 105, App
C 316	15.8	0.4	21	1	US-10-786-720-12250	Sequence 12250, A	C 389	15.2	0.4	20	1	US-10-008-789-75	Sequence 75, App1
C 317	15.8	0.4	21	1	US-10-786-720-12566	Sequence 12566, A	C 390	15.2	0.4	20	1	US-10-360-935-4	Sequence 4, App1
C 318	15.8	0.4	21	1	US-10-786-720-12567	Sequence 12567, A	C 391	15.2	0.4	20	1	US-10-448-935-17	Sequence 17, App1
C 319	15.8	0.4	21	1	US-10-786-720-20813	Sequence 20813, A	C 392	15.2	0.4	20	1	US-10-352-179-29	Sequence 29, App1
C 320	15.8	0.4	21	1	US-10-751-736-616	Sequence 616, App	C 393	15.2	0.4	20	1	US-10-528-841-31	Sequence 31, App1
C 321	15.8	0.4	21	1	US-10-751-736-1045	Sequence 1045, App	C 394	15.2	0.4	20	1	US-10-580-125-41	Sequence 41, App1
C 322	15.8	0.4	21	1	US-10-751-736-19103	Sequence 9103, Ap	C 395	15.2	0.4	20	1	US-10-580-954-20	Sequence 20, App1
C 323	15.8	0.4	21	1	US-10-751-736-19139	Sequence 19139, A	C 396	15.2	0.4	20	1	US-10-300-263-32	Sequence 32, App1
C 324	15.8	0.4	21	1	US-10-751-736-34602	Sequence 34602, A	C 397	15.2	0.4	20	1	US-10-300-263-107	Sequence 107, App
C 325	15.8	0.4	21	1	US-10-751-736-37757	Sequence 37757, A	C 398	15.2	0.4	20	1		

;; CURRENT FILING DATE: 2001-12-05
;; PRIOR APPLICATION NUMBER: PCT/US01/17329
;; PRIOR FILING DATE: 2001-05-30
;; PRIOR APPLICATION NUMBER: 09/724,755
;; PRIOR FILING DATE: 2000-11-28
;; PRIOR APPLICATION NUMBER: 09/584,905
;; PRIOR FILING DATE: 2000-05-30
;; NUMBER OF SEQ ID NOS: 37
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 35
;; LENGTH: 30
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Illustrative
;; OTHER INFORMATION: oligonucleotide
;; FEATURE:
;; OTHER INFORMATION: This sequence may encompass 1-10 cag repeats
US-10-011-993-35

Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 9.3;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 4
US-10-357-322-4
;; Sequence 4, Application US/10357322
;; Publication No. US20030180768A1
;; GENERAL INFORMATION:
;; APPLICANT: Rannum et al.
;; TITLE OF INVENTION: SCAY GENE AND METHODS OF USE
;; FILE REFERENCE: Regents of the University of Minnesota
;; CURRENT APPLICATION NUMBER: US/10/357,322
;; CURRENT FILING DATE: 2003-02-03
;; PRIOR APPLICATION NUMBER: US/09/684,843
;; PRIOR FILING DATE: 2000-10-06
;; PRIOR APPLICATION NUMBER: 60/056,170
;; PRIOR FILING DATE: 1997-08-19
;; PRIOR APPLICATION NUMBER: 09/135,994
;; PRIOR FILING DATE: 1998-08-18
;; NUMBER OF SEQ ID NOS: 14
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 4
;; LENGTH: 30
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-357-322-4

Query Match 0.7%; Score 28.4; DB 1; Length 30;
Best Local Similarity 96.7%; Pred. No. 9.3;
Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
Db 1 CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 5
US-10-418-182-55/c
;; Sequence 55, Application US/10418182
;; Publication No. US20030228302A1
;; GENERAL INFORMATION:
;; APPLICANT: Crea, Roberto
;; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
;; FILE REFERENCE: 1551.2001-001
;; CURRENT APPLICATION NUMBER: US/10/418,182
;; CURRENT FILING DATE: 2003-04-16
;; PRIOR APPLICATION NUMBER: 60/373,558

;; PRIOR FILING DATE: 2002-04-17
;; NUMBER OF SEQ ID NOS: 423
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 55
;; LENGTH: 36
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
US-10-418-182-55

Query Match 0.7%; Score 28.2; DB 1; Length 36;
Best Local Similarity 90.9%; Pred. No. 14;
Matches 30; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1115 AACAGCAGCAGCAGCTGCAGCAGCAGCAGCAGC 1147
Db 33 AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 1

RESULT 6
US-10-215-432-43
;; Sequence 43, Application US/10215432
;; Publication No. US20030109476A1
;; GENERAL INFORMATION:
;; APPLICANT: Eric B. Kmiec
;; TITLE OF INVENTION: Composition and methods for the
;; TITLE OF INVENTION: prevention and treatment of Huntington's disease
;; FILE REFERENCE: NaPro-10
;; CURRENT APPLICATION NUMBER: US/10/215,432
;; CURRENT FILING DATE: 2002-11-19
;; NUMBER OF SEQ ID NOS: 44
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 43
;; LENGTH: 30
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Converted HD sequence
US-10-215-432-43

Query Match 0.7%; Score 26.8; DB 1; Length 30;
Best Local Similarity 93.3%; Pred. No. 16;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
Db 1 CAGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAG 30

RESULT 7
US-10-029-115-9/c
;; Sequence 9, Application US/10029115
;; Publication No. US20030077597A1
;; GENERAL INFORMATION:
;; APPLICANT: Luo, Ying
;; APPLICANT: Fu, Alan C
;; APPLICANT: Shen, Mary
;; TITLE OF INVENTION: No. US20030077597A1 Germlinal Center Kinase Cell Cycle Problems,
;; TITLE OF INVENTION: Methods of Use
;; FILE REFERENCE: A-70229/RMS/DHR
;; CURRENT APPLICATION NUMBER: US/10/029,115
;; CURRENT FILING DATE: 2001-10-19
;; NUMBER OF SEQ ID NOS: 15
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 9
;; LENGTH: 31
;; TYPE: DNA
;; ORGANISM: Artificial sequence
;; FEATURE:
;; OTHER INFORMATION: synthetic
US-10-029-115-9

Query Match 0.7%; Score 26.2; DB 1; Length 31;
Best Local Similarity 90.3%; Pred. No. 20;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 152 AGCTGCTGCATCAAGTCATGATGTCAC 182
DB 31 AGCTTGACGACATCAAGTTATGATGTCAC 1

RESULT 8
US-10-493-164-9/c

; Sequence 9, Application US/10493164
; Publication No. US20050019771A1
; GENERAL INFORMATION:
; APPLICANT: Rigel Pharmaceuticals, Inc.
; APPLICANT: Leo, Cindy
; APPLICANT: Luo, Ying
; APPLICANT: XU, XIANG
; APPLICANT: YU, SIMON
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE PROTEINS, COMPOSITIONS,
; TITLE OF INVENTION: AND METHODS OF THEIR USE
; FILE REFERENCE: 021044-005600PC
; CURRENT APPLICATION NUMBER: US/10/493,164
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 10/029,115
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 9
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-10-493-164-9

Query Match 0.7%; Score 26.2; DB 1; Length 31;
Best Local Similarity 90.3%; Pred. No. 20;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 152 AGCTGCTGCATCAAGTCATGATGTCAC 182
DB 31 AGCTTGACGACATCAAGTTATGATGTCAC 1

RESULT 9
US-09-801-274-1526

; Sequence 1526, Application US/09801274
; Patent No. US20020032319A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2009-001
; CURRENT APPLICATION NUMBER: US/09/801,274
; PRIOR FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 60/187,510
; PRIOR FILING DATE: 2000-03-07
; PRIOR APPLICATION NUMBER: US 60/206,129
; NUMBER OF SEQ ID NOS: 1802
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1526
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-801-274-1526

Query Match 0.6%; Score 24.8; DB 1; Length 31;
Best Local Similarity 86.7%; Pred. No. 31;

Matches 26; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGTCGACGACGACGACGCG 1148
DB 2 GCAGCGGACGCGCGCGACGCGGACGACGCG 31

RESULT 10
US-10-029-115-8
; Sequence 8, Application US/10029115
; Publication No. US20030077597A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Ying
; APPLICANT: Fu, Alan C
; APPLICANT: Shen, Mary
; TITLE OF INVENTION: No. US20030077597A1 Germinal Center Kinase Cell Cycle Proteins,
; TITLE OF INVENTION: Methods of Use
; FILE REFERENCE: A-70229/RMS/DHR
; CURRENT APPLICATION NUMBER: US/10/029,115
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 8
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-029-115-8

Query Match 0.6%; Score 24.6; DB 1; Length 31;
Best Local Similarity 87.1%; Pred. No. 33;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGCTGCATCAAGTCATGATGTCAC 182
DB 1 AGCTTGACGACATCAAGTTATGATGTCAC 31

RESULT 11
US-10-493-164-8

; Sequence 8, Application US/10493164
; Publication No. US20050019771A1
; GENERAL INFORMATION:
; APPLICANT: Rigel Pharmaceuticals, Inc.
; APPLICANT: Leo, Cindy
; APPLICANT: Luo, Ying
; APPLICANT: XU, XIANG
; APPLICANT: YU, SIMON
; TITLE OF INVENTION: NOVEL GERMINAL CENTER KINASE PROTEINS, COMPOSITIONS,
; TITLE OF INVENTION: AND METHODS OF THEIR USE
; FILE REFERENCE: 021044-005600PC
; CURRENT APPLICATION NUMBER: US/10/493,164
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 10/029,115
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 8
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide for mutation
US-10-493-164-8

Query Match 0.6%; Score 24.6; DB 1; Length 31;
Best Local Similarity 87.1%; Pred. No. 33;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 152 AGCTGCTGCATCAAGTCATGATGTCAC 182


```
Db      1 ACCTGCACCATCAGGGTTATGATGATGC 31
|||||
RESULT 12
US-10-418-182-174
; Sequence 174, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 174
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-174

Query Match      0.6%; Score 23.8; DB 1; Length 27;
Best Local Similarity 92.6%; Pred. No. 34;
Matches 25; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1117 CAGCAGCAGCAGCTGCAGCAGCAGCAG 1143
Db      1 CAGCAGCAGCAGCAGCAGCAGCAGCAG 27
|||||
RESULT 13
US-09-291-417-60/C
; Sequence 60, Application US/09291417A
; Publication No. US20030050230A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 240/300
; CURRENT APPLICATION NUMBER: US/09/291,417A
; CURRENT FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,784
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized nucleic acid molecule
US-09-291-417-60

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3454 ACAGTAGAGAGGGGCGCGGCT 3476
Db      23 ACAGTAGAGAGGGGCGCGGCT 1
|||||
RESULT 14
US-09-291-417-61
; Sequence 61, Application US/09291417A
; Publication No. US20030050230A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
```

```
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 240/300
; CURRENT APPLICATION NUMBER: US/09/291,417A
; CURRENT FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,784
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 61
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized nucleic acid molecule
US-09-291-417-61

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      242 ACCGCAACATCGCAGCCTACTAC 264
Db      1 ACCGCAACATCGCAGCCTACTAC 23
|||||
RESULT 15
US-10-725-329-60/C
; Sequence 60, Application US/10725329
; Publication No. US20040224323A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/688,188B
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-725-329-60

Query Match      0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3454 ACAGTAGAGAGGGGCGCGGCT 3476
Db      23 ACAGTAGAGAGGGGCGCGGCT 1
|||||
RESULT 16
US-10-725-329-61
; Sequence 61, Application US/10725329
; Publication No. US20040224323A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
```

;; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
;; FILE REFERENCE: 038602/0328
;; CURRENT APPLICATION NUMBER: US/10/725,329
;; PRIOR FILING DATE: 2003-12-02
;; PRIOR APPLICATION NUMBER: US/09/688,188B
;; PRIOR FILING DATE: 2000-10-16
;; PRIOR APPLICATION NUMBER: 09/291,417
;; PRIOR FILING DATE: 1999-04-14
;; PRIOR APPLICATION NUMBER: 60/081,784
;; PRIOR FILING DATE: 1998-04-14
;; NUMBER OF SEQ ID NOS: 155
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 61
;; LENGTH: 23
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-725-329-61

Query Match 0.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 242 ACCGCAACATCGCCACCTACTAC 264
DB 1 ACCGCAACATCGCCACCTACTAC 23

RESULT 17
US-10-336-638-152
;; Sequence 152, Application US/10336638
;; Publication No. US20030170699A1
;; GENERAL INFORMATION:
;; APPLICANT: Fan, Jian Bing
;; APPLICANT: Chakravarti, Aravinda
;; APPLICANT: Halushka, Marc Kenneth
;; APPLICANT: Case Western Reserve University School of Medicine
;; APPLICANT: Affymetrix, Inc.
;; TITLE OF INVENTION: Polymorphisms Associated With
;; FILE REFERENCE: 018547-034210US
;; CURRENT APPLICATION NUMBER: US/10/336,638
;; CURRENT FILING DATE: 2003-01-02
;; PRIOR APPLICATION NUMBER: US/09/304,232
;; PRIOR FILING DATE: 1999-05-03
;; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/084,641
;; PRIOR FILING DATE: EARLIER FILING DATE: 1998-05-07
;; NUMBER OF SEQ ID NOS: 909
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 152
;; LENGTH: 29
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: APOA4 3058
US-10-336-638-152

Query Match 0.6%; Score 22.2; DB 1; Length 29;
Best Local Similarity 82.8%; Pred. No. 64;
Matches 24; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCA 1145
DB 1 CAGCAGGAACAGCAKCAAGCAGCAGCA 29

RESULT 18
US-10-494-343-535
;; Sequence 535, Application US/10494343
;; Publication No. US20040248138A1
;; GENERAL INFORMATION:
;; APPLICANT: Shannon, Mark

;; APPLICANT: Phan, Thuymy
;; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
;; FILE REFERENCE: PB0184
;; CURRENT APPLICATION NUMBER: US/10/494,343
;; CURRENT FILING DATE: 2004-04-30
;; PRIOR APPLICATION NUMBER: US to be assigned
;; PRIOR FILING DATE: to be assigned
;; PRIOR APPLICATION NUMBER: PCT/US2002/035129
;; PRIOR FILING DATE: 2002-11-01
;; PRIOR APPLICATION NUMBER: US 60/334,773
;; PRIOR FILING DATE: 2001-11-01
;; NUMBER OF SEQ ID NOS: 870
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 535
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-494-343-535

Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGCAG 1464
DB 4 GCAGCAGCAGCAACAGCAGCAG 25

RESULT 19
US-10-494-343-536
;; Sequence 536, Application US/10494343
;; Publication No. US20040248138A1
;; GENERAL INFORMATION:
;; APPLICANT: Shannon, Mark
;; APPLICANT: Phan, Thuymy
;; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
;; FILE REFERENCE: PB0184
;; CURRENT APPLICATION NUMBER: US/10/494,343
;; CURRENT FILING DATE: 2004-04-30
;; PRIOR APPLICATION NUMBER: US to be assigned
;; PRIOR FILING DATE: to be assigned
;; PRIOR APPLICATION NUMBER: PCT/US2002/035129
;; PRIOR FILING DATE: 2002-11-01
;; PRIOR APPLICATION NUMBER: US 60/334,773
;; PRIOR FILING DATE: 2001-11-01
;; NUMBER OF SEQ ID NOS: 870
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 536
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-494-343-536

Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGCAG 1464
DB 3 GCAGCAGCAGCAACAGCAGCAG 24

RESULT 20
US-10-494-343-537
;; Sequence 537, Application US/10494343
;; Publication No. US20040248138A1
;; GENERAL INFORMATION:
;; APPLICANT: Shannon, Mark
;; APPLICANT: Phan, Thuymy
;; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
;; FILE REFERENCE: PB0184
;; CURRENT APPLICATION NUMBER: US/10/494,343
;; CURRENT FILING DATE: 2004-04-30

PRIOR APPLICATION NUMBER: US to be assigned
PRIOR FILING DATE: to be assigned
PRIOR APPLICATION NUMBER: PCT/US2002/035129
PRIOR FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/334,773
PRIOR FILING DATE: 2001-11-01
NUMBER OF SEQ ID NOS: 870
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 537
LENGTH: 25
TYPE: DNA
ORGANISM: Homo sapiens
US-10-494-343-537

Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGCAG 1464
DB 2 GCAGCAGCAGCAACAGCAGCAG 23

RESULT 21
US-10-494-343-538
Sequence 538, Application US/10494343
Publication No. US20040248138A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
APPLICANT: Phan, Thuymy
TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
FILE REFERENCE: PB0184
CURRENT APPLICATION NUMBER: US/10/494,343
CURRENT FILING DATE: 2004-04-30
PRIOR APPLICATION NUMBER: US to be assigned
PRIOR FILING DATE: to be assigned
PRIOR APPLICATION NUMBER: PCT/US2002/035129
PRIOR FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/334,773
PRIOR FILING DATE: 2001-11-01
NUMBER OF SEQ ID NOS: 870
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 538
LENGTH: 25
TYPE: DNA
ORGANISM: Homo sapiens
US-10-494-343-538

Query Match 0.6%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGCAGCAG 1464
DB 1 GCAGCAGCAGCAACAGCAGCAG 22

RESULT 22
US-09-848-754A-9122
Sequence 9122, Application US/09848754A
Publication No. US20030073207A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
FILE REFERENCE: MBH00-958-1 (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: PatentIn version 3.0
SEQ ID NO 9122
LENGTH: 23
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic acid
US-09-848-754A-9122

Query Match 0.5%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 56;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGCAG 1140
DB 1 AGCAGCAGCAGCAGCAGCAGCAG 23

RESULT 23
US-09-848-754A-9375/C
Sequence 9375, Application US/09848754A
Publication No. US20030073207A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
FILE REFERENCE: MBH00-958-1 (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: PatentIn version 3.0
SEQ ID NO 9375
LENGTH: 25
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic acid
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: n stands for inverted deoxyabasic derivative
NAME/KEY: misc_feature
LOCATION: (25)..(25)
OTHER INFORMATION: n stands for inverted deoxyabasic derivative
NAME/KEY: misc_feature
LOCATION: (2)..(8)
OTHER INFORMATION: 2'-O-Methyl
NAME/KEY: misc_feature
LOCATION: (18)..(24)
OTHER INFORMATION: 2'-O-Methyl
NAME/KEY: misc_feature
LOCATION: (9)..(17)
OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-09-848-754A-9375

Query Match 0.5%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 64;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAGCAG 1140
DB 24 AGCAGCAGCAGCAGCAGCAGCAG 2

RESULT 24
US-09-291-417-58
Sequence 58, Application US/09291417A
Publication No. US20030050230A1
GENERAL INFORMATION:
APPLICANT: PLOWMAN, GREGORY
APPLICANT: MARTINEZ, RICARDO
APPLICANT: WHYTE, DAVID
TITLE OF INVENTION: STR20-RELATED PROTEIN KINASES
FILE REFERENCE: 240/300
CURRENT APPLICATION NUMBER: US/09/291,417A
CURRENT FILING DATE: 1999-04-13
EARLIER APPLICATION NUMBER: US 60/081,784
EARLIER FILING DATE: 1998-04-14

```
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 58
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized nucleic acid molecule
US-09-291-417-58

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3379 CCCAAACCTACCAAAATTC 3399
DB      1 CCCAAACCTACCAAAATTC 21

RESULT 25
US-10-725-329-58
; Sequence 58, Application US/10725329
; Publication No. US2004024323A1
; GENERAL INFORMATION:
; APPLICANT: PIOMMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/688,188B
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 58
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-725-329-58

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3379 CCCAAACCTACCAAAATTC 3399
DB      1 CCCAAACCTACCAAAATTC 21

RESULT 26
US-10-494-343-534
; Sequence 534, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
```

```
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 534
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-534

Query Match      0.5%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1443 GCAGCAGCAGCAGCAGCAGCA 1463
DB      5 GCAGCAGCAGCAGCAGCAGCA 25

RESULT 27
US-10-494-343-539
; Sequence 539, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 539
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-539

Query Match      0.5%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1444 CAGCAGCAGCAGCAGCAGCAG 1464
DB      1 CAGCAGCAGCAGCAGCAGCAG 21

RESULT 28
US-10-028-415-27/c
; Sequence 27, Application US/10028415
; Publication No. US20020151063A1
; GENERAL INFORMATION:
; APPLICANT: Lasham, Annette
; APPLICANT: Watson, James D.
; TITLE OF INVENTION: Methods for Modulating Apoptotic Cell
; FILE REFERENCE: 11000.1004c3
; CURRENT APPLICATION NUMBER: US/10/028,415
; CURRENT FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: PCT/NZ01/00286
; PRIOR FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: US 09/724,809
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/036,004
; PRIOR FILING DATE: 1998-03-04
; PRIOR APPLICATION NUMBER: US 08/713,557
; PRIOR FILING DATE: 1996-08-30
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 4.0
```

SEQ ID NO 27
LENGTH: 22
TYPE: DNA
ORGANISM: Human
US-10-028-415-27

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 71;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAGCAGCAGC 1465
DB 22 CACCAGCAGCAGCAGCAGC 1

RESULT 29
US-10-738-642-25
Sequence 25, Application US/10738642
Publication No. US20040241854A1
GENERAL INFORMATION:
APPLICANT: Paulson, Henry
APPLICANT: Miller, Victor
TITLE OF INVENTION: siRNA-Mediated Gene Silencing
FILE REFERENCE: 875.101US1
CURRENT APPLICATION NUMBER: US/10/738,642
PRIOR FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: US 10/212,322
PRIOR FILING DATE: 2002-08-05
PRIOR APPLICATION NUMBER: US 10/332,086
PRIOR FILING DATE: 2002-12-17
PRIOR APPLICATION NUMBER: US 10/430,351
PRIOR FILING DATE: 2003-05-05
PRIOR APPLICATION NUMBER: PCT/US03/16887
PRIOR FILING DATE: 2003-05-26
NUMBER OF SEQ ID NOS: 90
SOFTWARE: FaestSeq for Windows Version 4.0
SEQ ID NO 25
LENGTH: 22
TYPE: DNA
ORGANISM: Homo sapiens
US-10-738-642-25

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 71;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCAGCAGC 1138
DB 1 CAGCAGCAGCAGCAGCAGC 22

RESULT 30
US-10-738-642-26/c
Sequence 26, Application US/10738642
Publication No. US20040241854A1
GENERAL INFORMATION:
APPLICANT: Paulson, Henry
APPLICANT: Miller, Victor
TITLE OF INVENTION: siRNA-Mediated Gene Silencing
FILE REFERENCE: 875.101US1
CURRENT APPLICATION NUMBER: US/10/738,642
PRIOR FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: US 10/212,322
PRIOR FILING DATE: 2002-08-05
PRIOR APPLICATION NUMBER: US 10/332,086
PRIOR FILING DATE: 2002-12-17
PRIOR APPLICATION NUMBER: US 10/430,351
PRIOR FILING DATE: 2003-05-05
PRIOR APPLICATION NUMBER: PCT/US03/16887
PRIOR FILING DATE: 2003-05-26
NUMBER OF SEQ ID NOS: 90

SOFTWARE: FaestSeq for Windows Version 4.0
SEQ ID NO 26
LENGTH: 22
TYPE: DNA
ORGANISM: Homo sapiens
US-10-738-642-26

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 71;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCAGCAGCAG 1140
DB 22 GCAGCAGCAGCAGCAGCAG 1

RESULT 31
US-10-719-900-43548
Sequence 43548, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002-11-20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 43548
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-43548

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 93;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3253 AAGAGCAGGCTGAGCAGCCGTG 3277
DB 1 AAGAGCAGGCTGAGTCACTGTG 25

RESULT 32
US-10-719-900-181730
Sequence 181730, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002-11-20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 181730
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-181730

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 93;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3620 AATGCTGCTGTGCTACGAGAGA 3644
DB 1 AACTGCTGTGTGCTACGAGAGA 25

RESULT 33
US-09-291-417-59
; Sequence 59, Application US/09291417A
; Publication No. US20030050230A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 240/300
; CURRENT APPLICATION NUMBER: US/09/291,417A
; CURRENT FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,784
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized nucleic acid molecule
US-09-291-417-59

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 CCCCCGGAACGATGACCA 305
DB 1 CCCCCGGAACGATGACCA 20

RESULT 34
US-10-725-329-59
; Sequence 59, Application US/10725329
; Publication No. US20040224323A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/688,188B
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-725-329-59

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 CCCCCGGAACGATGACCA 305
DB 1 CCCCCGGAACGATGACCA 20

RESULT 35
US-10-494-343-533

; Sequence 533, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 533
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-533

Query Match 0.5%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACGAGCAGC 1462
DB 6 GCAGCAGCAGCAACGAGCAGC 25

RESULT 36
US-10-494-343-540
; Sequence 540, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 540
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-540

Query Match 0.5%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AGCAGCAGCAGCAACGAGCAGC 1464
DB 1 AGCAGCAGCAGCAACGAGCAGC 20

RESULT 37
US-10-198-447A-21/c
; Sequence 21, Application US/10198447A
; Publication No. US20040018622A1
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Puttaraaju, Madalan

```

; APPLICANT: Dallinger, Guenter
; APPLICANT: Klausegger, Alfred
; APPLICANT: Bauer, Johann
; TITLE OF INVENTION: SPLICEOSOME-MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: A35306 069906.0115
; CURRENT APPLICATION NUMBER: US/10/198,447A
; CURRENT FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FaastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-198-447A-21

Query Match
Best Local Similarity 91.3%; Score 19.8; DB 1; Length 24;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1473 GAAACAGCAGCAGCAGCAGCTCC 1495
Db 24 GAAGCAGCAGCAGCAGCAGCTCC 2

RESULT 38
US-10-621-867-21/C
; Sequence 21, Application US/10621867
; Publication No. US20040248141A1
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Puttaraju, Madalash
; APPLICANT: Dallinger, Guenter
; APPLICANT: Klausegger, Alfred
; APPLICANT: Bauer, Johann
; TITLE OF INVENTION: SPLICEOSOME-MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: A35306-A 069906.0161
; CURRENT APPLICATION NUMBER: US/10/621,867
; CURRENT FILING DATE: 2003-07-17
; PRIOR APPLICATION NUMBER: 10/198,447
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FaastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-621-867-21

Query Match
Best Local Similarity 91.3%; Score 19.8; DB 1; Length 24;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1473 GAAACAGCAGCAGCAGCAGCTCC 1495
Db 24 GAAGCAGCAGCAGCAGCAGCTCC 2

RESULT 39
US-10-719-900-505777
; Sequence 505777, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
```

```

; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 505777
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-505777

Query Match
Best Local Similarity 91.3%; Score 19.8; DB 1; Length 25;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3673 ATCATTAAAGATGTGTCTGCA 3695
Db 2 ATCATTAAAGATGTGTCTGCA 24

RESULT 40
US-10-467-019-7/C
; Sequence 7, Application US/10467019
; Publication No. US20040048314A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: No. US20040048314A1el Physiological Active Peptide and Its Use
; FILE REFERENCE: P01-0295PCT
; CURRENT APPLICATION NUMBER: US/10/467,019
; CURRENT FILING DATE: 2003-08-01
; PRIOR APPLICATION NUMBER: JP2001-026820
; PRIOR FILING DATE: 2001-02-02
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer, hbv8-F1 primer
US-10-467-019-7

Query Match
Best Local Similarity 84.6%; Score 19.6; DB 1; Length 26;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1115 AACAGCAGCAGCAGCTGCAGCAGCAG 1140
Db 26 AACAGCAGCAGCAGCAGCAGCAGTAG 1

RESULT 41
US-09-888-326-240/C
; Sequence 240, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weimer, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FaastSeq for Windows Version 3.0
; SEQ ID NO 240
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (0)...(0)
```

OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-240

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 42
US-09-776-479-780/c

Sequence 780, Application US/09776479
Publication No. US20030087848A1
GENERAL INFORMATION:
APPLICANT: Bratzler, Robert L.
APPLICANT: Petersen, Deanna M.
APPLICANT: Fourn, Yves
TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
TITLE OF INVENTION: Treatment of Asthma and Allergy
FILE REFERENCE: C1037/7013 (HCL/MAT)
CURRENT APPLICATION NUMBER: US/09/776,479
CURRENT FILING DATE: 2001-02-02
PRIOR APPLICATION NUMBER: US 60/179,991
PRIOR FILING DATE: 2000-02-03
NUMBER OF SEQ ID NOS: 1093
SOFTWARE: FaastSeq for Windows Version 3.0
SEQ ID NO 780
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Sequence
US-09-776-479-780

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 43
US-09-776-479-780/c

Sequence 780, Application US/09776479
Publication No. US20040067902A9
GENERAL INFORMATION:
APPLICANT: Bratzler, Robert L.
APPLICANT: Petersen, Deanna M.
APPLICANT: Fourn, Yves
TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
TITLE OF INVENTION: Treatment of Asthma and Allergy
FILE REFERENCE: C1037/7013 (HCL/MAT)
CURRENT APPLICATION NUMBER: US/09/776,479
CURRENT FILING DATE: 2001-02-02
PRIOR APPLICATION NUMBER: US 60/179,991
PRIOR FILING DATE: 2000-02-03
NUMBER OF SEQ ID NOS: 1093
SOFTWARE: FaastSeq for Windows Version 3.0
SEQ ID NO 780
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Sequence
US-09-776-479-780

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 44
US-10-112-653-753/c

Sequence 753, Application US/10112653
Publication No. US20030050268A1
GENERAL INFORMATION:
APPLICANT: Krieger, Arthur M.
APPLICANT: Berg, Daniel J.
TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
FILE REFERENCE: C01039/70060 (AMS)
CURRENT APPLICATION NUMBER: US/10/112,653
CURRENT FILING DATE: 2002-03-29
PRIOR APPLICATION NUMBER: US 60/279,642
PRIOR FILING DATE: 2001-03-29
NUMBER OF SEQ ID NOS: 1040
SOFTWARE: FaastSeq for Windows Version 3.0
SEQ ID NO 753
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-753

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 45
US-10-017-995-780/c

Sequence 780, Application US/10017995
Publication No. US20030055014A1
GENERAL INFORMATION:
APPLICANT: Bratzler, Robert L.
TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
FILE REFERENCE: C1037/7025 (HCL/MAT)
CURRENT APPLICATION NUMBER: US/10/017,995
CURRENT FILING DATE: 2001-12-18
PRIOR APPLICATION NUMBER: US 60/255,534
PRIOR FILING DATE: 2000-12-14
NUMBER OF SEQ ID NOS: 1093
SOFTWARE: FaastSeq for Windows Version 3.0
SEQ ID NO 780
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Sequence
US-10-017-995-780

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 46
US-10-314-578-780/c


```
/ Sequence 780, Application US/10314578
/ Publication No. US20030212026A1
/ GENERAL INFORMATION:
/ APPLICANT: Kries, Arthur M.
/ APPLICANT: Schetter, Christian
/ APPLICANT: Volmer, Jorg
/ TITLE OF INVENTION: Immunostimulatory Nucleic Acids
/ FILE REFERENCE: C1039/7035 (HCL/MAT)
/ CURRENT APPLICATION NUMBER: US/10/314,578
/ CURRENT FILING DATE: 2002-12-09
/ PRIOR APPLICATION NUMBER: US 60/156,113
/ PRIOR FILING DATE: 1999-09-25
/ PRIOR APPLICATION NUMBER: US 60/156,135
/ PRIOR FILING DATE: 1999-09-27
/ PRIOR APPLICATION NUMBER: US 60/227,436
/ PRIOR FILING DATE: 2000-08-23
/ NUMBER OF SEQ ID NOS: 1145
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 780
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Sequence
US-10-314-578-780

Query Match          0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
Db 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 47
US-10-418-182-96/c
/ Sequence 96, Application US/10418182
/ Publication No. US20030228302A1
/ GENERAL INFORMATION:
/ APPLICANT: Crea, Roberto
/ TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
/ FILE REFERENCE: 1551.2001-001
/ CURRENT APPLICATION NUMBER: US/10/418,182
/ CURRENT FILING DATE: 2003-04-16
/ PRIOR APPLICATION NUMBER: 60/373,558
/ PRIOR FILING DATE: 2002-04-17
/ NUMBER OF SEQ ID NOS: 423
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 96
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: oligonucleotide
US-10-418-182-96

Query Match          0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1121 AGCAGCAGCTGCAGCAGCAGC 1141
Db 21 AGCAGCAGCGCGCAGCAGCAGC 1

RESULT 48
US-10-831-778-780/c
/ Sequence 780, Application US/10831778
/ Publication No. US20040235774A1
/ GENERAL INFORMATION:
/ APPLICANT: Bratzler, Robert L.
/ APPLICANT: Petersen, Deanna M.
```

```
/ APPLICANT: Fouron, Yves
/ TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
/ TITLE OF INVENTION: Treatment of Asthma and Allergy
/ FILE REFERENCE: C1037/7013 (HCL/MAT)
/ CURRENT APPLICATION NUMBER: US/10/831,778
/ CURRENT FILING DATE: 2004-04-23
/ PRIOR APPLICATION NUMBER: US 60/179,991
/ PRIOR FILING DATE: 2000-02-03
/ NUMBER OF SEQ ID NOS: 1093
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 780
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Sequence
US-10-831-778-780

Query Match          0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
Db 21 CAGCAGCAGCAGCAGCAGCAG 1

RESULT 49
US-10-751-736-39220
/ Sequence 39220, Application US/10751736
/ Publication No. US20040265230A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Martinez, Robert
/ APPLICANT: Brown, Eugene
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
/ TITLE OF INVENTION: CANCERS
/ FILE REFERENCE: AML00927 (031896-002000)
/ CURRENT APPLICATION NUMBER: US/10/751,736
/ CURRENT FILING DATE: 2003-01-06
/ PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
/ PRIOR FILING DATE: 2003-01-06
/ NUMBER OF SEQ ID NOS: 54873
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 39220
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: homo sapiens
US-10-751-736-39220

Query Match          0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
Db 1 CAGCAGCAGCAGCTGCAGCAG 21

RESULT 50
US-10-433-561-46
/ Sequence 46, Application US/10433561
/ Publication No. US20040029178A1
/ GENERAL INFORMATION:
/ APPLICANT: Takeda Chemical Industries, Ltd.
/ TITLE OF INVENTION: No. US20040029178A1 G Protein-Coupled Receptor Proteins and DNA;
/ FILE REFERENCE: P01-0255PCT
/ CURRENT APPLICATION NUMBER: US/10/433,561
/ CURRENT FILING DATE: 2003-05-30
/ PRIOR APPLICATION NUMBER: JP 2000-364801
/ PRIOR FILING DATE: 2000-11-30
/ PRIOR APPLICATION NUMBER: JP 2001-087482
```

;; PRIOR FILING DATE: 2001-03-26
;; PRIOR APPLICATION NUMBER: JP 2001-145434
;; PRIOR FILING DATE: 2001-05-15
;; PRIOR APPLICATION NUMBER: JP 2001-270838
;; PRIOR FILING DATE: 2001-09-06
;; NUMBER OF SEQ ID NOS: 191
;; SEQ ID NO 46
;; LENGTH: 24
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
US-10-433-56146

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGACGACGACGACG 1146
DB 1 CAGCGGACGACGACGACGAG 21

RESULT 51
US-10-477-726-46
;; Sequence 46; Application US/10477726
;; Publication No. US20040110231A1
;; GENERAL INFORMATION:
;; APPLICANT: Takeda Chemical Industries, Ltd.
;; TITLE OF INVENTION: Screening method
;; FILE REFERENCE: F02-0058PCT
;; CURRENT APPLICATION NUMBER: US/10/477,726
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 2001-145411
;; PRIOR FILING DATE: 2001-05-15
;; NUMBER OF SEQ ID NOS: 135
;; SEQ ID NO 46
;; LENGTH: 24
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Primer
US-10-477-726-46

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGCTGACGACGACGACG 1146
DB 1 CAGCGGACGACGACGACGAG 21

RESULT 52
US-10-719-900-151739
;; Sequence 151739; Application US/10719900
;; Publication No. US20050026164A1
;; GENERAL INFORMATION:
;; APPLICANT: Xue Mei Zhou
;; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;; FILE REFERENCE: 3528.1
;; CURRENT APPLICATION NUMBER: US/10/719,900
;; PRIOR FILING DATE: 2003-11-20
;; PRIOR APPLICATION NUMBER: 60/427,808
;; PRIOR FILING DATE: 2002-11-20
;; NUMBER OF SEQ ID NOS: 982914
;; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
;; SEQ ID NO 151739
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Mus musculus
US-10-719-900-151739

Query Match 0.5%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3361 GAGGTGTATGCTGGGCCCCCAA 3384
DB 2 GAGATATATGCTGGGCCCCCTAAA 25

RESULT 53
US-10-719-900-199979
;; Sequence 199979; Application US/10719900
;; Publication No. US20050026164A1
;; GENERAL INFORMATION:
;; APPLICANT: Xue Mei Zhou
;; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;; FILE REFERENCE: 3528.1
;; CURRENT APPLICATION NUMBER: US/10/719,900
;; PRIOR FILING DATE: 2003-11-20
;; PRIOR APPLICATION NUMBER: 60/427,808
;; PRIOR FILING DATE: 2002-11-20
;; NUMBER OF SEQ ID NOS: 982914
;; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
;; SEQ ID NO 199979
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Mus musculus
US-10-719-900-199979

Query Match 0.5%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3821 GAGCTCAGAGCTCAAGTTCTGT 3844
DB 2 GGGCTCAGAGACTAAAGTTCTGT 25

RESULT 54
US-10-809-189-43760
;; Sequence 43760; Application US/10809189
;; Publication No. US20050048531A1
;; GENERAL INFORMATION:
;; APPLICANT: Michael Miltmann
;; APPLICANT: David Lockhart
;; APPLICANT: Affymetrix, Inc.
;; TITLE OF INVENTION: Methods of Genetic Analysis
;; FILE REFERENCE: 3101.1
;; CURRENT APPLICATION NUMBER: US/10/809,189
;; PRIOR FILING DATE: 2004-03-25
;; PRIOR APPLICATION NUMBER: 09/396,196
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: 60/100,678
;; PRIOR FILING DATE: 1998-09-17
;; NUMBER OF SEQ ID NOS: 127806
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 43760
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Mus musculus
US-10-809-189-43760

Query Match 0.5%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1444 CAGCAGACGACGACGACGAG 1467
DB 2 CAGCAGCTGGAACAGCAGAGCAG 25

RESULT 55

```
US-09-291-417-62/c
; Sequence 62, Application US/09291417A
; Publication No. US20030050230A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 240/300
; CURRENT APPLICATION NUMBER: US/09/291,417A
; CURRENT FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,784
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PaetSeq for Windows Version 3.0
; SEQ ID NO 62
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized nucleic acid molecule
US-09-291-417-62

Query Match          0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2544 GGTGTCACGACGTCGAG 2562
DB      19 GGTGTCACGACGTCGAG 1

RESULT 56
US-10-725-329-62/c
; Sequence 62, Application US/10725329
; Publication No. US2004022433A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/688,188B
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 62
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-725-329-62

Query Match          0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2544 GGTGTCACGACGTCGAG 2562
DB      19 GGTGTCACGACGTCGAG 1

RESULT 57
US-09-789-390-50
; Sequence 50, Application US/09789390
; Publication No. US20030059768A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Vernet, Corine
; APPLICANT: Fernandes, Elma
; APPLICANT: MacDougall, John
; APPLICANT: Shimkets, Richard A
; APPLICANT: Spaderna, Steven K
; TITLE OF INVENTION: NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 15966-692
; CURRENT APPLICATION NUMBER: US/09/789,390
; CURRENT FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: 60/185,548
; PRIOR FILING DATE: 2000-02-28
; PRIOR APPLICATION NUMBER: 60/199,957
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 60/184,951
; PRIOR FILING DATE: 2000-02-25
; PRIOR APPLICATION NUMBER: 60/185,967
; PRIOR FILING DATE: 2000-03-01
; PRIOR APPLICATION NUMBER: 60/197,723
; PRIOR FILING DATE: 2000-04-18
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Ag756 PCR
US-09-789-390-50

Query Match          0.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      496 AATGCTGAGTCAAGCTAG 514
DB      1 AATGCTGAGTCAAGCTAG 19

RESULT 58
US-10-494-343-532
; Sequence 532, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 532
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-532

Query Match          0.5%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1443 GAGCAGCAGCAACGACG 1461
DB      7 GAGCAGCAGCAACGACG 25
```

RESULT 59
US-10-494-343-541
; Sequence 541, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, ThuyMy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecmics Sequence Listing Engine
; SEQ ID NO 541
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-541

Query Match 0.5%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1446 GCAGCAGCAACGACGACG 1464
Db 1 GCAGCAGCAACGACGACG 19

RESULT 60
US-09-888-615-120/c
; Sequence 120, Application US/09888615
; Patent No. US20020064856A1
; GENERAL INFORMATION:
; APPLICANT: PLOMMAN, GREGORY
; APPLICANT: WMYTE, DAVID
; APPLICANT: CAENEPEEL, SEAN
; APPLICANT: CHARYDCZAK, GLEN
; APPLICANT: MANNING, GERRARD
; APPLICANT: SUDARSANAM, SUCHA
; TITLE OF INVENTION: NOVEL PROTEASES
; FILE REFERENCE: 038602/1214
; CURRENT APPLICATION NUMBER: US/09/888,615
; PRIOR FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: 60/214,047
; PRIOR FILING DATE: 2000-06-26
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 120
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-888-615-120

Query Match 0.5%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 CTGCAGCAGCAGCAACGACG 1462
Db 22 CTGCAGCAGCAGCAGCAGC 1

RESULT 61
US-09-729-653-6
; Sequence 6, Application US/09729653
; Patent No. US20020150893A1

; GENERAL INFORMATION:
; APPLICANT: Lin, Biaoyang
; TITLE OF INVENTION: Prostate-Specific Polypeptide PAMP and
; TITLE OF INVENTION: Encoding Nucleic Acid Molecules
; FILE REFERENCE: P-15 4367
; CURRENT APPLICATION NUMBER: US/09/729,653
; PRIOR FILING DATE: 2000-12-04
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-729-653-6

Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 63 GGACCTGCTGGATCTTGAG 84
Db 3 GGACCTGCTGGATGCTTGAG 24

RESULT 62
US-10-705-874-18/c
; Sequence 18, Application US/10705874
; Publication No. US20040096892A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor
; APPLICANT: Kinsler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Wang, Tian-Li
; TITLE OF INVENTION: DIGITAL KARYOTYPING
; FILE REFERENCE: 001107.00391
; CURRENT APPLICATION NUMBER: US/10/705,874
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: 60/426,406
; PRIOR FILING DATE: 2002-11-15
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-705-874-18

Query Match 0.5%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1104 AGAGCCTTAATAACGACGACG 1125
Db 24 AATGCTTAATAACGACGACG 3

RESULT 63
US-10-719-900-817718
; Sequence 817718, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Wei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 817718
; LENGTH: 25
; TYPE: DNA

ORGANISM: Mus musculus
US-10-719-900-817718

Query Match 0.5%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CCGGAGTTTCTCCGGCTCCAG 1083
DB 2 CCGGAGCTTTCTCCGGCTCCAG 23

RESULT 64

US-10-809-189-18665
Sequence 18665, Application US/10809189
Publication No. US20050048531A1

GENERAL INFORMATION:
APPLICANT: Michael Maltmann
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1
CURRENT APPLICATION NUMBER: US/10/809,189
CURRENT FILING DATE: 2004-03-25
PRIOR APPLICATION NUMBER: US/09/396,196
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: 60/100,678
PRIOR FILING DATE: 1998-09-17
NUMBER OF SEQ ID NOS: 127806
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 18665
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-809-189-18665

Query Match 0.5%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1130 TGCAGCAGCAGCAGCAGCA 1151
DB 4 TGCAGCAGCAGCAGCAGCAGCA 25

RESULT 65

US-09-861-893-15/c
Sequence 15, Application US/09861893
Patent No. US20020045257A1

GENERAL INFORMATION:
APPLICANT: Feinberg, Andrew
APPLICANT: Strichman-Almashanu, Liora
APPLICANT: Jiang, Shan
TITLE OF INVENTION: METHODS FOR ASSAYING GENE IMPRINTING AND
FILE REFERENCE: 01107.00128
CURRENT APPLICATION NUMBER: US/09/861,893
CURRENT FILING DATE: 2001-05-22
PRIOR APPLICATION NUMBER: 60/206,158
PRIOR FILING DATE: 2000-05-22
PRIOR APPLICATION NUMBER: 60/206,161
PRIOR FILING DATE: 2000-05-22
NUMBER OF SEQ ID NOS: 77
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 15
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-09-861-893-15

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAGCAGCA 1463
DB 20 CAGTACAGCAACAGCAGCA 1

RESULT 66

US-10-371-474-63
Sequence 63, Application US/10371474
Publication No. US20030144242A1

GENERAL INFORMATION:
APPLICANT: Donna T. Ward
APPLICANT: William Gaarde
APPLICANT: Brett P. Monia
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF MEK4 EXPRESSION
FILE REFERENCE: RTS-0169
CURRENT APPLICATION NUMBER: US/10/371,474
CURRENT FILING DATE: 2003-02-21
PRIOR APPLICATION NUMBER: US/09/676,436
PRIOR FILING DATE: 2000-09-29
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 63
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-371-474-63

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGC 1138
DB 1 GCAGCAGCAGCAGCAGCAGC 20

RESULT 67

US-10-154-708-25/c
Sequence 25, Application US/10154708
Publication No. US20030219895A1

GENERAL INFORMATION:
APPLICANT: Andrew T. Walt
TITLE OF INVENTION: ANTISENSE MODULATION OF CDC-LIKE KINASE 1 EXPRESSION
FILE REFERENCE: RTS-0213
CURRENT APPLICATION NUMBER: US/10/154,708
CURRENT FILING DATE: 2002-05-22
NUMBER OF SEQ ID NOS: 143
SEQ ID NO 25
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-154-708-25

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 TGCAGCAGCAGCGCAGTCA 1392
DB 20 TGCAGCAGCAGCAGCAGTCA 1

RESULT 68

US-10-154-708-98
Sequence 98, Application US/10154708
Publication No. US20030219895A1

GENERAL INFORMATION:

```

APPLICANT: Andrew T. Walt
TITLE OF INVENTION: ANTIENSE MODULATION OF CDC-LIKE KINASE 1 EXPRESSION
FILE REFERENCE: PFS-0213
CURRENT APPLICATION NUMBER: US/10/154,708
CURRENT FILING DATE: 2002-05-22
NUMBER OF SEQ ID NOS: 143
SEQ ID NO 98
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-154-708-98

Query Match
Best Local Similarity 95.0%; Score 18.4; DB 1; Length 20;
Matches 19; Conservative 0; Pred. No. 1.1e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 1373 TGGAGGAGCAGCGCAGCTCA 1392
Db 1 TGGAGGAGCAGCAGCAGCTCA 20
|||||

RESULT 69
US-10-418-182-132
Sequence 132, Application US/10418182
Publication No. US20030228302A1
GENERAL INFORMATION:
APPLICANT: Crea, Roberto
TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
FILE REFERENCE: 1551.2001-001
CURRENT APPLICATION NUMBER: US/10/418,182
CURRENT FILING DATE: 2003-04-16
PRIOR APPLICATION NUMBER: 60/373,558
PRIOR FILING DATE: 2002-04-17
NUMBER OF SEQ ID NOS: 423
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 132
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: oligonucleotide
US-10-418-182-132

Query Match
Best Local Similarity 95.0%; Score 18.4; DB 1; Length 21;
Matches 19; Conservative 0; Pred. No. 1.2e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 CAGCAGCAACGACGACGACA 1466
Db 1 CAGCAGCAACGACGACGACA 20
|||||

RESULT 70
US-10-357-488-20/c
Sequence 20, Application US/10357488
Publication No. US20030194730A1
GENERAL INFORMATION:
APPLICANT: Centre For DNA Fingerprinting and Diagnostics
TITLE OF INVENTION: No. US20030194730A1 FISSR-PCR primers and markers and a method
TITLE OF INVENTION: primers and markers for identifying genetic constitution and b
FILE REFERENCE: 782-Indian
CURRENT APPLICATION NUMBER: US/10/357,488
CURRENT FILING DATE: 2003-02-04
PRIOR APPLICATION NUMBER: 260/MAS/2002
PRIOR FILING DATE: 2002-04-08
NUMBER OF SEQ ID NOS: 37
SOFTWARE: PatentIn version 3.1
SEQ ID NO 20
LENGTH: 23
TYPE: DNA
ORGANISM: Artificial Sequence

```

```

; FEATURE INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
; OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-20

Query Match          0.5%; Score 18.4; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      1475 AACAGCAGCAGCAGCAGCTC 1494
      |||||||||||||||
Db      23  AGCAGCAGCAGCAGCAGCTC 4

RESULT 71
US-08-983-605-193/c
; Sequence 193, Application US/08983605A
; Publication No. US20020066118A1
GENERAL INFORMATION:
APPLICANT: Koder, Marion
TITLE OF INVENTION: Microsatellite Markers for Plants of the Species of
TITLE OF INVENTION: Triticum aestivum and Tribe Triticeae and the Use of
TITLE OF INVENTION: Seed Markers
FILE REFERENCE: 2936.10400
CURRENT APPLICATION NUMBER: US/08/983.605A
CURRENT FILING DATE: 1998-05-01
EARLIER APPLICATION NUMBER: DE 195 25 284.5
EARLIER FILING DATE: 1995-06-28
NUMBER OF SEQ ID NOS: 466
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 193
LENGTH: 23
TYPE: DNA
ORGANISM: Triticum aestivum
US-08-983-605-193

Query Match          0.5%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      101 GCAATGGAACCTACGACAGGTG 123
      |||||||||||||||
Db      23  GCAATGGAACCTACGTACAGTTG 1

RESULT 72
US-10-750-323-11/c
; Sequence 11, Application US/10750323
; Publication No. US20050032083A1
GENERAL INFORMATION:
APPLICANT: Pulst, Stefan M
TITLE OF INVENTION: NUCLEIC ACID ENCODING SPINOCEREULAR
ATAXIA-2 AND PRODUCTS RELATED THERETO
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Muelting, Raasch & Gebhardt, P.A.
STREET: 119 North Fourth Street
CITY: Minneapolis
STATE: Minnesota
COUNTRY: USA
ZIP: 55401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/750.323
FILING DATE: 30-Dec-2003
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/727,084
FILING DATE: 08-Oct-1996
ATTORNEY/AGENT INFORMATION:

```

NAME: Mueeling, Ann M.
REGISTRATION NUMBER: 33, 977
REFERENCE/DOCKET NUMBER: 232.00010101
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612/305-1220
TELEFAX: 612/305-1228
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-750-323-11

Query Match 0.5%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1432 CTGAATCTCTGACGACGACGA 1454
DB 23 CTGAAGCCCCGACGACGACGA 1

RESULT 73
US-10-198-447A-22/C
Sequence 22, Application US/10198447A
Publication No. US20040018622A1
GENERAL INFORMATION:
APPLICANT: Mitchell, Lloyd G.
APPLICANT: Puttaraju, Madalah
APPLICANT: Dallinger, Guenter
APPLICANT: Klaussegger, Alfred
APPLICANT: Bauer, Johann
TITLE OF INVENTION: SPLICEOSOME-MEDIATED RNA TRANS-SPLICING
FILE REFERENCE: A35306 069906.0115
CURRENT APPLICATION NUMBER: US/10/198,447A
CURRENT FILING DATE: 2002-07-17
NUMBER OF SEQ ID NOS: 31
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer
US-10-198-447A-22

Query Match 0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1473 GAAACGACGACGACGACGCTCC 1495
DB 24 GCAGCAGCAGCAGCAGCAGCTCC 2

RESULT 74
US-10-621-867-22/C
Sequence 22, Application US/10621867
Publication No. US20040248141A1
GENERAL INFORMATION:
APPLICANT: Mitchell, Lloyd G.
APPLICANT: Puttaraju, Madalah
APPLICANT: Dallinger, Guenter
APPLICANT: Klaussegger, Alfred
APPLICANT: Bauer, Johann
TITLE OF INVENTION: SPLICEOSOME-MEDIATED RNA TRANS-SPLICING
FILE REFERENCE: A35306-A 069906.0161
CURRENT APPLICATION NUMBER: US/10/621,867

CURRENT FILING DATE: 2003-07-17
PRIOR APPLICATION NUMBER: 10/198,447
PRIOR FILING DATE: 2002-07-17
NUMBER OF SEQ ID NOS: 38
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer
US-10-621-867-22

Query Match 0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1473 GAAACGACGACGACGACGCTCC 1495
DB 24 GCAGCAGCAGCAGCAGCAGCTCC 2

RESULT 75
US-10-054-387-48/C
Sequence 48, Application US/10054387
Publication No. US20030054365A1
GENERAL INFORMATION:
APPLICANT: Xu, Minzhen
APPLICANT: Qiu, Gang
APPLICANT: Humphreys, Robert
TITLE OF INVENTION: CANCER CELL VACCINE
FILE REFERENCE: U.S. Application 09/205,995. (CIP)
CURRENT APPLICATION NUMBER: US/10/054,387
CURRENT FILING DATE: 2002-01-22
PRIOR APPLICATION NUMBER: 09/036,746
PRIOR FILING DATE: 1998-03-09
PRIOR APPLICATION NUMBER: 08/661,627
PRIOR FILING DATE: 1996-06-11
NUMBER OF SEQ ID NOS: 79
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 48
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: antisense
OTHER INFORMATION: oligonucleotide corresponding to a specific region
OTHER INFORMATION: of the mouse Il gene.
US-10-054-387-48

Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAG 1464
DB 18 CAGCAGCAACAGCAGCAG 1

RESULT 76
US-10-436-231-1
Sequence 1, Application US/10436231
Publication No. US20040175704A1
GENERAL INFORMATION:
APPLICANT: Stratsene
APPLICANT: Sorge, Joseph A
APPLICANT: Flamin, Andrew
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE SEQUENCE DETECTION
FILE REFERENCE: 25436/2392
CURRENT APPLICATION NUMBER: US/10/436,231
CURRENT FILING DATE: 2003-05-12
PRIOR APPLICATION NUMBER: US 60/452,481
PRIOR FILING DATE: 2003-03-06

NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatentIn version 3.2
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Example Allele A comprising tandem repeats
US-10-436-231-1

Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1474 AAACAGCAGCAGCAGCAG 1491
DB 1 AAACAGCAGCAGCAGCAG 18

RESULT 77
US-10-436-231-2/c
Sequence 2, Application US/10436231
Publication No. US20040175704A1
GENERAL INFORMATION:
APPLICANT: Stratagene
APPLICANT: Sorge, Joseph A
APPLICANT: Firm, Andrew
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE SEQUENCE DETECTION
FILE REFERENCE: 25436/2392
CURRENT FILING DATE: 2003-05-12
PRIOR FILING DATE: 2003-03-06
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatentIn version 3.2
SEQ ID NO 2
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Example Allele A comprising tandem repeats
US-10-436-231-2

Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1474 AAACAGCAGCAGCAGCAG 1491
DB 18 AAACAGCAGCAGCAGCAG 1

RESULT 78
US-10-032-585-5708/c
Sequence 5708, Application US/10032585
Publication No. US20030180953A1
GENERAL INFORMATION:
APPLICANT: Terry, Roemer D.
APPLICANT: Bo, Jiang
APPLICANT: Charles, Boone
APPLICANT: Howard, Bussey
TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
FILE REFERENCE: 10182-005-999
CURRENT FILING DATE: 2001-12-20
NUMBER OF SEQ ID NOS: 8000
SOFTWARE: PatentIn version 3.1
SEQ ID NO 5708
LENGTH: 20
TYPE: DNA
ORGANISM: Candida albicans
US-10-032-585-5708

Query Match 0.5%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 AACAGCAGCAGCAGCAGC 1492
DB 18 AACAGCAGCAGCAGCAGC 1

RESULT 79
US-10-215-432-37
Sequence 37, Application US/10215432
Publication No. US20030109476A1
GENERAL INFORMATION:
APPLICANT: Eric B. Kmiec
APPLICANT: Hetal Parekh-Olmedo
TITLE OF INVENTION: Composition and methods for the prevention and treatment of Huntington's disease
FILE REFERENCE: Napro-10
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 44
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 37
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Isolated clone of gene-alteration directed by a
US-10-215-432-37

Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 1 CAGCAGCAGTACGACAGCAG 21

RESULT 80
US-10-215-432-44
Sequence 44, Application US/10215432
Publication No. US20030109476A1
GENERAL INFORMATION:
APPLICANT: Eric B. Kmiec
APPLICANT: Hetal Parekh-Olmedo
TITLE OF INVENTION: Composition and methods for the prevention and treatment of Huntington's disease
FILE REFERENCE: Napro-10
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 44
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 44
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Converted HD sequence
US-10-215-432-44

Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAG 1137
DB 1 CAGCAGCAGTACGACAGCAG 21

RESULT 81


```
US-10-751-736-40387
; Sequence 40387, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40387
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-40387

Query Match
Best Local Similarity 90.5%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 180 CACGAGACGACGAGAGAGA 200
DB 1 CATGGAGAGACGAGAGAGA 21

RESULT 82
US-10-764-730-11
; Sequence 11, Application US/10764730
; Publication No. US20050032134A1
; GENERAL INFORMATION:
; APPLICANT: Mueller-Hermelink, Hans Konrad
; APPLICANT: Vollmeier, Heinz Peter
; APPLICANT: Hensele, Frank
; TITLE OF INVENTION: Neoplasm-Specific Polypeptides and Their
; FILE REFERENCE: 50308/009002
; CURRENT APPLICATION NUMBER: US/10/764,730
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: PCT/DE02/02699
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: DE 10210425.5
; PRIOR FILING DATE: 2002-03-09
; PRIOR APPLICATION NUMBER: DE 10136009.6
; PRIOR FILING DATE: 2001-07-24
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-764-730-11

Query Match
Best Local Similarity 90.5%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1125 GCAGCTGCAGCAGCAGCAGA 1145
DB 1 GCAGCTTCAGCAGCAGCAGA 21

RESULT 83
US-09-291-417-133
; Sequence 133, Application US/09291417A
```

```
; Publication No. US20030050230A1
; GENERAL INFORMATION:
; APPLICANT: PLOOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 240/300
; CURRENT APPLICATION NUMBER: US/09/291,417A
; PRIOR FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,784
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 133
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Mammalian (Human) ZC1
US-09-291-417-133

Query Match
Best Local Similarity 90.5%; Score 17.8; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3858 CAAGGTGTTTGTGCTCAGT 3878
DB 1 CAAGGTGTTGCTTGTGCTCTGT 21

RESULT 84
US-10-182-243-74/c
; Sequence 74, Application US/10182243
; Publication No. US20040048310A1
; GENERAL INFORMATION:
; APPLICANT: PLOOMAN, GREGORY D.
; APPLICANT: WHITE, DAVID
; APPLICANT: MANNING, GERARD
; APPLICANT: SUDARSANAM, SUCHA
; APPLICANT: MARTINEZ, RICARDO
; TITLE OF INVENTION: NOVEL HUMAN PROTEIN KINASES AND PROTEIN KINASE-LIKE
; FILE REFERENCE: 038602/1366
; CURRENT APPLICATION NUMBER: US/10/182,243
; PRIOR FILING DATE: 2003-07-07
; PRIOR APPLICATION NUMBER: PCT/US01/02337
; PRIOR FILING DATE: 2001-01-25
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 74
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-182-243-74

Query Match
Best Local Similarity 90.5%; Score 17.8; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3625 CTGCTGTGCTAGCAGCAGCAG 3645
DB 22 CTGCTGTGCTGCGAAGCAGCAG 2

RESULT 85
US-10-725-329-133
; Sequence 133, Application US/10725329
; Publication No. US20040224323A1
; GENERAL INFORMATION:
; APPLICANT: PLOOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHITE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
```

```

; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/668,188B
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 133
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-725-329-133

Query Match
Best Local Similarity 90.5%; Score 17.8; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3858 CAAGGTGTTTTCCTCACT 3878
DB 1 CAAGGTGTTTTCCTCTGT 21

RESULT 86
US-09-563-728A-6/c
; Sequence 6, Application US/09563728A
; Publication No. US20030078216A1
; GENERAL INFORMATION:
; APPLICANT: Macleod, Alan R
; APPLICANT: Li, Zoumei
; APPLICANT: Besterman, Jeffrey M
; TITLE OF INVENTION: Inhibition of Histone Deacetylase
; FILE REFERENCE: 106101.229
; CURRENT APPLICATION NUMBER: US/09/563,728A
; CURRENT FILING DATE: 2000-05-03
; PRIOR APPLICATION NUMBER: 60/132,287
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-563-728A-6

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGC 1147
DB 20 CGCAGCAGCAGCAGCAGC 2

RESULT 87
US-09-563-728A-15/c
; Sequence 15, Application US/09563728A
; Publication No. US20030078216A1
; GENERAL INFORMATION:
; APPLICANT: Macleod, Alan R
; APPLICANT: Li, Zoumei
; APPLICANT: Besterman, Jeffrey M
; TITLE OF INVENTION: Inhibition of Histone Deacetylase
; FILE REFERENCE: 106101.229
; CURRENT APPLICATION NUMBER: US/09/563,728A
; CURRENT FILING DATE: 2000-05-03
; PRIOR APPLICATION NUMBER: 60/132,287
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 36
```

```

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: 1-4 and 17-20 are modified
; OTHER INFORMATION: Positions 1-4 and 17-20 are 2'-methoxyribose
; OTHER INFORMATION: substituted nucleotides; positions 5-16 are
US-09-563-728A-15

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGC 1147
DB 20 CGCAGCAGCAGCAGCAGC 2

RESULT 88
US-10-145-493B-51/c
; Sequence 51, Application US/10145493B
; Publication No. US20030096777A1
; GENERAL INFORMATION:
; APPLICANT: Besterman, Jeffrey
; APPLICANT: Macleod, Robert
; APPLICANT: Siders, William
; TITLE OF INVENTION: Modulation of Gene Expression by Combination Therapy
; FILE REFERENCE: MET-015DV
; CURRENT APPLICATION NUMBER: US/10/145,493B
; CURRENT FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 09/420,692
; PRIOR FILING DATE: 1999-10-19
; PRIOR APPLICATION NUMBER: US 60/104,804
; PRIOR FILING DATE: 1998-10-19
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-145-493B-51

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGCAGCAGCAGCAGC 1147
DB 20 CGCAGCAGCAGCAGCAGC 2

RESULT 89
US-10-032-585-4667/c
; Sequence 4667, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4667
```

LENGTH: 20
TYPE: DNA
ORGANISM: Candida albicans
US-10-032-585-4667

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAGCAGC 1468
DB 20 CAGCAACAGCAGCAGCAGC 2

RESULT 90
US-10-005-344-340/C

Sequence 340, Application US/10005344
Publication No. US20030203862A1
GENERAL INFORMATION:
APPLICANT: Loren J. Miraglia
APPLICANT: Pamela Nero
APPLICANT: Mark J. Graham
APPLICANT: Brett P. Monda
APPLICANT: Erich Koeller
APPLICANT: Mingyi Chiang
APPLICANT: Mano Manoharan
TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
FILE REFERENCE: ISPH-0622
CURRENT APPLICATION NUMBER: US/10/005,344
CURRENT FILING DATE: 2001-12-04
PRIOR APPLICATION NUMBER: US 09/048,810
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/280,805
PRIOR FILING DATE: 1999-03-26
NUMBER OF SEQ ID NOS: 379
SOFTWARE: FastSeq for Windows Version 4.0.
SEQ ID NO 340
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-340

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1135 CAGCAGCAGCAGCAGC 1153
DB 20 CAGCAGCAGCAGCAGC 2

RESULT 91
US-10-148-835-86/C
Sequence 86, Application US/10148835
Publication No. US20030207380A1
GENERAL INFORMATION:
APPLICANT: SAITO et al.
TITLE OF INVENTION: MUTANT ER alpha AND TEST SYSTEMS FOR TRANSACTIVATION
FILE REFERENCE: 2185-0648P
CURRENT APPLICATION NUMBER: US/10/148,835
CURRENT FILING DATE: 2002-10-11
NUMBER OF SEQ ID NOS: 213
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 86
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Designed
US-10-148-835-86

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1130 TGCAGCAGCAGCAGCAGC 1148
DB 20 TGCAGCAGCAGCAGCAGC 2

RESULT 92
US-10-380-126-39/C

Sequence 39, Application US/10380126
Publication No. US20040029824A1
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-1 EXPRESSION
FILE REFERENCE: RTS-0175
CURRENT APPLICATION NUMBER: US/10/380,126
CURRENT FILING DATE: 2003-03-10
PRIOR APPLICATION NUMBER: 09/657,042
PRIOR FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 39
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-126-39

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1121 AGCAGCAGCTGCAGCAGCA 1139
DB 20 AGCAGCAGCTGCAGCAGCA 2

RESULT 93
US-10-274-387-13/C
Sequence 13, Application US/10274387
Publication No. US20040077085A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freiler
TITLE OF INVENTION: ANTISENSE MODULATION OF CDC14A EXPRESSION
FILE REFERENCE: RTS-0172
CURRENT APPLICATION NUMBER: US/10/274,387
CURRENT FILING DATE: 2002-10-17
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 13
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-387-13

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1122 GCAGCAGCTGCAGCAGCAG 1140
DB 20 GCAGCAGCTGCAGCAGCAG 2

RESULT 94
US-10-274-311-13/C
Sequence 13, Application US/10274311

Publication No. US20040077571A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freiler
APPLICANT: Aparna Sathya
APPLICANT: Thomas McGonigal
TITLE OF INVENTION: ANTISENSE MODULATION OF CDC14A EXPRESSION
FILE REFERENCE: RTS-0262
CURRENT APPLICATION NUMBER: US/10/274,311
CURRENT FILING DATE: 2002-10-17
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 13
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-311-13

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1122 GCAGCAGCTGCAGCAGCAG 1140
DB 20 GCAGCAGCTGCAGCAGCAG 2

RESULT 95
US-10-315-962-67
Sequence 67, Application US/10315962
Publication No. US20040109848A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Nicholas M. Dean
APPLICANT: Susan M. Freiler
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF AP-2 ALPHA EXPRESSION
FILE REFERENCE: FTS-0046
CURRENT APPLICATION NUMBER: US/10/315,962
CURRENT FILING DATE: 2000-12-09
NUMBER OF SEQ ID NOS: 126
SEQ ID NO 67
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-315-962-67

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1128 GCTGCGAGCAGCAGCAG 1146
DB 1 GCGGCGAGCAGCAGCAG 19

RESULT 96
US-09-946-374-105/C
Sequence 105, Application US/09946374
Publication No. US20030073129A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.

APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same
FILE REFERENCE: P2830P1C1
CURRENT APPLICATION NUMBER: US/09/946,374
CURRENT FILING DATE: 2001-09-04
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683

;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100684
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100710
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100711
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100849
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102310
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06

;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103328
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104387
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 97
US-10-006-856A-105/c
; Sequence 105, Application US/1006856A
; Publication No. US20030044841A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Batton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Aubtin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC14

```

; CURRENT APPLICATION NUMBER: US/10/006,856A
; CURRENT FILING DATE: 2002-05-10
; NUMBER OF SEQ ID NOS: 477
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-856A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGCAGCAACAGCAGCAGC 2

RESULT 98
US-10-006-818A-105/c
; Sequence 105, Application US/10006818A
; Publication No. US20030054406A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C4
; CURRENT APPLICATION NUMBER: US/10/006,818A
; CURRENT FILING DATE: 2001-12-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-818A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGCAGCAACAGCAGCAGC 2

RESULT 99
US-10-006-485A-105/c
; Sequence 105, Application US/10006485A
; Publication No. US20030064062A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
```

```

; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C9
; CURRENT APPLICATION NUMBER: US/10/006,485A
; CURRENT FILING DATE: 2001-12-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-485A-105/c

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGCAGCAACAGCAGCAGC 2

RESULT 99
US-10-006-485A-105/c
; Sequence 105, Application US/10006485A
; Publication No. US20030064062A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
```

PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314

PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGCAGCAACAGCAGCAGC 2

RESULT 100
US-10-013-907A-105/c
Sequence 105, Application US/10013907A
Publication No. US20030064925A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.

```

; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC34
; CURRENT APPLICATION NUMBER: US/10/013,907A
; CURRENT FILING DATE: 2001-12-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-907A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 101
US-10-015-499A-105/c
; Sequence 105, Application US/10015499A
; Publication No. US20030065142A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC42
; CURRENT APPLICATION NUMBER: US/10/015,499A
; CURRENT FILING DATE: 2001-12-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 102
US-10-015-393A-105/c
; Sequence 105, Application US/10015393A
```

```

; Publication No. US20030069179A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC46
; CURRENT APPLICATION NUMBER: US/10/015,393A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-393A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 103
US-10-015-869A-105/c
; Sequence 105, Application US/10015869A
; Publication No. US20030073130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC45
; CURRENT APPLICATION NUMBER: US/10/015,869A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-869A-105
```


Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 104
US-10-012-121A-105/c
Sequence 105, Application US/10012121A
Publication No. US20030073810A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillen, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C20
CURRENT APPLICATION NUMBER: US/10/012,121A
CURRENT FILING DATE: 2001-12-07
Prior Application removed - See File Wrapper or Paim
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-121A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 105
US-10-006-116A-105/c
Sequence 105, Application US/10006116A
Publication No. US20030082626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillen, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830P1C15
CURRENT APPLICATION NUMBER: US/10/006,116A
CURRENT FILING DATE: 2001-12-16
Prior Application Number: 60/098716
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098723
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098749
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098750
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098803
Prior Filing Date: 1998-09-02
Prior Application Number: 60/098821
Prior Filing Date: 1998-09-02
Prior Application Number: 60/098843
Prior Filing Date: 1998-09-02
Prior Application Number: 60/099536
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099596
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099598
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099602
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099642
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099741
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099754
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099763
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099792
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099808
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099812
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099815
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099816
Prior Filing Date: 1998-09-10
Prior Application Number: 60/100385
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100388
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100390
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100584
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100627
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100661
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100662
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100664
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100683
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100684
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100710
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100711
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100848
Prior Filing Date: 1998-09-18
Prior Application Number: 60/100849
Prior Filing Date: 1998-09-18
Prior Application Number: 60/100919

;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103338
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07

;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAGCAGCAGCAGC 1465
DB 20 CAGAGCAGCAGCAGCAGC 2

RESULT 106
US-10-006-117A-105/c
; Sequence 105, Application US/1006117A
; Publication No. US20030082627A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guirney, Austin L.
; APPLICANT: Hillan, Kenneth L.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC13
; CURRENT APPLICATION NUMBER: US/10/006,117A
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION removed - See File Wrapper or Palm
; PRIOR FILING DATE: 2001-07-09
; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 105
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-117A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Fred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 107
US-10-017-527A-105/c
Sequence 105, Application US/10017527A
Publication No. US20030082628A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gutney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same
FILE REFERENCE: P2830PIC63
CURRENT APPLICATION NUMBER: US/10/017,527A
CURRENT FILING DATE: 2001-12-13
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-03
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10

PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207

PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105633
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 108
US-10-013-913A-105/c
Sequence 105, Application US/10013913A
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guirey, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830P1C40
CURRENT APPLICATION NUMBER: US/10/013,913A
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-913A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 109
US-10-007-194A-105/c
Sequence 105, Application US/10007194A
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guirey, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

Page 35

PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/1009930
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/101014
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101068
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101071
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101275
PRIOR FILING DATE:	1998-09-22
PRIOR APPLICATION NUMBER:	60/101472
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101474
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101475
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101476
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101477
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101479
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101733
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101744
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101745
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101915
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101916
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/102207
PRIOR FILING DATE:	1998-09-25
PRIOR APPLICATION NUMBER:	60/102240
PRIOR FILING DATE:	1998-09-25
PRIOR APPLICATION NUMBER:	60/102307
PRIOR FILING DATE:	1998-09-25
PRIOR APPLICATION NUMBER:	60/102330
PRIOR FILING DATE:	1998-09-25
PRIOR APPLICATION NUMBER:	60/102331
PRIOR FILING DATE:	1998-09-25
PRIOR APPLICATION NUMBER:	60/102488
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102487
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102570
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102571
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102688
PRIOR FILING DATE:	1998-10-01
PRIOR APPLICATION NUMBER:	60/102687
PRIOR FILING DATE:	1998-10-01
PRIOR APPLICATION NUMBER:	60/102965
PRIOR FILING DATE:	1998-10-02
PRIOR APPLICATION NUMBER:	60/103255
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/103314
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103315
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103328
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103395
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103396
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103401
PRIOR FILING DATE:	1998-10-07

PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 110
US-10-013-430A-105/c

Sequence 105, Application US/10013430A
Publication No. US20030092883A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C31
CURRENT APPLICATION NUMBER: US/10/013,430A
CURRENT FILING DATE: 2002-06-25
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105

LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-430A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 111
US-10-011-671A-105/c

Sequence 105, Application US/10011671A
Publication No. US20030096954A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C27
CURRENT APPLICATION NUMBER: US/10/011,671A
CURRENT FILING DATE: 2002-06-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105

PRIOR FILING DATE:	1998-09-10
PRIOR APPLICATION NUMBER:	60/099812
PRIOR FILING DATE:	1998-09-10
PRIOR APPLICATION NUMBER:	60/099815
PRIOR FILING DATE:	1998-09-10
PRIOR APPLICATION NUMBER:	60/099816
PRIOR FILING DATE:	1998-09-10
PRIOR APPLICATION NUMBER:	60/100385
PRIOR FILING DATE:	1998-09-15
PRIOR APPLICATION NUMBER:	60/100388
PRIOR FILING DATE:	1998-09-15
PRIOR APPLICATION NUMBER:	60/100390
PRIOR FILING DATE:	1998-09-15
PRIOR APPLICATION NUMBER:	60/100584
PRIOR FILING DATE:	1998-09-16
PRIOR APPLICATION NUMBER:	60/100627
PRIOR FILING DATE:	1998-09-16
PRIOR APPLICATION NUMBER:	60/100661
PRIOR FILING DATE:	1998-09-16
PRIOR APPLICATION NUMBER:	60/100662
PRIOR FILING DATE:	1998-09-16
PRIOR APPLICATION NUMBER:	60/100664
PRIOR FILING DATE:	1998-09-16
PRIOR APPLICATION NUMBER:	60/100663
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/100684
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/100711
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/100848
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/100849
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/100919
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/100930
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/101014
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101068
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101071
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101279
PRIOR FILING DATE:	1998-09-22
PRIOR APPLICATION NUMBER:	60/101471
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101472
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101474
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101475
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101476
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101477
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101479
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101738
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101741
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101743
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101915
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101916
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/102207
PRIOR FILING DATE:	1998-09-29

1	PRIOR APPLICATION NUMBER: 66/102240
2	PRIOR FILING DATE: 1998-09-29
3	PRIOR APPLICATION NUMBER: 66/102307
4	PRIOR FILING DATE: 1998-09-29
5	PRIOR APPLICATION NUMBER: 66/102330
6	PRIOR FILING DATE: 1998-09-29
7	PRIOR APPLICATION NUMBER: 66/102331
8	PRIOR FILING DATE: 1998-09-29
9	PRIOR APPLICATION NUMBER: 66/102484
10	PRIOR FILING DATE: 1998-09-30
11	PRIOR APPLICATION NUMBER: 66/102487
12	PRIOR FILING DATE: 1998-09-30
13	PRIOR APPLICATION NUMBER: 66/102570
14	PRIOR FILING DATE: 1998-09-30
15	PRIOR APPLICATION NUMBER: 66/102571
16	PRIOR FILING DATE: 1998-09-30
17	PRIOR APPLICATION NUMBER: 66/102684
18	PRIOR FILING DATE: 1998-10-01
19	PRIOR APPLICATION NUMBER: 66/102687
20	PRIOR FILING DATE: 1998-10-01
21	PRIOR APPLICATION NUMBER: 66/102965
22	PRIOR FILING DATE: 1998-10-02
23	PRIOR APPLICATION NUMBER: 66/103258
24	PRIOR FILING DATE: 1998-10-06
25	PRIOR APPLICATION NUMBER: 66/103314
26	PRIOR FILING DATE: 1998-10-07
27	PRIOR APPLICATION NUMBER: 66/103315
28	PRIOR FILING DATE: 1998-10-07
29	PRIOR APPLICATION NUMBER: 66/103328
30	PRIOR FILING DATE: 1998-10-07
31	PRIOR APPLICATION NUMBER: 66/103395
32	PRIOR FILING DATE: 1998-10-07
33	PRIOR APPLICATION NUMBER: 66/103366
34	PRIOR FILING DATE: 1998-10-07
35	PRIOR APPLICATION NUMBER: 66/103401
36	PRIOR FILING DATE: 1998-10-07
37	PRIOR APPLICATION NUMBER: 66/103459
38	PRIOR FILING DATE: 1998-10-06
39	PRIOR APPLICATION NUMBER: 66/103633
40	PRIOR FILING DATE: 1998-10-08
41	PRIOR APPLICATION NUMBER: 66/103711
42	PRIOR FILING DATE: 1998-10-08
43	PRIOR APPLICATION NUMBER: 66/104257
44	PRIOR FILING DATE: 1998-10-14
45	PRIOR APPLICATION NUMBER: 66/104987
46	PRIOR FILING DATE: 1998-10-20
47	PRIOR APPLICATION NUMBER: 66/105000
48	PRIOR FILING DATE: 1998-10-20
49	PRIOR APPLICATION NUMBER: 66/105002
50	PRIOR FILING DATE: 1998-10-20
51	PRIOR APPLICATION NUMBER: 66/105266
52	PRIOR FILING DATE: 1998-10-22
53	PRIOR APPLICATION NUMBER: 66/105104
54	PRIOR FILING DATE: 1998-10-21
55	PRIOR APPLICATION NUMBER: 66/105165
56	PRIOR FILING DATE: 1998-10-22
57	PRIOR APPLICATION NUMBER: 66/105266
58	PRIOR FILING DATE: 1998-10-22
59	PRIOR APPLICATION NUMBER: 66/105693
60	PRIOR FILING DATE: 1998-10-26
61	PRIOR APPLICATION NUMBER: 66/105694
62	PRIOR FILING DATE: 1998-10-26
63	PRIOR APPLICATION NUMBER: 66/105807
64	PRIOR FILING DATE: 1998-10-27
65	PRIOR APPLICATION NUMBER: 66/105881
66	PRIOR FILING DATE: 1998-10-27
67	PRIOR APPLICATION NUMBER: 66/105882
68	PRIOR FILING DATE: 1998-10-27
69	PRIOR APPLICATION NUMBER: 66/106023
70	PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 112

US-10-012-755A-105/C
Sequence 105, Application US/10012755A
Publication No. US20030096955A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC28
CURRENT FILING DATE: 2002-06-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-755A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 113

US-10-015-386A-105/C
Sequence 105, Application US/10015386A
Publication No. US20030099625A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC30
CURRENT FILING DATE: 2001-12-07
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-105

FILE REFERENCE: P2830PIC55
CURRENT APPLICATION NUMBER: US/10/015,386A
CURRENT FILING DATE: 2001-12-12
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-386A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 114
US-10-011-692A-105/C
Sequence 105, Application US/10011692A
Publication No. US20030109672A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC30
CURRENT FILING DATE: 2001-12-07
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 115
US-10-006-768A-105/C
Sequence 105, Application US/10006768A
Publication No. US20030113793A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc

FILE REFERENCE: P2830PIC30
CURRENT FILING DATE: 2001-12-07
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 115
US-10-006-768A-105/C
Sequence 105, Application US/10006768A
Publication No. US20030113793A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc

FILE REFERENCE: P2830PIC30
CURRENT FILING DATE: 2001-12-07
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2


```

APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas P.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830PIC64
CURRENT APPLICATION NUMBER: US/10/017,610A
CURRENT FILING DATE: 2001-12-13
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02

RESULT 116
US-10-017-610A-105/c
; Sequence 105, Application US/10017610A
; Publication No. US20030113795A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyer, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas P.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830PIC64
CURRENT APPLICATION NUMBER: US/10/006,768A
CURRENT FILING DATE: 2002-03-05
NUMBER OF SEQ ID NOS: 477
Prior Application removed - See File Wrapper or Palm
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-768A-105

Query Match          0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred.No.1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACGCGCAGC 1465
DB       20 CAGCAGCAACGCGCAGC 2


```

1	PRIOR APPLICATION NUMBER: 60/039536
2	PRIOR FILING DATE: 1998-09-09
3	PRIOR APPLICATION NUMBER: 60/039536
4	PRIOR FILING DATE: 1998-09-09
5	PRIOR APPLICATION NUMBER: 60/039538
6	PRIOR FILING DATE: 1998-09-09
7	PRIOR APPLICATION NUMBER: 60/039602
8	PRIOR FILING DATE: 1998-09-09
9	PRIOR APPLICATION NUMBER: 60/039642
10	PRIOR FILING DATE: 1998-09-09
11	PRIOR APPLICATION NUMBER: 60/039741
12	PRIOR FILING DATE: 1998-09-10
13	PRIOR APPLICATION NUMBER: 60/039754
14	PRIOR FILING DATE: 1998-09-10
15	PRIOR APPLICATION NUMBER: 60/039763
16	PRIOR FILING DATE: 1998-09-10
17	PRIOR APPLICATION NUMBER: 60/039815
18	PRIOR FILING DATE: 1998-09-10
19	PRIOR APPLICATION NUMBER: 60/039808
20	PRIOR FILING DATE: 1998-09-10
21	PRIOR APPLICATION NUMBER: 60/039812
22	PRIOR FILING DATE: 1998-09-10
23	PRIOR APPLICATION NUMBER: 60/039845
24	PRIOR FILING DATE: 1998-09-10
25	PRIOR APPLICATION NUMBER: 60/039816
26	PRIOR FILING DATE: 1998-09-10
27	PRIOR APPLICATION NUMBER: 60/100385
28	PRIOR FILING DATE: 1998-09-15
29	PRIOR APPLICATION NUMBER: 60/100388
30	PRIOR FILING DATE: 1998-09-15
31	PRIOR APPLICATION NUMBER: 60/100330
32	PRIOR FILING DATE: 1998-09-15
33	PRIOR APPLICATION NUMBER: 60/100584
34	PRIOR FILING DATE: 1998-09-16
35	PRIOR APPLICATION NUMBER: 60/100622
36	PRIOR FILING DATE: 1998-09-16
37	PRIOR APPLICATION NUMBER: 60/100651
38	PRIOR FILING DATE: 1998-09-16
39	PRIOR APPLICATION NUMBER: 60/100622
40	PRIOR FILING DATE: 1998-09-17
41	PRIOR APPLICATION NUMBER: 60/100684
42	PRIOR FILING DATE: 1998-09-17
43	PRIOR APPLICATION NUMBER: 60/100648
44	PRIOR FILING DATE: 1998-09-17
45	PRIOR APPLICATION NUMBER: 60/100710
46	PRIOR FILING DATE: 1998-09-17
47	PRIOR APPLICATION NUMBER: 60/100711
48	PRIOR FILING DATE: 1998-09-17
49	PRIOR APPLICATION NUMBER: 60/100848
50	PRIOR FILING DATE: 1998-09-18
51	PRIOR APPLICATION NUMBER: 60/100849
52	PRIOR FILING DATE: 1998-09-18
53	PRIOR APPLICATION NUMBER: 60/100919
54	PRIOR FILING DATE: 1998-09-17
55	PRIOR APPLICATION NUMBER: 60/100930
56	PRIOR FILING DATE: 1998-09-17
57	PRIOR APPLICATION NUMBER: 60/101014
58	PRIOR FILING DATE: 1998-09-18
59	PRIOR APPLICATION NUMBER: 60/101068
60	PRIOR FILING DATE: 1998-09-18
61	PRIOR APPLICATION NUMBER: 60/101471
62	PRIOR FILING DATE: 1998-09-23
63	PRIOR APPLICATION NUMBER: 60/101472
64	PRIOR FILING DATE: 1998-09-23
65	PRIOR APPLICATION NUMBER: 60/101474
66	PRIOR FILING DATE: 1998-09-23
67	PRIOR APPLICATION NUMBER: 60/101475
68	PRIOR FILING DATE: 1998-09-23
69	PRIOR APPLICATION NUMBER: 60/101475

PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102685
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20

PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 117
US-10-006-063A-105/c
Sequence 105, Application US/1006063A
Publication No. US20030114652A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C3
CURRENT APPLICATION NUMBER: US/10/006,063A
CURRENT FILING DATE: 2002-03-15
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-063A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 118
US-10-020-063A-105/c

```
; Sequence 105, Application US/10020063A
; Publication No. US20030119097A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C65
; CURRENT APPLICATION NUMBER: US/10/020,063A
; CURRENT FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-020-063A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 119
; US-10-015-391A-105/c
; Sequence 105, Application US/10015391A
; Publication No. US20030120053A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C59
; CURRENT APPLICATION NUMBER: US/10/015,391A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-015-391A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 120
; US-10-017-407A-105/c
; Sequence 105, Application US/10017407A
; Publication No. US20030125535A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C61
; CURRENT APPLICATION NUMBER: US/10/017,407A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-017-407A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2
```

```
RESULT 121
US-10-011-833A-105/c
; Sequence 105, Application US/10011833A
; Publication No. US20030129650A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C22
; CURRENT APPLICATION NUMBER: US/10/011,833A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-833A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGCAGC 2

RESULT 122
US-10-006-041A-105/c
; Sequence 105, Application US/10006041A
; Publication No. US20030130490A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C8
; CURRENT APPLICATION NUMBER: US/10/006,041A
; CURRENT FILING DATE: 2001-12-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-041A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGCAGC 2

RESULT 123
US-10-015-822A-105/c
; Sequence 105, Application US/10015822A
; Publication No. US20030130491A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C38
; CURRENT APPLICATION NUMBER: US/10/015,822A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-822A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGCAGC 2

RESULT 124
US-10-015-387A-105/c
; Sequence 105, Application US/10015387A
; Publication No. US20030135034A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```

; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C54
; CURRENT APPLICATION NUMBER: US/10/015,387A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-387A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGGAGCAACAGCAGCAGC 2

RESULT 125
US-10-006-130A-105/c
; Sequence 105, Application US/10006130A
; Publication No. US20030148375A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C7
; CURRENT APPLICATION NUMBER: US/10/006,130A
; CURRENT FILING DATE: 2002-03-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-130A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGGAGCAACAGCAGCAGC 2

RESULT 126
US-10-006-172A-105/c
; Sequence 105, Application US/10006172A
```

```

; Publication No. US20030153000A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C11
; CURRENT APPLICATION NUMBER: US/10/006,172A
; CURRENT FILING DATE: 2002-03-19
; Prior Application Number: 60/098716
; Prior Filing Date: 1998-09-01
; Prior Application Number: 60/098723
; Prior Filing Date: 1998-09-01
; Prior Application Number: 60/098749
; Prior Filing Date: 1998-09-01
; Prior Application Number: 60/098750
; Prior Filing Date: 1998-09-01
; Prior Application Number: 60/098803
; Prior Filing Date: 1998-09-02
; Prior Application Number: 60/098821
; Prior Filing Date: 1998-09-02
; Prior Application Number: 60/098843
; Prior Filing Date: 1998-09-02
; Prior Application Number: 60/099536
; Prior Filing Date: 1998-09-09
; Prior Application Number: 60/099596
; Prior Filing Date: 1998-09-09
; Prior Application Number: 60/099598
; Prior Filing Date: 1998-09-09
; Prior Application Number: 60/099602
; Prior Filing Date: 1998-09-09
; Prior Application Number: 60/099642
; Prior Filing Date: 1998-09-09
; Prior Application Number: 60/099741
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099754
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099763
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099792
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099808
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099812
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099815
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/099816
; Prior Filing Date: 1998-09-10
; Prior Application Number: 60/100385
; Prior Filing Date: 1998-09-15
; Prior Application Number: 60/100388
; Prior Filing Date: 1998-09-15
; Prior Application Number: 60/100390
; Prior Filing Date: 1998-09-15
; Prior Application Number: 60/100584
; Prior Filing Date: 1998-09-16
; Prior Application Number: 60/100627
; Prior Filing Date: 1998-09-16
; Prior Application Number: 60/100661
; Prior Filing Date: 1998-09-16
```

PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102584
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687

PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105861
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACGACGACG 1465
DB 20 CAGGAGCAACGACGACG 2

RESULT 127

US-10-017-253A-105/C
Sequence 105, Application US/10017253A
Publication No. US2003016055A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone

```

; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C62
; CURRENT APPLICATION NUMBER: US/10/017,253A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-253A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 128
US-10-015-392A-105/C
; Sequence 105, Application US/10015392A
; Publication No. US2003016901A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

```

; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C58
; CURRENT APPLICATION NUMBER: US/10/015,392A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-392A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGAGCAACAGCAGCAGC 2

RESULT 129
US-10-017-306A-105/C
; Sequence 105, Application US/10017306A
; Publication No. US20030170718A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C66
; CURRENT APPLICATION NUMBER: US/10/017,306A
; CURRENT FILING DATE: 2002-06-10
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-017-306A-105
Query Match      0.4% Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGCAGCAACAGCAGCAGC 2

RESULT 130
US-10-017-867A-105/c
; Sequence 105, Application US/10017867A
; Publication No. US20030180792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C60
; CURRENT APPLICATION NUMBER: US/10/017,867A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/102307
```

```

; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
```


PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105256
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105633
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1447 CAGCAGCAACAGCAGC 1465
DB 20 CAGCAGCAACAGCAGC 2

RESULT 131

US-10-012-064A-105/c
; Sequence 105, Application US/10012064A
; Publication No. US20030180836A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C19
; CURRENT APPLICATION NUMBER: US/10/012,064A
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-064A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1447 CAGCAGCAACAGCAGC 1465
DB 20 CAGCAGCAACAGCAGC 2

RESULT 132
US-10-013-909A-105/c
; Sequence 105, Application US/10013909A
; Publication No. US20030186318A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Pan, James
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC35
CURRENT APPLICATION NUMBER: US/10/013,909A
CURRENT FILING DATE: 2002-06-25
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-909A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 133
US-10-015-671A-105/c
Sequence 105, Application US/10015671A
Publication No. US20030186319A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Pan, James
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC47
CURRENT APPLICATION NUMBER: US/10/015,671A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-671A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 134
US-10-015-610A-105/c
Sequence 105, Application US/10015610A
Publication No. US20030186361A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC52
CURRENT APPLICATION NUMBER: US/10/015,610A
CURRENT FILING DATE: 2001-12-12
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-610A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 135

```
US-10-012-137A-105/c
; Sequence 105, Application US/10012137A
; Publication No. US20030187189A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C24
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-137A-105
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGAGCAACAGCAGCAGC 2

RESULT 136
US-10-012-752A-105/c
; Sequence 105, Application US/10012752A
; Publication No. US20030187190A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C24
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
```

```
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-105
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGAGCAACAGCAGCAGC 2

RESULT 137
US-10-012-754A-105/c
; Sequence 105, Application US/10012754A
; Publication No. US20030187191A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C18
; CURRENT APPLICATION NUMBER: US/10/012,754A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-754A-105
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGAGCAACAGCAGCAGC 2

RESULT 138
US-10-013-910A-105/c
; Sequence 105, Application US/10013910A
; Publication No. US20030187192A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C24
; CURRENT APPLICATION NUMBER: US/10/013,910A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
```

APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C3
CURRENT APPLICATION NUMBER: US/10/013,910A
CURRENT FILING DATE: 2002-06-25
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-910A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGCAGCAACAGCAGCAGC 2

RESULT 139
US-10-013-911A-105/c
Sequence 105, Application US/10013911A
Publication No. US20030187193A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desmoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guirney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C3
CURRENT APPLICATION NUMBER: US/10/013,911A
CURRENT FILING DATE: 2001-12-10
Prior Application Number: 60/098716
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098723
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098749
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098750
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098803
Prior Filing Date: 1998-09-02
Prior Application Number: 60/098821
Prior Filing Date: 1998-09-02
Prior Application Number: 60/098843
Prior Filing Date: 1998-09-02
Prior Application Number: 60/099536
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099596
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099598
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099602
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099642
Prior Filing Date: 1998-09-09

Prior Application Number: 60/099741
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099754
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099763
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099792
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099808
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099812
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099815
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099816
Prior Filing Date: 1998-09-10
Prior Application Number: 60/100385
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100388
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100390
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100584
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100627
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100661
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100662
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100664
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100683
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100684
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100710
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100711
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100848
Prior Filing Date: 1998-09-18
Prior Application Number: 60/100849
Prior Filing Date: 1998-09-18
Prior Application Number: 60/100919
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100930
Prior Filing Date: 1998-09-17
Prior Application Number: 60/101014
Prior Filing Date: 1998-09-18
Prior Application Number: 60/101068
Prior Filing Date: 1998-09-18
Prior Application Number: 60/101071
Prior Filing Date: 1998-09-18
Prior Application Number: 60/101279
Prior Filing Date: 1998-09-22
Prior Application Number: 60/101471
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101472
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101474
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101475
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101476
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101477
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101479
Prior Filing Date: 1998-09-23
Prior Application Number: 60/101738
Prior Filing Date: 1998-09-24
Prior Application Number: 60/101741

PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26

PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 CAGCAGCAGCAGCAGCAGC 1465
Db 20 CAGCAGCAGCAGCAGCAGC 2

RESULT 140

US-10-013-912A-105/c
; Sequence 105, Application US/10013912A
; Publication No. US20030187194A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C32
; CURRENT APPLICATION NUMBER: US/10/013,912A
; CURRENT FILING DATE: 2001-12-10
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-912A-105
Query Match 0.4%; Score 17.4; DB 1; Length 21;

APPLICANT: Ferrara, Napoleone
APPLICANT: Rong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC56
CURRENT APPLICATION NUMBER: US/10/015,715A
CURRENT FILING DATE: 2002-06-25
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-715A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
Db 20 CAGCAGCAACAGCAGCAGC 2

RESULT 145
US-10-012-237A-105/c
; Sequence 105, Application US/10012237A
; Publication No. US20030191281A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC21
CURRENT APPLICATION NUMBER: US/10/012,237A
CURRENT FILING DATE: 2002-06-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-237A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465

Db 20 CAGCAGCAACAGCAGCAGC 2

RESULT 146
US-10-013-906A-105/c
; Sequence 105, Application US/10013906A
; Publication No. US20030191282A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC36
CURRENT APPLICATION NUMBER: US/10/013,906A
CURRENT FILING DATE: 2002-06-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-906A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465

```
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100584
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100627
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100661
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100662
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100664
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100683
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100684
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100710
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100711
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100848
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100849
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100919
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100930
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/101014
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101068
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101071
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101279
/ PRIOR FILING DATE: 1998-09-22
/ PRIOR APPLICATION NUMBER: 60/101471
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101472
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101474
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101475
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101476
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101477
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101479
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101738
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101741
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101743
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101915
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/101916
/ PRIOR FILING DATE: 1998-09-24
/ PRIOR APPLICATION NUMBER: 60/102207
/ PRIOR FILING DATE: 1998-09-29
/ PRIOR APPLICATION NUMBER: 60/102240
/ PRIOR FILING DATE: 1998-09-29
/ PRIOR APPLICATION NUMBER: 60/102307
/ PRIOR FILING DATE: 1998-09-29
/ PRIOR APPLICATION NUMBER: 60/102330
/ PRIOR FILING DATE: 1998-09-29
/ PRIOR APPLICATION NUMBER: 60/102331
/ PRIOR FILING DATE: 1998-09-29
/ PRIOR APPLICATION NUMBER: 60/102484
/ PRIOR FILING DATE: 1998-09-30
/ PRIOR APPLICATION NUMBER: 60/102487
/ PRIOR FILING DATE: 1998-09-30

/ PRIOR APPLICATION NUMBER: 60/102570
/ PRIOR FILING DATE: 1998-09-30
/ PRIOR APPLICATION NUMBER: 60/102571
/ PRIOR FILING DATE: 1998-09-30
/ PRIOR APPLICATION NUMBER: 60/102684
/ PRIOR FILING DATE: 1998-10-01
/ PRIOR APPLICATION NUMBER: 60/102687
/ PRIOR FILING DATE: 1998-10-01
/ PRIOR APPLICATION NUMBER: 60/102965
/ PRIOR FILING DATE: 1998-10-02
/ PRIOR APPLICATION NUMBER: 60/103258
/ PRIOR FILING DATE: 1998-10-06
/ PRIOR APPLICATION NUMBER: 60/103314
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103315
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103328
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103395
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103396
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103401
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103449
/ PRIOR FILING DATE: 1998-10-06
/ PRIOR APPLICATION NUMBER: 60/103633
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103678
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103679
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103711
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/104257
/ PRIOR FILING DATE: 1998-10-14
/ PRIOR APPLICATION NUMBER: 60/104987
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105000
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105002
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105104
/ PRIOR FILING DATE: 1998-10-21
/ PRIOR APPLICATION NUMBER: 60/105169
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105266
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105693
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105694
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105807
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105881
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105882
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/106023
/ PRIOR FILING DATE: 1998-10-28

Query Match      0.4%  Score 17.4  DB 1  Length 21;
Best Local Similarity 94.7%  Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1447 CAGCAGCAACAGCAGCAGC 1465
DB      20 CAGGACCAACAGCAGCAGC 2

RESULT 147
US-10-015-388A-105/c
; Sequence 105, Application US/10015388A
```



```
Publication No. US20030191299A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC44
CURRENT APPLICATION NUMBER: US/10/015,388A
CURRENT FILING DATE: 2002-07-15
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-388A-105
```

```
Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGAGCAACAGCAGCAGC 2
```

```
RESULT 148
US-10-012-753A-105/c
Sequence 105, Application US/10012753A
Publication No. US20030195334A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC17
CURRENT APPLICATION NUMBER: US/10/012,753A
CURRENT FILING DATE: 2001-12-07
Prior application removed - See file wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-105
```

```
Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGAGCAACAGCAGCAGC 2
```

```
RESULT 149
US-10-015-385A-105/c
Sequence 105, Application US/10015385A
Publication No. US20030195347A1
GENERAL INFORMATION:
```

```
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC51
CURRENT APPLICATION NUMBER: US/10/015,385A
CURRENT FILING DATE: 2002-07-25
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 105
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-385A-105
```

```
Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1447 CAGCAGCAACAGCAGCAGC 1465
Db      20 CAGAGCAACAGCAGCAGC 2
```

```
RESULT 150
US-10-007-236A-105/c
Sequence 105, Application US/10007236A
Publication No. US2003019893A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: P2830P1C12
;; CURRENT APPLICATION NUMBER: US/10/007,236A
;; CURRENT FILING DATE: 2002-06-25
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 477
;; SEQ ID NO 105
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
US-10-007-236A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 151
US-10-015-389A-105/c
; Sequence 105, Application US/10015389A
; Publication No. US20030199675A1
; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2830P1C48
;; CURRENT APPLICATION NUMBER: US/10/015,389A
;; CURRENT FILING DATE: 2002-06-25
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 477
;; SEQ ID NO 105
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
US-10-015-389A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 152
US-10-015-519A-105/c
; Sequence 105, Application US/10015519A
; Publication No. US20030203401A1
; GENERAL INFORMATION:
;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David

;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2830P1C49
;; CURRENT APPLICATION NUMBER: US/10/015,519A
;; CURRENT FILING DATE: 2002-06-25
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 477
;; SEQ ID NO 105
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
US-10-015-519A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2

RESULT 153
US-10-013-915A-105/c
; Sequence 105, Application US/10013915A
; Publication No. US20030204053A1
; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2830P1C37
;; CURRENT APPLICATION NUMBER: US/10/013,915A
;; CURRENT FILING DATE: 2002-06-25
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 477
;; SEQ ID NO 105
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
US-10-013-915A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGC 1465
DB 20 CAGCAGCAACAGCAGC 2

RESULT 154

US-10-015-394A-105/c

Sequence 105, Application US/10015394A

Publication No. US20030204054A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnovers, Luc

APPLICANT: Baton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gao, Wei-Qiang

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, Christopher J.

APPLICANT: Gurney, Austin L.

APPLICANT: Hillan, Kenneth J.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

FILE REFERENCE: P2830P1C41

CURRENT APPLICATION NUMBER: US/10/015,394A

CURRENT FILING DATE: 2001-12-11

PRIOR APPLICATION NUMBER: 60/098716

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098723

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098749

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098750

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098803

PRIOR FILING DATE: 1998-09-02

PRIOR APPLICATION NUMBER: 60/098821

PRIOR FILING DATE: 1998-09-02

PRIOR APPLICATION NUMBER: 60/098843

PRIOR FILING DATE: 1998-09-02

PRIOR APPLICATION NUMBER: 60/099536

PRIOR FILING DATE: 1998-09-09

PRIOR APPLICATION NUMBER: 60/099596

PRIOR FILING DATE: 1998-09-09

PRIOR APPLICATION NUMBER: 60/099598

PRIOR FILING DATE: 1998-09-09

Remaining prior application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 477

SEQ ID NO 105

LENGTH: 21

TYPE: DNA

ORGANISM: Artificial Sequence

OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-015-394A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGC 1465
DB 20 CAGCAGCAACAGCAGC 2

RESULT 155
US-10-015-390A-105/c
Sequence 105, Application US/10015390A
Publication No. US20030216562A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnovers, Luc

APPLICANT: Baton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gao, Wei-Qiang

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, Christopher J.

APPLICANT: Gurney, Austin L.

APPLICANT: Hillan, Kenneth J.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

FILE REFERENCE: P2830P1C53

CURRENT APPLICATION NUMBER: US/10/015,390A

CURRENT FILING DATE: 2002-07-15

Prior Application removed - See File Wrapper or Palm

NUMBER OF SEQ ID NOS: 477

SEQ ID NO 105

LENGTH: 21

TYPE: DNA

ORGANISM: Artificial Sequence

OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-015-390A-105

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAACAGCAGC 1465
DB 20 CAGCAGCAACAGCAGC 2

RESULT 156

US-10-006-746A-105/c

Sequence 105, Application US/10006746A

Publication No. US20030220471A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnovers, Luc

APPLICANT: Baton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gao, Wei-Qiang

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, Christopher J.

APPLICANT: Gurney, Austin L.

APPLICANT: Hillan, Kenneth J.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

FILE REFERENCE: P2830P1C5

CURRENT APPLICATION NUMBER: US/10/006,746A

CURRENT FILING DATE: 2001-12-06

PRIOR APPLICATION NUMBER: 60/098716

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098723

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098749

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098750

PRIOR FILING DATE: 1998-09-01

PRIOR APPLICATION NUMBER: 60/098803

PRIOR FILING DATE: 1998-09-02

1 PRIOR APPLICATION NUMBER: 60/098821
2 PRIOR FILING DATE: 1998-09-02
3 PRIOR APPLICATION NUMBER: 60/098843
4 PRIOR FILING DATE: 1998-09-02
5 PRIOR APPLICATION NUMBER: 60/099536
6 PRIOR FILING DATE: 1998-09-09
7 PRIOR APPLICATION NUMBER: 60/099596
8 PRIOR FILING DATE: 1998-09-09
9 PRIOR APPLICATION NUMBER: 60/099598
10 PRIOR FILING DATE: 1998-09-09
11 PRIOR APPLICATION NUMBER: 60/099602
12 PRIOR FILING DATE: 1998-09-09
13 PRIOR APPLICATION NUMBER: 60/099642
14 PRIOR FILING DATE: 1998-09-09
15 PRIOR APPLICATION NUMBER: 60/099741
16 PRIOR FILING DATE: 1998-09-10
17 PRIOR APPLICATION NUMBER: 60/099754
18 PRIOR FILING DATE: 1998-09-10
19 PRIOR APPLICATION NUMBER: 60/099763
20 PRIOR FILING DATE: 1998-09-10
21 PRIOR APPLICATION NUMBER: 60/099792
22 PRIOR FILING DATE: 1998-09-10
23 PRIOR APPLICATION NUMBER: 60/099808
24 PRIOR FILING DATE: 1998-09-10
25 PRIOR APPLICATION NUMBER: 60/099812
26 PRIOR FILING DATE: 1998-09-10
27 PRIOR APPLICATION NUMBER: 60/099815
28 PRIOR FILING DATE: 1998-09-10
29 PRIOR APPLICATION NUMBER: 60/099816
30 PRIOR FILING DATE: 1998-09-10
31 PRIOR APPLICATION NUMBER: 60/100385
32 PRIOR FILING DATE: 1998-09-15
33 PRIOR APPLICATION NUMBER: 60/100388
34 PRIOR FILING DATE: 1998-09-15
35 PRIOR APPLICATION NUMBER: 60/100390
36 PRIOR FILING DATE: 1998-09-15
37 PRIOR APPLICATION NUMBER: 60/100584
38 PRIOR FILING DATE: 1998-09-16
39 PRIOR APPLICATION NUMBER: 60/100627
40 PRIOR FILING DATE: 1998-09-16
41 PRIOR APPLICATION NUMBER: 60/100661
42 PRIOR FILING DATE: 1998-09-16
43 PRIOR APPLICATION NUMBER: 60/100662
44 PRIOR FILING DATE: 1998-09-16
45 PRIOR APPLICATION NUMBER: 60/100664
46 PRIOR FILING DATE: 1998-09-16
47 PRIOR APPLICATION NUMBER: 60/100683
48 PRIOR FILING DATE: 1998-09-17
49 PRIOR APPLICATION NUMBER: 60/100684
50 PRIOR FILING DATE: 1998-09-17
51 PRIOR APPLICATION NUMBER: 60/100710
52 PRIOR FILING DATE: 1998-09-17
53 PRIOR APPLICATION NUMBER: 60/100711
54 PRIOR FILING DATE: 1998-09-17
55 PRIOR APPLICATION NUMBER: 60/100848
56 PRIOR FILING DATE: 1998-09-18
57 PRIOR APPLICATION NUMBER: 60/100849
58 PRIOR FILING DATE: 1998-09-18
59 PRIOR APPLICATION NUMBER: 60/100919
60 PRIOR FILING DATE: 1998-09-18
61 PRIOR APPLICATION NUMBER: 60/100930
62 PRIOR FILING DATE: 1998-09-17
63 PRIOR APPLICATION NUMBER: 60/101014
64 PRIOR FILING DATE: 1998-09-17
65 PRIOR APPLICATION NUMBER: 60/101014
66 PRIOR FILING DATE: 1998-09-18
67 PRIOR APPLICATION NUMBER: 60/101068
68 PRIOR FILING DATE: 1998-09-18
69 PRIOR APPLICATION NUMBER: 60/101071
70 PRIOR FILING DATE: 1998-09-18
71 PRIOR APPLICATION NUMBER: 60/101279
72 PRIOR FILING DATE: 1998-09-22
73 PRIOR APPLICATION NUMBER: 60/101471
74 PRIOR FILING DATE: 1998-09-23
75 PRIOR APPLICATION NUMBER: 60/101472

1 PRIOR FILING DATE: 1998-09-23
2 PRIOR APPLICATION NUMBER: 60/101474
3 PRIOR FILING DATE: 1998-09-23
4 PRIOR APPLICATION NUMBER: 60/101475
5 PRIOR FILING DATE: 1998-09-23
6 PRIOR APPLICATION NUMBER: 60/101476
7 PRIOR FILING DATE: 1998-09-23
8 PRIOR APPLICATION NUMBER: 60/101477
9 PRIOR FILING DATE: 1998-09-23
10 PRIOR APPLICATION NUMBER: 60/101479
11 PRIOR FILING DATE: 1998-09-23
12 PRIOR APPLICATION NUMBER: 60/101738
13 PRIOR FILING DATE: 1998-09-24
14 PRIOR APPLICATION NUMBER: 60/101741
15 PRIOR FILING DATE: 1998-09-24
16 PRIOR APPLICATION NUMBER: 60/101743
17 PRIOR FILING DATE: 1998-09-24
18 PRIOR APPLICATION NUMBER: 60/101915
19 PRIOR FILING DATE: 1998-09-24
20 PRIOR APPLICATION NUMBER: 60/101916
21 PRIOR FILING DATE: 1998-09-24
22 PRIOR APPLICATION NUMBER: 60/102207
23 PRIOR FILING DATE: 1998-09-29
24 PRIOR APPLICATION NUMBER: 60/102240
25 PRIOR FILING DATE: 1998-09-29
26 PRIOR APPLICATION NUMBER: 60/102307
27 PRIOR FILING DATE: 1998-09-29
28 PRIOR APPLICATION NUMBER: 60/102330
29 PRIOR FILING DATE: 1998-09-29
30 PRIOR APPLICATION NUMBER: 60/102331
31 PRIOR FILING DATE: 1998-09-29
32 PRIOR APPLICATION NUMBER: 60/102484
33 PRIOR FILING DATE: 1998-09-30
34 PRIOR APPLICATION NUMBER: 60/102487
35 PRIOR FILING DATE: 1998-09-30
36 PRIOR APPLICATION NUMBER: 60/102570
37 PRIOR FILING DATE: 1998-09-30
38 PRIOR APPLICATION NUMBER: 60/102571
39 PRIOR FILING DATE: 1998-09-30
40 PRIOR APPLICATION NUMBER: 60/102684
41 PRIOR FILING DATE: 1998-10-01
42 PRIOR APPLICATION NUMBER: 60/102687
43 PRIOR FILING DATE: 1998-10-01
44 PRIOR APPLICATION NUMBER: 60/102965
45 PRIOR FILING DATE: 1998-10-02
46 PRIOR APPLICATION NUMBER: 60/103258
47 PRIOR FILING DATE: 1998-10-06
48 PRIOR APPLICATION NUMBER: 60/103314
49 PRIOR FILING DATE: 1998-10-07
50 PRIOR APPLICATION NUMBER: 60/103315
51 PRIOR FILING DATE: 1998-10-07
52 PRIOR APPLICATION NUMBER: 60/103328
53 PRIOR FILING DATE: 1998-10-07
54 PRIOR APPLICATION NUMBER: 60/103395
55 PRIOR FILING DATE: 1998-10-07
56 PRIOR APPLICATION NUMBER: 60/103396
57 PRIOR FILING DATE: 1998-10-07
58 PRIOR APPLICATION NUMBER: 60/103401
59 PRIOR FILING DATE: 1998-10-07
60 PRIOR APPLICATION NUMBER: 60/103449
61 PRIOR FILING DATE: 1998-10-06
62 PRIOR APPLICATION NUMBER: 60/103633
63 PRIOR FILING DATE: 1998-10-08
64 PRIOR APPLICATION NUMBER: 60/103678
65 PRIOR FILING DATE: 1998-10-08
66 PRIOR APPLICATION NUMBER: 60/103679
67 PRIOR FILING DATE: 1998-10-08
68 PRIOR APPLICATION NUMBER: 60/103711
69 PRIOR FILING DATE: 1998-10-08
70 PRIOR APPLICATION NUMBER: 60/104257
71 PRIOR FILING DATE: 1998-10-14
72 PRIOR APPLICATION NUMBER: 60/104987
73 PRIOR FILING DATE: 1998-10-20

```
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2
```

RESULT 157

```
US-10-226-254A-105/c
; Sequence 105, Application US/10226254A
; Publication No. US20030224478A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C68
; CURRENT APPLICATION NUMBER: US/10/226,254A
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
```

```
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-226-254A-105
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2
```

RESULT 158

```
US-10-011-795A-105/c
; Sequence 105, Application US/10011795A
; Publication No. US20040005626A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C25
; CURRENT APPLICATION NUMBER: US/10/011,795A
; PRIOR FILING DATE: 2001-12-07
; Prior application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-795A-105
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1447 CAGCAGCAACAGCAGCAGC 1465
DB 20 CAGCAGCAACAGCAGCAGC 2
```

RESULT 159

```
US-10-012-231A-105/c
; Sequence 105, Application US/10012231A
; Publication No. US200400014130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
```

```

; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC23
; CURRENT APPLICATION NUMBER: US/10/012,231A
; PRIOR FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-231A-105

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1447 CAGCAGCAACGACGACG 1465
DB      20 CAGGAGCAACGACGACG 2
```

```

RESULT 160
US-10-015-395A-105/c
; Sequence 105, Application US/10015395A
; Publication No. US20040073015A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC57
; CURRENT APPLICATION NUMBER: US/10/015,395A
; PRIOR FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-395A-105
```

```

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1447 CAGCAGCAACGACGACG 1465
DB      20 CAGGAGCAACGACGACG 2
```

```

RESULT 161
US-10-751-736-39221
; Sequence 39221, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Weyth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AML00927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39221
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-39221
```

```

Query Match      0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1119 GCAGCAGCAGCTGCAGCAG 1137
DB      1 GCAGCAGCAGCUACGACG 19
```

```

RESULT 162
US-10-012-149A-105/c
; Sequence 105, Application US/10012149A
; Publication No. US20050043520A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC26
; CURRENT APPLICATION NUMBER: US/10/012,149A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 105
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-149A-105
```

```

Query Match      0.4%; Score 17.4; DB 1; Length 21;
```

Best Local Similarity 94.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 CAGCAGCAACAGCAGCAGC 1465

Db 20 CAGCAGCAACAGCAGCAGC 2

RESULT 163

US-10-730-771-62
; Sequence 62, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: PaacSeq for Windows Version 4.0
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-62

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1472 AGAAGCAGCAGCAGCAGC 1492

Db 1 AGGAACAGCAKCKAGCAGCAGC 21

RESULT 164

US-10-291-986-1/c
; Sequence 1, Application US/10291986
; Publication No. US20030215825A1
; GENERAL INFORMATION:
; APPLICANT: SUN-WING, TONG
; TITLE OF INVENTION: IMPROVED METHOD OF DETECTING MOLECULAR TARGET BY
; FILE REFERENCE: 5321-3
; CURRENT APPLICATION NUMBER: US/10/291,986
; CURRENT FILING DATE: 2002-11-12
; PRIOR APPLICATION NUMBER: AU P81597
; PRIOR FILING DATE: 2002-04-09
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-291-986-1

Query Match 0.4%; Score 17.4; DB 1; Length 23;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1444 CAGCAGCAGCAACAGCAGC 1462

Db 23 CAGCAGCAGCAACAGCGCC 5

RESULT 165

US-10-967-592-2/c
; Sequence 2, Application US/10967592
; Publication No. US20050053996A1
; GENERAL INFORMATION:
; APPLICANT: Tong, Sun-Wing
; TITLE OF INVENTION: MOLECULAR DETECTION AND ASSAY BY ELECTROBIOCHIP MICRO-ARRAY
; FILE REFERENCE: Dkt. #934-B-US
; CURRENT APPLICATION NUMBER: US/10/967,592
; CURRENT FILING DATE: 2004-10-18
; PRIOR APPLICATION NUMBER: 10/846,770
; PRIOR FILING DATE: 2004-05-13
; PRIOR APPLICATION NUMBER: 09/997,059
; PRIOR FILING DATE: 2001-11-29
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic probe
; NAME/KEY: misc.feature
; LOCATION: (1)..(23)
US-10-967-592-2

Query Match 0.4%; Score 17.4; DB 1; Length 23;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1444 CAGCAGCAGCAACAGCAGC 1462

Db 23 CAGCAGCAGCAACAGCGCC 5

RESULT 166

US-10-127-816-53/c
; Sequence 53, Application US/10127816
; Publication No. US20030104416A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Fox, Brian A.
; APPLICANT: Klucher, Kevin M.
; APPLICANT: Taft, David W.
; APPLICANT: Kindvogel, Wayne R.
; TITLE OF INVENTION: CYTOKINE PROTEIN FAMILY
; FILE REFERENCE: 01-17
; CURRENT APPLICATION NUMBER: US/10/127,816
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: US 60/285,408
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: US 60/286,482
; PRIOR FILING DATE: 2001-04-25
; PRIOR APPLICATION NUMBER: US 60/341,050
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/341,105
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 09/895,834
; PRIOR FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: US 60/285,424
; PRIOR FILING DATE: 2001-04-20
; NUMBER OF SEQ ID NOS: 59

```

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 53
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer ZC39687
US-10-127-816-53

Query Match          0.4%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1404 GAGGACAGCTGACGACGAGCAT 1425
DB      22  GAGGCAACAGCAGGAGGAGCAT 1

RESULT 167
US-10-114-270-284/c
; Sequence 284, Application US/10114270
; Publication No. US2004030110A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Xiaojia
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Miller, Charles E.
; APPLICANT: Malyskar, Uriel M.
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Patnurajan, Meera
; APPLICANT: Liu, Zichong
; APPLICANT: Gusev, Vladimir Y.
; APPLICANT: Li, Li
; APPLICANT: Vernet, Corine
; APPLICANT: Zehrusen, Bryan D.
; APPLICANT: Gorman, Linda
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Pena, Carol E.A.
; APPLICANT: Smithson, Glenda
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Gerlach, Valerie
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Shinkete, Richard A.
; APPLICANT: Gangoli, Esna A.
; APPLICANT: Taupier Jr., Raymond J.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Ji, Weizhen
; APPLICANT: Anderson, David W.
; APPLICANT: Liere, Mario W.
; APPLICANT: Rastelli, Luca
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Stone, David J.
; APPLICANT: MacDougall, John R.
; APPLICANT: Rothenberg, Mark E.
; TITLE OF INVENTION: NO. US20040030110A1el Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-322C
; CURRENT APPLICATION NUMBER: US/10/114,270
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/281,086
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: 60/281,136
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: 60/281,863
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/281,906
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/282,020
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 60/282,930
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: 60/282,934
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: 60/283,512
; PRIOR FILING DATE: 2001-04-12
```

```

; PRIOR APPLICATION NUMBER: 60/283,710
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 60/284,234
; PRIOR FILING DATE: 2001-04-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 470
; SEQ ID NO 284
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
US-10-114-270-284

Query Match          0.4%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2443 AGTGAGACGACGACGAGGAGAG 2464
DB      22  AGTGATGAGCAAGAGGAGGAGAG 1

RESULT 168
US-10-728-131-125
; Sequence 125, Application US/10728131
; Publication No. US20050075303A1
; GENERAL INFORMATION:
; APPLICANT: Neepet, Michael P.
; APPLICANT: McClements, William L.
; APPLICANT: Jansen, Kathrin U.
; APPLICANT: Schultz, Loren D.
; APPLICANT: Chen, Ling
; APPLICANT: Wang, Xin-Min
; TITLE OF INVENTION: SYNTHETIC HUMAN PAPILLOMAVIRUS GENES
; FILE REFERENCE: 20413YCA
; CURRENT APPLICATION NUMBER: US/10/728,131
; CURRENT FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: 09/642,405
; PRIOR FILING DATE: 2000-08-21
; PRIOR APPLICATION NUMBER: PCT/US00/22932
; PRIOR FILING DATE: 2000-08-21
; PRIOR APPLICATION NUMBER: 60/210,143
; PRIOR FILING DATE: 2000-06-07
; PRIOR APPLICATION NUMBER: 60/150,728
; PRIOR FILING DATE: 1999-08-25
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Codon-Optimized HPV6 E2 fragment
US-10-728-131-125

Query Match          0.4%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1441 CTGCAAGCAGCAGCAACAGCAGC 1462
DB      1  CCGCAACAACAGCAACAGCAGC 22

RESULT 169
US-10-215-432-43/c
; Sequence 43, Application US/10215432
; Publication No. US20030109476A1
; GENERAL INFORMATION:
; APPLICANT: Eric B. Kmiec
; APPLICANT: Hetal Parekh-Olmedo
; TITLE OF INVENTION: Composition and methods for the
```


;; TITLE OF INVENTION: prevention and treatment of Huntington's disease
;; FILE REFERENCE: Napco-10
;; CURRENT APPLICATION NUMBER: US/10/215,432
;; CURRENT FILING DATE: 2002-11-19
;; NUMBER OF SEQ ID NOS: 44
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 43
;; LENGTH: 30
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Converted HD sequence
US-10-215-432-43

Query Match 0.4%; Score 17.2; DB 1; Length 30;
Best Local Similarity 73.3%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCCTGCGAGCAGCAGCAG 1146
DB 30 CTGCTGCTGCTGCTGCTGCTGCTGCTG 1

RESULT 170
US-09-780-533A-2353
; Sequence 2353, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatz, Larry
; APPLICANT: McGwiggan, Jim
; APPLICANT: Chowdhra, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800, 878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2353
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2353

Query Match 0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 184 GAGCAGCAGCAGCAGCA 200
DB 1 GAGCAGCAGCAGCAGCA 17

RESULT 171
US-10-494-343-167
; Sequence 167, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01

;; NUMBER OF SEQ ID NOS: 870
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 167
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-494-343-167

Query Match 0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACAGC 1459
DB 1 GCAGCAGCAGCAACAGC 17

RESULT 172
US-10-494-343-168
; Sequence 168, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 168
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-168

Query Match 0.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAGCA 1460
DB 1 CAGCAGCAGCAACAGCA 17

RESULT 173
US-10-494-343-169
; Sequence 169, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 169
; LENGTH: 17
; TYPE: DNA

ORGANISM: Homo sapiens
US-10-494-343-169

Query Match
Best Local Similarity 100.0%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AGCAGCAGCAACAGCAG 1461
DB 1 AGCAGCAGCAACAGCAG 17

RESULT 174
US-10-494-343-170
Sequence 170, Application US/10494343
Publication No. US20040248138A1
GENERAL INFORMATION:

APPLICANT: Shannon, Mark
APPLICANT: Phan, Thuymy
TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
FILE REFERENCE: PB0184
CURRENT FILING DATE: 2004-04-30
PRIOR APPLICATION NUMBER: US to be assigned
PRIOR FILING DATE: to be assigned
PRIOR APPLICATION NUMBER: PCT/US2002/035129
PRIOR FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/334,773
PRIOR FILING DATE: 2001-11-01
NUMBER OF SEQ ID NOS: 870
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 170
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-494-343-170

Query Match
Best Local Similarity 100.0%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1446 GCAGCGACAGCAGCAGC 1462
DB 1 GCAGCGACAGCAGCAGC 17

RESULT 175
US-10-494-343-171
Sequence 171, Application US/10494343
Publication No. US20040248138A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
APPLICANT: Phan, Thuymy
TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
FILE REFERENCE: PB0184
CURRENT FILING DATE: 2004-04-30
PRIOR APPLICATION NUMBER: US to be assigned
PRIOR FILING DATE: to be assigned
PRIOR APPLICATION NUMBER: PCT/US2002/035129
PRIOR FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/334,773
PRIOR FILING DATE: 2001-11-01
NUMBER OF SEQ ID NOS: 870
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 171
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-494-343-171

Query Match
Best Local Similarity 100.0%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1447 CAGCAGCAGCAGCAGCA 1463
DB 1 CAGCAGCAGCAGCAGCA 17

RESULT 176
US-10-494-343-172
Sequence 172, Application US/10494343
Publication No. US20040248138A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
APPLICANT: Phan, Thuymy
TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
FILE REFERENCE: PB0184
CURRENT FILING DATE: 2004-04-30
PRIOR APPLICATION NUMBER: US to be assigned
PRIOR FILING DATE: to be assigned
PRIOR APPLICATION NUMBER: PCT/US2002/035129
PRIOR FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/334,773
PRIOR FILING DATE: 2001-11-01
NUMBER OF SEQ ID NOS: 870
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 172
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-494-343-172

Query Match
Best Local Similarity 100.0%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1448 AGCAGCAGCAGCAGCAG 1464
DB 1 AGCAGCAGCAGCAGCAG 17

RESULT 177
US-10-321-039-541
Sequence 541, Application US/10321039
Publication No. US20040014067A1
GENERAL INFORMATION:
APPLICANT: Lyamichev, Victor
APPLICANT: Lukowiak, Andrew
APPLICANT: Jarvis, Nancy
APPLICANT: Kurensky, David
TITLE OF INVENTION: Amplification Methods and Compositions
FILE REFERENCE: FORS-06960
CURRENT FILING DATE: 2002-12-17
PRIOR APPLICATION NUMBER: US/10/321,039
PRIOR FILING DATE: 2001-11-30
PRIOR APPLICATION NUMBER: 09/998,157
PRIOR FILING DATE: 2001-11-30
PRIOR APPLICATION NUMBER: 60/329,113
PRIOR FILING DATE: 2001-10-12
PRIOR APPLICATION NUMBER: 60/360,489
PRIOR FILING DATE: 2001-10-19
NUMBER OF SEQ ID NOS: 759
SOFTWARE: PatentIn version 3.2
SEQ ID NO 541
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-321-039-541

Query Match
Best Local Similarity 100.0%; Score 17; DB 1; Length 18;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCACGACGACGACG 1147
|||
DB 1 GCACGACGACGACG 17

RESULT 178
US-10-751-736-8809/C
; Sequence 8809, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeich
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8809
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8809

Query Match 0.4%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 AACACGACGACGACG 1491
|||
DB 19 AACACGACGACGACG 3

RESULT 179
US-10-751-736-8810/C
; Sequence 8810, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeich
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8810
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-8810

Query Match 0.4%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 AACACGACGACGACG 1491
|||
DB 17 AACACGACGACGACG 1

RESULT 180

US-09-969-852-11
; Sequence 11, Application US/09969852
; Patent No. US2002013721A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Tianyan
; APPLICANT: Liu, Huiyan
; APPLICANT: Li, Wei
; APPLICANT: Zhao, Libin
; TITLE OF INVENTION: A METHOD FOR ESTABLISHING AN EXPRESSION SYSTEM OF SPIDER DRAGLINE
; FILE REFERENCE: L10=65
; CURRENT APPLICATION NUMBER: US/09/969,852
; CURRENT FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: CN01106406.4
; PRIOR FILING DATE: 2001-01-02
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-969-852-11

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1281 GCACGACGCGCGCTGAGG 1300
|||
DB 1 GCACGACGACGACGCTGAGG 20

RESULT 181
US-09-291-417-136
; Sequence 136, Application US/09291417A
; Publication No. US20030050230A1
; GENERAL INFORMATION:
; APPLICANT: PLOMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 240/300
; CURRENT APPLICATION NUMBER: US/09/291,417A
; CURRENT FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,784
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mammalian (Human) ZC3
US-09-291-417-136

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAACGTGTGAAAGG 3949
|||
DB 1 CATCATGAACGTGTGACGG 20

RESULT 182
US-09-948-002-35
; Sequence 35, Application US/09948002
; Publication No. US20030050265A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan F. Murray
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH

```
; TITLE OF INVENTION: FACTOR BETA EXPRESSION
; FILE REFERENCE: ISPH-0607
; CURRENT APPLICATION NUMBER: US/09/948,002
; CURRENT FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 09/661,753
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/154,546
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-948-002-35

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 1.8e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGC 1138
DB 1 GTRAGCAGCAGCGCGCAGCAGC 20

RESULT 183
US-09-975-123-42
; Sequence 42, Application US/09975123
; Publication No. US20030087857A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Preler
; TITLE OF INVENTION: ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN
; FILE REFERENCE: RTS-0253
; CURRENT APPLICATION NUMBER: US/09/975,123
; CURRENT FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 43
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-975-123-42

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 1.8e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1267 CTGCAGCAGAGAGCAGCAGCA 1286
DB 1 CTGCAGCAGAGAGAGCGCGCA 20

RESULT 184
US-10-032-585-4054
; Sequence 4054, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jjiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Busey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4054
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Candida albicans
US-10-032-585-4054

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 1.8e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 CCGAGCAGCAGAGAGAGAG 201
DB 1 CCGAGCAGCAGAGAGAGAG 20

RESULT 185
US-10-032-585-4518/c
; Sequence 4518, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jjiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Busey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4518
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-4518

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 1.8e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGCAGCA 1142
DB 20 CATCAGCTTCAGCAGCAGCA 1

RESULT 186
US-10-174-465-19/c
; Sequence 19, Application US/10174465
; Publication No. US20030232772A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6
; FILE REFERENCE: PTS-0055
; CURRENT APPLICATION NUMBER: US/10/174,465
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-465-19

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 1.8e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1001 GCCATGAGAGAGAGAGAG 1020
DB 20 GCCATGAGAGAGAGAGAG 1

RESULT 187
US-10-348-431-19/c
```

; Sequence 19, Application US/10348431
; Publication No. US20030232778A1
; GENERAL INFORMATION:
; APPLICANT: Eric G. Marcuseon
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
; FILE REFERENCE: ISPH-0728
; CURRENT APPLICATION NUMBER: US/10/348,431
; CURRENT FILING DATE: 2003-01-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-431-19

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1001 GCCATGAGAGAGAGAGAG 1020
DB 20 GCCATGAGAGAGAGAGAG 1

RESULT 188
US-10-388-329-9
; Sequence 9, Application US/10388329
; Publication No. US20040002093A1
; GENERAL INFORMATION:
; APPLICANT: SHI, LIANG
; TITLE OF INVENTION: NUCLEIC ACID DETECTION METHOD
; FILE REFERENCE: 109845.191US2; TMR1-020US
; CURRENT APPLICATION NUMBER: US/10/388,329
; CURRENT FILING DATE: 2003-03-13
; PRIOR APPLICATION NUMBER: 60/364,230
; PRIOR FILING DATE: 2002-03-13
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide
US-10-388-329-9

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGGACGAGAGAGAGAGA 202
DB 1 GGAGGAGAGAGAGAGAGA 20

RESULT 189
US-10-380-126-38/c
; Sequence 38, Application US/10380126
; Publication No. US20040029824A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-1 EXPRESSION
; FILE REFERENCE: RTS-0175
; CURRENT APPLICATION NUMBER: US/10/380,126
; CURRENT FILING DATE: 2003-03-10

; PRIOR APPLICATION NUMBER: 09/657,042
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-126-38

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1479 GCAGCAGCAGCAGCTCTCC 1498
DB 20 GCCGAGCAGCAGCTCCAGC 1

RESULT 190
US-10-633-163-35
; Sequence 35, Application US/10633163
; Publication No. US20040063655A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan F. Murray
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH
; FILE REFERENCE: FACTOR BETA EXPRESSION
; FILE REFERENCE: ISPH-0607
; CURRENT APPLICATION NUMBER: US/10/633,163
; CURRENT FILING DATE: 2003-08-01
; PRIOR APPLICATION NUMBER: US/09/348,002
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 09/661,753
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/154,546
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-163-35

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCGAGCAGC 1138
DB 1 GTAGCAGCAGCGCGAGCAGC 20

RESULT 191
US-10-300-263-60
; Sequence 60, Application US/10300263
; Publication No. US20040096834A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
; FILE REFERENCE: RTS-0431
; CURRENT APPLICATION NUMBER: US/10/300,263
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-300-263-60

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 AGCAGCAGCAGCTTCAGAAA 1476

DB 1 AGCAGCAGCAGCTTCAGAAA 20

RESULT 192

US-10-300-263-129/C
; Sequence 129, Application US/10300263
; Publication No. US20040096834A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
; FILE REFERENCE: RTS-0431
; CURRENT APPLICATION NUMBER: US/10/300,263
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-300-263-129

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 AGCAGCAGCAGCTTCAGAAA 1476

DB 20 AGCAGCAGCAGCTTCAGAAA 1

RESULT 193

US-10-295-471-41/C
; Sequence 41, Application US/10295471
; Publication No. US20040097441A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF NIMA-RELATED KINASE 6 EXPRESSION
; FILE REFERENCE: RTS-0368
; CURRENT APPLICATION NUMBER: US/10/295,471
; CURRENT FILING DATE: 2002-11-16
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-295-471-41

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 451 GTGATCCATCGAGACATCAA 470

DB 20 GTGATCCATCGAGACATCAA 1

RESULT 194

US-10-295-471-112
; Sequence 112, Application US/10295471
; Publication No. US20040097441A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF NIMA-RELATED KINASE 6 EXPRESSION

; FILE REFERENCE: RTS-0368
; CURRENT APPLICATION NUMBER: US/10/295,471
; CURRENT FILING DATE: 2002-11-16
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-295-471-112

QY 451 GTGATCCATCGAGACATCAA 470

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 1 GTGATCCATCGAGACATCAA 20

RESULT 195

US-10-315-962-46
; Sequence 46, Application US/10315962
; Publication No. US20040109848A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF AP-2 ALPHA EXPRESSION
; FILE REFERENCE: RTS-0046
; CURRENT APPLICATION NUMBER: US/10/315,962
; CURRENT FILING DATE: 2000-12-09
; NUMBER OF SEQ ID NOS: 126
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-315-962-46

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGC 1138

DB 1 GCAGCAGCAGCAGCTGCAGCAGC 20

RESULT 196

US-10-316-755-19
; Sequence 19, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowart
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-755-19

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAGCAG 1150
DB 1 GCAGCAGCAGCAGCAGCAGC 20

RESULT 197
US-10-316-755-20
; Sequence 20, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-755-20

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1125 GCAGCTGCAGCAGCAGCAGC 1144
DB 1 GCAGCTGCAGCAGCAGCAGC 20

RESULT 198
US-10-316-755-174/C
; Sequence 174, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-755-174

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAGCAG 1150
DB 20 GCAGCAGCAGCAGCAGCAGC 1

RESULT 199
US-10-316-755-175/C
; Sequence 175, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-755-175

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1125 GCAGCTGCAGCAGCAGCAGC 1144
DB 20 GCAGCTGCAGCAGCAGCAGC 1

RESULT 200
US-10-725-329-136
; Sequence 136, Application US/10725329
; Publication No. US2004024323A1
; GENERAL INFORMATION:
; APPLICANT: PLOWMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/688,1888
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; PRIOR FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-725-329-136

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3930 CATCATGAACGTGTGAAGC 3949
DB 1 CATCATGAACGTGTGAAGC 20

RESULT 201
US-10-858-500-496/C
; Sequence 496, Application US/10858500
; Publication No. US20050014257A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: MODULATION OF C-REACTIVE PROTEIN EXPRESSION
; FILE REFERENCE: BIO00014US
; CURRENT APPLICATION NUMBER: US/10/858,500
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 09/912,724
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/475,272
; PRIOR FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: US 60/540,042
; PRIOR FILING DATE: 2004-01-28
; NUMBER OF SEQ ID NOS: 627
; SEQ ID NO 496

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-858-500-496

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3615 CATGAGATGCTGCTGCT 3634
Db      20 CATGAGAGAGCTGCTGCT 1

RESULT 202
US-10-491-712-42
; Sequence 42, Application US/10491712
; Publication No. US20050049211A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN
; FILE REFERENCE: ISFH-0849
; CURRENT APPLICATION NUMBER: US/10/491,712
; PRIOR FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: PCT/US02/32060
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: US 09/975,123
; NUMBER OF SEQ ID NOS: 43
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-491-712-42

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1267 CTGCAGAGAGAGAGAGCA 1286
Db      1 CTGCAGAGAGAGAGAGCGCA 20

RESULT 203
US-10-882-104-397
; Sequence 397, Application US/10882104
; Publication No. US20050079619A1
; GENERAL INFORMATION:
; APPLICANT: Roemer, Terry
; APPLICANT: Jiang, Bo
; APPLICANT: Boone, Charles
; APPLICANT: Bussey, Howard
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug
; FILE REFERENCE: 10182-004-999
; CURRENT APPLICATION NUMBER: US/10/882,104
; PRIOR FILING DATE: 2004-06-29
; PRIOR APPLICATION NUMBER: US/09/792,024
; PRIOR FILING DATE: 2001-02-20
; NUMBER OF SEQ ID NOS: 490
; SOFTWARE: PaatSeq for windows Version 4.0
; SEQ ID NO 397
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer
```

```
US-10-882-104-397

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      182 CCGAGAGAGAGAGAGAGAG 201
Db      1 CCGAGAGAGAGAGAGAGAG 20

RESULT 204
US-10-380-195A-15
; Sequence 15, Application US/10380195A
; Publication No. US2004007276A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Kiyama, Satoshi
; APPLICANT: Nelson, Colleen
; APPLICANT: Rennie, Paul
; TITLE OF INVENTION: Antisense Insulin-like Growth Factor Binding Protein (IGFBP)-2
; FILE REFERENCE: UBC-P-023
; CURRENT APPLICATION NUMBER: US/10/380,195A
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: PCT/US01/28748
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: US 60/232,641
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IGFBP2 antisense
US-10-380-195A-15

Query Match      0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1129 CTGCAGAGAGAGAGAGCG 1148
Db      1 CAGTAGCAGAGAGAGAGAGCG 20

RESULT 205
US-10-479-510-11/c
; Sequence 11, Application US/10479510
; Publication No. US20040157230A1
; GENERAL INFORMATION:
; APPLICANT: Cavidi Tech AB
; TITLE OF INVENTION: A method for measuring DNA polymerization and
; FILE REFERENCE: 110063501
; CURRENT APPLICATION NUMBER: US/10/479,510
; PRIOR FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 60/297,773
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: template
US-10-479-510-11

Query Match      0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
```


Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1442 TGCAGCAGCAGCAACAG 1461
DB 20 TTCAAGCAGCAGCAGCAG 1

RESULT 206

US-10-786-720-11947
; Sequence 11947, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 2135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11947
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-11947

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1460 AGCAGCAGCTTCAGAAACAG 1479
DB 2 AGCAACAGCTTCAGAAAGAG 21

RESULT 207

US-10-786-720-11949/c
; Sequence 11949, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 2135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11949
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI-antisense strand
US-10-786-720-11949

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1460 AGCAGCAGCTTCAGAAACAG 1479
DB 20 AGCAACAGCTTCAGAAAGAG 1

RESULT 208

US-10-852-997-42
; Sequence 42, Application US/10852997
; Publication No. US2004022013A1
; GENERAL INFORMATION:
; APPLICANT: Medtronic, Inc.

; APPLICANT: Medtronic, Inc.
; APPLICANT: Kaemmerer, William F.
; TITLE OF INVENTION: Treatment of Neurodegenerative Disease Through Intracranial Deliv
; TITLE OF INVENTION: siRNA
; FILE REFERENCE: P1089.02
; CURRENT APPLICATION NUMBER: US/10/852,997
; CURRENT FILING DATE: 2004-05-25
; PRIOR APPLICATION NUMBER: 10/721,693
; PRIOR FILING DATE: 2003-11-25
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (0358)..()
; OTHER INFORMATION: Oligonucleotide MD0358 to construct the DNA encoding for siRNA sc
; OTHER INFORMATION: acting at position 0358 within human Huntington cDNA (Genbank Acce
; OTHER INFORMATION: esion NM_002111.3. The first two 5' nucleotides AA are optional
US-10-852-997-42

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1435 AAGTCCCTGCAGCAGCAGCA 1454
DB 1 AAGTCCCTGCAGCAGCAGCA 20

RESULT 209

US-10-827-759A-235/c
; Sequence 235, Application US/1082759A
; Publication No. US2004024817A1
; GENERAL INFORMATION:
; APPLICANT: The Trustees of the University of Pennsylvania
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
; FILE REFERENCE: 43826-0005 US1
; CURRENT APPLICATION NUMBER: US/10/827,759A
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 60/463,981
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 736
; SOFTWARE: PaetSeq for Windows Version 4.0
; SEQ ID NO 235
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-827-759A-235

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1371 GCTGAGAGCAGCGCGCAGT 1390
DB 21 GCTGAGAGAGAGCGCGCAGT 2

RESULT 210

US-10-751-736-617
; Sequence 617, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 617
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-617

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 2e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      586 TGGATGGCTCCAGAGTCAT 605
DB      1 UGSAUGGCGCCAGAGGUAU 20

RESULT 211
US-10-751-736-11681/c
; Sequence 11681, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11681
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11681

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1474 AACAGCAGCAGCAGCAGCT 1493
DB      20 AATCAGCAGCGGAGCAGCT 1

RESULT 212
US-10-751-736-19135/c
; Sequence 19135, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19135
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-19135

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1475 AACAGCAGCAGCAGCTC 1494
DB      20 AACAGCAGCAGCAACTCTC 1

RESULT 213
US-10-751-736-34849/c
; Sequence 34849, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34849
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-34849

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      630 CACCTATGATTACAGAGTG 649
DB      20 CATCATGATTATCAGAGTG 1

RESULT 214
US-10-751-736-37756
; Sequence 37756, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37756
; LENGTH: 21
```

TYPE: DNA
ORGANISM: homo sapiens
US-10-751-736-37756

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1463 AGCAGCTTCAGAAACAGCAG 1482
DB 2 AGGAGCTCCAGAAACAGCAG 21

RESULT 215
US-10-751-736-42789/c

Sequence 42789, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:

APPLICANT: Wyeeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
CANCERS

FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736

PRIOR FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 42789

LENGTH: 21
TYPE: RNA
ORGANISM: RNAi
US-10-751-736-42789

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGCAGCAGCAGCAGCAG 202
DB 21 GGAGCAGCAGCAGCAGCAG 2

RESULT 216
US-10-418-182-55

Sequence 55, Application US/10418182
Publication No. US20030228302A1
GENERAL INFORMATION:

APPLICANT: Crea, Roberto
TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
FILE REFERENCE: 1551.2001-001

CURRENT APPLICATION NUMBER: US/10/418,182
PRIOR FILING DATE: 2003-04-17
PRIOR APPLICATION NUMBER: 60/373,558

NUMBER OF SEQ ID NOS: 423
SOFTWARE: PatentIn version 4.0
SEQ ID NO 55

LENGTH: 36
TYPE: DNA
ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: oligonucleotide
US-10-418-182-55

Query Match 0.4%; Score 16.6; DB 1; Length 36;
Best Local Similarity 71.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAGCAGCAGCAGC 1147

DB 2 CTGCTGCTGCCGCTGCCGCTGCTGCTGC 32

RESULT 217
US-10-440-850-1112/c

Sequence 1112, Application US/10440850
Publication No. US20030207837A1
GENERAL INFORMATION:

APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Stinchcomb, Dan
APPLICANT: Jarvis, Thale

APPLICANT: MCSwigen, Jim
TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal

FILE REFERENCE: 250/130 (MBH00-900-A)
CURRENT APPLICATION NUMBER: US/10/440,850

PRIOR FILING DATE: 2003-05-19
PRIOR APPLICATION NUMBER: US/09/650,012
PRIOR FILING DATE: 2000-08-28

PRIOR APPLICATION NUMBER: US 08/585,684
PRIOR FILING DATE: 1996-01-12
PRIOR APPLICATION NUMBER: US 60/000,951

PRIOR FILING DATE: 1995-07-07
PRIOR APPLICATION NUMBER: US 09/038,073
PRIOR FILING DATE: 1998-03-11

NUMBER OF SEQ ID NOS: 2285
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1112

LENGTH: 18
TYPE: RNA
ORGANISM: Homo sapiens
US-10-440-850-1112

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1440 CCTGCAGCAGCAGCAGCACA 1457
DB 18 CCTGCAGCAGCAGCAGCACA 1

RESULT 218
US-10-360-854-11

Sequence 11, Application US/10360854
Publication No. US20040157220A1
GENERAL INFORMATION:

APPLICANT: Kurmool, Purnima
APPLICANT: Wo, Betty
APPLICANT: Banks, Peter

TITLE OF INVENTION: Method and Apparatus for Sample Tracking
FILE REFERENCE: 10255-020-999
CURRENT APPLICATION NUMBER: US/10/360,854

PRIOR FILING DATE: 2003-02-10
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn version 3.1
SEQ ID NO 11

LENGTH: 18
TYPE: DNA
ORGANISM: mammalian

US-10-360-854-11

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCAGCTGCAG 1134
DB 1 CAGCAGCAGCAGCAGCAGCAG 18

RESULT 219

US-10-436-231-5
; Sequence 5, Application US/10436231
; Publication No. US20040175704A1
; GENERAL INFORMATION:
; APPLICANT: Stratagene
; APPLICANT: Sorge, Joseph A
; APPLICANT: Firm, Andrew
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE SEQUENCE DETECTION
; FILE REFERENCE: 25436/2392
; CURRENT APPLICATION NUMBER: US/10/436,231
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: US 60/452,481
; PRIOR FILING DATE: 2003-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Example Allele A comprising tandem repeats
US-10-436-231-5

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1477 CAGCAGCAGCAGCAGCTC 1494
DB 1 CAGCAGCAGCAGCAGCCC 18

RESULT 220
US-10-436-231-6/c
; Sequence 6, Application US/10436231
; Publication No. US20040175704A1
; GENERAL INFORMATION:
; APPLICANT: Stratagene
; APPLICANT: Sorge, Joseph A
; APPLICANT: Firm, Andrew
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE SEQUENCE DETECTION
; FILE REFERENCE: 25436/2392
; CURRENT APPLICATION NUMBER: US/10/436,231
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: US 60/452,481
; PRIOR FILING DATE: 2003-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Example Allele A comprising tandem repeats
US-10-436-231-6

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1477 CAGCAGCAGCAGCAGCTC 1494
DB 18 CAGCAGCAGCAGCAGCCC 1

RESULT 221
US-10-251-117-124
; Sequence 124, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSw19gen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R

; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MEHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 124
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-251-117-124

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.9e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2975 AGATCCGAGAGTACAGA 2992
DB 2 AGATCCGAGAGTACAGA 19

RESULT 222
US-10-251-117-373/c
; Sequence 373, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSw19gen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MEHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 373
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-373

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2975 AGATCCGAGAGTACAGA 2992
DB 18 AGATCCGAGAGTACAGA 1

RESULT 223
US-10-696-639-3083
; Sequence 3083, Application US/10696639
; Publication No. US20050037439A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corporation
; APPLICANT: Bourne, Maureen J.
; TITLE OF INVENTION: DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, THE
; TITLE OF INVENTION: POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING THE SAME
; FILE REFERENCE: 01040/1
; CURRENT APPLICATION NUMBER: US/10/696,639
; PRIOR FILING DATE: 2003-10-29
; PRIOR APPLICATION NUMBER: 60/442,176
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 3114
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 3083
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-696-639-3083

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3614 GCATGAGATGCTGCTGT 3631
Db 2 GCATGAGATGCTGCTGT 19

RESULT 224
US-10-830-569-94
; Sequence 94, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 94
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

US-10-830-569-94

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1670 CCCGAGGCCCCCAGAGAC 1687
Db 1 CCCGAGGCCCCCAGAGAC 18

RESULT 225
US-10-830-569-401/c
; Sequence 401, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 401
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

US-10-830-569-401

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1670 CCCGAGGCCCCCAGAGAC 1687
Db 19 CCCGAGGCCCCCAGAGAC 2

RESULT 226
US-09-954-556-52
; Sequence 52, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRES
; FILE REFERENCE: RTS-0250

;; CURRENT APPLICATION NUMBER: US/09/954,556
;; CURRENT FILING DATE: 2001-09-14
;; NUMBER OF SEQ ID NOS: 108
;; SEQ ID NO 52
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-52

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3490 GGCTCCAGTGTGCTTC 3507
DB 1 GGCTCCAGTGTGCTTC 18

RESULT 227
US-10-181-846-72/c
; Sequence 72, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RSP-0363
; CURRENT APPLICATION NUMBER: US/10/181,846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-72

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 183 GGAGGACGAGGAGAGA 200
DB 19 GGAGGACGAGGAGAGA 2

RESULT 228
US-10-187-049-10/c
; Sequence 10, Application US/10187049
; Publication No. US20030143218A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Wenfeng
; PRESNELI, Scott R.
; Yee, David P.
; Foster, Donald C.
; TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR
; PAR4 (ZCHEMR2)
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Zymogenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Diskette
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: DOS
;; SOFTWARE: FASTSEQ for Windows Version 2.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/10/187,049
;; FILING DATE: 28-Jun-2002
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: <Unknown>
;; FILING DATE: <Unknown>
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Leith, Debra K
;; REGISTRATION NUMBER: 32,619
;; REFERENCE/DOCKET NUMBER: 98-10
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6674
;; TELEFAX: 206-442-6678
;; TELEX: <Unknown>
;; INFORMATION FOR SEQ ID NO: 10:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-187-049-10

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3622 ATGCTGCTGTGCTACGAG 3639
DB 18 ATGCTGCTGTGCTACGAG 1

RESULT 229
US-10-032-585-4081/c
; Sequence 4081, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jlang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4081
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-4081

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1126 CAGTGCAGCAGCAGCAG 1143
DB 18 CAGTGCAGCAGCAGCAG 1

RESULT 230
US-10-215-448-53
; Sequence 53, Application US/10215448
; Publication No. US20040029273A1
; GENERAL INFORMATION:
; APPLICANT: Jacqueline Wyatt

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF EDG1 EXPRESSION
; FILE REFERENCE: RTS-0179
; CURRENT APPLICATION NUMBER: US/10/215,448
; CURRENT FILING DATE: 2002-08-09
; NUMBER OF SEQ ID NOS: 105
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-215-448-53

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1485 GCAGCAGCTCTGCTG 1502
DB 1 GCAGCAGCTCTGCTG 18

RESULT 231
US-10-688-706-319
; Sequence 319, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broesch, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: Patent version 3.2
; SEQ ID NO 319
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-319

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 ACTGAAGTTCCCTTCAT 872
DB 3 ACTGAAGTTCCCTTCAT 20

RESULT 232
US-10-688-706-419
; Sequence 419, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broesch, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: Patent version 3.2
; SEQ ID NO 419
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
```

```

; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-419

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 ACTGAAGTTCCCTTCAT 872
DB 1 ACTGAAGTTCCCTTCAT 18

RESULT 233
US-10-688-706-774
; Sequence 774, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broesch, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: Patent version 3.2
; SEQ ID NO 774
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-774

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 ACTGAAGTTCCCTTCAT 872
DB 2 ACTGAAGTTCCCTTCAT 19

RESULT 234
US-10-719-370A-222/c
; Sequence 222, Application US/10719370A
; Publication No. US20040220393A1
; GENERAL INFORMATION:
; APPLICANT: Ward, Donna T.
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Freiler, Susan M.
; TITLE OF INVENTION: MODULATION OF HIF1a AND HIF2a EXPRESSION
; FILE REFERENCE: ISPT-1010
; CURRENT APPLICATION NUMBER: US/10/719,370A
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: Patent version 3.2
; SEQ ID NO 222
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-719-370A-222

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

Qy      1478 AGCAGCAGCAGCAGCTCC 1495
          |||||
Db      20 AGCAGCAGCAGCTGCC 3

```

```

RESULT 235
US-10-719-370A-340
; Sequence 340. Application US/10719370A
; Publication No. US2004022033A1
; GENERAL INFORMATION:
; APPLICANT: Ward, Donna T.
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Marcuseon, Eric G.
; APPLICANT: Freiler, Susan M.
; TITLE OF INVENTION: MODULATION OF HIF1A AND HIF2A EXPRESSION
; FILE REFERENCE: ISPT-1010
; CURRENT APPLICATION NUMBER: US/10/719,370A
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 340
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-719-370A-340

```

Query Match	0.4%	Score 16.4;	DB 1;	Length 20;
Best Local Similarity	94.4%;	Pred. No. 2.1e+02;		
Matches 17; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

QY	1478	AGCAGCAGCAGCAGCTCC	1495
Db	1	AGCAGCAGCAGCTGCTCC	18

```

RESULT 236
US-09-765-081-353
; Sequence 353, Application US/09765081
; Patent No. US20020037508A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMERISMS
; FILE REFERENCE: 2825.2008-0-01
; CURRENT APPLICATION NUMBER: US/09/765,081
; CURRENT FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: US 60/176,861
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 461
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 353
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-765-081-353

```

Query Match	0.4%	Score 16.4;	DB 1;	Length 21;
Best Local Similarity	85.0%;	Pred. No. 2.2e+02;		
Matches 17; Conservative	1;	Mismatches 2;	Indels 0;	Gaps 0;

```

QY      1746 GTCCCTCAGGAGCCAGCCCA 1765
          ||||| : |||||
Db      2 GTCCAGCCRGACCAGCCCA 21

```

RESULT 237
US-10-303-109A-31/c
; Sequence 31, Application US/10303109A
; Publication No. US20030194726A1

```

; GENERAL INFORMATION:
; APPLICANT: BOLCHAKOVA, Elena
; APPLICANT: ROZZELLE, James
; TITLE OF INVENTION: Thermus Oshimai Nucleic Acid Polymerase
; FILE REFERENCE: 4777US
; CURRENT APPLICATION NUMBER: US/10/303,109A
; CURRENT FILING DATE: 2002-11-22
; PRIOR APPLICATION NUMBER: US 60/334,798
; PRIOR FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Thermus oshimai
; US-10-303-109A-31

```

Query Match	0.4%	Score 16.4;	DB 1;	length 21;
Best Local Similarity	94.4%;	Pred. No. 2.2e+02;		
Matches 17; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

Qy	372	CAACGCCCTGAAGGAGGA	385
Db	20	CAAGGCCCTGAAGGAGGA	3

```

RESULT 238
US-10-751-736-10540/c
; Sequence 10540. Application US/10751736
; Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE OF INVENTION: CANCERS
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: Patentin version 3.2
SEQ ID NO 10540
LENGTH: 21
TYPE: DNA
ORGANISM: homo sapiens
US-10-751-736-10540

```

Query Match	0.4%	Score 16.4;	DB 1;	Length 21;
Best Local Similarity	94.4%;	Pred. No. 2.2e+02;		
Matches 17; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

```

QY      1130 TGCAGCAGCAGCAGCAGC 1147
          |||||||
Db      21  TGCAGCAGCAGCAGCAGC 4

```

```

RESULT 239
US-10-751-736-10541/C
/ Sequence 10541, Application US/10751736
/ Publication NO. US20040265230A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Martinez, Robert
/ APPLICANT: Brown, Eugene
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
/ TITLE OF INVENTION: CANCERS
/ FILE REFERENCE: AM100927 (031896-002000)
/ CURRENT APPLICATION NUMBER: US/10/751,736
/ CURRENT FILING DATE: 2003-01-06

```


PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 10541
LENGTH: 21
TYPE: RNA
ORGANISM: RNAi
US-10-751-736-10541

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1130 TGCAGCAGCAGCAGCAGC 1147
DB 19 TGCAGCAGCAGCAGCAGC 2

RESULT 240
US-10-751-736-39223
Sequence 39223, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 39223
LENGTH: 21
TYPE: DNA
ORGANISM: homo sapiens
US-10-751-736-39223

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1120 CAGCAGCAGCAGCAGCAG 1137
DB 1 CAGCAGCAGCAGCAGCAG 18

RESULT 241
US-10-751-736-40388
Sequence 40388, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 40388
LENGTH: 21
TYPE: RNA

ORGANISM: RNAi
US-10-751-736-40388

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 183 GGAGCAGCAGCAGCAGCAG 200
DB 2 GGAGCAGCAGCAGCAGCAG 19

RESULT 242
US-10-751-736-40594
Sequence 40594, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 40594
LENGTH: 21
TYPE: DNA
ORGANISM: homo sapiens
US-10-751-736-40594

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGCAGCAGCAGCAGCAG 201
DB 1 GAGCAGCAGCAGCAGCAG 18

RESULT 243
US-10-393-815-165
Sequence 165, Application US/10393815
Publication No. US20030224413A1
GENERAL INFORMATION:
APPLICANT: Shinkens, Richard A
APPLICANT: Leach, Martin
TITLE OF INVENTION: Nucleic Acids Containing Single Nucleotide Polymorphisms
FILE REFERENCE: 15966-534B
CURRENT APPLICATION NUMBER: US/10/393,815
CURRENT FILING DATE: 2003-03-20
PRIOR APPLICATION NUMBER: 60/109,024
PRIOR FILING DATE: 1998-11-17
NUMBER OF SEQ ID NOS: 320
SOFTWARE: CuraGen Patent Formatter Version 0.9
SEQ ID NO 165
LENGTH: 51
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: allele
LOCATION: (26) .. (0)
OTHER INFORMATION: single nucleotide polymorphism
FEATURE:
NAME/KEY: misc_feature
LOCATION: (0) ... (0)
OTHER INFORMATION: Accession number cg43984259

;; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;; FILE REFERENCE: 031896-023000 (AM101331L)
;; CURRENT APPLICATION NUMBER: US/10/786,720
;; CURRENT FILING DATE: 2004-02-26
;; NUMBER OF SEQ ID NOS: 21135
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO: 12565
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-786-720-12565

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1458 GCAGCAGCAGCTTCAGAAACA 1478
DB 1 GAAGCAGCAGCTTCAGAAAGA 21

RESULT 249
US-10-786-720-15008/c
; Sequence 15008, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 15008
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-15008

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 205 AAACAGAGATCAACATGCTG 225
DB 21 AAACAGAGATGACATGCTG 1

RESULT 250
US-10-786-720-20812
; Sequence 20812, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 20812
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-20812

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3657 CAACAGTACGGGCGCATCAT 3677
DB 1 CATCAGTACGTGACATCAT 21

RESULT 251
US-10-725-329-54
; Sequence 54, Application US/10725329
; Publication No. US20040224323A1
; GENERAL INFORMATION:
; APPLICANT: PLOMMAN, GREGORY
; APPLICANT: MARTINEZ, RICARDO
; APPLICANT: WHYTE, DAVID
; TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
; FILE REFERENCE: 038602/0328
; CURRENT APPLICATION NUMBER: US/10/725,329
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/688,188B
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 09/291,417
; PRIOR FILING DATE: 1999-04-14
; PRIOR APPLICATION NUMBER: 60/081,784
; NUMBER OF SEQ ID NOS: 155
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 54
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-725-329-54

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 166 AAGTCATGATGATCAGCAGG 186
DB 1 AAGTTATGATGATCAGCAGG 21

RESULT 252
US-10-751-736-11485/c
; Sequence 11485, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 11485
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11485

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAGCTT 1470
DB 21 CATCAGCAGCGCAGCAGCTT 1

RESULT 253

US-10-751-736-11486/c
; Sequence 11486, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11486
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11486

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Pred. No. 2.3e+02;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGACAGC 1138
DB 21 AACATCAGCAGCGCAGCAGC 1

RESULT 254

US-10-751-736-11680/c
; Sequence 11680, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11680
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11680

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Pred. No. 2.3e+02;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1451 AGCAACAGCAGCAGCAGCTTC 1471
DB 21 ATCAGCAGCGCAGCAGCAGCTTC 1

RESULT 255

US-10-751-736-19138/c
; Sequence 19138, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19138
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-19138

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Pred. No. 2.3e+02;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1451 AGCAACAGCAGCAGCAGCTTC 1471
DB 21 AGTACAGCAGCAGCAGCAGCTTC 1

RESULT 256

US-10-751-736-24853
; Sequence 24853, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24853
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-24853

Query Match
Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Pred. No. 2.3e+02;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1459 CAGCAGCAGCTTCAGAAACAG 1479
DB 1 CAGCTGCTCTCTTCAGAAACAG 21

RESULT 257

US-10-751-736-25318/c
; Sequence 25318, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene

```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25318
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-25318

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      202 ATCAACAGAGATCAATG 222
DB      21 ATCAGCAGAGATCAGCATG 1

RESULT 258
US-10-751-736-38416
; Sequence 38416, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38416
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-38416

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1453 CAACAGCAGCAGCTTCAAG 1473
DB      1 CAAGAGACCAAGCAGCTTCAAG 21

RESULT 259
US-10-751-736-42683/c
; Sequence 42683, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42683
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-42683

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1475 AACGACGACGACGAGCTCC 1495
DB      21 AACGACGCTCTGACGAGCTCC 1

RESULT 260
US-10-751-736-49825
; Sequence 49825, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49825
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-49825

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1123 CAGCAGCTGACGACGACGAG 1143
DB      1 CAGCTGCTGACGACGAGCATG 21

RESULT 261
US-09-801-274-1526/c
; Sequence 1526, Application US/09801274
; Patent No. US20020032319A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825-2009-001
; CURRENT APPLICATION NUMBER: US/09/801,274
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 60/187,510
; PRIOR FILING DATE: 2000-03-07
; PRIOR APPLICATION NUMBER: US 60/206,129
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 1802
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1526
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
```

US-09-801-274-1526

Query Match 0.4%; Score 16.2; DB 1; Length 31;
Best Local Similarity 72.4%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGCAGCAGCAGC 1147

DB 30 GCTGTCGCGCTGCGCTGCGCTGCTGC 2

RESULT 262

US-09-780-533A-2354
; Sequence 2354, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blat, Larry
; APPLICANT: MCSwigen, Jim
; APPLICANT: Chowitra, Bharat
; APPLICANT: Haebertl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2354
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2354

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 185 AGCAGCAGCAGCAGCAGCAGCAGC 200

DB 1 AGCAGCAGCAGCAGCAGCAGCAGC 16

RESULT 263

US-09-792-818-383
; Sequence 383, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: MCSwigen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; PRIOR FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 383
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-383

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGC 1138

DB 2 CAGCAGCTGCAGCAGC 17

RESULT 264

US-09-792-818-524
; Sequence 524, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: MCSwigen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; PRIOR FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 524
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-524

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGC 1138

DB 1 CAGCAGCTGCAGCAGC 16

RESULT 265

US-10-494-343-166
; Sequence 166, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 166
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-166

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACG 1458

DB 2 GCAGCAGCAGCAACG 17

RESULT 266

US-10-494-343-173

```
; Sequence 173, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuyam
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 173
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-173

Query Match          0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1449 GCAGCAACAGCAGCAG 1464
DB 1 GCAGCAACAGCAGCAG 16

```
RESULT 267
US-10-181-603-11
; Sequence 11, Application US/10181603
; Publication No. US20030049662A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowart
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RISP-0342
; CURRENT APPLICATION NUMBER: US/10/181,603
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01165
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/487,444
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-603-11

Query Match          0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1476 ACAGCAGCAGCAGCAG 1491
DB 3 ACAGCAGCAGCAGCAG 18

```
RESULT 268
US-10-440-850-1113/C
; Sequence 1113, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
```

```
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revers
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MHB00-900-R)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1113
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-1113

Query Match          0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1439 CCCTGCAGCAGCAGCA 1454
DB 16 CCCTGCAGCAGCAGCA 1

```
RESULT 269
US-09-563-728A-7/C
; Sequence 7, Application US/09563728A
; Publication No. US20030078216A1
; GENERAL INFORMATION:
; APPLICANT: MacLeod, Alan R
; APPLICANT: Li, Zoumei
; APPLICANT: Besterman, Jeffrey M
; TITLE OF INVENTION: Inhibition of Histone Deacetylase
; FILE REFERENCE: 106101.229
; CURRENT APPLICATION NUMBER: US/09/563,728A
; CURRENT FILING DATE: 2000-05-03
; PRIOR APPLICATION NUMBER: 60/132,287
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-563-728A-7

Query Match          0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1131 GCAGCAGCAGCAGCAG 1146
DB 20 GCAGCAGCAGCAGCAG 5

```
RESULT 270
US-09-563-728A-16/C
; Sequence 16, Application US/09563728A
; Publication No. US20030078216A1
; GENERAL INFORMATION:
; APPLICANT: MacLeod, Alan R
; APPLICANT: Li, Zoumei
; APPLICANT: Besterman, Jeffrey M
```

;; TITLE OF INVENTION: Inhibition of Histone Deacetylase
;; FILE REFERENCE: 106101.229
;; CURRENT APPLICATION NUMBER: US/09/563,728A
;; CURRENT FILING DATE: 2000-05-03
;; PRIOR APPLICATION NUMBER: 60/132,287
;; PRIOR FILING DATE: 1998-05-03
;; NUMBER OF SEQ ID NOS: 36
;; SOFTWARE: Patentin Ver. 2.1
;; SEQ ID NO 16
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; NAME/KEY: modified_base
;; LOCATION: 1-4 and 17-20 are modified
;; OTHER INFORMATION: Positions 1-4 and 17-20 are 2'-methoxyribose
;; OTHER INFORMATION: substituted nucleotides; positions 5-16 are
;; OTHER INFORMATION: deoxyribonucleotides
US-09-563-728A-16

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
DB 20 GCAGCAGCAGCAGCAG 5

RESULT 271
US-10-145-493B-52/C
; Sequence 52, Application US/10145493B
; Publication No. US20030096777A1
; GENERAL INFORMATION:
; APPLICANT: Beeterman, Jeffrey
; APPLICANT: Macleod, Robert
; APPLICANT: Siders, William
; TITLE OF INVENTION: Modulation of Gene Expression by Combination Therapy
; FILE REFERENCE: MET-015DV
; CURRENT APPLICATION NUMBER: US/10/145,493B
; CURRENT FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 09/420,692
; PRIOR FILING DATE: 1999-10-19
; PRIOR APPLICATION NUMBER: US 60/104,804
; PRIOR FILING DATE: 1998-10-19
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-145-493B-52

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCAG 1146
DB 20 GCAGCAGCAGCAGCAG 5

RESULT 272
US-09-263-959-793/C
; Sequence 793, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Bowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTIL

;; NUMBER OF SEQUENCES: 1279
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Seed and Berry LLP
;; STREET: 6300 Columbia Center, 701 Fifth Avenue
;; CITY: Seattle
;; STATE: Washington
;; COUNTRY: US
;; ZIP: 98104-7092
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/263,959
;; FILING DATE: 05-MAR-1999
;; CLASSIFICATION:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Mcmasters, David D.
;; REGISTRATION NUMBER: 33,963
;; REFERENCE/DOCKET NUMBER: 920010.426C2
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (206) 622-4900
;; TELEFAX: (206) 682-6031
;; INFORMATION FOR SEQ ID NO: 793:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-09-263-959-793

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 AGCAGCAGCTGCAGCAGCA 1139
DB 19 AGCAGCAGCAAGCAGCAGCA 1

RESULT 273
US-10-251-117-754/C
; Sequence 754, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: MCSwigen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Re
; FILE REFERENCE: 900/042 (MHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 754
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-251-117-754

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 477 GAATGCTGCTGCAGACAG 495
DB 19 GAATGCTGCTGCAGACAG 1

RESULT 274
US-10-251-117-1061
; Sequence 1061, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1061
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-251-117-1061

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.3e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 477 GAATGCTGCTGCAGACAG 495
DB 1 GAUGUGUGUGUACACAG 19

RESULT 275
US-10-349-143-7203
; Sequence 7203, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7203
; LENGTH: 19

; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-2903 for SEQ 3269,
US-10-349-143-7203

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3243 AGAAGTGAGAGAGACAG 3261
DB 1 AGAAGTGAGAGAGAGTAG 19

RESULT 276
US-10-830-569-188/c
; Sequence 188, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MHB04-378-B)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 188
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense re

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2121 CCCTGCGCCGCCAAGCC 2139
DB 19 CCCTGCGCCGCCAAGGCC 1

RESULT 277
US-10-830-569-495
; Sequence 495, Application US/10830569
; Publication No. US20050054598A1

GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
FILE REFERENCE: 400/153 (MEHB04-378-A) (s1m)
CURRENT APPLICATION NUMBER: US/10/830,569
CURRENT FILING DATE: 2004-04-23
PRIOR APPLICATION NUMBER: US 10/825,485
PRIOR FILING DATE: 2004-04-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 821
SOFTWARE: PatentIn version 3.3
SEQ ID NO 495
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-830-569-495
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2121 CCCTGCGCCGCCACGCC 2139
Db 1 CCCUGGCGCGCCACGCGCC 19
RESULT 278
US-09-791-406-65/c
Sequence 65, Application US/09791406
Patent No. US20020147165A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Robert Kothlein
APPLICANT: Takashi Kei Kishimoto
APPLICANT: Lex M. Cowseert
TITLE OF INVENTION: ANTISENSE MODULATION OF CALRETICULIN EXPRESSION
FILE REFERENCE: RTS-0097
CURRENT APPLICATION NUMBER: US/09/791,406
CURRENT FILING DATE: 2001-02-22
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 65
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-791-406-65
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2446 GAGGACGACGAGGAGGAG 2464
Db 19 GAGGAGATGACGAGGAGGAG 1
RESULT 279
US-09-733-444-2/c
Sequence 2, Application US/09733444
Patent No. US20020150894A1
GENERAL INFORMATION:
APPLICANT: Batra, Surinder K.
APPLICANT: Brandt, Randall E.
APPLICANT: Ringel, J"erg
APPLICANT: Faulmann, Grit
APPLICANT: L"hr, Mathias
APPLICANT: Varshney, Grief C.
APPLICANT: University of Nebraska Board of Regents
TITLE OF INVENTION: Specific Mucin Expression as a Marker
FILE REFERENCE: UNMC 63155
CURRENT APPLICATION NUMBER: US/09/733,444
CURRENT FILING DATE: 2000-12-08
NUMBER OF SEQ ID NOS: 29
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-733-444-2
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 GGCTGCCATCAAGTCATG 174
Db 20 GGCTGCCCTCAAGTCATG 2
RESULT 280
US-09-733-444-26/c
Sequence 26, Application US/09733444
Patent No. US20020150894A1
GENERAL INFORMATION:
APPLICANT: Batra, Surinder K.
APPLICANT: Brandt, Randall E.
APPLICANT: Ringel, J"erg
APPLICANT: Faulmann, Grit
APPLICANT: L"hr, Mathias
APPLICANT: Varshney, Grief C.
APPLICANT: University of Nebraska Board of Regents
TITLE OF INVENTION: Specific Mucin Expression as a Marker
FILE REFERENCE: UNMC 63155
CURRENT APPLICATION NUMBER: US/09/733,444
CURRENT FILING DATE: 2000-12-08
NUMBER OF SEQ ID NOS: 29
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 26
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-733-444-26
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 156 GGCTGCCATCAAGTCATG 174
|||
Db 20 GGCTGCCCTCAAGTCGTG 2

RESULT 281
US-09-972-607-63/c
; Sequence 63, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-63

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1124 ACCAGCTGCAGCAGCACA 1142
|||
Db 19 ACCAGCTGCAGCAGCAGTCA 1

RESULT 282
US-10-181-846-153/c
; Sequence 153, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTSP-0363
; CURRENT APPLICATION NUMBER: US/10/181,846
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-153

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2444 GTGAGAGCAGCAGAGAGA 2462
|||
Db 20 GTGAGAGCAGCAGAGAGA 2

RESULT 283
US-10-279-454-2/c
; Sequence 2, Application US/10279454
; Publication No. US20030134343A1
; GENERAL INFORMATION:
; APPLICANT: Batra, Surinder K.

; APPLICANT: Brandt, Randall E.
; APPLICANT: Ringel, J"erg
; APPLICANT: Faulmann, Grit
; APPLICANT: L"hr, Matthias
; APPLICANT: Varshney, Gish C.
; APPLICANT: University of Nebraska Board of Regents
; TITLE OF INVENTION: Specific Mucin Expression as a Marker
; FILE REFERENCE: UMC 63155
; CURRENT APPLICATION NUMBER: US/10/279,454
; PRIOR FILING DATE: 2002-10-24
; PRIOR APPLICATION NUMBER: US/09/733,444
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-279-454-2

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 156 GGCTGCCATCAAGTCATG 174
|||
Db 20 GGCTGCCCTCAAGTCGTG 2

RESULT 284
US-10-279-454-26/c
; Sequence 26, Application US/10279454
; Publication No. US20030134343A1
; GENERAL INFORMATION:
; APPLICANT: Batra, Surinder K.
; APPLICANT: Brandt, Randall E.
; APPLICANT: Ringel, J"erg
; APPLICANT: Faulmann, Grit
; APPLICANT: L"hr, Matthias
; APPLICANT: Varshney, Gish C.
; APPLICANT: University of Nebraska Board of Regents
; TITLE OF INVENTION: Specific Mucin Expression as a Marker
; FILE REFERENCE: UMC 63155
; CURRENT APPLICATION NUMBER: US/10/279,454
; PRIOR FILING DATE: 2002-10-24
; PRIOR APPLICATION NUMBER: US/09/733,444
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-279-454-26

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 156 GGCTGCCATCAAGTCATG 174
|||
Db 20 GGCTGCCCTCAAGTCGTG 2

RESULT 285
US-10-420-845-13
; Sequence 13, Application US/10420845

Publication No. US20030180885A1
GENERAL INFORMATION:
APPLICANT: PILETZ, John E.
APPLICANT: IVANOV, Tina R.
TITLE OF INVENTION: DNA MOLECULES ENCODING IMIDALINE RECEPTIVE POLYPEPTIDES
FILE REFERENCE: Corrected Sequence Listing
CURRENT APPLICATION NUMBER: US/10/420,845
PRIOR FILING DATE: 2003-04-23
PRIOR APPLICATION NUMBER: US/08/922,635A
PRIOR FILING DATE: 1997-09-03
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/650,766
PRIOR FILING DATE: EARLIER FILING DATE: 1996-05-20
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/012,600
PRIOR FILING DATE: EARLIER FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 13
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-420-845-13

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1006 GGAGAGGAAGAGAGCCAA 1024
DB 2 GGAGAGAAAGCTGAGCCAA 20

RESULT 286
US-10-093-463-245
Sequence 245, Application US/10093463
Publication No. US20030208039A1
GENERAL INFORMATION:
APPLICANT: Padigaru, Muralidhara
APPLICANT: Shenoy, Suresh
APPLICANT: Kekuda, Ramesh
APPLICANT: Gusev, Vladimír
APPLICANT: Pochart, Pascal
APPLICANT: Zhong, Mei
APPLICANT: Rastelli, Luca
APPLICANT: Mezes, Peter
APPLICANT: Smithson, Glenda
APPLICANT: Guo, Xiaojia
APPLICANT: Gerlach, Valerie
APPLICANT: Casman, Stacie
APPLICANT: Boldog, Ferenc
APPLICANT: Li, Li
APPLICANT: Zernusen, Bryan
APPLICANT: Tchernev, Velikar
APPLICANT: Gangolli, Beha
APPLICANT: Verneq, Corine
APPLICANT: Pena, Carol
APPLICANT: Burgess, Catherine
APPLICANT: Liu, Xiaohong
APPLICANT: Spytek, Kimberly
APPLICANT: Gorman, Linda
APPLICANT: Spaderna, Steven
APPLICANT: Voss, Edward
APPLICANT: Malyankar, Uriel
APPLICANT: Anderson, David
APPLICANT: Patnurajan, Meera
APPLICANT: Miller, Charles
APPLICANT: Taupier, Raymond J. Jr.
TITLE OF INVENTION: No. US20030208039A1 Antibodies that Bind to Antigenic Polypepti
FILE REFERENCE: 21402-290A (Cura 590AT)
CURRENT APPLICATION NUMBER: US/10/093,463
PRIOR FILING DATE: 2002-06-24
PRIOR APPLICATION NUMBER: 60/283,675

PRIOR FILING DATE: 2001-04-14
PRIOR APPLICATION NUMBER: 60/338,092
PRIOR FILING DATE: 2001-12-03
PRIOR APPLICATION NUMBER: 60/274,281
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/274,101
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/325,681
PRIOR FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 60/304,354
PRIOR FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: 60/279,995
PRIOR FILING DATE: 2001-03-30
PRIOR APPLICATION NUMBER: 60/294,899
PRIOR FILING DATE: 2001-05-31
PRIOR APPLICATION NUMBER: 60/287,424
PRIOR FILING DATE: 2001-04-30
PRIOR APPLICATION NUMBER: 60/299,027
PRIOR FILING DATE: 2001-06-18
PRIOR APPLICATION NUMBER: 60/309,198
PRIOR FILING DATE: 2001-07-31
PRIOR APPLICATION NUMBER: 60/281,194
PRIOR FILING DATE: 2001-04-04
PRIOR APPLICATION NUMBER: 60/274,194
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/274,849
PRIOR FILING DATE: 2001-03-09
PRIOR APPLICATION NUMBER: 60/330,380
PRIOR FILING DATE: 2001-10-18
PRIOR APPLICATION NUMBER: 60/275,235
PRIOR FILING DATE: 2001-03-12
PRIOR APPLICATION NUMBER: 60/288,342
PRIOR FILING DATE: 2001-05-03
PRIOR APPLICATION NUMBER: 60/275,578
PRIOR FILING DATE: 2001-03-13
NUMBER OF SEQ ID NOS: 370
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 245
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-093-463-245

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2480 CAGAGGGAGCAGAGTAC 2498
DB 1 CCGAGAGGAGCAGAGTAC 19

RESULT 287
US-10-093-463-248
Sequence 248, Application US/10093463
Publication No. US20030208039A1
GENERAL INFORMATION:
APPLICANT: Padigaru, Muralidhara
APPLICANT: Shenoy, Suresh
APPLICANT: Kekuda, Ramesh
APPLICANT: Gusev, Vladimír
APPLICANT: Pochart, Pascal
APPLICANT: Zhong, Mei
APPLICANT: Rastelli, Luca
APPLICANT: Mezes, Peter
APPLICANT: Smithson, Glenda
APPLICANT: Guo, Xiaojia
APPLICANT: Gerlach, Valerie
APPLICANT: Casman, Stacie
APPLICANT: Boldog, Ferenc
APPLICANT: Li, Li

APPLICANT: Zerhusen, Bryan
APPLICANT: Tchernyev, Velizar
APPLICANT: Gangolli, Basha
APPLICANT: Vernec, Corine
APPLICANT: Pena, Carol
APPLICANT: Burgess, Catherine
APPLICANT: Liu, Xiaohong
APPLICANT: Spitek, Kimberly
APPLICANT: Gorman, Linda
APPLICANT: Spaderna, Steven
APPLICANT: Voss, Edward
APPLICANT: Malyankar, Uriel
APPLICANT: Anderson, David
APPLICANT: Patnrajan, Meera
APPLICANT: Miller, Charles
APPLICANT: Taupier, Raymond J. Jr.
TITLE OF INVENTION: No. US00030208039A1 Antibodies that Bind to Antigenic Polypeptide
FILE REFERENCE: 21402-290A (Cura 590AT)
CURRENT APPLICATION NUMBER: US/10/093,463
CURRENT FILING DATE: 2002-06-24
PRIOR APPLICATION NUMBER: 60/283,675
PRIOR FILING DATE: 2001-04-14
PRIOR APPLICATION NUMBER: 60/338,092
PRIOR FILING DATE: 2001-12-03
PRIOR APPLICATION NUMBER: 60/274,281
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/274,101
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/325,681
PRIOR FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 60/304,354
PRIOR FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: 60/279,995
PRIOR FILING DATE: 2001-03-30
PRIOR APPLICATION NUMBER: 60/294,899
PRIOR FILING DATE: 2001-05-31
PRIOR APPLICATION NUMBER: 60/287,424
PRIOR FILING DATE: 2001-04-30
PRIOR APPLICATION NUMBER: 60/289,027
PRIOR FILING DATE: 2001-06-18
PRIOR APPLICATION NUMBER: 60/309,198
PRIOR FILING DATE: 2001-07-31
PRIOR APPLICATION NUMBER: 60/281,194
PRIOR FILING DATE: 2001-04-04
PRIOR APPLICATION NUMBER: 60/274,194
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/274,849
PRIOR FILING DATE: 2001-03-09
PRIOR APPLICATION NUMBER: 60/330,380
PRIOR FILING DATE: 2001-10-18
PRIOR APPLICATION NUMBER: 60/275,235
PRIOR FILING DATE: 2001-03-12
PRIOR APPLICATION NUMBER: 60/288,342
PRIOR FILING DATE: 2001-05-03
PRIOR APPLICATION NUMBER: 60/275,578
PRIOR FILING DATE: 2001-03-13
NUMBER OF SEQ ID NOS: 370
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 248
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-093-463-248

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

2480 CAGAGCGAGCAGAGATAC 2498
|||||

Db 1 CCGAGAGAGCAGAGATAC 19

RESULT 288
US-10-421-763-14
Sequence 14, Application US/10421763
Publication No. US20030224429A1
GENERAL INFORMATION:
APPLICANT: PILETZ, John E.
TITLE OF INVENTION: DNA SEQUENCE ENCODING A HUMAN IMIDAZOLINE RECEPTOR AND
FILE REFERENCE: CORRECTED SEQUENCE LISTING
CURRENT APPLICATION NUMBER: US/10/421,763
CURRENT FILING DATE: 2003-04-24
PRIOR APPLICATION NUMBER: US/08/650,766D
PRIOR FILING DATE: 1996-05-20
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/012,600
PRIOR FILING DATE: EARLIER FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 21
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 14
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-421-763-14

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1006 CGAGAGAGAGAGCCAA 1024
|||||

Db 2 GGAGAGAAAGTGAGCCAA 20

RESULT 289
US-10-173-208-18/C
Sequence 18, Application US/10173208
Publication No. US20030232435A1
GENERAL INFORMATION:
APPLICANT: KENNETH W. DOBLE
TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN PRECURSOR EXPRESSION
FILE REFERENCE: HTS-0023
CURRENT APPLICATION NUMBER: US/10/173,208
CURRENT FILING DATE: 2002-06-14
NUMBER OF SEQ ID NOS: 78
SEQ ID NO 18
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-208-18

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1463 AGCAGCTTCAGAAACGCA 1481
|||||

Db 20 AGCTGCTTCAGAAAGCA 2

RESULT 290
US-10-173-208-54
Sequence 54, Application US/10173208
Publication No. US20030232435A1
GENERAL INFORMATION:
APPLICANT: KENNETH W. DOBLE
TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN PRECURSOR EXPRESSION
FILE REFERENCE: HTS-0023
CURRENT APPLICATION NUMBER: US/10/173,208

;; CURRENT FILING DATE: 2002-06-14
;; NUMBER OF SEQ ID NOS: 78
;; SEQ ID NO 54
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Homo sapiens
;; FEATURE:
US-10-173-208-54

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1463 AGCAGCTTCAAGAACGCA 1461
DB 1 AGCTGCTCAAGAACGAGCA 19

RESULT 291
US-10-289-762-2850
; Sequence 2850, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2850
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-2850

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1598 AGCAGCAGAACTTCCTT 1616
DB 2 AGCAGCAGAACTTCCTCAT 20

RESULT 292
US-10-289-762-6476/c
; Sequence 6476, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6476
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6476

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAGCAGC 1462
DB 19 CAGCAGCAGCAACAGCAGC 1

RESULT 293
US-10-454-224-29
; Sequence 29, Application US/10454224
; Publication No. US20040010814A1
; GENERAL INFORMATION:
; APPLICANT: HERRMANN, Bernhard
; APPLICANT: KOSCHORZ, Blyt
; APPLICANT: KISPERT, Andreas
; TITLE OF INVENTION: NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATIONS
; FILE REFERENCE: 258, 0009 0101
; CURRENT APPLICATION NUMBER: US/10/454,224

;; CURRENT FILING DATE: 2003-06-04
;; PRIOR APPLICATION NUMBER: US/09/554,726A
;; PRIOR FILING DATE: 2000-05-18
;; PRIOR APPLICATION NUMBER: PCT/EP 98/07395
;; PRIOR FILING DATE: 1998-11-18
;; PRIOR APPLICATION NUMBER: EP 98 10 3596.7
;; PRIOR FILING DATE: 1998-03-02
;; PRIOR APPLICATION NUMBER: EP 97 12 0190.0
;; PRIOR FILING DATE: 1997-11-18
;; NUMBER OF SEQ ID NOS: 53
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 29
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Primer
US-10-454-224-29

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1449 GCAGCAGCAGCAGCAGCAG 1467
DB 2 GCAGCAGCAGCAGCAGCAG 20

RESULT 294
US-10-199-199-70/c
; Sequence 70, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowse
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-199-70

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1126 CAGCTGACGACGACGACG 1144
DB 19 CGCTGACGACGACGCTGC 1

RESULT 295
US-10-199-199-135
; Sequence 135, Application US/10199199

Publication No. US20040014047A1
GENERAL INFORMATION:
APPLICANT: Lex M. Cowbert
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
FILE REFERENCE: RTS-0375
CURRENT APPLICATION NUMBER: US/10/199,199
CURRENT FILING DATE: 2002-07-18
NUMBER OF SEQ ID NOS: 148
SEQ ID NO 135
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-199-199-135

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 20;
Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1126 CAGCTGCAGCAGCAGCAGC 1144
DB 2 CGGCTGCAGCAGCAGCTGC 20

RESULT 296
US-10-628-841-63/c
Sequence 63, Application US/10628841
Publication No. US20040023918A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/10/628, 841
CURRENT FILING DATE: 2003-07-28
PRIOR APPLICATION NUMBER: US/09/972,607
PRIOR FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 63
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-63

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 20;
Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1124 AGCAGCTGCAGCAGCAGCA 1142
DB 19 AGCAGCTGCAGCAGCTGCA 1

RESULT 297
US-10-344-339B-35/c
Sequence 35, Application US/10344339B
Publication No. US20040082506A1
GENERAL INFORMATION:
APPLICANT: KIRIN BEER KAMUSHIKI KAISHA
TITLE OF INVENTION: DNA encoding a polypeptide regulating phosphate metabolism,
FILE REFERENCE: PH-1268PCT
CURRENT APPLICATION NUMBER: US/10/344,339B
CURRENT FILING DATE: 2003-10-03
PRIOR APPLICATION NUMBER: JP2000-245144
PRIOR FILING DATE: 2000-08-11
PRIOR APPLICATION NUMBER: JP2000-287864
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: JP2000-391027
PRIOR FILING DATE: 2000-12-22

PRIOR APPLICATION NUMBER: JP2001-121527
PRIOR FILING DATE: 2001-04-19
NUMBER OF SEQ ID NOS: 87
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 35
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
US-10-344-339B-35

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 20;
Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2208 TCACGGGCACTCCCCAG 2226
DB 19 TCCCGGGCACCTCCCCAG 1

RESULT 298
US-10-648-593-331/c
Sequence 331, Application US/10648593
Publication No. US20040106132A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: IDENTIFICATION OF GENES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT
INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR
TITLE OF INVENTION: PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS
FILE REFERENCE: D0273 NP
CURRENT APPLICATION NUMBER: US/10/648,593
CURRENT FILING DATE: 2003-08-26
PRIOR APPLICATION NUMBER: 60/406,385
PRIOR FILING DATE: 2002-08-27
NUMBER OF SEQ ID NOS: 557
SOFTWARE: PatentIn version 3.2
SEQ ID NO 331
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-648-593-331

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 20;
Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 GTGATCCCAACCAACCC 2953
DB 20 GTGATCCCAACCAACCC 2

RESULT 299
US-10-635-145-5
Sequence 5, Application US/10635145
Publication No. US20040142440A1
GENERAL INFORMATION:
APPLICANT: Hopkine, Nancy H.
APPLICANT: Amsterdam, Adam H.
TITLE OF INVENTION: SERP TRANSPORT RNA SYNTHETASE
TITLE OF INVENTION: POLYNUCLEOTIDES AND PEPTIDES AND METHODS OF USE THEREOF
FILE REFERENCE: 0050.2049-001
CURRENT APPLICATION NUMBER: US/10/635,145
CURRENT FILING DATE: 2003-08-06
PRIOR APPLICATION NUMBER: US 60/401,556
PRIOR FILING DATE: 2002-08-06
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 5
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Primer sequence
US-10-635-145-5

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3417 TGGCAGCTCCGCCACCGC 3435
DB 2 TCCTGACCAACCCACCGC 20

RESULT 300

US-10-418-780-27/c
Sequence 27, Application US/10418780
Publication No. US20040208856A1
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
FILE REFERENCE: BIO00004US
CURRENT APPLICATION NUMBER: US/10/418,780
CURRENT FILING DATE: 2003-04-16
NUMBER OF SEQ ID NOS: 221
SEQ ID NO 27
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-418-780-27

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1403 AGAGGAGCTGCAGCAGA 1421
DB 20 AGAGGAGCTGCCTCCAGCA 2

RESULT 301

US-10-418-780-124
Sequence 124, Application US/10418780
Publication No. US20040208856A1
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
FILE REFERENCE: BIO00004US
CURRENT APPLICATION NUMBER: US/10/418,780
CURRENT FILING DATE: 2003-04-16
NUMBER OF SEQ ID NOS: 221
SEQ ID NO 124
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-418-780-124

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1403 AGAGGAGCTGCAGCAGA 1421
DB 1 AGAGGAGCTGCCTCCAGCA 19

RESULT 302

US-10-487-176-6
Sequence 6, Application US/10487176
Publication No. US20040235096A1
GENERAL INFORMATION:
APPLICANT: PERLMANN, Thomas
APPLICANT: BERTRAND, Joseph
TITLE OF INVENTION: METHOD FOR REGULATING DOPAMINE PRODUCING CELLS
FILE REFERENCE: LUD 5781.1 PCT (10310371)
CURRENT APPLICATION NUMBER: US/10/487,176
CURRENT FILING DATE: 2004-02-17
PRIORITY FILING DATE: 2003-08-26
NUMBER OF SEQ ID NOS: 10
SEQ ID NO 6
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide probe
US-10-487-176-6

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 189 CGAGAGGAGAGATCAAA 207
DB 2 CGAGAGGAGAGATGTCAA 20

RESULT 303

US-10-672-866-201/c
Sequence 201, Application US/10672866
Publication No. US20050019915A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Kenneth Doble
TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
TITLE OF INVENTION: SOLUBLE
FILE REFERENCE: RTS-0242
CURRENT APPLICATION NUMBER: US/10/672,866
CURRENT FILING DATE: 2003-09-26
PRIORITY FILING DATE: 2003-08-04
PRIORITY FILING DATE: 2003-08-04
PRIORITY FILING DATE: 2001-06-21
NUMBER OF SEQ ID NOS: 339
SEQ ID NO 201
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-201

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2537 GCACCATGGTGTCCAGCA 2555
DB 19 GTACTATGGTGTCCAGCA 1

RESULT 304

US-10-730-771-348/c
Sequence 348, Application US/10730771
Publication No. US20050074787A1
GENERAL INFORMATION:
APPLICANT: Fan, Jian-Bing
APPLICANT: Hirschhorn, Joel N.

APPLICANT: Huang, Xiaohua
APPLICANT: Kaplan, Paul
APPLICANT: Lander, Eric S.
APPLICANT: Lockhart, David J.
APPLICANT: Ryder, Thomas
APPLICANT: Sklar, Pamela
TITLE OF INVENTION: UNIVERSAL ARRAYS
FILE REFERENCE: 2825.1016-007
CURRENT APPLICATION NUMBER: US/10/730,771
CURRENT FILING DATE: 2003-12-08
PRIOR APPLICATION NUMBER: US 60/126,473
PRIOR FILING DATE: 1999-03-26
PRIOR APPLICATION NUMBER: US 60/140,359
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: US 09/536,841
PRIOR FILING DATE: 2000-03-27
NUMBER OF SEQ ID NOS: 590
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 348
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Template sequence
US-10-730-771-348

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 991 GAAGATGACGACGATGAG 1009
DB 19 GAAGATGACGACGAG 1

RESULT 305
US-10-889-447-49/C
Sequence 49, Application US/10889447
Publication No. US2005075307A1
GENERAL INFORMATION:
APPLICANT: Bennett, C. Frank
APPLICANT: Jain, Ravi
TITLE OF INVENTION: MODULATION OF AMINOPEPTIDASE N EXPRESSION
FILE REFERENCE: RTS-0685US
CURRENT APPLICATION NUMBER: US/10/889,447
CURRENT FILING DATE: 2004-07-12
PRIOR APPLICATION NUMBER: 60/486,670
PRIOR FILING DATE: 2003-07-12
NUMBER OF SEQ ID NOS: 241
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 49
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Compound
US-10-889-447-49

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCA 1136
DB 19 AGCTGCAGCAGCTGCAGCA 1

RESULT 306
US-10-889-447-155
Sequence 155, Application US/10889447
Publication No. US20050075307A1
GENERAL INFORMATION:
APPLICANT: Bennett, C. Frank

APPLICANT: Jain, Ravi
TITLE OF INVENTION: MODULATION OF AMINOPEPTIDASE N EXPRESSION
FILE REFERENCE: RTS-0685US
CURRENT APPLICATION NUMBER: US/10/889,447
CURRENT FILING DATE: 2004-07-12
PRIOR APPLICATION NUMBER: 60/486,670
PRIOR FILING DATE: 2003-07-12
NUMBER OF SEQ ID NOS: 241
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 155
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
US-10-889-447-155

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCA 1136
DB 2 AGCTGCAGCAGCTGCAGCA 20

RESULT 307
US-10-947-444-13
Sequence 13, Application US/10947444
Publication No. US20050084911A1
GENERAL INFORMATION:
APPLICANT: Piletz, John E.
APPLICANT: IVANOV, Tina R.
TITLE OF INVENTION: DNA MOLECULES ENCODING IMIDALINE RECEPTIVE POLYPEPTIDES
FILE REFERENCE: Corrected Sequence Listing
CURRENT APPLICATION NUMBER: US/10/947,444
CURRENT FILING DATE: 2004-09-23
PRIOR APPLICATION NUMBER: US/08/922,635
PRIOR FILING DATE: 1999-05-07
PRIOR APPLICATION NUMBER: 08/550,766
PRIOR FILING DATE: 1996-05-20
PRIOR APPLICATION NUMBER: 60/012,600
PRIOR FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 13
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-947-444-13

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1006 GGAGAGAGAGAGCCAA 1024
DB 2 GGAGAGAGAGAGCCAA 20

RESULT 308
US-09-735-995-93
Sequence 93, Application US/09735995
Patent No. US20010034024A1
GENERAL INFORMATION:
APPLICANT: Keating, Mark T.
APPLICANT: Splawski, Igor
TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
FILE REFERENCE: 2323-136
CURRENT APPLICATION NUMBER: US/09/735,995
CURRENT FILING DATE: 2000-12-14
PRIOR APPLICATION NUMBER: 09/226,012
PRIOR FILING DATE: 1999-01-06

NUMBER OF SEQ ID NOS: 116
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 93
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens
US-09-735-995-93

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3252 GAAGAGCAGGCGCTGAC 3270
DB 1 GAGGAGCAGGCGCTGAGC 19

RESULT 309
US-09-765-081-248
Sequence 248, Application US/09765081
Patent No. US20020037508A1
GENERAL INFORMATION:
APPLICANT: Cargill, Michele
APPLICANT: Ireland, James S.
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
FILE REFERENCE: 2825.2008-001
CURRENT APPLICATION NUMBER: US/09/765,081
CURRENT FILING DATE: 2001-01-18
PRIOR APPLICATION NUMBER: US 60/176,861
PRIOR FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 461
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 248
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens
US-09-765-081-248

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2091 CCCAAGCCTCCAGGCCCC 2111
DB 1 CCCAGGCCCMCGGCCCC 21

RESULT 310
US-09-765-081-360
Sequence 360, Application US/09765081
Patent No. US20020037508A1
GENERAL INFORMATION:
APPLICANT: Cargill, Michele
APPLICANT: Ireland, James S.
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
FILE REFERENCE: 2825.2008-001
CURRENT APPLICATION NUMBER: US/09/765,081
CURRENT FILING DATE: 2001-01-18
PRIOR APPLICATION NUMBER: US 60/176,861
PRIOR FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 461
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 360
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens
US-09-765-081-360

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 586 TGGATGCTCCAGAGTCATC 606
DB 1 TGGACAGCTCYAGAGCCATC 21

RESULT 311
US-09-828-034-9/c
Sequence 9, Application US/09828034
Patent No. US20020064771A1
GENERAL INFORMATION:
APPLICANT: Zhong, Weidong
APPLICANT: Hong, Zhi
TITLE OF INVENTION: HCV REPLICASE COMPLEXES
FILE REFERENCE: IN01165
CURRENT APPLICATION NUMBER: US/09/828,034
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: U.S. 60/195,852
PRIOR FILING DATE: 2000-04-06
NUMBER OF SEQ ID NOS: 33
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 9
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic RNA
US-09-828-034-9

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGAGCAGAGAGAGAG 201
DB 21 GAGGAGAGAGAGAGAGAG 3

RESULT 312
US-10-005-956-473/c
Sequence 473, Application US/10005956
Publication No. US20030113726A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
FILE REFERENCE: D0053NP
CURRENT APPLICATION NUMBER: US/10/005,956
CURRENT FILING DATE: 2001-12-03
PRIOR APPLICATION NUMBER: 60/251,015
PRIOR FILING DATE: 2000-12-04
PRIOR APPLICATION NUMBER: 60/263,678
PRIOR FILING DATE: 2001-01-23
PRIOR APPLICATION NUMBER: 60/273,037
PRIOR FILING DATE: 2001-03-02
NUMBER OF SEQ ID NOS: 1579
SOFTWARE: Patentin version 3.0
SEQ ID NO 473
LENGTH: 21
TYPE: DNA
ORGANISM: homo sapiens
US-10-005-956-473

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 863 TTCCTTCATCCGGAGCA 881
DB 20 TTCCTTCATCTGAACCA 2

RESULT 313

```
US-10-696-708-93
; Sequence 93, Application US/10696708
; Publication No. US20040078833A1
; GENERAL INFORMATION:
; APPLICANT: Keating, Mark T.
; TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
; FILE REFERENCE: 2323-164
; CURRENT APPLICATION NUMBER: US/10/696,708
; PRIOR FILING DATE: 2003-10-30
; PRIOR APPLICATION NUMBER: US 09/735,995
; PRIOR FILING DATE: 2000-12-14
; PRIOR APPLICATION NUMBER: US 09/226,012
; PRIOR FILING DATE: 1999-01-06
; PRIOR APPLICATION NUMBER: 09/122,847
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 93
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-696-708-93

Query Match
Best Local Similarity 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3252 GAAGAAGCAGGCTGAGCC 3270
DB 1 GAGGAAGCAGGCTGAGGC 19

RESULT 314
US-10-383-864-14
; Sequence 14, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-14

Query Match
Best Local Similarity 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1200 AGAGGAGCAGAGAGAGAG 1218
DB 1 AGAGGAGCAGAGAGAGAG 19

RESULT 315
US-10-786-720-11948
; Sequence 11948, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
US-10-786-720-11948
```

```
APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 2135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11948
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-11948

Query Match
Best Local Similarity 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1461 GCAGCAGCTTCAGAAACAG 1479
DB 1 GCACAGCTTCAGAAAGAG 19

RESULT 316
US-10-786-720-12250
; Sequence 12250, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12250
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-12250

Query Match
Best Local Similarity 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1462 CAGCAGCTTCAGAAACAGC 1480
DB 1 CAGCAGCTTCAGAAAGGC 19

RESULT 317
US-10-786-720-12566
; Sequence 12566, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12566
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-12566
```

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1460 AGCAGCAGCTTCAGAAACA 1478
DB 1 AGCAGCAGCTTCAGAAAGA 19

RESULT 318

US-10-786-720-12567/C
; Sequence 12567, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12567
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-12567

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1460 AGCAGCAGCTTCAGAAACA 1478
DB 19 AGCAGCAGCTTCAGAAAGA 1

RESULT 319

US-10-786-720-20813
; Sequence 20813, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20813
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-20813

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 3660 CACGTACGGGGGATCAT 3678
DB 2 CACGTACGGGGGATCAU 20

RESULT 320

US-10-751-736-616
; Sequence 616, Application US/10751736

; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 616
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-616

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 586 TGGATGGCTCCAGAGTCA 604
DB 3 TGGATGGCTCCAGAGTTA 21

RESULT 321

US-10-751-736-1045
; Sequence 1045, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1045
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-1045

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 588 GATGGCTCCAGAGTCA 606
DB 1 GATGGCTCCAGAGTTATC 19

RESULT 322

US-10-751-736-9103/C
; Sequence 9103, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9103
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9103
```

```
Query Match          0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      155 TGGCTGCATCATGTCAT 173
DB      20 TGGATCCATCAATGTCAT 2
```

```
RESULT 323
US-10-751-736-19139/c
; Sequence 19139, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19139
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-19139
```

```
Query Match          0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1472 AGAAGACGACGACGACGA 1490
DB      19 AGTAACAGCAGCAGCAACA 1
```

```
RESULT 324
US-10-751-736-34602/c
; Sequence 34602, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34602
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-34602
```

```
Query Match          0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1269 GCAGAGAAAGACGACGACG 1287
DB      21 GCAGAGAAAGAGTAGAG 3
```

```
RESULT 325
US-10-751-736-37757
; Sequence 37757, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37757
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-37757
```

```
Query Match          0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1464 GCAGCTTCAGAAACGACG 1482
DB      1 GGAGCTCCAGAAACGACG 19
```

```
RESULT 326
US-10-751-736-37864
; Sequence 37864, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37864
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-37864
```

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1463 AGCAGCTTCAGAAACGCA 1481
DB 3 AGCAGCTTCAGAAACGCA 21

RESULT 327
US-10-751-736-37865
; Sequence 37865, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37865
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-37865

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1463 AGCAGCTTCAGAAACGCA 1481
DB 1 AGCAGCTTCAGAAACGCA 19

RESULT 328
US-10-751-736-38419
; Sequence 38419, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38419
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-38419

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1462 CAGCAGCTTCAGAAACGAGC 1480
DB 1 CAGCAGCTTCAGAAACGAGC 19

RESULT 329
US-10-751-736-42538
; Sequence 42538, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42538
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-42538

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1003 CATGAGAGAGAGAGAGAGC 1021
DB 1 CATGAGAGAGAGAGAGAGC 19

RESULT 330
US-10-751-736-49798
; Sequence 49798, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49798
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-49798

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1120 CAGCAGCAGCTGAGAGC 1138
DB 1 CAGCAGCAGCTGAGAGC 19

RESULT 331
US-10-011-993-35/c
; Sequence 35, Application US/10011993
; Publication No. US20030119004A1
; GENERAL INFORMATION:

APPLICANT: WENZ, H. MICHAEL
APPLICANT: SCHROTH, GARY P.
APPLICANT: CHEN, CAIFU
TITLE OF INVENTION: METHODS FOR QUANTITATING NUCLEIC ACIDS USING COUPLED
FILE REFERENCE: 07414.0030-00000
CURRENT APPLICATION NUMBER: US/10/011,993
CURRENT FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: PCT/US01/17329
PRIOR FILING DATE: 2001-05-30
PRIOR APPLICATION NUMBER: 09/724,755
PRIOR FILING DATE: 2000-11-28
PRIOR APPLICATION NUMBER: 09/584,905
PRIOR FILING DATE: 2000-05-30
NUMBER OF SEQ ID NOS: 37
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 35
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Illustrative
FEATURE:
OTHER INFORMATION: oligonucleotide
US-10-011-993-35
Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 3.9e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1117 CAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB 30 CTGCTGCTGCTGCTGCTGCTGCTGCTG 1
RESULT 332
US-10-357-322-4/C
Sequence 4, Application US/10357322
Publication No. US20030180768A1
GENERAL INFORMATION:
APPLICANT: Rannum et al.
TITLE OF INVENTION: SCAY GENE AND METHODS OF USE
FILE REFERENCE: Regents of the University of Minnesota
CURRENT APPLICATION NUMBER: US/10/357,322
CURRENT FILING DATE: 2003-02-03
PRIOR APPLICATION NUMBER: US/09/684,843
PRIOR FILING DATE: 2000-10-06
PRIOR APPLICATION NUMBER: 60/056,170
PRIOR FILING DATE: 1997-08-19
PRIOR APPLICATION NUMBER: 09/135,994
PRIOR FILING DATE: 1998-08-18
NUMBER OF SEQ ID NOS: 14
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 4
LENGTH: 30
TYPE: DNA
ORGANISM: Homo sapiens
US-10-357-322-4

Query Match 0.4%; Score 15.6; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 3.9e+02;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
QY 1117 CAGCAGCAGCTGCAGCAGCAGCAGCAG 1146
DB 30 CTGCTGCTGCTGCTGCTGCTGCTGCTG 1
RESULT 333
US-09-866-108-7802
Sequence 7802, Application US/09866108
Patent No. US20020048800A1

GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: A60MICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 7802
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7802

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1120 CAGCAGCAGCTGCAGCA 1136
DB 1 CAGCAGCAGCTGCAGCA 17

RESULT 334
US-09-780-533A-766
Sequence 766, Application US/09780533A
Publication No. US20030060611A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwigen, Jim
APPLICANT: Chowrira, Bharat
APPLICANT: Haeblerli, Pete
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
FILE REFERENCE: MBH00, 878-A (400/011)
CURRENT APPLICATION NUMBER: US/09/780,533A
CURRENT FILING DATE: 2001-02-09

```

; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 766
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-766

Query Match
Best Local Similarity 88.2%; Score 15.4; DB 1; Length 17;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1119 GCAGCAGCAGCTGCAGC 1135
DB 1 GCGCAGCAGCAGCTGCAGC 17

RESULT 335
US-09-780-533A-767
; Sequence 767, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: MCSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 767
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-767

Query Match
Best Local Similarity 88.2%; Score 15.4; DB 1; Length 17;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1122 GCAGCAGCTGCAGCAGC 1138
DB 1 GCAGCAGCTGCAGCAGC 17

RESULT 336
US-09-780-533A-1549
; Sequence 1549, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: MCSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1549
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo sapiens
US-09-780-533A-1549

Query Match
Best Local Similarity 88.2%; Score 15.4; DB 1; Length 17;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1123 CAGCAGCTGCAGCAGCA 1139
DB 1 CAGCAGCTGCAGCAGCA 17

RESULT 337
US-09-780-533A-1554
; Sequence 1554, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: MCSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1554
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1554

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 182 CCGAGAGCAGGAGGANA 198
DB 1 CCGAGAGCAGGAGGANA 17

RESULT 338
US-09-780-533A-1792
; Sequence 1792, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: MCSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1792
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1792

Query Match
Best Local Similarity 88.2%; Score 15.4; DB 1; Length 17;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```



```
QY      1120 CAGCAGCAGCTGCAGCA 1136
          | |||||:|||||
Db      1   CGGCAGCAGCTGCAGCA 17
```

```

RESULT 339
US-09-780-533A-2370
; Sequence 2370, Application US/09780533A
; Publication No. US20030060611A1
GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCOO Gene
; FILE REFERENCE: MBH900.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780.533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181.797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2370
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-2370

```

Query Match	0.4%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	94.1%;	Pred. No. 2.2e+02;		
Matches 16;	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

```

QY      184 GAGGACGAGGAGGAAGA 200
          |||||
Db      1 GAGGACGAGGAGCAAGA 17

```

```

RESULT 340
US-09-792-818-608
; Sequence 608, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MHHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 608
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-608

```

Query Match	0.4%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	88.2%	Pred. No. 2.2e+02;		
Matches	15;	Conservative	1;	Mismatches 1; Indels 0; Gaps 0;

```

QY      1129 CTGACGACGACGACGA 1145
          ||:||||||| |||||
Db      1 CUGCAGCAGCACCGACA 17

```

RESULT 341
US-10-061-201-221/c

```

Sequence 221, Application US/10061201
Publication No. US20030166229A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
FILE REFERENCE: P01718
CURRENT APPLICATION NUMBER: US/10/061,201
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 221
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-221

```

Query Match	0.4%	Score 15.4	DB 1	Length 17
Best Local Similarity	94.1%	Pred. No. 2.2e+02		
Matches 16; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

```

QY      1369 CAGCTGGAGGAGCAGCG 1385
          ||| ||||| |||||
Db      17 CACCTGGAGGAGCAGCG 1

```

```

RESULT 342
US-10-138-674-4506
: Sequence 4506, Application US/10138674
: Publication No. US20040077565A1
: GENERAL INFORMATION:
: APPLICANT: Ribozyme Pharmaceuticals, Inc.
: APPLICANT: Pavco, Pam
: APPLICANT: McSwigen, Jim
: APPLICANT: Stinchcomb, Dan
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
: TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
: FILE REFERENCE: MBH00-876-N (400/049)
: CURRENT APPLICATION NUMBER: US/10/138,674
: CURRENT FILING DATE: 2002-05-03
: NUMBER OF SEQ ID NOS: 20822
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 4506
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Homo sapiens
US-10-138-674-4506

```

Query Match	0.4%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	76.5%	Pred. No. 2.2e+02;		
Matches 13;	Conservative 3;	Mismatches 1;	Indels 0;	Gaps 0;

2641 CTGCATGCTGACAGCAA 2657

US-09-933-638A-9

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACGCA 1460
DB 1 CAGCAGCAGCAACGCA 17

RESULT 347
US-09-933-638A-10/c
; Sequence 10, Application US/09933638A
; Patent No. US20020160952A1
; GENERAL INFORMATION:
; APPLICANT: Kazantsev, Aleksey G.
; APPLICANT: Thompson, Leslie M.
; APPLICANT: Housman, David E.
; TITLE OF INVENTION: INHIBITION OF PROTEIN-PROTEIN INTERACTION
; FILE REFERENCE: 01997-289001
; CURRENT APPLICATION NUMBER: US/09/933,638A
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: US 60/226,502
; PRIOR FILING DATE: 2000-08-18
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated primer

US-09-933-638A-10
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAGCAACGCA 1463
DB 18 CAGCAGCAGCAACGCA 2

RESULT 348
US-10-194-584-1
; Sequence 1, Application US/10194584
; Publication No. US20030027288A1
; GENERAL INFORMATION:
; APPLICANT: Housman, David E.
; APPLICANT: Preisinger, Elizabeth A.
; APPLICANT: Kazantsev, Aleksey G.
; TITLE OF INVENTION: METHODS OF SCREENING FOR AGENTS WHICH INHIBIT AGGREGATION
; FILE REFERENCE: 01997-261002
; CURRENT APPLICATION NUMBER: US/10/194,584
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 09/405,048
; PRIOR FILING DATE: 1999-09-27
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated primer
US-10-194-584-1

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACGCA 1460
DB 1 CAGCAGCAGCAACGCA 17

RESULT 349
US-10-194-584-2/c
; Sequence 2, Application US/10194584
; Publication No. US20030027288A1
; GENERAL INFORMATION:
; APPLICANT: Housman, David E.
; APPLICANT: Preisinger, Elizabeth A.
; APPLICANT: Kazantsev, Aleksey G.
; TITLE OF INVENTION: METHODS OF SCREENING FOR AGENTS WHICH INHIBIT AGGREGATION
; FILE REFERENCE: 01997-261002
; CURRENT APPLICATION NUMBER: US/10/194,584
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 09/405,048
; PRIOR FILING DATE: 1999-09-27
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated primer
US-10-194-584-2

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1447 CAGCAGCAGCAACGCA 1463
DB 18 CAGCAGCAGCAACGCA 2

RESULT 350
US-10-327-805-30
; Sequence 30, Application US/10327805
; Publication No. US20030144241A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowart
; TITLE OF INVENTION: ANTISENSE MODULATION OF SWA6 EXPRESSION
; FILE REFERENCE: RTS-0045
; CURRENT APPLICATION NUMBER: US/10/327,805
; PRIOR FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US/09/679,298
; PRIOR FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 30
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-327-805-30

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1128 GCTGACGACGACGAC 1144
DB 1 GCTGACGACGACGAC 17

RESULT 351
US-10-169-983-27/c
; Sequence 27, Application US/10169983

```
; Publication No. US20030158250A1
; GENERAL INFORMATION:
; APPLICANT: Takara Shuzo Co., Ltd.
; TITLE OF INVENTION: Therapeutic agents
; FILE REFERENCE: 01-011-PCT
; CURRENT APPLICATION NUMBER: US/10/169,983
; CURRENT FILING DATE: 2002-07-14
; PRIOR APPLICATION NUMBER: JP 2000-4989
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: JP 2000-303711
; PRIOR FILING DATE: 2000-10-03
; NUMBER OF SEQ ID NOS: 61
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Designed primer based on nucleotide sequence of
; US-10-169-983-27
; OTHER INFORMATION: human macrophage inflammatory protein-2-alpha mRNA.
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1270 CAGGAGACGAGCAGCA 1286
Db 17 CAGGAGCAGGACGACGA 1
```

```
RESULT 352
US-10-380-002-13
; Sequence 13, Application US/10380002
; Publication No. US20050031631A1
; GENERAL INFORMATION:
; APPLICANT: Consiglio Nazionale delle Ricerche
; TITLE OF INVENTION: ne-ITPS allergen variants, uses thereof and compositions comprising
; FILE REFERENCE: BX157SR
; CURRENT APPLICATION NUMBER: US/10/380,002
; CURRENT FILING DATE: 2001-09-11
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (10)..(77)
; OTHER INFORMATION: Sequence mapping from nucleotide 88 to nucleotide 105 of Par1.01
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: Residue mutated with respect to the corresponding position in Par
; OTHER INFORMATION: j1.0102
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: Residue mutated with respect to the corresponding position in Par
; OTHER INFORMATION: j1.0102
US-10-380-002-13
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 18;
```

```
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1278 GGAGCAGCAGCGCGGC 1294
Db 2 GGAGCAGCAGCGCGGCC 18
```

```
RESULT 353
US-10-269-557-26/c
; Sequence 26, Application US/10269557
; Publication No. US20030099664A1
; GENERAL INFORMATION:
; APPLICANT: Wisniewski, Jan
; TITLE OF INVENTION: HEAT SHOCK GENES AND PROTEINS FROM
; TITLE OF INVENTION: NEISSERIA MENINGITIDIS, CANDIDA GLABRATA AND ASPERGILLUS
; FILE REFERENCE: PUMIGATUS
; CURRENT APPLICATION NUMBER: US/10/269,557
; CURRENT FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US/09/207,388
; PRIOR FILING DATE: 1998-12-08
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer used to clone Neisseria meningitidis Hsp70
; OTHER INFORMATION: gene and to construct Neisseria meningitidis Hsp70
; OTHER INFORMATION: expression vectors
US-10-269-557-26
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2979 CCGAAGTACAGAGAC 2995
Db 18 CCGAAGTACAGAGAGC 2
```

```
RESULT 354
US-10-349-143-5480/c
; Sequence 5480, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5480
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-4541 for SEQ 1546,
US-10-349-143-5480
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1568 GAGAGTACAGAGACGA 1584
|||||
```

Db 19 GAGAGCTAGAGAGAGA 3

RESULT 355

US-10-444-925-197

Sequence 197, Application US/10444925

Publication No. US2004000946A1

GENERAL INFORMATION:

APPLICANT: Lewis, Stephen Patrick

APPLICANT: Klinghoffer, Richard

APPLICANT: Wilson, Linda K.

TITLE OF INVENTION: MODULATION OF PTPLB SIGNAL TRANSDUCTION

FILE REFERENCE: 200125.441

CURRENT APPLICATION NUMBER: US/10/444,925

CURRENT FILING DATE: 2003-05-23

NUMBER OF SEQ ID NOS: 599

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 197

LENGTH: 19

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Small Interfering RNA

US-10-444-925-197

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 2.5e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1275 GAAGAGCAGCAGCGC 1291

Db 2 GAGGAGCAGCAGCGC 18

RESULT 356

US-09-923-517-28

Sequence 28, Application US/09923517

Publication No. US20020039741A1

GENERAL INFORMATION:

APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J. Miraglia; Brenda F. Baker

TITLE OF INVENTION: Antisense Oligonucleotide

Compositions and Methods for the Modulation of Activating Protein 1

NUMBER OF SEQUENCES: 139

CORRESPONDENCE ADDRESS:

ADDRESSEE: Law Offices of Jane Massey Licata

STREET: 66 East Main Street

CITY: Marlton

STATE: NJ

COUNTRY: USA

ZIP: 08053

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE

COMPUTER: IBM PS/2

OPERATING SYSTEM: WINDOWS 95

SOFTWARE: WORDPERFECT 6.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/923,517

FILING DATE: 07-Aug-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/364,416

FILING DATE: 1999-07-30

ATTORNEY/AGENT INFORMATION:

NAME: Jane Massey Licata

REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0209

TELECOMMUNICATION INFORMATION:

TELEPHONE: (609) 810-1515

TELEFAX: (609) 810-1454

INFORMATION FOR SEQ ID NO: 28:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

ANTI-SENSE: Yes

SEQUENCE DESCRIPTION: SEQ ID NO: 28;

US-09-923-517-28

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 CGGCCAGGCTCAGTC 770

Db 2 CTCGCCAGGCTCAGTC 18

RESULT 357

US-09-822-722-3

Sequence 3, Application US/09822722

Patent No. US20020114772A1

GENERAL INFORMATION:

APPLICANT: Kishimoto, Jiro

APPLICANT: Morgan, Bruce A.

APPLICANT: Burgess, Robert

TITLE OF INVENTION: METHODS OF MODULATING HAIR GROWTH

FILE REFERENCE: 10287-058001

CURRENT APPLICATION NUMBER: US/09/822,722

CURRENT FILING DATE: 2001-03-20

PRIOR APPLICATION NUMBER: 60/261,690

PRIOR FILING DATE: 2001-01-12

PRIOR APPLICATION NUMBER: 60/193,771

PRIOR FILING DATE: 2000-03-31

NUMBER OF SEQ ID NOS: 24

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 3

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Primer for PCR

US-09-822-722-3

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1400 TCCAGAGCAGGTCAG 1416

Db 4 TCCAGAGCAGGTCAG 20

RESULT 358

US-09-934-138B-3

Sequence 3, Application US/09934138B

Publication No. US20030039977A1

GENERAL INFORMATION:

APPLICANT: Cook, Phillip D.

APPLICANT: Manoharan, Muthiah

TITLE OF INVENTION: Carbanamide-Derivatized Nucleosides And Oligonucleosides

FILE REFERENCE: ISIS-4802

CURRENT APPLICATION NUMBER: US/09/934,138B

CURRENT FILING DATE: 2002-06-25

NUMBER OF SEQ ID NOS: 8

SOFTWARE: PatentIn version 3.1

SEQ ID NO 3

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Synthetic Oligonucleotide Sequence

US-09-934-138B-3

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCGAGCCTCC 1672
DB 3 CATCCCCGAGCAGCC 19

RESULT 359

US-09-919-197-33/C
; Sequence 33, Application US/09919197
; Publication No. US20030083484A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHORT HETERODIMER PARTNER-1 EXPRESSION
; FILE REFERENCE: ISPH-0553
; CURRENT APPLICATION NUMBER: US/09/919,197
; CURRENT FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-919-197-33

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1406 GGCAGCTGCAGCAGAG 1422
DB 18 GGCAGCTGCAGCAGAG 2

RESULT 360

US-09-953-318-45/C
; Sequence 45, Application US/09953318
; Publication No. US20030105036A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPT
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-45

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2641 CTGCATCTGACGAGCA 2657
DB 20 CTGCATCTGACGAGCA 4

RESULT 361
US-10-371-474-35
; Sequence 35, Application US/10371474

Publication No. US20030144242A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: William Gaarde
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEK4 EXPRESSION
; FILE REFERENCE: RTS-0169
; CURRENT APPLICATION NUMBER: US/10/371,474
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US/09/676,436
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-371-474-35

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3927 CTGCATCATGAAGTGT 3943
DB 3 CTGCATCATGAAGTGT 19

RESULT 362

US-10-430-196-28
; Sequence 28, Application US/10430196
; Publication No. US20030194738A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean, Robert A. McKay, Loren J.
; APPLICANT: Miraglia, Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; TITLE OF INVENTION: Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/430,196
; FILING DATE: 05-May-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517A
; FILING DATE: 07-Aug-2001
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid

```
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-10-430-196-28
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      754 CCGCCGAGGCTCAAGTC 770
Db      2 CCGCCGAGGCTCAAGTC 18

RESULT 363
US-10-446-373-45/c
; Sequence 45; Application US/10446373
; Publication No. US20030204076A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/10/446,373
; PRIOR FILING DATE: 2003-05-28
; PRIOR APPLICATION NUMBER: US/09/953,318
; PRIOR FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-446-373-45
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2641 CTGCATGCTGACAGCAA 2657
Db      20 CTGCATGCTGACAGCAA 4

RESULT 364
US-10-115-482-72
; Sequence 72; Application US/10115482
; Publication No. US20030212257A1
; GENERAL INFORMATION:
; APPLICANT: Spylek, et al.
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM
; TITLE OF INVENTION: AND METHODS
; FILE REFERENCE: 21404-322D
; CURRENT APPLICATION NUMBER: US/10/115,482
; PRIOR FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 60/281,086
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: 60/281,136
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: 60/281,863
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/281,906
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/282,934
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: 60/283,512
; PRIOR FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: 60/285,325
; PRIOR FILING DATE: 2001-04-19
```

```
; PRIOR APPLICATION NUMBER: 60/285,890
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: 60/286,068
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: 60/286,292
; PRIOR FILING DATE: 2001-04-25
; PRIOR APPLICATION NUMBER: 60/287,213
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: 60/288,257
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/291,134
; PRIOR FILING DATE: 2001-05-15
; PRIOR APPLICATION NUMBER: 60/282,020
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 60/291,725
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/294,771
; PRIOR FILING DATE: 2001-05-31
; PRIOR APPLICATION NUMBER: 60/296,965
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: 60/299,128
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 149
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
US-10-115-482-72
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1084 CAGGAATATGAGACAA 1100
Db      4 CAGGAATATGAGACAA 20

RESULT 365
US-10-210-723-20/c
; Sequence 20; Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
; FILE REFERENCE: PFS-0028
; CURRENT APPLICATION NUMBER: US/10/210,723
; PRIOR FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-20
Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2432 AGGTGGAAGCAGTGAG 2448
Db      17 AGGTGGAAGCAGTGAG 1

RESULT 366
US-10-210-723-92
; Sequence 92; Application US/10210723
```

```
/ Publication No. US20040023382A1
/ GENERAL INFORMATION:
/ APPLICANT: Nicholas M. Dean
/ APPLICANT: C. Frank Bennett
/ APPLICANT: Kenneth W. Doble
/ TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
/ FILE REFERENCE: PTS-0028
/ CURRENT APPLICATION NUMBER: US/10/210,723
/ CURRENT FILING DATE: 2002-07-31
/ NUMBER OF SEQ ID NOS: 141
/ SEQ ID NO 92
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-92

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2432 AGGTGAGAGCACTGAG 2448
DB 4 AGGTGAGAGCACTGAG 20

RESULT 367
US-10-298-954-32/C
/ Sequence 32, Application US/10298954
/ Publication No. US20040096833A1
/ GENERAL INFORMATION:
/ APPLICANT: Ming-Yi Chiang
/ APPLICANT: Kenneth W. Doble
/ TITLE OF INVENTION: MODULATION OF FBP-INTERACTING REPRESSOR EXPRESSION
/ FILE REFERENCE: HTS-0028
/ CURRENT APPLICATION NUMBER: US/10/298,954
/ CURRENT FILING DATE: 2002-11-16
/ NUMBER OF SEQ ID NOS: 73
/ SEQ ID NO 32
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-298-954-32

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 AGCAGCAGCAGCTC 1494
DB 20 ACCAGCAGCAGCTC 4

RESULT 368
US-10-298-954-63
/ Sequence 63, Application US/10298954
/ Publication No. US20040096833A1
/ GENERAL INFORMATION:
/ APPLICANT: Ming-Yi Chiang
/ APPLICANT: Kenneth W. Doble
/ TITLE OF INVENTION: MODULATION OF FBP-INTERACTING REPRESSOR EXPRESSION
/ FILE REFERENCE: HTS-0028
/ CURRENT APPLICATION NUMBER: US/10/298,954
/ CURRENT FILING DATE: 2002-11-16
/ NUMBER OF SEQ ID NOS: 73
/ SEQ ID NO 63
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
```

```
US-10-298-954-63

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 AGCAGCAGCAGCTC 1494
DB 1 ACCAGCAGCAGCTC 17

RESULT 369
US-10-688-706-310
/ Sequence 310, Application US/10688706
/ Publication No. US20040102412A1
/ GENERAL INFORMATION:
/ APPLICANT: Pharmacia Corp.
/ APPLICANT: Broesch, Kay
/ TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
/ FILE REFERENCE: 01393/1
/ CURRENT APPLICATION NUMBER: US/10/688,706
/ CURRENT FILING DATE: 2003-10-17
/ PRIOR APPLICATION NUMBER: 60/419,268
/ PRIOR FILING DATE: 2002-10-17
/ NUMBER OF SEQ ID NOS: 3071
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 310
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: human GFAT antisense
US-10-688-706-310

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 ACTGAAGTTCCCTTCA 871
DB 4 ACTGAAGTTCCCTTCA 20

RESULT 370
US-10-688-706-635
/ Sequence 635, Application US/10688706
/ Publication No. US20040102412A1
/ GENERAL INFORMATION:
/ APPLICANT: Pharmacia Corp.
/ APPLICANT: Broschat, Kay
/ TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
/ FILE REFERENCE: 01393/1
/ CURRENT APPLICATION NUMBER: US/10/688,706
/ CURRENT FILING DATE: 2003-10-17
/ PRIOR APPLICATION NUMBER: 60/419,268
/ PRIOR FILING DATE: 2002-10-17
/ NUMBER OF SEQ ID NOS: 3071
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 635
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: human GFAT antisense
US-10-688-706-635

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 856 CTGAAGTTCCCTTCA 872
DB 1 CTGAAGTTCCCTTCA 17
```



```
RESULT 371
US-10-319-893-69
; Sequence 69, Application US/10319893
; Publication No. US20040115649A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABCS EXPRESSION
; FILE REFERENCE: RTS-0419
; CURRENT APPLICATION NUMBER: US/10/319, 893
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-319-893-69

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 995 ATGACAGCCATGGAGAG 1011
DB 4 ATGACTGCGCATGGAGAG 20

RESULT 372
US-10-319-893-144/c
; Sequence 144, Application US/10319893
; Publication No. US20040115649A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABCS EXPRESSION
; FILE REFERENCE: RTS-0419
; CURRENT APPLICATION NUMBER: US/10/319, 893
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-319-893-144

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 995 ATGACAGCCATGGAGAG 1011
DB 17 ATGACTGCGCATGGAGAG 1

RESULT 373
US-10-791-368-3
; Sequence 3, Application US/10791368
; Publication No. US20040170611A1
; GENERAL INFORMATION:
; APPLICANT: Kishimoto, Jiro
; APPLICANT: Morgan, Bruce A.
; APPLICANT: Burgess, Robert
; TITLE OF INVENTION: METHODS OF MODULATING HAIR GROWTH
; FILE REFERENCE: 10287-058001
; CURRENT APPLICATION NUMBER: US/10/791,368
; CURRENT FILING DATE: 2004-03-02
; PRIOR APPLICATION NUMBER: US/09/822,722
; PRIOR FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 60/261,690
; PRIOR FILING DATE: 2001-01-12

; PRIOR APPLICATION NUMBER: 60/193,771
; PRIOR FILING DATE: 2000-03-31
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer for PCR
US-10-791-368-3

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1400 TCCAGAGCGAGCTGCAG 1416
DB 4 TCCAGAGCGAGGTGCAG 20

RESULT 374
US-10-835-208-33/c
; Sequence 33, Application US/10835208
; Publication No. US20040192633A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHORT HETERODIMER PARTNER-1 EXPRESSION
; FILE REFERENCE: ISPH-0593
; CURRENT APPLICATION NUMBER: US/10/835,208
; CURRENT FILING DATE: 2004-04-29
; PRIOR APPLICATION NUMBER: US/09/919,197
; PRIOR FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-835-208-33

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1406 GGCAGCTGCAGCAGAG 1422
DB 18 GGCAGCTGCAGCAGAG 2

RESULT 375
US-10-672-866-202/c
; Sequence 202, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 202
; LENGTH: 20
```

;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-202

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2539 ACCATGATGTCACCA 2555
DB 20 ACTATGTCGTCCACCA 4

RESULT 376
US-10-672-866-319/c
; Sequence 319, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth Dobie
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOURCE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 319
; SEQ ID NO 319
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-319

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2539 ACCATGATGTCACCA 2555
DB 19 ACTATGTCGTCCACCA 3

RESULT 377
US-10-628-043-3
; Sequence 3, Application US/10628043
; Publication No. US2005004771A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And Oligonucleosides
; FILE REFERENCE: ISIS-4802
; CURRENT APPLICATION NUMBER: US/10/628,043
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US/09/934,138
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-10-628-043-3

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1656 CATCCCCGAGCCTCCC 1672
DB 3 CATCCCCGAGCCTCCC 19

RESULT 378
US-10-800-350-165/c
; Sequence 165, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-165

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 CCTGTCGCCCTGCGGG 64
DB 17 CCTGTCGCCCTGCGGG 1

RESULT 379
US-09-758-881-23/c
; Sequence 23, Application US/09758881
; Patent No. US20010029250A1
; GENERAL INFORMATION:
; APPLICANT: Karas, James G
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
; FILE REFERENCE: ISPH-0532
; CURRENT APPLICATION NUMBER: US/09/758,881
; CURRENT FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: PCT/US00/09054
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 09/288,461
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 152
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-758-881-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCAGCAG 1137
DB 20 AGCAGCAGCAGCTGCAGCAG 1

RESULT 380

US-09-078-871A-2/c

Sequence 2, Application US/09078871A
Publication No. US20020016978A1

GENERAL INFORMATION:

APPLICANT: Zheng, et al.

TITLE OF INVENTION: Transgenic Animal Expressing
No. 6452065-Native Wild-Type and Familial
Alzheimer's Disease Mutant
Presenilin 1 Protein on Native

NUMBER OF SEQUENCES: 10

CORRESPONDENCE ADDRESS:

ADDRESSEE: Merck & Co., Inc.
STREET: P.O. Box 2000, 126 E. Lincoln Ave.
CITY: Rahway
STATE: NJ

COUNTRY: USA

ZIP: 07065-0900

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows

SOFTWARE: FastSeq for Windows Version 2.0b

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/078,871A

FILING DATE: 14-May-1998

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US98/09709

FILING DATE: 13-MAY-1998

APPLICATION NUMBER: 60/046,488

FILING DATE: 14-MAY-1997

APPLICATION NUMBER: 60/078,465

FILING DATE: 18-MAR-1998

ATTORNEY/AGENT INFORMATION:

NAME: Yablonsky, Michael D

REGISTRATION NUMBER: 40,407

REFERENCE/DOCKET NUMBER: 19954Y

TELEPHONE: 732-594-4678

TELEFAX: 732-594-4720

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

SEQUENCE DESCRIPTION: SEQ ID NO: 2:

US-09-078-871A-2

Query Match

Best Local Similarity 85.0%; Pred. No. 2.9e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1400 TCACAGAGCAGCTGCAGCAG 1419

DB 20 TCACAGAGCAGCTGCAGCAG 1

RESULT 381

US-09-854-883-17

Sequence 17, Application US/09854883
Patent No. US20020055479A1

GENERAL INFORMATION:

APPLICANT: Lex M. Cowser

APPLICANT: Jacqueline Wyatt

APPLICANT: Susan M. Freier

APPLICANT: Brett P. Monia

APPLICANT: Madeline M. Butler

APPLICANT: Robert McKay

TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION

FILE REFERENCE: ISPH-0576

CURRENT APPLICATION NUMBER: US/09/854,883

CURRENT FILING DATE: 2001-05-14

PRIOR APPLICATION NUMBER: US 09/629,644

PRIOR FILING DATE: 2000-07-31

PRIOR APPLICATION NUMBER: US 09/487,368

PRIOR FILING DATE: 2000-01-18

NUMBER OF SEQ ID NOS: 389

SEQ ID NO 17

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Antisense Oligonucleotide

US-09-854-883-17

Query Match

Best Local Similarity 85.0%; Pred. No. 2.9e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2114 CTCAGCCCCCTGCGCCGCC 2133

DB 1 CTCAGCCCCGAGCGCCGCC 20

RESULT 382

US-09-935-338-65

Sequence 65, Application US/09935338
Publication No. US20030073081A1

GENERAL INFORMATION:

APPLICANT: MUKAI, Hiroyuki

APPLICANT: SUGAMA, Hiroaki

APPLICANT: UEMORI, Takashi

APPLICANT: YAMAMOTO, Junko

APPLICANT: TOMONO, Jun

APPLICANT: KOBAYASHI, Eiji

APPLICANT: ENOKI, Tetsuji

APPLICANT: TAKEDA, Osamu

APPLICANT: MIYAKE, Kazuo

APPLICANT: SATO, Yoshimi

APPLICANT: MORIYAMA, Mariko

APPLICANT: SAMURAGI, Haruhisa

APPLICANT: HAGIYA, Michio

APPLICANT: ASADA, Kiyozo

APPLICANT: KATO, Ikunoshin

TITLE OF INVENTION: A method for amplification of nucleic acids

FILE REFERENCE: MUKAI-1

CURRENT APPLICATION NUMBER: US/09/935,338

CURRENT FILING DATE: 2001-08-23

PRIOR APPLICATION NUMBER: JP11-076966

PRIOR FILING DATE: 1999-03-19

PRIOR APPLICATION NUMBER: JP11-370035

PRIOR FILING DATE: 1999-12-27

PRIOR APPLICATION NUMBER: JP2000-251981

PRIOR FILING DATE: 2000-08-23

PRIOR APPLICATION NUMBER: JP2000-284419

PRIOR FILING DATE: 2000-09-19

PRIOR APPLICATION NUMBER: JP2000-288750

PRIOR FILING DATE: 2000-09-22

PRIOR APPLICATION NUMBER: JP2001-104191

PRIOR FILING DATE: 2001-04-03

PRIOR APPLICATION NUMBER: PCT/JP00/01534

PRIOR FILING DATE: 2000-03-14

NUMBER OF SEQ ID NOS: 290

SOFTWARE: PatentIn version 3.2

```
SEQ ID NO 65
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Designed chimeric oligonucleotide primer designated as M13RV-2N
OTHER INFORMATION: 20mer. "nucleotides 19 to 20 are ribonucleotides-other"
US-09-935-338-65
```

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      3524 ACTCGGGAAACGCTATGAC 3543
Db      1 ACACAGAAACGCTATGAC 20
```

RESULT 383

```
US-09-935-338-77
Sequence 77, Application US/09935338
Publication No. US20030073081A1
```

```
GENERAL INFORMATION:
APPLICANT: MUKAI, Hiroyuki
APPLICANT: SAGAWA, Hiroaki
APPLICANT: UEMORI, Takashi
APPLICANT: YAMAMOTO, Junko
APPLICANT: TOMONO, Jun
APPLICANT: KOBAYASHI, Eiji
APPLICANT: ENOKI, Tatsuji
APPLICANT: TAKEDA, Osamu
APPLICANT: MIYAKE, Kazuo
APPLICANT: SATO, Yoshimi
APPLICANT: MORIYAMA, Mariko
APPLICANT: HAGAII, Michio
APPLICANT: ASADA, Kiyozo
APPLICANT: KATO, Ikumoshin
TITLE OF INVENTION: A method for amplification of nucleic acids
FILE REFERENCE: MUKAI=1
```

```
CURRENT APPLICATION NUMBER: US/09/935,338
CURRENT FILING DATE: 2001-08-23
PRIOR APPLICATION NUMBER: JP11-076966
PRIOR FILING DATE: 1999-03-19
PRIOR APPLICATION NUMBER: JP11-370035
PRIOR FILING DATE: 1999-12-27
PRIOR APPLICATION NUMBER: JP2000-251981
PRIOR FILING DATE: 2000-08-23
PRIOR APPLICATION NUMBER: JP2000-284419
PRIOR FILING DATE: 2000-09-19
PRIOR APPLICATION NUMBER: JP2000-288750
PRIOR FILING DATE: 2000-09-22
PRIOR APPLICATION NUMBER: JP2001-104191
PRIOR FILING DATE: 2001-04-03
PRIOR APPLICATION NUMBER: PCT/JP00/01534
PRIOR FILING DATE: 2000-03-14
NUMBER OF SEQ ID NOS: 290
SOFTWARE: PatentIn version 3.2
SEQ ID NO 77
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial
```

```
FEATURE:
OTHER INFORMATION: Designed chimeric oligonucleotide primer designated as M13RV-3N
OTHER INFORMATION: 20mer. "nucleotides 18 to 20 are ribonucleotides-other"
OTHER INFORMATION: nucleotides are deoxyribonucleotides"
US-09-935-338-77
```

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      3524 ACTCGGGAAACGCTATGAC 3543
Db      1 ACACAGAAACGCTATGAC 20
```

RESULT 384

```
US-09-972-469-171
Sequence 171, Application US/09972469
Publication No. US20030073085A1
```

```
GENERAL INFORMATION:
APPLICANT: Lai, Fang
APPLICANT: Zhou, Daixing
TITLE OF INVENTION: AMPLIFYING EXPRESSED SEQUENCES FROM GENOMIC DNA OF HIGHER-ORDER
FILE REFERENCE: SP01-230
CURRENT APPLICATION NUMBER: US/09/972,469
CURRENT FILING DATE: 2001-10-05
NUMBER OF SEQ ID NOS: 196
SOFTWARE: PatentIn version 3.1
SEQ ID NO 171
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-09-972-469-171
```

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      411 GGAGATCCTCAGGCGCTCTG 430
Db      1 GGATCCTCAGTGGCTCTG 20
```

RESULT 385

```
US-09-922-146-23
Sequence 23, Application US/09922146
Publication No. US20030083285A1
```

```
GENERAL INFORMATION:
APPLICANT: Lex M. Cowseart
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
FILE REFERENCE: RTS-0252
CURRENT APPLICATION NUMBER: US/09/922,146
CURRENT FILING DATE: 2001-08-01
NUMBER OF SEQ ID NOS: 48
SEQ ID NO 23
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-23
```

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1277 AGGAGCAGCGGCGGCTG 1296
Db      1 AGAGCAGGAGCGCGCGC 20
```

RESULT 386

```
US-09-972-607-31/c
Sequence 31, Application US/09972607
Publication No. US20030105037A1
```

```
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
```

CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 31
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-31

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1307 AGGCTCTGCGCGGAGGAG 1326
DB 20 AGGCTCTGCGCGGAGGAG 1

RESULT 387
US-09-754-106-66
Sequence 66, Application US/09754106
Publication No. US20030224355A1
GENERAL INFORMATION:
APPLICANT: Bell, Graeme I.
APPLICANT: Yamagata, Kazuya
APPLICANT: Oda, Naohisa
APPLICANT: Kaisaki, Pamela J.
APPLICANT: Furuta, Hiroto
APPLICANT: Horikawa, Yukio
APPLICANT: Menzel, Stephen
TITLE OF INVENTION: MUTATIONS IN THE DIABETES SUSCEPTIBILITY
TITLE OF INVENTION: GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA, HNF-1BETA
TITLE OF INVENTION: AND HNF-4ALPHA
NUMBER OF SEQUENCES: 147
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/754,106
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/927,219
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/028,056
FILING DATE: 02-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/025,719
FILING DATE: 10-SEP-1996
ATTORNEY/AGENT INFORMATION:
NAME: Wilson, Mark B.
REGISTRATION NUMBER: 37,259
REFERENCE/DOCKET NUMBER: ARCD:272
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 66:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-754-106-66

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 481 GTGCTGTGACAGAGATGC 500
DB 1 GTGACAGGAGACAGAGATGC 20

RESULT 388
US-10-181-177-105/c
Sequence 105, Application US/10181177
Publication No. US20030083296A1
GENERAL INFORMATION:
APPLICANT: Hong Zhang
APPLICANT: Lex M. Cowart
TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 8 EXPRESSION
FILE REFERENCE: RTSP-0334
CURRENT APPLICATION NUMBER: US/10/181,177
CURRENT FILING DATE: 2002-07-12
PRIOR APPLICATION NUMBER: PCT/US01/00955
PRIOR FILING DATE: 2001-02-11
PRIOR APPLICATION NUMBER: 09/487,445
PRIOR FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 176
SEQ ID NO 105
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-177-105

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 154 CTGGCTGCATCAAGGTCT 173
DB 20 CTGGCTGCCTCAAGTTCT 1

RESULT 389
US-10-008-789-75
Sequence 75, Application US/10008789
Publication No. US20030125276A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Kenneth Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 6 EXP
FILE REFERENCE: RTS-0333
CURRENT APPLICATION NUMBER: US/10/008,789
CURRENT FILING DATE: 2001-11-08
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 75
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-008-789-75

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 951 GAAAGGAGACAGATATG 970
DB 1 GAAAGGAGACAGCATTTG 20

```
RESULT 390
US-10-360-510-17
; Sequence 17, Application US/10360510
; Publication No. US20030220282A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowbert
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/10/360,510
; CURRENT FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: US/09/854,883
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-17

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2114 CTCAGCCCCCTGGCGCCGCCC 2133
DB      1   CTTAGCCCGAGGCGCCGCC 20

RESULT 391
US-10-348-935-4/C
; Sequence 4, Application US/10348935
; Publication No. US20040002083A1
; GENERAL INFORMATION:
; APPLICANT: DING, YE
; APPLICANT: LAWRENCE, CHARLES E.
; TITLE OF INVENTION: STATISTICAL ALGORITHMS FOR FOLDING AND TARGET
; TITLE OF INVENTION: ACCESSIBILITY PREDICTION AND DESIGN OF NUCLEIC ACIDS
; FILE REFERENCE: 454311-2230.1
; CURRENT APPLICATION NUMBER: US/10/348,935
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 60/352,643
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-348-935-4

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3524 ACTCGGGAACAGCTATGAC 3543
DB      20   ACACAGGAACAGCTATGAC 1
```

```
RESULT 392
US-10-289-762-5002/C
; Sequence 5002, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5002
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-5002

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1443 GCAGCAGCAGCAACAGCAGC 1462
DB      20   GCAGCAGCATCATCGCAGC 1

RESULT 393
US-10-352-179-29/C
; Sequence 29, Application US/10352179
; Publication No. US20040006788A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Guo-Liang
; APPLICANT: Liu, Guifu
; TITLE OF INVENTION: Procedures and Materials for Conferring Disease Resistance in Plar
; FILE REFERENCE: 22727/04108
; CURRENT APPLICATION NUMBER: US/10/352,179
; CURRENT FILING DATE: 2003-01-27
; PRIOR APPLICATION NUMBER: 60/352,106
; PRIOR FILING DATE: 2002-01-25
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-352-179-29

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3580 CCCCATGCATCATCTTCT 3599
DB      20   CCCCATGCATCATCTTCT 1

RESULT 394
US-10-628-841-31/C
; Sequence 31, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: R15-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 31
```

LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-31

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1307 AGGCTGCGCGGAGAG 1326
DB 20 AGGCTGCGCGGAGAG 1

RESULT 395
US-10-380-125-41/c
Sequence 41, Application US/10380125
Publication No. US20040048818A1
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: Ian Popoff
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 2 EXPRESSION
FILE REFERENCE: RSP-0176
CURRENT APPLICATION NUMBER: US/10/380,125
CURRENT FILING DATE: 2003-03-10
PRIOR APPLICATION NUMBER: 09/658,679
PRIOR FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 41
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-125-41

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 784 AAGAGTTCATGACTTCAT 803
DB 20 AAGAGTTCATGACTTCCT 1

RESULT 396
US-10-298-954-20
Sequence 20, Application US/10298954
Publication No. US20040096833A1
GENERAL INFORMATION:
APPLICANT: Ming-Yi Chiang
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: MODULATION OF FBP-INTERACTING REPRESSOR EXPRESSION
FILE REFERENCE: RTS-0028
CURRENT APPLICATION NUMBER: US/10/298,954
CURRENT FILING DATE: 2002-11-16
NUMBER OF SEQ ID NOS: 73
SEQ ID NO 20
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-298-954-20

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1126 CAGCTGACGACGACGACA 1145

DB 1 CAGCTGACGACGACGACA 20

RESULT 397
US-10-300-263-32/c
Sequence 32, Application US/10300263
Publication No. US20040096834A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
FILE REFERENCE: RTS-0431
CURRENT APPLICATION NUMBER: US/10/300,263
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 154
SEQ ID NO 32
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-263-32

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3625 CTGCTGCTACGACGACGA 3644
DB 20 CTGCTGCTACGACGACGA 1

RESULT 398
US-10-300-263-107
Sequence 107, Application US/10300263
Publication No. US20040096834A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
FILE REFERENCE: RTS-0431
CURRENT APPLICATION NUMBER: US/10/300,263
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 154
SEQ ID NO 107
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-300-263-107

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3625 CTGCTGCTACGACGACGA 3644
DB 1 CTGCTGCTACGACGACGA 20

RESULT 399
US-10-317-277A-15
Sequence 15, Application US/10317277A
Publication No. US20040110159A1
GENERAL INFORMATION:
APPLICANT: Doble, Kenneth W.
TITLE OF INVENTION: Modulation of Estrogen-Responsive Finger Protein Expression
FILE REFERENCE: RTS-0473
CURRENT APPLICATION NUMBER: US/10/317,277A
CURRENT FILING DATE: 2002-12-10
NUMBER OF SEQ ID NOS: 168
SOFTWARE: PatentIn version 3.2
SEQ ID NO 15
LENGTH: 20

TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-277A-15

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1168 AACACCTGCTGCACGCG 1187
DB 1 ACACACTGCTGCACCGCG 20

RESULT 400
US-10-317-277A-93/C
Sequence 93, Application US/10317277A
Publication No. US20040110159A1
GENERAL INFORMATION:
APPLICANT: Dobie, Kenneth W.
TITLE OF INVENTION: Modulation of Estrogen-Responsive Finger Protein Expression
FILE REFERENCE: RTS-0473
CURRENT APPLICATION NUMBER: US/10/317,277A
CURRENT FILING DATE: 2002-12-10
NUMBER OF SEQ ID NOS: 168
SOFTWARE: PatentIn version 3.2
SEQ ID NO 93
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-317-277A-93

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1168 AACACCTGCTGCACGCG 1187
DB 20 ACACACTGCTGCACCGCG 1

RESULT 401
US-10-346-268-114/C
Sequence 114, Application US/10346268
Publication No. US20040137441A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Nicholas W. Dean
APPLICANT: Ravi Jain
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 3 EXPRESSION
FILE REFERENCE: PTS-0076
CURRENT APPLICATION NUMBER: US/10/346,268
CURRENT FILING DATE: 2003-01-15
NUMBER OF SEQ ID NOS: 200
SEQ ID NO 114
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-346-268-114

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 981 CAGCGAGAGAGATGACA 1000
DB 20 CAGTGTGAGAGAGATGACA 1

RESULT 402
US-10-776-013-42
Sequence 42, Application US/10776013
Publication No. US20040226056A1
GENERAL INFORMATION:
APPLICANT: MYRIAD GENETICS, INC.
APPLICANT: Koch, Jean-Marc
APPLICANT: Bartel, Paul
APPLICANT: Heichman, Karen
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND
FILE REFERENCE: 1600.24
CURRENT APPLICATION NUMBER: US/10/776,013
CURRENT FILING DATE: 2004-02-09
PRIOR APPLICATION NUMBER: 09/948904
PRIOR FILING DATE: 2001-09-10
PRIOR APPLICATION NUMBER: 09/466139
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: 60/113534
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: 60/124120
PRIOR FILING DATE: 1999-03-12
PRIOR APPLICATION NUMBER: 60/141243
PRIOR FILING DATE: 1999-06-30
PRIOR APPLICATION NUMBER: 09/975072
PRIOR FILING DATE: 2001-10-12
PRIOR APPLICATION NUMBER: 60/240790
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 10/194967
PRIOR FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 60/304775
PRIOR FILING DATE: 2001-07-13
NUMBER OF SEQ ID NOS: 695
SOFTWARE: PatentIn version 3.2
SEQ ID NO 42
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-776-013-42

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1648 GAGCCCCCATCCCGAGCG 1667
DB 1 GAGCCCCCATCCCGCGCC 20

RESULT 403
US-10-776-013-146/C
Sequence 146, Application US/10776013
Publication No. US20040226056A1
GENERAL INFORMATION:
APPLICANT: MYRIAD GENETICS, INC.
APPLICANT: Koch, Jean-Marc
APPLICANT: Bartel, Paul
APPLICANT: Heichman, Karen
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND
FILE REFERENCE: 1600.24
CURRENT APPLICATION NUMBER: US/10/776,013
CURRENT FILING DATE: 2004-02-09
PRIOR APPLICATION NUMBER: 09/948904
PRIOR FILING DATE: 2001-09-10
PRIOR APPLICATION NUMBER: 09/466139
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: 60/113534
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: 60/124120
PRIOR FILING DATE: 1999-03-12
PRIOR APPLICATION NUMBER: 60/141243
PRIOR FILING DATE: 1999-06-30

PRIOR APPLICATION NUMBER: 09/975072
PRIOR FILING DATE: 2001-10-12
PRIOR APPLICATION NUMBER: 60/240790
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 10/194967
PRIOR FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 60/304775
PRIOR FILING DATE: 2001-07-13
NUMBER OF SEQ ID NOS: 695
SOFTWARE: PatentIn version 3.2
SEQ ID NO 146
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-776-013-146

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1411 CTGCAGCAGCAGCATGCTTA 1430
DB 20 CTGCTGAGAGAGATGGCTA 1

RESULT 404
US-10-776-013-160
Sequence 160, Application US/10776013
Publication No. US20040226056A1
GENERAL INFORMATION:
APPLICANT: MYRIAD GENETICS, INC.
APPLICANT: Roch, Jean-Marie
APPLICANT: Bartel, Paul
APPLICANT: Heichman, Karen
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND
FILE REFERENCE: 1600.24
CURRENT APPLICATION NUMBER: US/10/776.013
CURRENT FILING DATE: 2004-02-09
PRIOR APPLICATION NUMBER: 09/948904
PRIOR FILING DATE: 2001-09-10
PRIOR APPLICATION NUMBER: 09/466139
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: 60/113534
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: 60/124120
PRIOR FILING DATE: 1999-03-12
PRIOR APPLICATION NUMBER: 60/141243
PRIOR FILING DATE: 1999-06-30
PRIOR APPLICATION NUMBER: 09/975072
PRIOR FILING DATE: 2001-10-12
PRIOR APPLICATION NUMBER: 60/240790
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 10/194967
PRIOR FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 60/304775
PRIOR FILING DATE: 2001-07-13
NUMBER OF SEQ ID NOS: 695
SOFTWARE: PatentIn version 3.2
SEQ ID NO 160
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-776-013-160

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1132 CAGCAGCAGCAGCAGAGA 1151
DB 1 CAGCGCATGAGCAGCAGAGA 20

RESULT 405
US-10-832-777-73/c
Sequence 73, Application US/10832777
Publication No. US20040266714A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freiler
APPLICANT: Kenneth Dobie
APPLICANT: Robert McKay
TITLE OF INVENTION: MODULATION OF GLUCAGON RECEPTOR EXPRESSION
FILE REFERENCE: BIOL0007US
CURRENT APPLICATION NUMBER: US/10/832.777
CURRENT FILING DATE: 2004-04-27
PRIOR APPLICATION NUMBER: 60/466,256
PRIOR FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 823
SEQ ID NO 73
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-832-777-73

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 57 CCTGCGGACCCCTGCTGGGA 76
DB 20 CTTTGAACCCCTGCTGGGA 1

RESULT 406
US-10-832-777-198
Sequence 198, Application US/10832777
Publication No. US20040266714A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freiler
APPLICANT: Kenneth Dobie
APPLICANT: Robert McKay
TITLE OF INVENTION: MODULATION OF GLUCAGON RECEPTOR EXPRESSION
FILE REFERENCE: BIOL0007US
CURRENT APPLICATION NUMBER: US/10/832.777
CURRENT FILING DATE: 2004-04-27
PRIOR APPLICATION NUMBER: 60/466,256
PRIOR FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 823
SEQ ID NO 198
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-832-777-198

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1640 CGGGGCTGAGCCGCCATC 1659
DB 1 CGGGTCTGAGCAGCCCATC 20

RESULT 407
US-10-832-777-619/c
Sequence 619, Application US/10832777
Publication No. US20040266714A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freiler
APPLICANT: Kenneth Dobie
APPLICANT: Robert McKay

```

; TITLE OF INVENTION: MODULATION OF GLUCAGON RECEPTOR EXPRESSION
; FILE REFERENCE: BIOL0007US
; CURRENT APPLICATION NUMBER: US/10/832,777
; CURRENT FILING DATE: 2004-04-27
; PRIOR APPLICATION NUMBER: 60/466,256
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 823
; SEQ ID NO 619
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-832-777-619

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1640 CGGGGCTGAGCCCCCATT 1659
DB 20 CGGGTCTGAGCAGCCCATC 1

RESULT 408
US-10-832-622B-73/c
; Sequence 73, Application US/10832622B
; Publication No. US20050014713A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF GLUCAGON RECEPTOR EXPRESSION
; FILE REFERENCE: 30566/39991
; CURRENT APPLICATION NUMBER: US/10/832,622B
; CURRENT FILING DATE: 2004-04-27
; PRIOR APPLICATION NUMBER: US 60/466,311
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 823
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-832-622B-73

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 57 CCTGCGGACCTGCTGGGA 76
DB 20 CCTTGTGAACCTGCTGGGA 1

RESULT 409
US-10-832-622B-198
; Sequence 198, Application US/10832622B
; Publication No. US20050014713A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF GLUCAGON RECEPTOR EXPRESSION
; FILE REFERENCE: 30566/39991
; CURRENT APPLICATION NUMBER: US/10/832,622B
; CURRENT FILING DATE: 2004-04-27
; PRIOR APPLICATION NUMBER: US 60/466,311
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 823
; SEQ ID NO 198
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-832-622B-198
```

```

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1640 CGGGGCTGAGCCCCCATT 1659
DB 1 CGGGTCTGAGCAGCCCATC 20

RESULT 410
US-10-832-622B-619/c
; Sequence 619, Application US/10832622B
; Publication No. US20050014713A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF GLUCAGON RECEPTOR EXPRESSION
; FILE REFERENCE: 30566/39991
; CURRENT APPLICATION NUMBER: US/10/832,622B
; CURRENT FILING DATE: 2004-04-27
; PRIOR APPLICATION NUMBER: US 60/466,311
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 823
; SEQ ID NO 619
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-832-622B-619

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1640 CGGGGCTGAGCCCCCATT 1659
DB 20 CGGGTCTGAGCAGCCCATC 1

RESULT 411
US-10-860-455-49/c
; Sequence 49, Application US/10860455
; Publication No. US20050042647A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Eldrup, Anne B.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bhat, Balakrishnan
; APPLICANT: Griffey, Richard
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Prakash, Stanley P.
; TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
; FILE REFERENCE: ISIS-5480
; CURRENT APPLICATION NUMBER: US/10/860,455
; CURRENT FILING DATE: 2004-06-03
; PRIOR APPLICATION NUMBER: US 10/700,688
; PRIOR FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/460,433
; PRIOR FILING DATE: 2003-06-12
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Patent version 3.3
; SEQ ID NO 49
```

LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
NAME/KEY: misc feature
LOCATION: (1)-(19)
OTHER INFORMATION: phosphorothioate
US-10-860-455-49

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 209 AGGAGTCAACATGCTGAAA 228
Db 20 AGGAGTCAACATTTTCAAA 1

RESULT 412
US-10-860-455-51/c
Sequence 51, Application US/10860455
Publication No. US20050042647A1
GENERAL INFORMATION:
APPLICANT: Baker, Brenda F.
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Bhat, Balkrishen
APPLICANT: Griffey, Richard
APPLICANT: Swayze, Eric E.
APPLICANT: Crooke, Stanley T.
APPLICANT: Prakash, Thazha P.
TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
FILE REFERENCE: ISIS-5480
CURRENT APPLICATION NUMBER: US/10/860,455
CURRENT FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/700,688
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 10/460,433
PRIOR FILING DATE: 2003-06-12
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 10/078,949
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/479,783
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 08/870,608
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: US 08/659,440
PRIOR FILING DATE: 1996-06-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: PatentIn version 3.3
SEQ ID NO 51
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
NAME/KEY: misc feature
LOCATION: (1)-(18)
OTHER INFORMATION: phosphorothioate
US-10-860-455-51

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 209 AGGAGTCAACATGCTGAAA 228
Db 20 AGGAGTCAACATTTTCAAA 1

RESULT 413
US-10-860-455-56
Sequence 56, Application US/10860455
Publication No. US20050042647A1
GENERAL INFORMATION:
APPLICANT: Baker, Brenda F.
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Bhat, Balkrishen
APPLICANT: Griffey, Richard
APPLICANT: Swayze, Eric E.
APPLICANT: Crooke, Stanley T.
APPLICANT: Prakash, Thazha P.
TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
FILE REFERENCE: ISIS-5480
CURRENT APPLICATION NUMBER: US/10/860,455
CURRENT FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/700,688
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 10/460,433
PRIOR FILING DATE: 2003-06-12
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 10/078,949
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/479,783
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 08/870,608
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: US 08/659,440
PRIOR FILING DATE: 1996-06-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: PatentIn version 3.3
SEQ ID NO 56
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
NAME/KEY: misc feature
LOCATION: (1)-(19)
OTHER INFORMATION: phosphorothioate
US-10-860-455-56

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 2.9e+02;
Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 209 AGGAGTCAACATGCTGAAA 228
Db 1 AGGAGTCAACATTTTCAAA 20

RESULT 414
US-10-860-455-59/c
Sequence 59, Application US/10860455
Publication No. US20050042647A1
GENERAL INFORMATION:
APPLICANT: Baker, Brenda F.
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Bhat, Balkrishen
APPLICANT: Griffey, Richard
APPLICANT: Swayze, Eric E.
APPLICANT: Crooke, Stanley T.
APPLICANT: Prakash, Thazha P.
TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
FILE REFERENCE: ISIS-5480

```

CURRENT APPLICATION NUMBER: US/10/860,455
CURRENT FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/700,688
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 10/460,433
PRIOR FILING DATE: 2003-06-12
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 10/078,949
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/479,783
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 08/870,608
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: US 08/659,440
PRIOR FILING DATE: 1996-06-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: PatentIn version 3.3
SEQ ID NO 59
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: phosphorothioate
US-10-860-455-59

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```

RESULT 415
US-10-860-455-60
Sequence 60, Application US/10860455
Publication No. US20050042647A1
GENERAL INFORMATION:
APPLICANT: Baker, Brenda F.
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Bhat, Balakrishnan
APPLICANT: Griffey, Richard
APPLICANT: Swayze, Eric E.
APPLICANT: Crooke, Stanley T.
APPLICANT: Prakash, Thazha P.
TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
FILE REFERENCE: ISIS-5480
CURRENT APPLICATION NUMBER: US/10/860,455
CURRENT FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/700,688
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 10/460,433
PRIOR FILING DATE: 2003-06-12
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 10/078,949
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/479,783
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 08/870,608
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: US 08/659,440
PRIOR FILING DATE: 1996-06-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: PatentIn version 3.3
SEQ ID NO 60
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(12)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
```

```
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: phosphorothioate
US-10-860-455-60

Query Match
Best Local Similarity 70.0%; Score 15.2; DB 1; Length 20;
Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 209 AGGAGATCAACATGCTGAAA 228
Db 1 AGGAGATCAACATGCTGAAA 20

RESULT 416
US-10-860-455-62
Sequence 62, Application US/10860455
Publication No. US20050042647A1
GENERAL INFORMATION:
APPLICANT: Baker, Brenda F.
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Bhat, Balkrishen
APPLICANT: Griffey, Richard
APPLICANT: Swayze, Eric E.
APPLICANT: Crooke, Stanley T.
APPLICANT: Prakash, Thazha P.
TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
FILE REFERENCE: ISIS-5480
CURRENT APPLICATION NUMBER: US/10/860,455
CURRENT FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/700,688
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 10/460,433
PRIOR FILING DATE: 2003-06-12
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 10/078,949
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/479,783
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 08/870,608
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: US 08/659,440
PRIOR FILING DATE: 1996-06-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: PatentIn version 3.3
SEQ ID NO 62
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: phosphorothioate
FEATURE:
```

```
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: phosphorothioate
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: phosphorothioate
US-10-860-455-62

Query Match
Best Local Similarity 70.0%; Score 15.2; DB 1; Length 20;
Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 209 AGGAGATCAACATGCTGAAA 228
Db 1 AGGAGATCAACATGCTGAAA 20

RESULT 417
US-10-860-455-65/c
Sequence 65, Application US/10860455
Publication No. US20050042647A1
GENERAL INFORMATION:
APPLICANT: Baker, Brenda F.
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Bhat, Balkrishen
APPLICANT: Griffey, Richard
APPLICANT: Swayze, Eric E.
APPLICANT: Crooke, Stanley T.
APPLICANT: Prakash, Thazha P.
TITLE OF INVENTION: PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
FILE REFERENCE: ISIS-5480
CURRENT APPLICATION NUMBER: US/10/860,455
CURRENT FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/700,688
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 10/460,433
PRIOR FILING DATE: 2003-06-12
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 10/078,949
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/479,783
PRIOR FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 08/870,608
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: US 08/659,440
PRIOR FILING DATE: 1996-06-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: PatentIn version 3.3
SEQ ID NO 65
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
```

```
/ OTHER INFORMATION: Synthetic Construct
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(12)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (4)..(4)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (6)..(6)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (8)..(8)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(10)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (12)..(12)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(16)
/ OTHER INFORMATION: phosphorothioate
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(18)
/ OTHER INFORMATION: phosphorothioate
/ US-10-860-455-65

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      209 AGGAGTCAACATGCTGAAA 228
DB      20 AGGAGTCAACATTTTCAAA 1

RESULT 418
US-10-860-455-71/c
/ Sequence 71, Application US/10860455
/ Publication No. US20050042647A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Brenda F.
/ APPLICANT: Eldrup, Anne B.
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Bhat, Balkrishen
/ APPLICANT: Griffey, Richard
/ APPLICANT: Swayze, Eric E.
/ APPLICANT: Crooke, Stanley T.
/ APPLICANT: Prakash, Thazha P.
/ TITLE OF INVENTION: PHOSPHORUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
/ FILE REFERENCE: ISIS-5480
/ CURRENT APPLICATION NUMBER: US/10/860,455
/ PRIORITY FILING DATE: 2004-06-03
/ PRIOR APPLICATION NUMBER: US 10/700,688
/ PRIOR FILING DATE: 2003-11-04
/ PRIOR APPLICATION NUMBER: US 10/460,433
/ PRIOR FILING DATE: 2003-06-12
/ PRIOR APPLICATION NUMBER: US 60/423,760
/ PRIOR FILING DATE: 2002-11-05
/ PRIOR APPLICATION NUMBER: US 10/078,949
```

```
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 09/479,783
/ PRIOR FILING DATE: 2000-01-07
/ PRIOR APPLICATION NUMBER: US 08/870,608
/ PRIOR FILING DATE: 1997-06-06
/ PRIOR APPLICATION NUMBER: US 08/559,440
/ PRIOR FILING DATE: 1996-06-06
/ NUMBER OF SEQ ID NOS: 82
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 71
/ LENGTH: 20
/ TYPE: RNA
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: Synthetic Construct
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(19)
/ OTHER INFORMATION: phosphorothioate
/ US-10-860-455-71

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      209 AGGAGTCAACATGCTGAAA 228
DB      20 AGGAGTCAACATTTTCAAA 1

RESULT 419
US-10-860-455-73
/ Sequence 73, Application US/10860455
/ Publication No. US20050042647A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Brenda F.
/ APPLICANT: Eldrup, Anne B.
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Bhat, Balkrishen
/ APPLICANT: Griffey, Richard
/ APPLICANT: Swayze, Eric E.
/ APPLICANT: Crooke, Stanley T.
/ APPLICANT: Prakash, Thazha P.
/ TITLE OF INVENTION: PHOSPHORUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE
/ FILE REFERENCE: ISIS-5480
/ CURRENT APPLICATION NUMBER: US/10/860,455
/ PRIORITY FILING DATE: 2004-06-03
/ PRIOR APPLICATION NUMBER: US 10/700,688
/ PRIOR FILING DATE: 2003-11-04
/ PRIOR APPLICATION NUMBER: US 10/460,433
/ PRIOR FILING DATE: 2003-06-12
/ PRIOR APPLICATION NUMBER: US 60/423,760
/ PRIOR FILING DATE: 2002-11-05
/ PRIOR APPLICATION NUMBER: US 10/078,949
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 09/479,783
/ PRIOR FILING DATE: 2000-01-07
/ PRIOR APPLICATION NUMBER: US 08/870,608
/ PRIOR FILING DATE: 1997-06-06
/ PRIOR APPLICATION NUMBER: US 08/559,440
/ PRIOR FILING DATE: 1996-06-06
/ NUMBER OF SEQ ID NOS: 82
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 73
/ LENGTH: 20
/ TYPE: RNA
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: Synthetic Construct
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(19)
```

OTHER INFORMATION: phosphorothioate
US-10-860-455-73

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 2.9e+02;
Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 209 AGGAGATCAACATGCTGAAA 228
DB 1 AGGAGATCAACATGCTGAAA 20

RESULT 420
US-10-773-678-23/C

Sequence 23, Application US/10773678
Publication No. US2005074879A1
GENERAL INFORMATION:
APPLICANT: Kartas, James G
TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
FILE REFERENCE: ISPH-0828
CURRENT APPLICATION NUMBER: US/10/773,678
PRIOR FILING DATE: 2004-02-06
PRIOR APPLICATION NUMBER: 10/713,139
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 09/758,881
PRIOR FILING DATE: 2001-01-11
PRIOR APPLICATION NUMBER: PCT/US00/09054
PRIOR FILING DATE: 2000-04-06
PRIOR APPLICATION NUMBER: 09/288,461
PRIOR FILING DATE: 1999-04-08
NUMBER OF SEQ ID NOS: 402
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 23
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-773-678-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1118 AGCAGCAGCAGCTGCGACGAG 1137
DB 20 AGCAGCAGCAGCTGCGACGAG 1

RESULT 421
US-10-773-678-305/C

Sequence 305, Application US/10773678
Publication No. US2005074879A1
GENERAL INFORMATION:
APPLICANT: Kartas, James G
TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
FILE REFERENCE: ISPH-0828
CURRENT APPLICATION NUMBER: US/10/773,678
PRIOR FILING DATE: 2004-02-06
PRIOR APPLICATION NUMBER: 10/713,139
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 09/758,881
PRIOR FILING DATE: 2001-01-11
PRIOR APPLICATION NUMBER: PCT/US00/09054
PRIOR FILING DATE: 2000-04-06
PRIOR APPLICATION NUMBER: 09/288,461
PRIOR FILING DATE: 1999-04-08
NUMBER OF SEQ ID NOS: 402
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 305
LENGTH: 20

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense oligonucleotide
US-10-773-678-305

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1120 CAGCAGCAGCTGCGACGACA 1139
DB 20 CAGCAGCAGCTGCGACGACA 1

RESULT 422
US-10-860-265-112/C

Sequence 112, Application US/10860265
Publication No. US2005080246A1
GENERAL INFORMATION:
APPLICANT: Allerson, Charles
APPLICANT: Bhat, Balakrishen
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Griffey, Richard H.
APPLICANT: Baker, Brenda F.
TITLE OF INVENTION: COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR
FILE REFERENCE: ISIS-5482
CURRENT APPLICATION NUMBER: US/10/860,265
PRIOR FILING DATE: 2004-06-03
PRIOR APPLICATION NUMBER: US 10/701,007
PRIOR FILING DATE: 2003-11-04
PRIOR APPLICATION NUMBER: US 60/555,521
PRIOR FILING DATE: 2004-03-22
PRIOR APPLICATION NUMBER: US 60/423,760
PRIOR FILING DATE: 2002-11-05
NUMBER OF SEQ ID NOS: 157
SOFTWARE: PatentIn version 3.3
SEQ ID NO 112
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc.feature
LOCATION: (1)-(20)
OTHER INFORMATION: ribo with phosphorothioate linkage
US-10-860-265-112

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 209 AGGAGATCAACATGCTGAAA 228
DB 20 AGGAGATCAACATGCTGAAA 1

RESULT 423
US-10-860-265-149/C

Sequence 149, Application US/10860265
Publication No. US2005080246A1
GENERAL INFORMATION:
APPLICANT: Allerson, Charles
APPLICANT: Bhat, Balakrishen
APPLICANT: Eldrup, Anne B.
APPLICANT: Manoharan, Muthiah
APPLICANT: Griffey, Richard H.
APPLICANT: Baker, Brenda F.
APPLICANT: Swayze, Eric E.

;; TITLE OF INVENTION: COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR
;; FILE REFERENCE: ISIS-5482
;; CURRENT APPLICATION NUMBER: US/10/860,265
;; PRIOR FILING DATE: 2004-06-03
;; PRIOR APPLICATION NUMBER: US 10/701,007
;; PRIOR FILING DATE: 2003-11-04
;; PRIOR APPLICATION NUMBER: US 60/555,521
;; PRIOR FILING DATE: 2004-03-22
;; PRIOR APPLICATION NUMBER: US 60/423,760
;; PRIOR FILING DATE: 2002-11-05
;; NUMBER OF SEQ ID NOS: 157
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 149
;; LENGTH: 20
;; TYPE: RNA
;; ORGANISM: Artificial
;; FEATURE:
;; OTHER INFORMATION: Synthetic Construct
;; NAME/KEY: misc.feature
;; LOCATION: (1)-(20)
;; OTHER INFORMATION: ribo with phosphorothioate linkage
US-10-860-265-149

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 209 AGGAGATCAACATGCTGAAA 228
DB 20 AGGAGATCAACATTTCAAA 1

RESULT 424
US-10-418-182-198/c
;; Sequence 198, Application US/10418182
;; Publication No. US20030228302A1
;; GENERAL INFORMATION:
;; APPLICANT: Crea, Roberto
;; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
;; FILE REFERENCE: 1551.2001-001
;; CURRENT FILING DATE: 2003-04-16
;; PRIOR APPLICATION NUMBER: 60/373,558
;; PRIOR FILING DATE: 2002-04-17
;; NUMBER OF SEQ ID NOS: 423
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 198
;; LENGTH: 15
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
US-10-418-182-198

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1449 GCAGCAGCAGCAGCA 1463
DB 15 GCAGCAGCAGCAGCA 1

RESULT 425
US-10-418-182-216
;; Sequence 216, Application US/10418182
;; Publication No. US20030228302A1
;; GENERAL INFORMATION:
;; APPLICANT: Crea, Roberto
;; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
;; FILE REFERENCE: 1551.2001-001

;; CURRENT APPLICATION NUMBER: US/10/418,182
;; PRIOR FILING DATE: 2003-04-16
;; PRIOR APPLICATION NUMBER: 60/373,558
;; PRIOR FILING DATE: 2002-04-17
;; NUMBER OF SEQ ID NOS: 423
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 216
;; LENGTH: 15
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
US-10-418-182-216

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAG 1464
DB 1 CAGCAACAGCAGCAG 15

RESULT 426
US-10-407-818-7/c
;; Sequence 7, Application US/10407818
;; Publication No. US20040198971A1
;; GENERAL INFORMATION:
;; APPLICANT: RABRANI, ELAZAR
;; APPLICANT: STAVRIANOPOLIS, JANNIS G.
;; APPLICANT: DONEGAN, JAMES J.
;; TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
;; FILE REFERENCE: ENZ-65
;; CURRENT APPLICATION NUMBER: US/10/407,818
;; CURRENT FILING DATE: 2003-04-03
;; NUMBER OF SEQ ID NOS: 16
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 7
;; LENGTH: 15
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;; OTHER INFORMATION: Synthetic oligonucleotide
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-407-818-7

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GCAGCAGCAGCAGCA 1145
DB 15 GCAGCAGCAGCAGCA 1

RESULT 427
US-10-776-934-135/c
;; Sequence 135, Application US/10776934
;; Publication No. US20050014712A1
;; GENERAL INFORMATION:
;; APPLICANT: HANSEN, BO
;; APPLICANT: THREE, CHARLOTTE ALBAEK
;; APPLICANT: WESTERGAARD, MAUKEN
;; APPLICANT: PETERSEN, KAMILLE DUMONG
;; APPLICANT: WISENBACH, MARGIT
;; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;; FILE REFERENCE: 58610(71432)
;; CURRENT APPLICATION NUMBER: US/10/776,934
;; CURRENT FILING DATE: 2004-02-10

PRIOR APPLICATION NUMBER: 60/446,372
PRIOR FILING DATE: 2003-02-10
PRIOR APPLICATION NUMBER: 60/523,591
PRIOR FILING DATE: 2003-11-19
NUMBER OF SEQ ID NOS: 741
SOFTWARE: PatentIn version 3.2
SEQ ID NO 135
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide
US-10-776-934-135

Query Match 0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 150 GCAGCTGGCTGCCAT 164
DB 15 GCAGCTGGCTGCCAT 1

RESULT 428
US-10-776-934-680/C
Sequence 680, Application US/10776934
Publication No. US20050014712A1
GENERAL INFORMATION:
APPLICANT: HANSEN, BO
APPLICANT: THRU, CHARLOTTE ALBAEK
APPLICANT: WESTERGAARD, MAJKEN
APPLICANT: PETERSEN, KAMILLE DUMONG
APPLICANT: WISSENBACH, MARGIT
TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: 58610(71432)
CURRENT APPLICATION NUMBER: US/10/776,934
CURRENT FILING DATE: 2004-02-10
PRIOR APPLICATION NUMBER: 60/446,372
PRIOR FILING DATE: 2003-02-10
PRIOR APPLICATION NUMBER: 60/523,591
PRIOR FILING DATE: 2003-11-19
NUMBER OF SEQ ID NOS: 741
SOFTWARE: PatentIn version 3.2
SEQ ID NO 680
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide
NAME/KEY: modified_base
LOCATION: (1)..(4)
OTHER INFORMATION: beta-D-oxy-LNA modified base
FEATURE:
NAME/KEY: modified_base
LOCATION: (13)..(16)
OTHER INFORMATION: beta-D-oxy-LNA modified base
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(16)
OTHER INFORMATION: phosphorothioate linkage
US-10-776-934-680

Query Match 0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 150 GCAGCTGGCTGCCAT 164
DB 15 GCAGCTGGCTGCCAT 1

RESULT 429

US-10-776-934-681/C
Sequence 681, Application US/10776934
Publication No. US20050014712A1
GENERAL INFORMATION:
APPLICANT: HANSEN, BO
APPLICANT: THRU, CHARLOTTE ALBAEK
APPLICANT: WESTERGAARD, MAJKEN
APPLICANT: PETERSEN, KAMILLE DUMONG
APPLICANT: WISSENBACH, MARGIT
TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: 58610(71432)
CURRENT APPLICATION NUMBER: US/10/776,934
CURRENT FILING DATE: 2004-02-10
PRIOR APPLICATION NUMBER: 60/446,372
PRIOR FILING DATE: 2003-02-10
PRIOR APPLICATION NUMBER: 60/523,591
PRIOR FILING DATE: 2003-11-19
NUMBER OF SEQ ID NOS: 741
SOFTWARE: PatentIn version 3.2
SEQ ID NO 681
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide
NAME/KEY: modified_base
LOCATION: (1)..(4)
OTHER INFORMATION: beta-D-oxy-LNA modified base
FEATURE:
NAME/KEY: modified_base
LOCATION: (13)..(15)
OTHER INFORMATION: beta-D-oxy-LNA modified base
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(16)
OTHER INFORMATION: phosphorothioate linkage
US-10-776-934-681

Query Match 0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 150 GCAGCTGGCTGCCAT 164
DB 15 GCAGCTGGCTGCCAT 1

RESULT 430
US-10-776-934-682/C
Sequence 682, Application US/10776934
Publication No. US20050014712A1
GENERAL INFORMATION:
APPLICANT: HANSEN, BO
APPLICANT: THRU, CHARLOTTE ALBAEK
APPLICANT: WESTERGAARD, MAJKEN
APPLICANT: PETERSEN, KAMILLE DUMONG
APPLICANT: WISSENBACH, MARGIT
TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: 58610(71432)
CURRENT APPLICATION NUMBER: US/10/776,934
CURRENT FILING DATE: 2004-02-10
PRIOR APPLICATION NUMBER: 60/446,372
PRIOR FILING DATE: 2003-02-10
PRIOR APPLICATION NUMBER: 60/523,591
PRIOR FILING DATE: 2003-11-19
NUMBER OF SEQ ID NOS: 741
SOFTWARE: PatentIn version 3.2
SEQ ID NO 682
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:

```
/ OTHER INFORMATION: Synthetic oligonucleotide
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (1)..(4)
/ OTHER INFORMATION: beta-D-oxy-LNA modified base
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (13)..(16)
/ OTHER INFORMATION: beta-D-oxy-LNA modified base
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (5)..(13)
/ OTHER INFORMATION: phosphorothioate linkage
US-10-776-934-682

Query Match      0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      150 GCAGCTGGCTGCCAT 164
DB      15 GCAGCTGGCTGCCAT 1

RESULT 431
US-10-776-934-683/C
/ Sequence 683, Application US/10776934
/ Publication No. US20050014712A1
/ GENERAL INFORMATION:
/ APPLICANT: HANSEN, BO
/ APPLICANT: THREE, CHARLOTTE ALBAEK
/ APPLICANT: WESTERGARD, MAJKEN
/ APPLICANT: PETERSEN, KAMILLE DUMONG
/ APPLICANT: WISSENBACH, MARGIT
/ TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
/ FILE REFERENCE: 58610(71432)
/ CURRENT APPLICATION NUMBER: US/10/776,934
/ CURRENT FILING DATE: 2004-02-10
/ PRIOR APPLICATION NUMBER: 60/446,372
/ PRIOR FILING DATE: 2003-02-10
/ PRIOR APPLICATION NUMBER: 60/523,591
/ PRIOR FILING DATE: 2003-11-19
/ NUMBER OF SEQ ID NOS: 741
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 683
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Artificial sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide
/ NAME/KEY: misc feature
/ LOCATION: (1)..(16)
/ OTHER INFORMATION: phosphorothioate linkage
US-10-776-934-683

Query Match      0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      150 GCAGCTGGCTGCCAT 164
DB      15 GCAGCTGGCTGCCAT 1

RESULT 432
US-09-912-014-20
/ Sequence 20, Application US/09912014
/ Publication No. US20030059929A1
/ GENERAL INFORMATION:
/ APPLICANT: Heller, Michael J.; and Tu, Eugene
/ TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
/ MICROELECTRONIC SYSTEMS AND DEVICES FOR
```

```
/ MOLECULAR BIOLOGICAL ANALYSIS AND
/ DIAGNOSTICS
/ NUMBER OF SEQUENCES: 31
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 611 West Sixth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: USA
/ ZIP: 90017
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
/ SOFTWARE: WordPerfect (Version 5.1)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/912,014
/ FILING DATE: 24-Jul-2001
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/146,504
/ FILING DATE: <Unknown>
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 203/218
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 20:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-09-912-014-20

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1005 TCGAGAGAGAGAGA 1019
DB      2 TCGAGAGAGAGAGA 16

RESULT 433
US-10-156-306-4918
/ Sequence 4918, Application US/10156306
/ Publication No. US20030119017A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyne Pharmaceuticals, Inc.
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
/ FILE REFERENCE: MBH01-664-A (400/050)
/ CURRENT APPLICATION NUMBER: US/10/156,306
/ CURRENT FILING DATE: 2002-05-28
/ NUMBER OF SEQ ID NOS: 8013
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4918
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-156-306-4918

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1128 GCTGAGAGAGAGCA 1142
```

Db 1 GCGGAGAGAGAGCA 15

RESULT 434

US-10-156-306-5857

Sequence 5857, Application US/10156306

Publication No. US20030119017A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: MCSw19gen, James

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

TITLE OF INVENTION: Levels of IKK-Gamma and PKR

FILE REFERENCE: MBH01-664-A (400/050)

CURRENT APPLICATION NUMBER: US/10/156,306

CURRENT FILING DATE: 2002-05-28

NUMBER OF SEQ ID NOS: 8013

SOFTWARE: PatentIn version 3.0

SEQ ID NO 5857

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-156-306-5857

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.5e+02; Indels 0; Gaps 0;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1128 GCTGAGAGAGCA 1142

Db 3 GCGGAGAGAGCA 17

RESULT 435

US-10-371-066-20

Sequence 20, Application US/10371066

Publication No. US20030162214A1

GENERAL INFORMATION:

APPLICANT: Heller, Michael J.; and Tu, Eugene

TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING MICROELECTRONIC SYSTEMS AND DEVICES FOR

TITLE OF INVENTION: MOLECULAR BIOLOGICAL ANALYSIS AND

DIAGNOSTICS

NUMBER OF SEQUENCES: 31

CORRESPONDENCE ADDRESS:

ADDRESSER: Lyon & Lyon

STREET: 611 West Sixth Street

CITY: Los Angeles

STATE: California

COUNTRY: USA

ZIP: 90017

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM compatible

OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)

SOFTWARE: WordPerfect (Version 5.1)

SOFTWARE: WordPerfect (Version 5.1)

APPLICATION NUMBER: US/10/371,066

FILING DATE: 21-Feb-2003

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/146,504

FILING DATE: NO. US20030162214A1ember 1, 1993

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 203/218

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEFAX: 67-3510

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 17
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-10-371-066-20

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1005 TGGAGAGAGAGA 1019

Db 2 TGGAGAGAGAGA 16

RESULT 436

US-10-170-172-20

Sequence 20, Application US/10170172

Publication No. US20030190632A1

GENERAL INFORMATION:

APPLICANT: SOSNOMSKI, RONALD G

APPLICANT: BUTLER, WILLIAM F

APPLICANT: TU, EUGENE

APPLICANT: NERENBERG, MICHAEL I

APPLICANT: HELLER, MICHAEL J

TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING MICROELECTRONIC

TITLE OF INVENTION: INTEGRATED SYSTEMS, COMPONENT DEVICES, MECHANISMS,

TITLE OF INVENTION: METHODS, AND PROCEDURES FOR MOLECULAR BIOLOGICAL

TITLE OF INVENTION: ANALYSIS AND DIAGNOSTICS

FILE REFERENCE: DAVID B. MURPHY: Nanogen 227/194

CURRENT APPLICATION NUMBER: US/10/170,172

CURRENT FILING DATE: 2002-06-11

PRIOR APPLICATION NUMBER: US/08/986,065

PRIOR FILING DATE: 1997-12-05

NUMBER OF SEQ ID NOS: 55

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 20

LENGTH: 17

TYPE: DNA

ORGANISM: Human

US-10-170-172-20

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1005 TGGAGAGAGAGA 1019

Db 2 TGGAGAGAGAGA 16

RESULT 437

US-10-170-172-46/C

Sequence 46, Application US/10170172

Publication No. US20030190632A1

GENERAL INFORMATION:

APPLICANT: SOSNOMSKI, RONALD G

APPLICANT: BUTLER, WILLIAM F

APPLICANT: TU, EUGENE

APPLICANT: NERENBERG, MICHAEL I

APPLICANT: HELLER, MICHAEL J

APPLICANT: EDMAN, CARL F

TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING MICROELECTRONIC

TITLE OF INVENTION: INTEGRATED SYSTEMS, COMPONENT DEVICES, MECHANISMS,

TITLE OF INVENTION: METHODS, AND PROCEDURES FOR MOLECULAR BIOLOGICAL

FILE REFERENCE: DAVID B. MURPHY: Nanogen 227/194

CURRENT APPLICATION NUMBER: US/10/170,172

CURRENT FILING DATE: 2002-06-11

PRIOR APPLICATION NUMBER: US/08/986,065

PRIOR FILING DATE: 1997-12-05

; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 46
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Human
US-10-170-172-46

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TCGAGAGGAAGAGA 1019
DB 16 TCGAGAGGAAGAGA 2

RESULT 438
US-10-170-172-55/c
; Sequence 55, Application US/10170172
; Publication No. US20030190632A1
; GENERAL INFORMATION:
; APPLICANT: SOSNOMSKI, RONALD G
; APPLICANT: BUTLER, WILLIAM F
; APPLICANT: TU, EUGENE
; APPLICANT: NERENBERG, MICHAEL I
; APPLICANT: HELLER, MICHAEL J
; APPLICANT: EDMAN, CARL F
; TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING MICROELECTRONIC
; TITLE OF INVENTION: INTEGRATED SYSTEMS, COMPONENT DEVICES, MECHANISMS,
; TITLE OF INVENTION: METHODS, AND PROCEDURES FOR MOLECULAR BIOLOGICAL
; FILE REFERENCE: DAVID B. MORPHY: Nanogen 227/194
; CURRENT APPLICATION NUMBER: US/10/170,172
; PRIOR FILING DATE: 2002-06-11
; PRIOR APPLICATION NUMBER: US/08/986,065
; PRIOR FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Human
US-10-170-172-55

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 TCGAGAGGAAGAGA 1019
DB 16 TCGAGAGGAAGAGA 2

RESULT 439
US-10-494-343-165
; Sequence 165, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 165
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-165

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 GCAGCAGCAGCAACA 1457
DB 3 GCAGCAGCAGCAACA 17

RESULT 440
US-10-494-343-174
; Sequence 174, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 174
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-174

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1450 CAGCAACAGCAGCAG 1464
DB 1 CAGCAACAGCAGCAG 15

RESULT 441
US-09-912-014-6/c
; Sequence 6, Application US/09912014
; Publication No. US20030059929A1
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J.; and Tu, Eugene
; TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
; MOLECULAR BIOLOGICAL SYSTEMS AND DEVICES FOR
; DIAGNOSTICS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/912,014
FILING DATE: 24-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/146,504
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 203/218
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-912-014-6
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1005 TGGAGAGGAAGAGA 1019
DB 16 TGGAGAGGAAGAGA 2

RESULT 442
US-10-371-066-6/c
Sequence 6, Application US/10371066
Publication No. US20030162214A1
GENERAL INFORMATION:
APPLICANT: Heller, Michael J. and Tu, Eugene
TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
MICROELECTRONIC SYSTEMS AND DEVICES FOR
MOLECULAR BIOLOGICAL ANALYSIS AND
DIAGNOSTICS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/371,066
FILING DATE: 21-Feb-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/146,504
FILING DATE: No. US20030162214A1ember 1, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 203/218
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-371-066-6
Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1005 TGGAGAGGAAGAGA 1019
DB 16 TGGAGAGGAAGAGA 2

RESULT 443
US-10-170-172-6/c
Sequence 6, Application US/10170172
Publication No. US20030190632A1
GENERAL INFORMATION:
APPLICANT: SOSNOSKI, RONALD G
APPLICANT: BUTLER, WILLIAM F
APPLICANT: TU, EUGENE
APPLICANT: NERENBERG, MICHAEL I
APPLICANT: HELLER, MICHAEL J
APPLICANT: EDMAN, CARL F
TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING MICROELECTRONIC
TITLE OF INVENTION: INTEGRATED SYSTEMS, COMPONENT DEVICES, MECHANISMS,
METHODS, AND PROCEDURES FOR MOLECULAR BIOLOGICAL
TITLE OF INVENTION: ANALYSIS AND DIAGNOSTICS
FILE REFERENCE: DAVID B. MURPHY: Nanogen 227/194
CURRENT APPLICATION NUMBER: US/10/170,172
CURRENT FILING DATE: 2002-06-11
PRIOR APPLICATION NUMBER: US/08/986,065
PRIOR FILING DATE: 1997-12-05
NUMBER OF SEQ ID NOS: 55
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 6
LENGTH: 18
TYPE: DNA
ORGANISM: Human
FEATURE:
NAME/KEY: rRNA
LOCATION: (18)
OTHER INFORMATION: Synthesized with U at 3' terminus to provide
OTHER INFORMATION: ribonucleic acid base for reactivity
US-10-170-172-6
Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1005 TGGAGAGGAAGAGA 1019
DB 16 TGGAGAGGAAGAGA 2

RESULT 444
US-10-198-235-28/c
Sequence 28, Application US/10198235
Publication No. US20030190634A1
GENERAL INFORMATION:
APPLICANT: Barany, Francis
APPLICANT: Liu, Jianshao
APPLICANT: Kivk, Brian W.
APPLICANT: Zivvi, Monib
APPLICANT: Geivry, No. US20030190634A1man P.
APPLICANT: Pety, Philip B
TITLE OF INVENTION: ACCELERATING IDENTIFICATION OF SINGLE NUCLEOTIDE
TITLE OF INVENTION: POLYMORPHISMS AND ALIGNMENT OF CLONES IN GENOMIC
FILE REFERENCE: 19603/2621
CURRENT APPLICATION NUMBER: US/10/198,235

```
/ CURRENT FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US/09/478,189
/ PRIOR FILING DATE: 2000-01-05
/ PRIOR APPLICATION NUMBER: 60/114,881
/ PRIOR FILING DATE: 1999-01-06
/ NUMBER OF SEQ ID NOS: 181
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 28
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: probe/primer
US-10-198-235-28

Query Match
Best Local Similarity 100.0%; Score 15; DB 1; Length 18;
Pred. No. 2.7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 1280 AGCAGCAGCGCGCGC 1294
DB 15 AGCAGCAGCGCGCGC 1

RESULT 445
US-10-377-628A-2
/ Sequence 2, Application US/10377628A
/ Publication No. US20040022768A1
/ GENERAL INFORMATION:
/ APPLICANT: Roy-Chowdhury, Jayanta
/ APPLICANT: Ilan, Yaron
/ APPLICANT: Rabbani, Elazar
/ APPLICANT: Englehardt, Dean L.
/ TITLE OF INVENTION: Process Useful for Producing Selective Immune Down Regulation (SI)
/ TITLE OF INVENTION: Subjects, Including Adult Subjects to Artificially Expressed Gen
/ TITLE OF INVENTION: Systems, Infectious Agents, and No. US20040022768A1-Cellular Imm
/ TITLE OF INVENTION: Processes for Producing Immunological Tolerance in Subjects Usin
/ FILE REFERENCE: 59046.000026
/ CURRENT APPLICATION NUMBER: US/10/377,628A
/ CURRENT FILING DATE: 2003-03-04
/ PRIOR APPLICATION NUMBER: US 08/808,629
/ PRIOR FILING DATE: 1997-02-28
/ NUMBER OF SEQ ID NOS: 2
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 2
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Primer
US-10-377-628A-2

Query Match
Best Local Similarity 100.0%; Score 15; DB 1; Length 19;
Pred. No. 2.8e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 1123 CAGCAGCTGAGCAG 1137
DB 2 CAGCAGCTGAGCAG 16

RESULT 446
US-09-863-049A-21/c
/ Sequence 21, Application US/09863049A
/ Publication No. US20030032055A1
/ GENERAL INFORMATION:
/ APPLICANT: Kenwright, Sue J.
/ APPLICANT: Nelson, David L.
/ APPLICANT: Aradhy, Swaroop
/ APPLICANT: D'Uro, Michele
/ APPLICANT: Woffendin, Hayley
/ APPLICANT: Munnich, Arnold
/ APPLICANT: Smah, Asmaa
```

```
/ APPLICANT: Israel, Alain
/ APPLICANT: Poustka, Annemarie
/ APPLICANT: Lewis, Richard A
/ APPLICANT: Levy, Moise
/ APPLICANT: Heiss, Nina
/ TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defe
/ TITLE OF INVENTION: NEFAPPA B (NF-KB) Activation
/ FILE REFERENCE: HO-P019610S1
/ CURRENT APPLICATION NUMBER: US/09/863,049A
/ CURRENT FILING DATE: 2001-05-22
/ PRIOR APPLICATION NUMBER: US 60/206,223
/ PRIOR FILING DATE: 2000-05-22
/ NUMBER OF SEQ ID NOS: 77
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Human
US-09-863-049A-21

Query Match
Best Local Similarity 100.0%; Score 15; DB 1; Length 20;
Pred. No. 3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 2047 TCGCCTGGCAATC 2061
DB 15 TCGCCTGGCAATC 1

RESULT 447
US-09-972-607-36/c
/ Sequence 36, Application US/09972607
/ Publication No. US20030105037A1
/ GENERAL INFORMATION:
/ APPLICANT: Bretz P. Monia
/ APPLICANT: Jacqueline Wyatt
/ TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
/ TITLE OF INVENTION: RTS-0191
/ FILE REFERENCE: RTS-0191
/ CURRENT APPLICATION NUMBER: US/09/972,607
/ CURRENT FILING DATE: 2001-10-06
/ NUMBER OF SEQ ID NOS: 88
/ SEQ ID NO 36
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-36

Query Match
Best Local Similarity 100.0%; Score 15; DB 1; Length 20;
Pred. No. 3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 1128 GCTGAGCAGCAGCA 1142
DB 17 GCTGAGCAGCAGCA 3

RESULT 448
US-10-285-976-73
/ Sequence 73, Application US/10285976
/ Publication No. US20030165500A1
/ GENERAL INFORMATION:
/ APPLICANT: Rhee, Chae-Seo
/ APPLICANT: Malini, Sen
/ APPLICANT: Wu, Christina
/ APPLICANT: Leon, Lorenzo M.
/ APPLICANT: Cort, Maripat
/ APPLICANT: Carson, Dennis A.
/ APPLICANT: The Regents of the University of California
/ TITLE OF INVENTION: Wnt and Fizzled Receptors as Targets for Immunotherapy
/ TITLE OF INVENTION: in Head and Neck Squamous Cell Carcinomas
/ FILE REFERENCE: 023070-130320US
```

CURRENT APPLICATION NUMBER: US/10/285,976
CURRENT FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/287,995
PRIOR FILING DATE: 2001-05-01
PRIOR APPLICATION NUMBER: WO PCT/US02/13802
PRIOR FILING DATE: 2002-05-01
NUMBER OF SEQ ID NOS: 232
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO: 73
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: real-time PCR
US-10-285-976-73

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3556 GTGCACATCCAGAC 3570
DB 1 GTGCACATCCAGAC 15

RESULT 449
US-10-162-846-57/c
Sequence 57, Application US/10162846
Publication No. US20030224516A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PROX-1 EXPRESSION
FILE REFERENCE: RTS-0421
CURRENT APPLICATION NUMBER: US/10/162,846
CURRENT FILING DATE: 2002-06-03
NUMBER OF SEQ ID NOS: 134
SEQ ID NO: 57
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-162-846-57

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAG 1458
DB 18 CAGCAGCAGCAACAG 4

RESULT 450
US-10-162-846-122
Sequence 122, Application US/10162846
Publication No. US20030224516A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PROX-1 EXPRESSION
FILE REFERENCE: RTS-0421
CURRENT APPLICATION NUMBER: US/10/162,846
CURRENT FILING DATE: 2002-06-03
NUMBER OF SEQ ID NOS: 134
SEQ ID NO: 122
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-162-846-122

Query Match 0.4%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 CAGCAGCAGCAACAG 1458
DB 3 CAGCAGCAGCAACAG 17

RESULT 451
US-10-094-886-223/c
Sequence 223, Application US/10094886
Publication No. US20040002120A1
GENERAL INFORMATION:
APPLICANT: Kekuda, Ramesh
APPLICANT: Tchernev, Velizar T.
APPLICANT: Liu, Xiaohong
APPLICANT: Spytek, Kimberly A.
APPLICANT: Patwardhan, Meera
APPLICANT: Burgess, Catherine
APPLICANT: Vernet, Corine A.
APPLICANT: Li, Li
APPLICANT: Gorman, Linda
APPLICANT: Malyankar, Uriel M.
APPLICANT: Boldog, Ferenc
APPLICANT: Guo, Xiaojia
APPLICANT: Shenoy, Suresh
APPLICANT: Padigar, Muralidhara
APPLICANT: Taupier, Raymond J., Jr.
APPLICANT: Miller, Charles
APPLICANT: Casman, Stacie
APPLICANT: Pena, Carol
APPLICANT: Gangoli, Bsha
APPLICANT: Gusev, Vladimir
APPLICANT: Smithson, Glenda
APPLICANT: Zernusen, Bryan
APPLICANT: Gerlach, Valerie
APPLICANT: Pochart, Pascal
APPLICANT: Fernandes, Elma
APPLICANT: Shinkets, Richard
APPLICANT: Rastelli, Luca
APPLICANT: Spaderna, Steven
APPLICANT: Larocheille, William
APPLICANT: Zhong, Mei
TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS
FILE REFERENCE: 21402-290 B
CURRENT APPLICATION NUMBER: US/10/094,886
CURRENT FILING DATE: 2002-03-07
PRIOR APPLICATION NUMBER: 60/274,322
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/313,182
PRIOR FILING DATE: 2001-08-17
PRIOR APPLICATION NUMBER: 60/288,052
PRIOR FILING DATE: 2001-05-02
PRIOR APPLICATION NUMBER: 60/318,510
PRIOR FILING DATE: 2001-09-10
PRIOR APPLICATION NUMBER: 60/274,281
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/314,018
PRIOR FILING DATE: 2001-08-21
PRIOR APPLICATION NUMBER: 60/274,194
PRIOR FILING DATE: 2001-03-08
PRIOR APPLICATION NUMBER: 60/274,849
PRIOR FILING DATE: 2001-03-09
PRIOR APPLICATION NUMBER: 60/296,693
PRIOR FILING DATE: 2001-06-07
PRIOR APPLICATION NUMBER: 60/313,626
PRIOR FILING DATE: 2001-08-21
Remaining Prior Application data removed - See file Wrapper or PALM.
NUMBER OF SEQ ID NOS: 298
SOFTWARE: PatentIn 2.1
SEQ ID NO: 223
LENGTH: 20
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
US-10-094-886-223

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3034 GTCACCTGCTGCTG 3048
Db 15 GTCACCTGCTGCTG 1

RESULT 452
US-10-289-762-2277
Sequence 2277, Application US/10289762
Publication No. US20040006218A1
GENERAL INFORMATION:
APPLICANT: Griffiths, R.
TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
FILE REFERENCE: 9710-003-999
CURRENT APPLICATION NUMBER: US/10/289,762
CURRENT FILING DATE: 2003-03-27
NUMBER OF SEQ ID NOS: 6849
SEQ ID NO 2277
LENGTH: 20
TYPE: DNA
ORGANISM: Chlamydia pneumoniae
US-10-289-762-2277

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 812 GTCTCATCAAGACTT 826
Db 3 GTCTCATCAAGACTT 17

RESULT 453
US-10-628-841-36/C
Sequence 36, Application US/10628841
Publication No. US20040023918A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/10/628,841
CURRENT FILING DATE: 2003-07-28
PRIOR APPLICATION NUMBER: US/09/972,607
PRIOR FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 36
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-36

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1128 GCTGACGACGACGCA 1142
Db 17 GCTGACGACGACGCA 3

RESULT 454
US-10-319-915-31/C
Sequence 31, Application US/10319915
Publication No. US20040115653A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
FILE REFERENCE: RTS-0447
CURRENT APPLICATION NUMBER: US/10/319,915
CURRENT FILING DATE: 2002-12-12
NUMBER OF SEQ ID NOS: 279
SEQ ID NO 31
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-319-915-31

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1266 GCTGACGACGACGCA 1280
Db 15 GCTGACGACGACGCA 1

RESULT 455
US-10-319-915-32/C
Sequence 32, Application US/10319915
Publication No. US20040115653A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
FILE REFERENCE: RTS-0447
CURRENT APPLICATION NUMBER: US/10/319,915
CURRENT FILING DATE: 2002-12-12
NUMBER OF SEQ ID NOS: 279
SEQ ID NO 32
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-319-915-32

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1266 GCTGACGACGACGCA 1280
Db 17 GCTGACGACGACGCA 3

RESULT 456
US-10-319-915-180
Sequence 180, Application US/10319915
Publication No. US20040115653A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
FILE REFERENCE: RTS-0447
CURRENT APPLICATION NUMBER: US/10/319,915
CURRENT FILING DATE: 2002-12-12
NUMBER OF SEQ ID NOS: 279
SEQ ID NO 180
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-319-915-180

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1266 GCTGCAGAGAGAGA 1280
|||||
Db 6 GCTGCAGAGAGAGA 20

RESULT 457

US-10-319-915-181
; Sequence 181, Application US/10319915
; Publication No. US20040115653A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
; FILE REFERENCE: RTS-0447
; CURRENT APPLICATION NUMBER: US/10/319,915
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 279
; SEQ ID NO 181
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-319-915-181

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1266 GCTGCAGAGAGAGA 1280
|||||
Db 4 GCTGCAGAGAGAGA 18

Search completed: May 12, 2005, 11:29:48
Job time : 23 secs

